PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	LaFleur, DW; Chiang, JL; Fagin, JA; Schwartz, SM; Shah, PK; Wallner, K; Forrester, JS; Sharifi, BG				LaFleur, DW; Chiang, JL; Fagin, JA; Schwartz, SM; Shah, PK; Wallner, K; Forrester, JS; Sharifi, BG			Aortic smooth muscle cells interact with tenascin-C through its fibrinogen-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; NEURAL CREST; HEXABRACHION TENASCIN; FIBRONECTIN RECEPTOR; MESSENGER-RNA; ADHESION; MIGRATION; EXPRESSION; BINDING; MAGNESIUM	The extracellular matrix protein tenascin-C is a multidomain protein that regulates cell adhesion. We used two different smooth muscle cell subtypes derived hom adult and newborn rat aorta to investigate the interaction of tenascin-C or its various domains with these cells using an adhesion assay. Newborn cells were three times more adherent to tenascin-C than adult cells, Tenascin C-adhering cells remained round, whereas they spread rapidly on a fibronectin substrate. Adhesion assays showed the interaction between tenascin-C and newborn cells to be predominantly RGD-independent, Mg2+ increased newborn cell adhesion to tenascin-C in a concentration-dependent manner, whereas Ca2+ had no effect, To analyze the structure-function relationships of different domains of tenascin-C, we used recombinant full-length fibronectin-like and fibrinogen-like domains and various subdomains corresponding to the alternatively spliced regions of tenascin-C, The cells adhered to the fibrinogen-like domain but not to the fibronectin-like domain or its subdomains, As with the intact tenascin-C molecule, adherent cells remained round, and the Mg2+, but not Ca2+, promoted this interaction, The interaction of cells with the fibrinogen-like region was further mapped to a 30-amino acid peptide located near the carboxyl-terminal part of the tenascin-C molecule, The same 30-amino acid peptide was active in promoting cell migration, Our results provide a basis for understanding the mechanism of interaction of tenascin-C with smooth muscle cells and a framework for isolating membrane binding sites that mediate the cellular responses to this molecule.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med,Burns & Allen Res Inst, Div Cardiol,Atherosclerosis Res Ctr, Los Angeles, CA 90048 USA; Univ Washington, Div Pathol, Seattle, WA 98195 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Washington; University of Washington Seattle	Sharifi, BG (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med,Burns & Allen Res Inst, Div Cardiol,Atherosclerosis Res Ctr, Davis Bldg 1016,8700 Beverly Blvd, Los Angeles, CA 90048 USA.				NHLBI NIH HHS [HL50566] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050566, R01HL050566] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUFDERHEIDE E, 1988, J CELL BIOL, V107, P2341, DOI 10.1083/jcb.107.6.2341; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; AUKHIL I, 1990, MATRIX, V10, P98, DOI 10.1016/S0934-8832(11)80176-9; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BRONNERFRASER M, 1991, J CRAN GENET DEV BIO, V11, P214; CADDELL JL, 1989, MAGNESIUM, V8, P65; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; Chung CY, 1996, MOL BIOL CELL, V7, P883, DOI 10.1091/mbc.7.6.883; Deryugina EI, 1996, J CELL SCI, V109, P643; EPPERLEIN HH, 1988, DEVELOPMENT, V103, P743; ERICKSON HP, 1994, PERSPECT DEV NEUROBI, V2, P9; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FRIEDLANDER DR, 1988, J CELL BIOL, V107, P2329, DOI 10.1083/jcb.107.6.2329; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HAHN AWA, 1995, J VASC RES, V32, P162, DOI 10.1159/000159090; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HENROTTE JG, 1988, MAGNESIUM, V7, P306; JOSHI P, 1993, J CELL SCI, V106, P389; KAPLONY A, 1991, DEVELOPMENT, V112, P605; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; LAFLEUR DW, 1994, J BIOL CHEM, V269, P20757; LEMIRE JM, 1994, AM J PATHOL, V144, P1068; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; LIGHTNER VA, 1990, J CELL SCI, V95, P263; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; Mackie EJ, 1988, ANN NY ACAD SCI, V540, P64; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; Olinger M L, 1989, Emerg Med Clin North Am, V7, P795; POLIMENI PI, 1973, CIRC RES, V33, P367, DOI 10.1161/01.RES.33.4.367; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; SAGINATI M, 1992, EUR J BIOCHEM, V205, P545, DOI 10.1111/j.1432-1033.1992.tb16811.x; SCHWARTZ SM, 1994, EXP NEPHROL, V2, P63; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SCHWARTZ SM, 1985, ANN NY ACAD SCI, V454, P292, DOI 10.1111/j.1749-6632.1985.tb11869.x; SCHWARTZ SM, 1995, ATHEROSCLEROSIS SUPP, V118, P125; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SPENCE SG, 1994, INT J DEV BIOL, V38, P85; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001	44	36	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32798	32803		10.1074/jbc.272.52.32798	http://dx.doi.org/10.1074/jbc.272.52.32798			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407055	hybrid			2022-12-25	WOS:000071182900016
J	Fujiwara, K; Okamura-Ikeda, K; Motokawa, Y				Fujiwara, K; Okamura-Ikeda, K; Motokawa, Y			Cloning and expression of a cDNA encoding bovine lipoyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOLOCARBOXYLASE SYNTHETASE; GLYCINE CLEAVAGE SYSTEM; ESCHERICHIA-COLI; H-PROTEIN; LIPOYLATION; SEQUENCE; COMPLEXES; MUTATIONS; ACID; GENE	Lipoyltransferase catalyzes the transfer of the lipoyl group from lipoyl-AMP to the specific lysine residue of the lipoate-dependent enzymes, We have isolated lipoyl-transferase I (LipTI) and II (LipTII) from bovine liver (Fujiwara, K., Okamura-Ikeda, K., and Motokawa, Y. (1994) J. Biol. Chem. 269, 16605-16609), N-terminal amino acid sequences of LipTI and LipTII were identical except that LipTI had an additional Asn residue on the N terminus. We cloned LipTII cDNA from a bovine liver cDNA library, The cDNA insert contained a 1119-base pair open reading frame encoding a precursor peptide of 373 amino acids including a mitochondrial targeting signal of 26 amino acids, The calculated molecular mass of the mature protein is 39,137 Da, The predicted amino acid sequence showed 35% identity with that of Escherichia coli lipoate-protein ligase A. Northern and Southern blot analyses showed a single band, and a single species of mRNA for lipoyltransferase was found by reverse transcription-polymerase chain reaction, Recombinant LipTII was expressed in E. coli and purified to apparent homogeneity. The K-m(app) values of the recombinant enzyme for lipoyl-AMP and apoH-protein were comparable with those of native LipTII, An antibody raised against recombinant enzyme cross-reacted with LipTI and LipTII in a similar manner. The results suggest that LipTI and LipTII are derived from the same translated product but processed differently.	Univ Tokushima, Inst Enzyme Res, Tokushima 770, Japan	Tokushima University	Motokawa, Y (corresponding author), Univ Tokushima, Inst Enzyme Res, Kuramotocho 3 Chome, Tokushima 770, Japan.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; FUJIWARA K, 1994, J BIOL CHEM, V269, P16605; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; FUJIWARA K, 1986, J BIOL CHEM, V261, P8836; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOWARD PK, 1985, GENE, V35, P321, DOI 10.1016/0378-1119(85)90011-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONDELRIO A, 1995, P NATL ACAD SCI USA, V92, P4626, DOI 10.1073/pnas.92.10.4626; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; ROISE D, 1988, J BIOL CHEM, V263, P4509; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI Y, 1994, NAT GENET, V8, P122, DOI 10.1038/ng1094-122; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9	21	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31974	31978		10.1074/jbc.272.51.31974	http://dx.doi.org/10.1074/jbc.272.51.31974			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405389	hybrid			2022-12-25	WOS:000071108000008
J	Wong, AKC; Pero, R; Ormonde, PA; Tavtigian, SV; Bartel, PL				Wong, AKC; Pero, R; Ormonde, PA; Tavtigian, SV; Bartel, PL			RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SACCHAROMYCES-CEREVISIAE; OVARIAN-CANCER; DIFFERENTIATION; PROLIFERATION; RECOMBINATION	Recent work has shown that the murine BRCA2 tumor suppressor protein interacts with the murine RAD51 protein, This interaction suggests that BRCA2 participates in DNA repair. Residues 3196-3232 of the murine BRCA2 protein were shown to be involved in this interaction. Here, we report the detailed mapping of additional domains that are involved in interactions between the human homologs of these two proteins. Through yeast two-hybrid and biochemical assays, we demonstrate that the RAD51 protein interacts specifically with the eight evolutionarily conserved BRC motifs encoded in exon 11 of brca2 and with a similar motif found in a Caenorhabditis elegans hypothetical protein. Deletion analysis demonstrates that residues 98-339 of human RAD51 interact with the 59-residue minimal region that is conserved in all BRC motifs. These data suggest that the BRC repeats function to bind RAD51.	Myriad Genet Inc, Salt Lake City, UT 84108 USA	Myriad Genetics, Inc	Wong, AKC (corresponding author), Myriad Genet Inc, 390 Wakara Way, Salt Lake City, UT 84108 USA.		Wong, Alexander/GZM-2929-2022	Wong, Alexander/0000-0002-5295-2797				Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; EASTON DF, 1993, AM J HUM GENET, V52, P678; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HEYER WD, 1994, EXPERIENTIA, V50, P223, DOI 10.1007/BF01924005; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; OGAWA T, 1992, J MOL BIOL, V226, P651, DOI 10.1016/0022-2836(92)90622-Q; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Sambrook J., 2002, MOL CLONING LAB MANU; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Vaughn JP, 1996, CANCER RES, V56, P4590; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	31	424	436	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31941	31944		10.1074/jbc.272.51.31941	http://dx.doi.org/10.1074/jbc.272.51.31941			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405383	hybrid			2022-12-25	WOS:000071108000002
J	Yao, ZB; Diener, K; Wang, XS; Zukowski, M; Matsumoto, G; Zhou, GS; Mo, R; Sasaki, T; Nishina, H; Hui, CC; Tan, TH; Woodgett, JP; Penninger, JM				Yao, ZB; Diener, K; Wang, XS; Zukowski, M; Matsumoto, G; Zhou, GS; Mo, R; Sasaki, T; Nishina, H; Hui, CC; Tan, TH; Woodgett, JP; Penninger, JM			Activation of stress-activated protein kinases c-Jun N-terminal protein kinases (SAPKs/JNKs) by a novel mitogen-activated protein kinase kinase (MKK7)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GENE; PHOSPHORYLATION; EXPRESSION; THREONINE; CYTOKINES; TYROSINE; CASCADES; INSULIN; CLONING	Mitogen-activated protein kinase (MAPK) kinases (MKKs) are dual-specificity protein kinases that phosphorylate and activate MAPK. We have isolated a cDNA encoding a novel protein kinase that has significant homology to MKKs. The novel kinase MKK7 has a nucleotide sequence that encodes an open reading frame of 347 amino acids with 11 kinase subdomains. MKK7 is ubiquitously expressed in all adult and embryonic organs but displays high expression in epithelial tissues at later stages of fetal development. When transiently expressed in 293 cells, MKK7 specifically activated stress-activated protein kinases (SAPKs)/c-Jun N-terminal protein kinases (JNKs) but not extracellular-regulated kinase or p38 kinase. A kinase-negative mutant of MKK7 inhibits interleukin-1 beta, lipopolysaccharide, and MEKK1-induced SAPK/JNH activation. Thus, MKK7 is a new member of the MAPK kinase family that functions upstream of SAPK/JNK in the SAPK/JNK signaling pathway.	Amgen Inc, Boulder, CO 80301 USA; Amgen Inst, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Univ Toronto, Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada	Amgen; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Baylor College of Medicine; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Penninger, JM (corresponding author), Amgen Inc, 3200 Walnut St,AC-4B, Boulder, CO 80301 USA.		Penninger, Josef M/I-6860-2013; Woodgett, Jim/F-1087-2010; Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Penninger, Josef M/0000-0002-8194-3777; Woodgett, Jim/0000-0003-3731-5797; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Sasaki, Takehiko/0000-0003-1837-3748				BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIENER D, 1997, IN PRESS P NATL ACAD; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NISHINA N, 1997, J EXP MED, V186, P941; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Wang XHS, 1996, J BIOL CHEM, V271, P31607; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	34	91	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32378	32383		10.1074/jbc.272.51.32378	http://dx.doi.org/10.1074/jbc.272.51.32378			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405446	hybrid			2022-12-25	WOS:000071108000065
J	Oh, HJ; Chen, X; Subjeck, JR				Oh, HJ; Chen, X; Subjeck, JR			hsp110 protects heat-denatured proteins and confers cellular thermoresistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEINS; LARGE HSP70-LIKE; IDENTIFICATION; SUBFAMILY; THERMOTOLERANCE; EXPRESSION; CLONING; HDJ-1	The 110-kDa heat shock protein (hsp110) has long been recognized as one of the primary heat shock proteins in mammalian cells. It belongs to a recently described protein family that is a significantly diverged subgroup of the hsp70 family and has been found in organisms as diverse as yeast and mammals. We describe here the first analysis of the ability of hsp110 to protect cellular and molecular targets from heat damage. It was observed that the overexpression in vivo of hsp110 conferred substantial heat resistance to both Rat-1 and HeLa cells. In vitro heat denaturation and refolding assays demonstrate that hsp110 is highly efficient in selectively recognizing denatured proteins and maintaining them in a soluble, folding-competent state and is significantly more efficient in performing this function than is hsc70. hsp110-bound proteins can then be refolded by the addition of rabbit reticulocyte lysate or hsc70 and Hdj-1, whereas Hdj-1 does not itself function as a co-chaperone in folding with hsp110. hsp110 is one of the principal molecular chaperones of mammalian cells and represents a newly identified component of the primary protection/repair pathway for denatured proteins and thermotolerance expression in vivo.	ROSWELL PK CANC INST,DEPT MOL & CELLULAR BIOL,BUFFALO,NY 14263	Roswell Park Cancer Institute				Oh, Kelly/0000-0001-8203-5247	NIGMS NIH HHS [GM45994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Chen X, 1996, FEBS LETT, V380, P68, DOI 10.1016/0014-5793(96)00011-7; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Ikeda J, 1997, BIOCHEM BIOPH RES CO, V230, P94, DOI 10.1006/bbrc.1996.5890; Just ML, 1997, DEV BIOL, V184, P25, DOI 10.1006/dbio.1997.8504; Kaneko Y, 1997, J BIOL CHEM, V272, P2640, DOI 10.1074/jbc.272.5.2640; Kaneko Y, 1997, GENE, V189, P19, DOI 10.1016/S0378-1119(96)00807-4; Kojima R, 1996, J BIOL CHEM, V271, P12327, DOI 10.1074/jbc.271.21.12327; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LANDRY J, 1982, CANCER RES, V42, P2457; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; Mauk R, 1997, DEV BIOL, V184, P31, DOI 10.1006/dbio.1997.8512; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MOROZOV A, 1995, FEBS LETT, V371, P214, DOI 10.1016/0014-5793(95)00884-C; MUKAI H, 1993, GENE, V132, P57; NEMMESGERN E, 1993, FEBS LETT, V331, P25; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; Storozhenko S, 1996, FEBS LETT, V390, P113, DOI 10.1016/0014-5793(96)00640-0; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; YASUDA K, 1995, J BIOL CHEM, V270, P29718, DOI 10.1074/jbc.270.50.29718; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	30	158	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31636	31640		10.1074/jbc.272.50.31636	http://dx.doi.org/10.1074/jbc.272.50.31636			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395504	hybrid			2022-12-25	WOS:A1997YL41900063
J	Orlando, S; Sironi, M; Bianchi, G; Drummond, AH; Boraschi, D; Yabes, D; Mantovani, A				Orlando, S; Sironi, M; Bianchi, G; Drummond, AH; Boraschi, D; Yabes, D; Mantovani, A			Role of metalloproteases in the release of the IL-1 type II decoy receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; FACTOR-ALPHA; RAPID RELEASE; TNF RECEPTOR; L-SELECTIN; INTERLEUKIN-1; INHIBITOR; CELLS; CLONING; EXPRESSION	The IL-1 type II receptor (decoy RII) is a nonsignaling molecule the only established function of which is to capture IL-1 and prevent it from interacting with signaling receptor. The decoy RII is released in a regulated way from the cell surface. Here, we reported that hydroxamic acid inhibitors of matrix metalloproteases inhibit different pathways of decoy RII release, including the following: (a) the slow (18 h) gene expression dependent release from monocytes and polymorphonuclear cells exposed to dexamethasone; (b) rapid release (minutes) from myelomonocytic cells exposed to tumor necrosis factor, chemoattractants, or phorbol myristate acetate; (c) phorbol myristate acetate-induced release from decoy RII-transfected fibroblasts and B cells. Inhibition of release was associated with increased surface expression of decoy RII. Inhibitors of other protease classes did not substantially affect release. However, serine protease inhibitors increased the molecular mass of the decoy RII released from polymorphonuclear cells from 45 to 60 kDa. Thus, irrespective of the pathway responsible for release and of the cellular context, matrix metalloproteases, rather than differential splicing, play a key role in production of soluble decoy RII.	MARIO NEGRI INST PHARMACOL RES, DEPT IMMUNOL & CELL BIOL, I-20157 MILAN, ITALY; BRITISH BIOTECH, OXFORD OX4 5LY, ENGLAND; RES CTR DOMPE SPA, I-67100 LAQUILA, ITALY; PHARMACIA & UPJOHN RES CTR, DEPT IMMUNOL, I-20014 NERVIANO, ITALY; UNIV BRESCIA, SECT GEN PATHOL, DEPT BIOTECHNOL, I-25100 BRESCIA, ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Dompe; University of Brescia			Boraschi, Diana/AAA-7171-2020; sironi, marina/AAB-5757-2020; Mantovani, Alberto/HCI-7449-2022	Boraschi, Diana/0000-0002-3953-4056; sironi, marina/0000-0002-3342-1149; Mantovani, Alberto/0000-0001-5578-236X				AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BAZIL V, 1995, IMMUNOL TODAY, V16, P135, DOI 10.1016/0167-5699(95)80130-8; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; COLOTTA F, 1995, J EXP MED, V181, P2181, DOI 10.1084/jem.181.6.2181; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Colotta F, 1996, J IMMUNOL, V156, P2534; COLOTTA F, 1984, J IMMUNOL, V132, P936; Couet J, 1996, J BIOL CHEM, V271, P4545; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GIRI JG, 1994, J IMMUNOL, V153, P5802; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Liu CL, 1996, J BIOL CHEM, V271, P20965, DOI 10.1074/jbc.271.34.20965; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MCKEAN DJ, 1993, J IMMUNOL, V151, P3500; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MUZIO M, 1995, J EXP MED, V182, P623, DOI 10.1084/jem.182.2.623; Orlando S, 1997, J IMMUNOL, V158, P3861; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PERI G, 1994, J IMMUNOL METHODS, V174, P249, DOI 10.1016/0022-1759(94)90029-9; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Pruitt JH, 1996, BLOOD, V87, P3282; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; Re F, 1996, J EXP MED, V183, P1841, DOI 10.1084/jem.183.4.1841; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Sambo P, 1996, BLOOD, V87, P1682; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SOZZANI S, 1991, J IMMUNOL, V147, P2215; STOPPACCIARO A, 1991, J IMMUNOL, V147, P1561; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; Williams LM, 1996, J CLIN INVEST, V97, P2833, DOI 10.1172/JCI118739	48	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31764	31769		10.1074/jbc.272.50.31764	http://dx.doi.org/10.1074/jbc.272.50.31764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395521	hybrid			2022-12-25	WOS:A1997YL41900080
J	Oyedotun, KS; Lemire, BD				Oyedotun, KS; Lemire, BD			The carboxyl terminus of the Saccharomyces cerevisiae succinate dehydrogenase membrane subunit, SDH4p, is necessary for ubiquinone reduction and enzyme stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDOREDUCTASE; COLI FUMARATE REDUCTASE; RESPIRATORY COMPLEX-II; ESCHERICHIA-COLI; FLAVOPROTEIN SUBUNIT; ELECTRON-TRANSFER; GENE; INFORMATION; INHIBITORS; QUINONES	The succinate dehydrogenase (SDH) of Saccharomyces cerevisiae is composed of four nonidentical subunits encoded by the nuclear genes SDH1, SDH2, SDH3, and SDH4. The hydrophilic subunits, SDH1p and SDH2p, comprise the catalytic domain involved in succinate oxidation. They are anchored to the inner mitochondrial membrane by two small, hydrophobic subunits, SDH3p and SDH4p, which are required for electron transfer and ubiquinone reduction. Comparison of the deduced primary sequence of the yeast SDH4p subunit to SDH4p subunits from other species reveals the presence of an unusual 25-30 amino acid carboxyl-terminal extension following the last predicted transmembrane domain. The extension is predicted to be on the cytoplasmic side of the inner mitochondrial membrane. To investigate the extension's function, three truncations were created and characterized. The results reveal that the carboxyl-terminal extension is necessary for respiration and growth on nonfermentable carbon sources, for ubiquinone reduction, and for enzyme stability. Combined with inhibitor studies using a ubiquinone analog, our results suggest that the extension and more specifically, residues 128-135 are involved in the formation of a ubiquinone binding site. Our findings support a two ubiquinone binding site model for the S. cerevisiae SDH.	UNIV ALBERTA,DEPT BIOCHEM,MRC,GRP MOL BIOL MEMBRANES,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Bruel C, 1995, J BIOENERG BIOMEMBR, V27, P527, DOI 10.1007/BF02110192; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; Burger G, 1996, P NATL ACAD SCI USA, V93, P2328, DOI 10.1073/pnas.93.6.2328; CAMMACK R, 1986, BIOCHEM SOC T, V14, P1207, DOI 10.1042/bst0141207; CHAPMAN KB, 1992, GENE, V118, P131, DOI 10.1016/0378-1119(92)90260-V; Cleland W W, 1979, Methods Enzymol, V63, P103; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; DAIGNANFORNIER B, 1994, J BIOL CHEM, V269, P15469; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; GIETZ RD, 1988, GENE AMST, V74, P427; GRIVENNIKOV AVG, 1982, BIOCHIM BIOPHYS ACTA, V682, P491; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KITA K, 1989, J BIOL CHEM, V264, P2672; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Robinson KM, 1996, J BIOL CHEM, V271, P4055; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SCHULKE N, 1992, P NATL ACAD SCI USA, V89, P8011, DOI 10.1073/pnas.89.17.8011; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; WRAIGHT CA, 1982, FUNCTIONS QUINONES E, P181; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; ZHU QS, 1988, J BIOL CHEM, V263, P193	29	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31382	31388		10.1074/jbc.272.50.31382	http://dx.doi.org/10.1074/jbc.272.50.31382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395469	hybrid			2022-12-25	WOS:A1997YL41900028
J	Tsoporis, JN; Marks, A; Kahn, HJ; Butany, JW; Liu, PP; OHanlon, D; Parker, TG				Tsoporis, JN; Marks, A; Kahn, HJ; Butany, JW; Liu, PP; OHanlon, D; Parker, TG			S100 beta inhibits alpha(1)-adrenergic induction of the hypertrophic phenotype in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ALPHA-ACTIN PROMOTER; HEAVY-CHAIN PROMOTER; AMINO-ACID-SEQUENCE; ENHANCER FACTOR-I; GENE-EXPRESSION; MYOCARDIAL-INFARCTION; MESSENGER-RNA; ALPHA-1-ADRENERGIC RECEPTOR; SKELETAL-MUSCLE	In an experimental rat model of myocardial infarction, surviving cardiac myocytes undergo hypertrophy in response to trophic effecters. This response involves gene reprogramming manifested by the re-expression of fetal genes, such as the previously reported isoform switch from adult alpha- to embryonic beta-myosin heavy chain. We now report the transient re-expression of a second fetal gene, skeletal alpha-actin in rat myocardium at 7 days post-infarction, and its subsequent down-regulation coincident with the delayed induction of S100 beta, a protein normally expressed in brain. In cultured neonatal rat cardiac myocytes, co-transfection with an S100 beta-expression vector inhibits a pathway associated with hypertrophy, namely, alpha(1)-adrenergic induction of beta-myosin heavy chain and skeletal alpha-actin promoters mediated by beta-protein kinase C. The induction of beta-myosin heavy chain by hypoxia was similarly blocked by forced expression of S100 beta. Our results suggest that S100 beta may be an intrinsic negative regulator of the hypertrophic response of surviving cardiac myocytes post-infarction. Such negative regulators may be important in limiting the adverse consequences of unchecked hypertrophy leading to ventricular remodeling and dysfunction.	UNIV TORONTO, TORONTO HOSP,DEPT MED,CARDIOVASC RES CTR, DIV CARDIOL, TORONTO, ON M5G 2C4, CANADA; UNIV TORONTO, TORONTO HOSP, DEPT PATHOL, TORONTO, ON M5G 2C4, CANADA; UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, WOMENS COLL HOSP, DEPT PATHOL, TORONTO, ON M5S 1B2, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital								ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; ALLORE RJ, 1990, J BIOL CHEM, V265, P15537; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; CAPASSO JM, 1993, AM J PHYSIOL, V265, pH1953, DOI 10.1152/ajpheart.1993.265.6.H1953; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DONATO R, 1985, CELL CALCIUM, V6, P343, DOI 10.1016/0143-4160(85)90004-1; DUNN R, 1987, J BIOL CHEM, V262, P3562; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; ECKEL J, 1991, J MOL CELL CARDIOL, V23, P617, DOI 10.1016/0022-2828(91)90053-O; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GIDHJAIN M, 1995, BIOCHEM BIOPH RES CO, V216, P892, DOI 10.1006/bbrc.1995.2705; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAIMOTO H, 1988, EUR J BIOCHEM, V171, P409, DOI 10.1111/j.1432-1033.1988.tb13805.x; HANATANI A, 1995, J MOL CELL CARDIOL, V27, P1905, DOI 10.1016/0022-2828(95)90013-6; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; ITAGAKI T, 1989, JPN CIRC J, V53, P313, DOI 10.1253/jcj.53.313; Ito H, 1996, J MOL CELL CARDIOL, V28, P1271, DOI 10.1006/jmcc.1996.0117; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; KAHN HJ, 1991, MODERN PATHOL, V4, P698; KANDA T, 1993, EXP CLIN ENDOCRINOL, V101, P173, DOI 10.1055/s-0029-1211226; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; NADALGINARD B, 1993, BASIC RES CARDIOL, V88, P65; ORENSTEIN TL, 1995, J CLIN INVEST, V96, P858, DOI 10.1172/JCI118132; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PARKER TG, 1993, HERZ, V18, P245; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROKOSH DG, 1994, BIOCHEM BIOPH RES CO, V200, P1177, DOI 10.1006/bbrc.1994.1575; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SHEU FS, 1994, MOL BRAIN RES, V21, P62, DOI 10.1016/0169-328X(94)90378-6; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIGURDSSON A, 1993, AM HEART J, V126, P1068, DOI 10.1016/0002-8703(93)90656-T; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; ZIMMER DB, 1987, AM J PHYSIOL, V252, pC285, DOI 10.1152/ajpcell.1987.252.3.C285	51	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31915	31921		10.1074/jbc.272.50.31915	http://dx.doi.org/10.1074/jbc.272.50.31915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395540	hybrid			2022-12-25	WOS:A1997YL41900099
J	Mummidi, S; Ahuja, SS; McDaniel, BL; Ahuja, SK				Mummidi, S; Ahuja, SS; McDaniel, BL; Ahuja, SK			The human CC chemokine receptor 5 (CCR5) gene - Multiple transcripts with 5 '-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR RECEPTOR; MESSENGER-RNA; HIV-1 INFECTION; FUNCTIONAL-CHARACTERIZATION; GENOMIC ORGANIZATION; MOLECULAR-CLONING; EXPRESSION; IDENTIFICATION; MIP-1-ALPHA; MIP-1-BETA	Human CC chemokine receptor 5 (CCR5), mediates the activation of cells by the chemokines macrophage inflammatory protein-la; macrophage inflammatory protein-1 beta, and RANTES, and serves as a fusion cofactor for macrophage-tropic strains of human immunodeficiency virus type 1. To understand the molecular mechanisms that regulate human CCR5 gene expression, we initiated studies to determine its genomic and mRNA organization, Previous studies have identified a single CCR5 mRNA isoform whose open reading frame is intronless, We now report the following novel findings, 1) Complex alternative splicing and multiple transcription start sites give rise to several distinct CCR5 transcripts that differ in their 5'-untranslated regions (UTR), 2) The gene is organized into four exons and two introns, Exons 2 and 3 are not interrupted by an intron, Exon 4 and portions of exon 3 are shared by all isoforms, Exon 4 contains the open reading frame, 11 nucleotides of the 5'-UTR and the complete 3'-UTR. 3) The transcripts appear to be initiated from two distinct promoters: an upstream promoter (P-U), upstream of exon 1, and a downstream promoter (P-D), that includes the "intronic" region between exons 1 and 3, 4) P-U and P-D lacked the canonical TATA or CAAT motifs, and are AT-rich, 5) P-D demonstrated strong constitutive promoter activity, whereas P-U was a weak promoter in all three leukocyte cell environments tested (THP-1, Jurkat, and K562), 6) We provide evidence for polymorphisms in the noncoding sequences, including the regulatory regions and 5'-UTRs, The structure of CCR5 was strikingly reminiscent of the overall structure of other chemokine/chemoattractant receptors, underscoring an important evolutionarily conserved function for a prototypical gene structure. This is the first description of functional pro meters for any CC chemokine receptor gene, and we speculate that the complex pattern of splicing events and dual promoter usage may function as a versatile mechanism to create diversity and flexibility in the regulation of CCR5 expression.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78284 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Ahuja, SK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Mummidi, Srinivas/C-1004-2008; Mummidi, Srinivas/H-3335-2017	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380				AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; AHUJA SK, 1994, J BIOL CHEM, V269, P26381; Ahuja SS, 1996, J IMMUNOL, V156, P4345; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, J BIOL CHEM, V272, P19771, DOI 10.1074/jbc.272.32.19771; ANGOTTI E, 1994, J BIOL CHEM, V269, P17371; AnsariLari MA, 1997, NAT GENET, V16, P221, DOI 10.1038/ng0797-221; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CURNOW KM, 1995, MOL ENDOCRINOL, V9, P1250, DOI 10.1210/me.9.9.1250; DallingaThie GM, 1997, J CLIN INVEST, V99, P953, DOI 10.1172/JCI119260; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; GERARD NP, 1993, BIOCHEMISTRY-US, V32, P1243, DOI 10.1021/bi00056a007; HUANG Y, 1996, NAT MED, V11, P1240; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; Iwamoto S, 1996, BLOOD, V87, P378; IWAMOTO S, 1995, BLOOD, V85, P622, DOI 10.1182/blood.V85.3.622.bloodjournal853622; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P209; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEEN MPJM, 1994, HUM IMMUNOL, V41, P112; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; MURPHY PM, 1993, GENE, V133, P285, DOI 10.1016/0378-1119(93)90653-K; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MUTOH H, 1993, FEBS LETT, V322, P129, DOI 10.1016/0014-5793(93)81552-B; Naganawa S, 1997, J CLIN INVEST, V99, P1958, DOI 10.1172/JCI119363; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; OLIVEIRA CC, 1995, J BIOL CHEM, V270, P8936, DOI 10.1074/jbc.270.15.8936; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PANG JHS, 1995, J BIOL CHEM, V270, P14123, DOI 10.1074/jbc.270.23.14123; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SLOAN JH, 1992, J IMMUNOL, V148, P2591; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Song ZM, 1996, J IMMUNOL, V156, P424; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	54	145	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30662	30671		10.1074/jbc.272.49.30662	http://dx.doi.org/10.1074/jbc.272.49.30662			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388201	hybrid			2022-12-25	WOS:000071640800014
J	Nemoto, Y; Arribas, M; Haffner, C; DeCamilli, P				Nemoto, Y; Arribas, M; Haffner, C; DeCamilli, P			Synaptojanin 2, a novel synaptojanin isoform with a distinct targeting domain and expression pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; SYNAPTIC VESICLE ENDOCYTOSIS; NERVE-TERMINALS; BOVINE BRAIN; SYNAPSIN-I; MEMBRANE; PROTEIN; POLYPHOSPHATE-5-PHOSPHATASE; DYNAMIN; PHOSPHATASES	Synaptojanin (synaptojanin 1) is a recently identified inositol 5'-phosphatase, which is highly enriched in nerve terminals and is implicated in synaptic vesicle recycling. It is composed of three domains: an aminoterminal SacI homology region, a central inositol 5'-phosphatase homology region, and a carboxyl-terminal proline rich region. We have now identified and characterized a novel form of synaptojanin, synaptojanin 2, which has a broader tissue distribution. Synaptojanin 2 cDNA from rat brain library encodes a protein of 1,248 amino acids with a predicted M-r of 138,268. The two synaptojanin isoforms share 57.2 and 53.8% amino acid identity in their SacI and phosphatase domains, respectively. In marked contrast, their carboxyl-terminal proline-rich regions bear little homology. Expression of synaptojanin 2 in COS7 cells produced a 110-kDa protein with inositol 5'-phosphatase activity. Protein binding assays demonstrated that among the major src homology 3-proteins known to bind to the proline-rich region of synaptojanin 1, Grb2, amphiphysin, and members of SH3p4/8/13 protein family, only Grb2 bound to that of synaptojanin 2. Furthermore, subcellular fractionation studies in transfected Chinese hamster ovary cells revealed that synaptojanin 2 was predominantly associated with the particulate fraction while synaptojanin 1 was mainly localized in the soluble fraction. This observation suggests that the proline-rich regions of synaptojanins 1 and 2 are implicated in different protein protein interactions and direct the two isoforms to different subcellular compartments. Our results demonstrate the presence of a family of synaptojanin-type inositol 5'-phosphatases with different tissue and subcellular distributions, which may be involved in distinct membrane trafficking and signal transduction pathways in mammalian cells.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol,Boyer Ctr Mol Med, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University	DeCamilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol,Boyer Ctr Mol Med, 295 Congress Ave, New Haven, CT 06510 USA.	pietro.decamilli@yale.edu	Haffner, Christof/AAG-6676-2020	Arribas, Monica/0000-0002-1405-9391	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER; NCI NIH HHS [CA48128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1997, NATURE, V387, pS; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; Bauerfeind Rudolf, 1995, Molecular Biology of the Cell, V6, p405A; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; Haffner Christof, 1996, Molecular Biology of the Cell, V7, p78A; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; Harlow E., 1988, ANTIBODIES LAB MANUA; HEJNA JA, 1995, GENOMICS, V29, P285, DOI 10.1006/geno.1995.1247; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; PALMER FBS, 1994, J BIOL CHEM, V269, P3403; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROSS TS, 1991, J BIOL CHEM, V266, P20283; Sambrook J., 2002, MOL CLONING LAB MANU; SRINIVASAN S, 1997, IN PRESS EUR J CELL, V73; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377	41	87	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30817	30821		10.1074/jbc.272.49.30817	http://dx.doi.org/10.1074/jbc.272.49.30817			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388224	hybrid			2022-12-25	WOS:000071640800037
J	Nishimori, H; Shiratsuchi, T; Urano, T; Kimura, Y; Kiyono, K; Tatsumi, K; Yoshida, S; Ono, M; Kuwano, M; Nakamura, Y; Tokino, T				Nishimori, H; Shiratsuchi, T; Urano, T; Kimura, Y; Kiyono, K; Tatsumi, K; Yoshida, S; Ono, M; Kuwano, M; Nakamura, Y; Tokino, T			A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis	ONCOGENE			English	Article						BAI1; thrombospondin type 1 repeat; p53; angiogenesis	GLIOBLASTOMA CELLS; P53; EXPRESSION; PROTEIN; METASTASIS; CANCERS; SITES; DNA	The genetic alteration of p53 is associated with neovascularization during progression of glioma to its more malignant form, glioblastoma, Hence, one or more of the genes transactivated by p53 is likely to function as an angiogenesis inhibitors, We isolated a novel p53-inducible gene that encodes a 1584-amino-acid product containing five thrombospondin type 1 (TSP-type 1) repeats and is specifically expressed in the brain, A recombinant protein corresponding to the TSP-type 1 repeats of this gene product inhibited in vivo neovascularization induced by bFGF in the rat cornea, The expression of this gene, designated BAI1 (brain-specific angiogenesis inhibitor 1) was absent or significantly reduced in eight of nine glioblastoma cell lines, suggesting BAI1 plays a significant role in angiogenesis inhibition, as a mediator of p53.	UNIV TOKYO, INST MED SCI, MOL MED LAB, TOKYO, JAPAN; KYUSHU UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 812, JAPAN; OTSUKA PHARMACEUT CO LTD, FUJII MEM RES INST, TOKUSHIMA, JAPAN	University of Tokyo; Kyushu University; Otsuka Pharmaceutical			Tokino, Takashi/AAI-9887-2021; Urano, Tomohiko/AFS-9574-2022	Yoshida, Shigeo/0000-0003-1049-8909				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Furuhata T, 1996, ONCOGENE, V13, P1965; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIMURA Y, IN PRESS ONCOGENE; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; TOKINO T, 1991, AM J HUM GENET, V48, P258; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VAN MEIR EG, 1994, CANCER RES, V54, P649; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; XU Y, 1995, COMPUT APPL BIOSCI, V11, P117	28	241	260	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2145	2150		10.1038/sj.onc.1201542	http://dx.doi.org/10.1038/sj.onc.1201542			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393972				2022-12-25	WOS:A1997YD01900002
J	Lakshminarayanan, V; Beno, DWA; Costa, RH; Roebuck, KA				Lakshminarayanan, V; Beno, DWA; Costa, RH; Roebuck, KA			Differential regulation of interleukin-8 and intercellular adhesion molecule-1 by H2O2 and tumor necrosis factor-alpha in endothelial and epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANTIOXIDANT-RESPONSE-ELEMENT; TRANSENDOTHELIAL NEUTROPHIL MIGRATION; NAD(P)H-QUINONE OXIDOREDUCTASE GENE; PRO-INFLAMMATORY CYTOKINES; OXIDATIVE STRESS; TRANSCRIPTIONAL REGULATION; COOPERATIVE INTERACTION; MONOCLONAL-ANTIBODY; HYDROGEN-PEROXIDE	The reactive oxygen intermediate H2O2 can function as a signaling molecule to activate gene expression. In this study, we demonstrate that oxidant stress induced by tumor necrosis factor alpha (TNF alpha) or H2O2 differentially regulates intercellular adhesion molecule-1 (ICAM-1) and interleukin-8 (IL-8) gene expression in endothelial and epithelial cells. Northern blot analysis revealed that TNF alpha induced both ICAM-1 and IL-8 expression in either the A549 lung epithelial cell line or the human microvessel endothelial cell line (HMEC-1). In contrast, H2O2 selectively induced only ICAM-1 in HMEC-1 and only IL-8 in A549. This cell type-specific pattern of IL-8 expression was also observed in several other endothelial and epithelial cells. TNF alpha induced greater IL-8 gene expression as compared with H2O2, but the kinetics of induction were similar. The induction of epithelial IL-8 message was accompanied by a corresponding increase in functional IL-8 protein secretion as determined by a neutrophil motility assay. The increased neutrophil motility stimulated by conditioned media from H2O2- or TNF alpha-exposed A549 cells was completely inhibited by an anti-IL-8 antibody. TNF alpha and H2O2 also induced a differential pattern of CC chemokine expression in A549. While TNF alpha induced both RANTES and MCP-1, H2O2 induced only MCP-1. These data suggest that epithelial cells under oxidant stress contribute to the inflammatory cytokine network by selective production of IL-8, MCP-1, and RANTES, which may critically influence the site-specific recruitment of leukocyte subsets.	Rush Presbyterian St Lukes Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Pediat, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem, Chicago, IL 60612 USA	Rush University; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roebuck, KA (corresponding author), Rush Med Coll, Dept Immunol Microbiol, 1653 W Comgress Pkwy, Chicago, IL 60612 USA.	kroebuck@rush.edu			NIGMS NIH HHS [R01 GM43241-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043241] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; ANDREW PJ, 1995, BIOCHEM BIOPH RES CO, V214, P949, DOI 10.1006/bbrc.1995.2378; Aoudjit F, 1997, CELL GROWTH DIFFER, V8, P335; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Becker S, 1997, AM J PHYSIOL-LUNG C, V272, pL512, DOI 10.1152/ajplung.1997.272.3.L512; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; BROADDUS VC, 1994, J IMMUNOL, V152, P2960; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; COLLETTI LM, 1995, J CLIN INVEST, V95, P134, DOI 10.1172/JCI117630; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DEFORGE LE, 1992, J CLIN INVEST, V90, P2123, DOI 10.1172/JCI116097; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; Gillitzer R, 1996, J INVEST DERMATOL, V107, P778, DOI 10.1111/1523-1747.ep12371803; Goebeler M, 1997, J INVEST DERMATOL, V108, P445, DOI 10.1111/1523-1747.ep12289711; Hendey B, 1996, BLOOD, V87, P2038; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; Kilgore KS, 1997, LAB INVEST, V76, P191; KUKIELKA GL, 1995, J CLIN INVEST, V95, P89, DOI 10.1172/JCI117680; Kumar NM, 1996, J CELL PHYSIOL, V169, P186, DOI 10.1002/(SICI)1097-4652(199610)169:1<186::AID-JCP19>3.3.CO;2-S; KUNSCH C, 1994, J IMMUNOL, V153, P153; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LO SK, 1993, AM J PHYSIOL, V264, pL406; LOOK DC, 1994, J BIOL CHEM, V269, P8952; Lukacs NW, 1997, J IMMUNOL, V158, P4398; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; MASSION PP, 1996, AM J PHYSIOL, V272, pL838; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; METINKO AP, 1992, J CLIN INVEST, V90, P791, DOI 10.1172/JCI115953; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; Munoz C, 1996, J IMMUNOL, V157, P3587; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; RIBEIRO MJA, 1995, THROMB RES, V79, P153, DOI 10.1016/0049-3848(95)00101-V; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; ROTHLEIN R, 1995, CIBA F SYMP, V189, P200; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSSO A, 1986, CANCER RES, V46, P2845; Saito T, 1997, J INFECT DIS, V175, P497, DOI 10.1093/infdis/175.3.497; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; Shono T, 1996, MOL CELL BIOL, V16, P4231; SICA A, 1990, IMMUNOLOGY, V69, P548; SMART SJ, 1993, AM J RESP CELL MOL, V9, P489, DOI 10.1165/ajrcmb/9.5.489; SMART SJ, 1994, AM J PHYSIOL, V266, pL238, DOI 10.1152/ajplung.1994.266.3.L238; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; Smith WB, 1996, J IMMUNOL, V157, P360; Song S, 1997, BLOOD, V89, P4461, DOI 10.1182/blood.V89.12.4461; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; Strieter RM, 1996, J IMMUNOL, V156, P3583; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; Tanaka C, 1997, BIOCHEM BIOPH RES CO, V232, P568, DOI 10.1006/bbrc.1997.6264; Tran MT, 1996, INVEST OPHTH VIS SCI, V37, P987; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WANG P, 1994, BLOOD, V83, P2678, DOI 10.1182/blood.V83.9.2678.bloodjournal8392678; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; XU YL, 1994, J INVEST DERMATOL, V102, P833, DOI 10.1111/1523-1747.ep12382086; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626	82	141	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32910	32918		10.1074/jbc.272.52.32910	http://dx.doi.org/10.1074/jbc.272.52.32910			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407069	hybrid			2022-12-25	WOS:000071182900030
J	Bae, H; Anderson, K; Flood, LA; Skiba, NP; Hamm, HE; Graber, SG				Bae, H; Anderson, K; Flood, LA; Skiba, NP; Hamm, HE; Graber, SG			Molecular determinants of selectivity in 5-hydroxytryptamine(1B) receptor-G protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; HETEROTRIMERIC G-PROTEINS; TRANSDUCIN ALPHA-SUBUNIT; GAMMA-SUBUNIT; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; CGMP PHOSPHODIESTERASE; GUANINE-NUCLEOTIDES; SYNTHETIC PEPTIDES; AGONIST BINDING	The recognition between G protein and cognate receptor plays a key role in specific cellular responses to environmental stimuli, Here we explore specificity in receptor-G protein coupling by taking advantage of the ability of the 5-hydroxytryptamine(1B) (5-HT1B) receptor to discriminate between G protein heterotrimers containing G alpha(i1) or G alpha(t). G(i1) can interact with the 5-HT1B receptor and stabilize a high affinity agonist binding state of this receptor, but G(t) cannot. A series of G alpha(t)/G alpha(i1) chimeric proteins have been generated in Escherichia coli, and their functional integrity has been reported previously (Skiba, N. P., Bae, H., and Hamm, H. E. (1996) J. Biol. Chem. 271, 413-424), We have tested the functional coupling abilities of the G alpha(t)/G alpha(i1) chimeras to 5-HT1B receptors using high affinity agonist binding and receptor-stimulated guanosine 5'-3-0-(thio)triphosphate (GTP gamma S) binding, In the presence of beta gamma subunits, amino acid residues 299-318 of G alpha(i1) increase agonist binding to the 5-HT1B receptor and receptor stimulation of GTP gamma S binding, Moreover, G alpha(i1) containing only G alpha(t) amino acid sequences from this region does not show any coupling ability to 5-HT1B receptors, Our studies suggest that the alpha 4 helix and alpha 4-beta 6 loop region of G alpha s are an important region for specific recognition between receptors and G(i) family members.	Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; W Virginia Univ, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; West Virginia University	Graber, SG (corresponding author), 3152 Hlth Sci N,POB 9223, Morgantown, WV 26506 USA.		Bae, Hyunsu/ABH-6248-2020; Hamm, Heidi E/G-2374-2014	Bae, Hyunsu/0000-0002-0299-3582	NEI NIH HHS [EY10291] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010291] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; ASANO T, 1985, J BIOL CHEM, V260, P2653; ASANO T, 1984, BIOCHEMISTRY-US, V23, P5460, DOI 10.1021/bi00318a013; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; Clawges HM, 1997, BIOCHEMISTRY-US, V36, P12930, DOI 10.1021/bi970112b; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Figler RA, 1996, MOL PHARMACOL, V50, P1587; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15162, DOI 10.1021/bi960757w; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; KERAVIS TM, 1991, EUR J PHARM-MOLEC PH, V207, P149, DOI 10.1016/0922-4106(91)90090-5; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE CH, 1995, MOL PHARMACOL, V47, P218; LEFKOWITZ RJ, 1976, J BIOL CHEM, V251, P4686; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; MAZZONI MR, 1991, J BIOL CHEM, V266, P1072; MIGEON JC, 1995, J BIOL CHEM, V270, P16070, DOI 10.1074/jbc.270.27.16070; MIGEON JC, 1994, J BIOL CHEM, V269, P9767; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; POBINER BF, 1991, MOL PHARMACOL, V40, P156; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; ROSSI GC, 1995, NEUROSCI LETT, V198, P99, DOI 10.1016/0304-3940(95)11977-5; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588	47	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32071	32077		10.1074/jbc.272.51.32071	http://dx.doi.org/10.1074/jbc.272.51.32071			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405403	hybrid, Green Published			2022-12-25	WOS:000071108000022
J	Brunn, GJ; Fadden, P; Haystead, TAJ; Lawrence, JC				Brunn, GJ; Fadden, P; Haystead, TAJ; Lawrence, JC			The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHAS-I; TRANSLATION INITIATION; INSULIN; CELLS; ADIPOCYTES; REGULATOR; COMPLEX; PATHWAY; BINDS	The eukaryotic initiation factor 4E (eIF4E)-binding protein, PHAS-I, was phosphorylated rapidly and stoichiometrically when incubated with [gamma-P-32]ATP and the mammalian target of rapamycin (mTOR) that had been immunoprecipitated with an antibody, mTAb1, directed against a region near the COOH terminus of mTOR. PHAS-I was phosphorylated more slowly by mTOR obtained either by immunoprecipitation with other antibodies or by affinity purification using a rapamycin/FKBP12 resin. Adding mTAb1 to either of these preparations of mTOR increased PHAS-I phosphorylation severalfold, indicating that mTAb1 activates the mTOR protein kinase. mTAb1-activated mTOR phosphorylated Thr(36), Thr(45), Ser(64), Thr(69), and Ser(82) in PHAS-I. All five of these sites fit a (Ser/Thr)-Pro motif and are dephosphorylated in response to rapamycin in rat adipocytes. Thus, our findings indicate that Pro is a determinant of the mTOR protein kinase specificity and that mTOR contributes to the phosphorylation of PHAS-I in cells.	Univ Virginia, Sch Med, Dept Pharmacol, Hlth Sci Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Lawrence, JC (corresponding author), Univ Virginia, Sch Med, Dept Pharmacol, Hlth Sci Ctr, Box 448, Charlottesville, VA 22908 USA.				NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052753, R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Fadden P, 1997, J BIOL CHEM, V272, P10240; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Kimball SR, 1996, AM J PHYSIOL-CELL PH, V270, pC705, DOI 10.1152/ajpcell.1996.270.2.C705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	26	143	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32547	32550		10.1074/jbc.272.51.32547	http://dx.doi.org/10.1074/jbc.272.51.32547			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405468	hybrid			2022-12-25	WOS:000071108000087
J	Communi, D; Govaerts, C; Parmentier, M; Boeynaems, JM				Communi, D; Govaerts, C; Parmentier, M; Boeynaems, JM			Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE NUCLEOTIDE RECEPTOR; FUNCTIONAL EXPRESSION; MEDIATED INHIBITION; TISSUE DISTRIBUTION; MOLECULAR-CLONING; NG108-15 CELLS; ATP RECEPTOR; CHO-K1 CELLS; CYCLIC-AMP; PURINOCEPTOR	Clones encoding a new human P2Y receptor, provisionally called P2Y(11), have been isolated from human placenta complementary DNA and genomic DNA libraries, The 1113-base pair open reading frame is interrupted by one intron, The P2Y(11) receptor is characterized by considerably larger second and third extracellular loops than the subtypes described so far. The deduced amino acid sequence exhibits 33% amino acid identity with the P2Y(1) receptor, its closest homolog. Northern blot analysis detected human P2Y(11) receptor messenger RNA in spleen and HL-60 cells. The level of P2Y(11) transcripts was strongly increased in these cells after granulocyte differentiation induced by retinoic acid or dimethyl sulfoxide. The new receptor was stably expressed in 1321N1 astrocytoma and CHO-K1 cells, where it couples to the stimulation of both the phosphoinositide and adenylyl cyclase pathways, a unique feature among the P2Y family. The rank order of agonists potency was: ATP > 8-methylthio-ATP >>> ADP, whereas UTP and UDP were inactive, indicating that it behaves as a selective purinoceptor.	Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Free Univ Brussels, Hop Erasme, Dept Med Chem, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Communi, D (corresponding author), Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, Campus Erasme,Bldg C,5th Floor,Route Lennik 808, B-1070 Brussels, Belgium.			Parmentier, Marc/0000-0001-8081-4685				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; BLAINEAU C, 1983, EMBO J, V11, P2007; Bogdanov YD, 1997, J BIOL CHEM, V272, P12583, DOI 10.1074/jbc.272.19.12583; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; COMMUNI D, 1995, CIRC RES, V76, P191, DOI 10.1161/01.RES.76.2.191; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; Communi D, 1996, EUR J PHARMACOL, V317, P383, DOI 10.1016/S0014-2999(96)00740-6; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; Godecke S, 1996, AM J PHYSIOL-CELL PH, V270, pC570, DOI 10.1152/ajpcell.1996.270.2.C570; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; Janssens R, 1996, BIOCHEM BIOPH RES CO, V221, P588, DOI 10.1006/bbrc.1996.0640; Janssens R, 1997, BIOCHEM BIOPH RES CO, V236, P106, DOI 10.1006/bbrc.1997.6895; Jiang LL, 1997, BIOCHEM BIOPH RES CO, V232, P626, DOI 10.1006/bbrc.1997.6345; Leon C, 1997, FEBS LETT, V403, P26, DOI 10.1016/S0014-5793(97)00022-7; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MATSUOKA I, 1995, MOL PHARMACOL, V47, P855; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Schachter JB, 1997, BRIT J PHARMACOL, V121, P338, DOI 10.1038/sj.bjp.0701136; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; Song SL, 1996, BRAIN RES, V734, P243, DOI 10.1016/0006-8993(96)00645-2; THEKKUMKARA TJ, 1995, MOL CELL BIOCHEM, V152, P77; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; Webb TE, 1996, MOL PHARMACOL, V50, P258; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	33	297	305	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31969	31973		10.1074/jbc.272.51.31969	http://dx.doi.org/10.1074/jbc.272.51.31969			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405388	hybrid			2022-12-25	WOS:000071108000007
J	Gibson, RM; Taylor, SS				Gibson, RM; Taylor, SS			Dissecting the cooperative reassociation of the regulatory and catalytic subunits of cAMP-dependent protein kinase - Role of Trp-196 in the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CYCLIC-AMP; BINDING-SITES; ESCHERICHIA-COLI; SKELETAL-MUSCLE; HOLOENZYME FORMATION; KINETIC-ANALYSIS; EXPRESSION; INHIBITOR; MUTATIONS	The catalytic (C) subunit of cAMP-dependent protein kinase requires two distinct surfaces to form a stable complex with its physiological inhibitors, the regulatory (R) subunits and the heat-stable protein kinase inhibitors. In addition to a substrate-like segment that is common to both inhibitors, R requires a peripheral recognition site, PRS2. This surface is comprised of the essential phosphorylation site, Thr-197, His-87, Trp-196, and several surrounding basic residues. To probe the role of Trp-196 in the recognition of R, Trp-196 was replaced with Arg and Ala. Although both rC(W196A) and rC(W196R) were inhibited readily with cAMP-free R, they failed to form an inhibited holoenzyme complex with native R under conditions in which wild-type holoenzyme formed readily. Pairing rC(W196R) with mutant forms of R lacking domain B or having defects in cAMP binding sites A or B highlighted the importance of the conformation of R, and, in particular, the accessibility of site A. One of these mutants, rR(R333K), having a defect in cAMP binding site B formed a stable complex with rC(W196R) in the absence of cAMP. However, unlike wild-type holoenzyme, this complex was active.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	staylor@ucad.edu	Gibson, Robin/A-6841-2009		NCI NIH HHS [T32 CA0952223-08] Funding Source: Medline; NIGMS NIH HHS [GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P5997, DOI 10.1021/bi00393a008; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BUBIS J, 1988, BIOCHEMISTRY-US, V27, P1570, DOI 10.1021/bi00405a026; BUECHLER YJ, 1993, J BIOL CHEM, V268, P16495; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Cox S, 1995, BIOCHEMISTRY-US, V34, P16203, DOI 10.1021/bi00049a036; COX S, 1994, J BIOL CHEM, V269, P22614; DOSTMANN WRG, 1995, FEBS LETT, V375, P231, DOI 10.1016/0014-5793(95)01201-O; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEN DA, 1991, BIOCHEMISTRY-US, V30, P3035; LEVIN LR, 1988, SCIENCE, V240, P68, DOI 10.1126/science.2832943; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; Narayana N, 1997, STRUCTURE, V5, P921, DOI 10.1016/S0969-2126(97)00246-3; Narayana N, 1997, BIOCHEMISTRY-US, V36, P4438, DOI 10.1021/bi961947+; OGREID D, 1981, FEBS LETT, V129, P282, DOI 10.1016/0014-5793(81)80184-6; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OGREID D, 1989, EUR J BIOCHEM, V181, P19; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; POTTER RL, 1978, ARCH BIOCHEM BIOPHYS, V190, P174, DOI 10.1016/0003-9861(78)90265-5; RIGHETTI PG, 1983, LABORATORY TECHNIQUE, P148; RINGHEIM GE, 1988, J BIOL CHEM, V263, P18247; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; WALSH DA, 1990, CRC CRIT REV BIOCH, P43; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WELDON SL, 1985, J BIOL CHEM, V260, P4203; WEN W, 1994, J BIOL CHEM, V269, P8423; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YONEMOTO W, 1997, IN PRESS PROTEIN ENG; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	53	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31998	32005		10.1074/jbc.272.51.31998	http://dx.doi.org/10.1074/jbc.272.51.31998			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405392	hybrid			2022-12-25	WOS:000071108000011
J	Ollendorf, V; Donoghue, DJ				Ollendorf, V; Donoghue, DJ			The serine/threonine phosphatase PP5 interacts with CDC16 and CDC27, two tetratricopeptide repeat-containing subunits of the anaphase-promoting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; MAMMALIAN-CELLS; PROTEIN-KINASE; HUMAN HOMOLOG; S-PHASE; MITOSIS; YEAST; PROTEOLYSIS; IDENTIFICATION; GENE	The evolutionarily conserved multisubunit complex known as the cyclosome or anaphase-promoting complex is involved in catalyzing the ubiquitination of diverse substrates in M phase, allowing their destruction by the 26 S proteasome and the completion of mitosis, Three of the eight subunits of the anaphase-promoting complex (CDC16, CDC23, and CDC27) have been shown to be phosphorylated in M phase, and their phosphorylation is required for the anaphase-promoting complex to be active as a ubiquitin ligase, Several subunits of the anaphase-promoting complex contain tetratricopeptide repeats, a protein motif involved in protein/protein interactions, PP5 is a serine/threonine phosphatase that also contains four copies of the tetratricopeptide repeats motif, Here we show by a combination of two-hybrid analysis and in vitro binding that PP5 interacts with CDC16 and CDC27, two subunits of the anaphase-promoting complex, Only the NH2-terminal domain of PP5, containing all four tetratricopeptide repeats, is required for this physical interaction, Deletion analysis suggests that the site of binding to PP5 is localized to the COOH-terminal block of tetratricopeptide repeats in CDC16 and CDC27, In addition, indirect immunofluorescence showed that PP5 localizes to the mitotic spindle apparatus, The direct interaction of PP5 with CDC16 and CDC27, as well as its overlapping spindle localization in mitosis, suggests that PP5 may be involved in the regulation of the activity of the anaphase-promoting complex.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Donoghue, DJ (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 6114 Urey Hall,9500 Gilman Dr, La Jolla, CA 92093 USA.			Ollendorff, Vincent/0000-0001-9751-2202	NATIONAL CANCER INSTITUTE [R01CA034456] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BECKER W, 1994, J BIOL CHEM, V269, P22586; BLANC S, 1993, VIROLOGY, V192, P651, DOI 10.1006/viro.1993.1081; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JAMES SW, 1995, J CELL SCI, V108, P3485; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xu XL, 1996, BIOCHEM BIOPH RES CO, V218, P514, DOI 10.1006/bbrc.1996.0092; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	43	65	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32011	32018		10.1074/jbc.272.51.32011	http://dx.doi.org/10.1074/jbc.272.51.32011			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405394	Green Published, hybrid			2022-12-25	WOS:000071108000013
J	Gringhuis, SI; deLeij, LFMH; Wayman, GA; Tokumitsu, H; Vellenga, E				Gringhuis, SI; deLeij, LFMH; Wayman, GA; Tokumitsu, H; Vellenga, E			The Ca2+/calmodulin-dependent kinase type IV is involved in the CD5-mediated signaling pathway in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INTRACELLULAR IONIZED CALCIUM; ANTIGEN RECEPTOR COMPLEX; TRANSCRIPTION FACTOR; GENE-EXPRESSION; C-JUN; RESPONSE ELEMENT; ACTIVATED LYMPHOCYTES; CELL-PROLIFERATION; TYROSINE KINASES	The CD5 receptor on T lymphocytes is involved in T cell activation and T-B cell interactions. In the present study, we have characterized the signaling pathways induced by anti-CD5 stimulation in human T lymphocytes, In T lymphocytes, anti-CD5 co-stimulation enhances the phytohemagglutinin/anti-CD28-induced interleukin-2 (IL-2) mRNA accumulation 1.6-fold and IL-2 protein secretion 2.2-fold, whereby the up-regulation is mediated at both the transcriptional and post-transcriptional level. The CD5 signaling pathway up-regulates the IL-2 gene expression by increasing the DNA binding and transactivation activity of activator protein 1 but affects none of the other transcription factors like nuclear factor of activated T cells, nuclear factor kappa B, OCt, and CD28-responsive complex/nuclear factor of mitogen-activated T cells involved in the regulation of the IL-2 promoter activity. The CD5-induced increase of the activator protein 1 activity is mediated through the activation of calcium/calmodulin-dependent (CaM) kinase type IV, and is independent of the activation of mitogen-activated protein kinases Jun N-terminal kinase, extracellular signal-regulated kinase, and p38/Mpk2, and calcium/calmodul-independent kinase type IL The expression of a dominant negative mutant of CaM kinase IV in T Iymphocytes transfected with an IL-2 promoter-driven reporter construct completely abrogates the response to CD5 stimulation, indicating that CaM kinase IV is essential to the CD5 signaling pathway, In addition, it is demonstrated that calciuml/calmodulin-dependent kinase type IV is also involved in the stabilization of the IL-2 transcripts, which is observed after co-stimulation of phytohemagglutinin/anti-CD28 activated T lymphocytes with anti-CD5.	UNIV GRONINGEN, DIV HEMATOL, DEPT INTERNAL MED, NL-9713 GZ GRONINGEN, NETHERLANDS; UNIV GRONINGEN, DIV CLIN IMMUNOL, DEPT INTERNAL MED, NL-9713 GZ GRONINGEN, NETHERLANDS; OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	University of Groningen; University of Groningen; Oregon Health & Science University			; Tokumitsu, Hiroshi/M-3978-2015	Gringhuis, Sonja/0000-0003-0383-4978; Tokumitsu, Hiroshi/0000-0002-2193-6794				ALBEROLAILA J, 1992, J IMMUNOL, V148, P1287; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; Biancone L, 1996, J EXP MED, V184, P811, DOI 10.1084/jem.184.3.811; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cerutti A, 1996, J IMMUNOL, V157, P1854; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; Civil A, 1996, J BIOL CHEM, V271, P8321, DOI 10.1074/jbc.271.14.8321; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAMBROSIO D, 1993, EUR J IMMUNOL, V23, P2993, DOI 10.1002/eji.1830231140; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Ishida A, 1996, BBA-MOL CELL RES, V1311, P211, DOI 10.1016/0167-4889(95)00197-2; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, J IMMUNOL, V148, P1240; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; JUNE CH, 1987, J IMMUNOL, V138, P2782; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LEDERER JA, 1994, J IMMUNOL, V152, P77; LI GD, 1992, MOL PHARMACOL, V42, P489; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NOBES CD, 1995, J CELL SCI, V108, P225; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OSMAN N, 1992, EUR J IMMUNOL, V22, P2995, DOI 10.1002/eji.1830221135; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PARK JH, 1993, J BIOL CHEM, V268, P6299; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; SIHRA TS, 1995, NEUROPHARMACOLOGY, V34, P731, DOI 10.1016/0028-3908(95)00051-7; SPERTINI F, 1991, J IMMUNOL, V146, P47; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; THOMAS Y, 1984, J IMMUNOL, V133, P724; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VAN DE VELDE H, 1991, NATURE, V351, P662; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VELLENGA E, 1988, BLOOD, V71, P1529; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xia ZG, 1996, J NEUROSCI, V16, P5425; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	86	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31809	31820		10.1074/jbc.272.50.31809	http://dx.doi.org/10.1074/jbc.272.50.31809			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395527	hybrid			2022-12-25	WOS:A1997YL41900086
J	Huang, CF; Wong, GW; Ghildyal, N; Gurish, MF; Sali, A; Matsumoto, R; Qiu, WT; Stevens, RL				Huang, CF; Wong, GW; Ghildyal, N; Gurish, MF; Sali, A; Matsumoto, R; Qiu, WT; Stevens, RL			The tryptase, mouse mast cell protease 7, exhibits anticoagulant activity in vivo and in vitro due to its ability to degrade fibrinogen in the presence of the diverse array of protease inhibitors in plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CHAIN; COMPLEMENTARY-DNA; ENDOTHELIAL-CELLS; PURIFICATION; CLONING; IDENTIFICATION; EXPRESSION; PEPTIDE; AIRWAY; GENE	Mouse mast cell protease (mMCP) 7 is a tryptase of unknown function expressed by a subpopulation of mast cells that reside in numerous connective tissue sites. Because enzymatically active mMCP-7 is selectively released into the plasma of V3 mastocytosis mice undergoing passive systemic anaphylaxis, we used this in vivo model system to identify a physiologic substrate of the tryptase. Plasma samples taken from V3 mastocytosis mice that had been sensitized with immunoglobulin (Ig) E and challenged with antigen were found to contain substantial amounts of four 34-55-kDa peptides, all of which were derived from fibrinogen. To confirm the substrate specificity of mMCP-7, a pseudozymogen form of the recombinant tryptase was generated that could be activated after its purification, The resulting 1 recombinant mMCP-7 exhibited potent anticoagulant activity in the presence of normal plasma and selectively cleaved the a-chain of fibrinogen to fragments of similar size as that seen in the plasma of the IgE/antigen-treated V3 mastocytosis mouse. Subsequent analysis of a tryptase-specific, phage display peptide library revealed that recombinant mMCP-7 preferentially cleaves an amino acid sequence that is nearly identical to that in the middle of the alpha-chain of rat fibrinogen. Because fibrinogen is a physiologic substrate of mMCP-7, this tryptase can regulate clot formation and fibrinogen/integrin-dependent cellular responses during mast cell-mediated inflammatory reactions.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RHEUMATOL ALLERGY & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; ROCKEFELLER UNIV,NEW YORK,NY 10021	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Rockefeller University				Wong, G. William/0000-0002-5286-6506	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, R01AI023483, U19AI031599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054762, R01GM054762] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31599, AI-23483] Funding Source: Medline; NIGMS NIH HHS [GM-54762] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAGANZA VJ, 1991, BIOCHEMISTRY-US, V30, P4997, DOI 10.1021/bi00234a023; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; BROWN B, 1988, HEMATOLOGY PRINCIPLE, P219; Cairns JA, 1996, J IMMUNOL, V156, P275; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P1333; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; CRABTREE GR, 1985, J MOL BIOL, V185, P1, DOI 10.1016/0022-2836(85)90179-2; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; DIEM K, 1970, SCI TABLES, P579; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FRANCONI GM, 1989, J PHARMACOL EXP THER, V248, P947; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GRANT RA, 1981, J BIOL CHEM, V256, P539; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; Gruber BL, 1997, J IMMUNOL, V158, P2310; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; GURISH MF, 1993, J BIOL CHEM, V268, P11372; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HAWIGER J, 1995, SEMIN HEMATOL, V32, P99; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IDE H, 1995, J BIOCHEM-TOKYO, V118, P210, DOI 10.1093/oxfordjournals.jbchem.a124880; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; LAM SCT, 1987, J BIOL CHEM, V262, P947; LIGHT A, 1989, TRENDS BIOCHEM SCI, V14, P110, DOI 10.1016/0968-0004(89)90133-3; LUTZELSCHWAB C, 1996, J EXP MED, V185, P13; MAIER M, 1983, J IMMUNOL, V130, P2352; MARGUERIE GA, 1984, EUR J BIOCHEM, V139, P5, DOI 10.1111/j.1432-1033.1984.tb07968.x; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MEKORI YA, 1990, J IMMUNOL, V145, P3719; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; MURAKUMO Y, 1995, BIOCHEM J, V309, P921, DOI 10.1042/bj3090921; PERONA JJ, 1993, J MOL BIOL, V230, P919, DOI 10.1006/jmbi.1993.1210; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SALI A, 1993, J BIOL CHEM, V268, P9023; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STACK MS, 1994, J BIOL CHEM, V269, P9416; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Svendsen L., 1972, THROMB RES, V1, P267, DOI 10.1016/0049-3848(72)90023-0; Thiagarajan P, 1996, BIOCHEMISTRY-US, V35, P4169, DOI 10.1021/bi952532b; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; WALLS AF, 1992, BIOCHEM PHARMACOL, V43, P1243, DOI 10.1016/0006-2952(92)90498-8	61	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31885	31893		10.1074/jbc.272.50.31885	http://dx.doi.org/10.1074/jbc.272.50.31885			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395536	hybrid			2022-12-25	WOS:A1997YL41900095
J	Nagy, JM; Cass, AEG; Brown, KA				Nagy, JM; Cass, AEG; Brown, KA			Purification and characterization of recombinant catalase-peroxidase, which confers isoniazid sensitivity in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID SYNTHESIS; NEW-YORK-CITY; ESCHERICHIA-COLI; RESISTANT TUBERCULOSIS; FRONT-LINE; GENE; DRUG; EXPRESSION; KATG; ETHIONAMIDE	The Mycobacterium tuberculosis katG gene encodes a dual-function enzyme called catalase-peroxidase, which confers sensitivity in M. tuberculosis to isonicotinic acid hydrazide. We have constructed a system for the high level expression of a recombinant form of this enzyme by amplifying the katG gene from the pYZ56 construct (1) and subcloning into a vector suitable for expression in Escherichia coli, The resulting plasmid, pTBCP, produced the catalase-peroxidase in large quantities, corresponding to 30% of total cell protein. The enzyme has been purified to homogeneity and appears to be a dimer in the native form, Using either hydrogen peroxide or t-butyl hydroperoxide and 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) as substrates, k(cat) and K-m values have been obtained for both catalatic and peroxidatic activities, respectively. The availability of significant quantities of an active, folded, recombinant form of M. tuberculosis catalase-peroxidase should thus facilitate future studies of its role in drug activation and antibiotic resistance.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND	Imperial College London								AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Basso LA, 1996, J AM CHEM SOC, V118, P11301, DOI 10.1021/ja962035y; Becker R, 1974, METHODS ENZYMATIC AN, V3, P286; BEERS RF, 1952, J BIOL CHEM, V195, P133; BEKIERKUNST A, 1967, ARCH BIOCHEM BIOPHYS, V122, P385, DOI 10.1016/0003-9861(67)90209-3; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; DAVIS WB, 1977, ANTIMICROB AGENTS CH, V12, P213, DOI 10.1128/AAC.12.2.213; Deretic V, 1996, NAT BIOTECHNOL, V14, P1557, DOI 10.1038/nbt1196-1557; DEVI BG, 1975, BIOCHEM J, V149, P187, DOI 10.1042/bj1490187; DIAZ GA, 1974, AM REV RESPIR DIS, V110, P312, DOI 10.1164/arrd.1974.110.3.312; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FUKUMORI Y, 1985, J BIOCHEM-TOKYO, V98, P1055, DOI 10.1093/oxfordjournals.jbchem.a135352; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; HOCHMAN A, 1987, J BIOL CHEM, V262, P6871; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; LOPRASERT S, 1989, J BACTERIOL, V171, P4871, DOI 10.1128/jb.171.9.4871-4875.1989; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V69, P471; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; NADLER V, 1986, BIOCHIM BIOPHYS ACTA, V882, P234, DOI 10.1016/0304-4165(86)90160-1; NAKANE PK, 1966, J HISTOCHEM CYTOCHEM, V14, P929, DOI 10.1177/14.12.929; NIES D, 1982, J GEN APPL MICROBIOL, V28, P311, DOI 10.2323/jgam.28.311; OGURA Y, 1955, ARCH BIOCHEM BIOPHYS, V57, P288, DOI 10.1016/0003-9861(55)90291-5; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; Quemard A, 1996, J AM CHEM SOC, V118, P1561, DOI 10.1021/ja950998b; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; RAINE BLT, 1988, J BACTERIOL, V170, P4415; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; SRIPRAKASH KS, 1970, J GEN MICROBIOL, V60, P125, DOI 10.1099/00221287-60-1-125; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TAKAYAMA K, 1979, ANTIBIOTICS, P98; WAYNE LG, 1986, ANAL BIOCHEM, V157, P89, DOI 10.1016/0003-2697(86)90200-9; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Wilson TM, 1996, MOL MICROBIOL, V19, P1025, DOI 10.1046/j.1365-2958.1996.449980.x; Winder F, 1982, BIOL MYCOBACTERIA, V1, P354; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WOODBURY W, 1971, ANAL BIOCHEM, V44, P301, DOI 10.1016/0003-2697(71)90375-7; YOUATT J, 1969, AM REV RESPIR DIS, V99, P729; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x; Zhang Ying, 1993, Trends in Microbiology, V1, P109, DOI 10.1016/0966-842X(93)90117-A	53	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31265	31271		10.1074/jbc.272.50.31265	http://dx.doi.org/10.1074/jbc.272.50.31265			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395452	hybrid			2022-12-25	WOS:A1997YL41900011
J	Tornaletti, S; Donahue, BA; Reines, D; Hanawalt, PC				Tornaletti, S; Donahue, BA; Reines, D; Hanawalt, PC			Nucleotide sequence context effect of a cyclobutane pyrimidine dimer upon RNA polymerase II transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; ELONGATION COMPLEX; EXCISION-REPAIR; ACTIVE GENE; DHFR GENE; STRAND; TRANSLOCATION; CLEAVAGE; REMOVAL; ADDUCTS	We have studied the role of sequence context upon RNA polymerase II arrest by a cyclobutane pyrimidine dimer using an in vitro transcription system consisting of templates containing a specifically located cyclobutane pyrimidine dimer (CPD) and purified RNA polymerase II (RNAP II) and initiation factors, We selected a model sequence containing a well characterized site for RNAP II arrest in vitro, the human histone H3.3 gene arrest site, The 13-base pair core of the arrest sequence contains two runs of T in the nontranscribed strand that impose a bend in the DNA. We hypothesized that arrest of RNAP II might be affected by the presence of a CPD, based upon the observation that a CPD located at the center of a dA(6).dT(6) tract eliminates bending (Wang, C.-I., and Taylor, J.-S. (1991) Proc. Natl. Acad Sci. U. S. A. 88, 9072-9076). We examined the normal H3.3 sequence and a mutant sequence containing a T --> G transversion, which reduces bending and efficiency of arrest, We show that a CPD in the transcribed strand at either of two locations in the arrest site is a potent block to transcription, However, a CPD in the nontranscribed strand only transiently pauses RNAP II. The CPD in concert with a mutation in the arrest site can reduce the extent of bending of the DNA and improve readthrough efficiency. These results demonstrate the potential importance of sequence context for the effect of CPDs within transcribed sequences.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Stanford University; Emory University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NCI NIH HHS [CA44349, R01 CA077712] Funding Source: Medline; NIGMS NIH HHS [R01 GM046331] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044349, R01CA077712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Donahue BA, 1996, J BIOL CHEM, V271, P10588, DOI 10.1074/jbc.271.18.10588; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; HANAWALT PC, 1991, MUTAT RES, V247, P203, DOI 10.1016/0027-5107(91)90016-H; KAHN M, 1974, BIOPOLYMERS, V13, P669, DOI 10.1002/bip.1974.360130403; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KIM SH, 1988, BIOCHEM PHARMACOL, V37, P1791, DOI 10.1016/0006-2952(88)90448-0; KUNALA S, 1992, P NATL ACAD SCI USA, V89, P11031, DOI 10.1073/pnas.89.22.11031; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LEADON SA, 1992, J BIOL CHEM, V267, P23175; Mann DB, 1997, P NATL ACAD SCI USA, V94, P2215, DOI 10.1073/pnas.94.6.2215; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; ORDOUKHANIAN P, 1997, IN PRESS NUCL ACIDS; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Tommasi S, 1996, BIOCHEMISTRY-US, V35, P15693, DOI 10.1021/bi962117z; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WEI D, 1995, P NATL ACAD SCI USA, V92, P2204, DOI 10.1073/pnas.92.6.2204	37	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31719	31724		10.1074/jbc.272.50.31719	http://dx.doi.org/10.1074/jbc.272.50.31719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395515	Green Accepted, hybrid			2022-12-25	WOS:A1997YL41900074
J	El-Shemerly, MYM; Besser, D; Nagasawa, M; Nagamine, Y				El-Shemerly, MYM; Besser, D; Nagasawa, M; Nagamine, Y			12-O-tetradecanoylphorbol-13-acetate activates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway upstream of SOS involving serine phosphorylation of Shc in NIH3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE-T ANTIGEN; PROTEIN-KINASE; GENE-EXPRESSION; RAS; TRANSDUCTION; TRANSFORMATION; DOMAINS; MANNER; RAF-1; DELTA	We investigated the activation of the Ras/ERK signaling pathway by 12-O-tetradecanoylphorbol-13-acetate (TPA) in NIH3T3 fibroblasts, Interestingly, the activation was suppressed not only by dominant negative Raf-1 but also by dominant negative Ras and SOS. Further analysis revealed that TPA treatment induced, dependently on protein kinase C, the mobility shift of p6(shc) in SDS-polyacrylamide gel electrophoresis, which could be prevented by treatment of the Shc immunoprecipitate with serine/threonine specific protein phosphatase 1 (PP1) or 2A (PPSA), Phosphoamino acid analysis of Shc showed that unlike growth factor-induced Shc phosphorylation, where Shc is mainly phosphorylated at tyrosine residues, TPA-induced phosphorylation was only at serine residues, Like growth factor-induced Shc phosphorylation, which leads to the association of Shc with Grb2, TPA also induced this association, but, correspondingly to the above results, the TPA-induced association was disrupted by in vitro treatment of the Shc immunoprecipitate with PP1, Taken together, these results suggest that the TPA signal was fed at or upstream of Shc to activate the Ras/ERK signaling pathway involving serine phosphorylation of Shc.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Nagamine, Y (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	nagamine@fmi.ch	Besser, Daniel/A-8304-2012	Besser, Daniel/0000-0002-4958-9624				ADCOCK MR, 1992, NATURE, V360, P689; Besser D, 1995, ONCOGENE, V11, P2383; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEREZ L, 1995, VIROLOGY, V208, P26, DOI 10.1006/viro.1995.1126; SALCINI AE, 1994, ONCOGENE, V9, P2827; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915	30	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30599	30602		10.1074/jbc.272.49.30599	http://dx.doi.org/10.1074/jbc.272.49.30599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388190	hybrid			2022-12-25	WOS:000071640800003
J	Emkey, R; Kahn, CR				Emkey, R; Kahn, CR			Cross-talk between phorbol ester-mediated signaling and tyrosine kinase proto-oncogenes I. Activation of protein kinase C stimulates tyrosine phosphorylation and activation of ErbB2 and ErbB3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; HUMAN-BREAST-CANCER; INSULIN-RECEPTOR; ENDOGENOUS SUBSTRATE; PHOSPHATIDYLINOSITOL 3'-KINASE; TRANSFORMED CELLS; EPITHELIAL-CELLS; TUMOR-CELLS; ECTO-ATPASE	The tumor-promoting phorbol ester, phorbol 12 myristate 13-acetate (PMA), acutely stimulates the tyrosine phosphorylation of proteins of approximately 190, 120, and 70 kDa in the well differentiated Fao rat hepatoma cell line, This phosphorylation is dependent on protein kinase C (PKC) and is abolished by down-regulation of PKC or pretreatment with a PKC inhibitor, Purification of the 190-kDa tyrosine phosphorylated protein revealed that it consists of both ErbB2 and ErbB3, Following PMA-induced tyrosine phosphorylation, ErbB2 and ErbB3 were able to associate with the SH2 domains of several signaling proteins including the p85 alpha subunit of phosphatidylinositol S-kinase, Syp, and Grb2, The 120-kDa protein phosphorylated in response to PMA consists of at least two proteins: focal adhesion kinase that exhibits a minor increase in tyrosine phosphorylation following treatment with PMA, and a major 120-kDa tyrosine-phosphorylated species in PMA-stimulated Fao cells which as yet is unidentified, Similarly, the 70 kDa tyrosine phosphorylated protein also appears to represent more than one protein, including paxillin and a second protein of similar mobility which appears to be the major tyrosine phosphorylation in response to PMA, Both ErbB2 and paxillin also exhibit reduced migration on SDS-polyacrylamide gel electrophoresis following PMA treatment, suggesting that they are also phosphorylated on serine/threonine residues, The mobility shift of both of these proteins is abolished by treatment with inhibitors of PKC or mitogen-activated protein kinase/extracellular signal-related kinase kinase, These results suggest a novel mechanism of cross-talk between the serine/threonine kinase PKC and tyrosine phosphorylation pathways, The activation of ErbB2 and ErbB3 that is initiated by PMA may contribute to the tumor promoting activity of these compounds.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Kahn, CR (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1986, ENDOCRINOLOGY, V119, P1274, DOI 10.1210/endo-119-3-1274; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BELL RM, 1991, J BIOL CHEM, V266, P4661; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Cohen BM, 1996, J BIOL CHEM, V271, P4813; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DICKER P, 1979, J SUPRAMOL STR CELL, V11, P79, DOI 10.1002/jss.400110109; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; EARP HS, 1995, J BIOL CHEM, V270, P28440; Emkey R, 1997, J BIOL CHEM, V272, P31182, DOI 10.1074/jbc.272.49.31182; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GRUNBERGER G, 1984, P NATL ACAD SCI-BIOL, V81, P2762, DOI 10.1073/pnas.81.9.2762; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MCMANUS MJ, 1995, J VIROL, V69, P3631, DOI 10.1128/JVI.69.6.3631-3638.1995; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOON SO, 1984, P NATL ACAD SCI-BIOL, V81, P2298, DOI 10.1073/pnas.81.8.2298; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NAJJAR SM, 1993, ADV EXP MED BIOL, V343; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; OGAWA W, 1995, ENDOCRINOLOGY, V136, P476, DOI 10.1210/en.136.2.476; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; SEGATTO O, 1993, ONCOGENE, V8, P2105; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	77	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31172	31181		10.1074/jbc.272.49.31172	http://dx.doi.org/10.1074/jbc.272.49.31172			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388271	hybrid			2022-12-25	WOS:000071640800084
J	Rodgers, AJW; Wilkens, S; Aggeler, R; Morris, MB; Howitt, SM; Capaldi, RA				Rodgers, AJW; Wilkens, S; Aggeler, R; Morris, MB; Howitt, SM; Capaldi, RA			The subunit delta subunit b domain of the Escherichia coli F(1)F(0)ATPase - The b subunits interact with F-1 as a dimer and through the delta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; ATP-SYNTHASE; H+-ATPASE; OXIDATIVE-PHOSPHORYLATION; EPSILON-SUBUNITS; CATALYTIC SITES; GAMMA-SUBUNITS; UNC OPERON; C-SUBUNIT; F1	The delta and b subunits are both involved in binding the F-1, to the F-0, part in the Escherichia coli ATP synthase (ECF1F0,). The interaction of the purified delta subunit and the isolated hydrophilic domain of the b subunit (b(sol),,,) has been studied here. Purified delta binds to b(sol),,, weakly in solution, as indicated by NMR studies and protease protection experiments. On F-1,, i.e. in the presence of ECF1-delta,, delta, and b(sol),,, interact strongly, and a complex of ECF1 . b(sol), b(sol),,, can be isolated by native gel electrophoresis. Both delta subunit and b(sol),,, are protected from trypsin cleavage in this complex. In contrast, the delta subunit is rapidly degraded by the protease when bound to ECF1, when b(sol),,, is absent. The interaction of b(sol),,, with ECF1, involves the C-terminal domain of delta as delta((1-134)), cannot replace intact delta in the binding experiments. As purified, b(sol),,, is a stable dimer with 80% alpha helix. A monomeric form of b(sol),,, can be obtained by introducing the mutation A128D (Howitt, S. M., Rodgers, A. J.,W., Jeffrey, P. D., and Cox, G., B. (1996) J. Biol. Chem. 271, 7038-7042). Monomeric b(sol),,, has less cu helix, i.e. only 58%, is much more sensitive to trypsin cleavage than dimer, and unfolds at much lower temperatures than the dimer in circular dichroism melting studies, indicating a less stable structure. The b(sol),,, dimer, but not monomer, binds to delta in ECF1,. To examine whether subunit b is a monomor or dimer in intact ECF1F0,, CuCl2, was used to induce cross-link formation in the mutants bS60C, bQ104C, bA128C, bG131C, and bS146C. With the exception of bS60C, CuCl2, treatment resulted in formation of b subunit dimers in all mutants. Cross-linking yield was independent of nucleotide conditions and did not affect ATPase activity. These results show the b subunit to be dimeric for a large portion of the C terminus, with residues 124-131 likely forming a pair of parallel alpha helices.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Sydney, Dept Pharm, Sydney, NSW 2006, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia	University of Oregon; University of Sydney; Australian National University; John Curtin School of Medical Research	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	rcapaldi@oregon.uoregon.edu	Howitt, Susan M/C-9308-2009; Morris, Michael/AAP-6590-2021; Rodgers, Andrew/H-3527-2013; Rodgers, Andrew/AAT-8756-2021	Howitt, Susan M/0000-0002-2192-2317; Rodgers, Andrew/0000-0002-8897-6221; Rodgers, Andrew/0000-0003-2063-4521; Morris, Michael/0000-0002-1286-4784	NHLBI NIH HHS [HL22450] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; COX GB, 1983, BIOCHEM J, V216, P143, DOI 10.1042/bj2160143; DOWNIE JA, 1980, J BACTERIOL, V143, P8, DOI 10.1128/JB.143.1.8-17.1980; DUNN SD, 1992, J BIOL CHEM, V267, P7630; GIBSON F, 1978, J BACTERIOL, V134, P728, DOI 10.1128/JB.134.3.728-736.1978; GIBSON F, 1977, BIOCHEM J, V164, P193, DOI 10.1042/bj1640193; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; HATCH L, 1993, BIOCHIM BIOPHYS ACTA, V1141, P183, DOI 10.1016/0005-2728(93)90041-D; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; HOWITT SM, 1992, P NATL ACAD SCI USA, V89, P9799, DOI 10.1073/pnas.89.20.9799; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; JANS DA, 1983, BIOCHEM J, V211, P717, DOI 10.1042/bj2110717; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Joshi S, 1996, BIOCHEMISTRY-US, V35, P12094, DOI 10.1021/bi9612327; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	34	63	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31058	31064		10.1074/jbc.272.49.31058	http://dx.doi.org/10.1074/jbc.272.49.31058			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388256	hybrid			2022-12-25	WOS:000071640800069
J	Xu, HJ; Zhou, YL; Ji, W; Perng, GS; Kruzelock, R; Kong, CT; Bast, RC; Mills, GB; Li, J; Hu, SX				Xu, HJ; Zhou, YL; Ji, W; Perng, GS; Kruzelock, R; Kong, CT; Bast, RC; Mills, GB; Li, J; Hu, SX			Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition	ONCOGENE			English	Article						tumor suppressor gene; retinoblastoma (RB) gene; p53; senescence; telomerase	BREAST-CARCINOMA CELLS; REPLICATIVE SENESCENCE; HUMAN FIBROBLASTS; GENE-EXPRESSION; IMMORTAL CELLS; RB PROTEIN; P53 GENE; SUPPRESSION; APOPTOSIS; FAILURE	Normal human diploid cells senesce in vitro and in vivo after a limited number of cell divisions, This process known as cellular senescence is an underlying cause of aging and a critical barrier for development of human cancers, We demonstrate here that reexpression of functional pRB alone in RB/p53-defective tumor cells via a modified tetracycline-regulated gene expression system resulted in a stable growth arrest at the G0/G1 phase of the cell cycle, preventing tumor cells from entering S phase in response to a variety of mitogenic stimuli, These cells displayed multiple morphological changes consistent with cellular senescence and expressed a senescence-associated beta-galactosidase biomarker, Further studies indicated that telomerase activity, which was assumably essential for an extended proliferative life-span of neoplastic cells, was abrogated or repressed in the tumor cell lines after induction of pRB (but not p53) expression, Strikingly, when returned to an nonpermissive medium for pRB expression, the pRB-induced senescent tumor cells resumed DNA synthesis, attempted to divide but most died in the process, a phenomenon similar to postsenescent crisis of SV40 T-antigen-transformed human diploid fibroblasts in late passage, These observations provide direct evidence that overexpression of pRB alone in RB/p53-defective tumor cells is sufficient to reverse their immortality and cause a phenotype that is, by all generally accepted criteria, indistinguishable from replicative senescence, The results suggest that pRB may play a causal role in the intrinsic cellular senescence program.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT HEMATOL,DIV MED,THE WOODLANDS,TX 77381; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL ONCOL,DIV MED,HOUSTON,TX 77030; BEIJING INST GERIATR,DEPT BIOCHEM,BEIJING 100730,PEOPLES R CHINA; BEIJING UNION MED COLL HOSP,BEIJING 100730,PEOPLES R CHINA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Xu, HJ (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL ONCOL,4000 RES FOREST DR,THE WOODLANDS,TX 77381, USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NCI NIH HHS [CA67274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Berry DE, 1996, ONCOGENE, V12, P1809; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dawson D. W., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P88; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FUTREAL PA, 1991, ONCOGENE, V6, P1109; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, BIOTECHNIQUES, V19, P213; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Li J, 1996, ONCOGENE, V13, P2379; LINSKENS MHK, 1995, SCIENCE, V267, P17, DOI 10.1126/science.7848496; LU YM, 1994, ONCOGENE, V9, P1015; Lu YM, 1996, J IMMUNOL, V156, P2495; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1985, J CELL PHYSL, V125, P35; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WANG E, 1995, CANCER RES, V55, P2284; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837; XU HJ, 1991, ONCOGENE, V6, P1139; XU HJ, 1997, GENE THERAPY ADV PHA, V40, P233; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	37	132	139	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2589	2596		10.1038/sj.onc.1201446	http://dx.doi.org/10.1038/sj.onc.1201446			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399646				2022-12-25	WOS:A1997YG73200008
J	Monaco, L; SassoneCorsi, P				Monaco, L; SassoneCorsi, P			Cross-talk in signal transduction: Ras-dependent induction of cAMP-responsive transcriptional repressor ICER by nerve growth factor	ONCOGENE			English	Article						transcription factors; cyclic AMP; CREM; nerve growth factor; Ras; c-fos	INDUCED NEURONAL DIFFERENTIATION; LONG-TERM DESENSITIZATION; PROTO-ONCOGENE FOS; PC12 CELLS; TYROSINE PHOSPHORYLATION; MAP KINASE; CYCLIC-AMP; CREM GENE; NEURITE OUTGROWTH; EXPRESSION	The CREM gene encodes both activators and repressors of cAMP-induced transcription. By virtue of an alternative, intronic promoter within the gene, the ICER (Inducible cAMP Early Repressor) isoform is generated. ICER acts as a dominant negative regulator and is cAMP-inducible in various neuroendocrine cells and tissues. ICER negatively autoregulates its own expression, and appears to participate in the molecular events governing oscillatory hormonal regulations. Here we report that ICER is inducible with nerve growth factor (NGF). This is the first example of cAMP-independent induction of ICER expression. Importantly, induction by NGF occurs via a subset of the CREs present in the ICER promoter which were previously shown to direct cAMP-inducibility. ICER induction correlates with a NGF-mediated phosphorylation of CREB. Both CREB phosphorylation and ICER inducibility require an intact Ras-dependent signalling pathway. We show that increased ICER levels result in the attenuation of c-fos expression. The activation of a powerful repressor of cAMP-responsive transcription by NGF, whose transduction signalling is cAMP-independent, constitutes a notable example of nuclear cross-talk and thus is likely to have relevant physiological implications.	INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Monaco, Lucia/A-4031-2010					BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUKUDA M, 1995, ONCOGENE, V11, P239; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNIPPER M, 1993, FEBS LETT, V324, P147, DOI 10.1016/0014-5793(93)81382-A; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LALLI E, 1994, J BIOL CHEM, V269, P17356; Lamas M, 1997, MOL ENDOCRINOL, V11, P1415, DOI 10.1210/me.11.10.1415; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHUBERT D, 1980, BRAIN RES, V190, P67, DOI 10.1016/0006-8993(80)91160-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	46	42	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2493	2500		10.1038/sj.onc.1201636	http://dx.doi.org/10.1038/sj.onc.1201636			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395245				2022-12-25	WOS:A1997YE96300011
J	Sokolowski, M; Zhao, CP; Tan, W; Schwartz, S				Sokolowski, M; Zhao, CP; Tan, W; Schwartz, S			AU-rich mRNA instability elements on human papillomavirus type 1 late mRNAs and c-fos mRNAs interact with the same cellular factors	ONCOGENE			English	Article						HPV-1; c-fos; RNA stability; hnRNPC	HUMAN-IMMUNODEFICIENCY-VIRUS; MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; OPEN READING FRAME; REV GENE-PRODUCT; 3'-UNTRANSLATED REGION; BINDING PROTEINS; DNA-REPLICATION; NUCLEAR; SEQUENCE	Expression levels of human papillomavirus type 1 late genes are determined in part by an AU-rich inhibitory sequence in the 3' untranslated region on the late mRNAs. Fine mapping of the AU rich inhibitory sequence revealed that it mapped to a 57 nucleotide sequence, consisting of an AU-rich region containing two AUUUA motifs and a U-rich region containing three UUUUU motifs. An internal deletion showed that the U-rich region was required for inhibition, Point mutations in the AUUUA- and UUUUU-motifs inactivated the inhibitory sequence. Analysis of the stability of mRNAs containing the AU-rich sequence in sense or anti-sense orientation showed that mRNAs containing the AU-rich sequence in sense orientation had reduced half life. Analysis of RNA-protein interactions revealed that binding to the inhibitory sequence of three poly(U) binding proteins (38, 44 and 46 kDa) correlated with inhibition and that the same proteins bind to the AU-rich mRNA instability element in the 3' untranslated region on the human c-fos mRNA. We speculate that the human papillomavirus late mRNAs, produced from several hundred copies of the virus genome present in infected cells, compete with the c-fos mRNAs for destabilizing cellular factors and that this may lead to elevated Fos protein levels in human papillomavirus infected cells.	KAROLINSKA INST, MICROBIOL & TUMORBIOL CTR, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet				Sokolowski, Marcus/0000-0003-3931-1810				BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CHEN CM, 1991, J BIOL CHEM, V266, P7754; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOU ZF, 1994, NUCLEIC ACIDS RES, V22, P2525, DOI 10.1093/nar/22.13.2525; CHOW LT, 1994, INTERVIROLOGY, V37, P150, DOI 10.1159/000150373; DANOS O, 1982, EMBO J, V1, P231, DOI 10.1002/j.1460-2075.1982.tb01152.x; DietrichGoetz W, 1997, P NATL ACAD SCI USA, V94, P163, DOI 10.1073/pnas.94.1.163; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; ENG AM, 1985, J CUTAN PATHOL, V12, P46, DOI 10.1111/j.1600-0560.1985.tb00429.x; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISHER C, 1991, DEVELOPMENT, V111, P253; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; FURTH PA, 1994, MOL CELL BIOL, V14, P5278, DOI 10.1128/MCB.14.8.5278; FURTH PA, 1991, J VIROL, V65, P5806, DOI 10.1128/JVI.65.11.5806-5812.1991; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; GRUSSENDORF EI, 1979, ARCH DERMATOL RES, V264, P55, DOI 10.1007/BF00417279; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HOWLEY P M, 1990, P1625; HOWLEY PM, 1991, FUNDAMENTAL VIROLOGY, V2, P743; JENSON AB, 1980, J NATL CANCER I, V64, P495; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KENNEDY IM, 1991, J VIROL, V65, P2093, DOI 10.1128/JVI.65.4.2093-2097.1991; KENNEDY IM, 1990, J VIROL, V64, P1825, DOI 10.1128/JVI.64.4.1825-1829.1990; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; LAMBERT PF, 1991, J VIROL, V65, P3417, DOI 10.1128/JVI.65.7.3417-3420.1991; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; RAYMOND V, 1989, ONCOGENE RES, V4, P861; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUTHER U, 1989, ONCOGENE, V4, P861; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TAN W, 1995, J VIROL, V69, P2932, DOI 10.1128/JVI.69.5.2932-2945.1995; TAN W, 1995, J VIROL, V69, P5607, DOI 10.1128/JVI.69.9.5607-5620.1995; TUREK LP, 1994, ADV VIRUS RES, V44, P305, DOI 10.1016/S0065-3527(08)60332-2; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292; Zhao CP, 1996, J VIROL, V70, P3659, DOI 10.1128/JVI.70.6.3659-3667.1996; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	57	50	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2303	2319		10.1038/sj.onc.1201415	http://dx.doi.org/10.1038/sj.onc.1201415			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393875	Bronze			2022-12-25	WOS:A1997YE15700005
J	Clare, SE; Fantz, DA; Kistler, WS; Kistler, MK				Clare, SE; Fantz, DA; Kistler, WS; Kistler, MK			The testis-specific histone H1t gene is strongly repressed by a G/C-rich region just downstream of the TATA box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; RAT FIBRONECTIN GENE; RNA POLYMERASE-II; TRANSFECTED CELLS; MAMMALIAN TESTES; GC-BOX; TRANSCRIPTION; PROMOTER; EXPRESSION; SP1	H1t is a testis-specific histone 1 variant restricted to the male germ line and expressed only in pachytene spermatocytes. Understanding the regulation of the H1t gene is an interesting challenge as its promoter shares all of the recognized control elements of standard somatic H1 genes, yet H1t is not expressed in somatic or in early spermatogenic cells. To investigate the mechanism of this apparent repression, we exchanged three promoter subregions between H1t and a major somatic H1 gene (H1d) by introduction of suitable restriction sites just 5' of the TATA box and 3' of the conserved H1 AC box. Hybrid promoters were joined to a lacZ reporter gene and assayed by transient transfection in NIH3T3 fibroblasts. In this system the wild type H1d promoter was 20-fold stronger than the H1t promoter. Much of this difference in activity was traced to inhibitory sequences immediately downstream of the TATA box in H1t, although sequences upstream of the H1t AC box and within the H1t 5'-untranslated region played some role as well. A series of deletions and short oligonucleotide mutations scanned across the region between the TATA box and cap site identified two tracts of C (GC box 2) as the inhibitory sequences. While both Sp1 and Sp3 bind to this region weakly in vitro, they are unlikely to be responsible for the inhibitory effect of GC box 2, and additional binding proteins (CTB-4 and CTB-5) were identified by electrophoretic mobility shift assays as better candidates for mediating the repressive effect. When repression of the H1t promoter was relieved by mutation of GC box 2, additional mutations introduced into GC box 1 upstream of the CAAT box led to a large decrease in activity, indicating that these two G/C-rich elements have opposite effects on promoter activity.	Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Kistler, MK (corresponding author), Univ S Carolina, Dept Chem, 7300 S Main St, Columbia, SC 29208 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD010793] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10793] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bartell JG, 1996, J BIOL CHEM, V271, P4046, DOI 10.1074/jbc.271.8.4046; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANSON RE, 1975, ARCH BIOCHEM BIOPHYS, V168, P403, DOI 10.1016/0003-9861(75)90269-6; Clare SE, 1997, BIOL REPROD, V56, P73, DOI 10.1095/biolreprod56.1.73; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; CLARK SP, 1990, NUCLEIC ACIDS RES, V18, P5119, DOI 10.1093/nar/18.17.5119; COLE KD, 1984, J BIOL CHEM, V259, P3695; COLE KD, 1986, J BIOL CHEM, V261, P7178; COLE KD, 1990, GENE, V89, P265, DOI 10.1016/0378-1119(90)90015-J; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; COLES LS, 1985, NUCLEIC ACIDS RES, V13, P585, DOI 10.1093/nar/13.2.585; CROUSE GF, 1983, METHOD ENZYMOL, V101, P78; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DONG YH, 1995, MOL CELL BIOL, V15, P1889; Drabent B, 1996, HISTOCHEM CELL BIOL, V106, P247; DRABENT B, 1991, GENE, V103, P263, DOI 10.1016/0378-1119(91)90284-I; DUNCLIFFE KN, 1995, GENE, V163, P227, DOI 10.1016/0378-1119(95)00370-L; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIMES SR, 1990, J CELL BIOCHEM, V44, P1, DOI 10.1002/jcb.240440102; GRIMES SR, 1992, EXP CELL RES, V201, P216, DOI 10.1016/0014-4827(92)90366-G; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JANKOWSKI JM, 1987, BIOSCIENCE REP, V7, P955, DOI 10.1007/BF01122129; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG SW, 1995, NUCLEIC ACIDS RES, V23, P3607, DOI 10.1093/nar/23.17.3607; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KARSENTY G, 1991, J BIOL CHEM, V266, P24842; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KISTLER WS, 1989, HISTONES OTHER BASIC, P331; KOPPEL DA, 1994, J CELL BIOCHEM, V54, P219, DOI 10.1002/jcb.240540210; KREMER EJ, 1991, EXP CELL RES, V197, P330, DOI 10.1016/0014-4827(91)90442-W; KREMER EJ, 1992, GENE, V110, P167, DOI 10.1016/0378-1119(92)90644-5; LENNOX RW, 1984, HISTONE GENES STRUCT, P373; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LEWIS CD, 1988, GENE DEV, V2, P863, DOI 10.1101/gad.2.7.863; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; OCONNOR KL, 1994, BIOTECHNIQUES, V17, P502; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEYEDIN SM, 1979, BIOCHEMISTRY-US, V18, P1371, DOI 10.1021/bi00574a038; SHIRES A, 1975, P NATL ACAD SCI USA, V72, P2714, DOI 10.1073/pnas.72.7.2714; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	58	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33028	33036		10.1074/jbc.272.52.33028	http://dx.doi.org/10.1074/jbc.272.52.33028			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407085	hybrid			2022-12-25	WOS:000071182900046
J	Hanasaki, K; Yokota, Y; Ishizaki, J; Itoh, T; Arita, H				Hanasaki, K; Yokota, Y; Ishizaki, J; Itoh, T; Arita, H			Resistance to endotoxic shock in phospholipase A(2) receptor-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-TYPE PHOSPHOLIPASE-A2; TUMOR-NECROSIS-FACTOR; RAT MESANGIAL CELLS; BINDING-SITE; PLASMINOGEN-ACTIVATOR; TISSUE DISTRIBUTION; 180-KDA RECEPTOR; EXPRESSION; DISEASE; CLONING	Mammals possess various types of secretory phospholipase A(2), which differ in the primary structure and tissue distribution. The phosholipase A(2) receptor (PLA(2)R) recognizes group IB phospholipase A(2) (PLA(2)-IB) and mediates the PLA(2)-IB-induced biological responses in non-digestive organs, including eicosanoid production and contraction of airway smooth muscles. In this study, we generated PLA(2)R-deficient mice to define its biological roles further. These mice are viable, fertile, and without evident histopathological abnormalities. There was no difference in the clearance of circulating PLA(2)-IB between wild-type and mutant mice. After challenge with bacterial lipopolysaccharide (LPS), PLA(2)-R-deficient mice exhibited longer survival than wild-type mice. The mutant mice were also resistant to lethal effects of exogenous PLA(2)-IB after sensitization with sublethal dose of LPS. The plasma levels of tumor necrosis factor-alpha and interleukin-1 beta elevated after LPS treatment were significantly reduced in mutant mice compared with wild-type mice. These findings suggest a potential role of PLA(2)R in the progression of endotoxic shock.	Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Osaka 553, Japan	Shionogi & Company Limited	Hanasaki, K (corresponding author), Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, 12-4 Sagisu,5 Chome, Osaka 553, Japan.							ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ARITA H, 1989, PROG LIPID RES, V28, P273, DOI 10.1016/0163-7827(89)90002-7; ARITA H, 1991, J BIOL CHEM, V266, P19139; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; CHAKRABORTI S, 1993, BIOCHEM J, V292, P585, DOI 10.1042/bj2920585; CHEN J, 1994, BBA-LIPID LIPID MET, V1215, P115, DOI 10.1016/0005-2760(94)90099-X; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1994, TRENDS BIOCHEM SCI, V22, P1; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; GIROIR BP, 1992, J CLIN INVEST, V90, P693, DOI 10.1172/JCI115939; Hagishita S, 1996, J MED CHEM, V39, P3636, DOI 10.1021/jm960395q; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ISHIZAKI J, 1994, J BIOL CHEM, V269, P597; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KANEMASA T, 1992, FEBS LETT, V303, P217, DOI 10.1016/0014-5793(92)80523-J; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KISHINO J, 1995, J BIOCHEM-TOKYO, V117, P420, DOI 10.1093/jb/117.2.420; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V117, P217; Kundu GC, 1997, J BIOL CHEM, V272, P2346; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARGARET M, 1983, JAMA-J AM MED ASSOC, V250, P3324; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; NAKANO T, 1994, BIOCHEM BIOPH RES CO, V198, P10, DOI 10.1006/bbrc.1994.1002; NISHIJIMA J, 1983, J BIOCHEM, V94, P137, DOI 10.1093/oxfordjournals.jbchem.a134322; NOMURA K, 1994, ENDOCRINOLOGY, V135, P603, DOI 10.1210/en.135.2.603; OGURA N, 1995, J PERIODONTAL RES, V30, P132, DOI 10.1111/j.1600-0765.1995.tb01262.x; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAE D, 1995, CLIN BIOCHEM, V28, P71, DOI 10.1016/0009-9120(94)00068-7; RAE D, 1994, LANCET, V344, P1472, DOI 10.1016/S0140-6736(94)90291-7; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; VADAS P, 1986, LAB INVEST, V55, P391; VANHINSBERGH VWM, 1990, BLOOD, V75, P1991; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	53	115	119	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32792	32797		10.1074/jbc.272.52.32792	http://dx.doi.org/10.1074/jbc.272.52.32792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407054	hybrid			2022-12-25	WOS:000071182900015
J	Matsui, T; Ozaki, S; Watanabe, Y				Matsui, T; Ozaki, S; Watanabe, Y			On the formation and reactivity of compound I of the His-64 myoglobin mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SPERM WHALE MYOGLOBIN; HORSERADISH-PEROXIDASE; EPOXIDATION; HISTIDINE; STYRENE; ROLES; CHLOROPEROXIDASE; CYSTEINE; TYR-103	Myoglobin (Mb) catalyzes various two-electron oxidations; however, ferryl porphyrin cation radical equivalent to peroxidase compound I has not been identified yet. Distal histidine mutants of sperm whale Mb (His-64 --> Ala, Ser, and Leu) afford an apparent intermediate followed by the formation of a ferryl heme (Mb-II) in the reaction with mchloroperbenzoic acid. Because the intermediate exhibits characteristic absorption spectrum of compound I and bears two electron oxidizing equivalents above the ferric state, we have assigned the species as compound I of myoglobin (Mb-I), Although we have recently observed compound I of the F43H/H64L Mb mutant, F43H and wild type Mb react with m-chloroperbenzoic acid to give Mb-II without any accumulation of Mb-I. The results unambiguously indicate that His-64 plays a key role in destabilizing wild type Mb-I. Furthermore, Mb-I is found to be capable of performing two-electron oxidation of styrene, thioanisole, and H2O2.	Inst Mol Sci, Okazaki, Aichi 444, Japan; Grad Univ Adv Studies, Dept Struct Mol Sci, Okazaki, Aichi 444, Japan	National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Graduate University for Advanced Studies - Japan	Watanabe, Y (corresponding author), Inst Mol Sci, Okazaki, Aichi 444, Japan.	yoshi@ims.ac.jp	Matsui, Toshitaka/B-1570-2008	Matsui, Toshitaka/0000-0003-3865-8468				ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; CASELLA L, 1992, BIOCHEMISTRY-US, V31, P9451, DOI 10.1021/bi00154a018; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V37, P301, DOI 10.1016/0003-9861(52)90194-X; DeGray JA, 1997, J BIOL CHEM, V272, P2359; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; Fenwick CW, 1996, J AM CHEM SOC, V118, P12236, DOI 10.1021/ja962764d; KING NK, 1966, AUST J BIOL SCI, V19, P211, DOI 10.1071/BI9660211; KING NK, 1963, J BIOL CHEM, V238, P1520; Matsui T, 1996, BIOCHEMISTRY-US, V35, P13118, DOI 10.1021/bi960459z; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; OZAKI S, 1995, J AM CHEM SOC, V117, P7056, DOI 10.1021/ja00132a003; Ozaki S, 1997, J AM CHEM SOC, V119, P6666, DOI 10.1021/ja970453c; Ozaki S, 1996, J AM CHEM SOC, V118, P9784, DOI 10.1021/ja961223l; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; RAO SI, 1993, J BIOL CHEM, V268, P803; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STILLMAN JS, 1975, BIOCHEMISTRY-US, V14, P3183, DOI 10.1021/bi00685a023; TEW D, 1988, J BIOL CHEM, V263, P17880; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531	24	70	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32735	32738		10.1074/jbc.272.52.32735	http://dx.doi.org/10.1074/jbc.272.52.32735			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407045	hybrid			2022-12-25	WOS:000071182900006
J	Sharma, J; Panico, M; Shipton, CA; Nilsson, F; Morris, HR; Barber, J				Sharma, J; Panico, M; Shipton, CA; Nilsson, F; Morris, HR; Barber, J			Primary structure characterization of the photosystem II D1 and D2 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; PHOTOSYNTHETIC REACTION-CENTER; MASS-SPECTROMETRY; THYLAKOID MEMBRANES; CHLOROPLAST DNA; SINGLET OXYGEN; PROTEIN; PHOTOINHIBITION; PHOSPHORYLATION; IDENTIFICATION	Mass spectrometry techniques have been applied in a protein mapping strategy to elucidate the majority of the primary structures of the D1 and D2 proteins present in the photosystem II reaction center. Evidence verifying the post-translational processing of the initiating methionine residue and acetylation of the free amino group, similar to those reported for other higher plant species, are presented for the two subunits from pea plants (Pisum sativum L.). Further covalent modifications observed on the D1 protein include the COOH-terminal processing with a loss of nine amino acids and phosphorylation of Thr(2). In addition, the studies reported in this paper provide the first definitive characterization of oxidations on specific amino acids of the D1 and D2 proteins. We believe that these oxidations, and to a much lesser extent the phosphorylations, are major contributors to the heterogeneity observed during the electrospray analysis of the intact subunits reported in the accompanying paper (Sharma, J., Panico, M., Barber, J., and Morris, H. R. (1997) J. Biol. Chem. 272, 33153-33157). Significantly, all of the regions that have been identified as those particularly susceptible to oxidation are anticipated (from current models) to be in close proximity to the redox active components of the photosystem II complex.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England	Imperial College London	Barber, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England.		choudhary, jyoti/S-1232-2017	choudhary, jyoti/0000-0003-0881-5477	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; Blenis J, 1993, CURR OPIN CELL BIOL, V5, P984, DOI 10.1016/0955-0674(93)90081-Z; CALLAHAN FE, 1990, J BIOL CHEM, V265, P15357; DELEPELAIRE P, 1984, EMBO J, V3, P701, DOI 10.1002/j.1460-2075.1984.tb01872.x; DINER BA, 1988, J BIOL CHEM, V263, P8972; DURRANT JR, 1990, BIOCHIM BIOPHYS ACTA, V1017, P167, DOI 10.1016/0005-2728(90)90148-W; EBBERT V, 1994, BBA-BIOENERGETICS, V1187, P335, DOI 10.1016/0005-2728(94)90007-8; ELICH TD, 1992, J BIOL CHEM, V267, P3523; Giorgi LB, 1996, J BIOL CHEM, V271, P2093, DOI 10.1074/jbc.271.4.2093; HAEBEL S, 1995, PROTEIN SCI, V4, P394; HIDEG E, 1994, PHOTOSYNTH RES, V39, P191, DOI 10.1007/BF00029386; KELLER M, 1986, FEBS LETT, V175, P173; KETTUNEN R, 1991, FEBS LETT, V290, P153, DOI 10.1016/0014-5793(91)81247-6; Kruse O, 1997, FEBS LETT, V408, P276, DOI 10.1016/S0014-5793(97)00439-0; KRUSE O, 1994, Z NATURFORSCH C, V49, P9651; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MILLNER PA, 1986, BIOCHIM BIOPHYS ACTA, V852, P30, DOI 10.1016/0005-2728(86)90053-8; MORRIS HR, 1981, BIOCHEM BIOPH RES CO, V101, P623, DOI 10.1016/0006-291X(81)91304-8; MORRIS HR, 1983, BIOCHEM BIOPH RES CO, V117, P299, DOI 10.1016/0006-291X(83)91575-9; NIXON PJ, 1994, BIOCHEM SOC T, V22, P338, DOI 10.1042/bst0220338; NIXON PJ, 1992, PLANT PROTEIN ENG, V2, P93; OWENS GC, 1982, J CELL BIOL, V93, P712, DOI 10.1083/jcb.93.3.712; RASMUSSEN OF, 1984, PLANT MOL BIOL, V3, P191, DOI 10.1007/BF00029654; SHAPIRO DR, 1986, PLANT MOL BIOL, V6, P1, DOI 10.1007/BF00021301; Sharma J, 1997, J BIOL CHEM, V272, P33153, DOI 10.1074/jbc.272.52.33153; STRUPAT K, 1994, ANAL CHEM, V66, P464, DOI 10.1021/ac00076a008; TAKAHASHI M, 1988, FEBS LETT, V420, P6; TELFER A, 1987, BIOCHIM BIOPHYS ACTA, V893, P557, DOI 10.1016/0005-2728(87)90107-1; TELFER A, 1994, J BIOL CHEM, V269, P13244; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WOLD F, 1992, FASEB J, V6, P404	34	69	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33158	33166		10.1074/jbc.272.52.33158	http://dx.doi.org/10.1074/jbc.272.52.33158			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407103	hybrid			2022-12-25	WOS:000071182900064
J	Simon, S; Massoulie, J				Simon, S; Massoulie, J			Cloning and expression of acetylcholinesterase from Electrophorus - Splicing pattern of the 3 ' exons in vivo and in transfected mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-FORMS; CATALYTIC SUBUNITS; PERIPHERAL SITE; ELECTRIC-EEL; TORPEDO; SEQUENCE; CHOLINESTERASE; PEPTIDE; BINDING; DNA	We cloned and expressed a cDNA encoding acetylcholinesterase (AChE) of type T from Electrophorus electricus organs. When expressed in COS, HEH, and Chinese hamster ovary cells, the AChE(T) subunits generated dimers and tetramers. The cells produced more activity at 27 than at 37 degrees C. The kinetic parameters of a recombinant enzyme, produced in the yeast Pichia pastoris, were close to those of the natural AChE. Analysis of genomic clones showed that the coding sequence is interrupted by an intron that does not exist in Torpedo and differs in its location from that observed in the mouse. This intron is preceded by a sequence encoding a non-conserved 29-amino acid peptide, which does not exist in Torpedo or mammalian AChEs. According to a three-dimensional model, this non-conserved peptide is located at the surface of the protein, opposite from the entry of the catalytic gorge; its deletion did not modify the catalytic parameters. Sequence analyses and expression of various constructs showed that the gene does not contain any H exon. We also found that splicing of transcripts in mammalian cells reveals cryptic donor sites in exons and acceptor sites in introns, which do not appear to be used in vivo.	Ecole Normale Super, Neurobiol Cellulaire & Mol Lab, CNRS, URA 1857, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS)	Simon, S (corresponding author), Ecole Normale Super, Neurobiol Cellulaire & Mol Lab, CNRS, URA 1857, 46 Rue Ulm, F-75005 Paris, France.		Simon, Stephanie/E-4289-2012	Simon, Stephanie/0000-0002-6071-8255				ANSELMET A, 1994, J NEUROCHEM, V62, P2158; BERTRAND C, 1996, ZEBRAFISH DEV GENETI, P105; BLONDEL A, 1991, NUCLEIC ACIDS RES, V19, P181, DOI 10.1093/nar/19.1.181; BON S, 1976, FEBS LETT, V71, P273, DOI 10.1016/0014-5793(76)80949-0; BON S, 1991, CELL MOL NEUROBIOL, V11, P157, DOI 10.1007/BF00712807; BON S, 1987, J NEUROCHEM, V49, P1720, DOI 10.1111/j.1471-4159.1987.tb02429.x; BON S, 1976, EUR J BIOCHEM, V68, P523, DOI 10.1111/j.1432-1033.1976.tb10840.x; BON S, 1988, J NEUROCHEM, V51, P776, DOI 10.1111/j.1471-4159.1988.tb01812.x; Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; CAMP S, 1995, J CLIN INVEST, V95, P333, DOI 10.1172/JCI117661; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cousin X, 1996, NUCLEIC ACIDS RES, V24, P132, DOI 10.1093/nar/24.1.132; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; Cousin X, 1997, NUCLEIC ACIDS RES, V25, P143, DOI 10.1093/nar/25.1.143; DUDAI Y, 1974, BIOCHEM BIOPH RES CO, V59, P117, DOI 10.1016/S0006-291X(74)80182-8; DURAN R, 1994, BBA-GEN SUBJECTS, V1201, P381, DOI 10.1016/0304-4165(94)90066-3; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; EICHLER J, 1994, MOL PHARMACOL, V45, P335; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KIEFFER B, 1986, FEBS LETT, V202, P91, DOI 10.1016/0014-5793(86)80655-X; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI Y, 1991, J BIOL CHEM, V266, P23083; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MASSOULIE J, 1976, EUR J BIOCHEM, V68, P531, DOI 10.1111/j.1432-1033.1976.tb10841.x; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; MOREL N, 1997, IN PRESS BIOCH J; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; ROSENBERRY TL, 1975, P NATL ACAD SCI USA, V72, P3834, DOI 10.1073/pnas.72.10.3834; SALIH E, 1994, BBA-PROTEIN STRUCT M, V1208, P324, DOI 10.1016/0167-4838(94)90120-1; SIKORAV JL, 1984, EUR J BIOCHEM, V145, P519, DOI 10.1111/j.1432-1033.1984.tb08587.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; VIGNY M, 1978, EUR J BIOCHEM, V85, P317, DOI 10.1111/j.1432-1033.1978.tb12241.x	42	46	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33045	33055		10.1074/jbc.272.52.33045	http://dx.doi.org/10.1074/jbc.272.52.33045			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407087	hybrid			2022-12-25	WOS:000071182900048
J	Aoki, H; Dekany, K; Adams, SL; Ganoza, MC				Aoki, H; Dekany, K; Adams, SL; Ganoza, MC			The gene encoding the elongation factor P protein is essential for viability and is required for protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPUSINE-CONTAINING PROTEIN; PEPTIDE-BOND SYNTHESIS; ESCHERICHIA-COLI; RIBOSOMAL-RNA; FACTOR-II; TRANSFERASE; TRANSLATION; IDENTIFICATION; SEQUENCE; CLONING	Elongation factor P (EFP) is a protein that stimulates the peptidyltransferase activity of fully assembled 70 S prokaryotic ribosomes and enhances the synthesis of certain dipeptides initiated by N-formylmethionine. This reaction appears conserved throughout species and is promoted in eukaryotic cells by a homologous protein, eIF5A. Here we ask whether the Escherichia coli gene encoding EFP is essential for cell viability, A kanamycin resistance (Kan(R)) gene was inserted near the N-terminal end of the efp gene and was cloned into a plasmid, pMAK705, that has a temperature-sensitive origin of replication. After transformation into a recA(+) E. coli strain, temperature-sensitive mutants were isolated, and their chromosomal DNA was sequenced. Mutants containing the efp-Kan(R) gene in the chromosome grew at 33 degrees C only in the presence of the wild-type copy of the efp gene in the pMAK705 plasmid and were unable to grow at 44 degrees C. Incorporation of various isotopes in vivo suggests that translation is impaired in the efp mutant at 44 degrees C. At 44 degrees C, mutant cells are severely defective in peptide-bond formation. We conclude that the efp gene is essential for cell viability and is required for protein synthesis.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto	Ganoza, MC (corresponding author), Univ Toronto, Charles H Best Inst, Toronto, ON M5G 1L6, Canada.	m.ganoza@utoronto.ca		GANOZA MELGAREJO, MICHAEL RICHARD/0000-0003-0196-8104				AN G, 1980, CAN J BIOCHEM, V97, P23; Aoki H, 1997, BIOCHIMIE, V79, P7, DOI 10.1016/S0300-9084(97)87619-5; AOKI H, 1991, NUCLEIC ACIDS RES, V19, P6215, DOI 10.1093/nar/19.22.6215; BARTIG D, 1992, EUR J BIOCHEM, V204, P751, DOI 10.1111/j.1432-1033.1992.tb16690.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOSCH L, 1990, BIOCHIM BIOPHYS ACTA, V1050, P293, DOI 10.1016/0167-4781(90)90184-4; CHUNG DG, 1990, RIBOSOMES PROTEIN SY, P69; COOPERMAN BS, 1990, RIBOSOME, P491; DABBS ER, 1983, MOL GEN GENET, V192, P301, DOI 10.1007/BF00392166; FELICETT.L, 1969, BIOCHEMISTRY-US, V8, P3428, DOI 10.1021/bi00836a044; GANOZA MC, 1993, EUR J BIOCHEM, V217, P839, DOI 10.1111/j.1432-1033.1993.tb18312.x; GANOZA MC, 1985, CELLULAR REGULATION, P123; GANOZA MC, 1985, EUR J BIOCHEM, V97, P23; GLICK BR, 1979, EUR J BIOCHEM, V97, P23, DOI 10.1111/j.1432-1033.1979.tb13081.x; GLICK BR, 1975, P NATL ACAD SCI USA, V72, P4257, DOI 10.1073/pnas.72.11.4257; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASHIMOTOGOTOH T, 1977, J BACTERIOL, V131, P405, DOI 10.1128/JB.131.2.405-412.1977; JANOSI L, 1994, P NATL ACAD SCI USA, V91, P4249, DOI 10.1073/pnas.91.10.4249; KANG HA, 1994, J BIOL CHEM, V269, P3934; KAWAKAMI K, 1990, P NATL ACAD SCI USA, V87, P8432, DOI 10.1073/pnas.87.21.8432; KUWANO M, 1971, BIOCHEM BIOPH RES CO, V42, P441, DOI 10.1016/0006-291X(71)90390-1; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; MANIATIS T, 1982, MOL CLONING LABORATO, P153; NIERHAUS KH, 1979, RIBOSOMES STRUCTURE, P267; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1993, J BACTERIOL, V175, P5297, DOI 10.1128/JB.175.17.5297-5300.1993; RACKEE ID, 1971, BIOCHEM BIOPH RES CO, V43, P169; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; RYDEN M, 1986, J BACTERIOL, V168, P1066, DOI 10.1128/jb.168.3.1066-1069.1986; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZE H, 1982, EMBO J, V1, P609, DOI 10.1002/j.1460-2075.1982.tb01216.x; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P1578; SPRINGER M, 1977, MOL GEN GENET, V151, P17, DOI 10.1007/BF00446908; SPRINGER M, 1977, P NATL ACAD SCI USA, V74, P3970, DOI 10.1073/pnas.74.9.3970; SYMONS RH, 1978, BIOORG CHEM, V4, P409; TOCCHINI.GP, 1968, P NATL ACAD SCI USA, V61, P146, DOI 10.1073/pnas.61.1.146; VERKAMP E, 1989, J BACTERIOL, V171, P4728, DOI 10.1128/jb.171.9.4728-4735.1989; VESTER B, 1988, EMBO J, V7, P3577, DOI 10.1002/j.1460-2075.1988.tb03235.x	41	68	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32254	32259		10.1074/jbc.272.51.32254	http://dx.doi.org/10.1074/jbc.272.51.32254			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405429	hybrid			2022-12-25	WOS:000071108000048
J	Chicheportiche, Y; Bourdon, PR; Xu, HD; Hsu, YM; Scott, H; Hession, C; Garcia, I; Browning, JL				Chicheportiche, Y; Bourdon, PR; Xu, HD; Hsu, YM; Scott, H; Hession, C; Garcia, I; Browning, JL			TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING RECEPTOR; MEDIATES APOPTOSIS; LYMPHOTOXIN-BETA; LYMPHOID ORGANS; MESSENGER-RNA; CELL-DEATH; T-CELLS; TNF; ANTIGEN; FAS	The members of the tumor necrosis factor (TNF) family play pivotal roles in the regulation of the immune system. Here we describe a new ligand in this family, designated TWEAK. The mouse and human versions of this protein are unusually conserved with 93% amino acid identity in the receptor binding domain. The protein was efficiently secreted from cells indicating that, like TNF, TWEAK may have the long range effects of a secreted cytokine. TWEAK transcripts were abundant and found in many tissues, suggesting that TWEAK and TRAIL belong to a new group of widely expressed ligands, Like many members of the TNF family, TWEAK was able to induce interleukin-8 synthesis in a number of cell lines. The human adenocarcinoma cell line, HT29, underwent apoptosis in the presence of both TWEAK and interferon-gamma. Thus, TWEAK resembles many other TNF ligands in the capacity to induce cell death; however, the fact that TWEAK-sensitive cells are relatively rare suggests that TWEAK. along with lymphotoxins alpha/beta and possibly CD30L trigger death via a weaker, nondeath domain-dependent mechanism.	Biogen Inc, Dept Cell Biol, Cambridge, MA 02142 USA; Univ Geneva, Dept Pathol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland; Biogen Inc, Dept Mol Genet, Cambridge, MA 02142 USA; Biogen Inc, Dept Prot Chem, Cambridge, MA 02142 USA	Biogen; University of Geneva; University of Geneva; Biogen; Biogen	Browning, JL (corresponding author), Biogen Inc, Dept Cell Biol, 12 Cambridge Ctr, Cambridge, MA 02142 USA.		Scott, Hamish/B-2122-2009	Scott, Hamish/0000-0002-5813-631X; Browning, Jeffrey/0000-0001-9168-5233				ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; AGEMATSU K, 1995, EUR J IMMUNOL, V25, P2825, DOI 10.1002/eji.1830251017; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; BROWNING J, 1989, J IMMUNOL, V143, P1859; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; BROWNING JL, 1991, J IMMUNOL, V147, P1230; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHICHEPORTICHE Y, 1995, BIOCHEM BIOPH RES CO, V209, P1076, DOI 10.1006/bbrc.1995.1607; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; DEBENEDETTE MA, 1995, J EXP MED, V181, P985, DOI 10.1084/jem.181.3.985; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GRELL M, 1994, J IMMUNOL, V153, P1963; GRUSS HJ, 1994, BLOOD, V83, P2045; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HANNUN YA, 1996, NATURE, V274, P1855; Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Mackay F, 1997, J IMMUNOL, V159, P3299; MEDVEDEV AE, 1994, EUR J IMMUNOL, V24, P2842, DOI 10.1002/eji.1830241139; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; SANTOS AA, 1993, ARCH SURG-CHICAGO, V128, P138; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Smith Geoffrey L., 1994, Trends in Microbiology, V2, P81, DOI 10.1016/0966-842X(94)90539-8; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STRUBER E, 1996, J EXP MED, V183, P979; Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	52	551	639	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32401	32410		10.1074/jbc.272.51.32401	http://dx.doi.org/10.1074/jbc.272.51.32401			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405449	hybrid			2022-12-25	WOS:000071108000068
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTED TRANSMEMBRANE DOMAIN; STIMULATED ATPASE ACTIVITY; FUNCTIONAL CONSEQUENCES; MUTATIONS; NUCLEOTIDE; CYSTEINE; MUTANTS; GENE; MDR1; SPECIFICITY	We identified a thiol-reactive compound, dibromobimane (dBBn), that was a potent stimulator (8.2-fold) of the ATPase activity of Cys-less P-glycoprotein, We then used this compound together with cysteine-scanning mutagenesis to identify residues in transmembrane segment (TM) 6 and TM12 that are important for function, TM6 and TM12 he close to each other in the tertiary structure and are postulated to be important for drug-protein interactions, The majority of P-glycoprotein mutants containing a single cysteine residue retained substantial amounts of drug-stimulated ATPase activity and were not inhibited by dBBn, The ATPase activities of mutants L339C, A342C, L975C, V982C, and A985C, however, were markedly inhibited (>60%) by dBBn, The drug substrates verapamil, vinblastine, and colchicine protected these mutants against inhibition by dBBn, suggesting that these residues are important for interaction of substrates with P-glycoprotein, We previously showed that residues Leu(339), Ala(342), Leu(975), Val(982), and Ala(985) lie along the point of contact between helices TM6 and TM12, when both are aligned in a left-handed coiled coil (Loo, T. W., and Clarke, D. M. (1997) J. Biol. Chem, 272, 20986-20989), Taken together, these results suggest that the interface between TM6 and TM12 likely forms part of the potential drug-binding pocket in P-glycoprotein.	Univ Toronto, Dept Med, MRC, Membrane Biol Grp, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Membrane Biol Grp, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; SCHEUTZ EG, 1996, P NATL ACAD SCI USA, V93, P4001; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	26	135	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31945	31948		10.1074/jbc.272.51.31945	http://dx.doi.org/10.1074/jbc.272.51.31945			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405384	hybrid			2022-12-25	WOS:000071108000003
J	Mallo, GV; Fiedler, F; Calvo, EL; Ortiz, EM; Vasseur, S; Keim, V; Morisset, J; Iovanna, JL				Mallo, GV; Fiedler, F; Calvo, EL; Ortiz, EM; Vasseur, S; Keim, V; Morisset, J; Iovanna, JL			Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INDUCED APOPTOSIS; EXOCRINE PANCREAS; PROTEIN; SEQUENCES; STRESS; CELLS; PROLIFERATION; THYMOCYTES; DEATH	To characterize at the molecular level the pancreatic emergency program set up by the pancreatic cells in response to pancreatitis, we have developed a strategy in which the phenotype of the pancreatitis affected pancreas is established by characterization of a large number of its transcripts. Herein, we describe the cloning, sequence, and expression of a new gene, named p8, which is strongly activated in pancreatic acinar cells during the acute phase of pancreatitis, in developing pancreas and during pancreatic regeneration. In acinar cells, p8 mRNA is expressed rapidly and specifically in response to cellular pancreatitis-induced injury; its induction occurred almost similarly in edematous and necrohemorrhagic pancreatitis, indicating that p8 mRNA is maximally activated even in response to a mild pancreatic injury. Furthermore, in vitro studies suggest that p8 mRNA is induced in pancreatic and non-pancreatic cells in response to some apoptotic stimuli. p8 acts as a promoter of cellular growth factor when its cDNA is transfected into COS-7 and AR4-2J cells. Although we failed to identify p8-related sequences, analysis of its primary and secondary structure suggests that p8 is a basic helix-turn-helix-containing gene with slight homology to several homeotic genes and sufficient signal to be targeted to the nucleus. We therefore propose p8 as a putative transcriptional factor which can regulate pancreatic growth.	INSERM, U315, F-13009 Marseille, France; Heidelberg Univ, Klinikum Mannheim, Inst Anasthesie, D-68167 Mannheim, Germany; Univ Sherbrooke, Fac Med, Dept Med, Gastroenterol Serv, Sherbrooke, PQ J1H 5N4, Canada; Univ Leipzig, Zentrum Innere Med, Med Klin 2, D-04103 Leipzig, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Ruprecht Karls University Heidelberg; University of Sherbrooke; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Iovanna, JL (corresponding author), INSERM, U315, 46 Bd De La Gaye, F-13009 Marseille, France.	iovanna@marseille.inserm.fr	Iovanna, Juan/M-9805-2017; vasseur, sophie/O-9803-2017	Iovanna, Juan/0000-0003-1822-2237; vasseur, sophie/0000-0002-2339-8854				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BRENNAN RG, 1989, TRENDS BIOCHEM SCI, V14, P286, DOI 10.1016/0968-0004(89)90066-2; Brown IR, 1995, NEUROPATH APPL NEURO, V21, P473, DOI 10.1111/j.1365-2990.1995.tb01088.x; Calvo E., 1993, Pancreas, V8, P751; Calvo E., 1993, Digestion, V54, P268; CALVO E, 1995, GASTROENTEROLOGY, V108, pA955; Calvo EL, 1997, J MOL ENDOCRINOL, V18, P233, DOI 10.1677/jme.0.0180233; Calvo EL, 1997, GASTROENTEROLOGY, V112, pA432; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS DK, 1995, J MOL CELL CARDIOL, V27, P181, DOI 10.1016/S0022-2828(08)80017-X; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUSETTI NJ, 1995, BIOCHEM J, V307, P9, DOI 10.1042/bj3070009; Foglia Virgilio G., 1944, REV SOC ARGENTINA BIOL, V20, P21; FRIGERIO JM, 1993, BIOCHEMISTRY-US, V32, P9236, DOI 10.1021/bi00086a032; GO VLW, 1993, PANCREAS BIOL PATHOB, P1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSILLI E, 1992, BIOCHEM BIOPH RES CO, V188, P1261, DOI 10.1016/0006-291X(92)91367-Y; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOBOHM U, 1995, J MOL BIOL, V251, P390, DOI 10.1006/jmbi.1995.0442; HUTTUNEN R, 1975, SCAND J GASTROENTERO, V10, P177; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; IOVANNA JL, 1992, PANCREAS, V7, P712, DOI 10.1097/00006676-199211000-00013; IOVANNA JL, 1991, AM J PHYSIOL, V261, pG485, DOI 10.1152/ajpgi.1991.261.3.G485; IWANIJ V, 1982, J CELL BIOL, V95, P742, DOI 10.1083/jcb.95.3.742; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; KEIM V, 1994, DIGESTION, V55, P65, DOI 10.1159/000201127; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; KOMMINOTH P, 1995, LAB INVEST, V72, P424; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LANKISCH PG, 1974, SCAND J GASTROENTERO, V9, P725; McIntosh TK, 1995, NEUROPATH APPL NEURO, V21, P477; OATES PS, 1989, J ANAT, V167, P235; OHLSSON K, 1991, PANCREATIC DIS PROGR, P213; PARSA I, 1969, AM J PATHOL, V57, P457; PARSA I, 1969, AM J PATHOL, V57, P489; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROUQUIER S, 1991, J BIOL CHEM, V266, P786; Sandoval D, 1996, GASTROENTEROLOGY, V111, P1081, DOI 10.1016/S0016-5085(96)70077-X; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SESSO A, 1973, ACTA PHYSIOL LAT AM, V23, P36; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; TROIANO L, 1995, BIOCHEM BIOPH RES CO, V214, P941, DOI 10.1006/bbrc.1995.2377; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILSON C, 1991, PANCREATIC DIS PROGR, P287; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YAMAGUCHI H, 1989, PANCREAS, V4, P565, DOI 10.1097/00006676-198910000-00007	56	196	201	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32360	32369		10.1074/jbc.272.51.32360	http://dx.doi.org/10.1074/jbc.272.51.32360			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405444	hybrid			2022-12-25	WOS:000071108000063
J	Nagel, G; Volk, C; Friedrich, T; Ulzheimer, JC; Bamberg, E; Koepsell, H				Nagel, G; Volk, C; Friedrich, T; Ulzheimer, JC; Bamberg, E; Koepsell, H			A reevaluation of substrate specificity of the rat cation transporter rOCT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MECHANISMS; SYSTEM; DRUGS; LIVER	The substrate specificity of the previously cloned rat cation transporter rOCT1, which is expressed in kidney, liver, and small intestine, was reevaluated. rOCT1 is the first member of a new protein family comprising electrogenic and polyspecific cation transporters that transport hydrophilic cations like tetraethylammonium, choline, and monoamine neurotransmitters. Previous electrical measurements suggested that cations like quinine, quinidine, and cyanine 863, which have been classified as type 2 cations in the liver, are also transported by rOCT1, since they may induce inward currents in rOCT1 expressing Xenopus oocytes (Busch, A. E., Quester, S., Ulzheimer, J. C., Waldegger, S., Gorboulev, V., Arndt, P., Lang, F., and Koepsell, H. (1996) J. Biol. Chem. 271, 32599-32604). Tracer flux measurements with oocytes and with stably transfected human embryonic kidney cells showed that [H-3]quinine and [H-3]quinidine are not transported by rOCT1. The voltage dependence observed for the quinine-or quinidine-induced inward currents in rOCT1-expressing oocytes, and tracer efflux measurements indicate that the in ward currents by type 2 cations are generated by the inhibition of electrogenic efflux of transported type I cations. Therefore, rOCT1 cannot contribute to transport of type 2 cations in the liver and the hepatic transporter for type 2 cations remains to be identified.	Max Planck Inst Biophys, D-60596 Frankfurt, Germany; Univ Frankfurt, Biozentrum, D-60439 Frankfurt, Germany; Univ Wurzburg, Inst Anat, D-97070 Wurzburg, Germany	Max Planck Society; Goethe University Frankfurt; University of Wurzburg	Nagel, G (corresponding author), Max Planck Inst Biophys, Kennedy Allee 70, D-60596 Frankfurt, Germany.		Friedrich, Thomas/AAA-3418-2022	Nagel, Georg/0000-0001-8174-8712				Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; Busch AE, 1996, FEBS LETT, V395, P153, DOI 10.1016/0014-5793(96)01030-7; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Groothuis GMM, 1996, J HEPATOL, V24, P3; Grundemann D, 1997, J BIOL CHEM, V272, P10408; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; Koepsell H, 1998, ANNU REV PHYSIOL, V60, P243, DOI 10.1146/annurev.physiol.60.1.243; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MOL WEM, 1988, J PHARMACOL EXP THER, V244, P268; Nagel G, 1995, FEBS LETT, V377, P263, DOI 10.1016/0014-5793(95)01356-3; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; ROCHRAMEL F, 1992, HDB PHYSL, P2189; Schweifer N, 1996, MAMM GENOME, V7, P735, DOI 10.1007/s003359900223; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; STEEN H, 1991, J PHARMACOL EXP THER, V258, P537; STEEN H, 1992, BIOCHEM PHARMACOL, V44, P2323, DOI 10.1016/0006-2952(92)90676-A; Zhang L, 1997, J BIOL CHEM, V272, P16548, DOI 10.1074/jbc.272.26.16548; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913	21	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31953	31956		10.1074/jbc.272.51.31953	http://dx.doi.org/10.1074/jbc.272.51.31953			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405386	hybrid			2022-12-25	WOS:000071108000005
J	Plant, PJ; Yeger, H; Staub, O; Howard, P; Rotin, D				Plant, PJ; Yeger, H; Staub, O; Howard, P; Rotin, D			The C2 domain of the ubiquitin protein ligase Nedd4 mediates Ca2+-dependent plasma membrane localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; GTPASE-ACTIVATING PROTEIN; LIPID-BINDING DOMAIN; KINASE-C; PHOSPHOLIPASE-C; SYNAPTOTAGMIN-I; LIDDLE SYNDROME; BETA-SUBUNIT; MISSENSE MUTATION; WW DOMAINS	Neuronal precursor cell-expressed developmentally down-regulated 4 (Nedd4) is a ubiquitin protein ligase (E3) containing a beet domain, 3 or 4 WW domains, and a putative C2 domain. We have recently demonstrated an association between the WW domains of Nedd4 and the proline-rich PY motifs (XPPXY) of the epithelial Na+ channel, as well as with PY motifs of several other proteins. The role of the putative C2 domain of Nedd4 has not been elucidated. Here we show that Nedd4, endogenously expressed in Madin-Darby canine kidney cells, was redistributed from the cytosolic to the particulate fraction in response to ionomycin plus Ca2+ treatment. A similar treatment of polarized Madin-Darby canine kidney cells led to an apical and lateral membrane localization of Nedd4, as determined by immunostaining and confocal microscopy. The C2 domain of Nedd4, expressed as a glutathione S-transferase (GST) fusion protein, was sufficient to bind cellular membranes in a Ca2+- dependent manner. Moreover, this GST-Nedd4-C2 domain was able to mediate Ca2+-dependent interactions with phosphatidylserine, phosphatidylinositol, and phosphatidylcholine liposomes in. vitro. An epitope-tagged Nedd4 lacking its C2 domain and stably expressed in Madin-Darby canine kidney cells failed to mediate the Ca2+-induced plasma membrane localization seen in wild-type (epitope-tagged) Nedd4. These results indicate that the putative C2 domain of Nedd4 acts as a bona fide C2 domain which binds phospholipids and membranes in a Ca2+-dependent fashion and is involved in localizing the protein primarily to the apical region of polarized epithelial cells in response to Ca2+.	Hosp Sick Children, Div Resp Res, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Rotin, D (corresponding author), Hosp Sick Children, Div Resp Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Howard, Perry/0000-0002-9837-9359				BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAMER CK, 1994, J BIOL CHEM, V269, P31115; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DELLES C, 1995, J PHYSIOL-LONDON, V486, P557, DOI 10.1113/jphysiol.1995.sp020834; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; EMORI Y, 1989, J BIOL CHEM, V264, P21885; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GAWLER DJ, 1995, BIOCHEM J, V307, P487, DOI 10.1042/bj3070487; GAWLER DJ, 1995, ONCOGENE, V10, P817; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LANG F, 1990, RENAL PHYSIOL BIOCH, V13, P82; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; PALMER LG, 1987, AM J PHYSIOL, V253, pF333, DOI 10.1152/ajprenal.1987.253.2.F333; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Ponting CP, 1996, PROTEIN SCI, V5, P162; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 1996, STRUCTURE, V4, P495, DOI 10.1016/S0969-2126(96)00054-8; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; ULRICH U, 1994, NEURON, V13, P1281; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	53	156	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32329	32336		10.1074/jbc.272.51.32329	http://dx.doi.org/10.1074/jbc.272.51.32329			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405440	hybrid			2022-12-25	WOS:000071108000059
J	DeFea, K; Roth, RA				DeFea, K; Roth, RA			Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; 3T3 CELLS; IN-VIVO; RESIDUES; ALPHA; IRS-1; DESENSITIZATION; IDENTIFICATION; SPECIFICITY; PATHWAYS	Increased serine phosphorylation of insulin receptor substrate-1 (IRS-1) has been observed in several systems to correlate with a decreased ability of the insulin receptor to tyrosine-phosphorylate this endogenous substrate and to inhibit its subsequent association with phosphatidylinositol 3-kinase. In the present studies we have examined the potential role of the mitogen-activated protein (MAP) kinase in the increased serine phosphorylation of IRS-1 observed in human embryonic kidney cells treated with an activator of protein kinase C, phorbol 12-myristate 13-acetate. First, recombinantly produced kinase was shown to phosphorylate intact IRS-1 in a way that decreased the ability of isolated insulin receptor to phosphorylate the tyrosines recognized by the SH2 domains of the phosphatidylinositol 3-kinase. Second, an inhibitor of MAP kinase activation, PD98059, blocked the phorbol 12-myristate 13-acetate-induced inhibition of the insulin-stimulated increase in IRS-1 associated phosphatidylinositol 3-kinase. Third, activation of MAP kinase in intact cells via a regulatable upstream kinase, a RAF:estrogen receptor construct, could also inhibit the insulin-stimulated increase in IRS-1-associated phosphatidylinositol 3-kinase. Fourth, an in gel kinase assay showed that MAP kinase was the primary renaturable kinase in cell extracts capable of phosphorylating an IRS-1 fusion protein. Finally, IRS-1 was found to associate in coprecipitation studies with endogenous MAP kinase. These studies implicate MAP kinase as one of the kinases capable of phosphorylating and regulating IRS-1 tyrosine phosphorylation.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University					NIDDK NIH HHS [DK 34926, DK09310] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, F32DK009310, R01DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CHANG PY, 1995, J BIOL CHEM, V270, P29928; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CHIN JE, 1993, J BIOL CHEM, V268, P6338; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DEFEA K, 1997, BIOCHEMISTRY-US, V36, P181; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Haddad TC, 1997, J BIOL CHEM, V272, P19525, DOI 10.1074/jbc.272.31.19525; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Leitner JW, 1997, ENDOCRINOLOGY, V138, P2211, DOI 10.1210/en.138.5.2211; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Valverde AM, 1997, ENDOCRINOLOGY, V138, P3195, DOI 10.1210/en.138.8.3195; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOOD ER, 1992, J BIOL CHEM, V267, P14138; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	36	245	250	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31400	31406		10.1074/jbc.272.50.31400	http://dx.doi.org/10.1074/jbc.272.50.31400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395471	hybrid			2022-12-25	WOS:A1997YL41900030
J	Okamoto, M; Sudhof, TC				Okamoto, M; Sudhof, TC			Mints, Munc18-interacting proteins in synaptic vesicle exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTB DOMAIN; SYNTAXIN; PHOSPHOTYROSINE; INTERACTS; BINDING; FUSION; SYNAPTOBREVIN; SNAP-25; DOCKING; SYSTEM	Munc18-1 is a neuronal protein that interacts with syntaxin 1 and is required for synaptic vesicle exocytosis. We have now identified two Munc18-1-interacting proteins called Mint1 and Mint2 that may mediate the function of Munc18-1. Mint proteins are detectable only in brain and are composed of an N-terminal sequence that binds Munc18-1, a middle phosphotyrosine-binding domain, and two C-terminal PDZ domains thought to attach proteins to the plasma membrane. In brain, Mint proteins are part of a multimeric complex containing Munc18-1 and syntaxin that likely functions as an intermediate in synaptic vesicle docking/fusion. The phosphotyrosine-binding domain specifically binds to phosphatidylinositol phosphates known to be produced during vesicle exocytosis (Hay, J. C., Fisette, P. L., Jenkins, G. H., Fukami, K., Takonawa, T., Anderson, R. A., and Martin, T. F. J. (1995) Nature 374, 173-177). Our data suggest a model whereby local production of phosphatidylinositol phosphates may trigger the binding of vesicles to the active zone via the Minc.Munc18-1 complex in conjunction with syntaxin 1.	UNIV TEXAS,SW MED SCH,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; DUCLOS F, 1995, MAMM GENOME, V6, P57, DOI 10.1007/BF00350899; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Sambrook J., 2002, MOL CLONING LAB MANU; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	29	263	277	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31459	31464		10.1074/jbc.272.50.31459	http://dx.doi.org/10.1074/jbc.272.50.31459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395480	hybrid			2022-12-25	WOS:A1997YL41900039
J	Force, WR; Cheung, TC; Ware, CF				Force, WR; Cheung, TC; Ware, CF			Dominant negative mutants of TRAF3 reveal an important role for the coiled coil domains in cell death signaling by the lymphotoxin-beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; TRANSDUCING PROTEINS; ACTIVATION; FAMILY; ALPHA; CD40; BINDING; LMP1; ASSOCIATION	Ligation of the lymphotoxin-beta receptor (LT beta R) recruits tumor necrosis factor receptor-associated factor-3 (TRAF3) and initiates cell death in HT29 adenocarcinoma cells. The minimal receptor binding domain (TRAF-C) defined by two hybrid analyses is not sufficient for direct recruitment to the ligated receptor. A series of TRAF3 deletion mutants reveal that a subregion of the coiled coil motif is required for efficient recruitment to the LT beta R. Furthermore, the ability of TRAF3 to self-associate maps to an adjacent subregion, A TRAF3 deletion mutant that lacks the N-terminal zinc RING and zinc finger motifs, but retains the coiled coil and TRAF-C motifs, competitively displaces endogenous TRAF3 from the LT beta R. A second TRAF3 mutant that lacks the receptor binding domain, yet contains the TRAF3 self association domain, prevents TRAF3 homodimers from being recruited to the LT beta R. Both of these mutants have a dominant negative effect on cell death and demonstrate that the recruitment of TRAF3 oligomers is necessary to initiate signal transduction that activates the cell death pathway.	La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Ware, CF (corresponding author), La Jolla Inst Allergy & Immunol, Div Mol Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	CarlWare@liai.org			NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROWNING J, 1989, J IMMUNOL, V143, P1859; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; FORCE WR, 1995, J IMMUNOL, V155, P5280; FORCE WR, 1994, J BIOL CHEM, V269, P8863; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Hochman PS, 1996, J INFLAMM, V46, P220; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KRAJEWSKI JS, 1997, IN PRESS J IMMUNOL; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1997, GENOMICS, V42, P26, DOI 10.1006/geno.1997.4697; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Shaw MK, 1997, J EXP MED, V185, P1711, DOI 10.1084/jem.185.9.1711; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5	44	78	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30835	30840		10.1074/jbc.272.49.30835	http://dx.doi.org/10.1074/jbc.272.49.30835			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388227	hybrid			2022-12-25	WOS:000071640800040
J	Johnson, JE; Edwards, AS; Newton, AC				Johnson, JE; Edwards, AS; Newton, AC			A putative phosphatidylserine binding motif is not involved in the lipid regulation of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HIGH-AFFINITY; NULL ALLELE; CLONING; DECARBOXYLASE; GENE; EXPRESSION; DOMAIN; DIACYLGLYCEROL; ACTIVATION	Protein kinase C is specifically regulated by diacylglycerol and the amino phospholipid, phosphatidylserine. The molecular basis for the phosphatidylserine specificity was recently proposed to arise hom the presence of a putative phosphatidylserine binding motif, FXFXLKXXXKXR, localized in the C2 domain of protein kinase C (Igarashi, K., Kaneda, M., Yamaji, A. Saido, T. C., Kikkawa, Il,, One, U,, Inoue, a, and Umeda, M, (1995) J. Biol. Chem. 270, 29075-29078). To determine whether this moth mediates the interaction of protein kinase C with phosphatidylserine, the carboxyl terminal basic residues were mutated to Ala in protein kinase C beta II (K236A and R238A), and the phosphatidylserine regulation of the mutant enzyme was examined. Membrane binding and activity measurements revealed that the phosphatidylserine regulation for the mutant protein was indistinguishable from that of wild-type protein kinase C. Specifically, neither the apparent membrane affinity for phosphatidylserine-containing membranes in the presence or absence of diacylglycerol nor the phosphatidyl-serine-dependence for activation was affected by removal of the conserved basic residues at the carboxyl terminus of the consensus sequence. In addition, a synthetic peptide corresponding to the amino terminus of the consensus sequence (FTFNVK) had no effect on the concentration of phosphatidylserine resulting in half-maximal activation of protein kinase C. These results reveal that the carboxyl-terminal basic residues in the consensus moth FXFXLKXXXKXR are not responsible for the phosphatidylserine selectivity of protein kinase C and that, furthermore, the region of the C2 domain containing this moth is not involved in the membrane binding of protein kinase C.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	anewton@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154, R37GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; EDWARDS AS, 1998, IN PRESS BIOCHEMISTR; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; JEAN T, 1986, J BIOL CHEM, V261, P6414; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KUGE O, 1991, J BIOL CHEM, V266, P6370; LEE MH, 1989, J BIOL CHEM, V264, P14797; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; ONO Y, 1988, J BIOL CHEM, V263, P6927; OREILLY DR, 1994, BACULOVIRUS EXPRESSI, P128; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Sato T, 1997, J BIOL CHEM, V272, P2192; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416	31	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30787	30792		10.1074/jbc.272.49.30787	http://dx.doi.org/10.1074/jbc.272.49.30787			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388219	hybrid			2022-12-25	WOS:000071640800032
J	Storm, D; Herz, J; Trinder, P; Loos, M				Storm, D; Herz, J; Trinder, P; Loos, M			C1 Inhibitor-C(1)over-bar-s complexes are internalized and degraded by the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; AMYLOID-BETA PEPTIDE; ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA-1-PROTEINASE INHIBITOR; ANTITHROMBIN-III; PLASMINOGEN-ACTIVATOR; SEC RECEPTOR; ASIALOGLYCOPROTEIN RECEPTOR; PROTEOLYTIC INACTIVATION; CULTURED-CELLS	Like other serpin-enzyme complexes (SECs), proteinase-complexed C1 inhibitor (C1-INH) is rapidly cleared from the circulation and thought to be a neutrophil chemoattractant, suggesting that complex formation causes structural rearrangements exposing a domain which is recognized by specific cell surface receptors. However, the cellular receptor(s) responsible for the catabolism and potential mediation of chemotaxis by C1-INH-protease complexes remained obscure, To determine whether the SEC receptor mediates the binding and potential chemotaxis of C1-INH . C (1) over bar s, we performed binding assays with HepG2 cells, neutrophils, and monocytes, and the results show that C1-INH . C (1) over bar s neither bind to these cells nor cause a chemotactic response of neutrophils and monocytes, Furthermore, C1-INH . C (1) over bar s, the COOH-terminal C1 inhibitor peptide, or the tetrameric C1-INH . C (1) over bar s . C (1) over bar r . C1-INH complex were found to be significantly less effective in competing with the SEC receptor ligand I-125-peptide 105Y for the binding to HepG2; cells than unlabeled 105Y, indicating that the SEC receptor does not sufficiently recognize C1-INH-proteaae complexes. The asialoglycoprotein receptor was also ruled out to be responsible for the removal of the heavily glycosylated C1-INH . C (1) over bar s complex, since asialoorosomucoid did not compete for the clearance of C1-INH .I-125-C (1) over bar s and asialoglycoprotein receptor knockout mice showed no alterations in the C1-INH .I-125-C (1) over bar s clearance rate. We found that C1-INH .I-125-C (1) over bar s complexes were efficiently degraded by normal murine fibroblasts expressing the low density lipoprotein receptor-related protein (LRP) and cellular degradation was significantly reduced by chloroquine and the receptor-associated protein, which is a potent inhibitor of the binding of all known ligands to LRP. Moreover, receptor-associated protein inhibited the in vivo clearance of C1-INH .I-125-C (1) over bar s .,and murine fibroblasts genetically deficient for LRP did not degrade C1-INH .I-125-C (1) over bar s. Our results demonstrate that C1-INH . C (1) over bar s complexes do not stimulate neutrophil or monocytic chemotaxis but are removed by LRP, further underscoring its role as a serpin-enzyme complex clearance receptor.	Univ Mainz, Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	Johannes Gutenberg University of Mainz; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Loos, M (corresponding author), Univ Mainz, Inst Med Microbiol & Hyg, Hochhaus Augustuspl, D-55101 Mainz, Germany.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALSENZ J, 1989, J CLIN INVEST, V83, P1794, DOI 10.1172/JCI114084; ALSENZ J, 1987, J IMMUNOL METHODS, V96, P107, DOI 10.1016/0022-1759(87)90373-5; ARLAUD GJ, 1993, METHOD ENZYMOL, V223, P61; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; BRANDES ME, 1991, J IMMUNOL, V147, P1600; BRENNEIS H, 1993, EUR J CLIN INVEST, V23, P693, DOI 10.1111/j.1365-2362.1993.tb01288.x; COUTINHO M, 1994, J IMMUNOL, V153, P3648; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DESMET BJGL, 1993, BLOOD, V81, P56, DOI 10.1182/blood.V81.1.56.bloodjournal81156; FUCHS HE, 1984, J CELL BIOCHEM, V25, P231, DOI 10.1002/jcb.240250405; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KURDOWSKA A, 1990, J BIOL CHEM, V265, P21023; Malek R, 1996, CLIN EXP IMMUNOL, V105, P191, DOI 10.1046/j.1365-2249.1996.d01-714.x; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MINTA JO, 1981, J IMMUNOL, V126, P245; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; NILSSON T, 1983, BIOCHEM J, V213, P617, DOI 10.1042/bj2130617; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PATSTON PA, 1993, BLOOD, V82, P3371; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIZZO SV, 1989, AM J MED, V87, pS10, DOI 10.1016/0002-9343(89)80524-8; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; REBOUL A, 1987, BIOCHEM J, V244, P117, DOI 10.1042/bj2440117; REID KBM, 1988, MOL IMMUNOL, P199; SALVESEN GS, 1985, J BIOL CHEM, V260, P2432; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; Storm D, 1996, J IMMUNOL METHODS, V199, P87, DOI 10.1016/S0022-1759(96)00172-X; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TOSI M, 1993, COMPLEMENT HLTH DIS, P248; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, METHOD CELL BIOL, V43, P305; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; ZICCARDI RJ, 1979, J IMMUNOL, V123, P788	55	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31043	31050		10.1074/jbc.272.49.31043	http://dx.doi.org/10.1074/jbc.272.49.31043			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388254	hybrid			2022-12-25	WOS:000071640800067
J	Bustelo, XR; Crespo, P; LopezBarahona, M; Gutkind, JS; Barbacid, M				Bustelo, XR; Crespo, P; LopezBarahona, M; Gutkind, JS; Barbacid, M			Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-mediated c-Jun N-terminal kinase activation	ONCOGENE			English	Article						Cbl family; Vav; tyrosine phosphorylation; JNK activation	PROTOONCOGENE PRODUCT; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; STEEL FACTOR; SH2 DOMAIN; T-CELLS; BINDING; RECEPTORS; P95(VAV)	We have used the yeast two-hybrid system to identify proteins that interact with Vav, a GDP/GTP exchange factor for the Rac-1 GTPase that plays an important role in cell signaling and oncogenic transformation, This experimental approach resulted in the isolation of Cbl-b, a signal transduction molecule highly related to the mammalian c-cbl proto-oncogene product and to the C. elegans Sli-1 protein, a negative regulator of the EGF-receptor-like Let23 protein, The interaction between Vav and Cbl-b requires the entire SH3-SH2-SH3 carboxy-terminal domain of Vav and a long stretch of proline-rich sequences present in the central region of Cbl-b. Stimulation of quiescent rodent fibroblasts with either epidermal or platelet-derived growth factors induces an increased affinity of Vav for Cbl-b and results in the subsequent formation of a Vav-dependent trimeric complex with the ligand-stimulated tyrosine kinase receptors. During this process, Vav, but not Cbl-b, becomes highly phosphorylated on tyrosine residues, Overexpression of Cbl-b inhibits the signal transduction pathway of Vav that leads to the stimulation of c-Jun N-terminal kinase. By contrast, expression of truncated Cbl-b proteins and of missense mutants analogous to those found in inactive Sli-1 proteins have no detectable effect on Vav activity, These results indicate that Vav and Cbl-b act coordinately in the first steps of tyrosine protein kinase receptor-mediated signaling and suggest that members of the Sli-l/Cbl family are also negative regulators of signal transduction in mammalian cells.	SUNY STONY BROOK,SCH MED,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,UNIV HOSP,STONY BROOK,NY 11794; NIDR,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bustelo, XR (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL ONCOL,POB 4000,PRINCETON,NJ 08543, USA.		Gutkind, J. Silvio/J-1201-2016; Bustelo, Xose R./AAD-2081-2022; Gutkind, J. Silvio/A-1053-2009; Bustelo, Xose R./A-9526-2010; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Crespo, Piero/0000-0003-2825-7783				ALAI M, 1992, J BIOL CHEM, V267, P18021; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; BUTELO XR, 1996, CRIT REV ONCOGEN, V7, P65; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1996, ONCOGENE, V13, P355; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FISHER KD, 1995, NATURE, V374, P474; Hobert O, 1996, ONCOGENE, V12, P1577; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KEANE MM, 1995, ONCOGENE, V10, P2367; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; MACHIDE M, 1995, ONCOGENE, V11, P619; Marengere LEM, 1997, J IMMUNOL, V159, P70; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Romero F, 1996, MOL CELL BIOL, V16, P37; Schuebel KE, 1996, ONCOGENE, V13, P363; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	37	73	77	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2511	2520		10.1038/sj.onc.1201430	http://dx.doi.org/10.1038/sj.onc.1201430			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399639				2022-12-25	WOS:A1997YG73200001
J	Walsh, AB; Dhanasekaran, M; BarSagi, D; Kumar, CC				Walsh, AB; Dhanasekaran, M; BarSagi, D; Kumar, CC			SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway	ONCOGENE			English	Article						RAS; RAC; membrane ruffles; signaling pathways	SIGNAL-TRANSDUCTION; FARNESYLTRANSFERASE INHIBITORS; ACTIN POLYMERIZATION; KINASE; ACTIVATION; PROTEINS; GROWTH; FARNESYLATION; ONCOGENES; INDUCTION	RAS interacts with multiple targets in the cell and controls at least two signaling pathways, one regulating extracellular signal-regulated kinase (ERK) activation and the other controlling membrane ruffling formation. These two pathways appear to act synergistically to cause: transformation. SCH 51344 is a pyrazolo-quinoline derivative identified based on its ability to derepress transformation sensitive alpha-actin promoter in RAS-transformed cells, Previous studies have shown that SCH 51344 is a potent inhibitor of RAS-transformation, However, SCH 51344 had very little effect on the activities of proteins in the ERI( pathway, suggesting that it inhibits RAS-transformation by a novel mechanism. In this study, we show that SCH 51344 specifically blocks membrane ruffling induced by activated forms of H-RAS, II-RAS, N-RAS and RAG. Treatment of fibroblast cells with this compound had very little effect on RAS-mediated activation of ERK and JUN kinase activities. SCH 51344 was effective in inhibiting the anchorage-independent growth of Rat-2 fibroblast cells transformed by the three forms of oncogenic RAS and RBC V12, These results indicate that SCH 51344 inhibits a critical component of the membrane ruffling pathway downstream from RAC and suggest that targeting this pathway may be an effective approach to inhibit transformation by RAS and other oncogenes.	SCHERING PLOUGH CORP,RES INST,DEPT TUMOR BIOL,KENILWORTH,NJ 07033; SUNY STONY BROOK,DEPT MICROBIOL & MOL GENET,STONY BROOK,NY 11794; SUNY STONY BROOK,GRAD PROGRAM PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; TEMPLE UNIV,SCH MED,FELS INST CANC RES,PHILADELPHIA,PA 19140	Merck & Company; Schering Plough Corporation; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA 55360] Funding Source: Medline; NIGMS NIH HHS [GM 49897] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055360, R37CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; BOS JL, 1989, CANCER RES, V49, P4682; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX LR, 1991, CANCER RES, V51, P4810; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; ITOH O, 1989, CANCER RES, V49, P996; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KUMAR CC, 1995, CANCER RES, V55, P5106; KUMAR CC, 1992, CANCER RES, V52, P6877; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; QUI RG, 1995, NATURE, V374, P457; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459	35	19	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2553	2560		10.1038/sj.onc.1201424	http://dx.doi.org/10.1038/sj.onc.1201424			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399643				2022-12-25	WOS:A1997YG73200005
J	Sherman, L; Xu, HM; Geist, RT; SaporitoIrwin, S; Howells, N; Ponta, H; Herrlich, P; Gutmann, DH				Sherman, L; Xu, HM; Geist, RT; SaporitoIrwin, S; Howells, N; Ponta, H; Herrlich, P; Gutmann, DH			Interdomain binding mediates tumor growth suppression by the NF2 gene product	ONCOGENE			English	Article						merlin; negative growth regulator; tumor suppressor gene; schwannomin; schwannoma; ERM proteins	NEUROFIBROMATOSIS TYPE-2 GENE; TERMINAL DOMAIN; CELL LINES; MUTATIONS; MEMBRANE; RADIXIN; MERLIN; EXPRESSION; LOCALIZES; ISOFORMS	The neurofibromatosis 2 (NF2) tumor suppressor gene encodes an intracellular membrane-associated protein, called merlin (or schwannomin), that belongs to the band 4.1 family of cytoskeleton-associated proteins, Inactivating NF2 mutations occur in several sporadic tumor types and have been linked to the NF2 disease, whose hallmark is the development of bilateral Schwann cell tumors (schwannomas) of the eighth cranial nerve, Two major alternatively spliced NI;2 variants are expressed in normal tissues:'NF2-17 lacking exon 16 and 'NF2-16' that contains exon 16 and encodes a merlin protein truncated at the C-terminus, We report that overexpression of NF2-17 in rat schwannoma cells inhibits their growth in vitro and in vivo, while NF2-16 fails to influence schwannoma growth, Tumor growth inhibition by merlin depends on an interdomain association occurring either in cis or in hans between the N- and C-termini, This association does not occur in the truncated NF2-16 protein nor in a mutant NF2-17 protein lacking C-terminal sequences, These data indicate that merlin has a unique mechanism of tumor suppression, inhibiting cell proliferation via self-association.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,D-76021 KARLSRUHE,GERMANY	Washington University (WUSTL); Helmholtz Association; Karlsruhe Institute of Technology				Gutmann, David/0000-0002-3127-5045				BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BIJISMA E, 1995, HUM GENET, V96, P1; DENBAKKER MA, 1995, ONCOGENE, V10, P757; EVANS DGR, 1995, J MED GENET, V32, P470, DOI 10.1136/jmg.32.6.470; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GUTMANN DH, 1995, HUM MOL GENET, V4, P471, DOI 10.1093/hmg/4.3.471; Gutmann DH, 1995, INT J DEV BIOL, V39, P895; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; HAASE VH, 1994, HUM MOL GENET, V3, P407, DOI 10.1093/hmg/3.3.407; HARA T, 1994, CANCER RES, V54, P330; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MACCOLLIN M, 1994, AM J HUM GENET, V55, P314; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Parry DM, 1996, AM J HUM GENET, V59, P529; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Sherman L, 1995, J NEURO-ONCOL, V26, P171, DOI 10.1007/BF01052620; SHORT MP, 1994, NEUROFIBROMATOSES PA, P414; SWAFFIELD JC, 1996, CURRENT PROTOCOLS MO, pCH20; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TOMOZAWA Y, 1978, P NATL ACAD SCI USA, V75, P6305, DOI 10.1073/pnas.75.12.6305; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G	30	187	189	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2505	2509		10.1038/sj.onc.1201418	http://dx.doi.org/10.1038/sj.onc.1201418			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395247				2022-12-25	WOS:A1997YE96300013
J	Hazzalin, CA; Cuenda, A; Cano, E; Cohen, P; Mahadevan, LC				Hazzalin, CA; Cuenda, A; Cano, E; Cohen, P; Mahadevan, LC			Effects of the inhibition of p38/RK MAP kinase on induction of five fos and jun genes by diverse stimuli	ONCOGENE			English	Article						MAP kinases; p38/RK; fos, jun; SB 203580	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; C-JUN; TRANSCRIPTIONAL ACTIVATION; OKADAIC ACID; HISTONE H3; PHOSPHORYLATION; STRESS; DOMAIN; IDENTIFICATION	The ERK, JNK/SAPK and p38/RK MAP kinase subtypes are differentially activated by physiological, pharmacological and stress stimuli; all three subtypes are implicated in immediate-early (IF) gene induction by these agents, Here, we have asked whether inhibition of a single MAP kinase subtype under these conditions would generally alter induction of several IF genes in a similar way or whether this would differentially up-and down-regulate particular IF genes, an issue which bears on the question of whether individual MAP kinases ape strictly targeted to specific IE genes, or whether they might catalyse phosphorylation events that affect several IF genes in the same way, SB 203580, an inhibitor of p38/RK, has been used to analyse the role of this kinase in the induction of five IF genes (c-fos, fosB, c-jun, junB and junD) under diverse conditions of stimulation, Bn C3H 10T1/2 cells, p38/RK and its downstream kinase MAPKAP K-2 are activated by all stimuli used with the exception of TPA, The specificity of SB 203580 as a p38/RK inhibitor in these cells is demonstrated; it does not affect ERKs or JNK/SAPKs but does result in a small increase in the activity of the upstream kinase MKK6, the principal p38/RK activator in these cells. We find that inhibition of p38/RK under these conditions produces general effects on all five IE genes as a group in three ways, First, induction of all five genes in response to okadaic acid or tumour necrosis factor-alpha (TNF-alpha) is not significantly altered by SB 203580, Second, in cells stimulated with anisomycin or U.V. radiation, SB 203580 potently inhibits all of the induced IE genes. Finally, SB 203580 enhances induction of all five IE genes in EGF-treated cells; these enhanced mRNA levels are not due to stabilisation of labile mRNA transcripts, The significance of these results to current thinking on the relationship between distinct MAP kinase subtypes and specific IF genes is discussed.	UNIV LONDON KINGS COLL,NUCL SIGNALLING LAB,DEV BIOL RES CTR,RANDALL INST,LONDON WC2B 5RL,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,MRC PROTEIN PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of London; King's College London; University of Dundee			Cano, Eva/A-2049-2010	Cano, Eva/0000-0003-2750-6135				ALESSI DR, 1995, P NATL ACAD SCI USA, V92, P7686; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BAYAERT R, 1996, EMBO J, V15, P1914; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; Cano E, 1996, ONCOGENE, V12, P805; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CUENDA A, 1996, EMBO J, V15, P4293; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOZA YN, 1995, FEBS LETT, V364, P233; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; PRICE MA, 1996, IN PRESS EMBO J; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; YAN MH, 1994, NATURE, V372, P798; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	60	89	93	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2321	2331		10.1038/sj.onc.1201403	http://dx.doi.org/10.1038/sj.onc.1201403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393876				2022-12-25	WOS:A1997YE15700006
J	Bachurski, CJ; Kelly, SE; Glasser, SW; Currier, TA				Bachurski, CJ; Kelly, SE; Glasser, SW; Currier, TA			Nuclear factor I family members regulate the transcription of surfactant protein-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CELL-SPECIFIC TRANSCRIPTION; DNA-BINDING; HUMAN LUNG; CTF/NF-I; B GENE; PROMOTER; EXPRESSION; ENHANCER; SITES	Transcription of the surfactant protein-C (SP-C) gene is restricted to Type II epithelial cells in the adult lung, We have shown previously that the 0.32-kilobase pair (kb) mouse SP-C promoter is functional in transient transfection assays of the lung epithelial cell-derived cell line, MLE-15, and that thyroid transcription factor 1 (TTF-1) transactivates promoter activity, The 0.32-kb SP-C promoter can be separated into a proximal promoter region (-230 to +18) and an enhancer region (-318 to -230), Three DNase I footprints were mapped in the promoter region (C1 through C3) and two in the enhancer region (C4 and C5), We now show that nuclear factor I (NFI) family members bind to both individual NFI half-sites in footprints C1, C3, and C5, and to a composite site in footprint C4 by competition gel retardation and antibody supershift analyses, Mutational analysis of the 0.32-kb mouse SP-C promoter and transient transfection of MLE-15 cells demonstrated that the NFI binding sites are required for promoter activity in this cell type, Site-specific mutation of the proximal or distal NFI sites drastically reduced transactivation by a co-transfected NFI-A expression vector in HeLa cells. These data indicate that NFI family member(s), binding to sites in both the promoter and enhancer regions, regulate SP-C gene expression in a process independent of TTF-1.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Bachurski, CJ (corresponding author), Childrens Hosp Res Fdn, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Bachurski, Cindy/0000-0002-3118-0636	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752, R01HL050046, R29HL050046] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07752, HL50046] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; BACHURSKI CJ, 1995, J BIOL CHEM, V270, P19402, DOI 10.1074/jbc.270.33.19402; BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOISJOYEUX B, 1994, BIOCHEM J, V301, P49, DOI 10.1042/bj3010049; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; COALSON JJ, 1995, AM J RESP CRIT CARE, V151, P854; ESKILD W, 1994, MOL ENDOCRINOL, V8, P732, DOI 10.1210/me.8.6.732; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GLASSER SW, 1994, AM J PHYSIOL-LUNG C, V267, pL489, DOI 10.1152/ajplung.1994.267.5.L489; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; Krebs CJ, 1996, J NEUROCHEM, V66, P1354; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; Liu YC, 1997, J BIOL CHEM, V272, P10739; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; OCONNOR M, 1995, VIROLOGY, V207, P77, DOI 10.1006/viro.1995.1053; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Puzianowska-Kuznicka M, 1996, J BIOL CHEM, V271, P6273, DOI 10.1074/jbc.271.11.6273; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084; Zsengeller ZK, 1997, HUM GENE THER, V8, P1331, DOI 10.1089/hum.1997.8.11-1331	47	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32759	32766		10.1074/jbc.272.52.32759	http://dx.doi.org/10.1074/jbc.272.52.32759			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407049	hybrid			2022-12-25	WOS:000071182900010
J	Chiara, DC; Cohen, JB				Chiara, DC; Cohen, JB			Identification of amino acids contributing to high and low affinity d-tubocurarine sites in the Torpedo nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; H-3 MEPROADIFEN MUSTARD; AGONIST-BINDING-SITE; ALPHA-SUBUNIT; DELTA-SUBUNIT; MOLECULAR DISSECTION; GEL-ELECTROPHORESIS; NONCOMPETITIVE ANTAGONIST; COMPETITIVE ANTAGONISTS; GAMMA-SUBUNIT	d-Tubocurarine (dTC) is a potent competitive antagonist of the Torpedo nicotinic acetylcholine receptor (nAChR) that binds non-equivalently to the two agonist sites (K-d values of 30 nM and 8 mu M). When nAChR-rich membranes equilibrated with [H-3]dTC are irradiated with 254 nm UV light, [H-3]dTC is covalently incorporated into the alpha-, gamma-, and delta-subunits in a concentration-dependent and agonist-inhibitable manner, consistent with the localization of the high and low affinity dTC binding sites at the alpha-gamma- and alpha-delta-subunit interfaces, respectively (Pedersen, S. E. and Cohen, J. B. (1990) Proc. Natl. Acad Sci. U. S. A. 87, 2785-2789). We report on the amino acids within alpha-, gamma-, and delta-subunits that are the sites of specific photoincorporation of [H-3]dTC. Subunits isolated from nAChR-rich membranes photolabeled with [H-3]dTC were subjected to enzymatic digestion, and peptides containing H-3 were isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and/or reversed-phase high performance liquid chromatography. Isolated peptides were then subjected to NH2-terminal sequence analysis to identify specifically labeled residues. Within the alpha-subunit, 95% of specific incorporation was contained within a 20-kDa proteolytic fragment beginning at Ser-173, with alpha Tyr-190 the primary site of [H-3]dTC photoincorporation and alpha Cys-192 and alpha Tyr-198 labeled at lower efficiency, Within gamma- and delta-subunits, specific labeling was contained within proteolytic fragments of 14 and 21 kDa, respectively, beginning at gamma Ala-49 and delta Thr-51. gamma Trp-55 and delta Trp-57 were identified as the sites of specific [H-3]dTC photoincorporation, Sequence alignment studies reveal gamma Trp-55 and delta Trp-57 to be homologous residues at whose position in receptor subunit primary structure a unique pattern of conservation exists in all nAChR (neuronal and muscle), Specifically, all subunits that associate with an cu-subunit to form an agonist site contain a tryptophan homologous to gamma Trp-55/delta Trp-57. This pattern of conservation may indicate a functional significance for tryptophan at that location in all nAChR agonist sites.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 200 Longwood Ave, Boston, MA 02115 USA.	jbcohen@warren.med.harvard.edu			NINDS NIH HHS [NS 19522] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019522] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ABRAMSON SN, 1988, J BIOL CHEM, V263, P18568; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; Buhr A, 1997, J BIOL CHEM, V272, P11799, DOI 10.1074/jbc.272.18.11799; CHIARA D C, 1992, Biophysical Journal, V61, pA106; CHIARA DC, 1997, THESIS WASHINGTON U; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DREYER EB, 1986, J BIOL CHEM, V261, P3727; FU DX, 1994, J BIOL CHEM, V269, P26152; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GALZI JL, 1990, J BIOL CHEM, V265, P10430; HAGGERTY JG, 1981, J BIOL CHEM, V256, P8294; Harvey SC, 1996, J NEUROSCI, V16, P3798; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; KAO PN, 1984, J BIOL CHEM, V259, P1662; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NOMOTO H, 1986, EUR J BIOCHEM, V157, P233, DOI 10.1111/j.1432-1033.1986.tb09661.x; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; POULTER L, 1989, P NATL ACAD SCI USA, V86, P6645, DOI 10.1073/pnas.86.17.6645; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1981, J BIOL CHEM, V256, P6692; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; STRECKER A, 1994, EUR J BIOCHEM, V220, P1005, DOI 10.1111/j.1432-1033.1994.tb18705.x; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; WEILL CL, 1974, BIOCHEM BIOPH RES CO, V61, P997, DOI 10.1016/0006-291X(74)90254-X; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Xie Y., 1994, Society for Neuroscience Abstracts, V20, P1129; Xie Y., 1995, Biophysical Journal, V68, pA406; Zhang Y., 1995, Society for Neuroscience Abstracts, V21, P1582	49	85	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32940	32950		10.1074/jbc.272.52.32940	http://dx.doi.org/10.1074/jbc.272.52.32940			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407073	hybrid			2022-12-25	WOS:000071182900034
J	Lokker, NA; O'Hare, JP; Barsoumian, A; Tomlinson, JE; Ramakrishnan, V; Fretto, LJ; Giese, NA				Lokker, NA; O'Hare, JP; Barsoumian, A; Tomlinson, JE; Ramakrishnan, V; Fretto, LJ; Giese, NA			Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains - Identification of PDGF binding site and neutralizing monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL FACTOR; SIGNAL-TRANSDUCTION; BB BINDING; LIGAND-BINDING; ALPHA-PDGF; EXPRESSION; AA; ACTIVATION; GLOMERULONEPHRITIS; MECHANISM	The biological effects of platelet-derived growth factor (PDGF) are mediated by alpha- and beta-PDGF receptors (PDGFR), which have an intracellular tyrosine kinase domain and an extracellular region comprising five immunoglobulin-like domains (D1-D5). Using deletion mutagenesis we mapped the PDGF binding site in each PDGFR to the D2-D3 region, In the case of alpha-PDGFR, I-125-PDGF AA and I-125-PDGF BB bound to the full-length extracellular domain, D1-D5, and D2-D3 with equal affinity (K-d = 0.21-0.42 nM). Identical results were obtained for I-125-PDGF BB binding to beta-PDGFR mutants D1-D5 and D2-D3, establishing that D1, D4, and D5 do not contribute to PDGF binding. Monoclonal antibodies (mAb) directed against individual PDGFR Ig-like domains were used to extend these observations. The anti-D1 mAb 1E10E2 and anti-D5 mAb 2D4G10 had no effect on alpha- or beta-PDGFR function, respectively. In contrast, mAb 2H7C5 and 2A1E2 directed against D2 of the alpha- and beta-receptor, respectively, blocked PDGF binding, receptor autophosphorylation and mitogenic signaling with IC50 values of 0.1-3.0 nM. An anti-D4 mAb 1C7D5 blocked beta-receptor autophosphorylation and signaling without inhibiting PDGF binding consistent with the observation that D4 is essential for PDGFR dimerization (Omura, T., Heldin, C.-H., and Ostman, A. (1997) J. Biol. Chem. 272, 12676-12682), mAbs identified here act as potent PDGFR antagonists that can be used as research tools and potentially as therapeutic agents for the treatment of diseases involving unwanted PDGFR signaling.	COR Therapeut Inc, San Francisco, CA 94080 USA		Giese, NA (corresponding author), COR Therapeut Inc, 256 E Grand Ave, San Francisco, CA 94080 USA.	neill_giese@corr.com						BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; ESCOBEDO JA, 1988, SCIENCE, V240, P1532, DOI 10.1126/science.2836953; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; GESUALDO L, 1991, LAB INVEST, V65, P160; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; Harlow E., 1988, ANTIBODIES LAB MANUA; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1992, KIDNEY INT, V41, P571, DOI 10.1038/ki.1992.84; HERREN B, 1993, J BIOL CHEM, V268, P15088; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; RAMAKRISHNAN V, 1993, GROWTH FACTORS, V8, P253, DOI 10.3109/08977199308991571; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Shulman T, 1997, J BIOL CHEM, V272, P17400, DOI 10.1074/jbc.272.28.17400; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU JC, 1994, J BIOL CHEM, V269, P10668; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348	39	45	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33037	33044		10.1074/jbc.272.52.33037	http://dx.doi.org/10.1074/jbc.272.52.33037			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407086	hybrid			2022-12-25	WOS:000071182900047
J	Melen, K; Julkunen, I				Melen, K; Julkunen, I			Nuclear cotransport mechanism of cytoplasmic human MxB protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORNE THOGOTO-VIRUS; INFLUENZA-VIRUS; CONFERS RESISTANCE; DHORI-VIRUS; MURINE MX1; GTPASE; GENE; MICE; EXPRESSION; REGION	Interferon-alpha/beta-inducible Mx proteins belong to the family of large GTPases and share high sequence homology with dynamins in their N-terminal GTP-binding domains, In addition, Nix proteins have a conserved C-terminal leucine zipper element that is involved in their oligomerization, Cytoplasmic human MxA protein mediates resistance to multiple RNA viruses, whereas no antiviral activity has been found for human MxB protein, We have previously shown that MxB protein exists as a nuclear 78-kDa and as a cytoplasmic 76-kDa form in interferon-alpha-induced human cells, Using various influenza hemagglutinin epitope-tagged MxB gene constructs in transient transfection experiments in COS-1 cells, we show that the cytoplasmic 76-kDa MxB protein forms hetero-oligomers with the nuclear 78-kDa MxB protein via the C-terminal leucine zipper element. This enables the cytoplasmic form of MxB protein to be translocated into the nucleus together with the nuclear form of MxB protein, This finding was confirmed in interferon-alpha-induced HEp-2 and T98G cells transfected with various MxB gene constructs, Cell fractionation studies also suggest that a considerable amount of the cytoplasmic MxB protein is also found in the nucleus, Using confocal laser microscopy, we also demonstrate that the cytoplasmic MxA and the nuclear MxB proteins do not colocalize/oligomerize with each other, and both of these proteins are retained in their specific cellular compartments.	Natl Publ Hlth Inst, Dept Virol, FIN-00300 Helsinki, Finland	Finland National Institute for Health & Welfare	Melen, K (corresponding author), Natl Publ Hlth Inst, Dept Virol, Mannerheimintie 166, FIN-00300 Helsinki, Finland.							AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; Arnheiter H, 1996, CURR TOP MICROBIOL, V206, P119; Cantell K, 1981, Methods Enzymol, V78, P29; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Frese M, 1996, J VIROL, V70, P915, DOI 10.1128/JVI.70.2.915-923.1996; HALLER O, 1995, J VIROL, V69, P2596, DOI 10.1128/JVI.69.4.2596-2601.1995; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; Kanerva M, 1996, VIROLOGY, V224, P55, DOI 10.1006/viro.1996.0506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEIER E, 1988, J VIROL, V62, P2386, DOI 10.1128/JVI.62.7.2386-2393.1988; MELEN K, 1992, J BIOL CHEM, V267, P25898; Melen K, 1996, J BIOL CHEM, V271, P23478, DOI 10.1074/jbc.271.38.23478; MELEN K, 1994, VIROLOGY, V205, P269, DOI 10.1006/viro.1994.1643; MELEN K, 1994, J BIOL CHEM, V269, P2009; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1992, VIRUS RES, V22, P227, DOI 10.1016/0168-1702(92)90054-D; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; NOTEBORN M, 1987, J INTERFERON RES, V7, P657, DOI 10.1089/jir.1987.7.657; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PAVLOVIC J, 1992, J VIROL, V66, P2564, DOI 10.1128/JVI.66.4.2564-2569.1992; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; Ronni T, 1997, J IMMUNOL, V158, P2363; RONNI T, 1993, J IMMUNOL, V150, P1715; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; Sareneva T, 1996, EUR J BIOCHEM, V242, P191, DOI 10.1111/j.1432-1033.1996.0191r.x; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; SURDEJ P, 1994, BIOTECHNIQUES, V17, P560; THIMME R, 1995, VIROLOGY, V211, P296, DOI 10.1006/viro.1995.1404; Trobridge GD, 1997, J VIROL, V71, P5304, DOI 10.1128/JVI.71.7.5304-5311.1997	31	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32353	32359		10.1074/jbc.272.51.32353	http://dx.doi.org/10.1074/jbc.272.51.32353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405443	hybrid			2022-12-25	WOS:000071108000062
J	Andjelkovic, M; Alessi, DR; Meier, R; Fernandez, A; Lamb, NJC; Frech, M; Cron, P; Cohen, P; Lucocq, JM; Hemmings, BA				Andjelkovic, M; Alessi, DR; Meier, R; Fernandez, A; Lamb, NJC; Frech, M; Cron, P; Cohen, P; Lucocq, JM; Hemmings, BA			Role of translocation in the activation and function of protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; C-AKT; SER/THR KINASE; EXPRESSION; ONCOGENE; CELLS; PHOSPHORYLATION; 3-KINASE; AMPLIFICATION	We have investigated the role of subcellular localization in the regulation of protein kinase B (PKB) activation. The myristoylation/palmitylation motif from the Lck tyrosine kinase was attached to the N terminus of protein kinase B to alter its subcellular location. Myristoylated/palmitylated (m/p)-PKB alpha was associated with the plasma membrane of transfected cells, whereas the wild-type kinase was mostly cytosolic. The activity of m/p-PKB alpha was 60-fold higher compared with the unstimulated wild-type enzyme, and could not be stimulated further by growth factors or phosphatase inhibitors. In vivo P-32 labeling and mutagenesis demonstrated that m/p-PKB alpha activity was due to phosphorylation on Thr(308) and Ser(473), that are normally induced on PKB following stimulation of the cells with insulin or insulin-like growth factor-1 (IGF-1). A dominant negative form of phosphoinositide 3-kinase (PI3-K) did not affect m/p-PKB alpha activity. The pleckstrin homology (PH) domain of m/p-PKB alpha was not required for its activation or phosphorylation on Thr(308) and Ser(473), suggesting that this domain may serve as a membrane-targeting module. Consistent with this view, PKB alpha was translocated to the plasma membrane within minutes after stimulation with IGF-1. This translocation required the PH domain and was sensitive to wortmannin. Our results indicate that PI3-K activity is required for translocation of PKB to the plasma membrane, where its activation occurs through phosphorylation of the same sites that are induced by insulin or IGF-1. Following activation the kinase detached from the membrane and translocated to the nucleus.	FRIEDRICH MIESCHER INST,CH-4056 BASEL,SWITZERLAND; UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND; CNRS,INSERM,CTR RECH BIOCHIM MACROMOL,DEPT CELL BIOL,F-34033 MONTPELLIER,FRANCE; UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 4HN,SCOTLAND	Friedrich Miescher Institute for Biomedical Research; University of Dundee; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Dundee				lucocq, john/0000-0002-5191-0093; Alessi, Dario/0000-0002-2140-9185				AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALESSI DR, 1977, CURR BIOL, V7, P776; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1996, CURR OPIN CELL BIOL, V8, P253; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; Harlow E., 1988, ANTIBODIES LAB MANUA; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LUCOCQ J, 1994, J ANAT, V184, P1; LUCOCQ JM, 1993, FINE STRUCTURE IMMUN, P279; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Zlatkine P, 1997, J CELL SCI, V110, P673	53	869	896	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31515	31524		10.1074/jbc.272.50.31515	http://dx.doi.org/10.1074/jbc.272.50.31515			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395488	hybrid			2022-12-25	WOS:A1997YL41900047
J	Meyer, WKH; Reichenbach, P; Schindler, U; Soldaini, E; Nabholz, M				Meyer, WKH; Reichenbach, P; Schindler, U; Soldaini, E; Nabholz, M			Interaction of STAT5 dimers on two low affinity binding sites mediates interleukin 2 (IL-2) stimulation of IL-2 receptor alpha gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; GAMMA-CHAIN; CYTOLYTIC ACTIVITY; TRANSGENIC MICE; BETA-CHAIN; EXPRESSION; ACTIVATION; ELEMENTS; CELLS; SEQUENCE	Stimulation of the interleukin 2 receptor alpha (IL-2R alpha) gene by IL-2 is important for the proliferation of antigen-activated T lymphocytes. IL-2 regulates IL-2R alpha transcription via a conserved 51-nucleotide IL-2 responsive enhancer. Mouse enhancer function depends on cooperative activity of three distinct sites. Two of these are weak binding sites for IL-2-activated STATE (signal transducer and activator of transcription) proteins, and mutational analysis indicates that binding of STAT5 to both sites is required for IL-2 responsiveness of the enhancer. The STATE dimers interact to form a STATE tetramer. The efficiency of tetramerization depends on the relative rotational orientation of the two STAT motifs on the DNA helix. STAT5 tetramerization on enhancer mutants correlates well with the IL-2 responsiveness of these mutants. This provides strong evidence that interactions between STAT dimers binding to a pair of weak binding sites play a biological role by controlling the activity of a well characterized, complex cytokine-responsive enhancer.	SWISS INST EXPT CANC RES,LYMPHOCYTE BIOL UNIT,CH-1066 EPALINGES,SWITZERLAND; TULARIK INC,S SAN FRANCISCO,CA 94080	Swiss Institute Experimental Cancer Research								ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BUCHER P, 1997, IMMUNOBIOLOGY, V197, P13; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; CONZELMANN A, 1982, NATURE, V298, P170, DOI 10.1038/298170a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEPPER JM, 1985, P NATL ACAD SCI USA, V82, P4230, DOI 10.1073/pnas.82.12.4230; ESPEL E, 1990, EMBO J, V9, P929, DOI 10.1002/j.1460-2075.1990.tb08191.x; GEERING G, 1966, J EXP MED, V124, P753, DOI 10.1084/jem.124.4.753; GUYER NB, 1995, J IMMUNOL, V155, P3472; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; KONDO M, 1994, EUR J IMMUNOL, V24, P2026, DOI 10.1002/eji.1830240914; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LOWENTHAL JW, 1985, J IMMUNOL, V134, P931; Mikita T, 1996, MOL CELL BIOL, V16, P5811; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; NISHI M, 1988, NATURE, V331, P267, DOI 10.1038/331267a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; PLAETINCK G, 1990, J IMMUNOL, V145, P3340; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; SILVA A, 1983, IMMUNOL REV, V76, P105, DOI 10.1111/j.1600-065X.1983.tb01099.x; SOLDAINI E, 1995, J BIOL CHEM, V270, P10733, DOI 10.1074/jbc.270.18.10733; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Sperisen P, 1992, PCR Methods Appl, V1, P164; TAGA T, 1995, CURR OPIN IMMUNOL, V7, P17, DOI 10.1016/0952-7915(95)80024-7; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1993, IMMUNOL TODAY, V14, P264, DOI 10.1016/0167-5699(93)90043-K; WILSON A, 1994, EUR J IMMUNOL, V24, P1729, DOI 10.1002/eji.1830240802; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8	53	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31821	31828		10.1074/jbc.272.50.31821	http://dx.doi.org/10.1074/jbc.272.50.31821			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395528	hybrid			2022-12-25	WOS:A1997YL41900087
J	Peters, MF; OBrien, KF; SadouletPuccio, HM; Kunkel, LM; Adams, ME; Froehner, SC				Peters, MF; OBrien, KF; SadouletPuccio, HM; Kunkel, LM; Adams, ME; Froehner, SC			beta-dystrobrevin, a new member of the dystrophin family - Identification, cloning, and protein associations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO ELECTRIC ORGAN; SKELETAL-MUSCLE; GLYCOPROTEIN-COMPLEX; SUBCELLULAR-DISTRIBUTION; INSITU HYBRIDIZATION; AGRIN RECEPTOR; SYNTROPHIN; UTROPHIN; DYSTROGLYCAN; BINDING	Dystrophin, the protein disrupted in Duchenne muscular dystrophy, is one of several related proteins that are key components of the submembrane cytoskeleton. Three dystrophin-related proteins (utrophin, dystrophin-related protein-2 (DRP2), and dystrobrevin) have been described. Here, we identify a human gene on chromosome 2p22-23 that encodes a novel protein, beta-dystrobrevin, with significant homology to the other known dystrobrevin (now termed alpha-dystrobrevin), Sequence alignments including this second dystrobrevin strongly support the concept that two distinct subfamilies exist within the dystrophin family, one composed of dystrophin, utrophin, and DRP2 and the other composed of alpha- and beta-dystrobrevin, The possibility that members of each subfamily form distinct protein complexes was examined by immunopurifying dystrobrevins and dystrophin. A beta-dystrobrevin antibody recognized a protein of the predicted size (71 kDa) that copurified with the dystrophin short form, Dp71, Thus, like alpha-dystrobrevin, beta-dystrobrevin is likely to associate directly with dystrophin. alpha- and beta-dystrobrevins failed to copurify with each other, however, These results suggest that members of the dystrobrevin subfamily form heterotypic associations with dystrophin and raise the possibility that pairing of a particular dystrobrevin with dystrophin may be regulated, thereby providing a mechanism for assembly of distinct submembrane protein complexes.	UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, DIV GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Puccio, Hélène/G-1717-2013	Puccio, Hélène/0000-0003-4711-2248	NINDS NIH HHS [NS33145, NS14871, NS23740-09] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023740, R01NS014871, R01NS033145] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; Bonnemann Carsten G., 1996, Current Opinion in Pediatrics, V8, P569; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FITZGERALD KM, 1994, J CLIN INVEST, V93, P2425, DOI 10.1172/JCI117250; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; Froehner SC, 1997, SOC GEN PHY, V52, P197; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1998, IN PRESS J NEUROSCI; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Gussoni E, 1996, NAT BIOTECHNOL, V14, P1012, DOI 10.1038/nbt0896-1012; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KHURANA TS, 1992, J CELL BIOL, V119, P357, DOI 10.1083/jcb.119.2.357; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; Roberts RG, 1996, NAT GENET, V13, P223, DOI 10.1038/ng0696-223; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Sadoulet-Puccio HM, 1997, NEUROGENETICS, V1, P37, DOI 10.1007/s100480050006; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; SadouletPuccio HM, 1996, BRAIN PATHOL, V6, P25, DOI 10.1111/j.1750-3639.1996.tb00780.x; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; Sharp AA, 1996, J NEUROSCI, V16, P6775; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; VERMA RS, 1989, HUMAN CHROMOSOMES MA; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S; Winder SJ, 1996, BIOCHEM SOC T, V24, P497, DOI 10.1042/bst0240497; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294; YANG B, 1994, J BIOL CHEM, V269, P6040; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	59	102	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31561	31569		10.1074/jbc.272.50.31561	http://dx.doi.org/10.1074/jbc.272.50.31561			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395493	hybrid			2022-12-25	WOS:A1997YL41900052
J	Antonny, B; Huber, I; Paris, S; Chabre, M; Cassel, D				Antonny, B; Huber, I; Paris, S; Chabre, M; Cassel, D			Activation of ADP-ribosylation factor 1 GTPase-activating protein by phosphatidylcholine-derived diacylglycerols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; PHOSPHOLIPASE-D; ALPHA-THROMBIN; ARF; FIBROBLASTS; HYDROLYSIS; EXCHANGE	Disassembly of the coatomer from Golgi vesicles requires that the small GTP-binding protein ADP-ribosylation factor 1 (ARF1) hydrolyzes its bound GTP by the action of a GTPase-activating protein. In vitro, the binding of the ARF1 GTPase-activating protein to lipid vesicles and its activity on membrane-bound ARF1(GTP) are increased by diacylglycerols with monounsaturated acyl chains, such as those arising in vivo as secondary products from the hydrolysis of phosphatidylcholine by ARF-activated phospholipase D. Thus, the phospholipase D pathway may provide a feedback mechanism that promotes GTP hydrolysis on ARF1 and the consequent uncoating of vesicles.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Technion Israel Institute of Technology	Antonny, B (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	antonny@unice.fr	Antonny, Bruno/ABH-7434-2020	Antonny, Bruno/0000-0002-9166-8668				Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; APPLEGATE KR, 1991, J LIPID RES, V32, P1645; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; HA KS, 1993, J BIOL CHEM, V268, P10534; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEACH KL, 1991, J BIOL CHEM, V266, P3215; MOREAU P, 1994, BBA-REV BIOMEMBRANES, V1197, P257; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Randazzo PA, 1997, BIOCHEM J, V324, P413, DOI 10.1042/bj3240413; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Stricker R, 1997, FEBS LETT, V405, P229, DOI 10.1016/S0014-5793(97)00188-9; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	27	131	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30848	30851		10.1074/jbc.272.49.30848	http://dx.doi.org/10.1074/jbc.272.49.30848			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388229	hybrid			2022-12-25	WOS:000071640800042
J	Ramirez, S; Ali, SAS; Robin, P; Trouche, D; Harel-Bellan, A				Ramirez, S; Ali, SAS; Robin, P; Trouche, D; Harel-Bellan, A			The CREB-binding protein (CBP) cooperates with the serum response factor for transactivation of the c-fos serum response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX-FORMATION; ETS TRANSCRIPTION FACTOR; COACTIVATOR CBP; CELL DIFFERENTIATION; INDUCED STIMULATION; FACTORS ELK-1; FACTOR P62TCF; IN-VIVO; ACTIVATION; DNA	The serum response element is one of the major promoter elements of the immediate early response to extracellular signals. The serum response element includes two main binding sites for proteins: the Ets box, which binds p62(TCF), and the CArG box, which binds p67(SRF). These two proteins are direct targets for signal transduction pathways; p62(TCF) is a nuclear end point of the Ras/mitogen-activated protein kinase pathway, and p67(SRF) is targeted by the Rho/Rac small G-proteins. The mechanism by which the signal is further transduced from the transcription factors to the basal transcriptional machinery is poorly understood. Recent data have suggested that the cAMP-responsive element-binding protein (CREB)-binding protein, a transcriptional adaptor involved in the transactivation through a wide variety of enhancer elements, participates in p62(TCF) activity., We here show that the CREB-binding protein also cooperates in the process of transactivation by p67(SRF). Cotransfections of expression vectors for the CREB-binding protein increased the expression, in response to serum, of reporters under the control of the c-fos serum response element, Interestingly, the C-terminal moiety of the CREB-binding protein was not necessary to observe this effect. The cooperation did not require the Ets box in the serum response element, and the CArG box was sufficient, indicating that the CREB-binding protein is able to cooperate with p67(SRF) in, the absence of an Ets protein, Co-immunoprecipitation experiments using cell extracts showed that p67(SRF) could be retained with antibodies directed against the CREB-binding protein, suggesting that the two proteins form a multimolecular complex in live cells, The physical interaction between p67(SRF) and the CREB-binding protein was further confirmed by two-hybrid assays in mammalian cells, Our results indicate that the CREB-binding protein cooperates with p67(SRF) and, thus, suggest that the serum response element is regulated by a multimolecular complex, which includes the CREB-binding protein, p67(SRF), and p62(TCF), With multiple interactions between the components of the complex.	Inst Federat Canc, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Harel-Bellan, A (corresponding author), Inst Federat Canc, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, 7 Rue Guy Moquet, F-94801 Villejuif, France.	ahbellan@vjf.cnrs.fr	Trouche, Didier/B-2854-2008; Harel-Bellan, Annick/M-9795-2015; Ramirez-Clavijo, Sandra/G-5268-2016	Trouche, Didier/0000-0003-1398-6481; Ramirez-Clavijo, Sandra/0000-0003-0336-5614; Harel-Bellan, Annick/0000-0002-2339-153X				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Groisman R, 1996, J BIOL CHEM, V271, P5258; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1996, ONCOGENE, V12, P1961; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIU SH, 1993, J BIOL CHEM, V268, P21147; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MagnaghiJaulin L, 1996, FEBS LETT, V391, P247, DOI 10.1016/0014-5793(96)00745-4; Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328; MCINTYRE P, 1988, ANAL BIOCHEM, V174, P209, DOI 10.1016/0003-2697(88)90537-4; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	63	90	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31016	31021		10.1074/jbc.272.49.31016	http://dx.doi.org/10.1074/jbc.272.49.31016			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388250	Green Published, hybrid			2022-12-25	WOS:000071640800063
J	Hamawy, MM; Swieter, M; Mergenhagen, SE; Siraganian, RP				Hamawy, MM; Swieter, M; Mergenhagen, SE; Siraganian, RP			Reconstitution of high affinity IgE receptor-mediated secretion by transfecting protein tyrosine kinase pp125(FAK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; BASOPHILIC LEUKEMIA-CELLS; FC-EPSILON-RI; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; RBL-2H3 CELLS; MAST-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; HISTAMINE-RELEASE; CALCIUM SIGNAL	To study the role of the focal adhesion tyrosine kinase (FAK) in receptor-mediated secretion, we transfected FAK cDNA into a variant (3B6) of the RBL-2H3 mast cell line. This 3B6 cell line expressed low levels of FAK and was defective in high affinity IgE receptor (Fc epsilon RI) but not Ca2+ ionophore-mediated secretion. Fc epsilon RI-mediated secretion was reconstituted after transfection of wild-type FAK. Histamine release was also enhanced by the stable expression of two mutants of FAK: a kinase-inactive form in which the ATP binding site Lys-454 was replaced by Arg or a mutant in which the autophosphorylation site Tyr-397 was replaced by Phe. Therefore, the catalytic activity and the autophosphorylation site of FAK are not essential for secretion. Fc epsilon RI aggregation increased. the tyrosine phosphorylation of both mutants of FAK to the same extent as wild-type FAK. Therefore, tyrosine kinases activated by Fc epsilon RI aggregation are phosphorylating FAK and some of these phosphorylation sites are other than Tyr-397. These results strongly suggest that FAK plays a role in Fc epsilon RI-induced secretion by functioning as an adapter or linker molecule.			Hamawy, MM (corresponding author), NIDR,IMMUNOL LAB,NIH,BLDG 10,RM 1N106,BETHESDA,MD 20892, USA.							ALESMARTINEZ JE, 1991, IMMUNOL TODAY, V12, P201, DOI 10.1016/0167-5699(91)90054-W; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; EISEMAN E, 1992, NATURE, V355, P78; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; HAMAWY MM, 1995, J BIOL CHEM, V270, P12305, DOI 10.1074/jbc.270.20.12305; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; ILLC D, 1995, NATURE, V377, P539; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LIN PY, 1991, J IMMUNOL, V146, P1609; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; RETH M, 1994, CURR OPIN IMMUNOL, V6, P3, DOI 10.1016/0952-7915(94)90026-4; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; TURNER CE, 1994, J CELL SCI, V107, P1583; WHITE KN, 1988, J IMMUNOL, V141, P942; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; YU KT, 1991, J BIOL CHEM, V266, P22564; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	50	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30498	30503		10.1074/jbc.272.48.30498	http://dx.doi.org/10.1074/jbc.272.48.30498			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374543	hybrid			2022-12-25	WOS:A1997YH61300075
J	Dietrich, C; Wallenfang, K; Oesch, F; Wieser, R				Dietrich, C; Wallenfang, K; Oesch, F; Wieser, R			Differences in the mechanisms of growth control in contact-inhibited and serum-deprived human fibroblasts	ONCOGENE			English	Article						cyclin-dependent kinase regulation; contact-inhibition; serum-deprivation	CYCLIN-DEPENDENT KINASES; PLASMA-MEMBRANE GLYCOPROTEINS; HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE; G1 PHASE; RETINOBLASTOMA PROTEIN; P27(KIP1); ARREST; PHOSPHORYLATION; EXPRESSION	In the present work we studied mechanisms of growth control in contact-inhibited and serum-deprived human diploid fibroblasts. The observation that the effects on [H-3]thymidine incorporation and reduction of retinoblastoma gene product-phosphorylation were additive when contact-inhibition and serum-deprivation were combined led us to the conclusion that the underlying mechanisms might be different. Both contact-inhibition and serum-deprivation led to a strong decrease of cdk4-kinase-activity and cdk2-phosphorylation at Thr 160, while the total amounts of cdk4 and cdk2 remained constant. In contact-inhibited cells, we revealed a strong protein accumulation of the cdk2-inhibitor p27 and a slight, but significant increase of the cdk4-inhibitor p16. In serum-deprived cells, the protein levels in p27 and p16 remained low. In contrast, we detected a rapid decrease of cyclin D1 and cyclin D3 which did not occur in contact-inhibited cells. These results indicate that serum-deprivation and contact-inhibition have different mechanisms although they affect the same pathway cyclin D-cdk4, pRB, cyclin E-cdk2.	UNIV MAINZ,INST TOXICOL,D-55131 MAINZ,GERMANY	Johannes Gutenberg University of Mainz			Oesch, Franz/AAA-8746-2020					APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORETON K, 1995, FEBS LETT, V372, P33, DOI 10.1016/0014-5793(95)00941-2; MORETON K, 1995, BIOCHEM SOC T, V23, pS446, DOI 10.1042/bst023446s; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	37	59	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2743	2747		10.1038/sj.onc.1201439	http://dx.doi.org/10.1038/sj.onc.1201439			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9401001				2022-12-25	WOS:A1997YH46800012
J	VarmehZiaie, S; Okan, I; Wang, YS; Magnusson, KP; Warthoe, P; Strauss, M; Wiman, KG				VarmehZiaie, S; Okan, I; Wang, YS; Magnusson, KP; Warthoe, P; Strauss, M; Wiman, KG			Wig-1, a new p53-induced gene encoding a zinc finger protein	ONCOGENE			English	Article						p53; differential display; zinc finger protein	WILD-TYPE P53; DIFFERENTIAL DISPLAY; MESSENGER-RNA; APOPTOSIS; EXPRESSION; ARREST; CELLS; BAX; IDENTIFICATION; ACTIVATION	Wild type p53 expressed from a temperature-sensitive (ts p53) construct induces both G1 cell cycle arrest and apoptosis in the p53-negative J3D mouse T lymphoma line (Wang et al., 1995). Using differential display analysis, we have identified one new p53-induced gene, wig-1 (for mild type p53-induced gene 1), whose 7.6 kb and 2.2 kb transcripts are upregulated in ts p53-transfected J3D cells following induction of wild type p53 expression by temperature shift to 32 degrees C. The wig-1 transcripts were also induced in irradiated NIH3T3 and p21(-/-) fibroblasts but not in irradiated p53(-/-) fibroblasts. Whole body gamma irradiation caused induction of both wig-1 transcripts in mouse brain, testis, kidney, spleen and lung. A basal wig-1 expression was detected in brain, testis and kidney. The WIG-1 protein contains three zinc finger motifs and a putative nuclear localization signal.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK	Karolinska Institutet; Danish Cancer Society			Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011; Wiman, Klas/AAB-8399-2021	Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826; Wiman, Klas/0000-0002-7113-524X; Warthoe, peterwarthoe@gmail.com/0000-0003-3840-5460				BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUNT T, 1985, NATURE, V316, P580, DOI 10.1038/316580a0; ISRAELI D, 1997, IN PRESS EMBO J; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; MacCallum DE, 1996, ONCOGENE, V13, P2575; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MIYASHITA T, 1995, CELL, V80, P293; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PIENTENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambrook J., 2002, MOL CLONING LAB MANU; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	25	54	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2699	2704		10.1038/sj.onc.1201454	http://dx.doi.org/10.1038/sj.onc.1201454			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400996				2022-12-25	WOS:A1997YH46800007
J	Chen, SL; Zhang, XK; Halverson, DO; Byeon, MK; Schweinfest, CW; Ferris, DK; Bhat, NK				Chen, SL; Zhang, XK; Halverson, DO; Byeon, MK; Schweinfest, CW; Ferris, DK; Bhat, NK			Characterization of human N8 protein	ONCOGENE			English	Article						leucine zipper protein; homodimerization; phosphorylation; cytoplasmic protein; epithelial cells	DNA-BINDING DOMAIN; LEUCINE ZIPPER; DIMERIZATION; EXPRESSION; SEQUENCE; COMPLEX; FAMILY; GENES; MYC; MAX	We have shown before that the N8 mRNA is expressed at higher levels in lung tumor and lung tumor-derived cell lines than normal lung cells. In this paper, we have characterized the N8 protein, and studied its properties. The N8 gene encodes a major 24 kDa protein and its expression correlates well with the N8 mRNA expression pattern observed in different cell lines. N8 protein is capable of forming a homodimer or multimeter in vitro. It is a phosphorylated cytoplasmic protein and phosphorylation occurs mainly at serine residues, N8 protein is expressed at higher levels in epithelial cells than in mesenchymal cells, Ns protein expression is induced in a fibroblast cell line expressing adenoviral Ela protein, which acquired epithelial-like characteristics. Furthermore, ectopic expression of N8 protein in NIH3T3 cells converts them into a spheroid form. These spheroids also have some of the characteristic features of epithelial cells. Taken together, these results suggest that the N8 protein may be associated with the development or maintenance of epithelial cell phenotype.	NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21702; NCI,MOL ONCOL LAB,FREDERICK,MD 21702; MED UNIV S CAROLINA,HOLLINGS CANC CTR,CTR MOL & STRUCT BIOL,CHARLESTON,SC 29425	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Medical University of South Carolina								ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BHAT NK, 1992, HYBRIDOMA, V11, P277, DOI 10.1089/hyb.1992.11.277; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BYRNE JA, 1995, CANCER RES, V55, P2896; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Chen SL, 1996, ONCOGENE, V12, P741; Coligan JKA, 1991, CURRENT PROTOCOLS IM; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872	15	23	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2577	2588		10.1038/sj.onc.1201437	http://dx.doi.org/10.1038/sj.onc.1201437			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399645				2022-12-25	WOS:A1997YG73200007
J	Asao, H; Sasaki, Y; Arita, T; Tanaka, N; Endo, K; Kasai, H; Takeshita, T; Endo, Y; Fujita, T; Sugamura, K				Asao, H; Sasaki, Y; Arita, T; Tanaka, N; Endo, K; Kasai, H; Takeshita, T; Endo, Y; Fujita, T; Sugamura, K			Hrs is associated with STAM, a signal-transducing adaptor molecule - Its suppressive effect on cytokine-induced cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RECEPTOR-BETA-CHAIN; IL-2 RECEPTOR; GAMMA-CHAIN; TYROSINE PHOSPHORYLATION; C-FOS; GM-CSF; PROLIFERATION; PROTEIN; DOMAIN	We previously reported a new type of signal-transducing adaptor molecule, STAM, which was shown to be involved in cytokine-mediated intracellular signal transduction, In this study, we molecularly cloned a 110-kDa phosphotyrosine protein inducible by stimulation with interleukin 2 (IL-2), The 110-kDa molecule was found to be a human counterpart of mouse Hrs (hepatocyte growth factor-regulated tyrosine kinase substrate) and to be associated with STAM. Tyrosine phosphorylation of Hrs is induced rapidly after stimulation with IL-2 and granulocyte-macrophage colony-stimulating factor as well as hepatocyte growth factor, The mutual associ ation sites of Hrs and STAM include highly conserved coiled-coil sequences, suggesting that their association is mediated by the coiled-coil structures, Exogenous introduction of the wild-type Hrs significantly suppressed DNA synthesis upon stimulation with IL-2 and granulocyte-macrophage colony-stimulating factor, while the Hrs mutant deleted of the STAM-binding site lost such suppressive ability. These results suggest that Hrs counteracts the STAM function which is critical for cell growth signaling mediated by the cytokines.	Tohoku Univ, Sch Med, Dept Microbiol & Immunol, Aoba Ku, Sendai, Miyagi 98077, Japan; Fukushima Med Coll, Dept Biochem, Fukushima 96012, Japan	Tohoku University; Fukushima Medical University	Sugamura, K (corresponding author), Tohoku Univ, Sch Med, Dept Microbiol & Immunol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 98077, Japan.		Takeshita, Toshikazu/AAL-1382-2021; Kasai, Hirotake/L-9668-2017	Kasai, Hirotake/0000-0002-5808-0803				ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ENDO Y, 1995, GENOMICS, V25, P760, DOI 10.1016/0888-7543(95)80028-K; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; Higuchi M, 1996, EUR J IMMUNOL, V26, P1322, DOI 10.1002/eji.1830260622; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; LOWENTHAL JW, 1985, J IMMUNOL, V135, P3988; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MINEGISHI N, 1994, J BIOL CHEM, V269, P27700; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NEMOTO T, 1995, EUR J IMMUNOL, V25, P3001, DOI 10.1002/eji.1830251102; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	33	162	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32785	32791		10.1074/jbc.272.52.32785	http://dx.doi.org/10.1074/jbc.272.52.32785			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407053	hybrid			2022-12-25	WOS:000071182900014
J	Bottazzi, B; Vouret-Craviari, V; Bastone, A; De Gioia, L; Matteucci, C; Peri, G; Spreafico, F; Pausa, M; D'Ettorre, C; Gianazza, E; Tagliabue, A; Salmona, M; Tedesco, F; Introna, M; Mantovani, A				Bottazzi, B; Vouret-Craviari, V; Bastone, A; De Gioia, L; Matteucci, C; Peri, G; Spreafico, F; Pausa, M; D'Ettorre, C; Gianazza, E; Tagliabue, A; Salmona, M; Tedesco, F; Introna, M; Mantovani, A			Multimer formation and ligand recognition by the long pentraxin PTX3 - Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE PROTEINS; COLLAGEN-LIKE REGION; AMINO-ACID-SEQUENCE; COMPLEMENT ACTIVATION; NEURONAL PENTRAXIN; LIMULUS-POLYPHEMUS; BINDING PROTEIN; PENTAXIN FAMILY; XENOPUS-LAEVIS; IMMUNE-SYSTEM	PTX3 is a prototypic long pentraxin consisting of a C-terminal 203-amino acid pentraxin-like domain coupled with an N-terminal 178-amino acid unrelated portion. The present study was designed to characterize the structure and ligand binding properties of human PTX3, in comparison with the classical pentraxins C-reactive protein and serum amyloid P component. Sequencing of Chinese hamster ovary cell-expressed PTX3 revealed that the mature secreted protein starts at residue 18 (Glu). Lectin binding and treatment with N-glycosidase F showed that PTX3 is N-glycosylated, sugars accounting for 5 kDa of the monomer mass (45 kDa). Circular dichroism analysis indicated that the protein consists predominantly of beta-sheets with a minor alpha-helical component. While in gel filtration the protein is eluted with a molecular mass of congruent to 900 kDa, gel electrophoresis using nondenaturing, nonreducing conditions revealed that PTX3 forms multimers predominantly of 440 kDa apparent molecular mass, corresponding to decamers, and that disulfide bonds are required for multimer formation. The ligand binding properties of PTX3 were then examined. As predicted based on modeling, inductive coupled plasma/atomic emission spectroscopy showed that PTX3 does not have coordinated Ca2+. Unlike the classical pentraxins CRP and SAP, PTX3 did not bind phosphoethanolamine, phosphocholine, or high pyruvate agarose, PTX3 in solution, bound to immobilized C1q, but not C1s, and, reciprocally, C1q bound to immobilized PTX3. Binding of PTX3 to C1q is specific and saturable with a K-d 7.4 x 10(-8) M as determined by solid phase binding assay. The Chinese hamster ovary cell-expressed pentraxin domain bound C1q when multimerized. Thus, as predicted on the basis of computer modeling, the prototypic long pentraxin PTX3 forms multimers, which differ from those formed by classical pentraxins in terms of protomer composition and requirement for disulfide bonds, and does not recognize CRP/SAP ligands. The capacity to bind C1q, mediated by the pentraxin domain, is consistent with the view that PTX3, produced in tissues by endothelial cells or macrophages in response to interleukin-1 and tumor necrosis factor, may act as a local regulator of innate immunity.	Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; IRCCS Burlo Garofolo, Ist Ostetr & Ginecol, Trieste, Italy; DOMPE SPA, Laquila, Italy; Univ Milan, Ist Sci Farmacol, Milan, Italy; Univ Trieste, Dipartimento Fisiol & Patol, Trieste, Italy; Univ Brescia, Dipartimento Biotecnol, Sez Patol & Immunol, Brescia, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Burlo Garofolo; Dompe; University of Milan; University of Trieste; University of Brescia	Mantovani, A (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.		bottazzi, barbara/ABH-9274-2020; De Gioia, Luca/K-6439-2016; Introna, Martino/AAA-5823-2019; Mantovani, Alberto/HCI-7449-2022; salmona, mario/ABI-4066-2020; salmona, mario/AAA-7116-2020; Tedesco, Francesco/F-1929-2011	bottazzi, barbara/0000-0002-1930-9257; Introna, Martino/0000-0001-6216-0892; Mantovani, Alberto/0000-0001-5578-236X; salmona, mario/0000-0002-9098-9873; 				ALLES VV, 1994, BLOOD, V84, P3483; BACHOFEN VK, 1991, IMMUNOBIOLOGY, V183, P133; BALTZ ML, 1982, ANN NY ACAD SCI, V389, P49, DOI 10.1111/j.1749-6632.1982.tb22125.x; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BENFENATI F, 1984, PRINCIPLES METHODS R, P41; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; BRISTOW CL, 1986, MOL IMMUNOL, V23, P1045, DOI 10.1016/0161-5890(86)90003-9; BUTLER PJG, 1990, J EXP MED, V172, P13, DOI 10.1084/jem.172.1.13; DE FRUTOS PG, 1995, J BIOL CHEM, V270, P26950, DOI 10.1074/jbc.270.45.26950; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; FIEDEL BA, 1982, IMMUNOLOGY, V45, P439; GEWURZ H, 1995, CURR OPIN IMMUNOL, V7, P54, DOI 10.1016/0952-7915(95)80029-8; GOTSCHLICH EC, 1965, P NATL ACAD SCI USA, V54, P558, DOI 10.1073/pnas.54.2.558; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; HICKS PS, 1992, J IMMUNOL, V149, P3686; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; HSU YC, 1995, GENOMICS, V28, P220, DOI 10.1006/geno.1995.1134; Introna M, 1996, BLOOD, V87, P1862; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; JIANG HX, 1991, J IMMUNOL, V146, P2324; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GW, 1994, J IMMUNOL, V153, P3700; LEE GW, 1993, J IMMUNOL, V150, P1804; LIN LW, 1993, J BIOL CHEM, V268, P6809; LOVELESS RW, 1992, EMBO J, V11, P813, DOI 10.1002/j.1460-2075.1992.tb05118.x; NAGPURKAR A, 1981, J BIOL CHEM, V256, P7440; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; NOLAND TD, 1994, J BIOL CHEM, V269, P32607; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; PEPYS MB, 1978, CLIN EXP IMMUNOL, V32, P119; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1982, BIOCHIM BIOPHYS ACTA, V704, P123, DOI 10.1016/0167-4838(82)90139-X; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; RASSOULI M, 1992, J BIOL CHEM, V267, P2947; REID MS, 1994, J BIOL CHEM, V269, P32615; ROBEY FA, 1983, J BIOL CHEM, V258, P3889; ROBEY FA, 1981, J BIOL CHEM, V256, P969; ROBEY FA, 1983, J BIOL CHEM, V258, P3895; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; SCHWALBE RA, 1992, BIOCHEMISTRY-US, V31, P4907, DOI 10.1021/bi00135a023; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; SRINIVASAN N, 1994, STRUCTURE, V2, P1017, DOI 10.1016/S0969-2126(94)00105-7; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; TAKETA K, 1987, ELECTROPHORESIS, V8, P409, DOI 10.1002/elps.1150080908; TENNENT GA, 1994, BIOCHEM SOC T, V22, P74, DOI 10.1042/bst0220074; TENNENT GA, 1993, EUR J BIOCHEM, V214, P91, DOI 10.1111/j.1432-1033.1993.tb17900.x; TENNER AJ, 1981, J IMMUNOL, V127, P648; Tsui CC, 1996, J NEUROSCI, V16, P2463; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VOLANAKIS JE, 1982, ANN NY ACAD SCI, V389, P235, DOI 10.1111/j.1749-6632.1982.tb22140.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YING SC, 1993, J IMMUNOL, V150, P169; Zahedi K, 1996, J BIOL CHEM, V271, P14897, DOI 10.1074/jbc.271.25.14897	57	329	348	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32817	32823		10.1074/jbc.272.52.32817	http://dx.doi.org/10.1074/jbc.272.52.32817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407058	hybrid			2022-12-25	WOS:000071182900019
J	Chai, XY; Zhai, Y; Napoli, JL				Chai, XY; Zhai, Y; Napoli, JL			cDNA cloning and characterization of a cis-retinol/3 alpha-hydroxysterol short-chain dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; BINDING-PROTEINS; ALCOHOL-DEHYDROGENASE; BETA-CAROTENE; CORTICOSTEROID 11-BETA-DEHYDROGENASE; ANDROGEN 5-ALPHA-REDUCTION; 13-CIS-RETINOIC ACID; 9-CIS-RETINOIC ACID; EXPRESSION; PROSTATE	We report a mouse cDNA that encodes a 317-amino acid short-chain dehydrogenase which recognizes as substrates 9-cis-retinol, 11-cis-retinol, 5 alpha-androstan-3 alpha,17 beta-diol, and 5 alpha-androstan-3 alpha-ol-17-one. This cis-retinol/androgen dehydrogenase (CRAD) shares closest amino acid similarity with mouse retinol dehydrogenase isozymes types 1 and 2 (86 and 91%, respectively). Recombinant CRAD uses NAD(+) as its preferred cofactor and exhibits cooperative kinetics for cis-retinoids, but Michaelis-Menten kinetics for 3 alpha-hydroxysterols. Unlike recombinant retinol dehydrogenase isozymes, recombinant CRAD was inhibited by 4-methylpyrazole, was not stimulated by ethanol, and did not require phosphatidylcholine for optimal activity. CRAD mRNA was expressed intensely in kidney and liver, in contrast to retinol dehydrogenase isozymes, which show strong mRNA expression only in liver. CRAD mRNA expression was widespread (relative abundance): kidney (100) > liver (92) > small intestine (9) = heart (9) > retinal pigment epithelium and sclera (4.5) > brain (2) > retina and vitreous (1.6) > spleen (0.7) > testis (0.6) > lung (0.4). CRAD may catalyze the first step in an enzymatic pathway from 9-cis-retinol to generate the retinoid X receptor ligand 9-cis-retinoic acid and/or may regenerate dihydrotestosterone from its catabolite 5 alpha-androstan-3 alpha,17 beta-diol. These data also illustrate the multifunctional. nature of short-chain dehydrogenases and provide a potential mechanism for androgen-retinoid interactions.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Napoli, JL (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047839] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47839] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ALLENBY G, 1994, J BIOL CHEM, V269, P16689; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BAKER ME, 1994, STEROIDS, V59, P248, DOI 10.1016/0039-128X(94)90109-0; BAKER ME, 1991, MOL CELL ENDOCRINOL, V78, pC99, DOI 10.1016/0303-7207(91)90178-U; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; BOUDOU P, 1994, J UROLOGY, V152, P226, DOI 10.1016/S0022-5347(17)32867-7; BOUDOU P, 1994, J CLIN ENDOCR METAB, V78, P1064, DOI 10.1210/jc.78.5.1064; BOUDOU P, 1995, J CLIN ENDOCR METAB, V80, P1158, DOI 10.1210/jc.80.4.1158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PS, 1959, NATURE, V184, P1377, DOI 10.1038/1841377a0; BRUCHOVSKY N, 1971, ENDOCRINOLOGY, V89, P1212, DOI 10.1210/endo-89-5-1212; BUSHWAY RJ, 1985, J LIQ CHROMATOGR, V8, P1527, DOI 10.1080/01483918508067163; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANDLER LA, 1987, J FOOD SCI, V52, P669, DOI 10.1111/j.1365-2621.1987.tb06700.x; CHURCHILL P, 1992, BIOCHEMISTRY-US, V31, P3793, DOI 10.1021/bi00130a009; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; Clinton SK, 1996, CANCER EPIDEM BIOMAR, V5, P823; DANIELPOUR D, 1994, CANCER RES, V54, P3413; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; EDWARDS CRW, 1993, J STEROID BIOCHEM, V45, P1, DOI 10.1016/0960-0760(93)90114-C; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HORST RL, 1995, ARCH BIOCHEM BIOPHYS, V322, P235, DOI 10.1006/abbi.1995.1457; HORST RL, 1995, BIOCHEMISTRY-US, V34, P1203, DOI 10.1021/bi00004a013; HUANG HFS, 1994, BIOL REPROD, V51, P541, DOI 10.1095/biolreprod51.3.541; Huang HFS, 1997, ENDOCRINOLOGY, V138, P553, DOI 10.1210/en.138.2.553; JAUHIAINEN M, 1988, J BIOL CHEM, V263, P6525; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KOJIMA R, 1994, J BIOL CHEM, V269, P32700; KROOK M, 1990, BIOCHEMISTRY-US, V29, P738, DOI 10.1021/bi00455a021; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MARKS AR, 1992, J BIOL CHEM, V267, P15459; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; MOORE RJ, 1973, ENDOCRINOLOGY, V93, P581, DOI 10.1210/endo-93-3-581; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; NEWCOMER ME, 1995, FASEB J, V9, P229, DOI 10.1096/fasebj.9.2.7781925; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; OLSON JA, 1995, NUTR BLINDNESS; ONEIL CA, 1992, J CHROMATOGR, V624, P235, DOI 10.1016/0021-9673(92)85682-J; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; SCHULTZ FM, 1974, ENDOCRINOLOGY, V94, P979; Shih TW, 1997, DRUG METAB DISPOS, V25, P27; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1996, GENOMICS, V36, P424, DOI 10.1006/geno.1996.0487; STAHL W, 1992, ARCH BIOCHEM BIOPHYS, V294, P173, DOI 10.1016/0003-9861(92)90153-N; STAHL W, 1993, CLIN CHEM, V39, P810; SUZUKI Y, 1993, BIOCHIM BIOPHYS ACTA, V1163, P201, DOI 10.1016/0167-4838(93)90182-Q; URBACH J, 1994, BIOCHEM J, V299, P459, DOI 10.1042/bj2990459; WU L, 1993, J BIOL CHEM, V268, P12964; Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594; YOUNG CYF, 1994, PROSTATE, V25, P39, DOI 10.1002/pros.2990250106	67	80	82	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33125	33131		10.1074/jbc.272.52.33125	http://dx.doi.org/10.1074/jbc.272.52.33125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407098	hybrid			2022-12-25	WOS:000071182900059
J	Djelidi, S; Fay, M; Cluzeaud, F; Escoubet, B; Eugene, E; Capurro, C; Bonvalet, JP; Farman, N; Blot-Chabaud, M				Djelidi, S; Fay, M; Cluzeaud, F; Escoubet, B; Eugene, E; Capurro, C; Bonvalet, JP; Farman, N; Blot-Chabaud, M			Transcriptional regulation of sodium transport by vasopressin in renal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; NA+-K+-ATPASE; MESSENGER-RNA EXPRESSION; RAT-KIDNEY; INSITU HYBRIDIZATION; BINDING PROTEINS; RESPONSE ELEMENT; GENE-EXPRESSION; ALPHA-SUBUNITS; GAMMA-SUBUNITS	We base examined whether arginine vasopressin (AVP) can induce a long-term modulation of transepithelial ion transport in addition to its well known shortterm effect, In the RCCD1 rat cortical collecting duct cell line, an increase in both short-circuit current and Na-22 transport was observed after several hours of 10(-8) M AVP treatment (a concentration above the in vivo physiological range), This delayed effect was partially prevented by apical addition of 10(-5) M amiloride and was blocked by 10(-6) M actinomycin D and 2 x 10(-6) hr cycloheximide. The amounts of mRNA encoding the alpha(1) (not beta(1)) subunit of Na+/K+-ATPase and the beta and gamma (not alpha) subunits of the amiloride-sensitive epithelial Na+ channel were significantly increased by AVP treatment, The increase in mRNA was blocked by actinomycin D, not by amiloride, suggesting a Na+-independent increase in the rate of transcription of these subunits, The translation rates of the alpha(1) subunit of Na+/K+-ATPase and the beta and gamma subunits of the rat epithelial sodium channel increased significantly, whereas the translation rates of the other subunits remained unchanged, Finally, the number of Na+ channels present in the apical membrane of the cells increased, as demonstrated by enhanced specific [H-3]phenamil binding.	Univ Paris 07, Inst Federatif Rech Cellules Epitheliales, INSERM, U246, F-75870 Paris 18, France; Univ Paris 07, Inst Federatif Rech Cellules Epitheliales, INSERM, U426, F-75870 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Blot-Chabaud, M (corresponding author), Univ Paris 07, Inst Federatif Rech Cellules Epitheliales, INSERM, U246, 16 Rue Henri Huchard, F-75870 Paris 18, France.	u246@bichat.inserm.fr	Blot-Chabaud, Marcel/D-4064-2017	Capurro, Claudia/0000-0003-3773-0202				AHMAD M, 1995, STEROIDS, V60, P147, DOI 10.1016/0039-128X(94)00019-9; Asher C, 1996, AM J PHYSIOL-CELL PH, V271, pC605, DOI 10.1152/ajpcell.1996.271.2.C605; BARBRY P, 1990, BIOCHEMISTRY-US, V29, P1039, DOI 10.1021/bi00456a028; BARBRY P, 1987, P NATL ACAD SCI USA, V84, P4836, DOI 10.1073/pnas.84.14.4836; BINDELS RJM, 1988, BIOCHIM BIOPHYS ACTA, V972, P320, DOI 10.1016/0167-4889(88)90208-X; BlotChabaud M, 1996, J MEMBRANE BIOL, V153, P233, DOI 10.1007/s002329900126; BlotChabaud M, 1996, KIDNEY INT, V50, P367, DOI 10.1038/ki.1996.325; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CANESSA CM, 1992, AM J PHYSIOL, V262, pF454, DOI 10.1152/ajprenal.1992.262.3.F454; Carranza ML, 1996, AM J PHYSIOL-CELL PH, V271, pC136, DOI 10.1152/ajpcell.1996.271.1.C136; COUTRY N, 1995, J MEMBRANE BIOL, V145, P99; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; Denault DL, 1996, AM J PHYSIOL-CELL PH, V271, pC423, DOI 10.1152/ajpcell.1996.271.1.C423; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; Escoubet B, 1996, AM J PHYSIOL-CELL PH, V270, pC1343, DOI 10.1152/ajpcell.1996.270.5.C1343; Escoubet B, 1997, AM J PHYSIOL-CELL PH, V272, pC1482, DOI 10.1152/ajpcell.1997.272.5.C1482; FARMAN N, 1991, AM J PHYSIOL, V260, pC468, DOI 10.1152/ajpcell.1991.260.3.C468; FARMAN N, 1992, AM J PHYSIOL, V263, pC810, DOI 10.1152/ajpcell.1992.263.4.C810; FENG JI, 1993, NUCLEIC ACIDS RES, V21, P2619, DOI 10.1093/nar/21.11.2619; FROMTER E, 1988, COMP BIOCHEM PHYS A, V90, P701, DOI 10.1016/0300-9629(88)90687-1; GIRARDET M, 1986, AM J PHYSIOL, V251, pF662, DOI 10.1152/ajprenal.1986.251.4.F662; GONZALEZMARTINEZ LM, 1994, SODIUM PUMP, P218; Habener Joel F., 1995, V51, P1; HULL G, 1990, GENOMICS, V6, P451; LINGUEGLIA E, 1993, EUR J BIOCHEM, V216, P679, DOI 10.1111/j.1432-1033.1993.tb18188.x; MEDFORD RM, 1991, COLLOQ INSE, V215, P131; MOREL F, 1987, KIDNEY INT, V31, P512, DOI 10.1038/ki.1987.30; MOREL F, 1986, PHYSIOL REV, V66, P377, DOI 10.1152/physrev.1986.66.2.377; REIF MC, 1986, J CLIN INVEST, V77, P1291, DOI 10.1172/JCI112433; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; SHORE EM, 1991, J BIOL CHEM, V266, P19672; Thomas CP, 1996, J BIOL CHEM, V271, P26062, DOI 10.1074/jbc.271.42.26062; TOMITA K, 1985, J CLIN INVEST, V76, P132, DOI 10.1172/JCI111935; TOMITA K, 1987, AM J PHYSIOL, V253, pF874, DOI 10.1152/ajprenal.1987.253.5.F874; Tsuchiya K, 1996, AM J PHYSIOL-RENAL, V271, pF7, DOI 10.1152/ajprenal.1996.271.1.F7; VALLEJO M, 1994, J NEUROENDOCRINOL, V6, P587, DOI 10.1111/j.1365-2826.1994.tb00623.x; WELLING PA, 1993, J BIOL CHEM, V268, P23469; [No title captured]	42	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32919	32924		10.1074/jbc.272.52.32919	http://dx.doi.org/10.1074/jbc.272.52.32919			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407070	hybrid			2022-12-25	WOS:000071182900031
J	Fujii, H; Ichimori, K; Hoshiai, K; Nakazawa, H				Fujii, H; Ichimori, K; Hoshiai, K; Nakazawa, H			Nitric oxide inactivates NADPH oxidase in pig neutrophils by inhibiting its assembling process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE ANION PRODUCTION; RESPIRATORY BURST OXIDASE; POLYMORPHONUCLEAR LEUKOCYTES; PORCINE NEUTROPHILS; CYTOCHROME B(558); HYDROGEN-PEROXIDE; OXIDATION; SYSTEM; CELLS; REDUCTASE	The effects of nitric oxide (NO) on superoxide (O-2 radical anion) generation of the NADPH oxidase in pig neutrophils were studied, NO dose-dependently suppressed O-2 radical anion generation of both neutrophil NADPH oxidase and reconstituted NADPH oxidase. Effects of NO on NADPH-binding site and the redox centers including FAD and low spin heme in cytochrome b(558) and the electron transfer rates from NADPH to heme via FAD were examined under anaerobic 'conditions. Both reaction rates and the K-m value for NADPH were unchanged by NO. Visible and EPR spectra of cytochrome b(558) showed that the structure of heme was unchanged by NO, indicating that NO does not affect the redox centers of the oxidase. In reconstituted NADPH oxidase system, NO did not inhibit O-2 radical anion generation of the oxidase when added after activation. The addition of NO to the membrane component or the cytosol component inhibited the activity by 24.0 +/- 5.3 or 37.4 +/- 7.1%, respectively. The addition of NO during the activation process or to the cytosol component simultaneously with myristate inhibited the activity by 74.0 +/- 5.2 or 70.0 +/- 8.3%, respectively, suggesting that cytosol protein(s) treated with myristate becomes susceptible to NO, Peroxynitrite did not interfere with O-2 radical anion generation.	Tokyo Metropolitan Inst Med Sci, Dept Inflammat Res, Bunkyo Ku, Tokyo 113, Japan; Tokai Univ, Sch Med, Dept Physiol, Kanagawa 25911, Japan	Tokyo Metropolitan Institute of Medical Science; Tokai University	Fujii, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Inflammat Res, Bunkyo Ku, 18-22 Honkomagome 3 Chome, Tokyo 113, Japan.	fujii@rinshoken.or.jp						BABIOR BM, 1976, J CLIN INVEST, V58, P989, DOI 10.1172/JCI108553; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; DIMMELER S, 1993, FEBS LETT, V315, P21, DOI 10.1016/0014-5793(93)81124-I; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; FUJII H, 1995, J BIOL CHEM, V270, P12685, DOI 10.1074/jbc.270.21.12685; FUJII H, 1991, BIOCHIM BIOPHYS ACTA, V1095, P201, DOI 10.1016/0167-4889(91)90100-C; Fujii H, 1995, FEBS LETT, V377, P345, DOI 10.1016/0014-5793(95)01372-5; FUKAHORI M, 1994, FREE RADICAL RES, V21, P203, DOI 10.3109/10715769409056572; Fukuyama N, 1996, BIOCHEM BIOPH RES CO, V224, P414, DOI 10.1006/bbrc.1996.1041; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; KAKINUMA K, 1987, J BIOL CHEM, V262, P12316; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; Liu PT, 1997, AM J PHYSIOL-HEART C, V272, pH2327, DOI 10.1152/ajpheart.1997.272.5.H2327; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; MIKI T, 1992, J BIOL CHEM, V267, P18695; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; REED JW, 1974, J AM CHEM SOC, V96, P1248, DOI 10.1021/ja00811a062; RIESCO A, 1993, BIOCHEM J, V292, P791, DOI 10.1042/bj2920791; RODENAS J, 1995, FREE RADICAL BIO MED, V18, P869, DOI 10.1016/0891-5849(94)00215-6; SHIGA T, 1969, BIOCHEMISTRY-US, V8, P378, DOI 10.1021/bi00829a052; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TURRENS JF, 1988, FEBS LETT, V227, P43, DOI 10.1016/0014-5793(88)81410-8; WAKEYAMA H, 1982, BIOCHEM J, V205, P593, DOI 10.1042/bj2050593; YOSHIMURA T, 1988, INORG CHIM A-BIOINOR, V152, P241, DOI 10.1016/S0020-1693(00)91476-2	33	119	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32773	32778		10.1074/jbc.272.52.32773	http://dx.doi.org/10.1074/jbc.272.52.32773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407051	hybrid			2022-12-25	WOS:000071182900012
J	Giangrande, PH; Pollio, G; McDonnell, DP				Giangrande, PH; Pollio, G; McDonnell, DP			Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; HEAT-SHOCK PROTEINS; BREAST-CANCER-CELLS; ESTROGEN-RECEPTOR; A-FORM; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; MESSENGER-RNA; IDENTIFICATION	In humans, the biological response to progesterone is mediated by two distinct forms of the progesterone receptor (human (h) PR-A, 94 kDa and hPR-B, 114 kDa), These two isoforms are transcribed from distinct estrogen-inducible promoters within a single copy PR gene; the only difference between them is that the first 164 amino acids of hPR-B (B-upstream sequence) are absent in hPR-A. In most cell lines such as MCF-7 (human breast cancer cells), CV-1 (monkey kidney fibroblasts), and HeLa (human cervical carcinoma cells), hPR-A functions as a transcriptional repressor, whereas hPR-B functions as a transcriptional activator of progesterone-responsive genes, Interestingly, in these cell contexts, hPR-A also acts as a trans-dominant repressor of the transcriptional activity of other steroid hormone receptors. In contrast to hPR-A, which functions predominantly as a ligand-dependent transcriptional repressor, we show in this study that the A isoform of the chicken PR (cPR-A) lacks this trans-dominant repressor function and is a transcriptional activator in all contexts examined, By constructing chimeras between the N-terminal domains of the chicken and human PR, we mapped the trans-dominant repressor function of hPR-A to the first 140 amino acids of the protein, Notably, when this 140-amino acid "repressor" domain is placed onto chicken PR-A, the activity of the latter changes from a transcriptional activator to a repressor, Interestingly, however, this "repressor domain" is necessary, but not sufficient, for trans-repression as it is inactive when it is tethered to a heterologous protein, This suggests that the transrepression function is comprised not only of the repressor domain of hPR-A but also requires the context of the receptor to function, The identification of a discrete inhibitory region within hPR-A which is transferable to another receptor implies that this region interacts with a set of transcription factors or adaptors that are distinct from those recognized by hPR-B, the identification of which will be required to define the mechanism by which hPR-A modulates steroid hormone receptor transcriptional activity, Thus, although chickens and humans both produce two very similar forms of the progesterone receptor, it is clear from these studies that the mechanism of action of progesterone in these two systems is quite different.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	McDonnell, DP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050495] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER IE, 1990, MOL ENDOCRINOL, V4, P821, DOI 10.1210/mend-4-6-821; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BAGCHI MK, 1991, MOL CELL BIOL, V11, P4998, DOI 10.1128/MCB.11.10.4998; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHALBOS D, 1994, J BIOL CHEM, V269, P23007; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; CONNEELY OM, 1987, BIOCHEM BIOPH RES CO, V149, P493, DOI 10.1016/0006-291X(87)90395-0; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HORWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195, DOI 10.1210/endo-113-6-2195; HSUEH AJW, 1975, NATURE, V254, P337, DOI 10.1038/254337a0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; LESSEY BA, 1983, ENDOCRINOLOGY, V112, P1267, DOI 10.1210/endo-112-4-1267; LOOSFELT H, 1986, P NATL ACAD SCI USA, V83, P9045, DOI 10.1073/pnas.83.23.9045; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MCDONNELL DP, 1994, SEMIN CANCER BIOL, V5, P327; MCDONNELL DP, 1994, J BIOL CHEM, V269, P11945; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MEYER ME, 1992, J BIOL CHEM, V267, P10882; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; POLETTI A, 1992, GENE, V114, P51, DOI 10.1016/0378-1119(92)90706-U; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; RENOIR JM, 1990, J BIOL CHEM, V265, P14402; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SCHNEIDER W, 1991, J STEROID BIOCHEM, V38, P285, DOI 10.1016/0960-0760(91)90099-Q; SMITH DF, 1990, J BIOL CHEM, V265, P3996; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TSENG L, 1975, J CLIN ENDOCR METAB, V41, P402, DOI 10.1210/jcem-41-2-402; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356	39	147	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32889	32900		10.1074/jbc.272.52.32889	http://dx.doi.org/10.1074/jbc.272.52.32889			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407067	hybrid			2022-12-25	WOS:000071182900028
J	Jiang, Q; Hurst, JK				Jiang, Q; Hurst, JK			Relative chlorinating, nitrating, and oxidizing capabilities of neutrophils determined with phagocytosable probes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOCHLOROUS ACID; HORSERADISH-PEROXIDASE; ANTIMICROBIAL ACTIVITY; TYROSYL RESIDUES; MYELOPEROXIDASE; NITRITE; SUPEROXIDE; PEROXYNITRITE; OXIDATION; MECHANISM	The capabilities of stimulated neutrophils to initiate intraphagosomal and extracellular chlorination, nitration, and other oxidative reactions has been evaluated using a fluorescent particle and soluble phenolic compounds as target molecules, Neutrophils activated by the soluble stimulus, phorbol myristate acetate, both chlorinated fluorescein that was covalently attached to polyacrylamide microspheres and initiated tyrosine dimerization. When nitrite ion was present at millimolar concentration levels in the medium, nitration of the phenolic rings also occurred; the relative extent of nitration increased as the nitrite concentration was increased. Myeloperoxidase (MPO) also catalyzed nitration and chlorination of fluorescein and the fluorescein-conjugated particles in cell-free solutions; the relative nitration yields increased with increasing [NO2-]/[Cl-] ratios, Nitration did not involve intermediary formation of nitrating agents derived from reaction between MPO-generated HOCl and NO2- because this reaction also occurred in chloride-free media and direct addition of HOCl to solutions containing NO2- and fluorescein gave only chlorinated products, In marked contrast to these extracellular reactions, intraphagosomal nitration of the fluorescein-conjugated particles could not be detected (even at [NO2-] as high as 0.1 M), whereas chlorination of the probe was extensive, These data indicate that intraphagosomal aromatic nitration in neutrophils is negligible, although extracellular nitration of phenolic compounds by secreted MPO could occur at physiological concentration levels of NO2-.	Washington State Univ, Dept Chem, Pullman, WA 99164 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Washington State University; Washington State University	Hurst, JK (corresponding author), Washington State Univ, Dept Chem, Pullman, WA 99164 USA.				NIAID NIH HHS [AI-15834] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015834] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; AMADO R, 1984, METHOD ENZYMOL, V107, P377; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; CANDEIAS LP, 1993, FEBS LETT, V333, P151, DOI 10.1016/0014-5793(93)80394-A; COOPER CE, 1992, FEBS LETT, V314, P58, DOI 10.1016/0014-5793(92)81461-T; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; ELSBACH P, 1983, REV INFECT DIS, V5, P843; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; Hampton MB, 1996, INFECT IMMUN, V64, P3512, DOI 10.1128/IAI.64.9.3512-3517.1996; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; HURST JK, 1984, J BIOL CHEM, V259, P4812; HURST JK, 1991, PEROXIDASES CHEM BIO, V1, P37; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; Jesaitis A. J., 1992, MOL BASIS OXIDATIVE; Jiang Q, 1997, CHEM RES TOXICOL, V10, P1080, DOI 10.1021/tx9700984; JOHNSON DW, 1991, INORG CHEM, V30, P4845, DOI 10.1021/ic00025a031; Kettle AJ, 1996, FEBS LETT, V379, P103, DOI 10.1016/0014-5793(95)01494-2; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; LYMAR SV, 1995, CHEM RES TOXICOL, V8, P833, DOI 10.1021/tx00048a003; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; ROMAN R, 1973, CAN J CHEM, V51, P588, DOI 10.1139/v73-089; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SHIBATA H, 1995, BBA-BIOENERGETICS, V1230, P45, DOI 10.1016/0005-2728(95)00031-D; Thomas E L, 1986, Methods Enzymol, V132, P585; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WOLCOTT RG, 1994, J BIOL CHEM, V269, P9721	37	81	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32767	32772		10.1074/jbc.272.52.32767	http://dx.doi.org/10.1074/jbc.272.52.32767			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407050	hybrid			2022-12-25	WOS:000071182900011
J	Logsdon, NJ; Kang, JS; Togo, JA; Christian, EP; Aiyar, J				Logsdon, NJ; Kang, JS; Togo, JA; Christian, EP; Aiyar, J			A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNELS	We have isolated a novel gene, hKCa4, encoding an intermediate conductance, calcium-activated potassium channel from a human lymph node library, The translated protein comprises 427 amino acids, has six transmembrane segments, S1-S6, and a pore motif between S5 and S6. hKCa4 shares 41-42% similarity at the amino acid level with three small conductance calcium-activated potassium channels cloned from brain, Northern blot analysis of primary human T lymphocytes reveals a 2.2-kilobase transcript that is highly up-regulated in activated compared with resting cells, concomitant with an increase in KCa current, hKCa4 transcript is also detected by Northern blots or by polymerase chain reaction in placenta, prostate, thymus, spleen, colon, and many cell lines of hematopoietic origin. Patch-clamp recordings of hKCa4-transfected HEK 293 cells reveal a large voltage-independent, inwardly rectifying potassium current that is blocked by externally applied tetraethylammonium (K-d = 30 +/- 7 mM), charybdotoxin (K-d = 10 +/- 1 nM and clotrimazole (K-d = 387 +/- 34 nM), but is resistant to apamin, iberiotoxin, kaliotoxin, scyllatoxin (K-d > 1 mu M), and margatoxin (K-d > 100 nM). Single hKCa4 channels have a conductance of 33 +/- 2 picosiemens in symmetrical potassium solutions. The channel is activated by intracellular calcium (K-d = 270 +/- 8 nM) with a highly cooperative interaction of approximately three calcium ions per channel, These properties of the cloned channel are very similar to those reported for the native KCa channel in activated human T lymphocytes, indicating that hKCa4 encodes this channel type.	Zeneca Pharmaceut, Target Discovery Dept, Wilmington, DE 19850 USA; Zeneca Pharmaceut, Resp Inflammatory & Neurol Dis Dept, Wilmington, DE 19850 USA		Aiyar, J (corresponding author), Zeneca Pharmaceut, Target Discovery Dept, Wilmington, DE 19850 USA.							ADELMAN JP, 1997, EUR J PHYSL S, V434, pR86; ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CHANDY KG, 1993, SEMIN NEUROSCI, V5, P125; Christian EP, 1996, J MEMBRANE BIOL, V150, P63, DOI 10.1007/s002329900030; GALLIN EK, 1989, AM J PHYSIOL, V257, pC77, DOI 10.1152/ajpcell.1989.257.1.C77; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; GRYGORCZYK R, 1984, BIOPHYS J, V45, P693, DOI 10.1016/S0006-3495(84)84211-3; HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85; KARLHEINZ K, 1990, J CLIN INVEST, V85, P491; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MAHAUTSMITH MP, 1989, J PHYSIOL-LONDON, V415, P69, DOI 10.1113/jphysiol.1989.sp017712; Rader RK, 1996, J IMMUNOL, V156, P1425; TRASK B, 1995, GENOME ANAL LAB MANU; Verheugen JAH, 1997, CELL CALCIUM, V21, P1, DOI 10.1016/S0143-4160(97)90092-0; VERHEUGEN JAH, 1995, CELL CALCIUM, V17, P287, DOI 10.1016/0143-4160(95)90075-6	17	248	257	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32723	32726		10.1074/jbc.272.52.32723	http://dx.doi.org/10.1074/jbc.272.52.32723			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407042	hybrid			2022-12-25	WOS:000071182900003
J	Rouille, Y; Kantengwa, S; Irminger, JC; Halban, PA				Rouille, Y; Kantengwa, S; Irminger, JC; Halban, PA			Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; PROPROTEIN CONVERTASES; BETA-CELLS; PC12 CELLS; PROINSULIN; CLEAVAGE; PROOPIOMELANOCORTIN; EXPRESSION; CONVERSION; PROTEINS	Proglucagon is processed differentially in pancreatic alpha-cells and intestinal endocrine L cells to release either glucagon or glucagon-like peptide-1-(7-36amide) (tGLP-1), two peptide hormones with opposing biological actions. Previous studies have demonstrated that the prohormone convertase PC2 is responsible for the processing of proglucagon to glucagon, and have suggested that the related endoprotease PC3 is involved in the formation of tGLP-1. To understand better the biosynthetic pathway of tGLP-1, proglucagon processing was studied in the mouse pituitary cell line AtT-20, a cell line that mimics the intestinal pathway of proglucagon processing and in the rat insulinoma cell line INS-1. In both of these cell lines, proglucagon was initially cleaved to glicentin and the major proglucagon fragment (MPGF) at the interdomain site Lys(70)-Arg(71). In both cell lines, MPGF was cleaved successively at the monobasic site Arg(77) and then at the dibasic site Arg(109)-Arg(110) thus releasing tGLP-1, the cleavages being less extensive in INS-1 cells. Glicentin was completely processed to glucagon in INS-1 cells, but was partially converted to oxyntomodulin and very low levels of glucagon in AtT-20 cells in the face of generation of tGLP-1. Adenovirus-mediated co-expression of PC3 and proglucagon in GH(4)C(1) cells (normally expressing no PC2 or PC3) resulted in the formation of tGLP-1, glicentin, and oxyntomodulin, but no glucagon. When expressed in alpha TC1-6 (transformed pancreatic cw-cells) or in rat primary pancreatic alpha-cells in culture, PC3 converted MPGF to tGLP-1. Finally, GLP-1-(1-37) was cleaved to tGLP-1 in vitro by purified recombinant PC3. Taken together, these results indicate that PC3 has the same specificity as the convertase that is responsible for the processing of proglucagon to tGLP-1, glicentin and oxyntomodulin in the intestinal L cell, and it is concluded that this enzyme is thus able to act alone in this processing pathway.	Ctr Med Univ Geneva, Labs Rech Louis Jeantet, CH-1211 Geneva 4, Switzerland	University of Geneva	Rouille, Y (corresponding author), Inst Pasteur, CNRS, EP 525, 1 Rue Calmette,BP 447, F-59021 Lille, France.	yrouille@infobiogen.fr	Rouillé, Yves/P-2405-2016	Rouille, Yves/0000-0003-0788-9271				ARDEN SD, 1994, BIOCHEM J, V298, P521, DOI 10.1042/bj2980521; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Badman MK, 1996, FEBS LETT, V378, P227, DOI 10.1016/0014-5793(95)01460-8; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLACHE P, 1994, FEBS LETT, V344, P65, DOI 10.1016/0014-5793(94)00371-8; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; Dhanvantari S, 1996, MOL ENDOCRINOL, V10, P342, DOI 10.1210/me.10.4.342; DICKINSON CJ, 1995, J CLIN INVEST, V96, P1425, DOI 10.1172/JCI118178; DRUCKER DJ, 1986, J BIOL CHEM, V261, P9637; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; GEORGE SK, 1985, FEBS LETT, V192, P275, DOI 10.1016/0014-5793(85)80124-1; HALBAN PA, 1994, BIOCHEM J, V299, P1; HOFLEHNER J, 1995, FEBS LETT, V360, P294, DOI 10.1016/0014-5793(95)00127-U; HOLST JJ, 1994, J BIOL CHEM, V269, P18827; Holst JJ, 1997, ANNU REV PHYSIOL, V59, P257, DOI 10.1146/annurev.physiol.59.1.257; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; Irminger JC, 1996, BIOCHEM J, V320, P11, DOI 10.1042/bj3200011; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; KERVRAN A, 1987, ENDOCRINOLOGY, V121, P704, DOI 10.1210/endo-121-2-704; KREYMANN B, 1987, LANCET, V2, P1300; LINDBERG I, 1992, BIOCHEM BIOPH RES CO, V183, P1, DOI 10.1016/0006-291X(92)91599-L; MARCINKIEWICZ M, 1994, ENDOCRINOLOGY, V135, P1651, DOI 10.1210/en.135.4.1651; MINEO I, 1995, BIOCHEM BIOPH RES CO, V207, P646, DOI 10.1006/bbrc.1995.1236; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; NAGAMUNE H, 1995, ENDOCRINOLOGY, V136, P357, DOI 10.1210/en.136.1.357; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NEERMANARBEZ M, 1994, BIOCHEM J, V300, P57, DOI 10.1042/bj3000057; NEERMANARBEZ M, 1993, J BIOL CHEM, V268, P16098; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1260, DOI 10.1210/en.132.3.1260; NILLNI EA, 1995, J NEUROCHEM, V65, P2462; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; Paquet L, 1996, J NEUROSCI, V16, P964; PATZELT C, 1979, NATURE, V282, P260, DOI 10.1038/282260a0; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; ROTHENBERG ME, 1995, J BIOL CHEM, V270, P10136, DOI 10.1074/jbc.270.17.10136; Rouille Y, 1997, FEBS LETT, V413, P119, DOI 10.1016/S0014-5793(97)00892-2; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOPSI L, 1995, J CLIN ENDOCR METAB, V80, P294, DOI 10.1210/jc.80.1.294; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; Tanaka S, 1996, ARCH HISTOL CYTOL, V59, P261, DOI 10.1679/aohc.59.261; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; UNGER RH, 1995, ENDOCRINOLOGY, P1337; VANDEWINKEL M, 1982, BIOCHEM BIOPH RES CO, V107, P525, DOI 10.1016/0006-291X(82)91523-6; VINDROLA O, 1994, NEUROPEPTIDES, V27, P109, DOI 10.1016/0143-4179(94)90051-5; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338; YI Z, 1993, J BIOL CHEM, V268, P5615; Yoon JY, 1997, J BIOL CHEM, V272, P9450; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702	68	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32810	32816		10.1074/jbc.272.52.32810	http://dx.doi.org/10.1074/jbc.272.52.32810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407057	hybrid, Green Published			2022-12-25	WOS:000071182900018
J	Sadoul, K; Berger, A; Niemann, H; Weller, U; Roche, PA; Klip, A; Trimble, WS; Regazzi, R; Catsicas, S; Halban, PA				Sadoul, K; Berger, A; Niemann, H; Weller, U; Roche, PA; Klip, A; Trimble, WS; Regazzi, R; Catsicas, S; Halban, PA			SNAP-23 is not cleaved by botulinum neurotoxin E and can replace SNAP-25 in the process of insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SYNAPTOSOMAL-ASSOCIATED PROTEIN; SYNAPTIC VESICLE DOCKING; CLOSTRIDIAL NEUROTOXINS; CHROMAFFIN CELLS; BINDING-PROTEIN; FUSION PROTEIN; SEROTYPE-A; SYNTAXIN; RELEASE	The synaptosomal-associated protein of 25 kDa (SNAP-25) is expressed in neurons and endocrine cells. It has been shown to play an important role in the release mechanism of neurotransmitters and peptide hormones, including insulin. Thus, when insulin-secreting cells are permeabilized and treated with botulinum neurotoxin E (BoNT/E), SNAP-25 is hydrolyzed, and insulin secretion is inhibited. Recently SNAP-23, a more generally expressed isoform of SNAP-25, has been described. The functional role of SNAP-23 has not been investigated to date. It is now shown that SNAP-23 is resistant to cleavage by BoNT/E. It was therefore possible to test whether transfection of HIT (transformed pancreatic B-) cells with SNAP-23 reconstitutes insulin release from BoNT/E treated cells, in which SNAP-25 is inactivated by the toxin. The results show that SNAP-23 is able to replace SNAP-25 when it is overexpressed. While these results demonstrate that SNAP-23 is a functional homologue of SNAP-25, able to function in regulated exocytosis, they indicate that SNAP-23 may be inefficient in this process. This suggests that both isoforms may have their own specific binding partners and discrete, albeit mechanistically similar, functional roles within the cell.	Ctr Med Univ Geneva, Lab Rech Louis Jeantet, CH-1211 Geneva 4, Switzerland; Med Hsch Hannover, Inst Biochem, D-30623 Hannover, Germany; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Inst Biol Cellulaire & Morphol, CH-1005 Lausanne, Switzerland	University of Geneva; Hannover Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Sadoul, K (corresponding author), Ctr Med Univ Geneva, Lab Rech Louis Jeantet, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.		Sadoul, Karin/N-2649-2013	Sadoul, Karin/0000-0001-7174-5016; Roche, Paul/0000-0002-8949-9172; Regazzi, Romano/0000-0002-9773-2915				Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1994, J PHYSIOLOGY-PARIS, V88, P235, DOI 10.1016/0928-4257(94)90086-8; BOYD RS, 1995, J BIOL CHEM, V270, P18216, DOI 10.1074/jbc.270.31.18216; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Chen FS, 1997, BIOCHEMISTRY-US, V36, P5719, DOI 10.1021/bi962331n; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; GUTIERREZ LM, 1995, FEBS LETT, V372, P39, DOI 10.1016/0014-5793(95)00944-5; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; KANAI F, 1993, J BIOL CHEM, V268, P14523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; MARTIN F, 1995, DIABETOLOGIA, V38, P860, DOI 10.1007/s001250050364; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Mollinedo F, 1997, BIOCHEM BIOPH RES CO, V231, P808, DOI 10.1006/bbrc.1997.6196; OsenSand A, 1996, J COMP NEUROL, V367, P222, DOI 10.1002/(SICI)1096-9861(19960401)367:2<222::AID-CNE5>3.0.CO;2-7; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang GY, 1997, J CELL SCI, V110, P505; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884	44	91	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33023	33027		10.1074/jbc.272.52.33023	http://dx.doi.org/10.1074/jbc.272.52.33023			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407084	hybrid			2022-12-25	WOS:000071182900045
J	Scholz, H; Bossone, SA; Cohen, HT; Akella, U; Strauss, WM; Sukhatme, VP				Scholz, H; Bossone, SA; Cohen, HT; Akella, U; Strauss, WM; Sukhatme, VP			A far upstream cis-element is required for Wilms' tumor-1 (WT1) gene expression in renal cell culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; HUMAN ERYTHROID-CELLS; BETA-GLOBIN GENE; FACTOR-A-CHAIN; KIDNEY DEVELOPMENT; TRANSGENIC MICE; DRASH SYNDROME; GENOMIC ORGANIZATION; CHROMATIN STRUCTURE; REGULATORY REGION	To identify novel cis-regulatory elements responsible for the tissue-restricted expression pattern of the Wihms' tumor-1 (WT1) gene, we mapped a total of 11 DNase I-hypersensitive sites in the 5'-flanking region and first intron of the human gene, six of which were specific for WT1 expressing cell lines. A 1.4-kilobase (kb) fragment from the mouse wt1 5'-flanking region contained cross-hybridizing sequence with significant homology to a region of DNase I hypersensitivity in the human WT1 gene which bound to nuclear matrix in human fetal kidney 293 cells. None of the DNase I-hypersensitive sites/matrix attachment regions, either alone or in combination, were sufficient for tissue-specific WT1 expression in transient and stably transfected cell lines. However, stable transfection of an approximately 620-kb yeast artificial chromosome (YAC) that carried the entire mouse wt1 locus into 293 cells resulted in wt1 (trans)gene expression at a level of approximately 30% of the endogenous human gene. Deletion of the 1.4-kb cross-hybridizing mouse fragment, located approximately 15 kb upstream of the transcription start site, caused complete loss of wt1 gene expression in the YAC-transfected 293 cells. In summary, we have identified a far upstream element that contains a region of DNase I hypersensitivity and that binds to nuclear matrix. This element includes phylogenetically conserved sequence and is required, although not sufficient, for mouse wt1 gene expression in human fetal kidney cells in culture.	Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Gerontol Div, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Sukhatme, VP (corresponding author), Beth Israel Deaconess Med Ctr, Div Renal, Dana 517,330 Brookline Ave, Boston, MA 02215 USA.		Sukhatme, Vikas/W-2776-2019		NIDDK NIH HHS [DK 537531, R01 DK45617, DK 53753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045617, R01DK053753] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1994, ONCOGENE, V9, P583; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P380; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GALLO CVD, 1992, BIOCHEM BIOPH RES CO, V184, P1226, DOI 10.1016/S0006-291X(05)80013-0; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GRUBB GR, 1994, LAB INVEST, V71, P472; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HABIB R, 1985, CLIN NEPHROL, V24, P269; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HOFMANN W, 1993, ONCOGENE, V8, P3123; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JADRESIC L, 1990, J PEDIATR-US, V117, P717, DOI 10.1016/S0022-3476(05)83327-X; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LI QL, 1994, BLOOD, V84, P1399; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; MANIVEL JC, 1987, HUM PATHOL, V18, P80; MAY G, 1995, EMBO J, V14, P564, DOI 10.1002/j.1460-2075.1995.tb07032.x; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Ragoussis J, 1996, Methods Mol Biol, V54, P69; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROMBEL I, 1995, P NATL ACAD SCI USA, V92, P6454, DOI 10.1073/pnas.92.14.6454; Roque MC, 1996, MOL CELL BIOL, V16, P3138; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Strauss W M, 1996, Methods Mol Biol, V54, P307; TADOKORO K, 1992, JPN J CANCER RES, V83, P1198, DOI 10.1111/j.1349-7006.1992.tb02745.x; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1693, DOI 10.1006/bbrc.1994.1647; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	69	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32836	32846		10.1074/jbc.272.52.32836	http://dx.doi.org/10.1074/jbc.272.52.32836			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407061	hybrid			2022-12-25	WOS:000071182900022
J	Nanbru, C; Lafon, I; Audigier, S; Gensac, MC; Vagner, S; Huez, G; Prats, AC				Nanbru, C; Lafon, I; Audigier, S; Gensac, MC; Vagner, S; Huez, G; Prats, AC			Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST GROWTH-FACTOR-2; ENCEPHALOMYOCARDITIS VIRUS-RNA; TRACT-BINDING PROTEIN; MESSENGER-RNA; INITIATED FORMS; EXPRESSION; GROWTH; CELLS; LYMPHOMAS; SEQUENCES	The human proto-oncogene c-myc encodes two proteins, c-Myc1 and c-Myc2, from two initiation codons, CUG and AUG, respectively. It is also transcribed from four alternative promoters (P0, P1, P2, and P3), giving rise to different RNA 5'-leader sequences, the long sizes of which suggest that they must be inefficiently translated by the classical ribosome scanning mechanism. Here we have examined the influence of three c-myc mRNA 5'-leaders on the translation of chimeric myc-CAT mRNAs. We observed that in the reticulocyte rabbit lysate, these 5'-leaders lead to cap-independent translation initiation. To determine whether this kind of initiation resulted from the presence of an internal ribosome entry site (IRES), COS-7 cells were transfected with bicistronic vectors containing the different c-myc 5'-leaders in the intercistronic region. An IRES was identified, requiring elements located within the P2 leader, between nucleotides -363 and -94 upstream from the CUG start codon. This is the first demonstration of the existence of IRES-dependent translation for a proto-oncogene. This IRES could be a translation enhancer, allowing activation of c-myc expression under the control of trans-acting factors and in response to specific cell stimuli.	CHU Rangueil, Inst Louis Bugnard, INSERM, U397, F-31403 Toulouse 04, France; Free Univ Brussels, Dept Biol Mol, Chim Biol Lab, B-1640 Rhode St Genese, Belgium	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, AC (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U397, Ave Jean Poulhes, F-31403 Toulouse 04, France.		Vagner, Stephan/G-3664-2013; Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; vagner, stephan/0000-0003-1452-7164				ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BERLIOZ C, 1995, J VIROL, V69, P2214, DOI 10.1128/JVI.69.4.2214-2222.1995; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; EICK D, 1990, ONCOGENE, V5, P1397; Fraser SD, 1996, ONCOGENE, V12, P1223; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; JACKSON RJ, 1991, NATURE, V353, P14, DOI 10.1038/353014a0; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; West MJ, 1995, ONCOGENE, V11, P2515; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	35	202	217	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32061	32066		10.1074/jbc.272.51.32061	http://dx.doi.org/10.1074/jbc.272.51.32061			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405401	hybrid			2022-12-25	WOS:000071108000020
J	Takahashi, H; Ishikawa, G; Ueki, K; Azumi, K; Yokosawa, H				Takahashi, H; Ishikawa, G; Ueki, K; Azumi, K; Yokosawa, H			Cloning and tyrosine phosphorylation of a novel invertebrate immunocyte protein containing immunoreceptor tyrosine-based activation motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DI-LEUCINE MOTIF; HEMOCYTE AGGREGATION; SIGNAL-TRANSDUCTION; ENDOCYTOSIS; RECEPTORS; CELLS	Immunoreceptor tyrosine-based activation motif (ITAM) plays an important role in signal transduction through mammalian T-cell and B-cell antigen receptors and Fe receptors. The ITAM has been found only in vertebrate immunocytes. Ascidians are intriguing invertebrates from the viewpoint of the evolution of immune systems because they are considered to be ancestors of the vertebrates. We have previously shown that the monoclonal antibody A74 inhibits cellular defense reactions of the ascidian. In the present studies, we found that the A74 antigen protein has two ITAMs and several motifs that are proposed to function in signal transduction, The A74 protein is tyrosine-phosphorylated and associated with other proteins in the initial stages of cellular defense reactions. The ITAMs of the A74 protein are tyrosine-phosphorylated by a c-Src kinase in vitro. The A74 protein provides a key to the understanding of the origin of vertebrate immune systems.	Hokkaido Univ, Fac Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 060, Japan	Hokkaido University	Yokosawa, H (corresponding author), Hokkaido Univ, Fac Pharmaceut Sci, Dept Biochem, Kita 12, Sapporo, Hokkaido 060, Japan.		Takahashi, Helio/J-1725-2012	Ishikawa, Go/0000-0002-4324-5185; Takahashi, Hiroki/0000-0002-7658-0246				Azumi Kaoru, 1996, P43; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Ottaviani E, 1997, IMMUNOL TODAY, V18, P169, DOI 10.1016/S0167-5699(97)84663-4; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Sambrook J., 2002, MOL CLONING LAB MANU; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; TAKAHASHI H, 1994, BIOL BULL, V186, P247, DOI 10.2307/1542270; TAKAHASHI H, 1995, EUR J BIOCHEM, V233, P778, DOI 10.1111/j.1432-1033.1995.778_3.x; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	18	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32006	32010		10.1074/jbc.272.51.32006	http://dx.doi.org/10.1074/jbc.272.51.32006			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405393	hybrid			2022-12-25	WOS:000071108000012
J	Wolner, BS; Gralla, JD				Wolner, BS; Gralla, JD			Promoter activation via a cyclic AMP response element in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BINDING PROTEIN CREB; TRANSCRIPTION FACTORS IIE; PREINITIATION COMPLEX; IN-VITRO; FACTOR ATF; INITIATION; CAMP; CLEARANCE; INTERACTS	Transcription activation via activating transcription factor cyclic AMP response element binding (ATF/CREB) sites in vitro was explored using transcription and permanganate assay for open complex formation. These sites were used to drive transcription from an adenovirus major late core sequence. Under conditions where activation is strong, 20-50-fold, ATF/CREB is required for preinitiation complexes to reach the open complex stage. Complete opening requires activator, ATP, and initiating nucleotides. In exploration of postinitiation steps, no stimulation of promoter clearance was observed but a modest stimulation of the rate of continuous transcription occurred. High amounts of DNA template, commonly used in in vitro studies, allows some templates to open without activator, but leaves the nucleotide requirements intact. This leads to a drastic lowering of the dependence on ATF/CREB. Taken together, the data indicate that ATF/CREB activates this system primarily by stimulating the formation of functional preinitiation complexes.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.		Wolner, Branden/A-9615-2015	Wolner, Branden/0000-0003-0021-2073	NIGMS NIH HHS [GM07185, GM49048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Blau J, 1996, MOL CELL BIOL, V16, P2044; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLANDER EW, 1991, NUCLEIC ACIDS RES, V19, P3369, DOI 10.1093/nar/19.12.3369; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JIANG Y, 1994, J BIOL CHEM, V269, P5505; JIANG Y, 1995, J BIOL CHEM, V270, P1277, DOI 10.1074/jbc.270.3.1277; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kobayashi M, 1997, NUCLEIC ACIDS RES, V25, P877, DOI 10.1093/nar/25.4.877; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; QUINN PG, 1993, J BIOL CHEM, V268, P16999; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Shopland LS, 1996, CHROMOSOMA, V105, P158, DOI 10.1007/BF02509497; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Wang JT, 1996, J BIOL CHEM, V271, P32707, DOI 10.1074/jbc.271.51.32707; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; XING LP, 1994, J BIOL CHEM, V269, P28732; YAN M, IN PRESS EMBO J; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Yean D, 1997, MOL CELL BIOL, V17, P3809, DOI 10.1128/MCB.17.7.3809; Yean D, 1996, NUCLEIC ACIDS RES, V24, P2723, DOI 10.1093/nar/24.14.2723; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	42	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32301	32307		10.1074/jbc.272.51.32301	http://dx.doi.org/10.1074/jbc.272.51.32301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405436	hybrid			2022-12-25	WOS:000071108000055
J	Chiron, MF; Fryling, CM; FitzGerald, D				Chiron, MF; Fryling, CM; FitzGerald, D			Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; RECEPTOR-RELATED PROTEIN; DIPHTHERIA-TOXIN; CYTOPLASMIC DOMAIN; CELL-SURFACE; MOUSE FURIN; ACTIVATION; LOCALIZATION; EXPRESSION; SEQUENCE	Pseudomonas exotoxin (PE) requires proteolytic cleavage to generate a 37-kDa C-terminal fragment that translocates to the cytosol and ADP-ribosylates elongation factor 2. Cleavage within cells is mediated by furin, occurs between arginine 279 and glycine 280, and requires an arginine at both P1 and P4 residues. To study the proteolytic processing of PE-derived chimeric toxins, TGF alpha-PE38 (transforming growth factor fused to the domains II and III of PE) and a mutant form, TGF alpha-PE38gly279, were each produced in Escherichia coli, When assessed on various epidermal growth factor (EGF) receptor-positive cell lines, TGF alpha-PE38 was 100-500-fold more toxic than TGF alpha-PE38gly279. In contrast to PE, where cleavage by furin is only evident at pH 5.5, furin cleaved TGF alpha-PE38 over a broad pH range, while TGF alpha-PE38gly279 was resistant to cleavage, TGF alpha-PE38 was poorly toxic for furin-deficient LoVo cells, unless it was first pretreated in vitro with furin, Furin treatment produced a nicked protein that was 30-fold more toxic than its unnicked counterpart. Using the single chain immunotoxin HB21scFv-PE40 as a substrate, furin-mediated processing of an antibody-based immunotoxin was also evaluated, HB21scFv-PE40, which targets cells expressing the transferrin receptor, was cleaved in a similar fashion to that of TGF alpha-PE38 and nicked HB21scFv-PE40 exhibited increased toxicity for LoVo cells, In short-term experiments, the rate of reduction in protein synthesis by furin-nicked immunotoxins was increased compared with unnicked protein, indicating that cleavage by furin can be a rate-limiting step, We conclude that furin-mediated cleavage of PE-derived immunotoxins is important for their cytotoxic activity.	NCI,BIOTHERAPY SECT,MOL BIOL LAB,DBS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BATRA JK, 1991, MOL CELL BIOL, V11, P2200, DOI 10.1128/MCB.11.4.2200; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; Chiron MF, 1996, MOL MICROBIOL, V22, P769, DOI 10.1046/j.1365-2958.1996.d01-1721.x; CHIRON MF, 1994, J BIOL CHEM, V269, P18167; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GARRED O, 1995, J BIOL CHEM, V270, P10817; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; GORDON VM, 1994, INFECT IMMUN, V62, P333, DOI 10.1128/IAI.62.2.333-340.1994; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGIEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KREITMAN RJ, 1995, BIOCHEM J, V307, P29, DOI 10.1042/bj3070029; LEPPLA SH, 1978, BIOCHEM BIOPH RES CO, V81, P532, DOI 10.1016/0006-291X(78)91567-X; Mansfield E, 1997, BIOCHEM SOC T, V25, P709, DOI 10.1042/bst0250709; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; OGATA M, 1990, J BIOL CHEM, V265, P20678; OGATA M, 1992, J BIOL CHEM, V267, P25396; PASTAN I, 1989, J BIOL CHEM, V264, P15157; PASTAN IH, 1995, ANN NY ACAD SCI, V758, P345, DOI 10.1111/j.1749-6632.1995.tb24840.x; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673	34	38	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31707	31711		10.1074/jbc.272.50.31707	http://dx.doi.org/10.1074/jbc.272.50.31707			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395513	hybrid			2022-12-25	WOS:A1997YL41900072
J	Das, S; Maiti, T; Das, K; Maitra, U				Das, S; Maiti, T; Das, K; Maitra, U			Specific interaction of eukaryotic translation initiation factor 5 (eIF5) with the beta-subunit of eIF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IMMUNOCHEMICAL CHARACTERIZATION; RABBIT RETICULOCYTES; PROTEIN-SYNTHESIS; KINASE-II; EXPRESSION; COMPLEX; BINDING; RELEASE; CLONING	Eukaryotic translation initiation factor 5 (eIF5) interacts with the 40 S initiation complex (40 S.mRNA. eIF3.Met-tRNA(f).eIF2.GTP) and mediates hydrolysis of the bound GTP, To characterize the molecular interactions involved in eIF5 function, we have used P-32-labeled recombinant rat eIF5 as a probe in filter overlay assay to identify eIF5 interacting proteins in crude initiation factor preparations. We observed that eIF5 specifically interacted with the beta subunit of initiation factor eIF2. No other initiation factors including the gamma subunit of eIF2 tested positive in this assay, Furthermore, both yeast and mammalian eIF5 bind to the beta subunit of either mammalian or yeast eIF2. Binding analysis with human eIF2 beta deletion mutants expressed in Escherichia coli identified a 22-amino acid domain, between amino acids 68 and 89, as the primary eIF5-binding region of eIF2 beta. These results along with our earlier observations that (a) eIF5 neither binds nor hydrolyzes free GTP or GTP bound as Met-tRNA(f).eIF2.GTP ternary complex, and (b) eIF5 forms a specific complex with eIF2 suggests that the specific interaction between eIF5 and the beta subunit of eIF2 may be critical for the hydrolysis of GTP during translation initiation.			Das, S (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOL BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [K04CA001330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA1330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRABARTI A, 1992, J BIOL CHEM, V267, P12964; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P5754; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; CHEVESICH J, 1993, J BIOL CHEM, V268, P20659; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; DAS K, 1995, THESIS A EINSTEIN CO; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; FASANO O, 1982, J BIOL CHEM, V257, P3145; GASPAR NJ, 1994, J BIOL CHEM, V269, P32415; GHOSH S, 1989, J BIOL CHEM, V264, P5134; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; KOZAK M, 1983, MICROBIOL REV, V47, P1; Maiti T, 1997, J BIOL CHEM, V272, P18333, DOI 10.1074/jbc.272.29.18333; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; Merrick WC., 1996, TRANSLATION CONTROL, P31; Metz AM, 1997, ARCH BIOCHEM BIOPHYS, V342, P187, DOI 10.1006/abbi.1997.0119; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; RAYCHAUDHURI P, 1987, J BIOL CHEM, V262, P14222; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; Sambrook J., 2002, MOL CLONING LAB MANU; Si KS, 1996, J BIOL CHEM, V271, P16934, DOI 10.1074/jbc.271.28.16934; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204	29	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31712	31718		10.1074/jbc.272.50.31712	http://dx.doi.org/10.1074/jbc.272.50.31712			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395514	hybrid			2022-12-25	WOS:A1997YL41900073
J	Johns, DC; Nuss, HB; Marban, E				Johns, DC; Nuss, HB; Marban, E			Suppression of neuronal and cardiac transient outward currents by viral gene transfer of dominant-negative Kv4.2 constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; RAT HIPPOCAMPAL-NEURONS; ION-CHANNEL EXPRESSION; K+ CHANNEL; POTASSIUM CHANNELS; VENTRICULAR MYOCYTES; DIFFERENTIAL EXPRESSION; XENOPUS-OOCYTES; IN-VITRO; HEART	To probe the molecular identity of transient outward (A-type) potassium currents, we expressed a truncated version of Kv4.2 in heart cells and neurons. The rat Kv4.2 coding sequence was truncated at a position just past the first transmembrane segment and subcloned into an adenoviral shuttle vector downstream of a cytomegalovirus promoter (pE1Kv4.2ST). We hypothesized that this construct would act as a dominant-negative suppressor of currents encoded by the Kv4 family by analogy to Kv1 channels. Cotransfection of wild-type Kv4.2 with a beta-galactosidase expression vector in Chinese hamster ovary (CHO)-K1 cells produced robust transient outward currents (I-to) after two days (14.0 pA/pF at 50 mV, n = 5). Cotransfection with pE1Kv4.2ST markedly suppressed the Kv4.2 currents (0.8 pA/pF, n = 6, p < 0.02; cDNA ratio of 2:1 Kv4.2ST:wild type), but in parallel experiments, it did not alter the current density of coexpressed Kv1.4 or Kv1.5 channels, Kv4.2ST also effectively suppressed rat Kv4.3 current when coexpressed in CHO-K1 cells. We then engineered a recombinant adenovirus (AdKv4.2ST) designed to overexpress Kv4.2ST in infected cells. A-type currents in rat cerebellar granule cells were decreased two days after AdKv4.2ST infection as compared with those infected by a beta-galactosidase reporter virus (116.0 pA/pF versus 281.4 pA/pF in Ad beta-galactosidase cells, n = 8 each group, p < 0.001). Likewise, I-to in adult rat ventricular myocytes was suppressed by AdKv4.2ST but not by Ad beta-galactosidase (8.8 pA/pF versus 21.4 pA/pF in beta-galactosidase cells, n = 6 each group, p < 0.05). Expression of a GFP-Kv4.2ST fusion construct enabled imaging of subcellular protein localization by confocal microscopy. The protein was distributed throughout the surface membrane and intracellular membrane systems, We conclude that genes from the Kv4 family are the predominant contributors to the A-type currents in cerebellar granule cells and I-to in rat ventricle. Overexpression of dominant-negative constructs may be of general utility in dissecting the contributions of various ion channel genes to excitability.	JOHNS HOPKINS UNIV,SECT MOL & CELLULAR CARDIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,GRAD PROGRAM CELLULAR & MOL MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University			Marban, Eduardo/GWC-8514-2022					BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Chen ML, 1996, NEURON, V17, P535, DOI 10.1016/S0896-6273(00)80185-3; CHUNG SW, 1995, P NATL ACAD SCI USA, V92, P5955, DOI 10.1073/pnas.92.13.5955; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; DIXON JE, 1994, CIRC RES, V75, P252, DOI 10.1161/01.RES.75.2.252; Fiset C, 1997, J PHYSIOL-LONDON, V500, P51, DOI 10.1113/jphysiol.1997.sp021998; Good TA, 1996, BIOPHYS J, V70, P296, DOI 10.1016/S0006-3495(96)79570-X; GORTER JA, 1995, J NEUROPHYSIOL, V74, P298, DOI 10.1152/jn.1995.74.1.298; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HILALDANDAN R, 1991, J MOL CELL CARDIOL, V23, P705, DOI 10.1016/0022-2828(91)90980-Z; Hitt M. M., 1994, CELL BIOL LAB HDB, V1, P479; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JOHNS DC, 1995, J CLIN INVEST, V96, P1152, DOI 10.1172/JCI118103; Kaab S, 1996, CIRC RES, V78, P262, DOI 10.1161/01.RES.78.2.262; Kass RS, 1996, CARDIOVASC RES, V32, P443, DOI 10.1016/S0008-6363(96)00122-8; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LEVI G, 1989, MANUAL NERVOUS SYSTE, P211; LI M, 1992, SCIENCE, V257, P125; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MORGAN RA, 1992, NUCLEIC ACIDS RES, V20, P1293, DOI 10.1093/nar/20.6.1293; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Panyi G, 1996, J GEN PHYSIOL, V107, P409, DOI 10.1085/jgp.107.3.409; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; PO S, 1992, CIRC RES, V71, P732, DOI 10.1161/01.RES.71.3.732; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; Ribera AB, 1996, J NEUROSCI, V16, P1123; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SCHREUR K, 1997, CIRCULATION, V96, P422; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; TOMITA F, 1994, CIRC RES, V75, P296, DOI 10.1161/01.RES.75.2.296; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; Yamamoto H, 1996, J BIOL CHEM, V271, P16253, DOI 10.1074/jbc.271.27.16253; ZEGARRAMORAN O, 1994, EXP BRAIN RES, V98, P298; ZYGMUNT AC, 1991, CIRC RES, V68, P424, DOI 10.1161/01.RES.68.2.424	45	138	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31598	31603		10.1074/jbc.272.50.31598	http://dx.doi.org/10.1074/jbc.272.50.31598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395498	hybrid			2022-12-25	WOS:A1997YL41900057
J	Katagiri, Y; Hirata, Y; Milbrandt, J; Guroff, G				Katagiri, Y; Hirata, Y; Milbrandt, J; Guroff, G			Differential regulation of the transcriptional activity of the orphan nuclear receptor NGFI-B by membrane depolarization and nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; INDUCIBLE MEMBER; GENE; PHOSPHORYLATION; SUPERFAMILY; ACTIVATION; EXPRESSION; KINASE; NUR77; PROTEIN	The immediate-early gene NGFI-B (also called nur77) encodes an orphan nuclear receptor that activates transcription through a unique response element (NBRE), NGFI-B is rapidly induced and modified via phosphorylation by a variety of stimuli that induce cells to differentiate or to proliferate, We have shown that the in vitro phosphorylation of Ser(350) located within the ''A-box,'' a motif necessary for DNA binding by NGFI-B, results in a decrease in the binding of NGFI-B to its response element (Hirata, Y., Kiuchi, K., Chen, H.-C., Milbrandt, J., and Guroff, G, (1993) J, Biol. Chem. 268, 24808-24812). We show here that nerve growth factor (NGF)-induced changes in the in vivo phosphorylation of Ser(350) accompany transcriptional deactivation of NGFI-B in PC12 cells, that membrane depolarization and NGF treatment cause differential phosphorylation of NGFI-B, and that the transcriptional activation caused by exogenous expression of NGFI-B or membrane depolarization can be inhibited by NGF treatment, In addition, the mutation of Ser(350) to Ala abolished the inhibitory effect of NGF on the transcriptional activation of NGFI-B in PC12 cells, These data could provide new insights into the regulation of transcriptional activity required for some neurons to switch from activity-dependent survival to neurotrophin-dependent survival during development.	NICHHD,NIH,GROWTH FACTORS SECT,BETHESDA,MD 20892; RIKEN,BIOMIMET CONTROL RES CTR,MORIYAMA KU,NAGOYA,AICHI 463,JAPAN; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); RIKEN; Washington University (WUSTL)			Hirata, Yoko/AAG-6798-2020; Hirata, Yoko/L-3142-2019	Hirata, Yoko/0000-0002-7081-4937; Milbrandt, Jeffrey/0000-0002-5477-7689				BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HIRATA Y, 1995, J NEUROCHEM, V65, P1780; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; ITOH K, 1995, SCIENCE, V270, P1369, DOI 10.1126/science.270.5240.1369; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; KUES WA, 1995, J CELL BIOL, V130, P949, DOI 10.1083/jcb.130.4.949; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	25	74	74	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31278	31284		10.1074/jbc.272.50.31278	http://dx.doi.org/10.1074/jbc.272.50.31278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395454	hybrid			2022-12-25	WOS:A1997YL41900013
J	Latinis, KM; Norian, LA; Eliason, SL; Koretzky, GA				Latinis, KM; Norian, LA; Eliason, SL; Koretzky, GA			Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SIGNAL-TRANSDUCTION; CD28 COSTIMULATION; INDUCED APOPTOSIS; ANTIGEN RECEPTOR; CYCLOSPORINE-A; DEATH; GENE; LYMPHOCYTES; FAMILY; REQUIREMENT	Antigen receptor engagement on T lymphocytes activates transcription factors important for stimulating cytokine gene expression, This is critical for clonal expansion of antigen-specific T cells and propagation of immune responses. Additionally, under some conditions antigen receptor stimulation initiates apoptosis of T lymphocytes through the induced expression of CD95 ligand and its receptor. Here we demonstrate that the transcription factor, NFAT, which is critical for the inducible expression of many cytokine genes, also plays a critical role in the regulation of T cell receptor-mediated CD95 ligand expression, Two sites within the CD95 ligand promoter, identified through DNase I footprinting, bind NFAT proteins from nuclear extracts of activated T cells. Although both sites appear important for optimal expression of CD95 ligand in activated T cells, mutational analysis suggests that the distal NFAT site plays a more significant role. Furthermore, these sites do not appear to be required for constitutive CD95 ligand expression in Sertoli cells.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,INTERDISCIPLINARY GRAD PROGRAM IMMUNOL,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa			Koretzky, Gary/AAU-5381-2021	Norian, Lyse/0000-0003-1016-313X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA66470] Funding Source: Medline; NIAID NIH HHS [T32-AI07485] Funding Source: Medline; NIGMS NIH HHS [5232-GM07337] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ANEL A, 1994, EUR J IMMUNOL, V24, P2469, DOI 10.1002/eji.1830241032; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Duncliffe KN, 1997, IMMUNITY, V6, P175, DOI 10.1016/S1074-7613(00)80424-0; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; HO S, 1994, ADV EXP MED BIOL, V365, P167; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Latinis KM, 1997, J IMMUNOL, V158, P4602; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Musci MA, 1997, CLIN IMMUNOL IMMUNOP, V83, P205, DOI 10.1006/clin.1996.4315; Noel PJ, 1996, J IMMUNOL, V157, P636; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; OYAIZU N, 1995, BIOCHEM BIOPH RES CO, V213, P994, DOI 10.1006/bbrc.1995.2227; PASTOR MI, 1995, CANCER SURV, V22, P75; Radvanyi LG, 1996, J IMMUNOL, V156, P1788; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WINGENDER E, 1994, J BIOTECHNOL, V35, P273, DOI 10.1016/0168-1656(94)90041-8	46	193	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31427	31434		10.1074/jbc.272.50.31427	http://dx.doi.org/10.1074/jbc.272.50.31427			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395475	hybrid			2022-12-25	WOS:A1997YL41900034
J	Pietroni, P; Young, MC; Latham, GJ; vonHippel, PH				Pietroni, P; Young, MC; Latham, GJ; vonHippel, PH			Structural analyses of gp45 sliding clamp interactions during assembly of the bacteriophage T4 DNA polymerase holoenzyme .1. Conformational changes within the gp44/62-gp45-ATP complex during clamp loading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN COMPLEX; SINGLE-STRANDED-DNA; PRIMER-TEMPLATE; REPLICATION COMPLEX; III HOLOENZYME; ATP HYDROLYSIS; CROSS-LINKING; PROCESSIVITY; JUNCTION; HELICASE	A multisubunit ring-shaped protein complex is used to tether the polymerase to the DNA at the primer-template junction in most DNA replication systems. This ''sliding clamp'' interacts with the polymerase, completely encircles the DNA duplex, and is assembled onto the DNA by a specific clamp loading complex in an ATP-driven process. Site-specific mutagenesis has been used to introduce single cysteine residues as reactive sites for adduct formation within each of the three subunits of the bacteriophage T4-coded sliding clamp complex (gp45). Two such mutants, gp45S19C and gp45K81C, are reacted with the cysteine-specific photoactivable crosslinker TFPAM-3 and used to track the changes in the relative positioning of the gp45 subunits with one another and with the other components of the clamp loading complex (gp44/62) in the various stages of the loading process. Cross linking interactions performed in the presence of nucleotide cofactors show that ATP binding and hydrolysis, interaction with primer-template DNA, and release of ADP all result in significant conformational changes within the clamp loading cycle, A structural model is presented to account for the observed rearrangements of intersubunit contacts within the complex during the loading process.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R01GM015792, R37GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Berdis AJ, 1997, BIOCHEMISTRY-US, V36, P2733, DOI 10.1021/bi962139l; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; ELLMANN GL, 1958, ARCH BIOCHEM BIOPHYS, V82, P70; FAIRFIELD FR, 1983, J BIOMOL STRUCT DYN, V1, P715, DOI 10.1080/07391102.1983.10507477; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15721; HUANG CC, 1981, J BIOL CHEM, V256, P4087; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; KEANA JFW, 1990, J ORG CHEM, V55, P3640, DOI 10.1021/jo00298a048; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latham GJ, 1997, J BIOL CHEM, V272, P31677, DOI 10.1074/jbc.272.50.31677; Latham GJ, 1996, J MOL BIOL, V264, P426, DOI 10.1006/jmbi.1996.0651; Latham GJ, 1997, J BIOL CHEM, V272, P31685, DOI 10.1074/jbc.272.50.31685; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; RUSH J, 1989, J BIOL CHEM, V264, P10943; Sexton DJ, 1996, J BIOL CHEM, V271, P28045, DOI 10.1074/jbc.271.45.28045; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	32	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31666	31676		10.1074/jbc.272.50.31666	http://dx.doi.org/10.1074/jbc.272.50.31666			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395508	hybrid			2022-12-25	WOS:A1997YL41900067
J	Simon, M; Montezin, M; Guerrin, M; Durieux, JJ; Serre, G				Simon, M; Montezin, M; Guerrin, M; Durieux, JJ; Serre, G			Characterization and purification of human corneodesmosin, an epidermal basic glycoprotein associated with corneocyte-specific modified desmosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRATUM-CORNEUM; DESQUAMATION; DIFFERENTIATION; ANTIGENS; INVITRO; PROTEIN; IDENTIFICATION; PROTEOLYSIS; EXPRESSION; EPITHELIA	Using monoclonal antibodies, we identified a new protein in mammalian epidermis, which we called corneodesmosin. It is located in the extracellular part of the modified desmosomes in the cornified layer of the tissue, and its proteolysis (from 52-56 to 33 kDa) is thought to be a major prerequisite of desquamation. We have now further characterized human corneodesmosin. Proteolysis of purified cornified cell envelopes produced immunoreactive fragments, confirming the covalent linkage of the protein to these structures. Sequential extraction of epidermal proteins indicated that the 52-56-kDa precursor form of the protein exists in two distinct pools, one extracted with a nondenaturing hypotonic buffer, and the other with urea. Two-dimensional gel analysis and reactivity with phosphoserine-specific antibodies showed that it is a basic phosphoprotein. Deglycosylation experiments, reactivity with lectins, and chromatography on concanavalin A-Sepharose indicated that corneodesmosin is N-glycosylated. Partial sequences, 10 and 15 amino acids long, of the purified 52-56-kDa corneodesmosin showed identity with sequences predicted from a previously cloned gene, proved to be expressed in the epidermis and designated S. This indicates that corneodesmosin is probably encoded by the S gene, the function of which was unknown until now. A model of corneodesmosin maturation during cornification is proposed.	INSERM, CJF 96 02, DEPT PATHOL & CELL BIOL, TOULOUSE, FRANCE; UNIV TOULOUSE 3, PURPAN SCH MED, IFR30, INSERM, CNRS, UPS, CHU, F-31073 TOULOUSE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier			Simon, Michel/B-7308-2011	Simon, Michel/0000-0003-3655-6329				ALLEN TD, 1975, J ULTRA MOL STRUCT R, V51, P94, DOI 10.1016/S0022-5320(75)80011-6; CHAPMAN SJ, 1990, ARCH DERMATOL RES, V282, P304, DOI 10.1007/BF00375724; CHAPMAN SJ, 1991, ARCH DERMATOL RES, V283, P167, DOI 10.1007/BF00372057; EGELRUD T, 1988, ACTA DERM-VENEREOL, V68, P93; ELIAS PM, 1983, J INVEST DERMATOL, V80, pS44, DOI 10.1038/jid.1983.12; HAFTEK M, 1991, J HISTOCHEM CYTOCHEM, V39, P1531, DOI 10.1177/39.11.1717544; HANSSON L, 1994, J BIOL CHEM, V269, P19420; HENSELER T, 1985, J AM ACAD DERMATOL, V13, P450, DOI 10.1016/S0190-9622(85)70188-0; HOLBROOK K, 1994, KERATINOCYTE HDB, P275; KAPPRELL HP, 1985, EUR J CELL BIOL, V36, P217; KING CS, 1979, BRIT J DERMATOL, V100, P165, DOI 10.1111/j.1365-2133.1979.tb05556.x; KING IA, 1989, J INVEST DERMATOL, V92, P22, DOI 10.1111/1523-1747.ep13070408; LUNDSTROM A, 1990, ARCH DERMATOL RES, V282, P234, DOI 10.1007/BF00371642; LUNDSTROM A, 1994, ARCH DERMATOL RES, V286, P369, DOI 10.1007/BF00371795; LUNDSTROM A, 1990, J INVEST DERMATOL, V94, P216, DOI 10.1111/1523-1747.ep12874531; MENTON DN, 1971, J ULTRA MOL STRUCT R, V35, P247, DOI 10.1016/S0022-5320(71)80155-7; MILS V, 1992, J HISTOCHEM CYTOCHEM, V40, P1329, DOI 10.1177/40.9.1506670; Montezin M, 1997, EXP CELL RES, V231, P132, DOI 10.1006/excr.1996.3452; RAWLINGS AV, 1994, J INVEST DERMATOL, V103, P731, DOI 10.1111/1523-1747.ep12398620; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; SANDILANDS A, 1995, EUR J CELL BIOL, V67, P238; SERRE G, 1991, J INVEST DERMATOL, V97, P1061, DOI 10.1111/1523-1747.ep12492589; Simon M, 1996, BIOCHEM J, V317, P173, DOI 10.1042/bj3170173; SKERROW CJ, 1989, J CELL SCI, V92, P667; SUZUKI Y, 1993, ARCH DERMATOL RES, V285, P372, DOI 10.1007/BF00371839; SUZUKI Y, 1994, ARCH DERMATOL RES, V286, P249, DOI 10.1007/BF00387596; Vicanova J, 1996, CELL TISSUE RES, V286, P115, DOI 10.1007/s004410050680; WALSH A, 1991, ARCH DERMATOL RES, V283, P174, DOI 10.1007/BF00372058; ZHOU YQ, 1993, P NATL ACAD SCI USA, V90, P9470, DOI 10.1073/pnas.90.20.9470	29	71	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31770	31776		10.1074/jbc.272.50.31770	http://dx.doi.org/10.1074/jbc.272.50.31770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395522	hybrid			2022-12-25	WOS:A1997YL41900081
J	Vu, TKH; Liu, RW; Haaksma, CJ; Tomasek, JJ; Howard, EW				Vu, TKH; Liu, RW; Haaksma, CJ; Tomasek, JJ; Howard, EW			Identification and cloning of the membrane-associated serine protease, hepsin, from mouse preimplantation embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; DORSAL-VENTRAL PATTERN; SPERM-EGG FUSION; DROSOPHILA EMBRYO; DISINTEGRIN DOMAIN; ASTACIN FAMILY; C-PROTEINASE; GENE ENCODES; FACTOR-VII; EXPRESSION	Previous studies have suggested the existence of a membrane-associated serine protease expressed by mammalian preimplantation embryos, In this study, we have identified hepsin, a type II transmembrane serine protease, in early mouse blastocysts. Mouse hepsin was highly homologous to the previously identified human and rat cDNAs. Two isoforms, differing in their cytoplasmic domains, were detected. The tissue distribution of mouse hepsin was similar to that seen in humans, with prominent expression in liver and kidney. In mouse embryos, hepsin expression was observed in the two-cell stage, reached a maximal level at the early blastocyst stage, and decreased subsequent to blastocyst hatching. Expression of a soluble form of hepsin revealed its ability to autoactivate in a concentration-dependent manner. Catalytically inactive soluble hepsin was unable to autoactivate. These results suggest that hepsin may be the first serine protease expressed during mammalian development, making its ability to autoactivate critical to its function.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT ANAT SCI,OKLAHOMA CITY,OK 73190; COLUMBIA PRESBYTERIAN MED CTR,CTR ASSISTED REPROD TECHNOL,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; Columbia University	Vu, TKH (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,BIOMED SCI BLDG,RM 434,940 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73190, USA.							APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELAROUSSI MA, 1994, BBA-GENE STRUCT EXPR, V1217, P1, DOI 10.1016/0167-4781(94)90116-3; EVANS JP, 1995, J CELL SCI, V108, P3267; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; Hishida R, 1996, EMBO J, V15, P4111, DOI 10.1002/j.1460-2075.1996.tb00786.x; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; Katagiri C, 1997, INT J DEV BIOL, V41, P19; KAZAMA Y, 1995, J BIOL CHEM, V270, P66, DOI 10.1074/jbc.270.1.66; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; McLaren A., 1982, REPROD MAMMALS; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; PERONA RM, 1986, DEV BIOL, V114, P42, DOI 10.1016/0012-1606(86)90382-9; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SAWADA H, 1990, J EXP ZOOL, V253, P83; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; STEARNS DJ, 1988, J BIOL CHEM, V263, P829; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; Tanimoto H, 1997, CANCER RES, V57, P2884; TORRESROSADO A, 1993, P NATL ACAD SCI USA, V90, P7181, DOI 10.1073/pnas.90.15.7181; TSUJI A, 1991, J BIOL CHEM, V266, P16948; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAN L, 1995, DEVELOPMENT, V121, P1591; YASUMASU S, 1992, DEV BIOL, V153, P250, DOI 10.1016/0012-1606(92)90110-3; Zhukov A, 1997, BBA-PROTEIN STRUCT M, V1337, P85, DOI 10.1016/S0167-4838(96)00152-5	39	63	73	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31315	31320		10.1074/jbc.272.50.31315	http://dx.doi.org/10.1074/jbc.272.50.31315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395459	hybrid			2022-12-25	WOS:A1997YL41900018
J	Phung, TL; Roncone, A; Jensen, KLD; Sparks, CE; Sparks, JD				Phung, TL; Roncone, A; Jensen, KLD; Sparks, CE; Sparks, JD			Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I PHOSPHATIDYLINOSITOL KINASE; PROTEIN DISULFIDE ISOMERASE; LOW-DENSITY LIPOPROTEINS; ZUCKER-FATTY RAT; 3T3-L1 ADIPOCYTES; GOLGI-APPARATUS; GROWTH-FACTOR; PRIMARY CULTURES; MESSENGER-RNA; BREFELDIN-A	Insulin inhibits apolipoprotein B (apoB) secretion by primary rat hepatocytes through activation of phosphoinositide 3-kinase (PI 3-K). Current studies demonstrate that the PI 3-K inhibitor wortmannin inhibits both basal and insulin-stimulated PI 3-K activities, Wortmannin and LY 294002, two structurally distinct PI 3-K inhibitors, prevent insulin-dependent inhibition of apoE secretion in a dose-dependent manner, To link PI 3-K activation to insulin action on apoB, we investigated whether insulin induced localization of activated PI 3-K to the endoplasmic reticulum (ER), where apoB biogenesis is initiated, Insulin action results in a significant redistribution of PI 3-K to a low density microsome (LDM) fraction containing apoB protein and apoB mRNA, Insulin stimulates a significant increase in PI 3-K activity associated with insulin receptor substrate-1 as well as an increase in insulin receptor substrate-1/PI 3-K mass in LDM. Subfractionation of LDM on sucrose density gradients shows that insulin significantly increases the amount of PI 3-K present in an ER fraction containing apoB. Insulin stimulates PI 3-K activity in smooth and rough microsomes isolated from rat hepatocytes, the latter of which contain rough ER as demonstrated by electron microscopy, Studies indicate that 1) PI 3-K activity is necessary for insulin-dependent inhibition of apoB secretion by rat hepatocytes; 2) insulin action leads to the activation and localization of PI 3-K in an ER fraction containing apoB; and 3) insulin stimulates PI 3-K activity in the rough ER.	Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA	University of Rochester	Sparks, JD (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Box 626,601 Elmwood Ave, Rochester, NY 14642 USA.		Adiels, Martin/C-9278-2011	Sparks, Janet/0000-0002-0072-766X	NHLBI NIH HHS [HL 29837] Funding Source: Medline; NIDDK NIH HHS [DK 50376S1, DK 50376] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050376] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BJORNSSON OG, 1992, BIOCHEM J, V281, P381; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BRAY GA, 1977, FED PROC, V36, P148; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTWRIGHT IJ, 1992, BIOCHEM J, V285, P153, DOI 10.1042/bj2850153; CHEN XL, 1993, J BIOL CHEM, V268, P21007; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DePierre J., 1976, BIOCH ANAL MEMBRANES, P79; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DURRINGTON PN, 1982, J CLIN INVEST, V70, P63, DOI 10.1172/JCI110604; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P2442; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy E, 1996, FEBS LETT, V393, P253, DOI 10.1016/0014-5793(96)00896-4; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NOIVA R, 1991, J BIOL CHEM, V266, P19645; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; PATSCH W, 1986, J BIOL CHEM, V261, P9603; PATSCH W, 1983, J CLIN INVEST, V71, P1161, DOI 10.1172/JCI110865; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; SALHANICK AI, 1991, METABOLISM, V40, P275, DOI 10.1016/0026-0495(91)90109-A; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SPARKS CE, 1986, METABOLISM, V35, P1128, DOI 10.1016/0026-0495(86)90026-0; Sparks Janet D., 1993, Current Opinion in Lipidology, V4, P177, DOI 10.1097/00041433-199306000-00002; Sparks JD, 1996, METHOD ENZYMOL, V263, P104; SPARKS JD, 1994, METABOLISM, V43, P681, DOI 10.1016/0026-0495(94)90115-5; SPARKS JD, 1986, ATHEROSCLEROSIS, V61, P205, DOI 10.1016/0021-9150(86)90139-5; Sparks JD, 1996, BIOCHEM J, V313, P567, DOI 10.1042/bj3130567; SPARKS JD, 1994, BIOCHEM BIOPH RES CO, V205, P417, DOI 10.1006/bbrc.1994.2681; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WADA I, 1991, J BIOL CHEM, V266, P19599; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WAY BA, 1993, J BIOL CHEM, V268, P26409; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WITZTUM JL, 1979, DIABETES, V28, P509, DOI 10.2337/diab.28.5.509; WONG L, 1987, EUR J BIOCHEM, V164, P357, DOI 10.1111/j.1432-1033.1987.tb11066.x; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	69	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30693	30702		10.1074/jbc.272.49.30693	http://dx.doi.org/10.1074/jbc.272.49.30693			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388205	hybrid			2022-12-25	WOS:000071640800018
J	Sewack, GF; Hansen, U				Sewack, GF; Hansen, U			Nucleosome positioning and transcription-associated chromatin alterations on the human estrogen-responsive pS2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; MAMMARY EPITHELIAL-CELLS; TUMOR VIRUS PROMOTER; DNA-BINDING DOMAINS; BREAST-CANCER CELLS; FACTOR ACCESS; IN-VIVO; VITELLOGENIN-B1 PROMOTER; REGULATED TRANSCRIPTION; TRANSLATIONAL POSITION	The positioning of nucleosomes on a promoter is a significant determinant in its responsiveness to inducing signals. We have mapped the chromatin structure of the human, estrogen-responsive pS2 promoter at nucleotide level resolution within the context of its normal genomic location in human mammary epithelial cells, In vivo digestion by nucleases followed by ligation-mediated polymerase chain reaction analysis revealed two rotationally phased and translationally positioned nucleosomes within the promoter between nucleotide positions -450 and +7, The estrogen response elements at -400 and TATAA box at -35 are each located at the edge of a nucleosome. The two precisely positioned nucleosomes exist in both transformed and nontransformed human mammary epithelial cells, regardless of estrogen receptor status or transcriptional activity of the gene, However, two structural alterations correlate with the transcriptional potential of the promoter, In MCF-7 cells, in which the pS2 promoter is inducible, the chromatin exhibits an increased sensitivity to DNase I in a region of DNA adjacent to the TATAA box and an additional micrococcal nuclease-hypersensitive site in the linker DNA between the two positioned nucleosomes. We were also able to demonstrate that nucleotides -1100 to +10 of the pS2 promoter are sufficient to determine the positioning of these two nucleosomes, Our results establish the structural features of the chromatin covering the pS2 promoter as well as transcriptionally associated alterations, suggesting how the nucleosomal template influences transcriptional regulation by estrogen receptor.	Dana Farber Canc Inst, Dept Mol Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Hansen, U (corresponding author), Dana Farber Canc Inst, Dept Mol Genet, Boston, MA 02115 USA.	ulla_hansen@dfci.harvard.edu		Hansen, Ulla/0000-0001-9803-4185				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ALMER A, 1986, EMBO J, V5, P2696; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CORTHESY B, 1990, MOL CELL BIOL, V10, P3926, DOI 10.1128/MCB.10.8.3926; COSTANZO G, 1995, J BIOL CHEM, V270, P11091, DOI 10.1074/jbc.270.19.11091; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CREMISI C, 1979, MICROBIOL REV, V43, P297; CULLEN KE, 1993, SCIENCE, V261, P203, DOI 10.1126/science.8327891; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DEPAMPHILIS ML, 1982, ORG REPLICATION VIRA, P37; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; Englander EW, 1996, J BIOL CHEM, V271, P5819, DOI 10.1074/jbc.271.10.5819; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GILBERT DM, 1992, NUCLEIC ACIDS RES, V20, P4525, DOI 10.1093/nar/20.17.4525; GODDE JS, 1995, NUCLEIC ACIDS RES, V23, P4557, DOI 10.1093/nar/23.22.4557; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORWITZ KB, 1978, CANCER RES, V38, P2434; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI Q, 1995, MOL CELL BIOL, V15, P4375; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; LOHR D, 1995, J BIOL CHEM, V270, P27671, DOI 10.1074/jbc.270.46.27671; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCGHEE JD, 1983, CELL, V32, P1205, DOI 10.1016/0092-8674(83)90303-3; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MYMRYK JS, 1995, MOL CELL BIOL, V15, P26, DOI 10.1128/MCB.15.1.26; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; NOLL M, 1974, NUCLEIC ACIDS RES, V1, P1573, DOI 10.1093/nar/1.11.1573; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PHAM TA, 1991, J BIOL CHEM, V266, P18179; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROBERTS MS, 1995, BIOCHEMISTRY-US, V34, P12470, DOI 10.1021/bi00038a046; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SEYFRED MA, 1990, MOL ENDOCRINOL, V4, P1226, DOI 10.1210/mend-4-8-1226; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TORMANEN VT, 1992, NUCLEIC ACIDS RES, V20, P5487, DOI 10.1093/nar/20.20.5487; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Verdone L, 1996, MOL CELL BIOL, V16, P1978; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WASSERMAN PM, 1989, METHOD ENZYMOL, V170, P3; WILLIAMS SP, 1986, BIOPHYS J, V49, P233, DOI 10.1016/S0006-3495(86)83637-2; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZAJCHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P1613, DOI 10.1210/mend-5-11-1613; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhu ZW, 1996, CELL, V87, P459, DOI 10.1016/S0092-8674(00)81366-5	77	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31118	31129		10.1074/jbc.272.49.31118	http://dx.doi.org/10.1074/jbc.272.49.31118			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388265	hybrid			2022-12-25	WOS:000071640800078
J	Shneider, BL; Thevananther, S; Moyer, MS; Walters, HC; Rinaldo, P; Devarajan, P; Sun, AQ; Dawson, PA; Ananthanarayanan, M				Shneider, BL; Thevananther, S; Moyer, MS; Walters, HC; Rinaldo, P; Devarajan, P; Sun, AQ; Dawson, PA; Ananthanarayanan, M			Cloning and characterization of a novel peptidase from rat and human ileum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID TRANSPORTER; MEMBRANE ANTIGEN; DIPEPTIDYLPEPTIDASE-IV; SEQUENCE-ANALYSIS; SMALL-INTESTINE; GENE; HYDROLASE; CDNA; PURIFICATION; EXPRESSION	A novel 100-kDa ileal brush border membrane protein (I100) has been purified by anionic glycocholate affinity chromatography, Polyclonal antibodies raised against this protein were utilized to clone and characterize I100 in rats, A partial length human I100 cDNA was identified by hybridization screening, In the rat, the I100 protein is a 746-amino acid glycosylated (calculated core molecular mass of 80 kDa) type II integral membrane protein found on the apical surface of ileal villus enterocytes, Its a,6-kilobase mRNA is expressed in distal small intestine in rats and in humans, The I100 cDNA is homologous to but distinct from human prostate-specific membrane antigen and rat brain N-acetylaspartylglutamate peptidase, It is expressed on both the basolateral and apical surfaces of stably transfected Madin Darby canine kidney cells, Analysis of these stably transfected Madin Darby canine kidney cells and I100 immunoprecipitates of rat ileal brush border membrane vesicles reveals that it has dipeptidyl peptidase TV activity. Future invesitgations will need to determine the exact substrate specificity of this novel peptidase.	Yale Univ, Sch Med, Dept Pediat, Div Pediat Gastroenterol Hepatol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pediat, Div Pediat Nephrol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med Gastroenterol, Winston Salem, NC 27157 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Yale University; Yale University; Yale University; Wake Forest University; Wake Forest Baptist Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Shneider, BL (corresponding author), Mt Sinai Med Ctr, Div Pediat Gastroenterol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002076, P30DK034989, R01DK043509, R29DK047987] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43509, DK-02076, DK-34989, R29 DK047987] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAI JPF, 1995, J PHARM PHARMACOL, V47, P698, DOI 10.1111/j.2042-7158.1995.tb05863.x; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BLACKMON DL, 1992, ANAL BIOCHEM, V200, P352, DOI 10.1016/0003-2697(92)90478-P; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; CASANOVA JE, 1991, J BIOL CHEM, V266, P24428; CONNELL C, 1987, BIOTECHNIQUES, V5, P342; DARMOUL D, 1990, ANN HUM GENET, V54, P191, DOI 10.1111/j.1469-1809.1990.tb00377.x; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DARMOUL D, 1994, BIOCHEM BIOPH RES CO, V203, P1224, DOI 10.1006/bbrc.1994.2313; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOOSSENS F, 1995, EUR J BIOCHEM, V233, P432, DOI 10.1111/j.1432-1033.1995.432_2.x; HARDISON WGM, 1991, HEPATOLOGY, V13, P68, DOI 10.1002/hep.1840130111; ISRAELI RS, 1993, CANCER RES, V53, P227; Jacotot E, 1996, EUR J BIOCHEM, V239, P248, DOI 10.1111/j.1432-1033.1996.0248u.x; JONES WM, 1991, P NATL ACAD SCI USA, V88, P2194, DOI 10.1073/pnas.88.6.2194; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAMER W, 1983, J BIOL CHEM, V258, P3623; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACK L, 1961, AM J PHYSIOL, V200, P313, DOI 10.1152/ajplegacy.1961.200.2.313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEK J, 1995, BRIT J CANCER, V72, P583, DOI 10.1038/bjc.1995.377; MARCUS SN, 1991, GASTROENTEROLOGY, V100, P212; MARGUET D, 1992, J BIOL CHEM, V267, P2200; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MENTLEIN R, 1993, REGUL PEPTIDES, V49, P133, DOI 10.1016/0167-0115(93)90435-B; Mentzel S, 1996, J HISTOCHEM CYTOCHEM, V44, P445, DOI 10.1177/44.5.8627002; OGATA S, 1989, J BIOL CHEM, V264, P3596; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Pederson RA, 1996, METABOLISM, V45, P1335, DOI 10.1016/S0026-0495(96)90112-2; Pinto JT, 1996, CLIN CANCER RES, V2, P1445; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RINKERSCHAEFFER CW, 1995, GENOMICS, V30, P105, DOI 10.1006/geno.1995.0019; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS KP, 1990, MOL CELL ENDOCRINOL, V14, P531; SCHIFF ER, 1972, J CLIN INVEST, V51, P1351, DOI 10.1172/JCI106931; SHNEIDER B, 1991, GASTROENTEROLOGY, V100, P796; SHNEIDER BL, 1993, PEDIATR RES, V33, P221, DOI 10.1203/00006450-199303000-00002; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SLUSHER BS, 1990, J BIOL CHEM, V265, P21297; SUN AQ, 1995, HEPATOLOGY, V22, P318; SUZUKI Y, 1993, AM J PHYSIOL, V264, pG1153, DOI 10.1152/ajpgi.1993.264.6.G1153; SWANSON ML, 1988, BIOCHEM J, V255, P229; TIRUPPATHI C, 1993, AM J PHYSIOL, V265, pG81, DOI 10.1152/ajpgi.1993.265.1.G81; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4351; VONDIPPE P, 1986, BIOCHIM BIOPHYS ACTA, V862, P352, DOI 10.1016/0005-2736(86)90238-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; WONG MH, 1994, J BIOL CHEM, V269, P1340; XU SY, 1986, GENE ANAL TECH, V3, P90	53	28	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31006	31015		10.1074/jbc.272.49.31006	http://dx.doi.org/10.1074/jbc.272.49.31006			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388249	hybrid			2022-12-25	WOS:000071640800062
J	Liu, LH; Paul, RJ; Sutliff, RL; Miller, ML; Lorenz, JN; Pun, RYK; Duffy, JJ; Doetschman, T; Kimura, Y; MacLennan, DH; Hoying, JB; Shull, GE				Liu, LH; Paul, RJ; Sutliff, RL; Miller, ML; Lorenz, JN; Pun, RYK; Duffy, JJ; Doetschman, T; Kimura, Y; MacLennan, DH; Hoying, JB; Shull, GE			Defective endothelium-dependent relaxation of vascular smooth muscle and endothelial cell Ca2+ signaling in mice lacking sarco(endo)plasmic reticulum Ca2+-ATPase isoform 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; RELAXING FACTOR; FUNCTIONAL CONSEQUENCES; SKELETAL-MUSCLE; CA-2+ PUMP; CA-2+-ATPASE GENE; CALCIUM PUMPS; CDNA CLONING	Sarco(endo)plasmic reticulum Ca2+ ATPase isoform 3 (SERCA3) is one of two Ca2+ pumps serving intracellular Ca2+ signaling pools in non-muscle tissues; however, unlike the ubiquitous SERCA2b, it exhibits a restricted cell-type distribution. Gene targeting was used to generate a mouse with a null mutation in the SERCA3 gene, Homozygous mutant mice were viable, fertile, and did not exhibit an overt disease phenotype. Because SERCA3 is expressed in arterial endothelial cells, aortic ring preparations were analyzed to determine whether it is involved in the regulation of vascular tone, Contraction-isometric force relations in response to phenylephrine or KCl, as well as relaxation produced by exposure to a nitric oxide donor, were similar in wild-type and null mutant aortas, Acetylcholine-induced endothelium-dependent relaxation of aortas after precontraction with phenylephrine was significantly reduced in homozygous mutants (61.3 +/- 5.6% in wild type, 35.4 +/- 7.3% in mutants). Ca2+ imaging of cultured aortic endothelial cells demonstrated that the acetylcholine-induced intracellular Ca2+ signal is sharply diminished in SERCA3-deficient cells and also indicated that replenishment of the acetylcholine-responsive Ca2+ stores is severely impaired. These results indicate that SERCA3 plays a critical role in endothelial cell Ca2+ signaling events involved in nitric oxide-mediated relaxation of vascular smooth muscle.	UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOL & CELLULAR PHYSIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Toronto					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, P01HL041496, R01HL023240] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23240, TG HL07382, HL41496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANGER M, 1993, FEBS LETT, V334, P45, DOI 10.1016/0014-5793(93)81677-R; ANGER M, 1994, J MOL CELL CARDIOL, V26, P539, DOI 10.1006/jmcc.1994.1064; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; BUSSE R, 1993, EUR HEART J, V14, P2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; DANTHULURI NR, 1988, AM J PHYSIOL, V255, pH1549, DOI 10.1152/ajpheart.1988.255.6.H1549; Dode L, 1996, BIOCHEM J, V318, P689, DOI 10.1042/bj3180689; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JARRELL B, 1984, J VASC SURG, V1, P757, DOI 10.1067/mva.1984.avs0010757; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Lalli J, 1997, CIRC RES, V80, P506, DOI 10.1161/01.RES.80.4.506; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHILLING WP, 1992, AM J PHYSIOL, V262, pH1617, DOI 10.1152/ajpheart.1992.262.6.H1617; SESSA WC, 1992, J BIOL CHEM, V267, P15274; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; WANG XD, 1995, CIRC RES, V77, P37, DOI 10.1161/01.RES.77.1.37; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Wuytack F, 1995, BIOSCIENCE REP, V15, P299, DOI 10.1007/BF01788362; WUYTACK F, 1994, J BIOL CHEM, V269, P1410	48	84	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30538	30545		10.1074/jbc.272.48.30538	http://dx.doi.org/10.1074/jbc.272.48.30538			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374548	hybrid			2022-12-25	WOS:A1997YH61300080
J	Meier, R; Alessi, DR; Cron, P; Andjelkovic, M; Hemmings, BA				Meier, R; Alessi, DR; Cron, P; Andjelkovic, M; Hemmings, BA			Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase B beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; SER/THR KINASE; C-AKT; ONCOGENE; AMPLIFICATION; INHIBITION; CARCINOMAS; EXPRESSION	Protein kinase B (PKB) is a member of the second messenger-dependent family of serine/threonine kinases that has been implicated in signaling pathways downstream of growth factor receptor tyrosine kinases and phosphatidylinositol 3-kinase. Here we report the characterization of the human beta-isoform of PKB (PKB beta). PKB beta is ubiquitously expressed in a number of human tissues, with mRNA and protein levels elevated in heart, liver, skeletal muscle, and kidney. After transfection into HEK-293 or COS-1 cells, PKB beta is activated 2- to 12-fold by mitogens and survival factors. Activation was due to phosphorylation on Thr-309 and Ser-474, which correspond to Thr-308 and Ser-473 implicated in the regulation of PKB alpha, Both phosphorylation and activation were prevented by the phosphatidylinositol 3-kinase inhibitor wortmannin, Moreover, membrane-targeted PKB beta was constitutively activated when overexpressed in HEK-293 cells, Although the specific activity of PKB beta was lower than that of PKB alpha toward Crosstide as a substrate (23 nmol/min/mg compared with 170 nmol/ min/mg for PKB alpha), both enzymes showed similar substrate specificities, Using confocal microscopy, we show that activation of PKB beta results in its nuclear translocation within 20 to 30 min after stimulation, These observations provide evidence that PKB beta undergoes nuclear translocation upon mitogenic activation and support a role for PKB in signaling from receptor tyrosine kinases to the nucleus through phosphatidylinositol 3-kinase.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	Friedrich Miescher Institute for Biomedical Research; University of Dundee				Alessi, Dario/0000-0002-2140-9185				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ANDJELKOVIC M, 1997, IN PRESS J BIOL CHEM; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; HASLAM RJ, 1993, NATURE, V363, P310; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648	38	314	339	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30491	30497		10.1074/jbc.272.48.30491	http://dx.doi.org/10.1074/jbc.272.48.30491			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374542	hybrid			2022-12-25	WOS:A1997YH61300074
J	Kiyokawa, N; Karunagaran, D; Lee, EK; Xie, YM; Yan, DH; Hung, MC				Kiyokawa, N; Karunagaran, D; Lee, EK; Xie, YM; Yan, DH; Hung, MC			Involvement of cdc2-mediated phosphorylation in the cell cycle-dependent regulation of p185(neu)	ONCOGENE			English	Article						cdc2; cell cycle; p185(neu); phosphoamino acid analysis; peptide mapping; serine/threonine kinases	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; NEU ONCOGENE; POINT MUTATION; PROTEIN-KINASE; TRANSMEMBRANE DOMAIN; MOLECULAR-CLONING; EGF RECEPTOR; GENE-PRODUCT; CDC2 KINASE	We previously reported cell cycle-dependent negative regulation of p185(neu) (decreased tyrosine phosphorylation and kinase activity, with electrophoretic mobility retarded by serine/threonine phosphorylation) in M phase and the escape of mutation-activated p185(neu*) from this regulation. Our present results showed that retardation of electrophoretic mobility occurs independently of the cells' transformed status. We found that normal p185(neu) lost its ability to dimerize in the M phase. We demonstrated a physical association between cdc2 (a serine/threonine kinase, active in NI phase) and p185(neu). We showed that the carboxy terminal portion of p185(neu) is phosphorylated in vitro by cdc2. Many phosphopeptides (at least three phosphoserine residues) unique to the M phase were identified, and the in vivo and irt vitro phosphopeptide patterns were superimposable. In contrast, mutation-activated p185(neu*) dimerized in the M phase with no changes in electrophoretic mobility, failed to associate with cdc2 and no unique phosphoserine residues could be identified in the M phase (data not shown), consistent with the escape of p185(neu*) from cell cycle-dependent regulation. Our results suggest that this escape is an intrinsic property of the mutation-activated p185(neu*) independent of its ability to transform cells. Our results also suggest the involvement of serine/threonine kinases such as cdc2 in the cell cycle-dependent negative regulation of p185(neu).	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Karunagaran, Devarajan/A-8148-2010; Hung, Mien-Chie/ABD-5911-2021	Karunagaran, Devarajan/0000-0001-9331-8947; Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [CA60856, CA58880, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO HN, 1991, ONCOGENE, V6, P705; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; FEINMESSER RL, 1986, ONCOGENE, V12, P2725; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATIN A, 1994, ONCOGENE, V9, P1333; MORRISON P, 1993, J BIOL CHEM, V268, P15536; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	49	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2633	2641		10.1038/sj.onc.1201442	http://dx.doi.org/10.1038/sj.onc.1201442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400990				2022-12-25	WOS:A1997YH46800001
J	Bellosta, P; Zhang, Q; Goff, SP; Basilico, C				Bellosta, P; Zhang, Q; Goff, SP; Basilico, C			Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation	ONCOGENE			English	Article						programmed cell death; gene knock-out; TWF; c-myc	PROGRAMMED CELL-DEATH; ARREST-SPECIFIC GENE-6; AXL; PROTEINS; LIGAND; GAS6; FIBROBLASTS; ACTIVATION; EXPRESSION; CLONING	ARK (AXL) is the prototype of a distinctive family of receptor tyrosine kinases which contain in their extracellular domains features reminiscent of cell adhesion molecules, ARK is capable of homophilic binding, which results in a degree of receptor activation, but can also be activated by a heterophilic ligand, Gas6, a member of the family of vitamin K dependent proteins that is preferentially expressed in quiescent cells, Since a number of tissues and cell lines express both ARK and Gas6, we studied the effect of endogenous and exogenous Gas6 on the phenotype of ARK expressing cells, Here we show that constitutive expression of Gas6 in an NIH3T3 cell line that does not spontaneously express this protein does not result in cell transformation or uncontrolled growth, but protects from apoptosis induced by serum deprivation. Recombinant exogenous Gas6 was also capable of protecting cells from apoptosis at concentrations that did not result in significant induction of DNA synthesis, Activation of ARK phosphorylation and a weak but significant induction of MAP kinase activity accompanied the increased survival of cells treated with Gas6. The antiapoptotic effect of ARK signaling was confirmed by studies using fibroblasts from ARK knock-out mice, that showed that the absence of ARK resulted in higher levels of serum deprivation-induced apoptosis, that could not be rescued by the addition of Gas6, Interestingly ARK signaling protects from apoptosis induced by serum deprivation, myc overexpression, or by TNF alpha but not from u.v. irradiation or Staurosporine. These results suggest that a major function of Gas6-ARK signaling is that of increasing cell survival under conditions which do not allow cell proliferation.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT BIOCHEM, NEW YORK, NY 10032 USA	New York University; New York University; Columbia University			Goff, Stephen P/K-6337-2014; Bellosta, Paola/AAA-3413-2020	Goff, Stephen P/0000-0003-0693-5547; Bellosta, Paola/0000-0003-1913-5661	NATIONAL CANCER INSTITUTE [R35CA042568] Funding Source: NIH RePORTER; NCI NIH HHS [CA42568] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHINNAIYAN AM, 1996, J BIOL CHEM, V271, P30022; Costa M, 1996, J CELL PHYSIOL, V168, P737, DOI 10.1002/(SICI)1097-4652(199609)168:3<737::AID-JCP27>3.0.CO;2-U; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1995, ONCOGENE, V10, P2349; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LAI C, 1994, ONCOGENE, V9, P2567; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LING L, 1995, MOL CELL BIOL, V15, P6582; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OHASHI K, 1994, ONCOGENE, V9, P699; PESCIGNO J, 1992, ONCOGENE, V6, P1909; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; RESCIGNO J, 1991, ONCOGENE, V6, P1909; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang QK, 1996, J VIROL, V70, P8089, DOI 10.1128/JVI.70.11.8089-8097.1996	50	122	138	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2387	2397		10.1038/sj.onc.1201419	http://dx.doi.org/10.1038/sj.onc.1201419			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395235	Green Published			2022-12-25	WOS:A1997YE96300001
J	Cortez, D; Reuther, G; Pendergast, AM				Cortez, D; Reuther, G; Pendergast, AM			The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells	ONCOGENE			English	Article						Bcr-Abl; tyrosine kinase; cell cycle; mitogenesis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC GRANULOCYTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PHILADELPHIA-CHROMOSOME; POSITIVE LEUKEMIAS; MAMMALIAN-CELLS; MAP KINASES; TRANSFORMATION; APOPTOSIS	Bcr-Abl is a constitutively active tyrosine kinase that is expressed in Philadelphia chromosome (Ph-1)-positive human leukemias. Bcr-Abl has been shown to inhibit apoptosis and cause anchorage independent growth. However, its ability to activate mitogenic signaling pathways is controversial. Here we show that Bcr-Abl signaling prevents down-regulation of cyclin-dependent kinase activity and cell cycle arrest after growth factor deprivation of hematopoietic progenitor cells, Using an inducible system to regulate Bcr-Abl expression, we also demonstrate that Bcr-Abl expression is sufficient to induce G1-to-S phase transition, DNA synthesis, and activation of cyclin-dependent kinases in cells that were arrested in G(0) by growth factor deprivation, Furthermore, Bcr-Abl activates Pas, Erk, and Jnk pathways as a primary consequence of expression. These data show that Bcr-Abl is one of a select group of oncogenes that is capable of both inhibiting apoptosis and deregulating cell proliferation. The combination of these activities is likely to be important for the progression of CML.	DUKE UNIV, MED CTR, DEPT PHARMACOL & CANC BIOL, DURHAM, NC 27710 USA	Duke University			Reuther, Gary/AFR-2892-2022	Pendergast, Ann Marie/0000-0002-1250-6880	NCI NIH HHS [CA61033] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061033] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; ATHENS JW, 1965, J CLIN INVEST, V44, P765, DOI 10.1172/JCI105189; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; CARLESSO N, 1994, ONCOGENE, V9, P149; CHERVENICK PA, 1968, SER HAEMATOL, V1, P24; CLARK SS, 1989, ANNU REV MED, V40, P113; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GALBRAITH PR, 1972, BRIT J HAEMATOL, V22, P135, DOI 10.1111/j.1365-2141.1972.tb08795.x; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOTO T, 1982, BLOOD, V59, P793; GROFFEN J, 1993, LEUKEMIA LYMPHOMA, V11, P19, DOI 10.3109/10428199309047857; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANEUVILLE P, 1994, CANCER RES, V54, P1360; MANDANAS RA, 1993, BLOOD, V82, P1838; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OGAWA M, 1970, CANCER-AM CANCER SOC, V25, P1031, DOI 10.1002/1097-0142(197005)25:5<1031::AID-CNCR2820250507>3.0.CO;2-N; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RIBEIRO RC, 1987, BLOOD, V70, P948; Roger R, 1996, BLOOD, V87, P1113, DOI 10.1182/blood.V87.3.1113.bloodjournal8731113; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCOTT JL, 1971, BLOOD-J HEMATOL, V38, P162, DOI 10.1182/blood.V38.2.162.162; SMETSERS TFCM, 1994, LEUKEMIA, V8, P129; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRIFE A, 1988, SEMIN HEMATOL, V25, P1; STRYCKMANS PA, 1977, CLIN HAEMATOL, V6, P21; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TSAI LH, 1993, ONCOGENE, V8, P1593; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; VONCKEN JW, 1992, CANCER RES, V52, P4534; WADA H, 1995, CANCER RES, V55, P3192; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	65	161	167	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2333	2342		10.1038/sj.onc.1201400	http://dx.doi.org/10.1038/sj.onc.1201400			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393877				2022-12-25	WOS:A1997YE15700007
J	Beer, HD; Florence, C; Dammeier, J; McGuire, L; Werner, S; Duan, DR				Beer, HD; Florence, C; Dammeier, J; McGuire, L; Werner, S; Duan, DR			Mouse fibroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression	ONCOGENE			English	Article						keratinocyte growth factor; secretion; wound repair; heparin; growth factor; regulation	LARGE INDUCTION; FACTOR FAMILY; FGF FAMILY; KERATINOCYTE; RECEPTOR; KGF; CELLS; GENE; DIFFERENTIATION; MORPHOGENESIS	Fibroblast growth factor 7 (FGF-7) or keratinocyte growth factor (KGF), is a potent and specific mitogen for epithelial cells, We have recently identified a novel human FGF-7 homologue, named FGF-10. To study the expression of this new FGF family member and its regulation in wound repair, we cloned the mouse FGF-10 (mFGF-10) cDNA, The encoded protein is 92% identical to human FGF-10 and 91% identical to rat FGF-10, When expressed in mammalian 293 cells, the mFGF-10 protein was glycosylated but remained cell- or extracellular matrix-associated. Upon addition of heparin, mFGF-10 protein was released into the media, mRNA encoding mFGF-10 was relatively abundant in lung, skin, brain and heart, In the skin, both FGF-7 and mFGF-10 were expressed in the dermal, but not the epidermal compartment, In contrast to FGF-7, mFGF-10 expression was not induced during cutaneous wound repair, In cultured fibroblasts, expression of mFGF-10 was strongly repressed by transforming growth factor beta and tumor necrosis factor alpha, whereas epidermal growth factor and interleukin-1 beta had no effect, These results demonstrate a differential regulation of mFGF-10 and FGF-7 expression in vitro and during the wound healing process.	HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	GlaxoSmithKline; Human Genome Sciences Inc; Max Planck Society				Werner, Sabine/0000-0001-7397-8710; Beer, Hans-Dietmar/0000-0002-8085-713X; Dammeier, Johanna/0000-0002-6040-2779				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P597; BROOKES S, 1989, ONCOGENE, V4, P429; CHEDID M, 1994, J BIOL CHEM, V269, P19753; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; JIMENEZ PA, 1997, UNPUB; Kiefer P, 1996, ONCOGENE, V12, P1503; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sambrook J., 2002, MOL CLONING LAB MANU; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; UENO H, 1993, J BIOL CHEM, V268, P22814; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wu LC, 1996, ARCH SURG-CHICAGO, V131, P660; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	34	107	110	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2211	2218		10.1038/sj.onc.1201383	http://dx.doi.org/10.1038/sj.onc.1201383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393979				2022-12-25	WOS:A1997YD01900009
J	Bobak, D; Moorman, J; Guanzon, A; Gilmer, L; Hahn, C				Bobak, D; Moorman, J; Guanzon, A; Gilmer, L; Hahn, C			Inactivation of the small GTPase Rho disrupts cellular attachment and induces adhesion-dependent and adhesion-independent apoptosis	ONCOGENE			English	Article						Rho; apoptosis; exoenzyme C3; adhesion	BINDING PROTEIN-RHO; DIFFICILE TOXIN-A; ADP-RIBOSYLTRANSFERASE; CLOSTRIDIUM-BOTULINUM; TRANSIENT EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; SINDBIS VIRUS; GENE-PRODUCT	Rho small GTPases regulate a variety of cellular signaling pathways involved in cell growth and transformation, In this study, we examined potential roles for Rho in adhesion-dependent and -independent pathways regulating apoptosis, Rho GTPases are specifically inactivated by exoenzyme C3 (C3) of Clostridium botulinum. Using a novel Sindbis virus-based gene expression system, we created a double subgenomic recombinant (dsSIN:C3) capable of expressing active C3 in intact cells, Infection of L929 fibroblasts with dsSIN:C3 caused essentially complete ADP-ribosylation of intracellular Rho within 1 h, dsSIN:C3-infected cells also became rounded within 1-2 h and detached by 5 h post-infection, Infection of L929 in suspension with dsSIN:C3 disrupted the ability for normal cellular attachment and spreading, Infection of primary cell explants of chicken embryo fibroblasts (CEF) and rat aortic smooth muscle cells (RSM) with dsSIN:C3 caused cytoskeletal effects similar to those seen in L929, We also observed that C3 markedly decreased the basal phosphorylation state of focal adhesion kinase (FAK), Most intriguingly, we found that dsSIN-based expression of C3 or loss of function mutants of Rho could each induce apoptosis and, in RSM, this effect was observed to be adhesion-independent. Rho GTPases, therefore, appear to regulate signal pathways that are required for cell survival and growth that are separate from, but likely overlap with, Rho-dependent pathways involved in cellular adhesion.	UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	Bobak, D (corresponding author), UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908, USA.				NIGMS NIH HHS [GM54572] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1994, MOL CELL BIOCHEM, V138, P167, DOI 10.1007/BF00928459; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BATES RC, 1995, CANCER METAST REV, V14, P191, DOI 10.1007/BF00690291; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEHAR S, 1995, CANCER METAST REV, V14, P165; DILLON ST, 1995, INFECT IMMUN, V63, P1421, DOI 10.1128/IAI.63.4.1421-1426.1995; Esteve P, 1995, ONCOGENE, V11, P2657; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Harlow E., 1989, ANTIBODIES LAB MANUA; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JIMENEZ B, 1995, ONCOGENE, V10, P811; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1992, BIOCHEM BIOPH RES CO, V183, P931, DOI 10.1016/S0006-291X(05)80279-7; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; LANG P, 1992, J BIOL CHEM, V267, P11677; Lebowitz PF, 1997, CANCER RES, V57, P708; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Malik RK, 1996, BBA-REV CANCER, V1287, P73, DOI 10.1016/0304-419X(96)00008-X; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Moorman JP, 1996, J IMMUNOL, V156, P4146; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PERONA R, 1993, ONCOGENE, V8, P1285; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PIERCE JS, 1973, J VIROL, V13, P1030; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Ruoslahti E, 1997, SCIENCE, V276, P1345, DOI 10.1126/science.276.5317.1345; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; SUGAI M, 1992, J BIOL CHEM, V267, P2600; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; THORNE J, 1997, UNPUB; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	67	67	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2179	2189		10.1038/sj.onc.1201396	http://dx.doi.org/10.1038/sj.onc.1201396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393976				2022-12-25	WOS:A1997YD01900006
J	Lane, TF; Philip, L				Lane, TF; Philip, L			Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice	ONCOGENE			English	Article						Wnt10b; FGF-3/int-2; oncogene; mammary adenocarcinoma; neoplasm	WNT GENE FAMILY; TRANSGENIC MICE; TUMOR VIRUS; PROVIRAL INSERTION; EPITHELIAL-CELLS; BREAST-CANCER; EXPRESSION; GROWTH; TUMORIGENESIS; ONCOGENE	Wnt-10b is expressed during the formation of the mammary rudiment in mouse embryos and its expression continues through puberty when the mammary ductal pattern is established under control of ovarian steroids, Recently, viral activation of the Wnt-10b locus has linked its overexpression to mammary tumor formation, suggesting a role for Wnt-10b in patterning and growth-regulation of the mammary gland, To test this notion, we created lines of transgenic mice that express elevated levels of Wnt-10b under the control of the MMTV promoter/enhancer. Overexpression of this gene resulted in profound developmental alterations in the mammary gland, including expanded glandular development and the precocious appearance of alveoli in virgin females, Moreover, transgenic male mice also exhibited dramatic mammary development involving highly branched mammary ducts and gynecomastia. Aberrant expression of Wnt-10b in the mammary rudiments of males evidently bypasses the normal requirement for ovarian hormonal control in stimulating mammary ductal growth and the repressive effects of androgens, In addition to these developmental effects, transgenic mice of both sexes were highly susceptible to the development of mammary adenocarcinomas, Such tumors arose in a solitary manner indicating that Wnt-10b is a proto-oncogene which provides a necessary, but insufficient signal for oncogenesis, Relevant to this, there was no evidence of amplified expression of FGF mRNAs in these tumors though the Fgf's are a class of genes often implicated as collaborators in Wilt-mediated tumor formation, Indeed, co-expression of MMTV-Wnt-10b and MMTV-FGF-3/int-2 resulted in sterile offspring with highly disorganized mammary epithelium, demonstrating a potent interaction between their respective developmental pathways, These results suggest that Wnt-10b, or other Wilt genes expressed early in mammary development, play a role in regulating sexual dimorphism and show potent transforming activity when overexpressed.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Lane, Timothy F./0000-0002-0210-970X				Amundadottir LT, 1996, ONCOGENE, V13, P757; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; BRADBURY JM, 1994, ONCOGENE, V9, P2579; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; CHOOI KF, 1994, CANCER RES, V54, P6434; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; DU SJ, 1995, MOL CELL BIOL, V15, P2625; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; Dunn T, 1959, PHYSIOPATHOLOGY CANC, P38; FAUKLIN LV, 1960, J NATL CANCER I, V24, P953; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Hardiman G, 1996, GENE, V172, P199, DOI 10.1016/0378-1119(96)00109-6; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MEDINA D, 1982, TRANSGENES MOUSE BIO; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NANDI S, 1958, J NATL CANCER I, V21, P1039; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; TZENG YJ, 1993, ONCOGENE, V8, P1965; Wang JW, 1996, ONCOGENE, V13, P1537; Wang YS, 1996, J BIOL CHEM, V271, P4468; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	42	120	127	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2133	2144		10.1038/sj.onc.1201593	http://dx.doi.org/10.1038/sj.onc.1201593			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393971				2022-12-25	WOS:A1997YD01900001
J	Abbott, DW; Holt, JT				Abbott, DW; Holt, JT			Finkel-Biskis-Reilly osteosarcoma virus v-Fos inhibits adipogenesis and both the activity and expression of CCAAT/enhancer binding protein alpha, a key regulator of adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; TRANSCRIPTION FACTORS; 3T3-L1 PREADIPOCYTES; ADIPOSE CONVERSION; GENE-EXPRESSION; ECTOPIC EXPRESSION; CELL-PROLIFERATION; NUCLEAR-PROTEIN; C/EBP; CHOP	Finkel-Biskis-Reilly (FBR) osteosarcoma virus v-Fos causes tumors of mesenchymal origin, including osteosarcomas, rhabdomyosarcomas, chondrosarcomas, and liposarcomas. Because the cell of origin in all these tumors is a pluripotent mesenchymal cell, the variety of tumors seen in mice which express FBR v-Fos implies that FBR v-Fos inhibits multiple differentiation pathways. To study the mechanism of FBR v-Fos' inhibition of mesenchymal differentiation, we utilized an in vitro model of adipocyte differentiation. We show by both morphological and biochemical means that FBR v-Fos inhibits adipocyte differentiation in vitro. This inhibition is due to FBR v-Fos' inhibition of the growth arrest characteristic of terminal differentiation and FBR v-Fos' inhibition of the expression and activity of a key regulator of this growth arrest, C/EBP alpha. The in vitro inhibition of adipogenesis by FBR v-Fos has in vivo significance as immunostaining of FBR v-Fos-induced tumors shows no CCAAT/enhancer binding protein (EBP)-alpha expression. These data implicate C/EBP alpha as a protein involved in the generation of liposarcomas.	Vanderbilt Univ, Ctr Canc, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Holt, JT (corresponding author), Vanderbilt Univ, Ctr Canc, Sch Med, 659 MRB II,2220 Pierce Ave S, Nashville, TN 37232 USA.			Abbott, Derek/0000-0003-4387-8094	NATIONAL CANCER INSTITUTE [R01CA051735] Funding Source: NIH RePORTER; NCI NIH HHS [523CMO734714, R01CA51735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1997, J BIOL CHEM, V272, P14005, DOI 10.1074/jbc.272.22.14005; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BIRKENMEIER E, 1989, GENE DEV, V2, P1146; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHENEVAL D, 1991, P NATL ACAD SCI USA, V88, P8465, DOI 10.1073/pnas.88.19.8465; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COTRAN RS, 1994, PATHOLOGICAL BASIS D, P153; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Funk M, 1997, MOL CELL BIOL, V17, P537, DOI 10.1128/MCB.17.2.537; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Jotte RM, 1996, J CELL BIOL, V135, P457, DOI 10.1083/jcb.135.2.457; JOTTE RM, 1994, J BIOL CHEM, V269, P16383; KAMATA N, 1992, MOL CELL BIOL, V12, P876, DOI 10.1128/MCB.12.2.876; KAMATA N, 1991, MOL CELL BIOL, V11, P765, DOI 10.1128/MCB.11.2.765; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; LEE CK, 1979, P SOC EXP BIOL MED, V162, P214, DOI 10.3181/00379727-162-40650; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; SERRERO G, 1996, INT J OBESITY, V3, P58; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TRAUTWEIN C, 1995, J BIOL CHEM, V270, P15130, DOI 10.1074/jbc.270.25.15130; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WISE LS, 1979, J BIOL CHEM, V254, P273; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, CURR OPIN CELL BIOL, V7, P885, DOI 10.1016/0955-0674(95)80074-3; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	53	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32454	32462		10.1074/jbc.272.51.32454	http://dx.doi.org/10.1074/jbc.272.51.32454			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405456	hybrid			2022-12-25	WOS:000071108000075
J	Faure, V; Courtois, Y; Goureau, O				Faure, V; Courtois, Y; Goureau, O			Inhibition of inducible nitric oxide synthase expression by interferons alpha and beta in bovine retinal pigmented epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE PERITONEAL-MACROPHAGES; FIBROBLAST GROWTH-FACTORS; FACTOR-KAPPA-B; NO SYNTHASE; REGULATORY FACTOR-1; MOLECULAR-CLONING; MOUSE MACROPHAGES; GLIAL-CELLS; IN-VITRO; INDUCTION	Bovine retinal pigmented epithelial (RPE) cells express an inducible nitric oxide synthase (NOS-2) after activation with interferon (IFN)-gamma and lipopolysaccharide (LPS). Experiments were performed to investigate the effects of IFN-alpha and IFN-beta on NOS-2 activity. These types of interferons did not aid LPS in the production of nitrite, but markedly inhibited in a concentration-dependent manner the nitrite release due to LPS/IFN-gamma. Analysis by Western and Northern blots showed that RPE cells co-stimulated with IFN-alpha or IFN-beta with LPS/IFN-gamma accumulated lower levels of NOS-2 protein and mRNA than in the presence of LPS/IFN-gamma alone. The presence of IFN-alpha or IFN-beta did not accelerate mRNA degradation, implying that these interferons did not affect NOS-2 mRNA stability, but more probably NOS-2 gene expression. Furthermore, IFN-gamma binding studies demonstrated that the inhibitory effect of IFN-alpha and IFN-beta is not caused by a blocking of IFN-gamma receptors. Analysis of NF-kappa B activation by electrophoretic mobility shift assay demonstrated that LPS/IFN-gamma-induced NF-kappa B binding was not changed by the presence of IFN-alpha. However, similar experiments revealed that the activation of interferon regulatory factor-1 (IRF-1) by LPS/IFN-gamma was decreased by IFN-alpha. This phenomenon could be due to the decline of IRF-1 mRNA and the up-regulation of IRF-2 mRNA, an IRF-1 repressor, by IFN-1. These results suggest that the inhibitory effect of IFN-alpha and -beta on NOS-2 induction could be partially explained by their effect on the induction of the IRFs, which were involved in NOS-2 gene transcription.	INSERM, Ass Claude Bernard, U450, F-75016 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Goureau, O (corresponding author), INSERM, Ass Claude Bernard, U450, F-75016 Paris, France.		GOUREAU, Olivier/F-2752-2017; GOUREAU, Olivier/ABH-9547-2020	GOUREAU, Olivier/0000-0001-7730-9143; GOUREAU, Olivier/0000-0001-7730-9143				BECQUET F, 1994, EXP CELL RES, V212, P374, DOI 10.1006/excr.1994.1157; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEGUCHI M, 1995, J INTERF CYTOK RES, V15, P977, DOI 10.1089/jir.1995.15.977; DEGUCHI M, 1995, IMMUNOL LETT, V45, P157, DOI 10.1016/0165-2478(94)00246-N; DIGHIERO P, 1994, NEUROSCI LETT, V166, P31, DOI 10.1016/0304-3940(94)90833-8; DING AH, 1988, J IMMUNOL, V141, P2407; FUJIHARA M, 1994, J BIOL CHEM, V269, P12773; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GOUREAU O, 1995, J IMMUNOL, V154, P6518; GOUREAU O, 1992, BIOCHEM BIOPH RES CO, V186, P854, DOI 10.1016/0006-291X(92)90824-5; GOUREAU O, 1994, BIOCHEM BIOPH RES CO, V198, P120, DOI 10.1006/bbrc.1994.1017; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GOUREAU O, 1995, EUR J BIOCHEM, V230, P1046, DOI 10.1111/j.1432-1033.1995.tb20654.x; GOUREAU O, 1994, J NEUROCHEM, V63, P310; GOUREAU O, 1993, NEUROREPORT, V5, P233, DOI 10.1097/00001756-199312000-00012; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hecker M, 1996, BRIT J PHARMACOL, V118, P2178, DOI 10.1111/j.1476-5381.1996.tb15660.x; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1145; KASAI K, 1995, ENDOCRINOLOGY, V136, P4261, DOI 10.1210/en.136.10.4261; KISHI H, 1994, CURR EYE RES, V13, P661, DOI 10.3109/02713689408999902; Kleinert H, 1996, MOL PHARMACOL, V49, P15; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KREIL TR, 1995, VIROLOGY, V212, P174, DOI 10.1006/viro.1995.1465; LePage C, 1996, IMMUNOLOGY, V89, P274, DOI 10.1046/j.1365-2567.1996.d01-728.x; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; LIVERSIDGE J, 1994, IMMUNOLOGY, V83, P404; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MASCARELLI F, 1993, GROWTH FACTORS, V8, P211, DOI 10.3109/08977199309011024; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V187, P1291, DOI 10.1016/0006-291X(92)90443-O; POLITIS AD, 1994, J IMMUNOL, V152, P2270; SIREN V, 1993, OPHTHALMIC RES, V26, P1; SPARROW JR, 1994, EXP EYE RES, V59, P129, DOI 10.1006/exer.1994.1091; Vaughan PS, 1997, J MOL MED-JMM, V75, P348, DOI 10.1007/s001090050120; Vodovotz Yoram, 1994, Progress in Growth Factor Research, V5, P341, DOI 10.1016/0955-2235(94)00004-5; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; ZHANG XO, 1994, INFECT IMMUN, V62, P33, DOI 10.1128/IAI.62.1.33-40.1994; ZHOU AQ, 1995, J INTERF CYTOK RES, V15, P897, DOI 10.1089/jir.1995.15.897	50	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32169	32175		10.1074/jbc.272.51.32169	http://dx.doi.org/10.1074/jbc.272.51.32169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405417	hybrid			2022-12-25	WOS:000071108000036
J	Mammen, AL; Kameyama, K; Roche, KW; Huganir, RL				Mammen, AL; Kameyama, K; Roche, KW; Huganir, RL			Phosphorylation of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit by calcium/calmodulin-dependent kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL-NEURONS; MINIATURE SYNAPTIC CURRENTS; PROTEIN-KINASE; GLUTAMATE RECEPTORS; MUTANT MICE; CALMODULIN; DEPRESSION; TRANSMISSION; PLASTICITY	Modulation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic Acid (AMPA) receptors in the brain by protein phosphorylation may play a crucial role in the regulation of synaptic plasticity. Previous studies have demonstrated that calmodulin (CaM) kinase II can phosphorylate and modulate AMPA receptors. However, the sites of CaM kinase phosphorylation have not been unequivocally identified. In the current study, we have generated two phosphorylation site-specific antibodies to analyze the phosphorylation of the glutamate receptor GluR1 subunit. These antibodies recognize GluR1 only when it is phosphorylated on serine residues 831 or 845. We have used these antibodies to demonstrate that serine 831 is specifically phosphorylated by CaM kinase II in transfected cells expressing GluR1 as well as in hippocampal slice preparations, Two-dimensional phosphopeptide mapping experiments indicate that Ser-831 is the major site of CaM kinase II phosphorylation on GluR1. In addition, treatment of hippocampal slice preparations with phorbol esters and forskolin increase the phosphorylation of serine 831 and 845, respectively, indicating that protein kinase C and protein kinase A phosphorylate these residues in hippocampal slices. These results identify the site of CaM kinase phosphorylation of the GluR1 subunit and demonstrate that GluR1 is multiply phosphorylated by protein kinase A, protein kinase C, and CaM kinase II in situ.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Huganir, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Howard Hughes Med Inst, 725 N Wolfe St,900 PCTB, Baltimore, MD 21205 USA.		Mammen, Andrew/AAF-2885-2021; Roche, Katherine/W-9893-2019	Roche, Katherine/0000-0001-7282-6539				ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLACKSTONE C, 1994, J NEUROSCI, V14, P7585; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; ITO I, 1991, NEUROSCI LETT, V121, P1119; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MOSS SJ, 1993, NEUROCHEM RES, V18, P105, DOI 10.1007/BF00966929; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P61; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; WANG LY, 1994, J PHYSIOL-LONDON, V475, P431, DOI 10.1113/jphysiol.1994.sp020083; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; YAKEL JL, 1995, P NATL ACAD SCI USA, V92, P1376, DOI 10.1073/pnas.92.5.1376	40	345	353	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32528	32533		10.1074/jbc.272.51.32528	http://dx.doi.org/10.1074/jbc.272.51.32528			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405465	hybrid			2022-12-25	WOS:000071108000084
J	Montmayeur, JP; Valius, M; Vandenheede, J; Kazlauskas, A				Montmayeur, JP; Valius, M; Vandenheede, J; Kazlauskas, A			The platelet-derived growth factor beta receptor triggers multiple cytoplasmic signaling cascades that arrive at the nucleus as distinguishable inputs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA; FACTOR-ALPHA-RECEPTOR; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASES; DNA-SYNTHESIS; RAS; ACTIVATION; SUBUNIT; BINDING	Stimulation of the platelet-derived growth factor beta receptor (beta PDGFR) activates enzymes such as phosphatidylinositol S-kinase (PER) and phospholipase C gamma 1 (PLC gamma), which ultimately initiate nuclear responses such as enhanced expression of immediate early genes. In an attempt to compare the signaling cascades initiated by PI3K and PLC gamma, we examined the activation of a panel of immediate early genes by beta PDGFR mutants, which preferentially engage PI3K or PLC gamma. When expressed in A431 cells, the wild type receptor and to a lesser extent the mutant receptor that associates with PLC gamma (Y1021) was able to up-regulate c-fos,junB, and KC mRNA expression. In contrast, the receptor mutant that engages PI3K (Y740/51) poorly stimulated c-fos mRNA expression and did not significantly stimulate expression of either JunB or KC. Receptor mutants that did not associate with either PI3K or PLC gamma were dramatically compromised or unable to increase expression of any of these immediate early genes. The differential ability of the Y1021 and Y740/51 receptors to activate c-fos correlated well with an apparent difference in their ability to engage distinct protein kinase C family members. However there did appear to be a degree of redundancy in the cytoplasmic signaling pathways initiated by PI3K and PLC gamma, since both the Y1021 and Y740/51 receptors were able to activate an AP-l-responsive element. We conclude that recruitment of signal relay enzymes to the beta PDGFR is necessary for PDGF-dependent activation of at least some immediate early genes. In addition, whereas the beta PDGFR activates multiple signaling enzymes capable of activating the same nuclear response (activation of c-fos), these signaling cascades do not appear to converge in the cytoplasm but arrive at the nucleus as distinguishable inputs.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Lithuania Acad Sci, Inst Biochem, LT-232600 Vilnius, Lithuania; Catholic Univ Louvain, Fac Med, Div Biochem, B-3000 Louvain, Belgium	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Vilnius University; Universite Catholique Louvain	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	kazlauskas@vision.eri.harvard.edu	Valius, Mindaugas/N-1220-2019; Montmayeur, Jean-Pierre R/A-5723-2009; Valius, Mindaugas/F-2734-2012	Valius, Mindaugas/0000-0001-8478-8517; Montmayeur, Jean-Pierre/0000-0002-0942-1114	NATIONAL CANCER INSTITUTE [R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55063] Funding Source: Medline; NIGMS NIH HHS [GM-48339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BAZENET CE, 1994, ONCOGENE, V9, P517; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MONTMAYEUR JP, 1991, P NATL ACAD SCI USA, V88, P3135, DOI 10.1073/pnas.88.8.3135; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SOLER C, 1994, J BIOL CHEM, V269, P12320; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WESTERMARK B, 1990, ACTA ENDOCRINOL-COP, V123, P131, DOI 10.1530/acta.0.1230131; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32670	32678		10.1074/jbc.272.51.32670	http://dx.doi.org/10.1074/jbc.272.51.32670			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405485	hybrid			2022-12-25	WOS:000071108000104
J	Xiao, ZC; Bartsch, U; Margolis, RK; Rougon, G; Montag, D; Schachner, M				Xiao, ZC; Bartsch, U; Margolis, RK; Rougon, G; Montag, D; Schachner, M			Isolation of a tenascin-R binding protein from mouse brain membranes - A phosphacan-related chondroitin sulfate proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; EXTRACELLULAR-MATRIX GLYCOPROTEINS; NEURITE OUTGROWTH; N-CAM; TYROSINE-PHOSPHATASE; CALCIUM-BINDING; ADULT-MOUSE; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; MARFAN-SYNDROME	We have isolated a chondroitin sulfate proteoglycan from mouse brain by affinity chromatography with a fragment of the extracellular matrix glycoprotein tenascin-a (TN-R) that comprises the amino-terminal cysteine-rich stretch and the 4.5 epidermal growth factor-like repeats. The isolated chondroitin sulfate proteoglycan has a molecular mass of 500-600 kDa and carries the HNK-1 carbohydrate epitope. Treatment with chondroitinase ABC reveals a major band of approximately 400 kDa and two minor bands at 200 and 150 kDa. Immunoblot analysis relates the molecule to phosphacan but not to the chondroitin sulfate proteoglycans neurocan and versican. Binding of the phosphacan-related molecule to the epidermal growth factor-like repeats of TN-R is Ca2+-dependent. Co-localization of the molecule with TN-R in the retina and optic nerve by immunocytochemistry suggests a functional relationship between the two molecules in vivo. Inhibition of neurite outgrowth from hippocampal neurons by the phosphacan-related molecule in vitro is neutralized by TN-R when coated as a uniform substrate. Furthermore, the phosphacan-related molecule neutralizes growth cone repulsion induced by TN-R coated as a sharp substrate boundary with or without prior treatment with chondroitinase ABC. These observations indicate that TN-R can interact with a phosphacan-related molecule and thereby modulate its inhibitory influence on neuritogenesis.	Swiss Fed Inst Technol, Dept Neurobiol, CH-8093 Zurich, Switzerland; Univ Hamburg, Zentrum Mol Biol, D-20246 Hamburg, Germany; SUNY Hlth Sci Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA; Fac Sci Luminy, CNRS 9943, Lab Genet & Physiol Dev, F-13288 Marseille 9, France	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Hamburg; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Schachner, M (corresponding author), Swiss Fed Inst Technol, Dept Neurobiol, CH-8093 Zurich, Switzerland.		Montag, Dirk/D-3925-2014; xiao, zhicheng/G-5887-2010; xiao, zhicheng/A-1529-2011; ROUGON, Genevieve/G-2578-2013	Montag, Dirk/0000-0002-4964-1330; ROUGON, Genevieve/0000-0003-1316-8200				ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; Bartsch U, 1996, PROG NEUROBIOL, V49, P145; BARTSCH U, 1993, GLIA, V9, P57, DOI 10.1002/glia.440090108; BARTSCH U, 1989, J COMP NEUROL, V284, P451, DOI 10.1002/cne.902840310; BOVOLENTA P, 1993, EUR J NEUROSCI, V5, P454, DOI 10.1111/j.1460-9568.1993.tb00512.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRAUNEWELL KH, 1995, EUR J NEUROSCI, V7, P792, DOI 10.1111/j.1460-9568.1995.tb00682.x; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; CHIQUETEHRISMANN R, 1994, PERSPECT DEV NEUROBI, V2, P3; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; Dorries U, 1996, J NEUROSCI RES, V43, P420; DOU CL, 1994, J NEUROSCI, V14, P7616; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; ERNST H, 1995, J CELL SCI, V108, P3807; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FAISSNER A, 1990, J NEUROCHEM, V54, P1004, DOI 10.1111/j.1471-4159.1990.tb02350.x; FISCHER G, 1986, J NEUROSCI, V6, P605; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FUSS B, 1991, J NEUROSCI RES, V29, P299, DOI 10.1002/jnr.490290305; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LOCHTER A, 1993, J NEUROSCI, V13, P3986; LOCHTER A, 1994, EUR J NEUROSCI, V6, P597, DOI 10.1111/j.1460-9568.1994.tb00304.x; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; OLIVE S, 1995, J NEUROCHEM, V65, P2307; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PINDZOLA RR, 1993, DEV BIOL, V156, P34, DOI 10.1006/dbio.1993.1057; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; ROUSSELET A, 1988, DEV BIOL, V129, P495, DOI 10.1016/0012-1606(88)90395-8; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; SCHULZ M, 1990, J NEUROCHEM, V55, P832, DOI 10.1111/j.1471-4159.1990.tb04567.x; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STREIT A, 1993, J CELL BIOL, V120, P799, DOI 10.1083/jcb.120.3.799; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; WINTERGERST ES, 1993, EUR J NEUROSCI, V5, P299, DOI 10.1111/j.1460-9568.1993.tb00497.x; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; YAMADA H, 1994, J BIOL CHEM, V269, P10119; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	68	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32092	32101		10.1074/jbc.272.51.32092	http://dx.doi.org/10.1074/jbc.272.51.32092			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405406	hybrid			2022-12-25	WOS:000071108000025
J	Dudek, AZ; Pennell, CA; Decker, TD; Young, TA; Key, NS; Slungaard, A				Dudek, AZ; Pennell, CA; Decker, TD; Young, TA; Key, NS; Slungaard, A			Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C - A potential mechanism for enhancing generation of activated protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN THROMBOMODULIN; HUMAN SOLUBLE THROMBOMODULIN; FACTOR-IV; RABBIT THROMBOMODULIN; GRANULE PROTEINS; RAT MODEL; ANTICOAGULANT ACTIVITIES; HEPARIN ANTICOAGULATION; VENOUS THROMBOSIS; COFACTOR ACTIVITY	Platelet factor 4 (PF4) is an abundant platelet alpha-granule heparin-binding protein. We have previously shown that PF4 accelerates up to 25-fold the proteolytic conversion of protein C to activated protein C by the thrombin thrombomodulin complex by increasing its affinity for protein C 30-fold. This stimulatory effect requires presence of the gamma-carboxyglutamic acid (Gla) domain in protein C and is enhanced by the presence of a chondroitin sulfate glycosaminoglycan (GAG) domain on thrombomodulin. We hypothesized that cationic PF4 binds to both protein C and thrombomodulin through these anionic domains. Qualitative SDS-polyacrylamide gel electrophoresis analysis of avidin extracts of solutions containing biotinylated PF4 and candidate ligands shows that PF4 binds to GAG+ but not GAG- forms of thrombomodulin and native but not Gla-domainless protein C. Quantitative analysis using the surface plasmon resonance-based BIAcore(TM) biosensor system confirms the extremely high affinity of PF4 for heparin (K-D = 4 nM) and shows that PF4 binds to GAG+ thrombomodulin with a K-D of 31 nM and to protein C with a K-D of 0.37 mu M. In contrast, PF4 had no measurable interaction with GAG- thrombomodulin or Gla-domainless protein C. Western blot analysis of normal human plasma extracted with biotinylated PF4 demonstrates PF4 binding to protein C in a physiologic context. Thus, PF4 binds with relative specificity and high affinity to the GAG-domain of thrombomodulin and the Gla domain of protein C, These interactions may enhance the affinity of the thrombin thrombomodulin complex for protein C and thereby promote the generation of activated protein C.	UNIV MINNESOTA,DEPT INTERNAL MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; BERLEX BIOSCI,RICHMOND,CA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Dudek, Arkadiusz Zbigniew/HGD-1339-2022	Dudek, Arkadiusz Zbigniew/0000-0002-9114-8945; Pennell, Christopher/0000-0002-2901-6554	NATIONAL CANCER INSTITUTE [R29CA059510] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055219] Funding Source: NIH RePORTER; NCI NIH HHS [CA59510] Funding Source: Medline; NHLBI NIH HHS [R29-HL55219] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOKI Y, 1994, THROMB HAEMOSTASIS, V71, P452; BERNABEI A, 1995, J THORAC CARDIOV SUR, V109, P765, DOI 10.1016/S0022-5223(95)70359-4; BOURIN MC, 1990, BIOCHEM J, V270, P419, DOI 10.1042/bj2700419; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CAPITANIO AM, 1985, BIOCHIM BIOPHYS ACTA, V839, P161, DOI 10.1016/0304-4165(85)90033-9; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; COOK JJ, 1992, CIRCULATION, V85, P1102, DOI 10.1161/01.CIR.85.3.1102; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; Dehmer GJ, 1996, CIRCULATION, V94, P347; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; DITTMAN WA, 1990, BLOOD, V75, P329; DUMENCO LL, 1988, J LAB CLIN MED, V112, P394; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; GRIFFIN JH, 1993, BLOOD, V82, P1989; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; HOLT JC, 1985, SEMIN HEMATOL, V22, P151; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; Kolset SO, 1996, J LEUKOCYTE BIOL, V59, P545, DOI 10.1002/jlb.59.4.545; KUROSAWA S, 1985, THROMB RES, V37, P353, DOI 10.1016/0049-3848(85)90064-7; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LEVINE SP, 1976, J BIOL CHEM, V251, P324; LIN JH, 1994, J BIOL CHEM, V269, P25021; MANN KG, 1990, BLOOD, V76, P1; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; MILETICH JP, 1983, BLOOD, V62, P1127; ONO M, 1994, THROMB HAEMOSTASIS, V72, P421; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, ADV EXP MED BIOL, V313, P177; PREISSNER KT, 1987, BIOCHEMISTRY-US, V26, P2521, DOI 10.1021/bi00383a018; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; RUCINSKI B, 1986, BIOCHEM J, V234, P485; SADLER JE, 1993, HAEMOSTASIS, V23, P183; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCULLY MF, 1980, THROMB RES, V20, P461, DOI 10.1016/0049-3848(80)90284-4; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SLUNGAARD A, 1994, J BIOL CHEM, V269, P25549; SLUNGAARD A, 1993, J CLIN INVEST, V91, P1721, DOI 10.1172/JCI116382; SLUNGAARD A, 1997, THROMB HAEMOSTASIS S, V77, P416; SOLIS MM, 1994, THROMB RES, V73, P385, DOI 10.1016/0049-3848(94)90040-X; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; TAI PC, 1987, LANCET, V1, P643; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	55	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31785	31792		10.1074/jbc.272.50.31785	http://dx.doi.org/10.1074/jbc.272.50.31785			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395524	hybrid			2022-12-25	WOS:A1997YL41900083
J	Bren, N; Sine, SM				Bren, N; Sine, SM			Identification of residues in the adult nicotinic acetylcholine receptor that confer selectivity for curariform antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT INTERFACES; MOLECULAR DISSECTION; LIGAND-BINDING; GAMMA-SUBUNIT; ALPHA-GAMMA; DETERMINANTS; SITES	We identify residues in the epsilon and delta subunits of the adult nicotinic acetylcholine receptor that give the alpha epsilon and alpha delta binding sites different affinities for the curariform antagonist dimethyl d-tubocurarine (DMT). By constructing epsilon-delta subunit chimeras, coexpressing them with complementary subunits, and measuring DMT binding, we identify two pairs of residues, Ile(epsilon 58)/His(delta 60) and Asp(epsilon 59)/Ala(delta 61), responsible for DMT site selectivity in the adult receptor. The two determinants contribute approximately equally to the binding site and interact in contributing to the site. Exchange of these residues from one subunit to the other exchanges the affinities of the resulting binding sites. These determinants in the adult receptor are far from those that confer site selectivity in the fetal receptor; determinants in the fetal receptor are Ile(gamma 116)/Val(delta 118), Tyr(gamma 117)/Thr(delta 119), and Ser(gamma 161)/Lys(delta 163). Thus, alternative residues confer DMT selectivity in fetal and adult acetylcholine receptors.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA	Mayo Clinic	Sine, SM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031744, R01NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOUNT P, 1991, J BIOL CHEM, V266, P14692; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHIARA D C, 1992, Biophysical Journal, V61, pA106; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; FU DX, 1994, J BIOL CHEM, V269, P26152; GARDNER PD, 1990, NUCLEIC ACIDS RES, V18, P6714, DOI 10.1093/nar/18.22.6714; Harvey SC, 1996, J NEUROSCI, V16, P3798; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1991, J BIOL CHEM, V266, P19369; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1981, J BIOL CHEM, V256, P6692; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0	20	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30793	30798		10.1074/jbc.272.49.30793	http://dx.doi.org/10.1074/jbc.272.49.30793			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388220	hybrid			2022-12-25	WOS:000071640800033
J	Kim, H; Baumann, H				Kim, H; Baumann, H			Transmembrane domain of gp130 contributes to intracellular signal transduction in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; CYTOPLASMIC DOMAIN; TRANSCRIPTIONAL INDUCTION; DIFFERENTIAL ACTIVATION; HEMATOPOIETIN RECEPTORS; INTERLEUKIN-6 RECEPTOR; CYTOKINE RECEPTORS; MOLECULAR-CLONING; GROWTH-FACTOR; EXPRESSION	Interleukin-6 (IL-6) induces the expression of acute phase plasma protein genes in hepatic cells through the action of gp130, the signal-transducing subunit of the IL-6 receptor, To identify whether the transmembrane domain of gp130 is required for signaling function, cytoplasmic forms of gp130 were constructed that consisted of the tetramerizing N-terminal domain of Bcr linked to the transmembrane and cytoplasmic domains of gp130 (Bcr/gp130) or just to the cytoplasmic domain of gp130 (Bcr/gp130 Delta TM), The expression and function of both constructs were determined in transiently transfected COS-1 and HepG2 cells, Bcr/gp130 is capable of interacting with JAK1, JAK2, and TYK2; is constitutively active; and induces gene expression through IL-6-responsive elements, In contrast, Bcr/gp130 Delta TM, while expressed at a higher level than Bcr/gp130 and still able to interact with JAK1, is ineffective in recruiting the endogenous signal transduction pathways for inducing gene expression, However, Bcr/gp130 Delta TM initiates par tial signaling in the presence of overexpressed JAK1 and TYK2, but not JAK2. The data suggest that the transmembrane domain of gp130 is necessary for signal transduction and determines the interaction with members of the Janus kinase family.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.			Kim, Hongkyun/0000-0002-4879-7122	NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; Baumann H, 1996, J IMMUNOL, V157, P284; BRECHNER T, 1991, MOL BIOL MED, V8, P267; DAWLEY GQ, 1990, SCIENCE, V247, P824; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; IMMENSCHUH S, 1994, J BIOL CHEM, V269, P12654; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WARD LD, 1994, J BIOL CHEM, V269, P23286; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	33	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30741	30747		10.1074/jbc.272.49.30741	http://dx.doi.org/10.1074/jbc.272.49.30741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388212	hybrid			2022-12-25	WOS:000071640800025
J	Saito, T; Hatada, M; Iwanaga, S; Kawabata, S				Saito, T; Hatada, M; Iwanaga, S; Kawabata, S			A newly identified horseshoe crab lectin with binding specificity to O-antigen of bacterial lipopolysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCKROACH PERIPLANETA-AMERICANA; C-REACTIVE PROTEIN; TACHYPLEUS-TRIDENTATUS; PURIFICATION; HEMOCYTES; HEMOLYMPH; RECOGNITION; PENTRAXINS; IMMUNITY; CLONING	We identified a novel horseshoe crab hemocyte-derived lectin, which we named tachylectin-4. It has more potent hemagglutinating activity against human A-type erythrocytes than a previously identified hemocyte lectin with an affinity to N-acetylglucosamine, tachylectin-2, The purified tachylectin-4 is an oligomeric glycoprotein of 470 kDa, composed of subunits of 30 and 31.5 kDa. Ca2+ at 10 mM enhanced the hemagglutinating activity 4-fold, and the activity was inhibited by EDTA and o-phenanthroline. L-Fucose and N-acetylneuraminic acid at 100 mM completely inhibited the activity of tachylectin-4. The activity was also inhibited more strongly by bacterial S-type lipopolysaccharides (LPS) but not by R-type LPS lacking O-antigen. The most effective S-type LPS was from Escherichia coli O111:B4, and the minimum concentration required for inhibiting agglutination against human A-type erythrocytes (0.1 mu g/ml) was 160-fold lower than those of S-type LPS from Salmonella minnesota, Therefore, colitose (3-deoxy-L-fucose), a unique sugar present in the O-antigen of E. coli O111:B4 with structural similarity to L-fucose, is the most probable candidate for a specific ligand of tachylectin-4. A cDNA coding for tachylectin-4 was isolated from a hemocyte cDNA library, The open reading frame of the 1344-base pair cDNA coded for the mature protein with 232 amino acids. There is no significant sequence similarity to any other known LPS-binding lectins, whereas tachylectin-4 is homologous to the NH2-terminal domain with unknown functions of Xenopus laevis pentraxin 1.	Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 81282, Japan	Kyushu University	Kawabata, S (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 81282, Japan.	skawascb@mbox.nc.kyushu-u.ac.jp		Saito, Tetsu/0000-0002-9045-6743				ARMSTRONG PB, 1991, IMMUNOLOGY INSECTS O, P4; ARMSTRONG PB, 1979, BIOMEDICAL APPLICATI, P73; Dodds Alister W., 1996, P303; DRICKAMER K, 1993, ANN REV CELL BIOL, V9, P236; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; FAYE I, 1990, RES IMMUNOL, V141, P927, DOI 10.1016/0923-2494(90)90195-5; FINSTAD CL, 1972, J IMMUNOL, V108, P1704; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1994, ANN NY ACAD SCI, V712, P102, DOI 10.1111/j.1749-6632.1994.tb33566.x; JOMORI T, 1991, J BIOL CHEM, V266, P13318; Kawabata Shun-ichiro, 1996, P255; Kawasaki K, 1996, INSECT BIOCHEM MOLEC, V26, P355, DOI 10.1016/0965-1748(95)00101-8; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; KUBO T, 1990, INSECT BIOCHEM, V20, P585, DOI 10.1016/0020-1790(90)90070-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TENNENT GA, 1994, BIOCHEM SOC T, V22, P74, DOI 10.1042/bst0220074; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; VASTA GR, 1990, UCLA SYM BI, V121, P183	32	86	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30703	30708		10.1074/jbc.272.49.30703	http://dx.doi.org/10.1074/jbc.272.49.30703			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388206	hybrid			2022-12-25	WOS:000071640800019
J	Habecker, BA; Symes, AJ; Stahl, N; Francis, NJ; Economides, A; Fink, JS; Yancopoulos, G; Landis, SC				Habecker, BA; Symes, AJ; Stahl, N; Francis, NJ; Economides, A; Fink, JS; Yancopoulos, G; Landis, SC			A sweat gland-derived differentiation activity acts through known cytokine signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; CULTURED SYMPATHETIC NEURONS; NEUROTRANSMITTER PLASTICITY INVIVO; NEUROPEPTIDE MESSENGER-RNAS; TRIPARTITE CNTF RECEPTOR; NEUROBLASTOMA CELL-LINE; ONCOSTATIN-M; CHOLINERGIC DIFFERENTIATION; NEUROPOIETIC CYTOKINES	The sympathetic innervation of sweat glands undergoes a target-induced noradrenergic to cholinergic/peptidergic switch during development. Similar changes are induced in cultured sympathetic neurons by sweat gland cells or by one of the following cytokines: leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), or cardiotrophin-1 (CT-1), None of these is the sweat gland-derived differentiation activity. LIF, CNTF, and CT-1 act through the known receptors LIF receptor beta (LIFR beta) and gp130 and well defined signaling pathways including receptor phosphorylation and STAT3 activation. Therefore, to determine whether the gland-derived differentiation activity was a member of the LIF/CNTF cytokine family, we tested whether it acted via these same receptors and signal cascades. Blockade of LIFR beta inhibited the sweat gland differentiation activity in neuron/gland co-cultures, and extracts of gland containing footpads stimulated tyrosine phosphorylation of LIFR beta and gp130, An inhibitor (CGX) of molecules that bind the CNTFR alpha, which is required for CNTF signaling, did not affect the gland derived differentiation activity. Soluble footpad extracts induced the same changes In NBFL neuroblastoma cells as LIF and CNTF, including increased vasoactive intestinal peptide mRNA, STAT3 dimerization, and DNA binding, and stimulation of transcription from the vasoactive intestinal peptide cytokine-responsive element. Thus, the sweat gland-derived differentiation activity uses the same signaling pathway as the neuropoietic cytokines, and is likely to be a family member.	CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106; MASSACHUSETTS GEN HOSP,MOL NEUROBIOL LAB,BOSTON,MA 02114; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; UNIFORMED SERV UNIV HLTH SCI,DEPT PHARMACOL,BETHESDA,MD 20814	Case Western Reserve University; Harvard University; Massachusetts General Hospital; Regeneron; Uniformed Services University of the Health Sciences - USA	Habecker, BA (corresponding author), NINCDS,NEURAL DEV SECT,NIH,BLDG 36-5A05,36 CONVENT DR,BETHESDA,MD 20892, USA.		Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939; Economides, Aris/0000-0002-6508-8942; Habecker, Beth/0000-0002-4658-8730	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027514, R01NS023678] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27514, NS023678] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRUCE AG, 1992, J IMMUNOL, V149, P1271; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DERIGS HG, 1993, LEUKEMIA, V7, P630; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FANN M, 1993, J NEUROCHEM, V61, P1359; FANN MJ, 1994, P NATL ACAD SCI USA, V91, P43, DOI 10.1073/pnas.91.1.43; FONNUM F, 1969, BIOCHEM J, V115, P465, DOI 10.1042/bj1150465; Francis NJ, 1997, DEV BIOL, V182, P76, DOI 10.1006/dbio.1996.8464; FUKADA K, 1985, P NATL ACAD SCI USA, V82, P8795, DOI 10.1073/pnas.82.24.8795; FUKADA K, 1992, NEUROREPORT, V3, P157, DOI 10.1097/00001756-199202000-00009; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Greenfield EM, 1996, J BIOL CHEM, V271, P10984, DOI 10.1074/jbc.271.18.10984; GRUNEBERG H, 1971, J EMBRYOL EXP MORPH, V25, P1; GUIDRY G, 1995, J NEUROSCI, V15, P7565; HABECKER BA, 1995, DEV BIOL, V167, P307, DOI 10.1006/dbio.1995.1025; HABECKER BA, 1994, SCIENCE, V264, P1602, DOI 10.1126/science.8202714; Habecker BA, 1995, NEUROREPORT, V7, P41, DOI 10.1097/00001756-199512000-00009; Habecker BA, 1996, J NEUROSCI, V16, P229; Hawrot E, 1979, Methods Enzymol, V58, P574; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP Y, 1992, CELL, V69, P1121; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LANDIS SC, 1988, DEV BIOL, V126, P129, DOI 10.1016/0012-1606(88)90246-1; LANDIS SC, 1983, DEV BIOL, V98, P349, DOI 10.1016/0012-1606(83)90365-2; LEBLANC G, 1986, J NEUROSCI, V6, P260; LEWIS SE, 1994, J NEUROCHEM, V63, P429; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MONTMINY MR, 1986, J NEUROSCI, V6, P1171; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NAWA H, 1991, J NEUROCHEM, V56, P2147, DOI 10.1111/j.1471-4159.1991.tb03479.x; OH YJ, 1994, NEUROREPORT, V5, P937, DOI 10.1097/00001756-199404000-00021; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; RAO MS, 1992, NEUROREPORT, V3, P865, DOI 10.1097/00001756-199210000-00011; RAO MS, 1993, NEURON, V11, P1175, DOI 10.1016/0896-6273(93)90229-K; RAO MS, 1992, DEVELOPMENT, V116, P731; RAO MS, 1990, NEURON, V5, P899, DOI 10.1016/0896-6273(90)90350-O; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; Richards LJ, 1996, EUR J NEUROSCI, V8, P291, DOI 10.1111/j.1460-9568.1996.tb01213.x; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; ROHRER H, 1992, DEVELOPMENT, V114, P689; ROSE TM, 1994, CYTOKINE, V6, P48, DOI 10.1016/1043-4666(94)90007-8; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SCHOTZINGER R, 1994, J NEUROBIOL, V25, P620, DOI 10.1002/neu.480250605; SCHOTZINGER RJ, 1988, NATURE, V335, P637, DOI 10.1038/335637a0; SCHOTZINGER RJ, 1990, NEURON, V5, P91, DOI 10.1016/0896-6273(90)90037-G; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEPHANS SE, 1994, SYNAPSE, V17, P203, DOI 10.1002/syn.890170310; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; SYMES AJ, 1995, J BIOL CHEM, V270, P8068, DOI 10.1074/jbc.270.14.8068; Taga T, 1996, J NEUROCHEM, V67, P1; THOMA B, 1994, J BIOL CHEM, V269, P6215; TSUKADA T, 1985, DNA-J MOLEC CELL BIO, V4, P293, DOI 10.1089/dna.1985.4.293; WARE CB, 1995, DEVELOPMENT, V121, P1283; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YIN TG, 1993, J IMMUNOL, V151, P2555; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	89	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30421	30428		10.1074/jbc.272.48.30421	http://dx.doi.org/10.1074/jbc.272.48.30421			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374533	hybrid			2022-12-25	WOS:A1997YH61300065
J	Geley, S; Hartmann, BL; Hattmannstorfer, R; Loffler, M; Ausserlechner, MJ; Bernhard, D; Sgonc, R; StrasserWozak, EMC; Ebner, M; Auer, B; Kofler, R				Geley, S; Hartmann, BL; Hattmannstorfer, R; Loffler, M; Ausserlechner, MJ; Bernhard, D; Sgonc, R; StrasserWozak, EMC; Ebner, M; Auer, B; Kofler, R			p53-induced apoptosis in the human T-ALL cell line CCRF-CEM	ONCOGENE			English	Article						p53; apoptosis; CCRF-CEM; human leukemia; caspase; chemotherapy	GLUCOCORTICOID-INDUCED APOPTOSIS; WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; PROTEASE INHIBITORS; ICE/CED-3 PROTEASE; BREAST-CANCER; DNA-BINDING; DEATH; GENE; RESISTANCE	The tumor suppressor p53 has been implicated in apoptosis induction and is mutated in human T-ALL CCRF-CEM cells. To investigate possible consequences of wild-type p53 loss, we reconstituted CEM-C7H2, a subclone of CCRF-CEM, with a temperature-sensitive p53 allele (p53ts). Stably transfected lines expressed high levels of p53ts and shift to the permissive temperature (32 degrees C) caused rapid induction of p53-regulated genes, such as p21(CIP1/WAF1), mdm-2 and bax. This was followed by extensive apoptosis within 24 h to 36 h, supporting the notion that mutational p53 inactivation contributed to the malignant phenotype. p53-dependent apoptosis was preceded by digestion of poly(ADP-ribose) polymerase, a typical target of interleukin-1 beta-converting enzyme (ICE)-like proteases/caspases, and was markedly resistant to the ICE/caspase-1 and FLICE/caspase-8 inhibitor acetyl-Tyr-Val-Afa-Asp.chloromethylketone (YVAD), but sensitive to the CPP32/caspase-3 inhibitor benzyloxycarbonyl-Asp-Glu-Val-Asp.fluoromethylketone (DEVD) and benzyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (zVAD), a caspase inhibitor with broader specificity. This indicated an essential involvement of caspases, but argued against a significant role of ICE/caspase-1 or FLICE/caspase-8. Actinomycin D or cycloheximide prevented cell death, suggesting that, in this system, p53-induced apoptosis depends upon macromolecule biosynthesis. Introduction of functional p53 into CEM cells enhanced their sensitivity to the DNA-damaging agent doxorubicin, but not to the tubulin-active compound vincristine. Thus, mutational p53 inactivation in ALL might entail relative resistance to DNA-damaging, but not to tubulin-destabilizing, chemotherapy.	UNIV INNSBRUCK, INST GEN & EXPT PATHOL, DIV MOL PATHOPHYSIOL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck; University of Innsbruck				Bernhard, David/0000-0002-2383-6607; Ausserlechner, Michael/0000-0002-1015-2302				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anthoney DA, 1996, CANCER RES, V56, P1374; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1996, CANCER RES, V56, P5033; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALDAR S, 1994, CANCER RES, V54, P2095; Haupt Y, 1996, Behring Inst Mitt, P32; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUIDA K, 1995, SCIENCE, V267, P200; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORMAN MR, 1977, CANCER RES, V37, P3785; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARK DJ, 1994, ONCOGENE, V9, P1899; Perego P, 1996, CANCER RES, V56, P556; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; PROKOCIMER M, 1994, BLOOD, V84, P2391; ROLLEY N, 1995, ONCOGENE, V11, P763; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Thomas A, 1996, ONCOGENE, V12, P1055; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1994, COLD SPRING HARB SYM, V59, P395, DOI 10.1101/SQB.1994.059.01.044; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	72	36	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2429	2437		10.1038/sj.onc.1201399	http://dx.doi.org/10.1038/sj.onc.1201399			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395239				2022-12-25	WOS:A1997YE96300005
J	Caterina, NCM; Windsor, LJ; Yermovsky, AE; Bodden, MK; Taylor, KB; Birkedal-Hansen, H; Engler, JA				Caterina, NCM; Windsor, LJ; Yermovsky, AE; Bodden, MK; Taylor, KB; Birkedal-Hansen, H; Engler, JA			Replacement of conserved cysteines in human tissue inhibitor of metalloproteinases-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; HUMAN-FIBROBLASTS; PLASMID DNA; COLLAGENASE INHIBITORS; DIRECTED MUTAGENESIS; TERMINAL DOMAIN; EXPRESSION; TIMP; GELATINASE; GROWTH	Tissue inhibitor of metalloproteinases-l (TIMP-1) is resistant to extremes of temperature and pH, This is thought to be due in part to the presence of six sulfhydryl bridges presumed to maintain the structural integrity of the molecule, As part of a study looking at structure-function relationships, a number of the conserved cysteine residues in TIMP-1 were targeted for replacement: with serine, Single and double replacements of these conserved cysteines, as well as replacements around these cysteines, were expressed using a vaccinia virus system and analyzed for functional and structural competence, Analysis by circular dichroism indicated that these mutants maintained secondary structures similar to those of mild-type TIMP-1. Trypsin susceptibility experiments indicated that the tertiary structure of the mutants had not been drastically changed, Analysis of functional competence demonstrated that there were significant changes in some of these mutants, Assays using collagen fibrils or gelatin as substrates indicated that the double mutant C1S/C70S, but not C3S/C99S, had lost inhibitory activity against human fibroblast-type collagenase (FIB-CL) and at high concentrations only had slight activity against M-r 72,000 gelatinase (M-r 72,000 gelatinase). Kinetic analysis of TIMP-1 inhibition of FIB-CL cleavage of a peptide substrate indicated that mutants C1S/C70S, C3S/C99S, and CEEC --> CQQC retained their ability to inhibit FIB-CL in a manner similar to wild-type TIMP-1, while mutants C1S and C70S showed little inhibitory activity, The mutants C99S and C137S could also inhibit FIB-CL cleavage of the peptide substrate, The results indicated that the degree of inhibition by the TIMP-1 mutants varied somewhat depending on the choice of substrates, interestingly replacing both cysteines from a disulfide bond in the wild-type molecule resulted in a more competent inhibitor than either of the single site "parent" mutations, Taken together, these experiments indicate that TIMP-1 can be rendered inactive by the loss of a single cysteine.	Univ Alabama, Dept Biochem & Mol Genet, Sch Med, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Oral Biol, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Restorat Dent, Birmingham, AL 35294 USA; Univ Alabama, Oral Biol Res Ctr, Birmingham, AL 35294 USA; NIDR, NIH, Bethesda, MD 20892 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Engler, JA (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, Sch Med, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010631, P50DE008228] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10631, DE08228, DE00283] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Akaike H., 1976, MATH SCI, V14, P5; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1997, IN PRESS P C INH MET; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CARMICHAEL DF, 1989, AGENTS ACTIONS, V27, P378, DOI 10.1007/BF01972827; CAWSTON TE, 1984, ARTHRITIS RHEUM, V27, P285, DOI 10.1002/art.1780270306; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; COLIGE AC, 1992, BIOCHEM J, V285, P215, DOI 10.1042/bj2850215; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HEMBRY RM, 1993, AM J PATHOL, V143, P628; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIEVRE Y, 1990, MATRIX, V10, P292, DOI 10.1016/S0934-8832(11)80184-8; LYONS JG, 1991, BIOCHEMISTRY-US, V30, P1450; *MICR SCI SOFTW, 1993, SCI HDB, P207; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1985, J BIOL CHEM, V260, P3079; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO SD, 1992, J BIOL CHEM, V267, P13890; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; SU TZ, 1988, GENE, V69, P81, DOI 10.1016/0378-1119(88)90380-0; Taylor KB, 1996, J BIOL CHEM, V271, P23938, DOI 10.1074/jbc.271.39.23938; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WINDSOR LJ, 1994, J BIOL CHEM, V269, P26201; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	46	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32141	32149		10.1074/jbc.272.51.32141	http://dx.doi.org/10.1074/jbc.272.51.32141			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405413	hybrid			2022-12-25	WOS:000071108000032
J	Matsuzawa, A; Hattori, K; Aoki, J; Arai, H; Inoue, K				Matsuzawa, A; Hattori, K; Aoki, J; Arai, H; Inoue, K			Protection against oxidative stress-induced cell death by intracellular platelet-activating factor-acetylhydrolase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; HUMAN-PLASMA; MONOCLONAL-ANTIBODIES; PHOSPHOLIPASE A(2); ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; NUCLEAR-ENVELOPE; PURIFICATION; PROTEIN; PHOSPHATIDYLCHOLINE	Platelet-activating factor-acetylhydrolase (PAF-AH), which removes the acetyl group at the sn-2 position of PAF, is distributed widely in tissues and plasma. Tissue cytosol contains at least two types of PAF-AH, isoforms Ib and II. Isoform Ib is a tertiary G-protein complex-like heterotrimeric enzyme that is involved in brain development such as formation of the brain cortex. Isoform II (PAF-AH(II)), however, is a 40-kDa monomer and has an amino acid sequence that exhibits a 41% identity with that of plasma PAF-AH. Although PAF-AH(II) preferentialy hydrolyzes oxidized phospholipids as well as PAF in vitro, the function of this enzyme has not, as yet, been elucidated. Here, we report that PAF-AH(II) functions as an anti-oxidant phospholipase. PAF-AH(II) was found to be an N-myristoylated enzyme that has never been reported among lipases and phospholipases. In MDBK cells treated with oxidants, PAF-AH(II) translocated from cytosol to membranes within 20 min, whereas in cells treated with anti-oxidants, it translocated, conversely, from membranes to cytosol. Overexpression of PAF-AH(II) in Chinese hamster ovary-K1 cells suppressed oxidative stress-induced cell death, which occurs by apoptosis. These findings suggest that intracellular PAF-AH(II) translocates between cytosol and membranes in response to a redox state of the cell and protects the cell against oxidative stress most probably by hydrolyzing oxidized phospholipids.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Arai, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Matsuzawa, Atsushi/GLU-1387-2022	Aoki, Junken/0000-0001-9435-1896; Matsuzawa, Atsushi/0000-0001-8303-3905				BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; BLANK ML, 1981, J BIOL CHEM, V256, P175; Borgese N, 1996, J CELL BIOL, V135, P1501, DOI 10.1083/jcb.135.6.1501; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DISTELHORST CW, 1996, ONCOGENE, V12, P21; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HHANAHAN DJ, 1996, ANN REV BIOCH, V55, P483; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IMAI H, 1995, J BIOCHEM-TOKYO, V118, P1061, DOI 10.1093/jb/118.5.1061; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADIN SH, 1958, P SOC EXP BIOL MED, V98, P574, DOI 10.3181/00379727-98-24111; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PATEL KD, 1992, J BIOL CHEM, V267, P15168; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Shimizu S, 1996, ONCOGENE, V13, P21; SPITZ M, 1986, METHOD ENZYMOL, V121, P33; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; SUNDE RA, 1993, BIOCHEM BIOPH RES CO, V193, P905, DOI 10.1006/bbrc.1993.1711; TAMATANI T, 1990, INT IMMUNOL, V2, P165, DOI 10.1093/intimm/2.2.165; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VENABLE ME, 1993, J LIPID RES, V34, P691; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATOSON AD, 1995, J CLIN INVEST, V95, P774; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YANOSHITA R, 1988, J BIOCHEM-TOKYO, V103, P815, DOI 10.1093/oxfordjournals.jbchem.a122352	44	105	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32315	32320		10.1074/jbc.272.51.32315	http://dx.doi.org/10.1074/jbc.272.51.32315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405438	hybrid			2022-12-25	WOS:000071108000057
J	Naito, Y; Watanabe, Y; Yokokura, H; Sugita, R; Nishio, M; Hidaka, H				Naito, Y; Watanabe, Y; Yokokura, H; Sugita, R; Nishio, M; Hidaka, H			Isoform-specific activation and structural diversity of calmodulin kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; CDNA CLONING; PROTEIN; PHOSPHORYLATION; PURIFICATION; IDENTIFICATION; CASCADE	We earlier confirmed that there are isoforms of Ca2+/calmodulin (CaM)-dependent protein kinase I (CaM kinase I) (CaM kinase I beta 1 and I gamma) beside CaM kinase Icu by cDNA cloning (Yokokura, H., Terada, O., Naito, Y., and Hidaka, H. (1997) Biochim. Biophys. Acta 1338, 8-12). Here, we demonstrate the existence of an isoform-specific activation mechanism of CaM kinase I and alternative splicing specifically regulating CaM kinase I (CaM kinase I beta 2) in the central nervous system. To cast light on isoform structure-enzyme activity relationships, CaM kinase I beta 1, I beta 2, and I alpha were expressed separately using a baculovirus/Sf9 cell expression system. The novel CaM kinase I beta 2 isoform demonstrated similar catalytic activity to those of CaM kinase I beta 1 and I alpha. Interestingly, CaM kinase I beta 1 and I beta 2 both can activate CaM kinase I alpha activity via phosphorylation at Thr(177). Reverse transcribed-polymerase chain reaction analysis showed that CaM kinase I beta 2 is dominant in the cerebrum and cerebellum, whereas CaM kinase I beta 1 is present in peripheral tissues such as liver, heart, lung, kidney, spleen, and testis. CaM kinase I beta 2 was also detected with an anti-CaM kinase I beta 2 antibody in PC12 cells. The results indicate that alternative splicing is a means for tissue-specific expression of CaM kinase I beta. Thus the Thr(177) residue of CaM kinase I alpha is phosphorylated by not only CaM kinase kinase but also CaM kinase I beta for activation of the enzyme.	Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 466, Japan	Nagoya University	Hidaka, H (corresponding author), Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 466, Japan.			Watanabe, Yasuo/0000-0003-2232-0091				Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO FS, 1994, BBA-MOL CELL RES, V1224, P156, DOI 10.1016/0167-4889(94)90123-6; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ENDO T, 1981, J BIOL CHEM, V256, P2485; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; INOUE S, 1995, BIOCHEM BIOPH RES CO, V215, P861, DOI 10.1006/bbrc.1995.2543; ITO T, 1994, BIOCHEM BIOPH RES CO, V201, P1561, DOI 10.1006/bbrc.1994.1882; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JSC, 1994, J BIOL CHEM, V269, P2158; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; Okuno S, 1997, J BIOCHEM-TOKYO, V121, P155; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; ROSKOSKI R, 1985, METHOD ENZYMOL, V99, P3; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; Yokokura H, 1997, BBA-PROTEIN STRUCT M, V1338, P8, DOI 10.1016/S0167-4838(97)00004-6	30	38	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32704	32708		10.1074/jbc.272.51.32704	http://dx.doi.org/10.1074/jbc.272.51.32704			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405489	hybrid			2022-12-25	WOS:000071108000108
J	Valiyaveetil, FI; Fillingame, RH				Valiyaveetil, FI; Fillingame, RH			On the role of Arg-210 and Glu-219 of subunit alpha in proton translocation by the Escherichia coli F0F1-ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1F0 ATP SYNTHASE; POLAR LOOP REGION; H+-ATPASE; A-SUBUNIT; SUPPRESSOR MUTATIONS; NUCLEOTIDE-SEQUENCE; MUTAGENIC ANALYSIS; UNC OPERON; F-0; BINDING	A strain of Escherichia coli was constructed which had a complete deletion of the chromosomal uncB gene encoding subunit alpha of the F0F1-ATP synthase, Gene replacement was facilitated by a selection protocol that utilized the sacB gene of Bacillus subtilis cloned in a kanamycin resistance cartridge (Ried, J. L., and Collmer, A. (1987) Gene (Amst.) 57, 239-246). F-0 subunits b and c inserted normally into the membrane in the Delta uncB strain. This observation confirms a previous report (Hermolin, J., and Fillingame, R. H. (1995) J. Biol. Chem, 270, 2815-2817) that subunit alpha is not required for the insertion of subunits b and c, The Delta uncB strain has been used to characterize mutations in Arg-210 and Glu-219 of subunit alpha, residues previously postulated to be essential in proton translocation, The alpha E219G and alpha E219K mutants grew on a succinate carbon source via oxidative phosphorylation and membranes from these mutants exhibited ATPase-coupled proton translocation (i.e. ATP driven 9-amino-6-chloromethoxyacridine quenching responses that were 60-80% of wild type membranes), We conclude that the alpha Glu-219 residue cannot play a critical role in proton translocation. The alpha R210A mutant did not grow on succinate and membranes exhibited no ATPase-coupled proton translocation, However, on removal of F-1 from membrane, the alpha R210A mutant F-0 was active in passive proton translocation, i.e. in dissipating the Delta pH normally established by NADH oxidation with these membrane vesicles. alpha R210A membranes with F-1 bound were also proton permeable. Arg-210 of subunit a may play a critical role in active H+ transport that is coupled to ATP synthesis or hydrolysis, but is not essential for the translocation of protons across the membranes.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 587 Med Sci Bldg, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; Barik S, 1996, Methods Mol Biol, V57, P203; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; BRUSILOW WSA, 1983, J BACTERIOL, V155, P1265, DOI 10.1128/JB.155.3.1265-1270.1983; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1989, J BIOL CHEM, V264, P3292; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; EYA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P71, DOI 10.1016/0003-9861(91)90265-K; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRAGA D, 1994, J BIOL CHEM, V269, P7532; FRAGA D, 1994, J BIOL CHEM, V269, P2562; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KLUGE C, 1993, BIOCHEMISTRY-US, V32, P10378, DOI 10.1021/bi00090a013; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; OKAMOTO H, 1977, J BIOL CHEM, V252, P6125; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; POSSMAYER FE, 1994, J BIOL CHEM, V269, P1896; RIED JL, 1987, GENE, V57, P239, DOI 10.1016/0378-1119(87)90127-2; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P355, DOI 10.1093/nar/16.1.355; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER E, 1984, P NATL ACAD SCI-BIOL, V81, P7279, DOI 10.1073/pnas.81.23.7279; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIK SB, 1994, J BIOL CHEM, V269, P30364; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; ZHANG Y, 1994, J BIOL CHEM, V269, P5473	41	102	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32635	32641		10.1074/jbc.272.51.32635	http://dx.doi.org/10.1074/jbc.272.51.32635			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405480	hybrid			2022-12-25	WOS:000071108000099
J	Kitagawa, H; Tsutsumi, K; Tone, Y; Sugahara, K				Kitagawa, H; Tsutsumi, K; Tone, Y; Sugahara, K			Developmental regulation of the sulfation profile of chondroitin sulfate chains in the chicken embryo brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6B4 PROTEOGLYCAN/PHOSPHACAN; 6-SULFOTRANSFERASE; EXPRESSION; CARTILAGE; PURIFICATION; AGE; ABC	Developmentally regulated and cell type-specific expression of distinct sulfated glycosaminoglycan structures on cell surface proteoglycans is increasingly recognized as providing information relevant to cell-cell interactions and differentiation in developing organisms. In this report, developmental regulation of both the sulfation profile of chondroitin sulfate chains and activities of chondroitin 4-sulfotransferase (C4ST) and chondroitin 6-sulfotransferase (C6ST) were evaluated in embryonic chicken brain. The results revealed that the sulfation profile and the sulfotransferase activities changed markedly with development, and these alterations were precisely coordinated. Specifically, the proportions of both chondroitin 6-sulfate to 4-sulfate and C6ST to C4ST activities progressively decreased with development. In addition, the total amounts of both chondroitin sulfate chains and the sulfotransferase activities were highest during early embryonic stages and decreased sharply as the development reached completion. The developmental expression of the C6ST gene was also found to parallel the developmental down-regulation of both the C6ST activity and the chondroitin 6-sulfate structure. These findings suggest that the developmentally regulated expression of the sulfotransferases is a predominant factor for stage-specific regulation of chondroitin sulfate structures.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN	Kobe Pharmaceutical University			Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				ADANY R, 1990, J BIOL CHEM, V265, P11389; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HABUCHI H, 1986, J BIOL CHEM, V261, P1031; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; INEROT S, 1983, COLLAGEN REL RES, V3, P245; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P221; KINOSHITA A, 1997, 19 JAP CARB S AUG 5, P106; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; Kitagawa H, 1996, J BIOL CHEM, V271, P6583, DOI 10.1074/jbc.271.12.6583; KITAGAWA H, 1997, BIOCHEMISTRY-US, V26, P3998; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MATHEWS MB, 1966, J CLIN INVEST, V45, P1103, DOI 10.1172/JCI105416; Nadanaka S, 1997, GLYCOBIOLOGY, V7, P253, DOI 10.1093/glycob/7.2.253; OOHIRA A, 1988, J BIOL CHEM, V263, P10240; POOLE AR, 1986, BIOCHEM J, V236, P1; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROBINSON HC, 1969, J BIOL CHEM, V244, P348; RODEN L, 1980, BIOCH GLYCOPROTEINS, pJ9U; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; SILBERT JE, 1991, TRENDS GLYCOSCI GLYC, V3, P343; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745	33	158	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31377	31381		10.1074/jbc.272.50.31377	http://dx.doi.org/10.1074/jbc.272.50.31377			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395468	hybrid			2022-12-25	WOS:A1997YL41900027
J	Jin, DY; Chae, HZ; Rhee, SG; Jeang, KT				Jin, DY; Chae, HZ; Rhee, SG; Jeang, KT			Regulatory role for a novel human thioredoxin peroxidase in NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; THIOL-SPECIFIC ANTIOXIDANT; ALKYL HYDROPEROXIDE REDUCTASE; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; REDOX REGULATION; BINDING-PROTEIN; CLONING; CELLS; GENE	Reduction-oxidation (redox) plays a critical role in NF-kappa B activation. Diverse stimuli appear to utilize reactive oxygen species (e.g. hydrogen peroxide) as common effecters for activating NF-kappa B. Antioxidants govern intracellular redox status, and many such molecules can reduce H2O2.,, However, functionally, it does appear that different antioxidants are variously selective for redox regulation of certain transcription factors such as NF-kappa B, For NF-kappa B, thioredoxin has been described to be a more potent antioxidant than either glutathione or N-acetylcysteine. Thioredoxin peroxidase is the immediate enzyme that links reduction of H2O2, to thioredoxin. Several putative human thioredoxin peroxidases have been identified using recursive sequence searches/ alignments with yeast or prokaryotic enzymes. None has been characterized in detail for intracellular function(s), Here, we describe a new human thioredoxin peroxidase, antioxidant enzyme AOE372, identified by virtue of its protein-protein interaction with the product of a proliferation association gene, pag, which is also a thiol specific antioxidant, In human cells, AOE372 defines a redox pathway that specifically regulates NF-kappa B activity via a modulation of I kappa B-alpha phosphorylation in the cytoplasm, We show that AOE372 activity is regulated through either home-or heterodimerization with other thiol peroxidases, implicating subunit assortment as a mechanism for regulating antioxidant specificities, AOE372 function suggests thioredoxin peroxidase as an immediate regulator of H2O2-mediated activation of NF-kappa B.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 4,Room 306,9000 Rockville Pike, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008					ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FIELDS S, 1989, NATURE, V340, P246; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P457; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUANG LM, 1993, J VIROL, V67, P6937, DOI 10.1128/JVI.67.12.6937-6944.1993; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; ISHII T, 1993, J BIOL CHEM, V268, P18633; IWAHARA S, 1995, BIOCHEMISTRY-US, V34, P13398, DOI 10.1021/bi00041a017; JIN DY, 1997, NUCLEIC ACIDS RES, V25, P378; JIN L, 1990, MOL BIOL EVOL, V7, P82; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KIM KW, 1988, J BIOL CHEM, V263, P4704; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Poole LB, 1996, BIOCHEMISTRY-US, V35, P65, DOI 10.1021/bi951888k; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Scandalios J.G., 1997, OXIDATIVE STRESS MOL; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1995, METHOD ENZYMOL, V252, P253; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STAAL FJT, 1995, METHOD ENZYMOL, V252, P168; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; WU BY, 1995, P NATL ACAD SCI USA, V92, P1480, DOI 10.1073/pnas.92.5.1480; YAMAMOTO T, 1989, GENE, V80, P337	54	368	385	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30952	30961		10.1074/jbc.272.49.30952	http://dx.doi.org/10.1074/jbc.272.49.30952			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388242	hybrid			2022-12-25	WOS:000071640800055
J	Miranda-Vizuete, A; Damdimopoulos, AE; Gustafsson, JA; Spyrou, G				Miranda-Vizuete, A; Damdimopoulos, AE; Gustafsson, JA; Spyrou, G			Cloning, expression, and characterization of a novel Escherichia coli thioredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; HYDROGEN DONOR; SALMONELLA-TYPHIMURIUM; PROTEIN; IDENTIFICATION; INSULIN; GROWTH; DNA; GLUTAREDOXIN-1; RESOLUTION	Thioredoxin (Trx) is a small ubiquitous protein that displays different functions mainly via redox mediated processes, We here report the cloning of a gene (trxC) coding for a novel thioredoxin in Escherichia coli as well as the expression and characterization of its product. The gene encodes a protein of 139 amino acids (Trx2) with a calculated molecular mass of 15.5 kDa, Trx2 contains two distinct domains: an N-terminal domain of 32 amino acids including two CXXC motifs and a C-terminal domain, with the conserved active site, Trp-Cys-Gly-Pro-Cys, showing high homology to the prokaryotic thioredoxins, Trx2 together with thioredoxin reductase and NADPH is an efficient electron donor for the essential enzyme ribonucleotide reductase and is also able to reduce the interchain disulfide bridges of insulin. The apparent K-m value of Trx2 for thioredoxin reductase is similar to that of the previously characterized E. coli thioredoxin (Trx1). The enzymatic activity of Trx2 as a protein-disulfide reductase is increased by preincubation with dithiothreitol, suggesting that oxidation of cysteine residues other than the ones in the active site might regulate its activity. A truncated form of the protein, lacking the N-terminal domain, is insensitive to the presence of dithiothreitol, further confirming the involvement of the additional cysteine residues in modulating Trx2 activity. In addition, the presence of the N-terminal domain appears to confer heat sensitivity to Trx2, unlike Trx1. Finally, Trx2 is present normally in growing E. coli cells as shown by Western blot analysis.	Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Spyrou, G (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, S-14157 Huddinge, Sweden.	Giannis.Spyrou@mbb.ki.se	IBIS, REDOX/J-7473-2017; Miranda-Vizuete, Antonio/D-6927-2012	Miranda-Vizuete, Antonio/0000-0002-6856-5396; Damdimopoulos, Anastasios/0000-0003-4425-1189				ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Besse I, 1997, BOT BULL ACAD SINICA, V38, P1; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; CHAMBERLIN M, 1974, J VIROL, V14, P509, DOI 10.1128/JVI.14.3.509-516.1974; CHEN HY, 1994, NUCLEIC ACIDS RES, V22, P4953, DOI 10.1093/nar/22.23.4953; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; EJIRI SI, 1979, J BACTERIOL, V139, P161, DOI 10.1128/JB.139.1.161-164.1979; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Fontecave M., 1992, ADV ENZYMOL RELAT AR, V65, P147; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1978, J BIOL CHEM, V253, P430; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; Lim CJ, 1996, BBA-GENE STRUCT EXPR, V1307, P13, DOI 10.1016/0167-4781(96)00038-3; LIM CJ, 1985, J BACTERIOL, V161, P799, DOI 10.1128/JB.161.2.799-802.1985; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNN CA, 1982, J BIOL CHEM, V257, P1424; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; RUSSEL M, 1985, P NATL ACAD SCI USA, V82, P29, DOI 10.1073/pnas.82.1.29; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SCHALLREUTER KU, 1986, BIOCHEM BIOPH RES CO, V136, P630, DOI 10.1016/0006-291X(86)90487-0; SONG CS, 1985, J IMMUNOL, V135, P3354; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Thelander L, 1978, Methods Enzymol, V51, P227; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; TSANG MLS, 1976, J BACTERIOL, V125, P923, DOI 10.1128/JB.125.3.923-933.1976; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698	49	121	125	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30841	30847		10.1074/jbc.272.49.30841	http://dx.doi.org/10.1074/jbc.272.49.30841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388228	hybrid			2022-12-25	WOS:000071640800041
J	Narayan, S; Jaiswal, AS				Narayan, S; Jaiswal, AS			Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N '-nitro-N-nitrosoguanidine requires p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; COLORECTAL TUMORIGENESIS; BETA-CATENIN; IN-VITRO; CANCER; PRODUCT; ASSOCIATION; MUTATIONS; PROMOTES; PROTEIN	Development of colon cancer is a multistep process frequently involving mutations in both the APC and p53 tumor suppressor genes. In this study we treated the HCT-116 colon cancer cell line with alkylating agents including N-methyl-N'-nitro-N-nitrosoguanidine (MNNG),which is known to cause colon cancer in animals, and examined the expression of both APC and p53 genes. Exposure of cells with MNNG caused an 8-12-fold increase in the level of APC mRNA and protein. APC induction was shown to result from increased nuclear transcription of the APC gene and correlated with a concomitant increase in the p53 protein level after MNNG treatment. A necessary role for p53 in APC gene regulation is supported by the failure of MNNG to induce APC expression in cell lines either expressing very low levels of p53 (HeLa cells) or no p53 (K562 erythroleukemia cells). The overexpression of wild-type p53 gene into HCT-116 cells mimicked the effect of MNNG-induced expression of APC mRNA. A direct causal role for p53 in APC gene regulation was further evaluated by transfecting the wild-type p53 gene into K562 cells and observing a B-fold increase in the APC gene expression. These results support a model featuring a direct link between p53 and APC in response to alkylation-induced DNA damage and suggest a novel role for p53 in a stress-response pathway involving APC.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Narayan, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, 9-104 Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	snarayan@mspo7.med.utmb.edu						BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Cheng KC, 1997, CURR TOP MICROBIOL, V221, P5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367; GRODEN J, 1995, CANCER RES, V55, P1531; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HARGEST R, 1995, GUT, V37, P826, DOI 10.1136/gut.37.6.826; HARPER JW, 1993, CELL, V75, P805; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; NAGAO M, 1993, MUTAT RES, V290, P43, DOI 10.1016/0027-5107(93)90031-A; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TASO J, 1994, AM J PATHOL, V145, P531; WALDMAN T, 1995, CANCER RES, V55, P5187; ZUSMAN I, 1995, BIOL REV, V70, P107, DOI 10.1111/j.1469-185X.1995.tb01441.x	34	59	59	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30619	30622		10.1074/jbc.272.49.30619	http://dx.doi.org/10.1074/jbc.272.49.30619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388195	hybrid			2022-12-25	WOS:000071640800008
J	Schweppe, RE; Frazer-Abel, AA; Gutierrez-Hartmann, A; Bradford, AP				Schweppe, RE; Frazer-Abel, AA; Gutierrez-Hartmann, A; Bradford, AP			Functional components of fibroblast growth factor (FGF) signal transduction in pituitary cells - Identification of fgf response elements in the prolactin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY XENOPUS DEVELOPMENT; PROTEIN-KINASE; MAP KINASE; MESODERM INDUCTION; NEUROENDOCRINE CELLS; TRANSCRIPTION FACTOR; TRANSFORMING GENE; OSTEOCALCIN GENE; RAF-1 KINASE; RAS	Fibroblast growth factors (FGFs) have been implicated in pituitary lactotroph tumorigenesis; however, little is known about the molecular mechanisms of FGF signal transduction. We used a transient transfection approach, in GH4 cells, to identify components of the FGF signaling pathway leading to activation of the rat prolactin (rPRL) promoter. Using dominant-negative constructs of p21(Ras), Raf-1 kinase, and mitogen activated protein (MAP) kinase, we show that FGF activation of the rPRL promoter is independent of Pas and Raf-1 but requires MAP kinase. Furthermore, MAP kinase but not Raf-1 kinase catalytic activity is stimulated by FGFs. The rPRL promoter FGF response maps to two Ets binding sites, centered at -212 (FRE1) and -96 (FRE2), and co transfection of dominant-negative Ets inhibits FGF activation, FRE1 co-localizes with a composite, Ets/GHF-1, has response element. However, overexpression of Ets-1 and GHF-1, which potentiate the Ras response, inhibits FGF stimulation of the rPRL promoter, implying that Ras and FGF signaling pathways target distinct factors to elicit their effects. These data suggest that Ets factors serve to sort and integrate MAP kinase-dependent growth factor signals, allowing highly specific transcriptional responses to be mediated via the interaction of distinct Ets proteins and cofactors at common response elements.	Univ Colorado, Hlth Sci Ctr, Dept Med, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Bradford, AP (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Program Mol Biol, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.		Gutierrez-Hartmann, Arthur/F-1295-2011	Schweppe, Rebecca/0000-0001-7502-0151	NIDDK NIH HHS [DK37667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbass SAA, 1997, J CLIN ENDOCR METAB, V82, P1160, DOI 10.1210/jc.82.4.1160; ATKIN SL, 1993, J CLIN ENDOCR METAB, V77, P831, DOI 10.1210/jcem.77.3.8370706; BAIRD A, 1985, P NATL ACAD SCI USA, V82, P5545, DOI 10.1073/pnas.82.16.5545; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carel K, 1996, J BIOL CHEM, V271, P30625, DOI 10.1074/jbc.271.48.30625; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; Diamond SE, 1996, J BIOL CHEM, V271, P28925, DOI 10.1074/jbc.271.46.28925; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; Estival A, 1996, BIOCHEM J, V315, P619, DOI 10.1042/bj3150619; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GONSKY R, 1991, MOL ENDOCRINOL, V5, P1687, DOI 10.1210/mend-5-11-1687; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; Hurley MM, 1996, J BONE MINER RES, V11, P1256; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LOGAN A, 1991, CELL SIGNAL, V3, P215, DOI 10.1016/0898-6568(91)90047-X; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; OBERWETTER JM, 1993, MOL ENDOCRINOL, V7, P915, DOI 10.1210/me.7.7.915; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEERS B, 1991, J BIOL CHEM, V266, P18127; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; PICKETT CA, 1994, P NATL ACAD SCI USA, V91, P8612, DOI 10.1073/pnas.91.18.8612; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHEDLICH LJ, 1994, J BONE MINER RES, V9, P143; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Shimon I, 1996, J CLIN INVEST, V97, P187, DOI 10.1172/JCI118388; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZIMERING MB, 1993, J CLIN ENDOCR METAB, V76, P1182, DOI 10.1210/jc.76.5.1182	66	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30852	30859		10.1074/jbc.272.49.30852	http://dx.doi.org/10.1074/jbc.272.49.30852			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388230	hybrid			2022-12-25	WOS:000071640800043
J	Leppa, S; Pirkkala, L; Chow, SC; Eriksson, JE; Sistonen, L				Leppa, S; Pirkkala, L; Chow, SC; Eriksson, JE; Sistonen, L			Thioredoxin is transcriptionally induced upon activation of heat shock factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; T-CELL LEUKEMIA; HSP70 GENE-TRANSCRIPTION; AUTOCRINE GROWTH-FACTOR; ARBITRARILY PRIMED PCR; NF-KAPPA-B; OXIDATIVE STRESS; FACTOR-II; EXPRESSION; PROTEIN	Heat shock gene expression is differentially regulated in cells exposed to stress stimuli and in cells undergoing processes of differentiation and development. Regulation of the classical heat shock response is mediated by heat shock factor 1 (HSF1), whereas heat shock factor 2 (HSF2) is activated in certain differentiating cells, for example during hemin-mediated differentiation of human K562 erythroleukemia cells, Hence, the signalling pathways leading to induction of heat shock gene expression upon different stimuli are likely to be distinct. We have used RNA arbitrarily primed polymerase chain reaction to identify genes that are differentially regulated upon activation of HSF1 and HSF2. In this study, me report that thioredoxin (TRX) expression is induced in K562 cells in response to hemin in an HSF2-dependent manner. Increased TRX expression was primarily detected on the transcriptional level, subsequently leading to elevated TRX mRNA and protein levels. Hemin treatment caused no reduction in cellular glutathione concentrations, indicating that the increased TRX expression was not due to oxidative stress. Studies using cell lines where overexpression of the HSF2-beta isoform represses HSF2 activation implied that active HSF2 is required for transcriptional induction of TRX. Unlike HSF2, activation of HSF1 did not induce TRX expression. Taken together, our results suggest that HSF1 and HSF2 may regulate distinct target genes, and activation of HSF2 could be involved in the regulation of TRX expression during hemin-mediated differentiation of K562 cells.	UNIV TURKU, ABO AKAD UNIV, TURKU CTR BIOTECHNOL, FIN-20521 TURKU, FINLAND; ABO AKAD UNIV, DEPT BIOL, FIN-20521 TURKU, FINLAND; UNIV LEICESTER, CTR MECHANISM HUMAN TOXIC, LEICESTER LE1 9HN, LEICS, ENGLAND	Abo Akademi University; University of Turku; Abo Akademi University; University of Leicester				Leppa, Sirpa/0000-0002-8265-511X; Sistonen, Lea/0000-0003-1341-2867				ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; Berggren M, 1996, ANTICANCER RES, V16, P3459; CHAPUT M, 1983, BIOCHIMIE, V65, P501, DOI 10.1016/S0300-9084(83)80132-1; Feige U., 1996, STRESS INDUCIBLE CEL; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; FRISCHER H, 1993, J CLIN INVEST, V92, P2761, DOI 10.1172/JCI116894; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GASDASKA PY, 1994, BBA-GENE STRUCT EXPR, V1218, P292, DOI 10.1016/0167-4781(94)90180-5; GOODSON ML, 1995, MOL CELL BIOL, V15, P5288; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HIGHTOWER L, 1991, HEAT SHOCK DEV; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JacquierSarlin MR, 1996, BIOCHEM J, V318, P187, DOI 10.1042/bj3180187; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; Leppa S, 1997, J BIOL CHEM, V272, P15293, DOI 10.1074/jbc.272.24.15293; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCCLELLAND M, 1995, TRENDS GENET, V11, P242, DOI 10.1016/S0168-9525(00)89058-7; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; POWIS G, 1996, ANTICANCER DRUGS S3, V7, P121; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Taniguchi Y, 1996, NUCLEIC ACIDS RES, V24, P2746, DOI 10.1093/nar/24.14.2746; THOR H, 1982, J BIOL CHEM, V257, P2419; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAMAUCHI A, 1992, MOL IMMUNOL, V29, P263; YODOI J, 1991, ADV CANCER RES, V57, P381	53	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30400	30404		10.1074/jbc.272.48.30400	http://dx.doi.org/10.1074/jbc.272.48.30400			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374530	hybrid			2022-12-25	WOS:A1997YH61300062
J	FitzerAttas, CJ; Do, MS; Feigelson, S; Vadai, E; Feldman, M; Eisenbach, L				FitzerAttas, CJ; Do, MS; Feigelson, S; Vadai, E; Feldman, M; Eisenbach, L			Modification of PDGF alpha receptor expression or function alters the metastatic phenotype of 3LL cells	ONCOGENE			English	Article						3LL cells; dominant negative; paracrine loop; PDGF alpha receptors; tumor metastases	GROWTH-FACTOR PDGF; LUNG-CARCINOMA CELLS; BETA-RECEPTOR; TUMOR-CELLS; DIFFERENTIAL EXPRESSION; SIGNAL TRANSDUCTION; NEGATIVE MUTATIONS; CANCER METASTASIS; PROTEIN PRODUCTS; TYROSINE KINASES	Functional PDGF alpha receptors are selectively expressed on highly lung-metastasizing clones of the 3LL Lewis lung carcinoma, but not on low-mestastatic clones. The highly metastatic clones are also growth induced in vitro by PDGF and lung conditioned medium. To investigate whether modification of PDGF alpha receptor expression or function can affect metastatic capability, we transfected cells of a low-metastatic 3LL clone with a full length PDGF alpha receptor gene and cells of a highly-metastatic clone with a truncated kinase domain PDGF alpha receptor gene. Introduction of the full length PDGF alpha receptor conferred upon low-metastatic cells the ability to grow in vitro in the presence of PDGF-AA and to colonize the lung in experimental and spontaneous metastases assays. Conversely, introduction of a truncated version of the PDGF alpha receptor into highly metastatic cells reduced their metastatic load to control levels. Accordingly, their responses to PDGF-AA, including growth stimulation and receptor autophosphorylation, were reduced. These results demonstrate that PDGF alpha receptor expression and function can control the capacity of tumor cells to generate metastases in the lung. The response of this receptor to lung-derived PDGF-like factors may define a paracrine mode of metastatic cell growth in the target organ.	WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Fitzer-Attas, Cheryl/0000-0002-8709-1384; Eisenbach, Lea R/0000-0002-4816-1968				ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DEBAETSELIER P, 1980, NATURE, V288, P179; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DO MS, 1992, ONCOGENE, V7, P1567; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; EISENBACH L, 1984, INT J CANCER, V34, P567, DOI 10.1002/ijc.2910340421; FIDLER IJ, 1989, CYTOMETRY, V10, P673, DOI 10.1002/cyto.990100602; FIDLER IJ, 1990, CANCER RES, V50, P6130; FITZERATTAS C, 1993, INT J CANCER, V53, P315, DOI 10.1002/ijc.2910530224; FITZERATTAS CJ, 1993, THESIS WEIZMANN I SC; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; Hall A, 1996, DEVELOPMENT, V122, P4085; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART IR, 1981, CANCER RES, V41, P1281; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HERMANSON M, 1992, CANCER RES, V52, P3213; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; KEMP PR, 1993, FEBS LETT, V336, P119, DOI 10.1016/0014-5793(93)81623-8; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LEVEEN P, 1990, INT J CANCER, V46, P1066, DOI 10.1002/ijc.2910460620; LIU M, 1995, AM J PHYSIOL, V269, P178; MALIK R, 1991, CANCER RES, V51, P5626; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1990, INT J CANCER, V46, P16, DOI 10.1002/ijc.2910460106; MORNEX JF, 1986, J CLIN INVEST, V78, P61, DOI 10.1172/JCI112574; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; PONTEN F, 1994, J INVEST DERMATOL, V102, P304, DOI 10.1111/1523-1747.ep12371787; PORGADOR A, 1993, J IMMUNOL, V150, P1458; RADINSKY R, 1992, In Vivo (Attiki), V6, P325; RUSCIANO D, 1992, BIOESSAYS, V14, P185, DOI 10.1002/bies.950140309; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHAMAH SM, 1995, METHOD ENZYMOL, V254, P565; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SMITS A, 1992, AM J PATHOL, V140, P639; SOUZA P, 1995, DEVELOPMENT, V121, P2559; STRAWN LM, 1994, J BIOL CHEM, V269, P21215; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TARIN D, 1984, CANCER RES, V44, P3584; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; Van Furth R, 1980, MONONUCLEAR PHAGOCYT; VIGNAUD JM, 1994, CANCER RES, V54, P5455; WANG JL, 1990, INT J CANCER, V46, P772, DOI 10.1002/ijc.2910460504; WESTERMARK B, 1993, ACTA ONCOL, V32, P101, DOI 10.3109/02841869309083897; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	58	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1545	1554		10.1038/sj.onc.1201321	http://dx.doi.org/10.1038/sj.onc.1201321			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380406				2022-12-25	WOS:A1997XX36900005
J	Wu, GF; Fan, RS; Li, WH; Ko, TC; Brattain, MG				Wu, GF; Fan, RS; Li, WH; Ko, TC; Brattain, MG			Modulation of cell cycle control by vitamin D-3 and its analogue, EB1089, in human breast cancer cells	ONCOGENE			English	Article						breast cancer; vitamin D-3; EB1089; p21(WAF-1)/(CIP-1); inactivation of Cdk2 activity	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; DNA-REPLICATION; MCF-7 CELLS; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; CDK INHIBITOR; P21; P27(KIP1); PHASE	Examination of a panel of ER positive breast cancer cell lines showed that they were differentially growth inhibited by vitamin D-3 and its analogue EB1089. EB1089 treatment of the breast cancer cell lines MCF-7 E, BT20, T47D, and ZR75 demonstrated a correlation between a reduction in Cdk2 kinase activity towards phosphorylation of histone H1 and a decrease in DNA synthesis, while no modulation of Cdk2 activity was observed in the vitamin D-3 and EB1089 resistant cell line MCF-7 L. This was accompanied by a time dependent decrease in the percentage of S phase cells in the responsive lines. Characterization of the expression levels of Cdk2 and its related cell cycle proteins in MCF-7 E cells showed that after EB1089 treatment, there was a concentration and time dependent up-regulation of p21 as well as a decrease in cyclin A proteins. Paradoxically, cyclin E levels were increased as a function of treatment. Analysis of cyclin-Cdk2-Cdki complex formation showed that in EB1089 treated MCF-7 E cells, Cdk2, cyclin A and cyclin E immunoprecipitates contained an increased abundance of p21. In contrast to MCF-7 E cells, increases in both p21 and p27 as well as their complex formation with Cdk2 were observed in BT20 and ZR75 cells. These findings indicate that up-regulation of p21 as well as p27 in some cell types mag account for the inactivation of Cdk2 activity and a G(1) block of the cell cycle following EB1089 treatment.	MED COLL OHIO,DEPT BIOCHEM & MOL BIOL,TOLEDO,OH 43699; UNIV TEXAS,MED BRANCH,DEPT SURG,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [CA72001, CA50457, CA38173] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA038173, R01CA038173, R01CA050457, R01CA072001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE J, 1991, ENDOCRINOLOGY, V129, P832, DOI 10.1210/endo-129-2-832; ABE J, 1986, CANCER RES, V46, P6316; BERGER U, 1987, CANCER RES, V47, P6793; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Brattain MG, 1996, J MAMMARY GLAND BIOL, V1, P365, DOI 10.1007/BF02017392; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHOUVET C, 1986, J STEROID BIOCHEM, V24, P373, DOI 10.1016/0022-4731(86)90085-3; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EISMAN JA, 1986, CANCER RES, V46, P5406; EISMAN JA, 1989, J CELL PHYSIOL, V138, P611, DOI 10.1002/jcp.1041380323; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P815; ELSTNER E, 1995, CANCER RES, V55, P2822; FELDMAN D, 1980, J CLIN ENDOCR METAB, V51, P1463, DOI 10.1210/jcem-51-6-1463; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar R, 1996, ONCOGENE, V12, P2155; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gorospe M, 1996, CANCER RES, V56, P475; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RIGBY WFC, 1985, J IMMUNOL, V135, P2279; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang QM, 1996, CANCER RES, V56, P264; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	55	95	96	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1555	1563		10.1038/sj.onc.1201329	http://dx.doi.org/10.1038/sj.onc.1201329			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380407				2022-12-25	WOS:A1997XX36900006
J	Danielson, MA; Bass, RB; Falke, JJ				Danielson, MA; Bass, RB; Falke, JJ			Cysteine and disulfide scanning reveals a regulatory alpha-helix in the cytoplasmic domain of the aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; COILED-COIL INTERACTIONS; DIRECTED CROSS-LINKING; SENSORY RHODOPSIN-I; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; COVALENT MODIFICATION; SERINE CHEMORECEPTOR; PROTEIN-STRUCTURE	The transmembrane, homodimeric aspartate receptor of Escherichia coli and Salmonella typhimurium controls the chemotactic response to aspartate, an attractant, by regulating the activity of a cytoplasmic histidine kinase, The cytoplasmic domain of the receptor plays a central role in both kinase regulation and sensory adaptation, although its structure and regulatory mechanisms are unknown, The present study utilizes cysteine and disulfide scanning to probe residues Leu-250 through Gln-309, a region that contains the first of two adaptive methylation segments within the cytoplasmic domain, Following the introduction of consecutive cysteine residues by scanning mutagenesis, the measurement of sulfhydryl chemical reactivities reveals an alpha-helical pattern of exposed and buried positions spanning residues 270-309. This detected helix, termed the "first methylation helix," is strongly amphiphilic; its exposed face is highly anionic and possesses three methylation sites, while its buried face is hydrophobic, In vivo and in vitro assays of receptor function indicate that inhibitory cysteine substitutions are most prevalent on the buried face of the first methylation helix, demonstrating that this face is involved in a critical packing interaction. The buried face is further analyzed by disulfide scanning which reveals three "lock-on" disulfides that covalently trap the receptor in its kinase-activating state, Each of the lock-on disulfides crosslinks the buried faces of the two symmetric first methylation helices of the dimer, placing these helices in direct contact at the subunit interface, Comparative sequence analysis of 56 related receptors suggests that the identified helix is a conserved feature of this large receptor family, wherein it is likely to play a general role in adaptation and kinase regulation, Interestingly, the rapid rates and promiscuous nature of disulfide formation reactions within the scanned region reveal that the cytoplasmic domain of the full-length, membrane-bound receptor has a highly dynamic structure. Overall, the results demonstrate that cysteine and disulfide scanning can identify secondary structure elements and functionally important packing interfaces, even in proteins that are inaccessible to other structural methods.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Falke, JJ (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	falke@colorado.edu	Danielson, Mary/GZK-8116-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040731] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40731, R01 GM040731, R01 GM040731-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; AMES P, 1988, COLD SPRING HARB SYM, V53, P59, DOI 10.1101/SQB.1988.053.01.010; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; Ames P, 1996, MOL MICROBIOL, V19, P737, DOI 10.1046/j.1365-2958.1996.408930.x; AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; Ausubel F.M, 1992, CURRENT PROTOCOLS MO, V1; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; Baumgartner JW, 1996, J BACTERIOL, V178, P4651, DOI 10.1128/jb.178.15.4651-4660.1996; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; Biemann HP, 1996, J BIOL CHEM, V271, P27927, DOI 10.1074/jbc.271.44.27927; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOURRET RB, 1993, J BIOL CHEM, V268, P13089; BOWIE JU, 1995, ACTA CRYSTALLOGR D, V51, P145, DOI 10.1107/S0907444994010498; Butler SL, 1996, BIOCHEMISTRY-US, V35, P10595, DOI 10.1021/bi961107v; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; DANIELSON MA, 1997, THESIS U COLORADO BO; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; FALKE JJ, 1995, MOL MICROBIOL, V16, P1037, DOI 10.1111/j.1365-2958.1995.tb02329.x; FOSTER DL, 1985, J BIOL CHEM, V260, P1706; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1002, DOI 10.1038/nsb1296-1002; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1011, DOI 10.1038/nsb1296-1011; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hughson AG, 1997, PROTEIN SCI, V6, P315; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; KEHRY MR, 1985, J BACTERIOL, V163, P983, DOI 10.1128/JB.163.3.983-990.1985; KEHRY MR, 1982, CELL, V29, P761, DOI 10.1016/0092-8674(82)90438-X; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE GF, 1994, J BIOL CHEM, V269, P29920; LEE GF, 1995, P NATL ACAD SCI USA, V92, P5416, DOI 10.1073/pnas.92.12.5416; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; Loomis WF, 1997, J CELL SCI, V110, P1141; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MANSON MD, 1998, IN PRESS J BACTERIOL; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MOWBRAY SL, 1985, J BIOL CHEM, V260, P1711; Nara T, 1996, J BIOL CHEM, V271, P17932, DOI 10.1074/jbc.271.30.17932; NINFA EG, 1991, J BIOL CHEM, V266, P9764; OOSAWA K, 1986, P NATL ACAD SCI USA, V83, P6930, DOI 10.1073/pnas.83.18.6930; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PALIAKASIS CD, 1992, PROTEIN ENG, V5, P739, DOI 10.1093/protein/5.8.739; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RUSSELL CB, 1989, J BACTERIOL, V171, P3609, DOI 10.1128/jb.171.7.3609-3618.1989; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Seeley SK, 1996, BIOCHEMISTRY-US, V35, P5199, DOI 10.1021/bi9524979; SHAPIRO MJ, 1995, P NATL ACAD SCI USA, V92, P1053, DOI 10.1073/pnas.92.4.1053; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; SPUDICH EN, 1988, J BACTERIOL, V170, P4280, DOI 10.1128/jb.170.9.4280-4285.1988; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK A, 1987, J BIOL CHEM, V262, P535; Stock AM, 1995, CURR OPIN STRUC BIOL, V5, P744, DOI 10.1016/0959-440X(95)80006-9; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; SWANSON RV, 1994, CURR BIOL, V4, P234, DOI 10.1016/S0960-9822(00)00052-X; TERWILLIGER TC, 1986, P NATL ACAD SCI USA, V83, P6707, DOI 10.1073/pnas.83.18.6707; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Wang H, 1997, J BACTERIOL, V179, P287, DOI 10.1128/jb.179.1.287-289.1997; WEIS RM, 1988, P NATL ACAD SCI USA, V85, P83, DOI 10.1073/pnas.85.1.83; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; WU JR, 1995, BIOCHEMISTRY-US, V34, P3056, DOI 10.1021/bi00009a037; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507	93	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32878	32888		10.1074/jbc.272.52.32878	http://dx.doi.org/10.1074/jbc.272.52.32878			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407066	Green Accepted, hybrid			2022-12-25	WOS:000071182900027
J	Huttenlocher, A; Palecek, SP; Lu, Q; Zhang, WL; Mellgren, RL; Lauffenburger, DA; Ginsberg, MH; Horwitz, AF				Huttenlocher, A; Palecek, SP; Lu, Q; Zhang, WL; Mellgren, RL; Lauffenburger, DA; Ginsberg, MH; Horwitz, AF			Regulation of cell migration by the calcium-dependent protease calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLASTS; INHIBITION; INVOLVEMENT; ADHESION; DYNAMICS; GROWTH	Integrin receptors play an important role during cell migration by mediating linkages and transmitting forces between the extracellular matrix and the actin cytoskeleton. The mechanisms by which these linkages are regulated and released during migration are not well understood, We show here that cell permeable inhibitors of the calcium-dependent protease calpain inhibit both beta 1 and beta 3 integrin-mediated cell migration. Calpain inhibition specifically stabilizes peripheral focal adhesions, increases adhesiveness, and decreases the rate of cell detachment. Furthermore, these inhibitors alter the fate of integrin receptors at the rear of the cell during migration, A Chinese hamster ovary cell line expressing low levels of calpain I also shows reduced migration rates with similar morphological changes, further implicating calpain in this process, Taken together, the data suggest that calpain inhibition modulates cell migration by stabilizing cytoskeletal linkages and decreasing the rate of retraction of the cell's rear. Inhibiting calpain-mediated proteolysis may therefore be a potential therapeutic approach to control pathological cell migration such as tumor metastasis.	Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, Urbana, IL 61801 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; Med Coll Ohio, Dept Therapeut & Pharmacol, Toledo, OH 43699 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Urbana-Champaign; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Scripps Research Institute	Huttenlocher, A (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, 601 S Goodwin Ave, Urbana, IL 61801 USA.							BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; CORRAY P, 1996, BIOCHEM J, V318, P41; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; DU X, 1996, J BIOL CHEM, V270, P26146; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; MAXFIELD F, 1993, TRENDS CELL BIOL, V4, P386; Mellgren RL, 1996, J BIOL CHEM, V271, P15568, DOI 10.1074/jbc.271.26.15568; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; Palecek SP, 1996, J CELL SCI, V109, P941; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6	22	316	321	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32719	32722		10.1074/jbc.272.52.32719	http://dx.doi.org/10.1074/jbc.272.52.32719			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407041	hybrid			2022-12-25	WOS:000071182900002
J	Li, R; Zhang, BL; Zheng, Y				Li, R; Zhang, BL; Zheng, Y			Structural determinants required for the interaction between rho GTPase and the GTPase-activating domain of p190	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; FAMILY GTPASES; BINDING-PROTEIN; CDC42 GTPASES; RAS; EFFECTOR; TARGET; FIBROBLASTS; FILOPODIA; EXCHANGE	The Rho family small GTP-binding proteins are subjected to regulation by Rho GTPase-activating proteins (GAPs) in the course of transmitting diverse intracellular signals. To understand the mechanism of GAP-catalyzed GTP hydrolysis of Rho GTPases, we have studied the interaction between RhoA and p190, the RasGAP binding phosphoprotein which has been implicated as a Rho-specific GAP, by delineating the structural determinants of RhoA and p190 GAP domain (p190GD) that are involved in their functional coupling. Besides the conserved residues Tyr(34), Thr(37), and Phe(39) in the switch I region of RhoA which are required for p190GD interaction, chimeras made between RhoA and Cdc42, a close relative of RhoA with which p190GD interacts 50-fold less efficiently, revealed that residues outside the switch I and neighboring regions of RhoA, residues 85-122 in particular, contain the major p190GD-specifying determinant(s). Mutation of the unique Asp(90) of RhoA in this region mostly abolished p190GD stimulation, whereas the corresponding reverse mutation of Cdc42 (S88D) was able to respond to p190GD-catalysis similarly as RhoA. Further kinetic analysis of these mutants provided evidence that Asp(90) of RhoA contributes primarily to the specific binding interaction with p190GD. On the other hand, two charged residues of p190GD, Arg(1283) and Lys(1321), which are located in the putative G-protein binding helix pocket of GAP domain, were found to be involved in different aspects of interaction with RhoA. The R1283L mutant of p190GD lost GAP activity but retained the ability to bind to RhoA, while K1321A failed to stimulate and to bind to RhoA. These results indicate that residue Asp(90) constitutes the second GAP-interactive site in RhoA which is mostly responsible for conferring p190GD-specificity, and suggest that the role of p190GD in the GTPase reaction of RhoA is in part to supply active site residue Arg(1283) for efficient catalysis.	Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Zheng, Y (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM53943] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DIEKMANN D, 1991, NATURE, V351, P40; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEUNG T, 1993, J BIOL CHEM, V268, P3813; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SELF AJ, 1993, ONCOGENE, V8, P655; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; XU XM, 1994, J BIOL CHEM, V269, P23569; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	46	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32830	32835		10.1074/jbc.272.52.32830	http://dx.doi.org/10.1074/jbc.272.52.32830			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407060	hybrid			2022-12-25	WOS:000071182900021
J	Capon, C; Wieruszeski, JM; Lemoine, J; Byrd, JC; Leffler, H; Kim, YS				Capon, C; Wieruszeski, JM; Lemoine, J; Byrd, JC; Leffler, H; Kim, YS			Sulfated Lewis X determinants as a major structural motif in glycans from LS174T-HM7 human colon carcinoma mucin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINE; MAGNETIC-RESONANCE SPECTROSCOPY; RESOLUTION H-1-NMR SPECTROSCOPY; MOLECULAR-DYNAMICS SIMULATIONS; GAS-LIQUID-CHROMATOGRAPHY; OLIGOSACCHARIDE STRUCTURES; LINKED OLIGOSACCHARIDES; CARBOHYDRATE STRUCTURES; MONOCLONAL-ANTIBODIES; RESPIRATORY MUCINS	This article describes oligosaccharide structures of mucin isolated from nude mouse xenograft tumors produced by LS174T-HM7 cells, a subline of the human colon carcinoma LS174T with higher metastatic tendency and higher mucin production. A striking feature of the oligosaccharides of the LS174T-HM7 xenograft tumor mucin was a predominance of sulfated Lewis X determinants: HSO3-Gal beta 1-4(Fuc alpha 1-3)GlcNAc. In addition to one previously known saccharide with one sulfated Lewis X determinant, the HM7 xenograft tumor mucin contained multiple novel structures containing one, two, or three sulfated Lewis X determinants. This determinant, known to act as a selectin ligand, has been found previously in minor saccharide components of human milk as well as mucins, but never before as a predominant structure in one mucin source.	Univ Calif San Francisco, Vet Affairs Med Ctr, GI Res Lab 151M2, San Francisco, CA 94121 USA; Univ Sci & Technol Lille, CNRS, Chim Biol Lab, Unite Mixte 111, F-59655 Villeneuve Dascq, France; Inst Pasteur, CNRS, Lab Chim Biomol, URA 1309, F-59019 Lille, France; Univ Calif San Francisco, Dept Psychiat, Ctr Neurobiol & Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kim, YS (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, GI Res Lab 151M2, San Francisco, CA 94121 USA.		Leffler, Hakon/A-2416-2019; lemoine, jerome/C-4272-2014	lemoine, jerome/0000-0002-5497-6880; Leffler, Hakon/0000-0003-4482-8945	NCI NIH HHS [CA 29321] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMINOFF D, 1980, ANAL BIOCHEM, V101, P44, DOI 10.1016/0003-2697(80)90038-X; BAENZIGER JU, 1981, ANAL BIOCHEM, V112, P357, DOI 10.1016/0003-2697(81)90305-5; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; Bresalier RS, 1996, CANCER RES, V56, P4354; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; BYRD JC, 1988, CANCER RES, V48, P6678; CAPON C, 1992, J BIOL CHEM, V267, P19248; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DICKENSON JM, 1990, BIOCHEM J, V269, P55, DOI 10.1042/bj2690055; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; GARRIGUES J, 1994, J CELL BIOL, V125, P129, DOI 10.1083/jcb.125.1.129; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; Gum JR, 1995, BIOCHEM SOC T, V23, P795, DOI 10.1042/bst0230795; HAKOMORI S, 1985, CANCER RES, V45, P2405; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; Irimura Tatsuro, 1994, Cancer Bulletin (Houston), V46, P336; ITZKOWITZ SH, 1989, CANCER RES, V49, P197; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KAMERLING JP, 1992, BIOL MAGN RESON, V10, P1; KEMPERMAN H, 1994, J CELL BIOL, V127, P2071, DOI 10.1083/jcb.127.6.2071; Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333; KIM YS, 1992, J CELL BIOCHEM, P91; KOCHETKOV NK, 1976, EUR J BIOCHEM, V67, P129, DOI 10.1111/j.1432-1033.1976.tb10641.x; KOGELBERG H, 1994, GLYCOBIOLOGY, V4, P49, DOI 10.1093/glycob/4.1.49; Kogelberg H, 1996, BIOCHEMISTRY-US, V35, P1954, DOI 10.1021/bi9521598; KUAN SF, 1987, CANCER RES, V47, P5715; KUROSAKA A, 1983, J BIOL CHEM, V258, P1594; Kurutz JW, 1997, GLYCOBIOLOGY, V7, P337, DOI 10.1093/glycob/7.3.337; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; MANNORI G, 1995, CANCER RES, V55, P4425; MAORET JJ, 1989, BIOCHEM J, V258, P793, DOI 10.1042/bj2580793; MCCOOL DJ, 1995, BIOCHEM J, V312, P125, DOI 10.1042/bj3120125; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; PIERCECRETEL A, 1989, EUR J BIOCHEM, V182, P457, DOI 10.1111/j.1432-1033.1989.tb14853.x; PODOLSKY DK, 1985, J BIOL CHEM, V260, P5510; PODOLSKY DK, 1986, J CLIN INVEST, V77, P1263, DOI 10.1172/JCI112429; PODOLSKY DK, 1985, J BIOL CHEM, V260, P8262; QI YM, 1995, J SURG ONCOL, V59, P3, DOI 10.1002/jso.2930590103; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SCHWARTZ B, 1992, INT J CANCER, V52, P60, DOI 10.1002/ijc.2910520113; SPENCER B, 1960, BIOCHEM J, V75, P435, DOI 10.1042/bj0750435; Stranahan PL, 1996, GLYCOCONJUGATE J, V13, P741, DOI 10.1007/BF00702338; STRECKER G, 1992, BIOCHIMIE, V74, P39, DOI 10.1016/0300-9084(92)90182-E; VANHALBEEK H, 1984, BIOCHEM SOC T, V12, P601, DOI 10.1042/bst0120601; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P7; VANHALBEEK H, 1994, GLYCOBIOLOGY, V4, P203, DOI 10.1093/glycob/4.2.203; VANHALBEEK H, 1980, BIOCHIM BIOPHYS ACTA, V623, P295, DOI 10.1016/0005-2795(80)90257-3; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; Veerman ECI, 1997, GLYCOBIOLOGY, V7, P37, DOI 10.1093/glycob/7.1.37; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VLIEGENTHART JFG, 1981, PURE APPL CHEM, V53, P45, DOI 10.1351/pac198153010045; YAMORI T, 1989, CANCER RES, V49, P887; Yoon WH, 1996, BIOCHEM BIOPH RES CO, V222, P694, DOI 10.1006/bbrc.1996.0806; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; Zhang K, 1997, CELL IMMUNOL, V176, P158, DOI 10.1006/cimm.1997.1085; Zhang K, 1997, TUMOR BIOL, V18, P175, DOI 10.1159/000218028	62	68	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31957	31968		10.1074/jbc.272.51.31957	http://dx.doi.org/10.1074/jbc.272.51.31957			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405387	hybrid			2022-12-25	WOS:000071108000006
J	Okazaki, H; Zhang, J; Hamawy, MM; Siraganian, RP				Okazaki, H; Zhang, J; Hamawy, MM; Siraganian, RP			Activation of protein-tyrosine kinase Pyk2 is downstream of Syk in Fc epsilon RI signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; LEUKEMIA RBL-2H3 CELLS; FOCAL ADHESION KINASE; TUMOR MAST-CELLS; IMMUNOGLOBULIN-E; CROSS-LINKING; PHOSPHOLIPASE C-GAMMA-1; HISTAMINE-RELEASE; PHOSPHORYLATION; TRANSDUCTION	Aggregation of the Fc epsilon RI, a member of the immune receptor family, induces the activation of protein-tyrosine kinases and results in tyrosine phosphorylation of proteins that are involved in downstream signaling pathways. Here we report that Pyk2, another member of the focal adhesion kinase family, was present in the RBL-2H3 mast cell line and was rapidly tyrosine-phosphorylated and activated after Fc epsilon RI aggregation. Tyrosine phosphorylation of Pyk2 was also induced by the calcium ionophore A23187, by phorbol myristate acetate, or by stimulation of G-protein-coupled receptors. Adherence of cells to fibronectin dramatically enhanced the induced tyrosine phosphorylation of Pyk2. Although Src family kinases are activated by Fc epsilon RI stimulation and tyrosine-phosphorylate the receptor subunits, the activation and tyrosine phosphorylation of Pyk2 were downstream of Syk. In contrast, tyrosine phosphorylation of Pyk2 by stimulation of G-protein-coupled receptors was independent of Syk. Therefore, the Fc epsilon RI-induced tyrosine phosphorylation of Pyk2 is downstream of Syk and may play a role in cell secretion.	NIDR, Receptors & Signal Transduct Sect, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Okazaki, H (corresponding author), NIDR, Receptors & Signal Transduct Sect, Oral Infect & Immun Branch, NIH, Bldg 10,Rm 1N106, Bethesda, MD 20892 USA.							Ali H, 1996, J BIOL CHEM, V271, P3200, DOI 10.1074/jbc.271.6.3200; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EISEMAN E, 1992, NATURE, V355, P78; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PFEIFFER JR, 1994, J IMMUNOL, V152, P270; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Raja S, 1997, J BIOL CHEM, V272, P10941; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; RAMKUMAR V, 1995, J IMMUNOL, V154, P5436; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SIRAGANIAN RP, 1993, ALLERGY PRINCIPLES P, P1105; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	49	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32443	32447		10.1074/jbc.272.51.32443	http://dx.doi.org/10.1074/jbc.272.51.32443			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405454	hybrid			2022-12-25	WOS:000071108000073
J	Staudinger, J; Lu, JR; Olson, EN				Staudinger, J; Lu, JR; Olson, EN			Specific interaction of the PDZ domain protein PICK1 with the COOH terminus of protein kinase C-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR SUBUNITS; NITRIC-OXIDE SYNTHASE; BINDING-PROTEIN; INTRACELLULAR RECEPTOR; GUANYLATE KINASES; 2-HYBRID SYSTEM; PSD-95; FAMILY; CELL; IDENTIFICATION	PICK1 is a protein kinase C (PKC) alpha-binding protein initially identified using the yeast two-hybrid system. Here we report that PICK1 contains a PDZ domain that interacts specifically with a previously unidentified PDZ-binding domain (QSAV) at the extreme COOH terminus of PKC alpha and that mutation of a putative carboxylate-binding loop within the PICK1 PDZ domain abolishes this interaction. The PDZ binding domain in PKC alpha is absent from other PKC isoforms that do not interact with PICK1, We also demonstrate that PICK1 can homooligomerize through sequences that are distinct from the carboxylate-binding loop, suggesting that self-association and PKC alpha binding are not mutually exclusive. A Caenorhabditis elegans PICK1-like protein is also able to bind to PKC alpha, suggesting a conservation of function through evolution. Association of PKC alpha with PICK1 provides a potential mechanism for the selective targeting of PKC alpha to unique subcellular sites.	Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Hamon Ctr Basic Canc Res, Dallas, TX 75235 USA; Glaxo Wellcome Inc, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; GlaxoSmithKline	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Hamon Ctr Basic Canc Res, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.		Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040				Angenstein F, 1997, BRAIN RES, V745, P46, DOI 10.1016/S0006-8993(96)01129-8; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BURNS DJ, 1992, PROTEIN KINASE C CUR, P25; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cowburn D, 1996, STRUCTURE, V4, P1005, DOI 10.1016/S0969-2126(96)00106-2; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FUJISAWA N, 1992, FEBS LETT, V309, P409, DOI 10.1016/0014-5793(92)80818-2; HALL AV, 1994, J BIOL CHEM, V269, P33082; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kornau HC, 1997, NAT BIOTECHNOL, V15, P319, DOI 10.1038/nbt0497-319; KVANTA A, 1991, FEBS LETT, V283, P321, DOI 10.1016/0014-5793(91)80618-D; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MUELLER BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Newton AC, 1996, CURR BIOL, V6, P806, DOI 10.1016/S0960-9822(02)00600-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; ROCHE KW, NEURON, V1179, P96; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SHARMA S, 1989, ONCOGENE RES, V5, P91; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539	45	198	206	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32019	32024		10.1074/jbc.272.51.32019	http://dx.doi.org/10.1074/jbc.272.51.32019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405395	hybrid			2022-12-25	WOS:000071108000014
J	Wang, SK; He, CG; Hashemi, T; Bayne, M				Wang, SK; He, CG; Hashemi, T; Bayne, M			Cloning and expressional characterization of a novel galanin receptor - Identification of different pharmacophores within galanin for the three galanin receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SEXUAL-BEHAVIOR; MALE-RATS; ALIGNMENT; BINDING; INHIBITION; ANTAGONIST	Galanin, a 29-30 amino acid neuropeptide, is found in the central and peripheral nervous systems and displays several important physiological activities, The actions are believed to be mediated through distinct G protein-coupled receptors. To date, two galanin receptor subtypes have been cloned. In this report, we describe the cloning and expression of a cDNA encoding a novel galanin receptor (GalR3). The receptor has 370 amino acids and shares 36 and 54% homology with the rat GalR1 and GalR2 receptors, I-125-Porcine galanin binds the rat GalR3 receptor expressed in COS-7 cells with high affinity (K-d = 0.6 nM) and could be displaced by galanin and galanin fragments and galanin-chimeric peptides, The pharmacological profile of this novel receptor is distinct from those of GalR1 and GalR2, revealing different pharmacophores within galanin for the three galanin receptor subtypes, Northern blot analysis showed expression in heart, spleen, and testis, Unlike GalR1 and GalR2, no expression of GalR3 was detectable in the brain, suggesting that GalR3 may mediate some of the peripheral functions of galanin.	Schering Plough Corp, Schering Plough Res Inst, Dept CNS CV Biol Res, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; Schering-Plough Research Institute	Wang, SK (corresponding author), Schering Plough Corp, Schering Plough Res Inst, Dept CNS CV Biol Res, Kenilworth, NJ 07033 USA.	suke.wang@spcorp.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEDECS K, 1995, NEUROPEPTIDES, V29, P137, DOI 10.1016/0143-4179(95)90015-2; BENELLI A, 1994, EUR J PHARMACOL, V260, P279, DOI 10.1016/0014-2999(94)90352-2; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BURGEVIN MC, 1995, J MOL NEUROSCI, V6, P33, DOI 10.1007/BF02736757; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CRAWLEY JN, 1990, J NEUROSCI, V10, P3695; CRAWLEY JN, 1995, REGUL PEPTIDES, V59, P1, DOI 10.1016/0167-0115(95)00083-N; DUNNING BE, 1986, AM J PHYSIOL, V251, pE127, DOI 10.1152/ajpendo.1986.251.1.E127; EKBLAD E, 1985, BRIT J PHARMACOL, V86, P241, DOI 10.1111/j.1476-5381.1985.tb09455.x; FISONE G, 1989, P NATL ACAD SCI USA, V86, P9589; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; HEIN J, 1990, METHOD ENZYMOL, V183, P626; Howard AD, 1997, FEBS LETT, V405, P285, DOI 10.1016/S0014-5793(97)00196-8; JUREUS A, 1997, 7 ANN SUMM NEOR C KE; Kakuyama H, 1997, BIOMED RES-TOKYO, V18, P49, DOI 10.2220/biomedres.18.49; PARKER EM, 1995, MOL BRAIN RES, V34, P17; POGGIOLI R, 1992, EUR J PHARMACOL, V213, P87, DOI 10.1016/0014-2999(92)90236-W; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROSSOWSKI WJ, 1990, PEPTIDES, V11, P333, DOI 10.1016/0196-9781(90)90089-N; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; ULMAN LG, 1994, REGUL PEPTIDES, V51, P17, DOI 10.1016/0167-0115(94)90130-9; ULMAN LG, 1992, NEUROSCI LETT, V136, P105, DOI 10.1016/0304-3940(92)90659-U; VERGE VMK, 1993, NEUROSCI LETT, V149, P193, DOI 10.1016/0304-3940(93)90769-H; Wang S, 1997, MOL PHARMACOL, V52, P337, DOI 10.1124/mol.52.3.337; Wang SK, 1997, FEBS LETT, V411, P225, DOI 10.1016/S0014-5793(97)00695-9; WYNICK D, 1993, P NATL ACAD SCI USA, V90, P4231, DOI 10.1073/pnas.90.9.4231	28	191	203	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31949	31952		10.1074/jbc.272.51.31949	http://dx.doi.org/10.1074/jbc.272.51.31949			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405385	hybrid			2022-12-25	WOS:000071108000004
J	ChiRosso, G; Gotwals, PJ; Yang, JL; Ling, L; Jiang, K; Chao, B; Baker, DP; Burkly, LC; Fawell, SE; Koteliansky, VE				ChiRosso, G; Gotwals, PJ; Yang, JL; Ling, L; Jiang, K; Chao, B; Baker, DP; Burkly, LC; Fawell, SE; Koteliansky, VE			Fibronectin type III repeats mediate RGD-independent adhesion and signaling through activated beta 1 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; MONOCLONAL-ANTIBODY; DEPENDENT EPITOPE; DIVALENT-CATIONS; LIGAND; BINDING; MATRIX; EXPRESSION; SUBUNIT; DOMAIN	Many cell-surface and extracellular matrix proteins contain multiple modular domains known as fibronectin type III (FNIII) repeats. Cells adhere to the extracellular matrix proteins fibronectin and tenascin in part by the interaction of certain integrins with the Arg-Gly-Asp (RGD) sequence, displayed on specific FNIII repeats, We have found that, after experimental activation of beta 1 integrins, a number of cell types adhere and spread on FNIII repeats lacking RGD, derived from extracellular matrix proteins and cytokine receptors, Interaction between individual FNIII domains and beta 1 integrins mediates focal adhesion kinase phosphorylation and subsequent stress fiber and focal contact formation, These data suggest that many FNIII-containing proteins may bind and signal through activated beta 1 integrins, dramatically expanding the potential for integrin-dependent intercellular and cell-matrix communication.	BIOGEN INC,CAMBRIDGE,MA 02142	Biogen								AOTA S, 1994, J BIOL CHEM, V269, P24756; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1995, EUR J IMMUNOL, V25, P1720, DOI 10.1002/eji.1830250635; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BROWN PJ, 1988, BIOCHEM BIOPH RES CO, V155, P603, DOI 10.1016/S0006-291X(88)80537-0; BRUMMENDORF T, 1995, PROTEIN PROFILE, V2, P963; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; Koyama N, 1996, AM J PATHOL, V148, P749; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEMIRE JM, 1994, AM J PATHOL, V144, P1068; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MENDRICK DL, 1995, LAB INVEST, V72, P367; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; SMITH JW, 1994, J BIOL CHEM, V269, P960; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; Wong LD, 1996, CELL ADHES COMMUN, V4, P201, DOI 10.3109/15419069609014223; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	39	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31447	31452		10.1074/jbc.272.50.31447	http://dx.doi.org/10.1074/jbc.272.50.31447			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395478	hybrid			2022-12-25	WOS:A1997YL41900037
J	Ghosh, JK; Shaool, D; Guillaud, P; Ciceron, L; Mazier, D; Kustanovich, I; Shai, Y; Mor, A				Ghosh, JK; Shaool, D; Guillaud, P; Ciceron, L; Mazier, D; Kustanovich, I; Shai, Y; Mor, A			Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic Plasmodium falciparium and the underlying molecular basis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMING PEPTIDE ALAMETHICIN; RED-BLOOD-CELLS; PHOSPHOLIPID-MEMBRANES; ANTIMICROBIAL ACTIVITY; INFECTED ERYTHROCYTES; MALARIA PARASITES; CHANNEL FORMATION; LIPID BILAYERS; FROG-SKIN; PARDAXIN	The antimicrobial activity of various naturally occurring microbicidal peptides was reported to result from their interaction with microbial membrane. In this study, we investigated the cytotoxicity of the hemolytic peptide dermaseptin S4 (DS4) and the nonhemolytic peptide dermaseptin S3 (DS3) toward human erythrocytes infected by the malaria parasite Plasmodium falciparum. Both DS4 and DS3 inhibited the parasite's ability to incorporate [H-3]hypoxanthine. However, while DS4 was toxic toward both the parasite and the host erythrocyte, DS3 was toxic only toward the intraerythrocytic parasite. To gain insight into the mechanism of this selective cytotoxicity, we labeled the peptides with fluorescent probes and investigated their organization in solution and in membranes. In Plasmodium-infected cells, rhodamine-labeled peptides interacted directly with the intracellular parasite, in contrast to noninfected cells, where the peptides remained bound to the erythrocyte plasma membrane. Binding experiments to phospholipid membranes revealed that DS3 and DS4 had similar binding characteristics. Membrane permeation studies indicated that the peptides were equally potent in permeating phosphatidylserine/phosphatidylcholine vesicles, whereas DS4 was more permeative with phosphatidylcholine vesicles. In aqueous solutions, DS4 was found to be in a higher aggregation state. Nevertheless, both DS3 and DS4 spontaneously dissociated to monomers upon interaction with vesicles, albeit with different kinetics. In light of these results, we propose a mechanism by which dermaseptins permeate cells and affect intraerythrocytic parasites.	HEBREW UNIV JERUSALEM, WOLFSON CTR APPL STRUCT BIOL, IL-91904 GIVAT RAM, JERUSALEM, ISRAEL; WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL; INST JACQUES MONOD, SERV IMAGERIE, F-75251 PARIS 05, FRANCE; UNIV PARIS 06, INSERM, U313, F-75634 PARIS 13, FRANCE	Hebrew University of Jerusalem; Weizmann Institute of Science; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BECHINGER B, 1992, BIOPHYS J, V62, P12, DOI 10.1016/S0006-3495(92)81763-0; BECHINGER B, 1993, PROTEIN SCI, V2, P2077, DOI 10.1002/pro.5560021208; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; FOX RO, 1982, NATURE, V300, P325, DOI 10.1038/300325a0; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P3429, DOI 10.1021/bi00064a029; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; GERO AM, 1994, PARASITOL TODAY, V10, P395, DOI 10.1016/0169-4758(94)90231-3; GRELLIER P, 1991, J CELL BIOL, V112, P267, DOI 10.1083/jcb.112.2.267; HALDAR K, 1994, PARASITOL TODAY, V10, P393, DOI 10.1016/0169-4758(94)90230-5; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; HIBBS RA, 1996, EUR J CELL BIOL, V72, P182; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; MATSUZAKI K, 1991, BIOCHIM BIOPHYS ACTA, V1063, P162, DOI 10.1016/0005-2736(91)90366-G; MIROVSKY P, 1990, T ROY SOC TROP MED H, V84, P511, DOI 10.1016/0035-9203(90)90018-A; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; MOR A, 1994, J BIOL CHEM, V269, P1934; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; OPDENKAMP JAF, 1985, TRENDS BIOCHEM SCI, V10, P320; Oren Z, 1996, EUR J BIOCHEM, V237, P303, DOI 10.1111/j.1432-1033.1996.0303n.x; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; PAPAHADJ.D, 1967, BIOCHIM BIOPHYS ACTA, V135, P624, DOI 10.1016/0005-2736(67)90094-6; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1991, J BIOL CHEM, V266, P22346; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SHAI Y, 1994, TOXICOLOGY, V87, P109, DOI 10.1016/0300-483X(94)90157-0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; TARASCHI TF, 1994, PARASITOL TODAY, V10, P399, DOI 10.1016/0169-4758(94)90232-1; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; Wuthrich K, 1986, NMR PROTEINS NUCL AC	49	133	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31609	31616		10.1074/jbc.272.50.31609	http://dx.doi.org/10.1074/jbc.272.50.31609			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395500	hybrid			2022-12-25	WOS:A1997YL41900059
J	Mehlen, P; Mehlen, A; Godet, J; Arrigo, AP				Mehlen, P; Mehlen, A; Godet, J; Arrigo, AP			hsp27 as a switch between differentiation and apoptosis in murine embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; PROMYELOCYTIC LEUKEMIA-CELLS; GROWTH ARREST; OXIDATIVE STRESS; HL-60 CELLS; CELLULAR THERMORESISTANCE; CARCINOMA-CELLS; RETINOIC ACID; EXPRESSION; PHOSPHORYLATION	Small stress proteins are developmentally regulated and Linked to cell growth and differentiation. The early phase of murine embryonic stem (ES) cell differentiation, characterized by a gradual growth arrest, is accompanied with hsp27 transient accumulation. This differentiation process also correlated with changes in hsp27 phosphorylation and oligomerization. The role of hsp27 was investigated in ES clones stably transfected with murine or human hsp27 genes, placed in sense or antisense orientation. Several clones were obtained that either underexpressed endogenous murine hsp27 or overexpressed murine or human hsp27. Maintained undifferentiated, these clones showed similar growth rates. We report here that hsp27 constitutive overexpression enhanced the differentiation-mediated decreased rate of ES cell proliferation but did not alter morphological changes. In contrast, hsp27 underexpression, which attenuated cell growth arrest, induced differentiation abortion because of an overall cell death by apoptosis. Recently, we showed that hsp27 interfered with cell death probably because of its ability to modulate intracellular glutathione. hsp27 accumulation during ES cell differentiation was also correlated with an increase in glutathione, which was attenuated by hsp27 down-expression. Hence, hsp27 transient expression seems essential for preventing differentiating ES cells from undergoing apoptosis, a switch that may be redox regulated.	UNIV LYON 1,CNRS,UMR 5534,LAB STRESS CELLULAIRE,CTR GENET MOL & CELLULAIRE,F-69622 VILLEURBANNE,FRANCE; UNIV LYON 1,CNRS,UMR 5534,LAB GENET THALASSEMIES,CTR GENET MOL & CELLULAIRE,F-69622 VILLEURBANNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; Arrigo AP, 1995, NEUROPATH APPL NEURO, V21, P488, DOI 10.1111/j.1365-2990.1995.tb01094.x; ARRIGO AP, 1991, HEAT SHOCK DEV, P106; ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; ARRIGO AP, 1995, HEAT SHOCK DEV, V21, P488; ATZORI L, 1994, EXP CELL RES, V211, P115, DOI 10.1006/excr.1994.1066; BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; BENNDORF R, 1988, BIOCHEM INT, V17, P225; BERNET A, 1995, BLOOD, V86, P1202; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chaufour S, 1996, CELL STRESS CHAPERON, V1, P225, DOI 10.1379/1466-1268(1996)001<0225:TAPACI>2.3.CO;2; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; HANASH SM, 1993, P NATL ACAD SCI USA, V90, P3314, DOI 10.1073/pnas.90.8.3314; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; Huot J, 1996, CANCER RES, V56, P273; HUOT J, 1991, CANCER RES, V51, P245; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Kohno T, 1996, J IMMUNOL, V156, P4722; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LIANG SM, 1991, J IMMUNOL, V146, P1909; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P239; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MEHLEN P, 1994, EUR J BIOCHEM, V221, P321; MINOWADA G, 1995, J BIOL CHEM, V270, P7047, DOI 10.1074/jbc.270.13.7047; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MUSCHEL RJ, 1995, CANCER RES, V55, P995; PARK JR, 1994, BLOOD, V84, P440; PAULI D, 1990, J CELL BIOL, V111, P817, DOI 10.1083/jcb.111.3.817; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; Savatier P, 1996, ONCOGENE, V12, P309; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPECTOR NL, 1994, FEBS LETT, V337, P184, DOI 10.1016/0014-5793(94)80270-X; SPECTOR NL, 1993, J CELL PHYSIOL, V156, P619, DOI 10.1002/jcp.1041560322; SPECTOR NL, 1995, J BIOL CHEM, V270, P1003, DOI 10.1074/jbc.270.3.1003; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; STAHL J, 1992, DIFFERENTIATION, V51, P33, DOI 10.1111/j.1432-0436.1992.tb00677.x; SUSUKI K, 1992, RADIAT RES, V129, P157; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; WANG R, 1992, DEVELOPMENT, V114, P303; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; YANG H, 1993, NUCLEIC ACIDS RES, V21, P3337, DOI 10.1093/nar/21.14.3337	65	195	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31657	31665		10.1074/jbc.272.50.31657	http://dx.doi.org/10.1074/jbc.272.50.31657			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395507	hybrid			2022-12-25	WOS:A1997YL41900066
J	Shaper, NL; Meurer, JA; Joziasse, DH; Chou, TDD; Smith, EJ; Schnaar, RL; Shaper, JH				Shaper, NL; Meurer, JA; Joziasse, DH; Chou, TDD; Smith, EJ; Schnaar, RL; Shaper, JH			The chicken genome contains two functional nonallelic beta 1,4-galactosyltransferase genes - Chromosomal assignment to syntenic regions tracks fate of the two gene lineages in the human genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE BETA-1,4-GALACTOSYLTRANSFERASE; HUMAN GALACTOSYLTRANSFERASE; CELL-MIGRATION; PROTEIN; BINDING; IDENTIFICATION; ENZYME; GOLGI; SITE; EXPRESSION	Two distinct but related groups of cDNA clones, CK beta 4GT-I and CK beta 4GT-II, have been isolated by screening a chicken hepatoma cDNA library with a bovine beta 1,4-galactosyltransferase (beta 4GT) cDNA clone, CK beta 4GT-I is predicted to encode a type II transmembrane glycoprotein of 41 kDa with one consensus site for N-linked glycosylation, CK beta 4GT-II is predicted to encode a type II transmembrane glycoprotein of 43 kDa with five potential N-linked glycosylation sites, At the amino acid level, the coding regions of CK beta 4GT-I and CK beta 4GT-II are 52% identical to each other and 62 and 49% identical, respectively, to bovine beta 4GT, Despite this divergence in amino acid sequence, high levels of expression of each cDNA in Trichoplusia ni insect cells demonstrate that both CK beta 4GT-I and CK beta 4GT-II encode an alpha-lactalbumin-responsive, UDP-galactose:N-acetylglucosamine beta 4-galactosyltransferase. An analysis of CK beta 4GT-I and CK beta 4GT-II, genomic clones established that the intron positions within the coding region are conserved when compared with each other, and these positions are identical to the mouse and human beta 4GT genes. Thus CK beta 4GT-I and CK beta 4GT-II are the result of the duplication of an ancestral gene and subsequent divergence, CK beta 4GT-I maps to chicken chromosome Z in a region of conserved synteny with the centromeric region of mouse chromosome 4 and human chromosome 9p, where beta 4-galactosyltransferase (EC 2.4.1.38) had previously been mapped, Consequently, during the evolution of mammals, it is the CK beta 4GT-I gene lineage that has been recruited for the biosynthesis of lactose, CK beta 4GT-II maps to a region of chicken chromosome 8 that exhibits conserved synteny with human chromosome Ip, An inspection of the current human gene map of expressed sequence tags reveals that there is a gene noted to be highly similar to beta 4GT located in this syntenic region on human chromosome Ip, Because both the CK beta 4GT-I and CK beta 4GT-II gene lineages are detectable in mammals, duplication of the ancestral beta 4-galactosyltransferase gene occurred over 250 million years ago in an ancestral species common to both mammals and birds.	JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, CELL STRUCT & FUNCT LAB, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOL SCI, BALTIMORE, MD 21287 USA; VRIJE UNIV AMSTERDAM, DEPT MED CHEM, NL-1081 BT AMSTERDAM, NETHERLANDS; USDA ARS, E LANSING, MI 48823 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Vrije Universiteit Amsterdam; United States Department of Agriculture (USDA)			Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014010] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038310] Funding Source: NIH RePORTER; NCI NIH HHS [CA45799] Funding Source: Medline; NICHD NIH HHS [HD14010] Funding Source: Medline; NIGMS NIH HHS [GM38310] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1974, BIKEN J, V17, P105; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; APPEDDU PA, 1994, P NATL ACAD SCI USA, V91, P2095, DOI 10.1073/pnas.91.6.2095; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; BEYER TA, 1982, GLYCOCONJUGATES, P25; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HATHAWAY HJ, 1992, J CELL BIOL, V117, P369, DOI 10.1083/jcb.117.2.369; Hill R L, 1968, Brookhaven Symp Biol, V21, P139; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1990, EUR J BIOCHEM, V191, P75, DOI 10.1111/j.1432-1033.1990.tb19095.x; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; Li QX, 1997, DEV BIOL, V181, P257, DOI 10.1006/dbio.1996.8444; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; Nanda I, 1996, GENE, V170, P159, DOI 10.1016/0378-1119(95)00828-4; POWELL JT, 1974, BIOCHEM J, V142, P203, DOI 10.1042/bj1420203; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; RUSSO RN, 1990, THESIS J HOPKINS U; Saitoh Y, 1993, CHROMOSOME RES, V1, P239, DOI 10.1007/BF00710129; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SHAPER JH, 1995, GLYCOCONJUGATE J, V12, P477; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, SOMAT CELL MOLEC GEN, V12, P633, DOI 10.1007/BF01671948; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHAPER NL, 1990, CYTOGENET CELL GENET, V54, P172, DOI 10.1159/000132987; Smith EJ, 1996, POULTRY SCI, V75, P642, DOI 10.3382/ps.0750642; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; ULRICH JT, 1986, J BIOL CHEM, V261, P7975; WATZELE G, 1990, NUCLEIC ACIDS RES, V18, P7174, DOI 10.1093/nar/18.23.7174; YADAV S, 1990, J BIOL CHEM, V265, P14163; YADAV SP, 1991, J BIOL CHEM, V266, P698	43	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31389	31399		10.1074/jbc.272.50.31389	http://dx.doi.org/10.1074/jbc.272.50.31389			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395470	Green Submitted, hybrid			2022-12-25	WOS:A1997YL41900029
J	Taura, T; Schlenstedt, G; Silver, PA				Taura, T; Schlenstedt, G; Silver, PA			Yrb2p is a nuclear protein that interacts with Prp20p, a yeast Rcc1 homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RNA1 GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; BINDING-PROTEINS; IMPORT SUBSTRATE; PORE COMPLEXES; RAN/TC4 GTPASE; MESSENGER-RNA; SCHIZOSACCHAROMYCES-POMBE	A conserved family of Ran binding proteins (RBPs) has been defined by their ability to bind to the Ran GTPase and the presence of a common region of approximately 100 amino acids (the Ran binding domain). The yeast Saccharomyces cerevisiae genome predicts only three proteins with canonical Ran binding domains. Mutation of one of these, YRB1, results in defects in transport of macromolecules across the nuclear envelope (Schlenstedt, G., Wong, D. H., Roepp, D. M., and Silver, P. A. (1995) EMBO J. 14, 5367-5378). The second one, encoded by YRB2, is a 327-amino acid protein with a Ran binding domain at its C terminus and an internal cluster of FXFG and FG repeats conserved in nucleoporins. Yrb2p is located inside the nucleus, and this localization relies on the N terminus. Results of both genetic and biochemical analyses show interactions of Yrb2p with the Ran nucleotide exchanger Prp20p/Rcc1. Yrb2p binding to Gsp1p (yeast Ran) as well as to a novel 150-kDa GTP-binding protein is also detected. The Ran binding domain of Yrb2p is essential for function and for its association with Prp20p and the GTP-binding proteins. Taken together, we suggest that Yrb2p may play a role in the Ran GTPase cycle distinct from nuclear transport.	CHILDRENS HOSP, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School								ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Avis JM, 1996, J CELL SCI, V109, P2423; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DEMETER J, 1995, P NATL ACAD SCI USA, V92, P1436, DOI 10.1073/pnas.92.5.1436; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FLEISCHMANN M, 1991, MOL GEN GENET, V227, P417, DOI 10.1007/BF00273932; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; HARTMANN E, 1995, TRENDS CELL BIOL, V5, P192, DOI 10.1016/S0962-8924(00)88992-8; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; HUTCHISON HT, 1969, J BACTERIOL, V99, P807, DOI 10.1128/JB.99.3.807-814.1969; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE A, 1993, J CELL SCI, V106, P287; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nakashima N, 1996, J CELL SCI, V109, P2311; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; Noguchi E, 1997, MOL CELL BIOL, V17, P2235, DOI 10.1128/MCB.17.4.2235; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; Pante N, 1995, J CELL SCI, P1; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; Turi TG, 1996, J BIOL CHEM, V271, P9166, DOI 10.1074/jbc.271.15.9166; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	74	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31877	31884		10.1074/jbc.272.50.31877	http://dx.doi.org/10.1074/jbc.272.50.31877			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395535	hybrid			2022-12-25	WOS:A1997YL41900094
J	Chaudhuri, J; Chakrabarti, A; Maitra, U				Chaudhuri, J; Chakrabarti, A; Maitra, U			Biochemical characterization of mammalian translation initiation factor 3 (eIF3) - Molecular cloning reveals that p110 subunit is the mammalian homologue of Saccharomyces cerevisiae protein Prt1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN MESSENGER-RNA; RABBIT RETICULOCYTES; IMMUNOCHEMICAL CHARACTERIZATION; BINDING-PROTEIN; HELA-CELLS; WHEAT-GERM; CALF LIVER; FACTOR-III; PURIFICATION; COMPLEX	Eukaryotic translation initiation factor 3 (eIF3), which plays an essential role in initiation of protein synthesis, was purified from rabbit reticulocyte lysates using an assay that specifically measures its ability to stimulate the binding of Met-tRNA(f), (as a Met-tRNA.eIF2. GTP ternary complex) to 40 S ribosomal subunits, Purified eIF3 consisted of six major polypeptides of molecular masses 110, 67, 42, 40, 36, and 35 kDa but lacked the 170-kDa polypeptide reported to be a constituent of other eIF3 preparations, Characterization of purified eIF3 lacking the 170-kDa polypeptide showed that the eIF3-mediated 40 S initiation complex formed in the presence of AUG codon efficiently joined 60 S ribosomal subunits in an eIF5-dependent reaction to form a functional 80 S initiation complex, eIF3, which was originally bound to the 40 S initiation complex, was released from the 40 S subunit during the subunit joining reaction, Additionally, chicken antibodies raised against rabbit reticulocyte eIF3 were used to immunochemically characterize eIF3 subunits and to isolate a 3.1-kilobase pair human cDNA that encodes the p110 subunit of mammalian eIF3, The derived amino acid sequence (calculated M-r, 95,214) shows that the p110 subunit is the mammalian homologue of Saccharomyces cerevisiae protein Prt1p, a subunit of yeast eIF3.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Chaudhuri, J (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [K04CA001330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA1330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMESZ H, 1979, EUR J BIOCHEM, V98, P513, DOI 10.1111/j.1432-1033.1979.tb13212.x; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; CARROLL SB, 1983, J BIOL CHEM, V258, P24; CHAKRABARTI A, 1992, J BIOL CHEM, V267, P12964; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P5754; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; Chaudhuri J, 1997, J BIOL CHEM, V272, P7883, DOI 10.1074/jbc.272.12.7883; CHECKLEY JW, 1981, J BIOL CHEM, V256, P1582; CHEVESICH J, 1993, J BIOL CHEM, V268, P20659; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; FEINBERG B, 1982, J BIOL CHEM, V257, P846; GHOSH S, 1989, J BIOL CHEM, V264, P5134; GOSS DJ, 1988, BIOCHEMISTRY-US, V27, P1489, DOI 10.1021/bi00405a014; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; KEIERLEBER C, 1986, MOL CELL BIOL, V6, P4419, DOI 10.1128/MCB.6.12.4419; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1983, MICROBIOL REV, V47, P1; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Merrick WC., 1996, TRANSLATION CONTROL, P31; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SEAL SN, 1983, J BIOL CHEM, V258, P866; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; SPREMULLI LL, 1979, J BIOL CHEM, V254, P143; STRINGER EA, 1979, J BIOL CHEM, V254, P6845; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; THOMPSON HA, 1977, BIOCHEMISTRY-US, V16, P2221, DOI 10.1021/bi00629a028; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; TRACHSEL H, 1996, TRANSLATIONAL CONTRO, P113; VALENZUELA DM, 1982, J BIOL CHEM, V257, P7712; WESTERMANN P, 1986, FEBS LETT, V205, P171, DOI 10.1016/0014-5793(86)80891-2; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	51	40	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30975	30983		10.1074/jbc.272.49.30975	http://dx.doi.org/10.1074/jbc.272.49.30975			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388245	hybrid			2022-12-25	WOS:000071640800058
J	Johnson, BD; Dombroski, AJ				Johnson, BD; Dombroski, AJ			The role of the pro sequence of Bacillus subtilis sigma(K) in controlling activity in transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; GENE-EXPRESSION; OPEN COMPLEX; AMINO-ACIDS; PROMOTER; BINDING; REGION; MECHANISM; DNA	The sigma (sigma) subunit of prokaryotic RNA polymerase is required for specific recognition of promoter DNA sequences and transcription initiation. Regulation of gene expression can therefore be achieved by modulating the activity of the sigma subunit, In Bacillus subtilis the mother cell-specific sporulation sigma factor, sigma(K), is synthesized as a precursor protein, pro-sigma(K), with 20-amino acid pro sequence. This pro sequence renders sigma(K) inactive for directing transcription of sigma(K)-dependent genes in vivo until the pro sequence is proteolytically removed. To understand the role of the pro sequence in controlling sigma(K) activity, we have constructed NH2,-terminal truncations of pro-sigma(K) and characterized their behavior in vitro at the gerE promoter, In this report me show that the pro sequence inactivates sigma(K) by interfering with the ability of sigma(K) to associate with the core subunits of polymerase and also influences the interactions between holoenzyme and promoter DNA. Additionally, removal of as few as 6 amino acids (pro-sigma(K) Delta 6) is sufficient to activate pro-sigma(K) for DNA binding and transcription initiation, Surprisingly, pro-sigma K Delta 6 binds to DNA with higher affinity and stimulates transcription 30-fold more efficiently than sigma(K), under certain conditions.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Dombroski, AJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, 6431 Fannin, Houston, TX 77030 USA.	dombros@utmmg.med.uth.tmc.edu						AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; Carlson HC, 1996, J BACTERIOL, V178, P546, DOI 10.1128/jb.178.2.546-549.1996; CHEN YF, 1992, P NATL ACAD SCI USA, V89, P5123, DOI 10.1073/pnas.89.11.5123; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HALDENWANG WG, 1995, MICROBIOL REV, V59, P1; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Joo DM, 1997, P NATL ACAD SCI USA, V94, P4907, DOI 10.1073/pnas.94.10.4907; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; LU SJ, 1994, J BACTERIOL, V176, P3936, DOI 10.1128/JB.176.13.3936-3943.1994; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MELANCON P, 1982, BIOCHEMISTRY-US, V21, P4318, DOI 10.1021/bi00261a022; Mita BC, 1995, J BIOL CHEM, V270, P30428, DOI 10.1074/jbc.270.51.30428; MORAN CP, 1988, BACILLUS SUBTILIS OT, P653; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OKE V, 1993, J BACTERIOL, V175, P7341, DOI 10.1128/JB.175.22.7341-7347.1993; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; RONG JC, 1994, J BACTERIOL, V176, P5218, DOI 10.1128/JB.176.17.5218-5224.1994; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SHORENSTEIN RG, 1973, J BIOL CHEM, V248, P6170; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; Zhang X, 1996, J MOL BIOL, V258, P14, DOI 10.1006/jmbi.1996.0230; ZHOU YN, 1992, J BACTERIOL, V174, P5005, DOI 10.1128/JB.174.15.5005-5012.1992	38	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31029	31035		10.1074/jbc.272.49.31029	http://dx.doi.org/10.1074/jbc.272.49.31029			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388252	hybrid			2022-12-25	WOS:000071640800065
J	Li, W; Wang, JC				Li, W; Wang, JC			Footprinting of yeast DNA topoisomerase II lysyl side chains involved in substrate binding and interdomainal interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; ELECTRON-MICROSCOPY; 2-GATE MECHANISM; RNA-POLYMERASE; TRANSPORT; PURIFICATION; COMPLEXES	Footprinting of yeast DNA topoisomerase II and its NH2- and COOH-terminal truncation derivatives was carried out to map the locations of lysyl side chains that are involved in enzyme-DNA interaction, in the binding of ATP, or in interaction between domains of the same enzyme molecule, Several conclusions were drawn based on these measurements and the crystal structures of a 92-kDa fragment of the yeast enzyme and a 43-kDa fragment of Escherichia coli gyrase B-subunit, First, the footprinting results support the model previously in ferred from the 92-kDa fragment crystal structure that the main site of DNA binding is comprised of a pair of semicircular grooves, Second, the binding of a nonhydrolyzable ATP analog to the yeast enzyme appears to affect citraconylation at a minimum of six lysines in the ATPase domain of each polypeptide, Two of these lysines are probably involved in contacting the nucleotide directly, and one probably becomes buried when the two ATPase domains of a dimeric enzyme come into contact upon ATP binding; for the others, changes in lysine reactivity appear to reflect allosteric changes following ATP binding, Third, from a comparison of the footprint of the intact enzyme and those of the truncated polypeptides comprised of either the NH2- or the COOH-terminal half of the intact polypeptide, it appears that there are few contacts between the NH2- and COOH-terminal half of yeast DNA topoisomerase II.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Li, W (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.				NIGMS NIH HHS [GM24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024544, R01GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Benedetti P, 1997, J BIOL CHEM, V272, P12132, DOI 10.1074/jbc.272.18.12132; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BERGER JM, 1995, THESIS HARVARD U; Caron P R, 1994, Adv Pharmacol, V29B, P271; GIAEVER GN, 1988, BIOPHYS CHEM, V29, P7, DOI 10.1016/0301-4622(88)87020-0; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; GOTO T, 1982, J BIOL CHEM, V257, P5866; Greiner DP, 1996, P NATL ACAD SCI USA, V93, P71, DOI 10.1073/pnas.93.1.71; Greiner DP, 1996, BIOCHEM BIOPH RES CO, V225, P1006, DOI 10.1006/bbrc.1996.1285; Hanai R, 1996, J BIOL CHEM, V271, P17469, DOI 10.1074/jbc.271.29.17469; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEMAIRE M, 1990, BIOCHEM J, V267, P431, DOI 10.1042/bj2670431; Lundblad R.L., 1994, TECHNIQUES PROTEIN M; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Schultz P, 1996, P NATL ACAD SCI USA, V93, P5936, DOI 10.1073/pnas.93.12.5936; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	28	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31190	31195		10.1074/jbc.272.49.31190	http://dx.doi.org/10.1074/jbc.272.49.31190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388273	hybrid			2022-12-25	WOS:000071640800086
J	Yao, M; Kow, YW				Yao, M; Kow, YW			Further characterization of Escherichia coli endonuclease V - Mechanism of recognition for deoxyinosine, deoxyuridine, and base mismatches in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; 3'-ENDONUCLEASE; CLEAVAGE; GLYCOSYLASE; REPAIR; ENZYME	Endonuclease V from Escherichia coli has a wide substrate spectrum. In addition to deoxyinosine-containing DNA, the enzyme cleaves DNA containing urea residues, AP sites, base mismatches, insertion/deletion mismatches, flaps, and pseudo-Y structures. The gene coding for the enzyme was identified to be orf 225 or nfi (endonuclease five). Using enzyme purified from an overproducing strain, the deoxyinosine-and mismatch-specific activities of endonuclease V was found to have different divalent metal requirements. The affinity of the enzyme is greater than 20-fold higher for DNA containing deoxyinosine than deoxynebularine or base mismatches. Under optimal cleavage conditions, endonuclease V forms two stable complexes with DNA containing deoxyinosine, but not with DNA containing base mismatches or deoxynebularine, suggesting that the 6-keto group of hypoxanthine in DNA is critical for stable interactions with the protein. The enzyme recognizes deoxyuridine in DNA but exhibits a much lower affinity to DNA containing deoxyuridine compared with DNA containing deoxyinosine. Interestingly, deoxyuridine-specific endonuclease activity of endonuclease V has a divalent metal requirement similar to the mismatch activity, A model for the mechanism of substrate recognition is proposed to explain these different activities.	Emory Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, Atlanta, GA 30335 USA	Emory University	Kow, YW (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, 145 Edgewood Ave SE, Atlanta, GA 30335 USA.				NIGMS NIH HHS [GM 37216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; DEMPLE B, 1982, J BIOL CHEM, V257, P2848; GATES FT, 1977, J BIOL CHEM, V252, P1647; Guo GM, 1997, J BACTERIOL, V179, P310, DOI 10.1128/jb.179.2.310-316.1997; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; Sambrook J., 2002, MOL CLONING LAB MANU; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; YAO M, 1995, J BIOL CHEM, V270, P28609, DOI 10.1074/jbc.270.48.28609; Yao M, 1996, J BIOL CHEM, V271, P30672, DOI 10.1074/jbc.271.48.30672; YAO M, 1994, J BIOL CHEM, V269, P31390; YAO M, 1994, J BIOL CHEM, V269, P16260	12	56	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30774	30779		10.1074/jbc.272.49.30774	http://dx.doi.org/10.1074/jbc.272.49.30774			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388217	hybrid			2022-12-25	WOS:000071640800030
J	Gommerman, JL; Rottapel, R; Berger, SA				Gommerman, JL; Rottapel, R; Berger, SA			Phosphatidylinositol 3-kinase and Ca2+ influx dependence for ligand-stimulated internalization of the c-Kit receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; CLATHRIN LIGHT-CHAINS; FACTOR-BETA-RECEPTOR; MAST-CELLS; TYROSINE KINASE; BINDING-SITE; INDEPENDENT MECHANISMS; SIGNAL TRANSDUCTION; COATED VESICLES	We have evaluated the role of phosphatidylinositol 3-kinase (PI3-kinase) and Ca2+ influx in ligand-stimulated internalization of the c-Kit receptor. The wild type (wt) c-Kit receptor and YF719, a mutant receptor in which the SH2-mediated binding site for the p85 subunit of PI3-kinase is disrupted, were expressed in DA-1 cells. YF719 internalized with similar kinetics as wt c-Kit although the receptor remained localized close to the plasma membrane. However, in the absence of extracellular Ca2+, or in the presence of the competitive Ca2+ influx blocker Ni2+, the YF719 mutant failed to internalize, Failure to internalize in the absence of Ca2+ was also observed for the wt c-Kit receptor in cells that were pretreated with the PI3-kinase inhibitor, wortmannin. Following stimulation with ligand, clathrin heavy chains were found to co-immunoprecipitate with c-Kit, However, under conditions in which PI3-kinase activity is inhibited and Ca2+ influx is blocked, clathrin failed to co-immunoprecipitate with c-Kit, Our results demonstrate that both Ca2+ influx and PI3-kinase activity influence c-Kit endocytosis, and inhibition of these two signals disrupts the earliest stages of ligand-mediated internalization.	WELLESLEY HOSP,RES INST,TORONTO,ON M4Y 1J3,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M4Y 1J3,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto				Gommerman, Jennifer/0000-0003-4576-6168; Rottapel, Robert/0000-0002-6024-5558				APODACA G, 1994, J BIOL CHEM, V269, P19005; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; CATT KJ, 1991, J BIOENERG BIOMEMBR, V23, P7; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU QL, 1995, J CLIN INVEST, V95, P2530, DOI 10.1172/JCI117954; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IHLE JN, 1985, CONTEMP TOP MOLEC IM, V10, P93; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOOIBROEK MJ, 1987, J BIOL CHEM, V262, P25; MORI S, 1994, J BIOL CHEM, V269, P4917; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; NATHKE I, 1990, J BIOL CHEM, V265, P18621; PLEY UM, 1995, J BIOL CHEM, V270, P2395, DOI 10.1074/jbc.270.5.2395; POWIS G, 1994, CANCER RES, V54, P2419; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; TAKUWA N, 1995, CELL SIGNAL, V7, P93, DOI 10.1016/0898-6568(94)00074-L; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YAMADA K, 1995, J BIOL CHEM, V270, P3115, DOI 10.1074/jbc.270.7.3115; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YEE NS, 1994, J BIOL CHEM, V269, P31991; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	49	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30519	30525		10.1074/jbc.272.48.30519	http://dx.doi.org/10.1074/jbc.272.48.30519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374546	hybrid			2022-12-25	WOS:A1997YH61300078
J	Ulitzur, N; Rancano, C; Pfeffer, SR				Ulitzur, N; Rancano, C; Pfeffer, SR			Biochemical characterization of mapmodulin, a protein that binds microtubule-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE 2A; IN-VIVO; LOCALIZATION; PURIFICATION; VESICLES; PHAPI	Mapmodulin is a 31-kDa protein that stimulates the microtubule- and dynein-dependent localization of Golgi complexes in semi-intact Chinese hamster ovary cells, We have shown previously that it binds the microtubule binding domains of the microtubule associated proteins, MAP2, MAP4, and tau, We also showed that mapmodulin is identical to a protein named PHAPI (Vaesen, M., Barnikol-Watanabe, S., Gotz, H., Awni, L.A., Cole, T., Zimmermann, B., Kratzin, H.D. and Hilschmann, N. (1994) Biol. Chem. Hoppe-Seyler 375, 113-126). We report here that mapmodulin is a phosphoprotein that is predominantly cytosolic but is also found peripherally associated with endoplasmic reticulum and Golgi membranes in mammalian cells, The protein occurs as a trimer in cytosol, and phosphorylation is required for its microtubule-associated protein-binding activity, Heat treatment of nonphosphorylated mapmodulin can render it competent for binding to microtubule-associated proteins, suggesting that phosphorylation induces a conformational change in mapmodulin. Finally, despite identity in polypeptide sequence with a protein reported to act as an inhibitor of protein phosphatase 2A, native mapmodulin was not able to inhibit protein phosphatase 2A in Chinese hamster ovary cell cytosol.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; FINK TM, 1995, GENOMICS, V29, P309, DOI 10.1006/geno.1995.1257; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; PIERRE P, 1994, J CELL SCI, V107, P1909; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; Ulitzur N, 1997, P NATL ACAD SCI USA, V94, P5084, DOI 10.1073/pnas.94.10.5084; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; Wang XM, 1996, J CELL BIOL, V132, P345, DOI 10.1083/jcb.132.3.345; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x	14	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30577	30582		10.1074/jbc.272.48.30577	http://dx.doi.org/10.1074/jbc.272.48.30577			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374554	hybrid			2022-12-25	WOS:A1997YH61300086
J	Grasso, AW; Wen, DZ; Miller, CM; Rhim, JS; Pretlow, TG; Kung, HJ				Grasso, AW; Wen, DZ; Miller, CM; Rhim, JS; Pretlow, TG; Kung, HJ			ErbB kinases and NDF signaling in human prostate cancer cells	ONCOGENE			English	Article						ErbB3; receptor tyrosine kinase; tyrosine phosphorylation; prostate cancer	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; MAMMARY EPITHELIAL-CELLS; PHOSPHOLIPASE C-GAMMA; FACTOR RECEPTOR FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TUMOR-CELLS; MAP KINASE	Prostate carcinoma (PCA) is the most commonly diagnosed malignancy in American men. Our knowledge of PCA growth regulation lags behind that of other cancers, such as breast and colon carcinomas. Among receptor tyrosine kinases, the ErbB family is most frequently implicated in neoplasia. We report here the expression of ErbB family kinases and their ligands in PCA cell lines and a xenograft. While ErbB1/EGFR, ErbB2/NEU, and ErbB3 were always observed in a distinct pattern, ErbB4 was not observed. Interestingly, while TGF-alpha was expressed in the majority of PCA lines, the ligand Neu Differentiation Factor/Heregulin (NDF) was expressed only in an immortalized, non-transformed prostate epithelial line. Concomitantly, there was a significant difference in biological response to these ligands, NDF inhibited LNCaP growth and induced an epithelial-like morphological change, in contrast to TGF-alpha, which accelerated cell growth. We also performed the first comprehensive analysis of NDF signaling in a prostate line, LNCaP stimulated with NDF demonstrated crosstalk between ErbB3 and ErbB2 which did not involve ErbB1. NDF also turned on several cascades, including those of PI3-K, ERK/MAPK, mHOG/p38 and JNK/SAPK, but not those of PLC gamma or the STAT family. This signaling pattern is distinct from that of TGF-alpha. The activation of mHOG by ErbB2 or ErbB3 has not been reported, and may contribute to the unusual phenotype, PI3-K activation is characterized by the formation of a striking 'activation complex' vith multiple tyrosine-phosphorylated species, including ErbB3. Our studies provide a framework in which to dissect the growth and differentiation signals of prostate cancer cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106; AMGEN INC,THOUSAND OAKS,CA 91320; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,CLEVELAND,OH 44106; NCI,BIOCHEM PHYSIOL LAB,FREDERICK,MD 21702	Case Western Reserve University; Amgen; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA39207, CA57179] Funding Source: Medline; NIDDK NIH HHS [DK52659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA057179, R01CA057179, R37CA039207, R01CA039207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Bacus SS, 1996, ONCOGENE, V12, P2535; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GAMETT DC, 1995, J BIOL CHEM, V270, P19022, DOI 10.1074/jbc.270.32.19022; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAUFMANNZEH A, 1997, NATURE, V385, P5442; KIM HH, 1994, J BIOL CHEM, V269, P24747; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kubota Y, 1996, LEUKEMIA, V10, P720; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE MS, 1994, INT J ONCOL, V4, P821; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OWENS RB, 1976, J NATL CANCER I, V56, P843, DOI 10.1093/jnci/56.4.843; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRIGENT SA, 1992, ONCOGENE, V7, P1273; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sen J, 1996, J IMMUNOL, V156, P4535; SEPPLORENZINO L, 1996, ONCOGENE, V11, P1679; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; Yao R, 1996, ONCOGENE, V13, P343; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	87	123	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2705	2716		10.1038/sj.onc.1201447	http://dx.doi.org/10.1038/sj.onc.1201447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400997				2022-12-25	WOS:A1997YH46800008
J	Bettati, S; Kwiatkowski, LD; Kavanaugh, JS; Mozzarelli, A; Arnone, A; Rossi, GL; Noble, RW				Bettati, S; Kwiatkowski, LD; Kavanaugh, JS; Mozzarelli, A; Arnone, A; Rossi, GL; Noble, RW			Structure and oxygen affinity of crystalline des-His-146 beta human hemoglobin in the T state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGANDED BETA-SUBUNITS; X-RAY-DIFFRACTION; FUNCTIONAL PROPERTIES; QUATERNARY STRUCTURE; BINDING; DEOXYHEMOGLOBIN; CRYSTALLOGRAPHY; CHLORIDE; TRP->ARG	To correlate directly structure with function, the oxygen affinity and the three-dimensional structure of crystals of the T quaternary state of des-His-146 beta human hemoglobin have been determined by polarized absorption microspectrophotometry and x-ray diffraction crystallography, In des-His-146 beta, the COOK-terminal histidine residues of the beta chains of hemoglobin A have been removed, Oxygen binding to crystalline des-His hemoglobin is non-cooperative and independent of pH. The oxygen affinity is 1.7-fold greater than that of the crystalline state of hemoglobin A. Removal of His-146 beta results in a small movement of the truncated COOH-terminal peptide and in a very small change in quaternary structure, Previously, similar studies on T state crystals of des-Arg-141 alpha hemoglobin showed that removal of the COOH termini of the cu chains results in much larger effects on oxygen affinity and on quaternary structure, Kinetic studies in solution reveal that at pH 7.0, the rates of CO combination with deoxygenated des-His-146 beta in the absence and presence of inositol hexaphosphate are 2.5- and 1.3-fold, respectively, more rapid than for hemoglobin A. The values for des-Arg are 7.6- and 3.9-fold, The properties of the T state of hemoglobin both in the crystal and in solution are influenced to a greater degree by the interactions associated with Arg-141 alpha than those associated with His-146 beta.	SUNY Buffalo, Vet Adm Med Ctr, Dept Med, Buffalo, NY 14215 USA; Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Parma; University of Iowa	Noble, RW (corresponding author), SUNY Buffalo, Vet Adm Med Ctr, Dept Med, Buffalo, NY 14215 USA.		Mozzarelli, Andrea/C-3615-2014; Bettati, Stefano/V-9975-2018	Mozzarelli, Andrea/0000-0003-3762-0062; Bettati, Stefano/0000-0001-6787-0594	NHLBI NIH HHS [T32-HL07344, P01 HL51084] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007344, P01HL051084] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM DJ, 1992, J MOL BIOL, V227, P480, DOI 10.1016/0022-2836(92)90902-V; ARNONE A, 1986, J MOL BIOL, V188, P693, DOI 10.1016/S0022-2836(86)80015-8; BONAVENTURA J, 1974, J MOL BIOL, V82, P499, DOI 10.1016/0022-2836(74)90244-7; BUCCI E, 1965, J BIOL CHEM, V240, P551; CAMBILLAU C, 1989, SILICON GRAPHICS GEO, P61; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; DVORAK JA, 1971, EXP CELL RES, V68, P144, DOI 10.1016/0014-4827(71)90596-9; FOWLER SA, 1992, BIOCHEMISTRY-US, V31, P717, DOI 10.1021/bi00118a012; GIBSON QH, 1964, BIOCHEM J, V91, P161, DOI 10.1042/bj0910161; Gouet P, 1996, NAT STRUCT BIOL, V3, P951, DOI 10.1038/nsb1196-951; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P4111, DOI 10.1021/bi00131a030; KAVANAUGH JS, 1995, J MOL BIOL, V248, P136, DOI 10.1006/jmbi.1995.0207; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P8640, DOI 10.1021/bi00151a034; KILMARTIN JV, 1978, BIOCHIM BIOPHYS ACTA, V534, P15, DOI 10.1016/0005-2795(78)90471-3; KILMARTIN JV, 1975, J MOL BIOL, V93, P203, DOI 10.1016/0022-2836(75)90128-X; KILMARTIN JV, 1970, NATURE, V228, P766, DOI 10.1038/228766a0; KILMARTIN JV, 1971, COLD SPRING HARB SYM, V36, P331; KWIATKOWSKI LD, 1994, BIOCHEMISTRY-US, V33, P5884, DOI 10.1021/bi00185a028; KWIATKOWSKI LD, 1987, PROTEINS, V2, P72, DOI 10.1002/prot.340020109; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Mozzarelli A, 1997, PROTEIN SCI, V6, P484; MOZZARELLI A, 1991, NATURE, V351, P416, DOI 10.1038/351416a0; Paoli M, 1996, J MOL BIOL, V256, P775, DOI 10.1006/jmbi.1996.0124; Park SY, 1996, J MOL BIOL, V255, P726, DOI 10.1006/jmbi.1996.0059; PARKHURST KM, 1992, INT J BIOCHEM, V24, P993, DOI 10.1016/0020-711X(92)90109-E; PERUTZ MF, 1971, COLD SPRING HARB SYM, V36, P295; Riggs A., 1981, Methods in Enzymology, V76, P5; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P6411, DOI 10.1021/bi00076a014; SHERIFF S, 1987, J APPL CRYSTALLOGR, V20, P53; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; YUEN PS, 1979, J APPL CRYSTALLOGR, V12, P258, DOI 10.1107/S002188987901236X	40	24	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33077	33084		10.1074/jbc.272.52.33077	http://dx.doi.org/10.1074/jbc.272.52.33077			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407091	hybrid			2022-12-25	WOS:000071182900052
J	Sharma, J; Panico, M; Barber, J; Morris, HR				Sharma, J; Panico, M; Barber, J; Morris, HR			Purification and determination of intact molecular mass by electrospray ionization mass spectrometry of the photosystem II reaction center subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS	A reverse phase high pressure liquid chromatography purification system for the rapid separation of photosystem II reaction center proteins free of salts and detergents is described. This procedure results in the isolation of the three small subunits: alpha- and beta-subunits of cytochrome b(559) and PsbI protein, with near base-line resolution between each peak, although the D1 and D2 proteins were partially deconvoluted. The molecular masses obtained by electrospray ionization mass spectrometry for the purified beta-subunit of cytochrome b(559), alpha-subunit of cytochrome b(559), and the PsbI protein, 4,394.8 +/- 0.4, 9,283.7 +/- 0.8, and 4,209.5 +/- 0.4 Da, respectively, are in excellent agreement with values obtained from previous characterization studies (Sharma, J., Panico, M., Barber, J., and Morris, H. R. (1997) J. Biol. Chem. 272, 3935-3943). Direct electrospray analysis of the D1 and D2 proteins suggests that these components exist in heterogeneous forms. The molecular mass ascribed to a predominant form of the D1 protein, 38,040.9 +/- 6.5 Da, and the D2 protein, 39,456.1 +/- 7.7, are also in agreement with those expected for the mature nonphosphorylated states of these subunits.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England	Imperial College London	Morris, HR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England.		choudhary, jyoti/S-1232-2017	choudhary, jyoti/0000-0003-0881-5477	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Babcock G. T., 1995, PHOTOSYNTHESIS LIGHT, V2, P209; BARBER J, 1989, OXFORD SURVEYS PLANT, V6, P115; CHAPMAN DJ, 1990, METHODS PLANT BIOCH, V5, P171; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDO VS, 1995, BRIT J HAEMATOL, V89, P589, DOI 10.1111/j.1365-2141.1995.tb08368.x; MICHEL H, 1988, J BIOL CHEM, V263, P1123; Sharma J, 1997, J BIOL CHEM, V272, P33158, DOI 10.1074/jbc.272.52.33158; Sharma J, 1997, J BIOL CHEM, V272, P3935, DOI 10.1074/jbc.272.7.3935; TAKAHASHI M, 1988, FEBS LETT, V420, P6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	12	37	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33153	33157		10.1074/jbc.272.52.33153	http://dx.doi.org/10.1074/jbc.272.52.33153			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407102	hybrid			2022-12-25	WOS:000071182900063
J	Arakane, F; King, SR; Du, Y; Kallen, CB; Walsh, LP; Watari, H; Stocco, DM; Strauss, JF				Arakane, F; King, SR; Du, Y; Kallen, CB; Walsh, LP; Watari, H; Stocco, DM; Strauss, JF			Phosphorylation of steroidogenic acute regulatory protein (StAR) modulates its steroidogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDIG TUMOR-CELLS; HORMONE STIMULATION; EXPRESSION; ACID; PHOSPHOPROTEIN; MITOCHONDRION; BIOSYNTHESIS; PRECURSORS; CLEAVAGE; CLONING	Steroidogenic acute regulatory protein (StAR) plays a critical role in steroid hormone synthesis, StAR is thought to increase the delivery of cholesterol to the inner mitochondrial membrane where P450scc resides, Tropic hormones acting through the intermediacy of cAMP rapidly increase pregnenolone synthesis, and this rapid steroidogenic response is believed to be due to StAR's action, The StAR protein contains two consensus sequences for phosphorylation catalyzed by protein kinase A that are conserved across all species in which the amino acid sequence of the StAR protein has been determined, We demonstrated that human StAR expressed in COS-1 cells exists in at least four species detectable by two-dimensional gel electrophoresis followed by Western blotting, The two more acidic species disappeared after treatment of the cell extracts with alkaline phosphatase, P-32 was incorporated into StAR protein immunoprecipitated from COS-1 cell extracts, and a 10-min treatment with 8-bromo-cAMP increased P-32 incorporation into the StAR preprotein, StAR protein generated by in vitro transcription/translation was phosphorylated by the protein kinase A catalytic subunit in the presence of [gamma-P-32]ATP. Mutation of potential sites for protein kinase A-mediated phosphorylation at serine 57 and serine 195 to alanines, individually, reduced P-32 incorporation from labeled ATP into StAR preprotein produced by in vitro transcription/translation when incubated with protein kinase A catalytic subunit, P-32 labeling of StAR protein expressed in COS-1 cells was also reduced when serine 57 or serine 195 were mutated to alanines, A double mutant in which both serine 57 and serine 195 were changed to alanines displayed markedly reduced P-32 incorporation, To determine the functional significance of StAR phosphorylation, we tested the steroidogenic activity of the wild-type StAR and mutated StAR proteins in COS-1 cells expressing the human cholesterol side chain cleavage enzyme system, Mutation of the conserved protein kinase A phosphorylation site at serine 57 had no effect on pregnenolone synthesis. However, mutation of the serine residue at 195 resulted in an approximately 50% reduction in pregnenolone production, The S195A mutant construct did not yield the more acidic species of StAR detected in two-dimensional Western blots, indicating that the mutation affected the ability of the protein to be post-translationally modified. Mutation of the corresponding serine residues in murine StAR (Ser(56) and Ser(194)) to alanines yielded results that were similar to those obtained with human StAR; the S56A mutant displayed a modest reduction in steroidogenic activity, whereas the S194A mutant had approximately 40% of the activity of murine wild-type StAR, In contrast to the human S195A mutation, conversion of serine 195 to an aspartic acid residue had no effect on steroidogenic activity, consistent with the idea that a negative charge at this site modulates StAR function, Our observations suggest that phosphorylation of serine 194/195 increases the biological activity of StAR and that this post- or co-translational event accounts, in part, for the immediate effects of cAMP on steroid production.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Strauss, JF (corresponding author), 778 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.		King, Steven/AAN-1385-2021	Kallen, Caleb/0000-0002-4156-6719	NICHD NIH HHS [HD06274, HD17481, HD07271] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017481, R01HD017481] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; CHAUDHARY LR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P175, DOI 10.1016/0167-4889(91)90006-J; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FILON N, 1997, ENDOCRINOLOGY, V138, P1085; Fleury A, 1996, ENDOCR RES, V22, P515, DOI 10.1080/07435809609043740; GARREN LD, 1965, P NATL ACAD SCI USA, V53, P1443, DOI 10.1073/pnas.53.6.1443; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HARTIGAN JA, 1995, J STEROID BIOCHEM, V53, P95, DOI 10.1016/0960-0760(95)00026-V; HARTUNG S, 1995, BIOCHEM BIOPH RES CO, V215, P646, DOI 10.1006/bbrc.1995.2513; JUENGEL JL, 1995, ENDOCRINOLOGY, V136, P5423, DOI 10.1210/en.136.12.5423; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; Kiriakidou M, 1996, J CLIN ENDOCR METAB, V81, P4122, DOI 10.1210/jc.81.11.4122; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; Pezzi V, 1996, J STEROID BIOCHEM, V58, P417, DOI 10.1016/0960-0760(96)00052-0; POLLACK SE, 1997, IN PRESS J CLIN ENDO; PON LA, 1986, J BIOL CHEM, V261, P3309; PRIVALLE CT, 1987, MOL CELL ENDOCRINOL, V53, P87, DOI 10.1016/0303-7207(87)90195-X; Sandhoff TW, 1996, ENDOCRINE, V4, P259, DOI 10.1007/BF02738692; SIMPSON ER, 1978, J BIOL CHEM, V253, P3135; SIMPSON ER, 1979, MOL CELL ENDOCRINOL, V13, P213, DOI 10.1016/0303-7207(79)90082-0; STOCCO DM, 1993, J STEROID BIOCHEM, V46, P337, DOI 10.1016/0960-0760(93)90223-J; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462	32	284	289	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32656	32662		10.1074/jbc.272.51.32656	http://dx.doi.org/10.1074/jbc.272.51.32656			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405483	hybrid			2022-12-25	WOS:000071108000102
J	Forman, MS; Cook, DG; Leight, S; Doms, RW; Lee, VMY				Forman, MS; Cook, DG; Leight, S; Doms, RW; Lee, VMY			Differential effects of the Swedish mutant amyloid precursor protein on beta-amyloid accumulation and secretion in neurons and nonneuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; SENILE PLAQUES; HIPPOCAMPAL-NEURONS; CLEAVAGE; MUTATION; PEPTIDE; RELEASE; APP; EXPRESSION; SYSTEM	Expression of the Swedish Delta NL mutation in the beta-amyloid precursor protein (APP Delta NL) dramatically increases A beta generation in nonneuronal cell. lines, although it is unclear whether intracellular levels of beta-amyloid (A beta) are also elevated after APP Delta NL expression. Furthermore, the effects of expressing APP Delta NL in neurons on the production and secretion of A beta-(1-40) and A beta-(1-42) are unknown. To address these issues, we examined the generation of both intracellular and secreted A beta-(1-40) and A beta-(1-42) in human neuronal NT2N cells, in primary rat astrocytes, and in Chinese hamster ovary cells engineered to express wild-type APP or APP Delta NL using a recombinant Semliki Forest virus expression system. Expression of APP Delta NL led to a marked increase in APP beta and the C-terminal fragment containing the entire A beta sequence (C99) in all cells tested. However, a dramatic elevation of intracellular and secreted A beta-(1-40) and A beta-(1-42) was seen only in astrocytes and Chinese hamster ovary cells. The Delta NL mutation did not cause a significant increase in intracellular or secreted A beta-(1-40) or A beta-(1-42) in NT2N cells. Since NT2N cells expressing APP Delta NL accumulate much higher levels of C99 than cells expressing wild-type APP, we conclude that the rate-limiting step in A beta production could be the further processing of C99 by gamma-secretase in these cells. These results show that the Swedish Delta NL mutation causes nonneuronal cells to process APP via pathways more in common with the metabolism of wild-type APP in neurons.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Lee, VMY (corresponding author), Hosp Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, 3400 Spruce St,Maloney 3, Philadelphia, PA 19104 USA.				NIA NIH HHS [P01 AG11542] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG011542] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREWS PW, 1984, LAB INVEST, V50, P147; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COOK DG, 1994, METHOD CELL BIOL, V43, P289; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; CRAS P, 1990, AM J PATHOL, V137, P241; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Essalmani R, 1996, BIOCHEM BIOPH RES CO, V218, P89, DOI 10.1006/bbrc.1996.0017; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Iizuka T, 1996, BIOCHEM BIOPH RES CO, V218, P238, DOI 10.1006/bbrc.1996.0042; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JOHNSTON JA, 1994, FEBS LETT, V354, P274, DOI 10.1016/0014-5793(94)01137-0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PROCTER AW, 1994, ACTA NEUROPATHOL, V88, P545; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1986, NEUROBIOL AGING, V7, P425, DOI 10.1016/0197-4580(86)90055-2; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Simons M, 1996, J NEUROSCI, V16, P899; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; TROJANOWSKI JQ, 1995, NEUROBIOL AGING, V16, P335, DOI 10.1016/0197-4580(94)00176-2; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113	51	51	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32247	32253		10.1074/jbc.272.51.32247	http://dx.doi.org/10.1074/jbc.272.51.32247			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405428	hybrid			2022-12-25	WOS:000071108000047
J	Fukuta, M; Inazawa, J; Torii, T; Tsuzuki, K; Shimada, E; Habuchi, O				Fukuta, M; Inazawa, J; Torii, T; Tsuzuki, K; Shimada, E; Habuchi, O			Molecular cloning and characterization of human keratan sulfate Gal-6-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACULAR CORNEAL-DYSTROPHY; CHONDROITIN 6-SULFOTRANSFERASE; ALZHEIMERS-DISEASE; PROTEOGLYCAN; EXPRESSION; PROTEIN; SV2; GLYCOSAMINOGLYCANS; SULFOTRANSFERASE; BIOSYNTHESIS	We have previously cloned chondroitin 6-sulfotransferase (C6ST) cDNA from chick embryo chondrocytes. C6ST catalyzes sulfation of chondroitin, keratan sulfate, and sialyl N-acetyllactosamine oligosaccharides. In this study, we report the cloning and characterization of a novel sulfotransferase that catalyzes sulfation of keratan sulfate, This new sulfotransferase cDNA clone was obtained from a human fetal brain library by cross-hybridization with chick C6ST cDNA. The cDNA clone obtained contains a single open reading frame that predicts a type II transmembrane protein composed of 411 amino acid residues, When the cDNA was introduced into a eukaryotic expression vector and transfected in COS-7 cells, keratan sulfate sulfotransferase activity was overexpressed, but C6ST activity was not increased over that of the control. Structural analysis of S-35-labeled glycosaminoglycan, which was formed from keratan sulfate by the reaction with S-35-labeled 3'-phosphoadenosine 5'-phosphosulfate and the recombinant sulfotransferase, showed that keratan sulfate was sulfated at position 6 of Gal residues, On the basis of the acceptor substrate specificity, we propose keratan sulfate Gal-6-sulfotransferase (KSGal6ST) for the name of the newly cloned sulfotransferase. KSGal6ST was assigned to chromosome 11p11.1-11.2 by fluorescence in situ hybridization. Among various human adult tissues, a 2.8-kilobase message of KSGal6ST was expressed mainly in the brain. When poly(A)(+) RNAs from the chick embryo cornea and brain were probed with the human KSGal6ST cDNA in Northern hybridization, a clear band with about 2.8 kilobases was detected. These observations suggest that KSGal6ST may participate in the biosynthesis of keratan sulfate in the brain and cornea.	Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 448, Japan; Univ Tokyo, Inst Med Sci, Lab Genome Med, Minato Ku, Tokyo 108, Japan	Aichi University Education; University of Tokyo	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 448, Japan.							ARUFFO A, 1991, CURRENT PROTOCOL M S, V17; BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Chiba A, 1997, J BIOL CHEM, V272, P2156; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Habuchi O, 1997, GLYCOBIOLOGY, V7, P405, DOI 10.1093/glycob/7.3.405; HART GW, 1976, J BIOL CHEM, V251, P6513; HASHIMOTO N, 1990, 15 INT CARB S YOK JA, P271; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lindahl B, 1996, J BIOL CHEM, V271, P16991, DOI 10.1074/jbc.271.29.16991; MIDURA RJ, 1990, J BIOL CHEM, V265, P15947; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; NAKAZAWA K, 1995, J BIOCHEM-TOKYO, V117, P707, DOI 10.1093/oxfordjournals.jbchem.a124767; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; QUANTOCK AJ, 1994, GLYCOSYLATION DIS, V1, P143; RAUCH U, 1991, J BIOL CHEM, V266, P1785; RUTER ER, 1984, J BIOL CHEM, V259, P1771; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCRANTON TW, 1993, J NEUROCHEM, V61, P29, DOI 10.1111/j.1471-4159.1993.tb03535.x; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; Snow AD, 1996, EXP NEUROL, V138, P305, DOI 10.1006/exnr.1996.0069; Tai GH, 1996, J BIOL CHEM, V271, P23535, DOI 10.1074/jbc.271.38.23535; WIGHT TN, 1993, CELL BIOL EXTRACELLU, P45; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	118	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32321	32328		10.1074/jbc.272.51.32321	http://dx.doi.org/10.1074/jbc.272.51.32321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405439	hybrid			2022-12-25	WOS:000071108000058
J	Kudlicki, W; Coffman, A; Kramer, G; Hardesty, B				Kudlicki, W; Coffman, A; Kramer, G; Hardesty, B			Renaturation of rhodanese by translational elongation factor (EF) Tu - Protein refolding by EF-Tu flexing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; ESCHERICHIA-COLI; FACTOR EF-1-ALPHA; KIRROMYCIN; RIBOSOMES; GTP; RNA	The translation elongation factor (EF) Tu has chaperone-like capacity to promote renaturation of denatured rhodanese. This renaturation activity is greatly increased under conditions in which the factor can oscillate between the open and closed conformations that are induced by GDP and GTP, respectively, Oscillation occurs during GTP hydrolysis and subsequent replacement of GDP by EF-Ts which is then displaced by GTP, Renaturation of rhodanese and GTP hydrolysis by EF-Tu are greatly enhanced by the guanine nucleotide exchange factor EF-Ts, However, renaturation is reduced under conditions that stabilize EF-Tu in either the open or closed conformation, Both GDP and the nonhydrolyzable analog of GTP, GMP-PCP, inhibit renaturation. Kirromycin and pulvomycin, antibiotics that specifically bind to EF-Tu and inhibit its activity in peptide elongation, also strongly inhibit EF-Tu-mediated renaturation of denatured rhodanese to levels near those observed for spontaneous, unassisted refolding, Kirromycin locks EF-Tu in the open conformation in the presence of either GTP or GDP, whereas pulvomycin locks the factor in the closed conformation, The results lead to the conclusion that flexing of EF-Tu, especially as occurs between its open and closed conformations, is a major factor in its chaperone-like refolding activity.	Univ Texas, Inst Mol Biol, Austin, TX 78712 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Hardesty, B (corresponding author), Univ Texas, Inst Mol Biol, Austin, TX 78712 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053152] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; BOCCHINI V, 1980, EUR J BIOCHEM, V113, P53; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; Gonen H, 1996, ADV EXP MED BIOL, V389, P209; HOROWITZ P, 1997, STRUCTURE FUNCTION M, P275; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; JARABAK R, 1993, J BIOCHEM TOXICOL, V8, P41, DOI 10.1002/jbt.2570080107; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; Kraal B, 1995, BIOCHEM CELL BIOL, V73, P1167, DOI 10.1139/o95-126; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; KUDLICKI W, 1994, J BIOL CHEM, V269, P16549; LEBERMAN R, 1980, ANAL BIOCHEM, V104, P29, DOI 10.1016/0003-2697(80)90272-9; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1994, J PROTEIN CHEM, V13, P15, DOI 10.1007/BF01891988; MESTERS JR, 1994, J MOL BIOL, V242, P644, DOI 10.1006/jmbi.1994.1614; NEIDHARDT F, 1996, ESCHERICHIA COLI SAL, P1562; PARMEGGIANI A, 1985, ANNU REV MICROBIOL, V39, P557, DOI 10.1146/annurev.mi.39.100185.003013; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1988, BIOCHIM BIOPHYS ACTA, V955, P19, DOI 10.1016/0167-4838(88)90175-6; WOLF H, 1978, P NATL ACAD SCI USA, V75, P5324, DOI 10.1073/pnas.75.11.5324; ZARDENETA G, 1992, EUR J BIOCHEM, V210, P831, DOI 10.1111/j.1432-1033.1992.tb17486.x	25	67	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32206	32210		10.1074/jbc.272.51.32206	http://dx.doi.org/10.1074/jbc.272.51.32206			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405422	hybrid			2022-12-25	WOS:000071108000041
J	Blackshear, PJ; Stumpo, DJ; Carballo, E; Lawrence, JC				Blackshear, PJ; Stumpo, DJ; Carballo, E; Lawrence, JC			Disruption of the gene encoding the mitogen-regulated translational modulator PHAS-I in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; MESSENGER-RNA; ORNITHINE DECARBOXYLASE; 3T3-L1 ADIPOCYTES; INITIATION FACTOR-4E; CELL-GROWTH; INSULIN; PHOSPHORYLATION; KINASE; EIF-4E	PHAS-I is the prototype of a group of eIF4E-binding proteins that can regulate mRNA translation in response to hormones and growth factors. To investigate the importance of PHAS-I in the physiology of the intact animal, we disrupted the PHAS-I gene in mice. Tissues and cells derived from the knockout mice contained no detectable PHAS-I protein. A related protein, PHAS-II, and eIF4E were readily detectable in tissues from these animals, but neither appeared to be changed in a compensatory manner. Mice lacking PHAS-I appeared normal at birth, However, male knockout mice weighed approximately 10% less than controls at all ages, whereas female weights were similar to those of controls. Both males and females were fertile. Tissues from adult animals appeared to be normal by routine histological staining techniques, as were routine blood cell counts and chemistries. Fibroblasts derived from PHAS-I-deficient mouse embryos exhibited normal rates of growth and overall protein synthesis, responded normally to serum stimulation of ornithine decarboxylase activity and cell growth, and rapamycin inhibition of cell growth. Under these experimental conditions, PHAS-I is apparently not required for the normal development and reproductive behavior of female mice, but is required for normal body weight in male mice; the mechanisms responsible for this phenotype remain to be determined.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DIV METAB ENDOCRINOL & NUTR, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, SECT DIABET & METAB, DURHAM, NC 27710 USA; UNIV VIRGINIA, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT MED, CHARLOTTESVILLE, VA 22908 USA	Duke University; Duke University; Duke University; Duke University; University of Virginia; University of Virginia			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NIDDK NIH HHS [DK 50628, DK 28302] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DENTON RM, 1981, DIABETOLOGIA, V21, P347; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HOVIS JG, 1986, J BIOL CHEM, V261, P380; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Lawrence John C. Jr.., 1997, V37, P239; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rousseau D, 1996, ONCOGENE, V13, P2415; SHATKIN AJ, 1987, BIOESSAYS, V7, P275, DOI 10.1002/bies.950070611; SMITH M R, 1990, New Biologist, V2, P648; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WARNER LM, 1994, ARTHRITIS RHEUM, V37, P289, DOI 10.1002/art.1780370219	32	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31510	31514		10.1074/jbc.272.50.31510	http://dx.doi.org/10.1074/jbc.272.50.31510			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395487	hybrid			2022-12-25	WOS:A1997YL41900046
J	DeMar, JC; Anderson, RE				DeMar, JC; Anderson, RE			Identification and quantitation of the fatty acids composing the CoA ester pool of bovine retina, heart, and liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-N-MYRISTOYLTRANSFERASE; ACYL-COENZYME-A; HUMAN MYRISTOYL-COA; PERFORMANCE LIQUID-CHROMATOGRAPHY; NH2-TERMINAL BLOCKING GROUP; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; ACYLATION; TISSUE; BRAIN	Several proteins found in retinal photoreceptor cells (guanylate cyclase activating protein, protein kinase A, recoverin, and transducin) are N-terminally modified with the fatty acids 12:0, 14:0, 14:1n-9, and 14:2n-6, whereas similar proteins in other tissues contain only 14:0. It has been hypothesized that the acyl-CoA pool of the retina contains amounts of 12:0, 14:1n-9, and 14:2n-6 elevated over 14:0, in comparison to other tissues, and this accounts for the specificity of N-terminal fatty acylation. To test this hypothesis, we performed fatty acid analysis on total acyl-CoAs purified from bovine retina (light-adapted), heart, and liver. We also examined the N- and S-linked fatty acid composition of the total protein pools from these tissues. Acyl-CoAs were prepared from heart, liver, and retina and separated by high performance Liquid chromatography (HPLC), Identities of peaks were based on HPLC of standard 12:0, 14:0, 14: 1n-9, and 14:2n-6 CoAs. Total protein was subjected to base hydrolysis followed by acidic methanolysis to release S- and N-linked fatty acids, respectively, and fatty acid phenacyl esters were prepared for HPLC analysis. Retina had levels of 12:0 (2.7 +/- 2.1%), 14:1n-9 (2.9 +/- 2.2%), and 14:2n-6 (1.6 +/- 0.7%) CoAs below that of 14:0 CoA (7.0 +/- 1.8%). Likewise, heart levels of 14:2n-6 CoA (3.7 +/- 0.1%) were near and 12:0 (2.6 +/- 0.6%) and 14:1n-9 (0.7 +/- 0.3%) CoAs were below that of 14:0 CoA (3.8 +/- 1.0%). Liver had levels of 12:0 (16.1 +/- 5.7%) and 14:2n-6 (8.1 +/- 1.2%) CoAs above and 14:1n-9 CoA (1.2 +/- 0.6%) below that of 14:0 CoA (5.9 +/- 0.8%). Fatty acid analysis of total protein showed that all tissues contained S-linked 16:0, 18:0, and 18:1n-9. Retina proteins contained N-linked 14:0, 14:1n-9, and 14:2n-6, whereas heart and liver had only 14:0. Our findings do not support the hypothesis that the CoA ester pool of the retina is enriched with 12:0, 14:1n-9, and 14:2n-6 over 14:0, in comparison to other tissues. This suggests that alternative models must be considered for the regulation of N-terminal fatty acylation of proteins in photoreceptor cells.	DEAN A MCGEE EYE INST, OKLAHOMA CITY, OK 73104 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; UNIV OKLAHOMA, HLTH SCI CTR, OKLAHOMA CTR NEUROSCI, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT OPHTHALMOL & BIOCHEM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MOL BIOL, OKLAHOMA CITY, OK 73104 USA	Baylor College of Medicine; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center					NEI NIH HHS [EY04149, EY07001, EY00871] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004149, R01EY000871] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERGER M, 1984, J BIOL CHEM, V259, P7245; Bhatnagar RS, 1997, BIOCHEMISTRY-US, V36, P6700, DOI 10.1021/bi970311v; BISHOP JE, 1980, ANAL BIOCHEM, V106, P344, DOI 10.1016/0003-2697(80)90531-X; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; CORKEY BE, 1981, ANAL BIOCHEM, V118, P30, DOI 10.1016/0003-2697(81)90152-4; DeMar JC, 1996, J BIOL CHEM, V271, P5007; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; Faergeman NJ, 1997, BIOCHEM J, V323, P1; GLOVER CJ, 1995, J BIOL CHEM, V270, P23226, DOI 10.1074/jbc.270.39.23226; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GORDON JI, 1990, CLIN RES, V38, P517; HAJRA AK, 1986, METHOD ENZYMOL, V122, P50; HALLAK H, 1994, J BIOL CHEM, V269, P4713; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KING MJ, 1994, MOL CELL BIOCHEM, V141, P79, DOI 10.1007/BF00926170; KING MJ, 1995, BIOCHEM BIOPH RES CO, V212, P580, DOI 10.1006/bbrc.1995.2009; KING MJ, 1993, BIOCHEM J, V291, P635, DOI 10.1042/bj2910635; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MCILHINNEY RAJ, 1995, BIOCHEM SOC T, V23, P549, DOI 10.1042/bst0230549; MCILHINNEY RAJ, 1993, BIOCHEM J, V290, P405, DOI 10.1042/bj2900405; McIlhinney RAJ, 1996, EXP CELL RES, V223, P348, DOI 10.1006/excr.1996.0090; MOLAPARASTSALESS F, 1988, LIPIDS, V23, P490, DOI 10.1007/BF02535525; MUSZBEK L, 1993, J BIOL CHEM, V268, P8251; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; OZOLS J, 1984, J BIOL CHEM, V259, P3349; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; POWELL GL, 1985, FED PROC, V44, P81; RAJALA RVS, 1995, BIOCHEM BIOPH RES CO, V208, P617, DOI 10.1006/bbrc.1995.1383; RAJU RVS, 1995, MOL CELL BIOCHEM, V149, P191, DOI 10.1007/BF01076577; RAJU RVS, 1994, J BIOL CHEM, V269, P12080; REDDY TS, 1984, CURR EYE RES, V3, P1225, DOI 10.3109/02713688409000826; REDDY TS, 1985, EXP EYE RES, V41, P87, DOI 10.1016/0014-4835(85)90097-1; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROSENDAL J, 1992, ANAL BIOCHEM, V207, P63, DOI 10.1016/0003-2697(92)90500-7; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1992, BIOCHEMISTRY-US, V89, P10507; SANADA K, 1995, J BIOL CHEM, V270, P15459, DOI 10.1074/jbc.270.26.15459; SCHLESINGER MJ, 1993, LIPID MODIFICATIONS, P2; SHRAGO E, 1995, PROSTAG LEUKOTR ESS, V52, P163, DOI 10.1016/0952-3278(95)90016-0; TARDI PG, 1992, LIPIDS, V27, P65, DOI 10.1007/BF02537062; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; WOOD R, 1983, J CHROMATOGR, V254, P237, DOI 10.1016/S0021-9673(01)88338-2	51	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31362	31368		10.1074/jbc.272.50.31362	http://dx.doi.org/10.1074/jbc.272.50.31362			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395466	hybrid			2022-12-25	WOS:A1997YL41900025
J	Durbin, DM; Jonas, A				Durbin, DM; Jonas, A			The effect of apolipoprotein A-II on the structure and function of apolipoprotein A-I in a homogeneous reconstituted high density lipoprotein particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; DISCOIDAL COMPLEXES; MICELLAR COMPLEXES; PHOSPHATIDYLCHOLINE; ACTIVATION; BINDING; HDL; ATHEROSCLEROSIS; KINETICS; CHOLATE	In this study we examined the effects of apoA-II on the structure and function of apoA-I in homogeneous reconstituted HDL (rHDL), First, we measured the binding of apoA-II to apoA-I-rHDL, containing dipalmitoylphosphatidylcholine or palmitoyloleoylphosphatidylcholine, and the degree of apoA-I displacement at various ratios of apolipoproteins. Using fluorescence methods, we determined that apoA-II binding is rapid, irreversible, and associated with apoA-I displacement only when the molar ratio of apoA-II/apoA-I is greater than 1:2, Next, we used the stable apoA-II/apoA-I-rHDL complex at the apoA-II/apoA-I ratio of 1:2 to examine its physical properties, apoA-I structure, and reactivity with lecithin: cholesterol acyltransferase (LCAT), Using chemical cross-linking in conjunction with fluorescence and electrophoretic methods, we demonstrated that the conformation of apoA-I must be flexible to allow apoA-II binding to the apoA-I-rHDL particles and showed that the hybrid particles have an unchanged Stokes diameter, Fluorescence and circular dichroism measurements revealed little or no change in the secondary structure or in the N-terminal domain of apoA-I, but showed a marked destabilization of apoA-I to denaturation by guanidine hydrochloride, Limited tryptic digestion indicated that the central region of apoA-I becomes accessible to proteolysis in the hybrid particles, Together, these results suggest that amphipathic alpha-helices of apoA-II replace four central helices of one apoA-I molecule (residues similar to 99-187) in the complex and in the process destabilize apoA-I, Thus, apoA-II binding at physiologic ratios may not completely displace apoA-I from HDL, but may provide a reservoir of easily exchangeable apoA-I, Finally, we showed that the reaction of the hybrid HDL with LCAT was inhibited 2-5-fold, relative to apoA-I-rHDL, due to a corresponding increase in the apparent K-m value. This suggests that LCAT binding to the hybrid particles is sterically hindered by the excess protein (portions of apoA-I and apoA-II not bound to lipid), Therefore, apoA-II can modulate the reaction of HDL with LCAT by decreasing LCAT binding to hybrid particles and making the enzyme available for reaction with other substrates.	UNIV ILLINOIS, COLL MED, DEPT BIOCHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign					NHLBI NIH HHS [HL 16059] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016059] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANCHE PJ, 1988, BIOCHIM BIOPHYS ACTA, V958, P143, DOI 10.1016/0005-2760(88)90171-3; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CHEN TC, 1979, BIOCHEMISTRY-US, V18, P1617, DOI 10.1021/bi00575a037; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; EDELSTEIN C, 1982, J BIOL CHEM, V257, P7189; FIELDING CJ, 1995, J LIPID RES, V36, P211; FORTE TM, 1995, J LIPID RES, V36, P148; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; JONAS A, 1985, J BIOL CHEM, V260, P2757; JONAS A, 1987, J BIOL CHEM, V262, P3969; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1984, J BIOL CHEM, V259, P6369; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Jonas A., 1992, STRUCTURE FUNCTION A, P217; Leren TP, 1997, J LIPID RES, V38, P121; LEROY A, 1993, J BIOL CHEM, V268, P4798; LEROY A, 1994, BIOCHIM BIOPHYS ACTA, V1213, P285; MAO SJT, 1977, BIOCHEMISTRY-US, V16, P4150, DOI 10.1021/bi00638a003; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASSEY JB, 1981, BIOCHEMISTRY-US, V20, P1569, DOI 10.1021/bi00509a025; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCVICAR JP, 1984, P NATL ACAD SCI-BIOL, V81, P1356, DOI 10.1073/pnas.81.5.1356; MINNICH A, 1992, J BIOL CHEM, V267, P16553; Mowri HO, 1996, ARTERIOSCL THROM VAS, V16, P755, DOI 10.1161/01.ATV.16.6.755; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; POWNALL HJ, 1986, METHOD ENZYMOL, V128, P515; POWNALL HJ, 1992, STRUCTURE FUNCTION A, P1; Pussinen PJ, 1997, J LIPID RES, V38, P12; RAY E, 1980, BIOCHIM BIOPHYS ACTA, V617, P318, DOI 10.1016/0005-2760(80)90174-5; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; VANTORNOUT P, 1981, BIOCHIM BIOPHYS ACTA, V663, P630, DOI 10.1016/0005-2760(81)90073-4; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; WEBER G, 1953, DISCUSS FARADAY SOC, P33; Weng W, 1996, P NATL ACAD SCI USA, V93, P14788, DOI 10.1073/pnas.93.25.14788; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134	41	57	65	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31333	31339		10.1074/jbc.272.50.31333	http://dx.doi.org/10.1074/jbc.272.50.31333			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395462	hybrid			2022-12-25	WOS:A1997YL41900021
J	Laufs, U; LaFata, V; Liao, JK				Laufs, U; LaFata, V; Liao, JK			Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY DISEASE; PULMONARY-HYPERTENSION; CHOLESTEROL REDUCTION; MEVALONATE PATHWAY; MESSENGER-RNA; EXPRESSION; DECREASES; BENEFITS; THERAPY; RATS	Hypoxia induces vasoconstriction, in part, by down-regulating endothelial cell nitric oxide synthase (ecNOS) expression, Previous studies indicate that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors improve endothelium-dependent relaxation by increasing ecNOS activity, To determine whether HMG CoA reductase inhibitors can prevent hypoxia-mediated down-regulation of ecNOS function and expression, human endothelial cells were exposed to hypoxia (3% O-2) in the presence of HMG CoA reductase inhibitors simvastatin and lovastatin for various durations (0-48 h). Hypoxia decreased ecNOS protein and mRNA levels in a time-dependent manner, resulting in a 4- and 9-fold reduction after 48 h, respectively, In a concentration-dependent manner, simvastatin, and to a lesser extent, lovastatin, prevented the down-regulation of ecNOS expression by hypoxia, Simvastatin-induced changes in ecNOS expression correlated with changes in endothelial NO production and were reversed by treatment with L-mevalonate, Actinomycin D studies revealed that under hypoxic conditions, simvastatin increased ecNOS mRNA half-life from 13 to 38 h. Nuclear run-on studies showed that simvastatin had no effect on repression of ecNOS gene transcription by hypoxia. These results indicate that HMG CoA reductase inhibitors regulate ecNOS function and expression through changes in ecNOS mRNA stability and suggest that treatment with HMG CoA reductase inhibitors may have beneficial effects in patients with hypoxia-mediated pulmonary hypertension.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; Andrews TC, 1997, CIRCULATION, V95, P324; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; FINEMAN JR, 1994, J CLIN INVEST, V93, P2675, DOI 10.1172/JCI117281; GERSON RJ, 1989, AM J MED, V87, pS28, DOI 10.1016/S0002-9343(89)80596-0; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOULD KL, 1994, CIRCULATION, V89, P1530, DOI 10.1161/01.CIR.89.4.1530; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOUYOUMDJIAN C, 1994, J CLIN INVEST, V94, P578, DOI 10.1172/JCI117372; LeCras TD, 1996, AM J PHYSIOL-LUNG C, V270, pL164, DOI 10.1152/ajplung.1996.270.1.L164; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; LUI J, 1996, BIOCHEMISTRY-US, V35, P13277; Massy ZA, 1996, LANCET, V347, P102, DOI 10.1016/S0140-6736(96)90217-2; MCQUILLAN LP, 1994, AM J PHYSIOL-HEART C, V267, pH1921; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; RASBAND W, 1993, NIH IMAGE PROGRAM VE; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; Scherrer U, 1996, NEW ENGL J MED, V334, P624, DOI 10.1056/NEJM199603073341003; Shaul PW, 1997, AM J PHYSIOL-LUNG C, V272, pL1005, DOI 10.1152/ajplung.1997.272.5.L1005; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; Takimoto M, 1996, ENDOCRINOLOGY, V137, P4542, DOI 10.1210/en.137.11.4542; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; vanVliet AK, 1996, BIOCHEM PHARMACOL, V52, P1387, DOI 10.1016/S0006-2952(96)00467-4; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; Ziesche R, 1996, P NATL ACAD SCI USA, V93, P12478, DOI 10.1073/pnas.93.22.12478	34	335	366	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31725	31729		10.1074/jbc.272.50.31725	http://dx.doi.org/10.1074/jbc.272.50.31725			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395516	hybrid			2022-12-25	WOS:A1997YL41900075
J	Palmieri, G; Giardina, P; Bianco, C; Scaloni, A; Capasso, A; Sannia, G				Palmieri, G; Giardina, P; Bianco, C; Scaloni, A; Capasso, A; Sannia, G			A novel white laccase from Pleurotus ostreatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN BIODEGRADATION; STRUCTURAL-ANALYSIS; GENE; OXIDASE; APPLICABILITY; DEGRADATION; CLEAVAGE; ENZYMES; CLONING; SYSTEM	Two laccase isoenzymes (POXA1 and POXA2) produced by Pleurotus ostreatus were purified and fully characterized, POXA1 and POXA2 are monomeric glycoproteins with 3 and 9% carbohydrate content, molecular masses of about 61 and 67 kDa by sodium dodecyl sulfate polyacrylamide gel electrophoresis, of about 54 and 59 kDa by gel filtration in native conditions, and of 61 kDa by matrix-assisted laser desorption ionization mass spectrometry (only for POXA1) and pI values of 6.7 and 4.0, respectively, The N terminus and three tryptic peptides of POXA1 have been sequenced, revealing clear homology with laccases from other microorganisms, whereas POXA2 showed a blocked N terminus, The stability of POXA2 as a function of temperature was particularly low, whereas POXA1 showed remarkable high stability with respect to both pH and temperature. Both enzymes oxidize syringaldazine and ABTS (2, 2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) together with a variety of different substituted phenols and aromatic amines with the concomitant reduction of oxygen, but POXA1 is unable to oxidize guaiacol, Both enzymes were strongly inhibited by sodium azide and thioglycolic acid but not by EDTA. UV/visible absorption spectra, atomic adsorption, and polarographic data indicated the presence of 4 copper atoms/mol of POXA2 but only one copper, two zinc, and one iron atoms were found/mol of POXA1. The neutral pI and the anomalous metal content of POXA1 laccase render this enzyme unique in its structural characteristics. The lack of typical absorbance at 600 nm allows its classification as a ''white'' laccase.	UNIV NAPLES,DIPARTIMENTO CHIM ORGAN & BIOL,I-80134 NAPLES,ITALY; IABBAM CONSIGLIO NAZL RIC,I-80147 NAPLES,ITALY; IBPE,I-80125 NAPLES,ITALY	University of Naples Federico II			Bianco, Carmelina/HHC-1591-2022; Giardina, Paola/F-4130-2011; Palmieri, Gianna/S-4872-2017; Palmieri, Gianna/AAW-6176-2020	Bianco, Carmelina/0000-0002-8489-3779; Giardina, Paola/0000-0002-5446-8130; Palmieri, Gianna/0000-0002-9007-4075; SANNIA, Giovanni/0000-0002-7986-6223; Scaloni, Andrea/0000-0001-9362-8515				BOURBONNAIS R, 1990, FEBS LETT, V267, P99, DOI 10.1016/0014-5793(90)80298-W; COHEN HJ, 1973, ANAL BIOCHEM, V53, P208, DOI 10.1016/0003-2697(73)90423-5; COLL PM, 1993, APPL ENVIRON MICROB, V59, P4129, DOI 10.1128/AEM.59.12.4129-4135.1993; Eggert C, 1996, APPL ENVIRON MICROB, V62, P1151, DOI 10.1128/AEM.62.4.1151-1158.1996; FLING M, 1963, J BIOL CHEM, V238, P2045; FUKUSHIMA Y, 1995, APPL ENVIRON MICROB, V61, P872, DOI 10.1128/AEM.61.3.872-876.1995; GIARDINA P, 1995, APPL ENVIRON MICROB, V61, P2408, DOI 10.1128/AEM.61.6.2408-2413.1995; Giardina P, 1996, EUR J BIOCHEM, V235, P508, DOI 10.1111/j.1432-1033.1996.00508.x; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HATAKKA A, 1994, FEMS MICROBIOL REV, V13, P125, DOI 10.1016/0168-6445(94)90076-0; JONSSON L, 1995, BBA-PROTEIN STRUCT M, V1251, P210, DOI 10.1016/0167-4838(95)00104-3; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KOJIMA Y, 1990, J BIOL CHEM, V265, P15224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARZULLO L, 1995, J BIOL CHEM, V270, P3823, DOI 10.1074/jbc.270.8.3823; PALMIERI G, 1993, APPL MICROBIOL BIOT, V39, P632, DOI 10.1007/BF00205066; PERRY CR, 1993, J GEN MICROBIOL, V139, P1209, DOI 10.1099/00221287-139-6-1209; REINHAMMAR B, 1981, METAL IONS BIOL COPP, V3, P109; SALAS C, 1995, BIOTECHNOL APPL BIOC, V21, P323; SALOHEIMO M, 1991, J GEN MICROBIOL, V137, P1537, DOI 10.1099/00221287-137-7-1537; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; THURSTON CF, 1994, MICROBIOL-SGM, V140, P19, DOI 10.1099/13500872-140-1-19; WOJTASWASILEWSKA M, 1983, ACTA BIOCHIM POL, V30, P291; YAROPOLOV AI, 1994, APPL BIOCHEM BIOTECH, V49, P257, DOI 10.1007/BF02783061	24	260	280	1	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31301	31307		10.1074/jbc.272.50.31301	http://dx.doi.org/10.1074/jbc.272.50.31301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395457	hybrid			2022-12-25	WOS:A1997YL41900016
J	Watson, DJ; Lander, AD; Selkoe, DJ				Watson, DJ; Lander, AD; Selkoe, DJ			Heparin-binding properties of the amyloidogenic peptides A beta and amylin - Dependence on aggregation state and inhibition by Congo red	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; ALZHEIMERS-DISEASE; SULFATE PROTEOGLYCAN; FIBRIL FORMATION; SENILE PLAQUES; CIRCULAR-DICHROISM; BASEMENT-MEMBRANE; PRECURSOR PROTEIN; DIABETES-MELLITUS; APOLIPOPROTEIN-E	Aggregation and deposition of the 40-42-residue amyloid beta-protein (A beta) are early and necessary neuropathological events in Alzheimer's disease. An understanding of the molecular interactions that trigger these events is important for therapeutic strategies aimed at blocking A beta plaque formation at the earliest stages. Heparan sulfate proteoglycans may play a fundamental role since they are invariably associated with A beta and other amyloid deposits at all stages. However, the nature of the A beta-heparan sulfate proteoglycan binding has been difficult to elucidate because of the strong tendency of A beta to self-aggregate. Affinity co-electrophoresis can measure the binding of proteoglycans or glycosaminoglycans to proteins without altering the physical state of the protein during the assay. We used affinity co-electrophoresis to study the interaction between A beta and the glycosaminoglycan heparin and found that the aggregation state of A beta governs its heparin-binding properties: heparin binds to fibrillar but not nonfibrillar A beta. The amyloid binding dye, Congo red, inhibited the interaction in a specific and dose-dependent manner. The ''Dutch'' mutant A beta(E22Q) peptide formed fibrils more readily than wild type A beta and it also attained a heparin-binding state more readily, but, once formed, mutant and wild type fibrils bound heparin with similar affinities. The heparin-binding ability of aggregated A beta(E22Q) was reversible with incubation in a solvent that promotes alpha-helical conformation, further suggesting that conformation of the peptide is important. Studies with another human amyloidogenic protein, amylin, suggested that its heparin-binding properties were also dependent on aggregation state. These results demonstrate the dependence of the A beta-heparin interaction on the conformation and aggregation state of A beta rather than primary sequence alone, and suggest methods of interfering with this association.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; UNIV CALIF IRVINE,DEPT DEV & CELL BIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92697	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California Irvine; University of California System; University of California Irvine	Watson, DJ (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,INST MED,CTR NEUROL DIS,77 AVE LOUIS PASTEUR 740,BOSTON,MA 02115, USA.		Lander, Arthur D/C-9008-2011; Lander, Arthur/L-2827-2019	Lander, Arthur D/0000-0002-4380-5525; Lander, Arthur/0000-0002-4380-5525	NIA NIH HHS [AG 06173, AG 12749] Funding Source: Medline; NINDS NIH HHS [NS 26862] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006173, R37AG006173, RF1AG006173, R01AG012749] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BUEE L, 1993, BRAIN RES, V627, P199, DOI 10.1016/0006-8993(93)90321-D; BUEE L, 1993, BRAIN RES, V601, P154, DOI 10.1016/0006-8993(93)91706-X; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; CORIA F, 1988, LAB INVEST, V58, P454; EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397; FABIAN H, 1993, BIOCHEM BIOPH RES CO, V191, P232, DOI 10.1006/bbrc.1993.1207; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; HERNDON ME, 1997, IN PRESS LAB GUIDE G; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Lander A D, 1994, Chem Biol, V1, P73, DOI 10.1016/1074-5521(94)90043-4; Lander AD, 1996, PERSPECT DEV NEUROBI, V3, P347; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LIM WA, 1991, METHOD ENZYMOL, V208, P196; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LUYENDIJK W, 1988, J NEUROL SCI, V85, P267, DOI 10.1016/0022-510X(88)90186-4; MANN DMA, 1989, NEUROPATH APPL NEURO, V15, P317, DOI 10.1111/j.1365-2990.1989.tb01232.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MERZ PA, 1983, ACTA NEUROPATHOL, V60, P113, DOI 10.1007/BF00685355; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NARANG HK, 1980, J NEUROPATH EXP NEUR, V39, P621, DOI 10.1097/00005072-198011000-00001; PIKE CJ, 1993, J NEUROSCI, V13, P1676; ROBER A, 1986, P NATL ACAD SCI USA, V83, P2662; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; SNOW AD, 1994, AM J PATHOL, V144, P337; SNOW AD, 1995, ARCH BIOCHEM BIOPHYS, V320, P84, DOI 10.1006/abbi.1995.1345; SNOW AD, 1990, AM J PATHOL, V137, P1253; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SNOW AD, 1988, AM J PATHOL, V133, P456; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; WISNIEWSKI T, 1993, ANN NEUROL, V34, P631, DOI 10.1002/ana.410340422; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; YAMAGUCHI H, 1992, AM J PATHOL, V141, P249; Yan G. M., 1996, Neurobiology of Aging, V17, pS109, DOI 10.1016/S0197-4580(96)80439-8; YOUNG ID, 1992, ARCH PATHOL LAB MED, V116, P951	52	123	127	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31617	31624		10.1074/jbc.272.50.31617	http://dx.doi.org/10.1074/jbc.272.50.31617			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395501	hybrid			2022-12-25	WOS:A1997YL41900060
J	Chang, XB; Hou, YX; Riordan, JR				Chang, XB; Hou, YX; Riordan, JR			ATPase activity of purified multidrug resistance-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; HUMAN P-GLYCOPROTEIN; CARCINOMA CELL-LINE; HAMSTER OVARY CELLS; HUMAN TUMOR-CELLS; LUNG-CANCER; LEUKOTRIENE C-4; MEMBRANE-VESICLES; DRUG-EFFLUX; MRP	Human multidrug resistance protein (MRP) was expressed at high levels in stably transfected baby hamster kidney (BHK-21) cells. These cells exhibited a pattern of cross-resistance to several different drugs typical of an MRP-mediated phenotype despite the addition of 10 histidine residues at the C terminus to facilitate purification, Consistent with this functional evidence of the presence of MRP at the surface of these transfectants, strong signals were detected by immunoblotting and immunofluorescence using a specific monoclonal antibody to MRP. There was intense uniform staining of the cell surface as well as weaker staining of intracellular membranes. MRP containing membranes were solubilized in 1% N-dodecyl-beta-D-maltoside in the presence of 0.4% sheep brain phospholipids. Two sequential affinity purification steps on Ni-NTA agarose and wheat germ agglutinin agarose provided substantial enrichment, and contaminating bands were not de detected. ATPase activity of the purified protein was assayed in the presence of the phospholipids, which had been maintained throughout all purification steps. ATP was hydrolyzed in proportion to the amount of purified protein assayed, and typical Michaelis-Menten behavior was exhibited, yielding estimations of K-m, of similar to 3.0 mM and V-max,,, of 0.46 mu mol mg(-1) min(-1). This activity was moderately stimulated by the drugs that others have shown to be transported by MRP-containing membrane vesicles. This stimulation was enhanced by reduced glutathione as is its drug transport, and oxidized glutathione, itself a substrate for transport, caused a strong stimulation. These data describe the first purification of MRP and provide the first direct evidence that the molecule possesses drug-stimulated ATPase activity.	Mayo Clin Arizona, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Chang, XB (corresponding author), Mayo Clin Arizona, SC Johnson Med Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.							ALMQUIST KC, 1995, CANCER RES, V55, P102; AMBUDKAR SV, 1995, J BIOENERG BIOMEMBR, V27, P23, DOI 10.1007/BF02110327; BREUNINGER LM, 1995, CANCER RES, V55, P5342; CHANG XB, 1993, J BIOL CHEM, V268, P11304; COLE SPC, 1989, BRIT J CANCER, V59, P42, DOI 10.1038/bjc.1989.9; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLE SPC, 1990, CANCER CHEMOTH PHARM, V26, P250, DOI 10.1007/BF02897225; EIJDEMS EWHM, 1995, BRIT J CANCER, V72, P298, DOI 10.1038/bjc.1995.328; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; GIBSON SL, 1995, PHOTOCHEM PHOTOBIOL, V61, P390, DOI 10.1111/j.1751-1097.1995.tb08628.x; GRANT CE, 1994, CANCER RES, V54, P357; Hollo Z, 1996, FEBS LETT, V383, P99, DOI 10.1016/0014-5793(96)00237-2; Jedlitschky G, 1996, CANCER RES, V56, P988; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; LAI SL, 1989, J NATL CANCER I, V81, P1144, DOI 10.1093/jnci/81.15.1144; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; MA LD, 1995, BIOCHEMISTRY-US, V34, P3338, DOI 10.1021/bi00010a024; MCGRATH T, 1987, BIOCHEM BIOPH RES CO, V145, P1171, DOI 10.1016/0006-291X(87)91560-9; MILROY R, 1992, ANTICANCER RES, V12, P193; MIRSKI SEL, 1987, CANCER RES, V47, P2594; Muller M, 1996, SEMIN LIVER DIS, V16, P211, DOI 10.1055/s-2007-1007233; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; Paul S, 1996, P NATL ACAD SCI USA, V93, P6929, DOI 10.1073/pnas.93.14.6929; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHLAIFER D, 1990, BRIT J CANCER, V62, P177, DOI 10.1038/bjc.1990.256; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Shen HX, 1996, BIOCHEMISTRY-US, V35, P5719, DOI 10.1021/bi960098n; Stride BD, 1996, MOL PHARMACOL, V49, P962; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zaman GJR, 1996, FEBS LETT, V391, P126, DOI 10.1016/0014-5793(96)00718-1; ZIJLSTRA JG, 1987, CANCER RES, V47, P1780	45	134	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30962	30968		10.1074/jbc.272.49.30962	http://dx.doi.org/10.1074/jbc.272.49.30962			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388243	hybrid			2022-12-25	WOS:000071640800056
J	Dufourny, B; Alblas, J; van Teeffelen, HAAM; van Schaik, FMA; van der Burg, B; Steenbergh, PH; Sussenbach, JS				Dufourny, B; Alblas, J; van Teeffelen, HAAM; van Schaik, FMA; van der Burg, B; Steenbergh, PH; Sussenbach, JS			Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; S6 KINASE; KERATINOCYTE DIFFERENTIATION; P21(WAF1/CIP1) EXPRESSION; CARCINOMA-CELLS; INTACT-CELLS; INHIBITION; RECEPTOR; PATHWAYS; STIMULATION	Addition of insulin-like growth factor I (IGF-I) to quiescent breast tumor-derived MCF-7 cells causes stimulation of cyclin D1 synthesis, hyperphosphorylation of the retinoblastoma protein pRb, DNA synthesis, and cell division. All of these effects are independent of the mitogen-activated protein kinase (MAPK) pathway since none of them is blocked by PD098059, the specific inhibitor of the MAPK activating kinase MEK1, This observation is consistent with the finding that the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), a strong inducer of MAPK activity in MCF-7 cells, effectively inhibits proliferation, The anti-proliferative effect of TPA in these cells may be accounted for, at least in part, by the MAPK-dependent stimulation of the synthesis of p21(WAF1/CIP1), inhibitor of cyclin/cyclin-dependent kinase complexes. In contrast, all of the observed stimulatory effects of IGF-I on cell cycle progression, cyclin D1 synthesis, and pRb hyperphosphorylation were blocked by the specific phosphatidylinositol 3-kinase inhibitor LY294002, suggesting that phosphatidylinositol 3-kinase activity but not MAPK activity is required for transduction of the mitogenic IGF-I signal in MCF-7 cells.	Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Utrecht Grad Sch Dev Biol, Utrecht, Netherlands	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University	Dufourny, B (corresponding author), Univ Utrecht, Physiol Chem Lab, POB 80043, NL-3508 TA Utrecht, Netherlands.			Alblas, Jacqueline/0000-0002-2996-9697				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBLAS J, 1997, IN PRESS ONCOGENE; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ARITA Y, 1994, INT J CANCER, V56, P229, DOI 10.1002/ijc.2910560215; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COPPOCK DL, 1995, EXP CELL RES, V221, P92, DOI 10.1006/excr.1995.1356; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dardevet D, 1996, ENDOCRINOLOGY, V137, P4087, DOI 10.1210/en.137.10.4087; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gorospe M, 1996, MOL CELL BIOL, V16, P762; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; HUFF KK, 1986, CANCER RES, V46, P4613; IZUMI T, 1987, J BIOL CHEM, V262, P1282; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JONES KT, 1994, J CELL PHYSIOL, V159, P324, DOI 10.1002/jcp.1041590215; KAREY KP, 1988, CANCER RES, V48, P4083; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KENNEDY MJ, 1992, CANCER RES, V52, P1278; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liu Y, 1996, CANCER RES, V56, P31; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MENAPACE L, 1987, BIOCHEM BIOPH RES CO, V148, P1295, DOI 10.1016/S0006-291X(87)80274-7; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OSAWA Y, 1995, BIOCHEM BIOPH RES CO, V216, P429, DOI 10.1006/bbrc.1995.2641; Parrizas M, 1997, J BIOL CHEM, V272, P154; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Takahashi Y, 1997, ENDOCRINOLOGY, V138, P741, DOI 10.1210/en.138.2.741; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VALETTE A, 1987, CANCER RES, V47, P1615; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WINKELSTEIN A, 1986, EXP HEMATOL, V14, P1023; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhou X, 1996, J CLIN INVEST, V98, P937, DOI 10.1172/JCI118877; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	59	231	245	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31163	31171		10.1074/jbc.272.49.31163	http://dx.doi.org/10.1074/jbc.272.49.31163			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388270	hybrid			2022-12-25	WOS:000071640800083
J	Suda, SA; Dolmer, K; Gettins, PGW				Suda, SA; Dolmer, K; Gettins, PGW			Critical role of asparagine 1065 of human alpha(2)-macroglobulin in formation and reactivity of the thiol ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COMPLEMENT COMPONENT-C4; THIOESTER BOND FORMATION; HUMAN ALPHA-2-MACROGLOBULIN; ALPHA-MACROGLOBULIN; INTERNAL THIOESTER; BINDING-PROPERTIES; MOLECULAR-CLONING; MESSENGER-RNA; CDNA; SEQUENCE	It has been shown that the relative reaction preference of the C4 thiol ester toward oxygen and nitrogen nucleophiles upon activation by proteinase depends on whether residue 1106 is aspartate or histidine (Dodds, A. W,, Ren, X. D., Willis, A. C., and Law, S, K, A. (1996) Nature 379, 177-179), To determine if the equivalent residue in the related thiol ester-containing protein human alpha(2)-macroglobulin (alpha(2)M), asparagine 1065, plays a similar role, we have expressed and characterized four alpha(2)M variants in which this asparagine has been replaced by aspartate, alanine, histidine, or lysine, The change from asparagine resulted in an altered ability to form the thiol ester. This ranged from failure to form the thiol ester (Asn --> Asp) to a maximum extent of formation of about 50% (Asn --> Ala), For the three variants that were able to form the thiol ester, the rates of thiol ester cleavage by a given amine were found to be different from one another and slower in nearly all cases than plasma alpha(2)M, but with the same relative reactivity of methylamine > ethylamine > ammonia, The rate of conformational change that follows cleavage of thiol esters in a functional half-molecule was also found to differ between the variants and to be slower than plasma alpha(2)M. TNS emission spectra indicated that the conformations of the transformed variants differed measurably from transformed plasma alpha(2)M. These findings suggest that residue 1065 plays a critical role in human alpha(2)M, for formation of the thiol ester, for its subsequent reaction with nucleophiles, and for the conformational change induced by this reaction, By analogy with C4, where this residue influences the nucleophile preference through direct interaction with the thiol ester, residue 1065 in alpha(2)M is expected to be located in or very close to the thiol ester region in alpha(2)M.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, MC 536,1819-1853 W Polk St, Chicago, IL 60612 USA.	pgettins@uic.edu	Dolmer, Klavs/G-5512-2012	Dolmer, Klavs/0000-0001-7359-360X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BELT KT, 1984, CELL, V36, P907; BJORK I, 1985, BIOCHEMISTRY-US, V24, P2653; BOEL E, 1990, BIOCHEMISTRY-US, V29, P4081, DOI 10.1021/bi00469a009; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dawson R. M. C., 1986, DATA BIOCH RES, P424; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DEVRIENDT K, 1991, BIOCHIM BIOPHYS ACTA, V1088, P95, DOI 10.1016/0167-4781(91)90157-H; Dodds AW, 1996, NATURE, V379, P177, DOI 10.1038/379177a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GETTINS PGW, 1994, FEBS LETT, V339, P276, DOI 10.1016/0014-5793(94)80430-3; GETTINS PGW, 1995, J BIOL CHEM, V270, P14160, DOI 10.1074/jbc.270.23.14160; Gron H, 1996, BIOCHEM J, V318, P539, DOI 10.1042/bj3180539; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; ISAAC L, 1992, J BIOL CHEM, V267, P10062; ISENMAN DE, 1984, J IMMUNOL, V132, P3019; Iwaki D, 1996, EUR J BIOCHEM, V242, P822, DOI 10.1111/j.1432-1033.1996.0822r.x; Iwasaki H, 1996, J BIOCHEM-TOKYO, V120, P1167, DOI 10.1093/oxfordjournals.jbchem.a021537; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON LJ, 1984, BIOCHEMISTRY-US, V23, P2802, DOI 10.1021/bi00307a041; LAW SKA, 1984, EMBO J, V3, P1819, DOI 10.1002/j.1460-2075.1984.tb02052.x; LAW SKA, 1984, BIOCHEMISTRY-US, V23, P3267, DOI 10.1021/bi00309a022; NIELSEN KL, 1994, ANN NY ACAD SCI, V737, P746; OVERBERGH L, 1991, J BIOL CHEM, V266, P16903; PANGBURN MK, 1992, FEBS LETT, V308, P280, DOI 10.1016/0014-5793(92)81293-U; PANGBURN MK, 1992, J BIOL CHEM, V267, P8584; SEPP A, 1993, PROTEIN SCI, V2, P706, DOI 10.1002/pro.5560020502; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1985, P NATL ACAD SCI USA, V82, P9, DOI 10.1073/pnas.82.1.9; STRICKLAND DK, 1984, BIOCHEMISTRY-US, V23, P3115, DOI 10.1021/bi00309a002; STRICKLAND DK, 1991, BIOCHEMISTRY-US, V30, P2797, DOI 10.1021/bi00225a009; VANLEUVEN F, 1992, EUR J BIOCHEM, V210, P319; WARMEGARD B, 1992, BIOCHEMISTRY-US, V31, P2346; WASSLER M, 1995, J BIOL CHEM, V270, P24598, DOI 10.1074/jbc.270.41.24598	38	9	9	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31107	31112		10.1074/jbc.272.49.31107	http://dx.doi.org/10.1074/jbc.272.49.31107			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388263	hybrid			2022-12-25	WOS:000071640800076
J	Kimmelman, A; Tolkacheva, T; Lorenzi, MV; Osada, M; Chan, AML				Kimmelman, A; Tolkacheva, T; Lorenzi, MV; Osada, M; Chan, AML			Identification and characterization of R-ras3: a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution	ONCOGENE			English	Article						Ras; TC21; R-ras; G-protein; transformation; MAPK	NUCLEOTIDE DISSOCIATION STIMULATOR; GTPASE-ACTIVATING PROTEIN; NIH 3T3 CELLS; R-RAS; ONCOGENIC RAS; MALIGNANT TRANSFORMATION; SIGNALING PATHWAY; K-RAS; H-RAS; KINASE	Members of the Ras subfamily of GTP-binding proteins, including Ras (H-, K-, and N-), TC21, and R-ras have been shown to display transforming activity, and activating lesions have been detected in human tumors. We have identified an additional member of the Ras gene family which shows significant sequence similarity to the human TC21 gene. This novel human ras-related gene, R-rad, encodes for a protein of 209 amino acids, and shows similar to 60-75% sequence identity in the N-terminal catalytic domain with members of the Ras subfamily of GTP-binding proteins. An activating mutation corresponding to the leucine 61 oncogenic lesion of the ras oncogenes when introduced into R-ras3, activates its transforming potential. R-ras3 weakly stimulates the mitogen-activated protein kinase (MAPK) activity, but this effect is greatly potentiated by the co-expression of c-raf-l. By the yeast two-hybrid system, R-rad interacts only weakly with known Ras effecters, such as Raf and RalGDS, but not with RglII. In addition, R-ras3 displays modest stimulatory effects on trans-activation from different nuclear response elements which bind transcription factors, such as SRF, ETS/TCF, Jun/Fos, and NF-kappa B/Rel. Interestingly, Northern blot analysis of total RNA isolated from various tissues revealed that the 3.8 kilobasepair (kb) transcript of R-rad is highly restricted to the brain and heart. The close evolutionary conservation between R-rad and Ras family members, in contrast to the significant differences in its biological activities and the pattern of tissue expression, raise the possibility that R-rad may control novel cellular functions previously not described for other GTP-binding proteins.	CUNY MT SINAI SCH MED,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464	NCI NIH HHS [CA66654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BOS JL, 1989, CANCER RES, V49, P4682; CHAN AML, 1994, P NATL ACAD SCI USA, V82, P2394; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GALANG CK, 1994, ONCOGENE, V9, P2913; GOLEMIS EA, 1997, GENE CLONING ANAL CU, V4, P11; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GOTOH T, 1997, BIOL CHEM, V272, P18602; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HATTORI S, 1992, ONCOGENE, V7, P481; HUANG Y, 1995, ONCOGENE, V11, P1255; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Li WQ, 1996, ONCOGENE, V13, P731; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAEZ R, 1994, ONCOGENE, V9, P2977; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	54	72	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2675	2685		10.1038/sj.onc.1201674	http://dx.doi.org/10.1038/sj.onc.1201674			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400994				2022-12-25	WOS:A1997YH46800005
J	Smilenov, LB; Morgan, SE; Mellado, W; Sawant, SG; Kastan, MB; Pandita, TK				Smilenov, LB; Morgan, SE; Mellado, W; Sawant, SG; Kastan, MB; Pandita, TK			Influence of ATM function on telomere metabolism	ONCOGENE			English	Article						telomeric associations; telomere length; telomerase activity; A-T; LZ; PI-3 kinase domain	CHROMOSOME END ASSOCIATIONS; ATAXIA-TELANGIECTASIA GENE; IMMORTAL CELLS; CANCER; LENGTH; SSCP	The ATM gene product, which is defective in the cancer-prone disorder ataxia telangiectasia, has been implicated in mitogenic signal transduction, chromosome condensation, meiotic recombination and cell cycle control. The ATM gene has homology with the TEL1 gene of yeast, mutations of which lead to shortened telomeres. To test the hypothesis that the ATM gene product is involved in telomere metabolism, we examined telomeric associations (TA), telomere length, and telomerase activity in human cells expressing either dominant-negative or complementing fragments of the ATM gene. The phenotype of RKO colorectal tumor cells expressing ATM fragments containing a leucine zipper (LZ) motif mimics that of ataxia telangiectasia (A-T) cells. These transfected RKO cells relative to transfected controls had a higher frequency of cells with TA and shortened telomeres, but no detectable change in telomerase activity. In addition, the percentage of cells with TA after gamma irradiation was higher in the transfected RKO cells with dominant negative activity of the ATM gene, compared to control cells. SV40 transformed fibroblasts derived from an A-T patient and transfected with a complementing carboxyl terminal kinase region of the ATM gene had a reduced frequency of cells with TA, with no effect on the telomere length or telomerase activity. The present studies using isogenic cells with manipulated ATM function demonstrate a role for the ATM gene product in telomere metabolism.	COLUMBIA UNIV, COLL PHYS & SURG, CTR RADIOL RES, NEW YORK, NY 10032 USA; JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21205 USA	Columbia University; Johns Hopkins University; Johns Hopkins Medicine			Pandita, Tej K/AAM-9188-2020		NATIONAL CANCER INSTITUTE [R01CA071387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [CA71387] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BRIDGES BA, 1982, CELLULAR MOL LINK CA; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; Cenci G, 1997, GENE DEV, V11, P863, DOI 10.1101/gad.11.7.863; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FANG G, 1995, TELOMERES, P69; Freyer GA, 1996, MUTAT RES-FUND MOL M, V357, P237, DOI 10.1016/0027-5107(96)00130-3; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRK KE, 1997, NATURE, V275, P1478; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; McClintock B, 1941, GENETICS, V26, P234; MEHLE C, 1994, CANCER RES, V54, P236; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Muller H.J., 1938, COLLECTING NET, V13, P181; OLOVNIKOV AM, 1992, IZV AN SSSR BIOL+, P641; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; PANDITA TK, 1993, 53 COLD SPRING HARB, P173; PATHAK S, 1988, CYTOGENET CELL GENET, V47, P227, DOI 10.1159/000132555; PRICE C M, 1992, Current Opinion in Cell Biology, V4, P379, DOI 10.1016/0955-0674(92)90002-T; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	47	80	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	1997	15	22					2659	2665		10.1038/sj.onc.1201449	http://dx.doi.org/10.1038/sj.onc.1201449			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400992				2022-12-25	WOS:A1997YH46800003
J	Coffer, PJ; vanPuijenbroek, A; Burgering, BMT; KlopdeJonge, M; Koenderman, L; Bos, JL; Kruijer, W				Coffer, PJ; vanPuijenbroek, A; Burgering, BMT; KlopdeJonge, M; Koenderman, L; Bos, JL; Kruijer, W			Insulin activates Stat3 independently of p21ras-ERK and PI-3K signal transduction	ONCOGENE			English	Article						insulin; STAT; Ras; ERK; PI-3K	EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; C-FOS EXPRESSION; PROTEIN-KINASE CASCADE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SERINE PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; CYTOKINE RECEPTORS	The binding of insulin to its receptor initiates multiple signal transduction pathways regulating such diverse processes as proliferation, differentiation, glucose transport, and glycogen metabolism, The STAT-family of transcription factors has been demonstrated to play a critical role in gene induction by a variety of hemopoietic cytokines and hormones, Furthermore, constitutive activation of STATs is observed in transformed cells, Here we describe activation of a transcriptional complex binding to a consensus STAT-transcriptional element in response to insulin challenge, This complex is induced rapidly after tyrosine autophosphorylation of the insulin receptor, and is sustained for several hours, Supershift analysis of the insulin-induced complex reveals that it specifically contains the transcription factor Stat3, DAN binding of this complex is inhibited by pre-incubation with tyrosine, but not serine/threonine protein kinase inhibitors, whereas transcriptional activation is inhibited by both, Utilising a dominant negative mutant of p21ras we demonstrate that both insulin-induced Stat3 DNA-binding and also transactivation do not require p21ras, Furthermore, although previous studies have suggested a role for MAP kinases (ERKs) and PI-3K in STAT activation, utilising the specific MEK inhibitor PD098059 and the PI-3K inhibitor wortmannin, we demonstrate that activation of ERKs or PI-3K are not required for insulin induced Stat3 phosphorylation or transactivation.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS; UNIV UTRECHT,PHYSIOL CHEM LAB,NL-3584 CG UTRECHT,NETHERLANDS; UNIV GRONINGEN,CTR BIOL,DEPT GENET,NL-9750 AA HAREN,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; University of Groningen	Coffer, PJ (corresponding author), UNIV UTRECHT HOSP,DEPT PULM DIS,G03-550,HEIDELBERGLAAN 100,NL-3584 CX UTRECHT,NETHERLANDS.		Coffer, Paul J/A-5769-2009; Koenderman, Leo/AAE-7870-2020; Coffer, Paul/AAF-7970-2020	Koenderman, Leo/0000-0002-5636-6453; 				ALLESSI DR, 1995, J BIOL CHEM, V270, P27489; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COFFER P, 1995, ONCOGENE, V10, P985; COFFER PJ, 1995, ONCOGENE, V11, P561; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; COFFER PJ, 1993, ONCOGENE, V9, P911; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DERIJARD B, 1994, CELL, V76, P727; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P221; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALANG CK, 1994, ONCOGENE, V9, P2913; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HEIDENREICH KA, 1993, J BIOL CHEM, V268, P14663; HILL CS, 1996, EMBO J, V15, P5037; HORN F, 1994, ANN NY ACAD SCI, V73, P308; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEE J, 1994, AM J PHYSIOL, V266, P319; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; OLSON AL, 1994, ENDOCRINOLOGY, V134, P271, DOI 10.1210/en.134.1.271; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1992, J CELL BIOCHEM, V48, P12, DOI 10.1002/jcb.240480104; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SETH A, 1992, J BIOL CHEM, V267, P24796; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, ONCOGENE, V13, P247; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WATLING D, 1993, NATURE, V366, P114; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	83	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2529	2539		10.1038/sj.onc.1201429	http://dx.doi.org/10.1038/sj.onc.1201429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399641				2022-12-25	WOS:A1997YG73200003
J	Barria, A; Derkach, V; Soderling, T				Barria, A; Derkach, V; Soderling, T			Identification of the Ca2+/calmodulin-dependent protein kinase II regulatory phosphorylation site in the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate-type glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CYCLIC-AMP; LTP; NEURONS; ACTIVATION; TRANSMISSION; HIPPOCAMPUS; MAINTENANCE; MODULATION; MECHANISM	Ca2+/CaM-dependent protein kinase II (CaM-KII) can phosphorylate and potentiate responses of alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate-type glutamate receptors in a number of systems, and recent studies implicate this mechanism in long term potentiation, a cellular model of learning and memory. In this study we have identified this CaM-KII regulatory site using deletion and site-specific mutants of glutamate receptor 1 (GluR1). Only mutations affecting Ser(831) altered the P-32 peptide maps of GluR1 from HEK-298 cells coexpressing an activated CaM-KII. Likewise, when CaM-KII was infused into cells expressing GluR1, the Ser(831) to Ala mutant failed to show potentiation of the GluR1 current. The Ser(831) site is specific to GluR1, and CaM-KII did not phosphorylate or potentiate current in cells expressing GluR2, emphasizing the importance of the GluR1 subunit in this regulatory mechanism. Because Ser(831) has previously been identified as a protein kinase C phosphorylation site (Roche, K. W., O'Brien, R. J., Mammen, A. L., Bernhardt, J., and Huganir, R. L. (1996) Neuron 16, 1179-1188), this raises the possibility of synergistic interactions between CaM-RII and protein kinase C in regulating synaptic plasticity.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Soderling, T (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L-474,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027037] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27037] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLACKSTONE C, 1994, J NEUROSCI, V14, P7585; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HOLLMANN M, 1997, IONOTROPIC GLUTAMATE, P39; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KOLAJ M, 1994, J NEUROPHYSIOL, V72, P2525, DOI 10.1152/jn.1994.72.5.2525; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MALINOW R, 1994, SCIENCE, V266, P1195, DOI 10.1126/science.7973700; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; NAKAZAWA K, 1995, NEURON, V15, P697, DOI 10.1016/0896-6273(95)90157-4; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; YAKEL JL, 1995, P NATL ACAD SCI USA, V92, P1376, DOI 10.1073/pnas.92.5.1376	32	273	282	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32727	32730		10.1074/jbc.272.52.32727	http://dx.doi.org/10.1074/jbc.272.52.32727			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407043	hybrid			2022-12-25	WOS:000071182900004
J	Fleming, IN; Elliott, CM; Collard, JG; Exton, JH				Fleming, IN; Elliott, CM; Collard, JG; Exton, JH			Lysophosphatidic acid induces threonine phosphorylation of Tiam1 in Swiss 3T3 fibroblasts via activation of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GDP DISSOCIATION INHIBITOR; ACTIN STRESS FIBERS; RAS TRANSFORMATION; REGULATORY PROTEIN; EXCHANGE PROTEIN; PHOSPHOLIPASE-D; CDC42 GTPASES; RHOB P20; INVASION	The Rho family of GTPases plays an important role in the control of cell shape, adhesion, movement, and growth. Several guanine nucleotide exchange factors have been identified that activate Rho family GTPases by promoting the binding of GTP to these proteins. However, little is known concerning the regulation of these GDP/GTP exchange factors. In this study, we demonstrate that lysophosphatidic acid (LPA) induces a rapid, sustainable phosphorylation of the Rac1-specific nucleotide exchange factor Tiam1 in Swiss 3T3 fibroblasts. LPA stimulated Tiam1 phosphorylation in a dose-dependent manner, and the protein was phosphorylated on threonine, but not tyrosine or serine, Tiam1 phosphorylation was also induced by platelet-derived growth factor, endothelin-1, bombesin, and bradykinin but not by epidermal growth factor. Significantly, pretreatment of Swiss 3T3 fibroblasts with 1 mu M phorbol 12-myristate 13-acetate for 24 h, or with the selective protein kinase C inhibitor Ro-31-8220, reduced LPA-stimulated phosphorylation of Tiam1 by approximately 75%. Moreover, acute stimulation with 100 nM phorbol 12-myristate 13-acetate was sufficient to induce Tiam1 phosphorylation in vivo, and protein kinase C could phosphorylate purified Tiam1 on threonine residues in vitro. These data indicate that agonist-induced phosphorylation of Tiam1 is a general mechanism and suggest that it is likely to be important in its regulation. Protein kinase C appears to play a key role in phosphorylation of Tiam1.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Netherlands Cancer Institute	Fleming, IN (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.			Fleming, Ian/0000-0001-9505-6418				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOWE LR, 1993, J BIOL CHEM, V268, P20717; ISOMURA M, 1991, ONCOGENE, V6, P119; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; THOMSON FJ, 1994, MOL PHARMACOL, V45, P718; UEDA T, 1990, J BIOL CHEM, V265, P9373; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	42	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33105	33110		10.1074/jbc.272.52.33105	http://dx.doi.org/10.1074/jbc.272.52.33105			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407095	hybrid			2022-12-25	WOS:000071182900056
J	Hobert, ME; Kil, SJ; Medof, ME; Carlin, CR				Hobert, ME; Kil, SJ; Medof, ME; Carlin, CR			The cytoplasmic juxtamembrane domain of the epidermal growth factor receptor contains a novel autonomous basolateral sorting determinant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; LIGAND-INDUCED INTERNALIZATION; CANINE KIDNEY-CELLS; DECAY-ACCELERATING FACTOR; EGF RECEPTOR; MDCK CELLS; TIGHT JUNCTION; A431 CELLS; PROTEIN; MEMBRANE	The epidermal growth factor receptor (EGFR) is localized at the basolateral membrane of most epithelial cells in vivo and in cell lines used to study membrane protein sorting. The goal of this study was to define the molecular basis of polar EGFR membrane expression using the Madin-Darby canine kidney cell model. We have identified a 23-amino acid segment located near the cytoplasmic face of the membrane spanning domain (residues Lys-652 to Ala-674) that is necessary and sufficient for targeting EGFRs from the trans-Golgi network directly to the basolateral plasma membrane. Furthermore, the sequence between residues Lys-652 and Ala-674 is sufficient to direct the extracellular domain of an apical membrane protein, decay accelerating factor, to the basolateral membrane. In the absence of this cytoplasmic basolateral sorting signal, information within the extracellular ligand binding domain is sufficient to target EGFRs from the trans-Golgi network directly to the apical plasma membrane. The EGFR basolateral sorting determinant does not have sequence and structural requirements common to most basolateral membrane proteins and does not overlap any of the known EGFR endocytic signals, This 23-residue sequence lies in a predicted amphipathic helical structure, leading us to postulate that hydrophobic and/or electrostatic interactions may be important for activity of this autonomous basolateral sorting determinant.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Cleveland, OH 44106 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Carlin, CR (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	cxc39@po.cwru.edu			NATIONAL CANCER INSTITUTE [R01CA049540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045669] Funding Source: NIH RePORTER; NCI NIH HHS [CA49540] Funding Source: Medline; NHLBI NIH HHS [T32-HL07717] Funding Source: Medline; NIDDK NIH HHS [DK45669] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CARLIN CR, 1984, J BIOL CHEM, V259, P7902; CARLIN CR, 1982, P NATL ACAD SCI-BIOL, V79, P5026, DOI 10.1073/pnas.79.16.5026; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CUMMINGS RD, 1985, J BIOL CHEM, V260, P1944; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; Grantham JJ, 1996, AM J KIDNEY DIS, V28, P788, DOI 10.1016/S0272-6386(96)90378-9; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; HOPKINS CR, 1991, CELL, V66, P827, DOI 10.1016/0092-8674(91)90427-Z; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MLETTINEN PJ, 1995, NATURE, V376, P337; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; MULLIN JM, 1988, CANCER RES, V48, P4886; ORELLANA SA, 1995, SEMIN NEPHROL, V15, P341; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schoenenberger C A, 1991, Trends Cell Biol, V1, P87, DOI 10.1016/0962-8924(91)90035-8; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Stanley KK, 1996, MOL MEMBR BIOL, V13, P19, DOI 10.3109/09687689609160570; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; Wilson P D, 1995, Curr Top Pathol, V88, P1; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	50	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32901	32909		10.1074/jbc.272.52.32901	http://dx.doi.org/10.1074/jbc.272.52.32901			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407068	hybrid			2022-12-25	WOS:000071182900029
J	Weber, JD; Hu, WM; Jefcoat, SC; Raben, DM; Baldassare, JJ				Weber, JD; Hu, WM; Jefcoat, SC; Raben, DM; Baldassare, JJ			Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G(1) progression through the independent regulation of cyclin D1 and p27(KIP1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G1 PHASE PROGRESSION; CELL-CYCLE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; INHIBITOR P27(KIP1); MAMMALIAN-CELLS; CDK INHIBITOR; FIBROBLASTS; ACTIVATION; PHOSPHORYLATION	Platelet-derived growth factor (PDGF)-induced Ras activation is required for G(1) progression in Chinese hamster embryo fibroblasts (IIC9 cells). Ras stimulates both extracellular signal-related kinase (ERK) activation and RhoA activation in response to PDGF stimulation. Inhibition of either of these Ras-stimulated pathways results in growth arrest. We have shown previously that has-stimulated ERK activation is essential for the induction and continued G(1) expression of cyclin D1. In this study we examine the role of Ras-induced RhoA activity in G(1) progression, Unstimulated IIC9 cells expressed high levels of the G(1) cyclin-dependent kinase inhibitor p27(KIP1). Stimulation with PDGF resulted in a dramatic decrease in p27(KIP1) protein expression. This decrease was attributed to increased p27(KIP1) protein degradation, Overexpression of dominant-negative forms of Ras or RhoA completely blocked PDGF-induced p27(KIP1) degradation, but only dominant-negative Ras inhibited cyclin D1 protein expression. C3 transferase also inhibited PDGF-induced p27(KIP1) degradation, thus further implicating RhoA in p27(KIP1) regulation, Overexpression of dominant-negative ERK resulted in inhibition of PDGF-induced cyclin D1 expression but had no effect on PDGF-induced p27(KIP1) degradation. These data suggest that Ras coordinates the independent regulation of cyclin D1 and p27(KIP1) expression by the respective activation of ERK and RhoA and that these pathways converge to determine the activation state of complexes of cyclin D1 and cyclin-dependent kinase in response to mitogen.	St Louis Univ, Hlth Sci Ctr, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; St Louis Univ, Hlth Sci Ctr, Dept Cell & Mol Biol, St Louis, MO 63104 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Saint Louis University; Saint Louis University; Johns Hopkins University	Baldassare, JJ (corresponding author), St Louis Univ, Hlth Sci Ctr, Dept Pharmacol & Physiol Sci, 1402 S Grand, St Louis, MO 63104 USA.			Weber, Jason/0000-0002-1069-6983	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM051593] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40901] Funding Source: Medline; NIGMS NIH HHS [GM51593] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GRANA X, 1995, ONCOGENE, V11, P211; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P397; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; LUKAS J, 1995, ONCOGENE, V10, P2125; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; NOBLES CD, 1995, CELL, V81, P1; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUI RG, 1995, P NATL ACAD SCI USA, V92, P11781; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P17320, DOI 10.1074/jbc.272.28.17320; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	42	173	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32966	32971		10.1074/jbc.272.52.32966	http://dx.doi.org/10.1074/jbc.272.52.32966			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407076	hybrid			2022-12-25	WOS:000071182900037
J	Ettinger, AJ; Feng, GP; Sanes, JR				Ettinger, AJ; Feng, GP; Sanes, JR			epsilon-Sarcoglycan, a broadly expressed homologue of the gene mutated in limb-girdle muscular dystrophy 2D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN COMPLEX; EXTRACELLULAR-MATRIX; GAMMA-SARCOGLYCAN; DELTA-SARCOGLYCAN; BETA-SARCOGLYCAN; MUSCLE; DYSTROGLYCAN; MUTATIONS; UTROPHIN; PROTEIN	The sarcoglycans are transmembrane components of the dystrophin-glycoprotein complex, which links the cytoskeleton to the extracellular matrix in adult muscle fibers. Mutations in all four known sarcoglycan genes (alpha, beta, gamma, and delta) have been found in humans with limb-girdle muscular dystrophy. We have identified a novel protein, epsilon-sarcoglycan, that shares 44% amino acid identity with alpha-sarcoglycan (adhalin). We show that epsilon-sarcoglycan is a membrane-associated glycoprotein and document its expression by Northern blotting, immunoblotting, and immunofluorescence. In contrast to alpha-delta sarcoglycans, which are expressed predominantly or exclusively in striated muscle, epsilon-sarcoglycan is broadly distributed in muscle and nonmuscle cells of both embryos and adults. These results raise the possibility that sarcoglycan-containing complexes mediate membrane-matrix interactions in many cell types.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave,Box 8108, St Louis, MO 63110 USA.		Feng, Guoping/Y-2827-2019					AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Carrie A, 1997, J MED GENET, V34, P470, DOI 10.1136/jmg.34.6.470; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DIXON AK, 1997, MOL BIOL, V270, P551; Duggan DJ, 1996, NEUROMUSCULAR DISORD, V6, P475, DOI 10.1016/S0960-8966(96)00388-4; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; Durbeej M, 1997, DEV BIOL, V181, P156, DOI 10.1006/dbio.1996.8430; Engel AG, 1994, MYOLOGY, pP1133; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; HIGUCHI I, 1994, J CLIN INVEST, V94, P601, DOI 10.1172/JCI117375; IBRAGHIMOV BO, 1992, NATURE, V355, P696; Jung D, 1996, FEBS LETT, V381, P15, DOI 10.1016/0014-5793(96)00056-7; Jung D, 1996, J BIOL CHEM, V271, P32321, DOI 10.1074/jbc.271.50.32321; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; Liu L, 1997, BIOCHEM BIOPH RES CO, V235, P227, DOI 10.1006/bbrc.1997.6757; Matsumura K, 1997, J BIOL CHEM, V272, P13904, DOI 10.1074/jbc.272.21.13904; MONTANARO F, 1995, J NEUROSCI RES, V42, P528, DOI 10.1002/jnr.490420411; Mora M, 1996, DEV BRAIN RES, V91, P70, DOI 10.1016/0165-3806(95)00169-7; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; Ohlendieck K, 1996, EUR J CELL BIOL, V69, P1; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOFIELD JN, 1995, DEV DYNAM, V204, P178, DOI 10.1002/aja.1002040208; SUNADA Y, 1995, CURR OPIN NEUROL, V8, P379, DOI 10.1097/00019052-199510000-00010; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TOME FMS, 1994, NEUROMUSCULAR DISORD, V4, P343, DOI 10.1016/0960-8966(94)90070-1; Vainzof M, 1996, HUM MOL GENET, V5, P1963, DOI 10.1093/hmg/5.12.1963; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; YAMADA H, 1995, LAB INVEST, V72, P715; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V225, P11, DOI 10.1006/bbrc.1996.1123	46	145	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32534	32538		10.1074/jbc.272.51.32534	http://dx.doi.org/10.1074/jbc.272.51.32534			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405466	hybrid			2022-12-25	WOS:000071108000085
J	Hammonds, TR; Maxwell, A				Hammonds, TR; Maxwell, A			The DNA dependence of the ATPase activity of human DNA topoisomerase II alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; CASEIN KINASE-II; GYRASE-B-PROTEIN; NUCLEOTIDE-SEQUENCE; NALIDIXIC-ACID; ENZYME; PHOSPHORYLATION; YEAST; MECHANISM; BINDING	We have purified human topoisomerase II alpha from HeLa cells and studied its ATPase reaction. The ATPase activity is stimulated by DNA and shows apparent Michaelis-Menten kinetics. Although the ATPase activity of human topoisomerase II alpha is lower than that of Saccharomyces cerevisiae, it is more active in decatenation, implying more efficient coupling of the ATPase to DNA strand passage under these conditions. Using plasmid pBR322 as the DNA cofactor, the reaction shows hyperstimulation by DNA at a base pair to enzyme dimer ratio of 100-200:1. When DNA fragments are used as the cofactor, the reaction requires >similar to 100 base pairs to stimulate the activity and fragments of similar to 300 base pairs show hyperstimulation. This behavior can be rationalized in terms of the enzyme requiring fragments that can bind to both the DNA gate and the ATP-operated clamp in order for the ATPase reaction to be stimulated. Hyperstimulation is a consequence of the saturation of DNA with enzyme. The mechanistic implications of these results are discussed.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Hammonds, TR (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.		Hammonds, Tim/GRF-5624-2022	Maxwell, Anthony/0000-0002-5756-6430				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; AUSTIN CA, 1995, J BIOL CHEM, V270, P15739, DOI 10.1074/jbc.270.26.15739; BATES AD, 1989, EMBO J, V8, P1861, DOI 10.1002/j.1460-2075.1989.tb03582.x; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARDENAS ME, 1993, J CELL SCI, V104, P219; Caron P R, 1994, Adv Pharmacol, V29B, P271; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHEN M, 1995, CANCER RES, V55, P1509; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; CULLIS PM, 1992, BIOCHEMISTRY-US, V31, P9642, DOI 10.1021/bi00155a017; DANG Q, 1994, J MOL BIOL, V243, P10, DOI 10.1006/jmbi.1994.1626; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; HUANG WM, 1990, DNA TOPOLOGY ITS BIO, P265; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Kimura K, 1996, J BIOL CHEM, V271, P10990, DOI 10.1074/jbc.271.18.10990; LEE MP, 1989, J BIOL CHEM, V264, P21779; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; ORPHANIDES G, 1994, NUCLEIC ACIDS RES, V22, P1567, DOI 10.1093/nar/22.9.1567; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TAMURA JK, 1992, J BIOL CHEM, V267, P9214; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WELLS NJ, 1995, J BIOL CHEM, V270, P28357; WESTERHOFF HV, 1988, CELL BIOPHYS, V12, P157, DOI 10.1007/BF02918357; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WIGLEY DB, 1995, ANNU REV BIOPH BIOM, V24, P185, DOI 10.1146/annurev.bb.24.060195.001153; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6	56	47	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32696	32703		10.1074/jbc.272.51.32696	http://dx.doi.org/10.1074/jbc.272.51.32696			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405488	hybrid			2022-12-25	WOS:000071108000107
J	Kamiguti, AS; Markland, FS; Zhou, Q; Laing, GD; Theakston, RDG; Zuzel, M				Kamiguti, AS; Markland, FS; Zhou, Q; Laing, GD; Theakston, RDG; Zuzel, M			Proteolytic cleavage of the beta(1) subunit of platelet alpha(2)beta(1), integrin by the metalloproteinase jararhagin compromises collagen-stimulated phosphorylation of pp72(syk)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; TYROSINE KINASE P72(SYK); BOTHROPS-JARARACA VENOM; SNAKE-VENOM; PHOSPHOLIPASE C-GAMMA-2; ANTIPLATELET PEPTIDE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; CELL-ADHESION; CROSS-LINKING	Early signaling events in the stimulation of platelets by collagen include the tyrosine phosphorylations of FcR gamma-chain, pp72(syk) and phospholipase C gamma 2. These events are dependent on the main platelet collagen receptor, alpha(2) beta(1) integrin (glycoprotein Ia-IIa complex), We recently found that jararhagin, a 52-kDa snake venom metalloproteinase, selectively inhibits collagen-induced platelet secretion and aggregation in parallel with the cleavage of the beta(1) subunit of the alpha(2) beta(1) integrin, The present study demonstrates that jararhagin also interferes with collagen-induced phosphorylation of the protein-tyrosine kinase pp72(syk). This effect is not observed when the platelet aggregation response to collagen is inhibited by two venom ROD-containing disintegrins, contortrostatin and echistatin, These disintegrins inhibit platelet aggregation through their high affinity binding to the platelet alpha(IIb)beta(3) integrin (glycoprotein IIb-IIIa complex), We also show that mild stimulation by ADP of jararhagin-treated platelets, but not of platelets treated with the RGD-containing disintegrins, restores the collagen-induced platelet aggregation, ADP also restored both pp72(syk) and pleckstrin phosphorylation of jararhagin-treated platelets in response to collagen, presumably via interaction of collagen with ADP-activated alpha(IIb)beta(3) integrin, Thus, ROD-containing disintegrins do not interfere with agonist-induced pp72(syk) phosphorylation but inhibit aggregation through occupancy of the alpha(IIb)beta(3) integrin. Conversely, jararhagin affects early platelet signaling events in response to collagen through its effects on the alpha(2) beta(1) integrin without interfering with the function of the alpha(IIb)beta(3) integrin, Our demonstration that the degradation of the beta(1) subunit of alpha(2) beta(1) by jararhagin results in the loss of pp72(syk) phosphorylation, suggests that this subunit is critically involved in collagen-induced platelet signaling.	Univ Liverpool, Royal Liverpool Hosp, Dept Haematol, Liverpool L69 3BX, Merseyside, England; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Liverpool, Liverpool Sch Trop Med, Alistair Reid Venom Res Unit, Liverpool L3 5QA, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Southern California; Liverpool School of Tropical Medicine; University of Liverpool	Kamiguti, AS (corresponding author), Univ Liverpool, Royal Liverpool Hosp, Dept Haematol, Prescot St, Liverpool L69 3BX, Merseyside, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAMS CS, 1995, J BIOL CHEM, V270, P23317, DOI 10.1074/jbc.270.40.23317; AIKEN ML, 1990, BLOOD, V76, P2501; ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Asazuma N, 1996, THROMB HAEMOSTASIS, V75, P648; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; CLARK EA, 1994, J BIOL CHEM, V269, P21940; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1989, BLOOD, V74, P182; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DECKMYN H, 1992, BLOOD, V79, P1466, DOI 10.1182/blood.V79.6.1466.bloodjournal7961466; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; FUJII C, 1994, EUR J BIOCHEM, V226, P243, DOI 10.1111/j.1432-1033.1994.tb20047.x; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HANDA M, 1995, THROMB HAEMOSTASIS, V73, P521; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUANG TF, 1992, ARCH BIOCHEM BIOPHYS, V298, P13, DOI 10.1016/0003-9861(92)90087-D; HUANG TF, 1987, J BIOL CHEM, V262, P16157; HUANG TF, 1991, THROMB HAEMOSTASIS, V66, P489; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ichinohe T, 1997, J BIOL CHEM, V272, P63; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; KAMIGUTI AS, 1991, TOXICON, V29, P1097, DOI 10.1016/0041-0101(91)90207-8; Kamiguti AS, 1997, BBA-GEN SUBJECTS, V1335, P209, DOI 10.1016/S0304-4165(96)00140-7; Kamiguti AS, 1996, BIOCHEM J, V320, P635, DOI 10.1042/bj3200635; KAMIGUTI AS, 1994, THROMB HAEMOSTASIS, V72, P244; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; KROLL MH, 1989, BLOOD, V74, P1181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEONG L, 1995, J CELL SCI, V108, P3817; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MARKLAND FS, 1991, THROMB HAEMOSTASIS, V65, P438; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NURDEN P, 1994, J LAB CLIN MED, V124, P579; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PHILLIPS DR, 1988, BLOOD, V71, P831; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Slupsky JR, 1997, EUR J BIOCHEM, V244, P168, DOI 10.1111/j.1432-1033.1997.00168.x; Slupsky JR, 1997, BRIT J HAEMATOL, V96, P275, DOI 10.1046/j.1365-2141.1997.d01-2011.x; SMYTH SS, 1993, BLOOD, V81, P2827; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKADA Y, 1989, J CELL BIOL, V111, P709; Tanaka T, 1996, FEBS LETT, V399, P53, DOI 10.1016/S0014-5793(96)01280-X; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TENG CM, 1991, THROMB HAEMOSTASIS, V65, P624; TIMMONS S, 1989, METHOD ENZYMOL, V169, P11; TRIKHA M, 1994, THROMB RES, V73, P39, DOI 10.1016/0049-3848(94)90052-3; USAMI Y, 1994, BIOCHEM BIOPH RES CO, V201, P331, DOI 10.1006/bbrc.1994.1706; YAMAMOTO N, 1992, BRIT J HAEMATOL, V81, P86, DOI 10.1111/j.1365-2141.1992.tb08177.x; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; Yang X, 1996, BLOOD, V88, P1676	64	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32599	32605		10.1074/jbc.272.51.32599	http://dx.doi.org/10.1074/jbc.272.51.32599			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405475	hybrid			2022-12-25	WOS:000071108000094
J	Khandekar, SS; Bettencourt, BM; Wyss, DF; Naylor, JW; Brauer, PP; Huestis, K; Dwyer, DS; Profy, AT; Osburne, MS; Banerji, J; Jones, B				Khandekar, SS; Bettencourt, BM; Wyss, DF; Naylor, JW; Brauer, PP; Huestis, K; Dwyer, DS; Profy, AT; Osburne, MS; Banerji, J; Jones, B			Conformational integrity and ligand binding properties of a single chain T-cell receptor expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	XVIIth International Conference on Magnetic Resonance in Biological Systems	AUG 18-23, 1996	KEYSTONE, COLORADO				SURFACE-PLASMON RESONANCE; CLASS-II MHC; PROTEIN SECONDARY STRUCTURE; NONOBESE DIABETIC MICE; V-ALPHA DOMAIN; ANTIGEN RECEPTOR; BETA-CHAIN; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; POSITIVE SELECTION	We recently showed that a soluble, heterodimeric murine D10 T-cell receptor (TCR) (V alpha 2C alpha, V beta 8.2C beta) expressed in insect cells binds both V beta 8.2-specific bacterial superantigen staphylococcal enterotoxin C2 (SECB) and a soluble, heterodimeric major histocompatibility complex class II I-A(k).conalbumin peptide complex with a low micromolar affinity, To define further the structural requirements for the TCR/ligand interactions, we have produced in Escherichia coli a soluble, functional D10 single chain (sc) TCR molecule in which the V alpha and V beta domains are connected by a flexible peptide linker, Purified and refolded D10 scTCR bound to SEC2 and murine major histocompatibility complex class II I-A(k).conalbumin peptide complex with thermodynamic and kinetic binding constants similar to those measured for the baculovirus-derived heterodimeric D10 TCR suggesting that neither the TCR constant domains nor potential N- or O-linked carbohydrate moieties are necessary for ligand recognition and for expression and proper folding of the D10 scTCR. Purified D10 scTCR remained soluble at concentrations up to 1 mM. Circular dichroism and NMR spectroscopy indicated that D10 scTCR is stabilized predominantly by beta-sheet secondary structure, consistent with its native-like conformation. Because of its limited size, high solubility, and structural integrity, purified D10 scTCR appears to be suitable for structural studies by multidimensional NMR spectroscopy.	Procept Inc, Cambridge, MA 02139 USA		Khandekar, SS (corresponding author), SmithKline Beecham Pharmaceut, UE 0435,709 Swedeland Rd, King Of Prussia, PA 19406 USA.							Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; AVERY AC, 1994, J IMMUNOL, V153, P4853; BALASUBRAMANIAN S, 1995, INT IMMUNOL, V7, P1839, DOI 10.1093/intimm/7.11.1839; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BREGEGERE F, 1994, PROTEIN ENG, V7, P271; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DECKHUT AM, 1994, J EXP MED, V180, P1931, DOI 10.1084/jem.180.5.1931; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Fremont DH, 1996, CURR OPIN IMMUNOL, V8, P93, DOI 10.1016/S0952-7915(96)80111-7; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GROSS KH, 1988, J MAGN RESON, V76, P87, DOI 10.1016/0022-2364(88)90203-X; GUAN C, 1988, GENE, V67, P21; Harlow E., 1988, ANTIBODIES LAB MANUA; HASKINS K, 1989, P NATL ACAD SCI USA, V86, P8000, DOI 10.1073/pnas.86.20.8000; HILYARD KL, 1994, P NATL ACAD SCI USA, V91, P9057, DOI 10.1073/pnas.91.19.9057; Hong SC, 1996, J EXP MED, V183, P1437, DOI 10.1084/jem.183.4.1437; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KANAGAWA O, 1989, J EXP MED, V170, P1513, DOI 10.1084/jem.170.5.1513; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Khandekar SS, 1997, MOL IMMUNOL, V34, P493, DOI 10.1016/S0161-5890(97)00044-8; KHANDEKAR SS, 1993, PROTEIN EXPRES PURIF, V4, P580, DOI 10.1006/prep.1993.1076; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KOZONO H, 1995, IMMUNITY, V3, P187, DOI 10.1016/1074-7613(95)90088-8; KURUCZ I, 1993, P NATL ACAD SCI USA, V90, P3830, DOI 10.1073/pnas.90.9.3830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE AN, 1994, METHOD ENZYMOL, V239, P596; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; MALMQVIST M, 1993, CURR OPIN IMMUNOL, V5, P282, DOI 10.1016/0952-7915(93)90019-O; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McKeever U, 1996, J EXP MED, V184, P1755, DOI 10.1084/jem.184.5.1755; MEUER SC, 1984, ANNU REV IMMUNOL, V2, P23, DOI 10.1146/annurev.immunol.2.1.23; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; O'Shannessy D J, 1994, Curr Opin Biotechnol, V5, P65, DOI 10.1016/S0958-1669(05)80072-2; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PAREKH RB, 1994, BIOLOGICALS, V22, P113, DOI 10.1006/biol.1994.1017; PENG JW, 1994, METHOD ENZYMOL, V239, P563; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; Plaksin D, 1996, J EXP MED, V184, P1251, DOI 10.1084/jem.184.4.1251; PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x; Sattler M, 1996, STRUCTURE, V4, P1245, DOI 10.1016/S0969-2126(96)00133-5; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SOOHOO WF, 1992, P NATL ACAD SCI USA, V89, P4759; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WOODLAND DL, 1993, IMMUNOL TODAY, V14, P208, DOI 10.1016/0167-5699(93)90164-G; WULFING C, 1994, J MOL BIOL, V242, P655, DOI 10.1006/jmbi.1994.1615; Wuthrich K, 1986, NMR PROTEINS NUCL AC	60	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32190	32197		10.1074/jbc.272.51.32190	http://dx.doi.org/10.1074/jbc.272.51.32190			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405420	hybrid			2022-12-25	WOS:000071108000039
J	Orlinick, JR; Elkon, KB; Chao, MV				Orlinick, JR; Elkon, KB; Chao, MV			Separate domains of the human Fas ligand dictate self-association and receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-MEDIATED CYTOTOXICITY; FACTOR-INDUCED APOPTOSIS; MUTATIONAL ANALYSIS; TNF RECEPTOR; FACTOR-ALPHA; LYMPHOPROLIFERATIVE DISEASE; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; T-LYMPHOCYTES	The Fas receptor rapidly induces apoptosis when activated by ligand binding or by cross-linking with anti-Fas antibody, The Fas ligand (Fast), a member of the tumor necrosis factor family of ligands, is a IO-kilodalton type II transmembrane protein which is cleaved to produce soluble ligand. Although the Fas-FasL interaction plays a critical role in peripheral T cell homeostasis and cytotoxic T lymphocyte-mediated target cell killing, the requirements for human Fast receptor binding and oligomerization have not been defined. Here we report two distinct domains of the ligand which are responsible for self-association and binding to the Fas receptor. A COOH-terminal sequence of the Fast was found to be required for binding and biological activity, as verified by deletion mutagenesis, use of the NOK-1 blocking antibody and the humanized gld Fast mutation, N-Linked glycosylation of the Fast was not required for biological activity. However, the Fast expression level was dependent upon the three N-linked glycosylation sites. Moreover, the ability of the Fast to self-associate was not dependent upon transmembrane or cytoplasmic sequences, but was localized to a 47-amino acid region in its extracellular domain, These results indicate that the FasL-Fas receptor complex depends upon independent motifs located within the extracellular domain of the Fast.	Cornell Univ Med Coll, Dept Anat & Cell Biol, New York, NY 10021 USA; Hosp Special Surg, New York, NY 10021 USA	Cornell University	Orlinick, JR (corresponding author), Cornell Univ Med Coll, Dept Anat & Cell Biol, New York, NY 10021 USA.			Chao, Moses/0000-0002-6969-3744	NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NCI NIH HHS [CA56490] Funding Source: Medline; NIAMS NIH HHS [P50AR-425888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOTHWELL ALM, 1982, NATURE, V298, P380, DOI 10.1038/298380a0; BROWNINGJ, 1989, J IMMUNOL, V147, P1230; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; ITOH N, 1993, J BIOL CHEM, V268, P10932; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lenardo MJ, 1996, J EXP MED, V183, P721, DOI 10.1084/jem.183.3.721; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PEITSCH MC, 1995, MOL IMMUNOL, V32, P761, DOI 10.1016/0161-5890(95)00016-8; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Suda T, 1996, J IMMUNOL, V157, P3918; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	52	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32221	32229		10.1074/jbc.272.51.32221	http://dx.doi.org/10.1074/jbc.272.51.32221			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405425	hybrid			2022-12-25	WOS:000071108000044
J	Papadopoulos, V; Amri, H; Li, H; Boujrad, N; Vidic, B; Garnier, M				Papadopoulos, V; Amri, H; Li, H; Boujrad, N; Vidic, B; Garnier, M			Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits steroidogenesis in the R2C Leydig tumor cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIAZEPAM-BINDING INHIBITOR; ACUTE REGULATORY PROTEIN; STEROID-HORMONE BIOSYNTHESIS; MITOCHONDRIAL PROTEINS; ADRENAL-CORTEX; CONSTITUTIVE STEROIDOGENESIS; HOMOLOGOUS RECOMBINATION; CHOLESTEROL; STIMULATION; INDUCTION	To evaluate the role of the mitochondrial peripheral-type benzodiazepine receptor (PER) in steroidogenesis, we developed a molecular approach based on the disruption of the PER gene, by homologous recombination, in the constitutive steroid producing R2C rat Leydig tumor cell line, Inactivation of one allele of the PER gene resulted in the suppression of PER mRNA and ligand binding expression, Immunoblot and electron microscopic immunogold labeling analyses confirmed the absence of the 18-kDa PER protein in the selected clone, Although mitochondria from the PER-negative cells contained high levels of the constitutively expressed 30-kDa steroidogenic activity regulator protein, these cells produced minimal amounts of steroids compared with normal cells (5%). Moreover, mitochondria from PER-negative cells failed to produce pregnenolone when supplied with exogenous cholesterol, Addition of the hydrosoluble cholesterol derivative, 22R-hydroxycholesterol, increased steroid production by the PBR-negative R2C cells, indicating that the cholesterol transport mechanism was impaired. Stable transfection of the PER-negative R2C Leydig cells with a vector containing the PER cDNA resulted in the recovery of the steroidogenic function of the cells. These data demonstrate that PER is an indispensable element of the steroidogenic machinery, where it mediates the delivery of the substrate cholesterol to the inner mitochondrial side chain cleavage cytochrome P-450.	Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Papadopoulos, V (corresponding author), Georgetown Univ, Med Ctr, Dept Cell Biol, 3900 Reservoir Rd, Washington, DC 20007 USA.	papadopv@gunet.georgetown.edu	BOUJRAD, Noureddine/L-1367-2015; Papadopoulos, Vassilios/AAI-2613-2019	Papadopoulos, Vassilios/0000-0002-1183-8568	NICHD NIH HHS [HD-01031] Funding Source: Medline; NIEHS NIH HHS [ES-07747] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007747] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACCILI D, 1991, P NATL ACAD SCI USA, V88, P4708, DOI 10.1073/pnas.88.11.4708; ALTUVIA S, 1993, J BIOL CHEM, V268, P27127; *AM TYP CULT COLL, 1992, ATCC CELL LIN HYBR; Amri H, 1996, ENDOCRINOLOGY, V137, P5707, DOI 10.1210/en.137.12.5707; AMSTERDAM A, 1991, ENDOCRINOLOGY, V129, P503, DOI 10.1210/endo-129-1-503; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BARNEA ER, 1989, MOL CELL ENDOCRINOL, V64, P155, DOI 10.1016/0303-7207(89)90141-X; BERNASSAU JM, 1993, J MOL GRAPHICS, V11, P236, DOI 10.1016/0263-7855(93)80003-A; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; BOUJRAD N, 1994, ENDOCRINOLOGY, V135, P1576, DOI 10.1210/en.135.4.1576; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CASALOTTI SO, 1992, GENE, V121, P377, DOI 10.1016/0378-1119(92)90147-H; CAVALLARO S, 1992, P NATL ACAD SCI USA, V89, P10598, DOI 10.1073/pnas.89.22.10598; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FREEMAN DA, 1987, ENDOCRINOLOGY, V120, P124, DOI 10.1210/endo-120-1-124; GARNIER M, 1994, J BIOL CHEM, V269, P22105; GARNIER M, 1994, MOL PHARMACOL, V45, P201; Hall P.F., 1988, P975; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; JOYNER AL, 1992, GENE TARGETING; KIMURA T, 1986, J STEROID BIOCHEM, V25, P711, DOI 10.1016/0022-4731(86)90299-2; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVER HA, 1981, J ENDOCRINOL, V91, P123, DOI 10.1677/joe.0.0910123; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAPADOPOULOS V, 1991, J BIOL CHEM, V266, P3682; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1481, DOI 10.1210/endo-129-3-1481; PAPADOPOULOS V, 1994, MOL CELL ENDOCRINOL, V104, pR5, DOI 10.1016/0303-7207(94)90061-2; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; PAPADOPOULOS V, 1996, LEYDIG CELL, P598; PON LA, 1986, J BIOL CHEM, V261, P6594; POTTS GO, 1978, STEROIDS, V32, P257, DOI 10.1016/0039-128X(78)90010-7; RITTA MN, 1989, NEUROENDOCRINOLOGY, V49, P262, DOI 10.1159/000125126; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SHIN SI, 1968, ENDOCRINOLOGY, V82, P614, DOI 10.1210/endo-82-3-614; SIMPSON ER, 1983, CAN J BIOCHEM CELL B, V61, P692, DOI 10.1139/o83-088; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1988, BIOCHEM J, V249, P95, DOI 10.1042/bj2490095; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; YANAGIBASHI K, 1989, J BIOCHEM, V106, P1026, DOI 10.1093/oxfordjournals.jbchem.a122958; YANAGIBASHI K, 1988, ENDOCRINOLOGY, V123, P2075, DOI 10.1210/endo-123-4-2075	52	193	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32129	32135		10.1074/jbc.272.51.32129	http://dx.doi.org/10.1074/jbc.272.51.32129			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405411	hybrid			2022-12-25	WOS:000071108000030
J	Wagenknecht, T; Radermacher, M; Grassucci, R; Berkowitz, J; Xin, HB; Fleischer, S				Wagenknecht, T; Radermacher, M; Grassucci, R; Berkowitz, J; Xin, HB; Fleischer, S			Locations of calmodulin and FK506-binding protein on the three-dimensional architecture of the skeletal muscle ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; FK506 BINDING-PROTEIN; WHEAT-GERM CALMODULIN; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL RECONSTRUCTION; CONFORMATIONAL-CHANGES; ELECTRON-MICROSCOPY; TERMINAL CISTERNAE	Isolated skeletal muscle ryanodine receptors (RyRs) complexed with the modulatory ligands, calmodulin (CaM) or 12-kDa FK506-binding protein (FKBP12), have been characterized by electron cryomicroscopy and three-dimensional reconstruction, RyRs are composed of 4 large subunits (molecular mass 565 kDa) that assemble to form a 4-fold symmetric complex that, architecturally, comprises two major substructures, a large (approximate to 80% of the total mass) cytoplasmic assembly and a smaller transmembrane assembly. Both CaM and FKBP12 bind to the cytoplasmic assembly at sites that are 10 and 12 nm, respectively, from the putative entrance to the transmembrane ion channel, FKBP12 binds along the edge of the square shaped cytoplasmic assembly near the face that interacts in vivo with the sarcolemma/transverse tubule membrane system, whereas CaM binds within a cleft that faces the junctional face of the sarcoplasmic reticulum membrane at the triad junction. Both ligands interact with a domain that connects directly to a cytoplasmic extension of the transmembrane assembly of the receptor, and thus might cause structural changes in the domain which in turn modulate channel gating.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Vanderbilt University	Wagenknecht, T (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32711] Funding Source: Medline; NIAMS NIH HHS [AR40615] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahern GP, 1997, BIOPHYS J, V72, P146, DOI 10.1016/S0006-3495(97)78654-5; Barg S, 1997, AM J PHYSIOL-CELL PH, V272, pC1726, DOI 10.1152/ajpcell.1997.272.5.C1726; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BURATTI R, 1995, BIOCHEM BIOPH RES CO, V213, P1082, DOI 10.1006/bbrc.1995.2238; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CHEN SRW, 1994, P NATL ACAD SCI USA, V91, P11953, DOI 10.1073/pnas.91.25.11953; CYRKLAFF M, 1990, J ELECTRON MICR TECH, V16, P351, DOI 10.1002/jemt.1060160407; FERGUSON DG, 1984, J CELL BIOL, V99, P1735, DOI 10.1083/jcb.99.5.1735; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1995, 3 DIMENSIONAL ELECT; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3288, DOI 10.1021/bi00127a034; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; Lamb GD, 1996, J PHYSIOL-LONDON, V494, P569, DOI 10.1113/jphysiol.1996.sp021514; Ma JJ, 1995, BIOPHYS J, V69, P2398, DOI 10.1016/S0006-3495(95)80109-8; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; ONDRIAS K, 1997, CIRCULATION, V92, P235; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; OTSU K, 1990, J BIOL CHEM, V265, P13472; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; RADERMACHER M, 1986, J MICROSC-OXFORD, V141, pRP1, DOI 10.1111/j.1365-2818.1986.tb02693.x; RADERMACHER M, 1992, BIOPHYS J, V61, P936, DOI 10.1016/S0006-3495(92)81900-8; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SAITO A, 1988, J CELL BIOL, V107, P211, DOI 10.1083/jcb.107.1.211; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; WAGENKNECHT T, 1994, BIOPHYS J, V67, P2286, DOI 10.1016/S0006-3495(94)80714-3; WAGENKNECHT T, 1995, FEBS LETT, V369, P43, DOI 10.1016/0014-5793(95)00581-S; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; WAGENKNECHT T, 1997, J STRUCT BIOL, V7, P258; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; YANO M, 1995, J BIOL CHEM, V270, P3017, DOI 10.1074/jbc.270.7.3017; YOSHIDA M, 1983, J BIOCHEM-TOKYO, V94, P1925, DOI 10.1093/oxfordjournals.jbchem.a134546; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	64	149	154	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32463	32471		10.1074/jbc.272.51.32463	http://dx.doi.org/10.1074/jbc.272.51.32463			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405457	hybrid			2022-12-25	WOS:000071108000076
J	Ji, ZS; Dichek, HL; Miranda, RD; Mahley, RW				Ji, ZS; Dichek, HL; Miranda, RD; Mahley, RW			Heparan sulfate proteoglycans participate in hepatic lipase- and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; REVERSE CHOLESTEROL TRANSPORT; SITE-DIRECTED MUTAGENESIS; ESTER TRANSFER PROTEIN; CELL-SURFACE; A-I; ALPHA-2-MACROGLOBULIN RECEPTOR; REMNANT LIPOPROTEINS; SELECTIVE UPTAKE; TRANSGENIC MICE	High density lipoprotein (HDL) particles and HDL cholesteryl esters are taken up by both receptor-mediated and non-receptor-mediated pathways. Here we show that cell surface heparan sulfate proteoglycans (HSPG) participate in hepatic lipase (HL)- and apolipoprotein (apo) E-mediated binding and uptake of mouse and human HDL by cultured hepatocytes. The HL secreted by HL-transfected McA-RH7777 cells enhanced both HDL binding at 4 degrees C (similar to 2-4-fold) and HDL uptake at 37 degrees C (similar to 2-5-fold). The enhanced binding and uptake of HDL were partially inhibited by the 39-kDa protein, an inhibitor of low density lipoprotein receptor-related protein (LRP), but were almost totally blocked by heparinase, which removes the sulfated glycosaminoglycan chains from HSPG. Therefore, HL may mediate the uptake of HDL by two pathways: an HSPG-dependent LRP pathway and an HSPG-dependent but LRP-independent pathway. The HL-mediated binding and uptake of HDL were only minimally reduced when catalytically inactive HL or LRP binding-defective HL was substituted for mild-type HL, indicating that much of the HDL uptake required neither HL binding to the LRP nor lipolytic processing. To study the role of HL in facilitating the selective uptake of cholesteryl esters, we used HDL into which radiolabeled cholesteryl ether had been incorporated. HL increased the selective uptake of HDL cholesteryl ether; this enhanced uptake was reduced by more than 80% by heparinase but was unaffected by the 39-kDa protein. Like HL, apoE enhanced the binding and uptake of HDL (similar to 2-fold) but had little effect on the selective uptake of HDL cholesteryl ether. In the presence of HL, apoE did not further increase the uptake of HDL, and at a high concentration apoE impaired or decreased the HL-mediated uptake of HDL. Therefore, HL and apoE may utilize similar (but not identical) binding sites to mediate HDL uptake. Although the relative importance of cell surface HSPG in the overall metabolism of HDL in vivo remains to be determined, cultured hepatocytes clearly displayed an HSPG-dependent pathway that mediates the binding and uptake of HDL. This study also demonstrates the importance of HL in enhancing the binding and uptake of remnant and low density lipoproteins via an HSPG-dependent pathway.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; AZHAR S, 1989, J LIPID RES, V30, P1799; BAMBERGER M, 1983, J LIPID RES, V24, P869; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BENGTSSON G, 1980, FEBS LETT, V119, P290, DOI 10.1016/0014-5793(80)80274-2; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; CISAR LA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P196, DOI 10.1016/0005-2760(89)90268-3; COLLET X, 1990, BIOCHIM BIOPHYS ACTA, V1043, P301, DOI 10.1016/0005-2760(90)90031-R; DAGGY BP, 1986, BIOCHIM BIOPHYS ACTA, V877, P252, DOI 10.1016/0005-2760(86)90302-4; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DECROM RPG, 1992, ARTERIOSCLER THROMB, V12, P325, DOI 10.1161/01.ATV.12.3.325; DIARD P, 1994, BIOCHEM J, V299, P889, DOI 10.1042/bj2990889; DICHEK HL, 1993, J LIPID RES, V34, P1393; DONG LM, 1994, J BIOL CHEM, V269, P22358; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ENERBACK S, 1987, GENE, V58, P1, DOI 10.1016/0378-1119(87)90023-0; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FIELDING CJ, 1995, J LIPID RES, V36, P211; GLASS C, 1985, J BIOL CHEM, V260, P744; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GROOT PHE, 1981, FEBS LETT, V129, P269, DOI 10.1016/0014-5793(81)80181-0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; JACKSON RL, 1983, ENZYMES, V16, P141; JANSEN H, 1981, BIOCHEM J, V196, P739, DOI 10.1042/bj1960739; JANSEN H, 1980, TRENDS BIOCHEM SCI, V5, P265, DOI 10.1016/0968-0004(80)90033-X; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; JONES AL, 1984, J LIPID RES, V25, P1151; KADOWAKI H, 1992, J LIPID RES, V33, P1689; KARLIN JB, 1987, J BIOL CHEM, V262, P12557; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; KOO C, 1985, J BIOL CHEM, V260, P1934; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; Krapp A, 1996, J LIPID RES, V37, P926; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKINNON AM, 1987, J LIPID RES, V28, P847; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MAHLEY RW, 1982, MED CLIN N AM, V66, P375, DOI 10.1016/S0025-7125(16)31426-2; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARQUESVIDAL P, 1994, J LIPID RES, V35, P373; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; OMALLEY JP, 1981, J LIPID RES, V22, P1214; OSWALD B, 1986, BIOCHEM BIOPH RES CO, V141, P158, DOI 10.1016/S0006-291X(86)80348-5; PITAS RE, 1980, J BIOL CHEM, V255, P5454; REAVEN E, 1995, J LIPID RES, V36, P1602; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; RIFICI VA, 1984, J BIOL CHEM, V259, P3814; RINNINGER F, 1990, BIOCHIM BIOPHYS ACTA, V1043, P318, DOI 10.1016/0005-2760(90)90033-T; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SEO T, 1995, CIRCULATION, V92, P3; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SPARKS DL, 1987, CLIN CHEM, V33, P390; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Steinberg D, 1996, SCIENCE, V271, P460, DOI 10.1126/science.271.5248.460; STROBEL JL, 1985, ARCH BIOCHEM BIOPHYS, V240, P635, DOI 10.1016/0003-9861(85)90071-2; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TALL AR, 1993, J LIPID RES, V34, P1255; VERHOEVEN AJM, 1994, BBA-LIPID LIPID MET, V1211, P121, DOI 10.1016/0005-2760(94)90146-5; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	93	130	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31285	31292		10.1074/jbc.272.50.31285	http://dx.doi.org/10.1074/jbc.272.50.31285			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395455	hybrid			2022-12-25	WOS:A1997YL41900014
J	Lupo, A; Costanzo, P; Medugno, L; Romeo, I; Salvatore, F; Izzo, P				Lupo, A; Costanzo, P; Medugno, L; Romeo, I; Salvatore, F; Izzo, P			Negative regulation of the mouse aldolase a gene - A cell cycle-dependent DNA binding activity functions as a silencer of gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; A GENE; MESSENGER-RNA; CONTROL ELEMENTS; PROMOTER; RAT; REPRESSION; IDENTIFICATION; SEQUENCES; MECHANISM	The expression of aldolase A L-type mRNA is increased in growth-arrested mouse NIH3T3 cells and remarkably down-regulated in actively proliferating cells. Treatment of proliferating cells with cycloheximide abolished the down-regulation of L-type mRNA expression, thus indicating that a protein factor acts as repressor in proliferating cells. Transient transfection experiments in NIH3T3 cells showed that a negative regulatory cis-element (NRE) is involved in the modulation of the transcriptional activity of the distal L promoter. The repressor, which is a protein of similar to 97 kDa, binds the murine aldolase A NRE, revealing a much more intense DNA-protein complex in proliferating NIH3T3 cells than in serum-deprived cells. Mutations in the negative regulatory cis-element showed that the GA-rich motif is required for protein binding and silencer function. We conclude that the expression of L-type mRNA is modulated by the interaction between a cell cycle-dependent DNA-binding protein and the murine aldolase A NRE.	UNIV NAPLES FEDERICO II, FAC MED & CHIRURG, DIPARTIMENTO BIOCHIM & BIOTECNOL MED, I-80131 NAPLES, ITALY; UNIV NAPLES FEDERICO II, CTR INGN GENET BIOTECNOL AVANZATE, I-80131 NAPLES, ITALY	University of Naples Federico II; University of Naples Federico II			Salvatore, Francesco/A-1966-2011	Salvatore, Francesco/0000-0002-2346-3564; Izzo, Paola/0000-0003-1549-0615; COSTANZO, Paola/0000-0002-0267-379X				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONCORDET JP, 1991, NUCLEIC ACIDS RES, V19, P4173, DOI 10.1093/nar/19.15.4173; COSTANZO P, 1993, BIOCHEM BIOPH RES CO, V195, P935, DOI 10.1006/bbrc.1993.2134; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hermfisse U, 1996, BIOCHEM BIOPH RES CO, V225, P997, DOI 10.1006/bbrc.1996.1284; IZZO P, 1989, FEBS LETT, V257, P75, DOI 10.1016/0014-5793(89)81790-9; IZZO P, 1988, EUR J BIOCHEM, V174, P569, DOI 10.1111/j.1432-1033.1988.tb14136.x; IZZO P, 1987, EUR J BIOCHEM, V164, P9, DOI 10.1111/j.1432-1033.1987.tb10984.x; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; LUPO A, 1994, EXP CELL RES, V213, P359, DOI 10.1006/excr.1994.1210; LUPO A, 1995, BIOCHEM BIOPH RES CO, V216, P69, DOI 10.1006/bbrc.1995.2593; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; MUKAI T, 1991, EUR J BIOCHEM, V195, P781, DOI 10.1111/j.1432-1033.1991.tb15766.x; MUKAI T, 1986, J BIOL CHEM, V261, P3347; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; SAKAKIBARA M, 1985, BIOCHEM BIOPH RES CO, V131, P413, DOI 10.1016/0006-291X(85)91818-2; SALMINEN M, 1994, MOL CELL BIOL, V14, P6797, DOI 10.1128/MCB.14.10.6797; Salvatore F, 1986, Horiz Biochem Biophys, V8, P611; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SIMKEVICH CP, 1992, BIOCHEM J, V286, P179, DOI 10.1042/bj2860179; STAUFFER JK, 1992, NUCLEIC ACIDS RES, V20, P327, DOI 10.1093/nar/20.2.327; STAUFFER JK, 1990, J BIOL CHEM, V265, P11773; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	33	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31641	31647		10.1074/jbc.272.50.31641	http://dx.doi.org/10.1074/jbc.272.50.31641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395505	hybrid			2022-12-25	WOS:A1997YL41900064
J	Persson, AL; Eriksson, M; Katterle, B; Potsch, S; Sahlin, M; Sjoberg, BM				Persson, AL; Eriksson, M; Katterle, B; Potsch, S; Sahlin, M; Sjoberg, BM			A new mechanism-based radical intermediate in a mutant R1 protein affecting the catalytically essential Glu(441) in Escherichia coli ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DIPHOSPHATE REDUCTASE; 2'-AZIDO-2'-DEOXYURIDINE 5'-DIPHOSPHATE; THIOREDOXIN REDUCTASE; PHENOTYPIC SELECTION; SUBUNIT INTERACTION; ELECTRON-TRANSFER; BOND-CLEAVAGE; IRON CENTER; INACTIVATION	The invariant active site residue Glu(441) in protein R1 of ribonucleotide reductase from Escherichia coli has been engineered to alanine, aspartic acid, and glutamic acid. Each mutant protein was structurally and enzymatically characterized, Glu(441) contributes to substrate binding, and a carboxylate side chain at position 441 is essential for catalysis. The most intriguing results are the suicidal mechanism-based reaction intermediates observed when R1 E441Q is incubated with protein R2 and natural substrates (CDP and GDP), In a consecutive reaction sequence, we observe at least three clearly discernible steps: (i) a rapid decay (k(1) greater than or equal to 1.2 s(-1)) of the catalytically essential tyrosyl radical of protein R2 concomitant with formation of an early transient radical intermediate species, (ii) a slower decay (k(2) = 0.03 s(-1)) of the early intermediate concomitant with formation of another intermediate with a triplet EPR signal, and (iii) decay (k(3) = 0.004 s(-1)) of the latter concomitant with formation of a characteristic substrate degradation product. The characteristics of the triplet EPR signal are compatible with a substrate radical intermediate (most likely localized at the S'-position of the ribose moiety of the substrate nucleotide) postulated to occur in the wild type reaction mechanism as well.	UNIV STOCKHOLM, DEPT MOL BIOL, S-10691 STOCKHOLM, SWEDEN; UNIV STOCKHOLM, DEPT BIOPHYS, S-10691 STOCKHOLM, SWEDEN; SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT MOL BIOL, S-75149 UPPSALA, SWEDEN	Stockholm University; Stockholm University; Swedish University of Agricultural Sciences				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; ATOR MA, 1986, J BIOL CHEM, V261, P3595; ATOR MA, 1985, BIOCHEMISTRY-US, V24, P7214, DOI 10.1021/bi00346a029; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Behravan G, 1995, BBA-GENE STRUCT EXPR, V1264, P323, DOI 10.1016/0167-4781(95)00168-9; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; Coves J, 1996, BIOCHEMISTRY-US, V35, P8595, DOI 10.1021/bi960355o; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; ERIKSSON S, 1977, J BIOL CHEM, V252, P6132; ERIKSSON S, 1975, EUR J BIOCHEM, V56, P289, DOI 10.1111/j.1432-1033.1975.tb02232.x; Fersht A., 1985, ENZYME STRUCTURE MEC; HARRIS G, 1984, BIOCHEMISTRY-US, V23, P5214, DOI 10.1021/bi00317a020; HELLWEGE KH, 1979, LANDOLTBORNSTEIN, V17; Himo F, 1997, BIOPHYS J, V72, P1556, DOI 10.1016/S0006-3495(97)78803-9; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LARSSON A, 1988, J BIOL CHEM, V263, P17780; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; Lenz R, 1997, J AM CHEM SOC, V119, P2784, DOI 10.1021/ja962974q; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; LUNN CA, 1984, J BIOL CHEM, V259, P469; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9744, DOI 10.1021/bi00155a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MORTON JR, 1964, CHEM REV, V64, P453, DOI 10.1021/cr60230a005; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; RUSSEL M, 1985, J BACTERIOL, V163, P238, DOI 10.1128/JB.163.1.238-242.1985; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SALOWE SP, 1987, BIOCHEMISTRY-US, V26, P3408, DOI 10.1021/bi00386a024; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; STUBBE JA, 1980, J BIOL CHEM, V255, P8027; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1976, J BIOL CHEM, V251, P1398; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Uhlin U, 1996, J MOL BIOL, V262, P358, DOI 10.1006/jmbi.1996.0519; UHLIN U, 1993, FEBS LETT, V336, P148, DOI 10.1016/0014-5793(93)81629-E; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003; vanderDonk WA, 1996, BIOCHEMISTRY-US, V35, P8381, DOI 10.1021/bi960190j	59	74	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31533	31541		10.1074/jbc.272.50.31533	http://dx.doi.org/10.1074/jbc.272.50.31533			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395490	hybrid			2022-12-25	WOS:A1997YL41900049
J	Cawthern, KM; Narayan, M; Chaudhuri, D; Permyakov, EA; Berliner, LJ				Cawthern, KM; Narayan, M; Chaudhuri, D; Permyakov, EA; Berliner, LJ			Interactions of alpha-lactalbumin with fatty acids and spin label analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; BETA-LACTOGLOBULIN; CALCIUM-BINDING; FLUORESCENCE; VESICLES; BOVINE; CONFORMATION; STATES	Bovine alpha-lactalbumin (alpha-LA) has been shown by intrinsic protein fluorescence and electron spin resonance methods to interact with the spin-labeled fatty acid analog, 5-doxylstearic acid, as well as stearic acid. An intrinsic fluorescence titration of various alpha-LA forms with 5-doxylstearic acid causes first an increase and then a decrease in emission intensity with concomitant shifts in tryptophan emission wavelength. In some cases, up to three steps in the fluorescence titration curves were visible, which were fit to apparent binding steps from 10(-6) to 10(-4) M. The binding parameters of 5-doxylstearic acid for apo- and Ca2+-alpha-LA were an order of magnitude different from one another; the stronger one, apo-alpha-lactalbumin, exhibited a K-d of 35 mu M. Electron spin resonance titrations of 5-doxylstearic acid-loaded apo-alpha-LA with stearate (micelles) seem to suggest separate binding loci if alpha-LA indeed binds stearate at these concentrations. The titration of alpha-LA by stearic acid results in a fluorescence emission red shift and an apparent stepped increase in fluorescence intensity. Lipid-protein association occurred at concentrations at which stearic acid micelles and aggregates begin to form in the absence of protein. Nonetheless, the relatively strong association between stearic acid and apo-alpha-LA was also confirmed by means of the fluorescent indicator acrylodated fatty acid binding protein, in which addition of alpha-LA to the stearate-loaded indicator protein reverses the decrease in fluorescence of the acrylodan chromophore conjugated to the protein.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA; Ohio State Univ, Biophys Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Berliner, LJ (corresponding author), Ohio State Univ, Dept Chem, 120 W 18Th Ave, Columbus, OH 43210 USA.	Berliner.2@osu.edu	Permyakov, Eugene A./M-8707-2014	Permyakov, Eugene A./0000-0002-9099-1148				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ACHARYA KR, 1991, J MOL BIOL, V221, P571; ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; BERLINER LJ, 1987, BIOCHEMISTRY-US, V26, P3006, DOI 10.1021/bi00385a008; Cawthern KM, 1996, PROTEIN SCI, V5, P1394, DOI 10.1002/pro.5560050718; FUGATE RD, 1980, BIOCHIM BIOPHYS ACTA, V625, P28, DOI 10.1016/0005-2795(80)90105-1; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; Grishchenko VM, 1996, BIOCHEM MOL BIOL INT, V38, P453; HANSSENS I, 1980, BIOCHIM BIOPHYS ACTA, V602, P539, DOI 10.1016/0005-2736(80)90333-8; HANSSENS I, 1985, BIOCHIM BIOPHYS ACTA, V817, P154, DOI 10.1016/0005-2736(85)90078-1; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; HIRAI Y, 1992, J PROTEIN CHEM, V11, P51, DOI 10.1007/BF01025092; HIRAOKA Y, 1980, BIOCHEM BIOPH RES CO, V95, P1098, DOI 10.1016/0006-291X(80)91585-5; KRONMAN MJ, 1964, BIOCHEMISTRY-US, V3, P1152, DOI 10.1021/bi00896a025; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LINDAHL L, 1984, ANAL BIOCHEM, V140, P394, DOI 10.1016/0003-2697(84)90184-2; MULQUEEN PM, 1982, ARCH BIOCHEM BIOPHYS, V215, P28, DOI 10.1016/0003-9861(82)90275-2; MURAKAMI K, 1982, BIOCHEMISTRY-US, V21, P5488, DOI 10.1021/bi00265a017; MURAKAMI K, 1983, BIOCHEMISTRY-US, V22, P3370, DOI 10.1021/bi00283a010; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P3852, DOI 10.1021/bi00336a006; NARAYAN M, 1997, BIOCHEMISTRY-US, V36, P190; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PERMYAKOV EA, 1988, GEN PHYSIOL BIOPHYS, V7, P95; PERMYAKOV EA, 1991, BIOPHYS CHEM, V39, P111, DOI 10.1016/0301-4622(91)85012-F; PERMYAKOV EA, 1991, J PROTEIN CHEM, V10, P577, DOI 10.1007/BF01025709; PERMYAKOV EA, 1985, BIOPHYS CHEM, V21, P21, DOI 10.1016/0301-4622(85)85003-1; PERMYAKOV EA, 1981, BIOCHEM BIOPH RES CO, V100, P191, DOI 10.1016/S0006-291X(81)80081-2; PUYOL P, 1991, AGR BIOL CHEM TOKYO, V55, P2515, DOI 10.1080/00021369.1991.10871001; REHFELD SJ, 1978, J LIPID RES, V19, P841; REICH JG, 1972, EUR J BIOCHEM, V26, P368, DOI 10.1111/j.1432-1033.1972.tb01776.x; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; SPECTOR AA, 1970, LIPIDS, V5, P403, DOI 10.1007/BF02532106; VOLWERK JJ, 1994, BIOCHEMISTRY-US, V33, P3464, DOI 10.1021/bi00178a002	33	52	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30812	30816		10.1074/jbc.272.49.30812	http://dx.doi.org/10.1074/jbc.272.49.30812			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388223	hybrid			2022-12-25	WOS:000071640800036
J	Currie, RA				Currie, RA			Functional interaction between the DNA binding subunit trimerization domain of NF-Y and the high mobility group protein HMG-I(Y)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II GENE-TRANSCRIPTION; IFN-BETA GENE; CCAAT-BINDING; VIRUS INDUCTION; DRA PROMOTER; FACTOR CBF; HMG I(Y); EXPRESSION; COMPLEX; ELEMENTS	The mammalian transcription factor, NF-Y(CBF), contains three known subunit components, NF-YA (CBF-B), NF-YB(CBF-A), and NF-YC(CBF-C), which are all required to reconstitute specific CCAAT box DNA binding activity. In this study, the high mobility group chromosomal protein, HMG-I(Y), has been shown to activate NF-Y in transient transfections in vivo using the natural murine alpha 2(I) collagen promoter and a multimerized version of the proximal NF-Y(CBF) CCAAT box element. In vitro analysis of the alpha 2(I) collagen promoter region inclusive of the NF-Y(CBF) binding site (-106 to -65 base pairs) failed to identify any high affinity HMG-I(Y) DNA-binding sites. However, the heterotrimeric NF-Y complex, as well as the NF-YA subunit alone, was shown to stably interact in vitro with both HMG-I(Y) and phosphorylated HMG-I, as modified by casein kinase II, using far Western and protein-protein interaction solution assays in the absence of CCAAT box DNA. Furthermore, the interaction between HMG-I(Y) and NF-Y was mapped to the highly conserved DNA binding-subunit interaction domain (DBD) of the NF-YA subunit and to a single AT-hook motif in HMG-I(Y). Recombinant HMG-I was also found to stabilize the CCAAT box DNA binding activity of recombinant NF-Y, as well as the native NF-Y complex, in vitro. Together, these results suggest a functional HMG-I(Y) protein binding site has been identified in the NF-Y complex and mapped to the conserved DBD and AT-hook regions of NF-YA and HMG-I(Y), respectively. This protein-protein interaction site may function to modulate NF-Y activity through stabilization of NF-Y binding to its CCAAT box DNA-binding site.	Picower Inst Med Res, Lab Gene Regulat, Manhasset, NY 11030 USA	Northwell Health	Currie, RA (corresponding author), Picower Inst Med Res, Lab Gene Regulat, 350 Community Dr, Manhasset, NY 11030 USA.	racurrie@picower.edu	Currie, Richard/N-6074-2017	Currie, Richard/0000-0002-6528-3326	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI037686] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37686] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDULKADIR SA, 1995, J EXP MED, V182, P487, DOI 10.1084/jem.182.2.487; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; CURRIE RA, 1992, ARCH BIOCHEM BIOPHYS, V298, P630, DOI 10.1016/0003-9861(92)90459-A; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; INOSTROZA JA, 1992, CELL, V70, P477; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LEGER H, 1995, MOL CELL BIOL, V15, P3738; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMIDT A, 1986, MOL CELL BIOL, V6, P347, DOI 10.1128/MCB.6.2.347; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1993, NUCLEIC ACIDS RES, V21, P6010, DOI 10.1093/nar/21.25.6010; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	45	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30880	30888		10.1074/jbc.272.49.30880	http://dx.doi.org/10.1074/jbc.272.49.30880			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388234	hybrid			2022-12-25	WOS:000071640800047
J	Lievremont, JP; Rizzuto, R; Hendershot, L; Meldolesi, J				Lievremont, JP; Rizzuto, R; Hendershot, L; Meldolesi, J			BiP, a major chaperone protein of the endoplasmic reticulum lumen, plays a direct and important role in the storage of the rapidly exchanging pool of Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; GLUCOSE-REGULATED PROTEIN; HAMSTER OVARY CELLS; DISULFIDE-ISOMERASE; CALRETICULIN INCREASES; MOLECULAR CHAPERONES; PC12 CELLS; CALCIUM; RAT; OVEREXPRESSION	The activity of BiP, the major chaperone of the endoplasmic reticulum (ER) lumen, is known to be Ca2+-regulated; however, the participation of this protein in the ER storage of the cation has not yet been investigated. Here such a role is demonstrated in human epithelial (HeLa) cells transiently transfected with the hamster BiP cDNA and incubated in Ca2+-free medium, as revealed by two different techniques. In the first, co-transfected aequorin was employed as a probe for assaying either the cytosolic of the mitochondrial free Ca2+ concentration. By this approach higher Ca2+ release responses were revealed in BiP-transfected cells by experiments in which extensive store depletion was induced either by repetitive stimulation with inositol 1,4,5-trisphosphate-generating agonists or by treatment with the Ca2+ ionophore, A23187. In the second technique the cells were loaded at the equilibrium with Ca-45, and the release of the tracer observed upon treatment with thapsigargin, a blocker of the ER Ca2+ ATPases, was larger in BiP-transfected than in control cells. The latter results were obtained also when BiP was overexpressed not via transfection but as a response to ER stress by tunicamycin, These results are sustained by increases of the ER Ca2+ storage capacity rather than by artifacts or indirect readjustments induced in the cells by the overexpression of the chaperone since (a) the exogenous and endogenous BiP were both confined to the ER, (b) the expression levels of other proteins active in the ER Ca2+ storage mere not changed, and (c) effects similar to those of wild type BiP were obtained with a deletion mutant devoid of chaperone activity. The specificity of the results was confirmed by parallel Ca-45 experiments carried out in HeLa cells transfected with two other Ca2+-binding proteins, calreticulin and CaBP2(ERp72), only the first of which induced increases of Ca2+ capacity. We conclude that BiP has a dual function, in addition to its chaperone role it is a bona fide ER lumenal Ca2+ storage protein contributing, under resting cell conditions, to around 25% of the store, with a stoichiometry of 1-2 moles of calcium/mole of BiP.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Mitochondrial Physiol, I-35121 Padua, Italy; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA; Univ Milan, CNR, Ctr Mol & Cellular Pharmacol, Dept Pharmacol, I-20132 Milan, Italy; Univ Milan, CNR, Ctr Mol & Cellular Pharmacol, C Ceccarelli Ctr Neurobiol, I-20132 Milan, Italy; Ist Sci San Raffaele, DIBIT, I-20132 Milan, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; St Jude Children's Research Hospital; Consiglio Nazionale delle Ricerche (CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Milan; Vita-Salute San Raffaele University	Meldolesi, J (corresponding author), Hosp San Raffaele, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.	meldolj@dibit.hsr.it	Rizzuto, Rosario/B-6312-2008; Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [652, 850] Funding Source: Medline	Telethon(Fondazione Telethon)		BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; Brewer J. W., 1997, MOL CHAPERONE PROTEI, P415; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GAUT JR, 1993, J BIOL CHEM, V268, P12691; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; LUCERO HA, 1994, J BIOL CHEM, V269, P23112; MACER DRJ, 1988, J CELL SCI, V91, P61; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PERRIN D, 1991, FEBS LETT, V294, P47, DOI 10.1016/0014-5793(91)81340-E; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RAICHMAN M, 1995, J CELL BIOL, V128, P341, DOI 10.1083/jcb.128.3.341; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; Rooney E, 1996, J BIOL CHEM, V271, P29304, DOI 10.1074/jbc.271.46.29304; RUPP K, 1994, J BIOL CHEM, V269, P2501; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; VAN PN, 1989, J BIOL CHEM, V264, P17494; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; VILLA A, 1992, NEUROSCIENCE, V49, P467, DOI 10.1016/0306-4522(92)90111-E; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WADA I, 1994, J BIOL CHEM, V269, P7464; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797	45	214	221	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30873	30879		10.1074/jbc.272.49.30873	http://dx.doi.org/10.1074/jbc.272.49.30873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388233	hybrid			2022-12-25	WOS:000071640800046
J	Pechatnikova, E; Taylor, EW				Pechatnikova, E; Taylor, EW			Kinetic mechanism of monomeric non-claret disjunctional protein (Ncd) ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR DOMAIN; CRYSTAL-STRUCTURE; KINESIN ATPASE; MICROTUBULE; MYOSIN	The non-claret disjunctional protein (Ncd) is a kinesin-related microtubule motor that moves toward the negative end of microtubules. The kinetic mechanism of the monomer motor domain, residues 335-700, satisfied a simple scheme for the binding of 2'-3'-O-(N-methylanthraniloyl) (MANT) ATP, the hydrolysis step, and the binding and release of MANT ADP, [GRAPHICS] where T, D, and P-i refer to nucleotide triphosphate, nucleotide diphosphate, and inorganic phosphate, respectively, and MtN is the complex of an Ncd motor domain with a microtubule site, Rate constants k(1) and k(-4) are the rates of a first order step, an isomerization induced by nucleotide binding, The apparent second order rate constants for the binding steps are 1.5 x 10(6) M-1 s(-1) for MANT ATP and 3.5 x 10(6) M-1 s(-1) for MANT ADP (conditions, 50 mM NaCl, pH 6.9, 21 degrees C), The rate constant of the hydrolysis step (k(2)) was obtained from quench flow measurements of the phosphate burst phase corrected for the contribution of the rate of product release to the transient rate constant, The rate of phosphate dissociation was not measured; the value was assigned to account for a steady state rate of 3 s(-1). The MtN complex is dissociated by ATP at a rate of 10 s(-1) based on light scattering measurements, Dissociation constants of Ncd-nucleotide complexes from microtubules increased in the order adenosine 5'-O-(thiotriphosphate) (ATP gamma S) < ADP-AlF4 < ATP < ADP < ADP-vanadate, Comparison of the properties of Ncd with a monomeric kinesin K332 (Ma and Taylor (1997) J. Biol. Chem, 272, 717-723) showed a close similarity, except that the rate constants for the hydrolysis and ADP re lease steps and the steady state rate are approximately 15-20 times smaller for Ncd, There are two differences that may affect the reaction pathway, The rate of dissociation of MtN by ATP is comparable to the rate of the hydrolysis step, and N . T may dissociate in the cycle, whereas for kinesin, dissociation occurs after hydrolysis, The rate of dissociation of MtN by ADP is larger than the rate of ADP release from MtN . D, whereas for the microtubule-kinesin complex, the rate of dissociation by ADP is smaller than the rate of ADP release, The monomeric Mt . Ncd complex is not processive.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Taylor, EW (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58th St, Chicago, IL 60637 USA.				NIGMS NIH HHS [GM 51858] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; MACDONALD HB, 1990, CELL, V63, P1159; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SADHU A, 1992, J BIOL CHEM, V267, P11352; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0	16	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30735	30740		10.1074/jbc.272.49.30735	http://dx.doi.org/10.1074/jbc.272.49.30735			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388211	hybrid			2022-12-25	WOS:000071640800024
J	Aoki, N; Ito, K; Ito, M				Aoki, N; Ito, K; Ito, M			Isolation and characterization of mouse high-glycine/tyrosine proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIR FOLLICLE DIFFERENTIATION; KERATIN-ASSOCIATED PROTEIN; GENE-EXPRESSION; SEQUENCE; RICH; GLYCINE; GROWTH; SKIN	During hair follicle differentiation, several families of keratin proteins are synthesized sequentially. In the present study, cDNA clones encoding six members of mouse high-glycine/tyrosine protein were isolated by screening a cDNA library prepared from the mouse skin of an anagen phase with a differential hybridization technique, On the basis of their nucleotide and deduced amino acid sequences, they were found to encode two members of high-glycine/tyrosine protein type I and four of type II, Interestingly, one of the four type II proteins had been encoded by two distinct cDNAs. Among the cDNA clones isolated were included the ones encoding a new member of type I and II protein, respectively, which possessed an entire open reading frame. Novel type II protein, termed type II.4, with a molecular mass of 15,130 Da was revealed to have significant direct repeats and a cysteine residue at the carboxyl terminus, which indicates that this protein has characteristics intermediate between high-glycine/tyrosine proteins and cysteine-rich proteins, In addition, the new member of type I protein has some features common with type II protein. We propose to term this protein type I alpha until it is further characterized Northern blot analysis demonstrated that gene expression of mouse high-glycine/tyrosine proteins followed the hair cycle growth fundamentally and reached its peak at day 9 in the first hair cycle, while two peaks of their expression were observed at day 33 and day 39 in the second cycle, Their transcripts were expressed in the cortical cells of hair follicles but not in the cells of the outer root sheath, inner root sheath, or medulla. Moreover, their gene expression commenced at different levels in cortical cells, The novel findings that each gene is activated transcriptionally with a distinct expression pattern spatially and temporally suggest that there is a remarkable difference in the distribution of these proteins in hair.			Aoki, N (corresponding author), NIIGATA UNIV, SCH MED, DEPT DERMATOL, ASAHIMACHI DORI, NIIGATA 951, JAPAN.							DOPHEIDE TA, 1973, EUR J BIOCHEM, V34, P120, DOI 10.1111/j.1432-1033.1973.tb02737.x; Emonet N, 1997, J DERMATOL SCI, V14, P1, DOI 10.1016/S0923-1811(96)00541-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRATINI A, 1993, J BIOL CHEM, V268, P4511; FRENKEL MJ, 1975, J CHROMATOGR, V111, P397, DOI 10.1016/S0021-9673(00)99289-6; FRENKEL MJ, 1973, EUR J BIOCHEM, V34, P112, DOI 10.1111/j.1432-1033.1973.tb02736.x; GILLESPIE JM, 1974, COMP BIOCHEM PHYSIOL, V47, P339, DOI 10.1016/0305-0491(74)90063-7; Gillespie JM, 1990, CELLULAR MOL BIOL IN, P95; GILLESPIE JM, 1983, BIOCH PHYSL SKIN, V2, P475; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUCZEK ES, 1987, EUR J BIOCHEM, V166, P79, DOI 10.1111/j.1432-1033.1987.tb13486.x; MARSHALL RC, 1976, AUST J BIOL SCI, V29, P1; MARSHALL RC, 1980, P 6 INT WOOL TEXT RE, V2, P147; MCNAB AR, 1989, J INVEST DERMATOL, V92, P263, DOI 10.1111/1523-1747.ep12276832; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; POWELL BC, 1991, ANN NY ACAD SCI, V642, P1; POWELL BC, 1990, EMBO J, V9, P1485, DOI 10.1002/j.1460-2075.1990.tb08266.x; POWELL BC, 1995, DIFFERENTIATION, V58, P227, DOI 10.1046/j.1432-0436.1995.5830227.x; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; Rogers G. E., 1989, BIOL WOOL HAIR, P69; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; WOOD L, 1990, J BIOL CHEM, V265, P21375	25	25	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30512	30518		10.1074/jbc.272.48.30512	http://dx.doi.org/10.1074/jbc.272.48.30512			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374545	hybrid			2022-12-25	WOS:A1997YH61300077
J	Sattler, M; Salgia, R; Shrikhande, G; Verma, S; Choi, JL; Rohrschneider, LR; Griffin, JD				Sattler, M; Salgia, R; Shrikhande, G; Verma, S; Choi, JL; Rohrschneider, LR; Griffin, JD			The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors	ONCOGENE			English	Article						BCR/ABL; SHIP; SHP-2; CBL	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; MULTIPLE CYTOKINES; RECEPTOR; ACTIVATION; BINDING; KINASE; SHC; PHOSPHORYLATION; P210(BCR/ABL); GRB2	We report here that interleukin-3 (IL-3) and erythropoietin (EPO) induce formation of a complex composed of two SH2-containing phosphatases, the tyrosine phosphatase SHP-2 and the SH2 containing inositol 5-phosphatase (SHIP), Both SHP-2 and SHIP are known to be involved in growth factor signal transduction, but their potential interaction in the same pathway is novel, SHIP has previously been shown to associate with SHC, and potentially to be involved in regulating apoptosis, In contrast, in some model systems, SHP-2 has been demonstrated to positively regulate cell growth, Both phosphatases in the complex were tyrosine phosphorylated, and the amount of SHIP coprecipitating with SHP-2 was inversely related to the amount of SHIP coprecipitating with SHC, In hematopoietic cells transformed by the BCR/ABL oncogene, this phosphatase complex was found to be constitutively present with both components heavily tyrosine phosphorylated, Also, other proteins were detected in the complex, including BCR/ABL itself and c-CBL, However, transformation by BCR/ABL was associated with a reduced SHIP protein expression, which could further affect the accumulation of various inositol polyphosphates in these leukemic cells, These data suggest that the function of SHIP and SHP-2 in normal cells are linked and that BCR/ABL alters the function of this signaling complex.	CHILDRENS HOSP,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,DPET ADULT ONCOL,BOSTON,MA 02115; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98125	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Center					NCI NIH HHS [CA01730] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BEDI A, 1994, BLOOD, V83, P2038; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P10998; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; Salgia R, 1996, EXP HEMATOL, V24, P310; Sattler M, 1996, ONCOGENE, V12, P839; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217	22	65	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2379	2384		10.1038/sj.onc.1201422	http://dx.doi.org/10.1038/sj.onc.1201422			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393882				2022-12-25	WOS:A1997YE15700012
J	Gutmann, DH; SaporitoIrwin, S; DeClue, JE; Wienecke, R; Guha, A				Gutmann, DH; SaporitoIrwin, S; DeClue, JE; Wienecke, R; Guha, A			Alterations in the rap1 signaling pathway are common in human gliomas	ONCOGENE			English	Article						astrocytomas; tumor suppressor gene; tuberous sclerosis complex 2; tuberin	CELL-LINES; GENE; AMPLIFICATION; TUMORS; PRODUCT; TUBERIN; CDK4; OVEREXPRESSION; NEUROBLASTOMA; EXPRESSION	Several inherited predisposition to cancer syndromes are associated with the development of nervous system tumors. Tuberous sclerosis complex (TSC) is an autosomal dominant disorder in which affected individuals are at risk for developing astrocytomas. One of the genes responsible for this disorder is TSC2, located on chromosome 16p, and encoding a 180 kDa protein (tuberin) that functions in part as a negative regulator of rap1. Previous studies from our laboratory demonstrated that 30% of sporadic astrocytomas have reduced or absent tuberin expression, In addition to loss of tuberin in sporadic astrocytomas, aberrant rap1 mediated signaling may also result from overexpression of rap1. In this study, we test the hypothesis that alterations in the rap1 signaling pathway are frequently observed in certain subsets of gliomas compared to other tumors of the nervous system. Analysis of sporadic astrocytomas and ependymomas demonstrated either increased rap1 or reduced/absent tuberin protein expression in 50-60% of different cohorts of these gliomas, compared to 30-33% of sporadic schwannomas and meningiomas and none of eight oligodendrocyte tumors. These results suggest that alterations in the rap1 signaling pathway are important in the development of certain sporadic human gliomas.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; UNIV TORONTO,MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV NEUROSURG,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,TORONTO HOSP,TORONTO,ON M5T 2S8,CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Gutmann, DH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,BOX 8111,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.			Gutmann, David/0000-0002-3127-5045				CHENG YT, 1995, MOL CARCINOGEN, V13, P173, DOI 10.1002/mc.2940130307; Geist RT, 1996, NEUROBIOL DIS, V3, P111, DOI 10.1006/nbdi.1996.0011; Gutmann DH, 1996, ONCOGENE, V12, P2121; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HEWETT SJ, 1995, NEUROREPORT, V6, P1505; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; KHATIB ZA, 1993, CANCER RES, V53, P5535; KRAUS J, 1996, J NEUROPATH EXPER NE, V54, P91; LOUIS DN, 1995, TRENDS GENET, V11, P111; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; OLSON JJ, 1995, NEUROSURGERY, V36, P740, DOI 10.1227/00006123-199504000-00015; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; ROY NV, 1995, CANC GENET CYTOGENET, V82, P151; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; Wienecke R, 1996, ONCOGENE, V13, P913; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WIENECKE R, 1997, IN PRESS ANN NEUROLO; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	22	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1611	1616		10.1038/sj.onc.1201314	http://dx.doi.org/10.1038/sj.onc.1201314			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380414				2022-12-25	WOS:A1997XX36900013
J	Hirsch, T; Marchetti, P; Susin, SA; Dallaporta, B; Zamzami, N; Marzo, I; Geuskens, M; Kroemer, G				Hirsch, T; Marchetti, P; Susin, SA; Dallaporta, B; Zamzami, N; Marzo, I; Geuskens, M; Kroemer, G			The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death	ONCOGENE			English	Article						mitochondrial transmembrane potential; permeability transition; programmed cell death; proteases	CULTURED-HEPATOCYTES; CYCLOSPORINE-A; ICE INHIBITORS; BCL-2; INDUCTION; 1-METHYL-4-PHENYLPYRIDINIUM; IDENTIFICATION; DEPOLARIZATION; PROTECTION; GENERATION	Mitochondrial alterations including permeability transition (PT) constitute critical events of the apoptotic cascade and are under the control of Bcl-2 related gene products, Here we show that induction of PT is sufficient to activate CPP32-like proteases with DEVDase activity and the associated cleavage of the nuclear DEVDase substrate poly(ADP-ribose) polymerase (PARP). Thus, direct intervention on mitochondria using a ligand of the mitochondrial benzodiazepin receptor or a protonophore causes DEVDase activation. In addition, the DEVDase activation triggered by conventional apoptosis inducers (glucocorticoids or topoisomerase inhibitors) is prevented by inhibitors of PT. The protease inhibitor N-benzyloxycabonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD.fmk) completely prevents the activation of DEVDase and PARP cleavage, as well as the manifestation of nuclear apoptosis (chromatin condensation, DNA fragmentation, hypoploidy). In addition, Z-VAD.fmk delays the manifestation of apoptosis-associated changes in cellular redox potentials (hypergeneration of superoxide anion, oxidation of compounds of the inner mitochondrial membrane, depletion of non-oxidized glutathione), as well as the exposure of phosphatidylserine residues in the outer plasma membrane leaflet. Although Z-VAD.fmk retards cytolysis, it is incapable of preventing disruption of the plasma membrane during protracted cell culture (12-24 h), even in conditions in which it completely blocks nuclear apoptosis (chromatin condensation and DNA fragmentation). Electron microscopic analysis confirms that cells treated with PT inducers alone undergo apoptosis, whereas cells kept in identical conditions in the presence of Z-VAD.fmk die from necrosis. These observations are compatible with the hypothesis that PT would be a rate limiting step in both the apoptotic and the necrotic modes of cell death. In contrast, it would be the availability of apoptogenic proteases that would determine the choice between the two death modalities.	CNRS,UNITE PROPRE RECH 420,F-94801 VILLEJUIF,FRANCE; FREE UNIV BRUSSELS,DEPT MOL BIOL,B-1640 RHODE ST GENESE,BELGIUM	Centre National de la Recherche Scientifique (CNRS)			Susin, Santos A/Q-6754-2017; Kroemer, Guido/AAY-9859-2020; Marzo, Isabel/E-6918-2016; KROEMER, Guido/B-4263-2013	Susin, Santos A/0000-0002-3366-1628; Marzo, Isabel/0000-0002-2315-9079; KROEMER, Guido/0000-0002-9334-4405; MARCHETTI, Philippe/0000-0002-4663-6800				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ARORA AS, 1977, HEPATOLOGY, V25, P958; BERNARDI P, 1996, J BIOENERG BIOMEMBR, V28, P129; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fiskum G., 1996, Molecular Biology of the Cell, V7, p33A; ITOH G, 1995, AM J PATHOL, V146, P1325; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KROEMER G, 1995, ADV IMMUNOL, V58, P211, DOI 10.1016/S0065-2776(08)60621-5; Kroemer Guido, 1997, P1111; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marchetti P., 1996, APOPTOSIS, V1, P119; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOTERA P, 1997, IN PRESS CELL DEATH; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; NIEMINEN AL, 1997, AM J PHYSIOL-CELL PH, V41, pC1286; OSBORNE BA, 1994, IMMUNOL REV, V142, P301, DOI 10.1111/j.1600-065X.1994.tb00894.x; Packer MA, 1996, BIOCHEM PHARMACOL, V51, P267, DOI 10.1016/0006-2952(95)02165-5; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sasaki H, 1996, TRANSPLANT P, V28, P1908; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schinder AF, 1996, J NEUROSCI, V16, P6125; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2045; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SNYDER JW, 1992, BIOCHEM PHARMACOL, V44, P833, DOI 10.1016/0006-2952(92)90425-I; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Trost LC, 1996, J PHARMACOL EXP THER, V278, P1000; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zha HB, 1996, MOL CELL BIOL, V16, P6494	58	423	434	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1573	1581		10.1038/sj.onc.1201324	http://dx.doi.org/10.1038/sj.onc.1201324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380409				2022-12-25	WOS:A1997XX36900008
J	Lupher, ML; Zhou, SY; Shoelson, SE; Cantley, LC; Band, H				Lupher, ML; Zhou, SY; Shoelson, SE; Cantley, LC; Band, H			The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and finds to the Tyr(292) negative regulatory phosphorylation site of ZAP-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTORS; PTB DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODIES; SH2 DOMAIN; ZETA-CHAIN; T-CELLS; C-CBL; ACTIVATION	The Cbl protooncogene product has emerged as a novel negative regulator of receptor and non-receptor tyrosine kinases through currently undefined mechanisms. Therefore, determining how Cbl physically interacts with tyrosine kinases is of substantial interest. We recently identified a phosphotyrosine binding (PTB) domain residing within the N-terminal transforming region of Cbl (Cbl-N), which mediated direct binding to ZAP-70 tyrosine kinase. Here, we have screened a degenerate phosphopeptide library and show that the Cbl-PTB domain selects a D(N/D)XpY motif, reminiscent of but distinct from the NPXpY motif recognized by the PTB domains of Shc and IRS-1/2. A phosphopeptide predicted by this motif and corresponding to the in vivo negative regulatory phosphorylation site of ZAP-70 (Tyr(P)(292)) specifically inhibited binding of ZAP-70 to Cbl-N, A ZAP-70/Y292F mutant failed to bind to Cbl-N, whereas a D290A mutant resulted in a 64% decrease in binding, confirming the importance of the Tyr(P) and Y-2 residues in Cbl-PTB domain recognition. Finally the ZAP-70/Y292F mutant also failed to associate with Cbl-N or full-length Cbl in vivo. These results identify a potential Cbl-PTB domain-dependent role for Cbl in the negative regulation of ZAP-70 and predict potential Cbl-PTB domain binding sites on other protein tyrosine kinases known to interact with Cbl.	Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Lymphocyte Sect, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Joslin Diabet Ctr,Res Div, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Band, H (corresponding author), Smith Bldg,Rm 538C,75 Francis St, Boston, MA 02115 USA.	hband@rics.bwh.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL CANCER INSTITUTE [R55CA064503, R01CA064503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER; NCI NIH HHS [CA64503] Funding Source: Medline; NIAMS NIH HHS [AR36308] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FitzerAttas CJ, 1997, J BIOL CHEM, V272, P8551, DOI 10.1074/jbc.272.13.8551; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Kong GH, 1996, MOL CELL BIOL, V16, P5026; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; LUPHER ML, 1997, IN PRESS INT J BIOCH; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zhao QH, 1996, MOL CELL BIOL, V16, P6765; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	179	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33140	33144		10.1074/jbc.272.52.33140	http://dx.doi.org/10.1074/jbc.272.52.33140			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407100	hybrid			2022-12-25	WOS:000071182900061
J	Allen, JR; Ensign, SA				Allen, JR; Ensign, SA			Purification to homogeneity and reconstitution of the individual components of the epoxide carboxylase multiprotein enzyme complex from Xanthobacter strain Py2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DEGRADATION; METABOLISM; EPOXYALKANES; OXIDE	Epoxide metabolism in the aerobic bacterium Xanthobacter strain Py2 proceeds by an NADPH-and NAD(+)-dependent carboxylation reaction that forms beta-keto acids as products, Epoxide carboxylase, the enzyme catalyzing this reaction, was resolved from the soluble fraction of cell-free extracts into four protein components that are obligately required for functional reconstitution of epoxide carboxylase activity, One of these components, component II, has previously been purified and characterized as an NADPH:disulfide oxidoreductase, In the present study, the three additional epoxide carboxylase components have been purified to homogeneity and characterized, These component proteins are as follows: component I, a homohexameric protein consisting of 41.7-kDa subunits; component III, a dimeric protein consisting of 26.0- and 26.2-kDa polypeptides; and component TV, a dimeric protein consisting of a single 25.4-kDa polypeptide, Component I contained 5 mol of tightly bound zinc per mol of protein, Component I was specifically inactivated by methylepoxypropane, a time-dependent irreversible inactivator of epoxide carboxylase activity, suggesting that this component plays an integral role in epoxide binding and activation, No metals or organic cofactors were detected for components III and IV, The molecular weights, N-terminal sequences, and amino acid compositions of the purified epoxide carboxylase components were determined and found to correlate with open reading frames within and adjacent to a cloned fragment of DNA that complements Xanthobacter Py2 mutants defective in epoxide degradation, Using the purified epoxide carboxylase system, epoxide carboxylation was found to be stoichiometrically coupled to the transhydrogenation of pyridine nucleotide cofactors according to the following equation: epoxypropane + CO2 + NADPH + NAD(+) --> acetoacetate + H+ + NADP(+) + NADH.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Ensign, SA (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.				NIGMS NIH HHS [GM51805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051805, R01GM051805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JR, 1997, J BACTERIOL, V179, P3110, DOI 10.1128/jb.179.10.3110-3115.1997; Allen JR, 1996, J BACTERIOL, V178, P1469, DOI 10.1128/jb.178.5.1469-1472.1996; Chion CKNCK, 1996, BIOCHEM J, V319, P499, DOI 10.1042/bj3190499; CHROMY V, 1974, CLIN CHEM, V20, P1362; Ensign SA, 1996, APPL ENVIRON MICROB, V62, P61, DOI 10.1128/AEM.62.1.61-66.1996; HARTMANS S, 1989, FEMS MICROBIOL LETT, V63, P235, DOI 10.1016/0168-6445(89)90034-X; HARTMANS S, 1989, APPL ENVIRON MICROB, V55, P2850, DOI 10.1128/AEM.55.11.2850-2855.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; Sluis MK, 1996, J BACTERIOL, V178, P4020, DOI 10.1128/jb.178.14.4020-4026.1996; Small FJ, 1997, J BIOL CHEM, V272, P24913, DOI 10.1074/jbc.272.40.24913; SMALL FJ, 1995, J BACTERIOL, V177, P6170, DOI 10.1128/jb.177.21.6170-6175.1995; Swaving J, 1996, J BACTERIOL, V178, P6644, DOI 10.1128/jb.178.22.6644-6646.1996; SWAVING J, 1995, MICROBIOL-UK, V141, P477, DOI 10.1099/13500872-141-2-477; THOMAS H, 1990, PRINCIPLES MECHANISM, V2, P280; WADE DR, 1978, MUTAT RES, V58, P217, DOI 10.1016/0165-1218(78)90012-5; WEIJERS CAGM, 1995, APPL MICROBIOL BIOT, V42, P775, DOI 10.1007/BF00171961	17	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32121	32128		10.1074/jbc.272.51.32121	http://dx.doi.org/10.1074/jbc.272.51.32121			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405410	hybrid			2022-12-25	WOS:000071108000029
J	Bjorbaek, C; Uotani, S; da Silva, B; Flier, JS				Bjorbaek, C; Uotani, S; da Silva, B; Flier, JS			Divergent signaling capacities of the long and short isoforms of the leptin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; STIMULATING FACTOR-RECEPTOR; ACTIVATED PROTEIN-KINASES; OBESE GENE-PRODUCT; OB/OB MICE; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS; CYTOPLASMIC DOMAIN; DISTINCT REGIONS; NEUROPEPTIDE-Y	Leptin receptors include a long form (OBRl) with 302 cytoplasmic residues that is presumed to mediate most or all of leptins signaling, and several short forms, including one (OBRs) that has 34 cytoplasmic residues, is widely expressed, and is presumed not to signal but to mediate transport or clearance of leptin. We studied the abilities of these two receptor isoforms to mediate signaling in transfected cells. In response to leptin, OBRl, but not OBRs, underwent tyrosine phosphorylation that was enhanced by co-expression with JAK2. In cells expressing receptors and JAK2, both OBRs and OBRl mediated leptin-dependent tyrosine phosphorylation of JAK2, and this was abolished with OBRs when the Box 1 motif was mutated. In cells expressing receptors, JAK2 and IRS-I, leptin induced tyrosine phosphorylation of IRS-1 through OBRs and OBRl. In COS cells expressing hemagglutinin-ERK1 and receptors, leptin increased ERK1 kinase activity through OBRl, with the magnitude increased by co-expression of JAK1 or JAK2, and to a lesser degree through OBRs, despite greater receptor expression. In stable Chinese hamster ovary cell lines expressing OBRs or OBRl, leptin stimulated endogenous ERK2 phosphorylation. Whereas leptin stimulated tyrosine phosphorylation of hemagglutinin-STAT3 and induction of a c-fos luciferase reporter plasmid through OBRl, OBRs was without effect in these assays. In conclusion, OBRl is capable of signaling to IRS-1 and mitogen-activated protein kinase via JAK, in addition to activating STAT pathways. Although substantially weaker than OBRl, OBRs is capable of mediating signal transduction via JAK, but these activities are of as yet unknown significance for leptin biology in vivo.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol,Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Flier, JS (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol,Dept Med, Res N,99 Brookline Ave, Boston, MA 02215 USA.		Flier, jeffrey/AAG-6223-2019; Bjorbaek, Christian/S-4727-2019		NIDDK NIH HHS [DK 28082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028082, R37DK028082] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cardone MH, 1996, J CELL BIOL, V133, P997, DOI 10.1083/jcb.133.5.997; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Cumin F, 1996, INT J OBESITY, V20, P1120; Cusin I, 1996, DIABETES, V45, P1446, DOI 10.2337/diabetes.45.10.1446; DAS R, 1995, MOL ENDOCRINOL, V9, P1750, DOI 10.1210/me.9.12.1750; Dyer CJ, 1997, DOMEST ANIM ENDOCRIN, V14, P119, DOI 10.1016/S0739-7240(96)00119-1; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOGGARD N, 1997, BIOCHEM BIOPH RES CO, V232, P353; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Joneja B, 1997, J BIOL CHEM, V272, P11176, DOI 10.1074/jbc.272.17.11176; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Luoh SM, 1997, J MOL ENDOCRINOL, V18, P77, DOI 10.1677/jme.0.0180077; Mikhail AA, 1997, BLOOD, V89, P1507, DOI 10.1182/blood.V89.5.1507.1507_1507_1512; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Murakami T, 1997, BIOCHEM BIOPH RES CO, V231, P26, DOI 10.1006/bbrc.1996.6030; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; Nakashima K, 1997, FEBS LETT, V401, P49, DOI 10.1016/S0014-5793(96)01430-5; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Takaya K, 1996, NAT GENET, V14, P130, DOI 10.1038/ng1096-130; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; UJITANI Y, 1997, ONCOGENE, V14, P751; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; Zachow RJ, 1997, ENDOCRINOLOGY, V138, P847, DOI 10.1210/en.138.2.847; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	67	721	745	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32686	32695		10.1074/jbc.272.51.32686	http://dx.doi.org/10.1074/jbc.272.51.32686			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405487	hybrid			2022-12-25	WOS:000071108000106
J	Quevillon, S; Agou, F; Robinson, JC; Mirande, M				Quevillon, S; Agou, F; Robinson, JC; Mirande, M			The p43 component of the mammalian multi-synthetase complex is likely to be the precursor of the endothelial monocyte-activating polypeptide II cytokine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; METHIONYL-TRANSFER-RNA; MACROMOLECULAR COMPLEXES; MULTISYNTHETASE COMPLEX; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; TRNA SYNTHETASE; IN-VITRO; PROTEIN; SUBUNIT	p43 is one of the three auxiliary components invariably associated with nine aminoacyl-tRNA synthetases as a multienzyme complex ubiquitous to all eukaryotic cells from flies to humans, The cDNA encoding the hamster protein was isolated by using mixed oligonucleotides deduced from peptide sequences, The 359-amino acid protein is the hamster homologue of the recently reported murine and human EMAP II cytokine implicated in a variety of inflammatory disorders, The sequence of several proEMAP II proteins suggests that the p43 component of the complex is the precursor of the active mature cytokine after cleavage at a conserved Asp residue, The COOH-terminal moiety of p43 is also homologous to polypeptide domains found in bacterial methionyl- or phenylalanyl-tRNA synthetases and in the yeast Arc1p/G4p1 protein that associates with yeast methionyl-tRNA synthetase, Our results implicate the COOH-terminal moiety of p43 as a RNA binding domain. In the native state, as a component of the multisynthetase complex, p43 may be required for tRNA channeling and, after proteolytic processing occurring in tumor cells, would acquire inflammatory properties possibly related to apoptosis. The release of a truncated p43 from the complex could be involved in mediation of the signaling of tumor cells and stimulation of an acute inflammatory response.	CNRS, Lab Enzymol & Biochim Struct, UPR 9063, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mirande, M (corresponding author), CNRS, Lab Enzymol & Biochim Struct, UPR 9063, F-91190 Gif Sur Yvette, France.	marc.mirande@lebs.cnrs-gif.fr	, AGOU/GXA-2760-2022					Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; ALEXANDRESCU AT, 1995, J MOL BIOL, V250, P134, DOI 10.1006/jmbi.1995.0365; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BEC G, 1994, J BIOL CHEM, V269, P2086; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CASSIO D, 1971, EUR J BIOCHEM, V20, P283, DOI 10.1111/j.1432-1033.1971.tb01393.x; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHOLI T, 1989, J CHROMATOGR, V476, P59, DOI 10.1016/S0021-9673(01)93856-7; Davies C, 1996, STRUCTURE, V4, P55, DOI 10.1016/S0969-2126(96)00009-3; FILONENKO VV, 1994, J BIOL CHEM, V269, P17375; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Goldgur Y, 1997, STRUCTURE, V5, P59, DOI 10.1016/S0969-2126(97)00166-4; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; JACOBOMOLINA A, 1988, FEBS LETT, V232, P65, DOI 10.1016/0014-5793(88)80387-9; KAO J, 1994, J BIOL CHEM, V269, P25106; KAO J, 1994, J BIOL CHEM, V269, P9774; KERJAN P, 1994, BBA-GEN SUBJECTS, V1199, P293, DOI 10.1016/0304-4165(94)90009-4; KERJAN P, 1992, BIOCHIMIE, V74, P195, DOI 10.1016/0300-9084(92)90046-H; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD M, 1993, GENE, V132, P237, DOI 10.1016/0378-1119(93)90201-D; MELLOT P, 1989, J MOL BIOL, V208, P429, DOI 10.1016/0022-2836(89)90507-X; MIRANDE M, 1985, EUR J BIOCHEM, V147, P281, DOI 10.1111/j.1432-1033.1985.tb08748.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1982, J BIOL CHEM, V257, P1056; MIRANDE M, 1982, J BIOL CHEM, V257, P1049; MIRANDE M, 1982, EMBO J, V1, P733, DOI 10.1002/j.1460-2075.1982.tb01238.x; MIRANDE M, 1993, TRANSLATIONAL APPARATUS, P657; MOSYAK L, 1995, NAT STRUCT BIOL, V2, P537, DOI 10.1038/nsb0795-537; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; NORCUM MT, 1989, J BIOL CHEM, V264, P15043; PENDERGAST AM, 1985, J BIOL CHEM, V260, P1769; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; VANDAMME H, 1991, EUR J BIOCHEM, V197, P505, DOI 10.1111/j.1432-1033.1991.tb15938.x	45	162	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32573	32579		10.1074/jbc.272.51.32573	http://dx.doi.org/10.1074/jbc.272.51.32573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405472	hybrid			2022-12-25	WOS:000071108000091
J	Ye, LH; Hayakawa, K; Kishi, H; Imamura, M; Nakamura, A; Okagaki, T; Takagi, T; Iwata, A; Tanaka, T; Kohama, K				Ye, LH; Hayakawa, K; Kishi, H; Imamura, M; Nakamura, A; Okagaki, T; Takagi, T; Iwata, A; Tanaka, T; Kohama, K			The structure and function of the actin-binding domain of myosin light chain kinase of smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT INTERACTION; CHICKEN GIZZARD MYOSIN; PROTEIN; CALDESMON; LOCALIZATION; PURIFICATION; STIMULATION; CALMODULIN; FILAMENTS; ANTIBODY	In addition to its kinase activity, the myosin light chain kinase (MLCK) of smooth muscle has an actin binding activity through which it can regulate the actin-myosin interaction of smooth muscle (Kohama, K., Okagaki, T., Hayakawa, K., Lin, Y., Ishikawa, R., Shimmen, T., and Inoue, A (1992) Biochem. Biophys. Res. Commun. 184, 1204-1211). In this study, we have analyzed the actin binding activity of MLCK and related it to its amino acid sequence by producing native and recombinant fragments of MLCK. Parent MLCK exhibited both calcium ion (Ca2+) and calmodulin (Ca2+/CaM)-sensitive and Ca2+/CaM-insensitive binding to actin filaments. The native fragment, which consists of the Met(1)-Lys(114) sequence (Kanoh, S., Ito, M., Niwa, E., Kawano, Y., and Hartshorne, D. J. (1993) Biochemistry 32, 8902-8907), and the recombinant NN fragment, which contains this 1-114 sequence, showed only Ca2+/CaM-sensitive binding. An inhibitory effect of the NN fragment on the actin-myosin interaction was observed by assaying in vitro motility and by measuring the actin-activated ATPase activity of myosin. The recombinant NN/41 fragment, which is constructed without the Met(1)-Pro(41) sequence of the NN fragment, lost both the actin binding activity and the inhibitory effect. We confirmed the importance of the 1-41 sequence by using a few synthetic peptides to compete against the NN fragment in binding to actin filaments. The experiments using recombinant fragments and synthetic peptides also revealed that the site for CaM-binding is the Pro(26)-Pro(41) sequence. The site for the Ca2+/CaM-insensitive binding, which is shown to be localized between the Ca2+/CaM-sensitive site and the central kinase domain of MLCK, exerted no regulatory effects on the actin-myosin interaction.	Gunma Univ, Sch Med, Dept Pharmacol, Gunma 371, Japan; Tohoku Univ, Fac Sci, Inst Biol, Sendai, Miyagi 980, Japan; Japanese Red Cross Saitama Blood Ctr, Div Res, Yono, Saitama 338, Japan	Gunma University; Tohoku University	Kohama, K (corresponding author), Gunma Univ, Sch Med, Dept Pharmacol, Gunma 371, Japan.		Kishi, Hiroko/AAR-9148-2021	Kishi, Hiroko/0000-0003-2896-7355				ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DABROWSKA R, 1982, BIOCHEM BIOPH RES CO, V107, P1524, DOI 10.1016/S0006-291X(82)80172-1; EBASHI S, 1976, J BIOCHEM-TOKYO, V79, P229, DOI 10.1093/oxfordjournals.jbchem.a131052; GUERRIERO V, 1981, CELL, V27, P449, DOI 10.1016/0092-8674(81)90386-X; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; HARTSHORNE DJ, 1977, BIOCH SMOOTH MUSCLE, P513; HAYAKAWA K, 1994, BIOCHEM BIOPH RES CO, V199, P786, DOI 10.1006/bbrc.1994.1298; ISHIKAWA R, 1991, J BIOL CHEM, V266, P21784; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KOBAYASHI H, 1992, J BIOCHEM-TOKYO, V112, P786, DOI 10.1093/oxfordjournals.jbchem.a123976; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOHAMA K, 1992, BIOCHEM BIOPH RES CO, V184, P1204, DOI 10.1016/S0006-291X(05)80010-5; KUWAYAMA H, 1988, J BIOCHEM-TOKYO, V104, P862, DOI 10.1093/oxfordjournals.jbchem.a122565; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN Y, 1994, CELL MOTIL CYTOSKEL, V29, P250, DOI 10.1002/cm.970290308; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMURA F, 1982, J MOL BIOL, V157, P163, DOI 10.1016/0022-2836(82)90520-4; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; MIMURA N, 1986, J BIOL CHEM, V261, P680; NAKAMURA S, 1984, J BIOCHEM-TOKYO, V96, P575, DOI 10.1093/oxfordjournals.jbchem.a134870; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; Okagaki Tsuyoshi, 1995, P17; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; SATO M, 1995, J BIOCHEM, V118, P1; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; SOBUE K, 1991, J BIOL CHEM, V266, P12115; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; YAMAZAKI K, 1987, J BIOCHEM-TOKYO, V101, P1; YE LH, 1994, J BIOCHEM, V116, P1377, DOI 10.1093/oxfordjournals.jbchem.a124690; YE LH, 1995, REGULATION CONTRACTI, P159	37	39	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32182	32189		10.1074/jbc.272.51.32182	http://dx.doi.org/10.1074/jbc.272.51.32182			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405419	hybrid			2022-12-25	WOS:000071108000038
J	Gueguen, Y; Voorhorst, WGB; vanderOost, J; deVos, WM				Gueguen, Y; Voorhorst, WGB; vanderOost, J; deVos, WM			Molecular and biochemical characterization of an endo-beta-1,3-glucanase of the hyperthermophilic archaeon Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BACILLUS-CIRCULANS WL-12; ACID-SEQUENCE SIMILARITIES; ESCHERICHIA-COLI; BETA-GLUCANASE; 1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE; NUCLEOTIDE-SEQUENCE; GLYCOSYL HYDROLASES; ACTIVE-SITE; ENDO-1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE	We report here the first molecular characterization of an endo-beta-1,3-glucanase from an archaeon. Pyrococcus furiosus is a hyperthermophilic archaeon that is capable of saccharolytic growth. The isolated lamA gene encodes an extracellular enzyme that shares homology with both endo-beta-1,3- and endo-beta-1,3-1,4-glucanases of the glycosyl hydrolase family 16. After deletion of the N-terminal leader sequence, a lamA fragment encoding an active endo-beta-1,3-glucanase was overexpressed in Escherichia coli using the T7-expression system. The purified P. furiosus endoglucanase has highest hydrolytic activity on the beta-1,3 glucose polymer laminarin and has some hydrolytic activity on the beta-1,3-1,4 glucose polymers lichenan and barley beta-glucan. The enzyme is the most thermostable endo-beta-1,3- glucanase described up to now; it has optimal activity at 100-105 degrees C. In the predicted active site of glycosyl hydrolases of family 16 that show predominantly endo-beta-1,3-glucanase activity, an additional methionine residue is present. Deletion of this methionine did not change the substrate specificity of the endoglucanase, but it did cause a severe reduction in its catalytic activity, suggesting a structural role of this residue in constituting the active site. High performance liquid chromatography analysis showed in vitro hydrolysis of laminarin by the endo-beta-1,3 glucanase proceeds more efficiently in combination with an exo-beta-glycosidase from P. furiosus (CelB). This most probably reflects the physiological role of these enzymes: cooperation during growth of P. furiosus on beta-glucans.	AGR UNIV WAGENINGEN, DEPT MICROBIOL, BACTERIAL GENET GRP, NL-6703 CT WAGENINGEN, NETHERLANDS	Wageningen University & Research			Gueguen, Yannick/O-3248-2014; van+der+Oost, John/Y-2548-2019	Gueguen, Yannick/0000-0002-8749-9582; 				BACON JSD, 1970, BIOCHEM J, V120, P67, DOI 10.1042/bj1200067; BATCHMAN ES, 1996, P NATL ACAD SCI USA, V93, P6808; Bauer MW, 1996, J BIOL CHEM, V271, P23749, DOI 10.1074/jbc.271.39.23749; BORRISS R, 1990, MOL GEN GENET, V222, P278, DOI 10.1007/BF00633829; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUENO A, 1990, J BACTERIOL, V172, P2160, DOI 10.1128/jb.172.4.2160-2167.1990; CHEN L, 1993, J BIOL CHEM, V268, P13318; DAKHOVA ON, 1993, BIOCHEM BIOPH RES CO, V194, P1359, DOI 10.1006/bbrc.1993.1974; DELACRUZ J, 1995, J BACTERIOL, V177, P6937, DOI 10.1128/jb.177.23.6937-6945.1995; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; ERFLE JD, 1988, BIOCHEM J, V255, P833, DOI 10.1042/bj2550833; Ferrer P, 1996, J BACTERIOL, V178, P4751, DOI 10.1128/jb.178.15.4751-4757.1996; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FISKE MJ, 1990, J GEN MICROBIOL, V136, P2377, DOI 10.1099/00221287-136-12-2377; FLINT HJ, 1989, APPL ENVIRON MICROB, V55, P1230, DOI 10.1128/AEM.55.5.1230-1233.1989; FLINT HJ, 1993, J BACTERIOL, V175, P2943, DOI 10.1128/JB.175.10.2943-2951.1993; GEBLER J, 1992, J BIOL CHEM, V267, P12559; GIBSON TJ, 1994, THESIS CAMBRIDGE U C; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOSALBES MJ, 1991, J BACTERIOL, V173, P7705, DOI 10.1128/jb.173.23.7705-7710.1991; GRENIER J, 1993, PLANT PHYSIOL, V103, P1277, DOI 10.1104/pp.103.4.1277; HAHN M, 1995, J BIOL CHEM, V270, P3081, DOI 10.1074/jbc.270.7.3081; HAHN M, 1995, EUR J BIOCHEM, V232, P849, DOI 10.1111/j.1432-1033.1995.tb20883.x; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HO NS, 1990, DNA PROTEIN ENG TECH, V2, P50; HOFEMEISTER J, 1986, GENE, V49, P177, DOI 10.1016/0378-1119(86)90278-7; HOJ PB, 1992, J BIOL CHEM, V267, P25059; IRVIN JE, 1988, APPL ENVIRON MICROB, V54, P2672, DOI 10.1128/AEM.54.11.2672-2676.1988; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KEITEL T, 1994, EUR J BIOCHEM, V222, P203, DOI 10.1111/j.1432-1033.1994.tb18858.x; Kengen SWM, 1996, FEMS MICROBIOL REV, V18, P119; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KENGEN SWM, 1993, EUR J BIOCHEM, V213, P305, DOI 10.1111/j.1432-1033.1993.tb17763.x; KONIG H, 1983, H-S Z PHYSIOL CHEM, V364, P627, DOI 10.1515/bchm2.1983.364.1.627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOBERAS J, 1991, EUR J BIOCHEM, V197, P337, DOI 10.1111/j.1432-1033.1991.tb15916.x; LOUW ME, 1993, APPL MICROBIOL BIOT, V38, P507, DOI 10.1007/BF00242946; MA KS, 1994, FEMS MICROBIOL LETT, V122, P245, DOI 10.1016/0378-1097(94)00330-0; MALET C, 1993, BIOCHEM J, V296, P753, DOI 10.1042/bj2960753; MURPHY N, 1984, NUCLEIC ACIDS RES, V12, P5355, DOI 10.1093/nar/12.13.5355; PARRISH FW, 1960, CAN J CHEM, V38, P2094, DOI 10.1139/v60-284; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; Rink R, 1997, J BIOL CHEM, V272, P14650, DOI 10.1074/jbc.272.23.14650; SAKELLARIS H, 1993, FEMS MICROBIOL LETT, V109, P269, DOI 10.1016/0378-1097(93)90031-V; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMING S, 1992, EUR J BIOCHEM, V204, P13, DOI 10.1111/j.1432-1033.1992.tb16600.x; SCHIMMING S, 1991, BIOCHEM BIOPH RES CO, V177, P447, DOI 10.1016/0006-291X(91)92004-4; SCHWARTZ WH, 1988, BIOTECHNOL LETT, V101, P225; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SPILLIAERT R, 1994, EUR J BIOCHEM, V224, P923, DOI 10.1111/j.1432-1033.1994.00923.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMER JB, 1949, DINITROSALISYLIC MET; Sunna A, 1997, EXTREMOPHILES, V1, P2, DOI 10.1007/s007920050009; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; VARGHESE JN, 1994, P NATL ACAD SCI USA, V91, P2785, DOI 10.1073/pnas.91.7.2785; VOORHORST WGB, 1995, J BACTERIOL, V177, P7105, DOI 10.1128/JB.177.24.7105-7111.1995; WATANABE T, 1992, J BACTERIOL, V174, P186, DOI 10.1128/jb.174.1.186-190.1992; WELFLE K, 1995, EUR J BIOCHEM, V229, P726, DOI 10.1111/j.1432-1033.1995.tb20520.x; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; ZVERLOV VV, 1991, BIOCHEM BIOPH RES CO, V181, P507, DOI 10.1016/0006-291X(91)91217-Z	65	108	112	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31258	31264		10.1074/jbc.272.50.31258	http://dx.doi.org/10.1074/jbc.272.50.31258			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395451	hybrid			2022-12-25	WOS:A1997YL41900010
J	Hanemaaijer, R; Sorsa, T; Konttinen, YT; Ding, YL; Sutinen, M; Visser, H; vanHinsbergh, VWM; Helaakoski, T; Kainulainen, T; Ronka, H; Tschesche, H; Salo, T				Hanemaaijer, R; Sorsa, T; Konttinen, YT; Ding, YL; Sutinen, M; Visser, H; vanHinsbergh, VWM; Helaakoski, T; Kainulainen, T; Ronka, H; Tschesche, H; Salo, T			Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells - Regulation by tumor necrosis factor-alpha and doxycycline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; DEGRADING METALLOPROTEINASES; SUBSTRATE-SPECIFICITY; CLEAVAGE SITES; TETRACYCLINES; MMP-8; ACTIVATION; CARTILAGE; ARTHRITIS; GINGIVAL	Neutrophil collagenase (matrix metalloproteinase-8 or MMP-8) is regarded as being synthesized exclusively by polymorphonuclear neutrophils (PMN). However, in vivo MMP-8 expression was observed in mononuclear fibroblast-like cells in the rheumatoid synovial membrane. In addition, we detected MMP-8 mRNA expression in cultured rheumatoid synovial fibroblasts and human endothelial cells. Up-regulation of MMP-8 was observed after treatment of the cells with either tumor necrosis factor-alpha (10 ng/ml) or phorbol 12-myristate 13-acetate (10 nM). Western analysis showed a similar regulation at the protein level. The size of secreted MMP-8 was 50 kDa, which is about 30 kDa smaller than MMP-8 from PMN. Conditioned media from rheumatoid synovial fibroblasts contained both type I and II collagen degrading activity. However, degradation of type II collagen, but not that of type I collagen, was completely inhibited by 50 mu M doxycycline, suggesting specific MMP-8 activity. In addition, doxycycline down-regulated MMP-8 induction, at both the mRNA and protein levels. Thus MMP-8 exerts markedly wider expression in human cells than had been thought previously, implying that PMN are not the only source of cartilage degrading activity at arthritic sites. The inhibition of both MMP-8 activity and synthesis by doxycycline provides an incentive for further studies on the clinical effects of doxycycline in the treatment of rheumatoid arthritis.	UNIV OULU,DEPT ORAL SURG,FIN-90220 OULU,FINLAND; TNO,PG,GAUBIUS LAB,NL-2301 CE LEIDEN,NETHERLANDS; UNIV HELSINKI,DEPT PERIODONTOL & MED CHEM,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT ANAT,FIN-00014 HELSINKI,FINLAND; UNIV OULU,DEPT MED BIOCHEM,FIN-90220 OULU,FINLAND; OULU UNIV HOSP,OULU,FINLAND; MEDIX BIOCHEM OY AB,KAUNIAINEN,FINLAND; UNIV BIELEFELD,FAC CHEM,DEPT BIOCHEM,D-33501 BIELEFELD,GERMANY	University of Oulu; Netherlands Organization Applied Science Research; University of Helsinki; University of Helsinki; University of Oulu; University of Oulu; University of Bielefeld			, tuula/ABG-2051-2021	Salo, Tuula/0000-0001-6039-0088				BALLAGIPORDANY A, 1991, ANAL BIOCHEM, V196, P89, DOI 10.1016/0003-2697(91)90122-A; BERGMANN U, 1989, J CLIN CHEM CLIN BIO, V29, P351; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chubinskaya S, 1996, LAB INVEST, V74, P232; Cole AA, 1996, J BIOL CHEM, V271, P11023, DOI 10.1074/jbc.271.18.11023; COLE AA, 1995, ACTA ORTHOP SCAND, V26, P98; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Golub L M, 1992, Curr Opin Dent, V2, P80; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HASTY KA, 1986, J BIOL CHEM, V261, P5645; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; HIBBS MS, 1984, COLLAGEN REL RES, V4, P467; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KONTTINEN YT, 1991, MATRIX, V11, P395, DOI 10.1016/S0934-8832(11)80194-0; Kylmaniemi M, 1996, J DENT RES, V75, P919, DOI 10.1177/00220345960750030901; LAUHIO A, 1995, LANCET, V346, P645, DOI 10.1016/S0140-6736(95)91484-6; LAUHIO A, 1994, CLIN EXP IMMUNOL, V98, P21; MAINARDI CL, 1991, AM J MED SCI, V302, P171, DOI 10.1097/00000441-199109000-00010; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Matsuki H, 1996, CLIN CHIM ACTA, V244, P129, DOI 10.1016/0009-8981(95)06197-5; MICHAELIS J, 1990, BIOCHEM J, V270, P809, DOI 10.1042/bj2700809; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; OIKARINEN K S, 1987, Endodontics and Dental Traumatology, V3, P95; POWER C, 1994, AM J RESP CRIT CARE, V150, P818, DOI 10.1164/ajrccm.150.3.8087357; SALO T, 1991, J BIOL CHEM, V266, P11436; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID TM, 1986, J BIOL CHEM, V261, P4184; SELTZER JL, 1981, J BIOL CHEM, V256, P4662; SEPPER R, 1995, CHEST, V107, P1641, DOI 10.1378/chest.107.6.1641; SORSA T, 1994, ANN NY ACAD SCI, V732, P112, DOI 10.1111/j.1749-6632.1994.tb24729.x; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SUOMALAINEN K, 1992, ANTIMICROB AGENTS CH, V36, P227, DOI 10.1128/AAC.36.1.227; TONETTI MS, 1993, J PERIODONTAL RES, V28, P511, DOI 10.1111/j.1600-0765.1993.tb02114.x; TSCHESCHE H, 1991, BIOMED BIOCHIM ACTA, V50, P755; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	42	407	418	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31504	31509		10.1074/jbc.272.50.31504	http://dx.doi.org/10.1074/jbc.272.50.31504			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395486	hybrid, Green Published			2022-12-25	WOS:A1997YL41900045
J	Lu, DS; Yuan, X; Zheng, XL; Sadler, JE				Lu, DS; Yuan, X; Zheng, XL; Sadler, JE			Bovine proenteropeptidase is activated by trypsin, and the specificity of enteropeptidase depends on the heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROKINASE; PURIFICATION; EXPRESSION; INHIBITORS; PROTEINS	Enteropeptidase, also known as enterokinase, initiates the activation of pancreatic hydrolases by cleaving and activating trypsinogen, Enteropeptidase is synthesized as a single-chain protein, whereas purified enteropeptidase contains a approximate to 47-kDa serine protease domain (light chain) and a disulfide-linked approximate to 120-kDa heavy chain, The heavy chain contains an amino-terminal membrane-spanning segment and several repeated structural motifs of unknown function, To study the role of heavy chain motifs in substrate recognition, secreted variants of recombinant bovine proenteropeptidase were constructed by replacing the transmembrane domain with a signal peptide, Secreted variants containing both the heavy chain (minus the transmembrane domain) and the catalytic light chain (pro-HL-BEK (where BEK is bovine enteropeptidase)) or only the catalytic domain (pro-L-BEK) were expressed in baby hamster kidney cells and purified, Single-chain pro-HL-BEK and pro-L-BEK were zymogens with extremely low catalytic activity, and both were activated readily by trypsin cleavage, Trypsinogen was activated efficiently by purified enteropeptidase from bovine intestine (K-m = 5.6 mu M and k(cat) = 4.0 s(-1)) and by HL-BEK (K-m = 5.6 mu M and k(cat) = 2.2 s(-1)), but not by L-BEK (K-m = 133 mu M and k(cat) = 0.1 s(-1)); HL-BEK cleaved trypsinogen at pH 5.6 with 520-fold greater catalytic efficiency than did L-BEK. Qualitatively similar results were obtained at pH 8.4. In contrast to this striking difference in trypsinogen recognition, the small synthetic substrate Gly-Asp-Asp-Asp-Asp-Lys-beta-naphthylamide was cleaved with similar kinetic parameters by both HL-BEK (K-m = 0.27 mM and k(cat) = 0.07 s(-1)) and L-BEK (K-m = 0.60 mM and k(cat) = 0.06 s(-1)). The presence of the heavy chain also influenced the rate of reaction with protease inhibitors, Bovine pancreatic trypsin inhibitor preferred HL-BEK (initial K-i = 99 nM and final Ki* = 1.8 nM) over L-BEK (K-i = 698 nM and K-i* = 6.2 nM). Soybean trypsin inhibitor exhibited a reciprocal pattern, inhibiting L-BEK (K-i* = 1.6 nM), but not HL-BEK. These kinetic data indicate that the enteropeptidase heavy chain has little influence on the recognition of small peptides, but strongly influences macromolecular substrate recognition and inhibitor specificity.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Sadler, Evan/D-8556-2011; Zheng, X. Long/ABD-7362-2021	Zheng, X. Long/0000-0003-1680-5295; Sadler, J. Evan/0000-0001-5705-469X	NIDDK NIH HHS [DK50053] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050053] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON LE, 1977, BIOCHEMISTRY-US, V16, P3354, DOI 10.1021/bi00634a011; BARATTI J, 1976, BIOCHIM BIOPHYS ACTA, V42, P488; BARNS RJ, 1974, BIOCHIM BIOPHYS ACTA, V350, P495, DOI 10.1016/0005-2744(74)90527-0; BRICTEUX.S, 1972, COMP BIOCHEM PHYSIOL, V42, P23, DOI 10.1016/0305-0491(72)90055-7; CHASE T, 1970, METHOD ENZYMOL, V19, P20; FONSECA P, 1983, J BIOL CHEM, V258, P3069; GRANT DAW, 1979, BIOCHIM BIOPHYS ACTA, V567, P207, DOI 10.1016/0005-2744(79)90187-6; GREEN GM, 1983, CLIN CHIM ACTA, V134, P363, DOI 10.1016/0009-8981(83)90375-3; HADORN B, 1969, LANCET, V1, P812; HAWORTH JC, 1971, J PEDIATR-US, V78, P481, DOI 10.1016/S0022-3476(71)80231-7; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; Kunitz M, 1939, J GEN PHYSIOL, V22, P429, DOI 10.1085/jgp.22.4.429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, J BIOL CHEM, V268, P23311; LIEPNIEKS JJ, 1979, J BIOL CHEM, V254, P1677; LIGHT A, 1984, J BIOL CHEM, V259, P3195; LIVINGSTON DC, 1981, BIOCHEMISTRY-US, V20, P4298, DOI 10.1021/bi00518a010; LU D, 1997, IN PRESS HDB PROTEOL; MAROUX S, 1971, J BIOL CHEM, V246, P5031; MATSUSHIMA M, 1994, J BIOL CHEM, V269, P19976; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PAVLOV IP, 1902, WORK DIGESTIVE GLAND, P148; WU QY, 1994, J BIOL CHEM, V269, P3725	26	82	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31293	31300		10.1074/jbc.272.50.31293	http://dx.doi.org/10.1074/jbc.272.50.31293			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395456	hybrid			2022-12-25	WOS:A1997YL41900015
J	Shao, RG; Cao, CX; Pommier, Y				Shao, RG; Cao, CX; Pommier, Y			Activation of PKC alpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DNA FRAGMENTATION; HL-60 CELLS; THYMOCYTE APOPTOSIS; SELECTIVE INHIBITOR; ANTITUMOR-ACTIVITY; ICE-LIKE; IN-VIVO; INDUCTION; UCN-01	We previously demonstrated that the anticancer agent and protein kinase C (PKC) inhibitor 7-hydroxy-staurosporine (UCN-01) induces apoptosis independently of p53 and protein synthesis in HL60 cells, We now report the associated changes of PKC isoforms, PKC alpha, beta I, beta II, delta, and zeta activities were measured after immunoprecipitation of cytosols from UCN-01-treated HL60 cells. UCN-01 had no effect on PKC zeta and inhibited kinase activity of PKC beta I, beta II, and delta. PKC alpha activity was initially inhibited at 1 h, and subsequently increased as cells underwent apoptosis 3 h after the beginning of UCN-01 treatment, Camptothecin (CPT) and etoposide (VP-16) also markedly enhanced PKC alpha activity during apoptosis in HL60 cells. However, CPT did not affect PKC beta I, beta II and zeta, and activated PKC delta, PKC alpha activation was not due to increased protein levels or proteolytic cleavage but was associated with PKC alpha autophosphorylation in vitro and increased phosphorylation in vivo, We also found that not only PKC delta but also PKC beta I was proteolytically activated in HL60 cells during apoptosis. The PKC alpha activation and hyperphosphorylation were abrogated by N-benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoro-methylketone (z-VAD-fmk) under conditions that abrogated apoptosis, z-VAD-fmk also prevented PKC delta and beta I proteolytic activation, Together these findings suggest that caspases regulate PKC activity during apoptosis in HL60 cells, At least two modes of activation were observed: hyperphosphorylation for PKC alpha and proteolytic activation for PKC delta and beta I.	NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1991, CANCER RES, V51, P4888; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; JARVIS WD, 1994, CANCER RES, V54, P1707; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MERCEP M, 1989, J IMMUNOL, V142, P4085; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OJEDA F, 1990, CELL IMMUNOL, V125, P535, DOI 10.1016/0008-8749(90)90106-2; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Shao RG, 1996, EXP CELL RES, V227, P190, DOI 10.1006/excr.1996.0266; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; SHIMIZU T, 1995, CANCER RES, V55, P228; Shimizu T, 1996, EXP CELL RES, V226, P292, DOI 10.1006/excr.1996.0230; SOLARY E, 1993, BLOOD, V81, P1359; SUZUKI K, 1991, CELL IMMUNOL, V134, P235, DOI 10.1016/0008-8749(91)90346-D; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	36	66	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31321	31325		10.1074/jbc.272.50.31321	http://dx.doi.org/10.1074/jbc.272.50.31321			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395460	hybrid			2022-12-25	WOS:A1997YL41900019
J	Tvrdik, P; Asadi, A; Kozak, LP; Nedergaard, J; Cannon, B; Jacobsson, A				Tvrdik, P; Asadi, A; Kozak, LP; Nedergaard, J; Cannon, B; Jacobsson, A			Cig30, a mouse member of a novel membrane protein gene family, is involved in the recruitment of brown adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC STIMULATION; SACCHAROMYCES-CEREVISIAE; UNCOUPLING PROTEIN; GLUCOSE-TRANSPORT; MESSENGER-RNA; COLD-EXPOSURE; SN-GLYCEROL-3-PHOSPHATE DEHYDROGENASE; NOREPINEPHRINE INFUSION; LIPOPROTEIN-LIPASE; MOLECULAR-CLONING	We have identified a previously uncharacterized gene that is implicated in the thermogenic function of brown adipose tissue of mice. This gene, termed Cig30, is the first mammalian member of a novel gene family comprising several nematode and yeast genes, such as SUR4 and FEN1, mutation of which is associated with highly pleiotropic phenotypes. It codes for a 30-kDa plasma membrane glycoprotein with five putative transmembrane domains. The Cig30 mRNA was readily detected only in brown fat and liver. When animals were exposed to a 3-day cold stress, the Cig30 expression was selectively elevated in brown fat more than 200-fold, Similar increases were brought about in two other conditions of brown fat recruitment, namely during perinatal development and after cafeteria diet, The magnitude of Cig30 mRNA induction in the cold could be mimicked by chronic norepinephrine treatment in vivo. However, in primary cultures of brown adipocytes, a synergistic action of norepinephrine and dexamethasone was required for full expression of the gene, indicating that both catecholamines and glucocorticoids are required for the induction of Cig30. We propose that the CIG30 protein is involved in a pathway connected with brown fat hyperplasia.	JACKSON LAB,BAR HARBOR,ME 04609	Jackson Laboratory	Tvrdik, P (corresponding author), UNIV STOCKHOLM,ARRHENIUS LABS F3,WENNER GREN INST,S-10691 STOCKHOLM,SWEDEN.		Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Tvrdik, Petr/AAK-4398-2021; Cannon, Barbara/B-3089-2016	Nedergaard, Jan/0000-0003-2070-1587; Cannon, Barbara/0000-0001-6594-2363; Tvrdik, Petr/0000-0002-8750-9672				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARNARD T, 1980, BIOGENIC AMINES DEV; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; CAMERON IL, 1964, J CELL BIOL, V23, P89, DOI 10.1083/jcb.23.1.89; CARNEHEIM C, 1984, AM J PHYSIOL, V246, pE327, DOI 10.1152/ajpendo.1984.246.4.E327; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURRENS P, 1995, CURR GENET, V27, P213, DOI 10.1007/BF00326151; ELSHERBEINI M, 1995, J BACTERIOL, V177, P3227, DOI 10.1128/jb.177.11.3227-3234.1995; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GARCIAARRANZ M, 1994, J BIOL CHEM, V269, P18076; GELOEN A, 1988, AM J PHYSIOL, V254, pC175, DOI 10.1152/ajpcell.1988.254.1.C175; JACOBSSON A, 1994, AM J PHYSIOL-REG I, V267, pR999, DOI 10.1152/ajpregu.1994.267.4.R999; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KOZAK LP, 1983, P NATL ACAD SCI-BIOL, V80, P3020, DOI 10.1073/pnas.80.10.3020; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIU XL, 1994, AM J PHYSIOL, V266, pR914, DOI 10.1152/ajpregu.1994.266.3.R914; LORENZ RT, 1991, ANTIMICROB AGENTS CH, V35, P1532, DOI 10.1128/AAC.35.8.1532; MARETTE A, 1991, BIOCHEM J, V277, P119, DOI 10.1042/bj2770119; MITCHELL JRD, 1992, AM J PHYSIOL, V263, pE500, DOI 10.1152/ajpendo.1992.263.3.E500; MOHELL N, 1984, MOL PHARMACOL, V25, P64; MORY G, 1988, BIOSCIENCE REP, V8, P465, DOI 10.1007/BF01121645; NEDERGAARD J, 1982, INT REV CYTOL, V74, P187, DOI 10.1016/S0074-7696(08)61173-0; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23; Nedergaard J., 1986, BROWN ADIPOSE TISSUE; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OmatsuKanbe M, 1996, BIOCHEM J, V315, P25, DOI 10.1042/bj3150025; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; RATNER PL, 1981, J BIOL CHEM, V256, P3576; REHNMARK S, 1989, EXP CELL RES, V182, P75, DOI 10.1016/0014-4827(89)90280-2; REHNMARK S, 1989, EXP CELL RES, V180, P574, DOI 10.1016/0014-4827(89)90086-4; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENAULT C, 1988, COMP BIOCHEM PHYS A, V91, P141, DOI 10.1016/0300-9629(88)91606-4; SHIMIZU Y, 1993, AM J PHYSIOL, V264, pE890, DOI 10.1152/ajpendo.1993.264.6.E890; SHIMIZU Y, 1991, J BIOCHEM, V110, P688, DOI 10.1093/oxfordjournals.jbchem.a123642; SHIMIZU Y, 1994, J BIOCHEM-TOKYO, V115, P1069, DOI 10.1093/oxfordjournals.jbchem.a124459; Silve S, 1996, MOL CELL BIOL, V16, P2719; SMITH RE, 1963, SCIENCE, V140, P199, DOI 10.1126/science.140.3563.199; STRUNECKA A, 1981, PHYSIOL BOHEMOSLOV, V30, P307; VALLERAND AL, 1990, AM J PHYSIOL, V259, pR1043, DOI 10.1152/ajpregu.1990.259.5.R1043; VITIELLO F, 1978, J CHROMATOGR, V166, P637, DOI 10.1016/S0021-9673(00)95654-1	47	92	102	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31738	31746		10.1074/jbc.272.50.31738	http://dx.doi.org/10.1074/jbc.272.50.31738			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395518	hybrid			2022-12-25	WOS:A1997YL41900077
J	Aslund, F; Berndt, KD; Holmgren, A				Aslund, F; Berndt, KD; Holmgren, A			Redox potentials of glutaredoxins and other thiol-disulfide oxidoreductases of the thioredoxin superfamily determined by direct protein-protein redox equilibria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GLUTAREDOXIN; SITE CYSTEINE RESIDUES; ACTIVE-SITE; BOND FORMATION; FUNCTIONAL-CHARACTERIZATION; RIBONUCLEOTIDE REDUCTASE; MIXED DISULFIDE; HYDROGEN DONOR; ISOMERASE DSBA; GLUTATHIONE	Glutaredoxins belong to the thioredoxin superfamily of structurally similar thiol-disulfide oxidoreductases catalyzing thiol-disulfide exchange reactions via reversible oxidation of two active-site cysteine residues separated by two amino acids (CX1X2C). Standard state redox potential (E-o') values for glutaredoxins are presently unknown, and use of glutathione/glutathione disulfide (GSH/GSSG) redox buffers for determining E-o' resulted in variable levels of GSH mixed disulfides. To overcome this complication, we have used reverse-phase high performance liquid chromatography to separate and quantify the oxidized and reduced forms present in the thiol-disulfide exchange reaction at equilibrium after mixing one oxidized and one reduced protein. This allowed for direct and quantitative pairwise comparisons of the reducing capacities of the proteins and mutant forms. Equilibrium constants from pair-wise reaction with thioredoxin or its P34H mutant, which have accurately determined E-o' values from their redox equilibrium with NADPH catalyzed by thioredoxin reductase, allowed for transformation into standard state values. Using this new procedure, the standard state redox potentials for the Escherichia coli glutaredoxins 1 and 3, which contain identical active site sequences CPYC, mere found to be E-o' = -233 and -198 mV, respectively. These values were confirmed independently by using the thermodynamic linkage between the stability of the disulfide bond and the stability of the protein to denaturation, Comparison of calculated E-o' values from a number of proteins ranging from -270 mV for E, coli Trx to -124 mV for DsbA obtained using this method with those determined using glutathione redox buffers provides independent confirmation of the standard state redox potential of glutathione as -240 mV. Determining redox potentials through direct protein-protein equilibria is of general interest as it overcomes errors in determining redox potentials calculated from large equilibrium constants with the strongly reducing NADPH or by accumulating mixed disulfides with GSH.	Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Karolinska Institutet	Berndt, KD (corresponding author), Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	kurt.berndt@mbb.ki.se	Berndt, Kurt/J-8574-2015	Berndt, Kurt/0000-0002-3049-967X				Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; CHAN HS, 1990, J CHEM PHYS, V92, P3118, DOI 10.1063/1.458605; CLARK WM, 1960, OXIDATIONREDUCTION P, P471; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; Hennecke J, 1997, J BIOL CHEM, V272, P189; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; JOELSON T, 1990, J BIOL CHEM, V265, P3183; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; KELLEY JJ, 1977, BIOCHEMISTRY-US, V36, P5029; KELLEY RF, 1987, BIOCHEMISTRY-US, V26, P1406, DOI 10.1021/bi00379a029; Kortemme T, 1996, BIOCHEMISTRY-US, V35, P14503, DOI 10.1021/bi9617724; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LIN TY, 1991, P NATL ACAD SCI USA, V88, P10573, DOI 10.1073/pnas.88.23.10573; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Nozaki Y, 1972, Methods Enzymol, V26, P43; PACE CN, 1988, J BIOL CHEM, V263, P11820; ROST J, 1964, NATURE, V201, P185, DOI 10.1038/201185a0; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; SANDBERG VA, 1991, BIOCHEMISTRY-US, V30, P5475, DOI 10.1021/bi00236a021; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCOTT EM, 1963, J BIOL CHEM, V238, P3928; SIEDLER F, 1993, BIOCHEMISTRY-US, V32, P7488, DOI 10.1021/bi00080a021; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	42	319	329	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30780	30786		10.1074/jbc.272.49.30780	http://dx.doi.org/10.1074/jbc.272.49.30780			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388218	hybrid			2022-12-25	WOS:000071640800031
J	Chang, HC; Bush, DR				Chang, HC; Bush, DR			Topology of NAT2, a prototypical example of a new family of amino acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; LYSINE-SPECIFIC PERMEASE; SUGAR-BEET LEAVES; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; BAKERS-YEAST; H+-ATPASE	Amino acids are the predominant form of nitrogen available to the heterotrophic tissues of plants. These essential organic nutrients are transported across the plasma membrane of plant cells by proton-amino acid symporters, Our lab has cloned an amino acid transporter from Arabidopsis, NAT2/AAP1, that represents the first example of a new class of membrane transporters. We are investigating the structure and function of this porter because it is a member of a large gene family in plants and because its wide expression pattern suggests it plays a central role in resource allocation. In the results reported here, we investigated the topology of NAT2 by engineering a c-myc epitope on either the N or C terminus of the protein, We then used in vitro translation, partial digestion with proteinase K, and immunoprecipitation to identify a group of oriented peptide fragments, We modeled the topology of NAT2 based on the lengths of the peptide fragments that allowed us to estimate the location of protease accessible cleavage sites. We independently identified the location of the N and C termini using immunofluorescence microscopy of NAT2 expressed in COS-1 cells, We also investigated the glycosylation status of several sites of potential N-linked glycosylation. Based on the combined data, me propose a novel 11 transmembrane domain model with the N terminus in the cytoplasm and C terminus facing outside the cell. This model of protein topology anchors our complementary investigations of porter structure and function using site-directed and random mutagenesis.	UNIV ILLINOIS, USDA ARS, PHOTOSYNTH RES UNIT, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT PLANT BIOL, URBANA, IL 61801 USA	United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Bush, Daniel R/AAG-8444-2019	Bush, Daniel/0000-0002-9160-5077				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; BRISKIN DP, 1990, BIOCHIM BIOPHYS ACTA, V1019, P95, DOI 10.1016/0005-2728(90)90129-R; Bush DR, 1996, J EXP BOT, V47, P1205, DOI 10.1093/jxb/47.Special_Issue.1205; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; BUSH DR, 1991, RECENT ADV PHLOEM TR, P148; BUSH DR, 1998, IN PRESS PLANT AMINO; Chen LS, 1997, PLANT PHYSIOL, V115, P1127, DOI 10.1104/pp.115.3.1127; CLARK JA, 1993, BIOESSAYS, V15, P323, DOI 10.1002/bies.950150506; Dauterive R, 1996, J BIOL CHEM, V271, P11414, DOI 10.1074/jbc.271.19.11414; ELLIS J, 1995, MICROBIOL-UK, V141, P1927, DOI 10.1099/13500872-141-8-1927; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; Frommer WB, 1995, P NATL ACAD SCI USA, V92, P12036, DOI 10.1073/pnas.92.26.12036; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HONORE N, 1990, NUCLEIC ACIDS RES, V18, P653, DOI 10.1093/nar/18.3.653; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; KAVANAUGH MP, 1994, J BIOL CHEM, V269, P15445; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI ZC, 1990, PLANT PHYSIOL, V94, P268, DOI 10.1104/pp.94.1.268; LI ZC, 1992, ARCH BIOCHEM BIOPHYS, V294, P519, DOI 10.1016/0003-9861(92)90719-D; LI ZC, 1991, PLANT PHYSIOL, V96, P1338, DOI 10.1104/pp.96.4.1338; LIVELY MO, 1983, J BIOL CHEM, V258, P9488; MADDY AH, 1976, J THEOR BIOL, V62, P315, DOI 10.1016/0022-5193(76)90123-5; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Muchhal US, 1996, P NATL ACAD SCI USA, V93, P10519, DOI 10.1073/pnas.93.19.10519; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; PATE JS, 1983, PLANT PHYSL TREATISE, V8, P335; PI J, 1991, J BACTERIOL, V173, P3622, DOI 10.1128/JB.173.12.3622-3629.1991; Rentsch D, 1996, PLANT CELL, V8, P1437, DOI 10.1105/tpc.8.8.1437; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER N, 1994, PLANT J, V6, P67, DOI 10.1046/j.1365-313X.1994.6010067.x; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; Smith FW, 1997, PLANT J, V11, P83, DOI 10.1046/j.1365-313X.1997.11010083.x; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; STEFFES C, 1992, J BACTERIOL, V174, P3242, DOI 10.1128/jb.174.10.3242-3249.1992; SYCHROVA H, 1993, YEAST, V9, P771, DOI 10.1002/yea.320090711; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; Tanner W, 1996, ANNU REV PLANT PHYS, V47, P595, DOI 10.1146/annurev.arplant.47.1.595; VANDENBOL M, 1989, GENE, V83, P153, DOI 10.1016/0378-1119(89)90413-7; WILLIAMS LE, 1992, PLANTA, V186, P541, DOI 10.1007/BF00198034; WILLIAMS LE, 1990, PLANTA, V182, P540, DOI 10.1007/BF02341029	55	44	48	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30552	30557		10.1074/jbc.272.48.30552	http://dx.doi.org/10.1074/jbc.272.48.30552			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374550	hybrid			2022-12-25	WOS:A1997YH61300082
J	Hughes, FM; Bortner, CD; Purdy, GD; Cidlowski, JA				Hughes, FM; Bortner, CD; Purdy, GD; Cidlowski, JA			Intracellular K+ suppresses the activation of apoptosis in lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ACID CLEAVAGE ACTIVITY; PROTEIN-SYNTHESIS; CAENORHABDITIS-ELEGANS; PROLYL OLIGOPEPTIDASE; THYMOCYTE APOPTOSIS; DNA-DEGRADATION; MICE DEFICIENT; ICE FAMILY; PROTEASES	Little is known about the mechanisms of suppression of apoptosis. We have addressed the novel possibility that the level of intracellular K+ regulates the apoptotic process by controlling the activity of death enzymes. We show that K+, at normal intracellular levels, inhibits both apoptotic DNA fragmentation and caspase-3(CPP32)-like protease activation, suggesting that intracellular K+ loss must occur early during apoptosis. Direct measurement of K+ by inductively coupled plasma/ mass spectrometry and flow cytometry indicates a major decrease in intracellular K+ concentration in the apoptotic cell. Flow cytometric analysis revealed that caspase and nuclease activity were restricted to the subpopulation of cells with reduced K+, Disruption of the natural K+ electrochemical gradient suppressed the activity of both caspase and nuclease independent of the mode of activation of the apoptotic inducing agent, demonstrating that a decrease in intracellular K+ concentration is a necessary, early event in programmed cell death.	NIEHS, LAB SIGNAL TRANSDUCT, NIH, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Cidlowski, John A/G-2548-2019; Hughes, Francis M/G-8036-2017	Cidlowski, John A/0000-0003-1420-0516; Hughes, Francis/0000-0003-3776-3653				Adamska I, 1996, EUR J BIOCHEM, V236, P591, DOI 10.1111/j.1432-1033.1996.00591.x; Alberts B., 1983, MOL BIOL CELL, P286; ALHABORI M, 1994, INT J BIOCHEM, V26, P319, DOI 10.1016/0020-711X(94)90052-3; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, PROGRAMMED CELL DEATH, P63; BORTNER CD, 1997, IN PRESS J BIOL CHEM; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARONLESLIE LAM, 1994, ENDOCRINE, V2, P47; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHOW SC, 1995, EXP CELL RES, V216, P149, DOI 10.1006/excr.1995.1019; CIDLOWSKI JA, 1982, ENDOCRINOLOGY, V111, P184, DOI 10.1210/endo-111-1-184; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; COTTER TG, 1990, ANTICANCER RES, V10, P1153; Creighton TE, 1983, PROTEINS STRUCTURES; DIPAOLO ML, 1995, ARCH BIOCHEM BIOPHYS, V323, P329, DOI 10.1006/abbi.1995.9957; Dixon M., 1979, ENZYMES, Vthird; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GRINSTEIN S, 1982, J GEN PHYSIOL, V80, P801, DOI 10.1085/jgp.80.6.801; Hasegawa J, 1996, CANCER RES, V56, P1713; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hughes FM, 1997, CELL DEATH DIFFER, V4, P200; HUGHES FM, 1998, IN PRESS J STEROID B; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JONAS D, 1994, INFECT IMMUN, V62, P1304, DOI 10.1128/IAI.62.4.1304-1312.1994; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KREGENOW FM, 1981, ANNU REV PHYSIOL, V43, P493, DOI 10.1146/annurev.ph.43.030181.002425; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACKNIGHT ADC, 1977, PHYSIOL REV, V57, P510, DOI 10.1152/physrev.1977.57.3.510; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1990, BIOCHEM SOC T, V18, P634, DOI 10.1042/bst0180634; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MINTA A, 1989, J BIOL CHEM, V264, P19449; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NALL BT, 1991, CONFORMATIONS FORCES; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Perregaux DG, 1996, J BIOL CHEM, V271, P29830, DOI 10.1074/jbc.271.47.29830; POLGAR L, 1995, BIOCHEM J, V312, P267, DOI 10.1042/bj3120267; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P10769, DOI 10.1021/bi00159a018; SARKADI B, 1985, AM J PHYSIOL, V248, pC480, DOI 10.1152/ajpcell.1985.248.5.C480; SCHWARTZMAN RA, 1993, ENDOCRINOLOGY, V133, P591, DOI 10.1210/en.133.2.591; SCHWARTZMAN RA, 1991, ENDOCRINOLOGY, V128, P1190, DOI 10.1210/endo-128-2-1190; SKALKA M, 1976, FEBS LETT, V72, P271, DOI 10.1016/0014-5793(76)80984-2; STRICKLAND JA, 1991, BIOCHEMISTRY-US, V30, P9749, DOI 10.1021/bi00104a026; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VUKELIC B, 1995, APPL MICROBIOL BIOT, V43, P1056, DOI 10.1007/BF00166925; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; WONDRAK EM, 1991, FEBS LETT, V280, P344, DOI 10.1016/0014-5793(91)80327-Y; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	70	412	431	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30567	30576		10.1074/jbc.272.48.30567	http://dx.doi.org/10.1074/jbc.272.48.30567			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374553	hybrid			2022-12-25	WOS:A1997YH61300085
J	Pearson, A; Greenblatt, J				Pearson, A; Greenblatt, J			Modular organization of the E2F1 activation domain and its interaction with general transcription factors TBP and TFIIH	ONCOGENE			English	Review						E2F1; TBP; TFIIH; transactivation	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; EUKARYOTIC DNA-REPLICATION; HYDROPHOBIC AMINO-ACIDS; C-TERMINAL DOMAIN; RETINOBLASTOMA PROTEIN; MOLECULAR-CLONING; GROWTH SUPPRESSION; TRANS-ACTIVATION; PROMOTER DNA	The transcriptional activator E2F1 regulates the expression of genes at the G1/S boundary. We have characterized interactions of the E2F1 activation domain with two general transcription factors, the TATA-box binding protein (TBP) and TFIIH. Two distinct binding sites on E2F1 were identified for TBP (amino acids 386-417 and 415-437) each of which supported activation in mammalian cells when expressed as a fusion to a heterologous DNA-binding domain. Neither of these minimal activation domains independently bound TFIIH; rather, the TFIIH binding site of E2F1 overlaps both domains. Loss of TFIIH-binding by E2F1 resulted in a 60-65% reduction in transactivation, suggesting that the E2F1/TFIIH interaction is important, but not essential, for transactivation. The retinoblastoma protein (Rb) binds directly to E2F1 and represses E2F1-mediated transactivation. We have demonstrated that recombinant Rb can compete with TBP and the p62 subunit of TFIIH for binding to immobilized E2F1. A tumorigenic form of Rb deficient in repressing E2F1-mediated transactivation is likewise deficient in displacing TBP from E2F1. We propose that competition between Rb and both TBP and TFIIH for binding to E2F1 is a mechanism by which Rb inhibits transactivation by E2F1.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5G 1L6,CANADA	University of Toronto; University of Toronto				Pearson, Angela/0000-0002-5997-2846				ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; AUERSPERG N, 1964, J NATL CANCER I, V32, P135; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Blau J, 1996, MOL CELL BIOL, V16, P2044; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; GE H, 1994, J BIOL CHEM, V269, P17136; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; ING NH, 1992, J BIOL CHEM, V267, P17617; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PAN GH, 1994, J BIOL CHEM, V269, P30101; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PUGH BF, 1992, J BIOL CHEM, V267, P679; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; SOPTA M, 1985, J BIOL CHEM, V260, P353; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TANTIN D, 1994, J BIOL CHEM, V269, P17397; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TONG X, 1995, P NATL ACAD SCI USA, V92, P3259, DOI 10.1073/pnas.92.8.3259; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOONTNER M, 1989, J BIOL CHEM, V265, P8979; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHU H, 1994, J BIOL CHEM, V269, P3489	112	48	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2643	2658		10.1038/sj.onc.1201451	http://dx.doi.org/10.1038/sj.onc.1201451			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400991				2022-12-25	WOS:A1997YH46800002
J	Benz, CC; OHagan, RC; Richter, B; Scott, GK; Chang, CH; Xiong, XH; Chew, K; Ljung, BM; Edgerton, S; Thor, A; Hassell, JA				Benz, CC; OHagan, RC; Richter, B; Scott, GK; Chang, CH; Xiong, XH; Chew, K; Ljung, BM; Edgerton, S; Thor, A; Hassell, JA			HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer	ONCOGENE			English	Article						breast cancer; HER2/Neu; PEA3; Ets transcription factor	EWINGS-SARCOMA TRANSLOCATION; MESSENGER-RNA; DNA-BINDING; CHROMOSOME-TRANSLOCATION; C-ERBB-2 EXPRESSION; MAMMARY-CARCINOMA; MOLECULAR-CLONING; PHORBOL-ESTER; GENE FAMILY; EWS GENE	HER2/Neu is overexpressed in 25-30% of all human breast cancers as a result of both gene amplification and enhanced transcription. Transcriptional upregulation of HER2/neu leads to a 6-8-fold increased abundance of its mRNA per gene copy and likely results from the elevated activity of transcription factors acting on the HER2/neu promoter, Here we report that transcripts of PEA3, an ETS transcription factor implicated in oncogenesis, were increased in 93% of HER2/Neu-overexpressing human breast tumor samples, Analyses to uncover the molecular basis for elevated PEA3 transcripts in HER2/Neu-positive breast tumors revealed that the HER2/Neu receptor tyrosine kinase initiated an intracellular signaling cascade resulting in increased PEA3 transcriptional activity; transcriptionally-activated PEA3 stimulated HER2/neu and PEA3 gene transcription by binding to sites in the promoters of these genes, PEA3 also activates transcription of genes encoding matrix-degrading proteinases, enzymes required for tumor cell migration and invasion, These findings implicate PEA3 in the initiation and progression of HER2/Neu positive breast cancer, and suggest that PEA3 and signaling proteins affecting its regulation are appropriate therapeutic targets.	MCMASTER UNIV, INST MOL BIOL & BIOTECHNOL, CANC RES GRP, HAMILTON, ON L8S 4K1, CANADA; UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV MOL CYTOMETRY, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV VERMONT, DEPT PATHOL, BURLINGTON, VT 05405 USA	McMaster University					NATIONAL CANCER INSTITUTE [P01CA044768, R01CA036773, P50CA058207] Funding Source: NIH RePORTER; NCI NIH HHS [CA44768, CA58207, CA36773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1995, GENE, V159, P3, DOI 10.1016/0378-1119(95)00147-X; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; DANKORT DL, 1996, MAMMARY TUMOR CELL C, P71; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGLEHART JD, 1990, CANCER RES, V50, P6701; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KING CR, 1989, CANCER RES, V49, P4185; KOHN EC, 1995, CANCER RES, V55, P1856; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIU E, 1992, ONCOGENE, V7, P1027; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MATRISIAN LM, 1994, ANN NY ACAD SCI, V91, P10129; MONTE D, 1994, ONCOGENE, V9, P1397; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OHagan RC, 1996, ONCOGENE, V13, P1323; PARKES HC, 1990, BRIT J CANCER, V61, P39, DOI 10.1038/bjc.1990.9; PASLEAU F, 1993, ONCOGENE, V8, P849; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; TRIPATHY D, 1994, HEMATOL ONCOL CLIN N, V8, P29, DOI 10.1016/S0889-8588(18)30186-2; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	49	146	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1513	1525		10.1038/sj.onc.1201331	http://dx.doi.org/10.1038/sj.onc.1201331			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380403				2022-12-25	WOS:A1997XX36900002
J	Liu, C; Shen, K; Liu, ZY; Noguchi, CT				Liu, C; Shen, K; Liu, ZY; Noguchi, CT			Regulated human erythropoietin receptor expression in mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; GENE-EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; ERYTHROID-CELLS; NERVOUS-SYSTEM; TRANSCRIPTION; DIFFERENTIATION; PROLIFERATION; HEMATOPOIESIS	Erythropoietin (Epo) is known for its role in erythropoiesis and acts by binding to its receptor (EpoR) on the surface of erythroid progenitors, EpoR activity follows the site of hematopoiesis from the embryonic yolk sac to the fetal liver and then the adult spleen and bone marrow, Expression of EpoR has also been observed in selected cells of non-hematopoietic origin, such as the embryonic mouse brain during mid-gestation, at levels comparable to adult bone marrow, EpoR transcripts in brain decrease during development falling by birth to less than 1-3% of the level in hematopoietic tissue, We have now recapitulated this pattern of expression using a human EpoR transgene consisting of an 80-kb human EpoR genomic fragment. The highest level of expression was observed in the embryonic yolk sac and fetal liver, analogous to the endogenous gene, in addition to ex- pression in adult spleen and bone marrow, Although activity of this transgene in brain is initially lower than the endogenous gene, it does exhibit the down-regulation observed for the endogenous gene in adult brain, The expression pattern of hybrid transgenes of an hEpoR promoter fused to beta-galactosidase in 9.5-day embryos suggested that the hEpoR promoter region between -1778 and -150 bp 5' of the transcription start site is necessary to direct EpoR expression in the neural tube, EpoR expression in the neural tube may be the origin of the EpoR transcripts detected in brain during development, These data demonstrate that both the mouse and human EpoR genes contain regulatory elements to direct significant levels of expression in a developmentally controlled manner in brain and suggest that in addition to its function during erythropoiesis, EpoR may play a role in the development of selected non-hematopoietic tissue.	NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Noguchi, CT (corresponding author), NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA.	cnoguchi@helix.nih.gov						ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CARLINI RG, 1995, J CARDIOVASC PHARM, V26, P889, DOI 10.1097/00005344-199512000-00006; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; FLAMME I, 1992, DEVELOPMENT, V116, P435; Haller H, 1996, KIDNEY INT, V50, P481, DOI 10.1038/ki.1996.339; ISHIBASHI T, 1987, J CLIN INVEST, V79, P286, DOI 10.1172/JCI112796; KIMATA H, 1991, CLIN EXP IMMUNOL, V85, P151; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; Li Y, 1996, PEDIATR RES, V40, P376, DOI 10.1203/00006450-199609000-00002; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Liu C, 1996, P ASSOC AM PHYSICIAN, V108, P449; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; MAOUCHE L, 1991, BLOOD, V78, P2557; MAOUCHE L, 1994, NUCLEIC ACIDS RES, V22, P338, DOI 10.1093/nar/22.3.338; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Morishita E, 1996, BLOOD, V88, P465, DOI 10.1182/blood.V88.2.465.bloodjournal882465; NITTA K, 1995, EUR J PHARM-ENVIRON, V293, P491, DOI 10.1016/S0014-2999(95)80109-X; NOGUCHI CT, 1991, BLOOD, V78, P2548; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PENNY LA, 1991, GENOMICS, V11, P974, DOI 10.1016/0888-7543(91)90022-7; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; TABIRA T, 1995, INT J DEV NEUROSCI, V13, P241, DOI 10.1016/0736-5748(94)00020-4; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x; YASUDA Y, 1993, DEV GROWTH DIFFER, V35, P711; YOUSSOUFIAN H, 1993, MOL CELL BIOL, V13, P98, DOI 10.1128/MCB.13.1.98; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; YOUSSOUFIAN H, 1994, BLOOD, V83, P1428; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	42	123	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32395	32400		10.1074/jbc.272.51.32395	http://dx.doi.org/10.1074/jbc.272.51.32395			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405448	hybrid			2022-12-25	WOS:000071108000067
J	Huang, XF; Shelness, GS				Huang, XF; Shelness, GS			Identification of cysteine pairs within the amino-terminal 5% of apolipoprotein B essential for hepatic lipoprotein assembly and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; HETEROLOGOUS EXPRESSION; ENDOPLASMIC-RETICULUM; CELLS; HYPOBETALIPOPROTEINEMIA; LOCALIZATION; DENSITY; BINDING; MUTANT; LIPASE	There is growing evidence that the amino-terminal globular domain of apolipoprotein B (apoB) is essential for lipoprotein particle formation in the hepatic endoplasmic reticulum, To identify the structural requirements for its function in lipoprotein assembly, cysteine (Cys) pairs required to form the seven disulfide bonds within the amino-terminal 21% of apoB were replaced in groups or individually by serine. Substitution of Cys pairs required for formation of disulfide bonds 1-3 or 4-7 (numbered from amino to carboxyl terminus) completely blocked the secretion of apoB28 in transfected HepG2 cells. To identify the specific disulfide bonds required for secretion, Cys pairs were mutated individually, Substitution of Cys pairs required for disulfide bonds 1, 3, 5, 6, or 7 had little or no impact on apoB28 secretion or buoyant density. In contrast, individual substitution of Cys pair 2 (amino acid residues 51 and 70) or 4 (218 and 234) severely inhibited apoB28 secretion and its capacity to undergo intracellular assembly with lipid. The same assembly and secretion defects were observed when these mutations were expressed as part of apoB50. These studies provide direct evidence that the ability of the internal lipophilic regions of apoB to engage in the recruitment and sequestration of lipid during translation is critically dependent upon a structural configuration contained within or affected by the amino terminal 5% of the protein.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT COMPARAT MED,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NHLBI NIH HHS [HL49373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; COLLINS DR, 1988, NUCLEIC ACIDS RES, V16, P8361, DOI 10.1093/nar/16.17.8361; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HAVEL RJ, 1995, METABOLIC MOL BASES, P1841; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HUANG LS, 1989, J BIOL CHEM, V264, P11394; Ingram MF, 1997, J BIOL CHEM, V272, P10279; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LINTON MF, 1993, J LIPID RES, V34, P521; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PATEL SB, 1995, J LIPID RES, V36, P2090; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PRICE NC, 1989, PROTEOLYTIC ENZYMES, P163; Rusinol AE, 1997, J BIOL CHEM, V272, P8019, DOI 10.1074/jbc.272.12.8019; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; TANIYAMA Y, 1992, J BIOL CHEM, V267, P4619; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YUK MH, 1995, J BIOL CHEM, V270, P20169, DOI 10.1074/jbc.270.34.20169	36	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31872	31876		10.1074/jbc.272.50.31872	http://dx.doi.org/10.1074/jbc.272.50.31872			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395534	hybrid			2022-12-25	WOS:A1997YL41900093
J	Latham, GJ; Bacheller, DJ; Pietroni, P; vonHippel, PH				Latham, GJ; Bacheller, DJ; Pietroni, P; vonHippel, PH			Structural analyses of gp45 sliding clamp interactions during assembly of the bacteriophage T4 DNA polymerase holoenzyme .2. The gp44/62 clamp loader interacts with a single defined face of the sliding clamp ring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN COMPLEX; HEXAMERIC HELICASES; III HOLOENZYME; HYDROLYSIS; MECHANISM	The phage T4 gp45 sliding clamp is a ring-shaped replication accessory protein that is mounted onto DNA in an ATP-dependent manner by the gp44/62 clamp loader, In the preceding paper (Pietroni, P., Young, M. C., Latham, G. J., and von Hippel, P. H. (1997) J. Biol. Chem. 272, 31666-31676), two gp45 mutants were exploited to probe interactions of the sliding clamp ring with the gp44/62 loading machinery at various steps during the clamp loading process. In this report, these studies are extended to examine the polarity of the binding interaction between gp45 and gp44/62. Three different gp45 mutants containing a single cysteine in three topographically distinct positions were used, Several different reporter groups, including extrinsic fluorophores, a photo-cross-linker, and a biotin linker for use in a novel ''streptavidin interference assay,'' were covalently attached to these cysteine residues, Since gp45 is a trimeric protein, these three different mutations allowed us to probe up to nine distinct local environments along the surface of the sliding clamp in the presence and absence of other replication proteins. The results show that the gp44/62-ATP clamp loader complex binds exclusively to the C-terminal (S19C) face of the gp45 ring.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R01GM015792, R37GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker T. A., 1992, DNA REPLICATION; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; ELLMANN GL, 1958, ARCH BIOCHEM BIOPHYS, V82, P70; HAUGLAND RP, 1992, MOL PROBES HDB FLUOR; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Latham GJ, 1996, J MOL BIOL, V264, P426, DOI 10.1006/jmbi.1996.0651; LATHAM GJ, 1997, J BIOL CHEM, V272, P31666; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; PIETRONI P, 1997, J BIOL CHEM, V272, P31685; RUSH J, 1989, J BIOL CHEM, V264, P10943; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER RL, 1994, CELL, V77, P225, DOI 10.1016/0092-8674(94)90315-8; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	23	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31677	31684		10.1074/jbc.272.50.31677	http://dx.doi.org/10.1074/jbc.272.50.31677			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395509	hybrid			2022-12-25	WOS:A1997YL41900068
J	Wiemelt, AP; Engleka, MJ; Skorupa, AF; McMorris, FA				Wiemelt, AP; Engleka, MJ; Skorupa, AF; McMorris, FA			Immunochemical visualization and quantitation of cyclic AMP in single cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CENTRAL NERVOUS-SYSTEM; OLIGODENDROCYTE DIFFERENTIATION; SIGNAL-TRANSDUCTION; NITRIC-OXIDE; CAMP; INDUCTION; RADIOIMMUNOASSAY; ANTIBODIES; IMMUNOCYTOCHEMISTRY	Adenosine 3':5'-cyclic monophosphate (cAMP) is a key second messenger in signaling pathways governing many cellular processes. To define the subcellular localization and relative abundance of cAMP, we developed a novel immunochemical approach based on acrolein fixation to visualize cAMP within cells. We describe here the fixation and immobilization of cAMP within cells and the production of specific, high titer polyclonal antibodies that recognize cAMP. Relative levels of cAMP immunofluorescence were quantitated in glial cells (oligodendrocytes, astrocytes, Schwann cells, and glioma cells) that were either untreated or treated with activators of endogenous adenylyl cyclase to raise cAMP levels, In treated cells, cAMP immunofluorescence is strongly localized in the perinuclear cytoplasm.	WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DAVID MAHONEY INST NEUROL SCI, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of Pennsylvania					NINDS NIH HHS [NS32394, NS26119, NS32122] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032122, R01NS026119, R01NS032394] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BOLSOVER S, 1995, BIOCHEM SOC T, V23, P627, DOI 10.1042/bst0230627; CAILLA HL, 1973, ANAL BIOCHEM, V56, P394, DOI 10.1016/0003-2697(73)90205-4; CUMMING R, 1980, J HISTOCHEM CYTOCHEM, V28, P54, DOI 10.1177/28.1.6243322; DEVENTE J, 1993, HISTOCHEMISTRY, V99, P457, DOI 10.1007/BF00274098; DEVENTE J, 1987, NEUROSCIENCE, V22, P361, DOI 10.1016/0306-4522(87)90226-0; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DILIBERTO PA, 1994, METHOD CELL BIOL, V40, P243; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; Horton J K, 1995, Methods Mol Biol, V41, P91; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; JESSEN KR, 1991, ANN NY ACAD SCI, V633, P78; KAPOOR CL, 1982, HDB EXPT PHARM, P333; KING JC, 1983, J HISTOCHEM CYTOCHEM, V31, P62, DOI 10.1177/31.1.6187805; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LAD PJ, 1981, BIOCHEM BIOPH RES CO, V103, P629, DOI 10.1016/0006-291X(81)90497-6; LESTER DS, 1988, AM J PHYSIOL, V254, pC802, DOI 10.1152/ajpcell.1988.254.6.C802; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MCMORRIS FA, 1983, BIOCHIM BIOPHYS ACTA, V762, P560, DOI 10.1016/0167-4889(83)90060-5; MCMORRIS FA, 1983, J NEUROCHEM, V41, P506, DOI 10.1111/j.1471-4159.1983.tb04768.x; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MIRSKY R, 1990, SEMINARS NEUROSCIENC, V2, P423; PETER ME, 1992, EMBO J, V11, P933, DOI 10.1002/j.1460-2075.1992.tb05132.x; PRADELLES P, 1989, ANAL CHEM, V61, P447, DOI 10.1021/ac00180a014; RAIBLE DW, 1990, J NEUROSCI RES, V27, P43, DOI 10.1002/jnr.490270107; RAIBLE DW, 1989, DEV BIOL, V133, P437, DOI 10.1016/0012-1606(89)90047-X; RAIBLE DW, 1993, J NEUROSCI RES, V34, P287, DOI 10.1002/jnr.490340305; RALL TW, 1982, J CYCLIC NUCL PROT, V8, P243; RATNER N, 1984, J CELL BIOL, V98, P1150, DOI 10.1083/jcb.98.3.1150; SCHERER SS, 1994, J NEUROSCI, V14, P1930; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; STEIN JC, 1987, J BIOL CHEM, V262, P3002; Steiner A L, 1976, Adv Cyclic Nucleotide Res, V7, P115; STEINER AL, 1972, J BIOL CHEM, V247, P1106; TSIEN RY, 1992, AM J PHYSIOL, V263, pC723, DOI 10.1152/ajpcell.1992.263.4.C723; Villegas S, 1996, ANAL BIOCHEM, V235, P102, DOI 10.1006/abio.1996.0097; Zhang QH, 1996, DEV BIOL, V176, P51, DOI 10.1006/dbio.1996.9995; Zufall F, 1993, EXS, V66, P135	47	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31489	31495		10.1074/jbc.272.50.31489	http://dx.doi.org/10.1074/jbc.272.50.31489			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395484	hybrid			2022-12-25	WOS:A1997YL41900043
J	Takemura, T; Kondo, S; Homma, T; Sakai, M; Harris, RC				Takemura, T; Kondo, S; Homma, T; Sakai, M; Harris, RC			The membrane-bound form of heparin-binding epidermal growth factor-like growth factor promotes survival of cultured renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE TUBULAR-NECROSIS; FACTOR RECEPTOR; RAT-KIDNEY; EXTRACELLULAR-MATRIX; PHORBOL ESTER; FACTOR-ALPHA; APOPTOSIS; EGF; PROTEIN; REGENERATION	To understand whether expression of membrane-anchored heparin binding epidermal growth factor (proHB-EGF) is involved in renal epithelial cell survival, rat membrane-bound HB-EGF precursor was stably transfected into a renal epithelial cell line, NRK 52E cells (NRKproHB-EGF). When exposed to 10% fetal calf serum (FCS), there were no differences in growth rates among wild-type (WT), vector-transfected (NRKvector), and NRKproHB-EGF., However, when cells were grown in the presence of 1% FCS, the growth rate of NRKproHB-EGF was 65% faster, When confluent cell monolayers were exposed to H-2,O-2, or etoposide, WT or NRKvector exhibited significant apoptotic bodies and DNA laddering; in contrast, NRKproHB-EGF were resistant to both stimuli, as indicated by increased cell viability and marked decrease of apoptotic bodies and DNA laddering, When plated at high density onto plastic dishes without FCS, WT and NRKvector formed few attachments, did not proliferate, and underwent apoptosis, By day 3, no cells survived, Addition of exogenous recombinant HB-EGF (10(-8) nr) to WT or NRKvector increased cell survival by <10% and incubation with conditioned media of NRKproHB-EGF EGF had no effect, In contrast, NRKproHB-EGF attached and formed epithelial colonies, although they did not proliferate, After 3 days, cell viability was 84% of the initial cell number plated, and no evidence of apoptosis was present, When plated in 10% FCS, NRKproHB-EGF attachment to plastic substratum at 1, 2, and 3 h was 250% greater than that of WT or NRKvector. Addition of exogenous recombinant human HB-EGF to WT or NRKvector increased attachment by <50%., When grown on poly(2-hydroxyethyl methacrylate) or in the presence of the integrin receptor-blocking peptide GRG-DTP, neither WT nor NRKvector attached to the substratum or formed cell-cell attachments, Compared with WT or, NRKvector, NRKproHB-EGF exhibited 300% greater cell viability on either poly(a-hydroxyethyl methacrylate)coated dishes or in the presence of GRGDTP and formed cell clusters, When plated at low density (1 x 10(3) cells/1.5-cm dish) or at high density in the presence of an anti-HB-EGF blocking antibody, NRKproHB-EGF failed to form epithelial colonies, Addition of formalin fixed NRKproHB-EGF promoted EGF receptor tyrosine phosphorylation in quiescent A431 cells and stimulated DNA synthesis and prevented H-2,O-2,-induced apoptosis in renal epithelial cells, These results indicate that membrane bound HB-EGF promotes renal epithelial cell survival, possibly by promoting cell-matrix and cell-cell interactions, The failure of either conditioned media or exogenous HB-EGF to reproduce these findings suggests that juxtacrine or tightly coupled paracrine interactions underlie this cytoprotection.	Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Harris, RC (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol, S-3223 Med Ctr N, Nashville, TN 37232 USA.				NIDDK NIH HHS [DK51265, DK39261] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, R01DK051265] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ALLEN J, 1992, RENAL FAILURE, V14, P453, DOI 10.3109/08860229209047652; BEHRENS MT, 1989, AM J PHYSIOL, V257, pF1059, DOI 10.1152/ajprenal.1989.257.6.F1059; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COIMBRA TM, 1990, AM J PHYSIOL, V259, pF438, DOI 10.1152/ajprenal.1990.259.3.F438; COLES HSR, 1993, DEVELOPMENT, V118, P777; CREELY JJ, 1988, CONNECT TISSUE RES, V18, P107, DOI 10.3109/03008208809008063; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GOBE GC, 1990, LAB INVEST, V63, P770; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HOMMA T, 1995, J CLIN INVEST, V96, P1018, DOI 10.1172/JCI118087; HUMES HD, 1989, J CLIN INVEST, V84, P1757, DOI 10.1172/JCI114359; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KENNEDY WA, 1994, J UROLOGY, V152, P658, DOI 10.1016/S0022-5347(17)32675-7; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCCARTHY SA, GENES DEV, V9, P1953; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MILLER SB, 1992, P NATL ACAD SCI USA, V89, P11876, DOI 10.1073/pnas.89.24.11876; MOLITORIS BA, 1990, J CLIN INVEST, V85, P3, DOI 10.1172/JCI114427; NAKAJIMA M, 1994, NEUROSCI LETT, V176, P161, DOI 10.1016/0304-3940(94)90072-8; NORMAN J, 1990, CLIN SCI, V78, P445, DOI 10.1042/cs0780445; NOUWEN EJ, 1994, LAB INVEST, V70, P479; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; RACUSEN LC, 1994, J LAB CLIN MED, V123, P357; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REISS R, 1990, KIDNEY INT, V37, P492; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; Sakai M, 1997, J CLIN INVEST, V99, P2128, DOI 10.1172/JCI119386; SCHUMER M, 1992, AM J PATHOL, V140, P831; TOBACK FG, 1992, KIDNEY INT, V41, P226, DOI 10.1038/ki.1992.32; WALKER C, 1991, CANCER RES, V51, P2973; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871	43	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31036	31042		10.1074/jbc.272.49.31036	http://dx.doi.org/10.1074/jbc.272.49.31036			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388253	hybrid			2022-12-25	WOS:000071640800066
J	DuflotDancer, A; Mesnil, M; Yamasaki, H				DuflotDancer, A; Mesnil, M; Yamasaki, H			Dominant-negative abrogation of connexin-mediated cell growth control by mutant connexin genes	ONCOGENE			English	Article						gap junction; cell-cell communication; tumor suppression; Cx26	MARIE-TOOTH DISEASE; JUNCTIONAL INTERCELLULAR COMMUNICATION; TUMOR-SUPPRESSOR GENES; C6 GLIOMA-CELLS; GAP-JUNCTIONS; LIVER TUMOR; MUTATIONS; PROTEIN; CDNA; TRANSFECTION	Connexin genes exert negative growth control when transfected into various types of tumor cell lines, We previously demonstrated that connexin 26 (Cx26) suppresses in vitro and in vivo growth of HeLa cells, In this study, we have examined whether certain Cx26 mutants can abrogate cell growth control and the gap junctional intercellular communication (GJIC) capacity of such Cx26-transfected HeLa cells, For this purpose, we transfected three mutated Cx26 genes (C60F, P87L and R143W) into HeLa cells already containing the wild-type Cx26 gene, which are GJIC-competent and non-tumorigenic. Transfection of P87L and R143W mutants enhanced the tumorigenicity of the HeLa Cx26 cells in nude mice without any change in GJIC capacity, On the other hand, transfection of the C60F mutant reduced the GJIC capacity of HeLa Cx26 cells without affecting their growth in vivo. Immunostaining studies demonstrated that the Cx26 proteins were localized mainly at cell-cell contact areas in the Hel,a Cx26 cells both before and after transfection of mutated Cx26 genes, These results suggest that certain mutant Cx26 proteins exert a dominant-negative effect on Cx26-regulated growth of HeLa cells and that such effects may be independent of the effect on GJIC ability, It is proposed that wild-type and mutant Cx26 proteins produce heteromeric connexons and that such heteromeric connexons may exert different effects on growth control from those of homomeric connexons.	INT AGCY RES CANC,UNIT MULTISTAGE CARCINOGENESIS,F-69372 LYON 08,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC)				Mesnil, Marc/0000-0003-4922-0365	NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-40534] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BRUZZONE R, 1994, NEURON, V13, P1253, DOI 10.1016/0896-6273(94)90063-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dahl E, 1996, J BIOL CHEM, V271, P17903, DOI 10.1074/jbc.271.30.17903; deFeijter AW, 1996, MOL CARCINOGEN, V16, P203, DOI 10.1002/(SICI)1098-2744(199608)16:4<203::AID-MC4>3.3.CO;2-F; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FAIRWEATHER N, 1994, HUM MOL GENET, V3, P29, DOI 10.1093/hmg/3.1.29; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; Krutovskikh V, 1996, CARCINOGENESIS, V17, P1761, DOI 10.1093/carcin/17.8.1761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; MESNIL M, 1993, MOL CARCINOGEN, V7, P14, DOI 10.1002/mc.2940070103; MESNIL M, 1993, EUR J PHARM-ENVIRON, V248, P59, DOI 10.1016/0926-6917(93)90025-L; MIRONOV NM, 1994, CANCER RES, V54, P41; NAUS CCG, 1992, CANCER RES, V52, P4208; Omori Y, 1996, CARCINOGENESIS, V17, P2077, DOI 10.1093/carcin/17.9.2077; Omori Y, 1996, MOL BIOL CELL, V7, P907, DOI 10.1091/mbc.7.6.907; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; Saito T, 1997, CANCER RES, V57, P375; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SATO K, 1997, IN PRESS NEUROPATHOL; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	33	73	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2151	2158		10.1038/sj.onc.1201393	http://dx.doi.org/10.1038/sj.onc.1201393			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393973				2022-12-25	WOS:A1997YD01900003
J	Duh, FM; Scherer, SW; Tsui, LC; Lerman, MI; Zbar, B; Schmidt, L				Duh, FM; Scherer, SW; Tsui, LC; Lerman, MI; Zbar, B; Schmidt, L			Gene structure of the human MET proto-oncogene	ONCOGENE			English	Article						MET proto-oncogene; HGF/SF receptor; renal carcinoma	RENAL-CELL CARCINOMA; TYROSINE KINASE; C-MET; GROWTH-FACTOR; HGF RECEPTOR; OVEREXPRESSION; SEQUENCE; MUTATION; LINE; KIT	By direct sequencing of cosmids using primers designed from the known cDNA sequence, we identified 19 exons in the human MET proto-oncogene, and sequenced the corresponding 5' and 3' exon-intron junctions. By homology search in the database of the Washington University Genome Sequence Center (GSC), we identified one additional exon. These 20 exons, together with a previously reported exon, bring the total exon number of MET to 21. Oligonucleotide primers were designed to amplify each exon and adjacent intronic sequences to permit examination of each exon for mutations. By restriction mapping, we assembled a 110 kb genomic contig that covered almost the entire MET protooncogene, This information is relevant for the screening of recently reported mutations of the MET gene which cause hereditary papillary renal carcinomas and for the search for additional mutations of the same gene which may play a role in the pathogenesis of common human carcinomas including carcinomas of the breast, ovary and pancreas.	NCI,INTRAMURAL RES SUPPORT PROGRAM,SAIC FREDERICK,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; NCI,IMMUNOBIOL LAB,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDRE C, 1992, ONCOGENE, V7, P685; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KWOK JBJ, 1993, ONCOGENE, V8, P2575; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1991, ONCOGENE, V6, P553; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; ZBAR B, 1995, J UROLOGY, V153, P907, DOI 10.1016/S0022-5347(01)67601-8	17	44	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1583	1586		10.1038/sj.onc.1201338	http://dx.doi.org/10.1038/sj.onc.1201338			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380410				2022-12-25	WOS:A1997XX36900009
J	Zimmermann, S; Rommel, C; Ziogas, A; Lovric, J; Moelling, K; Radziwill, G				Zimmermann, S; Rommel, C; Ziogas, A; Lovric, J; Moelling, K; Radziwill, G			MEK1 mediates a positive feedback an Raf-1 activity independently of Ras and Src	ONCOGENE			English	Article						feedback loop; mitogen-activated protein kinase cascade; MEK1; Raf-1 activation	PROTEIN-TYROSINE-PHOSPHATASE; MAP KINASE-KINASE; PLASMA-MEMBRANE; PHOSPHORYLATION; ACTIVATION; C-RAF-1; INSULIN; IDENTIFICATION; MUTANTS; BINDING	Growth factor stimulated receptor tyrosine kinases activate a protein kinase cascade via the serine/threonine protein kinase Raf-1, Direct upstream activators of Raf-1 are Ras and Src, This study shows that MEK1, the direct downstream effector of Raf-1, can also stimulate Raf-1 kinase activity by a positive feedback loop, Activated MEK1 mediates hyperphosphorylation of the amino terminal regulatory as well as of the carboxy terminal catalytic domain of Raf-1. The hyperphosphorylation of Raf-1 correlates with a change in the tryptic phosphopeptide pattern only at terminus of Raf-1 and an increase in activity, MEK1-mediated Raf-1 activation is inhibited by co-expression of the MAPK specific phosphatase MKP-1 indicating that the MEK1 effect is exerted through a MAPK dependent pathway. Stimulation of Raf-1 activity by MEK1 is independent of Ras, Src and tyrosine phosphorylation of Raf-1, MEK1 can however synergize with Ras and leads to further increase of the Raf-1 kinase activity, Thus, MEK1 can mediate activation of Raf-1 by a novel positive feedback mechanism which allows fast signal amplification and could prolong activation of Raf-1.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND	University of Zurich				Lovric, Josip/0000-0002-0338-6581				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Alessandrini A, 1996, J BIOL CHEM, V271, P31612, DOI 10.1074/jbc.271.49.31612; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENT P, 1995, MOL CELL BIOL, V15, P4125; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Holt KH, 1996, MOL CELL BIOL, V16, P577; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JOHN J, 1988, J BIOL CHEM, V263, P11792; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Lovric J, 1996, ONCOGENE, V12, P1109; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NEBREDA AR, 1994, TRENDS BIOCHEM SCI, V19, P1, DOI 10.1016/0968-0004(94)90163-5; NIEHOF M, 1995, BIOCHEM BIOPH RES CO, V206, P46, DOI 10.1006/bbrc.1995.1007; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; Radziwill G, 1996, BIOCHEM BIOPH RES CO, V227, P20, DOI 10.1006/bbrc.1996.1461; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUEN KL, 1995, SCIENCE, V264, P1463; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; UEKI K, 1994, J BIOL CHEM, V269, P15756; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	50	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1503	1511		10.1038/sj.onc.1201322	http://dx.doi.org/10.1038/sj.onc.1201322			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380402				2022-12-25	WOS:A1997XX36900001
J	Barr, AJ; Manning, DR				Barr, AJ; Manning, DR			Agonist-independent activation of G(z) by the 5-hydroxytryptamine(1A) receptor co-expressed in Spodoptera frugiperda cells - Distinguishing inverse agonists from neutral antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEINS; TERNARY COMPLEX MODEL; HAMSTER OVARY CELLS; 5-HT1A RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; INSECT CELLS; SF9 CELLS; NEUROLEPTIC RECEPTORS; TRANSGENIC MICE; RAT-BRAIN	The human 5-hydroxytryptamine(1A) receptor, when expressed in Spodoptera frugiperda (Sf9) cells, facilitates the binding of [S-35]GTP gamma S to a co-expressed GTP-binding regulatory protein, G(z), consistent with constitutive activity. The antagonists 4-(2'-methoxyphenyl)-1-[2'-(n-2 "-pyridinyl)-p-iodobenzamido]ethyl-piperazine (p-MPPI) and the related fluorobenzamido analogue p-MPPF had little (p-MPPI) or no (p-MPPF) effect on this activity, In contrast, a third antagonist, the neuroleptic spiperone, produced an almost complete suppression. Thus, using G protein activation as an index of receptor activity, p-MPPF was classified as a neutral antagonist, p-MPPI as a partial inverse agonist, and spiperone as essentially a full inverse agonist, As predicted, spiperone displayed properties consistent with a special form of noncompetitive antagonism when used to displace the agonist [I-125]R-(+)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin. Our data profile Sf9 cells as a unique vehicle for the characterization of inverse agonists, as these cells support a systematic pairing of mammalian receptors and G proteins, quantitative assays of G protein activation, and unambiguously labeled populations of coupled and uncoupled receptors.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.			Barr, Alastair/0000-0001-7738-8419	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH048125] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51196] Funding Source: Medline; NIMH NIH HHS [MH48125] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERT PR, 1990, J BIOL CHEM, V265, P5825; BARKER EL, 1994, J BIOL CHEM, V269, P11687; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BRAESTRUP C, 1982, SCIENCE, V216, P1241, DOI 10.1126/science.6281892; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; Cowen DS, 1997, MOL PHARMACOL, V52, P221, DOI 10.1124/mol.52.2.221; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FLETCHER A, 1993, TRENDS PHARMACOL SCI, V14, P441, DOI 10.1016/0165-6147(93)90185-M; Garnovskaya MN, 1997, J BIOL CHEM, V272, P7770, DOI 10.1074/jbc.272.12.7770; GOZLAN H, 1983, NATURE, V305, P140, DOI 10.1038/305140a0; GUAN XM, 1992, MOL PHARMACOL, V41, P695; HALL MD, 1985, J NEUROCHEM, V44, P1685, DOI 10.1111/j.1471-4159.1985.tb07155.x; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Hensler JG, 1996, J PHARMACOL EXP THER, V278, P1138; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HOYER D, 1994, PHARMACOL REV, V46, P157; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Kenakin T, 1996, PHARMACOL REV, V48, P413; KENAKIN T, 1993, PHARM ANAL DRUG RECE, P334; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KREISS DS, 1993, NEUROSCIENCE, V52, P295, DOI 10.1016/0306-4522(93)90157-B; KUNG HF, 1994, LIFE SCI, V55, P1459, DOI 10.1016/0024-3205(94)00686-5; Kung HF, 1996, SYNAPSE, V23, P344, DOI 10.1002/(SICI)1098-2396(199608)23:4<344::AID-SYN13>3.0.CO;2-X; KUNG MP, 1995, J PHARMACOL EXP THER, V272, P429; LABRECQUE J, 1995, MOL PHARMACOL, V48, P150; LAI HWL, 1995, FEBS LETT, V360, P97, DOI 10.1016/0014-5793(95)00088-Q; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEYSEN JE, 1978, NATURE, V272, P168, DOI 10.1038/272168a0; LEYSEN JE, 1978, BIOCHEM PHARMACOL, V27, P307, DOI 10.1016/0006-2952(78)90233-2; LIU YF, 1991, J BIOL CHEM, V266, P23689; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; NewmanTancredi A, 1997, BRIT J PHARMACOL, V120, P737, DOI 10.1038/sj.bjp.0701025; PARKER EM, 1991, J BIOL CHEM, V266, P519; PARKER EM, 1994, EUR J PHARM-MOLEC PH, V268, P43, DOI 10.1016/0922-4106(94)90118-X; PEROUTKA SJ, 1986, J NEUROCHEM, V47, P529; RAYMOND JR, 1989, MOL PHARMACOL, V36, P15; ROBINS LS, 1993, CELL, V72, P827; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; SUNDARAM H, 1995, J NEUROCHEM, V65, P1909; SUNDARAM H, 1993, BIOCHEM PHARMACOL, V45, P1003, DOI 10.1016/0006-2952(93)90243-P; THOMAS DR, 1995, J RECEPT SIGNAL TR R, V15, P199, DOI 10.3109/10799899509045217; TIAN WN, 1994, MOL PHARMACOL, V45, P524; TIBERI M, 1994, J BIOL CHEM, V269, P27925; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WREGGETT KA, 1984, MOL PHARMACOL, V26, P214; ZHUANG ZP, 1994, J MED CHEM, V37, P1406, DOI 10.1021/jm00036a003; ZHUANG ZP, 1993, J MED CHEM, V36, P3161, DOI 10.1021/jm00073a016	59	49	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32979	32987		10.1074/jbc.272.52.32979	http://dx.doi.org/10.1074/jbc.272.52.32979			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407078	Green Accepted, hybrid			2022-12-25	WOS:000071182900039
J	Cosenza, L; Sweeney, E; Murphy, JR				Cosenza, L; Sweeney, E; Murphy, JR			Disulfide bond assignment in human interleukin-7 by matrix-assisted laser desorption/ionization mass spectroscopy and site-directed cysteine to serine mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE INTERLEUKIN-7; RECEPTOR SUPERFAMILY; CLONING; GROWTH; PROTEIN; IL-7	Interleukin-7 (IL-7) is a proteinaceous biological response modifier that has a bioactive tertiary structure dependent on disulfide bond formation, Disulfide bond assignments in human (h)IL-7 are based upon the results of matrix-assisted laser desorption/ionization (MALDI) mass spectroscopy and Cys to Ser mutational analyses. A gene encoding the hIL-7 was synthesized incorporating Escherichia coli codon usage bias and was used to express biologically active protein as determined by stimulation of precursor B-cell proliferation. MALDI mass spectroscopic analysis of trypsin-digested hIL-7 was performed and compared with the anticipated results of a simulated tryptic digestion, Many of the anticipated hIL-7 tryptic fragments were detected including one with a molecular mass equivalent to the sum of two polypeptides linked through a disulfide bond formed from Cys residues (Cys(3) and Cys(142)). Subsequently, Cys to Ser substitution mutational analyses were performed, A hIL-7 variant with all six Cys substituted with Ser was found to be biologically inactive (EC50 > 1 x 10(-7) M). In contrast, a family of single disulfide bond-forming variants of hIL-7 were constructed by reintroducing Cys pairs (Cys(3)-Cys(142), Cys(35)-Cys(130), and Cys(48)-Cys(93)), and each could stimulate cell proliferation with an EC50 of 4 x 10(-9), 2 x 10(-8), and 2 x 10(-9) M, respectively, In single disulfide bond-forming mutants of hIL-7, the ability to stimulate cell proliferation was abolished in the presence of 2 mM dithiothreitol, The results presented strongly suggest that only a single disulfide bond is required for hIL-7 to form a tertiary structure capable of stimulating precursor B-cell proliferation.	Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Clin Res, Sect Biomol Med, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Murphy, JR (corresponding author), Boston Univ, Med Ctr, Evans Dept Med, Sect Biomol Med, 88 E Newton St, Boston, MA 02118 USA.							ARMITAGE RJ, 1990, J IMMUNOL, V144, P938; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CONLON PJ, 1989, BLOOD, V74, P1368; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; DIEZEL W, 1972, ANAL BIOCHEM, V48, P617, DOI 10.1016/0003-2697(72)90117-0; DIGEL W, 1991, BLOOD, V78, P53; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HENNEY CS, 1989, IMMUNOL TODAY, V10, P170, DOI 10.1016/0167-5699(89)90175-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING LAB MANU; MERLEBERAL H, 1993, NOUV REV FR HEMATOL, V35, P31; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; PIETRANGELI CE, 1988, EUR J IMMUNOL, V18, P863, DOI 10.1002/eji.1830180606; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P350; TUOW I, 1990, BLOOD, V75, P2097; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	21	27	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32995	33000		10.1074/jbc.272.52.32995	http://dx.doi.org/10.1074/jbc.272.52.32995			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407080	hybrid			2022-12-25	WOS:000071182900041
J	Hasegawa, M; Crowther, RA; Jakes, B; Goedert, M				Hasegawa, M; Crowther, RA; Jakes, B; Goedert, M			Alzheimer-like changes in microtubule-associated protein tau induced by sulfated glycosaminoglycans - Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; GLYCOGEN-SYNTHASE KINASE-3; NEUROFIBRILLARY TANGLES; MONOCLONAL-ANTIBODY; HEPARAN-SULFATE; DISEASE BRAIN; FETAL TAU; SITES; IDENTIFICATION; PROTEOGLYCANS	Hyperphosphorylated microtubule-associated protein tau is the major proteinaceous component of the paired helical and straight filaments which constitute a defining neuropathological characteristic of Alzheimer's disease and a number of other neurodegenerative disorders. We have recently shown that full-length recombinant tau assembles into Alzheimer-like filaments upon incubation with heparin. Heparin also promotes phosphorylation of tau by a number of protein kinases, prevents tan from binding to taxol-stabilized microtubules, and produces rapid disassembly of microtubules assembled from tau and tubulin. Here, we have used the above parameters to study the interactions between tau protein and a number of naturally occurring and synthetic glycosaminoglycans. We show that the magnitude of the glycosaminoglycan effects is proportional to their degree of sulfation. Thus, the strongly sulfated glycosaminoglycans dextran sulfate, pentosan polysulfate, and heparin were the most potent, whereas the non-sulfated dextran and hyaluronic acid were without effect. The moderately sulfated glycosaminoglycans heparan sulfate, chondroitin sulfate, and dermatan sulfate had intermediate effects, whereas keratan sulfate had little or no effect. These in vitro interactions between tau protein and sulfated glycosaminoglycans reproduced the known characteristics of paired helical filament-tau from Alzheimer's disease brain. Sulfated glycosaminoglycans are present in nerve cells in Alzheimer's disease brain in the early stages of neurofibrillary degeneration, suggesting that their interactions with tau may constitute a central event in the development of the neuronal pathology of Alzheimer's disease.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Hasegawa, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BUEESCHERRER V, 1995, AM J PATHOL, V146, P924; BueeScherrer V, 1996, MOL BRAIN RES, V39, P79, DOI 10.1016/0169-328X(96)00003-4; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DUNCAN MW, 1992, J NEUROSCI, V12, P1523, DOI 10.1523/jneurosci.12-04-01523.1992; FREDERICKSON CJ, 1983, BRAIN RES, V273, P335, DOI 10.1016/0006-8993(83)90858-2; Ginsberg SD, 1997, ANN NEUROL, V41, P200, DOI 10.1002/ana.410410211; Goedert M, 1996, COLD SPRING HARB SYM, V61, P565; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; Goedert M., 1997, MOL GENETIC BASIS NE, P613; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hasegawa M, 1996, FEBS LETT, V384, P25, DOI 10.1016/0014-5793(96)00271-2; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HUANG DY, 1995, NEUROSCI LETT, V192, P209, DOI 10.1016/0304-3940(95)11649-H; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MORENO FJ, 1995, FEBS LETT, V372, P65, DOI 10.1016/0014-5793(95)00934-2; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Perez M, 1996, J NEUROCHEM, V67, P1183; PERRY G, 1991, J NEUROSCI, V11, P3679; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SERRANO L, 1985, EUR J BIOCHEM, V153, P595, DOI 10.1111/j.1432-1033.1985.tb09342.x; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SNOW AD, 1989, ACTA NEUROPATHOL, V78, P113, DOI 10.1007/BF00688198; SNOW AD, 1992, J HISTOCHEM CYTOCHEM, V40, P105, DOI 10.1177/40.1.1370306; SNOW AD, 1990, AM J PATHOL, V137, P1253; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; Stieber A, 1996, AM J PATHOL, V148, P415; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; YANG SD, 1994, J NEUROCHEM, V63, P1416; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	57	186	190	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33118	33124		10.1074/jbc.272.52.33118	http://dx.doi.org/10.1074/jbc.272.52.33118			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407097	hybrid			2022-12-25	WOS:000071182900058
J	Kumari, K; Weigel, PH				Kumari, K; Weigel, PH			Molecular cloning, expression, and characterization of the authentic hyaluronan synthase from group C Streptococcus equisimilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; ACID; GENE; BINDING; IDENTIFICATION; BIOSYNTHESIS; LOCALIZATION; ACTIVATION; PYOGENES; BACTERIA	We previously reported the first cloning of a functional glycosaminoglycan synthase, the hyaluronan synthase (HAS) from Group A Streptococcus pyogenes (spHAS) (DeAngelis, P. L., Papaconstantinou, J., and Weigel, P. H. (1993) J. Biol. Chem. 268, 19181-19184). Group A spHAS was unrelated to a putative Group C HA synthase reported by others (Lansing, M., Lellig, S., Mausolf, A., Martini, I., Crescenzi, F., Oregon, M., and Prehm, P., (1993) Biochem. J. 289, 179-184). Here we report the isolation of a bona fide HA synthase gene from a highly encapsulated strain of Group C Streptococcus equisimilis. The encoded protein, designated seHAS, is 417 amino acids long (calculated molecular weight, 47,778; calculated pi, 9.1) and is the smallest member of the HAS family identified thus far. The enzyme migrates anomalously fast in SDS-polyacrylamide gel electrophoresis (similar to 42,000 Da). The seHAS protein shows no similarity (<2% identity) to the previously reported Group C gene, which is not an HA synthase. The seHAS and spHAS protein and coding sequences are 72 and 70% identical, respectively. seHAS is also similar to eukaryotic HAS1 (similar to 31% identical), HAS2 (similar to 28% identical), and HAS3 (28% identical). The deduced protein sequence of seHAS was confirmed by reactivity with a synthetic peptide antibody, Recombinant seHAS expressed in Escherichia coli was recovered in membranes as a major protein (similar to 10% of the total protein) and synthesized very large HA (M-r >7 x 10(6)) in the presence of UDP-GlcNAc and UDP-GlcA. The product contained equimolar amounts of both sugars and was degraded by the specific Streptomyces hyaluronidase. Comparison of the two recombinant streptococcal enzymes in isolated membranes showed that seHAS and spHAS are essentially identical in the steady-state size distribution of HA chains they synthesize, but seHAS has an intrinsic 2-fold faster rate of chain elongation (V-max) than spHAS. seHAS is the most active HA synthase identified thus far; it polymerizes HA at an average rate of 160 monosaccharides/s. The two bacterial HA synthase genes may have arisen from a common ancient gene shared with the early evolving vertebrates.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@uokhsc.edu			NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLOING G, 1990, MOL MICROBIOL, V4, P633, DOI 10.1111/j.1365-2958.1990.tb00632.x; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; HELDERMON C, 1996, MOL BIOL CELL, V7, P55; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Husmann LK, 1997, INFECT IMMUN, V65, P1422, DOI 10.1128/IAI.65.4.1422-1430.1997; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; ITO K, 1977, CELL, V11, P551, DOI 10.1016/0092-8674(77)90073-3; KLEWES L, 1994, J CELL PHYSIOL, V160, P539, DOI 10.1002/jcp.1041600317; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSING M, 1993, BIOCHEM J, V289, P179, DOI 10.1042/bj2890179; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PITSILLIDES AA, 1995, J HISTOCHEM CYTOCHEM, V43, P263, DOI 10.1177/43.3.7868856; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PREHM S, 1995, J ANAT, V187, P271; RITTIG M, 1993, GRAEF ARCH CLIN EXP, V231, P313, DOI 10.1007/BF00919026; RITTIG M, 1992, EXP EYE RES, V54, P455, DOI 10.1016/0014-4835(92)90057-Y; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; Schmidt KH, 1996, MED MICROBIOL IMMUN, V184, P169, DOI 10.1007/PL00008248; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; Spicer AP, 1997, GENOMICS, V41, P493, DOI 10.1006/geno.1997.4696; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Spicer AP, 1997, J BIOL CHEM, V272, P8957; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	45	65	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32539	32546		10.1074/jbc.272.51.32539	http://dx.doi.org/10.1074/jbc.272.51.32539			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405467	hybrid			2022-12-25	WOS:000071108000086
J	Thevissen, K; Osborn, RW; Acland, DP; Broekaert, WF				Thevissen, K; Osborn, RW; Acland, DP; Broekaert, WF			Specific, high affinity binding sites for an antifungal plant defensin on Neurospora crassa hyphae and microsomal membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; TOMATO CELLS; L SEEDS; INHIBITION; PROTEINS; THIONINS; CHANNELS; RADISH; GROWTH	Hs-AFP1 an antifungal plant defensin from seed of the plant Heuchera sanguinea, was radioactively labeled using t-butoxycarbonyl-[S-35]L-methionine N-hydroxysuccinimidyl ester, resulting in a S-35-labeled peptide with unaltered antifungal activity. [S-35]Hs-AFP1 was used to assess binding on living hyphae of the fungus Neurospora crassa. Binding of [S-35]Hs-AFP1 was found to be competitive, reversible, and saturable with an apparent K-d of 29 nM and a B-max of 1.4 pmol/mg protein. [S-35]Hs-AFP1 also bound specifically and reversibly to microsomal membranes derived hom N. crassa hyphae with a K-d of 27 nM and a B-max of 102 pmol/mg protein. The similarity in K-d value between binding sites on hyphae and microsomes indicates that Hs-AFP1 binding sites reside on the plasma membrane. Binding of [S-35]Hs-AFP1 to both hyphae and microsomal membranes could be competed to some extent by four different structurally related plant defensins but not by various structurally unrelated antimicrobial peptides. In addition, an inactive single amino acid substitution variant of the antifungal plant defensin Rs-AFP2 from Raphanus sativus seed was also unable to displace [S-35]Hs-AFP1 from its binding sites, whereas Rs-AFP2 itself was able to compete with [S-35]Hs-AFP1.	Katholieke Univ Leuven, FA Janssens Lab Genet, B-3001 Heverlee, Belgium; Zeneca Agrochem, Jealotts Hill Res Stn, Bracknell RG42 6ET, Berks, England	KU Leuven	Broekaert, WF (corresponding author), Katholieke Univ Leuven, FA Janssens Lab Genet, K Mercierlaan 92, B-3001 Heverlee, Belgium.	willem.broekaert@agr.kuleuven.ac.be	Thevissen, Karin/B-7003-2015	Thevissen, Karin/0000-0003-0275-9072				BASSE CW, 1993, J BIOL CHEM, V268, P14724; BAUREITHEL K, 1994, J BIOL CHEM, V269, P17931; BOWMAN EJ, 1988, METHOD ENZYMOL, V157, P562; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; BROEKAERT WF, 1992, BIOCHEMISTRY-US, V31, P4308, DOI 10.1021/bi00132a023; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; Caaveiro JMM, 1997, FEBS LETT, V410, P338, DOI 10.1016/S0014-5793(97)00613-3; Cai G, 1997, TRENDS PLANT SCI, V2, P86, DOI 10.1016/S1360-1385(96)10057-1; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; CAMMUE BRUNO PA, 1995, PLANT PHYSIOL, V109, P445, DOI 10.1104/pp.109.2.445; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; DeSamblanx GW, 1997, J BIOL CHEM, V272, P1171, DOI 10.1074/jbc.272.2.1171; JACKSON SL, 1993, MICROBIOL REV, V57, P367, DOI 10.1128/MMBR.57.2.367-382.1993; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; LAKEY JH, 1994, TOXICOLOGY, V87, P85, DOI 10.1016/0300-483X(94)90156-2; LEHRER RI, 1988, BLOOD, V72, P507; MORENO M, 1994, EUR J BIOCHEM, V223, P135, DOI 10.1111/j.1432-1033.1994.tb18974.x; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; Schmitt MJ, 1995, ARCH MICROBIOL, V164, P435; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tailor RH, 1997, J BIOL CHEM, V272, P24480, DOI 10.1074/jbc.272.39.24480; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; TERRAS FRG, 1993, PLANT PHYSIOL, V103, P1311, DOI 10.1104/pp.103.4.1311; Thevissen K, 1996, J BIOL CHEM, V271, P15018, DOI 10.1074/jbc.271.25.15018	25	89	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32176	32181		10.1074/jbc.272.51.32176	http://dx.doi.org/10.1074/jbc.272.51.32176			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405418	hybrid			2022-12-25	WOS:000071108000037
J	Faiman, GA; Horovitz, A				Faiman, GA; Horovitz, A			Thermodynamic analysis of the interaction between the 0.5 beta Fv fragment and the RP135 peptide antigen derived from the V3 loop of HIV-1 gp120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTRALIZING ANTIBODY; HEAT-CAPACITY; CRYSTAL-STRUCTURE; BINDING; SITE; PROTEINS; DETERMINANT; RECOGNITION; ASSOCIATION	The Fv fragment of the 0.5 beta monoclonal antibody has recently been constructed, expressed, and purified. It binds with nanomolar affinity to the immunogenic RP135 peptide that is derived from the principal neutralizing determinant of HIV-1 in the third hypervariable region of gp120. Here, we analyzed the temperature-dependence of binding of the 0.5 beta Fv fragment to the RP135 peptide and a series of mutants thereof. Our results show that there is almost complete enthalpy-entropy compensation in the effects of mutations in the peptide on binding to the Fv, indicating that the mutations do not change the binding mechanism. There is good correlation, for residues within the antigenic epitope, between mutational effects on Delta C-p and calculated values of Delta Delta C-p, based on the extent of burial of polar and non-polar surface areas of amino acids. The value of Delta C-p for the binding of the 0.5 beta Fv fragment to the wild-type RP135 peptide is found to be -5.0 (+/- 0.9) heal K-1 mol(-1) in the presence of 0.1% Tween-20 but only -0.1 (+/- 0.9) kcal K-1 mol(-1) in its absence. This result has important implications for the successful application of the structural parameterization approach to predicting changes in heat capacity that accompany binding reactions carried out in the presence of detergent or protein-stabilizing agents.	WEIZMANN INST SCI, DEPT BIOL STRUCT, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AYALA YM, 1995, J MOL BIOL, V253, P787, DOI 10.1006/jmbi.1995.0591; DECRISTOFARO R, 1994, J MOL BIOL, V239, P569, DOI 10.1006/jmbi.1994.1396; Faiman GA, 1996, J BIOL CHEM, V271, P13829, DOI 10.1074/jbc.271.23.13829; Frisch C, 1997, J MOL BIOL, V267, P696, DOI 10.1006/jmbi.1997.0892; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; GOMEZ J, 1995, J MOL BIOL, V252, P337, DOI 10.1006/jmbi.1995.0501; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HIBBITS KA, 1994, BIOCHEMISTRY-US, V33, P3584, DOI 10.1021/bi00178a015; Hurle Mark R., 1994, Current Opinion in Biotechnology, V5, P428, DOI 10.1016/0958-1669(94)90053-1; LADBURY JE, 1994, J MOL BIOL, V238, P669, DOI 10.1006/jmbi.1994.1328; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leffler J. E., 1963, RATES EQUILIBRIA ORG, P315; Mandiyan V, 1996, J BIOL CHEM, V271, P4770; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1995, PROTEINS, V21, P83, DOI 10.1002/prot.340210202; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; NILSSON B, 1995, CURR OPIN STRUC BIOL, V5, P450, DOI 10.1016/0959-440X(95)80028-X; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x; REES AR, 1994, TRENDS BIOTECHNOL, V12, P199, DOI 10.1016/0167-7799(94)90083-3; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; STOLL VS, 1990, METHOD ENZYMOL, V182, P24; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015; ZVI A, 1995, EUR J BIOCHEM, V229, P178, DOI 10.1111/j.1432-1033.1995.tb20453.x; Zvi A, 1997, BIOCHEMISTRY-US, V36, P8619, DOI 10.1021/bi970520f	34	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31407	31411		10.1074/jbc.272.50.31407	http://dx.doi.org/10.1074/jbc.272.50.31407			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395472	hybrid			2022-12-25	WOS:A1997YL41900031
J	Kim, TD; Eddlestone, GT; Mahmoud, SF; Kuchtey, J; Fewtrell, C				Kim, TD; Eddlestone, GT; Mahmoud, SF; Kuchtey, J; Fewtrell, C			Correlating Ca2+ responses and secretion in individual RBL-2H3 mucosal mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CALCIUM OSCILLATIONS; INTRACELLULAR CA-2+; HISTAMINE-RELEASE; QUANTAL SECRETION; VESICLE FUSION; TUMOR PROMOTER; EXOCYTOSIS; CATECHOLAMINES; STORES	The role of Ca2+ in stimulus-response coupling in nonexcitable cells is still not well understood. The Ca2+ responses of individual cells are extremely diverse, often displaying marked oscillations, and almost nothing is known about the specific features of these Ca2+ signals that are important for the functional response of a cell. Using the RBL-2H3 mucosal mast cell as a model, we have studied the temporal relationship between changes in intracellular Ca2+ and serotonin secretion at the single-cell level using simultaneous indo-1 photometry and constant potential amperometry. Secretion in response to antigen never occurs until intracellular Ca2+ is elevated, nor is it seen during the first few oscillations in Ca2+, Exocytotic events tend to be clustered around the peaks of oscillations, but excellent secretion is also seen in cells with sustained elevations in Ca2+. Ca2+ release from stores in the absence of influx fails to elicit secretion, If refilling and continued release of Ca2+ from stores is prevented with thapsigargin, Ca2+ influx can still trigger secretion, suggesting that store-associated microdomains of Ca2+ are not required for exocytosis. Our findings demonstrate the importance of an amplitude-encoded Ca2+ signal and Ca2+ influx for stimulus-secretion coupling in these nonexcitable cells.	CORNELL UNIV, DEPT PHARMACOL, ITHACA, NY 14853 USA	Cornell University								Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1997, NATURE, V759, P760; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; EISEN HN, 1959, J EXP MED, V110, P187, DOI 10.1084/jem.110.2.187; FEWTRELL C, 1989, CIBA F SYMP, V147, P114; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; LAWSON D, 1978, J CELL BIOL, V79, P394, DOI 10.1083/jcb.79.2.394; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PENNER R, 1988, J EXP BIOL, V139, P329; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SALATHE M, 1995, J CELL SCI, V108, P431; SHUTTLEWORTH TJ, 1994, CELL CALCIUM, V15, P457, DOI 10.1016/0143-4160(94)90110-4; SJODIN L, 1991, J PHYSIOL-LONDON, V444, P763; TATHAM PER, 1991, PFLUG ARCH EUR J PHY, V419, P409, DOI 10.1007/BF00371124; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WEINTRAUB WH, 1994, J CELL PHYSIOL, V160, P389, DOI 10.1002/jcp.1041600220; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	41	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31225	31229		10.1074/jbc.272.50.31225	http://dx.doi.org/10.1074/jbc.272.50.31225			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395446	hybrid			2022-12-25	WOS:A1997YL41900005
J	Rellahan, BL; Graham, LJ; Stoica, B; DeBell, KE; Bonvini, E				Rellahan, BL; Graham, LJ; Stoica, B; DeBell, KE; Bonvini, E			Cbl-mediated regulation of T cell receptor-induced AP1 activation - Implications for activation via the Ras signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; PRODUCT C-CBL; ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT; SH3 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEINS; PHOSPHOLIPASE-C; EXCHANGE FACTOR	The functional role of Cbl in regulating T cell receptor (TCR)-mediated signal transduction pathways is unknown. This study uses Cbl overexpression in conjunction with a Ras-sensitive AP1 reporter construct to examine its role in regulating TCR mediated activation of the Ras pathway, Cbl overexpression in Jurkat T cells inhibited AP1 activity after TCR ligation, However, AP1 induction by 4 beta-phorbol 12-myristate 13-acetate, which up-regulates Ras activity in a protein kinase C-dependent, TCR/tyrosine kinase-independent manner was not affected by Cbl overexpression. Cbl overexpression also did not affect AP1 induction by an activated Ras protein or a membrane bound form of the guanine nucleotide exchange factor Sos. In addition, activation of the mitogen-activated protein kinase Erk2 was decreased by Cbl overexpression. Therefore, Cbl regulates events that are required for full TCR-mediated Ras activation, and data are presented to support a model whereby Cbl regulates events required for Ras activation via its association with Grb2.	US FDA, Immunobiol Lab, Div Monoclonal Antibodies, Off Therapeut Res & Review,Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Rellahan, BL (corresponding author), US FDA, Ctr Biol Evaluat & Res, HFM 564,Bldg 29B,Rm 5E16,1401 Rockville Pike, Rockville, MD 20852 USA.	rellahan@a1.cber.fda.gov	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434				BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; Lee JM, 1996, ONCOGENE, V12, P253; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RELLAHAN BL, 1994, J EXP MED, V180, P1529, DOI 10.1084/jem.180.4.1529; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SASTRY L, 1995, ONCOGENE, V11, P1107; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WILLIAMS DH, 1995, EUR J IMMUNOL, V25, P42, DOI 10.1002/eji.1830250109; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	63	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30806	30811		10.1074/jbc.272.49.30806	http://dx.doi.org/10.1074/jbc.272.49.30806			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388222	hybrid			2022-12-25	WOS:000071640800035
J	Yamanaka, Y; Wilson, EM; Rosenfeld, RG; Oh, Y				Yamanaka, Y; Wilson, EM; Rosenfeld, RG; Oh, Y			Inhibition of insulin receptor activation by insulin-like growth factor binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; DEPENDENT DIABETES-MELLITUS; SERUM PROTEASE ACTIVITY; FACTOR IGF BINDING; FACTOR-II; EPITHELIAL-CELLS; KINASE-ACTIVITY; RETINOIC ACID; PREGNANCY; COMPLEX	The insulin-like growth factors (IGFs) are transported by a family of high-affinity binding proteins (IGFBPs) that protect IGFs from degradation, limit their binding to IGF receptors, and modulate IGF actions. The six classical IGFBPs have been believed to have no affinity for insulin. We now demonstrate that IGFBP-7/mac25, a newly identified member of the IGFBP superfamily that binds IGFs specifically with low affinity is a high-affinity insulin binding protein. IGFBP-7 blocks insulin binding to the insulin receptor and thereby inhibiting the earliest steps in insulin action, such as autophosphorylation of the insulin receptor beta subunit and phosphorylation of IRS-1, indicating that IGFBP-7 is a functional insulin-binding protein. The affinity of other IGFBPs for insulin can be enhanced by modifications that disrupt disulfide bonds or remove the conserved COOH terminus. Like IGFBP-7, an NH2-terminal fragment of IGFBP-3 (IGFBP-3((1-87))), also binds insulin with high affinity and blocks insulin action. IGFBPs with enhanced affinity for insulin might contribute to the insulin resistance of pregnancy, type II diabetes mellitus, and other pathological conditions.	Oregon Hlth Sci Univ, Sch Med, Dept Pediat, Portland, OR 97201 USA	Oregon Health & Science University	Oh, Y (corresponding author), Oregon Hlth Sci Univ, Sch Med, Dept Pediat, 3181 SW Sam Jackson Pk Rd,NRC5, Portland, OR 97201 USA.				NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER; NCI NIH HHS [CA58110] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; BANG P, 1994, J CLIN ENDOCR METAB, V78, P1119, DOI 10.1210/jc.78.5.1119; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P1312, DOI 10.1210/jc.80.4.1312; BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; CARO JF, 1986, J CLIN INVEST, V78, P249, DOI 10.1172/JCI112558; CASELLA SJ, 1986, J BIOL CHEM, V261, P9268; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; Conover CA, 1996, ENDOCRINOLOGY, V137, P2286, DOI 10.1210/en.137.6.2286; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; FIELDER PJ, 1990, ENDOCRINOLOGY, V127, P2270, DOI 10.1210/endo-127-5-2270; FREIDENBERG GR, 1988, J CLIN INVEST, V82, P1398, DOI 10.1172/JCI113744; GIUDICE LC, 1990, J CLIN ENDOCR METAB, V71, P806, DOI 10.1210/jcem-71-4-806; Gucev ZS, 1996, CANCER RES, V56, P1545; HARING H, 1989, DIABETES METAB REV, V5, P431; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HOSSENLOPP P, 1990, J CLIN ENDOCR METAB, V71, P797, DOI 10.1210/jcem-71-4-797; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KIM HS, 1997, IN PRESS P NATL ACAD; Lalou C, 1996, ENDOCRINOLOGY, V137, P3206, DOI 10.1210/en.137.8.3206; LASSARRE C, 1994, ENDOCRINOLOGY, V134, P1254, DOI 10.1210/en.134.3.1254; LIU F, 1990, J CLIN ENDOCR METAB, V70, P620, DOI 10.1210/jcem-70-3-620; LIU F, 1992, J CLIN ENDOCR METAB, V75, P1261, DOI 10.1210/jc.75.5.1261; MARSHALL RN, 1974, J CLIN ENDOCR METAB, V39, P283, DOI 10.1210/jcem-39-2-283; MCCUSKER RH, 1991, ENDOCRINOLOGY, V129, P939, DOI 10.1210/endo-129-2-939; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rosenfeld R G, 1990, Recent Prog Horm Res, V46, P99; RUTISHAUSER J, 1993, FEBS LETT, V334, P23, DOI 10.1016/0014-5793(93)81672-M; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; Spratt SK, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037503; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	42	164	178	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30729	30734		10.1074/jbc.272.49.30729	http://dx.doi.org/10.1074/jbc.272.49.30729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388210	hybrid			2022-12-25	WOS:000071640800023
J	Schwartz, D; Almog, N; Peled, A; Goldfinger, N; Rotter, V				Schwartz, D; Almog, N; Peled, A; Goldfinger, N; Rotter, V			Role of wild type p53 in the G(2) phase: regulation of the gamma-irradiation-induced delay and DNA repair	ONCOGENE			English	Article						p53; G(2) checkpoint; DNA damage; micronucleated cells	NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE CHECKPOINTS; SUPPRESSOR PROTEIN P53; C-TERMINAL DOMAIN; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; TUMOR-SUPPRESSOR; FLOW-CYTOMETRY; NUCLEAR ACCUMULATION; INDUCED MICRONUCLEI	Upregulation of the p53 protein was shown to induce cell cycle arrest at the G(1)/S border and in some cases at the G(2)/M border. Furthermore, it was suggested that p53 is associated with the induction of the various DNA repair pathways. Previously, we demonstrated that cells coexpressing endogenous wild type p53 protein, together with dominant negative mutant p53, exhibit deregulation of apoptosis, G(1) arrest and delay in G(2) following gamma-irradiation. In the present study, we investigated the role of p53 protein in the DNA damage response at the G(2) phase. Using p53-null, wild type p53 and mutant p53-producer cell lines, we found that the two C-terminally spliced p53 forms could prevent gamma-irradiation induced mutagenesis prior to mitosis, at the G(2)/M checkpoint. We found that at the G(2) phase, p53 may facilitate repair of DNA breaks giving rise to micronuclei, and regulate the exit from the G(2) checkpoint. At the G(1) phase, only the regularly spliced form of p53 caused growth arrest. In contrast, both the regularly and the alternatively spliced p53 forms directed postmitotic micronucleated cells towards apoptosis. These results provide a functional explanation for the cell cycle-independent expression of p53 in normal cycling cells, as well as in cells where p53 is up-regulated, following DNA damage.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRAIN R, 1994, ONCOGENE, V9, P1775; CHEN IT, 1995, ONCOGENE, V11, P1931; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, V1, P261; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAWLEY RS, 1996, GENE DEV, V10, P2382; HEDDLE JA, 1977, MUTAT RES, V44, P63, DOI 10.1016/0027-5107(77)90115-4; HONG JH, 1994, RADIAT RES, V140, P17, DOI 10.2307/3578563; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1995, CANCER RES, V55, P7; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McDonald E, 1996, CANCER RES, V56, P2250; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NUSSE M, 1994, METHOD CELL BIOL, V42, P149; NUSSE M, 1992, INT J RADIAT BIOL, V62, P587, DOI 10.1080/09553009214552511; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAULES RS, 1995, CANCER RES, V55, P1763; Peled A, 1996, ONCOGENE, V13, P1677; POWELL SN, 1995, CANCER RES, V55, P1643; REMVIKOS Y, 1990, INT J CANCER, V45, P450, DOI 10.1002/ijc.2910450313; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHREIBER GA, 1992, INT J RADIAT BIOL, V62, P695, DOI 10.1080/09553009214552651; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; STEWART N, 1995, ONCOGENE, V10, P109; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER C, 1994, CANCER RES, V54, P3651; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	75	71	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2597	2607		10.1038/sj.onc.1201436	http://dx.doi.org/10.1038/sj.onc.1201436			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399647				2022-12-25	WOS:A1997YG73200009
J	Muller, C; Salles, B				Muller, C; Salles, B			Regulation of DNA-dependent protein kinase activity in leukemic cells	ONCOGENE			English	Article						DNA-PK; Ku autoantigen; CLL lymphocytes	CHRONIC LYMPHOCYTIC-LEUKEMIA; STRAND BREAK REPAIR; V(D)J RECOMBINATION; KU-PROTEIN; BINDING; EXPRESSION; AUTOANTIGEN; RESISTANCE; ANTIBODIES; ENDS	The DNA-dependent protein kinase (DNA-PK) complex is composed of a catalytic (DNA-PKcs), and a regulatory subunit (Ku70/Ku86 heterodimer), The expression and function of DNA-PK subunits was investigated in purified blood lymphocytes obtained from patients with chronic lymphocytic leukemia (CLL) either refractory to chemotherapy or untreated, Variations in DNA-PK activity were found amongst CLL samples by comparison to human cell lines, It was noticeable that the low DNA-PK activity was associated with samples from untreated patients that exhibited a sensitivity phenotype, determined in vitro, to the radiomimetic agent neocarcinostatin by comparison to samples from refractory patients, The regulation in DNA-PK activity was associated with Ku heterodimer expression while DNA-PKcs was unaffected, Moreover, the presence of an altered form of the Ku86 subunit was identified in samples with low DNA-PK activity, These results suggest a regulation process of the DNA-PK activity in fresh human cells.	CNRS,UPR 9062,INST PHARMACOL & BIOL STRUCT,F-31077 TOULOUSE,FRANCE; CHU PURPAN,SERV HEMATOL,F-31300 TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse			salles, bernard/B-8531-2008; MULLER, Catherine/M-2185-2018; MULLER, Catherine/E-2060-2011					ANDERSON CW, 1994, J PROTEIN CHEM, V13, P500; Barret JM, 1996, MOL PHARMACOL, V49, P766; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BRAMSON J, 1995, MUTAT RES-DNA REPAIR, V336, P269, DOI 10.1016/0921-8777(94)00063-C; BRAMSON J, 1995, CANCER LETT, V90, P139, DOI 10.1016/0304-3835(95)03696-T; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; FALZON M, 1993, J BIOL CHEM, V268, P10546; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KIPPS TJ, 1995, CHRONIC LYMPHOCYTIC, P1017; MINORI T, 1986, J BIOL CHEM, V261, P10375; MULLER C, 1994, INT J CANCER, V56, P749, DOI 10.1002/ijc.2910560523; ORFAO A, 1992, LEUKEMIA, V6, P47; PANASCI L, 1988, CANCER RES, V48, P1972; REEVES WH, 1987, J RHEUMATOL, V14, P97; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	25	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2343	2348		10.1038/sj.onc.1201402	http://dx.doi.org/10.1038/sj.onc.1201402			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393878				2022-12-25	WOS:A1997YE15700008
J	Hui, R; Campbell, DH; Lee, CSL; McCaul, K; Horsfall, DJ; Musgrove, EA; Daly, RJ; Seshadri, R; Sutherland, RL				Hui, R; Campbell, DH; Lee, CSL; McCaul, K; Horsfall, DJ; Musgrove, EA; Daly, RJ; Seshadri, R; Sutherland, RL			EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer	ONCOGENE			English	Article						EMS1; 11q13; prognosis; breast cancer	TYROSINE KINASE-ACTIVITY; SQUAMOUS-CELL CARCINOMA; PP60C-SRC PROTEIN-KINASE; CHROMOSOME 11Q13; CYCLIN D1; ONCOGENE AMPLIFICATION; POOR-PROGNOSIS; C-SRC; CLINICAL-SIGNIFICANCE; EXPRESSION	Chromosome 11q13 is amplified in about 13% of primary breast cancers, CCND1, encoding the cell cycle regulatory gene cyclin D1, and EMS1, encoding a filamentous actin binding protein, are favoured candidate onocogenes, whereas INT-2 is an unexpressed gene at this locus. In this study we tested the possibility that different regions of this large amplicon could be independently amplified and subsequently defined the phenotype of EMS1 amplified tumours in a series of 961 primary breast carcinomas. Using DNA slot blots, EMS1 was amplified in 15.2% of samples: 5.4% were coamplified for CCND1; 7.9% coamplified for INT-2 and 6.7% showed EMS1 amplification alone. The degree of amplification of CCND1 and INT-2 was highly correlated (P=0.0001). In contrast, no such relationship existed between EMS1 and CCND1 or INT-2 amplification, demonstrating independent amplification of EMS1 in 44% of amplified tumours. EMS1 amplification (greater than or equal to twofold increase in copy number) was positively correlated with patient age greater than or equal to 50 years (P=0.025), ER positivity (P=0.022), PgR positivity (P = 0.018), and was negatively correlated with HER-2/neu (c-erbB2) amplification (P=0.01). In common with CCND1/INT-2, EMS1 amplification was associated with increased risk of relapse in patients with lymph node-negative disease (P=0.028). In contrast, EMS1 and CCND1/INT-2 amplification appeared to confer different phenotypes in ER positive and negative tumours. A greater than or equal to threefold increase in EMS1 copy number was associated with an apparent increased risk of relapse and death in patients with ER negative tumours, but was without effect in ER positive tumours. In contrast, CCND1/INT-2 amplification had no effect in the patients with ER negative tumours but was associated with early relapse in ER positive patients. Thus EMS1 amplification may identify subgroups of breast cancer patients with increased probability of relapse and death distinct from those identified by CCND1/INT-2 amplification. Further studies are required to more clearly determine the functional consequences of EMS1 overexpression and a biological basis for the relationship between EMS1 amplification and phenotype in breast cancer.	ST VINCENTS HOSP, GARVAN INST MED RES, CANC RES PROGRAM, SYDNEY, NSW 2010, AUSTRALIA; S AUSTRALIAN HLTH COMMISS, EPIDEMIOL UNIT, ADELAIDE CITY CTR, SA 5000, AUSTRALIA; FLINDERS MED CTR, DEPT SURG, BEDFORD PK, SA 5042, AUSTRALIA; FLINDERS MED CTR, DEPT HAEMATOL, BEDFORD PK, SA 5042, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Flinders Medical Centre; Flinders Medical Centre			Sutherland, Robert L/A-8378-2008; McCaul, Kieran A/B-8751-2008; Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027; Campbell, Douglas/0000-0001-9699-1854				ADNANE J, 1989, ONCOGENE, V4, P1389; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; BERNS EMJJ, 1992, EUR J CANCER, V28A, P697, DOI 10.1016/S0959-8049(05)80129-7; BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; BORG A, 1990, CANCER RES, V50, P4332; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Bringuier PP, 1996, ONCOGENE, V12, P1747; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FANTL V, 1993, CANCER SURV, V18, P77; GAFFEY MJ, 1993, MODERN PATHOL, V6, P654; Hui R, 1996, CLIN CANCER RES, V2, P923; HUI R, 1997, UNPUB; JACOBS C, 1983, CANCER RES, V43, P1696; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MAA MC, 1992, ONCOGENE, V7, P2429; MACHOTKA SV, 1989, CLIN CHIM ACTA, V184, P207, DOI 10.1016/0009-8981(89)90053-3; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Patel AM, 1996, ONCOGENE, V12, P31; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; ROMAIN S, 1994, BRIT J CANCER, V70, P304, DOI 10.1038/bjc.1994.297; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; Seshadri R, 1996, INT J CANCER, V69, P135, DOI 10.1002/(SICI)1097-0215(19960422)69:2<135::AID-IJC12>3.0.CO;2-8; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; THEILLET C, 1990, ONCOGENE, V5, P147; TSUDA H, 1989, CANCER RES, V49, P3104; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WILLIAMS ME, 1993, ARCH OTOLARYNGOL, V119, P1238; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221	46	81	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1617	1623		10.1038/sj.onc.1201311	http://dx.doi.org/10.1038/sj.onc.1201311			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380415				2022-12-25	WOS:A1997XX36900014
J	Shao, RP; Karunagaran, D; Zhou, BHP; Li, KY; Lo, SS; Deng, J; Chiao, P; Hung, MC				Shao, RP; Karunagaran, D; Zhou, BHP; Li, KY; Lo, SS; Deng, J; Chiao, P; Hung, MC			Inhibition of nuclear factor-kappa B activity is involved in E1A-mediated sensitization of radiation-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA CELL-LINES; ADENOVIRUS E1A; GAMMA-RADIATION; GENE; DNA; EXPRESSION; MALIGNANCY; PROTEINS; AGENTS; DEATH	The adenoviral E1A protein has been implicated in the potentiation of apoptosis induced by various external stimuli, but the exact mechanism of that potentiation is not clear. In this study, we compared the sensitivity to ionizing gamma-irradiation of E1A transfectants with that of parental cells in a human ovarian cancer cell line (SKOV3.ip1); we found that the E1A transfectants became sensitive to radiation-induced apoptosis, Recently, activation of the transcription factor nuclear factor-kappa B (NF-kappa B) has been shown to play a key role in the anti-apoptotic pathway of radiation-induced apoptosis. In an attempt to determine whether NF-kappa B was involved in the E1A-mediated sensitization of radiation-induced apoptosis, we found that radiation induced activation of NP-kappa B occurred in the parental cells but was blocked in the E1A transfectants. Furthermore, parental cells co-transfected with NF-kappa B and E1A were better protected from undergoing apoptosis upon irradiation than those transfected with E1A alone. Thus, our results suggest that inhibition of NF-kappa B activation by E1A is a plausible mechanism for E1A-mediated sensitization of radiation-induced apoptosis.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Breast Canc Res Program, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Breast Canc Res Program, Box 79,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021; Karunagaran, Devarajan/A-8148-2010	Hung, Mien-Chie/0000-0003-4317-4740; Karunagaran, Devarajan/0000-0001-9331-8947	NCI NIH HHS [R01-CA60858, R01-CA58880] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRACEY TS, 1995, ONCOGENE, V10, P2391; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; CAULEY K, 1994, P NATL ACAD SCI USA, V91, P390, DOI 10.1073/pnas.91.1.390; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Cosulich S, 1996, CURR BIOL, V6, P1586, DOI 10.1016/S0960-9822(02)70779-3; Frisch SM, 1996, MUTAT RES-FUND MOL M, V350, P261, DOI 10.1016/0027-5107(95)00103-4; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; YU DH, 1993, CANCER RES, V53, P891	25	111	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32739	32742		10.1074/jbc.272.52.32739	http://dx.doi.org/10.1074/jbc.272.52.32739			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407046	hybrid			2022-12-25	WOS:000071182900007
J	Weng, K; Lu, CC; Daggett, LP; Kuhn, R; Flor, PJ; Johnson, EC; Robinson, PR				Weng, K; Lu, CC; Daggett, LP; Kuhn, R; Flor, PJ; Johnson, EC; Robinson, PR			Functional coupling of a human retinal metabotropic glutamate receptor (hmGluR6) to bovine rod transducin and rat G(o) in an in vitro reconstitution system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIPOLAR CELLS; AGONIST SELECTIVITY; OUTER SEGMENTS; CDNA LIBRARIES; G-PROTEIN; RHODOPSIN; EXPRESSION; TRANSMISSION; CONDUCTANCE; ACTIVATION	The cDNA encoding hmGluR6, appended with a 15-amino acid antibody epitope (1D4), was transiently transfected in COS-7 cells. The receptor was purified from COS cell membranes using an antibody affinity column. The purified receptor was then reconstituted into lipid vesicles, and its ability to activate either transducin, the rod photoreceptor-specific GTP-binding protein, or the alpha subunit of G(o) was assayed in vitro using a guanosine 5'-3-O-(thio)triphosphate binding assay. Activation of both transducin and G(o) was observed. The rate of G(o) activation was 18-fold greater than the rate of transducin activation. This indicates that the coupling of mGluR6 to G(o) is more efficient and suggests that G(o) may be involved in coupling to mGluR6 in ON-bipolar cells.	Univ Maryland Baltimore Cty, Dept Biol Sci, Baltimore, MD 21250 USA; SIBIA Neurosci Inc, La Jolla, CA 92037 USA; Novartis Pharma AG, Basel, Switzerland	University System of Maryland; University of Maryland Baltimore County; Novartis	Robinson, PR (corresponding author), Univ Maryland Baltimore Cty, Dept Biol Sci, Baltimore, MD 21250 USA.				NEI NIH HHS [EY10205-02] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY010205] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAEHR W, 1982, J BIOL CHEM, V257, P6452; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; DAGGETT LP, 1995, NEUROPHARMACOLOGY, V34, P871, DOI 10.1016/0028-3908(95)00085-K; DEVRIES SH, 1993, NEURON S, V10, P139; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; JANE DE, 1995, NEUROPHARMACOLOGY, V34, P851, DOI 10.1016/0028-3908(95)00063-C; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPEYRE B, 1985, GENE, V37, P215, DOI 10.1016/0378-1119(85)90275-6; Laurie DJ, 1997, NEUROPHARMACOLOGY, V36, P145, DOI 10.1016/S0028-3908(96)00172-4; Lin FF, 1997, NEUROPHARMACOLOGY, V36, P917, DOI 10.1016/S0028-3908(97)00078-6; MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2; MCPHEE JC, 1991, DESIGN SYNTHESIS EXP; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1995, TRENDS NEUROSCI, V18, P359, DOI 10.1016/0166-2236(95)93929-R; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NAWY S, 1991, NEURON, V7, P677, DOI 10.1016/0896-6273(91)90380-I; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NOGA V, 1993, VISUAL NEUROSCI, V10, P473; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OPRIAN DD, 1993, METH NEUROSCI, V15, P301; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SEAL AJ, 1994, NEUROPHARMACOLOGY, V33, P1065, DOI 10.1016/0028-3908(94)90144-9; SHEILS RA, 1992, P R SOC LOND B, V247, P21; SHIELLS RA, 1990, P ROY SOC B-BIOL SCI, V242, P91, DOI 10.1098/rspb.1990.0109; SHIELLS RA, 1981, NATURE, V294, P592, DOI 10.1038/294592a0; SLAUGHTER MM, 1981, SCIENCE, V211, P182, DOI 10.1126/science.6255566; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TANABE Y, 1993, J NEUROSCI, V13, P1372; Ueda Y, 1997, J NEUROSCI, V17, P3014; VILLA P, 1995, J NEUROSCI, V15, P3571; WASSLE H, 1992, NEUROSCI LETT, V134, P199, DOI 10.1016/0304-3940(92)90516-A; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	46	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33100	33104		10.1074/jbc.272.52.33100	http://dx.doi.org/10.1074/jbc.272.52.33100			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407094	hybrid			2022-12-25	WOS:000071182900055
J	Czurylo, EA; Kulikova, N; Dabrowska, R				Czurylo, EA; Kulikova, N; Dabrowska, R			Does calponin interact with caldesmon?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CONTRACTION; FLUORESCENT-PROBE; HEAVY-MEROMYOSIN; CHICKEN GIZZARD; F-ACTIN; TROPOMYOSIN; BINDING; PURIFICATION; FLUORIMETRY; FRAGMENTS	The roles of calponin and caldesmon and their interaction in regulation of smooth muscle contraction are controversial, Recently, strong binding between these two proteins has been reported (Graceffa, P., Adam, L. P., and Morgan, K. G. (1996) J. Biol. Chem. 271, 30336-30339), Results in this paper fail to confirm their data and are consistent with the concept of independent functions for calponin and caldesmon. To examine the ability of duck gizzard caldesmon to interact with calponin, three caldesmon derivatives, each containing a different sulfhydryl-specific reporter probe (6-acryloyl-2-dimethylaminonaphtalene, N-(1-pyrenyl)iodoacetamide, and N-iodoacetyl-N'-(5-sulfo-1-naphtylo)ethylenediamine) attached to a single cysteine located in the C-terminal domain, were synthesized, Addition of calponin to labeled caldesmon at both low and physiological salt concentrations did not induce any changes in fluorescence intensity or maximum shift, Under the same conditions, calmodulin and tropomyosin (known to bind to the C terminus of caldesmon) produced substantial changes in these spectral parameters, Gel filtration of an equimolar caldesmon-calponin mixture on a fast protein liquid chromatography Superose-12 column revealed two base-line-separated peaks, the first containing only caldesmon and the second only calponin, thus confirming the lack of any interaction between these two proteins, Also, the addition of calponin did not change the fluorescence parameters of labeled caldesmon in complexes with F-actin and F-actin-tropomyosin.	M Nencki Inst Expt Biol, Dept Muscle Biochem, PL-02093 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Dabrowska, R (corresponding author), M Nencki Inst Expt Biol, Dept Muscle Biochem, 3 Pasteur St, PL-02093 Warsaw, Poland.							ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; COLLINS J H, 1991, Protein Sequences and Data Analysis, V4, P29; CROSBIE RH, 1995, J MUSCLE RES CELL M, V16, P509, DOI 10.1007/BF00126435; CZURYLO EA, 1993, BIOCHEM J, V293, P363, DOI 10.1042/bj2930363; Czurylo EA, 1997, BIOPHYS J, V72, P835, DOI 10.1016/S0006-3495(97)78717-4; CZURYLO EA, 1991, BIOPHYS CHEM, V40, P181, DOI 10.1016/0301-4622(91)87007-R; DABROWSKA A, 1994, AIRWAYS SMOOTH MUSCL, P31; DABROWSKA R, 1980, COMP BIOCHEM PHYS B, V65, P75, DOI 10.1016/0305-0491(80)90114-5; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Graceffa P, 1996, J BIOL CHEM, V271, P30336, DOI 10.1074/jbc.271.48.30336; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; LEHRER SS, 1984, BIOCHEMISTRY-US, V23, P1591, DOI 10.1021/bi00303a001; LU FWM, 1995, BIOCHEMISTRY-US, V34, P11864, DOI 10.1021/bi00037a026; Mabuchi K, 1996, J MUSCLE RES CELL M, V17, P243, DOI 10.1007/BF00124246; MAKUCH R, 1991, BIOCHEM J, V280, P33, DOI 10.1042/bj2800033; MARSTON SB, 1991, BIOCHEM J, V279, P1; NORTH AJ, 1994, J CELL SCI, V107, P437; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKAHASHI K, 1986, BIOCH BIOPHYS RES CO; TAWADA K, 1978, EUR J BIOCHEM, V88, P411, DOI 10.1111/j.1432-1033.1978.tb12463.x; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; VOROTNIKOV AV, 1991, BIOCHEM J, V273, P161, DOI 10.1042/bj2730161; Winder SJ, 1996, CURR TOP CELL REGUL, V34, P33, DOI 10.1016/S0070-2137(96)80002-1; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WOLFF DJ, 1977, J BIOL CHEM, V252, P4108	33	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32067	32070		10.1074/jbc.272.51.32067	http://dx.doi.org/10.1074/jbc.272.51.32067			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405402	hybrid			2022-12-25	WOS:000071108000021
J	de Jong, R; van Wijk, A; Haataja, L; Heisterkamp, N; Groffen, J				de Jong, R; van Wijk, A; Haataja, L; Heisterkamp, N; Groffen, J			BCR/ABL-induced leukemogenesis causes phosphorylatiorm of Hef1 and its association with Crkl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; ADAPTER PROTEIN; V-CRK; C-ABL; SIGNALING COMPLEX; TRANSGENIC MICE; CELL-LINES; P130(CAS)	BCR/ABL is considered responsible for the development of Philadelphia chromosome-positive leukemia, Experimental animal models, such as transgenic mice, have demonstrated unambiguously that Bcr/Abl is capable of inducing leukemogenesis, The adaptor molecule Crkl is a major in vivo substrate of the deregulated Bcr/Abl tyrosine binase and functions as a molecular link with other signaling proteins, While associated in vivo with Bcr/Abl through its SH3 domain, Crkl can interact simultaneously via its SH2 domain with other tyrosine-phosphorylated proteins. Here we report the identification of prominently tyrosine-phosphorylated proteins with a molecular mass of approximately 110 kDa, which bind specifically to the Crkl SH2 domain in leukemic tissues of P190BCR/ABL transgenic mice. We demonstrate that these proteins are identical to Hef1/Cas-L, which is related to p130(Cas). The proto-oncoprotein p120(Cbl) and Hef1, but not p130(Cas), were detectably phosphorylated on tyrosine in P190Bcr/Abl-expressing leukemic cells and were found in complex with Crkl, showing the existence of protein complexes in P190Bcr/Abl leukemic cells, consisting of P190Bcr/Abl, Crkl, and Hef1 or p120(Cbl). This supports a model in which Crkl acts as mediator between Bcr/Abl and downstream effecters, Since Hef1 is involved in the beta(1)-integrin signaling pathway, our study demonstrates that Bcr/Abl could specifically interfere with normal beta(1)-integrin signaling.	Childrens Hosp Los Angeles, Dept Pathol, Sect Mol Carcinogenesis, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles	Groffen, J (corresponding author), Childrens Hosp Los Angeles, Dept Pathol, Sect Mol Carcinogenesis, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NCI NIH HHS [CA 47456, CA 50248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA047456, R01CA047456, R01CA050248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; DEJONG R, 1995, ONCOGENE, V11, P1469; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1995, ONCOGENE, V10, P1465; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KEANE MM, 1995, ONCOGENE, V10, P2367; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Law SF, 1996, MOL CELL BIOL, V16, P3327; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; NICHOLS GL, 1994, BLOOD, V84, P2912; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; ODA T, 1994, J BIOL CHEM, V269, P22925; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, ONCOGENE, V11, P1149; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1996, ONCOGENE, V12, P839; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; VONCKEN JW, 1992, CANCER RES, V52, P4534; Vuori K, 1996, MOL CELL BIOL, V16, P2606; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32649	32655		10.1074/jbc.272.51.32649	http://dx.doi.org/10.1074/jbc.272.51.32649			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405482	hybrid			2022-12-25	WOS:000071108000101
J	Milgrom, YM; Cross, RL				Milgrom, YM; Cross, RL			Nucleotide-depleted beef heart F-1-ATPase exhibits strong positive catalytic cooperativity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ATP HYDROLYSIS; BINDING-SITES; F1-ATPASE; MECHANISM; ROTATION	Catalytic cooperativity is a central feature of the binding change mechanism for F0F1-ATP synthases, However, in a recent publication (Reynafarje, B. D., and Pedersen, P. L. (1996) J. Biol. Chen. 271, 32546-32550), Reynafarje and Pedersen claim that cooperative effects are an artifact caused by endogenous nucleotides and that when such nucleotides are removed, the multiple catalytic sites on MF1 behave independently during ATP hydrolysis, In contrast to this conclusion, we show here that when ATP is loaded at a single catalytic site on nucleotide-depleted MF1, the rate of product release is accelerated by up to 5 x 10(4)-fold by the binding of ATP at adjacent catalytic sites, Hence, nucleotide-depleted MF1 is not an exception but does in fact show strong cooperative interactions, In addition, evidence is presented supporting a random order for product release during ATP hydrolysis.	SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Cross, RL (corresponding author), SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Syracuse, NY 13210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023152, R37GM023152] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Reynafarje BD, 1996, J BIOL CHEM, V271, P32546, DOI 10.1074/jbc.271.51.32546; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YALAMOVA MV, 1982, BIOCHEM INT, V4, P337	25	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32211	32214		10.1074/jbc.272.51.32211	http://dx.doi.org/10.1074/jbc.272.51.32211			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405423	hybrid			2022-12-25	WOS:000071108000042
J	Schreiber, J; Enderich, J; Sock, E; Schmidt, C; Richter-Landsberg, C; Wegner, M				Schreiber, J; Enderich, J; Sock, E; Schmidt, C; Richter-Landsberg, C; Wegner, M			Redundancy of class III POU proteins in the oligodendrocyte lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHWANN-CELL DIFFERENTIATION; TRANSCRIPTION FACTOR SCIP; DOMAIN GENE; JC VIRUS; FACTOR BRN-2; RAT-BRAIN; EXPRESSION; MYELINATION; OCTAMER; OCT-6	Class III POU proteins are prominent regulators of neural development. Tst-1/Oct6/SCIP, for instance, is essential for terminal differentiation of myelinating Schwann cells in the peripheral nervous system. Although Tst-1/Oct6/SCIP is also expressed in the myelin forming oligodendrocytes of the central nervous system, targeted deletion of Tst-1/Oct6/SCIP failed to reveal a gross alteration of myelination in the central nervous system. To better understand this apparent discrepancy, we examined the expression of POU proteins in both cultured primary oligodendrocytes and in the oligodendrocyte-like CG-4 cell line. These cells expressed Tst-1/Oct6/SCIP, Bm-l, and Brn-2 in significant amounts, indicating that Bm-l and Brn-2 might have the capacity to compensate loss of Tst-1/Oct6/SCIP, We show that Tst-1/Oct6/SCIP, Bm-l, and Brn-2 were all down-regulated during the early phases of oligodendrocyte development both on RNA and protein level. All three POU proteins exhibited similar DNA binding characteristics. When promoters consisting of a single POU protein-binding site adjacent to a TATA box were used as reporters in transient transfections, Bm-l proved to be a weaker transcriptional activator than Tst-1/Oct6/SCIP. In agreement with this, we found the transactivation domain of Bm-l, which we mapped between amino acids 119 and 237, significantly weaker than the transactivation domain of Tst-1/Oct6/SCIP. Taken together, our data imply a partial, but not complete redundancy between POU proteins in oligodendrocytes.	Univ Hamburg, Zentrum Mol Biol, D-20246 Hamburg, Germany; Carl von Ossietzky Univ Oldenburg, Dept Biol, D-26111 Oldenburg, Germany	University of Hamburg; Carl von Ossietzky Universitat Oldenburg	Wegner, M (corresponding author), Univ Hamburg, Zentrum Mol Biol, Martinistr 52, D-20246 Hamburg, Germany.	wegner@plexus.uke.uni-hamburg.de	Schreiber, Jacob/GWC-3164-2022	Wegner, Michael/0000-0002-4586-3294; Sock, Elisabeth/0000-0001-9925-3136				ALVAREZBOLADO G, 1995, J COMP NEUROL, V355, P237, DOI 10.1002/cne.903550207; APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; Blanchard AD, 1996, J NEUROSCI RES, V46, P630, DOI 10.1002/(SICI)1097-4547(19961201)46:5<630::AID-JNR11>3.0.CO;2-0; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLARINI EJ, 1992, DEVELOPMENT, V116, P193; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HART IK, 1992, GLIA, V6, P310, DOI 10.1002/glia.440060409; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; Jaegle M, 1996, SCIENCE, V273, P507, DOI 10.1126/science.273.5274.507; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; LEMOINE C, 1992, P NATL ACAD SCI USA, V89, P3285, DOI 10.1073/pnas.89.8.3285; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; MCKINNON RD, 1993, GLIA, V7, P245, DOI 10.1002/glia.440070308; MEIJER D, 1992, NUCLEIC ACIDS RES, V20, P2241, DOI 10.1093/nar/20.9.2241; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; MONUKI ES, 1993, P NATL ACAD SCI USA, V90, P9978, DOI 10.1073/pnas.90.21.9978; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; PENDE M, 1994, P NATL ACAD SCI USA, V91, P3215, DOI 10.1073/pnas.91.8.3215; PORTER S, 1986, J NEUROSCI, V6, P3070; Renner K, 1996, NUCLEIC ACIDS RES, V24, P4552, DOI 10.1093/nar/24.22.4552; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; RichterLandsberg C, 1996, J NEUROSCI RES, V45, P161, DOI 10.1002/(SICI)1097-4547(19960715)45:2<161::AID-JNR8>3.0.CO;2-8; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHREIBER E, 1994, NEUROSURGERY, V34, P129; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Sock E, 1996, J VIROL, V70, P1512, DOI 10.1128/JVI.70.3.1512-1520.1996; Sock E, 1997, J NEUROCHEM, V68, P1911; Sumiyama K, 1996, J MOL EVOL, V43, P170, DOI 10.1007/PL00006075; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	50	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32286	32293		10.1074/jbc.272.51.32286	http://dx.doi.org/10.1074/jbc.272.51.32286			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405434	hybrid			2022-12-25	WOS:000071108000053
J	Xu, SC; Cobb, MH				Xu, SC; Cobb, MH			MEKK1 binds directly to the c-Jun N-terminal kinases stress-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PATHWAY; PHOSPHORYLATION; IDENTIFICATION; DOMAIN; ERK	Mitogen-activated protein (MAP) kinases mediate responses to a wide array of cellular stimuli, These cascades consist of a MAP kinase or extracellular signal-regulated kinase (ERK), activated by a MAP/ERK kinase (MEK), in turn activated by a MEK kinase (MEKK). MEKK1 has been shown to be a strong activator of the c-Jun N-terminal kinase/stress-actived protein kinase (JNK/SAPK) pathway. We report here that JNK/SAPK binds directly to the N-terminal, noncatalytic domain of MEKK1 in vitro and in transfected cells. Immobilized MEKK1-derived peptides extract JNK/SAPK selectively from cell lysates. MEKK1 coimmunoprecipitates with multiple JNK/SAPK isoforms in transfected cells. Expression of the N terminus of MEKK1 lacking the kinase domain increases activation of endogenous JNK/SAPK by MEKK1. The data are consistent with a model in which MEKK1-JNK/SAPK binding facilitates the receipt of signals from upstream inputs and localizes JNK/SAPK to intracellular targets of the pathway.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline; NIGMS NIH HHS [GM56498] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; CHOI KY, 1994, CELL, V78, P499; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirai S, 1996, ONCOGENE, V12, P641; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN A, 1995, SCIENCE, V268, P8286; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	31	99	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32056	32060		10.1074/jbc.272.51.32056	http://dx.doi.org/10.1074/jbc.272.51.32056			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405400	hybrid			2022-12-25	WOS:000071108000019
J	Sun, WM; Zhang, JZ; Hankinson, O				Sun, WM; Zhang, JZ; Hankinson, O			A mutation in the aryl hydrocarbon receptor (AHR) in a cultured mammalian cell line identifies a novel region of AHR that affects DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATOR PROTEIN; MOUSE HEPATOMA LINE; HELIX-LOOP-HELIX; DIOXIN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; FUNCTIONAL DOMAINS; GENE; HYDROXYLASE; EXPRESSION	Introduction of a retroviral expression vector far the aryl hydrocarbon receptor (AHR) restores CYPIA1 inducibility to a mutant derivative of the Hepa-1 cell line that is defective in induction of CYP1A1 by ligands for the receptor. An AHR protein with normal ligand binding activity is expressed in the mutant but ligand treatment of mutant cell extract fails to induce binding of the AHR.ARNT (aryl hydrocarbon receptor nuclear translocator) dimer to the xenobiotic responsive element (XRE). ABR cDNAs derived from the mutant encode a protein that is unimpaired in ligand-dependent dimerization with ARNT, but the AHR.ARNT dimer so formed is severely impaired in XRE binding activity. The mutant cDNAs contain a C to G mutation at base 648, causing a cysteine to tryptophan alteration at amino acid 216, located between the PER-ARNT-SIM homology region (PAS) A and PAS B repeats, Introduction of the same mutation in the wild-type AHR sequence by site-directed mutagenesis similarity impaired XRE binding activity. Substitution with the conservative amino acid, serine, had no effect on XRE binding, The tryptophan mutation, but not the wild-type allele, was detectable in genomic DNA of the mutant, The implication that an amino acid within the PAS region may be involved in DNA binding indicates that the DNA binding behavior of AHR may be more anomalous than previously suspected.	UNIV CALIF LOS ANGELES, SCH MED,CTR HLTH SCI,DEPT PATHOL & LAB MED, JONSSON COMPREHEN CANC CTR, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NCI NIH HHS [CA 28868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHANG CY, 1993, PHARMACOGENETICS, V3, P312, DOI 10.1097/00008571-199312000-00005; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; Grosovsky AJ, 1996, MOL CELL BIOL, V16, P6252; GUDAS JM, 1987, SOMAT CELL MOLEC GEN, V13, P513, DOI 10.1007/BF01534493; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1994, ADV ENZYME REGUL, V34, P159, DOI 10.1016/0065-2571(94)90015-9; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HANKINSON O, 1981, SOMAT CELL GENET, V7, P373, DOI 10.1007/BF01542983; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HANKINSON O, 1991, METHOD ENZYMOL, V206, P381; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOEBEE B, 1988, NUCLEIC ACIDS RES, V16, P8147, DOI 10.1093/nar/16.16.8147; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; IRELAND RC, 1995, ARCH BIOCHEM BIOPHYS, V319, P470, DOI 10.1006/abbi.1995.1319; JAIN S, 1994, J BIOL CHEM, V269, P31518; KARENLAMPI SO, 1988, J BIOL CHEM, V263, P10111; KIMURA S, 1987, EMBO J, V6, P1929, DOI 10.1002/j.1460-2075.1987.tb02453.x; LEBEAU MM, 1994, CYTOGENET CELL GENET, V66, P172, DOI 10.1159/000133694; LI H, 1994, J BIOL CHEM, V269, P28098; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; MEYUHAS O, 1990, J BIOL CHEM, V265, P11465; MILES C, 1989, MUTAT RES, V227, P97, DOI 10.1016/0165-7992(89)90004-3; MIMURA J, 1994, PHARMACOGENETICS, V4, P349, DOI 10.1097/00008571-199412000-00008; MONTISANO DF, 1985, MOL CELL BIOL, V5, P698, DOI 10.1128/MCB.5.4.698; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; POLAND A, 1994, MOL PHARMACOL, V46, P915; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; Swanson HI, 1996, J BIOL CHEM, V271, P31657, DOI 10.1074/jbc.271.49.31657; TRASK BJ, 1991, METHOD CELL BIOL, V35, P3; Vasiliou V, 1996, DNA CELL BIOL, V15, P235, DOI 10.1089/dna.1996.15.235; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; Zhang JZ, 1996, MOL PHARMACOL, V50, P1454	54	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31845	31854		10.1074/jbc.272.50.31845	http://dx.doi.org/10.1074/jbc.272.50.31845			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395531	hybrid			2022-12-25	WOS:A1997YL41900090
J	WechslerReya, R; Sakamuro, D; Zhang, J; Duhadaway, J; Prendergast, GC				WechslerReya, R; Sakamuro, D; Zhang, J; Duhadaway, J; Prendergast, GC			Structural analysis of the human BIN1 gene - Evidence for tissue-specific transcriptional regulation and alternate RNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIFF-MAN SYNDROME; HUMAN AMPHIPHYSIN; TUMOR-SUPPRESSOR; PROTEIN; HYBRIDIZATION; CANCER; REGION	BIN1 is a putative tumor suppressor that was identified through its interaction with the MYC oncoprotein. To begin to identify elements of BIN1 whose alteration may contribute to malignancy, we cloned and characterized the human BIN1 gene and promoter, Nineteen exons were identified in a region of >54 kilobases, six of which were alternately spliced in a cell type-specific manner. One alternately spliced exon encodes part of the MYC-binding domain, suggesting that splicing controls the MYC-binding capacity of BIN1 polypeptides. Four other alternately spliced exons encode amphiphysin-related sequences that were included in brain-specific BIN1 species, also termed amphiphysin isoforms or amphiphysin II. The 5'-flanking region of BIN1 is GC-rich and lacks a TATA box but directs transcriptional initiation from a single site, A similar to 0.9-kilobase fragment from this region was sufficient for basal transcription and transactivation by MyoD, which may account for the high levels of BIN1. observed in skeletal muscle. This study lays the foundation for genetic and epigenetic investigations into the role of BIN1 in normal and neoplastic cell regulation.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute								BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cher ML, 1996, CANCER RES, V56, P3091; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; Dropcho EJ, 1996, ANN NEUROL, V39, P659, DOI 10.1002/ana.410390516; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Negorev D, 1996, GENOMICS, V33, P329, DOI 10.1006/geno.1996.0205; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; WechslerReya R, 1997, CANCER RES, V57, P3258; WECHSLERREYA R, 1998, IN PRESS MOL CELL BI; YAMAMOTO R, 1995, HUM MOL GENET, V4, P265, DOI 10.1093/hmg/4.2.265	18	111	119	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31453	31458		10.1074/jbc.272.50.31453	http://dx.doi.org/10.1074/jbc.272.50.31453			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395479	hybrid			2022-12-25	WOS:A1997YL41900038
J	Nieto, C; Espinosa, M; Puyet, A				Nieto, C; Espinosa, M; Puyet, A			The maltose/maltodextrin regulon of Streptococcus pneumoniae - Differential promoter regulation by the transcriptional repressor MalR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; MALTOSE REGULON; GENES; EXPRESSION; OPERON; PURR; OPERATOR	The Streptococcus pneumoniae MalR protein regulates the transcription of two divergent operons, malXCD and malMP, involved in maltosaccharide uptake and utilization, respectively. MalR belongs to the LacI-GalR family of transcription repressors. The protein binds specifically to two operator sequences in the intergenic region between these operons. The affinity of MalR for the malMP binding sequence is higher than for the malXCD site. Results obtained in vivo using transcriptional fusions with reporter genes indicate low repression level of malXCD by MalR when compared with malMP. This behavior may be correlated with the existence of separate induction pathways for maltose, maltotriose, and maltotetraose. The similarities found at the operator sequences and binding domains for MalR and enterococcal repressor proteins suggest that the pneumococcal maltosaccharide regulation system is closely related to several Gram-negative metabolic pathways, but not to the structurally similar Escherichia coli maltose regulon.	Univ Complutense Madrid, Fac Vet, Dept Bioquim & Biol Mol 4, E-28040 Madrid, Spain; CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Puyet, A (corresponding author), Univ Complutense Madrid, Fac Vet, Dept Bioquim & Biol Mol 4, E-28040 Madrid, Spain.		Espinosa, Manuel/M-5282-2019; Nieto, Concha/ABG-2127-2020; Puyet, Antonio/I-4720-2014	Nieto, Concha/0000-0003-0790-3440; Puyet, Antonio/0000-0002-2026-7955				ALBERTI S, 1991, NEW BIOL, V3, P57; ASLANIDIS C, 1990, J BACTERIOL, V172, P2178, DOI 10.1128/jb.172.4.2178-2180.1990; CHAPON C, 1982, J BACTERIOL, V150, P722, DOI 10.1128/JB.150.2.722-729.1982; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; deLorenzo V, 1996, MOL MICROBIOL, V19, P1177; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; EGAN SM, 1994, J MOL BIOL, V243, P821, DOI 10.1006/jmbi.1994.1684; GEANACOPOULOS M, 1997, J BACTERIOL, V179, P28; GILSON E, 1991, NUCLEIC ACIDS RES, V19, P1375, DOI 10.1093/nar/19.7.1375; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; JAENICKE R, 1990, FEBS LETT, V260, P233, DOI 10.1016/0014-5793(90)80111-U; KIM JH, 1995, J BACTERIOL, V177, P5129, DOI 10.1128/jb.177.17.5129-5134.1995; LACKS S, 1968, GENETICS, V60, P685; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Maniatis T., 1989, MOL CLONING LAB MANU; Maxam A M, 1980, Methods Enzymol, V65, P499; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; Miller J.H., 1972, EXPT MOL GENETICS; MUIZNIEKS I, 1994, MOL GEN GENET, V242, P90, DOI 10.1007/BF00277352; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PUYET A, 1993, J BIOL CHEM, V268, P25402; PUYET A, 1993, J MOL BIOL, V230, P800, DOI 10.1006/jmbi.1993.1202; PUYET A, 1993, WORLD J MICROB BIOT, V9, P455, DOI 10.1007/BF00328033; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; ROJO F, 1995, METHODS MOL GENET, V6; ROLFES RJ, 1988, J BIOL CHEM, V263, P19653; ROLFES RJ, 1990, J BACTERIOL, V172, P5758, DOI 10.1128/jb.172.10.5758-5766.1990; RONALD SL, 1990, GENE, V90, P145, DOI 10.1016/0378-1119(90)90451-V; SCARABEL M, 1995, GENE, V153, P9, DOI 10.1016/0378-1119(94)00660-K; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Schwartz M, 1987, MALTOSE REGULON ESCH; STASSI DL, 1981, P NATL ACAD SCI-BIOL, V78, P7028, DOI 10.1073/pnas.78.11.7028; STASSI DL, 1982, GENE, V20, P359, DOI 10.1016/0378-1119(82)90204-9; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; vanWezel GP, 1997, MOL MICROBIOL, V23, P537, DOI 10.1046/j.1365-2958.1997.d01-1878.x; WEICKERT MJ, 1993, J BACTERIOL, V175, P251, DOI 10.1128/JB.175.1.251-258.1993; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WEINRAUCH Y, 1981, MOL GEN GENET, V183, P7, DOI 10.1007/BF00270130	40	45	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30860	30865		10.1074/jbc.272.49.30860	http://dx.doi.org/10.1074/jbc.272.49.30860			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388231	hybrid, Green Published			2022-12-25	WOS:000071640800044
J	Ueda, A; Ishigatsubo, Y; Okubo, T; Yoshimura, T				Ueda, A; Ishigatsubo, Y; Okubo, T; Yoshimura, T			Transcriptional regulation of the human monocyte chemoattractant protein-1 gene - Cooperation of two NF-kappa B sites and NF-kappa B/Rel subunit specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDIOPATHIC PULMONARY FIBROSIS; GROWTH-FACTOR INDUCTION; TUMOR-NECROSIS-FACTOR; IFN-BETA GENE; MESSENGER-RNA; P65 SUBUNIT; ATHEROSCLEROTIC LESIONS; VIRUS INDUCTION; E-SELECTIN; CELL-LINE	Human monocyte chemoattractant protein-1 (human MCP-1) mRNA accumulated in THP-1 cells 2 h after lipopolysaccharide (LPS) stimulation, DNase I footprinting revealed that LPS stimulation induced protein binding to the two closely located NF-kappa B sites, A1 and A2, By electrophoretic gel mobility shift assay and supershift assay, the binding of (p65)(2), c-Rel/p65, p50/p65, and p50/c-Rel to the A2 oligonucleotide probe was detected after LPS stimulation, In contrast, 12-o-tetradecanoylphorbol 13-acetate did not induce a significant amount of MCP-1 mRNA in THP-1 cells 2 h after stimulation, and only p50/p65 bound to the A2 probe, trans Activity of each NF-kappa B/Rel dimer was investigated by transfecting P19 cells with p65, p50, and/or c-Rel expression vectors, and a luciferase construct containing the enhancer region of the human MCP-1 gene, Expression of recombinant p65 or p65 and c-Rel resulted in elevated luciferase activities, indicating that (p65)(2) and c-Rel/p65 had trans-activity, The binding of (p65)(2) and/or c-Rel/p65 to the A2 probe was also detected from 12-o-tetradecanoylphorbol 13-acetate-stimulated HeLa, HOS, and A172 cells in which expression of MCP-1 mRNA was elevated. Finally, the role of the Al site was investigated, Both (p65)(2) and c-Rel/p65 bound to the Al probe by electrophoretic mobility shift assay and a mutation in the A1 or A2 site resulted in a loss of the enhancer activity, These results suggest that the binding of (p65)(2) and c-Rel/p65 to the A1 and A2 sites of this gene is important for the tissue-and stimulus-specific transcription of the human MCP-1 gene.	NCI, Frederick Canc Res & Dev Ctr, Immunopathol Sect, Immunobiol Lab, Frederick, MD 21702 USA; Yokohama City Univ, Sch Med, Dept Internal Med 1, Yokohama, Kanagawa 236, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Yokohama City University	Yoshimura, T (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Immunopathol Sect, Immunobiol Lab, Bldg 560,Rm 12-71, Frederick, MD 21702 USA.	yoshimur@ncifcrf.gov						AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P5371, DOI 10.1073/pnas.89.12.5371; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GRAVES DT, 1989, SCIENCE, V245, P1490, DOI 10.1126/science.2781291; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; IYONAGA K, 1994, HUM PATHOL, V25, P455, DOI 10.1016/0046-8177(94)90117-1; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Kuratsu J, 1996, BRAIN TUMOR, P305; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LI YC, 1994, J BIOL CHEM, V269, P30616; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STAUSS F, 1984, CELL, V37, P889; TAKESHIMA H, 1994, J NEUROSURG, V80, P1056, DOI 10.3171/jns.1994.80.6.1056; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1996, J BIOL CHEM, V271, P20265, DOI 10.1074/jbc.271.34.20265; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VILLIGER PM, 1992, J IMMUNOL, V149, P722; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YOSHIMURA T, 1993, J IMMUNOL, V151, P6225; Yoshimura T, 1996, HUMAN CYTOKINES HDB, VII, P198	53	278	280	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31092	31099		10.1074/jbc.272.49.31092	http://dx.doi.org/10.1074/jbc.272.49.31092			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388261	hybrid			2022-12-25	WOS:000071640800074
J	Tommasi, S; Pfeifer, GP				Tommasi, S; Pfeifer, GP			Constitutive protection of E2F recognition sequences in the human thymidine kinase promoter during cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-MYB TRANSCRIPTION; IMR-90 DIPLOID FIBROBLASTS; PROTEIN-DNA INTERACTIONS; LIGATION MEDIATED PCR; CCAAT-BINDING PROTEIN; GENE PROMOTER; IN-VIVO; METHYLATION ANALYSIS; GROWTH-REGULATION; TRANS-ACTIVATION	The sequences responsible for S phase-specific induction of the human thymidine kinase (TK) gene have been mapped to a small region that contains putative E2F binding sites, We have analyzed protein-DNA interactions at the TK promoter during cell cycle progression in human fibroblasts using an in vivo footprinting approach, We found 14 protein binding sites that were occupied in vivo, All of the sites (among them two inverted CCAAT boxes and several Spl sites) bound transcription factors constitutively throughout the cell cycle, i.e. none of the factor binding was cell cycle-dependent, An E2F-like site located between nucleotides -97 and -89 relative to the major transcription start site was protected in G(0), G(1), S, and G(2) phases, This cell cycle-independent protection of E2F sequences in the TK promoter differs from the G(0)/G(1)-restricted binding of E2F complexes observed for genes in which the E2F sites function as repressor elements (Tommasi, S., and Pfeifer, G. P. (1995) Mol. Cell. Biol. 15, 6901-6913; Zwicker, J., Liu, N., Engeland, K., Lucibello, F. C., and Muller, R. (1996) Science 271, 1595-1597). A comparison of several genes containing E2F motifs indicates that E2F sites located in proximity to the transcription initiation site (-50 to +20) in TATA-less promoters predominantly function as repressor elements, while in other genes constitutively bound E2F complexes located further upstream mediate activation presumably in conjunction with a functional TATA box.	CITY HOPE NATL MED CTR,BECKMAN RES INST,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope				Tommasi, Stella/0000-0001-6897-4985	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070, R37ES006070] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06070] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Bennett JD, 1996, ONCOGENE, V13, P1073; CHANG ZF, 1995, J BIOL CHEM, V270, P27374, DOI 10.1074/jbc.270.45.27374; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHEN ZF, 1993, CANCER RES, V53, P3253; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DOU QP, 1994, J BIOL CHEM, V269, P1306; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; GOOD L, 1995, J CELL PHYSIOL, V163, P636, DOI 10.1002/jcp.1041630326; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kim EC, 1996, CELL GROWTH DIFFER, V7, P1741; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIM YK, 1992, J BIOL CHEM, V267, P2723; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; LIPSON KE, 1995, J CELL BIOCHEM, V57, P711, DOI 10.1002/jcb.240570416; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; MAO XZ, 1995, J CELL BIOCHEM, V57, P701, DOI 10.1002/jcb.240570415; Maxam A M, 1980, Methods Enzymol, V65, P499; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OSWALD F, 1994, ONCOGENE, V9, P2029; Oswald F, 1996, MOL CELL BIOL, V16, P1889; PANG JH, 1993, J BIOL CHEM, V268, P2909; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PLET A, 1992, ONCOGENE, V7, P1847; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wells J, 1996, MOL CELL BIOL, V16, P634; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	69	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30483	30490		10.1074/jbc.272.48.30483	http://dx.doi.org/10.1074/jbc.272.48.30483			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374541	hybrid			2022-12-25	WOS:A1997YH61300073
J	Deutsch, WA; Yacoub, A; Jaruga, P; Zastawny, TH; Dizdaroglu, M				Deutsch, WA; Yacoub, A; Jaruga, P; Zastawny, TH; Dizdaroglu, M			Characterization and mechanism of action of Drosophila ribosomal protein S3 DNA glycosylase activity for the removal of oxidatively damaged DNA bases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; ESCHERICHIA-COLI; HUMAN-CELLS; G.C->T.A TRANSVERSIONS; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; EXCISION-REPAIR; 8-HYDROXYGUANINE; 8-OXOGUANINE; 7,8-DIHYDRO-8-OXOGUANINE	We recently demonstrated that Drosophila ribosomal protein S3 specifically cleaved duplex oligodeoxynucleotides at sites of 7,8-dihydro-8-oxoguanine (8-oxoGua), presumably due to S3 protein possessing an N-glycosylase activity that is associated with its known apurinic/apyrimidinic (AP) lyase activity. Here we show, using DNA substrates prepared by gamma-irradiation under N2O and analyzed by gas chromatography/isotope-dilution mass spectrometry, that S3 protein efficiently liberates 8-oxoGua as a free base from the damaged DNA substrate. Of the 15 additional modified bases present in the DNA substrate, the only other one acted on by S3 protein was 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyGua). Specificity constants measured for the removal of 8-oxoGua and FapyGua indicate that S3 protein has a similar preference for both of these modified purines. Having established that S3 protein contains an N-glycosylase activity, we next examined the repair of duplex oligonucleotides containing 8-oxoGua (8-oxoGua-37-mer) positioned opposite Cyt, Gua, Thy, or Ade, Significant cleavage of the 8-oxoGua-37-mer was only detected for an opposing Cyt. Moreover, we show that an imino covalent enzyme-substrate intermediate is formed between S3 protein and 8-oxoGua-37-mer, a result similar to other DNA repair enzymes that catalyze N-glycosylase/AP lyase-type reactions at sites of DNA damage.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA; Med Acad, Dept Clin Biochem, PL-85094 Bydgoszez, Poland	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institute of Standards & Technology (NIST) - USA	Deutsch, WA (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.		Jaruga, Pawel/M-4378-2015	Jaruga, Pawel/0000-0001-9192-6084	NCRR NIH HHS [RR09884] Funding Source: Medline; NIEHS NIH HHS [ES07815] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007815] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aburatani H, 1997, CANCER RES, V57, P2151; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; CHENG KC, 1992, J BIOL CHEM, V267, P166; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIZDAROGLU M, 1994, METHOD ENZYMOL, V234, P3; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; Dizdaroglu M., 1993, DNA FREE RADICALS, P19; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Gutfreund H., 1972, ENZYMES PHYSICAL PRI, P116; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; Karakaya A, 1997, NUCLEIC ACIDS RES, V25, P474, DOI 10.1093/nar/25.3.474; KIM J, 1995, J BIOL CHEM, V270, P13620, DOI 10.1074/jbc.270.23.13620; MARUSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; Sandigursky M, 1997, J BIOL CHEM, V272, P17480, DOI 10.1074/jbc.272.28.17480; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WILSON DM, 1994, J BIOL CHEM, V269, P25359; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x	35	80	82	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32857	32860		10.1074/jbc.272.52.32857	http://dx.doi.org/10.1074/jbc.272.52.32857			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407063	hybrid			2022-12-25	WOS:000071182900024
J	Ahnert, P; Patel, SS				Ahnert, P; Patel, SS			Asymmetric interactions of hexameric bacteriophage T7 DNA helicase with the 5 '- and 3 '-tails of the forked DNA substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZO<A>PYRENE-DNA ADDUCTS INHIBIT; GENE-4 PROTEIN; DEOXYRIBONUCLEIC-ACID; OLIGOMERIC STRUCTURE; STRANDED-DNA; REPLICATION; BINDING; ASSAY	Bacteriophage T7 DNA helicase requires two noncomplementary single-stranded DNA (ssDNA) tails next to a double-stranded DNA (dsDNA) region to initiate DNA unwinding. The interactions of the helicase with the DNA were investigated using a series of forked DNAs. Our results show that the helicase interacts asymmetrically with the two tails of the forked DNA. When the helicase was preassembled on the forked DNA before the start of unwinding, a DNA with 15-nucleotide (nt) 3'-tail and 35-nt 5'-tail was unwound with optimal rates close to 60 base pairs/s at 18 degrees C. When the helicase was not preassembled on the DNA, a >65-nt long 5'-tail was required for maximal unwinding rates of 12 base pairs/s. We show that the helicase interacts specifically with the ssDNA region and maintains contact with both ssDNA strands during DNA unwinding, since conversion of the two ssDNA tails to dsDNA structures greatly inhibited unwinding, and the helicase was unable to unwind past a nick in the dsDNA region. These studies have provided new insights into the mechanism of DNA unwinding. We propose an exclusion model of DNA unwinding in which T7 helicase hexamer interacts mainly with the ssDNA strands during DNA unwinding, encircling the 5'-strand and excluding the 3'-strand from the hole.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Patel, SS (corresponding author), Ohio State Univ, Dept Biochem, 484 W 12Th Ave, Columbus, OH 43210 USA.		Ahnert, Peter/I-8150-2015	Ahnert, Peter/0000-0002-1771-0856	NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BC, 1996, J BIOL CHEM, V271, P21462, DOI 10.1074/jbc.271.35.21462; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WC, 1989, J BIOL CHEM, V264, P6748; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FULLER CW, 1985, J BIOL CHEM, V260, P3185; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; HOUSTON P, 1994, P NATL ACAD SCI USA, V91, P5471, DOI 10.1073/pnas.91.12.5471; KORNBERG A, 1992, DNA REPLICATION, P355; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; PATEL SS, 1993, J BIOL CHEM, V268, P10668; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J., 2002, MOL CLONING LAB MANU; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; Yong YQ, 1996, CHEM RES TOXICOL, V9, P179, DOI 10.1021/tx950112h; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; ZHUANG W, 1992, THESIS PURDUE U ANN	39	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32267	32273		10.1074/jbc.272.51.32267	http://dx.doi.org/10.1074/jbc.272.51.32267			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405431	hybrid			2022-12-25	WOS:000071108000050
J	Badou, A; Savignac, M; Moreau, M; Leclercq, C; Pasquier, R; Druet, P; Pelletier, L				Badou, A; Savignac, M; Moreau, M; Leclercq, C; Pasquier, R; Druet, P; Pelletier, L			HgCl2-induced interleukin-4 gene expression in T cells involves a protein kinase C-dependent calcium influx through L-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CYTOKINE PRODUCTION; MERCURIC-CHLORIDE; IL-4 PRODUCTION; IN-VIVO; NF-AT; ACTIVATION; AUTOIMMUNITY; LYMPHOCYTES; TRANSCRIPTION	Mercuric chloride (HgCl2) induces T helper 2 (Th2) autoreactive anti-class II T cells in Brown Norway rats. These cells produce interleukin (IL)-4 and induce a B cell polyclonal activation that is responsible for autoimmune disease. In Brown Norway rats, HgCl2 triggers early IL-4 mRNA expression both in vivo and in vitro by T cells, which may explain why autoreactive anti-class II T cells acquire a Th2 phenotype. The aim of this study was to explore the transduction pathways by which this chemical operates, By using two murine T cell hybridomas that express IL-4 mRNA upon stimulation with HgCl2, we demonstrate that: 1) HgCl2 acts at the transcriptional level without requiring de novo protein synthesis; 2) HgCl2 induces a protein kinase C-dependent Ca2+ influx through L-type calcium channels; 3) calcium/calcineurin-dependent pathway and protein kinase C activation are both implicated in HgCl2-induced IL-4 gene expression; and 4) HgCl2 can activate directly protein kinase C, which might be one of the main intracellular target for HgCl2. These data are in agreement with an effect of HgCl2 which is independent of antigen-specific recognition. It may explain the T cell polyclonaI activation in the mercury model and the expansion of pathogenic autoreactive anti-class II Th2 cells in this context.	Hop Purpan, Inst Federat Rech 30, INSERM, Unite 28, F-31059 Toulouse, France; Univ Toulouse 3, UMR 5547, CNRS, F-31062 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Badou, A (corresponding author), INSERM, U28, Pavillon Lefebvre,Pl Dr Baylac, F-31059 Toulouse, France.	Abdellah.Badou@purpan.inserm.fr	Leclerc, Catherine/O-6514-2015; Savignac, Magali/K-1757-2014; Pelletier, Lucette/L-2956-2014	Badou, Abdallah/0000-0003-4849-9085				ADORINI L, 1991, J EXP MED, V174, P945, DOI 10.1084/jem.174.4.945; ADORINI L, 1988, P NATL ACAD SCI USA, V85, P5181, DOI 10.1073/pnas.85.14.5181; ADORINI L, 1993, J IMMUNOL, V151, P3576; Biancone L, 1996, J EXP MED, V183, P1473, DOI 10.1084/jem.183.4.1473; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; Fillion J, 1997, INT IMMUNOL, V9, P263, DOI 10.1093/intimm/9.2.263; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GAJEWSKI TF, 1989, IMMUNOL REV, V111, P79, DOI 10.1111/j.1600-065X.1989.tb00543.x; GAJEWSKI TF, 1994, J EXP MED, V179, P481, DOI 10.1084/jem.179.2.481; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; Guery JC, 1996, J EXP MED, V183, P485, DOI 10.1084/jem.183.2.485; Heo Y, 1996, TOXICOL APPL PHARM, V138, P149, DOI 10.1006/taap.1996.0108; KATO H, 1992, BIOCHEM BIOPH RES CO, V188, P934, DOI 10.1016/0006-291X(92)91145-G; KELLER HU, 1993, BIOCHEM BIOPH RES CO, V194, P1111, DOI 10.1006/bbrc.1993.1936; KUNERTRADEK J, 1990, AGENTS ACTIONS, V29, P254, DOI 10.1007/BF01966455; LAMONT AG, 1990, J IMMUNOL, V145, P1687; Launois P, 1995, EUR J IMMUNOL, V25, P3298, DOI 10.1002/eji.1830251215; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; MIURA K, 1995, HANDB EXP PHARMACOL, V115, P163; MOREAU M, 1994, P NATL ACAD SCI USA, V91, P12639, DOI 10.1073/pnas.91.26.12639; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORDLIND K, 1984, INT ALLERGY APPL IMM, V77, P405; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OLIVEIRA DBG, 1995, EUR J IMMUNOL, V25, P2259, DOI 10.1002/eji.1830250822; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; PRIGENT P, 1995, J CLIN INVEST, V96, P1484, DOI 10.1172/JCI118185; Pu MY, 1996, J CELL BIOCHEM, V63, P104; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Rolfe FG, 1997, J IMMUNOL METHODS, V202, P143, DOI 10.1016/S0022-1759(96)00245-1; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SAOUDI A, 1995, EUR J IMMUNOL, V25, P1972, DOI 10.1002/eji.1830250726; SAOUDI A, 1995, J EXP MED, V182, P335, DOI 10.1084/jem.182.2.335; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; TAMURA T, 1993, J IMMUNOL, V151, P6051; TAMURA T, 1995, J IMMUNOL, V155, P4692; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YOUNG W, 1988, MOL PHARMACOL, V34, P239; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0	51	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32411	32418		10.1074/jbc.272.51.32411	http://dx.doi.org/10.1074/jbc.272.51.32411			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405450	hybrid			2022-12-25	WOS:000071108000069
J	Karaoglu, D; Kelleher, DJ; Gilmore, R				Karaoglu, D; Kelleher, DJ; Gilmore, R			The highly conserved Stt3 protein is a subunit of the yeast oligosaccharyltransferase and forms a subcomplex with Ost3p and Ost4p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; TRANSFERASE-ACTIVITY; SHUTTLE VECTORS; RIBOPHORIN-I; COMPLEX; GENE; GLYCOSYLATION; WBP1P; MUTAGENESIS; MUTATIONS	The oligosaccharyltransferase has been purified from Saccharomyces cerevisiae as an hetero-oligomeric complex composed of four or six subunits. Here, the in vivo subunit composition and stoichiometry of the oligosaccharyltransferase were investigated by attaching an epitope coding sequence to a previously characterized subunit gene, OST3. Five (Ost1p, Wbp1p, Swp1p, Ost2p, and Ost5p) of the seven polypeptides that were coimmunoprecipitated with the epitope-tagged Ost3p were identical to those obtained by the conventional purification procedure. Two additional coprecipitating polypeptides with apparent molecular masses of 60 and 3.6 kDa were identified as the 78-bDa Stt3 protein and the 36-residue Ost4 protein, respectively. Stt3p and Ost4p were previously identified in screens for gene products involved in N-linked glycosylation, Quantification of the in vivo radiolabeled subunits and the radioiodinated purified enzyme shows that the yeast oligosaccharyltransferase is composed of equimolar amounts of eight subunits. Exposure of the immunoprecipitated oligosaccharyltransferase to mild protein denaturants yielded a subcomplex comprised of Stt3p, Ost3p, and Ost4p. These experiments, taken together with genetic and biochemical evidence for subunit interactions, suggest that the enzyme is composed of the following three subcomplexes: (a) Stt3p-Ost4p-Ost3p, (b) Swp1p-Wbp1p-Ost2p, and (c) Ost1p-Ost5p.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Gilmore, R (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI SA, 1995, BIOTECHNIQUES, V18, P746; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; Bause E, 1997, BIOCHEM J, V322, P95, DOI 10.1042/bj3220095; BREUER W, 1995, EUR J BIOCHEM, V228, P689, DOI 10.1111/j.1432-1033.1995.0689m.x; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; KARAOGLU D, 1995, J CELL BIOL, V130, P567, DOI 10.1083/jcb.130.3.567; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; KUMAR V, 1994, J BIOL CHEM, V269, P13451; Lissy NA, 1996, BBA-GENE STRUCT EXPR, V1306, P137, DOI 10.1016/0167-4781(96)00025-5; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; Pathak R, 1997, ARCH BIOCHEM BIOPHYS, V338, P1, DOI 10.1006/abbi.1996.9812; PATHAK R, 1995, BIOCHEMISTRY-US, V34, P4179, DOI 10.1021/bi00013a005; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SPIRIG U, 1997, IN PRESS MOL GEN GEN; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOSHIDA S, 1995, GENE, V164, P167, DOI 10.1016/0378-1119(95)00431-5; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	39	76	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32513	32520		10.1074/jbc.272.51.32513	http://dx.doi.org/10.1074/jbc.272.51.32513			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405463	hybrid			2022-12-25	WOS:000071108000082
J	Nomizu, M; Kuratomi, Y; Song, SY; Ponce, ML; Hoffman, MP; Powell, SK; Miyoshi, K; Otaka, A; Kleinman, HK; Yamada, Y				Nomizu, M; Kuratomi, Y; Song, SY; Ponce, ML; Hoffman, MP; Powell, SK; Miyoshi, K; Otaka, A; Kleinman, HK; Yamada, Y			Identification of cell binding sequences in mouse laminin gamma 1 chain by systematic peptide screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTGROWTH-PROMOTING DOMAIN; CAPILLARY-LIKE STRUCTURES; TERMINAL GLOBULAR DOMAIN; HUMAN-ENDOTHELIAL CELLS; AMINO-ACID-SEQUENCE; EGF-LIKE MOTIF; NEURITE OUTGROWTH; B2 CHAIN; SYNTHETIC PEPTIDES; BASEMENT-MEMBRANE	Laminin-1, a major component of basement membranes, consists of three different chains designated alpha 1, beta 1, and gamma 1 and has diverse biological functions. We have identified cell binding sites on the mouse laminin gamma 1 chain, using systematic screening of 165 overlapping synthetic peptides covering the entire chain. We identified 12 cell binding sequences using HT-1080 human fibrosarcoma and B16-F10 mouse melanoma cells in two independent assays employing peptide-conjugated Sepharose beads and peptide-coated dishes. Four peptides (C-16, C-28, C-64, and C-68) located on the globular domains of the gamma 1 chain were the most active and showed dose-dependent cell attachment. Cell attachment to C-68 was inhibited by EDTA and by anti-alpha(2) beta(1) integrin antibodies. Cell attachment to C-16 and C-64 was partially inhibited by EDTA but was not inhibited by anti-integrin antibodies. EDTA and anti-integrin antibodies did not affect cell attachment to C-28. The four peptides were tested in adhesion and differentiation assays with endothelial, neuronal, and human salivary gland cells. C-16 was the most active for all of the cells, whereas the other three peptides showed cell type specificity in their activities. The active core sequences of C-16, C-28, C-64, and C-68 are YVRL, IRVTLN, TTVKYIFR, and SIKIRGTY, respectively. These sequences are highly conserved among the different species and in the laminin gamma 2 chain. These results suggest that the specific sequences on the laminin gamma 1 chain are biologically active and interact with distinct cell surface receptors.	NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Kyoto Univ, Fac Pharmaceut Sci, Sakyo Ku, Kyoto 606, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Kyoto University	Yamada, Y (corresponding author), NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg30,Rm 405, Bethesda, MD 20892 USA.							BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; Bodanszky M., 1983, PEPTIDES, V5, P111; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hoffman M. P., 1995, Molecular Biology of the Cell, V6, p169A; Hoffman MP, 1996, J CELL SCI, V109, P2013; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MURTOMAKI S, 1992, J NEUROSCI RES, V32, P261, DOI 10.1002/jnr.490320216; NOMIZU M, 1992, J BIOL CHEM, V267, P14118; NOMIZU M, 1994, J BIOL CHEM, V269, P30386; Nomizu M, 1996, FEBS LETT, V396, P37, DOI 10.1016/0014-5793(96)01060-5; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; OTAKA A, 1995, J ORG CHEM, V60, P3967, DOI 10.1021/jo00118a011; PIERSHBACHER MD, 1984, NATURE, V301, P30; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; SAKAMOTO N, 1991, CANCER RES, V51, P903; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SKUBITZ APN, 1990, CANCER RES, V50, P7612; STACK S, 1991, BIOCHEMISTRY-US, V30, P2073, DOI 10.1021/bi00222a011; SUGIYAMA S, 1995, EUR J BIOCHEM, V228, P120, DOI 10.1111/j.1432-1033.1995.0120o.x; Takagi Y, 1996, J BIOL CHEM, V271, P18074, DOI 10.1074/jbc.271.30.18074; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; Utani A, 1997, J BIOL CHEM, V272, P2814, DOI 10.1074/jbc.272.5.2814; WUJEK JR, 1990, DEV BRAIN RES, V55, P237, DOI 10.1016/0165-3806(90)90205-D; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L	46	100	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32198	32205		10.1074/jbc.272.51.32198	http://dx.doi.org/10.1074/jbc.272.51.32198			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405421	hybrid			2022-12-25	WOS:000071108000040
J	Okazaki, T; Ishikawa, T; Nishimori, S; Igarashi, T; Hata, K; Fujita, T				Okazaki, T; Ishikawa, T; Nishimori, S; Igarashi, T; Hata, K; Fujita, T			Hyperosmolarity-induced gene stimulation is mediated by the negative calcium responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MEDULLARY COLLECTING DUCT; PARATHYROID-HORMONE GENE; EXTRACELLULAR CALCIUM; MAMMALIAN-CELLS; PROTEIN; STRESS; ACTIVATION; PROMOTER; REF1	The negative calcium responsive elements of the parathyroid hormone gene bind to a specific set of nuclear proteins in an extracellular calcium (Ca-e(2+))-dependent manner. We have found that one of the negative calcium responsive elements, named oligo B, is found in the 5'-flanking region of such vasoactive genes as the vasopressin and atrial natriuretic polypeptide genes. Furthermore, the oligo B-like sequence in the former gene is conserved throughout evolution, Because expression of some of these vasoactive genes is altered by external stimuli which change cell volume, we examined whether oligo B is involved in gene regulation by hyperosmolarity. Here, we demonstrate that the binding between oligo B and its binding nuclear proteins including a redox factor 1 was reduced by hyperosmolarity generated by sodium chloride but not by urea, Such attenuated binding was reversed by dephosphorylating nuclear proteins by a potato acid phosphatase, suggesting that NaCl treatment elicited phosphorylation of these nuclear proteins to weaken their binding activity to oligo B. Furthermore, these nuclear events led to hyperosmolarity-mediated transcriptional stimulation of the genes bearing this DNA element in the cultured cells.	Univ Tokyo, Sch Med, Dept Internal Med 4, Endocrine Genet & Hyperten Unit,Bunkyo Ku, Tokyo 112, Japan; Mitsubishi Kagaku Bioclin Lab Inc, Itabashi Ku, Tokyo 174, Japan	University of Tokyo; Mitsubishi Kagaku Bio-Clinical Laboratories	Okazaki, T (corresponding author), Univ Tokyo, Sch Med, Dept Internal Med 4, Endocrine Genet & Hyperten Unit,Bunkyo Ku, Tokyo 112, Japan.							BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHEN CJ, 1987, ENDOCRINOLOGY, V121, P958, DOI 10.1210/endo-121-3-958; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KOHAN DE, 1993, J CLIN INVEST, V91, P1235, DOI 10.1172/JCI116286; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; OKAZAKI T, 1991, J BIOL CHEM, V266, P21903; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; OKAZAKI T, 1992, J CLIN INVEST, V89, P1268, DOI 10.1172/JCI115711; PU LP, 1995, P NATL ACAD SCI USA, V92, P10653, DOI 10.1073/pnas.92.23.10653; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROBINSON AG, 1990, J CLIN INVEST, V86, P1023, DOI 10.1172/JCI114804; Ruepp B, 1996, P NATL ACAD SCI USA, V93, P8624, DOI 10.1073/pnas.93.16.8624; SATO N, 1990, AM J MED SCI, V299, P309, DOI 10.1097/00000441-199005000-00004; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; SZASZI S, 1997, J BIOL CHEM, V272, P16670; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	26	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32274	32279		10.1074/jbc.272.51.32274	http://dx.doi.org/10.1074/jbc.272.51.32274			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405432	hybrid			2022-12-25	WOS:000071108000051
J	Dumoulin, A; Manning, LR; Jenkins, WT; Winslow, RM; Manning, JM				Dumoulin, A; Manning, LR; Jenkins, WT; Winslow, RM; Manning, JM			Exchange of subunit interfaces between recombinant adult and fetal hemoglobins - Evidence for a functional inter-relationship among regions of the tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE HEMOGLOBIN; PROTEIN; SITE; 2,3-DIPHOSPHOGLYCERATE; BINDING; GLOBIN; MUTANT; OXYGEN; YEAST	The inter-relationship between the interior subunit interfaces and the exterior diphosphoglycerate (DPG) binding region of the hemoglobin tetramer and the effects of a specific N-terminal acetylation on tetramer assembly have been evaluated, Tetrameric fetal hemoglobin F in the liganded state was found to dissociate to dimers much less than previously appreciated, i.e, about 70 times less than adult hemoglobin A (K-d = 0.01 mu M and 0.68 mu M, for HbF and HbA, at pH 7.5, respectively) over the pH range 6.2-7.5, whereas HbF(1), in which the N termini of the gamma-chains are acetylated, dissociates like HbA, To determine whether this feature of HbF could be transferred to hemoglobin A, the single amino acid difference in their alpha(1) beta(2)/alpha(1) gamma(2) interfaces and the 4 amino acid differences in their alpha(1) beta(1)/alpha(1) gamma(1) interfaces have been substituted in HbA to those in HbF, This pentasubstituted recombinant HbA/F had the correct molecular weight as determined by mass spectrometry, the expected mobility on isoelectric focusing, the calculated amino acid composition, and normal circular dichroism properties, oxygen binding, and cooperativity, Although HbA/F has the same amino acid side chains that bind DPG as HbA, its diminished response to 2,3-DPG resembled that of HbF. However, its tetramer-dimer dissociation constant (K-d = 0.14 mu M) was between that of HbA and HbF despite the fact that it was composed entirely of HbF subunit interfaces, The results indicate that regions of the tetramer distant from the tetramer-dimer interface influence its dissociation and, reciprocally, that the interfaces affect regions involved in the binding of allosteric regulators, suggesting flexible long range inter-relationships in hemoglobin.	NORTHEASTERN UNIV, DEPT BIOL, BOSTON, MA 02115 USA; INDIANA UNIV, DEPT CHEM, BLOOMINGTON, IN 47405 USA; UNIV CALIF SAN DIEGO, VET AFFAIRS MED CTR, DEPT MED, SAN DIEGO, CA 92161 USA	Northeastern University; Indiana University System; Indiana University Bloomington; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NHLBI NIH HHS [HL-58512, HL-48018, HL-18819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018819, P01HL058512, P01HL048018, R37HL018819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1965, P NATL ACAD SCI USA, V53, P342, DOI 10.1073/pnas.53.2.342; ACKERS GK, 1975, PROTEINS, V1, P2; BENESCH RE, 1995, J BIOL CHEM, V270, P13785, DOI 10.1074/jbc.270.23.13785; BENESCH RE, 1990, P NATL ACAD SCI USA, V77, P5130; BONAVENTURA J, 1976, J BIOL CHEM, V251, P7563; BOOKCHIN RM, 1975, NATURE, V256, P667, DOI 10.1038/256667a0; BUNN HF, 1974, BIOCHEMISTRY-US, V13, P988, DOI 10.1021/bi00702a024; BUNN HF, 1970, J CLIN INVEST, V49, P1088, DOI 10.1172/JCI106324; CHIANCONE E, 1968, J BIOL CHEM, V243, P1212; CHU AH, 1981, J BIOL CHEM, V256, P1199; CY IP, 1986, ANAL BIOCHEM, V156, P348, DOI 10.1016/0003-2697(86)90264-2; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; DELLANO JJM, 1994, PROTEIN SCI, V3, P1206, DOI 10.1002/pro.5560030806; EATON WA, 1995, SCIENCE, V268, P1142, DOI 10.1126/science.7539154; FRIER JA, 1977, J MOL BIOL, V112, P97, DOI 10.1016/S0022-2836(77)80158-7; FRONTICELLI C, 1994, BIOPHYS CHEM, V51, P53, DOI 10.1016/0301-4622(94)00028-X; GERSHEY EL, 1968, J BIOL CHEM, V243, P5018; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUEHNS ER, 1964, BIOCHEM J, V92, P444, DOI 10.1042/bj0920444; LONGO LD, 1991, FETAL GAS EXCHANGE L, P1699; MANNING JM, 1997, PROTEIN SCI, V6, P103; Manning LR, 1996, PROTEIN SCI, V5, P775; MILITELLO V, 1991, BIOPHYS CHEM, V39, P161, DOI 10.1016/0301-4622(91)85018-L; MRABET NT, 1986, J BIOL CHEM, V261, P1111; PARK CM, 1973, ANN NY ACAD SCI, V209, P237, DOI 10.1111/j.1749-6632.1973.tb47532.x; Pennisi E, 1997, SCIENCE, V275, P155, DOI 10.1126/science.275.5297.155; PERUTZ MF, 1990, MECHANISMS COOPERATI, P7; POYART C, 1978, PFLUG ARCH EUR J PHY, V376, P169, DOI 10.1007/BF00581580; SCALONI A, 1994, J BIOL CHEM, V269, P15076; SCHEEPENS A, 1995, BIOCHEM J, V310, P597, DOI 10.1042/bj3100597; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WILLIAMS RC, 1976, BIOCHEMISTRY-US, V15, P2207, DOI 10.1021/bi00655a028; WIND M, 1976, BIOCHEMISTRY-US, V15, P5161, DOI 10.1021/bi00668a033; YANASE H, 1994, PROTEIN SCI, V3, P1213, DOI 10.1002/pro.5560030807	37	52	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31326	31332		10.1074/jbc.272.50.31326	http://dx.doi.org/10.1074/jbc.272.50.31326			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395461	hybrid			2022-12-25	WOS:A1997YL41900020
J	Sleeman, JP; Kondo, K; Moll, J; Ponta, H; Herrlich, P				Sleeman, JP; Kondo, K; Moll, J; Ponta, H; Herrlich, P			Variant exons v6 and v7 together expand the repertoire of glycosaminoglycans bound by CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; RAT-TUMOR; MONOCLONAL-ANTIBODIES; METASTATIC BEHAVIOR; BINDING-PROTEINS; SPLICE VARIANTS; CARCINOMA-CELLS; RECEPTOR CD44; HYALURONATE; PROTEOGLYCAN	Isoforms of the glycoprotein CD44 are cell surface receptors for the glycosaminoglycan hyaluronate. They have been implicated in many biological processes, but their function in these is poorly understood and cannot be explained solely by hyaluronate binding. In the present work we examine the ligand binding properties of alternatively spliced CD44 variant isoforms which are functionally involved in the immune system, embryonic development, and tumor behavior. We shaw that these isoforms bind directly to the purified glycosaminoglycans chondroitin sulfate, heparin, and heparin sulfate, in addition to being able to bind to hyaluronate. Binding to this extended repertoire of glycosaminoglycans by CD44 depends on the inclusion of peptide sequences encoded by the alternatively spliced exons v6 and v7, and occurs both when the CD44 is solubilized from the plasma membrane and when it is expressed on intact cells. A single point mutation in the most N-terminal hyaluronate binding motif of CD44 ablates both hyaluronate and chondroitin sulfate binding, suggesting that glycosaminoglycans are bound through a common motif, and that only one of the hyaluronate binding motifs is responsible for the majority of glycosaminoglycan binding by CD44 on the cell. surface. Taken together, these observations indicate that alternative splicing regulates the ligand binding specificity of CD44 and suggest that structural changes in the CD44 protein have a profound effect on the range of ligands to which this molecule can bind with potentially wide-ranging functional consequences.			Sleeman, JP (corresponding author), FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,POB 3640,D-76021 KARLSRUHE,GERMANY.		Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687; KONDO, Kazuhiro/0000-0002-3731-6258				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DROLL A, 1995, J BIOL CHEM, V270, P11567, DOI 10.1074/jbc.270.19.11567; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; GORMAN CM, 1985, DNA CLONING PRACTICA, P143; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Harlow E., 1988, ANTIBODIES LAB MANUA; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MATZKU S, 1983, INVAS METAST, V3, P109; MATZKU S, 1989, CANCER RES, V49, P1294; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; PONTA H, 1994, INVAS METAST, V14, P82; RUDY W, 1993, CANCER RES, V53, P1262; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SALMIVIRTA M, 1995, EXPERIENTIA, V51, P863, DOI 10.1007/BF01921737; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; Sleeman JP, 1996, CANCER RES, V56, P3134; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; WAINWRIGHT D, 1996, ANN NY ACAD SCI, V758, P345; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	46	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31837	31844		10.1074/jbc.272.50.31837	http://dx.doi.org/10.1074/jbc.272.50.31837			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395530	hybrid			2022-12-25	WOS:A1997YL41900089
J	Meyer, T; Carlstedt-Duke, J; Starr, DB				Meyer, T; Carlstedt-Duke, J; Starr, DB			A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RESPONSE ELEMENT; NEGATIVE REGULATION; DNA-BINDING; TRANSCRIPTION; RECEPTOR; COMPLEX; YEAST; PROMOTER; EXPRESSION	The TATA box element is not only important for establishing basal levels of transcription, but it can also be used to modulate cell type or stage specific gene activity. In the case of the human osteocalcin gene, which is transcriptionally repressed by glucocorticoids, a specific binding element for the glucocorticoid receptor (GR) overlaps a noncanonical TATA box, In the present study, the relevance and function of the TATA element in glucocorticoid-mediated repression of the human osteocalcin gene was characterized, Mutating this noncanonical TATA box into a consensus TATA box within the context of the osteocalcin promoter greatly decreased hormone-dependent transcriptional repression by GR. TATA-binding protein (TBP) bound this mutated element much more strongly suggesting a physiologically relevant role for the weak osteocalcin TATA element in the regulation of this bone specific gene. The optimization of the putative transcription factor IIB recognition site did not affect the level of GR-mediated repression. Our results support a model wherein competitive DNA binding of GR and TBP for their overlapping sites explains conditional repression of the osteocalcin gene by glucocorticoids.	Karolinska Inst, Novum, Huddinge Hosp, Dept Med Nutr, S-14186 Huddinge, Sweden; Karolinska Inst, Novum, Huddinge Hosp, Dept Biosci, S-14186 Huddinge, Sweden; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Karolinska Institutet; Karolinska Institutet; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Meyer, T (corresponding author), Karolinska Inst, Novum, Huddinge Hosp, Dept Med Nutr, S-14186 Huddinge, Sweden.	thomas.meyer@mednut.ki.se			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007731] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL 07731] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAIRNS C, 1993, DNA CELL BIOL, V12, P695, DOI 10.1089/dna.1993.12.695; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; DEVOS P, 1994, NUCLEIC ACIDS RES, V22, P1161, DOI 10.1093/nar/22.7.1161; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; KALLIO PJ, 1993, ANN NY ACAD SCI, V684, P233, DOI 10.1111/j.1749-6632.1993.tb32295.x; KARAGIANNI N, 1994, ONCOGENE, V9, P2327; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLUG J, 1994, MOL CELL BIOL, V14, P6208, DOI 10.1128/MCB.14.9.6208; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033; Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Pei L, 1996, J BIOL CHEM, V271, P20879; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SRINIVASAN G, 1992, MOL ENDOCRINOL, V6, P857, DOI 10.1210/me.6.6.857; STARR DB, 1995, J MOL BIOL, V250, P434; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	31	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30709	30714		10.1074/jbc.272.49.30709	http://dx.doi.org/10.1074/jbc.272.49.30709			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388207	hybrid			2022-12-25	WOS:000071640800020
J	Xiong, ZH; Ridgley, EL; Enis, D; Olness, F; Ruben, L				Xiong, ZH; Ridgley, EL; Enis, D; Olness, F; Ruben, L			Selective transfer of calcium from an acidic compartment to the mitochondrion of Trypanosoma brucei - Measurements with targeted aequorins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; RAT-LIVER MITOCHONDRIA; IN-VITRO IMPORT; RECOMBINANT AEQUORIN; CA2+ RELEASE; CYTOSOLIC CA2+; CELLS; HOMEOSTASIS; NUCLEAR; PROTEIN	Organelle compartments are used by cells as reservoirs of exchangeable Ca2+ and as Ca2+ buffers, The following study uses recombinant aequorins (CYT-AEQ and MT-AEQ) to measure the dynamics of Ca2+ flux between organelles in procyclic forms of the pathogenic protozoan, Trypanosoma brucei. Emphasis is placed on the exchange between an acidic Ca2+ reservoir and the mitochondrion, The mammalian mitochondrial targeting sequence was functional in trypanosomes as determined by immunoblots, immunolocalizations, and the observation that MT-AEQ was in a compartment whose Ca2+ uptake was inhibited 82% with carbonyl cyanide p-trifluoromethoxyphenylhydrazone and KCN, The resting level of free calcium ion concentration in the mitochondrion ([Ca2+](mit),,,) was slightly higher than that in the cytoplasm ([Ca2+],(cyt)) (400 +/- 50 nM and 290 +/- 40 nM?I, respectively), Melittin (125 nM) disrupted Ca2+ homeostasis by inducing Ca2+ influx across the plasma membrane, [Ca2+](cyt) became slightly elevated to 410 +/- 100 nM, whereas [Ca2+],(mit), was selectively increased approximately la fold, with a broad peak at 4.8 +/- 1.9 mu M. At the peak, the mitochondrion contained approximately three times more free Ca2+ than the cytosol. However, mitochondrial retention of the Ca2+ was transient, Similar selective transport into the mitochondrion was observed when Ca2+ efflux from an acidic compartment was induced with monensin (2 mu g/ml) in the presence of 5 mM EGTA, [Ca2+](cyt) was transiently elevated to 400 +/- 50 nM, whereas [Ca2+],(mit), was elevated to 3.3+/-1.3 mu M. When cells were treated sequentially with monensin (2 mu g/ml) and then melittin (200 nM), mitochondrial Ca2+ transport was normal, However, [Ca2+](cyt),, became elevated to a level that was 1.4-fold higher than with melittin alone, Overall, these data demonstrate that the trypanosome mitochondrion is not a reservoir of exchangeable Ca2+ in the resting cell, However, Ca2+ is selectively channeled to the mitochondrion from the plasma membrane or acidic Ca2+ storage compartment, Additionally, the acidic compartment contributes to maintenance of Ca2+ homeostasis in response to melittin.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; So Methodist Univ, Dept Phys, Dallas, TX 75275 USA	Southern Methodist University; Southern Methodist University	Ruben, L (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.	Iruben@post.smu.edu		Olness, Fredrick/0000-0001-6799-2436	NIAID NIH HHS [AI24627] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024627] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Badminton MN, 1996, J BIOL CHEM, V271, P31210, DOI 10.1074/jbc.271.49.31210; BADMINTON MN, 1995, EXP CELL RES, V216, P236, DOI 10.1006/excr.1995.1030; BECKER GL, 1980, BIOCHIM BIOPHYS ACTA, V591, P234, DOI 10.1016/0005-2728(80)90155-3; BENAIM G, 1993, BIOCHEM J, V296, P759, DOI 10.1042/bj2960759; BIENEN EJ, 1991, MOL BIOCHEM PARASIT, V45, P185, DOI 10.1016/0166-6851(91)90085-K; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BRUN R, 1979, ACTA TROP, V36, P289; CLARKSON AB, 1989, J BIOL CHEM, V264, P17770; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hauser R, 1996, J CELL SCI, V109, P517; Hausler T, 1997, EUR J CELL BIOL, V73, P240; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; HECKER H, 1980, PATHOL RES PRACT, V166, P203; Kendall JM, 1996, CELL CALCIUM, V19, P133, DOI 10.1016/S0143-4160(96)90082-2; KENDALL JM, 1990, BIOCHEM BIOPH RES CO, V189, P1008; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LEIPE DD, 1993, MOL BIOCHEM PARASIT, V59, P41, DOI 10.1016/0166-6851(93)90005-I; MORENO SNJ, 1992, J BIOL CHEM, V267, P6020; NOLAN DP, 1992, EUR J BIOCHEM, V209, P207, DOI 10.1111/j.1432-1033.1992.tb17278.x; NOLAN DP, 1994, J BIOL CHEM, V269, P26045; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; Priest JW, 1996, J BIOL CHEM, V271, P20060, DOI 10.1074/jbc.271.33.20060; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RUBEN L, 1992, EXP PARASITOL, V74, P332, DOI 10.1016/0014-4894(92)90157-6; Ruben L, 1996, MOL BIOCHEM PARASIT, V81, P191, DOI 10.1016/0166-6851(96)02707-7; RUBEN L, 1991, J BIOL CHEM, V266, P24351; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; Sloof P, 1997, TRENDS MICROBIOL, V5, P189, DOI 10.1016/S0966-842X(97)01034-2; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; VERCESI AE, 1993, J BIOL CHEM, V268, P8564; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; VICKERMAN K, 1965, NATURE, V208, P762, DOI 10.1038/208762a0; WILLIAMSON J, 1981, J PROTOZOOL, V28, P460, DOI 10.1111/j.1550-7408.1981.tb05320.x; WU YM, 1992, BIOCHEM J, V287, P187, DOI 10.1042/bj2870187; Xiong ZH, 1996, MOL BIOCHEM PARASIT, V83, P57, DOI 10.1016/S0166-6851(96)02750-8	48	35	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31022	31028		10.1074/jbc.272.49.31022	http://dx.doi.org/10.1074/jbc.272.49.31022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388251	hybrid			2022-12-25	WOS:000071640800064
J	Zhou, GS; Seibenhener, ML; Wooten, MW				Zhou, GS; Seibenhener, ML; Wooten, MW			Nucleolin is a protein kinase C-zeta substrate - Connection between cell surface signaling and nucleus in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FACTOR-INDUCED DIFFERENTIATION; NEURITE OUTGROWTH; BINDING-PROTEIN; EXPRESSION PATTERN; CHO CELLS; PHOSPHORYLATION; ACTIVATION; ISOFORM; LOCALIZATION	We have previously shown that protein kinase C (PKC)-zeta is activated and required for nerve growth factor (NGF)-induced differentiation of rat pheochromocytoma PC12 cells (Wooten, M, W,, Zhou, G., Seibenhener M. L,, and Coleman, E. S, (1994) Cell Growth & Diff. 5, 395-403; Coleman, E, S,, and Wooten, M, W, (1994) J, Mol, Neurosci, 5, 39-57), Here we report the characterization and identification of a 106-kDa nuclear protein as a specific substrate of PKC-zeta, NGF treatment of PC12 cells resulted in translocation of PKC-zeta and coincident phosphorylation of a protein that was localized within the nucleoplasm of nuclei isolated from PC12 cells, Addition of PKC-zeta pseudosubstrate peptide in vitro or myristoylated peptide in vivo diminished phosphorylation of pp106 in a dose-dependent fashion, Likewise, addition of purified PKC-zeta, but neither PKC-alpha nor delta, to nuclear extracts resulted in an incremental increase in the phosphorylation of pp106, Expression of dominant-negative PKC-zeta inhibited NGF-induced phosphorylation of pp106, by comparison overexpression of PKC-zeta enhanced basal phosphorylation without a noticeable effect upon NGF-induced effects, Amino acid sequence analysis of four peptides derived from purified pp106 revealed that this protein was homologous to nucleolin, Using an in vitro reconstitution system, purified nucleolin was likewise shown to be phosphorylated by purified PKC-zeta. The staining intensity of both enzyme and substrate in the nucleus increased upon treatment with NGF, In vivo labeling with P-32(i) and stimulation of PC12 cells with NGF followed by immunoprecipitation with anti-nucleolin antibody corroborated the in vitro approach documenting enhanced phosphorylation of nucleolin by NGF treatment, Taken together, the findings presented herein document that nucleolin is a target of PKC-zeta that serves to relay NGF signals from cell surface to nucleus in PC12 cells.	Auburn Univ, Dept Zool, Auburn, AL 36849 USA	Auburn University System; Auburn University	Wooten, MW (corresponding author), Auburn Univ, Dept Zool, Auburn, AL 36849 USA.	mwwooten@acesag.auburn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033661] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-33661] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIN JG, 1992, MOL BIOL CELL, V3, P323, DOI 10.1091/mbc.3.3.323; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BRADY MJ, 1993, J BIOL CHEM, V268, P17951; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; COLEMAN ES, 1994, J MOL NEUROSCI, V5, P39, DOI 10.1007/BF02736693; Cosgaya JM, 1996, J NEUROCHEM, V67, P98; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; END D, 1982, J BIOL CHEM, V257, P9223; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; ESCANDEGERAUD ML, 1985, EXP CELL RES, V161, P353, DOI 10.1016/0014-4827(85)90092-8; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRILLI M, 1995, J BIOL CHEM, V270, P26774, DOI 10.1074/jbc.270.45.26774; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HALL FL, 1988, J BIOL CHEM, V263, P4460; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER SE, 1995, DEV BRAIN RES, V85, P239, DOI 10.1016/0165-3806(94)00219-P; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KILEY SC, 1995, J CELL SCI, V108, P1003; KONDRATYEV AD, 1990, FEBS LETT, V264, P75, DOI 10.1016/0014-5793(90)80768-E; LANDRETH GE, 1985, J CELL BIOL, V100, P677, DOI 10.1083/jcb.100.3.677; LEHRICH RW, 1994, J BIOL CHEM, V269, P32446; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MCTIGUE M, 1985, J BIOL CHEM, V260, P9047; MIRANDA GA, 1995, EXP CELL RES, V217, P294, DOI 10.1006/excr.1995.1090; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3345, DOI 10.1021/bi00283a007; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; REINHOLD DS, 1989, J BIOL CHEM, V264, P3538; ROSENBERGER U, 1995, BIOCHEM J, V305, P269, DOI 10.1042/bj3050269; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SANZ L, 1994, J BIOL CHEM, V269, P10044; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SIGMUND O, 1990, J BIOL CHEM, V265, P2257; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; YU MW, 1980, J BIOL CHEM, V255, P481; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292	69	113	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31130	31137		10.1074/jbc.272.49.31130	http://dx.doi.org/10.1074/jbc.272.49.31130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388266	hybrid			2022-12-25	WOS:000071640800079
J	Viglietto, G; Romano, A; Manzo, G; Chiappetta, G; Paoletti, I; Califano, D; Galati, MG; Mauriello, V; Bruni, P; Lago, CT; Fusco, A; Persico, VG				Viglietto, G; Romano, A; Manzo, G; Chiappetta, G; Paoletti, I; Califano, D; Galati, MG; Mauriello, V; Bruni, P; Lago, CT; Fusco, A; Persico, VG			Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization	ONCOGENE			English	Article						PlGF; VEGF; TSH; thyroid goiter; hypervascularization	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE KINASE; PLACENTA; CELLS; EXPRESSION; HEPARIN; IDENTIFICATION; THYROTROPIN; STIMULATION	Placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) represent two closely related angiogenic growth factors active as homodimers or heterodimers. Since goiters of the thyroid gland are extremely hypervascular, we investigated the expression of PlGF, VEGF and their receptors, Flt-1 and Flk-1/KDR, in a small panel of human goiters from patients with Graves's disease, in an animal model of thyroid goitrogenesis and in in vitro cultured thyroid cells. Here we report that the mRNA expression of PlGF, VEGF and their receptors is markedly enhanced in biopsies of goiters resected from Graves's patients. in vivo studies demonstrated that in the thyroid gland of thiouracil-fed rats, increased mRNA and protein expression of PlGF, VEGF, Flt-1 and Flk-1/KDR occurred subsequent to the rise in the serum thyroid stimulating hormone (TSH) levels and in parallel with thyroid capillary proliferation. In vitro studies confirmed the existence of such TSH-dependent paracrine communication between thyroid epithelial cells and endothelium since the conditioned medium collected from TSH-stimulated thyrocytes acquired mitogenic activity for human umbilical vein endothelial (HUVE) cells, Altogether, these data suggest that PlGF and VEGF, released by thyrocytes in response to the chronic activation of the TSH receptor pathway, may act through a paracrine mechanism on thyroid endothelium.	CNR, INT INST GENET & BIOPHYS, I-80125 NAPLES, ITALY; IST NAZL TUMORI FONDAZ SENATORE PASCALE, I-80131 NAPLES, ITALY; UNIV REGGIO CALABRIA, FAC MED & CHIRURG CATANZARO, DIPARTIMENTO MED SPERIMENTALE & CLIN, CALABRIA, ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Universita Mediterranea di Reggio Calabria			Viglietto, Giuseppe/AAC-2852-2019; Califano, Daniela/Y-6313-2018	Viglietto, Giuseppe/0000-0003-2327-7515; Califano, Daniela/0000-0001-6945-3209; Fusco, Alfredo/0000-0003-3332-5197				BRANDT R, 1994, J BIOL CHEM, V269, P17320; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DiPalma T, 1996, MAMM GENOME, V7, P6, DOI 10.1007/s003359900003; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GOODMAN AL, 1987, ENDOCRINOLOGY, V121, P2131, DOI 10.1210/endo-121-6-2131; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; ROGNONI JB, 1984, ACTA ENDOCRINOL-COP, V105, P40, DOI 10.1530/acta.0.1050040; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SMEDS S, 1983, LAB INVEST, V48, P285; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; VANSANDE J, 1975, ENDOCRINOLOGY, V96, P781, DOI 10.1210/endo-96-3-781; Viglietto G, 1996, ONCOGENE, V13, P577; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WILSON JD, 1989, THYROID TXB ENDOCRIN; WOLLMAN SH, 1978, ENDOCRINOLOGY, V103, P2306, DOI 10.1210/endo-103-6-2306; WYNFORDTHOMAS D, 1982, J ENDOCRINOL, V94, P131, DOI 10.1677/joe.0.0940131; YUN K, 1986, J ENDOCRINOL, V111, P397, DOI 10.1677/joe.0.1110397; Ziche M, 1997, LAB INVEST, V76, P517	33	90	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	1997	15	22					2687	2698		10.1038/sj.onc.1201456	http://dx.doi.org/10.1038/sj.onc.1201456			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400995				2022-12-25	WOS:A1997YH46800006
J	Kovar, H; Jug, G; Aryee, DNT; Zoubek, A; Ambros, P; Gruber, B; Windhager, R; Gadner, H				Kovar, H; Jug, G; Aryee, DNT; Zoubek, A; Ambros, P; Gruber, B; Windhager, R; Gadner, H			Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors	ONCOGENE			English	Article						Ewing tumors; p16; Rb; cyclin D; prognosis	KINASE-4 INHIBITOR GENE; P53 MUTATIONS; HOMOZYGOUS DELETIONS; CHIMERIC TRANSCRIPTS; CDK4 AMPLIFICATION; SOMATIC MUTATIONS; P16/MTS1 GENE; ABSENCE; CANCER; EXPRESSION	The pRB cell cycle regulatory cascade is frequently perturbed in neoplasia by overexpression of a component of the pRB-phosphorylating cyclin D1/CDK4 complex or by inactivation of pRB or the CDK4 inhibitors p16 and p15, We investigated the status and expression of p16, p15, CCND1, CDK4 and RE genes in the Ewing family of tumors, P16 loss was observed in 8 of 27 tumors (30%) and in 12 of 23 (52%) tumor cell lines from unrelated patients, There were no discrepancies in the p16 status between primary tumors and the corresponding cell lines and between cell Lines established from consecutive tumor samples, p15 was codeleted in most cases but p15 mRNA was absent also in cell lines retaining the gene, In addition, posttranscriptional p16 inactivation was observed in two cases, Although no evidence for CDK4 or CCND1 amplification was obtained, expression of these genes varied considerably in the cell lines in a case specific manner, In wild-type p16 cell lines, pRB expression was lost in one case, Our data indicate that, despite the absence of cytogenetically detectable 9p21 chromosomal aberrations, p16 deletions constitute the most frequent secondary molecular aberration in Ewing tumors so far, These results are discussed in the context of the stage of disease and the clinical outcome of the patients, The potential prognostic impact of these findings remains to be further evaluated.	UNIV VIENNA, DEPT ORTHOPED, A-1090 VIENNA, AUSTRIA	University of Vienna	Kovar, H (corresponding author), ST ANNA CHILDRENS HOSP, CHILDRENS CANC RES INST, KINDERSPITALGASSE 6, A-1090 VIENNA, AUSTRIA.		Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Windhager, Reinhard/0000-0002-6321-1804; Kovar, Heinrich/0000-0001-6873-9109				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; BARTKOVA J, 1995, CANCER RES, V55, P949; BELTINGER CP, 1995, CANCER RES, V55, P2053; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN TC, 1995, J PATHOL, V176, P243, DOI 10.1002/path.1711760306; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DURO D, 1995, ONCOGENE, V11, P21; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HE J, 1994, CANCER RES, V54, P5804; Hengstschlager M, 1996, DNA CELL BIOL, V15, P41, DOI 10.1089/dna.1996.15.41; HIRAMA T, 1995, BLOOD, V86, P841; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hui AM, 1996, HEPATOLOGY, V24, P575, DOI 10.1002/hep.510240319; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MALKIN D, 1994, CANCER RES, V54, P2077; MAO L, 1995, CANCER RES, V55, P2995; MORI T, 1994, CANCER RES, V54, P3396; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; PETER M, 1997, IN PRESS ONCOGENE; RAFFEL C, 1993, NEUROSURGERY, V33, P301, DOI 10.1227/00006123-199308000-00018; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, CANCER RES, V55, P2988; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VOGAN K, 1993, CANCER RES, V53, P5269; WADA M, 1993, BLOOD, V82, P3163; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	41	107	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2225	2232		10.1038/sj.onc.1201397	http://dx.doi.org/10.1038/sj.onc.1201397			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393981				2022-12-25	WOS:A1997YD01900011
J	Rousseau, S; Houle, F; Landry, J; Huot, J				Rousseau, S; Houle, F; Landry, J; Huot, J			p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells	ONCOGENE			English	Article						VEGF; p38 MAP kinase; cell migration	HEAT-SHOCK PROTEIN; GTP-BINDING PROTEIN; SIGNAL-TRANSDUCTION; TYROSINE KINASE; INFLAMMATORY CYTOKINES; SMOOTH-MUSCLE; STRESS FIBERS; FACTOR VEGF; PHOSPHORYLATION; MITOGEN	Vascular endothelial growth factor (VEGF) is a potent chemotactic agent for endothelial cells. Yet the signalling pathways that modulate the motogenic effects of VEGF in vascular endothelial cells are still ill defined. In the present study, we found in primary cultures of human umbilical vein endothelial cells (HUVEC) that VEGF increased cell migration and induced a marked reorganization of the microfilament network that was characterized by the formation of stress fibers and the recruitment of vinculin to focal adhesions, VEGF also stimulated the mitogen activated protein (MAP) kinases ERK (extracellular signal-regulated kinase) and p38 (stress activated protein kinase-2), but not SAPK1/JNK (stress activated protein kinase-1/c-Jun NH2-terminal kinase). Activation of p38 resulted in activation of MAP kinase activated protein kinase-2/3 and phosphorylation of the F-actin polymerization modulator, heat shock protein 27 (HSP27). Inhibiting the VEGF-induced activation of ERK with PD098059 did mot influence actin organization or cell migration but totally inhibited the VEGF-induced incorporation of thymidine into DNA. Inhibition of p38 activity by the specific inhibitor SB203580 led to an inhibition of HSP27 phosphorylation, actin reorganization and cell migration. The results indicate that the p38 pathway conveys the VEGF signal to microfilaments inducing rearrangements of the actin cytoskeleton that regulate cell migration. By modulating cell migration, p38 may thus be an important regulator of angiogenesis.	UNIV LAVAL,CTR RECH CANCEROL,HOTEL DIEU,QUEBEC CITY,PQ G1R 2J6,CANADA	Laval University			Rousseau, Simon/A-1800-2009	Rousseau, Simon/0000-0002-8773-575X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Guay J, 1997, J CELL SCI, V110, P357; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1996, CANCER RES, V56, P273; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Hyder SM, 1996, CANCER RES, V56, P3954; JONGSTRABILEN J, 1992, J CELL BIOL, V118, P1443, DOI 10.1083/jcb.118.6.1443; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUZUYA M, 1994, EXP CELL RES, V215, P310, DOI 10.1006/excr.1994.1347; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEVESQUE L, 1995, BRIT J PHARMACOL, V116, P1673, DOI 10.1111/j.1476-5381.1995.tb16390.x; MADRI JA, 1988, ENDOTHELIAL CELL BIO, P167; MARCEAU F, 1992, INT J IMMUNOPHARMACO, V14, P525, DOI 10.1016/0192-0561(92)90113-Y; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORIOKA K, 1987, BIOCHEM BIOPH RES CO, V145, P969, DOI 10.1016/0006-291X(87)91060-6; OBERG C, 1994, GROWTH FACTORS, V10, P115, DOI 10.3109/08977199409010985; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SEETHARAM L, 1995, ONCOGENE, V10, P135; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; TAKAISHI K, 1994, ONCOGENE, V9, P273; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	55	696	709	0	39	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2169	2177		10.1038/sj.onc.1201380	http://dx.doi.org/10.1038/sj.onc.1201380			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393975				2022-12-25	WOS:A1997YD01900005
J	Lee, MG; Zeng, WZ; Muallem, S				Lee, MG; Zeng, WZ; Muallem, S			Characterization and localization of P-2 receptors in rat submandibular gland acinar and duct cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY ION-TRANSPORT; EXTRACELLULAR ATP; CYSTIC-FIBROSIS; GRANULAR DUCTS; STRIATED DUCTS; SALIVARY-GLAND; STORED CA2+; AGONISTS; CHANNELS	[Ca2+](i) and the Cl- current were measured in isolated submandibular gland acinar and duct cells to characterize and localize the purinergic receptors expressed in these cells. In both cell types 2'-3'-benzoylbenzoyl (Bz)-ATP and ATP increased [Ca2+](i) mainly by activation of Ca2+ influx, UTP had only minimal effect on [Ca2+](i) at concentrations between 0.1 and 1 mM. However, a whole cell current recording showed that all nucleotides effectively activated Cl- currents. Inhibition of signal transduction through G proteins by guanyl-5'-beta-thiophosphate revealed that the effect of ATP on Cl- current was mediated in part by activation of a G protein-coupled and in part by a G protein-independent receptor. BzATP activated exclusively the G protein-independent portion, whereas UTP activated only the G protein-dependent portion of the Cl- current, Measurement of [Ca2+](i) in the microperfused duct showed that ATP stimulated a [Ca2+](i) increase when applied to the luminal or the basolateral sides. BzATP increased [Ca2+](i) only when applied to the luminal side, whereas UTP at 100 mu M increased [Ca2+](i) only when applied to the basolateral side. The combined results suggest that duct and possibly acinar cells express P(2)z receptors in the luminal and P(2)u receptors in the basolateral membrane.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Lee, Min Goo/D-5635-2012; Lee, Min Goo/AAS-4636-2020	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK046591] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK46591, DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amsallem H, 1996, AM J PHYSIOL-CELL PH, V271, pC1546, DOI 10.1152/ajpcell.1996.271.5.C1546; Barnard EA, 1996, CIBA F SYMP, V198, P166; Boeynaems JM, 1996, CIBA F SYMP, V198, P266; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BRETSCHNEDIER F, 1995, PFLUGERS ARCH, V426, P691; Cook D. I., 1994, P1061; DEHAYE JP, 1993, AM J PHYSIOL, V265, pC1356, DOI 10.1152/ajpcell.1993.265.5.C1356; DEHAYE JP, 1991, AM J PHYSIOL, V61, pC490; DENNISS AR, 1978, AM J PHYSIOL, V253, pF548; DINUDOM A, 1993, CELL CALCIUM, V14, P631, DOI 10.1016/0143-4160(93)90088-N; EVANS RL, 1993, EXP PHYSIOL, V78, P49, DOI 10.1113/expphysiol.1993.sp003670; Evans RL, 1997, J PHYSIOL-LONDON, V499, P351, DOI 10.1113/jphysiol.1997.sp021932; GALLACHER DV, 1982, NATURE, V296, P83, DOI 10.1038/296083a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HURLEY TW, 1994, ARCH ORAL BIOL, V39, P205, DOI 10.1016/0003-9969(94)90046-9; HURLEY TW, 1993, AM J PHYSIOL, V265, pC1472, DOI 10.1152/ajpcell.1993.265.6.C1472; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; MARTIN CJ, 1971, PFLUG ARCH EUR J PHY, V327, P303, DOI 10.1007/BF00588450; MCMILLIAN MK, 1993, BRIT J PHARMACOL, V108, P453, DOI 10.1111/j.1476-5381.1993.tb12825.x; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; NUTTLE LC, 1993, MOL PHARMACOL, V44, P93; PAULAIS M, 1994, AM J PHYSIOL, V266, pC1594, DOI 10.1152/ajpcell.1994.266.6.C1594; QUINTON PM, 1994, CURR BIOL, V4, P742, DOI 10.1016/S0960-9822(00)00166-4; REUSS L, 1996, HDB PHYSL CELL PHS 7, P309; SCHNEYER LH, 1973, AM J PHYSIOL, V224, P136, DOI 10.1152/ajplegacy.1973.224.1.136; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; Turner JT, 1997, AM J PHYSIOL-CELL PH, V273, pC1100, DOI 10.1152/ajpcell.1997.273.3.C1100; VALDEZ IH, 1991, AM J PHYSIOL, V261, pG359, DOI 10.1152/ajpgi.1991.261.2.G359; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; XU X, 1995, J BIOL CHEM, V270, P19606, DOI 10.1074/jbc.270.33.19606; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599	37	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32951	32955		10.1074/jbc.272.52.32951	http://dx.doi.org/10.1074/jbc.272.52.32951			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407074	hybrid			2022-12-25	WOS:000071182900035
J	Ridder, IS; Rozeboom, HJ; Kalk, KH; Janssen, DB; Dijkstra, BW				Ridder, IS; Rozeboom, HJ; Kalk, KH; Janssen, DB; Dijkstra, BW			Three-dimensional structure of L-2-haloacid dehalogenase from Xanthobacter autotrophicus GJ10 complexed with the substrate-analogue formate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOALKANE DEHALOGENASE; REACTION-MECHANISM; CRYSTAL-STRUCTURE; PROTEIN MODELS; REFINEMENT; YL; MUTATION; DETECTOR; CLONING; SYSTEMS	The L-2-haloacid dehalogenase from the 1,2-dichloroethane degrading bacterium Xanthobacter autotrophicus GJ10 catalyzes the hydrolytic dehalogenation of small L-2-haloalkanoic acids to yield the corresponding D-2-hydroxyalkanoic acids. Its crystal structure was solved by the method of multiple isomorphous replacement with incorporation of anomalous scattering information and solvent flattening, and was refined at 1.95-Angstrom resolution to an R factor of 21.3%. The three-dimensional structure is similar to that of the homologous L-2-haloacid dehalogenase from Pseudomonas sp, YL (1), but the X. autotrophicus enzyme has an extra dimerization domain, an active site cavity that is completely shielded from the solvent, and a different orientation of several catalytically important amino acid residues, Moreover, under the conditions used, a formate ion is bound in the active site, The position of this substrate-analogue provides valuable information on the reaction mechanism and explains the limited substrate specificity of the Xanthobacter L-2-haloacid dehalogenase.	Univ Groningen, Dept Chem, Lab Biophys Chem, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Chem, Biochem Lab, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Dept Chem, Lab Biophys Chem, Nyenborgh 4, NL-9747 AG Groningen, Netherlands.		Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Rozeboom, Henriette/0000-0002-1656-6477; Ridder, Ivo Steven/0000-0002-1669-4161				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARTH PT, 1992, J BACTERIOL, V174, P2612, DOI 10.1128/jb.174.8.2612-2619.1992; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; EISENHABER F, 1993, J COMPUT CHEM, V14, P1272, DOI 10.1002/jcc.540141103; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; FETZNER S, 1994, MICROBIOL REV, V58, P641, DOI 10.1128/MMBR.58.4.641-685.1994; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; JANSSEN DB, 1985, APPL ENVIRON MICROB, V49, P673, DOI 10.1128/AEM.49.3.673-677.1985; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAWASAKI H, 1994, BIOSCI BIOTECH BIOCH, V58, P160, DOI 10.1271/bbb.58.160; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; Liu JQ, 1997, J BIOL CHEM, V272, P3363, DOI 10.1074/jbc.272.6.3363; LUZZATI V, 1953, ACTA CRYSTALLOGR, V6, P142, DOI 10.1107/S0365110X53000508; MCCONNELL G, 1975, ENDEAVOUR, V34, P13, DOI 10.1016/0160-9327(75)90062-9; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, GRASP; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RIDDER IS, 1995, PROTEIN SCI, V4, P2619, DOI 10.1002/pro.5560041220; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; RUDIGER M, 1995, EMBO J, V14, P1599, DOI 10.1002/j.1460-2075.1995.tb07148.x; Taylor KL, 1997, BIOCHEMISTRY-US, V36, P1349, DOI 10.1021/bi962765i; VANDERPLOEG J, 1991, J BACTERIOL, V173, P7925, DOI 10.1128/jb.173.24.7925-7933.1991; Vellieux FMD, 1997, J APPL CRYSTALLOGR, V30, P396, DOI 10.1107/S0021889896012551; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0	41	89	96	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33015	33022		10.1074/jbc.272.52.33015	http://dx.doi.org/10.1074/jbc.272.52.33015			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407083	Green Published, hybrid			2022-12-25	WOS:000071182900044
J	Almeida, R; Amado, M; David, L; Levery, SB; Holmes, EH; Merkx, G; van Kessel, AG; Rygaard, E; Hassan, H; Bennett, E; Clausen, H				Almeida, R; Amado, M; David, L; Levery, SB; Holmes, EH; Merkx, G; van Kessel, AG; Rygaard, E; Hassan, H; Bennett, E; Clausen, H			A family of human beta 4-galactosyltransferases - Cloning and expression of two novel UDP-galactose: beta-N-acetylglucosamine beta 1,4-galactosyltransferases, beta 4Gal-T2 and beta 4Gal-T3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; MEMBRANE-BOUND FORM; FULL-LENGTH CDNA; GDP-L-FUCOSE; HUMAN GALACTOSYLTRANSFERASE; GENE FAMILY; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; RHEUMATOID-ARTHRITIS; SACCHAROMYCES-CEREVISIAE; DETERMINES EXPRESSION	BLAST analysis of expressed sequence tags (ESTs) using the coding sequence of the human UDP-galactose:beta-N-acetylglucosamine beta 1,4-galactosyltransferase, designated beta 4Gal-T1, revealed a large number of ESTs with identical as well as similar sequences. ESTs with sequences similar to that of beta 4Gal-T1 could be grouped into at least two non-identical sequence sets. Analysis of the predicted amino acid sequence of the novel ESTs with beta 4Gal-T1 revealed conservation of short sequence motifs as well as cysteine residues previously shown to be important for the function of beta 4Gal-T1. The likelihood that the identified ESTs represented novel galactosyltransferase genes was tested by cloning and sequencing of the full coding region of two distinct genes, followed by expression. Expression of soluble secreted constructs in the baculovirus system showed that these genes represented genuine UDP-galactose:beta-N-acetylglucosamine beta 1,4-galactosyltransferases, thus designated beta 4Gal-T2 and beta 4Gal-T3. Genomic cloning of the genes revealed that they have identical genomic organizations compared with beta 4Gal-T1. The two novel genes were located on 1p32-33 and 1q23. The results demonstrate the existence of a family of homologous galactosyltransferases with related functions. The existence of multiple beta 4-galactosyltransferases with the same or overlapping functions may be relevant for interpretation of biological functions previously assigned to beta 4Gal-T1.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Univ Porto, Inst Mol Pathol & Immunol, P-4200 Porto, Portugal; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; NW Hosp, Dept Cell Surface Biochem, Seattle, WA 98125 USA; Univ Nijmegen Hosp, Dept Human Genet, NL-6050 HB Nijmegen, Netherlands	University of Copenhagen; Universidade do Porto; University System of Georgia; University of Georgia; Radboud University Nijmegen	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.	henrik.clausen@odont.ku.dk	van Kessel, Ad Geurts/A-2810-2010; Bennett, Eric/AAG-6120-2020; David, Leonor/A-4829-2008; Almeida, Raquel/B-9647-2012; clausen, henrik/AAD-8016-2021	Bennett, Eric/0000-0002-4976-0647; David, Leonor/0000-0003-4207-9258; Almeida, Raquel/0000-0002-5622-1633; Clausen, Henrik/0000-0002-0915-5055				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; AXFORD JS, 1994, AUTOIMMUNITY, V17, P157, DOI 10.3109/08916939409014671; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BAKKER H, 1994, J BIOL CHEM, V269, P30326; Bakker H, 1997, GLYCOBIOLOGY, V7, P539, DOI 10.1093/glycob/7.4.539; BENDIAK B, 1993, EUR J BIOCHEM, V216, P405, DOI 10.1111/j.1432-1033.1993.tb18158.x; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; BOEGGEMAN EE, 1995, GLYCOCONJUGATE J, V12, P865, DOI 10.1007/BF00731249; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; CHIEN JL, 1978, J BIOL CHEM, V253, P4031; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Dennis J W, 1991, Semin Cancer Biol, V2, P411; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; DUBOIS DH, 1995, ADV EXP MED BIOL, V376, P105; FUJITAYAMAGUCHI Y, 1981, J BIOL CHEM, V256, P2701; Fukuda M, 1996, GLYCOBIOLOGY, V6, P683, DOI 10.1093/glycob/6.7.683; FURUKAWA K, 1990, INT IMMUNOL, V2, P105, DOI 10.1093/intimm/2.1.105; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gerhold D, 1996, BIOESSAYS, V18, P973, DOI 10.1002/bies.950181207; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P633, DOI 10.1016/0003-9861(89)90479-7; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KEUSCH J, 1995, GLYCOBIOLOGY, V5, P365, DOI 10.1093/glycob/5.4.365; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; KochNolte F, 1997, GENOMICS, V39, P370, DOI 10.1006/geno.1996.4520; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEVERY SB, 1992, BIOCHEMISTRY-US, V31, P5335, DOI 10.1021/bi00138a013; LEVERY SB, 1988, CARBOHYD RES, V178, P121, DOI 10.1016/0008-6215(88)80106-X; Li QX, 1997, DEV BIOL, V181, P257, DOI 10.1006/dbio.1996.8444; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LOWE JB, 1993, BAILLIERE CLIN HAEM, V6, P465, DOI 10.1016/S0950-3536(05)80155-6; Malissard M, 1996, EUR J BIOCHEM, V239, P340, DOI 10.1111/j.1432-1033.1996.0340u.x; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; MOLLICONE R, 1995, TRANSFUS CLIN BIOL, V2, P235, DOI 10.1016/S1246-7820(05)80089-8; MOSCARELLO MA, 1985, BIOCHIM BIOPHYS ACTA, V831, P192, DOI 10.1016/0167-4838(85)90035-4; NAKAZAWA K, 1993, J BIOCHEM-TOKYO, V113, P747; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NAKAZAWA K, 1991, EUR J BIOCHEM, V196, P363, DOI 10.1111/j.1432-1033.1991.tb15825.x; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; PAQUET MR, 1984, BIOCHEM J, V218, P745, DOI 10.1042/bj2180745; POWELL JT, 1974, EUR J BIOCHEM, V48, P217, DOI 10.1111/j.1432-1033.1974.tb03759.x; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1997, MOL GLYCOBIOLOGY, P88; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SHAPER JH, 1995, ADV EXP MED BIOL, V376, P95; SHAPER JH, 1995, GLYCOCONJUGATE J, V12, P477; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, SOMAT CELL MOLEC GEN, V12, P633, DOI 10.1007/BF01671948; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHEARES BT, 1984, J BIOL CHEM, V259, P8045; SHUR BD, 1982, J BIOL CHEM, V257, P6871; SHUR BD, 1988, J BIOL CHEM, V263, P17706; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SUIJKERBUIJK RF, 1991, AM J HUM GENET, V48, P269; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Uehara K, 1997, EUR J BIOCHEM, V244, P706, DOI 10.1111/j.1432-1033.1997.00706.x; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WANG Y, 1994, BIOCHEM BIOPH RES CO, V204, P701, DOI 10.1006/bbrc.1994.2516; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WILSON IBH, 1993, J RHEUMATOL, V20, P1282; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YOUAKIM A, 1994, P NATL ACAD SCI USA, V91, P10913, DOI 10.1073/pnas.91.23.10913	85	155	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31979	31991		10.1074/jbc.272.51.31979	http://dx.doi.org/10.1074/jbc.272.51.31979			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405390	Green Published, hybrid			2022-12-25	WOS:000071108000009
J	Kelleher, NL; Nicewonger, RB; Begley, TP; McLafferty, FW				Kelleher, NL; Nicewonger, RB; Begley, TP; McLafferty, FW			Identification of modification sites in large biomolecules by stable isotope labeling and tandem high resolution mass spectrometry - The active site nucleophile of thiaminase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED MULTIPHOTON DISSOCIATION; MULTIPLY-CHARGED IONS; ELECTROSPRAY; PROTEINS; FRAGMENTS; RESONANCE; ANALOGS; PHASE	A widely used procedure for site localization of covalent protein modifications involves proteolysis, partial chromatographic separation of the resulting complex mixture, and tandem mass spectrometry (MS/MS) to identify peptides whose molecular weight (M-r) has been increased appropriately by the modification, As found previously for MS of small molecules, this study shows that protein fragment identification can be greatly simplified by labeling the modification with stable isotopes. Further, the high resolution capabilities of Fourier transform MS make possible the direct identification of CH3/CD3-labeled peptides without chromatographic separation. Although separate Asp-N, Lys-C, and alpha-chymotrypsin digests of thiaminase I (42 kDa) yielded as many as 70 peptides, FTMS identification of the labeled peptide localized the modification site of a mechanism-based inhibitor to Arg(101)-Lys(121), Asp(90)-Gly(122), and Gly(107)-Tyr(119), respectively. The measured mass difference values of the two labels agreed with that expected for CH3/CD3, 3.019 Ha, with a standard deviation of 0.005 Da, providing persuasive identity verification. MS/MS fragmentation narrowed the site to pro(109)-Phe(118) and also caused loss of the derivative with a sulfur atom, uniquely identifying Cys(113) as the thiaminase I active-site nucleophile among the 379 amino acids.	Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA	Cornell University	McLafferty, FW (corresponding author), Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA.		Begley, Tadhg/B-5801-2015		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK044083, R01DK044083, R37DK044083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM016609, R01GM016609, T32GM007273] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44083] Funding Source: Medline; NIGMS NIH HHS [8-T2GM07273, GM16609] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Begley TP, 1996, NAT PROD REP, V13, P177, DOI 10.1039/np9961300177; BEU SC, 1993, J AM SOC MASS SPECTR, V4, P557, DOI 10.1016/1044-0305(93)85017-R; BIEMANN K, 1994, ACCOUNTS CHEM RES, V27, P370, DOI 10.1021/ar00047a008; Blackburn RK, 1997, J AM SOC MASS SPECTR, V8, P483; Campbell S, 1995, J AM CHEM SOC, V117, P12840, DOI 10.1021/ja00156a023; CAPRIOLI RM, 1972, BIOCH APPLICATIONS M, P735; COMISAROW MB, 1974, CHEM PHYS LETT, V25, P282, DOI 10.1016/0009-2614(74)89137-2; Costello CA, 1996, J BIOL CHEM, V271, P3445, DOI 10.1074/jbc.271.7.3445; COX FB, 1943, ORGANIC SYNTHESIS CO, V2, P279; Creighton T.E., 1993, PROTEINS; Deery MJ, 1997, J AM SOC MASS SPECTR, V8, P253, DOI 10.1016/S1044-0305(96)00197-3; EARL JW, 1994, NATURE, V368, P683, DOI 10.1038/368683a0; FUJITA A, 1954, ADV ENZYMOL REL S BI, V15, P389; Gaskell S.J., 1986, MASS SPECTROMETRY BI; GAUTHIER JW, 1991, ANAL CHIM ACTA, V246, P211, DOI 10.1016/S0003-2670(00)80678-9; HUTTER JA, 1987, BIOCHEMISTRY-US, V261, P1969; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KELLEHER NL, 1995, J AM SOC MASS SPECTR, V6, P981, DOI 10.1016/1044-0305(95)00584-Z; Kellner R., 1994, MICROCHARACTERIZATIO; Kurian E, 1997, J AM SOC MASS SPECTR, V8, P8, DOI 10.1016/S1044-0305(97)82228-3; Little DP, 1996, J AM CHEM SOC, V118, P9352, DOI 10.1021/ja9533611; LITTLE DP, 1994, ANAL CHEM, V66, P2809, DOI 10.1021/ac00090a004; Loo J.A., 1988, RAPID COMMUN MASS SP, V2, P207; Lundblad R.L., 1991, CHEM REAGENTS PROTEI; Marshall AG, 1996, ACCOUNTS CHEM RES, V29, P307, DOI 10.1021/ar9501481; Marshall AG, 1997, J AM CHEM SOC, V119, P433, DOI 10.1021/ja9630046; MCCLOSKEY JA, 1990, METHOD ENZYMOL, V193, P329, DOI 10.1016/0076-6879(90)93424-J; MCLAFFERTY FW, 1994, ACCOUNTS CHEM RES, V27, P379, DOI 10.1021/ar00047a009; Miranker A, 1996, J AM CHEM SOC, V118, P7402, DOI 10.1021/ja9531236; Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264; MURATA K, 1982, ANN NY ACAD SCI, V378, P146, DOI 10.1111/j.1749-6632.1982.tb31193.x; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schnier PD, 1996, J AM CHEM SOC, V118, P7178, DOI 10.1021/ja9609157; Schnolzer M, 1996, ELECTROPHORESIS, V17, P945, DOI 10.1002/elps.1150170517; SENKO MW, 1995, J AM SOC MASS SPECTR, V6, P229, DOI 10.1016/1044-0305(95)00017-8; SENKO MW, 1994, ANAL CHEM, V66, P2801, DOI 10.1021/ac00090a003; SILVERMAN PB, 1992, ORGANIC CHEM DRUG DE, P178; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; VALASKOVIC GA, 1995, ANAL CHEM, V67, P3802, DOI 10.1021/ac00116a030; Valaskovic GA, 1996, SCIENCE, V273, P1199, DOI 10.1126/science.273.5279.1199; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	41	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32215	32220		10.1074/jbc.272.51.32215	http://dx.doi.org/10.1074/jbc.272.51.32215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405424	hybrid			2022-12-25	WOS:000071108000043
J	Li, Y; Asahara, H; Patel, VS; Zhou, S; Linn, S				Li, Y; Asahara, H; Patel, VS; Zhou, S; Linn, S			Purification, cDNA cloning, and gene mapping of the small subunit of human DNA polymerase epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; INSITU HYBRIDIZATION; CATALYTIC SUBUNIT; REPAIR SYNTHESIS; HELA-CELLS; REPLICATION; DELTA; IDENTIFICATION; ALPHA; ALIGNMENT	HeLa DNA polymerase epsilon (pol epsilon), possibly involved in both DNA replication and DNA repair, consists of a catalytic subunit of 261 kDa and a tightly bound peptide with a relative molecular mass of 55 kDa. The cDNA of the 261-kDa polypeptide has been independently cloned, sequenced, and then overexpressed in insect cells to give a soluble, but catalytically unstable protein, suggesting that the small subunit of HeLa pol epsilon might be important for stability. HeLa pol epsilon has been isolated by immunoaffinity purification to obtain sequence information which enabled the cloning of a full-length human cDNA encoding the small subunit. The clone encoded nine proteolytic peptides obtained from the subunit. The 59,434-Da predicated polypeptide has 26% identity and 44% homology to the yeast pol epsilon 80-kDa subunit, DPB2, Using fluorescence in situ hybridization, the human pol epsilon p59 locus (DPE2) was assigned to chromosome 14q13-q21.	Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Linn, S (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, Barker Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030415] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01GM30415] Funding Source: Medline; PHS HHS [P30E08196] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aoyagi N, 1997, BIOCHEM BIOPH RES CO, V230, P297, DOI 10.1006/bbrc.1996.5945; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; CHUI G, 1995, THESIS U CALIF, P377; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HARLOW E, 1988, ANTIBODIES LABORATOR, P524; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENIKOFF S, 1995, GENE, V163, P17; HUANG PH, 1995, THESIS U CALIF, P16; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; KESTI T, 1993, J BIOL CHEM, V268, P10238; KESTI T, 1991, J BIOL CHEM, V266, P6336; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NIRANJANAKUMARI S, 1993, J BIOL CHEM, V268, P15557; NISHIDA C, 1988, J BIOL CHEM, V263, P501; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; SZPIRER J, 1994, GENOMICS, V20, P223, DOI 10.1006/geno.1994.1156; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UITTO L, 1995, NUCLEIC ACIDS RES, V23, P244, DOI 10.1093/nar/23.2.244; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; Zhou JQ, 1996, J BIOL CHEM, V271, P29740, DOI 10.1074/jbc.271.47.29740; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	42	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32337	32344		10.1074/jbc.272.51.32337	http://dx.doi.org/10.1074/jbc.272.51.32337			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405441	hybrid			2022-12-25	WOS:000071108000060
J	Liu, GM; Nellaiappan, K; Kagan, HM				Liu, GM; Nellaiappan, K; Kagan, HM			Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues - Implications for homocystinuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN CROSS-LINKING; PROTON ABSTRACTION; CHEMICAL PATHOLOGY; RISK FACTOR; PLASMA; ATHEROSCLEROSIS; METABOLISM; DIAMINES; PROTEIN; CELLS	Homocysteine thiolactone, selenohomocysteine lactone, and homoserine lactone were found to be competitive, irreversible inhibitors of lysyl oxidase, with K-I values of 21 +/- 3 mu M, 8.3 +/- 2.2 mu M, and 420 +/- 56 mu M, respectively. The first order rate constants for inactivation (k(2)) of the enzyme varied over a much smaller range, ranging from 0.12 to 0.18 to 0.28 min(-1) for the Se-, thio-, and O-lactones, respectively. Mutually exclusive labeling of the enzyme by [1-C-14]beta-aminopropionitrile, [U-C-14]phenylhydrazine, or [S-35]homocysteine thiolactone was observed. These labeling results, together with the closely similar perturbations of the near UV-visible spectra of lysyl oxidase and of a model of its lysine tyrosylquinone cofactor by the thiolactone, indicate that the lactones likely derivatize and reduce the active site carbonyl cofactor. Substitution with deuterium at the alpha-carbon of the thiolactone caused a deuterium kinetic isotope effect on k(2) of 3.2 +/- 0.2, consistent with the involvement of rate-limiting alpha-proton abstraction during lactone-induced inactivation of the enzyme. The activities of plasma amine oxidase and diamine oxidase were only minimally reduced at concentrations of the sulfur or selenium lactones that fully inhibited lysyl oxidase. Thus, these lactones constitute a new category of mechanism-based inactivators selective for lysyl oxidase. Further, these results may relate to the development of connective tissue defects seen in homocystinuria.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kagan, HM (corresponding author), Boston Univ, Sch Med, Dept Biochem, 80 E Concord St, Boston, MA 02118 USA.				NIAMS NIH HHS [R37 AR 18880] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018880] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baernstein HD, 1934, J BIOL CHEM, V106, P451; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; BENESCH R, 1956, J AM CHEM SOC, V78, P1597, DOI 10.1021/ja01589a025; BIRD TA, 1983, BIOCHEM J, V108, P1172; CALLERY PS, 1992, CHEM-BIOL INTERACT, V85, P15, DOI 10.1016/0009-2797(92)90049-Q; CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; DAVIDSON VL, 1989, BIOCHEM J, V261, P107, DOI 10.1042/bj2610107; DUDMAN NPB, 1991, ARTERIOSCLER THROMB, V11, P663, DOI 10.1161/01.ATV.11.3.663; FUJIHARA H, 1984, J ORG CHEM, V49, P2819, DOI 10.1021/jo00189a037; GACHERU SN, 1989, J BIOL CHEM, V264, P12963; GACHERU SN, 1988, J BIOL CHEM, V263, P16704; HARTMANN C, 1991, BIOCHEMISTRY-US, V30, P46056; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; KAGAN HM, 1995, METHOD ENZYMOL, V258, P122; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Klinman JP, 1996, J BIOL CHEM, V271, P27189, DOI 10.1074/jbc.271.44.27189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarus HM, 1995, MATRIX BIOL, V14, P727, DOI 10.1016/S0945-053X(05)80015-0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Lubec B, 1996, BBA-MOL BASIS DIS, V1315, P159, DOI 10.1016/0925-4439(95)00119-0; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MCCULLY KS, 1993, ANN CLIN LAB SCI, V23, P477; MCCULLY KS, 1994, ANN CLIN LAB SCI, V24, P27; MCCULLY KS, 1976, CANCER RES, V36, P3198; MCCULLY KS, 1989, RES COMMUN CHEM PATH, V59, P107; MENDENHALL W, 1975, INTRO PROBABILITY ST, P250; MUDD SH, 1964, SCIENCE, V143, P1443, DOI 10.1126/science.143.3613.1443; MUDD SH, 1989, RES COMMUN CHEM PATH, V63, P297; MYERS BA, 1985, BIOCHEM J, V229, P153, DOI 10.1042/bj2290153; NAGAN N, 1994, J BIOL CHEM, V269, P22366; NEUMANN R, 1975, J BIOL CHEM, V250, P6362; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P108; SHAH MA, 1993, J BIOL CHEM, V268, P11573; SIEGEL RC, 1974, P NATL ACAD SCI USA, V71, P4826, DOI 10.1073/pnas.71.12.4826; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; TANG SS, 1984, J BIOL CHEM, V259, P975; TANG SS, 1989, CONNECT TISSUE RES, V19, P93, DOI 10.3109/03008208909016817; TRACKMAN PC, 1981, ANAL BIOCHEM, V113, P336, DOI 10.1016/0003-2697(81)90086-5; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; UELAND PM, 1989, J LAB CLIN MED, V114, P473; VIDAL M, 1986, BIOCHIMIE, V68, P723, DOI 10.1016/S0300-9084(86)80166-3; WALSH C, 1979, ENZYMATIC REACTION M, P86; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9; WILLIAMSON PR, 1987, J BIOL CHEM, V262, P14520; WILLIAMSON PR, 1987, J BIOL CHEM, V262, P8196; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P9477	49	110	118	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32370	32377		10.1074/jbc.272.51.32370	http://dx.doi.org/10.1074/jbc.272.51.32370			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405445	hybrid			2022-12-25	WOS:000071108000064
J	Deng, L; Beigelman, L; MatulicAdamic, J; Karpeisky, A; Gershon, PD				Deng, L; Beigelman, L; MatulicAdamic, J; Karpeisky, A; Gershon, PD			Specific recognition of an rU(2)-N-15-rU motif by VP55, the vaccinia virus poly(A) polymerase catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; POLYADENYLATION; NUCLEOTIDE; BINDING; TAIL	VP55, the vaccinia poly(A) polymerase catalytic subunit, interacts with oligonucleotide primers via two uridylate recognition sites (Deng, L., and Gershon, P. D. (1997) EMBO J. 16, 1103-1113), Here, we show that the cognate RNA sequence comprises a 5'-rU(2)-N-15-rU-3' motif (where N = any deoxyribo or ribonucleotide), embedded within oligonucleotide primers 29-30 nucleotides (nt), or greater, in length, Nine residues separate the 3'-most ribouridylate of the optimally positioned motif from the primer 3'-OH. A ribose sugar at the extreme 3'-terminal nucleotide of the primer is absolutely required for VP55's adenylyltransferase activity, but not for stable VP55-RNA interaction, A ribose at position -3 markedly stimulates both adenylyltransferase activity and stable binding. The use of uridine analogs indicated (i) those functional groups of the uracil base which contribute to stable VP55-primer interaction, and (ii) that VP55's ability to discriminate uracil from cytosine stems largely from the requirement for a protonated N3 nitrogen within the pyrimidine ring. The rU(2)-N-15-rU motif was identified within the uridylate-rich 3' end of a naturally occurring vaccinia mRNA, However, oligonucleotides whose only internal uridylates comprised the motif supported only a 3-5-nt processive burst of oligo(A) tail addition, as opposed to the similar to 30-35-nt burst observed with the naturally occurring 3' end.	TEXAS A&M UNIV, ALBERT B ALKEK INST BIOSCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, HOUSTON, TX 77030 USA; RIBOZYME PHARMACEUT INC, BOULDER, CO 80301 USA	Texas A&M University System				Karpeisky, Alexander/0000-0002-9226-8789	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051953] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 R01 GM51953-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEIGELMAN L, 1995, NUCLEOS NUCLEOT, V14, P895, DOI 10.1080/15257779508012497; Burgin AB, 1996, BIOCHEMISTRY-US, V35, P14090, DOI 10.1021/bi961264u; GERSHON PD, 1993, EMBO J, V12, P4705, DOI 10.1002/j.1460-2075.1993.tb06159.x; GERSHON PD, 1993, J BIOL CHEM, V268, P2203; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GERSHON PD, 1992, GENE DEV, V6, P1575, DOI 10.1101/gad.6.8.1575; Li DN, 1997, EMBO J, V16, P1103, DOI 10.1093/emboj/16.5.1103; MatulicAdamic J, 1996, BIOORG MED CHEM LETT, V6, P373, DOI 10.1016/0960-894X(96)00030-3; MOSS B, 1975, J BIOL CHEM, V250, P4722; MURRAY JB, 1995, BIOCHEM J, V311, P487, DOI 10.1042/bj3110487; NEVINS JR, 1977, J BIOL CHEM, V252, P6939; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; STROBEL SA, 1994, BIOCHEMISTRY-US, V33, P13824, DOI 10.1021/bi00250a037; SUCK D, 1972, J AM CHEM SOC, V94, P6520, DOI 10.1021/ja00773a041; THOMSON JG, 1995, BIOTECHNIQUES, V19, P416; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	19	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31542	31552		10.1074/jbc.272.50.31542	http://dx.doi.org/10.1074/jbc.272.50.31542			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395491	hybrid			2022-12-25	WOS:A1997YL41900050
J	Fitzsimmons, TJ; McRoberts, JA; Tachiki, KH; Pandol, SJ				Fitzsimmons, TJ; McRoberts, JA; Tachiki, KH; Pandol, SJ			Acyl-coenzyme A causes Ca2+ release in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; COA ESTERS; RYANODINE RECEPTORS; EXOCRINE PANCREAS; CALCIUM; OSCILLATIONS; POOL; ACTIVATION; MECHANISM	The regulation of cytosolic Ca2+ is important for a variety of cell functions. One non-inositol 1,4,5-trisphosphate (IP3) compound that may regulate Ca2+ is palmitoyl-coenzyme A (CoA), a fatty acid-CoA that is reported to cause Ca2+ release from intracellular stores of oocytes, myocytes, and hepatocytes. To study the role of palmitoyl-CoA in the pancreatic acinar cell, rat pancreatic acini were isolated by collagenase digestion, permeablized with streptolysin O, and the release of Ca2+ from internal stores was measured with fura-2. Palmitoyl-CoA released Ca2+ from internal stores (EC50 = 14 mu M). The palmitoyl-CoA-sensitive pool was distinct from, and overlapping with the IP3-sensitive Ca2+ pool. The effects of submaximal doses of IP3 or cyclic ADP-ribose plus palmitoyl-CoA were additive. Fatty acid-CoA derivatives with carbon chain lengths of 16-18 were the most potent and efficacious. Ryanodine and caffeine or elevated resting [Ca2+] sensitized the Ca2+ pool to the actions of palmitoyl-CoA. Fatty acid-CoA levels in pancreatic acini were measured by extraction with 2-propanol/acetonitrile, followed by separation and quantification using reverse phase high performance liquid chromatography, and were found to be 10.17 +/- 0.93 nmol/mg protein. These data suggest the presence of an IP3-insensitive palmitoyl-CoA-sensitive Ca2+ store in pancreatic acinar cells and suggest that palmitoyl-CoA may be needed for Ca2+-induced Ca2+ release.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Fitzsimmons, TJ (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,11301 WILSHIRE BLVD 151,BLDG 258,RM 340,LOS ANGELES,CA 90073, USA.				NIDDK NIH HHS [DK 33010] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033010] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BINDOLI A, 1983, INT J BIOCHEM, V15, P1219, DOI 10.1016/0020-711X(83)90210-0; Chini EN, 1996, AM J PHYSIOL-CELL PH, V270, pC530, DOI 10.1152/ajpcell.1996.270.2.C530; CONNELLY T, 1994, FEBS LETT, V352, P285, DOI 10.1016/0014-5793(94)00969-4; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; ELHAYEK R, 1993, BIOPHYS J, V65, P779, DOI 10.1016/S0006-3495(93)81101-9; FULCERI R, 1994, CELL CALCIUM, V15, P109, DOI 10.1016/0143-4160(94)90049-3; Fulceri R, 1997, BIOCHEM J, V325, P423, DOI 10.1042/bj3250423; FULCERI R, 1993, BIOCHEM J, V295, P663, DOI 10.1042/bj2950663; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOKINNEAVERSON M, 1974, BIOCHEM BIOPH RES CO, V58, P763, DOI 10.1016/S0006-291X(74)80483-3; KAO JPY, 1988, BIOPHYS J, V53, P635, DOI 10.1016/S0006-3495(88)83142-4; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KOLMER M, 1995, BIOCHEM J, V306, P327, DOI 10.1042/bj3060327; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; PANDOL SJ, 1982, J BIOL CHEM, V257, P2024; RICH GT, 1995, BIOCHEM J, V306, P703, DOI 10.1042/bj3060703; RYSSIKORA KE, 1994, J BIOL CHEM, V269, P31607; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; WHITMER JT, 1978, J BIOL CHEM, V253, P4305; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737	28	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31435	31440		10.1074/jbc.272.50.31435	http://dx.doi.org/10.1074/jbc.272.50.31435			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395476	hybrid			2022-12-25	WOS:A1997YL41900035
J	Luttrell, LM; Daaka, Y; DellaRocca, GJ; Lefkowitz, RJ				Luttrell, LM; Daaka, Y; DellaRocca, GJ; Lefkowitz, RJ			G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts - Shc phosphorylation and receptor endocytosis correlate with activation of Erk kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; FOCAL ADHESION KINASE; MAP KINASE; ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; EGF RECEPTOR; SRC; SEQUESTRATION; PP60(C-SRC)	The Ras-dependent activation of Erk kinases by G protein-coupled receptors (GPCRs) is thought to involve tyrosine phosphorylation of docking proteins that serve as scaffolds for the plasma membrane recruitment of Ras guanine nucleotide exchange factors, such as the Grb2-mSos complex. We have investigated the role of two GPCR-regulated tyrosine phosphoproteins, p125(FAK) (FAK) and Shc, in the Ras-dependent activation of Erk kinases by endogenously expressed GPCRs in Rat 1a fibroblasts, Several lines of evidence suggest that tyrosine phosphorylation of FAK and Shc are independently regulated. The GPCRs for lysophosphatidic acid (LPA), thrombin, and bombesin mediate equivalent increases in FAK tyrosine phosphorylation and FAK-Grb2 association, In contrast, only LPA and thrombin receptors significantly stimulate Shc tyrosine phosphorylation and Shc-Grb2 complex formation. Tyrosine phosphorylation of FAK is pertussis toxin-insensitive, can be mimicked by calcium ionophore, and is inhibited by treatment with cytochalasin D, which depolymerizes the actin cytoskeleton, In contrast, tyrosine phosphorylation of Shc is inhibited by pertussis toxin treatment, is not induced by calcium ionophore, and is insensitive to cytochalasin D, In each case, the rapid stimulation of Erk 1/2 correlates with tyrosine phosphorylation of Shc but not of FAK, The dissociation of FAK-Grb2 complex formation from receptor-mediated activation of Erk 1/2 indicates that recruitment of Grb2-mSos to the plasma membrane is not sufficient to mediate rapid Erk activation, Using four mechanistically distinct inhibitors of clathrin-mediated endocytosis, concanavalin A, hypertonic medium, depletion of intracellular potassium, and monodansylcadaverine, we find that GPCR-mediated Erk 1/2 activation is also endocytosis-dependent. Thus, we propose that an additional step involving vesicle-mediated endocytosis is required for the rapid, Ras-dependent activation of Erk kinases in fibroblasts.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University			Lefkowitz, Robert/AAW-2649-2021; Della Rocca, Gregory/AAM-5281-2021	Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [T32GM-07171] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BARAK LS, 1994, J BIOL CHEM, V269, P2790; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EGUCHI S, 1996, J BIOL CHEM, V271, P1169; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; PHONPHOK Y, 1991, FEBS LETT, V281, P188, DOI 10.1016/0014-5793(91)80390-O; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROZENGURT E, 1995, CANCER SURV, V24, P81; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533; WATANABE T, 1995, J BIOL CHEM, V270, P8984, DOI 10.1074/jbc.270.15.8984; WIDMANN C, 1995, BIOCHEM J, V310, P203, DOI 10.1042/bj3100203; YU SS, 1993, J BIOL CHEM, V268, P337	51	165	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31648	31656		10.1074/jbc.272.50.31648	http://dx.doi.org/10.1074/jbc.272.50.31648			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395506	hybrid			2022-12-25	WOS:A1997YL41900065
J	Rybina, IV; Liu, H; Gor, Y; Feinmark, SJ				Rybina, IV; Liu, H; Gor, Y; Feinmark, SJ			Regulation of leukotriene A(4) hydrolase activity in endothelial cells by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-LUNG; SULFIDOPEPTIDE-LEUKOTRIENES; EICOSANOID SYNTHESIS; MOLECULAR-CLONING; ESCHERICHIA-COLI; DE-GRANULATION; GUINEA-PIG; BIOSYNTHESIS; ACID	Endothelial cells contain leukotriene (LT) A(4) hydrolase (LTA-H) as detected by Northern and Western blotting, but several studies have been unable to detect the activity of this enzyme. Since LTA-H could play a hey role in determining what biologically active lipids are generated by activated endothelium during the inflammatory process, we studied possible mechanisms by which this enzyme may be regulated, We find that LTA-H is phosphorylated under basal conditions in human endothelial cells and in this state does not exhibit epoxide hydrolase activity (i.e. conversion of LTA(4) to LTB4). LTA-H purified from endothelial cells is efficiently dephosphorylated by incubation with protein phosphatase-1 in the presence of an LTA-H peptide substrate and not at all in the absence of substrate. Under conditions that lead to dephosphorylation, protein phosphatase-1 activates the epoxide hydrolase activity of LTA-H. Using peptide mapping and site-directed mutagenesis, we have identified serine 415 as the site of phosphorylation of LTA-H by a kinase found in endothelial cell cytosol. In parallel, we have studied a human lung carcinoma cell line that expresses active LTA-H. Although these cells have cytosolic kinases that phosphorylate recombinant LTA-H, they do not target serine 415 and thus do not inhibit LTA-H activity. We believe that LTA-H is regulated in intact cells by a kinase/phosphatase cycle and further that the kinase in endothelial cells specifically recognizes and phosphorylates a regulatory site in the LTA-H.	COLUMBIA UNIV, DEPT PHARMACOL, COLL PHYS & SURG, NEW YORK, NY 10032 USA	Columbia University								BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN KA, 1993, J IMMUNOL METHODS, V163, P13, DOI 10.1016/0022-1759(93)90234-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; CLAESSON HE, 1984, BIOCHIM BIOPHYS ACTA, V804, P52, DOI 10.1016/0167-4889(84)90098-3; CUNNINGHAM FM, 1980, J PHARM PHARMACOL, V32, P377, DOI 10.1111/j.2042-7158.1980.tb12946.x; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FEINMARK SJ, 1990, METHOD ENZYMOL, V187, P559; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; FEINMARK SJ, 1992, AM REV RESPIR DIS, V146, pS51, DOI 10.1164/ajrccm/146.5_Pt_2.S51; FEINMARK SJ, 1981, FEBS LETT, V136, P141, DOI 10.1016/0014-5793(81)81233-1; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FITZPATRICK F, 1984, J BIOL CHEM, V259, P1403; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FU JY, 1989, BIOCHIM BIOPHYS ACTA, V1006, P121; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; GIMBRONE MA, 1984, J CLIN INVEST, V74, P1552, DOI 10.1172/JCI111570; GRIMMINGER F, 1990, J IMMUNOL, V144, P1866; GRIMMINGER F, 1990, J EXP MED, V172, P1115, DOI 10.1084/jem.172.4.1115; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V172, P965, DOI 10.1016/0006-291X(90)91540-9; HOOVER RL, 1984, P NATL ACAD SCI-BIOL, V81, P2191, DOI 10.1073/pnas.81.7.2191; IBE BO, 1988, BIOCHIM BIOPHYS ACTA, V960, P309, DOI 10.1016/0005-2760(88)90039-2; IZUMI T, 1986, BIOCHEM BIOPH RES CO, V135, P139, DOI 10.1016/0006-291X(86)90953-8; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; MACLOUF J, 1989, BLOOD, V74, P703; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MANCINI JA, 1995, EUR J BIOCHEM, V231, P65, DOI 10.1111/j.1432-1033.1995.tb20671.x; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; MEDINA JF, 1988, BIOCHIM BIOPHYS ACTA, V961, P203, DOI 10.1016/0005-2760(88)90115-4; MINAMI M, 1988, FEBS LETT, V229, P279, DOI 10.1016/0014-5793(88)81140-2; MINAMI M, 1987, J BIOL CHEM, V262, P13873; Nohgawa M, 1997, J LEUKOCYTE BIOL, V62, P203, DOI 10.1002/jlb.62.2.203; OFLAHERTY JT, 1981, BIOCHEM BIOPH RES CO, V101, P1290, DOI 10.1016/0006-291X(81)91587-4; OHISHI N, 1990, J BIOL CHEM, V265, P7520; OHISHI N, 1987, J BIOL CHEM, V262, P10200; OHISHI N, 1990, METHOD ENZYMOL, V187, P286; RADMARK O, 1984, J BIOL CHEM, V259, P2339; Sala A, 1996, FEBS LETT, V388, P94, DOI 10.1016/0014-5793(96)00539-X; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SALA A, 1993, BRIT J PHARMACOL, V110, P1206, DOI 10.1111/j.1476-5381.1993.tb13943.x; Sala A, 1996, BLOOD, V87, P1824; SHIMIZU T, 1988, INT J BIOCHEM, V20, P661, DOI 10.1016/0020-711X(88)90160-7; TONNESEN MG, 1989, J CLIN INVEST, V83, P637, DOI 10.1172/JCI113928; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	48	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31865	31871		10.1074/jbc.272.50.31865	http://dx.doi.org/10.1074/jbc.272.50.31865			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395533	hybrid			2022-12-25	WOS:A1997YL41900092
J	Zhang, WY; Gaynor, PM; Kruth, HS				Zhang, WY; Gaynor, PM; Kruth, HS			Aggregated low density lipoprotein induces and enters surface-connected compartments of human monocyte-macrophages - Uptake occurs independently of the low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; FOAM-CELL-FORMATION; CULTURED-CELLS; CHOLESTEROL; LDL; PHAGOCYTOSIS; METABOLISM; OXIDATION; MECHANISM; DEGRADATION	Aggregation of low density lipoprotein (LDL) stimulates its uptake by macrophages. We have now shown by electron microscopic and chemical experiments that aggregated LDL (produced by vortexing (VxLDL) or treatment with phospholipase C) induced and became sequestered in large amounts within surface-connected compartments (SCC) of human monocyte-derived macrophages. This occurred through a process different from phagocytosis, Formation of SCC and accumulation of aggregated LDL in SCC are cell-mediated processes that were temperature-dependent (10 x greater cell as association at 37 degrees C than at 4 degrees C) and blocked by cytochalasin D but not by nocodazole, Because of the surface connections of SCC, trypsin could release aggregated EDL from SCC, Degradation of I-125-VxLDL through the SCC pathway showed delayed and a lower rate of degradation (10-55%) compared with nonaggregated I-125-acetylated LDL that did not enter SCC. However, similar to I-125-acetylated LDL degradation, I-125-VxLDL degradation occurred through a chloroquine-sensitive pathway. Uptake of VxLDL into SCC was not mediated by the LDL receptor, Methylation of LDL prevents its binding to the LDL receptor, However, methylated LDL still entered SCC after it was aggregated by vortexing, On the other hand, degradation of I-125-VxLDL was substantially decreased by methylation of LDL and by cholesterol enrichment of macrophages, which decreases macrophage LDL receptor expression, The results suggest that whereas uptake of aggregated LDL into SCC occurs independently of the LDL receptor, movement of aggregated LDL from SCC to lysosomes may depend in part on LDL receptor function. Sequestration into SCC is a novel endocytosis pathway for uptake of aggregated LDL that allows the macrophage to store large amounts of this lipoprotein before it is further processed.	NHLBI,SECT EXPT ATHEROSCLEROSIS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; GAMBLE W, 1978, J LIPID RES, V19, P1068; GIANTURCO SH, 1994, J LIPID RES, V35, P1674; GIANTURCO SH, 1995, CIRCULATION S1, V92, P690; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUYTON JR, 1991, J LIPID RES, V32, P953; HEINECKE JW, 1991, ARTERIOSCLER THROMB, V11, P1643, DOI 10.1161/01.ATV.11.6.1643; HOFF HF, 1993, J LIPID RES, V34, P1919; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOFF HF, 1989, ARTERIOSCLEROSIS, V9, P538, DOI 10.1161/01.ATV.9.4.538; HOFF HF, 1991, LAB INVEST, V64, P254; KAWABE Y, 1994, ARCH BIOCHEM BIOPHYS, V310, P489, DOI 10.1006/abbi.1994.1197; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KOO C, 1988, J CLIN INVEST, V81, P1332, DOI 10.1172/JCI113460; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MAEBA R, 1994, BBA-LIPID LIPID MET, V1215, P79, DOI 10.1016/0005-2760(94)90094-9; MORGANELLI PM, 1995, J LIPID RES, V36, P714; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NARUSZEWICZ M, 1994, NUTR METAB CARDIOVAS, V4, P70; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; SHECHTER I, 1981, J LIPID RES, V22, P63; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TERTOV VV, 1992, CIRC RES, V71, P218, DOI 10.1161/01.RES.71.1.218; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111	34	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31700	31706		10.1074/jbc.272.50.31700	http://dx.doi.org/10.1074/jbc.272.50.31700			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395512	hybrid			2022-12-25	WOS:A1997YL41900071
J	Sica, A; Dorman, L; Viggiano, V; Cippitelli, M; Ghosh, P; Rice, N; Young, HA				Sica, A; Dorman, L; Viggiano, V; Cippitelli, M; Ghosh, P; Rice, N; Young, HA			Interaction of NF-kappa B and NFAT with the interferon-gamma promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; HUMAN INTERLEUKIN-4 GENE; DNA-BINDING SUBUNIT; IFN-GAMMA; NUCLEAR FACTOR; TRANSCRIPTIONAL ACTIVATION; REGULATORY ELEMENTS; IMMUNE INTERFERON; MESSENGER-RNA; LYMPHOCYTE-T	Interferon-gamma (IFN-gamma) is a pleiotropic lymphokine whose production is restricted to activated T cells and NK cells. Along with other cytokines, IFN-gamma gene expression is inhibited by the immunosuppressant cyclosporin A. We have previously identified an intronic enhancer region (C3) of the IFN-gamma gene that binds the NF-kappa B protein c-Rel and that shows partial DNA sequence homology with the cyclosporin A-sensitive NFAT binding site and the 3'-half of the NF-kappa B consensus site. Sequence analysis of the IFN-gamma promoter revealed the presence of two additional C3-related elements (C3-1P and C3-3P). In addition, an NF-kappa B site (IFN-gamma kappa B) was identified within the promoter region. Based on this observation, we have analyzed the potential role of NF-kappa B and NFAT family members in regulating IFN-gamma transcription. Electrophoretic mobility shift assay analysis demonstrated that after T cell activation, the p50 and p65 NF-kappa B subunits bind specifically to the newly identified IFN-gamma kappa B and C3-related sites. In addition, we identified the NFAT proteins as a component of the inducible complexes that bind to the C3-3P site. Site-directed mutagenesis and transfection studies demonstrate that calcineurin-inducible transcriptional factors enhance the transcriptional activity of the IFN-gamma promoter through the cyclosporin-sensitive C3-3P site, whereas NF-kappa B proteins functionally interact with the C3-related sites. In addition, when located downstream to the beta-galactosidase gene driven by the IFN-gamma promoter, the intronic C3 site worked in concert with both the IFN-gamma kappa B and the C3-3P site to enhance gene transcription. These results demonstrate that the coordinate activities of NFAT and NF-kappa B proteins are involved in the molecular mechanisms controlling IFN-gamma gene transcription.	NCI,FREDERICK CANC RES & DEV CTR,DIV BASIC SCI,EXPT IMMUNOL LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,SAIC,BIOL CARCINOGENESIS DEV PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Sica, A (corresponding author), IST RIC FARMACOL MARIO NEGRI,DEPT IMMUNOL & CELL BIOL,VIA ERITREA 62,MILAN,ITALY.		Sica, Antonio/AAB-9546-2020; Cippitelli, Marco/AAF-4857-2021; Young, Howard/A-6350-2008	Cippitelli, Marco/0000-0002-9620-538X; Young, Howard/0000-0002-3118-5111				ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; Aune TM, 1997, MOL CELL BIOL, V17, P199, DOI 10.1128/MCB.17.1.199; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Barbulescu K, 1997, EUR J IMMUNOL, V27, P1098, DOI 10.1002/eji.1830270509; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BROWN DA, 1991, EUR J IMMUNOL, V21, P1879, DOI 10.1002/eji.1830210815; Campbell PM, 1996, TRANSPLANTATION, V61, P933, DOI 10.1097/00007890-199603270-00016; CHRIVIA JC, 1990, J EXP MED, V172, P661, DOI 10.1084/jem.172.2.661; CICCARONE VC, 1990, J IMMUNOL, V144, P725; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DIMARZIO P, 1994, J EXP MED, V179, P1731, DOI 10.1084/jem.179.5.1731; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FOX HS, 1991, J IMMUNOL, V146, P4362; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUPTA SL, 1990, INT J CELL CLONING, V8, P92, DOI 10.1002/stem.5530080709; Howie SEM, 1996, J INVEST DERMATOL, V106, P1218, DOI 10.1111/1523-1747.ep12348507; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; Kanno T, 1996, J IMMUNOL, V157, P5277; KASAHARA T, 1983, J IMMUNOL, V130, P1784; KEVIN WB, 1993, P NATL ACAD SCI USA, V90, P9707; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAMKHIOUED B, 1996, ANN NY ACAD SCI, V797, P203; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYAKH L, 1977, MOL CELL BIOL, V17, P2475; MATSUDA I, 1994, BIOCHEM BIOPH RES CO, V199, P439, DOI 10.1006/bbrc.1994.1248; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Penix LA, 1996, J BIOL CHEM, V271, P31964, DOI 10.1074/jbc.271.50.31964; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; Webber S, 1997, INT ARCH ALLERGY IMM, V113, P275, DOI 10.1159/000237571; WILLIAMS CMM, 1995, IMMUNOLOGY, V86, P244; WILLIAMS JG, 1993, J SURG RES, V54, P79, DOI 10.1006/jsre.1993.1013; XU Z, 1996, SCIENCE, V273, P794; YE JP, 1995, J LEUKOCYTE BIOL, V58, P225, DOI 10.1002/jlb.58.2.225; YE JP, 1994, J BIOL CHEM, V269, P25728; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q; YOUNG HA, 1987, J IMMUNOL, V139, P724; YOUNG LLD, 1996, CELL IMMUNOL, V168, P133	55	361	369	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30412	30420		10.1074/jbc.272.48.30412	http://dx.doi.org/10.1074/jbc.272.48.30412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374532	hybrid			2022-12-25	WOS:A1997YH61300064
J	Haas, K; Johannes, C; Geisen, C; Schmidt, T; Karsunky, H; BlassKampmann, S; Obe, G; Moroy, T				Haas, K; Johannes, C; Geisen, C; Schmidt, T; Karsunky, H; BlassKampmann, S; Obe, G; Moroy, T			Malignant transformation by cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4	ONCOGENE			English	Article						cyclin E; malignant transformation; Myc; CDK inhibitors; polyploidy	RETINOBLASTOMA-PROTEIN; COLORECTAL CARCINOMAS; PHASE-TRANSITION; KINASE-ACTIVITY; BREAST-CANCER; E GENE; C-MYC; D1; FIBROBLASTS; INHIBITION	We demonstrate in this paper that the G1 phase specific cell cycle regulator cyclin E is able to provoke focus formation when cotransfected with activated Ha-ras into primary rat embryo fibroblasts (REFs). Cyclin E/Ha-ras transformed cells are highly tumorigenic in synergeneic rats, are able to form colonies in soft agar and show protection towards apoptosis upon serum starvation or DNA damage compared to cells transformed by the combination of Myc, cyclin D1 or SV40 large T-antigen and Ha-ras. Lines that were established after cyclin El Ha-ras or cyclin D1/Ha-ras transformation contain a large percentage of polyploid cells, This was not observed in cells transformed with other oncoproteins and Ha-ras pointing to an involvement of D-and E type cyclins in genomic instability. The cyclin dependent kinase inhibitors p21 and p27 but also p16 completely abrogate focus formation by cyclin E and Ha-ras suggesting that the oncogenic activity of cyclin E still requires functional G1 specific cyclin/CDK complexes. Moreover, inhibition of Myc function also blocks the oncogenic activity of cyclin E indicating a requirement of Myc for cyclin E function, The findings presented here demonstrate that cyclin E can act as an oncoprotein with a potential involvement in genomic instability and the prevention of cell death, Our data also present more evidence for a strict functional interdependency between G1 cyclin/CDK complexes and c-Myc.	UNIV ESSEN GESAMTHSCH KLINIKUM,IFZ,INST ZELLBIOL TUMORFORSCH,D-45172 ESSEN,GERMANY; UNIV ESSEN GESAMTHSCH,GENET ABT,D-45172 ESSEN,GERMANY	University of Duisburg Essen; University of Duisburg Essen			Moroy, Tarik/D-9923-2011					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Botz J, 1996, MOL CELL BIOL, V16, P3401; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Draetta G.F., 1997, CURR BIOL, V7, P50; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Geng Y, 1996, ONCOGENE, V12, P1173; GONG JP, 1994, CANCER RES, V54, P4285; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HALL M, 1995, ONCOGENE, V11, P1581; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HU J, 1992, MOL CELL BIOL, V12, P971; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P940; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEACH FS, 1993, CANCER RES, V53, P1986; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mumberg D, 1996, ONCOGENE, V13, P2493; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SoferLevi Y, 1996, ONCOGENE, V13, P2431; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Zhang Y, 1996, J BIOL CHEM, V271, P4266	54	47	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2615	2623		10.1038/sj.onc.1201434	http://dx.doi.org/10.1038/sj.onc.1201434			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399649				2022-12-25	WOS:A1997YG73200011
J	Bettati, S; Mozzarelli, A				Bettati, S; Mozzarelli, A			T state hemoglobin binds oxygen noncooperatively with allosteric effects of protons, inositol hexaphosphate, and chloride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADULT HEMOGLOBIN; SOL-GEL ENCAPSULATION; HYBRID HEMOGLOBINS; SINGLE-CRYSTALS; MOLECULAR CODE; COOPERATIVITY; MODEL; STEREOCHEMISTRY; MECHANISMS; BIOSENSORS	Hemoglobin is the paradigm of allosteric proteins. Over the years, cooperative oxygen binding has been explained by different models predicting that the T state of hemoglobin binds oxygen either noncooperatively or with some degree of cooperativity or with strong cooperativity. Therefore, a critical test that discriminates among models is to determine the oxygen binding by the T state of hemoglobin. Fixation of hemoglobin in the T state has been achieved either by crystallization from polyethylene glycol solutions or by encapsulation in wet porous silica gels. Hemoglobin crystals bind oxygen noncooperatively with reduced affinity compared with solution, with no Bohr effect and with no influence of other allosteric effecters. In this study, we have determined accurate oxygen-binding curves to the T state of hemoglobin in silica gels with the same microspectrophotometric apparatus and multiwavelengths analysis used in crystal experiments. The T state of hemoglobin in silica gels binds oxygen noncooperatively with an affinity and a Bohr effect similar to those observed in solution for the binding of the first oxygen molecule. Other allosteric effecters such as inositol hexaphosphate, bezafibrate, and chloride significantly affect oxygen affinity. Therefore, T state hemoglobins that are characterized by strikingly different functional properties share the absence of cooperativity in the binding of oxygen. These findings are fully consistent with the Monod, Wyman, and Changeux model and with most features of Perutz's stereochemical model, but they are not consistent with models of both Koshland and Ackers.	Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy	University of Parma	Mozzarelli, A (corresponding author), Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy.		Mozzarelli, Andrea/C-3615-2014; Bettati, Stefano/V-9975-2018	Mozzarelli, Andrea/0000-0003-3762-0062; Bettati, Stefano/0000-0001-6787-0594				ABRAHAM DJ, 1992, J MOL BIOL, V227, P480, DOI 10.1016/0022-2836(92)90902-V; Ackers GK, 1997, BIOCHEMISTRY-US, V36, P10822, DOI 10.1021/bi971382x; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Ariga O, 1996, J FERMENT BIOENG, V82, P341, DOI 10.1016/0922-338X(96)89147-1; ASAKURA T, 1978, P NATL ACAD SCI USA, V75, P5462, DOI 10.1073/pnas.75.11.5462; Bettati S, 1996, PROTEINS, V25, P425, DOI 10.1002/(SICI)1097-0134(199608)25:4<425::AID-PROT3>3.3.CO;2-A; BETTATI S, 1998, IN PRESS J BIOL CHEM, V273; BLYTH DJ, 1995, ANALYST, V120, P2725, DOI 10.1039/an9952002725; BRINKER CJ, 1990, SOL GEL SCI PHYSICS; BRZOZOWSKI A, 1984, NATURE, V307, P74, DOI 10.1038/307074a0; CHU AH, 1984, BIOCHEMISTRY-US, V23, P604, DOI 10.1021/bi00299a004; CHUNG KE, 1995, ANAL CHEM, V67, P1505, DOI 10.1021/ac00105a004; DAVE BC, 1994, ANAL CHEM, V66, pA1120, DOI 10.1021/ac00094a001; DVORAK JA, 1971, EXP CELL RES, V68, P144, DOI 10.1016/0014-4827(71)90596-9; Edelstein SJ, 1996, J MOL BIOL, V257, P737, DOI 10.1006/jmbi.1996.0198; EDELSTEIN SJ, 1975, ANNU REV BIOCHEM, V44, P209, DOI 10.1146/annurev.bi.44.070175.001233; ELLERBY LM, 1992, SCIENCE, V255, P1113, DOI 10.1126/science.1312257; Henry ER, 1997, BIOCHEMISTRY-US, V36, P6511, DOI 10.1021/bi9619177; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; HOLT JM, 1995, FASEB J, V9, P210, DOI 10.1096/fasebj.9.2.7781923; Imai K., 1982, ALLOSTERIC EFFECTS H; KAVANAUGH JS, 1995, J MOL BIOL, V248, P136, DOI 10.1006/jmbi.1995.0207; KISTER J, 1987, J BIOL CHEM, V262, P12085; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; LINDSTROM TR, 1972, P NATL ACAD SCI USA, V69, P1707, DOI 10.1073/pnas.69.7.1707; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; MARDEN MC, 1990, BIOPHYS J, V57, P397, DOI 10.1016/S0006-3495(90)82556-X; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mozzarelli A, 1996, J BIOL CHEM, V271, P3627; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Mozzarelli A, 1997, PROTEIN SCI, V6, P484; MOZZARELLI A, 1991, NATURE, V351, P416, DOI 10.1038/351416a0; NARANG U, 1994, ANAL CHEM, V66, P3139, DOI 10.1021/ac00091a023; Paoli M, 1996, J MOL BIOL, V256, P775, DOI 10.1006/jmbi.1996.0124; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; POYART CF, 1978, EUR J BIOCHEM, V87, P75, DOI 10.1111/j.1432-1033.1978.tb12353.x; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P6411, DOI 10.1021/bi00076a014; ROSSI GL, 1992, PHILOS T R SOC A, V340, P191, DOI 10.1098/rsta.1992.0060; SAWICKI CA, 1977, J BIOL CHEM, V252, P7538; Shen CY, 1997, J AM CHEM SOC, V119, P1304, DOI 10.1021/ja961867t; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; Shibayama N, 1997, BIOCHEMISTRY-US, V36, P4375, DOI 10.1021/bi970009m; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; SHIBAYAMA N, 1995, BIOCHEMISTRY-US, V34, P4773, DOI 10.1021/bi00014a035; SHTELZER S, 1994, BIOTECHNOL APPL BIOC, V19, P293; SHULMAN RG, 1975, Q REV BIOPHYS, V8, P325, DOI 10.1017/S0033583500001840; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0; WU SG, 1994, APPL BIOCHEM BIOTECH, V47, P11, DOI 10.1007/BF02788671	57	129	130	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32050	32055		10.1074/jbc.272.51.32050	http://dx.doi.org/10.1074/jbc.272.51.32050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405399	hybrid			2022-12-25	WOS:000071108000018
J	Gruic-Sovulj, I; Ludemann, HC; Hillenkamp, F; Weygand-Durasevic, I; Kucan, Z; Peter-Katalinic, J				Gruic-Sovulj, I; Ludemann, HC; Hillenkamp, F; Weygand-Durasevic, I; Kucan, Z; Peter-Katalinic, J			Detection of noncovalent tRNA-aminoacyl-tRNA synthetase complexes by matrix-assisted laser desorption/ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; SACCHAROMYCES-CEREVISIAE; NEUTRON-SCATTERING; CRYSTAL-STRUCTURE; GENETIC-CODE; YEAST; RECOGNITION; BINDING	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-MS) was used for the study of complexes formed by yeast seryl-tRNA synthetase (SerRS) and tyrosyl-tRNA synthetase (TyrRS) with tRNA(Ser) and tRNA(Tyr). Cognate and noncognate complexes were easily distinguished due to a large mass difference between the two tRNAs, Both homodimeric synthetases gave MS spectra indicating intact desorption of dimers. The spectra of synthetase-cognate tRNA mixtures showed peaks of free components and peaks assigned to complexes, Noncognate complexes were also detected. In competition experiments, where both tRNA species were mixed with each enzyme only cognate alpha(2).tRNA complexes were observed. Only cognate alpha(2).tRNA(2) complexes were detected with each enzyme. These results demonstrate that MALDI-MS can be used successfully for accurate mass and, thus, stoichiometry determination of specific high molecular weight noncovalent protein-nucleic acid complexes.	Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Univ Zagreb, Fac Sci, Dept Chem, Zagreb 10000, Croatia	University of Munster; University of Zagreb	Peter-Katalinic, J (corresponding author), Univ Munster, Inst Med Phys & Biophys, Robert Koch Str 31, D-48149 Munster, Germany.	jkp@uni-muenster.de						ANDACHI Y, 1989, J MOL BIOL, V209, P37, DOI 10.1016/0022-2836(89)90168-X; AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5312, DOI 10.1021/bi00071a005; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CARTER P, 1986, P NATL ACAD SCI USA, V83, P1189, DOI 10.1073/pnas.83.5.1189; CAVARELLI J, 1993, FASEB J, V7, P79, DOI 10.1096/fasebj.7.1.8422978; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Cheng XH, 1996, ANAL BIOCHEM, V239, P35, DOI 10.1006/abio.1996.0287; CHOW CM, 1993, J BIOL CHEM, V268, P12855; Cohen LRH, 1997, J AM SOC MASS SPECTR, V8, P1046, DOI 10.1016/S1044-0305(97)00148-7; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DELARUE M, 1995, CURR OPIN STRUC BIOL, V5, P48, DOI 10.1016/0959-440X(95)80008-O; DESSEN P, 1982, J MOL BIOL, V154, P603, DOI 10.1016/S0022-2836(82)80017-X; DESSEN P, 1982, J MOL BIOL, V159, P651, DOI 10.1016/0022-2836(82)90106-1; DOCKBREGEON AC, 1990, EUR J BIOCHEM, V188, P283, DOI 10.1111/j.1432-1033.1990.tb15401.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Glocker MO, 1996, J MASS SPECTROM, V31, P1221, DOI 10.1002/(SICI)1096-9888(199611)31:11<1221::AID-JMS410>3.0.CO;2-P; GruicSovulj I, 1997, NUCLEIC ACIDS RES, V25, P1859, DOI 10.1093/nar/25.9.1859; HARTLEIN M, 1995, J MOL EVOL, V40, P519; HAYASE Y, 1992, EMBO J, V11, P4159, DOI 10.1002/j.1460-2075.1992.tb05509.x; HILLENKAMP F, 1996, IN PRESS NATO ADV RE; IBBA M, 1995, FEBS LETT, V358, P293, DOI 10.1016/0014-5793(94)01454-9; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; KUCAN Z, 1973, J BIOCHEM, V73, P811; LECCHI P, 1995, J AM SOC MASS SPECTR, V6, P972, DOI 10.1016/1044-0305(95)00524-H; MAXWELL IH, 1968, BIOCHEMISTRY-US, V7, P2629, DOI 10.1021/bi00847a027; Mazauric MH, 1996, EUR J BIOCHEM, V241, P814, DOI 10.1111/j.1432-1033.1996.00814.x; Meinnel Thierry, 1995, P251; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Nordhoff E, 1996, MASS SPECTROM REV, V15, P67, DOI 10.1002/(SICI)1098-2787(1996)15:2<67::AID-MAS1>3.0.CO;2-8; PACHMANN U, 1978, NUCLEIC ACIDS RES, V5, P975, DOI 10.1093/nar/5.3.975; PLOHL M, 1988, BIOCHIMIE, V70, P637, DOI 10.1016/0300-9084(88)90247-7; PRAMANIK BN, 1996, P 44 ASMS C MASS SPE; RIESNER D, 1976, EUR J BIOCHEM, V68, P71, DOI 10.1111/j.1432-1033.1976.tb10765.x; RIGLER R, 1971, FEBS LETT, V11, P320; Rogers M J, 1990, Prog Nucleic Acid Res Mol Biol, V39, P185, DOI 10.1016/S0079-6603(08)60627-3; ROSINKE B, 1995, J MASS SPECTROM, V30, P1462, DOI 10.1002/jms.1190301012; RUBELJ I, 1990, EUR J BIOCHEM, V193, P783, DOI 10.1111/j.1432-1033.1990.tb19400.x; SHERMAN JM, 1992, NUCLEIC ACIDS RES, V20, P2847, DOI 10.1093/nar/20.11.2847; SUZUKI T, 1994, NUCLEIC ACIDS RES, V22, P115, DOI 10.1093/nar/22.2.115; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; TANG XD, 1995, ANAL CHEM, V67, P4542, DOI 10.1021/ac00120a018; VINCENT C, 1995, NUCLEIC ACIDS RES, V23, P1113, DOI 10.1093/nar/23.7.1113; WEYGANDDURASEVIC I, 1987, NUCLEIC ACIDS RES, V15, P1887, DOI 10.1093/nar/15.5.1887; WeygandDurasevic I, 1996, J BIOL CHEM, V271, P2455, DOI 10.1074/jbc.271.5.2455; WOODS AS, 1995, ANAL CHEM, V67, P4462, DOI 10.1021/ac00120a005; ZACCAI G, 1979, J MOL BIOL, V129, P483, DOI 10.1016/0022-2836(79)90508-4; Zhu YF, 1996, RAPID COMMUN MASS SP, V10, P1591, DOI 10.1002/(SICI)1097-0231(199610)10:13<1591::AID-RCM715>3.0.CO;2-W; Zhu YF, 1996, RAPID COMMUN MASS SP, V10, P383, DOI 10.1002/(SICI)1097-0231(199602)10:3<383::AID-RCM485>3.0.CO;2-W	53	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32084	32091		10.1074/jbc.272.51.32084	http://dx.doi.org/10.1074/jbc.272.51.32084			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405405	hybrid			2022-12-25	WOS:000071108000024
J	Hanada, K; Hara, T; Nishijima, M; Kuge, O; Dickson, RC; Nagiec, MM				Hanada, K; Hara, T; Nishijima, M; Kuge, O; Dickson, RC; Nagiec, MM			A mammalian homolog of the yeast LCB1 encodes a component of serine palmitoyltransferase, the enzyme catalyzing the first step in sphingolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; HAMSTER OVARY CELLS; LONG-CHAIN BASES; BIOSYNTHESIS; MUTANT; SACCHAROMYCES; GENE; LOCALIZATION; ALIGNMENT; CLONING	Serine palmitoyltransferase (SPT; EC 2.3.1.50) catalyzes the initial step dedicated to sphingolipid biosynthesis and is thought to be a key enzyme for regulating cellular sphingolipid content. For SPT activity, the yeast Saccharomyces cerevisiae requires two genes, LCB1 and LCB2. We isolated mammalian LCB1 cDNA homologs from mouse and Chinese hamster ovary (CHO) cells and an LCB2 cDNA homolog from CHO cells. The mammalian LCB1 proteins are predicted to have about 35% amino acid identity to the yeast Lcb1 protein, whereas the CHO LCB2 protein is predicted to have about 40% amino acid identity to the yeast Lcb2 protein. Northern blot analysis of mRNA isolated from various mouse tissues revealed that the tissue distribution of both LCB1 and LCB2 messengers followed a similar pattern. Transfection of an SPT-defective CHO mutant strain with a CHO LCB1-expressing plasmid restored both SPT activity and de novo sphingolipid synthesis to the wild type levels, whereas transfection of the mutant strain with a CHO LCB2-expressing plasmid did not exhibit any recovery effects, indicating that the SPT defect in the mutant cells is specifically complemented by the CHO LCB1 homolog. Furthermore, when the SPT-defective mutant cells were transfected with a plasmid encoding a His(6)-tagged CHO LCB1 protein, SPT activity bound to a Ni2+-immobilized resin. These results indicate that the CHO LCB1 homolog encodes a component of SPT.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 162, Japan; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA	National Institute of Infectious Diseases (NIID); University of Kentucky; University of Kentucky	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 162, Japan.			Kuge, Osamu/0000-0003-4962-3519; Hanada, Kentaro/0000-0003-1383-2781				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; HAKOMORI S, 1983, HDB LIPID RES, V3, P1; HANADA K, 1993, J BIOL CHEM, V268, P13820; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HANADA K, 1990, J BIOL CHEM, V265, P22137; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HORI T, 1993, PROG LIPID RES, V32, P25, DOI 10.1016/0163-7827(93)90003-F; KARLSSON KA, 1970, LIPIDS, V5, P878, DOI 10.1007/BF02531119; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LESTER RL, 1993, ADV LIPID RES, V26, P253; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1985, J LIPID RES, V26, P617; Merrill Jr A. H., 1996, BIOCH LIPIDS LIPOPRO, P309; MUKHERJEE JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P24, DOI 10.1016/0167-4838(90)90097-Y; Nagiec MM, 1996, GENE, V177, P237, DOI 10.1016/0378-1119(96)00309-5; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; WELLS GB, 1983, J BIOL CHEM, V258, P200; ZHAO C, 1994, J BIOL CHEM, V269, P21480; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	36	114	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32108	32114		10.1074/jbc.272.51.32108	http://dx.doi.org/10.1074/jbc.272.51.32108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405408	hybrid			2022-12-25	WOS:000071108000027
J	Krupnick, JG; Santini, F; Gagnon, AW; Keen, JH; Benovic, JL				Krupnick, JG; Santini, F; Gagnon, AW; Keen, JH; Benovic, JL			Modulation of the arrestin-clathrin interaction in cells - Characterization of beta-arrestin dominant-negative mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; VISUAL ARRESTIN; 48-KDA PROTEIN; WILD-TYPE; RHODOPSIN; BINDING; PHOSPHORYLATION; DESENSITIZATION; KINASE	We recently demonstrated that nonvisual arrestins interact via a C-terminal binding domain with clathrin and function as adaptor proteins to promote beta(2)-adrenergic receptor (beta(2)AR) internalization. Here, we investigated the potential utility of a mini-gene expressing the clathrin-binding domain of beta-arrestin (beta-arrestin (319-418)) to function as a dominant-negative with respect to beta(2)AR internalization and compared its properties with those of beta-arrestin and beta-arrestin-V53D, a previously reported dominant-negative mutant. In vitro studies demonstrated that beta-arrestin-V53D bound better to clathrin than beta-arrestin but was significantly impaired in its interaction with phosphorylated G protein-coupled receptors, In contrast, whereas beta-arrestin (319-418) also bound well to clathrin it completely lacked receptor binding activity. When coexpressed with the beta(2)AR in HEK298 cells, beta-arrestin (319-418) effectively inhibited agonist-promoted receptor internalization, whereas beta-arrestin-V53D was only modestly effective, However, both constructs significantly inhibited the stimulation of beta(2)AR internalization by beta-arrestin in COS-1 cells. Interestingly, immunofluorescence microscopy analysis reveals that both beta-arrestin (319-418) and beta-arrestin-V53D are constitutively localized in clathrin-coated pits in COS-1 cells, These results indicate the potential usefulness of beta-arrestin (319-418) to effectively block arrestin-clathrin interaction in cells and suggest that this construct may prove useful in further defining the mechanisms involved in G protein-coupled receptor trafficking.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.				NIGMS NIH HHS [GM44944, GM47419, GM28526] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028526, R01GM044944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; Diviani D, 1996, J BIOL CHEM, V271, P5049; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; FERGUSON SSG, 1996, JSCIENCE, V271, P363; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KEEN JH, 1981, J BIOL CHEM, V256, P2538; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553	29	182	182	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32507	32512		10.1074/jbc.272.51.32507	http://dx.doi.org/10.1074/jbc.272.51.32507			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405462	hybrid			2022-12-25	WOS:000071108000081
J	Zhao, XD; Liu, JQ; Hsu, DS; Zhao, SY; Taylor, JS; Sancar, A				Zhao, XD; Liu, JQ; Hsu, DS; Zhao, SY; Taylor, JS; Sancar, A			Reaction mechanism of (6-4) photolyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(6-4)-PHOTOPRODUCT DNA PHOTOLYASE; BLUE-LIGHT PHOTORECEPTORS; ABSOLUTE ACTION SPECTRUM; TRANSITION-STATE ANALOG; ESCHERICHIA-COLI; SKIN-CANCER; ADENOSINE-DEAMINASE; REPAIR ACTIVITY; TARGET BASE; CIS-SYN	The (6-4) photolyase catalyzes the photoreversal of the (6-4) dipyrimidine photoproducts induced in DNA by ultraviolet light, Using the cloned Drosophila melanogaster (6-4) photolyase gene, we overproduced and purified the recombinant enzyme. The binding and catalytic properties of the enzyme were investigated using natural substrates, T[6-4]T and T[6-4]C, and the Dewar isomer of (6-4) photoproduct and substrate analogs s(5)T[6-4]T/thietane, mes(5)T[6-4]T, and the N-methyl-3'T thietane analog of the oxetane intermediate, The enzyme binds to the natural substrates and to mes(5)T[6-4]T with high affinity (K-D similar to 10(-9)-10(-10) M) and produces a DNase I footprint of about 20 base pairs around the photolesion. Several lines of evidence suggest that upon binding by the enzyme, the photoproduct flips out of the duplex, Of the four substrates that bind with high affinity to the enzyme, T[6-4]T and T[6-4]C are repaired with relatively high quantum yields compared with the Dewar isomer and the mes(5)T[6-4]T which are repaired with 300-400-fold lower quantum yield than the former two photoproducts. Reduction of the FAD cofactor with dithionite increases the quantum yield of repair. Taken together, the data are consistent with photoinduced electron transfer from reduced FAD to substrate, in a manner analogous to the cyclobutane pyrimidine dimer photolyase.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Washington University (WUSTL)	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, CB 7260, Chapel Hill, NC 27599 USA.		Taylor, John-Stephen/AAA-3218-2020; Liu, Jianquan/B-5740-2011	Taylor, John-Stephen/0000-0002-8615-7257; Liu, Jianquan/0000-0002-4773-4250	NCI NIH HHS [CA40463] Funding Source: Medline; NIGMS NIH HHS [GM31082] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040463, R37CA040463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031082, R01GM031082] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAER M, 1989, MOL CELL BIOL, V9, P4777, DOI 10.1128/MCB.9.11.4777; BEGLEY TP, 1994, ACCOUNTS CHEM RES, V27, P394, DOI 10.1021/ar00048a002; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; Cal S, 1997, J BIOL CHEM, V272, P490; CLIVIO P, 1991, J AM CHEM SOC, V113, P13535; COLEMAN RS, 1994, J AM CHEM SOC, V116, P11636, DOI 10.1021/ja00105a002; DEMPLE B, 1995, CURR BIOL, V5, P719, DOI 10.1016/S0960-9822(95)00143-6; EKER AP, 1988, BIOCHEMISTRY-US, V27, P1758, DOI 10.1021/bi00405a056; ELLENBERGER T, 1995, CHEM BIOL, V2, P351, DOI 10.1016/1074-5521(95)90213-9; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Heelis PF, 1997, J AM CHEM SOC, V119, P2936, DOI 10.1021/ja9639877; HEELIS PF, 1995, CHEM SOC REV, V24, P289, DOI 10.1039/cs9952400289; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; HOYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1107; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; KIENER A, 1989, J BIOL CHEM, V264, P13880; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; Kim ST, 1996, MUTAT RES-DNA REPAIR, V363, P97, DOI 10.1016/0921-8777(96)00003-1; KIM ST, 1994, J BIOL CHEM, V269, P8535; Kim ST, 1996, PHOTOCHEM PHOTOBIOL, V63, P292, DOI 10.1111/j.1751-1097.1996.tb03028.x; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; Liu JQ, 1996, J AM CHEM SOC, V118, P3287, DOI 10.1021/ja952450a; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MOORE JA, 1983, CHEM HETEROCYCL COMP, V42, P1; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; PRAKASH G, 1995, J AM CHEM SOC, V117, P11375, DOI 10.1021/ja00150a050; RAHN RO, 1969, PHOTOCHEM PHOTOBIOL, V10, P131, DOI 10.1111/j.1751-1097.1969.tb07230.x; RAO SN, 1985, PHOTOCHEM PHOTOBIOL, V42, P465, DOI 10.1111/j.1751-1097.1985.tb01596.x; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; RUPERT CS, 1962, J GEN PHYSIOL, V45, P725, DOI 10.1085/jgp.45.4.725; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 1996, SCIENCE, V272, P48, DOI 10.1126/science.272.5258.48; SANCAR GB, 1987, J BIOL CHEM, V262, P492; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; SMITH CA, 1993, J BIOL CHEM, V268, P11143; SPECKAMP WN, 1985, TETRAHEDRON, V41, P4367, DOI 10.1016/S0040-4020(01)82334-6; TAYLOR JS, 1994, ACCOUNTS CHEM RES, V27, P76, DOI 10.1021/ar00039a003; TAYLOR JS, 1995, PURE APPL CHEM, V67, P183, DOI 10.1351/pac199567010183; Todo T, 1997, NUCLEIC ACIDS RES, V25, P764, DOI 10.1093/nar/25.4.764; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; TROST BM, 1971, J AM CHEM SOC, V93, P676, DOI 10.1021/ja00732a021; TROST BM, 1969, J AM CHEM SOC, V91, P4320, DOI 10.1021/ja01043a069; WALSH C, 1986, ACCOUNTS CHEM RES, V19, P216, DOI 10.1021/ar00127a004; WILSON DK, 1993, BIOCHEMISTRY-US, V32, P1689, DOI 10.1021/bi00058a001; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WOLFENDEN R, 1991, ACCOUNTS CHEM RES, V24, P209, DOI 10.1021/ar00007a004; XIANG SB, 1995, BIOCHEMISTRY-US, V34, P4516, DOI 10.1021/bi00014a003; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; ZHAO X, 1995, THESIS WASHINGTON U	58	128	129	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32580	32590		10.1074/jbc.272.51.32580	http://dx.doi.org/10.1074/jbc.272.51.32580			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405473	Green Published, hybrid			2022-12-25	WOS:000071108000092
J	Aspinwall, CA; Brooks, SA; Kennedy, RT; Lakey, JRT				Aspinwall, CA; Brooks, SA; Kennedy, RT; Lakey, JRT			Effects of intravesicular H+ and extracellular H+ and Zn2+ on insulin secretion in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-MEDULLARY CELLS; INDIVIDUAL CHROMAFFIN CELLS; VESICLE FUSION; AMPEROMETRIC DETECTION; QUANTAL SECRETION; GRANULE MATRIX; CHROMOGRANIN-A; TIME-COURSE; B-CELL; RELEASE	The effects of extracellular Zn2+ and pH and intravesicular pH on insulin and 5-hydroxytryptamine (5-HT) secretion from pancreatic beta cells were investigated. Insulin and 5-HT secretion from single cells was detected by amperometry as a series of current spikes corresponding to detection of multimolecular packets secreted by exocytosis. Spike width was used as a measure of the kinetics of clearance from the cell and the area of spikes as a measure of amount released. Changes in extracellular pH from 6.9 to 7.9 caused insulin spikes to become narrower with no change in area, whereas the same treatments had no effect on 5-HT secretion. Treatment of cells with Bafilomycin A(1) or N-ethylmaleimide, both of which are expected to increase intravesicular pH by inhibiting V-type H+-ATPase, had no effect on 5-HT secretion but caused insulin spikes to become more narrow. These results indicate that exposure to high pH, whether intravesicular or extracellular, accelerates release of insulin during exocytosis without affecting the amount of insulin released. Increasing extracellular Zn2+ concentration from 0 to 25 mu M increased the width and decreased the area of insulin spikes without affecting 5-HT secretion. Zn2+ effects were likely exerted through a common-ion effect on Zn2+-insulin dissociation. It was concluded that intravesicular storage conditions and extracellular ions can affect free insulin concentration in the vicinity of beta cells during secretion.	UNIV FLORIDA,DEPT CHEM,GAINESVILLE,FL 32611; UNIV ALBERTA,DEPT SURG,COMPREHENS TISSUE CTR,EDMONTON,AB T6H 2R8,CANADA	State University System of Florida; University of Florida; University of Alberta			Kennedy, Robert/G-9095-2016	Kennedy, Robert/0000-0003-2447-7471; Aspinwall, Craig/0000-0002-4359-5812	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046960] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46960-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNETT DW, 1994, J MEMBRANE BIOL, V138, P113; BERSON SA, 1966, AM J MED, V40, P676, DOI 10.1016/0002-9343(66)90148-3; Blundell T., 1972, ADV PROTEIN CHEM, V26, P279; BONNER FW, 1979, CHEM-BIOL INTERACT, V27, P343, DOI 10.1016/0009-2797(79)90137-6; Borges R, 1997, J BIOL CHEM, V272, P8325, DOI 10.1074/jbc.272.13.8325; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHEN MD, 1995, BIOL TRACE ELEM RES, V50, P119, DOI 10.1007/BF02789414; CHEN TK, 1994, ANAL CHEM, V66, P3031, DOI 10.1021/ac00091a007; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CIOLKOWSKI EL, 1992, J AM CHEM SOC, V114, P2815, DOI 10.1021/ja00034a009; COORE HG, 1969, BIOCHEM J, V111, P107, DOI 10.1042/bj1110107; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; EHRHART M, 1986, J HISTOCHEM CYTOCHEM, V34, P1673, DOI 10.1177/34.12.2878021; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; EPAND RM, 1985, MOL PHARMACOL, V27, P366; FERNANDEZCHACON R, 1995, FEBS LETT, V363, P221, DOI 10.1016/0014-5793(95)00319-5; FOSTER MC, 1993, BIOPHYS J, V64, P525, DOI 10.1016/S0006-3495(93)81397-3; GAZZANO H, 1985, BIOCHEM J, V226, P867, DOI 10.1042/bj2260867; GOLD G, 1984, EXPERIENTIA, V40, P1105, DOI 10.1007/BF01971458; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; Hazelwood R.L., 1989, ENDOCRINE PANCREAS; HELMERHORST E, 1986, ARCH BIOCHEM BIOPHYS, V245, P238, DOI 10.1016/0003-9861(86)90210-9; HUANG L, 1995, P NATL ACAD SCI USA, V92, P608; HURLEY LS, 1969, AM J CLIN NUTR, V22, P1332; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; HUTTON JC, 1988, ENDOCRINOLOGY, V122, P1014, DOI 10.1210/endo-122-3-1014; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; JANKOWSKI JA, 1994, J NEUROCHEM, V63, P1739; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; KELLY RS, 1986, ANAL CHIM ACTA, V187, P79, DOI 10.1016/S0003-2670(00)82900-1; KENNEDY RT, 1993, ANAL CHEM, V65, P1882, DOI 10.1021/ac00062a012; Kennedy RT, 1996, J AM CHEM SOC, V118, P1795, DOI 10.1021/ja953271w; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; NANAVATI C, 1993, SCIENCE, V259, P963, DOI 10.1126/science.8438154; Oberhauser AF, 1996, BIOPHYS J, V71, P1131, DOI 10.1016/S0006-3495(96)79315-3; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Paras CD, 1997, ELECTROANAL, V9, P203, DOI 10.1002/elan.1140090303; PARAS CD, 1995, ANAL CHEM, V67, P3633, DOI 10.1021/ac00116a003; PATEL YC, 1982, SCIENCE, V217, P1155, DOI 10.1126/science.6126003; Pihel K, 1996, BIOPHYS J, V71, P1633, DOI 10.1016/S0006-3495(96)79368-2; Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; SCHROEDER TJ, 1992, ANAL CHEM, V64, P3077, DOI 10.1021/ac00048a003; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; SMITH P, 1994, J PHYSIOL-LONDON, V475P, pP157; SMITH PA, 1995, PFLUG ARCH EUR J PHY, V430, P808, DOI 10.1007/BF00386180; TANFORD C, 1954, J AM CHEM SOC, V76, P2170, DOI 10.1021/ja01637a036; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; Walker A, 1996, PFLUG ARCH EUR J PHY, V431, P729, DOI 10.1007/s004240050058; WARNOCK GL, 1994, PANCREATIC ISLET TRA, V1, P81; WIGHTMAN RM, 1995, BIOPHYS J, V68, P383, DOI 10.1016/S0006-3495(95)80199-2; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Xu G, 1996, BIOCHEM J, V318, P623, DOI 10.1042/bj3180623; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403; ZHOU Z, 1995, P NATL ACAD SCI USA, V92, P6938, DOI 10.1073/pnas.92.15.6938; Zhou Z, 1996, J BIOL CHEM, V271, P270, DOI 10.1074/jbc.271.1.270; ZIMMERBERG J, 1987, BIOSCIENCE REP, V7, P251, DOI 10.1007/BF01121447	62	81	82	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31308	31314		10.1074/jbc.272.50.31308	http://dx.doi.org/10.1074/jbc.272.50.31308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395458	hybrid			2022-12-25	WOS:A1997YL41900017
J	Kappeler, F; Klopfenstein, DRC; Foguet, M; Paccaud, JP; Hauri, HP				Kappeler, F; Klopfenstein, DRC; Foguet, M; Paccaud, JP; Hauri, HP			The recycling of ERGIC-53 in the early secretory pathway - ERGIC-53 carries a cytosolic endoplasmic reticulum exit determinant interacting with COPII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; GTP-BINDING-PROTEINS; TRANSPORT VESICLES; MEMBRANE-PROTEIN; COATED VESICLES; BETA-COP; TRANSMEMBRANE PROTEINS; MONOCLONAL-ANTIBODIES; LEGUMINOUS LECTINS; BREFELDIN-A	Further investigation of the targeting of the intracellular membrane lectin endoplasmic reticulum (ER)-Golgi intermediate compartment-53 (ERGIC-53) by site-directed mutagenesis revealed that its lumenal and transmembrane domains together confer ER retention. In addition we show that the cytoplasmic domain is required for exit from the ER indicating that ERGIC-53 carries an ER-exit determinant. Two phenylalanines at the C terminus are essential for ER-exit. Thus, ERGIC-53 contains determinants for ER retention as well as anterograde transport which, in conjunction with a dilysine ER retrieval signal, control the continuous recycling of ERGIC-53 in the early secretory pathway, In vitro binding studies revealed a specific phenylalanine-dependent interaction between an ERGIC-53 cytosolic tail peptide and the COPII coat component Sec23p. These results suggest that the ER-exit of ERGIC-53 is mediated by direct interaction of its cytosolic tail with the Sec23p.Sec24p complex of COPII and that protein sorting at the level of the ER occurs by a mechanism similar to receptor-mediated endocytosis or Golgi to ER retrograde transport.	UNIV BASEL,BIOZENTRUM,DEPT PHARMACOL,CH-4056 BASEL,SWITZERLAND; UNIV GENEVA,MED CTR,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND	University of Basel; University of Geneva								AHLE S, 1989, J BIOL CHEM, V264, P20089; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BANHYKH SI, 1997, J CELL BIOL, V138, P1; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARQUHAR MG, 1997, GOLGI APPARATUS, P63; Bednarek SY, 1996, TRENDS CELL BIOL, V6, P468, DOI 10.1016/0962-8924(96)84943-9; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GERICH B, 1995, P NATL ACAD SCI USA, V92, P3229, DOI 10.1073/pnas.92.8.3229; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HAURI HP, 1997, HDB PHYSIOL 14, P605; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; ITIN C, 1995, BIOCHEM SOC T, V23, P541, DOI 10.1042/bst0230541; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WADA I, 1991, J BIOL CHEM, V266, P19599; WHITNEY JA, 1995, CELL, V83, P703	79	222	226	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31801	31808		10.1074/jbc.272.50.31801	http://dx.doi.org/10.1074/jbc.272.50.31801			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395526	hybrid			2022-12-25	WOS:A1997YL41900085
J	Suzuki, M; Raab, G; Moses, MA; Fernandez, CA; Klagsbrun, M				Suzuki, M; Raab, G; Moses, MA; Fernandez, CA; Klagsbrun, M			Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; SELECTIN ADHESION MOLECULE; DIPHTHERIA-TOXIN RECEPTOR; PHORBOL-ESTER; FACTOR-ALPHA; TRANSMEMBRANE FORM; TISSUE INHIBITOR; T-LYMPHOCYTES; MESSENGER-RNA; SURFACE	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is synthesized as a membrane-anchored precursor that is cleaved to release the soluble mature growth factor. The two forms are active as juxtacrine and paracrine/autocrine growth factors, respectively, The enzymes that process the HB EGF transmembrane form are unknown, Accordingly, an in vitro assay was established using a fusion protein in which alkaline phosphatase (AP) replaced the transmembrane and cytoplasmic domains of HB-EGF (HB-EGF JM-AP). The fusion protein was anchored to agarose beads coated with anti-AP antibodies, Several matrix metalloproteinases (MMPs) were tested for the ability to release soluble HB-EGF in the in vitro system. MMP-3 released soluble 12-kDa immunoreactive and mitogenic HB-EGF within 30 min. On the other hand neither MMP-2 nor MMP-9 had any cleavage activities. A non-cleavable mutant was prepared by replacing the juxtamembrane (JM) region of HB-EGF with the JM region of CD4. The mutant HB-EGF, which in its full-length form was as active a juxtacrine growth factor as was the wild type HB-EGF in vivo, was not cleaved by MMP-3 in the in vitro assay. The C-terminal portion of the cleaved HB-EGF JM-AP that remained attached to the anti-AP beads was N-terminally sequenced and the MMP-3 cleavage site was determined to be Glu(151)-Asn(152), a site within the JM domain. MMP-3 treatment also released soluble HB-EGF in vivo from MC2 cells expressing transmembrane HB-EGF precursor, at a level of about 2-fold above control. It was concluded that MMP-3 cleaves HB-EGF at a specific site in the JM domain and that this enzyme might regulate the conversion of HB-EGF from being a juxtacrine to a paracrine/autocrine growth factor.	CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; NATL INST BIOSCI & HUMAN TECHNOL,BIOSIGNALING DEPT,TSUKUBA,IBARAKI 305,JAPAN	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; National Institute of Advanced Industrial Science & Technology (AIST)			Suzuki, Masashi/M-1696-2018	Suzuki, Masashi/0000-0002-7218-0923	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47397] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Bramhall SR, 1996, BRIT J CANCER, V73, P972, DOI 10.1038/bjc.1996.190; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; Couet J, 1996, J BIOL CHEM, V271, P4545; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hosono T, 1996, FEBS LETT, V381, P115, DOI 10.1016/0014-5793(96)00081-6; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Knox JB, 1997, CIRCULATION, V95, P205, DOI 10.1161/01.CIR.95.1.205; LANZREIN M, 1995, BIOCHEM J, V310, P285, DOI 10.1042/bj3100285; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; McCarthy DW, 1996, J INVEST DERMATOL, V106, P49, DOI 10.1111/1523-1747.ep12327214; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; NAGASE H, 1994, J BIOL CHEM, V269, P20952; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Nakagawa T, 1996, J BIOL CHEM, V271, P30858, DOI 10.1074/jbc.271.48.30858; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OCHIENG J, 1994, BIOCHEMISTRY-US, V33, P14109, DOI 10.1021/bi00251a020; ONO M, 1994, J BIOL CHEM, V269, P31315; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; PIERCE JH, 1994, SCIENCE, V91, P2890; POWELL PP, 1993, AM J PATHOL, V143, P784; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Raab G, 1996, DEVELOPMENT, V122, P637; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; ROHER AE, 1994, BIOCHEM BIOPH RES CO, V205, P1755, DOI 10.1006/bbrc.1994.2872; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; UNEMORI EN, 1994, EXP CELL RES, V210, P166, DOI 10.1006/excr.1994.1025; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wiesen JF, 1996, ENZYME PROTEIN, V49, P174, DOI 10.1159/000468624; WILHELM SM, 1993, J BIOL CHEM, V268, P21906; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	67	259	270	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31730	31737		10.1074/jbc.272.50.31730	http://dx.doi.org/10.1074/jbc.272.50.31730			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395517	hybrid			2022-12-25	WOS:A1997YL41900076
J	Zhao, JK; Trewhella, J; Corbin, J; Francis, S; Mitchell, R; Brushia, R; Walsh, D				Zhao, JK; Trewhella, J; Corbin, J; Francis, S; Mitchell, R; Brushia, R; Walsh, D			Progressive cyclic nucleotide-induced conformational changes in the cGMP-dependent protein kinase studied by small angle X-ray scattering in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP BINDING DOMAINS; CRYSTAL-STRUCTURE; PREDICTED STRUCTURES; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; CATALYTIC SUBUNIT; DELETION MUTANT; TERMINAL DOMAIN; TROPONIN-C; SITES	Small angle scattering data from bovine lung type I alpha cGRSP-dependent protein kinase (PKG) in the absence of cGMP show the protein to have a highly asymmetric structure with a radius of gyration (R-g) of 45 Angstrom and a maximum linear dimension (d(max)) of 165 Angstrom. The addition of cGMP induces a marked conformational change in PKG. The R-g and d(max) increase 25-30%, and the protein's mass moves further away from the center of mass; this results in an even more asymmetric structure, Fourier transform infrared spectroscopy data suggest that the conformational change induced by cGMP binding is primarily due to a topographical movement of the structural domains of PKG rather than to secondary structural changes within one or more of the individual domains. Each monomer of the dimeric PKG contains one high and one low affinity cGMP-binding site. A prominent increase in the asymmetry of PKG occurs with binding to high affinity cGMP-binding sites alone, but the full domain movements require the binding to both sets of sites, These conformational changes occurring in PKG with the progressive binding of cGMP to both sets of cGMP-binding sites correlate with past data, which have indicated that cGMP binding to both sets of sites is required for the fall activation of the enzyme, These results provide the first quantitative measurement of the overall PKG structure, as well as an assessment of the structural events that accompany the activation of a protein kinase upon binding a small molecular weight ligand.	VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, NASHVILLE, TN 37232 USA; UNIV CALIF DAVIS, DEPT BIOL CHEM, DAVIS, CA 95616 USA	Vanderbilt University; University of California System; University of California Davis	Zhao, JK (corresponding author), LOS ALAMOS NATL LAB, DIV CHEM SCI & TECHNOL, LOS ALAMOS, NM 87545 USA.		Zhao, Jinkui/B-7872-2013	Zhao, Jinkui/0000-0002-7756-1952; Trewhella, Jill/0000-0002-8555-6766	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013613, R01DK040029] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13613, DK40029] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BUBIS J, 1985, BIOCHEMISTRY-US, V24, P2163, DOI 10.1021/bi00330a009; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; Corbin J D, 1978, Adv Cyclic Nucleotide Res, V9, P159; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1988, METHOD ENZYMOL, V159, P74; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DONG A, 1992, BIOCHEMISTRY-US, V31, P182, DOI 10.1021/bi00116a027; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; Feigin L. A., 1987, STRUCTURE ANAL SMALL, P25, DOI DOI 10.1007/978-1-4757-6624-0; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P322; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GLASS DB, 1980, ANNU REV PHARMACOL, V20, P363, DOI 10.1146/annurev.pa.20.040180.002051; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; Glatter O., 1982, SMALL ANGLE XRAY SCA, P17; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JOHNSON DA, 1993, BIOCHEMISTRY-US, V32, P6402, DOI 10.1021/bi00076a013; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KREUGER JK, 1997, BIOCH, V36, P6017; KRINGBAUM WR, 1970, BIOCHEMISTRY-US, V9, P1216; KUO JF, 1970, J BIOL CHEM, V245, P2493; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LEHMANN MS, 1984, BIOCHEMISTRY-US, V23, P1939, DOI 10.1021/bi00304a008; LINCOLN TM, 1977, P NATL ACAD SCI USA, V74, P3239, DOI 10.1073/pnas.74.8.3239; LINCOLN TM, 1976, P NATL ACAD SCI USA, V73, P2559, DOI 10.1073/pnas.73.8.2559; LINCOLN TM, 1977, J BIOL CHEM, V252, P4269; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MITCHELL RD, 1995, BIOCHEMISTRY-US, V34, P528, DOI 10.1021/bi00002a018; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; SU Y, 1993, J MOL BIOL, V230, P1091, DOI 10.1006/jmbi.1993.1224; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TREWHELLA J, 1989, BIOCHEMISTRY-US, V28, P1294, DOI 10.1021/bi00429a052; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WAKATSUKI S, 1992, REV SCI INSTRUM, V63, P1736, DOI 10.1063/1.1143332; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WOLFE L, 1987, J BIOL CHEM, V262, P16906; WOLFE L, 1989, J BIOL CHEM, V264, P7734; YANG SM, 1995, BIOCHEMISTRY-US, V34, P6267, DOI 10.1021/bi00019a002; ZACCAI G, 1986, J MOL BIOL, V190, P97, DOI 10.1016/0022-2836(86)90078-1; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	61	47	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31929	31936		10.1074/jbc.272.50.31929	http://dx.doi.org/10.1074/jbc.272.50.31929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395542	hybrid			2022-12-25	WOS:A1997YL41900101
J	Clum, S; Ebner, KE; Padmanabhan, R				Clum, S; Ebner, KE; Padmanabhan, R			Cotranslational membrane insertion of the serine proteinase precursor NS2B-NS3(Pro) of dengue virus type 2 is required for efficient in vitro processing and is mediated through the hydrophobic regions of NS2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER VIRUS; PROTEASE DOMAIN; NONSTRUCTURAL PROTEINS; STRUCTURAL PROTEINS; VIRAL REPLICATION; POLYPROTEIN PRECURSOR; ENDOPLASMIC-RETICULUM; CLEAVAGE SITE; NS3 PROTEIN; IN-VITRO	Polyprotein processing of dengue virus type 2, a positive strand RNA virus, is carried out by the host signal peptidase and a novel two-component viral proteinase of the serine proteinase family, NS2B/NS3(Pro), in the endoplasmic reticulum, Using an in vitro processing system, we examined the cis and trans cleavages of the 2B/3 and 4B/5 sites by NS2B/NS3(Pro), respectively, Lysates of BHK-21 cells coexpressing NS2B and NS3(Pro) mediated trans cleavage of the 4B/5 site in vitro, and the protease activity was associated with the membrane fraction, To study the role of membranes in the protease activity of NS2B/NS3(Pro), labeled precursors, NS2B-NS3(Pro) and the mutant ndNS2B-NS3(Pro) in which the functional hydrophilic domain of NS2B was deleted, were analyzed using a coupled in vitro transcription/translation system (TnT), The results showed that cotranslational addition of microsomal membranes to the TnT reaction markedly enhanced the cis cleavage of the 2B/3 site in a dose-dependent manner, NS2B synthesized in the presence of membranes also facilitated trans cleavage of the 2B/3 site in the mutant precursor, The cleavage products, NS2B and NS3(Pro), were membrane-associated, Furthermore, this membrane requirement was dictated by the hydrophobic regions of NS2B, Deletion of hydrophobic regions of NS2B, leaving only the conserved hydrophilic domain of 40 amino acids, resulted in highly efficient processing of the 2B-3 site in vitro in the absence of microsomal membranes.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Padmanabhan, R (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032078, R21AI032078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBERG SM, 1994, J VIROL, V68, P3794, DOI 10.1128/JVI.68.6.3794-3802.1994; ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; CHAMBERS TJ, 1993, J VIROL, V67, P6797, DOI 10.1128/JVI.67.11.6797-6807.1993; CHAMBERS TJ, 1995, J VIROL, V69, P1600, DOI 10.1128/JVI.69.3.1600-1605.1995; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Chen H, 1997, Methods Mol Biol, V62, P199; COTTEN M, 1995, VIROLOGY, V213, P494, DOI 10.1006/viro.1995.0022; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7; JAN LR, 1995, J GEN VIROL, V76, P573, DOI 10.1099/0022-1317-76-3-573; KAPOOR M, 1995, J BIOL CHEM, V270, P1910; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993; LOBIGS M, 1993, P NATL ACAD SCI USA, V90, P6218, DOI 10.1073/pnas.90.13.6218; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; MARKOFF L, 1989, J VIROL, V63, P3345, DOI 10.1128/JVI.63.8.3345-3352.1989; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NESTOROWICZ A, 1994, VIROLOGY, V199, P114, DOI 10.1006/viro.1994.1103; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; PREUGSCHAT F, 1991, VIROLOGY, V185, P689, DOI 10.1016/0042-6822(91)90540-R; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; PREUGSCHAT F, 1991, J VIROL, V65, P4749, DOI 10.1128/JVI.65.9.4749-4758.1991; PUGACHEV KV, 1993, FEBS LETT, V328, P115, DOI 10.1016/0014-5793(93)80977-3; RANDOLPH VB, 1990, VIROLOGY, V174, P450, DOI 10.1016/0042-6822(90)90099-D; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SVITKIN YV, 1984, VIROLOGY, V135, P536, DOI 10.1016/0042-6822(84)90207-1; Teo KF, 1997, J GEN VIROL, V78, P337, DOI 10.1099/0022-1317-78-2-337; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; YAMSHCHIKOV VF, 1993, VIROLOGY, V192, P38, DOI 10.1006/viro.1993.1006; YAMSHCHIKOV VF, 1994, J VIROL, V68, P5765, DOI 10.1128/JVI.68.9.5765-5771.1994; ZHANG L, 1993, GENE, V129, P197, DOI 10.1016/0378-1119(93)90269-9; ZHANG LW, 1992, J VIROL, V66, P7549, DOI 10.1128/JVI.66.12.7549-7554.1992; ZHAO LJ, 1993, GENE, V137, P345, DOI 10.1016/0378-1119(93)90032-X; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	44	160	169	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30715	30723		10.1074/jbc.272.49.30715	http://dx.doi.org/10.1074/jbc.272.49.30715			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388208	hybrid			2022-12-25	WOS:000071640800021
J	Duan, HW; Lin, CY; Mazzone, T				Duan, HW; Lin, CY; Mazzone, T			Degradation of macrophage ApoE in a nonlysosomal compartment - Regulation by sterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-DERIVED MACROPHAGES; HEPARAN-SULFATE PROTEOGLYCANS; UBIQUITIN-PROTEASOME PATHWAY; BONE-MARROW TRANSPLANTATION; HUMAN APOLIPOPROTEIN-E; E-DEFICIENT MICE; GOLGI-APPARATUS; NIEMANN-PICK; REMNANT LIPOPROTEINS; PROTEIN-DEGRADATION	Macrophage derived apoE has been shown to play an important role in the susceptibility of the vessel wall to atherosclerosis. Previous studies have shown that macrophage sterol content modulates apoE synthesis and secretion, associated with a large transcriptional response of the apoE gene, The current studies were undertaken to evaluate the existence of additional posttranscriptional regulatory loci for the effect of sterols on apoE synthesis and secretion, Using a macrophage cell line transfected to constitutively express an apoE cDNA to facilitate detection of a post-transcriptional regulatory locus, we demonstrated that preincubations in 25-hydroxycholesterol and cholesterol lead to increased apoE secretion in pulse/chase experiments, Examination of cell lysates in these experiments showed that apoE not secreted by control cells was degraded and not detectable, suggesting that the preincubation in sterols increased secretion by decreasing degradation of newly synthesized apoE, The measurement of total protein and apoE degradation in cell fractions revealed an intermediate density fraction that degraded significant amounts of newly synthesized total protein and newly synthesized apoE, In this fraction, degradation of total protein and apoE was unaffected by chloroquine but was substantially reduced by N-acetyl-Leu-Leu-nor-leucinal plus N-acetyl-Leu-Leu-methioninal or by lacta-cystin, suggesting the involvement of proteasomes, Preincubation in sterol/oxysterol or acetylated low density lipoprotein did not modify total protein degradation by this fraction but inhibited apoE degradation, Similar results were obtained using intermediate density fractions isolated from human monocyte-derived macrophages, The results of our studies indicate that newly synthesized apoE in the macrophage can be degraded in an intermediate density nonlysosomal cellular compartment, which is sensitive to proteasomal inhibitors. Alteration of cellular lipid homeostasis by preincubation in sterol/oxysterol or acetylated low density lipoprotein inhibits apoE, but not total protein, degradation in this fraction, Inhibition of the degradation of apoE in this fraction likely contributes to the increased apoE secretion observed in sterol-enriched cells.	Rush Med Coll, Dept Med, Chicago, IL 60612 USA; Rush Med Coll, Dept Biochem, Chicago, IL 60612 USA	Rush University; Rush University	Mazzone, T (corresponding author), Rush Med Ctr, 1653 W Congress Pkwy, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL 39653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Cader AA, 1997, J LIPID RES, V38, P981; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COXEY RA, 1993, J LIPID RES, V34, P1165; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DENG JT, 1995, J LIPID RES, V36, P2129; Dick LR, 1997, J BIOL CHEM, V272, P182; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; HAMILTON RL, 1991, J LIPID RES, V32, P529; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HONGWEI D, 1995, J CLIN INVEST, V96, P915; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KAYDEN HJ, 1985, ARCH BIOCHEM BIOPHYS, V239, P388, DOI 10.1016/0003-9861(85)90704-0; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; LANGE Y, 1988, J BIOL CHEM, V263, P9366; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lucas M, 1997, J BIOL CHEM, V272, P13000, DOI 10.1074/jbc.272.20.13000; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; MAZZONE T, 1989, J LIPID RES, V30, P1055; MAZZONE T, 1994, J LIPID RES, V35, P1345; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; STAUDERMAN ML, 1993, J LIPID RES, V34, P190; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WANGIVERSON P, 1985, BIOCHIM BIOPHYS ACTA, V834, P256, DOI 10.1016/0005-2760(85)90163-8; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WERB Z, 1989, AM J PATHOL, V134, P661; Wu XJ, 1996, J LIPID RES, V37, P1198; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	49	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31156	31162		10.1074/jbc.272.49.31156	http://dx.doi.org/10.1074/jbc.272.49.31156			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388269	hybrid			2022-12-25	WOS:000071640800082
J	Kim, YM; Talanian, RV; Billiar, TR				Kim, YM; Talanian, RV; Billiar, TR			Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; WILD-TYPE P53; S-NITROSYLATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; MEDIATED APOPTOSIS; ICE/CED-3 PROTEASE; HEPATIC DAMAGE; C-ELEGANS; SYNTHASE; EXPRESSION	Nitric oxide (NO) has emerged as an important endogenous inhibitor of apoptosis, and here we report that NO prevents hepatocyte apoptosis initiated by the removal of growth factors or exposure to TNF alpha or anti-Fas antibody, We postulated that the mechanism of the inhibition of apoptosis by NO would include an effect on caspase-3-like protease activity, Caspase-3-like activity increased coincident with apoptosis due to all three stimuli, and treatment with the caspase-3-like protease inhibitor N-acetyl-Asp-Glu-Val-Asp-aldehyde inhibited both proteolytic activity and apoptosis, Endogenous or exogenous sources of NO prevented the increase in caspase-3-like activity in hepatocytes. Exposure of purified recombinant caspase-3 to an NO or NO+ donor inhibited proteolytic activity, Dithiothreitol (DTT), but not glutathione, reversed the inhibition of recombinant caspase-3 by NO, When lysates from cells stimulated to express inducible NO synthase or cells exposed to NO donors were incubated in DTT, caspase-3-like activity increased to about 55% of cells not exposed to a source of NO. Similarly, administration of an NO donor to rats treated with TNF alpha and D-galactosamine also prevented the increase in caspase-3-like activity as measured in liver homogenates. The effect of the NO donor was reversed by about 50% if the homogenate was incubated with DTT, TNF alpha-induced apoptosis and caspase-3-like activity were also reduced in cultured hepatocytes exposed to 8-bromo-cGMP, and both effects were inhibited by the cGMP-dependent kinase inhibitor KT5823, The suppression in caspase-3-like activity in hepatocytes exposed to an NO donor was partially blocked by an inhibitor of soluble guanylyl cyclase, 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one, (ODQ), while the incubation of these lysates in DTT almost completely restored caspase-3-like activity to the level of TNF alpha-treated controls. These data indicate that NO prevents apoptosis in hepatocytes by either directly or indirectly inhibiting caspase-3-like activation via a cGMP-dependent mechanism and by direct inhibition of caspase-3-like activity through protein S-nitrosylation.	Univ Pittsburgh, Coll Med, Dept Surg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Coll Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; BASF Biores Corp, Worcester, MA 01605 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; BASF	Billiar, TR (corresponding author), A1010 Presbyterian Univ Hosp, 200 Lothrop St, Pittsburgh, PA 15213 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044100, R37GM044100, R01GM037753, R01GM044100] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37753, GM-44100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; BILLIAR TR, 1990, J LEUKOCYTE BIOL, V48, P565, DOI 10.1002/jlb.48.6.565; BILLIAR TR, 1995, ANN SURG, V221, P339, DOI 10.1097/00000658-199504000-00003; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; Bohlinger I, 1995, HEPATOLOGY, V22, P1829, DOI 10.1016/0270-9139(95)90212-0; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; COBBS CS, 1995, CANCER RES, V55, P727; Dawson VL, 1996, J NEUROSCI, V16, P2479; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HARBRECHT BG, 1994, AM J PHYSIOL, V266, pG1004, DOI 10.1152/ajpgi.1994.266.6.G1004; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; Ientile R, 1996, FEBS LETT, V379, P82, DOI 10.1016/0014-5793(95)01490-X; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuo PC, 1996, IMMUNOLOGY, V87, P647, DOI 10.1046/j.1365-2567.1996.468592.x; LEIST M, 1995, AM J PATHOL, V146, P1220; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; LYSIAK JJ, 1995, J BIOL CHEM, V270, P21919, DOI 10.1074/jbc.270.37.21919; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MartinSanz P, 1996, HEPATOLOGY, V23, P1200; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; Messmer UK, 1996, ARCH BIOCHEM BIOPHYS, V327, P1, DOI 10.1006/abbi.1996.0085; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; Mohr S, 1996, J BIOL CHEM, V271, P4209; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; POSPISIL R, 1995, P NATL ACAD SCI USA, V92, P6961, DOI 10.1073/pnas.92.15.6961; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; REAP EA, 1995, J IMMUNOL, V154, P936; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEPPERMAN BL, 1993, AM J PHYSIOL, V265, pG214, DOI 10.1152/ajpgi.1993.265.2.G214; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WADE RS, 1990, CHEM RES TOXICOL, V3, P289, DOI 10.1021/tx00016a002; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WOOD KS, 1987, J BIOL CHEM, V262, P5020; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	73	760	783	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31138	31148		10.1074/jbc.272.49.31138	http://dx.doi.org/10.1074/jbc.272.49.31138			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388267	hybrid			2022-12-25	WOS:000071640800080
J	Chen, Q; Turner, J; Watson, AJM; Dive, C				Chen, Q; Turner, J; Watson, AJM; Dive, C			v-Abl protein tyrosine kinase (PTK) mediated suppression of apoptosis is associated with the up-regulation of Bcl-X-L	ONCOGENE			English	Article						apoptosis; v-Abl tyrosine kinase; Bcl-X-L survival signals	PROGRAMMED CELL-DEATH; HEMATOPOIETIC-CELLS; ACTIVATION; INTERLEUKIN-3; GROWTH; GENE; SURVIVAL; LINE; BAX; PHOSPHORYLATION	We demonstrated previously that the activation of v-Abl protein tyrosine kinase (PTK) in IC.DP murine pre-mast cells resulted in suppression of apoptosis after withdrawal of interleukin 3 (IL-3), that protein kinase C (PKC) translocated to the nucleus 6 h after v-Abl PTK activation and that inhibition of PKC restored apoptosis after IL-3 deprivation in the presence of v-Abl PTK activity. Here we demonstrate that v-Abl PTK activation is followed by an approximately twofold increase in mRNA level of Bcl-X-L by 6 h and a corresponding increase in Bcl-X-L protein level by 24 h. Bcl-x(L) RNA and protein decreased in IL-3 deprived cells in the absence of v-Abl PTK activity. Exposure of cells with v-Abl PTK active to the PKC inhbitor calphostin C (125 ng/ml) prevented the increase in Bcl-x(L) protein and resulted in apoptosis. No changes in Bax or Bcl-2 protein level were noted after IL-3 withdrawal and/or activation of v-Abl PTK. Bak was barely detectable and Bad protein level decreased in cells undergoing apoptosis. The data suggest that suppression of apoptosis by v-Abl PTK in the absence of IL-3 is associated with PKC signalling and the upregulation of Bcl-x(L) in IC.DP cells.	UNIV MANCHESTER, SCH BIOL SCI, MOL PHARMACOL GRP, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV MANCHESTER, DEPT MED, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester; University of Manchester				Dive, Caroline/0000-0002-1726-8850				BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHAPMAN RS, 1994, CANCER RES, V54, P5131; CHAPMAN RS, 1995, MOL PHARMACOL, V48, P334; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen Q, 1997, J CELL SCI, V110, P379; CHUNG SW, 1995, ONCOGENE, V10, P1261; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Dive C, 1992, Semin Cancer Biol, V3, P417; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; EVANS CA, 1995, J CELL SCI, V108, P2591; EVANS CA, 1993, CANCER RES, V53, P1735; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Guan RJ, 1996, ONCOGENE, V12, P2605; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KORSMEYER SJ, 1992, BLOOD, V80, P879; Maniatis T, 1989, MOL CLONING; MAY WS, 1994, J BIOL CHEM, V269, P26865; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shuai K, 1996, ONCOGENE, V13, P247; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	43	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2249	2254		10.1038/sj.onc.1201371	http://dx.doi.org/10.1038/sj.onc.1201371			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393984				2022-12-25	WOS:A1997YD01900014
J	Gulliford, TJ; Huang, GC; Ouyang, XM; Epstein, RJ				Gulliford, TJ; Huang, GC; Ouyang, XM; Epstein, RJ			Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2	ONCOGENE			English	Article						ErbB2; transforming growth factor-alpha; EGF; oligomerization; downregulation	AUTOPHOSPHORYLATION SITES; BIOLOGICAL-ACTIVITIES; KINASE-ACTIVITY; A431 CELLS; NEU; ACTIVATION; EXPRESSION; C-ERBB-2; IDENTIFICATION; ANTIBODIES	The epidermal growth factor receptor (EGFR) is activated by a variety of ligands including EGF and transforming growth factor-alpha (TGF alpha), whereas no ligand for the homologous ErbB2 oncoprotein has yet been identified. Here we use both an ErbB2 phosphoantibody (aPY(1222)) and an activation-specific EGFR antibody to show that low concentrations of EGF induce more efficient tyrosine phosphorylation of ErbB2 in A431 cells than does equimolar TGF alpha, while EGFR is more potently activated by TGF alpha. Co-precipitation studies confirm that heterodimerization of activated EGFR and transphosphorylated ErbB2 is readily induced by EGF but not TGF alpha. ECFR downregulation is also more efficiently induced by EGF, suggesting that ligand-dependent modification of ErbB2 may be required to terminate EGFR signalling in cells expressing both receptor types. These findings indicate that EGF and TGF alpha differ in their abilities to induce tyrosine phosphorylation and heterodimerization of ErbB2, and raise the possibility that ErbB2 exerts its oncogenic effect in part by impairing TGF alpha-dependent EGFR downregulation.	UNIV LONDON IMPERIAL COLL SCI & TECHNOL, SCH MED, DIV MED, LONDON W6 8RF, ENGLAND; CHARING CROSS HOSP, CANC RES CAMPAIGN LABS, LONDON W6 8RF, ENGLAND	Imperial College London; Imperial College London					PHS HHS [R0169513] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; EPSTEIN RJ, 1995, ONCOGENE, V11, P315; GABELMAN BM, 1992, EXP CELL RES, V201, P113, DOI 10.1016/0014-4827(92)90354-B; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GAN BS, 1987, J PHARMACOL EXP THER, V242, P331; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LEE DC, 1995, PHARMACOL REV, V47, P51; Mellon JK, 1996, BRIT J CANCER, V73, P654, DOI 10.1038/bjc.1996.114; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; Ouyang XM, 1996, J BIOL CHEM, V271, P21786, DOI 10.1074/jbc.271.36.21786; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STROMBERG K, 1992, CANCER RES, V52, P341; Taylor ICA, 1995, ONCOGENE, V11, P2619; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; XIE YM, 1995, ONCOGENE, V10, P2409; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	34	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2219	2223		10.1038/sj.onc.1201595	http://dx.doi.org/10.1038/sj.onc.1201595			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393980				2022-12-25	WOS:A1997YD01900010
J	Rao, L; Modha, D; White, E				Rao, L; Modha, D; White, E			The E1B 19K protein associates with lamins in vivo and its proper localization is required for inhibition of apoptosis	ONCOGENE			English	Article						apoptosis; adenovirus E1B 19K; lamins	ADENOVIRUS TUMOR-ANTIGEN; PROGRAMMED CELL-DEATH; FATTY-ACID ACYLATION; BCL-2 HOMOLOG BAK; 19-KILODALTON PROTEIN; INTERMEDIATE FILAMENTS; TRANSFORMED-CELLS; NUCLEAR LAMINA; MEMBRANE; DNA	Expression of the E1B 19K protein is required to inhibit apoptosis induced by E1A during adenovirus infection and transformation. E1B 19K is homologous to Bcl-2 in function and the two proteins also share limited amino acid sequence homology. Consequently, the E1B 19K and Bcl-2 proteins bind to and inhibit the cellular death-inducing proteins Bax, Bak and Nbk/Bik. Both E1B 19K and Bcl-2 localize to membranes of the nucleus and the endoplasmic reticulum. In addition to membrane association, and unlike Bcl-2, the E1B 19K protein is found associated with intermediate filament proteins in the cytoplasm and the nuclear lamina and copurifies with the lamins both during infection and transformation. While a membrane targeting domain at the C-terminus of Bcl-2 ensures its proper localization, the mechanism by which the E1B 19K protein localizes is unknown. Not surprisingly, lamin A fragments were cloned from a yeast two-hybrid screen for E1B 19K-interacting proteins. The interaction was demonstrated in yeast and mammalian cells in vivo and in vitro and was unique and specific to E1B 19K, with no interaction evident between Bcl-2 and lamin A. Mutants of lamin A/C which localized inappropriately in the cytoplasm or nucleus but retained E1B 19K binding, interfered with the nuclear envelope and cytoplasmic membrane targeting of the E1B 19K protein. Improper localization impaired the ability of the E1B 19K protein to inhibit apoptosis. Thus, proper localization of the E1B 19K protein is required for its function and the interaction of the E1B 19K protein with lamin A/C may represent a means for nuclear envelope localization.	CANC INST NEW JERSEY, CTR ADV BIOTECHNOL & MED, PISCATAWAY, NJ 08854 USA; CANC INST NEW JERSEY, DEPT MOL BIOL & BIOCHEM, PISCATAWAY, NJ 08854 USA; RUTGERS STATE UNIV, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick			White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA53370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, R01CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GRAND RJA, 1985, FEBS LETT, V181, P229, DOI 10.1016/0014-5793(85)80265-9; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MCGLADE CJ, 1987, J VIROL, V61, P3227, DOI 10.1128/JVI.61.10.3227-3234.1987; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; NIGG EA, 1993, CELL BIOL, V3, P245; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PERSSON H, 1982, J VIROL, V42, P905, DOI 10.1128/JVI.42.3.905-917.1982; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHLESINGER MJ, 1983, METHOD ENZYMOL, V96, P795; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TARODI B, 1993, INT J ONCOL, V3, P467; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHITE E, 1994, SEMIN VIROL, V5, P341, DOI 10.1006/smvy.1994.1038; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZHANG S, 1992, J VIROL, V66, P2302, DOI 10.1128/JVI.66.4.2302-2309.1992	56	57	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1587	1597		10.1038/sj.onc.1201323	http://dx.doi.org/10.1038/sj.onc.1201323			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380411				2022-12-25	WOS:A1997XX36900010
J	Aoki, K; Taguchi, H; Shindo, Y; Yoshida, M; Ogasahara, K; Yutani, K; Tanaka, N				Aoki, K; Taguchi, H; Shindo, Y; Yoshida, M; Ogasahara, K; Yutani, K; Tanaka, N			Calorimetric observation of a GroEL-protein binding reaction with little contribution of hydrophobic interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; APO-ALPHA-LACTALBUMIN; CHAPERONIN GROEL; PORCINE PEPSIN; ATP; STABILITY; CONSTANTS	Binding of Escherichia coli chaperonin, GroEL, to substrate proteins with non-native structure, reduced alpha-lactalbumin (rLA) and denatured pepsin, were analyzed by isothermal titration calorimetry at various temperatures in the presence of salt (0.2 M KCI). Both proteins bound to GroEL with 1:1 stoichiometry and micromolar affinity at all temperatures tested. However, thermodynamic properties of their binding to GroEL are remarkably different from each other. While heat capacity changes (Delta Cp) of rLA-GroEL binding showed large negative values, -4.19 kJ mol(-1) K-1, that of denatured pepsin-GroEL binding was only -0.2 kJ mol(-1) K-1. These values strongly indicate that the hydrophobic interaction is a major force of rLA-GroEL binding but not so for denatured pepsin-GroEL binding. When salt was omitted hom the solution, the affinity and Delta Cp of the rLA-GroEL binding reaction were not significantly changed whereas denatured pepsin lost affinity to GroEL. Thus, in the non-native protein-GroEL binding reaction, thermodynamic properties, as well as the effect of salt, differ from protein to protein and hydrophobic interaction may not always be a major driving force.	Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 226, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 565, Japan	Tokyo Institute of Technology; Osaka University	Yoshida, M (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, 4259 Nagatsuta,R-1, Yokohama, Kanagawa 226, Japan.		taguchi, hideki/AAM-2663-2021; Taguchi, Hideki/B-6946-2009	taguchi, hideki/0000-0002-6612-9339; Taguchi, Hideki/0000-0002-6612-9339				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRANDTS JF, 1990, AM LAB, V22, P30; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FORMISANO S, 1977, P NATL ACAD SCI USA, V74, P3340, DOI 10.1073/pnas.74.8.3340; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gorovits BM, 1997, J BIOL CHEM, V272, P32; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hoshino M, 1996, J MOL BIOL, V262, P575, DOI 10.1006/jmbi.1996.0536; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; KUWAJIMA K, 1975, J BIOCHEM-TOKYO, V78, P205; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; LIN XL, 1993, PROTEIN SCI, V2, P1383, DOI 10.1002/pro.5560020903; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MAKINO Y, 1993, FEBS LETT, V336, P363, DOI 10.1016/0014-5793(93)80838-L; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; MURAI N, 1995, J BIOL CHEM, V270, P19957, DOI 10.1074/jbc.270.34.19957; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; PRIVALOV PL, 1981, J MOL BIOL, V152, P455; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YUTANI K, 1992, J MOL BIOL, V228, P347, DOI 10.1016/0022-2836(92)90824-4; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	31	61	62	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32158	32162		10.1074/jbc.272.51.32158	http://dx.doi.org/10.1074/jbc.272.51.32158			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405415	hybrid			2022-12-25	WOS:000071108000034
J	Blount, P; Schroeder, MJ; Kung, C				Blount, P; Schroeder, MJ; Kung, C			Mutations in a bacterial mechanosensitive channel change the cellular response to osmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PATCH-CLAMP; ION CHANNELS; FUNCTIONAL RECONSTITUTION; QUANTITATIVE MEASUREMENTS; ACTIVATED CHANNELS; BACILLUS-SUBTILIS; GIANT LIPOSOMES; MEMBRANE; TRANSPORT	MscL is a channel found in bacterial plasma membranes that opens a large pore in response to mechanical stress. Here we demonstrate that some mutations within this channel protein (K31D and K31E) evoke a cellular phenotype in which the growth rate is severely depressed. Increasing the osmolarity of the growth medium partially rescues this "slowed growth" phenotype and decreases an abnormal cytosolic potassium loss observed in cells expressing the mutants. In addition, upon sudden decrease in osmolarity (osmotic downshock) more cytoplasmic potassium is released from cells expressing the mutants than cells expressing wild-type MscL. After osmotic downshock, all cells remained viable; hence, the differences in potassium efflux observed are not due to cell lysis but instead appear to be an exaggeration of the normal response to this sudden change in environmental osmolarity. Patch clamp studies in native bacterial membranes substantiate the hypothesis that these mutant channels are more sensitive to mechanical stresses, especially at voltages approaching those estimated for bacterial membrane potentials. These data are consistent with a crucial role for MscL in the adaptation to large osmotic downshock and suggest that if the normally tight regulation of MscL gating is disrupted, cell growth can be severely inhibited.	Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Blount, P (corresponding author), Univ Wisconsin, Dept Mol Biol, 1525 Linden Dr, Madison, WI 53706 USA.	plblount@facstaff.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047856] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47856] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1981, BIOCHEM J, V200, P573, DOI 10.1042/bj2000573; BERRIER C, 1992, FEBS LETT, V306, P251, DOI 10.1016/0014-5793(92)81011-A; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; Blount P, 1996, BIOL CELL, V87, P1, DOI 10.1016/S0248-4900(97)89832-2; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Booth I. R., 1996, HDB BIOL PHYS, V2, P693; BOOTH IR, 1980, BIOCHEM J, V188, P467, DOI 10.1042/bj1880467; BRITTEN RJ, 1962, BACTERIOL REV, V26, P292, DOI 10.1128/MMBR.26.3.292-335.1962; CUI C, 1995, J MEMBRANE BIOL, V144, P31; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; FELLE H, 1980, BIOCHEMISTRY-US, V19, P3585, DOI 10.1021/bi00556a026; FORST S, 1988, J BACTERIOL, V170, P5080, DOI 10.1128/jb.170.11.5080-5085.1988; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamill OP, 1996, PHARMACOL REV, V48, P231; HAMILL OP, 1994, TRENDS NEUROSCI, V17, P439, DOI 10.1016/0166-2236(94)90125-2; Harold F. M., 1986, VITAL FORCE STUDY BI; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Jackson M.B., 1993, THERMODYNAMICS MEMBR, P327; KOO SP, 1991, J GEN MICROBIOL, V137, P2617, DOI 10.1099/00221287-137-11-2617; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MARTINAC B, 1992, ADV COMP ENV PHYSL, V10, P3; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MITCHELL P, 1979, EUR J BIOCHEM, V95, P1, DOI 10.1111/j.1432-1033.1979.tb12934.x; RHOADS DB, 1978, J GEN PHYSIOL, V72, P283, DOI 10.1085/jgp.72.3.283; RUTHE HJ, 1985, BIOCHIM BIOPHYS ACTA, V819, P105, DOI 10.1016/0005-2736(85)90200-7; SACHS F, 1992, SENSORY TRANSDUCTION, P242; SCHLEYER M, 1993, ARCH MICROBIOL, V160, P424, DOI 10.1007/BF00245302; Sukharev Sergei I., 1994, Methods (Orlando), V6, P51, DOI 10.1006/meth.1994.1007; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SZABO I, 1992, BIOCHIM BIOPHYS ACTA, V1112, P29, DOI 10.1016/0005-2736(92)90250-P; SZABO I, 1993, J MEMBRANE BIOL, V131, P203, DOI 10.1007/BF02260109; TSAPIS A, 1977, BIOCHIM BIOPHYS ACTA, V469, P1, DOI 10.1016/0005-2736(77)90320-0; WALSBY AE, 1986, FEMS MICROBIOL LETT, V39, P45; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X; ZORATTI M, 1990, BIOCHEM BIOPH RES CO, V168, P443, DOI 10.1016/0006-291X(90)92341-V	43	95	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32150	32157		10.1074/jbc.272.51.32150	http://dx.doi.org/10.1074/jbc.272.51.32150			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405414	hybrid			2022-12-25	WOS:000071108000033
J	Joe, YA; Wolff, EC; Lee, YB; Park, MH				Joe, YA; Wolff, EC; Lee, YB; Park, MH			Enzyme-substrate intermediate at a specific lysine residue is required for deoxyhypusine synthesis - The role of Lys(329) in human deoxyhypusine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; HYPUSINE DEPLETION; MOLECULAR-CLONING; CELL VIABILITY; INHIBITION; GENE; INITIATION; CDNA; IDENTIFICATION	Deoxyhypusine synthase catalyzes the first step in the post-translational synthesis of hypusine [N-epsilon-(4-amino-2-hydroxybutyl)lysine] in eukaryotic translation initiation factor 5A. We recently reported biochemical evidence for a covalent enzyme-substrate intermediate involving a specific lysine residue (Lys(329)) in human deoxyhypusine synthase (Wolff, E. C., Polk, J. E., and Park, M. H. (1997) J. Biol. Chem. 272, 15865-15871), In an effort to evaluate the role of this enzyme-substrate intermediate in catalysis, we carried out site-directed mutagenesis (Lys to Arg and/or Ala) of the conserved lysine residues in human deoxyhypusine synthase. A drastic reduction in enzyme intermediate formation and enzymatic activities was observed with mutant proteins with substitution at Lys(287) but, not with those with mutations at residues 141, 156, 205, 212, 226, 251, or 338. Lys to Ala or Lys to Arg substitution at Lys(329) totally abolished covalent enzyme-substrate intermediate formation and deoxyhypusine synthesis activity, indicating that Lys(329) is the unique site for the enzyme intermediate and that it is absolutely required for deoxyhypusine synthesis in the eukaryotic translation initiation factor 5A precursor. The K329A mutant showed spermidine cleavage activity (similar to 6% of the wild type enzyme) suggesting that in contrast to deoxyhypusine synthesis, spermidine cleavage can occur without enzyme intermediate formation.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Park, MH (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, Bldg 30,Rm 211, Bethesda, MD 20892 USA.							ADACHI O, 1966, AGR BIOL CHEM TOKYO, V30, P1202, DOI 10.1080/00021369.1966.10858750; BEVEC D, 1996, FEBS LETT, V378, P15; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; KANG KR, 1995, J BIOL CHEM, V270, P18408, DOI 10.1074/jbc.270.31.18408; KLIER H, 1995, FEBS LETT, V364, P807; MANN PJG, 1955, BIOCHEM J, V61, P89, DOI 10.1042/bj0610089; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; SAFER B, 1989, EUR J BIOCHEM, V186, P1, DOI 10.1111/j.1432-1033.1989.tb15169.x; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SMIUTH TA, 1988, ADV EXP MED BIOL, V250, P573; TABOR CW, 1970, J BIOL CHEM, V245, P5424; TAO Y, 1995, J BIOL CHEM, V270, P383, DOI 10.1074/jbc.270.1.383; TAO Y, 1995, J BIOL CHEM, V270, P23984, DOI 10.1074/jbc.270.41.23984; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660; Wolff EC, 1997, J BIOL CHEM, V272, P15865, DOI 10.1074/jbc.272.25.15865; Yan YP, 1996, BIOCHEM J, V315, P429, DOI 10.1042/bj3150429	27	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32679	32685		10.1074/jbc.272.51.32679	http://dx.doi.org/10.1074/jbc.272.51.32679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405486	hybrid			2022-12-25	WOS:000071108000105
J	Nibbs, RJB; Wylie, SM; Yang, JY; Landau, NR; Graham, GJ				Nibbs, RJB; Wylie, SM; Yang, JY; Landau, NR; Graham, GJ			Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CELL-LINE; CYTOKINE FAMILY; HIV-1 ENTRY; MIP-1-ALPHA; LIGAND; LESTR/FUSIN; MIP-1-BETA	Members of the chemokine family of chemotactic peptides interact with their target cells through heptahelical cell surface receptors, An understanding of the biochemistry and expression patterns of these receptors is therefore central to our overall understanding of the roles played by chemokines in both physiological and pathological processes, To date, eight receptors for the beta-chemokine subfamily have been described, We have recently cloned a novel murine beta-chemokine receptor and report here the identification and characterization of a highly homologous human gene termed human D6 (hD6). This is a promiscuous beta-chemokine receptor and appears to be able to bind the majority of members of the beta-chemokine family. It is, however, specific for this family and shows no detectable affinity for members of the alpha-chemokine or the C or CXXXC chemokines, Unlike the majority of other chemokine receptors, human D6 does not appear to be able to flux calcium following ligand binding, thus it is currently not clear if this novel receptor is indeed a signaling receptor. Human D6 is expressed in a range of tissues including hemopoietic cells although it appears not to be ubiquitously expressed in hemopoietic cells. Human D6, unlike some other beta-chemokine receptors, appears not to be able to function as an entry co-factor for human immunodeficiency virus type 1 (HIV)1 on CD4-expressing cells.	Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Beatson Institute; Rockefeller University	Graham, GJ (corresponding author), Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Graham, Gerard/D-1240-2009	Graham, Gerard/0000-0002-7801-204X; Nibbs, Robert/0000-0002-8150-0044				AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dorner B, 1997, J BIOL CHEM, V272, P8817, DOI 10.1074/jbc.272.13.8817; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; GAO JL, 1994, J BIOL CHEM, V269, P28539; Graham GJ, 1996, EMBO J, V15, P6506, DOI 10.1002/j.1460-2075.1996.tb01041.x; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; GRAHAM GJ, 1993, CELL GROWTH DIFFER, V4, P137; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1994, J BIOL CHEM, V269, P17730; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; LIU R, 1996, CELL, V86, P867; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Zhao-Hai Lu, 1995, Journal of Biological Chemistry, V270, P26239	39	193	206	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32078	32083		10.1074/jbc.272.51.32078	http://dx.doi.org/10.1074/jbc.272.51.32078			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405404	hybrid			2022-12-25	WOS:000071108000023
J	Wigle, JT; Demchyshyn, L; Pratt, MAC; Staines, WA; Salih, M; Tuana, BS				Wigle, JT; Demchyshyn, L; Pratt, MAC; Staines, WA; Salih, M; Tuana, BS			Molecular cloning, expression, and chromosomal assignment of sarcolemmal-associated proteins - A family of acidic amphipathic alpha-helical proteins associated with the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU HYBRIDIZATION; CALCIUM CHANNELS; LEUCINE ZIPPER; RECEPTOR GENE; COILED-COIL; CARCINOMA; MUSCLE; HETERODIMER; MECHANISM; REGIONS	Two overlapping cDNAs encoding a novel sarcolemmal associated protein (SLAP) were isolated from a cardiac cDNA expression library by immunoscreening with anti-sarcolemmal antibodies, Further characterization of these clones showed that they belonged to a family of related cDNAs that potentially encode polypeptides of 37, 46, and 74 kDa designated SLAP1, SLAP2, and SLAP3, respectively, The SLAP3 transcript was ubiquitously expressed, whereas SLAP1 and SLAP2 transcripts were predominantly expressed in cardiac, soleus, and smooth muscle, SLAP was encoded by a single gene that mapped to chromosome 3p14.3-21.2, and the various transcripts are likely generated by alternative splicing, The primary structure of SLAP predicted that it would have large regions of coiled-coil structure including an 11-heptad acidic amphipathic alpha-helical segment, The carboxyl-terminal region of the SLAP proteins was predicted to have a transmembrane domain, although there was no discernible signal sequence, SLAPs could only be solubilized from cardiac membrane with detergents suggesting that they were integral membrane proteins, Subcellular distribution studies showed that MYC epitope-tagged SLAP localized to regions of juxtaposition between neighboring cell membranes although an intracellular pool of the protein was also present in cells undergoing apparent cleavage, Immunohistochemical localization of SLAP in cardiac muscle revealed that SLAP associated with the sarcolemma and also displayed a reticular pattern of staining that resembled the transverse tubules and the sarcoplasmic reticulum, The SLAPs define a new family of tail-anchored membrane proteins that exhibit tissue-specific expression and are uniquely situated to serve a variety of roles through their coiled-coil motifs.	Univ Ottawa, Dept Pharmacol, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Anat & Neurobiol, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa	Tuana, BS (corresponding author), Univ Ottawa, Dept Pharmacol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.		Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684; Staines, Willim/0000-0002-7288-5026				Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; EVAN GI, 1985, MOL CELL BIOL, V5, P387; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HIBI K, 1992, ONCOGENE, V7, P445; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LI ZP, 1993, J BIOL CHEM, V268, P11489; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Meng HP, 1996, J BIOL CHEM, V271, P12364, DOI 10.1074/jbc.271.21.12364; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1991, SCIENCE, V254, P646; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUANA BS, 1987, MOL CELL BIOCHEM, V76, P173; TUANA BS, 1991, BIOCHIM BIOPHYS ACTA, V1091, P236, DOI 10.1016/0167-4889(91)90067-8; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	50	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32384	32394		10.1074/jbc.272.51.32384	http://dx.doi.org/10.1074/jbc.272.51.32384			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405447	hybrid			2022-12-25	WOS:000071108000066
J	Kinoshita, A; Greenwel, P; Tanaka, S; DiLiberto, M; Yoshioka, H; Ramirez, F				Kinoshita, A; Greenwel, P; Tanaka, S; DiLiberto, M; Yoshioka, H; Ramirez, F			A transcription activator with restricted tissue distribution regulates cell-specific expression of alpha 1(XI) collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TRANSGENIC MICE; FUNCTIONAL-ANALYSIS; GENE-EXPRESSION; PROMOTER; BINDS; IDENTIFICATION; SEQUENCE; ELEMENTS; PROTEIN	Different regulatory programs are likely to control expression of the alpha 1(XI) collagen (COL11A1) gene in cartilaginous and non-cartilaginous tissues and in coordination with different collagen genes Here, we report the identification of a cis-acting element that is required for constitutive and tissue-specific activity of the proximal COL11A1 promoter, The element binds an apparently novel activator whose expression is restricted mostly, but not exclusively, to cells of mesenchymal origin, Transient transfection experiments using wild-type and mutant constructs demonstrated the critical contribution of a 45-base pair upstream element (FP9) to promoter activity, The same functional tests and DNA binding assays narrowed down the critical portion of FP9 to a 20-base pair sequence, which consists of an imperfect palindrome with strong homology to the GATA consensus motif. Despite being able to bind GATA proteins in vitro, FP9 is actually recognized by a distinct similar to 100-kDa polypeptide (FP9C) probably belonging to the zinc-finger family of transcription factors. FP9C binding was mostly identified in nuclei from cells of mesenchymal origin, including those actively engaged in COL11A1 transcription, A positive correlation was also established between the level of FP9C binding and the degree of cell differentiation in vitro, Thus, FP9C represents an unusual example of tissue-specific and differentiation-related transcription factor with overlapping expression in hard and soft connective tissues.	CUNY MT SINAI SCH MED,BROOKDALE CTR DEV & MOL BIOL,NEW YORK,NY 10029; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; OKAYAMA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,OKAYAMA 565,JAPAN	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Okayama University					PHS HHS [R37-38648] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BOAST S, 1990, J BIOL CHEM, V265, P13351; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; Hay ED., 1991, CELL BIOL EXTRACELLU, P7; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LACKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1421; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; ROSSERT JA, 1995, J CELL BIOL, V123, P1421; Sambrook J., 1983, MOL CLONING LAB MANU; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TRUTER S, 1992, J BIOL CHEM, V267, P25389; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; YOSHIOKA H, 1995, J BIOL CHEM, V270, P418, DOI 10.1074/jbc.270.1.418	36	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31777	31784		10.1074/jbc.272.50.31777	http://dx.doi.org/10.1074/jbc.272.50.31777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395523	hybrid, Green Published			2022-12-25	WOS:A1997YL41900082
J	Soker, S; GollamudiPayne, S; Fidder, H; Charmahelli, H; Klagsbrun, M				Soker, S; GollamudiPayne, S; Fidder, H; Charmahelli, H; Klagsbrun, M			Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF(165)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-LIKE MOLECULES; FACTOR VEGF; TYROSINE KINASE; TUMOR-GROWTH; SIGNAL-TRANSDUCTION; PERMEABILITY FACTOR; RECEPTOR SYSTEM; BINDING-SITES; FACTOR FAMILY; ANGIOGENESIS	Vascular endothelial growth factor (VEGF) is a potent mitogen for endothelial cells (EC) in vitro and a major regulator of angiogenesis in vivo. VEGF(121) and VEGF(165) are the most abundant of the five known VEGF isoforms. The structural difference between these two is the presence in VEGF(165) of 44 amino acids encoded by exon 7 lacking in VEGF(121). It was previously shown that VEGF(165) and VEGF(121) both bind to KDR/Flk-1 and Flt-1 but that VEGF(165) binds in addition to a novel receptor (Soker, S., Bidder, Il., Neufeld, G., and Klagsbrun, M. (1996) J. Biol. Chem. 271, 5761-5767). The binding of VEGF(165) to this VEGF(165)-specific receptor (VEGF(165)R) is mediated by the exon 7-encoded domain. To investigate the biological role of this domain further, a glutathione S-transferase fusion protein corresponding to the VEQF(165) exon 7-encoded domain was prepared. The fusion protein inhibited binding of I-125-VEGF(165) to VEGF(165)R on human umbilical vein-derived EC (HUVEC) and MDA-MB-231 tumor cells. The fusion protein also inhibited significantly I-125-VEGF(165) binding to KDR/Flk-1 on HUVEC but not on porcine EC which express KDR/Flk-1 alone. VEGF(165) had a 2-fold higher mitogenic activity for HUVEC than did VEGF(121). The exon 7 fusion protein inhibited VEGF(165)-induced HUVEC proliferation by 60% to about the level stimulated by VEGF(121). Unexpectedly, the fusion protein also inhibited HUVEC proliferation in response to VEGF(121). Deletion analysis revealed that a core inhibitory domain exists within the C-terminal 23-amino acid portion of the exon 7-encoded domain and that a cysteine residue at position 22 in exon 7 is critical for inhibition. It was concluded that the exon 7-encoded domain of VEGF(165) enhances its mitogenic activity for HUVEC by interacting with VEGF(165)R and modulating KDR/Flk-1-mediated mitogenicity indirectly and that exon 7-derived peptides may be useful VEGF antagonists in ansogenesis-associated diseases.	CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOINT CTR RADIOTHERAPY,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392, R56CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER; NCI NIH HHS [CA37392] Funding Source: Medline; NIGMS NIH HHS [GM47397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BATTEGAY EJ, 1995, J MOL MED, V73, P333; BRIER G, 1992, DEVELOPMENT, V114, P521; CLAFFEY KP, 1995, BBA-PROTEIN STRUCT M, V1246, P1, DOI 10.1016/0167-4838(94)00144-6; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PLATE KH, 1993, CANCER RES, V53, P5822; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; SAKAMOTO N, 1991, CANCER RES, V51, P903; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Strawn LM, 1996, CANCER RES, V56, P3540; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566	54	164	190	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31582	31588		10.1074/jbc.272.50.31582	http://dx.doi.org/10.1074/jbc.272.50.31582			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395496	hybrid			2022-12-25	WOS:A1997YL41900055
J	de Rocquigny, H; Petitjean, P; Tanchou, V; Decimo, D; Drouot, L; Delaunay, T; Darlix, JL; Roques, BP				de Rocquigny, H; Petitjean, P; Tanchou, V; Decimo, D; Drouot, L; Delaunay, T; Darlix, JL; Roques, BP			The zinc fingers of HIV nucleocapsid protein NCp7 direct interactions with the viral regulatory protein Vpr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; CELL-CYCLE; NUCLEAR-LOCALIZATION; VIRION INCORPORATION; ANNEALING ACTIVITIES; H-1-NMR STRUCTURE; GENE-PRODUCT; IN-VITRO; BINDING	The 96-amino acid protein Vpr functions as a regulator of cellular processes involved in human immunodeficiency virus, type 1 (HIV-1) life cycle, in particular by interrupting cells division in the G(2) phase, Incorporation of Vpr in the virion was reported to be mediated by the C-terminal domain of the pr55(Gag) polyprotein precursor, which includes NCp7, a protein involved in the genomic RNA encapsidation and p6, a protein required for particle budding, To precisely define the Gag and Vpr sequences involved in this protein-protein interaction, NCp7, p6, and Vpr as well as a series of derived peptides were synthesized using Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry, Binding assays were carried out by Far Western experiments and by competition studies using (52-96)Vpr immobilized onto agarose beads, The results show that interaction between NCp7 and Vpr occurs in vitro by a recognition mechanism requiring the zinc fingers of NCp7 and the last 16 amino acids of Vpr, Moreover, NCp10, the equivalent of NCp7 in Moloney murine leukemia virus but not polysine inhibits Vpr-NCp7 complexation, Interestingly enough, Vpr was found to interact with Gag, NCp15, and NCp7 but not with mature p6 in vitro. In vive mutations in NCp7 zinc fingers in an HIV-1 molecular clone led to viruses with important defects in Vpr encapsidation. Together, these results suggest that NCp7 cooperates with p6 to induce Vpr encapsidation in HIV-1 mature particles, The NCp7-Vpr complex could also be important for interaction of Vpr with cellular proteins involved in cell division.	UFR Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, CNRS, URA D1500,INSERM,U266, F-75270 Paris 06, France; Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon, France; Inst Sante Rech Med, F-69364 Lyon, France; INRA, Dept Virol & Immunol Mol, F-78352 Jouy En Josas, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); INRAE; UDICE-French Research Universities; Universite Paris Saclay	Roques, BP (corresponding author), UFR Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, CNRS, URA D1500,INSERM,U266, 4 Ave Observ, F-75270 Paris 06, France.		LUC, DARLIX JEAN/AAE-9268-2020	Decimo, Didier/0000-0002-0390-1205				Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; Beissinger M, 1996, EUR J BIOCHEM, V237, P383, DOI 10.1111/j.1432-1033.1996.0383k.x; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; CARRIERE C, 1995, J VIROL, V69, P2366; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; Colgan J, 1996, J VIROL, V70, P4299, DOI 10.1128/JVI.70.7.4299-4310.1996; CORNILLE F, 1990, INT J PEPT PROT RES, V36, P551; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEMENE H, 1994, J BIOMOL NMR, V4, P153, DOI 10.1007/BF00175244; DEMENE H, 1994, BIOCHEMISTRY-US, V33, P11707, DOI 10.1021/bi00205a006; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DONG CZ, 1997, IN PRESS J PEPTIDES, V49; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; GORELICK RJ, 1996, RETROVIRUSES 1996S R, P356; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; GRASMASSE H, 1990, INT J PEPT PROT RES, V36, P219; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kondo E, 1996, J VIROL, V70, P159, DOI 10.1128/JVI.70.1.159-164.1996; KONDO E, 1995, J VIROL, V69, P2759, DOI 10.1128/JVI.69.5.2759-2764.1995; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; LAVALLEE C, 1994, J VIROL, V68, P1926; Li MS, 1996, BIOCHEM BIOPH RES CO, V218, P352, DOI 10.1006/bbrc.1996.0061; LIM THY, 1997, FEBS LETT, V401, P197; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; LU YL, 1995, J VIROL, V69, P6873, DOI 10.1128/JVI.69.11.6873-6879.1995; MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794; Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d; MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; ROQUES BP, IN PRESS BIOCHIMIE P; Sato A, 1996, VIROLOGY, V220, P208, DOI 10.1006/viro.1996.0302; Serio D, 1997, P NATL ACAD SCI USA, V94, P3346, DOI 10.1073/pnas.94.7.3346; SOUTH TL, 1993, PROTEIN SCI, V2, P3; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; TANCHOU V, 1994, AIDS RES HUM RETROV, V10, P983, DOI 10.1089/aid.1994.10.983; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; ZHANG YQ, 1995, J VIROL, V69, P5716, DOI 10.1128/JVI.69.9.5716-5722.1995; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131	53	65	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30753	30759		10.1074/jbc.272.49.30753	http://dx.doi.org/10.1074/jbc.272.49.30753			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388214	hybrid			2022-12-25	WOS:000071640800027
J	Gnatt, A; Fu, JH; Kornberg, RD				Gnatt, A; Fu, JH; Kornberg, RD			Formation and crystallization of yeast RNA polymerase II elongation complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION; ESCHERICHIA-COLI; TERNARY COMPLEXES; INITIATION; DNA; PROTEIN; PURIFICATION; CLEAVAGE; TEMPLATE; INVITRO	Minimal templates were devised for the efficient generation of yeast RNA polymerase II transcription elongation complexes. A 33-base pair DNA with a 15-residue dC tail at one 3'-end supported the formation of a complex containing the polymerase paused at nucleotide 11 of the duplex region and an RNA of 14-16 residues. The same template could yield an arrested complex with the enzyme at nucleotide 13-15 and RNA of 15-17 residues. These complexes were stable for at least a week under various conditions and could be resolved by gel electrophoresis or purified by ion exchange chromatography. The purified paused complex formed crystals capable of x-ray diffraction to 3.5 Angstrom resolution. The complex remained active in the crystal and, in the presence of nucleoside triphosphates, could efficiently extend the transcript in situ.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.				NCI NIH HHS [5T32CA09151] Funding Source: Medline; NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM49985] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P899; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; DUAN RD, 1995, SCIENCE, V269, P1402; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1994, NAT STRUCT BIOL, V1, P195, DOI 10.1038/nsb0394-195; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GU WG, 1993, J BIOL CHEM, V268, P25604; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; Maniatis T., 1982, MOL CLONING LAB MANU; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; REINBERG D, 1987, J BIOL CHEM, V262, P3322; REINES D, 1989, J BIOL CHEM, V264, P10799; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RODGERS DW, 1994, STRUCTURE, V2, P1135, DOI 10.1016/S0969-2126(94)00116-2; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; Wang DG, 1997, J BIOL CHEM, V272, P5989, DOI 10.1074/jbc.272.9.5989; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	38	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30799	30805		10.1074/jbc.272.49.30799	http://dx.doi.org/10.1074/jbc.272.49.30799			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388221	hybrid			2022-12-25	WOS:000071640800034
J	Zhang, P; Liu, B; Kang, SW; Seo, MS; Rhee, SG; Obeid, LM				Zhang, P; Liu, B; Kang, SW; Seo, MS; Rhee, SG; Obeid, LM			Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; SACCHAROMYCES-CEREVISIAE; CELL-DEATH; FACTOR ADF; GENE; INDUCTION; REDUCTASE; CANCER; YEAST; LOCALIZATION	Thioredoxin peroxidase (TPx) is a member of a newly discovered family of proteins that are conserved from yeast to mammals and to which natural killer enhancing factor belongs. These proteins are antioxidants that function as peroxidases only when coupled to a sulfhydryl reducing system, The physiological function of TPx in cells is not yet known, Here we demonstrate that when the human TPx II, a member of this family, is stably overexpressed in Molt-4 leukemia cells, it protects from apoptosis induced by serum deprivation, ceramide, or etoposide. TPx II, like Bcl-2, is able to inhibit release of cytochrome c from mitochondria to cytosol, and it inhibits lipid peroxidation in cells, TPx II, unlike Bcl-2, could prevent hydrogen peroxide accumulation in cells, suggesting that it functions upstream of Bcl-2 in the protection from apoptosis and may be implicated as an endogenous regulator of apoptosis.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Vet Affairs Geriatr Res Educ & Clin Ctr, Durham, NC 27710 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	Duke University; Duke University; Duke University; Geriatric Research Education & Clinical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Obeid, LM (corresponding author), Duke Univ, Med Ctr, Dept Med, Box3345, Durham, NC 27710 USA.			obeid, lina/0000-0002-0734-0847	NIA NIH HHS [1R29-AG-12467] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG012467] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAKER MS, 1989, MED HYPOTHESES, V29, P187, DOI 10.1016/0306-9877(89)90193-X; BANKSON DD, 1993, CLIN LAB MED, V13, P463, DOI 10.1016/S0272-2712(18)30449-9; BREDESEN DE, 1996, NEUROLOGY S, V47, P38; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Dobmeyer TS, 1997, FREE RADICAL BIO MED, V22, P775, DOI 10.1016/S0891-5849(96)00403-0; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; GASDASKA PY, 1994, BBA-GENE STRUCT EXPR, V1218, P292, DOI 10.1016/0167-4781(94)90180-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JENNER P, 1996, NEUROLOGY S3, V47, P161; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MATSUDA M, 1991, J IMMUNOL, V147, P3837; Othmane Kamel Ben, 1992, Nature Genetics, V2, P315; PAHL P, 1995, GENOMICS, V26, P602, DOI 10.1016/0888-7543(95)80183-M; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SATCH T, 1996, J BIOCHEM-TOKYO, V120, P540; SHAU HG, 1994, IMMUNOGENETICS, V40, P129; SHAU HY, 1993, CELL IMMUNOL, V147, P1, DOI 10.1006/cimm.1993.1043; SHAU HY, 1994, BIOCHEM BIOPH RES CO, V199, P83, DOI 10.1006/bbrc.1994.1197; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Slater AFG, 1995, TOXICOL LETT, V82-3, P149, DOI 10.1016/0378-4274(95)03474-9; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STADTMAN ER, 1993, TOXICOL IND HEALTH, V9, P187, DOI 10.1177/0748233793009001-213; Wang JX, 1997, BLOOD, V89, P2480, DOI 10.1182/blood.V89.7.2480; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	41	331	339	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30615	30618		10.1074/jbc.272.49.30615	http://dx.doi.org/10.1074/jbc.272.49.30615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388194	hybrid			2022-12-25	WOS:000071640800007
J	Kovalchuk, AL; Muller, JR; Janz, S				Kovalchuk, AL; Muller, JR; Janz, S			Deletional remodeling of c-myc-deregulating chromosomal translocations	ONCOGENE			English	Article						BALB/c plasmacytomas; chromosomal translocation; deregulation of c-myc; isotype switching	IMMUNOGLOBULIN HEAVY-CHAIN; CLASS SWITCH RECOMBINATION; MURINE PLASMACYTOMA; ABERRANT REARRANGEMENT; ENHANCER ELEMENT; IGH 3'-ENHANCER; B-CELLS; REGION; LOCUS; GENE	Evidence is presented for the existence of a novel remodeling-by-deletion mechanism that alters the fine structure of c-myc-deregulating chromosomal translocations in t(12;15)-positive BALB/c plasmacytomas. DNA sequence analysis of the t(12;15) in five primary tumors revealed the co-existence of precursor cells harboring genetic recombinations between the immunoglobulin heavy-chain mu locus (Igh mu) and c-myc with clonally related progenitors containing rearrangements between the immunoglobulin heavy-chain alpha locus (Igh alpha) and c-myc. Clonal relatedness was based upon unique junction fragments between the snitch region of Igh mu and c-myc. S mu/c-myc junctions are thus useful clonotypic markers for monitoring the conversion of Igh mu/c-myc-positive tumor precursor clones into Igh alpha/c-myc-positive plasmacytomas. Aberrant isotype switch recombination appears to be the most likely mechanism effecting this conversion event (other possibilities are discussed) which may help to explain the preferred usage of the Igh alpha locus in recombinations with c-myc in t(12;15)-positive plasma cell tumors in BALB/c mice.	NCI,GENET LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Kovalchuk, Alexander/0000-0003-2761-0442				Akasaka T, 1996, BLOOD, V88, P985; Arulampalam V, 1995, MOL IMMUNOL, V32, P1369, DOI 10.1016/0161-5890(95)00102-6; BARD JA, 1995, J IMMUNOL, V154, P201; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROSSEN PE, 1993, GENE CHROMOSOME CANC, V8, P60, DOI 10.1002/gcc.2870080110; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DUNNICK W, 1989, MOL CELL BIOL, V9, P1850, DOI 10.1128/MCB.9.5.1850; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; ELENICH LA, 1991, NUCLEIC ACIDS RES, V19, P396; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GREENBERG R, 1982, NUCLEIC ACIDS RES, V10, P7751, DOI 10.1093/nar/10.23.7751; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; JANZ S, 1993, P NATL ACAD SCI USA, V90, P7361, DOI 10.1073/pnas.90.15.7361; KOTTMANN AH, 1994, EUR J IMMUNOL, V24, P817, DOI 10.1002/eji.1830240407; Kovalchuk AL, 1996, IMMUNOGENETICS, V44, P151, DOI 10.1007/s002510050104; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MATTHIAS P, 1993, MOL CELL BIOL, V13, P1547, DOI 10.1128/MCB.13.3.1547; Mautner J, 1996, ONCOGENE, V12, P1299; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; Michaelson JS, 1996, J IMMUNOL, V156, P2828; MICHAELSON JS, 1995, NUCLEIC ACIDS RES, V23, P975, DOI 10.1093/nar/23.6.975; MORSE HC, 1976, J IMMUNOL, V117, P541; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; MULLER JR, 1995, CANCER RES, V55, P5012; MULLER JR, 1994, P NATL ACAD SCI USA, V91, P12066, DOI 10.1073/pnas.91.25.12066; OHNO S, 1989, ONCOGENE, V4, P1513; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; PEAR WS, 1988, ONCOGENE, V2, P499; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; POTTER M, 1983, J NATL CANCER I, V71, P391; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; POTTER M, 1994, CANCER RES, V54, P969; RADBRUCH A, 1986, IMMUNOL REV, V89, P69, DOI 10.1111/j.1600-065X.1986.tb01473.x; SIGURDARDOTTIR D, 1995, J IMMUNOL, V154, P2217; Singh M, 1996, P NATL ACAD SCI USA, V93, P4392, DOI 10.1073/pnas.93.9.4392; VANNESS BG, 1983, NATURE, V301, P425, DOI 10.1038/301425a0; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WINTER E, 1987, EMBO J, V6, P1663, DOI 10.1002/j.1460-2075.1987.tb02415.x; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; ZELENETZ AD, 1993, GENE CHROMOSOME CANC, V6, P140, DOI 10.1002/gcc.2870060303	44	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2369	2377		10.1038/sj.onc.1201409	http://dx.doi.org/10.1038/sj.onc.1201409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393881				2022-12-25	WOS:A1997YE15700011
J	Li, M; Pullano, R; Yang, HL; Lee, HK; Miyamoto, NG; Filmus, J; Buick, RN				Li, M; Pullano, R; Yang, HL; Lee, HK; Miyamoto, NG; Filmus, J; Buick, RN			Transcriptional regulation of OCI-5/glypican 3: Elongation control of confluence-dependent induction	ONCOGENE			English	Article						proteoglycan; SGBS; intestine; promoter; elongation; confluence	HEPARAN-SULFATE PROTEOGLYCAN; RNA-POLYMERASE-II; GOLABI-BEHMEL SYNDROME; INCREASING CELL-DENSITY; PROTEIN-KINASE-C; Z-DNA; NERVOUS-SYSTEM; GENOMIC ORGANIZATION; OVERGROWTH SYNDROME; ENHANCER ELEMENTS	OCI-5/Glypican 3, a member of the glypican family of proteoglycans, is the defective gene in the Simpson-Golabi-Behmel overgrowth syndrome. OCI-5 expression is developmentally regulated in the intestinal epithelium, and the mechanism of its regulation was studied in the rat intestinal epithelial cell line IEC-18. A large induction of OCI-5 transcript and protein was observed at high cell density, Among other glypican family members, kappa-glypican also exhibited a confluence-dependent induction in select cell types. Nuclear run-on analysis indicated that cell-density regulation of OCI-5 occurs at the level of transcription, The rat and mouse OCI-5 promoters were cloned and found to be highly conserved, located within CpG islands and contain regions of alternating purine and pyrimidine residues, No TATA-box or recognizable INR element was observed, Consensus binding sites for AP-2, SP-1, zeste and NF-1/CTF are conserved across human, mouse and rat promoters, 5' deletion mapping of the rat promoter identified regions which enhance and repress promoter activity, with no apparent confluence-dependence or tissue-specificity. Nuclear run-on analysis probing different regions of the gene suggests that elongation control plays a role in the induction of OCI-5 by confluence.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DIV CANC RES,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Li, M (corresponding author), UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,610 UNIV AVE,TORONTO,ON M5G 2M9,CANADA.		Li, Madeline/Q-8300-2017	Li, Madeline/0000-0002-3977-7437				Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BANERJEE R, 1986, P NATL ACAD SCI USA, V83, P4988, DOI 10.1073/pnas.83.14.4988; BENGAL E, 1991, J VIROL, V65, P4910, DOI 10.1128/JVI.65.9.4910-4918.1991; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BIRD AP, 1989, NUCLEIC ACIDS RES, V17, P9485, DOI 10.1093/nar/17.22.9485; BLAT C, 1994, EXP CELL RES, V215, P114, DOI 10.1006/excr.1994.1322; BOST LM, 1993, GROWTH FACTORS, V9, P195, DOI 10.3109/08977199309010832; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; ELLIOTT EM, 1985, CAN J BIOCHEM CELL B, V63, P511, DOI 10.1139/o85-070; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUNG WP, 1987, J BIOL CHEM, V262, P9298; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLABI M, 1984, AM J MED GENET, V17, P345, DOI 10.1002/ajmg.1320170128; HAMBURGER AW, 1991, PATHOBIOLOGY, V59, P329, DOI 10.1159/000163672; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HU YL, 1993, J BIOL CHEM, V268, P27214; HU ZB, 1995, LEUKEMIA, V9, P789; HUGHESBENZIE RM, 1992, AM J MED GENET, V43, P428, DOI 10.1002/ajmg.1320430165; HughesBenzie RM, 1996, AM J MED GENET, V66, P227, DOI 10.1002/(SICI)1096-8628(19961211)66:2<227::AID-AJMG20>3.0.CO;2-U; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; INGBER DE, 1994, INT REV CYTOL, V150, P173; Iwasaki T, 1996, J BIOL CHEM, V271, P22183, DOI 10.1074/jbc.271.36.22183; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAMINE J, 1993, J VIROL, V67, P6828, DOI 10.1128/JVI.67.11.6828-6834.1993; KITAOKA T, 1993, CURR EYE RES, V12, P993, DOI 10.3109/02713689309029225; KRAJEWSKI WA, 1995, FEBS LETT, V358, P13, DOI 10.1016/0014-5793(94)01377-D; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KUMATORI A, 1991, BIOCHEM BIOPH RES CO, V178, P480, DOI 10.1016/0006-291X(91)90132-Q; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LI M, 1997, IN PRESS EXP CELL RE; Lindsay S, 1997, J MED GENET, V34, P480, DOI 10.1136/jmg.34.6.480; LITWACK ED, 1994, J NEUROSCI, V14, P3713; LORIES V, 1992, J BIOL CHEM, V267, P1116; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; Oesterreich S, 1996, BIOCHEM BIOPH RES CO, V222, P155, DOI 10.1006/bbrc.1996.0714; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PEREZCASTRO AV, 1995, GENOMICS, V30, P157, DOI 10.1006/geno.1995.9890; Perkinson RA, 1996, J CELL BIOCHEM, V63, P74; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; RAJAGOPALAN M, 1990, J BIOL CHEM, V265, P17294; RAJCHEL A, 1988, NUCLEIC ACIDS RES, V16, P2347, DOI 10.1093/nar/16.5.2347; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SATO T, 1995, J BIOL CHEM, V270, P10314, DOI 10.1074/jbc.270.17.10314; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; TERESPOLSKY D, 1995, AM J MED GENET, V59, P329, DOI 10.1002/ajmg.1320590310; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WICE BM, 1995, J BIOL CHEM, V270, P21907, DOI 10.1074/jbc.270.37.21907; Wolfl S, 1996, P NATL ACAD SCI USA, V93, P3664, DOI 10.1073/pnas.93.8.3664; YU M, 1995, ARCH BIOCHEM BIOPHYS, V316, P407, DOI 10.1006/abbi.1995.1054	67	11	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1535	1544		10.1038/sj.onc.1201325	http://dx.doi.org/10.1038/sj.onc.1201325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380405				2022-12-25	WOS:A1997XX36900004
J	Bird, TA; Schooley, K; Dower, SK; Hagen, H; Virca, GD				Bird, TA; Schooley, K; Dower, SK; Hagen, H; Virca, GD			Activation of nuclear transcription factor NF-kappa B by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-INDUCED PHOSPHORYLATION; SITE-SPECIFIC PHOSPHORYLATION; DNA-BINDING SUBUNIT; PROTEIN-KINASE; ALPHA PROTEOLYSIS; REGULATED KINASES; GROWTH-FACTOR; BETA-CASEIN; CELLS	In fibroblasts and hepatoma cells, interleukin-l (IL-1) treatment results in the rapid nuclear accumulation of the transcription factor NF-kappa B, present largely as p65 (RelA)/p50 heterodimers. It is well established that this process is dependent in large part upon the phosphorylation and subsequent degradation of the cytosolic inhibitor I kappa B. We looked for other IL-l-induced modifications of NF-kappa B components and found that, in both cell types, IL-1 stimulation led, within minutes, to phosphorylation of both NF-kappa B p65 and p50. Phosphorylation of p65 was sustained for at least 30 min after addition of the cytokine and occurred principally upon serine residues. Immunoprecipitates of NF-kappa B complexes contained an associated protein kinase, the biochemical characteristics of which were indistinguishable from casein kinase II (CKII), Purified CKII efficiently phosphorylated p65 in vitro, apparently on the same major sites that became phosphorylated in intact IL-l-treated cells. Although IL-1 treatment caused little apparent stimulation of total cellular CKII activity, the fraction that was specifically associated with NF-kappa B complexes was markedly elevated by the cytokine. The association of CKII with NF-kappa B occurred in the cytoplasm, suggesting that this phosphorylation might be involved either in control of translocation of the activated complex or in modulation of its DNA binding properties.	Immunex Res & Dev Corp, Dept Biochem, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Prot Chem, Seattle, WA 98101 USA		Bird, TA (corresponding author), Immunex Res & Dev Corp, Dept Biochem, 51 Univ St, Seattle, WA 98101 USA.	bird@immunex.com		dower, steve/0000-0002-4675-4225				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOUSSET K, 1993, ONCOGENE, V8, P3211; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DOWER SK, 1992, CHEM IMMUNOL, V51, P33; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GONZALEZCRESPO S, 1994, SCIENCE, V264, P255, DOI 10.1126/science.8146656; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUESDON F, 1994, BIOCHEM J, V304, P761, DOI 10.1042/bj3040761; GUESDON F, 1995, CYTOKINE, V7, P603; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANLINT J, 1992, J BIOL CHEM, V267, P25916; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	53	188	192	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32606	32612		10.1074/jbc.272.51.32606	http://dx.doi.org/10.1074/jbc.272.51.32606			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405476	hybrid			2022-12-25	WOS:000071108000095
J	Fuchs, SY; Xie, B; Adler, V; Fried, VA; Davis, RJ; Ronai, Z				Fuchs, SY; Xie, B; Adler, V; Fried, VA; Davis, RJ; Ronai, Z			c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; DELTA-DOMAIN; UV IRRADIATION; IN-VIVO; V-JUN; PHOSPHORYLATION; STRESS; BINDING; DEGRADATION; INDUCTION	Regulatory proteins are often ubiquitinated, depending on their phosphorylation status as well as on their association with ancillary proteins that serve as adapters of the ubiquitination machinery, We previously demonstrated that c-Jun is targeted for ubiquitination by its association with inactive c-Jun NH2-terminal kinase (JNK), Phosphorylation by activated JNK protects c-Jun from ubiquitination, thus by prolonging its half-life, In the study reported here, we determined the ability of JNK to target ubiquitination of its other substrates (Elk1 and activating transcription factor 2 (ATF2)) and associated proteins (ATF2 and JunB), We demonstrate that phosphorylation by JNK protects ATF2, but not Elk1, from JNK-targeted ubiquitination. We also show that association of inactive JNK with JunB or ATF2 is necessary to target them for ubiquitination, Unlike its targeting of c-Jun, JNK requires additional cellular components, yet to be identified, to target the ubiquitination of ATF2., Elk1 is phosphorylated by JNK, but JNK neither associates with nor targets Elk1 for ubiquitination. The implications for the dual role of JNK in the regulation of ubiquitination and stability of c-Jun, ATF2, and JunB in normally growing versus stressed cells are discussed.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Worcester, MA 01605 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York Medical College; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA-59908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BLACK EJ, 1994, ONCOGENE, V9, P2363; Bocco JL, 1996, ONCOGENE, V12, P1971; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAI TN, 1995, ONCOGENE, V10, P849; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Fuchs SY, 1996, ONCOGENE, V13, P1531; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RONAI Z, 1994, ENVIRON MOL MUTAGEN, V23, P157, DOI 10.1002/em.2850230302; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	41	125	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32163	32168		10.1074/jbc.272.51.32163	http://dx.doi.org/10.1074/jbc.272.51.32163			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405416	hybrid			2022-12-25	WOS:000071108000035
J	AlAoukaty, A; Rolstad, B; Maghazachi, AA				AlAoukaty, A; Rolstad, B; Maghazachi, AA			Functional coupling of NKR-P1 receptors to various heterotrimeric G proteins in rat interleukin-2-activated natural killer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING EVENTS; T-LYMPHOCYTES; GENE-COMPLEX; CLASS-I; CLONING; KINASE; NK; INVOLVEMENT; INHIBITION; MOLECULE	NKR-P1 molecules constitute a family of type II membrane receptors in natural killer (NK) cells that preferentially activate NK cell killing and release of interferon-gamma from these cells. Here, we demonstrate that anti NKR-P1 enhances GTP binding in rat interleukin-2- activated NK cell membranes; GTP binding to G(i3)alpha, G(s) alpha, G(q,11)alpha and G(z) alpha increased noticeably in these cell membranes after treatment with anti-NKR-P1. Western blot analysis of membrane proteins prepared from interleukin-2-activated NK cells reveals the presence of G(i1,2)alpha, G(i3)alpha, G(o) alpha, G(s) alpha, G(q,11)alpha, G(z) alpha, and G(12)alpha, but not G(13)alpha. However, only alpha(i3), alpha(s), alpha(q,11), and alpha(z), but not alpha(i1,2), alpha(o), alpha(12), or alpha(13) subunits when immunoprecipitated with the appropriate anti-G protein antibodies, are associated with NKR-P1 when immunoblotted with anti-NKR-P1. Reciprocally, NKR-P1 immunoprecipitated with anti-NKR-P1 is associated with alpha(i3), alpha(s), alpha(q,11), and alpha(z) immunoblotted with anti-G proteins. These results are the first to demonstrate the physical and functional coupling of NKR-P1 to the heterotrimeric G proteins in NK cells.			AlAoukaty, A (corresponding author), UNIV OSLO, DEPT ANAT, INST BASIC MED SCI, POB 1105 BLINDERN, N-0317 OSLO, NORWAY.			Maghazachi, Azzam/0000-0002-3310-678X				AlAoukaty A, 1996, BLOOD, V87, P4255, DOI 10.1182/blood.V87.10.4255.bloodjournal87104255; ALAOUKATY A, 1994, BLOOD, V83, P1299; Biron Christine A., 1996, Methods (Orlando), V9, P379, DOI 10.1006/meth.1996.0043; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; DAVIES P, 1994, J CELL PHYSIOL, V159, P399, DOI 10.1002/jcp.1041590303; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; GIORDA R, 1991, J IMMUNOL, V147, P1701; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GIORDA R, 1992, SCIENCE, V147, P1701; HISASHI A, 1996, J EXP MED, V183, P2391; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KAUFMAN DS, 1995, P NATL ACAD SCI USA, V92, P6484, DOI 10.1073/pnas.92.14.6484; Lanier L L, 1995, Semin Immunol, V7, P75, DOI 10.1006/smim.1995.0011; LANIER LL, 1994, J IMMUNOL, V153, P2417; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Litosch I, 1996, BIOCHEM J, V319, P173, DOI 10.1042/bj3190173; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maghazachi AA, 1997, BIOCHEM BIOPH RES CO, V236, P270, DOI 10.1006/bbrc.1997.6937; Maghazachi AA, 1997, FASEB J, V11, P765, DOI 10.1096/fasebj.11.10.9271361; Maghazachi AA, 1996, J IMMUNOL, V157, P5308; MAGHAZACHI AA, 1994, J BIOL CHEM, V269, P6796; MAGHAZACHI AA, 1993, INT IMMUNOL, V5, P825, DOI 10.1093/intimm/5.8.825; Moretta L, 1996, J CLIN IMMUNOL, V16, P243, DOI 10.1007/BF01541388; NAPER C, 1995, EUR J IMMUNOL, V25, P1249, DOI 10.1002/eji.1830250518; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PITCHER JA, 1995, CELL, V83, P821; PROCOPIO ADG, 1991, J IMMUNOL, V146, P3550; RAULET DH, 1992, NATURE, V358, P21, DOI 10.1038/358021a0; RYAN JC, 1992, J IMMUNOL, V149, P1631; RYAN JC, 1991, J IMMUNOL, V147, P3244; Ryan JC, 1997, IMMUNOL REV, V155, P79, DOI 10.1111/j.1600-065X.1997.tb00941.x; SEBOK K, 1993, J IMMUNOL, V150, P1524; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TING AT, 1992, J BIOL CHEM, V267, P23957; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	41	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31604	31608		10.1074/jbc.272.50.31604	http://dx.doi.org/10.1074/jbc.272.50.31604			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395499	hybrid			2022-12-25	WOS:A1997YL41900058
J	Chin, D; Winkler, KE; Means, AR				Chin, D; Winkler, KE; Means, AR			Characterization of substrate phosphorylation and use of calmodulin mutants to address implications from the enzyme crystal structure of calmodulin-dependent protein kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; RAT-BRAIN; PEPTIDE COMPLEX; PURIFICATION; RECOGNITION; ACTIVATION; BINDING; IDENTIFICATION; SPECIFICITIES; RESIDUES	Calcium/calmodulin (CaM) directly activates CaM-dependent protein kinase I (CaMKI) by binding to the enzyme and indirectly promotes the phosphorylation and synergistic activation of CaMKI by an exogenous kinase. We have evaluated the initial CaM-dependent activation of the unphosphorylated form of CaMKI, The kinetics of bacterially expressed human CaMKI show that the peptide syntide-2 is a relatively poor substrate, whereas the synapsin site-1 peptide is 17-fold more specific. The peptide ADR1G is 400-fold more specific than syntide-2, and its catalytic rate is among the highest reported for a kinase peptide substrate. To understand how CaM activates CaMKI, we have characterized the activation of the enzyme by CaM mutants with substitutions at hydrophobic residues. The point mutant M124Q located in the C-terminal domain of CaM produced a 57-fold increase in the CaM activation constant for CaMKI and suggests the involvement of methionine 124 in an important hydrophobic interaction with tryptophan 303 of CaMKI. Substituting two, three, and five hydrophobic residues in the N-terminal domain of CaM increased the CaM activation constant for CaMKI by 10-190-fold and lowered the maximal enzyme activity by more than 80%. Two of these N-terminal mutants of CaM do not affect the K-m for peptide substrate but instead produce a 5-10-fold higher K-m for ATP. This result demonstrates the critical role of the N-terminal domain of CaM in regulating the access of ATP to CaMKI.	DUKE UNIV, MED CTR, DEPT PHARMACOL & CANC BIOL, DURHAM, NC 27710 USA	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33976] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; Chin D, 1997, J BIOL CHEM, V272, P5510, DOI 10.1074/jbc.272.9.5510; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DENIS CL, 1991, J BIOL CHEM, V266, P17932; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; Dixon M., 1979, ENZYMES, Vthird; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INOUE S, 1995, BIOCHEM BIOPH RES CO, V215, P861, DOI 10.1006/bbrc.1995.2543; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KEMP BE, 1994, PROTEIN KINASES, P30; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; MATSUSHIMA S, 1994, BIOCHEM BIOPH RES CO, V202, P1329, DOI 10.1006/bbrc.1994.2076; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P23851; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	35	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31235	31240		10.1074/jbc.272.50.31235	http://dx.doi.org/10.1074/jbc.272.50.31235			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395448	hybrid			2022-12-25	WOS:A1997YL41900007
J	Yamaguchi, A; Urano, T; Goi, T; Feig, LA				Yamaguchi, A; Urano, T; Goi, T; Feig, LA			An eps homology (EH) domain protein that binds to the Ral-GTPase target, RalBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; TYROSINE KINASE SUBSTRATE; ACTIVATING PROTEIN; PUTATIVE EFFECTOR; SH3 DOMAIN; VESICLES; IDENTIFICATION; ENDOCYTOSIS; INTERACTS; GENE	Ral proteins constitute a family of small GTPases that can be activated by Ras in cells, In the GTP-bound state, Ral proteins bind to RalBP1, a GTPase-activating protein for CDC42 and Rac GTPases. We have used the two-hybrid system in yeast to clone a cDNA for a novel similar to 85-kDa protein that can bind to an additional site on RalBP1, This newly identified protein contains an Eps homology (EH) domain, which was first detected in the epidermal growth factor (EGF) receptor substrate Eps15. Recently, the EH domain of Eps15 has been shown to bind to proteins containing an asparagine-proline-phenylalanine motif. Moreover, EH domains have been found in proteins involved in endocytosis and/or actin cytoskeleton regulation. The RalBP1 associated Eps-homology domain protein, Reps1, is tyrosine-phosphorylated in response to EGF stimulation of cells. In addition, Reps1 has the capacity to form a complex with the SH3 domains of the adapter proteins Crk and Grb2, which may link Reps1 to an EGF-responsive tyrosine kinase. Thus, Reps1 may coordinate the cellular actions of activated EGF receptors and Ral-GTPases.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts University				Urano, Takeshi/0000-0003-3383-3554	NIGMS NIH HHS [GM47707] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; BENMERAH A, 1996, J BIOL CHEM, V271, P28727; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMKEY R, 1991, J BIOL CHEM, V266, P9703; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FEIG LA, 1993, RAS SUPERFAMILY GTPA, P247; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Iannolo G, 1997, CANCER RES, V57, P240; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Park SH, 1995, ONCOGENE, V11, P2349; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	41	102	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31230	31234		10.1074/jbc.272.50.31230	http://dx.doi.org/10.1074/jbc.272.50.31230			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395447	hybrid			2022-12-25	WOS:A1997YL41900006
J	Athlan, ES; Mushynski, WE				Athlan, ES; Mushynski, WE			Heterodimeric associations between neuronal intermediate filament proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFILAMENT TRIPLET PROTEINS; COILED-COIL; NF-L; MOLECULAR MASSES; ALPHA-INTERNEXIN; EXPRESSION; POLYPEPTIDES; PERIPHERIN; INVITRO; SUBUNIT	Formation of protein dimers involving alpha-internexin, peripherin, and the neurofilament (NF) proteins NFH, NFM, and NFL was investigated by partial renaturation of various combinations of individually purified subunits in buffered 2 M urea, Oligomers that were formed were resolved by "blue" native electrophoresis (Schagger, H.,, Cramer, W., A., and von Jagow, G. (1994) Anal, Biochem. 217, 220-230) modified to include urea in the polyacrylamide gels, Combining this method with Western blot analysis, disulfide cross-linking, and SDS-polyacrylamide gel electrophoresis in the second dimension showed that NFL readily forms significant amounts of heterodimer with NFH, NFM, alpha-internexin, or peripherin in the presence of 2 M urea, alpha-Internexin and peripherin also formed heterodimers with NFH or NFM under these conditions, The modified version of blue native gel electrophoresis described here may be useful in monitoring the impact of post-translational modifications and mutations on the dimerization of intermediate filament proteins.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Mushynski, WE (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Athlan ES, 1997, J NEUROSCI RES, V47, P300; BRAGG PD, 1975, ARCH BIOCHEM BIOPHYS, V167, P311, DOI 10.1016/0003-9861(75)90467-1; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; CARDEN MJ, 1986, BIOCHEM J, V234, P587, DOI 10.1042/bj2340587; Carpenter DA, 1996, J CELL SCI, V109, P2493; CHADAN S, 1994, J NEUROCHEM, V62, P1894; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CHIU FC, 1989, NEURON, V2, P1435, DOI 10.1016/0896-6273(89)90189-X; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COHLBERG JA, 1995, J BIOL CHEM, V270, P9334, DOI 10.1074/jbc.270.16.9334; COHLBERG JA, 1987, J BIOL CHEM, V262, P17009; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FLIEGNER KH, 1994, J COMP NEUROL, V342, P161, DOI 10.1002/cne.903420202; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; Giasson BI, 1997, NEUROSCI LETT, V229, P77, DOI 10.1016/S0304-3940(97)00425-4; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HISANAGA S, 1990, J MOL BIOL, V211, P857, DOI 10.1016/0022-2836(90)90079-2; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; JULIEN JP, 1982, J BIOL CHEM, V257, P467; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Leung CL, 1996, J BIOL CHEM, V271, P14041, DOI 10.1074/jbc.271.24.14041; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; MULLIGAN L, 1991, J STRUCT BIOL, V106, P145, DOI 10.1016/1047-8477(91)90084-A; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; PARRY DAD, 1985, BIOCHEM BIOPH RES CO, V127, P1012, DOI 10.1016/S0006-291X(85)80045-0; PARYSEK LM, 1987, J NEUROSCI, V7, P781; PARYSEK LM, 1991, J NEUROSCI RES, V30, P80, DOI 10.1002/jnr.490300110; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; *SIGM, 1988, SIGM TECHN B; SOKOLOFF RL, 1981, ANAL BIOCHEM, V118, P138, DOI 10.1016/0003-2697(81)90169-X; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Sun DM, 1997, J NEUROCHEM, V68, P917; WEBER K, 1969, J BIOL CHEM, V244, P4406; WONG J, 1990, J NEUROSCI RES, V27, P332, DOI 10.1002/jnr.490270312; ZACKROFF RV, 1982, P NATL ACAD SCI-BIOL, V79, P754, DOI 10.1073/pnas.79.3.754	47	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31073	31078		10.1074/jbc.272.49.31073	http://dx.doi.org/10.1074/jbc.272.49.31073			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388258	hybrid			2022-12-25	WOS:000071640800071
J	Barone, LM; Shih, C; Wasserman, BP				Barone, LM; Shih, C; Wasserman, BP			Mercury-induced conformational changes and identification of conserved surface loops in plasma membrane aquaporins from higher plants - Topology of PMIP31 from Beta vulgaris L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(1,3)-BETA-GLUCAN CALLOSE SYNTHASE; TONOPLAST INTRINSIC PROTEIN; WATER CHANNEL PROTEINS; CELL CHIP28 PROTEIN; ARABIDOPSIS-THALIANA; VACUOLAR MEMBRANE; ENDOPLASMIC-RETICULUM; XENOPUS-OOCYTES; EXPRESSION; FAMILY	Aquaporins are integral membrane proteins occurring in mammals, plants, and microorganisms, which serve as channels that permit the bidirectional passage of water through cellular membranes, Higher plants contain abundant levels of aquaporins in both the tonoplast and plasma membrane, Aquaporins contain six transmembrane segments with three surface loops located at the apoplastic face of the membrane and two loops at the cytosolic side, In this study, we probed the topology of plasma membrane aquaporins to determine the effects of divalent cations on aquaporin conformation, and to identify structural features that distinguish plasma membrane intrinsic proteins from tonoplast intrinsic proteins, Plasma membrane vesicles from storage tissue of Beta vulgaris L. were subjected to limited proteolysis, and proteolytic fragmentation patterns were detected using affinity-purified antibodies recognizing aquaporins of 31-kDa, In its native membrane-associated state, the 31 aquaporin band, PMIP31, was refractory to proteolysis by trypsin, However,mercuric compounds specifically induced a conformational change resulting in the exposure of a proteolytic cleavage site and formation of a unique 22-kDa proteolytic fragment (p22), N-terminal sequence analysis of p22 established its identity as an aquaporin-derived fragment, Topological studies using sealed right-side-out plasma membrane vesicles established that the proteolytic cleavage site is located at surface loop C, the second apoplastic loop, immediately preceding the sequence Gly-Gly-Gly-Ala-Asn, The Gly-Gly-Gly-Ala-Asn-X-X-X-X-Gly-Tyr motif of loop C and a 14 amino acid motif in apoplastic loop E, Thr-Gly-Ile-Thr-Asn-Pro-Ala-Arg-Ser-Leu/Phe-Gly-Ala-Ala-Ile/Val-Ile/Val-Phe/Tyr-Asn are completely conserved in all known higher plant aquaporins of plasma membrane origin and are not present in any of the known tonoplast intrinsic proteins. These results demonstrate that the two highly conserved plasma membrane intrinsic protein surface loops are structural features that clearly distinguish plasma membrane from tonoplast aquaporins.	Rutgers State Univ, Cook Coll, Dept Food Sci, New Jersey Agr Expt Stn, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick	Wasserman, BP (corresponding author), Rutgers State Univ, Cook Coll, Dept Food Sci, New Jersey Agr Expt Stn, New Brunswick, NJ 08903 USA.	wasserman@aesop.rutgers.edu						AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BROOKER RJ, 1983, J BIOL CHEM, V258, P8827; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; CHRISPEELS MJ, 1994, PLANT PHYSIOL, V105, P9, DOI 10.1104/pp.105.1.9; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; DANIELS MJ, 1994, PLANT PHYSIOL, V106, P1325, DOI 10.1104/pp.106.4.1325; Daniels MJ, 1996, PLANT CELL, V8, P587, DOI 10.1105/tpc.8.4.587; FARINAS J, 1993, BIOCHEMISTRY-US, V32, P11857, DOI 10.1021/bi00095a014; FRAY RG, 1994, PLANT MOL BIOL, V24, P539, DOI 10.1007/BF00024122; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GUERRERO FD, 1990, PLANT MOL BIOL, V15, P11, DOI 10.1007/BF00017720; HOFTE H, 1992, PLANT PHYSIOL, V99, P561, DOI 10.1104/pp.99.2.561; Ikeda S, 1997, SCIENCE, V276, P1564, DOI 10.1126/science.276.5318.1564; INOUE K, 1995, PLANT MOL BIOL, V28, P1089, DOI 10.1007/BF00032669; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Johansson I, 1996, PLANT CELL, V8, P1181, DOI 10.1105/tpc.8.7.1181; JOHNSON KD, 1990, PLANT CELL, V2, P525, DOI 10.1105/tpc.2.6.525; JOHNSON KD, 1992, PLANT PHYSIOL, V100, P1787, DOI 10.1104/pp.100.4.1787; KALDENHOFF R, 1993, PLANT MOL BIOL, V23, P1187, DOI 10.1007/BF00042352; KAMMERLOHER W, 1994, PLANT J, V6, P187, DOI 10.1046/j.1365-313X.1994.6020187.x; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESNIAK W, 1994, BIOCHEMISTRY-US, V33, P13678, DOI 10.1021/bi00250a018; MAESHIMA M, 1992, PLANT PHYSIOL, V98, P1248, DOI 10.1104/pp.98.4.1248; Maurel C, 1997, ANNU REV PLANT PHYS, V48, P399, DOI 10.1146/annurev.arplant.48.1.399; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; NIELSEN S, 1995, KIDNEY INT, V48, P1057, DOI 10.1038/ki.1995.389; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; QI X, 1996, PLANT PHYSIOL, V112, P861; QI XQ, 1995, PLANT PHYSIOL, V108, P387, DOI 10.1104/pp.108.1.387; Robinson DC, 1996, PLANT PHYSIOL, V111, P645, DOI 10.1104/pp.111.2.645; TANG WJY, 1993, ANTIBODIES CELL BIOL, P95; Umbach AL, 1996, J BIOL CHEM, V271, P25019, DOI 10.1074/jbc.271.40.25019; VANHOEK AN, 1993, BIOCHEMISTRY-US, V32, P11847, DOI 10.1021/bi00095a013; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WASSERMAN BP, 1989, MOD METHOD PLANT, V10, P1; WASSERMAN BP, 1996, MOD METHOD PLANT, V17, P181; WU A, 1993, PLANT J, V4, P683, DOI 10.1046/j.1365-313X.1993.04040683.x; WU AY, 1991, PLANT PHYSIOL, V97, P684, DOI 10.1104/pp.97.2.684; YAMADA S, 1995, PLANT CELL, V7, P1129, DOI 10.1105/tpc.7.8.1129; YAMAGUCHISHINOZAKI K, 1992, PLANT CELL PHYSIOL, V33, P217, DOI 10.1093/oxfordjournals.pcp.a078243; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	53	45	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30672	30677		10.1074/jbc.272.49.30672	http://dx.doi.org/10.1074/jbc.272.49.30672			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388202	hybrid			2022-12-25	WOS:000071640800015
J	Mhaouty-Kodja, S; Bouet-Alard, R; Limon-Boulez, I; Maltier, JP; Legrand, C				Mhaouty-Kodja, S; Bouet-Alard, R; Limon-Boulez, I; Maltier, JP; Legrand, C			Molecular diversity of adenylyl cyclases in human and rat myometrium - Correlation with global adenylyl cyclase activity during mid- and term pregnancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHORBOL ESTER TREATMENT; CALCIUM INHIBITION; MESSENGER-RNA; MUSCLE-CELLS; EXPRESSION; PROTEIN; BRAIN; RECEPTOR; PROGESTERONE	Expression and regulation of myometrial adenylyl cyclases (AC) were studied during pregnancy, Hybridization of poly(A)(+) RNA with specific cDNA probes for enzyme types I-IX indicated 1) the presence of transcripts encoding types II-VI and type IX in rat and human, and type VII in rat and 2) the absence of detectable mRNA for types I and VIII in both species, No substantial change was observed in the amount of specific mRNA and basal AC activity from mid-pregnancy to term, However, activation of the alpha(2)-adrenergic receptor/G(i) protein pathway resulted in potentiation of G(s)-stimulated AC activity at mid-pregnancy but not at term (Mhaouty, S., Cohen-Tannoudji, J,, Bouet-Alard, R,, Limon-Boulez, I., Maltier, J, P,, and Legrand, C, (1995) J, Biol, Chem. 270, 11012-11016), We demonstrate in the present work that beta gamma scavengers transducin-alpha and QEHA peptide abolished this positive input, On the other hand, increasing submicromolar concentrations of free Ca2+, a situation that mimics late term, reduced the forskolin-stimulated AC activity with an IC50 of 3.9 mu M. Thus, the presence in myometrium of AC II family (types II, IV, VII) confers ability to G inhibitory proteins to stimulate enzyme activity via beta gamma complexes at mid-pregnancy, whereas expression of AC III, V, and VI isoforms confers to the myometrial AC system a high sensitivity to inhibition by Ca2+-dependent processes at term. These data suggest that in the pregnant myometrium, the expression of different species of AC with distinct regulatory properties provides a mechanism for integrating positively or negatively the responses to various hormonal inputs existing either during pregnancy or in late term.	Univ Paris 06, Reprod Physiol Lab, CNRS, URA 1449, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Legrand, C (corresponding author), Univ Paris 06, Reprod Physiol Lab, CNRS, URA 1449, 4 Pl Jussieu, F-75252 Paris 05, France.		Limon, Isabelle/P-2750-2017; Limon, Isabelle/AAJ-6169-2020	Limon, Isabelle/0000-0002-8773-6971; Limon, Isabelle/0000-0002-8773-6971; Mhaouty-Kodja, Sakina/0000-0001-9743-5243				BARBER R, 1988, SEC MESS PHOSPHOPROT, V12, P59; BREUILLER M, 1990, J CLIN ENDOCR METAB, V70, P1299, DOI 10.1210/jcem-70-5-1299; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COHEN-TANNOUDJI J, 1995, BIOL REPROD, V53, P55, DOI 10.1095/biolreprod53.1.55; COHEN-TANNOUDJI J, 1991, J MOL ENDOCRINOL, V6, P137, DOI 10.1677/jme.0.0060137; COLVIN RA, 1991, CELL CALCIUM, V12, P19, DOI 10.1016/0143-4160(91)90081-O; COOPER DMF, 1994, CELL SIGNAL, V6, P823, DOI 10.1016/0898-6568(94)90016-7; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; ELWARDYMEREZAK J, 1994, J MOL ENDOCRINOL, V13, P23, DOI 10.1677/jme.0.0130023; ESPINASSE I, 1995, J MOL CELL CARDIOL, V27, P1789, DOI 10.1016/0022-2828(95)90002-0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FURUYAMA T, 1993, MOL BRAIN RES, V19, P165, DOI 10.1016/0169-328X(93)90163-J; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HOUDEAU E, 1994, CELL TISSUE RES, V277, P579; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LASKER RD, 1982, ARCH BIOCHEM BIOPHYS, V216, P345, DOI 10.1016/0003-9861(82)90220-X; LEGRAND C, 1986, J REPROD FERTIL, V76, P415, DOI 10.1530/jrf.0.0760415; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MAGOCSI M, 1991, BIOCHIM BIOPHYS ACTA, V1063, P7, DOI 10.1016/0005-2736(91)90346-A; MAKA FDK, 1990, GYNECOL OBSTET INVES, V30, P169; Marjamaki A, 1997, J BIOL CHEM, V272, P16466, DOI 10.1074/jbc.272.26.16466; MHAOUTY S, 1995, J BIOL CHEM, V270, P11012, DOI 10.1074/jbc.270.18.11012; MONS N, 1993, SYNAPSE, V14, P51, DOI 10.1002/syn.890140108; NELSON CA, 1986, J BIOL CHEM, V261, P3469; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PIASCIK MT, 1995, ARCH BIOCHEM BIOPHYS, V241, P28; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; STRITTMATTER S, 1980, P NATL ACAD SCI-BIOL, V77, P6344, DOI 10.1073/pnas.77.11.6344; TANFIN Z, 1991, FEBS LETT, V278, P4, DOI 10.1016/0014-5793(91)80070-J; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; VIVAT V, 1992, J BIOL CHEM, V267, P7975; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; WEILAND T, 1992, J BIOL CHEM, V267, P20791; WENG G, 1996, J BIOL CHEM, V2271, P26445; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; Zimmermann G, 1996, J BIOL CHEM, V271, P27161, DOI 10.1074/jbc.271.43.27161	47	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31100	31106		10.1074/jbc.272.49.31100	http://dx.doi.org/10.1074/jbc.272.49.31100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388262	hybrid			2022-12-25	WOS:000071640800075
J	Toretsky, JA; Kalebic, T; Blakesley, V; LeRoith, D; Helman, LJ				Toretsky, JA; Kalebic, T; Blakesley, V; LeRoith, D; Helman, LJ			The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUND-CELL TUMORS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; T(1122) TRANSLOCATION; CHIMERIC TRANSCRIPTS; EWING SARCOMA; GENE; PROTEIN; FUSION; PHOSPHATASE	Ewing's family of tumors is characterized by a well described reciprocal translocation, t(11;22)(q24;q12), which produces a fusion protein (EWS/FLI-1) that transforms mouse fibroblasts. The EWS/FLI-1 fusion protein has been shown to act as a potent chimeric transcription factor. Overexpression of insulin like growth factor-I receptor (IGF-IR) has been implicated in many tumor models as playing a role in cell growth and tumorigenesis. In addition, blockade of the IGF-IR inhibits the growth of Ewing's family of tumors cells. Therefore, we first studied whether the presence of the IGF-IR is required for transformation by the EWS/FLI-1 fusion protein. To perform this study, we used two previously described fibroblast cell lines, R- and W, derived from an IGF-IR knockout mouse and a wild-type littermate, respectively. Neither W nor R-cells without the fusion protein formed soft agar colonies. However, W clones expressing the fusion message (WF cells) formed soft agar colonies, whereas R-clones expressing the fusion message (R-F cells) did not form soft agar colonies. Because the IGF-IR is required for EWS/FLI-1 transformation, we chose to investigate whether altered signaling occurs from the IGF-IR when the EWS/FLI-1 fusion is present. WF cells demonstrated a greater degree of ligand-stimulated insulin receptor substrate-1 phosphorylation when compared with W cells, suggesting that expression of the EWS/FLI-1 fusion protein alters the IGF-IR signaling pathway.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Toretsky, JA (corresponding author), Univ Maryland, Dept Pediat Hematol Oncol, 22 S Greene St,Rm N5E16, Baltimore, MD 21201 USA.	jt@helix.nih.gov						BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; DAmbrosio C, 1996, ONCOGENE, V12, P371; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DOCKHORNDWORNICZAK B, 1994, VIRCHOWS ARCH, V425, P107, DOI 10.1007/BF00230345; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; FURLANETTO RW, 1993, CANCER RES, V53, P2522; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; RUBIN R, 1995, LAB INVEST, V73, P311; Scotlandi K, 1996, CANCER RES, V56, P4570; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	40	182	188	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30822	30827		10.1074/jbc.272.49.30822	http://dx.doi.org/10.1074/jbc.272.49.30822			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388225	hybrid			2022-12-25	WOS:000071640800038
J	Anderson, KM; Roshak, A; Winkler, JD; McCord, M; Marshall, LA				Anderson, KM; Roshak, A; Winkler, JD; McCord, M; Marshall, LA			Cytosolic 85-kDa phospholipase A(2)-mediated release of arachidonic acid is critical for proliferation of vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; GROUP-II PHOSPHOLIPASE-A2; MESSENGER-RNA LEVELS; MESANGIAL CELLS; PROSTAGLANDIN BIOSYNTHESIS; GENE-EXPRESSION; SYNOVIAL-FLUID; A(2); RAT; GROWTH	Recent evidence suggests that arachidonic acid (AA) may be involved in regulating cellular proliferation, The predominant mechanism of AA release from cellular phospholipids is via phospholipase A(2) (PLA(2)) hydrolysis, The purpose of this study was to examine the roles of the distinct 14-kDa and 85-kDa PLA(2) enzymes in human coronary artery vascular smooth muscle cell (hCAVSMC) proliferation, Cultured hCAVSMCs proliferate in the presence of growth medium with a typical doubling time of 30-40 h, grow at a slower proliferative rate upon reaching confluency (day 8), and eventually undergo contact inhibition of growth (day 10), Neither Type II 14-kDa PLA(2) activity nor mass changed over a 10-day culture period, In contrast, 85-kDa PLA(2) protein activity and mRNA decreased as time in culture progressed. This reduction in 85-kDa PLA(2) correlated with reductions in DNA synthesis and suggested a possible association between 85-kDa PLA(2) and proliferation, To directly evaluate the role of the 85-kDa PLA(2) in proliferation we examined the effects of an 85-kDa PLA(2) inhibitor (AACOCF(3)) and 85-kDa PLA(2) antisense oligonucleotides on proliferation. Both reagents dose dependently inhibited proliferation, whereas a 14-kDa PLA(2) inhibitor (SB203347), a calcium-independent PLA(2) inhibitor (HELSS), all 85-kDa sense oligonucleotide, and a nonrelevant scrambled control oligonucleotide had no effect, The mechanism by which 85-kDa PLA(2) influences cellular proliferation remains unclear. Inhibition of 85-kDa PLA(2) activity produced neither phase-specific cell cycle arrest nor apoptosis (fluorescence-activated cell sorter analysis). Addition of AA (20 mu M) attenuated the effects of both AACOCF(3) and 85-kDa antisense oligonucleotides implicating AA as a key mediator in cellular proliferation However, although prostaglandin E-2 (PGE(2)) was present in the culture medium, it peaked early (day 3) in culture, and indomethacin had no effect on cellular proliferation indicating that hCAVSMC proliferation was not mediated through PGE(2). These data provide the first direct evidence that PLA(2) is involved in control of VSMC proliferation and indicate that 85-kDa PLA(2)-mediated liberation of AA is critical for cellular proliferation.	SMITHKLINE BEECHAM PHARMACEUT,DEPT IMMUNOPHARMACOL,KING OF PRUSSIA,PA 19406	GlaxoSmithKline	Anderson, KM (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT CARDIOVASC PHARMACOL,POB 1539,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406, USA.							AMAEGADZIE BY, 1993, GENE AMST, V128, P307; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARSAGI D, 1986, SCIENCE, V233, P1062; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BRINKMAN HJM, 1990, THROMB HAEMOSTASIS, V63, P291; CAMEJO EH, 1995, CIRCULATION S1, V92, P424; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHAPMAN RS, 1995, CYTOMETRY, V20, P245, DOI 10.1002/cyto.990200308; CHEPENIK KP, 1994, J BIOL CHEM, V269, P21786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; Corda D, 1996, ANTICANCER RES, V16, P1341; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; DIEZ E, 1992, J BIOL CHEM, V267, P18342; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GORCZYCA W, 1993, CANCER RES, V53, P1945; Griswold DE, 1996, MED RES REV, V16, P181, DOI 10.1002/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.0.CO;2-X; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IVANDIC B, 1996, CIRCULATION S1, V94, P1; KANDA A, 1989, BIOCHEM BIOPH RES CO, V163, P42, DOI 10.1016/0006-291X(89)92096-2; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KERR JS, 1989, BIOCHEM BIOPH RES CO, V165, P1079, DOI 10.1016/0006-291X(89)92712-5; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1990, PHOSPHOLIPASE A2, P35; LAI CY, 1988, BIOCHEM BIOPH RES CO, V157, P488, DOI 10.1016/S0006-291X(88)80275-4; LIN LL, 1992, J BIOL CHEM, V267, P23451; Liu Y, 1997, BBA-MOL CELL RES, V1355, P270, DOI 10.1016/S0167-4889(96)00148-6; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P709; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; MARSHALL LA, 1993, BIOCHEM CELL BIOL, V71, P331, DOI 10.1139/o93-050; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MIYAKE R, 1992, BIOCHIM BIOPHYS ACTA, V1165, P167, DOI 10.1016/0005-2760(92)90183-V; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; OKA S, 1991, J BIOL CHEM, V266, P9956; OWEN NE, 1986, AM J PHYSIOL, V250, pC584, DOI 10.1152/ajpcell.1986.250.4.C584; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Roshak A, 1996, J RHEUMATOL, V23, P420; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V248, P1; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SCHWARTZ SM, 1996, CORONARY RESTENOSIS, P5; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SPRARAGEN SC, 1962, CIRC RES, V11, P329, DOI 10.1161/01.RES.11.2.329; STADEL JM, 1993, J MOL RECOGNIT, V5, P145; SUNG CP, 1994, J PHARMACOL EXP THER, V271, P429; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WAITE M, 1996, BIOCH LIPIDS LIPOPRO, P211; WOJTASZEK PA, 1995, FEBS LETT, V367, P228, DOI 10.1016/0014-5793(95)00556-O	72	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30504	30511		10.1074/jbc.272.48.30504	http://dx.doi.org/10.1074/jbc.272.48.30504			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374544	hybrid			2022-12-25	WOS:A1997YH61300076
J	Rintamaki, E; Salonen, M; Suoranta, UM; Carlberg, I; Andersson, B; Aro, EM				Rintamaki, E; Salonen, M; Suoranta, UM; Carlberg, I; Andersson, B; Aro, EM			Phosphorylation of light-harvesting complex II and photosystem II core proteins shows different irradiance-dependent regulation in vivo - Application of phosphothreonine antibodies to analysis of thylakoid phosphoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PHOTOINHIBITION; PHOTOSYNTHESIS; DEGRADATION; CHLOROPLASTS; DEACTIVATION; D1-PROTEIN; MEMBRANES	An immunological approach using a polyclonal phosphothreonine antibody is introduced for the analysis of thylakoid protein phosphorylation in vivo, Virtually the same photosystem II (PSII) core phosphoproteins (D1, D2, CP43, and the psbH gene product) and the light-harvesting chlorophyll a/b complex II (LHCII) phosphopolypeptides (LHCB1 and LHCB2), as earlier identified by radiolabeling experiments, were recognized in both pumpkin and spinach leaves, Notably, the PSII core proteins and LHCII polypeptides were found to have a different phosphorylation pattern in vivo with respect to increasing irradiance. Phosphorylation of the PSII core proteins in leaf discs attained the saturation level at the growth light intensity, and this level was also maintained at high irradiances, Maximal phosphorylation of LHCII polypeptides only occurred at low light intensities, far below the growth irradiance, and then drastically decreased at higher irradiances. These observations are at variance with traditional studies in vitro, where LHCII shows a light-dependent increase in phosphorylation, which is maintained even at high irradiances, Only a slow restoration of the phosphorylation capacity for LHCII polypeptides at the low light conditions occurred in vivo after the high light-induced inactivation, Furthermore, if thylakoid membranes were isolated from the high light-inactivated leaves, no restoration of LHCII phosphorylation took place in vitro, However, both the high light-induced inactivation and low light-induced restoration of LHCII phosphorylation seen in vivo could be mimicked in isolated thylakoid membranes by incubating with reduced and oxidized diothiothreitol, respectively, We propose that stromal components are involved in the regulation of LHCII phosphorylation in vivo, and inhibition of LHCII phosphorylation under increasing irradiance results from reduction of the thiol groups in the LHCII kinase.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN	Stockholm University	Rintamaki, E (corresponding author), UNIV TURKU,DEPT BIOL,FIN-20014 TURKU,FINLAND.		Aro, Eva-Mari/Q-8664-2017; Andersson, Bertil/C-9328-2009; Rintamaki, Eevi/T-6903-2017	Aro, Eva-Mari/0000-0002-2922-1435; Rintamaki, Eevi/0000-0002-1353-3995				Allen J. F., 1981, NATURE, V291, P21; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ANDERSON JM, 1988, TRENDS BIOCHEM SCI, V13, P351, DOI 10.1016/0968-0004(88)90106-5; ARO EM, 1992, FEBS LETT, V297, P29, DOI 10.1016/0014-5793(92)80320-G; BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BUCHANAN BB, 1992, PHOTOSYNTH RES, V33, P147, DOI 10.1007/BF00039177; CALLAHAN FE, 1990, J BIOL CHEM, V265, P15357; Carlberg I, 1996, PHOTOSYNTH RES, V47, P145, DOI 10.1007/BF00016177; EBBERT V, 1994, BBA-BIOENERGETICS, V1187, P335, DOI 10.1016/0005-2728(94)90007-8; FRID D, 1992, J BIOL CHEM, V267, P25908; Gal A, 1997, PHYSIOL PLANTARUM, V100, P869, DOI 10.1034/j.1399-3054.1997.1000413.x; GAL A, 1990, J BIOL CHEM, V265, P19742; HAMMER MF, 1997, PLANT PHYSIOL, V133, P227; Hast T, 1996, J PHOTOCH PHOTOBIO B, V36, P313, DOI 10.1016/S1011-1344(96)07383-6; HIND G, 1995, BIOCHEMISTRY-US, V34, P8157, DOI 10.1021/bi00025a022; HORTON P, 1985, PLANTA, V165, P37, DOI 10.1007/BF00392209; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; Kettunen R, 1997, EUR J BIOCHEM, V247, P441, DOI 10.1111/j.1432-1033.1997.00441.x; Koivuniemi A, 1995, BIOCHEMISTRY-US, V34, P16022, DOI 10.1021/bi00049a016; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; Kruse O, 1997, FEBS LETT, V408, P276, DOI 10.1016/S0014-5793(97)00439-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P59, DOI 10.1016/0005-2728(87)90212-X; MCCORMAC DJ, 1994, BBA-BIOENERGETICS, V1187, P301, DOI 10.1016/0005-2728(94)90004-3; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MILLNER PA, 1982, J BIOL CHEM, V257, P1736; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Race HL, 1996, BIOCHEMISTRY-US, V35, P13006, DOI 10.1021/bi961809k; Rintamaki E, 1996, J BIOL CHEM, V271, P14870, DOI 10.1074/jbc.271.25.14870; SCHEIBE R, 1987, PHYSIOL PLANTARUM, V71, P393, DOI 10.1111/j.1399-3054.1987.tb04362.x; SCHUSTER G, 1986, J CELL BIOL, V103, P71, DOI 10.1083/jcb.103.1.71; SILVERSTEIN T, 1993, BIOCHIM BIOPHYS ACTA, V1183, P215, DOI 10.1016/0005-2728(93)90022-8; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225	35	199	209	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30476	30482		10.1074/jbc.272.48.30476	http://dx.doi.org/10.1074/jbc.272.48.30476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374540	hybrid			2022-12-25	WOS:A1997YH61300072
J	Woodring, PJ; Garrison, JC				Woodring, PJ; Garrison, JC			Expression, purification, and regulation of two isoforms of the inositol 1,4,5-trisphosphate 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; POLYACRYLAMIDE-GEL ELECTROPHORESIS; V-SRC ONCOGENE; RAT-BRAIN; MOLECULAR-CLONING; HUMAN-PLATELETS; SMOOTH-MUSCLE; IDENTIFICATION; STIMULATION; FIBROBLASTS	The level of inositol 1,4,5-trisphosphate in the cytoplasm is tightly regulated by two enzymes, the inositol 1,4,5,5-phosphatase and the inositol 1,4,5-trisphosphate 3-kinase. Two isoforms of the inositol 1,4,5-trisphosphate S-kinase have been identified, the A form and the B form. The regulatory properties of the two isoforms were compared following overexpression and purification of the proteins from a v-src transformed mammalian cell line. The highly purified, recombinant inositol 1,4,5-trisphosphate 3-kinases were differentially regulated by calcium/calmodulin and via phosphorylation by protein kinase C or the cyclic AMP-dependent protein kinase. Both enzymes had similar affinities for inositol 1,4,5-trisphosphate (K-m 2-5 mu m). Calcium/calmodulin stimulated the activity of isoform A about 2.5-fold, whereas the activity of isoform B was increased 20-fold. The cyclic AMP-dependent protein kinase phosphorylated the inositol 1,4,5-trisphosphate 3-kinase A to the extent of 0.9 mol/mol and isoform B to 1 mol/mol. Protein kinase C phosphorylated isoform A to the extent of 2 mol/mol and isoform B to 2.7 mol/mol. Phosphorylation of isoform A by the cyclic AMP-dependent protein kinase caused a 2.5-fold increase in its activity when assayed in the absence of calcium/calmodulin, whereas phosphorylation by protein kinase C decreased activity by 72%. The activity of isoform B in the absence of calcium/calmodulin was not affected by phosphorylation using either kinase. When assayed in the presence of calcium/calmodulin, phosphorylation of isoform A by the cyclic AMP-dependent protein kinase increased activity 1.5-fold, whereas phosphorylation of isoform B decreased activity by 45%. Phosphorylation of either isoform A or B by protein kinase C resulted in a 70% reduction of calcium/calmodulin-stimulated activity. Differential expression and regulation of the two inositol 1,4,5-trisphosphate 3-kinase isoforms provides multiple mechanisms for regulating the cytosolic level of inositol 1,4,5-trisphosphate in cells.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,CANC RES CTR,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NCI NIH HHS [P01-CA 40042] Funding Source: Medline; NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLA T, 1991, J BIOL CHEM, V266, P24719; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BIDEN TJ, 1988, BIOCHEM J, V256, P697, DOI 10.1042/bj2560697; BIDEN TJ, 1988, BIOCHEM J, V251, P435, DOI 10.1042/bj2510435; Bornstein P, 1977, Methods Enzymol, V47, P132; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; COMMUNI D, 1994, BIOCHEM J, V298, P669, DOI 10.1042/bj2980669; Communi D, 1997, EMBO J, V16, P1943, DOI 10.1093/emboj/16.8.1943; CONIGRAVE A, 1992, CELL SIGNAL, V4, P303, DOI 10.1016/0898-6568(92)90070-O; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DSANTOS CS, 1994, CELL SIGNAL, V6, P335, DOI 10.1016/0898-6568(94)90038-8; ERNEUX C, 1993, EUR J BIOCHEM, V214, P497, DOI 10.1111/j.1432-1033.1993.tb17947.x; ERNEUX C, 1991, TRENDS PHARMACOL SCI, V12, P174, DOI 10.1016/0165-6147(91)90539-5; HOGAN SP, 1994, CELL SIGNAL, V6, P233, DOI 10.1016/0898-6568(94)90081-7; IMBODEN JB, 1987, J CLIN INVEST, V79, P1538, DOI 10.1172/JCI112986; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; JOHANSON RA, 1988, J BIOL CHEM, V263, P7465; KING WG, 1989, J BIOL CHEM, V264, P6070; LEE SY, 1990, J BIOL CHEM, V265, P9434; LIN A, 1993, ARCH BIOCHEM BIOPHYS, V303, P412, DOI 10.1006/abbi.1993.1303; LIN AN, 1990, BIOCHEM BIOPH RES CO, V170, P1371, DOI 10.1016/0006-291X(90)90546-Y; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTINGLY RR, 1992, FEBS LETT, V296, P225, DOI 10.1016/0014-5793(92)80385-T; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SIM SS, 1990, J BIOL CHEM, V265, P10367; Soriano S, 1997, FEBS LETT, V403, P1, DOI 10.1016/S0014-5793(96)01516-5; TAKAZAWA K, 1991, BIOCHEM J, V280, P125, DOI 10.1042/bj2800125; TAKAZAWA K, 1995, J ENDOCRINOL, V144, P527, DOI 10.1677/joe.0.1440527; TAKAZAWA K, 1990, BIOCHEM J, V268, P213, DOI 10.1042/bj2680213; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; TAKAZAWA K, 1991, BIOCHEM BIOPH RES CO, V174, P529, DOI 10.1016/0006-291X(91)91449-M; TAKAZAWA K, 1989, BIOCHEM J, V261, P483, DOI 10.1042/bj2610483; Thomas S, 1996, BIOCHEM J, V319, P713, DOI 10.1042/bj3190713; THOMAS S, 1994, BBA-MOL CELL RES, V1220, P219, DOI 10.1016/0167-4889(94)90139-2; VANWEYENBERG V, 1995, BIOCHEM J, V306, P429, DOI 10.1042/bj3060429; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; WANG XL, 1995, BIOCHEM J, V308, P1009, DOI 10.1042/bj3081009; Woodring PJ, 1996, BIOCHEM J, V319, P73, DOI 10.1042/bj3190073; YAMAGUCHI K, 1988, BIOCHEM J, V251, P129, DOI 10.1042/bj2510129	46	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30447	30454		10.1074/jbc.272.48.30447	http://dx.doi.org/10.1074/jbc.272.48.30447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374536	hybrid			2022-12-25	WOS:A1997YH61300068
J	deMora, JF; Uren, A; Heidaran, M; Santos, E				deMora, JF; Uren, A; Heidaran, M; Santos, E			Biological activity of p27(kip1) and its amino- and carboxy-terminal domains in G2/M transition of Xenopus oocytes	ONCOGENE			English	Article						p27(kip1); Xenopus oocytes; cell cycle; cdc2 kinase; MPF; GVBD	DEPENDENT-KINASE INHIBITOR; P34CDC2 PROTEIN-KINASE; FIBROBLAST CELL-CYCLE; PHOSPHORYLATION SITES; TYROSINE PHOSPHATASE; ACTIVATING KINASE; CDK6 INHIBITOR; CDC2; P27; CLONING	p27(kip1) is a general inhibitor of Cdks that preferentially accumulates and functions during G1 phase, before the restriction point of the mammalian cell cycle. We observed that injection of purified p27(kip1) into Xenopus oocytes potently inhibits the G2/M transition and activation/dephosphorylation of the maturation promoting factor (MPF, p34(cdc2)/cyclin B complex) kinase associated with germinal vesicle breakdown (GVBD) induced by progesterone or insulin. Addition of exogenous p27(kip1) in vitro to lysates of hormonally matured oocytes blocked the enzymatic activity of the activated MPF kinase present in those extracts. Interestingly, the isolated amino-terminal region of p27(kip1) (p27N), encompassing only the Cdk binding site, exhibited a similar inhibitory behavior in vitro and a weaker inhibitory effect in vivo than the complete p27(kip1) protein. Surprisingly, the remaining carboxy-terminal region of p27(kip1) (p27C) actually induced GVBD when injected alone into the oocytes, and also accelerated the kinetics of insulin-or progesterone-induced GVBD. Consistent with the in vivo observations, p27C formed a complex with, and activated, the MPF kinase in lysates of immature oocytes, although this activation was blocked by simultaneous addition of p27N or complete p27(kip1). Active MPF was able to phosphorylate p27C only in the absence of p27N or whole p27(kip1), suggesting that the inhibitory activity associated with the amino terminus is dominant over the activation produced by p27C. These results demonstrate the functional interaction of p27(kip1) with cyclin B/p34(cdc2) complexes during G2/M progression in oocytes, and suggest that the amino and carboxy terminal portions of this protein may play opposite regulatory roles, reminiscent of the corresponding N- and C-terminal portions of p21(waf). We speculate that accumulation of a truncated, C-terminal p27 fragment may play a physiological regulatory role in progression through G2 and later stages of the cell cycle.			deMora, JF (corresponding author), NCI, MOL & CELLULAR BIOL LAB, DBS, BETHESDA, MD 20892 USA.		de Mora, Jaime Font/H-6304-2015; de Mora, Jaime Font/AAK-7591-2021	de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095				APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GRIGORESCU F, 1994, HORM RES, V42, P5; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee TH, 1996, P NATL ACAD SCI USA, V93, P352, DOI 10.1073/pnas.93.1.352; LOUNDGREN K, 1991, CELL, V64, P1111; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MALLER JL, 1994, SEMIN DEV BIOL, V5, P138; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PALEMBELLA VJ, 1994, CELL, V78, P773; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang QM, 1996, CANCER RES, V56, P264	55	16	17	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2541	2551		10.1038/sj.onc.1201420	http://dx.doi.org/10.1038/sj.onc.1201420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399642				2022-12-25	WOS:A1997YG73200004
J	Gottgens, B; McLaughlin, F; Bockamp, EO; Fordham, JL; Begley, CG; Kosmopoulos, K; Elefanty, AG; Green, AR				Gottgens, B; McLaughlin, F; Bockamp, EO; Fordham, JL; Begley, CG; Kosmopoulos, K; Elefanty, AG; Green, AR			Transcription of the SCL gene in erythroid and CD34 positive primitive myeloid cells is controlled by a complex network of lineage-restricted chromatin-dependent and chromatin-independent regulatory elements	ONCOGENE			English	Article						SCL/TAL-1; transcription; regulation; chromatin; enhancer; silencer	LOCUS-CONTROL REGION; LOOP-HELIX PROTEIN; BETA-GLOBIN GENE; FACTOR GATA-1; HEMATOPOIETIC LINEAGES; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; TAL-1 GENE; DIFFERENTIATION; EXPRESSION	The SCL gene (also known as TAL-1) encodes a basic helix-loop-helix transcription factor that is essential for the development of all haematopoietic lineages, and ectopic expression of which results in T cell leukaemia, SCL is expressed in normal pluripotent haematopoietic stem cells and its expression is maintained during differentiation along erythroid, mast and megakaryocytic lineages, but is extinguished following commitment to other cell types, The mechanisms responsible for this pattern of expression are poorly understood, but are likely to illuminate the molecular basis for stem cell development and lineage commitment. We have identified multiple lineage-restricted DNase I hypersensitive sites in a 45 kb region spanning the murine SCL locus, Committed erythroid cells and CD34 positive primitive myeloid cells exhibited both shared and unique DNase I hypersensitive sites whereas none were found in T cells, The function of each hypersensitive site was studied using both transient and stable reporter assays in erythroid, primitive myeloid and T cells, Multiple positive and negative regulatory elements were characterised and found to display lineage-specificity, promoter-specificity and/or chromatin-dependence. These results represent the first description of key components of a complex network of regulatory elements controlling SCL expression during haematopoiesis.	UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, CAMBRIDGE CB2 2QH, ENGLAND; WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA	University of Cambridge; Walter & Eliza Hall Institute			Elefanty, Andrew G/A-6066-2008	Gottgens, Berthold/0000-0001-6302-5705; Green, Anthony/0000-0002-9795-0218; Bockamp, Ernesto/0000-0002-6181-1734; Elefanty, Andrew/0000-0001-6448-8314	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BENZ EJ, 1980, P NATL ACAD SCI-BIOL, V77, P3509, DOI 10.1073/pnas.77.6.3509; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; Bockamp EO, 1997, J BIOL CHEM, V272, P8781, DOI 10.1074/jbc.272.13.8781; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BONIFER C, 1994, NUCLEIC ACIDS RES, V22, P4202, DOI 10.1093/nar/22.20.4202; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CROSS MA, 1994, ONCOGENE, V9, P3013; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GOLDFARB AN, 1992, BLOOD, V58, P537; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; LEROYVIARD K, 1994, BLOOD, V84, P3819, DOI 10.1182/blood.V84.11.3819.bloodjournal84113819; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MAY G, 1995, EMBO J, V14, P564, DOI 10.1002/j.1460-2075.1995.tb07032.x; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MOUTHON MA, 1993, BLOOD, V81, P647; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZEHETNER G, 1994, NATURE, V367, P489, DOI 10.1038/367489a0; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	79	53	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	1997	15	20					2419	2428		10.1038/sj.onc.1201426	http://dx.doi.org/10.1038/sj.onc.1201426			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395238				2022-12-25	WOS:A1997YE96300004
J	Nofer, JR; Tepel, M; Walter, M; Seedor, U; Assmann, G; Zidek, W				Nofer, JR; Tepel, M; Walter, M; Seedor, U; Assmann, G; Zidek, W			Phosphatidylcholine-specific phospholipase C regulates thapsigargin-induced calcium influx in human lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTRACELLULAR CA2+ STORES; PANCREATIC ACINAR-CELLS; CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; INOSITOL-TRISPHOSPHATE; T-CELLS; CA-2+ CONCENTRATION; CYCLOPIAZONIC ACID; HL-60 GRANULOCYTES	The involvement of phosphatidylcholine-specific phospholipase C (PC-PLC) and D (PC-PLD) in the regulation of the thapsigargin-induced Ca2+ increase was investigated, Pretreatment of human lymphocytes with the PC-PLC inhibitors D609 or U73122 enhanced the thapsigargin-induced Ca2+ influx. Ey contrast, no effect was observed in the presence of phospholipase D inhibitor butanol, Addition of exogenous PC-PLC but not PC-PLD to lymphocytes prestimulated with thapsigargin led to a decrease of intracellular Ca2+. In addition, thapsigargin was shown to release diacylglycerol (DAG) from cellular phosphatidylcholine pools, The thapsigargin-induced DAG formation was inhibited by U73122 and D609 but not by butanol, Moreover, no formation of the PC-PLD activity marker phosphatidylbutanol was detected, Thapsigargin-induced DAG formation was dependent on the Ca2+ entry, as it was abolished in the absence of extracellular Ca2+ or in the presence of Ni2+. Further investigations demonstrated that the inhibition of the cellular DAG target, protein kinase C (PKC), enhanced thapsigargin-induced Ca2+ increase, whereas direct PKC activation had an inhibitory effect. Taken together, our results reveal the involvement of PC-PLC in the regulation of the thapsigargin-induced Ca2+ increase and point to the existence of a physiologic feedback mechanism activated by Ca2+ influx and acting via consecutive activation of PC-PLC and PKC to limit the rise of intracellular Ca2+.	Ruhr Univ Bochum, Univ Klin Marienhosp, D-44625 Herne, Germany; Univ Munster, Inst Klin Chem & Lab Med, Zent Lab, D-4400 Munster, Germany; Univ Munster, Inst Arterioskleroseforsch, D-48129 Munster, Germany	Ruhr University Bochum; St. Marien Hospital; University of Munster; University of Munster	Zidek, W (corresponding author), Ruhr Univ Bochum, Univ Klin Marienhosp, Holkeskampring 40, D-44625 Herne, Germany.		Tepel, Martin/GRS-9581-2022	Tepel, Martin/0000-0002-0086-0997				ALI H, 1994, BIOCHEM J, V304, P431, DOI 10.1042/bj3040431; BALASUBRAMANYAM M, 1993, AM J PHYSIOL, V265, pC321, DOI 10.1152/ajpcell.1993.265.2.C321; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIANCHINI L, 1993, J BIOL CHEM, V268, P3357; CANTRELL DA, 1989, J IMMUNOL, V143, P3653; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CONROY LA, 1994, BIOCHEM J, V303, P671, DOI 10.1042/bj3030671; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; FRIEDLAENDER MM, 1992, AM J PHYSIOL, V264, pF845; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; GELFAND EW, 1988, EUR J IMMUNOL, V18, P917, DOI 10.1002/eji.1830180613; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASLAM RJ, 1993, ADV EXP MED BIOL, V344, P149; HEEMSKERK JWM, 1994, EUR J BIOCHEM, V223, P543, DOI 10.1111/j.1432-1033.1994.tb19023.x; HORWITZ J, 1995, NEUROCHEM RES, V20, P1041, DOI 10.1007/BF00995558; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P14858; IZUMI S, 1992, ENDOCRINOLOGY, V131, P1936; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; Louzao MC, 1996, J BIOL CHEM, V271, P14807, DOI 10.1074/jbc.271.25.14807; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MERRITT JE, 1988, J BIOL CHEM, V263, P6161; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MOLLINEDO F, 1994, J IMMUNOL, V153, P2457; MONTERO M, 1994, BIOCHEM J, V303, P559, DOI 10.1042/bj3030559; NOFER JR, 1995, BIOCHEM BIOPH RES CO, V207, P148, DOI 10.1006/bbrc.1995.1165; PAREKH AB, 1995, PFLUG ARCH EUR J PHY, V430, P954, DOI 10.1007/BF01837409; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PERKINS RS, 1995, BIOCHEM J, V310, P795, DOI 10.1042/bj3100795; PETERSON MW, 1992, AM J PHYSIOL, V263, pC1216, DOI 10.1152/ajpcell.1992.263.6.C1216; PFEILSCHIFTER J, 1993, BRIT J PHARMACOL, V110, P847, DOI 10.1111/j.1476-5381.1993.tb13890.x; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; PYNE S, 1995, BIOCHEM J, V311, P637, DOI 10.1042/bj3110637; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RUFFINI L, 1993, AM J PHYSIOL, V265, pC1100; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Sciorra VA, 1996, J BIOL CHEM, V271, P14226, DOI 10.1074/jbc.271.24.14226; SHIVNAN E, 1995, J IMMUNOL, V154, P1146; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TEPEL M, 1995, CIRC RES, V77, P1024, DOI 10.1161/01.RES.77.5.1024; TEPEL M, 1994, J BIOL CHEM, V269, P26239; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORNQUIST K, 1993, BIOCHEM J, V290, P443; TORNQUIST K, 1994, J CELL PHYSIOL, V160, P40, DOI 10.1002/jcp.1041600106; TROYER DA, 1992, AM J PHYSIOL, V262, pF185, DOI 10.1152/ajprenal.1992.262.2.F185; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; VICKERS JD, 1993, J PHARMACOL EXP THER, V266, P1156; WACHOLTZ MC, 1993, J IMMUNOL, V150, P5338; WALTER M, 1995, ARTERIOSCLER THROMB, V15, P1024; WILLEMS PHGM, 1994, PFLUG ARCH EUR J PHY, V427, P233, DOI 10.1007/BF00374529; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; WOLF RA, 1985, J BIOL CHEM, V260, P7295; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; XU X, 1994, J BIOL CHEM, V269, P12645; YADA T, 1989, J BIOL CHEM, V264, P2455; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	69	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32861	32868		10.1074/jbc.272.52.32861	http://dx.doi.org/10.1074/jbc.272.52.32861			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407064	hybrid			2022-12-25	WOS:000071182900025
J	Ishizaka, N; Alexander, RW; Laursen, JB; Kai, H; Fukui, T; Oppermann, M; Lefkowitz, RJ; Lyons, PR; Griendling, KK				Ishizaka, N; Alexander, RW; Laursen, JB; Kai, H; Fukui, T; Oppermann, M; Lefkowitz, RJ; Lyons, PR; Griendling, KK			G protein-coupled receptor kinase 5 in cultured vascular smooth muscle cells and rat aorta - Regulation by angiotensin II and hypertension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT PHOSPHORYLATION; DESENSITIZATION; TACHYPHYLAXIS; INVOLVEMENT; SPECIFICITY; PHOSPHATIDYLCHOLINE; DIACYLGLYCEROL; EXPRESSION; ACTIVATION; SUBUNITS	GRK5, a recently cloned member of the G protein-coupled receptor kinase family, has been shown to phosphorylate and participate in the desensitization of angiotensin II (Ang II) type 1A (AT(1A)) receptors. In this study, the effect of angiotensin II on GRK5 expression was examined in cultured vascular smooth muscle cells and aortas of Ang II-infused hypertensive rats. In vascular smooth muscle cells, Ang II (100 nM) up-regulated GRK5 mRNA as early as 1 h, with a peak at 16 h. This up-regulation was dose- and calcium-dependent. The increase in GRK5 mRNA was reflected in a smaller increase in protein expression, which nonetheless had functional significance since AT(1) receptor phosphorylation was increased and phospholipase C activation was decreased following prolonged incubation with Ang II. In aortas of Ang II-infused hypertensive rats, both GRK5 mRNA and protein levels increased similar to 3-fold compared with sham-operated rats at 5 and 7 days, respectively. This up-regulation was blocked either by losartan or by the nonspecific vasodilator hydralazine. Since a subpressor dose of Ang II did not increase GRK5 mRNA levels and norepinephrine infusion also increased GRK5 mRNA expression, we conclude that Ang II-induced GRK5 up-regulation in rat aortas may be due to hypertension per se. Hormone-and hemodynamic stress-induced GRK5 regulation may provide a novel molecular basis for long-term regulation of agonist sensitivity of vascular cells.	Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA; Kurume Univ, Sch Med, Dept Internal Med, Kurume, Fukuoka 830, Japan; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Emory University; Kurume University; Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Ishizaka, N (corresponding author), Emory Univ, Sch Med, Div Cardiol, Dept Med, 319 Woodruff Mem Bldg,1639 Pierce Dr, Atlanta, GA 30322 USA.		Lefkowitz, Robert/AAW-2649-2021	Griendling, Kathy/0000-0002-9456-8582	NHLBI NIH HHS [HL47557] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047557] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKEN JW, 1974, POL J PHARMACOL PHAR, V26, P217; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Fukui T, 1997, CIRC RES, V80, P45, DOI 10.1161/01.RES.80.1.45; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; GRIENDLING KK, 1989, J CARDIOVASC PHARM, V14, pS27, DOI 10.1097/00005344-198906146-00008; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GUNTHER S, 1980, NATURE, V287, P230, DOI 10.1038/287230a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; Ishizaka N, 1997, CIRCULATION, V96, P1923, DOI 10.1161/01.CIR.96.6.1923; ISHIZAKA N, 1996, FASEB J, V10, pA1134; Kai H, 1996, MOL PHARMACOL, V49, P96; KHAIRALLAH PA, 1966, CIRC RES, V19, P247, DOI 10.1161/01.RES.19.2.247; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; LASSEGUE B, 1993, BIOCHEM J, V292, P509, DOI 10.1042/bj2920509; LASSEGUE B, 1991, BIOCHEM J, V276, P19, DOI 10.1042/bj2760019; Nagayama Y, 1996, J BIOL CHEM, V271, P10143, DOI 10.1074/jbc.271.17.10143; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; OSHIRO MEM, 1984, BLOOD VESSELS, V21, P72; PALAIC D, 1971, J PHARMACOL EXP THER, V179, P522; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PEI G, 1995, MOL PHARMACOL, V48, P173; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; Ungerer M, 1996, CIRC RES, V79, P455, DOI 10.1161/01.RES.79.3.455	35	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32482	32488		10.1074/jbc.272.51.32482	http://dx.doi.org/10.1074/jbc.272.51.32482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405459	hybrid			2022-12-25	WOS:000071108000078
J	Adachi, H; Tsujimoto, M; Arai, H; Inoue, K				Adachi, H; Tsujimoto, M; Arai, H; Inoue, K			Expression cloning of a novel scavenger receptor from human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MESSENGER-RNA; PROTEIN; MACROPHAGES; CHOLESTEROL; METABOLISM; ARTERIES; BINDING	Scavenger receptors mediate the endocytosis of chemically modified lipoproteins, such as acetylated low density lipoprotein (Ac-LDL) and oxidized LDL (Ox-LDL), and have been implicated in the pathogenesis of atherosclerosis. The evidence that endothelial cells possess scavenger receptor activity is substantial, and this property is widely used in the isolation of endothelial cells from vascular tissues. In the current study, we have isolated, by expression cloning, the cDNA encoding a novel type of scavenger receptor expressed by endothelial cells (SREC), which mediates the binding and degradation of Ac-LDL. The primary structure of the molecule has no significant homology to other types of scavenger receptors, including the recently cloned endothelial cell Ox-LDL receptor, a member of the C-type lectin family. The cDNA encodes a protein of 830 amino acids with a calculated molecular mass of 85,735 Da (mature peptide). Chinese hamster ovary cells stably expressing SREC bound I-125-labeled Ac-LDL with high affinity (K-d = 3.0 mu g/ml, approximately 1.7 nM) and degraded them via an endocytic pathway. Association of DiII-Ac-LDL were effectively inhibited by Ox-LDL, malondialdehyde-modified LDL, dextran sulfate, and polyinosinic acid, but not by natural LDL and heparin. The cloned receptor has several characteristic domain structures, including an N-terminal extracellular domain with five epidermal growth factor-like cysteine pattern signatures and an unusually long C-terminal cytoplasmic domain (391 amino acids) composed of a Ser/Pro-rich region followed by a Gly-rich region.	UNIV TOKYO,GRAD SCH PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	Adachi, H (corresponding author), RIKEN,INST PHYS & CHEM RES,BIOORGAN CHEM LAB,2-1 HIROSAWA,WAKO,SAITAMA 35101,JAPAN.							ACTON SL, 1994, J BIOL CHEM, V269, P21003; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ARENDT RM, 1990, CIRCULATION, V82, P248; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; BROMQUIST MC, 1984, P NATL ACAD SCI USA, V81, P7363; COOPER JA, 1984, J BIOL CHEM, V259, P7835; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FUKASAWA M, 1995, J BIOL CHEM, V270, P1921, DOI 10.1074/jbc.270.4.1921; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; KODOMA T, 1990, NATURE, V343, P531; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; PALKAMA T, 1993, CLIN EXP IMMUNOL, V92, P353; ROHER L, 1990, NATURE, V343, P570; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; STANTON LW, 1992, J BIOL CHEM, V267, P22446; VANHINSBERGH VWM, 1983, ARTERIOSCLEROSIS, V3, P547, DOI 10.1161/01.ATV.3.6.547; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	25	150	155	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31217	31220		10.1074/jbc.272.50.31217	http://dx.doi.org/10.1074/jbc.272.50.31217			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395444	hybrid			2022-12-25	WOS:A1997YL41900003
J	Xie, Z; Price, D				Xie, Z; Price, D			Drosophila factor 2, an RNA polymerase II transcript release factor, has DNA-dependent ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI REP; ELONGATION COMPLEXES; GENE-EXPRESSION; TERMINATION; PROTEIN; RHO; PURIFICATION; HYDROLYSIS; HELICASE	Drosophila factor 2 has been identified as a component of negative transcription elongation factor (N-TEF) that causes the release of RNA polymerase II transcripts in an ATP-dependent manner (Xie, Z. and Price D. H. (1996) J. Biol. Chem. 271, 11043-11046). We show here that the transcript release activity of factor 2 requires ATP or dATP and that adenosine 5'-O-(thiotriphosphate) (ATP gamma S), adenosine 5'-(beta,gamma-imino)triphosphate (AMP-PNP), or other NTPs do not support the activity, Factor 2 demonstrated a strong DNA-dependent ATPase activity that correlated with its transcript release activity, At 20 mu g/ml DNA, the ATPase activity of factor 2 had an apparent K-m(ATP) Of 28 mu M and an estimated K-cat of 140 min(-1). Factor 2 caused the release of nascent transcripts. associated with elongation complexes generated by RNA polymerase II on a dC-tailed template, Therefore, no other protein cofactors are required for the transcript release activity of factor 2, Using the dC-tailed template assay, it was found that renaturation of the template was required for factor 2 function.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NIGMS NIH HHS [R01-GM35500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; Deng L, 1996, J BIOL CHEM, V271, P29386, DOI 10.1074/jbc.271.46.29386; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KUMAR KA, 1993, J BIOL CHEM, V268, P26162; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; Verhage RA, 1997, MOL GEN GENET, V254, P284, DOI 10.1007/s004380050417; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036	33	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31902	31907		10.1074/jbc.272.50.31902	http://dx.doi.org/10.1074/jbc.272.50.31902			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395538	hybrid			2022-12-25	WOS:A1997YL41900097
J	Laune, D; Molina, F; Ferrieres, G; Mani, JC; Cohen, P; Simon, D; Bernardi, T; Piechaczyk, M; Pau, B; Granier, C				Laune, D; Molina, F; Ferrieres, G; Mani, JC; Cohen, P; Simon, D; Bernardi, T; Piechaczyk, M; Pau, B; Granier, C			Systematic exploration of the antigen binding-activity of synthetic peptides isolated from the variable regions of immunoglobulins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; 3-DIMENSIONAL STRUCTURE; LIGHT-CHAINS; LYSOZYME; FRAGMENT; COMPLEMENTARITY; COMPLEXES; AFFINITY; SITES	Sets of short (12 residues) cellulose-bound synthetic overlapping peptides derived from the sequences of the variable regions of the heavy and light chains of three different antibodies (an anti-thyroglobulin antibody, the HyHEL-5 anti-lysozyme antibody, and an anti-angiotensin II antibody) were used to systematically assess the antigen binding capacity of peptides from the antibody paratope outside their natural molecular context. Peptides enclosing one or several of the complementarity determining region (CDR) residues had antigen binding activity, although the most active peptides were not necessarily those bearing the greatest number of CDR residues. Several residues from the framework region, preceding or following the CDR, were found to play a role in binding. Affinity constants from 4.1 x 10(-7) to 6.7 x 10(-8) M-1 for the soluble form of 9 lysozyme-binding dodecapeptides were measured by BIAcore analysis. Alanine scanning of lysozyme-binding hexapeptides from the HyHEL-5 sequence identified 38 residues important for binding, of which 22 corresponded to residues that had been shown by x-ray crystallography to be at the interface between HyHEL-5 and lysozyme. Our results could be of interest for the rational identification of biologically active peptides derived from antibody sequences and in providing an experimental basis for mutagenesis of the antibody paratope.	Fac Pharm Montpellier, CNRS, UMR 9921, F-34000 Montpellier, France; Sanofi Rech, F-34000 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Sanofi-Aventis; Sanofi France	Granier, C (corresponding author), Fac Pharm Montpellier, CNRS, UMR 9921, Ave Charles Flahault, F-34000 Montpellier, France.	granier@pharma.univ-montpl.fr	GRANIER, Claude/A-8841-2008; Molina, Franck/E-8419-2011; Cohen, Pascale/I-5875-2012	Cohen, Pascale/0000-0001-7016-9598				AMIT A, 1986, NATURE, V313, P156; BENJAMIN DC, 1992, BIOCHEMISTRY-US, V31, P9539, DOI 10.1021/bi00155a005; Cohen GH, 1996, ACTA CRYSTALLOGR D, V52, P315, DOI 10.1107/S0907444995014855; DAVIES D, 1990, ANNU REV BIOCHEM, V50, P439; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; IGARASHI K, 1995, J BIOCHEM-TOKYO, V117, P452, DOI 10.1093/jb/117.2.452; KANG CY, 1988, SCIENCE, V240, P1034, DOI 10.1126/science.3368787; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; LEVI M, 1993, P NATL ACAD SCI USA, V90, P4373; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; Molina F, 1996, PEPTIDE RES, V9, P151; Noel D, 1996, J IMMUNOL METHODS, V193, P177, DOI 10.1016/0022-1759(96)00043-9; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PIECHACZYK M, 1985, HYBRIDOMA, V4, P351; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; Reineke U, 1996, MOL DIVERS, V1, P141, DOI 10.1007/BF01544952; SARAGOVI UH, 1992, IMMUNOMETHODS, V1, P5; Sheriff S, 1996, NAT STRUCT BIOL, V3, P733, DOI 10.1038/nsb0996-733; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SIMON D, 1992, CLIN CHEM, V38, P1963; TAUB R, 1989, J BIOL CHEM, V264, P259; TRIFILIEFF E, 1991, MOL IMMUNOL, V28, P889, DOI 10.1016/0161-5890(91)90053-M; WELLING GW, 1991, J CHROMATOGR, V548, P235, DOI 10.1016/S0021-9673(01)88605-2; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; WILSON IA, 1994, RES IMMUNOL, V145, P73, DOI 10.1016/S0923-2494(94)80049-9; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472	36	58	79	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30937	30944		10.1074/jbc.272.49.30937	http://dx.doi.org/10.1074/jbc.272.49.30937			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388240	hybrid			2022-12-25	WOS:000071640800053
J	Maddox, BK; Keene, DR; Sakai, LY; Charbonneau, NL; Morris, NP; Ridgway, CC; Boswell, BA; Sussman, MD; Horton, WA; Bachinger, HP; Hecht, JT				Maddox, BK; Keene, DR; Sakai, LY; Charbonneau, NL; Morris, NP; Ridgway, CC; Boswell, BA; Sussman, MD; Horton, WA; Bachinger, HP; Hecht, JT			The fate of cartilage oligomeric matrix protein is determined by the cell type in the case of a novel mutation in pseudoachondroplasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; ENDOPLASMIC-RETICULUM; PERICENTROMERIC REGION; GENETIC-LINKAGE; COLLAGEN; COMP; CHROMOSOME-19; BINDING; IX; THROMBOSPONDIN-1	We have identified a novel missense mutation in a pseudoachondroplasia (PSACH) patient in one of the type III repeats of cartilage oligomeric matrix protein (COMP), Enlarged lamellar rough endoplasmic reticulum vesicles were shown to contain accumulated COMP along with type IX collagen, a cartilage-specific component. COMP was secreted and assembled normally into the extracellular matrix of tendon, demonstrating that the accumulation of COMP in chondrocytes was a cell-specific phenomenon. We believe that the intracellular storage of COMP causes a nonspecific aggregation of cartilage-specific molecules and results in a cartilage matrix deficient in required structural components leading to impaired cartilage growth and maintenance, These data support a common pathogenetic mechanism behind two clinically related chondrodysplasias, PSACH and multiple epiphyseal dysplasia.	Shriners Hosp Crippled Childrens, Res Dept, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX 77225 USA; Shriners Hosp Crippled Children, Houston, TX 77225 USA	Oregon Health & Science University; Oregon Health & Science University; University of Texas System	Horton, WA (corresponding author), Shriners Hosp Crippled Childrens, Res Dept, Portland, OR 97201 USA.							Beck K, 1996, J BIOL CHEM, V271, P21566, DOI 10.1074/jbc.271.35.21566; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; BRIGGS MD, 1994, AM J HUM GENET, V55, P678; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; COOPER RR, 1973, J BONE JOINT SURG AM, VA 55, P475, DOI 10.2106/00004623-197355030-00003; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Horton William A., 1993, P641; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LAWLER J, 1983, J BIOL CHEM, V258, P2098; Maddox BK, 1997, MATRIX BIOL, V16, P93, DOI 10.1016/S0945-053X(97)90038-X; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MAYNARD JA, 1972, LAB INVEST, V26, P40; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OEHLMANN R, 1994, AM J HUM GENET, V54, P3; Prabakaran D, 1996, EUR J CELL BIOL, V70, P134; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; STANESCU V, 1984, J BONE JOINT SURG AM, V66A, P817, DOI 10.2106/00004623-198466060-00002; STANESCU V, 1982, EUR J PEDIATR, V138, P221, DOI 10.1007/BF00441206; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; WARMAN ML, 1994, GENOMICS, V23, P158, DOI 10.1006/geno.1994.1472	33	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30993	30997		10.1074/jbc.272.49.30993	http://dx.doi.org/10.1074/jbc.272.49.30993			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388247	hybrid			2022-12-25	WOS:000071640800060
J	Ji, C; Marnett, LJ; Pietenpol, JA				Ji, C; Marnett, LJ; Pietenpol, JA			Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels	ONCOGENE			English	Article						p53; p21; cell cycle synchronization; mimosine; aphidicolin	P53-INDEPENDENT PATHWAY; HUMAN FIBROBLASTS; GROWTH ARREST; DNA-SYNTHESIS; DIFFERENTIATION; MIMOSINE; CHECKPOINTS; SUPPRESSION; IRRADIATION; INHIBITION	Mimosine (MIM) and aphidicolin (APH) are two agents frequently used in tissue culture-based experiments to achieve cell synchronization at late G1 and S phases. Following MIM or APH treatment of human cancer cell lines, a reversible growth arrest in late G1 and S phases of the cell cycle was correlated with moderate increases in p53 and p21 protein levels. Both p53-dependent and -independent increases in p21 were observed following treatment with either agent. However, a striking increase in p21 protein levels and a continuous elevation in both p53 and p21 protein levels were observed over 48 h after cells re-entered the cell cycle following the chemically-induced synchronization. In addition, the increase in p21 protein levels typically seen following treatment of cells with DNA damaging agents, was enhanced when cells were treated with genotoxic agents following MIM or APH synchronization. These findings suggest that caution should be exercised when interpreting results from experiments using cell synchronization agents, in particular, studies designed to investigate p53- and p21-regulatory pathways.	VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,DEPT CHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,VANDERBILT CANC CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University				Li, Tao/0000-0003-3831-901X	NCI NIH HHS [CA68485, CA47479, CA68450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479, P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; CHUAN J, 1997, P AM ASSOC CANC RES, V38, P1324; DAI YM, 1994, VIROLOGY, V205, P210, DOI 10.1006/viro.1994.1636; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1995, ENV HLTH PERSPECT, V5, P55; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STEWART N, 1995, ONCOGENE, V10, P109; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; ZHANG W, 1995, CANCER RES, V55, P668	27	32	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2749	2753		10.1038/sj.onc.1201441	http://dx.doi.org/10.1038/sj.onc.1201441			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9401002				2022-12-25	WOS:A1997YH46800013
J	Kwon, HJ; Yoshida, M; Nagaoka, R; Obinata, T; Beppu, T; Horinouchi, S				Kwon, HJ; Yoshida, M; Nagaoka, R; Obinata, T; Beppu, T; Horinouchi, S			Suppression of morphological transformation by radicicol is accompanied by enhanced gelsolin expression	ONCOGENE			English	Article						radicicol; transformation; oncogene; actin stress fiber; gelsolin	TYROSINE KINASE INHIBITORS; RAT-KIDNEY CELLS; TRICHOSTATIN-A; CARCINOMA-CELLS; NIH3T3 CELLS; HISTONE DEACETYLASE; ACTIN EXPRESSION; FLAT REVERTANTS; PROTEIN; FIBROBLASTS	Radicicol, an inhibitor of Src-family protein-tyrosine kinases, causes morphological reversion of v-src-and v-Ha-ras-transformed fibroblasts and arrest of the cell cycle at both the G1 and the G2 phases, Radicicol was found to inhibit the growth of several other oncogene-transformed cell lines and human carcinoma cell lines and to revert their cell morphology to be flat, In the radicicol-treated flat cells, actin stress fiber bundles were reorganized, Since this effect of radicicol on these cell lines was inhibited by cycloheximide, de novo protein synthesis is required for the morphological reversion, Screening of cellular proteins enhanced in response to radicicol by two-dimensional gel electrophoresis suggested that the amount of gelsolin, an actin regulatory. protein, was distinctly increased upon radicicol treatment, Western blot and Northern blot analyses showed that radicicol enhanced transcription of the gelsolin gene in human carcinoma cell lines, as a result of,which the amount of gelsolin was increased several folds, Injection with an anti-gelsolin antibody into cells and successive treatment with radicicol resulted in approximately 80% reduction of the number of flat cells with stress fibers in comparison with controls treated with an irrelevant antibody, These results show that elevated expression of gelsolin is suppression of transformation actin stress fibers in human carcinoma cells by radicicol.	UNIV TOKYO,GRAD SCH AGR & LIFE SCI,DEPT BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,CHIBA 263,JAPAN	University of Tokyo; Chiba University			Yoshida, Minoru/C-8049-2014; 권, 호정/AAS-3642-2021	Yoshida, Minoru/0000-0002-4376-5674; 				Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BANNO Y, 1992, J BIOL CHEM, V267, P6488; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DELCASTILLO AR, 1992, THROMB HAEMOSTASIS, V67, P248; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; FUJITA H, 1995, EUR J BIOCHEM, V229, P615, DOI 10.1111/j.1432-1033.1995.tb20505.x; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HALL MD, 1988, EXP CELL RES, V179, P115, DOI 10.1016/0014-4827(88)90353-9; HIGGINS PJ, 1991, BIOCHEM J, V279, P883, DOI 10.1042/bj2790883; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MORIYA S, 1994, INT J ONCOL, V5, P1347; MULLAUER L, 1990, BIOCHEM BIOPH RES CO, V171, P852, DOI 10.1016/0006-291X(90)91224-G; MULLAUER L, 1993, ONCOGENE, V8, P2531; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PATTON WF, 1990, BIOTECHNIQUES, V8, P518; PORTER RM, 1993, J PATHOL, V170, P435, DOI 10.1002/path.1711700406; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sonoda H, 1996, ONCOGENE, V13, P143; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; SUGITA K, 1992, CANCER RES, V52, P168; TANAKA M, 1995, CANCER RES, V55, P3228; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZHAO JF, 1995, ONCOGENE, V11, P161	43	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2625	2631		10.1038/sj.onc.1201443	http://dx.doi.org/10.1038/sj.onc.1201443			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399650				2022-12-25	WOS:A1997YG73200012
J	Muller, D; Bouchard, C; Rudolph, B; Steiner, P; Stuckmann, I; Saffrich, R; Ansorge, W; Huttner, W; Eilers, M				Muller, D; Bouchard, C; Rudolph, B; Steiner, P; Stuckmann, I; Saffrich, R; Ansorge, W; Huttner, W; Eilers, M			Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes	ONCOGENE			English	Article						Myc; p27; cyclin E; cdk2	UBIQUITIN-PROTEASOME PATHWAY; C-MYC; DEPENDENT KINASES; CELL-CYCLE; TRANSCRIPTIONAL REPRESSOR; ACTIVATES TRANSCRIPTION; IN-VIVO; MAX; GENE; PROTEINS	Activation of Myc triggers a rapid induction of cyclin El cdk2 kinase activity and degradation of p27. Overt degradation of p27 is preceded by a specific dissociation of p27 from cyclin E/cdk2, but not from cyclin D/cdk4 complexes. We now show that cyclin E/cdk2 phosphorylates p27 at a carboxy-terminal threonine residue (T187) in vitro; mutation of this residue to valine stabilises cyclin E/cdk2 complexes. This reaction is not significantly inhibited by high concentrations of p27, suggesting that cdk2 bound to p27 is catalytically active. In vivo, p27 bound to cyclins E and A, but not to D-type cyclins is phosphorylated. Myc-induced release of p27 from cdk2 requires cdk2 kinase activity and is delayed in a T187V mutant of p27. After induction of MSc, p27 phosphorylated at threonine 187 transiently accumulates in a non cdk2 bound form. Our data suggest a mechanism in which p27 is released from cyclin E/cdk2 upon phosphorylation; in Myc-transformed cells, release is efficient as phosphorylated p27 is transiently bound in a non-cdk2 containing complex and subsequently degraded.	ZENTRUM MOL BIOL, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, DEPT NEUROBIOL, D-69120 HEIDELBERG, GERMANY; EUROPEAN MOL BIOL LAB, BIOCHEM INSTRUMENTAT PROGRAMME, D-69117 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL)			Ansorge, Wilhelm/AAN-8780-2020	Eilers, Martin/0000-0002-0376-6533; Saffrich, Rainer/0000-0002-0547-4550				ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; An SK, 1996, FEBS LETT, V386, P115, DOI 10.1016/0014-5793(96)00427-9; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BERNS K, 1997, IN PRESS ONCOGENE; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Celis JE, 1995, ELECTROPHORESIS, V16, P2177, DOI 10.1002/elps.11501601355; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAAS K, 1997, IN PRESS ONCOGENE; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEREIRA MEF, 1994, J NEUROCHEM, V63, P1578; PEREZROGER I, 1997, IN PRESS ONCOGENE; PEUKERT K, 1997, IN PRESS EMBO J; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PUSCH O, 1997, IN PRESS ONCOGENE; Rao G, 1996, ONCOGENE, V12, P1165; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wilmut I., 1990, TRENDS BIOTECHNOLOGY; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	64	146	149	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	1997	15	21					2561	2576		10.1038/sj.onc.1201440	http://dx.doi.org/10.1038/sj.onc.1201440			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399644				2022-12-25	WOS:A1997YG73200006
J	Widmann, C; Johnson, NL; Gardner, AM; Smith, RJ; Johnson, GL				Widmann, C; Johnson, NL; Gardner, AM; Smith, RJ; Johnson, GL			Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1	ONCOGENE			English	Article						MEK kinase 1; apoptosis; UVC; cisplatin	PROTEIN-KINASE; C-JUN; BINDING PROTEINS; TYROSINE KINASE; CERAMIDE; PATHWAY; GROWTH; ERK; MYC	MEK kinases (MEKKs) are serine-threonine kinases that regulate sequential protein phosphorylation pathways involving mitogen-activated protein kinases (MAPKs), including members of the Jun kinase (JNK) family. MEKK1 is a 196 kDa protein that when cleaved by caspase-3-like proteases generates an active COOH-terminal kinase domain. Expression of the MEKK1 kinase domain is sufficient to induce apoptosis. Mutation of MEKK1 to prevent its proteolytic cleavage protects cells from MEKK1-mediated cell death even though the JNK pathway is still activated, indicating that JNK activation is not sufficient to induce cell death. The inducible acute expression at modest levels of the activated MEKK1 kinase domain can be used to potentiate the apoptotic response to low dose ultraviolet irradiation and cisplatin. Similarly, in L929 fibrosarcoma cells inducible acute expression of the kinase domain of MEKK1 markedly increased the cell death response to tumor necrosis factor alpha(TNF alpha). The findings demonstrate that acute expression of an active farm of MEKK1 can potentiate the cell death response to external stress stimuli. Manipulation of MEKK1 proteolysis and its regulation of signal pathways involved in apoptosis has significant potential for anticancer therapies when used in combination with therapeutic agents at doses that alone have little or modest effects on cell viability.	NATL JEWISH CTR IMMUNOL & RESP MED,PROGRAM MOL SIGNAL TRANSDUCT,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Gardner, Anne/0000-0001-7095-772X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871, R01DK048845] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58157] Funding Source: Medline; NIDDK NIH HHS [DK 37871, DK 48845] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CHU G, 1994, J BIOL CHEM, V269, P787; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANGER GR, 1997, IN PRESS EMBO J; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FESHEL K, 1991, AM J PATHOL, V139, P251; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEIBI M, 1993, GENE DEV, V7, P2135; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; JNO P, 1997, MOL CELL BIOL, V17, P24; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KRYPRIANOU N, 1991, J NATL CANCER I, V83, P346; KRYRIAKIS JM, 1994, NATURE, V369, P156; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LASSIGNALJOHNSO.N, 1996, J BIOL CHEM, V271, P3229; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; ROITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WYLLIE AH, 1987, BRIT J CANCER, V56, P151; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	32	62	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2439	2447		10.1038/sj.onc.1201421	http://dx.doi.org/10.1038/sj.onc.1201421			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395240				2022-12-25	WOS:A1997YE96300006
J	Qing, J; Maher, VM; Tran, H; Argraves, WS; Dunstan, RW; McCormick, JJ				Qing, J; Maher, VM; Tran, H; Argraves, WS; Dunstan, RW; McCormick, JJ			Suppression of anchorage-independent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines	ONCOGENE			English	Article						differential mRNA display; fibulin-1D; anchorage-independent growth; tumorigenicity; matrigel invasion	LAMININ-BINDING INTEGRIN; EXTRACELLULAR-MATRIX; MALIGNANT TRANSFORMATION; DIFFERENTIAL DISPLAY; MESSENGER-RNA; HUMAN-FIBROBLASTS; PROTEIN; FIBRONECTIN; ONCOGENE; GENE	Using differential display, we identified an mRNA that is markedly down-regulated in cell line 6A/SB1, derived from a fibrosarcoma formed in an athymic mouse following injection of carcinogen-transformed MSU-1.1 cells, The nontumorigenic parental cell strain, MSU-1.1, expresses high levels of this mRNA, Sequencing of the corresponding cDNA fragment revealed that it corresponded to an expressed sequence tag, which ultimately led to its identification as the fibulin-1D gene, Fibulin-1 is a cysteine-rich, calcium-binding extracellular matrix and plasma protein, which has four isoforms, A-D, derived from alternative splicing, Northern and Western blotting analysis of 16 cell lines established from tumors formed in athymic mice by MSU-1.1-derived cell strains independently transformed in culture showed that 44% exhibited low level or lack of expression of fibulin-1D mRNA and protein, In a similar analysis of 15 malignant cell lines derived from patients, 80% showed low level or no expression, To study the role of fibulin-1D in transformation, we transfected 6A/SB1 cells and a human fibrosarcoma-derived cell line (SHAC) with a fibulin-1D cDNA expression construct, Transfectants displaying high levels of fibulin-1D were isolated and characterized, Elevated expression of fibulin-1D led to reduced ability to form colonies in soft agar and reduced invasive potential as tested in a matrigel in vitro invasion assay, Furthermore, expression of fibulin-1D resulted in a markedly extended latency in tumor formation in athymic mice, These results indicate that low expression of fibulin-1D plays a role in tumor formation and invasion.	MICHIGAN STATE UNIV,DEPT BIOCHEM,CARCINOGENESIS LAB,E LANSING,MI 48824; MICHIGAN STATE UNIV,CTR CANC,DEPT MICROBIOL,E LANSING,MI 48824; MED UNIV S CAROLINA,DEPT CELL BIOL & ANAT,CHARLESTON,SC 29425; MICHIGAN STATE UNIV,DEPT PATHOL,E LANSING,MI 48824	Michigan State University; Michigan State University; Medical University of South Carolina; Michigan State University					NCI NIH HHS [CA60907] Funding Source: Medline; NIA NIH HHS [AG11026] Funding Source: Medline; NIGMS NIH HHS [GM42912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011026] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akamatsu H, 1996, CANCER RES, V56, P4541; ALBINI A, 1987, CANCER RES, V47, P3239; ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1991, IN VIVO, V5, P489; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BROWN JC, 1994, J CELL SCI, V107, P329; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEE SH, 1993, J BIOL CHEM, V268, P14972; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mok SC, 1996, ONCOGENE, V12, P1895; MORGAN TL, 1991, EXP CELL RES, V197, P125, DOI 10.1016/0014-4827(91)90489-H; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; Sasaki T, 1996, EUR J BIOCHEM, V240, P427, DOI 10.1111/j.1432-1033.1996.0427h.x; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; STEEL DM, 1989, J CELL SCI, V93, P515; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; VONDERMARK H, 1991, J BIOL CHEM, V266, P23595; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILSON DM, 1990, CANCER RES, V50, P5587; YANG DJ, 1992, P NATL ACAD SCI USA, V89, P2237, DOI 10.1073/pnas.89.6.2237; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404	43	82	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2159	2168		10.1038/sj.onc.1201385	http://dx.doi.org/10.1038/sj.onc.1201385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393974				2022-12-25	WOS:A1997YD01900004
J	Ohsugi, M; Kuramochi, S; Matsuda, S; Yamamoto, T				Ohsugi, M; Kuramochi, S; Matsuda, S; Yamamoto, T			Molecular cloning and characterization of a novel cytoplasmic protein-tyrosine phosphatase that is specifically expressed in spermatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTICULAR GERM-CELLS; C-MOS; PHOSPHOTYROSINE PHOSPHATASE; MEIOTIC MATURATION; TRANSCRIPT FERT; MOUSE; IDENTIFICATION; KINASE; GENE; PROTOONCOGENE	We identified a novel gene encoding protein-tyrosine phosphatase using a polymerase chain reaction-based method, Northern blot hybridization of RNAs from various tissues with the polymerase chain reaction-amplified DNA fragment showed that this gene was expressed exclusively in the testis. Complementary DNAs for this gene, termed typ (testis-specific tyrosine phosphatase), were obtained from a mouse testis cDNA library. Nucleotide sequencing of the cDNAs revealed an open reading frame that encoded 426 amino acids. The predicted Typ protein contained a single catalytic domain at the carboxyl-terminal half, No hydrophobic stretch for a possible transmembrane sequence or signal sequence was found, suggesting that Typ is a cytoplasmic protein-tyrosine phosphatase, The amino-terminal half of Typ did not share significant homologies with the other known proteins but contained a region rich in PEST residues. Indirect immunofluorescence studies and in situ hybridization analysis showed that Typ was specifically expressed in testicular germ cells that underwent meiosis. Developmentally, Typ was detected between 2 and 3 weeks after birth, in parallel with the onset of meiosis. Thus, Typ is a new member of the cytoplasmic protein-tyrosine phosphatases that may play an important role(s) in spermatogenesis and/or meiosis.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 108, Japan	University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.		Ohsugi, Miho/AAY-9339-2020	Ohsugi, Miho/0000-0003-0288-3428				ADACHI M, 1992, CANCER RES, V52, P737; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IWAOKI Y, 1993, EXP CELL RES, V206, P212, DOI 10.1006/excr.1993.1140; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Kuramochi S, 1996, FEBS LETT, V378, P7, DOI 10.1016/0014-5793(95)01415-2; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MAURO LJ, 1994, J BIOL CHEM, V269, P30659; MIZUNO K, 1993, MOL CELL BIOL, V13, P5513, DOI 10.1128/MCB.13.9.5513; MURAMATSU T, 1992, P NATL ACAD SCI USA, V89, P529, DOI 10.1073/pnas.89.2.529; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; NOCE T, 1992, DEV BIOL, V153, P356, DOI 10.1016/0012-1606(92)90120-6; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORRENTINO V, 1991, ONCOGENE, V6, P149; STONE RL, 1994, J BIOL CHEM, V269, P31323; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; TAKEBE Y, 1988, P NATL ACAD SCI USA, V90, P5404; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	46	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33092	33099		10.1074/jbc.272.52.33092	http://dx.doi.org/10.1074/jbc.272.52.33092			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407093	hybrid			2022-12-25	WOS:000071182900054
J	Vulsteke, V; Beullens, M; Waelkens, E; Stalmans, W; Bollen, M				Vulsteke, V; Beullens, M; Waelkens, E; Stalmans, W; Bollen, M			Properties and phosphorylation sites of baculovirus-expressed nuclear inhibitor of protein phosphatase-1 (NIPP-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; SUBUNIT; TYPE-1; MUSCLE; ENZYME	NIPP-1 is the RNA-binding subunit of a major species of protein phosphatase-1 in the nucleus. We have expressed nuclear inhibitor of protein phosphatase-1 (NIPP-1) in Sf9 cells, using the baculovirus-expression system. The purified recombinant protein was a potent (K-i = 9.9 +/- 0.3 pM) and specific inhibitor of protein phosphatase-1 and was stoichiometrically phosphorylated by protein kinases A and CK2. At physiological ionic strength, phosphorylation by these protein kinases drastically decreased the inhibitory potency of free NIPP-1. Phosphorylation of NIPP-1 in a heterodimeric complex with the catalytic subunit of protein phosphatase-1 resulted in an activation of the holoenzyme without a release of NIPP-1. Sequencing and phosphoamino acid analysis of tryptic phosphopeptides enabled us to identify Ser(178) and Ser(199) as the phosphorylation sites of protein kinase A, whereas Thr(161) and Ser(204) were phosphorylated by protein kinase CK2. These residues all conform to consensus recognition sites for phosphorylation by protein kinases A or CK2 and are clustered near a RVXF sequence that has been identified as a motif that interacts with the catalytic subunit of protein phosphatase-1.	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	KU Leuven	Bollen, M (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Mathieu.Bollen@med.KILeuven.ac.Be						AGOSTINIS P, 1992, FEBS LETT, V305, P121, DOI 10.1016/0014-5793(92)80877-J; AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ANTONIW JF, 1977, BIOCHEM J, V162, P423, DOI 10.1042/bj1620423; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; BOLLEN M, 1994, FEBS LETT, V344, P196, DOI 10.1016/0014-5793(94)00391-2; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Cadefau J, 1997, BIOCHEM J, V322, P745, DOI 10.1042/bj3220745; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DeCorte V, 1996, BIOCHEMISTRY-US, V35, P5472, DOI 10.1021/bi952237r; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; Derua R, 1997, EXP CELL RES, V230, P310, DOI 10.1006/excr.1996.3436; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jagiello I, 1997, J BIOL CHEM, V272, P22067, DOI 10.1074/jbc.272.35.22067; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; MERCIER JC, 1968, B SOC CHIM BIOL, V50, P521; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; TAKAI A, 1991, BIOCHEM J, V275, P233, DOI 10.1042/bj2750233; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; VAN EYNDE A, 1994, BIOCHEM J, V297, P447, DOI 10.1042/bj2970447; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X; Wera S, 1997, EUR J BIOCHEM, V247, P411, DOI 10.1111/j.1432-1033.1997.00411.x	33	46	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32972	32978		10.1074/jbc.272.52.32972	http://dx.doi.org/10.1074/jbc.272.52.32972			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407077	hybrid			2022-12-25	WOS:000071182900038
J	Zeng, WZ; Lee, MG; Muallem, S				Zeng, WZ; Lee, MG; Muallem, S			Membrane-specific regulation of Cl- channels by purinergic receptors in rat submandibular gland acinar and duct cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY ION-TRANSPORT; CHLORIDE CHANNELS; EXTRACELLULAR ATP; CYSTIC-FIBROSIS; STORED CA2+; LOCALIZATION; SECRETION; NA+; CONDUCTANCE; EPITHELIUM	Measurement of [Cl-](i) and the Cl- current in the rat salivary submandibular gland (SMG) acinar and duct cells was used to evaluate the role of Cl- channels in the regulation of [Cl-](i) during purinergic stimulation, Under resting conditions [Cl-](i) averaged 56 +/- 8 and 26 +/- 7 mM in acinar and duct cells, respectively, In both cells, stimulation with 1 mM ATP resulted in Cl- efflux and subsequent influx. Inhibition of NaKCl2 cotransport had no effect on [Cl-](i) changes in duct cells and inhibited only about 50% of Cl- uptake in acinar cells, Accordingly, low levels of expression of NaKCl2 cotransporter protein were found in duct cells, Acinar cells expressed high levels of the cotransporter. Measurement of Cl- current under selective conditions revealed that acinar and duct cells express at least five distinct Cl- channels; a ClCO-like, volume-sensitive, inward rectifying, Ca2+-activated and CFTR-like Cl- currents, ATP acting on both cell types activated at least two channels, the Ca2+-activated Cl- channel and a Ca2+-independent glibenclamide-sensitive Cl--current, possibly cystic fibrosis transmembrane regulator (CFTR). Of the many nucleotides tested only 2'-3'-benzoylbenzoyl (Bz)-ATP and UTP activated Cl- channels in SMG cells. Despite their relative potency in increasing [Ca2+](i), BzATP in both SMG cell types largely activated the Ca2+-independent, glibenclamide-sensitive Cl- current, whereas UTP activated only the Ca2+-dependent Cl- current, We interpret this to suggest that BzATP and UTP largely activate Cl- channels residing in the membrane expressing the receptor for the active nucleotide, The present studies reveal a potentially new mechanism for transcellular Cl- transport in a CFTR-expressing tissue, the SMG. Coordinated action of the P(2)z (luminal) and P(2)u (basolateral) receptors can mediate part of the transcellular Cl- transport by acinar and duct cells to determine the final electrolyte composition of salivary fluid.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	smuall@medet.swmed.edu	Lee, Min Goo/AAS-4636-2020; Lee, Min Goo/D-5635-2012	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X	NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK46591, DK38938] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK046591] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arreola J, 1996, J PHYSIOL-LONDON, V490, P351, DOI 10.1113/jphysiol.1996.sp021149; Arreola J, 1996, J GEN PHYSIOL, V108, P35, DOI 10.1085/jgp.108.1.35; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; AUGUSTUS J, 1978, J MEMBRANE BIOL, V43, P203, DOI 10.1007/BF01933479; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BRETSCHNEDIER F, 1995, PFLUGERS ARCH, V426, P691; Cook D. I., 1994, P1061; COOK DI, 1995, P 8 INT S RUM PHYS, P151; DINUDOM A, 1995, AM J PHYSIOL-GASTR L, V268, pG806, DOI 10.1152/ajpgi.1995.268.5.G806; Evans RL, 1997, J PHYSIOL-LONDON, V499, P351, DOI 10.1113/jphysiol.1997.sp021932; FOSKETT JK, 1989, P NATL ACAD SCI USA, V86, P167, DOI 10.1073/pnas.86.1.167; GALLACHER DV, 1982, NATURE, V296, P83, DOI 10.1038/296083a0; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; HURLEY TW, 1994, ARCH ORAL BIOL, V39, P205, DOI 10.1016/0003-9969(94)90046-9; HURLEY TW, 1993, AM J PHYSIOL, V265, pC1472, DOI 10.1152/ajpcell.1993.265.6.C1472; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KOMWATANA P, 1994, PFLUG ARCH EUR J PHY, V428, P641, DOI 10.1007/BF00374588; LAU KR, 1994, PFLUG ARCH EUR J PHY, V427, P24, DOI 10.1007/BF00585938; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; Ludewig U, 1997, J PHYSIOL-LONDON, V498, P691, DOI 10.1113/jphysiol.1997.sp021893; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; MARTINEZ JR, 1983, AM J PHYSIOL, V245, pG711, DOI 10.1152/ajpgi.1983.245.5.G711; MCMILLIAN MK, 1993, BRIT J PHARMACOL, V108, P453, DOI 10.1111/j.1476-5381.1993.tb12825.x; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; NUTTLE LC, 1993, MOL PHARMACOL, V44, P93; Pasyk EA, 1997, J BIOL CHEM, V272, P7746, DOI 10.1074/jbc.272.12.7746; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; QUINTON PM, 1994, CURR BIOL, V4, P742, DOI 10.1016/S0960-9822(00)00166-4; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; SUPRENANT A, 1996, SCIENCE, V277, P735; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; Turner R. J., 1993, BIOL SALIVARY GLANDS, P105; VALVERDE MA, 1995, FASEB J, V9, P509, DOI 10.1096/fasebj.9.7.7737459; WEBSTER P, 1994, AM J PHYSIOL, V267, pC340, DOI 10.1152/ajpcell.1994.267.2.C340; Wiley JS, 1996, CIBA F SYMP, V198, P149; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442; ZHANG BX, 1993, AM J PHYSIOL, V264, pC54; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599; Zhao H, 1995, J GEN PHYSIOL, V106, P1225, DOI 10.1085/jgp.106.6.1225	49	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32956	32965		10.1074/jbc.272.52.32956	http://dx.doi.org/10.1074/jbc.272.52.32956			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407075	hybrid			2022-12-25	WOS:000071182900036
J	Bortner, CD; Hughes, FM; Cidlowski, JA				Bortner, CD; Hughes, FM; Cidlowski, JA			A primary role for K+ and Na+ efflux in the activation of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; VOLUME; FAS; THYMOCYTES	Cell shrinkage is a major characteristic of apoptosis, but the mechanism and role of this process in cell death are poorly understood. The primary factor that controls volume regulation in all cells is ions, and thus we have examined the movement of ions at the single cell level in lymphocytes during apoptosis, Activation of the death program with several stimuli that act through independent pathways to stimulate apoptosis results in a synchronous shift of cells from a normal cell size to a shrunken cell size. Only the shrunken cells exhibit DNA fragmentation and an approximate 4-fold elevation of caspase-3-like activity. Analysis of K+ and Na+ ion content of individual cells by flow cytometry revealed that the intracellular ionic strength of apoptotic cells decreased substantially from their non-shrunken counterparts. Additionally, we show apoptosis is enhanced under conditions where the intracellular K+ concentration is diminished and that apoptosis is inhibited when K+ efflux is prevented. These data show that the efflux of ions, primarily potassium, plays a necessary and perhaps a pivotal role in the cell death program.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019; Hughes, Francis M/G-8036-2017	Cidlowski, John A/0000-0003-1420-0516; Hughes, Francis/0000-0003-3776-3653				ALHABORI M, 1994, INT J BIOCHEM, V26, P319, DOI 10.1016/0020-711X(94)90052-3; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; HAUSSINGER D, 1994, AM J PHYSIOL, V267, pE343, DOI 10.1152/ajpendo.1994.267.3.E343; HOFFMANN EK, 1987, CURR TOP MEMBR TRANS, V30, P125; HUGHES FM, 1997, J BIOL CHEM, V272; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McConkey David J., 1994, Trends in Cell Biology, V4, P370, DOI 10.1016/0962-8924(94)90087-6; MINTA A, 1989, J BIOL CHEM, V264, P19449; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NORMAN MR, 1977, CANCER RES, V37, P3785; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; THOMAS N, 1981, MOL CELL ENDOCRINOL, V22, P71, DOI 10.1016/0303-7207(81)90103-9; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; WYLLIE AH, 1982, AM J PATHOL, V109, P78; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	26	476	491	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32436	32442		10.1074/jbc.272.51.32436	http://dx.doi.org/10.1074/jbc.272.51.32436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405453	hybrid			2022-12-25	WOS:000071108000072
J	Ren, HM; Allison, WS				Ren, HM; Allison, WS			Photoinactivation of the F-1-ATPase from spinach chloroplasts by dequalinium is accompanied by derivatization of methionine beta 183	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; NUCLEOTIDE-BINDING-SITES; BOVINE HEART MITOCHONDRIAL-F1-ATPASE; ADENOSINE-TRIPHOSPHATASE; QUINACRINE MUSTARD; GAMMA-SUBUNIT; EPSILON-SUBUNIT; ATPASE ACTIVITY; BACILLUS PS3; H+-ATPASE	In contrast to the F-1-ATPases from bovine mitochondria and the thermophilic Bacillus PS3, which are reversibly inhibited by dequalinium in the absence of irradiation, the Mg2+-ATPase activity of heat- or dithiothreitol-activated chloroplast F-1 (CF1) from spinach chloroplasts is slightly stimulated by dequalinium. Conversely, dequalinium is a partial inhibitor (maximal inhibition is 85-90%) of the Ca2+-ATPase of CF1 activated by heat, dithiothreitol, or octylglucoside. The Mg2+- and Ca2+-ATPase activities of CF1 respond differently in the presence of lauryl dimethylamine oxide (LDAO) in the assay medium. Whereas the Mg2+-ATPase activity of heat-or dithiothreitol-activated CF1 is stimulated up to 14-fold by increasing concentrations of LDAO, the Ca2+-ATPase is inhibited in a biphasic manner by increasing concentrations of LDAO. In the presence of LDAO, dequalinium does not stimulate the heat-activated Mg2+-ATPase over that promoted by LDAO alone. That dequalinium slightly stimulates Mg2+-ATPase activity although it inhibits Ca2+-ATPase activity can be reconciled by assuming that dequalinium binds to two sites in CF1, a stimulatory site that also binds LDAO and an inhibitory site. By acting as a partial inhibitor of the Mg2+-ATPase activity that it activates, the combined effect of dequalinium is modest stimulation. Irradiation of heat-or dithiothreitol-activated CF1 or the alpha(3) beta(3) gamma subcomplex of CF1 in the presence of 12 mu M dequalinium led to rapid photoinactivation. ATP and ADP, separately or in combination with Mg2+, protect against photoinactivation. After photoinactivating the alpha(3) beta(3) gamma subcomplex of CF1 with [C-14]dequalinium, tryptic and peptic digests of the isolated, derivatized beta subunit were fractionated by high performance liquid chromatography. Sequencing of the isolated, radioactive tryptic and peptic peptides revealed that Met(beta 183), which is at or near the catalytic site, is derivatized in a single beta subunit when CF1 is photoinactivated with [C-14]dequalinium.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Allison, WS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM-16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANDREWS WW, 1984, BIOCHEM BIOPH RES CO, V123, P1040, DOI 10.1016/S0006-291X(84)80238-7; ANTHON GE, 1986, BIOCHIM BIOPHYS ACTA, V848, P92, DOI 10.1016/0005-2728(86)90164-7; ARANA JL, 1982, J BIOL CHEM, V257, P1125; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; BRUIST MF, 1982, BIOCHEMISTRY-US, V21, P3370, DOI 10.1021/bi00257a019; BULLOUGH DA, 1989, BIOCHIM BIOPHYS ACTA, V975, P377, DOI 10.1016/S0005-2728(89)80346-9; BULLOUGH DA, 1989, J BIOL CHEM, V264, P9155; CHAZOTTE B, 1982, BIOCHIM BIOPHYS ACTA, V680, P310, DOI 10.1016/0005-2728(82)90144-X; DUNN SD, 1990, BIOCHEMISTRY-US, V29, P4335, DOI 10.1021/bi00470a011; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; FARRON F, 1970, BIOCHEMISTRY-US, V9, P3823, DOI 10.1021/bi00821a023; FENG Y, 1985, ARCH BIOCHEM BIOPHYS, V238, P61; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GROTH G, 1995, BIOCHEMISTRY-US, V34, P8589, DOI 10.1021/bi00027a008; Helenius A, 1979, Methods Enzymol, V56, P734; Hightower KE, 1996, BIOCHEMISTRY-US, V35, P4846, DOI 10.1021/bi952913p; JAGENDORF AT, 1982, METHODS CHLOROPLAST, P881; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KAGAWA Y, 1981, BIOCHEM BIOPH RES CO, V100, P1370, DOI 10.1016/0006-291X(81)91975-6; LAIKIND PK, 1983, J BIOL CHEM, V258, P1700; LECKBAND D, 1987, BIOCHEMISTRY-US, V26, P2306, DOI 10.1021/bi00382a035; MCCARTY RE, 1968, J BIOL CHEM, V243, P129; MICHEL L, 1992, FEBS LETT, V313, P90, DOI 10.1016/0014-5793(92)81191-N; MORIYAMA Y, 1995, FEBS LETT, V359, P69, DOI 10.1016/0014-5793(95)00013-Y; MORONEY JV, 1983, FEBS LETT, V158, P58, DOI 10.1016/0014-5793(83)80676-0; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; NELSON N, 1972, J BIOL CHEM, V247, P6506; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; PALATINI P, 1982, MOL PHARMACOL, V21, P415; PATRIE WJ, 1984, J BIOL CHEM, V259, P1121; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PICK U, 1982, BIOCHEMISTRY-US, V21, P6144, DOI 10.1021/bi00267a019; Racker E., 1971, METHOD ENZYMOL, V23, P547; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; SAKURAI H, 1981, J BIOCHEM, V90, P95, DOI 10.1093/oxfordjournals.jbchem.a133473; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VALLEJOS RH, 1977, BIOCHIM BIOPHYS ACTA, V459, P20, DOI 10.1016/0005-2728(77)90004-4; VAMBUSTA.VK, 1965, J BIOL CHEM, V240, P2660; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; VITSEVA OI, 1990, BIOCHEMISTRY-MOSCOW, V61, P251; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WIEKER HJ, 1987, BIOCHIM BIOPHYS ACTA, V892, P108, DOI 10.1016/0005-2728(87)90253-2; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027; ZHUO SQ, 1988, BIOCHEM BIOPH RES CO, V152, P968, DOI 10.1016/S0006-291X(88)80378-4; ZHUO SQ, 1993, BIOCHEMISTRY-US, V32, P2219, DOI 10.1021/bi00060a013	49	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32294	32300		10.1074/jbc.272.51.32294	http://dx.doi.org/10.1074/jbc.272.51.32294			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405435	hybrid			2022-12-25	WOS:000071108000054
J	Shinoda, K; Morishita, Y; Sasaki, K; Matsuda, Y; Takahashi, I; Nishi, T				Shinoda, K; Morishita, Y; Sasaki, K; Matsuda, Y; Takahashi, I; Nishi, T			Enzymatic characterization of human alpha 1,3-fucosyltransferase Fuc-TVII synthesized in a B cell lymphoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCOSYL-TRANSFERASE; MOLECULAR-CLONING; ACCEPTOR SPECIFICITY; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; SUBSTRATE SPECIFICITIES; LEUKOCYTE TRAFFICKING; DETERMINES EXPRESSION; SELECTIN LIGAND	The human alpha 1,3-fucosyltransferase, Fuc-TVII, a key enzyme in the biosynthesis of selectin ligands, was expressed as a soluble protein-A chimeric form in a human B cell lymphoma cell line, Namalwa KJM-1, and purified using IgG-Sepharose. The enzymatic properties of recombinant soluble Fuc-TVII were then examined. Its enzyme activity was highest at pH 7.5, and the presence of 25 mM Mn2+ was required for full activity. Fuc-TVII exhibits an acceptor specificity restricted to alpha 2,3-sialylated type 2 oligosaccharides, and the apparent K-m values for alpha 2,3-sialyl lacto-N-neotetraose and GDP-fucose were 3.08 mM and 16.4 mu M, respectively. The inhibitory effects of various nucleotides on the activity of Fuc-TVII reflected its donor specificity for the nucleotide portion of GDP. Fuc-TVII was demonstrated to be useful for the synthesis of a sialyl Lewis x hexasaccharide from lacto-N-neotetraose in combination with an alpha 2,3-sialyltransferase, ST3Gal IV. Polyethylene glycols enhanced the thermal stability of Fuc-TVII, leading to increased formation of the reaction product.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 194, Japan	Kyowa Kirin Ltd	Nishi, T (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahimachi, Machida, Tokyo 194, Japan.							BORSIG L, 1995, BIOCHEM BIOPH RES CO, V210, P14, DOI 10.1006/bbrc.1995.1621; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; DELBOURG MF, 1993, BIOTECHNOL LETT, V15, P157, DOI 10.1007/BF00133016; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; Fukuda M., 1992, CELL SURFACE CARBOHY; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAYASHIDA K, 1992, J FERMENT BIOENG, V73, P239, DOI 10.1016/0922-338X(92)90170-Y; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; ICHIKAWA Y, 1992, J AM CHEM SOC, V114, P9283, DOI 10.1021/ja00050a007; JAENICKE R, 1987, BIOL CHEM H-S, V368, P871, DOI 10.1515/bchm3.1987.368.2.871; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIYAJI H, 1990, CYTOTECHNOLOGY, V4, P173, DOI 10.1007/BF00365098; Miyamoto D, 1995, BIOCHEM BIOPH RES CO, V217, P852, DOI 10.1006/bbrc.1995.2850; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; VALKI A, 1994, P NATL ACAD SCI USA, V91, P7390; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575	34	27	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31992	31997		10.1074/jbc.272.51.31992	http://dx.doi.org/10.1074/jbc.272.51.31992			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405391	hybrid			2022-12-25	WOS:000071108000010
J	Chu, DM; Corbin, JD; Grimes, KA; Francis, SH				Chu, DM; Corbin, JD; Grimes, KA; Francis, SH			Activation by cyclic GMP binding causes an apparent conformational change in cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; BOVINE AORTA; I-BETA; CIRCULAR-DICHROISM; TERMINAL DOMAIN; CAMP; PURIFICATION; SEQUENCE; ISOZYMES; ANALOGS	Cyclic nucleotide binding activates cyclic nucleotide-dependent protein kinases, but the molecular mechanism is unknown. In the present studies, cGMP binding to type I alpha or type I beta cGMP-dependent protein kinase (PKG) caused (i) a large electronegative charge shift of each enzyme on ion exchange chromatography, (ii) an increase in the Stokes radius (>3 Angstrom) of each enzyme, and (iii) a decreased mobility of type I beta PKG on native gel electrophoresis, These physical changes were not detected in the monomeric form of type I beta PKG upon activation by cGMP, However, the results of partial proteolysis of type I alpha PKG revealed some degree of cGMP-induced conformational change within the PKG-monomer, since cGMP binding protects the PKG-monomer against chymotryptic cleavage, The altered sensitivity to proteolysis occurs at Met-200, which is located between the B and C alpha-helices in the high affinity site (site A), and implies that the cGMP-induced structural perturbations in this region may participate in activation of dimeric PKG, The cGMP-induced conformational effects observed using the physical separation methods are likely to reflect altered interactions within the dimeric PKG that are caused by structural alterations within the subunits.	VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University					NIDDK NIH HHS [DK40029] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BUBIS J, 1987, J BIOL CHEM, V262, P14961; CARPENTER FH, 1972, J BIOL CHEM, V247, P5580; COBB CE, 1987, J BIOL CHEM, V262, P16566; COHN EJ, 1943, PROTEINS AMINO ACIDS, P424; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1988, METHOD ENZYMOL, V159, P74; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LANDGRAF W, 1989, EUR J BIOCHEM, V181, P643, DOI 10.1111/j.1432-1033.1989.tb14771.x; LINCOLN TM, 1988, J BIOL CHEM, V263, P17632; MIGLIETTA LAP, 1988, J BIOL CHEM, V263, P16096; PORATH J, 1959, NATURE, V183, P1657, DOI 10.1038/1831657a0; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; RANNELS SR, 1983, METHOD ENZYMOL, V99, P55; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SCATCHARD G, 1962, J AM CHEM SOC, V84, P127, DOI 10.1021/ja00861a001; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEBER IT, 1982, P NATL ACAD SCI-BIOL, V79, P7679, DOI 10.1073/pnas.79.24.7679; WOLFE L, 1987, J BIOL CHEM, V262, P16906; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	40	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31922	31928		10.1074/jbc.272.50.31922	http://dx.doi.org/10.1074/jbc.272.50.31922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395541	hybrid			2022-12-25	WOS:A1997YL41900100
J	Dean, N; Zhang, YB; Poster, JB				Dean, N; Zhang, YB; Poster, JB			The VRG4 gene is required for GDP-mannose transport into the lumen of the Golgi in the yeast, Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE-N-ACETYLGLUCOSAMINE; ROUGH ENDOPLASMIC-RETICULUM; PROTEIN GLYCOSYLATION; GUANOSINE DIPHOSPHATASE; SPHINGOLIPIDS; MUTANTS; PHOSPHATE; APPARATUS; VESICLES; FAMILY	In the yeast Saccharomyces cerevisiae, glycoproteins and sphingolipids are modified in the Golgi by the addition of mannose residues. The critical mannosyl donor for these reactions is the nucleotide sugar, GDP-mannose, whose transport into the Golgi from the cytoplasm is required for mannosylation. This transport reaction has been well characterized, but the nucleotide sugar transporter has yet to be identified in yeast, VRG4 is an essential gene whose product is required for a number of Golgi-specific functions, including glycosylation and the organization of the endomembrane system. Here, data are presented that demonstrate that the primary role of Vrg4p is in the transport of GDP-mannose into the Golgi. The vrg4 mutation causes a general impairment in mannosylation, affecting N-linked and O-linked glycoprotein modifications as well as the mannosylation of sphingolipids. By using an in vitro assay, vrg4 mutants were shown to be specifically defective in the transport of GDP-mannose into Golgi vesicles. The Vrg4 protein localizes to the Golgi complex in a pattern that suggests a wide distribution throughout the Golgi. Vrg4p displays homology to other putative nucleotide sugar transporters, suggesting that the VRG4 gene encodes a Golgi GDP-mannose transporter. As Vrg4p is essential, these results suggest that a complete lack of mannosylation of glycoproteins in the Golgi leads to inviability. Alternatively, the essential function of Vrg4p in yeast involves its effect on sphingolipids, which would imply a critical role for mannosylinositol phosphorylceramides or mannosyl diphosphoinositol ceramides on growth and viability.			Dean, N (corresponding author), SUNY STONY BROOK, INST CELL & DEV BIOL, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA.				NIGMS NIH HHS [GM48467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1996, J BIOL CHEM, V271, P8851, DOI 10.1074/jbc.271.15.8851; ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; ALBER T, 1982, Journal of Molecular and Applied Genetics, V1, P419; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; COTTAREL G, 1995, CURR GENET, V28, P380, DOI 10.1007/BF00326437; Dean N, 1996, GLYCOBIOLOGY, V6, P73, DOI 10.1093/glycob/6.1.73; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANIKENNULAT C, 1995, GENETICS, V140, P933; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LESTER RL, 1993, ADV LIPID RES, V26, P253; Lussier M, 1997, J BIOL CHEM, V272, P15527, DOI 10.1074/jbc.272.24.15527; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Neiman AM, 1997, GENETICS, V145, P637; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; Poster JB, 1996, J BIOL CHEM, V271, P3837; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; Sherman F., 1983, METHODS YEAST GENETI; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SMITH SW, 1974, J BIOL CHEM, V249, P3395; WAECHTER CJ, 1973, J BIOL CHEM, V248, P7570; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; WU WI, 1993, J BIOL CHEM, V268, P13830	41	115	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31908	31914		10.1074/jbc.272.50.31908	http://dx.doi.org/10.1074/jbc.272.50.31908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395539	hybrid			2022-12-25	WOS:A1997YL41900098
J	Dobrosotskaya, I; Guy, RK; James, GL				Dobrosotskaya, I; Guy, RK; James, GL			MAGI-1, a membrane-associated guanylate kinase with a unique arrangement of protein-protein interaction domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; SYNAPSE-ASSOCIATED PROTEIN; NMDA RECEPTOR SUBUNITS; WW DOMAIN; PSD-95 FAMILY; PDZ DOMAIN; BINDING; HOMOLOG; SAP90; GENE	Membrane-associated guanylate kinase (MAGUK) proteins participate in the assembly of multiprotein complexes on the inner surface of the plasma membrane at regions of cell-cell contact. MAGUKs are characterized by three types of protein-protein interaction modules: the PDZ domain, the Src homology 3 (SH3) domain, and the guanylate kinase (GuK) domain. The arrangement of these domains is conserved in all previously known MAGUKs: either one or three PDZ domains in the NH2-terminal half, followed by the SH3 domain, followed by a COOH-terminal GuK domain. In this report, we describe the cDNA cloning and subcellular distribution of MAGI-1, a MAGUK with three unique structural features: 1) the GuK domain is at the NH2 terminus, 2) the SH3 domain is replaced by two WW domains, and 3) it contains five PDZ domains, MAGI-1 mRNA was detected in several adult mouse tissues. Sequence analysis of overlapping cDNAs revealed the existence of three splice variants that are predicted to encode MAGI-1 proteins with different COOH termini. The longest variant, MAGI-1c, contains three bipartite nuclear localization signals in its unique COOH-terminal sequence and was found predominantly in the nucleus of Madin-Darby canine kidney cells. A shorter form lacking these signals was found primarily in membrane and cytoplasmic fractions. This distribution, which is reminiscent of that seen for the tight junction protein ZO-1, suggests that MAGI-1 may participate in the transmission of regulatory signals from the cell surface to the nucleus.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Guy, Rodney/J-7107-2013	Guy, Rodney/0000-0002-9638-2060	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hata Y, 1996, J NEUROSCI, V16, P2488; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; JAMES GL, 1994, J BIOL CHEM, V269, P14182; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAUB O, 1996, CURR BIOL, V4, P495; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	51	164	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31589	31597		10.1074/jbc.272.50.31589	http://dx.doi.org/10.1074/jbc.272.50.31589			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395497	hybrid			2022-12-25	WOS:A1997YL41900056
J	Ray, K; Fan, GF; Goldsmith, PK; Spiegel, AM				Ray, K; Fan, GF; Goldsmith, PK; Spiegel, AM			The carboxyl terminus of the human calcium receptor - Requirements for cell-surface expression and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; MUTATIONS; RAT; PROTEINS	The G-protein-coupled calcium receptor plays a key role in extracellular calcium homeostasis. To examine the role of the membrane-spanning domains and the similar to 200-residue cytoplasmic carboxyl terminus of the calcium receptor-in cell-surface expression and signal transduction, we transfected HEK-293 cells with a series of truncation and carboxyl-terminal missense mutants and analyzed expression by immunoblotting, glycosidase digestion, intact cell immunoassay, and extracellular calcium-stimulated phosphoinositide hydrolysis assay. Two truncation mutants terminating at residues 706 and 802 within the second and third intracellular loops, respectively, were not properly glycosylated, failed to reach the cell-surface, and showed no calcium response, indicating that mutant receptors with the full extracellular domain but only three or five transmembrane domains are improperly folded and/or processed. Truncation mutants terminating at residues 888 and 903 within the carboxyl terminus were equivalent to the wild type in all assays, whereas mutants truncated at residues 865 and 874 showed no response to calcium, despite only similar to 25% reduction in cell-surface expression. Mutants with a full-length carboxyl terminus but with residues between positions 874 and 888 replaced with alanines showed either no (Ala(875), Ala(876), and Ala(879)) or significantly reduced (Ala(881)-Ala(883)) calcium response at levels of cell-surface expression equivalent to those of the wild-type receptor. These results indicate that deletion of the majority of the carboxyl terminus is compatible with normal processing, cell-surface expression, and signal transduction of the receptor. The truncation and alanine substitution mutants identify a small region between residues 874 and 888 critical for normal signal transduction by the receptor.	NIDDK,METAB DIS BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BARSOMIAN GD, 1990, J BIOL CHEM, V265, P6967; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Butters RR, 1997, J BONE MINER RES, V12, P568, DOI 10.1359/jbmr.1997.12.4.568; CHANG W, 1996, 10 INT C END JUN 12, P725; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Heymann JAW, 1997, P NATL ACAD SCI USA, V94, P4966, DOI 10.1073/pnas.94.10.4966; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KIFOR O, 1990, J BONE MINER RES, V5, P1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720	22	107	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31355	31361		10.1074/jbc.272.50.31355	http://dx.doi.org/10.1074/jbc.272.50.31355			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395465	hybrid			2022-12-25	WOS:A1997YL41900024
J	StraussSoukup, JK; Maher, LJ				StraussSoukup, JK; Maher, LJ			Role of asymmetric phosphate neutralization in DNA bending by PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOMAL DNA; RECOGNITION; COMPLEX	The PU.1 transcription factor is a member of the Ets family of DNA binding proteins, PU.1 binds to DNA via a loop-helix-loop domain and functions in the differentiation of hematopoietic cells, The structure of a PU.1-DNA complex was recently reported (Kodandapani, R., Pio, F., Ni, C.-Z., Piccialli, G., Klemsz, M., McKercher, S., Maki, R., and Ely, K. (1996) Nature 380, 456-460). The DNA in this complex is deformed by 8 degrees as it curves around the protein, The pattern of electrostatic contacts between PU.1, and its DNA binding site suggests that laterally asymmetric phosphate neutralization accompanies PU.1 binding, Because of our previous studies showing that such neutralization can induce bending in naked DNA, we have explored the effect of phosphate neutralization by substituting neutral methylphosphonate internucleoside linkages at relevant positions within DNA containing the PU.1 binding sequence, Consistent with the prediction that DNA will collapse toward its partially neutralized surface, DNA neutralized at seven positions to simulate PU.1 binding is observed to bend by 28 degrees. The directions of DNA curvature are slightly different in the co-crystal versus the partially neutralized duplexes, The electrostatic component of the binding energy appears more than enough to account for the DNA bending observed in the PU.1-DNA complex.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOL BIOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198	Mayo Clinic; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NIGMS NIH HHS [GM47814, GM54411] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047814, R01GM054411] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P46; HOGREFE RI, 1993, NUCLEIC ACIDS RES, V21, P2031, DOI 10.1093/nar/21.9.2031; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; MANNING GS, 1989, J BIOMOL STRUCT DYN, V6, P877, DOI 10.1080/07391102.1989.10506519; MIRZABEKOV AD, 1979, P NATL ACAD SCI USA, V76, P1118, DOI 10.1073/pnas.76.3.1118; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; Strauss JK, 1996, P NATL ACAD SCI USA, V93, P9515, DOI 10.1073/pnas.93.18.9515; Strauss JK, 1996, CHEM BIOL, V3, P671, DOI 10.1016/S1074-5521(96)90135-0; StraussSoukup JK, 1997, BIOCHEMISTRY-US, V36, P8692, DOI 10.1021/bi9705467	14	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31570	31575		10.1074/jbc.272.50.31570	http://dx.doi.org/10.1074/jbc.272.50.31570			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395494	hybrid			2022-12-25	WOS:A1997YL41900053
J	Traub, O; Monia, BP; Dean, NM; Berk, BC				Traub, O; Monia, BP; Dean, NM; Berk, BC			PKC-epsilon is required for mechano-sensitive activation of ERK1/2 in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; SHEAR-STRESS; MAP KINASE; ALPHA EXPRESSION; GENE-EXPRESSION; FLOW; CALCIUM; INHIBITION; RAF	Mechano-sensitive regulation of endothelial cells (EC) function by shear stress is critical for flow-induced vasodilation and gene expression. Previous studies by our laboratory demonstrated that shear stress activates the 44- and 42-kDa extracellular signal-regulated kinases (ERK1/2) in EC in a time-and force-dependent manner. ERK1/2 activation was inhibited by protein kinase C (PKC) down-regulation with phorbol 12,13-dibutyrate (1 mu M for 24 h) but not by calcium chelation with BAPTA-AM (acetoxymethyl ester of BAPTA) (75 mu M for 30 min), suggesting that a novel PKC isoform (delta, epsilon, eta, theta) mediates shear stress-induced ERK1/2 activation. Western blotting with PKC isoform-specific antibodies demonstrated expression of PKC-alpha, -epsilon, and -zeta isoforms in EC. PKC-epsilon was specifically inhibited by transfection with antisense PKC-epsilon phosphorothioate oligonucleotides (1,000 nM for 6 h). Antisense treatment decreased PKC-epsilon protein levels by 80 +/- 13% after 72 h and completely inhibited shear stress-stimulated ERK1/2 activation. Scrambled PKC-epsilon oligonucleotides and antisense PKC-alpha and PKC-zeta oligonucleotides had no effect on ERK1/2 activity. PKC-epsilon appeared specific for mechano-sensitive ERK1/2 activation, as antisense PKC-epsilon oligonucleotides did not inhibit ERK1/2 activation by EGF or bradykinin but did inhibit ERK1/2 activation upon EC adhesion to fibronectin. These results define a pathway for shear stress-mediated ERK1/2 activation and establish a new function for PKC-epsilon as part of a mechano-sensitive signal transduction pathway in EC.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,DIV CARDIOL,SEATTLE,WA 98195; ISIS PHARMACEUT,DEPT MOL PHARMACOL,CARLSBAD,CA 92008	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Isis Pharmaceuticals Inc				Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266] Funding Source: NIH RePORTER; NHLBI NIH HHS [IH PO1 HL18645] Funding Source: Medline; NIGMS NIH HHS [NIGM-GM07266] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai H, 1996, MOL PHARMACOL, V50, P522; Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; BISWAS P, 1995, FEBS LETT, V373, P146, DOI 10.1016/0014-5793(95)01025-A; CACACE AM, 1993, ONCOGENE, V8, P2095; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; CORSON MA, 1993, CIRCULATION, V88, P183; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; DEAN NM, 1994, J BIOL CHEM, V269, P16416; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Girard Peggy R., 1993, Frontiers of Medical and Biological Engineering, V5, P31; HERSHENSON MB, 1995, J BIOL CHEM, V270, P19908, DOI 10.1074/jbc.270.34.19908; Horowitz A, 1996, AM J PHYSIOL-CELL PH, V271, pC589, DOI 10.1152/ajpcell.1996.271.2.C589; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Li YS, 1996, MOL CELL BIOL, V16, P5947; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Liao DF, 1996, CIRC RES, V79, P1007, DOI 10.1161/01.RES.79.5.1007; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MITSUMATA M, 1993, AM J PHYSIOL, V265, pH3, DOI 10.1152/ajpheart.1993.265.1.H3; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; Plevin R, 1996, BIOCHEM J, V318, P657, DOI 10.1042/bj3180657; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; UEMATSU M, 1993, CIRCULATION, V88, P184; VUORI K, 1993, J BIOL CHEM, V268, P21459; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; Young SW, 1996, FEBS LETT, V384, P181, DOI 10.1016/0014-5793(96)00287-6; YU SM, 1996, J CELL BIOL, V50, P1000	45	98	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31251	31257		10.1074/jbc.272.50.31251	http://dx.doi.org/10.1074/jbc.272.50.31251			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395450	hybrid			2022-12-25	WOS:A1997YL41900009
J	Anand-Apte, B; Zetter, BR; Viswanathan, A; Qiu, RG; Chen, J; Ruggieri, R; Symons, M				Anand-Apte, B; Zetter, BR; Viswanathan, A; Qiu, RG; Chen, J; Ruggieri, R; Symons, M			Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; ACTIN STRESS FIBERS; TRANSFORMATION; CELLS; BINDING; SCATTER; RHO; CHEMOTAXIS; TRANSCRIPTION; FIBROBLASTS	Directed cell migration is essential for a variety of important biological processes ranging from development and angiogenesis to metastasis. Ras plays a pivotal role in the signaling cascade that governs chemotaxis of fibroblasts toward platelet-derived growth factor-BB (PDGF-BB), Ras activates multiple downstream pathways, which include the extracellular signal-regulated kinase (ERK), Rac, and Ral signaling cascades, We therefore investigated the role of the Rac and ERK pathways in cell migration, We showed that migration of fibroblasts toward PDGF-BB is inhibited by expression of dominant negative Asn-17 Rad. Blocking of the ERK pathway by either expression of dominant negative Ala-218/Ala-222-mitogen-activated protein kinase kinase (A218/A222-MEK1) or by a MEK-specific inhibitor did not inhibit migration toward PDGF-BB, In contrast, migration toward soluble fibronectin was suppressed by inhibition of the ERK pathway but not by Asn-17 Rad expression, These results indicate that directed cell migration mediated by different receptor classes in response to different ligands differentially utilizes the Rac and ERK pathways and suggest that Rac might play a critical role in pathological processes such as angiogenesis and metastasis.	ONYX Pharmaceut, Richmond, CA 94806 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Symons, M (corresponding author), ONYX Pharmaceut, 3031 Res Dr, Richmond, CA 94806 USA.	msymons@onyx-pharm.com		viswaanathan, akila/0000-0002-1896-2924	NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornfeldt KE, 1996, TRENDS CARDIOVAS MED, V6, P143, DOI 10.1016/1050-1738(96)00038-2; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BRONNERFRASER M, 1995, TRENDS GENET, V11, P423, DOI 10.1016/S0168-9525(00)89136-2; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cramer LP, 1997, J CELL BIOL, V136, P1287, DOI 10.1083/jcb.136.6.1287; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Godwin SL, 1997, J BIOL CHEM, V272, P11307; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHagan RC, 1996, ONCOGENE, V13, P1323; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SCHLAEPFER DD, 1994, NATURE, V372, P786; STOKES CL, 1991, J THEOR BIOL, V152, P377, DOI 10.1016/S0022-5193(05)80201-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WENNSTROM S, 1994, ONCOGENE, V9, P651; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILKINSON PC, 1988, METHOD ENZYMOL, V162, P3; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	46	157	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30688	30692		10.1074/jbc.272.49.30688	http://dx.doi.org/10.1074/jbc.272.49.30688			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388204	hybrid			2022-12-25	WOS:000071640800017
J	Balasubramanian, K; Chandra, J; Schroit, AJ				Balasubramanian, K; Chandra, J; Schroit, AJ			Immune clearance of phosphatidylserine-expressing cells by phagocytes - The role of beta(2)-glycoprotein I in macrophage recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-GLYCOPROTEIN-I APOLIPOPROTEIN-H; LOW-DENSITY-LIPOPROTEIN; RED-BLOOD-CELLS; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; APOPTOTIC CELLS; BINDING; MEMBRANE; PROTEIN; AUTOANTIBODIES	The function of beta(2)-glycoprotein I (beta(2)GPI), a 50-kDa serum glycoprotein, is not completely understood but has been suggested to be involved in the regulation of thrombosis (Brighten, T. A., Hogg, P, J,, Dal, Y,-P,, Murray, B, H., Choing, B, H,, and Chesterman, C, N, (1996) Br, J. Haematol, 93, 185-194) and the clearance of phosphatidylserine (PS)-expressing cells (Chonn, A., Semple S, C,, and Cullis P, R, (1995) J, Biol, Chem. 270, 25845-25849). To further understand the role of this protein, we characterized the ability of beta(2)GPI to interact with PS vesicles and influence their uptake by macrophages in vitro. beta(2)GPI bound to and precipitated vesicles containing anionic but not zwitterionic phospholipids in a gel diffusion assay, beta(2)GPI also inhibited the procoagulant activity of PS liposomes, In vitro phagocytosis studies showed 20-fold greater uptake of PS liposomes over phosphatidylcholine liposomes. This enhanced uptake was maintained even after PS was "shielded" with beta(2)GPI and further increased upon the addition of beta(2)GPI antibodies, Similar to liposomes, PS-expressing apoptotic thymocytes and lipid symmetric red blood cell ghosts bound beta(2)GPI. Macrophage uptake of these cells was also maintained or enhanced in the presence of beta(2)GPI and further increased upon the addition of beta(2)GPI antibodies, It is concluded that beta(2)GPI can play a critical role in hemostasis by influencing both thrombosis and the clearance of PS-expressing cells.	Univ Texas, MD Anderson Canc Ctr, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Schroit, AJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Cell Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.				NIDDK NIH HHS [DK 41714] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041714] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brighton TA, 1996, BRIT J HAEMATOL, V93, P185, DOI 10.1046/j.1365-2141.1996.446981.x; CHONN A, 1995, J BIOL CHEM, V270, P25845, DOI 10.1074/jbc.270.43.25845; CINES DB, 1995, J CLIN IMMUNOL S, V15, P86; CONNOR J, 1990, BIOCHIM BIOPHYS ACTA, V1025, P82, DOI 10.1016/0005-2736(90)90193-R; CONNOR J, 1994, J BIOL CHEM, V269, P2399; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; HAGIHARA Y, 1995, J BIOCHEM-TOKYO, V118, P129, DOI 10.1093/oxfordjournals.jbchem.a124867; HUNT J, 1994, J IMMUNOL, V152, P653; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; NIMPF J, 1986, BIOCHIM BIOPHYS ACTA, V884, P142, DOI 10.1016/0304-4165(86)90237-0; OOSTING JD, 1993, BLOOD, V81, P2618; POLTZ E, 1979, FEBS LETT, V102, P183; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROUBEY RAS, 1995, J IMMUNOL, V154, P954; ROUBEY RAS, 1994, BLOOD, V84, P2854; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHOUSBOE I, 1979, BIOCHIM BIOPHYS ACTA, V579, P396, DOI 10.1016/0005-2795(79)90067-9; SCHROIT AJ, 1983, BIOCHEMISTRY-US, V22, P3617, DOI 10.1021/bi00284a012; STEINKASSERER A, 1991, BIOCHEM J, V277, P387, DOI 10.1042/bj2770387; Sugi T, 1996, THROMB RES, V84, P97, DOI 10.1016/0049-3848(96)00165-X; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; Willems GM, 1996, BIOCHEMISTRY-US, V35, P13833, DOI 10.1021/bi960657q; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121; ZWAAL RFA, 1993, BIOCHEM SOC T, V21, P248, DOI 10.1042/bst0210248	31	137	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31113	31117		10.1074/jbc.272.49.31113	http://dx.doi.org/10.1074/jbc.272.49.31113			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388264	hybrid			2022-12-25	WOS:000071640800077
J	Bomer, U; Meijer, M; Guiard, B; Dietmeier, K; Pfanner, N; Rassow, J				Bomer, U; Meijer, M; Guiard, B; Dietmeier, K; Pfanner, N; Rassow, J			The sorting route of cytochrome b(2) branches from the general mitochondrial import pathway at the preprotein translocase of the inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-70; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; C PEROXIDASE; MATRIX HSP70; SIGNAL; PRESEQUENCE; TRANSPORT; COMPLEX	Cytochrome b(2) is synthesized in the cytosol with a bipartite presequence. The first part of the presequence targets the protein to mitochondria and mediates translocation into the mitochondrial matrix compartment; the second part contains the sorting signal that is required for delivery of the protein to the intermembrane space, The localization of the structures that recognize the sorting signal is unclear, Here we show that upon import in vivo, the sorting signal of cytochrome b(2) causes an early divergence from the general matrix import pathway and thereby prevents translocation of a folded C-terminal domain into mitochondria. By co-immunoprecipitations we find that translocation intermediates of cytochrome b(2) are associated with Tim23, a component of the inner membrane protein import machinery, Cytochrome b(2) constructs with an alteration in the sorting signal are mistargeted to the matrix of wildtype mitochondria, In mitochondria containing a mutant form of Tim23, however, the translocation of the altered sorting signal across the inner membrane is inhibited, and cytochrome b(2) is correctly sorted to the intermembrane space, We suggest that the sorting signal of cytochrome b(2) is recognized within the inner membrane in close vicinity to Tim23.	UNIV FREIBURG, INST BIOCHEM & MOL BIOL, D-79104 FREIBURG, GERMANY; BIOCTR AMSTERDAM, INST MOL CELL BIOL, NL-1098 SM AMSTERDAM, NETHERLANDS; UNIV PARIS 06, CNRS, CTR GENET MOL, F-91190 GIF SUR YVETTE, FRANCE	University of Freiburg; University of Amsterdam; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay			Pfanner, Nikolaus/AAV-7878-2021					Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOM J, 1995, EUR J BIOCHEM, V232, P309, DOI 10.1111/j.1432-1033.1995.tb20813.x; Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; Bomer U, 1996, J MOL BIOL, V262, P389, DOI 10.1006/jmbi.1996.0522; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; CUTHRIE C, 1991, METHODS ENZYMOLOGY G, V194, P1; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GARTNER F, 1995, EMBO J, V14, P6043, DOI 10.1002/j.1460-2075.1995.tb00293.x; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; Horst M, 1996, PROTEIN SCI, V5, P759; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; Kanamori T, 1997, P NATL ACAD SCI USA, V94, P485, DOI 10.1073/pnas.94.2.485; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; Lithgow T, 1997, TRENDS BIOCHEM SCI, V22, P110, DOI 10.1016/S0968-0004(97)01007-4; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; ONO H, 1995, J BIOL CHEM, V270, P16932, DOI 10.1074/jbc.270.28.16932; PFANNER N, 1995, CURR BIOL, V5, P132; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; PFANNER N, 1990, J BIOL CHEM, V265, P16324; PFANNER N, 1997, IN PRESS ANN REV CEL, V13; PON L, 1991, MOL CELLULAR BIOL YE, V1, P333; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; Rassow J, 1996, CURR BIOL, V6, P115, DOI 10.1016/S0960-9822(02)00437-2; REID GA, 1982, J BIOL CHEM, V257, P3068; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; RYAN KR, 1993, J BIOL CHEM, V268, P23743; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601	65	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30439	30446		10.1074/jbc.272.48.30439	http://dx.doi.org/10.1074/jbc.272.48.30439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374535	Green Published, hybrid			2022-12-25	WOS:A1997YH61300067
J	Fanen, P; Labarthe, R; Garnier, F; Benharouga, M; Goossens, M; Edelman, A				Fanen, P; Labarthe, R; Garnier, F; Benharouga, M; Goossens, M; Edelman, A			Cystic fibrosis phenotype associated with pancreatic insufficiency does not always reflect the cAMP-dependent chloride conductive pathway defect - Analysis of C225R-CFTR and R1066C-CFTR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONS; REGULATOR; CFTR; CHANNEL; RESIDUES; LOOP	We have previously screened the cystic fibrosis transmembrane conductance regulator (CFTR) gene and identified new disease-causing mutations. C225R and R1066C are both associated with pancreatic insufficiency, but the former mutation is associated with mild and unusual lung disease, whereas the latter is associated with severe lung disease, In the present study, we expressed these mutants heterologously in HeLa cells, and we analyzed protein synthesis by immunoprecipitation and chloride channel function by using a halide-sensitive fluorescent dye, 6-methoxy-N-ethylquinolinium, Immunoprecipitation and functional studies showed that cells transfected with C225R-CFTR exhibit cAMP-dependent chloride fluxes; C225R-CFTR protein is poorly expressed but fully glycosylated and can be compared with R117H-CFTR. R1066C-CFTR protein is not correctly processed and, unlike Delta F508-CFTR, this defect cannot be corrected by reduced temperature or overexpression in butyrate-treated cells; defective processing may occur at a different step in the biosynthetic pathway, These results point to two different mechanisms underlying the same pancreatic status and suggest that it is unwise to use pancreatic sufficiency and insufficiency to define mild and severe cystic fibrosis (CF) disease, respectively, Finally, the experimental model described here may be helpful to predict the pulmonary status of CF patients bearing mutations located in putative membrane-spanning domains of the CFTR protein.	FAC MED NECKER ENFANTS MALAD,INSERM,U467,F-75015 PARIS,FRANCE; HOP HENRI MONDOR,INSERM,U468,F-94010 CRETEIL,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Garnier, Fabien/O-7950-2016	Fanen, Pascale/0000-0002-3273-5349; Garnier, Fabien/0000-0002-7749-952X				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BIWERSI J, 1991, BIOCHEMISTRY-US, V30, P7879, DOI 10.1021/bi00246a001; CHENG SH, 1995, AM J PHYSIOL-LUNG C, V268, pL615, DOI 10.1152/ajplung.1995.268.4.L615; Cotten JF, 1996, J BIOL CHEM, V271, P21279, DOI 10.1074/jbc.271.35.21279; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I; HIPPER A, 1995, FEBS LETT, V374, P312, DOI 10.1016/0014-5793(95)01132-X; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; Sheppard DN, 1996, J BIOL CHEM, V271, P14995, DOI 10.1074/jbc.271.25.14995; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	17	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30563	30566		10.1074/jbc.272.48.30563	http://dx.doi.org/10.1074/jbc.272.48.30563			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374552	hybrid			2022-12-25	WOS:A1997YH61300084
J	Shaulian, E; Resnitzky, D; Shifman, O; Blandino, G; Amsterdam, A; Yayon, A; Oren, M				Shaulian, E; Resnitzky, D; Shifman, O; Blandino, G; Amsterdam, A; Yayon, A; Oren, M			Induction of Mdm2 and enhancement of cell survival by bFGF	ONCOGENE			English	Article						Mdm2; bFGF; p53; apoptosis; cisplatin	WILD-TYPE P53; FIBROBLAST GROWTH-FACTOR; AUTOREGULATORY FEEDBACK LOOP; CYCLE CHECKPOINT PATHWAY; TUMOR-SUPPRESSOR PROTEIN; TYROSINE KINASE-ACTIVITY; MYC-INDUCED APOPTOSIS; DNA-DAMAGING AGENTS; HEMATOPOIETIC-CELLS; FACTORS STIMULATE	Basic fibroblast growth factor (bFGF) can exert mitogenic and viability-promoting effects in a wide range of biological systems. The biochemical activities mediating the cell survival function of bFGF are largely unknown. We report here that exposure of fibroblasts to bFGF, which confers upon them increased survival, also causes at the same time an increase in cellular levels of the Mdm2 oncoprotein. Cells constitutively exposed to a bFGF autocrine loop are more refractory to killing by cisplatin. This increased chemoresistance coincides with elevated Mdm2 and reduced activation of the endogenous p53, resulting in inefficient transcriptional activation of the bar gene promoter. Importantly, unlike Mdm2 accumulation in fibroblasts exposed to DNA damage, induction of Mdm2 by bFGF does not occur through a p53-mediated pathway. The role of p53 in DNA damage-induced apoptosis and the ability of Mdm2 to block p53-mediated cell death are well established. These findings therefore suggest that induction of Mdm2 and the subsequent inhibition of p53 function may contribute, at least partially, to the anti-apoptotic effects of bFGF and possibly some other survival factors.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHARONI D, 1995, EXP CELL RES, V218, P271, DOI 10.1006/excr.1995.1156; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BLANDINO G, 1995, ONCOGENE, V10, P731; BLOTTNER D, 1992, EXP NEUROL, V118, P35, DOI 10.1016/0014-4886(92)90020-Q; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDONCARDO C, 1994, CANCER RES, V54, P794; CORVI R, 1995, ONCOGENE, V10, P1081; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Fox JC, 1996, J BIOL CHEM, V271, P12578, DOI 10.1074/jbc.271.21.12578; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUKS Z, 1994, CANCER RES, V54, P2582; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERENTAL I, 1995, EXP CELL RES, V218, P283, DOI 10.1006/excr.1995.1157; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LADANYI M, 1993, CANCER RES, V53, P16; LANDGREN E, 1995, ONCOGENE, V10, P2027; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1995, CELL, V80, P293; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; MOSNER J, 1994, ONCOGENE, V9, P3321; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11653; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PRICE BD, 1994, CANCER RES, V54, P896; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SoferLevi Y, 1996, ONCOGENE, V13, P2431; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xiang H, 1996, J NEUROSCI, V16, P6753; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zawada WM, 1996, EXP NEUROL, V140, P60, DOI 10.1006/exnr.1996.0115; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	96	92	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2717	2725		10.1038/sj.onc.1201453	http://dx.doi.org/10.1038/sj.onc.1201453			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400998				2022-12-25	WOS:A1997YH46800009
J	Bundy, DL; McKeithan, TW				Bundy, DL; McKeithan, TW			Diverse effects of BCL3 phosphorylation on its modulation of NF-kappa B p52 homodimer binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE PROTOONCOGENE BCL-3; TRANSCRIPTION FACTOR; C-REL; ONCOPROTEIN BCL-3; IN-VIVO; SUBUNIT; PROTEINS; ENCODES; INHIBITION; ACTIVATION	I kappa B proteins control the subcellular localization and DNA binding activity of NF-kappa B transcription factors. BCL3 is a nuclear I kappa B that can inhibit or enhance the binding of NF-kappa B p50 or p52 homodimers to consensus DNA-binding (kappa B) sequences or form a kappa B-binding complex with homodimers. To study BCL3 function, we have used gel shift analysis and tagged protein and tagged DNA coprecipitation analyses. Our results show that at intermediate ratios of BCL3 to p52 all observed phosphoforms of BCL3 are able to form a kappa B-binding complex with p52 homodimers. At low BCL3/p52 ratios, BCL3 increases the rate of p52 homodimer binding to ICE sites in the presence of nonconsensus DNA and dissociates from the complex. At high BCL3/p52 ratios, BCL3 forms a higher order inhibitory complex with p52 homodimers. All of these effects depend on BCL3 phosphorylation and relative concentration. These results indicate that BCL3 phosphorylation may affect its regulation of NF-kappa B-dependent transcription in vivo.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	McKeithan, TW (corresponding author), Dept Pathol MC3083, 5841 S Maryland Ave, Chicago, IL 60637 USA.			McKeithan, Timothy/0000-0003-2242-3074	NATIONAL CANCER INSTITUTE [R01CA055356] Funding Source: NIH RePORTER; NCI NIH HHS [CA55356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HAY RT, 1993, NUCLEIC ACIDS RES, V21, P4592, DOI 10.1093/nar/21.19.4592; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE J, 1993, ONCOGENE, V8, P2067; ISODA K, 1994, P NATL ACAD SCI USA, V91, P5350, DOI 10.1073/pnas.91.12.5350; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; Leveillard Thierry, 1993, Gene Expression, V3, P135; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MATTHEWS JR, 1995, NUCLEIC ACIDS RES, V23, P3393, DOI 10.1093/nar/23.17.3393; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SACHDEV S, 1995, ONCOGENE, V11, P811; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; STICKLE DF, 1994, J THEOR BIOL, V168, P1, DOI 10.1006/jtbi.1994.1082; Suyang H, 1996, MOL CELL BIOL, V16, P5444; TATEI K, 1995, MOL CELL BIOL, V15, P3627; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; WULCZYN FG, 1996, MOL MED, V74, P749; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	54	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33132	33139		10.1074/jbc.272.52.33132	http://dx.doi.org/10.1074/jbc.272.52.33132			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407099	hybrid			2022-12-25	WOS:000071182900060
J	Hastings, GA; Coleman, TA; Haudenschild, CC; Stefansson, S; Smith, EP; Barthlow, R; Cherry, S; Sandkvist, M; Lawrence, DA				Hastings, GA; Coleman, TA; Haudenschild, CC; Stefansson, S; Smith, EP; Barthlow, R; Cherry, S; Sandkvist, M; Lawrence, DA			Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons - Implications for the regulation of motor learning and neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE INHIBITOR; REACTIVE CENTER; NERVOUS-SYSTEM; MESSENGER-RNA; EXPRESSION; SEIZURE; GENE; SPECIFICITY; INDUCTION; COMPLEXES	A cDNA clone for the serine proteinase inhibitor (serpin), neuroserpin, was isolated from a human whole brain cDNA library, and recombinant protein was expressed in insect cells, The purified protein is an efficient inhibitor of tissue type plasminogen activator (tPA), having an apparent second-order rate constant of 6.2 x 10(5) M-1 s(-1) for the two-chain form. However, unlike other known plasminogen activator inhibitors, neuroserpin is a more effective inactivator of tPA than of urokinase-type plasminogen activator, Neuroserpin also effectively inhibited trypsin and nerve growth factor-gamma but reacted only slowly with plasmin and thrombin, Northern blot analysis showed a 1.8 kilobase messenger RNA expressed predominantly in adult human brain and spinal cord, and immunohistochemical studies of normal mouse tissue detected strong staining primarily in neuronal cells with occasionally positive microglial cells. Staining was most prominent in the ependymal cells of the choroid plexus, Purkinje cells of the cerebellum, select neurons of the hypothalamus and hippocampus, and in the myelinated axons of the commissura, Expression of tPA within these regions is reported to be high and has previously been correlated with both motor learning and neuronal survival, Taken together, these data suggest that neuroserpin is likely to be a critical regulator of tPA activity in the central nervous system, and as such may play an important role in neuronal plasticity and/or maintenance.	Amer Red Cross, Jerome H Holland Lab, Dept Biochem, Rockville, MD 20855 USA; Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; Human Genome Sci Inc, Dept Prot Therapeut, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Prot Express, Rockville, MD 20850 USA	American Red Cross; American Red Cross; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc	Lawrence, DA (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Biochem, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55374] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARROLL PM, 1994, DEVELOPMENT, V120, P3173; Coleman TA, 1997, PROTEIN EXPRES PURIF, V9, P40, DOI 10.1006/prep.1996.0670; FRIEDMAN GC, 1994, DEV BRAIN RES, V81, P41, DOI 10.1016/0165-3806(94)90066-3; FRIEDMAN GC, 1995, J COMP NEUROL, V360, P658; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P65; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P33; Gualandris A, 1996, J NEUROSCI, V16, P2220; KEIJER J, 1991, BLOOD, V78, P1254; KITZ R, 1962, J BIOL CHEM, V237, P3245; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; LAWRENCE DA, 1995, MOL BASIS THROMBOSIS, P517; LAWRENCE DA, 1997, J BIOL CHEM, V4, P339; MANSUY IM, 1993, DEVELOPMENT, V119, P1119; OLSON ST, 1995, J BIOL CHEM, V270, P30007; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; Padro T, 1990, Blood Coagul Fibrinolysis, V1, P601; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; Schrimpf SP, 1997, GENOMICS, V40, P55, DOI 10.1006/geno.1996.4514; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; WARE JH, 1995, BRAIN RES BULL, V37, P275, DOI 10.1016/0361-9230(95)00008-3; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354	33	193	203	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33062	33067		10.1074/jbc.272.52.33062	http://dx.doi.org/10.1074/jbc.272.52.33062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407089	hybrid			2022-12-25	WOS:000071182900050
J	Ichetovkin, IE; Abramochkin, G; Shrader, TE				Ichetovkin, IE; Abramochkin, G; Shrader, TE			Substrate recognition by the leucyl/phenylalanyl-tRNA-protein transferase - Conservation within the enzyme family and localization to the trypsin-resistant domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; ESCHERICHIA-COLI; CLONING; GROWTH; GENE; PURIFICATION; EXPRESSION; CYDD	The leucyl/phenylalanyl-tRNA-protein transferase (L/F-transferase) from Escherichia coli catalyzes a peptidyltransferase reaction that results in the N-terminal aminoacylation of acceptor proteins using Leu-, Phe-, and Met-tRNAs as amino acid donors, We demonstrated that L/F-transferase homologs are widely distributed throughout the eubacteria, supporting our proposal that the enzyme family is ancient and catalyzes early peptide bond synthesis, However, here we present data suggesting that the L/F-transferase is not a homolog of the peptidyltransferase enzymes involved in cell wall peptidoglycan biosynthesis in Gram-positive species, such as Staphylococcus aureus. A sequence comparison of the known L/F-transferase homologs began to identify the essential residues required to catalyze a peptidyltransferase reaction and revealed that <20% of the residues were invariant within the L/F-transferase family, Despite this sequence variation, substrate specificity was broadly conserved, and L/F-transferase homologs from Providencia stuartii, Vibrio cholerae, Neisseria gonorrhoeae, and the cyanobacterium Synechocystis sp, all complemented an E. coli aat mutant (lacking L/F-transferase activity) for the degradation of N-end rule substrates, In vitro comparison of the most divergent L/F-transferase homologs, from E. coli and the cyanobacterium Synechocystis sp., revealed near-complete conservation of both substrate specificity and secondary structure. Finally, we demonstrated that variants of the E. coli L/F-transferase, lacking either 33 or 78 N-terminal residues, retained measurable peptidyl-transferase activity and wild type substrate specificity, Overall, our results identified an essential core of an L/F-transferase and revealed that a peptidyltransferase catalyst may be constructed from similar to 120 amino acids.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Shrader, TE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			ICHETOVKIN, ILIA/0000-0003-4662-3513	NIGMS NIH HHS [GM52440] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052440] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramochkin G, 1996, J BIOL CHEM, V271, P22901, DOI 10.1074/jbc.271.37.22901; ABRAMOCHKIN G, 1995, J BIOL CHEM, V270, P20621, DOI 10.1074/jbc.270.35.20621; BALZI E, 1990, J BIOL CHEM, V265, P7464; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CUMMINGS HS, 1991, J BIOL CHEM, V266, P16491; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; KAJI A, 1965, J BIOL CHEM, V240, P1185; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; LEIBOWITZ MJ, 1970, J BIOL CHEM, V246, P4431; LIEBOWITZ MJ, 1971, J BIOL CHEM, V246, P5207; Macinga DR, 1996, MOL MICROBIOL, V19, P511, DOI 10.1046/j.1365-2958.1996.385912.x; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; MUNOZ E, 1967, BIOCHEMISTRY-US, V6, P3659, DOI 10.1021/bi00864a007; PLAPP R, 1970, J BIOL CHEM, V245, P3667; POOLE RK, 1993, MOL MICROBIOL, V10, P421, DOI 10.1111/j.1365-2958.1993.tb02673.x; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCARPULLA RC, 1976, BIOCHEM BIOPH RES CO, V71, P584, DOI 10.1016/0006-291X(76)90827-5; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SIEGELE DA, 1993, GENE DEV, V7, P2629, DOI 10.1101/gad.7.12b.2629; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MC, 1988, J BIOL CHEM, V263, P7211; SOFFER RL, 1974, ADV ENZYMOL RAMB, V40, P91; STAHL SJ, 1981, J MOL BIOL, V148, P481, DOI 10.1016/0022-2836(81)90187-X; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; YANG JT, 1986, METHOD ENZYMOL, V130, P208	34	38	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33009	33014		10.1074/jbc.272.52.33009	http://dx.doi.org/10.1074/jbc.272.52.33009			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407082	hybrid			2022-12-25	WOS:000071182900043
J	Morita, T; Mitsialis, SA; Koike, H; Liu, YX; Kourembanas, S				Morita, T; Mitsialis, SA; Koike, H; Liu, YX; Kourembanas, S			Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; NITRIC-OXIDE SYNTHASE; HEME OXYGENASE; E2F FAMILY; INDUCIBLE FACTOR-1; ENDOTHELIAL-CELLS; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; GROWTH-FACTORS; IN-VIVO	Excess vascular smooth muscle cell (VSMC) proliferation and contractility are key events in the pathophysiology of vascular disorders induced by hypoxia, We have recently reported that carbon monoxide (CO), produced by VSMC under conditions of hypoxia, can be a modulator of cGMP levels in both endothelial and smooth muscle cells. In this respect, some of the physiologic effects of CO in the vasculature parallel those of nitric oxide (NO), a well characterized regulator of vascular tone. We report here that under hypoxia, VSMC-derived CO is an important regulator of VSMC proliferation, Inhibiting CO formation or scavenging CO with hemoglobin increased VSMC proliferation in response to serum or to mitogens such as endothelin, whereas increasing CO production or exposing cells to exogenous CO lead to a markedly attenuated growth response. The effects of CO on VSMC proliferation correlated with changes in E2E-1 expression, the prototype member of a family of transcription factors that participate in the control of cell cycle progression, CO significantly suppressed E2F-1 ex; pression, whereas, removal of CO from the cultures with hemoglobin lead to increased E2F-1 gene transcription, mRNA, and protein production as well as mRNA levels of c-myc, a target gene of E2F-1. Moreover, the actions of CO were mediated by the second messenger molecule, cGMP. Limiting VSMC growth by increasing the release of CO may represent a key event in the body's compensatory responses to hypoxia.	Harvard Univ, Sch Med, Dept Pediat, Joint Program Neonatol, Boston, MA 02115 USA; Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA	Harvard University; Harvard Medical School; Boston University	Kourembanas, S (corresponding author), Childrens Hosp, Joint Program Neonatol, 300 Longwood Ave,Enders 9, Boston, MA 02115 USA.	kourembanas@a1.tch.harvard.edu		Mitsialis, S. Alex/0000-0001-8315-7828	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046491, R01HL055454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044520] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL55454, 1P50HL46491] Funding Source: Medline; NIGMS NIH HHS [GM44520] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; BRUNE B, 1987, MOL PHARMACOL, V32, P497; COOK MN, 1995, CAN J PHYSIOL PHARM, V73, P515, DOI 10.1139/y95-065; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MAINES MD, 1986, J BIOL CHEM, V261, P411; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; RAMOS KS, 1989, BIOCHEM PHARMACOL, V38, P1368, DOI 10.1016/0006-2952(89)90347-X; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHACTER BA, 1988, SEMIN HEMATOL, V25, P349; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; STORCH TG, 1988, EXP CELL RES, V175, P317, DOI 10.1016/0014-4827(88)90195-4; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	36	278	304	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32804	32809		10.1074/jbc.272.52.32804	http://dx.doi.org/10.1074/jbc.272.52.32804			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407056	hybrid			2022-12-25	WOS:000071182900017
J	Bu, X; Quertermous, T				Bu, X; Quertermous, T			Identification of an endothelial cell-specific regulatory region in the murine endothelin-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; WILLEBRAND-FACTOR GENE; TRANSCRIPTION FACTOR GATA-2; FOS-PROTEIN COMPLEXES; FUNCTIONAL-ANALYSIS; ADHESION MOLECULE-1; BINDING PROTEIN; PREPROENDOTHELIN-1 PROMOTER; TRANSGENIC MICE; SELECTIN GENE	Endothelin-1 is a 21-amino acid peptide first characterized as a potent vasoactive compound synthesized by endothelial cells, Because of its high level cell-restricted pattern of expression, we have employed this gene as a model for investigating the DNA and protein elements that mediate endothelial cell-specific gene expression. In this study we have identified a complex positive regulatory region located at base pairs -364 to -320 in the murine endothelin-l gene. This region consists of three functionally dependent elements, ETE-C, ETE-D, and ETE-E, which are all required for full activity, When a 43-base pair fragment containing these three elements was employed in heterologous promoter experiments, this sequence was capable of increasing transcriptional activity in an endothelial cell-specific fashion. None of the elements contains a recognized consensus sequence known to bind transcriptional regulatory proteins in higher eukaryotes; however, each element does appear to mediate protein binding. The combination of all three elements promotes binding of a protein complex that is endothelial cell-specific. This is the first evidence for an endothelial cell-specific DNA regulatory element and cognate binding proteins.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Quertermous, T (corresponding author), Falk Cardiovasc Res Ctr, 300 Pasteur Dr, Stanford, CA 94305 USA.			Quertermous, Thomas/0000-0002-7645-9067	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046994] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46994] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; FERREIRA V, 1993, BIOCHEM J, V293, P641, DOI 10.1042/bj2930641; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; HADMAN M, 1993, ONCOGENE, V8, P1895; HARATS D, 1995, J CLIN INVEST, V95, P1335, DOI 10.1172/JCI117784; HILKERT RJ, 1992, TRENDS CARDIOVAS MED, V2, P129, DOI 10.1016/1050-1738(92)90019-O; HILKERT RJ, 1993, J VASC MED BIOL, V4, P143; HUBERT C, 1991, J BIOL CHEM, V266, P15377; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; ISSEKUTZ TB, 1992, CURR OPIN IMMUNOL, V4, P287, DOI 10.1016/0952-7915(92)90078-S; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KAUSHANSKY K, 1989, J IMMUNOL, V143, P2525; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE ME, 1991, J BIOL CHEM, V266, P19034; LUSCHER TF, 1992, HYPERTENSION, V19, P117, DOI 10.1161/01.HYP.19.2.117; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MASAKI T, 1993, ENDOCR REV, V14, P256, DOI 10.1210/er.14.3.256; MASAKI T, 1991, CIRCULATION, V84, P1456; MEYRICK B, 1994, AM J RESP CELL MOL, V10, P113, DOI 10.1165/ajrcmb.10.1.8292376; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NUNOKAWA Y, 1994, BIOCHEM BIOPH RES CO, V200, P802, DOI 10.1006/bbrc.1994.1522; ORKIN SH, 1992, BLOOD, V80, P575; Osada S, 1996, J BIOL CHEM, V271, P3891; PAN JL, 1993, J BIOL CHEM, V268, P22600; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SIMONS M, 1997, NAT MED, V3, P182; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TAZAWA R, 1993, J BIOCHEM-TOKYO, V113, P600, DOI 10.1093/oxfordjournals.jbchem.a124089; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WILLIAMS TJ, 1992, AM REV RESPIR DIS, V146, pS45, DOI 10.1164/ajrccm/146.5_Pt_2.S45; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	47	23	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32613	32622		10.1074/jbc.272.51.32613	http://dx.doi.org/10.1074/jbc.272.51.32613			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405477	hybrid			2022-12-25	WOS:000071108000096
J	Fukuda, M; Gotoh, I; Adachi, M; Gotoh, Y; Nishida, E				Fukuda, M; Gotoh, I; Adachi, M; Gotoh, Y; Nishida, E			A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade - Role of nuclear export signal of MAP kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SOMATIC-CELLS; NIH 3T3 CELLS; IN-VITRO; PHOSPHORYLATION SITES; MESODERM INDUCTION; PLASMA-MEMBRANE; GROWTH-FACTOR; RAF; PATHWAY; IDENTIFICATION	Mitogen-activated protein kinase (MAPK) kinase (MAPKK, also known as MEK), a direct activator for MAPK/extracellular signal-regulated kinase, localizes to the cytoplasm excluded from the nucleus during signal transmission. This nuclear exclusion of MAPKK is directed by its nuclear export signal (NES), but its physiological significance has been unknown. We have found that disruption of the NES dramatically potentiates the ability of constitutively active MAPKK to induce morphological changes and malignant transformation of fibroblastic cells. Readdition of the MES sequence reversed the effects induced by the NES disruption. Moreover, we observed that a dramatic increase of activated MAPK in the nucleus was induced by the NES-disrupted MAPKK and that coexpression of MAPK phosphatase-1 (CL-100) or a kinase negative form of MAPK counteracted the phenotypes induced by the NES-disrupted MAPKK, indicating the crucial role of MAPK in the responses. These findings reveal a novel regulatory role of the NES of MAPKK that may be essential for proper signal transductions.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 60601, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 60601, Japan	Kyoto University; Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 60601, Japan.		Fukuda, Makoto/C-9745-2009; Fukuda, Makoto/S-9748-2019; Fukuda, Makoto/I-7915-2014	Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; GUKUDA M, 1996, J BIOL CHEM, V251, P80024; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LABONNE CV, 1995, DEVELOPMENT, V11, P1475; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MORIGUCHI T, 1995, EUR J BIOCHEM, V234, P32, DOI 10.1111/j.1432-1033.1995.032_c.x; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEGER R, 1994, J BIOL CHEM, V269, P25699; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; THOMAS G, 1992, CELL, V68, P1; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	48	157	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32642	32648		10.1074/jbc.272.51.32642	http://dx.doi.org/10.1074/jbc.272.51.32642			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405481	hybrid			2022-12-25	WOS:000071108000100
J	Qin, XX; Coyne, KJ; Waite, JH				Qin, XX; Coyne, KJ; Waite, JH			Tough tendons - Mussel byssus has collagen with silk-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYTILUS-EDULIS; SPIDER SILK; PROTEINS; SEQUENCE; QUINONE; OXIDASE; GLAND	The primary structure of the alpha-chain of preCol-D (molecular mass = 80 kDa), a tanned collagenous protein predominating in the distal portion of the byssal threads of the mussel Mytilus edulis, was deduced from cDNA to encode an unprecedented natural block copolymer with three major domain types: a central collagen domain flanked by fibroin-like domains and followed by histidine-rich termini, The fibroin-like domains have sequence motifs that strongly resemble the crystalline polyalanine-rich and amorphous glycine-rich regions of spider dragline silk fibroins. The terminal regions resemble the histidine-rich domains of a variety of metal-binding proteins. The silk domains may toughen the collagen by increasing its strength and extensibility. PreCol-D expression is limited to the mussel foot, which contains a longitudinal gradient of preCol-D mRNA. This gradient increases linearly in the proximal to distal direction and reaches a maximum just before the distal depression of the foot.	Univ Delaware, Coll Marine Studies, Newark, DE 19716 USA; Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Univ Delaware, Coll Marine Studies, Lewes, DE 19958 USA	University of Delaware; University of Delaware; University of Delaware	Waite, JH (corresponding author), Univ Delaware, Coll Marine Studies, Newark, DE 19716 USA.			Coyne, Kathryn/0000-0001-8846-531X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010042] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 10042] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bell EC, 1996, J EXP BIOL, V199, P1005; BRYAN GW, 1979, J MAR BIOL ASSOC UK, V59, P969, DOI 10.1017/S0025315400036961; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOMBS TL, 1981, AQUAT TOXICOL, V1, P291, DOI 10.1016/0166-445X(81)90023-0; Coyne KJ, 1997, SCIENCE, V277, P1830, DOI 10.1126/science.277.5333.1830; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Denny M. W., 1988, BIOL MECH WAVE SWEPT; GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9; Guerette PA, 1996, SCIENCE, V272, P112, DOI 10.1126/science.272.5258.112; Hall, 1981, POLYM MAT, DOI 10.1007/978-1-349-10187-0_4; Hijirida DH, 1996, BIOPHYS J, V71, P3442, DOI 10.1016/S0006-3495(96)79539-5; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; Kummerlen J, 1996, MACROMOLECULES, V29, P2920, DOI 10.1021/ma951098i; LEWIS RV, 1992, ACCOUNTS CHEM RES, V25, P392, DOI 10.1021/ar00021a002; LILIUS G, 1991, EUR J BIOCHEM, V198, P499, DOI 10.1111/j.1432-1033.1991.tb16042.x; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; LUCAS F, 1958, ADV PROTEIN CHEM B, V4, P313; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; Mercer E. H., 1952, Australian Journal of Marine and Freshwater Research, V3, P199; PAPOV VV, 1995, J BIOL CHEM, V270, P20183, DOI 10.1074/jbc.270.34.20183; PIKKARAINEN J, 1968, EUR J BIOCHEM, V4, P555, DOI 10.1111/j.1432-1033.1968.tb00248.x; QIN XX, 1995, J EXP BIOL, V198, P633; Rudall K. M., 1955, S SOC EXP BIOL, V9, P49; Shah NK, 1997, BIOCHEMISTRY-US, V36, P5878, DOI 10.1021/bi963146c; SIMLONS AH, 1996, SCIENCE, V271, P84; SMEATHERS JE, 1979, J MOLLUS STUD, V49, P219; SMITH MC, 1987, INORG CHEM, V26, P1965, DOI 10.1021/ic00259a030; Sudo S, 1997, NATURE, V387, P563, DOI 10.1038/42391; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; Thiel BL, 1997, BIOPOLYMERS, V41, P703, DOI 10.1002/(SICI)1097-0282(199706)41:7<703::AID-BIP1>3.0.CO;2-T; VANNESS KP, 1988, COMP BIOCHEM PHYS B, V91, P531, DOI 10.1016/0305-0491(88)90017-X; WAITE JH, 1995, METHOD ENZYMOL, V258, P1; WAITE JH, 1989, BIOCHEMISTRY-US, V28, P6104, DOI 10.1021/bi00440a056; WAITE JH, 1985, J MAR BIOL ASSOC UK, V65, P359, DOI 10.1017/S0025315400050487; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WARWICKER JO, 1960, J MOL BIOL, V2, P350, DOI 10.1016/S0022-2836(60)80046-0; Xu RD, 1996, ARCH BIOCHEM BIOPHYS, V329, P56, DOI 10.1006/abbi.1996.0191; [No title captured]	39	112	119	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32623	32627		10.1074/jbc.272.51.32623	http://dx.doi.org/10.1074/jbc.272.51.32623			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405478	hybrid			2022-12-25	WOS:000071108000097
J	Backlund, M; Johansson, I; Mkrtchian, S; IngelmanSundberg, M				Backlund, M; Johansson, I; Mkrtchian, S; IngelmanSundberg, M			Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; CULTURED RABBIT HEPATOCYTES; HEAT-SHOCK PROTEIN; AH DIOXIN RECEPTOR; HYDROXYLASE INDUCTION; ENZYME-ACTIVITY; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; DEPENDENT ACTIVATION; HUMAN KERATINOCYTES	We have investigated mechanisms of omeprazole (OME)-mediated induction of CYP1A1 and CYP3A, using the rat hepatoma H4IIE cell line, in comparison with mechanisms exerted by traditional aryl hydrocarbon receptor (AhR) ligands such as benso(a)pyrene (B(a)P) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). OME did not bind specifically to AhR, and it could not activate the AhR complex in rat cytosol to a xenobiotic-responsive element (XRE)-binding form in vitro. Genistein, a tyrosine kinase inhibitor, and daidzein, an inhibitor of casein kinase II, efficiently inhibited OME-mediated but not B(a)P-or TCDD-mediated induction of CYP1A1, as monitored at the transcriptional, mRNA, and protein levels as well as by analysis of activation of XRE-luciferase reporter constructs transfected into H4IIE cells. The protease inhibitor N-alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) and lavendustin A also had similar OME-specific effects. In addition, insulin pretreatment caused an almost complete inhibition of OME-dependent CYP1A1 induction but only partially affected TCDD and B(a)P-mediated induction of CYPIA1. Staurosporine, an inhibitor of protein kinase C, impaired the induction by both B(a)P and OME. OME caused an approximately 2-fold increase in the level of CYP3A expression, but all inhibitors used were ineffective in preventing this induction. Gel shift analysis with radiolabeled XRE and specific peptide antibodies toward AhR and aryl hydrocarbon receptor nuclear translocator protein (Arnt) revealed an OME-mediated translocation of the AhR.Arnt complex into the nuclei. Genistein inhibited the specific nuclear XRE binding caused by OME, but it potentiated the formation of the TCDD-induced XRE.AhR complex. Although daidzein was able to effectively inhibit the OME-stimulated CYP1A1 gene transcription, it did not influence the OME-dependent AhR.XRE complex formation, The data are consistent with a mechanism for OME-mediated induction of CYP1A1 that involves activation of the AhR complex via intracellular signal transduction systems and that is distinct from induction mediated by AhR ligands.	KAROLINSKA INST, INST ENVIRONM MED, DIV MOL TOXICOL, S-17177 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska Institutet			Ingelman-Sundberg, Magnus/ABD-9302-2021	Mkrtchian, Souren/0000-0001-9801-2736				AIX L, 1994, BIOCHEM BIOPH RES CO, V202, P1483, DOI 10.1006/bbrc.1994.2098; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHEN YT, 1980, BIOCHEM BIOPH RES CO, V143, P343; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURIPEDROSA R, 1994, J PHARMACOL EXP THER, V269, P384; Daujat M, 1996, EUR J BIOCHEM, V237, P642, DOI 10.1111/j.1432-1033.1996.0642p.x; DAUJAT M, 1992, BIOCHEM BIOPH RES CO, V188, P820, DOI 10.1016/0006-291X(92)91130-I; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DIAZ D, 1990, GASTROENTEROLOGY, V99, P737, DOI 10.1016/0016-5085(90)90963-2; Dzeletovic N, 1997, J BIOL CHEM, V272, P12705, DOI 10.1074/jbc.272.19.12705; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; GIELEN JE, 1972, J BIOL CHEM, V247, P7591; GLEIZES C, 1991, BIOCHEM PHARMACOL, V41, P1813, DOI 10.1016/0006-2952(91)90119-P; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GRADIN K, 1994, J BIOL CHEM, V269, P23800; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HIGASHI K, 1994, BBA-MOL CELL RES, V1221, P29, DOI 10.1016/0167-4889(94)90212-7; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; JURUTKA PW, 1993, BIOCHEMISTRY-US, V32, P8184, DOI 10.1021/bi00083a019; KIKUCHI H, 1995, ARCH BIOCHEM BIOPHYS, V316, P649, DOI 10.1006/abbi.1995.1085; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIND T, 1983, GUT, V24, P270, DOI 10.1136/gut.24.4.270; Lindros KO, 1997, J PHARMACOL EXP THER, V280, P506; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONNELL WM, 1992, GASTROENTEROLOGY, V103, P1509, DOI 10.1016/0016-5085(92)91171-Y; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; OWENS IS, 1975, MOL PHARMACOL, V11, P94; OWENS IS, 1976, BIOCHEM PHARMACOL, V25, P805, DOI 10.1016/0006-2952(76)90151-9; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PUGA A, 1992, FASEB J, V6, P777, DOI 10.1096/fasebj.6.2.1311272; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ReyGrobellet X, 1996, BIOCHEM BIOPH RES CO, V220, P789, DOI 10.1006/bbrc.1996.0482; SADEK CM, 1994, J BIOL CHEM, V269, P16067; SADEK CM, 1994, J BIOL CHEM, V269, P31505; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; SOUHAILIELAMRI H, 1988, TOXICOL APPL PHARM, V92, P141, DOI 10.1016/0041-008X(88)90236-0; STRUHL K, 1990, CURRENT PROTOCOLS MO	51	109	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31755	31763		10.1074/jbc.272.50.31755	http://dx.doi.org/10.1074/jbc.272.50.31755			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395520	hybrid			2022-12-25	WOS:A1997YL41900079
J	Inoue, K; Dreyfuss, BW; Kindle, KL; Stern, DB; Merchant, S; Sodeinde, OA				Inoue, K; Dreyfuss, BW; Kindle, KL; Stern, DB; Merchant, S; Sodeinde, OA			Ccs1, a nuclear gene required for the post-translational assembly of chloroplast c-type cytochromes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEINS; CHLAMYDOMONAS-REINHARDTII; B(6)F COMPLEX; COMPLEMENTARY-DNA; HEME ATTACHMENT; BF COMPLEX; EXPRESSION; BIOGENESIS; SEQUENCE; MUTATIONS	Nuclear genes play important regulatory roles in the biogenesis of the photosynthetic apparatus of eukaryotic cells by encoding factors that control steps ranging from chloroplast gene transcription to post-translational processes, However, the identities of these genes and the mechanisms by which they govern these processes are largely unknown. By using glass bead-mediated transformation to generate insertional mutations in the nuclear genome of Chlamydomonas reinhardtii, we have generated four mutants that are defective in the accumulation of the cytochrome b(6)f complex. One of them, strain abf3, also fails to accumulate holocytochrome c(6). We have isolated a gene, Ccs1, from a C. reinhardtii genomic library that complements both the cytochrome b(6)f and cytochrome c(6) deficiencies in abf3. The predicted protein product displays significant identity with Ycf44 from the brown alga Odontella sinensis, the red alga Porphyra purpurea, and the cyanobacterium Synechocystis strain PCC 6803 (25-33% identity), In addition, we note limited sequence similarity with ResB of Bacillus subtilis and an open reading frame in a homologous operon in Mycobacterium leprae (11-12% identity). On the basis of the pleiotropic e-type cytochrome deficiency in the ccs1 mutant, the predicted plastid localization of the protein, and its relationship to candidate cytochrome biosynthesis proteins in Gram-positive bacteria, we conclude that Ccs1 encodes a protein that is required for chloroplast c-type holocytochrome formation.	PENN STATE UNIV, DEPT BIOCHEM & MOL BIOL, UNIVERSITY PK, PA 16802 USA; UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90095 USA; CORNELL UNIV, PLANT SCI CTR, ITHACA, NY 14853 USA; CORNELL UNIV, BOYCE THOMPSON INST PLANT RES, ITHACA, NY 14853 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California Los Angeles; Cornell University; Cornell University; Boyce Thompson Institute for Plant Research			Stern, David B/H-7852-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K04GM000594, F32GM017483, R01GM048350] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17483, GM48350, GM00594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARKAN A, 1995, PHYSIOL PLANTARUM, V93, P163, DOI 10.1034/j.1399-3054.1995.930123.x; BECKMAN DL, 1992, GENE DEV, V6, P268, DOI 10.1101/gad.6.2.268; BENDALL DS, 1986, FEBS LETT, V203, P31, DOI 10.1016/0014-5793(86)81430-2; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; CHEN XM, 1993, EMBO J, V12, P3627, DOI 10.1002/j.1460-2075.1993.tb06036.x; Cramer WA, 1997, PHYSIOL PLANTARUM, V100, P852, DOI 10.1111/j.1399-3054.1997.tb00011.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; deVitry C, 1996, J BIOL CHEM, V271, P10667, DOI 10.1074/jbc.271.18.10667; DEVITRY C, 1994, J BIOL CHEM, V269, P7603; GAL A, 1990, CURRENT RES PHOTOSYN, V2, P779; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; GOLDSCHMIDTCLERMONT M, 1986, J MOL BIOL, V191, P421, DOI 10.1016/0022-2836(86)90137-3; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; GRUISSEM W, 1993, CRIT REV PLANT SCI, V12, P19, DOI 10.1080/07352689309382355; Gumpel NJ, 1995, PLANT MOL BIOL, V29, P921, DOI 10.1007/BF00014966; Harris E., 1989, CHLAMYDOMONAS SOURCE, P575; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; HILL KL, 1991, J BIOL CHEM, V266, P15060; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOWE G, 1994, J BIOL CHEM, V269, P5824; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; IMBAULT P, 1988, GENE, V73, P397, DOI 10.1016/0378-1119(88)90504-5; Kaneko T, 1996, DNA Res, V3, P109; Ketchner SL, 1996, BBA-BIOENERGETICS, V1273, P195, DOI 10.1016/0005-2728(95)00157-3; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; Kowallik KV, 1995, PLANT MOL BIOL REP, V13, P336, DOI 10.1007/BF02669188; KUCHKA MR, 1988, EMBO J, V7, P319, DOI 10.1002/j.1460-2075.1988.tb02815.x; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LEE SY, 1990, BIOTECHNIQUES, V9, P676; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; Li HH, 1996, J BIOL CHEM, V271, P31283, DOI 10.1074/jbc.271.49.31283; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MATSUMOTO T, 1991, PLANT CELL PHYSIOL, V32, P863; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; QUINN J, 1998, IN PRESS METHODS ENZ; QUINN JM, 1995, PLANT CELL, V7, P623, DOI 10.1105/tpc.7.5.623; RAMSEIER TM, 1991, J BIOL CHEM, V266, P7793; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNELL RA, 1993, GENETICS, V134, P737; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; SHEPHERD HS, 1983, CELL, V32, P99, DOI 10.1016/0092-8674(83)90500-7; SODEINDE OA, 1993, P NATL ACAD SCI USA, V90, P9199, DOI 10.1073/pnas.90.19.9199; SOROKIN A, 1993, MOL MICROBIOL, V10, P385, DOI 10.1111/j.1365-2958.1993.tb02670.x; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; TAM LW, 1993, GENETICS, V135, P375; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; WAFFENSCHMIDT S, 1993, PLANT CELL, V5, P809, DOI 10.1105/tpc.5.7.809; Xie ZY, 1996, J BIOL CHEM, V271, P4632; YOUNGBLOM J, 1984, MOL CELL BIOL, V4, P2686, DOI 10.1128/MCB.4.12.2686; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	67	52	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31747	31754		10.1074/jbc.272.50.31747	http://dx.doi.org/10.1074/jbc.272.50.31747			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395519	hybrid			2022-12-25	WOS:A1997YL41900078
J	Latham, GJ; Bacheller, DJ; Pietroni, P; vonHippel, PH				Latham, GJ; Bacheller, DJ; Pietroni, P; vonHippel, PH			Structural analyses of gp45 sliding clamp interactions during assembly of the bacteriophage T4 DNA polymerase holoenzyme .3. The gp43 DNA polymerase binds to the same face of the sliding clamp as the clamp loader	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; III HOLOENZYME; REPLICATION COMPLEX; TRACKING PROTEIN; SUBUNIT; PROCESSIVITY; ENHANCEMENT; HYDROLYSIS; MECHANISM; PROMOTER	In the preceding paper (Latham, G. J., Bacheller, D. J., Pietroni, P., and von Hippel, P. H. (1997) J. Biol. Chem. 272, 31677-31684), we demonstrated that the T4 gp44/62-ATP clamp loader binds to the C-terminal face of the gp45 sliding clamp. Here we extend these results by exploring the structural relationship between the gp43 polymerase and the gp45 sliding clamp, Using fluorescence intensity and polarization techniques, as well as photo-cross-linking methods, we present evidence that gp43, like gp44/62, binds to the C-terminal face of gp45, In addition, we show that g43 binds to the gp45 clamp in two distinct interaction modes, depending on the presence or absence of template-primer DNA. When template-primer DNA is present, gp43 binds tightly to gp45 to form the highly processive DNA polymerase holoenzgme, Gp43 also binds to gp45 in the absence of template-primer DNA, but this interaction is more than 100 times weaker than gp43-gp45 binding on DNA. Specific interactions between gp43 and the C-terminal face of gp45 are maintained in both modes of binding. These results underscore the pivotal role of template-primer DNA in modulating the strength of protein-protein interactions during DNA synthesis and provide additional insight into the structural requirements of the replication process.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015792, R01GM029158, R37GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Arroyo MP, 1996, J BIOL CHEM, V271, P15971, DOI 10.1074/jbc.271.27.15971; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; BRODY EN, 1995, FEMS MICROBIOL LETT, V128, P1; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; Fu TJ, 1996, EMBO J, V15, P4414, DOI 10.1002/j.1460-2075.1996.tb00814.x; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Latham GJ, 1997, J BIOL CHEM, V272, P31677, DOI 10.1074/jbc.272.50.31677; Latham GJ, 1996, J MOL BIOL, V264, P426, DOI 10.1006/jmbi.1996.0651; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MCCARTHY D, 1976, J MOL BIOL, V106, P963, DOI 10.1016/0022-2836(76)90346-6; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NEWPORT JW, 1980, MECHANISTIC STUDIES, P485; Pietroni P, 1997, J BIOL CHEM, V272, P31666, DOI 10.1074/jbc.272.50.31666; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; RUSH J, 1989, PREP BIOCHEM, V19, P329, DOI 10.1080/10826068908544921; SANDERS GM, 1995, EMBO J, V14, P3966, DOI 10.1002/j.1460-2075.1995.tb00068.x; Sexton DJ, 1996, J BIOL CHEM, V271, P28045, DOI 10.1074/jbc.271.45.28045; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER RL, 1994, CELL, V77, P225, DOI 10.1016/0092-8674(94)90315-8; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TinkerKulberg RL, 1996, EMBO J, V15, P5032, DOI 10.1002/j.1460-2075.1996.tb00883.x; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	30	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31685	31692		10.1074/jbc.272.50.31685	http://dx.doi.org/10.1074/jbc.272.50.31685			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395510	hybrid			2022-12-25	WOS:A1997YL41900069
J	Umayahara, Y; Ji, CH; Centrella, M; Rotwein, P; McCarthy, TL				Umayahara, Y; Ji, CH; Centrella, M; Rotwein, P; McCarthy, TL			CCAAT/enhancer-binding protein delta activates insulin-like growth factor-I gene transcription in osteoblasts - Identification of a novel cyclic AMP signaling pathway in bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; MESSENGER-RIBONUCLEIC-ACID; CAMP RESPONSE ELEMENT; PARATHYROID-HORMONE; PROSTAGLANDIN E(2); ENRICHED CULTURES; MOLECULAR CHARACTERIZATION; TYROSINE PHOSPHORYLATION; HYPOPHYSECTOMIZED RATS; CELLS	Insulin-like growth factor-I (IGF-I) plays a key role in skeletal growth by stimulating bone cell replication and differentiation. We previously showed that prostaglandin E-2 (PGE(2)) and other cAMP-activating agents enhanced IGF-I gene transcription in cultured primary rat osteoblasts through promoter 1, the major IGF-I promoter, and identified a short segment of the promoter, termed HS3D, that was essential for hormonal regulation of IGF-I gene expression, We now demonstrate that CCAAT/enhancer-binding protein (C/EBP) delta is a major component of a PGE(2)-stimulated DNA-protein complex involving HS3D and find that C/EBP delta transactivates IGF-I promoter 1 through this site, Competition gel shift studies first indicated that a core C/EBP half-site (GCAAT) was required for binding of a labeled HS3D oligomer to osteoblast nuclear proteins. Southwestern blotting add UV-cross-linking studies showed that the HS3D probe recognized a similar to 35-kDa nuclear protein, and antibody supershift assays indicated that C/EBP delta comprised most of the PGE(2)-activated gel-shifted complex, C/EBP delta was detected by Western immunoblotting in osteoblast nuclear extracts after treatment of cells with PGE(2). An HS3D oligonucleotide competed effectively with a high affinity C/EBP site from the rat albumin gene for binding to osteoblast nuclear proteins, Cotransfection of osteoblast cell cultures with a C/EBP delta expression plasmid enhanced basal and PGE(2)-activated IGE-I promoter 1-luciferase activity but did not stimulate a reporter gene lacking an HS3D site, By contrast, an expression plasmid for the related protein, C/EBP beta, did not alter basal IGF-I gene activity but did increase the response to PGE,. In osteoblasts and in COS-7 cells, C/EBP delta, but not C/EBP beta, transactivated a reporter gene containing four tandem copies of HS3D fused to a minimal promoter; neither transcription factor stimulated a gene with four copies of an HS3D mutant that was unable to bind osteoblast nuclear proteins. These results identify C/EBP delta as a hormonally activated inducer of IGF-I gene transcription in osteoblasts and show that the HS3D element within IGF-I promoter 1 is a high affinity binding site for this protein.	OREGON HLTH SCI UNIV,DEPT MED,DIV MOL MED,PORTLAND,OR 97201; YALE UNIV,SCH MED,SECT PLAST SURG,NEW HAVEN,CT 06520	Oregon Health & Science University; Yale University			Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NICHD NIH HHS [5-PO1-HD20805] Funding Source: Medline; NIDDK NIH HHS [5-RO1-DK37449, 5-RO1-DK47421] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD020805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421, R01DK037449] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CHODOSH LA, 1997, CURRENT PROTOCOLS MO; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FOURNIER T, 1995, J IMMUNOL, V155, P2123; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; JEE WSS, 1990, BONE MINER, V15, P175; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KACHRA Z, 1991, ENDOCRINOLOGY, V128, P1723, DOI 10.1210/endo-128-4-1723; KACHRA Z, 1994, ENDOCRINOLOGY, V135, P1722, DOI 10.1210/en.135.5.1722; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LIN T, 1994, ENDOCRINOLOGY, V134, P2142, DOI 10.1210/en.134.5.2142; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MCCARTHY TL, 1993, ADV EXPT MED BIOL, P407; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; NGAN P, 1990, ARCH ORAL BIOL, V35, P717, DOI 10.1016/0003-9969(90)90094-Q; NOLTEN LA, 1994, MOL ENDOCRINOL, V8, P1636, DOI 10.1210/me.8.12.1636; Osada S, 1996, J BIOL CHEM, V271, P3891; PASH JM, 1995, ENDOCRINOLOGY, V136, P33, DOI 10.1210/en.136.1.33; POLL V, 1990, CELL, V63, P643; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUSSELL SM, 1985, ENDOCRINOLOGY, V116, P2563, DOI 10.1210/endo-116-6-2563; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOTTNER A, 1987, J ENDOCRINOL, V112, P123, DOI 10.1677/joe.0.1120123; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; THOMAS MJ, 1994, ENDOCRINOLOGY, V135, P1584, DOI 10.1210/en.135.4.1584; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; THOMAS MJ, 1995, MOL CELL BIOL, V15, P12, DOI 10.1128/MCB.15.1.12; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974	48	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31793	31800		10.1074/jbc.272.50.31793	http://dx.doi.org/10.1074/jbc.272.50.31793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395525	hybrid			2022-12-25	WOS:A1997YL41900084
J	Fournier, T; Fadok, V; Henson, PM				Fournier, T; Fadok, V; Henson, PM			Tumor necrosis factor-alpha inversely regulates prostaglandin D-2 and prostaglandin E-2 production in murine macrophages - Synergistic action of cyclic amp on cyclooxygenase-2 expression and prostaglandin E-2 synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; RENAL MESANGIAL CELLS; SMOOTH-MUSCLE CELLS; ENDOPEROXIDE SYNTHASE-1; GENE-EXPRESSION; PHOSPHOLIPASE A(2); BLOOD MONOCYTES; MESSENGER-RNA; PHORBOL ESTER; MAST-CELLS	Increased synthesis of insulin-like growth factor-1 is induced in murine macrophages by prostaglandin E-2 (PGE(2),) and tumor necrosis factor-alpha (TNF alpha). Accordingly, we have investigated mechanisms regulating synthesis of PGE(2), that might contribute to autocrine/paracrine effects on insulin-like growth factor-1 production. In response to zymosan, TNF alpha specifically induced a 5-fold increase in PGE(2), synthesis, at the same time decreasing PGD(2), production in a reciprocal fashion. Activators of cyclic AMP-dependent protein kinase (PKA), such as PGE(2), itself or dibutyryl cyclic AMP, did not modify PGE(2), production by themselves but potentiated the TNF alpha-induced increase in PGE(2),; this effect required both RNA and protein synthesis, No significant change in arachidonate release or production of other eicosanoids was observed. The inducible form of cyclooxygenase-a (COX2) but not of the constitutive form COX1 was implicated in the generation of both PGE(2), and PGD(2), in these cells by use of specific inhibitors and effects of dexamethasone. Neither COX1 nor COX2 protein levels were affected by TNF alpha or PKA activators used alone, whereas in association, marked up-regulation of COX2 mRNA and protein was observed. Incubations of cells carried out with PGH(2), demonstrated that PGE(2), synthase activity was increased after a TNF alpha pretreatment. Taken together, our results suggest that TNF alpha induced a switch from the PGD(2), to PGE(2), synthesis pathway by regulating PGE(2), synthase expression and/or activity and that activators of PKA markedly potentiated the TNF alpha-induced increase in PGE(2), through up-regulation of COX2 gene expression.	Natl Jewish Ctr Immunol & Resp Med, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	National Jewish Health	Fournier, T (corresponding author), Fac Xavier Bichat, INSERM, U408, BP 416, F-75870 Paris 18, France.		Fournier, Thierry C/E-5836-2016	Fournier, Thierry/0000-0002-7515-339X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027353, P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27353, HL34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGARWAL BB, 1993, LYMPHOKINE CYTOK RES, V12, P149; ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; ANTOINE C, 1992, BIOCHIM BIOPHYS ACTA, V1128, P139, DOI 10.1016/0005-2760(92)90299-B; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BETZ M, 1991, J IMMUNOL, V146, P108; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; BONNEY RJ, 1980, BIOCHIM BIOPHYS ACTA, V633, P410, DOI 10.1016/0304-4165(80)90199-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; CHU E, 1993, J CLIN IMMUNOL, V13, P49, DOI 10.1007/BF00920635; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DeWitt DL, 1993, AM J MED S2A, V95, P40, DOI DOI 10.1016/0002-9343(93)90396-7; DIAZ A, 1993, J BIOL CHEM, V268, P10364; ELIAS JA, 1985, AM REV RESPIR DIS, V131, P94; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FOURNIER T, 1995, J IMMUNOL, V155, P2123; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GREWE M, 1992, BIOL CHEM H-S, V373, P655, DOI 10.1515/bchm3.1992.373.2.655; HADLEY JS, 1988, BIOMED ENVIRON MASS, V15, P175, DOI 10.1002/bms.1200150309; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; HEMPEL SL, 1994, AM J PHYSIOL, V266, pC1392, DOI 10.1152/ajpcell.1994.266.5.C1392; HENSON PM, 1994, ANN NY ACAD SCI, V725, P298, DOI 10.1111/j.1749-6632.1994.tb39813.x; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUMES JL, 1977, NATURE, V269, P149, DOI 10.1038/269149a0; KELLY RW, 1986, PROSTAG LEUKOTR ESS, V24, P1, DOI 10.1016/0262-1746(86)90201-5; KELNER MJ, 1994, BIOCHEM BIOPH RES CO, V198, P298, DOI 10.1006/bbrc.1994.1042; KONIECZKOWSKI M, 1993, J CLIN INVEST, V92, P2425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LASZLO DJ, 1993, AM J PATHOL, V143, P587; LEE SH, 1992, J BIOL CHEM, V267, P25934; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MUHL H, 1992, FEBS LETT, V301, P190, DOI 10.1016/0014-5793(92)81245-H; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; OTTO JC, 1995, J LIPID MEDIAT CELL, V12, P139, DOI 10.1016/0929-7855(95)00015-I; PACE JL, 1985, J IMMUNOL, V134, P977; PFEILSCHIFTER J, 1989, BIOCHEM BIOPH RES CO, V159, P385, DOI 10.1016/0006-291X(89)90003-X; PFEILSCHIFTER J, 1991, BIOCHEM J, V273, P199, DOI 10.1042/bj2730199; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; RICHES DWH, 1988, J IMMUNOL, V141, P180; ROPER RL, 1990, J IMMUNOL, V145, P2644; RUSSELL SW, 1984, J LEUKOCYTE BIOL, V35, P291; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SPATZ M, 1993, PROSTAG LEUKOTR ESS, V49, P789, DOI 10.1016/0952-3278(93)90027-T; TAFFET SM, 1981, J IMMUNOL, V126, P424; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; WESTCOTT JY, 1990, J APPL PHYSIOL, V68, P2640, DOI 10.1152/jappl.1990.68.6.2640	58	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31065	31072		10.1074/jbc.272.49.31065	http://dx.doi.org/10.1074/jbc.272.49.31065			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388257	hybrid			2022-12-25	WOS:000071640800070
J	Spiecker, M; Peng, HB; Liao, JK				Spiecker, M; Peng, HB; Liao, JK			Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-SELECTIN; ACTIVATION; GENE; PHOSPHORYLATION; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; TRANSCRIPTION; MECHANISM; PROTEIN; PATHWAY	The induction of vascular cell adhesion molecule-1 (VCAM-1) expression by tumor necrosis factor (TNF)-alpha requires the activation of nuclear factor-kappa B (NF-kappa B) via a process involving the phosphorylation and degradation of its cytoplasmic inhibitor, I kappa B alpha. We have shown that nitric oxide (NO) decreases VCAM-1 expression via inhibition of NF-kappa B activation. To determine how NO inhibits NF-kappa B, we studied the fate of I kappa B alpha following TNF-alpha stimulation in the presence of NO donors S-nitrosoglutathione and sodium nitroprusside, Activation of NF-kappa B by TNF-alpha occurred within 15 min and coincided with rapid degradation of I kappa B alpha, Go-treatment with NO donors did not prevent I kappa B alpha phosphorylation or degradation, However, after 2 h of TNF-alpha stimulation, NO donors inhibited NF-kappa B activation and augmented I kappa B alpha resynthesis and nuclear translocation by 2.5- and 3-fold, respectively, This correlated with a 75% reduction in TNF-alpha-induced VCAM-1 expression. In a time-dependent manner, NO donors alone caused the nuclear translocation of I kappa B alpha. TO confirm that NO donors have similar effects as endogenously derived NO, murine macrophage-like cells, RAW264.,7, were co-cultured with endothelial cells, Induction of RAW264.,7-derived NO inhibited lipopolysaccharide-induced endothelial VCAM-1 expression, which was reversed by the NO synthase inhibitor N-omega-monomethyl-L-arginine. These findings indicate that NO inhibits NF-kappa B activation and VCAM-1 expression by increasing the expression and nuclear translocation of I kappa B alpha.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Vasc Med & Atherosclerosis Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liao, JK (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Vasc Med & Atherosclerosis Unit, 221 Longwood Ave,LMRC-316, Boston, MA 02115 USA.	jkliao@bics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009650, R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52233, HL-09650] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; COLLINS T, 1995, FASEB J, V9, P1; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DAVIES MJ, 1993, J PATHOL, V171, P223, DOI 10.1002/path.1711710311; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; MACKAY CR, 1993, IMMUNOL TODAY, V14, P99, DOI 10.1016/0167-5699(93)90205-Y; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; Pierce JW, 1996, J IMMUNOL, V156, P3961; RASBAND W, 1993, NIH IMAGE VERSION 1; Read MA, 1996, J IMMUNOL, V157, P3472; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; SMITH CW, 1993, SEMIN HEMATOL, V30, P45; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V10, P4159	31	208	220	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30969	30974		10.1074/jbc.272.49.30969	http://dx.doi.org/10.1074/jbc.272.49.30969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388244	hybrid			2022-12-25	WOS:000071640800057
J	Gavrilova, O; Barr, V; MarcusSamuels, B; Reitman, M				Gavrilova, O; Barr, V; MarcusSamuels, B; Reitman, M			Hyperleptinemia of pregnancy associated with the appearance of a circulating form of the leptin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE; BINDING-PROTEIN; WEIGHT; SERUM; MICE; EXPRESSION; RODENT; HUMANS; RNA	Leptin is a hormone produced in adipose cells that regulates energy expenditure, food intake, and adiposity, In mice, we observed that circulating leptin levels increase 20-40-fold during pregnancy, Pregnant ob/ob females had no detectable serum leptin, demonstrating that the heterozygous conceptus was not the source of the leptin. However, leptin RNA and protein levels in maternal adipose tissue were not elevated, The circulating leptin was in a high molecular weight complex, suggesting that the rise in leptin was due to expression of a binding protein, Indeed, quantitative assays of serum leptin binding capacity revealed a 40-fold increase, coincident with the rise in serum leptin, Leptin binding activity reached a capacity of 207 +/- 15 nmol/liter of serum at day 18 of gestation, and half-maximal binding was observed with similar to 3 nM leptin, The binding protein was purified and partially sequenced, revealing sequence identity to the extracellular domain of the leptin receptor, We found that the placenta produces large amounts of the OB-Re isoform of leptin receptor mRNA, which encodes a soluble binding protein, Thus, the extreme hyperleptinemia of late pregnancy is attributable to binding of the leptin by a secreted form of the leptin receptor made by the placenta.	NIDDK,DIABET BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475				Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BARR VA, 1997, ENDOCRINOLOGY, V38, P4463; BAUMANN G, 1995, EXP CLIN ENDOCR DIAB, V103, P2, DOI 10.1055/s-0029-1211322; BAXTER RC, 1994, HORM RES, V42, P140, DOI 10.1159/000184186; BEHAN DP, 1995, FRONT NEUROENDOCRIN, V16, P362, DOI 10.1006/frne.1995.1013; BI S, 1997, IN PRESS J BIOL CHEM, V272; Butte NF, 1997, J CLIN ENDOCR METAB, V82, P585, DOI 10.1210/jc.82.2.585; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CATZEFLIS FM, 1987, MOL BIOL EVOL, V4, P242; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Cumin F, 1996, INT J OBESITY, V20, P1120; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; GREEN ED, 1995, GENOME RES, V5, P5, DOI 10.1101/gr.5.1.5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HEANEY ML, 1993, BLOOD, V82, P1945, DOI 10.1182/blood.V82.7.1945.bloodjournal8271945; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; HYTTEN FE, 1991, CLIN PHYSL OBSTET, P196; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mounzih K, 1997, ENDOCRINOLOGY, V138, P1190, DOI 10.1210/en.138.3.1190; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; ROBINSON JJ, 1986, P NUTR SOC, V45, P71, DOI 10.1079/PNS19860037; Schubring C, 1996, EUR J PEDIATR, V155, P830, DOI 10.1007/BF02002918; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; SMITHBERG M., 1957, JOUR HEREDITY, V48, P97; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TALAMANTES F, 1994, P SOC EXP BIOL MED, V206, P254; TARGAGLIA LA, 1995, CELL, V83, P1263; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	37	198	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30546	30551		10.1074/jbc.272.48.30546	http://dx.doi.org/10.1074/jbc.272.48.30546			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374549	hybrid			2022-12-25	WOS:A1997YH61300081
J	Mancini, A; Niedenthal, R; Joos, H; Koch, A; Trouliaris, S; Niemann, H; Tamura, T				Mancini, A; Niedenthal, R; Joos, H; Koch, A; Trouliaris, S; Niemann, H; Tamura, T			Identification of a second Grb2 binding site in the v-Fms tyrosine kinase	ONCOGENE			English	Article						M-CSF receptor; v-Fms tyrosine kinase; Grb2; tyrosine phosphorylation; SH2 domain	FACTOR-I RECEPTOR; GREEN FLUORESCENT PROTEIN; FELINE SARCOMA-VIRUS; ONCOGENE PRODUCT; CSF-1 RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; POINT MUTATION; GROWTH-FACTOR; SH2 DOMAINS	Tyrosine autophosphorylation of the v-Fms oncogene product results in the formation of high-affinity binding sites for cellular proteins containing Src homology 2 (SH2) domains. These proteins transduce various mitogenic and morphogenic signals. As reported previously, (YKNI)-K-696 in the kinase insert domain of v-Fms binds to the growth factor receptor bound protein 2 (Grb2), a stimulator of the Ras/Raf1 pathway. Here, we mapped (YTNL)-T-921 within the C-terminal domain of Fms as a novel autophosphorylation site. We demonstrate that this site constitutes a second Grb2 binding site: a recombinant fusion protein (residues 904-944) containing phosphorylated Y921 bound Grb2 from FDCP-1Mac11 cell extracts significantly more efficiently than a corresponding protein (residues 617-759) containing Y696. A yeast two-hybrid system which allowed the formation of a functional Fms tyrosine kinase was employed to quantify binding of Grb2. Fms-protein containing either one of the two phosphorylation sites bound Grb2 equally well, binding was increased for proteins carrying both sites. In contrast, the simultaneous substitution of Y696 and Y921 by phenylalanines abolished Grb2 binding. Mouse NIH3T3 cells expressing the Y921F mutant Fms-protein showed a substantially higher content of fibronectin network than wild-type transformed cells and had largely lost their serum independent growth phenotype.	HANNOVER MED SCH,INST PHYSIOL CHEM,OE 4310,D-30623 HANNOVER,GERMANY	Hannover Medical School								BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P15337; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Joos H, 1996, J BIOL CHEM, V271, P24476, DOI 10.1074/jbc.271.40.24476; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Novak U, 1996, ONCOGENE, V13, P2607; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMOLA U, 1991, J VIROL, V65, P6181, DOI 10.1128/JVI.65.11.6181-6187.1991; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TAYOR GR, 1989, EMBO J, V8, P2029; TROULIARIS S, 1995, ARCH VIROL, V140, P179, DOI 10.1007/BF01309733; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5	36	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1565	1572		10.1038/sj.onc.1201518	http://dx.doi.org/10.1038/sj.onc.1201518			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380408				2022-12-25	WOS:A1997XX36900007
J	Liang, JO; Sung, TC; Morris, AJ; Frohman, MA; Kornfeld, S				Liang, JO; Sung, TC; Morris, AJ; Frohman, MA; Kornfeld, S			Different domains of mammalian ADP-ribosylation factor 1 mediate interaction with selected target proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; NUCLEOTIDE EXCHANGE FACTORS; AP-1 ADAPTER COMPLEX; GUANINE-NUCLEOTIDE; PHOSPHOLIPASE-D; GOLGI MEMBRANES; BREFELDIN-A; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL INTERACTION; CHOLERA-TOXIN	Mammalian ADP-ribosylation factor 1 (mARF1) is a small GTP-binding protein that is activated by a Golgi guanine nucleotide exchange factor. Once bound to the Golgi membranes in the GTP form, mARF1 initiates the recruitment of the adaptor protein 1 (AP-1) complex and coatomer (COPI) onto these membranes and activates phospholipase D1 (PLD1). To map the domains of mARF1 that are important for these activities, we constructed chimeras between mARF1 and Saccharomyces cerevisiae ARF2, which functions poorly in all of these processes except COPI recruitment. The carboxyl half of mARF1 (amino acids 95-181) was essential for activation by the Golgi guanine nucleotide exchange factor, whereas a separate domain (residues 35-94) was required to effectively activate PLD1 and to promote efficient AP-1 recruitment. Since residues 35-94 of mARF1 are critical for optimal activity in both PLD1 activation and AP-1 recruitment, we hypothesize that this region of ARF contains residues that interact with effector molecules.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell Dev Biol, Stony Brook, NY 11794 USA	Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.		Morris, Andrew/B-7869-2010		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029758] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050388] Funding Source: NIH RePORTER; NCI NIH HHS [CA08759] Funding Source: Medline; NICHD NIH HHS [HD29758] Funding Source: Medline; NIGMS NIH HHS [GM50388] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Barr FA, 1996, FEBS LETT, V384, P65, DOI 10.1016/0014-5793(96)00285-2; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Burton JL, 1997, J BIOL CHEM, V272, P3663, DOI 10.1074/jbc.272.6.3663; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; Dittie AS, 1996, J CELL BIOL, V132, P523, DOI 10.1083/jcb.132.4.523; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOWE LR, 1993, ONCOGENE, V8, P2583; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LEE FJS, 1992, J BIOL CHEM, V267, P24441; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	54	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33001	33008		10.1074/jbc.272.52.33001	http://dx.doi.org/10.1074/jbc.272.52.33001			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407081	hybrid			2022-12-25	WOS:000071182900042
J	Van Troys, M; Dewitte, D; Verschelde, JL; Goethals, M; Vandekerckhove, J; Ampe, C				Van Troys, M; Dewitte, D; Verschelde, JL; Goethals, M; Vandekerckhove, J; Ampe, C			Analogous F-actin binding by cofilin and gelsolin segment 2 substantiates their structural relationship	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPOLYMERIZING FACTOR; PORCINE BRAIN; MUTATIONAL ANALYSIS; ALPHA-ACTININ; PROTEIN; SITE; IDENTIFICATION; FILAMENTS; POLYMERIZATION; SEQUENCE	Cofilin is representative for a family of low molecular weight actin filament binding and depolymerizing proteins. Recently the three-dimensional structure of yeast cofilin and of the cofilin homologs destrin and actophorin were resolved, and a striking similarity to segments of gelsolin and related proteins was observed (Hatanaka, H., Ogura, K., Moriyama, K., Ichikawa, S., Yahara, I., and Inagaka, F. (1996) Cell 85, 1047-1055; Fedorov, A. A., Lappalainen, P., Fedorov, E. V., Drubin, D. G., and Almo, S. C. (1997) Not. Struct. Biol. 4, 366-369; Leonard, S. A., Gittis, A. G., Petrella, E. C., Pollard, T. D., and Lattman, E. E. (1997) Not. Struct. Biol. 4, 369-373). Using peptide mimetics, we show that the actin binding site stretches over the entire cofilin alpha-helix 112-128. In addition, we demonstrate that cofilin and its actin binding peptide compete with gelsolin segments 2-3 for binding to actin filaments. Based on these competition data, we propose that cofilin and segment 2 of gelsolin use a common structural topology to bind to actin and probably share a similar target site on the filament. This adds a functional dimension to their reported structural homology, and this F-actin binding mode provides a basis to further enlighten the effect of members of the cofilin family on actin filament dynamics.	State Univ Ghent VIB, Fac Med, Dept Biochem, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Ampe, C (corresponding author), State Univ Ghent VIB, Fac Med, Dept Biochem, Ledeganckstr 35, B-9000 Ghent, Belgium.	Champ@gengenp.rug.ac.be	Ampe, Christophe/B-5534-2012	Van Troys, Marleen/0000-0003-4283-8103				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Carlier M. F., 1996, Molecular Biology of the Cell, V7, p546A; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; Fedorov AA, 1997, NAT STRUCT BIOL, V4, P366, DOI 10.1038/nsb0597-366; Feinberg J, 1997, BIOPOLYMERS, V41, P647; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; IIDA K, 1993, GENE, V124, P115; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Leonard SA, 1997, NAT STRUCT BIOL, V4, P369, DOI 10.1038/nsb0597-369; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; MCGOUGH A, 1995, J STRUCT BIOL, V115, P144, DOI 10.1006/jsbi.1995.1038; MCGOUGH A, 1994, J CELL BIOL, V126, P433, DOI 10.1083/jcb.126.2.433; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MIMURA N, 1987, J BIOL CHEM, V262, P4717; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; MORIYAMA K, 1990, J BIOL CHEM, V265, P5768; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; MUHLRAD A, 1994, J BIOL CHEM, V269, P11852; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; MUNEYUKI F, 1985, J BIOCHEM-TOKYO, V97, P563, DOI 10.1093/oxfordjournals.jbchem.a135091; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NISHIDA E, 1984, J BIOCHEM-TOKYO, V95, P387, DOI 10.1093/oxfordjournals.jbchem.a134619; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; QUIRK S, 1993, BIOCHEMISTRY-US, V32, P8525, DOI 10.1021/bi00084a019; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; Rosenblatt J., 1996, Molecular Biology of the Cell, V7, p545A; SASAGAWA T, 1983, ANAL BIOCHEM, V128, P371, DOI 10.1016/0003-2697(83)90388-3; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; SUN HQ, 1994, J BIOL CHEM, V269, P9473; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P6186, DOI 10.1021/bi00368a053; Thorn KS, 1997, STRUCTURE, V5, P19, DOI 10.1016/S0969-2126(97)00163-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEKERCKHOVE J, 1992, Current Opinion in Cell Biology, V4, P36, DOI 10.1016/0955-0674(92)90056-I; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VanTroys M, 1996, FEBS LETT, V397, P191, DOI 10.1016/S0014-5793(96)01086-1; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; Weeds A. G., 1996, Molecular Biology of the Cell, V7, p202A; WEEDS AG, 1993, CURR OPIN CELL BIOL, V119, P835; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YONEZAWA N, 1988, BIOCHEM J, V251, P121, DOI 10.1042/bj2510121; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485	66	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32750	32758		10.1074/jbc.272.52.32750	http://dx.doi.org/10.1074/jbc.272.52.32750			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407048	hybrid			2022-12-25	WOS:000071182900009
J	MacLean, DW; Meedel, TH; Hastings, KEM				MacLean, DW; Meedel, TH; Hastings, KEM			Tissue-specific alternative splicing of ascidian troponin I isoforms - Redesign of a protein isoform-generating mechanism during chordate evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC TROPONIN; TRANSGENIC MICE; DEVELOPMENTAL EXPRESSION; STRIATED MUSCLES; MESSENGER-RNA; NEURAL CREST; CDNA CLONE; RAT-HEART; GENE; SLOW	In vertebrates, troponin I (TnI) exists as shorter and longer isoforms encoded by distinct genes expressed in skeletal and cardiac muscle, respectively. We report that the protochordate ascidian Ciona intestinalis expresses a homologous set of shorter and longer TnI isoforms in body wall muscle and heart, respectively. The heart-specific segment of the ascidian longer TnI isoform shares several sequence features with vertebrate cardiac TnI but lacks the protein kinase A phosphorylation sites implicated in sympatho-adrenal control of cardiac function, In contrast with vertebrates, the ascidian longer and shorter TnI isoforms are produced from a single gene by tissue-specific alternative RNA splicing; remarkably, the molecular mechanism of TnI isoform generation has been entirely reworked during ascidian/vertebrate evolution. Because alternative splicing is the more probable chordate ancestral condition, the long/cardiac versus short/somatic muscle pattern of TnI: isoforms likely existed before the occurrence of the gene duplication events that created the vertebrate TnI gene family. Thus, gene duplication was apparently not the primary engine of isoform diversity in this aspect of TnI gene family evolution; rather, it simply provided an alternative (transcriptional) means of maintaining a previously established system of isoform diversity and tissue specificity based on alternative RNA splicing.	McGill Univ, Dept Biol, Montreal, PQ H3A 2B4, Canada; Rhode Isl Coll, Dept Biol, Providence, RI 02908 USA; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Hastings, KEM (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.							ARAKI I, 1994, ROUX ARCH DEV BIOL, V203, P320, DOI 10.1007/BF00457803; AUSONI S, 1994, J BIOL CHEM, V269, P339; AUSONI S, 1991, DEVELOPMENT, V112, P1041; BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BANERJEEBASU S, 1993, MOL CELL BIOL, V13, P7019, DOI 10.1128/MCB.13.11.7019; BANERJEEBASU S, 1994, GENE, V145, P241, DOI 10.1016/0378-1119(94)90013-2; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941; Berrill N.J., 1955, ORIGIN VERTEBRATES; CORIN SJ, 1994, J BIOL CHEM, V269, P10651; DRYSDALE TA, 1994, DEV BIOL, V165, P432, DOI 10.1006/dbio.1994.1265; ENDO T, 1981, J BIOCHEM, V89, P1599, DOI 10.1093/oxfordjournals.jbchem.a133355; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GOODBODY I, 1974, ADV MAR BIOL, V12, P1; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; Guenet JL, 1996, MAMM GENOME, V7, P13, DOI 10.1007/s003359900004; HALLAUER PL, 1993, DEVELOPMENT, V119, P691; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; HOLLAND PWH, 1994, DEVELOPMENT, P125; JIANG HB, 1994, J BIOL CHEM, V269, P55; KATZ MJ, 1983, BIOL BULL-US, V164, P1, DOI 10.2307/1541186; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LEDOUARIN NM, 1980, NATURE, V286, P663, DOI 10.1038/286663a0; LEVITT LK, 1995, DNA CELL BIOL, V14, P599, DOI 10.1089/dna.1995.14.599; LITMAN GW, 1993, MOL BIOL EVOL, V10, P60; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MEEDEL TH, 1993, J BIOL CHEM, V268, P6755; Meedel TH, 1997, DEVELOPMENT, V124, P1711; MEEDEL TH, REPROD BIOL INVERTEB, V8; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; Ohno S., 1970, EVOLUTION GENE DUPLI; OHNO S, 1974, PROTOCHORDATA CYCLOS; OHTA T, 1989, GENOME, V31, P304, DOI 10.1139/g89-048; PERRY SV, 1994, MYOLOGY BASIC CLIN, V1, P529; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SABRY MA, 1989, J MUSCLE RES CELL M, V10, P85, DOI 10.1007/BF01739858; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; ZHU L, 1995, DEV BIOL, V169, P487, DOI 10.1006/dbio.1995.1163	40	35	36	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32115	32120		10.1074/jbc.272.51.32115	http://dx.doi.org/10.1074/jbc.272.51.32115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405409	hybrid			2022-12-25	WOS:000071108000028
J	Mandala, SM; Thornton, RA; Rosenbach, M; Milligan, J; Garcia-Calvo, M; Bull, HG; Kurtz, MB				Mandala, SM; Thornton, RA; Rosenbach, M; Milligan, J; Garcia-Calvo, M; Bull, HG; Kurtz, MB			Khafrefungin, a novel inhibitor of sphingolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SERINE PALMITOYLTRANSFERASE; PHOSPHOLIPID BIOSYNTHESIS; CERAMIDE; YEAST; PHOSPHATIDYLINOSITOL; FERMENTATION; SPHINGANINE; SPHINGOSINE; TRANSFERASE	In the course of screening for antifungal agents we have discovered a novel compound isolated from an endophytic fungus that inhibits fungal sphingolipid synthesis, Khafrefungin, which is composed of aldonic acid Linked via an ester to a C22 modified alkyl chain, has fungicidal activity against Candida albicans, Cryptococcus neoformans, and Saccharomyces cerevisiae. Sphingolipid synthesis is inhibited in these organisms at the step in which phosphoinositol is transferred to ceramide, resulting in accumulation of ceramide and loss of all of the complex sphingolipids, In vitro, khafrefungin inhibits the inositol phosphoceramide synthase of C. albicans with an IC50 of 0.6 nM. Khafrefungin does not inhibit the synthesis of mammalian sphingolipids thus making this the first reported compound that is specific for the fungal pathway.	Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Biochem, Rahway, NJ 07065 USA	Merck & Company	Mandala, SM (corresponding author), Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Biochem, R80Y-230,POB 2000, Rahway, NJ 07065 USA.	suzanne_mandala@merck.com						BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BOAS MHSV, 1994, CHEM PHYS LIPIDS, V70, P11; BRAYBILL JR, 1996, CLIN INFECT DIS, V22, pS166; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Horn W. S., 1992, J ANTIBIOT, V47, P376; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; KO JS, 1994, J BACTERIOL, V176, P5181, DOI 10.1128/jb.176.16.5181-5183.1994; LESTER RL, 1993, ADV LIPID RES, V26, P253; LESTER RL, 1993, J BIOL CHEM, V268, P845; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; Mandala SM, 1997, J ANTIBIOT, V50, P339, DOI 10.7164/antibiotics.50.339; MANDALA SM, 1994, J ANTIBIOT, V47, P376, DOI 10.7164/antibiotics.47.376; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Onishi JC, 1997, J ANTIBIOT, V50, P334, DOI 10.7164/antibiotics.50.334; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; RILEY RT, 1994, J FOOD PROTECT, V57, P638, DOI 10.4315/0362-028X-57.7.638; Schneiter R, 1997, CELL, V88, P431, DOI 10.1016/S0092-8674(00)81882-6; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TAKESAKO K, 1991, J ANTIBIOT, V44, P919, DOI 10.7164/antibiotics.44.919; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VINCENT VL, 1995, MICROBIOL-UK, V141, P1829, DOI 10.1099/13500872-141-8-1829; WANG E, 1991, J BIOL CHEM, V266, P14486; Wells GB, 1996, J BACTERIOL, V178, P6223, DOI 10.1128/jb.178.21.6223-6226.1996; WELLS GB, 1983, J BIOL CHEM, V258, P200; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	38	106	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32709	32714		10.1074/jbc.272.51.32709	http://dx.doi.org/10.1074/jbc.272.51.32709			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405490	hybrid			2022-12-25	WOS:000071108000109
J	Roullet, JB; Luft, UC; Xue, H; Chapman, J; Bychkov, R; Roullet, CM; Luft, FC; Haller, H; McCarron, DA				Roullet, JB; Luft, UC; Xue, H; Chapman, J; Bychkov, R; Roullet, CM; Luft, FC; Haller, H; McCarron, DA			Farnesol inhibits L-type Ca2+ channels in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CALCIUM CHANNELS; MEVALONATE AVAILABILITY; DIHYDROPYRIDINE AGONIST; SIGNAL-TRANSDUCTION; RESISTANCE ARTERIES; CA-2+; RAT; REDUCTASE; IDENTIFICATION	Earlier experiments with animal and human arteries have shown that farnesol, a natural 15-carbon (C-15) isoprenoid, is an inhibitor of vasoconstriction (Roullet, J.-B., Xue, H., Chapman, J., McDougal, P., Roullet, C. M., and McCarron, D. A. (1996) J. Clin. Invest. 97, 2384-2390). We report here that farnesol reduced KCl- and norepinephrine-dependent cytosolic Ca2+ transients in fura-2-loaded intact arteries. An effect on Ca2+ signaling was also observed in cultured aortic smooth muscle cells (A10 cells). In these cells, farnesol reduced KCl-induced [Ca2+](i) transients and mimicked the inhibitory effect of Ca2+-free medium on the [Ca2+](i) response to both 12,13-phorbol myristate acetate, a protein kinase C activator, and thapsigargin, a specific endoplasmic reticulum ATPase inhibitor. Perforated patch-clamp experiments further showed in two vascular smooth muscle cell lines (A10 and A7r5), a reversible, dose-dependent inhibitory effect of farnesol on L-type Ca2+ currents (IC50 = 2.2 mu M). Shorter (C-10, geraniol) and longer (C-20, geranylgeraniol) isoprenols were inactive. L-type Ca2+ channel blockade also occurred under tight (gigaohm) seal configuration using cell-attached, single-channel analysis, thus suggesting a possible action of farnesol from within the intracellular space. We finally demonstrated that farnesol did not affect Ca2+-sensitive pathways implicated in smooth muscle contraction, as tested with alpha-toxin permeabilized arteries. Altogether, our results indicate that farnesol is an inhibitor of vascular smooth muscle Ca2+ signaling with plasma membrane Ca2+ channel blocker properties. The data have implications for the endogenous and pharmacological regulation of vascular tone by farnesol or farnesol analogues.	Oregon Hlth & Sci Univ, Dept Nephrol Hypertens & Clin Pharmacol, Portland, OR 97201 USA; Max Delbruck Ctr Mol Med, Franz Volhard Klin, D-13122 Berlin, Germany	Oregon Health & Science University; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Roullet, JB (corresponding author), Oregon Hlth & Sci Univ, Dept Nephrol Hypertens & Clin Pharmacol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	roulletj@ohsu.edu		Luft, Friedrich/0000-0002-8635-1199				ADANY I, 1994, CANCER LETT, V79, P175, DOI 10.1016/0304-3835(94)90257-7; ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIAN K, 1995, HYPERTENSION, V25, P110, DOI 10.1161/01.HYP.25.1.110; Bostedor RG, 1997, J BIOL CHEM, V272, P9197; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; BUKOSKI RD, 1990, J HYPERTENS, V8, P37, DOI 10.1097/00004872-199001000-00007; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; CRICK DC, 1995, BIOCHEM BIOPH RES CO, V211, P590, DOI 10.1006/bbrc.1995.1854; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gollasch M, 1996, AM J PHYSIOL-CELL PH, V271, pC842, DOI 10.1152/ajpcell.1996.271.3.C842; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; GONZALESPACANOW.D, 1988, J BIOL CHEM, V263, P1304; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAUG JS, 1994, BBA-MOL CELL RES, V1223, P133, DOI 10.1016/0167-4889(94)90082-5; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; JENSEN PE, 1994, EXP BIOL M, P23; JIANG MJ, 1987, AM J PHYSIOL, V253, pH1365, DOI 10.1152/ajpheart.1987.253.6.H1365; Keller RK, 1996, ARCH BIOCHEM BIOPHYS, V328, P324, DOI 10.1006/abbi.1996.0180; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOTHAPALLI R, 1994, BIOCHEM PHARMACOL, V47, P1909, DOI 10.1016/0006-2952(94)90322-0; MARKS TN, 1990, PFLUG ARCH EUR J PHY, V417, P433, DOI 10.1007/BF00370664; MCCREERY MJ, 1978, NEUROPHARMACOLOGY, V17, P451, DOI 10.1016/0028-3908(78)90050-3; MCEWEN BF, 1985, J CELL BIOL, V100, P1922, DOI 10.1083/jcb.100.6.1922; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; MIRONNEAU J, 1995, CELL SIGNAL, V7, P471, DOI 10.1016/0898-6568(95)00014-G; MIRONNEAU J, 1995, PFLUEGERS ARCH, V430, P590; NG LL, 1994, CIRC RES, V74, P173, DOI 10.1161/01.RES.74.2.173; NISHIMURA J, 1989, BIOCHEM BIOPH RES CO, V163, P929, DOI 10.1016/0006-291X(89)92311-5; NISHIMURA J, 1990, AM J PHYSIOL, V259, pH2, DOI 10.1152/ajpheart.1990.259.1.H2; OBrien ML, 1996, CARCINOGENESIS, V17, P185, DOI 10.1093/carcin/17.2.185; Ohanian V, 1996, CIRC RES, V78, P806, DOI 10.1161/01.RES.78.5.806; ROULLET JB, 1994, J CLIN INVEST, V93, P2244, DOI 10.1172/JCI117222; ROULLET JB, 1993, P NATL ACAD SCI USA, V90, P11728, DOI 10.1073/pnas.90.24.11728; ROULLET JB, 1995, J CLIN INVEST, V96, P239, DOI 10.1172/JCI118027; Roullet JB, 1996, J CLIN INVEST, V97, P2384, DOI 10.1172/JCI118682; ROULLET JB, 1996, AM J HYPERTENS, V9, P81; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STRUBING C, 1993, BRIT J PHARMACOL, V108, P884, DOI 10.1111/j.1476-5381.1993.tb13482.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRIBE RM, 1994, P NATL ACAD SCI USA, V91, P5908, DOI 10.1073/pnas.91.13.5908; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VOZIYAN PA, 1995, BIOCHEM BIOPH RES CO, V212, P479, DOI 10.1006/bbrc.1995.1995; WALTER A, 1986, J MEMBRANE BIOL, V90, P207, DOI 10.1007/BF01870127; XIONG ZL, 1995, J MOL CELL CARDIOL, V27, P75, DOI 10.1016/S0022-2828(08)80009-0; XIONG ZL, 1994, PFLUG ARCH EUR J PHY, V428, P105, DOI 10.1007/BF00374847; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887; YAZLOVITSKAYA EM, 1995, CANCER LETT, V88, P179, DOI 10.1016/0304-3835(94)03635-V	55	59	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32240	32246		10.1074/jbc.272.51.32240	http://dx.doi.org/10.1074/jbc.272.51.32240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405427	hybrid			2022-12-25	WOS:000071108000046
J	Shi, CS; Kehrl, JH				Shi, CS; Kehrl, JH			Activation of stress-activated protein kinase c-Jun N-terminal kinase, but not NF-kappa B, by the tumor necrosis factor (TNF) receptor 1 through a TNF receptor-associated factor 2- and germinal center kinase related-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN; PHOSPHORYLATION; IDENTIFICATION; APOPTOSIS; CASCADE; DEATH; LIGHT; ERK	A key step by which tumor necrosis factor (TNF) signals the activation of nuclear factor-kappa B (NF-kappa B) and the stress-activated protein kinase (SAPK, also called c-Jun N-terminal kinase or JNK) is the recruitment to the TNF receptor of TNF receptor-associated factor 2 (TRAF2). However, the subsequent steps in TRAF2-induced SAPK and NF-kappa B activation remain unresolved. Here we report the identification of a TNF-responsive serine/threonine protein kinase termed GCK related (GCKR) that likely signals via mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase kinase 1 (MEKK1) to activate the SAPK pathway. TNF, TRAF2, and ultraviolet (UV) light, which in part uses the TNF receptor signaling pathway, all increased GCKR activity. A TRAF2 mutant, which inhibits both TRAF2-induced NF-kappa B and SAPK activation, blocked TNF-induced GCKR activation. Finally, interference with GCKR expression impeded TRAF2- and TNF-induced SAPK activation but not that of NF-kappa B. This suggests a divergence in the TNF signaling pathway that leads to SAPK and NF-kappa B activation, which is located downstream of TRAF2 but upstream of GCKR.	NIAID, Immunoregulat Lab, B Cell Mol Immunol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kehrl, JH (corresponding author), NIAID, Immunoregulat Lab, B Cell Mol Immunol Sect, Bldg 10,Rm 11B-13,10 Ctr Dr,MSC 1876, Bethesda, MD 20892 USA.		Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; EZOE K, 1994, ONCOGENE, V9, P935; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ING YL, 1994, ONCOGENE, V9, P1745; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; YAN MH, 1994, NATURE, V372, P798	34	96	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32102	32107		10.1074/jbc.272.51.32102	http://dx.doi.org/10.1074/jbc.272.51.32102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405407	hybrid			2022-12-25	WOS:000071108000026
J	Pearce, DA; Sherman, F				Pearce, DA; Sherman, F			Differential ubiquitin-dependent degradation of the yeast apo-cytochrome c isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PROTEIN-DEGRADATION; AMINO-ACID REPLACEMENTS; SACCHAROMYCES-CEREVISIAE; IN-VIVO; SYNTHETIC OLIGONUCLEOTIDES; HEME LYASE; ISO-1-CYTOCHROME-C; ENDOCYTOSIS; GENE; PROTEOLYSIS	The yeast Saccharomyces cerevisiae contains two forms of cytochrome c, iso-1- and iso-2-cytochrome c, which are encoded by the nuclear genes CYC1 and CYC7, respectively, The cytochromes c are synthesized in the cytosol, imported into mitochondria, and subsequently modified by the covalent attachment of heme through the action of cytochrome c heme lyase, which is encoded by CYC3. Apo-iso-2-cytochrome c but not apo-iso-1-cytochrome c was observed in cyc3(-) mutants. Furthermore, pulse-chase experiments previously demonstrated that the lack of apo-iso-1-cytochrome c was due to its rapid degradation. We report herein that this degradation of apo-iso-1-cytochrome c is dependent on ubiquitination and on the action of the proteasome. Diminished degradation of apo-iso-1-cytochrome c was observed in pre2-2 and pre1-1 mutants having altered proteasome subunits; in ubc1, ubc4, and ubc5 strains lacking one or more of the ubiquitin-conjugating enzymes; and in strains blocked in multi-ubiquitination by overproduction of the abnormal ubiquitin-K48R ubiquitin. In addition, we have used epitope-tagged ubiquitin to demonstrate that apo-iso-1-cytochrome c but not apo-iso-2-cytochrome c is ubiquitinated. Furthermore, the degradation of apo-iso-1-cytochrome c was diminished when the N-terminaI region was replaced with the N-terminal region of apo-iso-2-cytochrome c, indicating that this region may be the target for degradation. We suggest that ubiquitin-dependent degradation of apo-iso-1-cytochrome c is part of the regulatory process controlling the preferential expression of the iso-cytochromes c.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14642	University of Rochester					NIGMS NIH HHS [R01 GM 12702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BERROTERAN RW, 1991, ARCH BIOCHEM BIOPHYS, V288, P261, DOI 10.1016/0003-9861(91)90193-M; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DUMONT MD, 1990, J BIOL CHEM, V265, P2733; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1993, MOL CELL BIOL, V13, P6442, DOI 10.1128/MCB.13.10.6442; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; EGNER R, 1995, MOL CELL BIOL, V15, P5879; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HICKEY DR, 1991, J BIOL CHEM, V266, P11686; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4021; HOCHSTRASSER M, 1990, CELL, V61, P507; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1990, NATURE, V346, P278; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; LINSKEOCONNELL LI, 1995, BIOCHEMISTRY-US, V34, P7094, DOI 10.1021/bi00021a022; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MATNER RR, 1983, J BIOL CHEM, V257, P9811; MOERSCHELL RP, 1988, P NATL ACAD SCI USA, V85, P524, DOI 10.1073/pnas.85.2.524; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; PEARCE DA, 1995, MOL GEN GENET, V249, P155, DOI 10.1007/BF00290361; PEARCE DA, 1995, P NATL ACAD SCI USA, V92, P3735, DOI 10.1073/pnas.92.9.3735; REID GA, 1983, METHOD ENZYMOL, V97, P324; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SADIS S, 1995, MOL CELL BIOL, V15, P4086; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFER PW, 1987, ENVIRON ENTOMOL, V16, P368, DOI 10.1093/ee/16.2.368; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHERMAN F, 1971, ANNU REV GENET, V5, P257, DOI 10.1146/annurev.ge.05.120171.001353; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; YAMAMOTO T, 1992, YEAST, V8, P935, DOI 10.1002/yea.320081104	54	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31829	31836		10.1074/jbc.272.50.31829	http://dx.doi.org/10.1074/jbc.272.50.31829			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395529	hybrid			2022-12-25	WOS:A1997YL41900088
J	Napierala, M; Krzyzosiak, WJ				Napierala, M; Krzyzosiak, WJ			CUG repeats present in myotonin kinase RNA form metastable "slippery" hairpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; YEAST TRANSFER RNAPHE; TRIPLET REPEAT; RIBOSOMAL-RNA; HUMAN-DISEASE; DYSTROPHY MUTATION; ESCHERICHIA-COLI; MOLECULAR-BASIS; CTG REPEATS; DNA	We show that CUG repeats form "slippery" hairpins in their natural sequence context of the myotonin kinase gene transcript. This novel type of RNA structure is characterized by strong S-1 and T-1 nuclease and lead cleavages in the terminal loop and by mild lead cleavages in the hairpin stem. The latter effect indicates a relaxed metastable structure of the stem. (CUG)(5) repeats do not form any detectable secondary structure, whereas hairpins of increasing stability are formed by (CUG)(11), (CUG)(21), and (CUG)(49). The potential role of the RNA hairpin structure in the pathogenesis of myotonic dystrophy is discussed.	Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, PL-61704 Poznan, Poland	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Krzyzosiak, WJ (corresponding author), Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, Noskowskiego 12-14, PL-61704 Poznan, Poland.	wlodkrzy@man.poznan.pl						BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; Bhagwati S, 1996, BIOCHEM BIOPH RES CO, V228, P55, DOI 10.1006/bbrc.1996.1615; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BROWN RS, 1983, NATURE, V303, P543, DOI 10.1038/303543a0; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; CIESIOLKA J, 1992, EUR J BIOCHEM, V204, P575, DOI 10.1111/j.1432-1033.1992.tb16670.x; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GACY AM, 1995, CELL, V81, P533; GORNICKI P, 1989, J BIOMOL STRUCT DYN, V6, P971, DOI 10.1080/07391102.1989.10506525; Harris S, 1996, HUM MOL GENET, V5, P1417, DOI 10.1093/hmg/5.Supplement_1.1417; HUMMERICH H, 1995, ELECTROPHORESIS, V16, P1698, DOI 10.1002/elps.11501601282; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P775, DOI 10.1093/nar/24.4.775; Michalowski D, 1996, BIOCHEMISTRY-US, V35, P10727, DOI 10.1021/bi9530393; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; NEVILLE CE, 1994, HUM MOL GENET, V3, P45; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; RUBIN JR, 1983, J BIOMOL STRUCT DYN, V1, P639, DOI 10.1080/07391102.1983.10507471; SAMPSON JR, 1987, COLD SPRING HARB SYM, V52, P267, DOI 10.1101/SQB.1987.052.01.032; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; VARANI G, 1994, RNA PROTEIN INTERACT, P1; Wahl MC, 1996, NAT STRUCT BIOL, V3, P24, DOI 10.1038/nsb0196-24; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; Wang YX, 1996, NUCLEIC ACIDS RES, V24, P2666, DOI 10.1093/nar/24.14.2666; WATKINS WS, 1995, HUM MOL GENET, V4, P1485, DOI 10.1093/hmg/4.9.1485; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a; YU AD, 1995, NUCLEIC ACIDS RES, V23, P2706, DOI 10.1093/nar/23.14.2706; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	38	130	136	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31079	31085		10.1074/jbc.272.49.31079	http://dx.doi.org/10.1074/jbc.272.49.31079			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388259	hybrid			2022-12-25	WOS:000071640800072
J	Wu, C; Lytvyn, V; Thomas, DY; Leberer, E				Wu, C; Lytvyn, V; Thomas, DY; Leberer, E			The phosphorylation site for Ste20p-like protein kinases is essential for the function of myosin-I in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; CDC42; IDENTIFICATION; PURIFICATION; LOCALIZATION; FILOPODIA; SEQUENCE; GTPASES; ACID; RAC	The budding yeast Saccharomyces cerevisiae has two functionally redundant myosin-I isoforms encoded by the MYO3 and MYO5 genes. The function shared by these myosin proteins is required for proper yeast budding, Serine residue 357 in the head domain of Myo3p, conserved among myosin-I proteins including yeast Myo5p, was identified as a unique phosphorylation site for the serine/threonine protein kinase Ste20p and its closely related isoform Cla4p. These protein kinases share a function that is also essential for budding. Replacement of serine 357 with alanine disrupted the in vivo function of Myo3p, whereas this function was maintained by changing the serine residue to aspartate, This mutant version failed to compensate the growth defect of cells which lack both Ste20p and Cla4p, suggesting that myosin-I is not the only essential target of these protein kinases, Our results suggest that phosphorylation of the head domain by Ste20p-like protein kinases plays an essential role in the function of myosin-I in yeast cells.	Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, Montreal, PQ H4P 2R2, Canada	National Research Council Canada	Leberer, E (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.		Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; FUJISAKI H, 1985, J BIOL CHEM, V260, P1183; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Rose MD., 1990, METHODS YEAST GENETI; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIKORSKI RS, 1989, GENETICS, V122, P19; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	33	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30623	30626		10.1074/jbc.272.49.30623	http://dx.doi.org/10.1074/jbc.272.49.30623			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388196	hybrid			2022-12-25	WOS:000071640800009
J	Li, S; Kim, M; Hu, YL; Jalali, S; Schlaepfer, DD; Hunter, T; Chien, S; Shyy, JYJ				Li, S; Kim, M; Hu, YL; Jalali, S; Schlaepfer, DD; Hunter, T; Chien, S; Shyy, JYJ			Fluid shear stress activation of focal adhesion kinase - Linking to mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; GROWTH-FACTOR; ADAPTER PROTEIN; BINDING-SITE; SH3 DOMAIN; KAPPA-B; RAS	Shear stress, the tangential component of hemodynamic forces, activates the extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) signal transduction pathways in cultured vascular endothelial cells to induce the transcriptional activation of many immediate early genes. It appears that integrins, protein-tyrosine kinases, and the structural integrity of actin are important factors involved in these shear stress-induced responses. The underlying molecular events were investigated by the application of a shear stress of 12 dyn/cm(2) on bovine aortic endothelial cells (BAEC), We found that such a shear stress increased the tyrosine phosphorylation and the kinase activity of focal adhesion kinase (FAK) and its association with growth factor receptor binding protein 2 (Grb2) in a rapid and transient manner, suggesting that FAK may be linked to these mitogen-activated protein kinase signaling pathways through a Grb2.Son of sevenless (Sos) complex, FAK(F397Y), which encodes a dominant negative mutant of FAK, attenuated the shear stress-induced kinase activity of Myc epitope-tagged ERK2 and hemagglutinin epitope-tagged JNK1. Delta mSos1, encoding a dominant negative mutant of Sos in which the guanine nucleotide exchange domain has been deleted, also attenuated shear stress activation of Myc-ERK2 and hemagglutinin-JNK1, Pretreating the confluent BAEC monolayers with a blocking type antivitronectin receptor monoclonal antibody had similar inhibitory effects in these shear stress-activated ERKs and JNKs. Confocal microscopic observation further demonstrated that FAK tended to cluster with vitronectin receptor near the abluminal side of the sheared BAEC. These results demonstrate that FAK signaling is critical in the shear stress-induced dual activation of ERK and JNK.	UNIV CALIF SAN DIEGO, DEPT BIOENGN, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, INST BIOMED ENGN, LA JOLLA, CA 92093 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute; Salk Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019454, R29HL056707, R01HL056707, P01HL043026] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43026, HL56707, HL19454] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; GIRARD PR, 1995, J CELL PHYSIOL, V163, P179, DOI 10.1002/jcp.1041630121; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HOSHIGA M, 1995, CIRC RES, V77, P1129, DOI 10.1161/01.RES.77.6.1129; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; JALALI S, 1997, FASEB J, V11, pA18; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li YS, 1996, MOL CELL BIOL, V16, P5947; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Malek AM, 1996, J CELL SCI, V109, P713; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NEREM RM, 1993, J CARDIOVASC PHARM, V21, pS6; PARSONS JT, 1994, J CELL SCI, P109; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293	51	335	346	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30455	30462		10.1074/jbc.272.48.30455	http://dx.doi.org/10.1074/jbc.272.48.30455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374537	hybrid			2022-12-25	WOS:A1997YH61300069
J	Spataro, V; Toda, T; Craig, R; Seeger, M; Dubiel, W; Harris, AL; Norbury, C				Spataro, V; Toda, T; Craig, R; Seeger, M; Dubiel, W; Harris, AL; Norbury, C			Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; MAMMALIAN-CELL LINES; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; ATPASE SUBUNIT; CDNA CLONING; IN-VIVO; C-JUN	We have investigated the usefulness of the fission yeast Schizosaccharomyces pombe as a model organism for the discovery of novel modes of drug resistance in human cells, In fission yeast, overexpression of the essential pad1(+) gene confers pleiotropic drug resistance through a pathway involving an AP-1 transcription factor encoded by pap1(+), We have identified POH1, a human pad1 homologue that can substitute fully for pad1(+) and induce AP-1-dependent drug resistance in fission yeast, POH1 also confers P-glycoprotein-independent resistance to taxol (paclitaxel), doxorubicin, 7-hydroxy-staurosporine, and ultraviolet Light when transiently overexpressed in mammalian cells, Poh1 is a previously unidentified component of the human 26 S proteasome, a multiprotein complex that degrades proteins targeted for destruction by the ubiquitin pathway. Hence, Poh1 is part of a conserved mechanism that determines cellular susceptibility to cytotoxic agents, perhaps by influencing the ubiquitin-dependent proteolysis of transcription factors.	UNIV OXFORD, JOHN RADCLIFFE HOSP,INST MOL MED, IMPERIAL CANC RES FUND,MOL ONCOL LAB, OXFORD OX3 9DS, ENGLAND; IMPERIAL CANC RES FUND, CELL REGULAT LAB, LONDON WC2A 3PX, ENGLAND; HUMBOLDT UNIV BERLIN, CHARITE, INST BIOCHEM, D-10117 BERLIN, GERMANY	University of Oxford; Cancer Research UK; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Dubiel, Wolfgang/0000-0002-3393-0701				AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DEXTER D, 1994, GENETICS, V136, P505; DUBIEL W, 1995, FEBS LETT, V363, P97, DOI 10.1016/0014-5793(95)00288-K; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREY M, 1994, CURR GENET, V25, P469, DOI 10.1007/BF00351788; Harlow E., 1988, ANTIBODIES LAB MANUA; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; Kaye SB, 1995, AM J MED, V99, pS40, DOI 10.1016/S0002-9343(99)80285-X; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MOFFAT GJ, 1994, J BIOL CHEM, V269, P16397; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; PINKUS R, 1993, BIOCHEM J, V290, P637, DOI 10.1042/bj2900637; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; SHIMANUKI M, 1995, J CELL SCI, V108, P569; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, BIOCHEM BIOPH RES CO, V210, P600, DOI 10.1006/bbrc.1995.1701; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; USUI T, 1995, GENE, V161, P93, DOI 10.1016/0378-1119(95)00229-Y; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; YAO KS, 1995, CANCER RES, V55, P4367	42	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30470	30475		10.1074/jbc.272.48.30470	http://dx.doi.org/10.1074/jbc.272.48.30470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374539	hybrid			2022-12-25	WOS:A1997YH61300071
J	Bocciardi, R; Mograbi, B; Pasini, B; Borrello, MG; Pierotti, MA; Bourget, I; Fischer, S; Romeo, G; Rossi, B				Bocciardi, R; Mograbi, B; Pasini, B; Borrello, MG; Pierotti, MA; Bourget, I; Fischer, S; Romeo, G; Rossi, B			The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck	ONCOGENE			English	Article						RET; multiple endocrine neoplasia type 2B; Crk; Nck; paxillin	PHOSPHORYLATION-DEPENDENT MANNER; GROWTH-FACTOR RECEPTOR; COMPLEXES IN-VIVO; V-CRK; PROTO-ONCOGENE; HIGH-AFFINITY; MOLECULAR CHARACTERIZATION; TRANSFORMING ACTIVITY; ADAPTER PROTEINS; ENDOGENOUS CRK	The RET proto-oncogene encodes a Tyrosine Kinase Receptor (RTK) which plays an important function in the proliferation and/or differentiation of neuroectodermic cells, Germline mutation of a methionine to a threonine within the RET TK domain predisposes to the Multiple Endocrine Neoplasia type 2B (MEN 2B), It has been demonstrated that, unlike c-Ret, the MEN 2B mutated Ret displays constitutive TK activity, tyrosine autophosphorylation and transforms fibroblasts, However, this oncoprotein is more than a fully activated wildtype (WT) Ret TK since it also displays modified substrate specificity, Change in substrate specificity leads to the tyrosine autophosphorylation of MEN 2B Ret on new sites as well as the phosphorylation of several novel downstream targets, But, none of these substrates have been identified and the ability of MEN 2B Ret phosphoprotein to interact with Src Homology 2 (SH2) domain containing molecules has been poorly investigated, In this report, using a constitutively activated Ret TK form, Ret-ptc 2, we demonstrate that the MEN 2B as the activated WT Ret TK binds to several SH, signalling proteins such as Shc, Grb-2, Phospholipase C gamma, Crk and Nck, However, in contrast to the activated WT form, expression of the MEN 2B mutated Ret-ptc 2 results in the tyrosine phosphorylation of a panel of proteins which interestingly interact with Crk and Nck, We identified Paxillin, a cytoskeletal protein as one of the Crk associated proteins that is dramatically phosphorylated in MEN 2B but WT expressing cells, These data suggest that MEN 2B mutated Ret triggers distinct signalling pathways that might be related to its transforming power.	INSERM U364, FAC MED PASTEUR, NICE, FRANCE; IST GIANNINA GASLINI, GENET MOL LAB, I-16148 GENOA, ITALY; IST NAZL TUMORI, DIV ONCOL SPERIMENTALE A, I-20133 MILAN, ITALY; HOP COCHIN, INSERM U363, INST COCHIN GENET MOL, F-75674 PARIS, FRANCE; INT AGCY RES CANC, F-69372 LYON, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Genoa; IRCCS Istituto Giannina Gaslini; Fondazione IRCCS Istituto Nazionale Tumori Milan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; World Health Organization; International Agency for Research on Cancer (IARC)			Pierotti, Marco Alessandro/AAC-4728-2022; Bocciardi, Renata/J-8577-2016; Mograbi, Baharia/N-5531-2018; Mograbi, Baharia/Q-7953-2019; Borrello, Maria Grazia/C-3161-2017; Pasini, Barbara/AHI-2004-2022	Pierotti, Marco Alessandro/0000-0002-7431-8332; Bocciardi, Renata/0000-0001-8415-3802; Borrello, Maria Grazia/0000-0002-6854-2848; Pasini, Barbara/0000-0002-4373-1212; Mograbi, Baharia/0000-0002-1025-3429; BOURGET, Isabelle/0000-0001-6369-8176				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Fugazzola L, 1996, ONCOGENE, V13, P1093; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Iwashita T, 1996, ONCOGENE, V12, P481; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROMANO A, 1994, ONCOGENE, V9, P2923; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Torres M, 1996, ONCOGENE, V12, P77; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Vuori K, 1996, MOL CELL BIOL, V16, P2606; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	61	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2257	2265		10.1038/sj.onc.1201413	http://dx.doi.org/10.1038/sj.onc.1201413			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393871				2022-12-25	WOS:A1997YE15700001
J	Reinke, V; Lozano, G				Reinke, V; Lozano, G			The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo	ONCOGENE			English	Article						apoptosis; p53; targets; ionizing radiation; mice	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL ACTIVATION; GROWTH-CHARACTERISTICS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; DNA-REPLICATION; CELL-GROWTH; BAX GENE	The tumor suppressor p53 can exert its anti-oncogenic activity in part by inducing apoptosis in cells that have sustained damage to their DNA. It is likely that p53 activates the transcription of target genes that mediate this response. Known p53 targets with potential roles in cell cycle control and apoptosis induction include: p21(WAF1/CIP1), mdm2, cyclin G, bax and Fas. We examined the p53 pathway in the thymus of the mouse after irradiation, FACS analysis demonstrated that the thymocytes of mice with wild-type p53, but not those lacking p53, underwent apoptosis after irradiation. Expression analysis of the target genes revealed that all tested genes underwent p53-dependent induction, although the extent and timing varied. The target genes implicated in cell cycle (p21, mdm2 and cyclin G) were induced 2 h after irradiation, in contrast to targets with a possible role in apoptosis (bax and Fas), which were induced at 4 h. This analysis is the first demonstration that Fas is a p53-responsive gene in vivo. Since p21 and bax expression are not required for p53-dependent apoptosis, we tested whether other target genes affected apoptosis in vivo. We discovered that mdm2 has no role in preventing apoptosis independently of p53 inactivation, and that Fas, like p21 and bax, is not necessary for p53-mediated induction of apoptosis. Therefore, no p53 target identified and tested to date is singly responsible for p53-dependent apoptosis in response to DNA damage in vivo.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McMasters KM, 1996, ONCOGENE, V13, P1731; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TAMURA T, 1995, ONCOGENE, V11, P1939; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	49	59	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1527	1534		10.1038/sj.onc.1201316	http://dx.doi.org/10.1038/sj.onc.1201316			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380404				2022-12-25	WOS:A1997XX36900003
J	Backlund, PS				Backlund, PS			Post-translational processing of RhoA - Carboxyl methylation of the carboxyl-terminal prenylcysteine increases the half-life of RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; FARNESYLCYSTEINE ANALOGS; ADENOSYLHOMOCYSTEINE HYDROLASE; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; MEMBRANE-BINDING; AMINO-ACIDS; STE14 GENE; A-FACTOR; METHYLTRANSFERASE	RhoA and related GTP-binding proteins are modified post-translationally at their carboxyl terminus to form a prenylcysteine methyl ester. The synthesis and posttranslational modification of RhoA and Cdc42 were examined in the RAW264 macrophage cell line, and the effect of carboxyl methylation on protein turnover was determined. Cells were labeled with [S-35]cysteine, and RhoA or Cdc42 was immunoprecipitated with specific antibodies. Both RhoA and Cdc42 were methylated rapidly in control cells, with little accumulation of unmethylated protein. Carboxyl methylation of RhoA was inhibited by incubation of cells with a carbocyclic adenosine analog, 3-deazaaristeromycin, resulting in the accumulation of unmethylated RhoA. Under these conditions, Cdc42 methylation was inhibited only partially, When methylation was inhibited, the RhoA half-life decreased from 31 to 12 h, and the Cdc42 half-life decreased from 15 to 11 h. The increased degradation of unmethylated RhoA demonstrates a novel function for carboxyl-terminal prenylcysteine carboxyl methylation in protecting RhoA and related proteins from degradation.	NIMH, Lab Genet & Comparat Biochem, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Backlund, PS (corresponding author), NICHD, LCMB, Bldg 10,Rm 10D-14,10 Ctr Dr MSC 1855, Bethesda, MD 20892 USA.							AKSAMIT RR, 1981, J IMMUNOL, V126, P2194; AKSAMIT RR, 1983, J BIOL CHEM, V258, P20; BACKLUND PS, 1993, BIOCHEM BIOPH RES CO, V196, P534, DOI 10.1006/bbrc.1993.2283; BACKLUND PS, 1992, J BIOL CHEM, V267, P18432; BACKLUND PS, 1988, J BIOL CHEM, V263, P15864; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DILLON ST, 1995, INFECT IMMUN, V63, P1421, DOI 10.1128/IAI.63.4.1421-1426.1995; DING JB, 1994, J BIOL CHEM, V269, P16837; DUNTEN RL, 1995, BIOCHEM BIOPH RES CO, V208, P174, DOI 10.1006/bbrc.1995.1320; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KIM IK, 1982, J BIOL CHEM, V257, P4726; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MA YT, 1994, BIOCHEMISTRY-US, V33, P5414, DOI 10.1021/bi00184a009; MONTGOMERY JA, 1982, J MED CHEM, V25, P626, DOI 10.1021/jm00348a004; NOBES CD, 1995, J CELL SCI, V108, P225; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHEER A, 1993, FEBS LETT, V319, P110, DOI 10.1016/0014-5793(93)80047-X; SHI YQ, 1992, J BIOL CHEM, V267, P9547; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAN EW, 1992, BIOCHEMISTRY-US, V31, P5572, DOI 10.1021/bi00139a021; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	42	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33175	33180		10.1074/jbc.272.52.33175	http://dx.doi.org/10.1074/jbc.272.52.33175			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407105	hybrid			2022-12-25	WOS:000071182900066
J	Gilchrist, CA; Gray, DA; Baker, RT				Gilchrist, CA; Gray, DA; Baker, RT			A ubiquitin-specific protease that efficiently cleaves the ubiquitin-proline bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; GLUTATHIONE-S-TRANSFERASE; FIBROBLAST GROWTH-FACTOR; SHORT-LIVED PROTEIN; DEGRADATION SIGNAL; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; GENE; EXPRESSION	Ubiquitin is a small eukaryotic protein that is synthesized naturally as one of several fusion proteins, which are processed by ubiquitin-specific proteases to release free ubiquitin. The expression of heterologous proteins as fusions to ubiquitin in either prokaryotic or eukaryotic hosts often dramatically enhances their yield, and allows the exposure of any amino acid following cleavage of ubiquitin. The single exception is when proline is the amino acid immediately following ubiquitin; the ubiquitin-proline bond is poorly cleaved by presently studied ubiquitin-specific proteases. We show that the mouse ubiquitin-specific protease Unp, and its human homolog Unph, can efficiently cleave the ubiquitin-proline bond in ubiquitin fusion proteins of different sizes. N-terminal sequencing of the cleavage products reveals that cleavage occurs precisely at the ubiquitin-proline junction. The biological significance of this cleavage activity is unclear, as ubiquitin-proline fusions do not occur naturally. However, it may indicate a different catalytic mechanism for these ubiquitin-specific proteases and/or that they can cleave ubiquitin-like proteins. Unp and Unph thus represent versatile ubiquitin-specific proteases for cleaving ubiquitin-fusion proteins in biotechnology and basic research, regardless of both the amino acid immediately following ubiquitin, and the size of the fusion partner.	Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia; Ottawa Reg Canc Ctr, Canc Res Grp, Ottawa, ON K1H 8L6, Canada	Australian National University; John Curtin School of Medical Research; University of Ottawa; Ottawa Hospital Research Institute	Baker, RT (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, GPO Box 334, Canberra, ACT 2601, Australia.	Rohan.Baker@anu.edu.au	/U-3554-2018	/0000-0002-8634-4984; Gilchrist, Catherine/0000-0002-7467-7933				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALIN P, 1985, FEBS LETT, V182, P319, DOI 10.1016/0014-5793(85)80324-0; Amerik AY, 1997, EMBO J, V16, P4826; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1994, J BIOL CHEM, V269, P25381; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; Baker RT, 1996, CURR OPIN BIOTECH, V7, P541, DOI 10.1016/S0958-1669(96)80059-0; BAKER RT, 1992, J BIOL CHEM, V267, P23364; Baker RT, 1996, J BIOL CHEM, V271, P13549, DOI 10.1074/jbc.271.23.13549; BENCHEKROUN MT, 1993, BRIT J PHARMACOL, V109, P902, DOI 10.1111/j.1476-5381.1993.tb13705.x; BROSIUS J, 1987, METHOD ENZYMOL, V153, P54; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; LOWE G, 1971, BIOCHEM J, V124, P107, DOI 10.1042/bj1240107; LOWE G, 1971, BIOCHEM J, V124, P117, DOI 10.1042/bj1240117; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MAULE AG, 1991, PARASITOLOGY, V102, P309, DOI 10.1017/S0031182000062648; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schlesinger M J, 1987, Oxf Surv Eukaryot Genes, V4, P77; SUZUKI T, 1987, ANN HUM GENET, V51, P95, DOI 10.1111/j.1469-1809.1987.tb01051.x; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; YOO Y, 1989, J BIOL CHEM, V264, P17078	49	43	46	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32280	32285		10.1074/jbc.272.51.32280	http://dx.doi.org/10.1074/jbc.272.51.32280			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405433	hybrid			2022-12-25	WOS:000071108000052
J	Kakinoki, Y; Somers, J; Brautigan, DL				Kakinoki, Y; Somers, J; Brautigan, DL			Multisite phosphorylation and the nuclear localization of phosphatase inhibitor 2-green fluorescent protein fusion protein during S phase of the cell growth cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CASEIN KINASE-II; AMINO-ACID-SEQUENCE; PHOSPHOPROTEIN PHOSPHATASE; ESCHERICHIA-COLI; SYNERGISTIC PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; MODULATOR INHIBITOR-2; SITE; EXPRESSION	Human phosphatase inhibitor 2 (Inh2) is a phosphoprotein that complexes with type 1 protein phosphatase, and its expression peaks during S phase and mitosis during the cell cycle. Localization of Inh2 was visualized in HS68 human fibroblasts by fusing Inh2 to green fluorescent protein (GFP). During G(1) phase, Inh2-GFP was localized in the cytoplasm, and as cells progressed into S phase Inh2-GFP accumulated in the nucleus, Known phosphorylation sites of Inh2 at Thr-72, Ser-86, and Ser120/121 were each replaced with alanine. None of the mutated Inh2-GFP proteins accumulated in the nucleus during S phase, indicating that all of these phosphorylation sites were required, Mutation of two lysine residues in a putative nuclear localization sequence in Inh2 also prevented the Inh2-GFP fusion protein from accumulating in the nucleus during S phase. Recombinant Inh2 was phosphorylated by kinases in cytosols prepared from G(1) and S phase cells, The amount of Inh2 kinase attributed to casein kinase 2, based on inhibition by heparin, increased 2.6-fold from G(1) to S phase, In addition, kinases in G(1) versus S phase cytosols produced distinct Inh2 phosphopeptides. The results indicate that changes in phosphorylation of Inh2 are involved in intracellular redistribution of the protein during the cell cycle.	Univ Virginia, Hlth Sci Ctr, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Hlth Sci Ctr, Ctr Cell Signaling, Box 577,Hosp W 7196, Charlottesville, VA 22908 USA.	db8g@virginia.edu			NIGMS NIH HHS [GM-56362] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P288, DOI 10.1016/0167-4838(84)90034-7; ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BALLOU LM, 1985, CURR TOP CELL REGUL, V27, P183; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; BOLLEN M, 1994, FEBS LETT, V344, P196, DOI 10.1016/0014-5793(94)00391-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRAUTIGAN DL, 1991, ADV PROTEIN PHOSPHAT, V6, P375; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CANNON JF, 1994, GENETICS, V136, P485; CANNON JF, 1995, ADV PROTEIN PHOSPHAT, V9, P211; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAN CSM, 1995, ADV PROTEIN PHOSPHAT, V9, P383; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DEPAOLIROACH AA, 1985, FEBS LETT, V183, P430, DOI 10.1016/0014-5793(85)80824-3; FOULKES JG, 1980, EUR J BIOCHEM, V105, P195, DOI 10.1111/j.1432-1033.1980.tb04489.x; Gerdes HH, 1996, FEBS LETT, V389, P44, DOI 10.1016/0014-5793(96)00586-8; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HELPS NR, 1994, FEBS LETT, V340, P93, DOI 10.1016/0014-5793(94)80179-7; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LAWRENCE JC, 1988, BIOCHEM BIOPH RES CO, V150, P197, DOI 10.1016/0006-291X(88)90505-0; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MacKintosh C, 1996, FEBS LETT, V397, P235, DOI 10.1016/S0014-5793(96)01175-1; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PARK IK, 1994, J BIOL CHEM, V269, P28919; PARK IK, 1994, J BIOL CHEM, V269, P944; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PUNTONI F, 1995, BIOCHEM BIOPH RES CO, V207, P732, DOI 10.1006/bbrc.1995.1248; RESINK TJ, 1983, EUR J BIOCHEM, V133, P455, DOI 10.1111/j.1432-1033.1983.tb07485.x; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; VANDENHEEDE JR, 1981, J BIOL CHEM, V256, P5894; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS JP, 1995, J CELL BIOCHEM, V57, P415, DOI 10.1002/jcb.240570307; YANG SD, 1981, J BIOL CHEM, V256, P231; YANG SD, 1981, FEBS LETT, V132, P293, DOI 10.1016/0014-5793(81)81182-9; ZHANG ZJ, 1994, ARCH BIOCHEM BIOPHYS, V308, P37, DOI 10.1006/abbi.1994.1005; ZHANG ZJ, 1992, BIOCHEM BIOPH RES CO, V186, P1168, DOI 10.1016/0006-291X(92)90869-M	56	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32308	32314		10.1074/jbc.272.51.32308	http://dx.doi.org/10.1074/jbc.272.51.32308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405437	hybrid			2022-12-25	WOS:000071108000056
J	Shen, XY; Belcher, AM; Hansma, PK; Stucky, GD; Morse, DE				Shen, XY; Belcher, AM; Hansma, PK; Stucky, GD; Morse, DE			Molecular cloning and characterization of lustrin A, a matrix protein from shell and pearl nacre of Haliotis rufescens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED KALLMANN SYNDROME; AMINO-ACID-SEQUENCE; MOLLUSK SHELLS; ORGANIC MATRIX; CELL-ENVELOPE; CRYSTAL-STRUCTURE; FIBROIN GENE; 5' FLANKING; FAMILY; RICH	A specialized extracellular matrix of proteins and polysaccharides controls the morphology and packing of calcium carbonate crystals and becomes occluded within the mineralized composite during formation of the molluscan shell and pearl. We have cloned and characterized the cDNA coding for Lustrin A, a newly described matrix protein from the nacreous layer of the shell and pearl produced by the abalone, Haliotis rufescens, a marine gastropod mollusc. The full-length cDNA is 4,439 base pairs (bp) long and contains an open reading frame coding for 1,428 amino acids. The deduced amino acid sequence reveals a highly modular structure with a high proportion of Ser (16%), Pro (14%), Gly (13%), and Cys (9%). The protein contains ten highly conserved cysteine-rich domains interspersed by eight proline-rich domains; a glycine-and serine-rich domain lies between the two cysteine-rich domains nearest the C terminus, and these are followed by a basic domain and a C-terminal domain that is highly similar to known protease inhibitors. The glycine-and serine-rich domain and at least one of the proline-rich domains show sequence similarity to proteins of two extracellular matrix superfamilies (one of which also is involved in the mineralized matrixes of bone, dentin, and avian eggshell). The arrangement of alternating cysteine-rich domains and proline-rich domains is strikingly similar to that found in frustulins, the proteins that are integral to the silicified cell wall of diatoms. Its modular structure suggests that Lustrin A is a multifunctional protein, whereas the occurrence of related sequences suggest it is a member of a multiprotein family.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Ctr Marine Biotechnol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Mat Res Lab, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Morse, DE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.							ARIAS JL, 1993, INT REV CYTOL, V145, P217, DOI 10.1016/S0074-7696(08)60428-3; BEG OU, 1986, EUR J BIOCHEM, V159, P195, DOI 10.1111/j.1432-1033.1986.tb09852.x; Belcher AM, 1996, NATURE, V381, P56, DOI 10.1038/381056a0; BELCHER AM, 1996, THESIS U CALIFORNIA; BELCHER AM, 1997, IN PRESS ACTA METAL; BEVELANDER G, 1969, CALC TISS RES, V3, P84, DOI 10.1007/BF02058648; Bowen CE, 1996, COMP BIOCHEM PHYS A, V115, P269, DOI 10.1016/S0300-9629(96)00059-X; BRUNET PCJ, 1967, ENDEAVOUR, V26, P68; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURLEY SK, 1989, TRENDS BIOTECHNOL, V7, P354, DOI 10.1016/0167-7799(89)90036-X; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; CARIOLOU MA, 1988, J COMP PHYSIOL B, V157, P717, DOI 10.1007/BF00691002; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Crenshaw M.A., 1972, Biomineralization Res Rep, V6, P6; CRENSHAW MA, 1972, BIOL BULL, V143, P506, DOI 10.2307/1540180; CURREY JD, 1977, PROC R SOC SER B-BIO, V196, P443, DOI 10.1098/rspb.1977.0050; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; ERBEN HK, 1974, NATURE, V248, P128, DOI 10.1038/248128a0; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; FARMER SJ, 1990, MOL ENDOCRINOL, V4, P1095, DOI 10.1210/mend-4-8-1095; FIETZEK PP, 1972, EUR J BIOCHEM, V30, P163, DOI 10.1111/j.1432-1033.1972.tb02083.x; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; FRITZ M, 1994, NATURE, V371, P49, DOI 10.1038/371049a0; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GORDON J, 1980, MAR BIOL, V57, P251, DOI 10.1007/BF00387568; Gregoire C., 1972, P45; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; HENNINGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P3733, DOI 10.1093/nar/10.12.3733; HOHL D, 1991, J BIOL CHEM, V266, P6626; JACKSON AP, 1988, PROC R SOC SER B-BIO, V234, P415, DOI 10.1098/rspb.1988.0056; KATO I, 1979, FED PROC, V38, P832; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAKI T, 1994, PEPT CHEM, P405; KRAMER JM, 1982, CELL, V30, P599, DOI 10.1016/0092-8674(82)90256-2; KROGER N, 1994, EMBO J, V13, P4676, DOI 10.1002/j.1460-2075.1994.tb06791.x; Kroger N, 1996, EUR J BIOCHEM, V239, P259, DOI 10.1111/j.1432-1033.1996.0259u.x; LANGBEIN L, 1993, DIFFERENTIATION, V55, P57, DOI 10.1111/j.1432-0436.1993.tb00033.x; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEGOUIS R, 1993, GENOMICS, V17, P516, DOI 10.1006/geno.1993.1360; MANNE S, 1994, P ROY SOC B-BIOL SCI, V256, P17, DOI 10.1098/rspb.1994.0043; MEENAKHS.VR, 1971, COMP BIOCHEM PHYSIOL, V40, P1037, DOI 10.1016/0305-0491(71)90048-4; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Miyamoto H, 1996, P NATL ACAD SCI USA, V93, P9657, DOI 10.1073/pnas.93.18.9657; MORSE DE, 1993, MATER RES SOC SYMP P, V292, P59; Mutvei H, 1979, SCANNING ELECT MICRO, V2, P457; NAKAHARA H, 1982, Venus the Japanese Journal of Malacology, V41, P33; Nakahara H., 1991, P343; NAKAHARA H, 1979, JPN J MALACOL, V38, P205; Nakahara H., 1983, BIOMINERALIZATION BI, P225; OKAMOTO H, 1982, J BIOL CHEM, V257, P5192; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIKAYA M, 1994, MICROSC RES TECHNIQ, V27, P360, DOI 10.1002/jemt.1070270503; Schaffer TE, 1997, CHEM MATER, V9, P1731, DOI 10.1021/cm960429i; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; SUDO S, 1997, NATURE, V387, P583; TAKAHASHI M, 1992, FEBS LETT, V308, P79, DOI 10.1016/0014-5793(92)81055-Q; TOWE KM, 1968, CALC TISS RES, V1, P306; TSUJIMOTO Y, 1979, CELL, V18, P591, DOI 10.1016/0092-8674(79)90075-8; Tsunemi M, 1996, BIOCHEMISTRY-US, V35, P11570, DOI 10.1021/bi960900l; VEIS A, 1964, BIOCHEMISTRY-US, V3, P1650, DOI 10.1021/bi00899a009; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wada K., 1972, BIOMINERALISATION, V6, P141; Wada K., 1961, B NATN PEARL RES LAB, V7, P703; Walters DA, 1997, BIOPHYS J, V72, P1425, DOI 10.1016/S0006-3495(97)78789-7; WATABE N, 1981, PROG CRYST GROWTH CH, V4, P99, DOI 10.1016/0146-3535(81)90050-2; WEINER S, 1979, CALCIFIED TISSUE INT, V29, P163, DOI 10.1007/BF02408072; WEINER S, 1986, CRC CR REV BIOCH MOL, V20, P365, DOI 10.3109/10409238609081998; WEINER S, 1984, PHILOS T ROY SOC B, V304, P425, DOI 10.1098/rstb.1984.0036; WEINER S, 1980, FEBS LETT, V111, P311, DOI 10.1016/0014-5793(80)80817-9; WEINER S, 1975, SCIENCE, V190, P987, DOI 10.1126/science.1188379; Weiner S, 1997, J MATER CHEM, V7, P689, DOI 10.1039/a604512j; WEINER S, 1992, CHEM BIOL MINERALIZE; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WISE S JR, 1970, Eclogae Geologicae Helvetiae, V63, P775; WISE SW, 1970, SCIENCE, V167, P1486, DOI 10.1126/science.167.3924.1486; WONG M, 1984, DEV BIOL, V104, P28, DOI 10.1016/0012-1606(84)90033-2; WORMS D, 1986, J EXP ZOOL, V237, P11, DOI 10.1002/jez.1402370104; ZAREMBA C, 1996, CHEM MATER, V8, P676	83	299	316	2	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32472	32481		10.1074/jbc.272.51.32472	http://dx.doi.org/10.1074/jbc.272.51.32472			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405458	hybrid			2022-12-25	WOS:000071108000077
J	McDonald, KK; Zharikov, S; Block, ER; Kilberg, MS				McDonald, KK; Zharikov, S; Block, ER; Kilberg, MS			A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the ''arginine paradox''	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; PLASMA-MEMBRANE; DEPENDENT RELAXATION; SEROTONIN TRANSPORT; RELAXING FACTOR; CELLS; RELEASE; ARTERY; PALMITOYLATION; PURIFICATION	Immunohistochemistry of porcine pulmonary artery endothelial cells (PAEC) with antibodies specific for caveolin, endothelial nitric-oxide synthase (eNOS), and the arginine transporter (CAT1) demonstrates that all of these proteins co-localize in plasma membrane caveolae. When incubated with solubilized PAEC plasma membrane proteins, eNOS-specific antibody immunoprecipitates CAT1-mediated arginine transport. These results document the existence of a caveolar complex between CAT1 and eNOS in PAEC that provides a mechanism for the directed delivery of substrate arginine to eNOS. Direct transfer of extracellular arginine to membrane-bound eNOS accounts for the ''arginine paradox'' and explains why caveolar localization of eNOS is required for optimal nitric oxide production by endothelial cells.	UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOL BIOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, COLL MED, CTR STRUCT BIOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, COLL MED, DEPT MED, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, COLL MED, GAINESVILLE VA MED CTR, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida			Zharikov, Sergey/G-1636-2011; Zharikov, Sergey/A-2981-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL052136, R01HL052136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028374] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52136] Funding Source: Medline; NIDDK NIH HHS [DK-28374] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AISAKA K, 1989, BIOCHEM BIOPH RES CO, V163, P710, DOI 10.1016/0006-291X(89)92281-X; Anderson R G, 1993, Trends Cell Biol, V3, P177, DOI 10.1016/0962-8924(93)90205-F; ARNAL JF, 1995, J CLIN INVEST, V95, P2565, DOI 10.1172/JCI117957; BAYDOUN AR, 1990, BIOCHEM BIOPH RES CO, V173, P940, DOI 10.1016/S0006-291X(05)80876-9; BHAT GB, 1990, AM J RESP CELL MOL, V3, P363, DOI 10.1165/ajrcmb/3.4.363; BHAT GB, 1992, AM J RESP CELL MOL, V6, P633, DOI 10.1165/ajrcmb/6.6.633; BLOCK ER, 1995, AM J PHYSIOL-LUNG C, V269, pL574, DOI 10.1152/ajplung.1995.269.5.L574; Bogle RG, 1996, J PHYSIOL-LONDON, V490, P229, DOI 10.1113/jphysiol.1996.sp021138; BUSSOLATI O, 1993, AM J PHYSIOL, V265, pC1006, DOI 10.1152/ajpcell.1993.265.4.C1006; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; Closs EI, 1996, AMINO ACIDS, V11, P193, DOI 10.1007/BF00813860; COOKE JP, 1991, CIRCULATION, V83, P1057, DOI 10.1161/01.CIR.83.3.1057; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; EDDAHIBI S, 1992, AM J PHYSIOL, V263, pL194, DOI 10.1152/ajplung.1992.263.2.L194; FAFOURNOUX P, 1989, J BIOL CHEM, V264, P4805; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GOLD ME, 1989, BIOCHEM BIOPH RES CO, V164, P714, DOI 10.1016/0006-291X(89)91518-0; GREENE B, 1993, AM J PHYSIOL, V264, pL351, DOI 10.1152/ajplung.1993.264.4.L351; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; Kakuda DK, 1993, TRANSGENE, V1, P91; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; Kurz S, 1997, J CLIN INVEST, V99, P369, DOI 10.1172/JCI119166; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; McDonald KK, 1997, BBA-BIOMEMBRANES, V1324, P133, DOI 10.1016/S0005-2736(96)00226-X; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; MONCADA S, 1991, PHARMACOL REV, V43, P109; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; ROSSITCH E, 1991, J CLIN INVEST, V87, P1295, DOI 10.1172/JCI115132; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SIMIONESCU M, 1987, PULMONARY ENDOTHELIU, P35; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; TAYLOR PD, 1994, BRIT J PHARMACOL, V113, P801, DOI 10.1111/j.1476-5381.1994.tb17064.x; TEITEL JM, 1986, J CELL PHYSIOL, V128, P329, DOI 10.1002/jcp.1041280227; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; ZHARIKOV SI, 1997, IN PRESS BIOCH BIOPH	51	382	391	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31213	31216		10.1074/jbc.272.50.31213	http://dx.doi.org/10.1074/jbc.272.50.31213			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395443	hybrid			2022-12-25	WOS:A1997YL41900002
J	Ratcliffe, MJ; Rubin, LL; Staddon, JM				Ratcliffe, MJ; Rubin, LL; Staddon, JM			Dephosphorylation of the cadherin-associated p100/p120 proteins in response to activation of protein kinase C in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT POLARITY GENE; ADHESION MOLECULE UVOMORULIN; TIGHT JUNCTION PERMEABILITY; GLYCOGEN-SYNTHASE KINASE-3; EPIDERMAL GROWTH-FACTOR; BETA-CATENIN COMPLEX; TYROSINE PHOSPHORYLATION; SELECTIVE INHIBITOR; MDCK CELLS; PARACELLULAR PERMEABILITY	Protein kinase C signaling pathways have been implicated in the disruption of intercellular junctions, but mechanisms are not clear. p100 and p120 are members of the Armadillo family of proteins and are localized to cellular adherens junctions. In strain I Madin-Darby canine kidney cells, protein kinase C activation leads to disruption of tight junctions and an increase in permeability of cell monolayers. We show that this permeability increase is accompanied by dephosphorylation of p100/p120 on serine and threonine residues, The dephos phorylation of these proteins can also be induced by the kinase inhibitors staurosporine, KT5926, and G(o) double over dot 6976. Treatment of cells with phosphatase inhibitors induced hyperphosphorylation of p100 and p120. Thus, p100 and p120 participate in a regulatable cycle of serine/threonine phosphorylation and dephosphorylation. Protein kinase C must act, directly or indirectly, by perturbing this phosphorylation cycle, by inhibition of a p100/p120 kinase and/or activation of a phosphatase. These data clearly show that p100 and p120 are targets of a novel protein kinase C signaling pathway. Dephosphorylation of these proteins precedes the permeability increase across epithelial cell monolayers seen in response to phorbol esters, raising the possibility that this pathway may play a role in the modulation of intercellular junctions.	UCL, EISAI LONDON RES LABS LTD, LONDON WC1E 6BT, ENGLAND	Eisai Co Ltd; University of London; University College London				Rubin, Lee/0000-0002-8658-841X				AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DOWNING JR, 1991, ONCOGENE, V6, P607; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GOODE N, 1992, J BIOL CHEM, V267, P16878; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HASHIMOTO Y, 1991, BIOCHEM BIOPH RES CO, V181, P423, DOI 10.1016/S0006-291X(05)81436-6; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KLEINSCHROTH J, 1995, BIOORG MED CHEM LETT, V5, P55, DOI 10.1016/0960-894X(94)00458-R; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; MAHER PA, 1988, J CELL BIOL, V106, P1747, DOI 10.1083/jcb.106.5.1747; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McCarthy KM, 1996, J CELL SCI, V109, P2287; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PIERCE SB, 1995, DEVELOPMENT, V121, P755; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SOLER AP, 1993, EXP CELL RES, V207, P398, DOI 10.1006/excr.1993.1207; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; STADDON JM, 1995, J CELL SCI, V108, P609; STENSON WF, 1993, AM J PHYSIOL, V265, pG955, DOI 10.1152/ajpgi.1993.265.5.G955; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	77	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31894	31901		10.1074/jbc.272.50.31894	http://dx.doi.org/10.1074/jbc.272.50.31894			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395537	hybrid			2022-12-25	WOS:A1997YL41900096
J	Rice, WJ; Green, NM; MacLennan, DH				Rice, WJ; Green, NM; MacLennan, DH			Site-directed disulfide mapping of helices M4 and M6 in the Ca2+ binding domain of SERCA1a, the Ca2+ ATPase of fast twitch skeletal muscle sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; CROSS-LINKING; AMINO-ACIDS; ADENOSINE-TRIPHOSPHATASE; TRANSMEMBRANE DOMAIN; ASPARTATE RECEPTOR; ESCHERICHIA-COLI; CALCIUM-BINDING; CA2+-ATPASE; CA-2+-ATPASE	In an attempt to define the spatial relationships among SERCA1a transmembrane helices M4, M5, M6, and M8, involved in Ca2+ binding, all six cysteine residues were removed from predicted transmembrane sequences by substitution with Ser or Ala. The cysteine-depleted protein retained 44% of wild type Ca2+ transport activity. Pairs of cysteine residues were then reintroduced to determine whether their juxtaposition would result in the formation of disulfide cross-links between transmembrane helices. In initial studies de signed to map the juxtaposition of Ca2+ binding residues, Cys was substituted for Glu(309) or Gly(310) in transmembrane sequence M4, in combination with the substitution of Cys for Glu(771) in M5; for Asn(796), Thr(789), or Asp(800) in M6; or for Glu(908) in M8. These double mutants all retained the capacity to form a phosphoenzyme intermediate from P-i (but not from ATP in the presence of Ca2+), and in all but mutants E309C/N796C and G310C/N796C, phosphoenzyme formation was insensitive to 100 mu M Ca2+. These results support the view that both Glu(309) and Asn(796) contribute to Ca2+ binding site II, which is not required for conversion of E-2, the substrate for P-i phosphorylation, to E-1. Cross linking in mutants E309C/N796C and G310C/D800C established reference points for the orientation of M4 and M6 relative to each other and provided the basis for the prediction of potential additional cross-links. Strong links were formed with the pairs T317C/A804C and T317C/L807C near the cytoplasmic ends of the two helices and with A305C/L792C and A305C/L793C near the lumenal ends. These combined results support the conclusion that M4 and M6 form a right-handed coiled-coil structure that forms part of the pathway of Ca2+ translocation. In addition to providing a possible explanation for the mutation sensitivity of several pairs of residues in these helices, the proposed association of M4 and M6 supports a new model for the orientation of the two Ca2+ binding sites among transmembrane helices M4, M5, and M6.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5S 1A6, CANADA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	University of Toronto; University of Toronto; MRC National Institute for Medical Research				Rice, William/0000-0002-5187-255X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039280] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR 39280] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FORGE V, 1995, J BIOL CHEM, V270, P18271, DOI 10.1074/jbc.270.31.18271; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GF, 1994, J BIOL CHEM, V269, P29920; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; ROSS DC, 1987, J BIOL CHEM, V262, P2042; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; STEWART PS, 1974, J BIOL CHEM, V249, P985; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; THORLEYL.DA, 1973, EUR J BIOCHEM, V40, P403, DOI 10.1111/j.1432-1033.1973.tb03209.x; THORLEYLAWSON DA, 1977, BIOCHEM J, V167, P739, DOI 10.1042/bj1670739; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1991, J BIOL CHEM, V266, P18839; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WEBER K, 1969, J BIOL CHEM, V244, P4406; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	51	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31412	31419		10.1074/jbc.272.50.31412	http://dx.doi.org/10.1074/jbc.272.50.31412			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395473	hybrid			2022-12-25	WOS:A1997YL41900032
J	Vega, RB; Kelly, DP				Vega, RB; Kelly, DP			A role for estrogen-related receptor alpha in the control of mitochondrial fatty acid beta-oxidation during brown adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; TRANSCRIPTION FACTORS; TRANSGENIC MICE; C/EBP-ALPHA; PPAR-GAMMA; EXPRESSION; TISSUE; CELLS; DEHYDROGENASE; SUPERFAMILY	Little is known about the factors involved in the brown adipocyte gene regulatory program. In contrast to the white adipocyte, the brown adipocyte is characterized by abundant mitochondria and high level expression of mitochondrial fatty acid beta-oxidation enzymes. Previous studies in transgenic mice have shown that the brown adipose-enriched expression of a key beta-oxidation enzyme, medium chain acyl-coenzyme A dehydrogenase (MCAD), requires cis-acting elements located within the proximal promoter region of the MCAD gene. The levels of mRNA encoding MCAD and several other beta-oxidation cycle enzymes were coordinately induced during differentiation of brown adipocytes in culture. Expression of transgenes comprised of MCAD gene promoter fragments fused to chloramphenicol acetyltransferase reporters in differentiating brown adipocytes revealed that a known nuclear receptor response element (NRRE-1) was required for the transcriptional induction of the MCAD gene during brown adipocyte differentiation. Electrophoretic mobility shift assays and antibody recognition studies identified distinct brown adipocyte differentiation stage-specific, NRRE-1-protein complexes; the orphan nuclear receptors, chicken ovalbumin upstream promoter transcription factors I and II, were identified as major the NRRE-1 binding proteins in the pre-adipocyte, whereas the estrogen-related receptor alpha (ERR alpha) bound NRRE-1 in extracts prepared from differentiated brown adipocytes. DNA binding studies performed with a series of NRRE-1 mutant probes indicated that ERR alpha was capable of binding two distinct sites within NRRE-1, each of which conform to the known ERR alpha monomeric binding consensus. The expression of ERR alpha paralleled NRRE-1 binding activities and MCAD expression during brown adipocyte differentiation, cardiac development, and among a variety of adult mouse tissues. These results identify a new class of ERR alpha target genes and implicate ERR alpha and chicken ovalbumin upstream promoter transcription factor in the control of a pivotal metabolic pathway during brown adipocyte differentiation.	WASHINGTON UNIV,SCH MED,CARDIOVASC RES CTR,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Kelly, Daniel/ABG-2056-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045416] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK45416] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beinert H., 1963, ENZYMES, P447; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BREMER J, 1984, FATTY ACID OXIDATION, P13; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTLER AJ, 1995, NUCLEIC ACIDS RES, V23, P4143, DOI 10.1093/nar/23.20.4143; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; Disch DL, 1996, MOL CELL BIOL, V16, P4043; FLUERY C, 1997, NAT GENET, V15, P269; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KELLY DP, 1989, J BIOL CHEM, V264, P18921; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; NECHAD M, 1983, EXP CELL RES, V149, P105, DOI 10.1016/0014-4827(83)90384-1; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; ZUO FR, 1995, P NATL ACAD SCI USA, V92, P8586, DOI 10.1073/pnas.92.19.8586	34	132	142	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31693	31699		10.1074/jbc.272.50.31693	http://dx.doi.org/10.1074/jbc.272.50.31693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395511	hybrid			2022-12-25	WOS:A1997YL41900070
J	Bauerfeind, R; Takei, K; De Camilli, P				Bauerfeind, R; Takei, K; De Camilli, P			Amphiphysin I is associated with coated endocytic intermediates and undergoes stimulation-dependent dephosphorylation in nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIFF-MAN SYNDROME; ADRENAL CHROMAFFIN CELLS; PROTEIN-KINASE-C; SYNAPTIC VESICLES; ACTIN CYTOSKELETON; BREAST-CANCER; DYNAMIN-I; SACCHAROMYCES-CEREVISIAE; INTERNALIZATION STEP; TRIGGERED EXOCYTOSIS	Amphiphysin I is an abundant presynaptic protein that interacts via its COOH-terminal src homology 3 (SH3) domain with the GTPase dynamin I and the inositol-5-phosphatase synaptojanin., Both dynamin I and synaptojanin I have a putative role in synaptic vesicle recycling and undergo rapid dephosphorylation in rat brain synaptosomes stimulated to secrete by a depolarizing stimulus, We show here that amphiphysin I also undergoes constitutive phosphorylation and stimulationdependent dephosphorylation, Dephosphorylation of amphiphysin I requires extracellular Ca2+ and is unaffected by pretreatment of synaptosomes with tetanus toxin, Thus, Ca2+ influx, but not synaptic vesicle exocytosis, is required for dephosphorylation. Dephosphorylation of amphiphysin I, like dephosphorylation of dynamin I and synaptojanin I, is inhibited by cyclosporin A and FK-506 (0.5 mu M), two drugs that specifically block the Ca2+/calmodulin-dependent phosphatase 2B calcineurin, but not by okadaic acid (1 mu M), which blocks protein phosphatases 1 and 2B. We also show by immunogold electron microscopy immunocytochemistry that amphiphysin I is localized in the nerve terminal cytomatrix and is partially associated with endocytic intermediates, These include the clathrin-coated buds and dynamin-coated tubules, which accumulate in nerve terminal membranes incubated in the presence of guanosine 5'-3-O-(thio)triphosphate. These data support the hypothesis that amphiphysin I, dynamin I, and syaptojanin I are physiological partners in some step(s) of synaptic vesicle endocytosis, We hypothesize that the parallel Ca2+-dependent calcineurin-dependent dephosphorylation of amphiphysin I and of its two major binding proteins is part of a process that primes the nerve terminal for endocytosis in response to a burst of exocytosis.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, 295 Congress Ave, New Haven, CT 06510 USA.	pietro.decamilli@yale.edu		Takei, Kohji/0000-0002-6555-9425	NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; CREUTZ CE, 1984, NATURE, V308, P208, DOI 10.1038/308208a0; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECAMILLI P, 1993, J EXP MED, V178, P2219, DOI 10.1084/jem.178.6.2219; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; Gad H., 1995, Society for Neuroscience Abstracts, V21, P332; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KLEE CB, 1990, FID RES FDN, V4, P95; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; Kuromi H, 1997, NEUROSCI RES, V27, P101, DOI 10.1016/S0168-0102(96)01132-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LIU JP, 1994, J BIOL CHEM, V269, P21043; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; MUNDIGI O, 1997, IN PRESS J NEUROSCI; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NEMOTO Y, 1997, IN PRESS J BIOL CHEM; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SALISBURY JL, 1980, J CELL BIOL, V87, P132, DOI 10.1083/jcb.87.1.132; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; Smith CB, 1996, NATURE, V380, P531, DOI 10.1038/380531a0; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; VONGRAFENSTEIN H, 1986, J CELL BIOL, V103, P2343, DOI 10.1083/jcb.103.6.2343; VONGRAFENSTEIN H, 1993, J MEMBRANE BIOL, V134, P1; WANG JKT, 1988, J NEUROSCI, V8, P281; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8	65	131	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30984	30992		10.1074/jbc.272.49.30984	http://dx.doi.org/10.1074/jbc.272.49.30984			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388246	hybrid			2022-12-25	WOS:000071640800059
J	Benkirane, M; Jin, DY; Chun, RF; Koup, RA; Jeang, KT				Benkirane, M; Jin, DY; Chun, RF; Koup, RA; Jeang, KT			Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5 Delta 32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; RECEPTOR; ENTRY; GENE; LESTR/FUSIN; MIP-1-ALPHA; INDIVIDUALS; PROGRESSION; REPLICATION; MIP-1-BETA	Human chemokine receptor 5 (CCRB) functions as a co-receptor for Human immunodeficiency virus (HIV-1) infection, CCR5 is a seven-transmembrane cell surface receptor, Recently, a naturally occurring mutation of CCRB, ccr5 Delta 32, has been described, A small number of Caucasians are homozygously ccr5 Delta 32/ccr5 Delta 32, while a larger number of individuals are heterozygously CCR5/ccr5 Delta 32. The ccr5 Delta 32/ccr5 Delta 32 genotype has been linked to a phenotype that is "highly" protected from HIV-1 infection, On the other hand, several studies have shown that the CCR5/ccr5 Delta 32 genotype confers "relative" protection from AIDS with onset of disease being delayed by 2-4 years, Although it is known that peripheral blood lymphocytes from heterozygous individuals (CCR5/ccr5 Delta 32) support ex vivo HTV-1 replication at a reduced level compared with CCR5/CCR5 cells, the molecular basis for this observation is unknown, Here we report on events that post-translationally modify CCRB, We show that CCR5 progresses through the endoplasmic reticulum prior to appearing on the cell surface, Mature CCRB can be post-translationally modified by phosphorylation and/or co-translationally by multimerization, By contrast, mutant ccr5 Delta 32, although retaining the capacity for multimerization, was incapable of being phosphorylated. ccr5 Delta 32 heterocomplexes with CCR5, and this interaction retains CCR5 in the endoplasmic reticulum resulting in reduced cell surface expression, Thus, co-expression in cells of ccr5 Delta 32 with CCR5 produces a trans-inhibition by the former of ability by the latter to support HIV-1 infection, Taken together, our findings suggest CCR5/ccr5 Delta 32 heterodimerization as a molecular explanation for the delayed onset of AIDS in CCR5/ccr5 Delta 32 individuals.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, Dallas, TX 75235 USA; Ctr Rech Biochim Macromol, CNRS, ERS 0155, Montpellier, France	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Benkirane, M (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008; Chun, Rene/A-9415-2010	Chun, Rene/0000-0002-0190-0807	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035522, R01AI042397, R01AI035522] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35522, AI42397] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Clapham PR, 1997, NATURE, V388, P230, DOI 10.1038/40758; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Theodore TS, 1996, AIDS RES HUM RETROV, V12, P191, DOI 10.1089/aid.1996.12.191; WU BL, 1997, J EXP MED, V185, P1681	27	306	315	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30603	30606		10.1074/jbc.272.49.30603	http://dx.doi.org/10.1074/jbc.272.49.30603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388191	hybrid			2022-12-25	WOS:000071640800004
J	de Chaves, EIP; Rusinol, AE; Vance, DE; Campenot, RB; Vance, JE				de Chaves, EIP; Rusinol, AE; Vance, DE; Campenot, RB; Vance, JE			Role of lipoproteins in the delivery of lipids to axons during axonal regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SYMPATHETIC NEURONS; LOW-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-A-I; PERIPHERAL-NERVE; CHOLESTEROL-SYNTHESIS; MEMBRANE-LIPIDS; SCHWANN-CELLS; SCIATIC-NERVE; RECEPTORS; MYELIN	Nerve fiber elongation involves the input of lipids to the growing axons. Since cell bodies are often a great distance from the regenerating tips, alternative sources of lipids have been proposed. We previously demonstrated that axonal synthesis of phosphatidylcholine is required for axonal growth (Posse de Chaves, E., Vance, D. E., Campenot, R. B. and Vance, J. E. (1995) J. Cell Biol, 128, 913-918; Posse de Chaves, E., Vance, D. E., Campenot, R. B. and Vance, J. E. (1995) Biochem, J. 312, 411-417), In contrast, cholesterol is not made in axons. We now show that when compartmented cultures of rat sympathetic neurons are incubated with pravastatin, in the absence of exogenously supplied lipids, cholesterol synthesis is inhibited and axonal growth is impaired. The addition of cholesterol to the axons or cell bodies of neurons treated with this inhibitor restores normal axonal elongation. Similarly, a supply of cholesterol via lipoproteins restores normal axonal growth. In contrast, lipoproteins do not provide axons with sufficient phosphatidylcholine for normal elongation when axonal phosphatidylcholine synthesis is inhibited. Thus, our studies support the idea that during axonal regeneration lipoproteins can be taken up by axons from the microenvironment and supply sufficient cholesterol, but not phosphatidylcholine, for growth, We also show that neither apoE nor apoA-I within the lipoproteins is essential for axonal growth.	Univ Alberta, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol & Anat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ALBERTS B, 1989, MOL BIOL CELL, P1059; BEUCHE W, 1984, J NEUROCYTOL, V13, P767, DOI 10.1007/BF01148493; BOIRON F, 1993, J NEUROCHEM, V60, P320, DOI 10.1111/j.1471-4159.1993.tb05854.x; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BROUSSEAU T, 1993, CLIN CHEM, V39, P960; CAMPENOT RB, 1991, J NEUROSCI, V11, P1126; CAMPENOT RB, 1989, NEURON, V3, P733, DOI 10.1016/0896-6273(89)90242-0; CAMPENOT RB, 1992, CELL CELL INTERACTIO, P275; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; DECHAVES EP, 1995, J CELL BIOL, V128, P913, DOI 10.1083/jcb.128.5.913; DECHAVES EP, 1995, BIOCHEM J, V312, P411, DOI 10.1042/bj3120411; FALKENBACH A, 1990, MED HYPOTHESES, V33, P57, DOI 10.1016/0306-9877(90)90085-S; FOLCH J, 1957, J BIOL CHEM, V226, P497; GOODRUM JF, 1993, J NEUROCHEM, V60, P1564, DOI 10.1111/j.1471-4159.1993.tb03322.x; GOODRUM JF, 1995, J NEUROCHEM, V64, P408; GOODRUM JF, 1991, J NEUROCHEM, V56, P2082, DOI 10.1111/j.1471-4159.1991.tb03469.x; GOODRUM JF, 1990, J NEUROCHEM, V54, P1709, DOI 10.1111/j.1471-4159.1990.tb01225.x; GOODRUM JF, 1994, J NEUROSCI, V14, P357; GOULD RM, 1987, J NEUROCHEM, V48, P1121, DOI 10.1111/j.1471-4159.1987.tb05636.x; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HAVEL RJ, 1995, METABOLIC MOL BASES, P1841; Ignatius MJ, 1987, PROG BRAIN RES <D>, V71, P177; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; ISHIBASHI S, 1993, HORM METAB RES, V25, P82, DOI 10.1055/s-2007-1002048; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1194, DOI 10.1073/pnas.78.2.1194; LEDEEN RW, 1992, MOL NEUROBIOL, V6, P179, DOI 10.1007/BF02780551; LEDEEN RW, 1985, PHOSPHOLIPIDS NERVOU, P135; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MULLER HW, 1986, J CELL BIOL, V102, P393, DOI 10.1083/jcb.102.2.393; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; NAKAYA N, 1986, ATHEROSCLEROSIS, V61, P125, DOI 10.1016/0021-9150(86)90071-7; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; POPKO B, 1993, J NEUROCHEM, V60, P1155, DOI 10.1111/j.1471-4159.1993.tb03268.x; RAWLINS FA, 1970, LAB INVEST, V22, P237; RAWLINS FA, 1972, J CELL BIOL, V52, P615, DOI 10.1083/jcb.52.3.615; ROTHE T, 1991, J NEUROCHEM, V57, P2016, DOI 10.1111/j.1471-4159.1991.tb06417.x; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; SKENE JHP, 1983, P NATL ACAD SCI-BIOL, V80, P4169, DOI 10.1073/pnas.80.13.4169; SNIPES GJ, 1983, SOC NEUR ABSTR, V9, P52; TSUJITA Y, 1986, BIOCHIM BIOPHYS ACTA, V877, P50, DOI 10.1016/0005-2760(86)90117-7; VANCE JE, 1994, J NEUROCHEM, V62, P329; VANCE JE, 1991, J CELL BIOL, V115, P1061, DOI 10.1083/jcb.115.4.1061; WEISGRABER KH, 1980, J LIPID RES, V21, P316; YAO ZM, 1988, J BIOL CHEM, V263, P2998; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	48	132	133	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30766	30773		10.1074/jbc.272.49.30766	http://dx.doi.org/10.1074/jbc.272.49.30766			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388216	hybrid			2022-12-25	WOS:000071640800029
J	Gray, MO; Karliner, JS; Mochly-Rosen, D				Gray, MO; Karliner, JS; Mochly-Rosen, D			A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-HEART; INTRACELLULAR RECEPTOR; VENTRICULAR MYOCYTES; GENE-EXPRESSION; STRESS PROTEIN; ISOZYME; CARDIOMYOCYTES; LOCALIZATION; TRANSLOCATION; INCREASES	Protein kinase C activation is thought to protect cardiac tissue from subsequent ischemic injury by a process termed preconditioning, The protein kinase C isozyme that mediates preconditioning has not yet been identified, Using a cell culture model of hypoxic preconditioning, we found that cardiac myocyte viability after 9 h of hypoxia was increased by more than 50% over control, Preconditioning activated protein kinase C isozymes as evidenced by translocation from one cell compartment to another as follows: there was a a,l-fold increase in epsilon-protein kinase C activation, a 2.8-fold increase in delta-protein kinase C activation, and no increase in beta(1)-protein kinase C activation, 4 beta-Phorbol la-myristate 13-acetate mimicked hypoxic preconditioning, increasing myocyte survival after prolonged hypoxia by 34% compared with control, We previously identified an epsilon-protein kinase C-selective antagonist, epsilon V1-2 peptide, that inhibits epsilon-protein kinase C translocation and function in cardiac myocytes (Johnson, J, A., Gray, M. O., Chen, C.-H,, and Mochly-Rosen, D. (1996) J, Biol, Chem, 271, 24962-24966), epsilon V1-2 peptide abolished hypoxic preconditioning and phorbol ester mediated cardiac protection, Therefore, preconditioning can be induced in this culture model, and activation of epsilon-protein kinase C is critical for cardiac myocyte protection.	Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94121 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	Karliner, JS (corresponding author), Vet Affairs Med Ctr, Cardiol Sect, 111C,4150 Clement St, San Francisco, CA 94121 USA.			Mochly-Rosen, Daria/0000-0002-6691-8733	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL025847] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52141, HL-25847] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREW EC, 1995, AM J PHYSIOL-HEART C, V269, pH1370, DOI 10.1152/ajpheart.1995.269.4.H1370; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; CLERK A, 1995, AM J PHYSIOL-HEART C, V269, pH1087, DOI 10.1152/ajpheart.1995.269.3.H1087; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1995, J MOL CELL CARDIOL, V27, P2473, DOI 10.1006/jmcc.1995.0235; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; Henry P, 1996, CIRC RES, V78, P161, DOI 10.1161/01.RES.78.1.161; HU KL, 1995, CIRCULATION, V92, P2259, DOI 10.1161/01.CIR.92.8.2259; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; IRONS CE, 1992, J BIOL CHEM, V267, P5211; Jiang TR, 1996, CIRC RES, V78, P724, DOI 10.1161/01.RES.78.4.724; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; JOHNSON JA, 1995, CIRC RES, V76, P654, DOI 10.1161/01.RES.76.4.654; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LIU YG, 1995, J MOL CELL CARDIOL, V27, P883, DOI 10.1016/0022-2828(95)90038-1; Liu YG, 1996, CIRC RES, V78, P443, DOI 10.1161/01.RES.78.3.443; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MITCHELL MB, 1995, CIRC RES, V76, P73, DOI 10.1161/01.RES.76.1.73; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Morris SD, 1996, J CLIN INVEST, V97, P706, DOI 10.1172/JCI118468; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; PRYZKLENK K, 1995, CIRCULATION, V92, P1546; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; ROCHASINGH KJ, 1991, J CLIN INVEST, V88, P204, DOI 10.1172/JCI115279; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Schultz JEJ, 1996, CIRC RES, V78, P1100, DOI 10.1161/01.RES.78.6.1100; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SPEECHLYDICK ME, 1994, CIRC RES, V75, P586, DOI 10.1161/01.RES.75.3.586; WEBSTER KA, 1995, J MOL CELL CARDIOL, V27, P453, DOI 10.1016/S0022-2828(08)80041-7; YAMASHITA N, 1994, J CLIN INVEST, V94, P2193, DOI 10.1172/JCI117580; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417	41	328	345	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30945	30951		10.1074/jbc.272.49.30945	http://dx.doi.org/10.1074/jbc.272.49.30945			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388241	hybrid			2022-12-25	WOS:000071640800054
J	Lee, FJS; Huang, CF; Yu, WL; Buu, LM; Lin, CY; Huang, MC; Moss, J; Vaughan, M				Lee, FJS; Huang, CF; Yu, WL; Buu, LM; Lin, CY; Huang, MC; Moss, J; Vaughan, M			Characterization of an ADP-ribosylation factor-like 1 protein in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; PHOSPHOLIPASE-D ACTIVITY; CHOLERA-TOXIN; GOLGI MEMBRANES; NUCLEOTIDE-BINDING; ARF PROTEINS; FACTOR-I; SELECTIVE AMPLIFICATION; DROSOPHILA-MELANOGASTER; ENDOPLASMIC-RETICULUM	ADP-ribosylation factors (ARFs) are highly conserved similar to 20-kDa guanine nucleotide-binding proteins that enhance the ADP-ribosyltransferase activity of cholera toxin and are believed to participate in vesicular transport in both exocytic and endocytic pathways. Several ARF-like proteins (ARLs) have been cloned from Drosophila, rat, and human; however, the biological functions of ARLs are unknown. We have identified a yeast gene (ARL1) encoding a protein that is structurally related (>60% identical) to human, rat, and Drosophila ARL1. Biochemical analyses of purified recombinant yeast ARL1 (yARL1) protein revealed properties similar to those ARF and ARL1 proteins, including the ability to bind and hydrolyze GTP. Like other ARLs, recombinant yARL1 protein did not stimulate cholera toxin-catalyzed auto-ADP-ribosylation. yARL1 was not recognized by antibodies against mammalian ARLs or yeast ARFs. Anti-yARL1 antibodies did not cross-react with yeast ARFs, but did react with human ARLs. On subcellular fractionation, yARL1, similar to yARF1, was localized to the soluble fraction. The amino terminus of yARL1, like that of ARF, was myristoylated. Unlike Drosophila Arl1, yeast ARL1 was not essential for cell viability. Like rat ARL1, yARL1 might be associated in part with the Golgi complex. However, yARL1 was not required for endoplasmic reticulum-to-Golgi protein transport, and it may offer an opportunity to define an ARL function in another kind of vesicular trafficking, such as the regulated secretory pathway.	Natl Taiwan Univ, Sch Med, Inst Mol Med, Taipei 10764, Taiwan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Taiwan University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lee, FJS (corresponding author), Natl Taiwan Univ, Sch Med, Inst Mol Med, 7 Chung Shan S Rd, Taipei 10764, Taiwan.			LEE, FANG-JEN/0000-0002-2167-2426; HUANG, MIN-CHUAN/0000-0002-0704-3447				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BALCH WE, 1992, J BIOL CHEM, V267, P13053; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; LEE FJS, 1994, J BIOL CHEM, V269, P20931; LEE FJS, 1992, J BIOL CHEM, V267, P24441; Lee FJS, 1997, MOL BIOCHEM PARASIT, V87, P217, DOI 10.1016/S0166-6851(97)00061-3; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1994, J BIOL CHEM, V269, P21555; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Lowe SL, 1996, J CELL SCI, V109, P209; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; MURTAGH JJ, 1993, BIOCHEMISTRY-US, V32, P6011, DOI 10.1021/bi00074a012; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; OSSIG R, 1995, EMBO J, V14, P3645, DOI 10.1002/j.1460-2075.1995.tb00034.x; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Schurmann A, 1995, J BIOL CHEM, V270, P30657, DOI 10.1074/jbc.270.51.30657; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON SM, 1992, J BIOL CHEM, V267, P3922; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TSAI SC, 1993, J BIOL CHEM, V268, P10820; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WEISS O, 1989, J BIOL CHEM, V264, P21066; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; WHITNEY JA, 1995, CELL, V83, P703; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	78	68	72	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30998	31005		10.1074/jbc.272.49.30998	http://dx.doi.org/10.1074/jbc.272.49.30998			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388248	hybrid			2022-12-25	WOS:000071640800061
J	Yamamoto, T; Horikoshi, M				Yamamoto, T; Horikoshi, M			Novel substrate specificity of the histone acetyltransferase activity of HIV-1-Tat interactive protein Tip60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION; YEAST; ACTIVATION; SINGLE; GCN5P; GENES	Tip60, originally isolated as an HIV-1-Tat interactive protein, contains an evolutionarily conserved domain with yeast silencing factors, We demonstrate here direct biochemical evidence that this domain of Tip60 has histone acetyltransferase activity, The purified recombinant effectively acetylates H2A, H3, and H4 but not H2B of core histone mixtures, This substrate specificity has not been observed among histone acetyltransferases analyzed to date. These results indicate that Tip60 is a histone acetyltransferase with a novel property, suggesting that Tip60 and its related factors may introduce a distinct alteration on chromatin.	Univ Tokyo, Inst Mol & Cellular Biol, Dept Cellular Biol, Dev Biol Lab,Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Horikoshi, M (corresponding author), Univ Tokyo, Inst Mol & Cellular Biol, Dept Cellular Biol, Dev Biol Lab,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.		Yamamoto, Tohru/A-3801-2012	Yamamoto, Tohru/0000-0002-1652-0233				Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yamamoto T, 1997, GENES CELLS, V2, P245, DOI 10.1046/j.1365-2443.1997.1180316.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	24	198	201	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30595	30598		10.1074/jbc.272.49.30595	http://dx.doi.org/10.1074/jbc.272.49.30595			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388189	hybrid			2022-12-25	WOS:000071640800002
J	Yamasaki, K; Daiho, T; Saino, T; Kanazawa, T				Yamasaki, K; Daiho, T; Saino, T; Kanazawa, T			Modification of histidine 5 in sarcoplasmic reticulum Ca2+-ATPase by diethyl pyrocarbonate causes strong inhibition of formation of the phosphoenzyme intermediate from inorganic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITE; CA-2+-DEPENDENT CONFORMATIONAL CHANGE; ADENOSINE-TRIPHOSPHATASE; TIGHT-BINDING; ACTIVE-SITE; HIGH-AFFINITY; CA-2+ PUMP; CALCIUM; VANADATE; PHOSPHORYLATION	Sarcoplasmic reticulum vesicles were modified with diethyl pyrocarbonate (DEPC), a histidine-modifying reagent, Phosphoenzyme formation from P-i in the Ca2+-ATPase (reversal of hydrolysis of the phosphoenzyme intermediate) was almost completely inhibited by this modification, Tight binding of F- and Mg2+ and high affinity binding of vanadate in the presence of Mg2+, both of which produce transition state analogs for phosphoenzyme formation from the magnesium-enzyme-phosphate complex, were also inhibited, Formation of the phosphoenzyme from acetyl phosphate in the forward reaction was only weakly inhibited, but hydrolysis of the phosphoenzyme was strongly inhibited, The enzyme was protected by tight binding of F- and Mg2+ or by high affinity binding of vanadate in the presence of Mg2+ against the DEPC-induced inhibition of phosphoenzyme formation from P-i. The enzyme was also pro tected by tight binding of F- and Mg2+ against the DEPC-induced inhibition of phosphoenzyme hydrolysis, Peptide mapping of the tryptic digests, detection of peptides containing DEPC-modified histidine by UV absorption at 240 nm, amino acid analysis, sequencing, and mass spectrometry showed that His-5 was a single major residue protected by the above transition state analogs against the modification with DEPC, These results indicate that modification of His-Fi with DEPC is responsible for the DEPC induced inhibition of phosphoenzyme formation from P-i and of phosphoenzyme hydrolysis and suggest that His-5 is located in or very close to the catalytic site in the transition state for phosphoenzyme formation from the magnesium-enzyme-phosphate complex and is likely involved in the catalytic process of this reaction step.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 078, Japan	Asahikawa Medical College	Kanazawa, T (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 078, Japan.	kanazawa@asahikawa-med.ac.jp		Saino, Tomoyuki/0000-0001-6360-9516				ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; Christendat D, 1996, BIOCHEMISTRY-US, V35, P4468, DOI 10.1021/bi9525637; COAN C, 1990, J BIOL CHEM, V265, P5376; COFFEY RL, 1975, ARCH BIOCHEM BIOPHYS, V170, P37, DOI 10.1016/0003-9861(75)90095-8; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DEMEIS L, 1982, J BIOL CHEM, V257, P4993; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; INESI G, 1984, J BIOL CHEM, V259, P996; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; Kimura K, 1996, J BIOL CHEM, V271, P28933, DOI 10.1074/jbc.271.46.28933; KOLASSA N, 1979, FEBS LETT, V108, P495, DOI 10.1016/0014-5793(79)80596-7; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundblad RL., 1995, TECHNIQUES PROTEIN M; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MARTINEZAZORIN F, 1995, BIOCHEM J, V309, P499, DOI 10.1042/bj3090499; MARTONOSI A, 1973, COLD SPRING HARB SYM, V37, P455, DOI 10.1101/SQB.1973.037.01.057; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MEDDA P, 1983, EUR J BIOCHEM, V137, P7, DOI 10.1111/j.1432-1033.1983.tb07788.x; Miles E W, 1977, Methods Enzymol, V47, P431; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; PUCELL A, 1971, J BIOL CHEM, V246, P3389; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; REITHMEIER RAF, 1981, J BIOL CHEM, V256, P5957; Saino T, 1997, J BIOL CHEM, V272, P21142, DOI 10.1074/jbc.272.34.21142; SKERJANC IS, 1993, FEBS LETT, V336, P168, DOI 10.1016/0014-5793(93)81633-B; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; TENU JP, 1976, J BIOL CHEM, V251, P4322; TONG SW, 1977, BIOCHEM BIOPH RES CO, V74, P1242, DOI 10.1016/0006-291X(77)91651-5; VERMA AK, 1988, J BIOL CHEM, V263, P14152; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; YAMASAKI K, 1994, J BIOL CHEM, V269, P4129; YAMASAKI K, 1991, J BIOCHEM, V110, P915, DOI 10.1093/oxfordjournals.jbchem.a123689; YU BP, 1974, BIOCHEMISTRY-US, V13, P5083, DOI 10.1021/bi00722a004	51	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30627	30636		10.1074/jbc.272.49.30627	http://dx.doi.org/10.1074/jbc.272.49.30627			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388197	hybrid			2022-12-25	WOS:000071640800010
J	Zhang, ZX; Jones, S; Hagood, JS; Fuentes, NL; Fuller, GM				Zhang, ZX; Jones, S; Hagood, JS; Fuentes, NL; Fuller, GM			STAT3 acts as a co-activator of glucocorticoid receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHASE RESPONSE FACTOR; NF-KAPPA-B; TRANSCRIPTION FACTOR; INTERLEUKIN-6 RECEPTOR; FUNCTIONAL ANTAGONISM; PROTEIN-INTERACTION; HORMONE RECEPTORS; DNA-BINDING; GENE	Interleukin 6 (IL-6) and glucocorticoids are important mediators of inflammatory and immunological responses. Glucocorticoids are known to synergistically enhance IL-B-mediated cellular responses. We now show that IL-6 also has a synergistic effect upon glucocorticoid signaling, In particular, IL-6-activated STAT3 associates with ligand-bound glucocorticoid receptor to form a transactivating/signaling complex, which can function through either an IL-6-responsive element or a glucocorticoid-responsive element. These findings reveal a new level of interaction between these two crucial signaling cascades and indicate that activated STAT3 can also act as a transcriptional co-activator without direct association with its DNA binding motif.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pediat, Div Pulm, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Fuller, GM (corresponding author), Univ Alabama, Dept Cell Biol, BHSB Suite 680, Birmingham, AL 35294 USA.		Jones, Simon Arnett/Q-7017-2018	Jones, Simon Arnett/0000-0001-7297-9711; Zhang, Zhixin/0000-0003-3924-1082				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAUMANN H, 1990, J BIOL CHEM, V265, P20390; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Darnell JE, 1996, P NATL ACAD SCI USA, V93, P6221, DOI 10.1073/pnas.93.13.6221; DOBNER PR, 1981, P NATL ACAD SCI-BIOL, V78, P2230, DOI 10.1073/pnas.78.4.2230; Duncan SA, 1997, DEV DYNAM, V208, P190, DOI 10.1002/(SICI)1097-0177(199702)208:2<190::AID-AJA6>3.0.CO;2-D; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMAI E, 1993, J BIOL CHEM, V268, P5353; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; NAKAJIMA K, 1996, EMBO J, V15, P3051; NESBITT JE, 1992, MOL BIOL CELL, V3, P103, DOI 10.1091/mbc.3.1.103; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; PIETZKO D, 1993, J BIOL CHEM, V268, P4250; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STAHL N, 1995, SCIENCE, V267, P5; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Zhang ZX, 1997, BIOCHEM BIOPH RES CO, V237, P90, DOI 10.1006/bbrc.1997.7082; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	47	187	188	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30607	30610		10.1074/jbc.272.49.30607	http://dx.doi.org/10.1074/jbc.272.49.30607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388192	hybrid			2022-12-25	WOS:000071640800005
J	Couet, J; Sargiacomo, M; Lisanti, MP				Couet, J; Sargiacomo, M; Lisanti, MP			Interaction of a receptor tyrosine kinase, EGF-R, with caveolins - Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MEMBRANE-PROTEIN; CELLS; INTERNALIZATION; LOCALIZATION; PURIFICATION; SEQUENCE; DOMAINS	Caveolin, a 21-24-kDa integral membrane protein, is a principal component of caveolae membranes. We and others have suggested that caveolin functions as a scaffolding protein to organize and concentrate certain caveolin-interacting signaling molecules within caveolae membranes. In this regard, it has been shown that a 20-amino acid membrane-proximal region of the cytosolic NH2-terminal domain of caveolin is sufficient to mediate the interaction of caveolin with signaling proteins, namely G-proteins, Src-Like kinases, eNOS, and H-Ras. This caveolin-derived protein domain has been termed the caveolin scaffolding domain. Binding of the caveolin-scaffolding domain functionally suppresses the activity of G-protein alpha subunits, eNOS, and Src-Like kinases, suggesting that caveolin binding may also play a negative regulatory role in signal transduction. Here, we report the direct interaction of caveolin with a growth factor receptor, EGF-R, a known caveollae-associated receptor tyrosine kinase. Two consensus caveolin binding motifs have been previously defined using phage display technology. One of these motifs is present within the conserved kinase domains of most known receptor tyrosine kinases (termed region IX). We now show that this caveolin binding motif within the kinase domain of the EGF-R can mediate the interaction of the EGF-R with the scaffolding domains of caveolins 1 and 3 but not with caveolin 2, In addition, the scaffolding do mains of caveolins 1 and 3 both functionally inhibit the autophosphorylation of the EGF-R kinase in vitro. Importantly, this caveolin mediated inhibition of the EGF-R kinase could be prevented by the addition of an EGF-R-derived peptide that (i) contains a well conserved caveolin binding motif and (ii) is located within the kinase domain of the EGF-R and most known receptor tyrosine kinases. Similar results were obtained with protein kinase C, a serine/threonine kinase, suggesting that caveolin may function as a general kinase inhibitor, The implications of our results are discussed within the context of caveolae-mediated signal transduction. In this regard, caveolae-coupled signaling might explain how linear signaling pathways can branch and interconnect extensively, forming a signaling module or network.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA; UNIV LAVAL, LAVAL HOSP RES CTR, Ste Foy, PQ G1V 4G5, CANADA; IST SUPER SANITA, DEPT HEMATOL & ONCOL, I-00161 ROME, ITALY	Yeshiva University; Albert Einstein College of Medicine; Laval University; Istituto Superiore di Sanita (ISS)			Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Sargiacomo, Massimo/0000-0003-4040-706X; Couet, Jacques/0000-0001-5409-8689				Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gleizes PE, 1996, EUR J CELL BIOL, V71, P144; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	37	529	545	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30429	30438		10.1074/jbc.272.48.30429	http://dx.doi.org/10.1074/jbc.272.48.30429			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374534	hybrid			2022-12-25	WOS:A1997YH61300066
J	Lally, ET; Kieba, IR; Sato, A; Green, CL; Rosenbloom, J; Korostoff, J; Wang, JF; Shenker, BJ; Ortlepp, S; Robinson, MK; Billings, PC				Lally, ET; Kieba, IR; Sato, A; Green, CL; Rosenbloom, J; Korostoff, J; Wang, JF; Shenker, BJ; Ortlepp, S; Robinson, MK; Billings, PC			RTX toxins recognize a beta 2 integrin on the surface of human target cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTINOBACILLUS-ACTINOMYCETEMCOMITANS LEUKOTOXIN; THURINGIENSIS DELTA-ENDOTOXINS; BRUSH-BORDER MEMBRANE; ALPHA-SUBUNIT; EXPRESSION; LFA-1; DOMAIN; SPECIFICITY; RECEPTORS; HEMOLYSIN	Actinobacillus actinomycetemcomitans leukotoxin and Escherichia coli alpha-hemolysin are RTX toxins that kill human immune cells. We have obtained a monoclonal antibody (295) to a cell surface molecule present on toxin-sensitive HL60 cells that can inhibit cytolysis by both RTX toxins. Utilization of this monoclonal antibody for immunoaffinity purification of detergent-solubilized target cell membranes yielded two polypeptide chains of approximate molecular masses of 100 and 170 kDa. Microsequencing of tryptic peptides from the two proteins showed complete homology with CD11a and CD18, the two subunits of the beta 2 integrin, lymphocyte function-associated antigen 1 (LFA-1). Anti-CD11a and CD18 monoclonal antibodies also inhibited RTX toxin-mediated cytolysis. Direct binding experiments demonstrated the ability of an immobilized RTX to bind LFA-1 heterodimers present in a deter gent lysate of human HL60 target cells. Transfection of CD11a and CD18 integrin genes into a cell line (K562) that is not sensitive to either RTX toxin resulted in LFA-1 expressing cells, KL/4, that were sensitive to both toxins. These experiments identify LFA-1 as a cell surface recep- tor that mediates toxicity of members of this family of pore-forming toxins.	UNIV OHU,SCH DENT MED,DEPT ORAL SURG 1,KORIYAMA,FUKUSHIMA 963,JAPAN; CELLTECH LTD,SLOUGH SL1 4EN,BERKS,ENGLAND	Celltech Group Ltd	Lally, ET (corresponding author), UNIV PENN,LEON LEVY RES CTR ORAL BIOL,4010 LOCUST ST,PHILADELPHIA,PA 19104, USA.		Korostoff, Jonathan/GRO-5722-2022; Korostoff, Jonathan/AAM-1691-2021		NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008239] Funding Source: NIH RePORTER; NIDCR NIH HHS [5 P50 DE08239-10, R01 DE09517-06] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BROGAN JM, 1994, INFECT IMMUN, V62, P501, DOI 10.1128/IAI.62.2.501-508.1994; CARRERA AC, 1988, J IMMUNOL, V141, P1919; CAVALIERI SJ, 1984, MICROBIOL REV, V48, P326, DOI 10.1128/MMBR.48.4.326-343.1984; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; FIGDOR CG, 1990, IMMUNOL TODAY, V11, P277, DOI 10.1016/0167-5699(90)90112-M; HOGG N, 1986, EUR J IMMUNOL, V16, P240, DOI 10.1002/eji.1830160306; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; LALLY ET, 1994, J BIOL CHEM, V269, P31289; LALLY ET, 1989, BIOCHEM BIOPH RES CO, V159, P256, DOI 10.1016/0006-291X(89)92431-5; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LEAR JD, 1995, BBA-BIOMEMBRANES, V1238, P34, DOI 10.1016/0005-2736(95)00086-I; LIAN CJ, 1989, INFECT IMMUN, V57, P3377, DOI 10.1128/IAI.57.11.3377-3382.1989; LO RYC, 1985, INFECT IMMUN, V50, P667, DOI 10.1128/IAI.50.3.667-671.1985; MERRITT EA, 1995, CURR OPIN STRUC BIOL, V5, P165, DOI 10.1016/0959-440X(95)80071-9; MOBLEY HLT, 1991, INFECT IMMUN, V59, P2036, DOI 10.1128/IAI.59.6.2036-2042.1991; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PATTUS F, 1990, EXPERIENTIA, V46, P180; REED JC, 1997, LYMPHOID SYSTEM; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SCHNUR RA, 1990, J IMMUNOL, V144, P4765; SIMPSON DL, 1988, INFECT IMMUN, V56, P1162, DOI 10.1128/IAI.56.5.1162-1166.1988; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STRATHDEE CA, 1989, J BACTERIOL, V171, P916, DOI 10.1128/jb.171.2.916-928.1989; Taichman N S, 1987, Oral Microbiol Immunol, V2, P97, DOI 10.1111/j.1399-302X.1987.tb00270.x; TAICHMAN NS, 1984, J PERIODONTAL RES, V19, P133, DOI 10.1111/j.1600-0765.1984.tb00802.x; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; 1987, LEUC TYP, V3	41	212	219	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30463	30469		10.1074/jbc.272.48.30463	http://dx.doi.org/10.1074/jbc.272.48.30463			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374538	hybrid			2022-12-25	WOS:A1997YH61300070
J	Weyman, CM; Wolfman, A				Weyman, CM; Wolfman, A			Oncogenic Ras-induced secretion of a novel inhibitor of skeletal myoblast differentiation	ONCOGENE			English	Article						myoblast; differentiation; inhibition; oncogenic Ras	FIBROBLAST GROWTH-FACTOR; PROTEIN-KINASE KINASE; MYOGENIC DIFFERENTIATION; CELL-CYCLE; MUSCLE DIFFERENTIATION; EPITHELIAL-CELLS; G1 PHASE; N-RAS; EXPRESSION; INDUCTION	Expression of oncogenic H-Ras in 23A2 myoblasts (A2:H-Ras cells) is sufficient to induce both a transformed phenotype and a differentiation-defective phenotype, Because oncogenic Pas is known to induce the secretion of several different growth factors involved in maintaining the transformed phenotype of both fibroblast and epithelial cells, we explored the possibility that expression of oncogenic Ras in 23A2 myoblasts might lead to the secretion of a factor which inhibits differentiation, The differentiation of 23A2 myoblasts was inhibited (i) by coculture with an equal number of A2:H-Ras cells, (ii) by culture with an equal number of A2:H-Ras cells in the same tissue culture medium on an insert which allowed equilibration of molecules smaller than I micron, and (iii) by culture in media previously conditioned by A2:H-Ras cells, Similar results were obtained when 23A2 myoblasts expressing oncogenic N-Ras were substituted for A2:H-Ras cells in each assay, No inhibition of differentiation was observed, however, when differentiation-defective E1A-expressing 23A2 cells or C3H10T1/2 fibroblasts were substituted for A2:H-Ras cells, The differentiation inhibitor(s) in media conditioned by A2:K-Ras cells is heat stable, larger than 3 kD, and sensitive to the non-specific growth factor antagonist, suramin, Western analyses failed to detect either FGF-2 or TGF beta (the known inhibitors of myoblast differentiation) in media conditioned by A2:H-Ras cells, Furthermore, while FGF-2 is a potent activator of MAP kinase and TGF beta is a potent inhibitor of mink lung epithelial cell (CCL64) growth, conditioned media from A2:H-Ras cells does not activate MAP kinase and does not inhibit the growth of CCL64 cells. These results indicate that expression of oncogenic Pas induces the secretion of a novel inhibitor of skeletal myoblast differentiation, Furthermore, these results are the first to implicate an autocrine/paracrine mechanism in the inhibition of differentiation by oncogenic Ras.			Weyman, CM (corresponding author), CLEVELAND CLIN FDN,DEPT CELL BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049652, R55GM049652] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49652] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Berkowitz EA, 1996, ONCOGENE, V12, P1991; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; DAWSON TP, 1995, CANCER RES, V55, P915; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GIOVANNI C, 1995, BRIT J CANCER, V72, P1224; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LATHROP B, 1985, J CELL BIOL, V101, P2194, DOI 10.1083/jcb.101.6.2194; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; PIRONIN M, 1992, INT J CANCER, V51, P908; RAK J, 1995, CANCER RES, V55, P4575; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SCHRELL UMH, 1995, J NEUROSURG, V82, P600, DOI 10.3171/jns.1995.82.4.0600; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VISSCHER DA, 1996, ADV ONCOBIOLOGY; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; WEYMAN CM, 1996, ADV ONCOBIOLOGY	37	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2521	2528		10.1038/sj.onc.1201423	http://dx.doi.org/10.1038/sj.onc.1201423			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399640	Bronze			2022-12-25	WOS:A1997YG73200002
J	Cao, GP; Garcia, CK; Wyne, KL; Schultz, RA; Parker, KL; Hobbs, HH				Cao, GP; Garcia, CK; Wyne, KL; Schultz, RA; Parker, KL; Hobbs, HH			Structure and localization of the human gene encoding SR-BI/CLA-1 - Evidence for transcriptional control by steroidogenic factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CHAIN-CLEAVAGE ENZYME; GLYCOPROTEIN-IV CD36; B SCAVENGER RECEPTOR; MEMBRANE-PROTEIN; SR-BI; EXPRESSION CLONING; NUCLEAR RECEPTOR; PROMOTER REGION; LIMP-II	The scavenger receptor, class B, type 1 receptor (SR-BI) mediates the selective transport of lipids from high density lipoprotein to cells. We describe the structure and subchromosomal location of human SR-BI and provide evidence that it is regulated by the transcription factor, steroidogenic factor 1 (SF-1). SR-BI resides on chromosome 12q24.2-qter, spans similar to 75 kilobase pairs, and contains 13 exons. RNA blot analysis of human tissues reveals an expression pattern similar to that described previously for rodents with the highest levels of mRNA in the adrenal gland, ovary, and liver. Unlike rodents, human SR-BI was expressed at high levels in the placenta. The transcription start site for SR-BI was mapped, and DNA sequence analysis revealed a binding site for SF-1 in the proximal 5'-flanking sequence. SF-1, an orphan member of the nuclear hormone receptor gene family, plays a key role in the regulation of steroidogenesis and is expressed at high levels in steroidogenic tissues. SF-1 binds to the SR-BI promoter in a sequence-specific manner, and efficient transcription from this promoter in adrenocortical Y1 cells is dependent on an intact SF-1 site. These data extend our understanding of SF-1 function within steroidogenic tissues and suggest that SR-BI, which serves to supply selected tissues with lipoprotein-derived lipids, is part of the repertoire of SF-1-responsive genes involved in steroidogenesis.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; AKASAKI K, 1994, J BIOCHEM, V116, P670; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BAKKE M, 1995, ENDOCR RES, V21, P509, DOI 10.3109/07435809509030468; Brown M S, 1979, Recent Prog Horm Res, V35, P215; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; CALVO D, 1993, J BIOL CHEM, V268, P18929; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; CARR BR, 1980, ENDOCRINOLOGY, V107, P1034, DOI 10.1210/endo-107-4-1034; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FERNANDEZRUIZ E, 1993, GENOMICS, V17, P759, DOI 10.1006/geno.1993.1401; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GLASS C, 1985, J BIOL CHEM, V260, P744; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; GREENWALT DE, 1992, BLOOD, V80, P1105; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; HONDA S, 1993, J BIOL CHEM, V268, P7494; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; KENNEY DS, 1995, MOL ENDOCRINOL, V9, P1091; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Mesiano S, 1997, ENDOCR REV, V18, P378, DOI 10.1210/er.18.3.378; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MOUW AR, 1989, J BIOL CHEM, V264, P1305; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NOGUCHI K, 1993, BIOCHEM BIOPH RES CO, V192, P88, DOI 10.1006/bbrc.1993.1385; OHASHI M, 1981, ENDOCRINOLOGY, V109, P783, DOI 10.1210/endo-109-3-783; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; RICE DA, 1990, J BIOL CHEM, V265, P11713; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SAVILL J, 1991, CHEST S, V99, P7; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANG YL, 1994, J BIOL CHEM, V269, P6011; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; TAYLOR KT, 1993, GENE, V133, P205, DOI 10.1016/0378-1119(93)90639-K; Tonk V, 1996, AM J MED GENET, V61, P16, DOI 10.1002/(SICI)1096-8628(19960102)61:1<16::AID-AJMG3>3.0.CO;2-V; VEGA MA, 1991, J BIOL CHEM, V266, P16818; Webb NR, 1997, J LIPID RES, V38, P1490	59	218	230	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33068	33076		10.1074/jbc.272.52.33068	http://dx.doi.org/10.1074/jbc.272.52.33068			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407090	hybrid			2022-12-25	WOS:000071182900051
J	Miller, CA				Miller, CA			Expression of the human aryl hydrocarbon receptor complex in yeast - Activation of transcription by indole compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; HEAT-SHOCK PROTEIN; AH RECEPTOR; SACCHAROMYCES-CEREVISIAE; DIOXIN RECEPTOR; CELLS; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; INDUCTION; SYSTEM; ARNT	The human aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator protein (ARNT) were coexpressed in the yeast Saccharomyces cerevisiae to create a system for the study of this heterodimeric transcription factor. Specific transcriptional activation mediated by AHR/ARNT heterodimer, which is a functional indicator of receptor expression, was assessed by beta-galactosidase activity produced from a reporter plasmid, Yeast expressing AHR and ARNT displayed constitutive transcriptional activity that was not augmented by addition of ABR agonists in strains that required exogenous tryptophan for viability. In contrast, strains with an intact pathway for tryptophan biosynthesis responded to AHR agonists and had lower levels of background beta-galactosidase activity. Hexachlorobenzene, benzo(a)pyrene, and beta-naphthoflavone were effective AHR agonists in the yeast system, and had EC50 values of 200, 40, and 20 nM, respectively, for beta-galactosidase activity induction. Tryptophan, indole, indole acetic acid, and tryptamine activated transcription in yeast coexpressing AHR and ARNT (EC50 values similar to 300 mu M). Indole-3-carbinol was an exceptionally potent AHR agonist (EC50 similar to 10 mu M) in yeast. This yeast system is useful for the study of AHR/ARNT protein complexes, and may be generally applicable to the investigation of other multiprotein complexes.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Environm Hlth Sci, New Orleans, LA 70112 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Ctr Bioenvironm Res, New Orleans, LA 70112 USA	Tulane University; Tulane University	Miller, CA (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Environm Hlth Sci, New Orleans, LA 70112 USA.	rellim@mailhost.tcs.tulane.edu	Miller, Charles A/I-3978-2019	Miller, Charles A/0000-0003-0644-7455	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P20ES006435] Funding Source: NIH RePORTER; NIEHS NIH HHS [P20 ES06435-01] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; CHEN HS, 1994, J BIOL CHEM, V269, P27554; Chen I, 1996, BIOCHEM PHARMACOL, V51, P1069, DOI 10.1016/0006-2952(96)00060-3; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; GIELEN JE, 1972, J BIOL CHEM, V247, P7591; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILLNER M, 1985, MOL PHARMACOL, V28, P357; HAHN ME, 1989, ARCH BIOCHEM BIOPHYS, V270, P344, DOI 10.1016/0003-9861(89)90037-4; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kaiser C., 1994, METHODS YEAST GENETI; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; Kleman M, 1996, BIOL CHEM, V377, P741; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Ma Q, 1997, J BIOL CHEM, V272, P8878; MILLER CA, 1993, MOL CELL BIOL, V13, P5360, DOI 10.1128/MCB.13.9.5360; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Rannug U, 1995, CHEM BIOL, V2, P841, DOI 10.1016/1074-5521(95)90090-X; Rowlands JC, 1996, MOL PHARMACOL, V50, P538; SADEK CM, 1994, J BIOL CHEM, V269, P16067; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SHIMOSAKA M, 1991, J FERMENT BIOENG, V72, P485, DOI 10.1016/0922-338X(91)90061-K; Sindhu RK, 1996, BIOCHEM PHARMACOL, V52, P1883, DOI 10.1016/S0006-2952(97)81491-8; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; YAMAGUCHI Y, 1995, BIOCHEM PHARMACOL, V50, P1295, DOI 10.1016/0006-2952(95)02016-6; [No title captured]	38	114	120	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32824	32829		10.1074/jbc.272.52.32824	http://dx.doi.org/10.1074/jbc.272.52.32824			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407059	hybrid			2022-12-25	WOS:000071182900020
J	Baek, SH; Kwak, JY; Lee, SH; Lee, T; Ryu, SH; Uhlinger, DJ; Lambeth, JD				Baek, SH; Kwak, JY; Lee, SH; Lee, T; Ryu, SH; Uhlinger, DJ; Lambeth, JD			Lipase activities of p37, the major envelope protein of vaccinia virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE ACTIVATION; PHOSPHOLIPASE-D; DIACYLGLYCEROL KINASE; MEMBRANE-FUSION; INHIBITION; IDENTIFICATION; POLYPEPTIDE; MECHANISM; VESICLES; SYSTEM	p37, the major protein of the extracellular enveloped form of vaccinia virus, is involved in the biogenesis of the viral double membrane and in egress of virus from the cell, p37 was expressed as a glutathione S-transferase fusion protein and was purified to homogeneity by silver staining using glutathione-agarose, Sephacryl S-200, and DEAE-cellulose chromatography, Incubation of p37 with phosphatidylcholine labeled in the fatty acyl side chains resulted in the production of multiple lipid products that were identified by thin layer chromatography and mass spectrometry as diacylglycerol, free fatty acid, monoacylglycerol, and lysophosphatidylcholine, Lipid-metabolizing activities colocalized with p37-containing fractions throughout the chromatographic steps, p37 also metabolized phosphatidylethanolamine efficiently, but it had less activity toward phosphatidylinositol and little or no activity toward phosphatidylserine, The purified enzyme also metabolized triacylglycerol to diacylglycerol but was inactive toward sn-1,2-diacylglycerol. p37 was also expressed in insect cells as a poly-His fusion protein; cell lysates and partially purified proteins also generated products expected from phospholipase C and A activities, Thus, p37 is a broad specificity lipase with phospholipase C, phospholipase A, and triacylglycerol lipase activities.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Emory University; Pohang University of Science & Technology (POSTECH)	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.			Ryu, Sung Ho/0000-0003-0913-3048	NCI NIH HHS [CA46508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLASCO R, 1991, J VIROL, V65, P5910, DOI 10.1128/JVI.65.11.5910-5920.1991; BRADFORD PG, 1986, BIOCHEM J, V239, P97, DOI 10.1042/bj2390097; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; Cao JX, 1997, VIRUS RES, V48, P11, DOI 10.1016/S0168-1702(96)01422-0; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Heller M, 1978, Adv Lipid Res, V16, P267; KARLI UO, 1990, P NATL ACAD SCI USA, V87, P5912, DOI 10.1073/pnas.87.15.5912; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MORORA S, 1995, BIOCHEMISTRY-US, V34, P11062; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; NIEVA JL, 1993, BIOCHEMISTRY-US, V32, P1054, DOI 10.1021/bi00055a009; PAYNE L, 1978, J VIROL, V27, P28, DOI 10.1128/JVI.27.1.28-37.1978; PAYNE LG, 1979, J VIROL, V31, P147, DOI 10.1128/JVI.31.1.147-155.1979; PEREZ L, 1993, VIROLOGY, V194, P28, DOI 10.1006/viro.1993.1231; Ponting CP, 1996, PROTEIN SCI, V5, P914; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; SCHMUTZ C, 1995, VIROLOGY, V213, P19, DOI 10.1006/viro.1995.1542; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P3703, DOI 10.1021/bi00435a012; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; ULAETO D, 1995, J GEN VIROL, V76, P103, DOI 10.1099/0022-1317-76-1-103; VOGEL SS, 1993, J BIOL CHEM, V268, P25764; WAITE M, 1996, BIOCH LIPIDS LIPOPRO, P211; WALSH JP, 1995, J BIOL CHEM, V270, P28647, DOI 10.1074/jbc.270.48.28647; YAMADA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P211; [No title captured]	36	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32042	32049		10.1074/jbc.272.51.32042	http://dx.doi.org/10.1074/jbc.272.51.32042			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405398	hybrid			2022-12-25	WOS:000071108000017
J	Hiraki, Y; Inoue, H; Iyama, K; Kamizono, A; Ochiai, M; Shukunami, C; Iijima, S; Suzuki, F; Kondo, J				Hiraki, Y; Inoue, H; Iyama, K; Kamizono, A; Ochiai, M; Shukunami, C; Iijima, S; Suzuki, F; Kondo, J			Identification of chondromodulin I as a novel endothelial cell growth inhibitor - Purification and its localization in the avascular zone of epiphysical cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CAROTID-ARTERY; PLATELET FACTOR-IV; VASCULARIZED MESENCHYME; ANGIOGENESIS INHIBITOR; TUBULAR MORPHOGENESIS; TUMOR ANGIOGENESIS; CHONDROCYTES; EXPRESSION; INVITRO; NEOVASCULARIZATION	Cartilage is unique among tissues of mesenchymal origin in that it is resistant to vascular invasion due to an intrinsic angiogenic inhibitor, During endochondral bone formation, however, calcified cartilage formed in the center of the cartilaginous bone rudiment allows vascular invasion, which initiates the replacement of cartilage by bone, The transition of cartilage from the angioresistant to the angiogenic status thus plays a key role in bone formation, However, the molecular basis of this phenotypic transition of cartilage has been obscure, We report here purification of an endothelial cell growth inhibitor from a guanidine extract of bovine epiphyseal cartilage, The N-terminal amino acid sequence indicated that the inhibitor was identical to chondromodulin I (ChM-I), a cartilage-specific growth-modulating factor, Purified ChM-I inhibited DNA synthesis and proliferation of vascular endothelial cells as well as tube morphogenesis in vitro, Expression of ChM-I cDNA in COS7 cells indicated that mature ChM-I molecules were secreted from the cells after post-translational modifications and cleavage from the transmembrane precursor at the predicted processing signal, Recombinant ChM-I stimulated DNA synthesis and proteoglycan synthesis of cultured growth plate chondrocytes, but inhibited tube morphogenesis of endothelial cells, In situ hybridization and immunohistochemical studies indicated that ChM-I is specifically expressed in the avascular zone of cartilage in developing bone, but not present in calcifying cartilage, These results suggest a regulatory role of ChM-I in vascular invasion during endochondral bone formation.	Osaka Univ, Fac Dent, Dept Biochem, Suita, Osaka 565, Japan; Kumamoto Univ, Sch Med, Univ Hosp, Dept Surg Pathol, Kumamoto 860, Japan; Mitsubishi Chem Corp, Res Ctr, Yokohama, Kanagawa 227, Japan	Osaka University; Kumamoto University; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical	Hiraki, Y (corresponding author), Osaka Univ, Fac Dent, Dept Biochem, 1-8 Yamadaoka, Suita, Osaka 565, Japan.		Ochiai, Masanori/A-4372-2012; Shukunami, Chisa/G-2887-2019	Ochiai, Masanori/0000-0002-0022-347X; Shukunami, Chisa/0000-0001-5616-6761				ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; Alini M, 1996, DEV BIOL, V176, P124, DOI 10.1006/dbio.1996.9989; AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; BROWN RA, 1987, BONE MINER, V3, P143; BROWN RA, 1992, BONE MINER, V17, P49, DOI 10.1016/0169-6009(92)90709-M; DIMUZIO MT, 1987, J RHEUMATOL, V14, P45; EISENSTEIN R, 1973, AM J PATHOL, V73, P765; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GELB DE, 1990, ENDOCRINOLOGY, V127, P1941, DOI 10.1210/endo-127-4-1941; GOETZ IE, 1985, IN VITRO CELL DEV B, V21, P172, DOI 10.1007/BF02621355; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; HAGIWARA H, 1984, THROMB RES, V33, P363, DOI 10.1016/0049-3848(84)90075-6; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HAYASHI M, 1986, J CELL BIOL, V102, P2302, DOI 10.1083/jcb.102.6.2302; HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5; Hiraki Y, 1996, J BIOL CHEM, V271, P22657, DOI 10.1074/jbc.271.37.22657; HIRAKI Y, 1991, J BONE MINER RES, V6, P1373; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IYAMA K, 1991, ANAT RECORD, V229, P462, DOI 10.1002/ar.1092290405; KANAYASU T, 1989, BIOCHEM BIOPH RES CO, V159, P572, DOI 10.1016/0006-291X(89)90032-6; Kuettner K.E., 1983, SEFER RABIAH, V1, P281; KUETTNER KE, 1976, BIOCHEM BIOPH RES CO, V72, P40, DOI 10.1016/0006-291X(76)90957-8; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MOSES MA, 1992, J CELL BIOL, V119, P475, DOI 10.1083/jcb.119.2.475; MOSES MA, 1991, J CELL BIOCHEM, V47, P230, DOI 10.1002/jcb.240470308; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; NEAME PJ, 1990, J BIOL CHEM, V265, P9628; OHBA Y, 1995, BBA-GEN SUBJECTS, V1245, P1, DOI 10.1016/0304-4165(95)00065-J; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; POOLE AR, 1991, CARTILAGE MOL ASPECT, P179; SCHENK RK, 1968, ACTA ANAT, V69, P1; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; SORGENTE N, 1975, LAB INVEST, V32, P217; SUZUKI F, 1987, METHOD ENZYMOL, V146, P313; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKIGAWA M, 1985, CELL BIOL INT REP, V9, P619, DOI 10.1016/0309-1651(85)90054-2; TAKIGAWA M, 1988, J BONE MINER METAB, V6, P83; TWAL WO, 1994, J BONE MINER RES, V9, P1737; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	46	160	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32419	32426		10.1074/jbc.272.51.32419	http://dx.doi.org/10.1074/jbc.272.51.32419			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405451	hybrid			2022-12-25	WOS:000071108000070
J	Jenkins, GM; Richards, A; Wahl, T; Mao, CG; Obeid, L; Hannun, Y				Jenkins, GM; Richards, A; Wahl, T; Mao, CG; Obeid, L; Hannun, Y			Involvement of yeast sphingolipids in the heat stress response of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEINS; CERAMIDE; STRAINS; DIFFERENTIATION; TREHALOSE; HL-60	A role for sphingolipids in the yeast heat stress response has been suggested by the isolation of suppressors of mutants lacking these lipids, which are unable to grow at elevated temperatures. The current study examines the possible role of sphingolipids in the heat adaptation of yeast cells as monitored by growth and viability studies. The suppressor of long chain base auxotrophy (SLC, strain 7R4) showed a heat-sensitive phenotype that was corrected by transformation with serine palmitoyltransferase. Thus, the deficiency in sphingolipids and not the suppressor mutation was the cause of the heat-sensitive phenotype of the SLC strain 7R4. The ability of sphingolipids to rescue the heat-sensitive phenotype was examined, and two endogenous yeast sphingoid backbones, phytosphingosine and dihydrosphingosine, were found to be most potent in this effect. Next, the effect of heat stress on the levels of the three major classes of sphingolipids was determined. The inositol phosphoceramides showed no change over a 1.5-h time course, However, the four detected species of sphingoid bases increased after 15 min of heat stress from 1.4- to 10.8-fold. The largest increases were seen in two sphingoid bases, C-20 phytosphingosine and C-20 dihydrosphingosine, which increased 6.4- and 10.8-fold over baseline, respectively. At 60 min of heat stress two species of yeast ceramide increased by 9.2- and 10.6-fold over baseline. The increase seen in the ceramides was partially decreased by Fumonisin B1, a ceramide synthase inhibitor. Therefore, heat stress induces accumulation of sphingoid bases and of ceramides, probably through de novo synthesis, Taken together, these results demonstrate that sphingolipids are involved in the yeast heat stress adaptation.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Durham Vet Affairs Geriatr Res & Clin Ctr, Durham, NC 27710 USA	Duke University; Duke University	Hannun, Y (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3355, Durham, NC 27710 USA.			obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOTTIGER T, 1992, EUR J BIOCHEM, V210, P125, DOI 10.1111/j.1432-1033.1992.tb17399.x; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; LESTER RL, 1993, J BIOL CHEM, V268, P845; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; MCALISTER L, 1985, J BIOL CHEM, V260, P5019; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MILLER MJ, 1979, P NATL ACAD SCI USA, V76, P5222, DOI 10.1073/pnas.76.10.5222; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; SHIN DY, 1987, MOL CELL BIOL, V7, P244, DOI 10.1128/MCB.7.1.244; TANAKA H, 1982, BIOCHEM J, V204, P713, DOI 10.1042/bj2040713; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WELLS GB, 1983, J BIOL CHEM, V258, P200; WIEMKEN A, 1990, ANTON LEEUW INT J G, V58, P209, DOI 10.1007/BF00548935; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171	25	251	254	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32566	32572		10.1074/jbc.272.51.32566	http://dx.doi.org/10.1074/jbc.272.51.32566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405471	hybrid			2022-12-25	WOS:000071108000090
J	Jiang, DY; Hatahet, Z; Melamede, RJ; Kow, YW; Wallace, SS				Jiang, DY; Hatahet, Z; Melamede, RJ; Kow, YW; Wallace, SS			Characterization of Escherichia coli endonuclease VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; 5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; APURINIC APYRIMIDINIC SITES; FPG PROTEIN; SUBSTRATE-SPECIFICITY; BASE-EXCISION; DAMAGED DNA; SACCHAROMYCES-CEREVISIAE; G.C->T.A TRANSVERSIONS; IONIZING-RADIATION	Escherichia coli endonuclease VIII (endo VIII) was identified as an enzyme that, like endonuclease III (endo III), removes radiolysis products of thymine including thymine glycol, dihydrothymine, beta-ureidoisobutyric acid, and urea from double-stranded plasmid or phage DNA and cleaves the DNA strand at abasic (AP) sites (Melamede, R. J., Hatahet, Z., Kow, Y. W., Ide., H., and Wallace, S. S. (1994) Biochemistry 33, 1255-1264). Using apparently homogeneous endo Vm protein, we now show that endo MI removes from double-stranded oligodeoxyribonucleotides the stable oxidative products of cytosine, 5-hydroxycytosine and 5-hydroxyuracil. Endo VIII cleaved the damage-containing DNA strand by beta,delta-elimination as does formamidopyrimidine DNA glycosylase (Fpg). Like Fpg, endo VIII also excised the 5'-terminal deoxyribose phosphate from an endonuclease IV (endo TV) pre-incised AP site. Thus, in addition to amino acid sequence homology (Jiang, D., Hatahet, Z., Blaisdell, J., Melamede, R. J., and Wallace, S. S. (1997) J. Bacteriol 179, 3773-3782), endo VIII shares a number of catalytic properties with Fpg. In addition, endo WI specifically bound to oligodeoxynucleotides containing a reduced AP site with a stoichiometry of 1:1 for protein to DNA with an apparent equilibrium dissociation constant of 3.9 nM. Like Fpg and endo III, the DNase I footprint was small with contact sites primarily on the damage-containing strand; unlike Fpg and endo III, the DNA binding of endo VIII to DNA was asymmetric, 3' to the reduced AP site.	Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont	Wallace, SS (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Stafford Hall, Burlington, VT 05405 USA.	swallace@zoo.uvm.edu		Wallace, Susan S./0000-0002-3906-0321	NATIONAL CANCER INSTITUTE [R37CA033657] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA33657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOORSTEIN RJ, 1989, BIOCHEMISTRY-US, V28, P6164, DOI 10.1021/bi00441a007; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; BREIMER LH, 1984, NUCLEIC ACIDS RES, V12, P6359, DOI 10.1093/nar/12.16.6359; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; Cadenas E., 1995, OXIDATIVE STRESS ANT, P1, DOI 10.1007/978-1- 4615-9689-9_1; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; EVANS J, 1993, MUTAT RES, V175, P41; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; GATES FT, 1977, J BIOL CHEM, V252, P2802; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HATAHET Z, 1993, NUCLEIC ACIDS RES, V21, P1563, DOI 10.1093/nar/21.7.1563; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; MOSBAUGH DW, 1982, J BIOL CHEM, V257, P575; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3723; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NOLLING J, 1992, NUCLEIC ACIDS RES, V24, P6501; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; OHANDLEY S, 1995, BIOCHEMISTRY-US, V34, P2528, DOI 10.1021/bi00008a017; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P72, DOI 10.1093/nar/22.1.72; RADMAN M, 1976, J BIOL CHEM, V251, P1438; RoldanArjona T, 1996, NUCLEIC ACIDS RES, V24, P3307, DOI 10.1093/nar/24.17.3307; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; STRNISTE GF, 1975, P NATL ACAD SCI USA, V72, P1997, DOI 10.1073/pnas.72.6.1997; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TCHOU J, 1993, J BIOL CHEM, V268, P26738; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; VERLY WG, 1974, P NATL ACAD SCI USA, V71, P2273, DOI 10.1073/pnas.71.6.2273; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; WALLACE SS, 1997, OXIDATIVE STRESS MOL, P49; WEISS B, 1981, ENZYMES, P203; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	66	138	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32230	32239		10.1074/jbc.272.51.32230	http://dx.doi.org/10.1074/jbc.272.51.32230			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405426	hybrid			2022-12-25	WOS:000071108000045
J	Therien, AG; Goldshleger, R; Karlish, SJD; Blostein, R				Therien, AG; Goldshleger, R; Karlish, SJD; Blostein, R			Tissue-specific distribution and modulatory role of the gamma subunit of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; SODIUM-PUMP; NA/K-ATPASE; PROTEIN; TRANSPORT; OCCLUSION; NA+,K+-ATPASE; PURIFICATION; POLYPEPTIDE; EXPRESSION	The Na,K-ATPase comprises a catalytic alpha subunit and a glycosylated beta subunit. Another membrane polypeptide, gamma, first described by Forbush et al. (Forbush, B., III, Kaplan, J. H., and Hoffman, J. F. (1978) Biochemistry 17, 3667-3676) associates with alpha and beta in purified kidney enzyme preparations. In this study, we have used a polyclonal anti-gamma antiserum to define the tissue specificity and topology of gamma and to address the question of whether gamma has a functional role. The trypsin sensitivity of the amino terminus of the gamma subunit in intact right-side-out pig kidney microsomes has confirmed that it is a type I membrane protein with an extracellular amino terminus. Western blot analysis shows that gamma subunit protein is present only in membranes from kidney tubules (rat, dog, pig) and not those from axolemma, heart, red blood cells, kidney glomeruli, cultured glomerular cells, a,transfected HeLa cells, all derived from the same (rat) species, nor from three cultured cell lines derived from tubules of the kidney, namely NRK-52E (rat), LLC-PK (pig), or MDCK (dog). To gain insight into gamma function, the effects of the anti-gamma serum on the kinetic behavior of rat kidney sodium pumps was examined. The following evidence suggests that gamma stabilizes E(1) conformation(s) of the enzyme and that anti-gamma counteracts this effect: (i) anti-gamma inhibits Na,K-ATPase, and the inhibition increases at acidic pH under which condition the E(2)(K) --> E(1) phase of the reaction sequence becomes more rate-limiting, (ii) the oligomycin-stimulated increase in the level of phosphoenzyme was greater in the presence of anti-gamma indicating that the antibody shifts the E(1) <----><----> E(2)P equilibria toward E(2)P, and (iii) when the Na(+)-ATPase reaction is assayed with the Na(+) concentration reduced to levels (less than or equal to 2 mM) which limit the rate of the E(1) --> --> E(2)P transition, anti-gamma is stimulatory. These observations taken together with evidence that the pig gamma subunit, which migrates as a doublet on polyacrylamide gels, is sensitive to digestion by trypsin, and that Rb(+) ions partially protect it against this effect, indicate that the gamma subunit is a tissue-specific regulator which shifts the steady-state equilibria toward E(1). Accordingly, binding of anti-gamma disrupts alpha beta-gamma interactions and counteracts these modulatory effects of the gamma subunit.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Weizmann Inst Sci, Dept Biochem, IL-76100 Rehovot, Israel	McGill University; Weizmann Institute of Science	Blostein, R (corresponding author), Montreal Gen Hosp, 1650 Cedar Ave,Room L11-132, Montreal, PQ H3G 1A4, Canada.		Therien, Alex/AAS-8437-2021					APPEL HJ, 1990, BIOCHIM BIOPHYS ACTA, V1023, P81; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; BLOSTEIN R, 1968, J BIOL CHEM, V243, P1957; BLOSTEIN R, 1985, J BIOL CHEM, V260, P829; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHOW DC, 1995, J EXP BIOL, V198, P1; COLLINS JH, 1982, BIOCHIM BIOPHYS ACTA, V686, P7, DOI 10.1016/0005-2736(82)90145-6; COLLINS JH, 1987, BIOCHEMISTRY-US, V26, P8665, DOI 10.1021/bi00400a026; Creighton T. E., 1993, PROTEINS STRUCTURES; CYBULSKY AV, 1989, AM J PHYSIOL, V257, pF826, DOI 10.1152/ajprenal.1989.257.5.F826; Daly SE, 1997, J BIOL CHEM, V272, P6341, DOI 10.1074/jbc.272.10.6341; DOUCET A, 1988, KIDNEY INT, V34, P749, DOI 10.1038/ki.1988.245; DOUCET A, 1984, ADV NEPHROL, P87; Dunham PB, 1997, AM J PHYSIOL-CELL PH, V272, pC357, DOI 10.1152/ajpcell.1997.272.2.C357; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; FORBUSH B, 1991, SOC GEN PHY, V46, P211; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; HARDWICKE PMD, 1981, BIOCHEM BIOPH RES CO, V102, P250, DOI 10.1016/0006-291X(81)91514-X; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; Kim JW, 1997, BBA-GENE STRUCT EXPR, V1350, P133, DOI 10.1016/S0167-4781(96)00219-9; KREISBERG JI, 1988, J ELECTRON MICR TECH, V9, P235, DOI 10.1002/jemt.1060090303; MARTIN SS, 1980, BIOCHIM BIOPHYS ACTA, V602, P401, DOI 10.1016/0005-2736(80)90320-X; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; OER E, 1996, BIOCHEMISTRY-US, V35, P6853; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; REPHAELI A, 1986, J BIOL CHEM, V261, P2437; SCHEINERBOBIS G, 1994, BBA-BIOMEMBRANES, V1193, P226, DOI 10.1016/0005-2736(94)90157-0; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Therien A. G., 1997, Biophysical Journal, V72, pA289; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; VASILETS LA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P201, DOI 10.1016/0304-4157(93)90012-D; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WHITE B, 1982, BIOCHIM BIOPHYS ACTA, V688, P685, DOI 10.1016/0005-2736(82)90280-2; YING S, 1992, AM J PHYSIOL, V262, pC1491	40	129	131	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32628	32634		10.1074/jbc.272.51.32628	http://dx.doi.org/10.1074/jbc.272.51.32628			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405479	hybrid			2022-12-25	WOS:000071108000098
J	JahnenDechent, W; Schinke, T; Trindl, A; MullerEsterl, W; Sablitzky, F; Kaiser, S; Blessing, M				JahnenDechent, W; Schinke, T; Trindl, A; MullerEsterl, W; Sablitzky, F; Kaiser, S; Blessing, M			Cloning and targeted deletion of the mouse fetuin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; GROWTH-FACTOR-BETA; INSULIN-RECEPTOR; HUMAN ALPHA-2-HS-GLYCOPROTEIN; ALPHA(2)-MACROGLOBULIN GENE; ALPHA-MACROGLOBULINS; RAT FETUIN; STEM-CELLS; INHIBITOR; MICE	We proposed that the alpha(2)-Heremans Schmid glycoprotein/fetuin family of serum proteins inhibits unwanted mineralization. To test this hypothesis in animals, we cloned the mouse fetuin gene and generated mice lacking fetuin. The gene consists of seven exons and six introns. The cystatin-like domains D1 and D2 of mouse fetuin are encoded by three exons each, whereas a single terminal exon encodes the carboxyl-terminal domain D3. The promoter structure is well conserved between rat and mouse fetuin genes within the regions shown to bind transcription factors in the rat system. Expression studies demonstrated that mice homozygous for the gene deletion lacked fetuin protein and that mice heterozygous for the null mutation produced roughly half the amount of fetuin protein produced by wild-type mice. Fetuin-deficient mice were fertile and showed no gross anatomical abnormalities. However, the serum inhibition of apatite formation was compromised in these mice as well as in heterozygotes. In addition, some homozygous fetuin-deficient female ex-breeders developed ectopic microcalcifications in soft tissues. These results corroborate a role for fetuin in serum calcium homeostasis. The fact that generalized ectopic calcification did not occur in fetuin-deficient mice proves that additional inhibitors of phase separation exist in serum.	BOEHRINGER INGELHEIM FORSCHERGRP, SFB 311, D-55101 MAINZ, GERMANY; UCL, SCH MED, DEPT MED, LONDON W1P 8BT, ENGLAND	Boehringer Ingelheim; University of London; University College London; UCL Medical School	JahnenDechent, W (corresponding author), UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, DUESBERGWEG 6, D-55099 MAINZ, GERMANY.		Sablitzky, Fred/A-2276-2011; Jahnen-Dechent, Willi/A-7608-2011	Sablitzky, Fred/0000-0001-9718-1546; Jahnen-Dechent, Willi/0000-0003-1315-4407				AKHOUNDI C, 1994, J BIOL CHEM, V269, P15925; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; BLUMENTHAL NC, 1975, CALC TISS RES, V18, P81, DOI 10.1007/BF02546228; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; Demetriou M, 1996, J BIOL CHEM, V271, P12755, DOI 10.1074/jbc.271.22.12755; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Dziegielewska K., 1995, MOL BIOL INTELLIGENC; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FALQUERHO L, 1991, GENE, V98, P209, DOI 10.1016/0378-1119(91)90175-B; FALQUERHO L, 1992, NUCLEIC ACIDS RES, V20, P1983, DOI 10.1093/nar/20.8.1983; GARNETT J, 1990, BIOCHEM J, V266, P863; HAYASE T, 1992, BIOCHEMISTRY-US, V31, P4915, DOI 10.1021/bi00135a024; HEERZE LD, 1992, J BIOL CHEM, V267, P25810; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOGAN BL, 1995, MANIPULATING MOUSE E; JAHNENDECHENT W, 1994, EUR J BIOCHEM, V226, P59, DOI 10.1111/j.1432-1033.1994.tb20026.x; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P502; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; KOIDE T, 1988, THROMB RES, P91; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KUMBLA L, 1991, FASEB J, V5, P2971, DOI 10.1096/fasebj.5.14.1721594; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LECAM A, 1992, CELL, V68, P8, DOI 10.1016/0092-8674(92)90201-M; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCKAY PAZ, 1996, MOL CELL BIOL, V16, P4024; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; Nawratil P, 1996, J BIOL CHEM, V271, P31735, DOI 10.1074/jbc.271.49.31735; Neuman W. F., 1980, FUNDAMENTAL CLIN BON, P83; Ohnishi T, 1997, EUR J BIOCHEM, V243, P753, DOI 10.1111/j.1432-1033.1997.00753.x; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; RAUTH G, 1992, EUR J BIOCHEM, V204, P523, DOI 10.1111/j.1432-1033.1992.tb16663.x; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAUNDERS NR, 1994, HISTOCHEMISTRY, V102, P457, DOI 10.1007/BF00269578; Schinke T, 1997, FEBS LETT, V412, P559, DOI 10.1016/S0014-5793(97)00827-2; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SCHULTZE HE, 1962, NATURWISSENSCHAFTEN, V49, P15, DOI 10.1007/BF00632835; SELBY PB, 1987, STAIN TECHNOL, V62, P143, DOI 10.3109/10520298709107984; Sladek FM, 1992, CURR OPIN GENET DEV, V2, P256, DOI 10.1016/S0959-437X(05)80282-5; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; SRINIVAS PR, 1993, MOL ENDOCRINOL, V7, P1445, DOI 10.1210/me.7.11.1445; SULLENBARGER BA, 1995, BLOOD, V86, P135, DOI 10.1182/blood.V86.1.135.bloodjournal861135; Sumner C, 1996, J NEUROVIROL, V2, P87, DOI 10.3109/13550289609146542; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; Webb DJ, 1996, J BIOL CHEM, V271, P24982, DOI 10.1074/jbc.271.40.24982; WESTWOOD SA, 1988, ELECTROPHORESIS, V9, P432, DOI 10.1002/elps.1150090816; YAMAMOTO K, 1993, J BIOL CHEM, V268, P17750; YANG FM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P149, DOI 10.1016/0167-4781(92)90522-2	54	211	224	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31496	31503		10.1074/jbc.272.50.31496	http://dx.doi.org/10.1074/jbc.272.50.31496			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395485	hybrid			2022-12-25	WOS:A1997YL41900044
J	Klinge, CM; Silver, BF; Driscoll, MD; Sathya, G; Bambara, RA; Hilf, R				Klinge, CM; Silver, BF; Driscoll, MD; Sathya, G; Bambara, RA; Hilf, R			Chicken ovalbumin upstream promoter transcription factor interacts with estrogen receptor, binds to estrogen response elements and half-sites, and inhibits estrogen-induced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; MONOCLONAL-ANTIBODIES; NUCLEAR RECEPTORS; COUP-TF; POLYCLONAL ANTIBODIES; HORMONE RECEPTORS; ORPHAN RECEPTORS; DNA; PURIFICATION; SUPERFAMILY	Chicken ovalbumin upstream promoter-transcription factor (COUP-TF) was identified as a low abundance protein in bovine uterus that co-purified with estrogen receptor (ER) in a ligand-independent manner and was separated from the ER by its lower retention on estrogen response element (ERE)-Sepharose. In gel mobility shift assays, COUP-TF bound as an apparent dimer to ERE and ERE half-sites. COUP-TF bound to an ERE half-site with high affinity, K-d = 1.24 nM. In contrast, ER did not bind a single ERE half-site. None of the class II nuclear receptors analyzed, i.e. retinoic acid receptor, retinoid X receptor, thyroid receptor, peroxisome proliferator-activated receptor, or vitamin D receptor, were constituents of the COUP-TF.DNA binding complex detected in gel mobility shift assays. Direct interaction of COUP-TF with ER was indicated by GST ''pull-down'' and co-immunoprecipitation assays. The nature of the ER ligand influenced COUP-TF-ERE half-site binding. When ER was liganded by the antiestrogen 4-hydroxytamoxifen (4-OHT), COUP-TF-half-site interaction decreased. Conversely, COUP-TF transcribed and translated in vitro enhanced the ERE binding of purified estradiol (E-2)-liganded ER but not 4-OHT-liganded ER. Co-transfection of ER-expressing MCF-7 human breast cancer cells with an expression vector for COUP-TFI resulted in a dose-dependent inhibition of E-2-induced expression of a luciferase reporter gene under the control of three tandem copies of EREc38. The ability of COUP-TF to bind specifically to EREs and half-sites, to interact with ER, and to inhibit E-2-induced gene expression suggests COUP-TF regulates ER action by both direct DNA binding competition and through protein-protein interactions.	UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester	Klinge, CM (corresponding author), UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM & MOL BIOL,LOUISVILLE,KY 40292, USA.			Klinge, Carolyn/0000-0002-3358-4378	NICHD NIH HHS [HD24459] Funding Source: Medline; NIEHS NIH HHS [1P20 ES06832-12] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P20ES006832] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBONDANZA C, 1993, STEROIDS, V58, P4, DOI 10.1016/0039-128X(93)90011-B; Anolik JH, 1996, J STEROID BIOCHEM, V59, P413, DOI 10.1016/S0960-0760(96)00129-X; ANOLIK JH, 1995, BIOCHEMISTRY-US, V34, P2511, DOI 10.1021/bi00008a015; ANOLIK JH, 1993, J STEROID BIOCHEM, V46, P713, DOI 10.1016/0960-0760(93)90312-K; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BAGCHI MK, 1987, MOL CELL BIOL, V7, P4151, DOI 10.1128/MCB.7.12.4151; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Driscoll MD, 1996, J STEROID BIOCHEM, V58, P45, DOI 10.1016/0960-0760(96)00015-5; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; Fu GK, 1996, J BIOL CHEM, V271, P19599, DOI 10.1074/jbc.271.32.19599; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Graumann K, 1996, J STEROID BIOCHEM, V57, P293, DOI 10.1016/0960-0760(95)00274-X; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HERSCROFT NJ, 1997, BIOTECHNIQUES, V22, P224; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOOPES BC, 1992, J BIOL CHEM, V267, P11589; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IKEDA M, 1994, BIOCHEM MOL BIOL INT, V33, P447; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KATO S, 1995, MOL CELL BIOL, V15, P5858; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Klinge CM, 1997, NUCLEIC ACIDS RES, V25, P1903, DOI 10.1093/nar/25.10.1903; KLINGE CM, 1992, J STEROID BIOCHEM, V43, P249, DOI 10.1016/0960-0760(92)90159-G; Klinge CM, 1996, J STEROID BIOCHEM, V57, P51, DOI 10.1016/0960-0760(95)00246-4; Klinge CM, 1996, STEROIDS, V61, P278, DOI 10.1016/0039-128X(95)00219-G; KLINGE CM, 1992, CANCER RES, V52, P1073; KLINGE CM, 1987, CANCER RES, V47, P2852; KLINGE CM, 1992, ONCOL RES, V4, P1073; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lin BC, 1997, J BIOL CHEM, V272, P9860; LUDWIG LB, 1990, MOL ENDOCRINOL, V4, P1027, DOI 10.1210/mend-4-7-1027; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKS MS, 1992, MOL ENDOCRINOL, V6, P219, DOI 10.1210/me.6.2.219; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; ONATE SA, 1995, SCIENCE, V270, P1354; PAVLIK EJ, 1976, J STEROID BIOCHEM, V7, P357, DOI 10.1016/0022-4731(76)90095-9; PEALE FV, 1988, P NATL ACAD SCI USA, V85, P1038, DOI 10.1073/pnas.85.4.1038; PEALE FV, 1989, BIOCHEMISTRY-US, V28, P8671, DOI 10.1021/bi00448a001; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RITCHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857, DOI 10.1093/nar/18.23.6857; Sambrook J., 2002, MOL CLONING LAB MANU; SAUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRAISH A, 1989, ENDOCRINOLOGY, V125, P172, DOI 10.1210/endo-125-1-172; TRAISH AM, 1990, STEROIDS, V55, P551, DOI 10.1016/0039-128X(90)90051-C; TRAISH AM, 1990, STEROIDS, V55, P196, DOI 10.1016/0039-128X(90)90017-6; TRAISH AM, 1995, STEROIDS, V60, P467, DOI 10.1016/0039-128X(95)00061-T; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; YANG N, 1996, J BIOL CHEM, V271, P5796	71	96	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31465	31474		10.1074/jbc.272.50.31465	http://dx.doi.org/10.1074/jbc.272.50.31465			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395481	hybrid			2022-12-25	WOS:A1997YL41900040
J	Racine-Samson, L; Rockey, DC; Bissell, DM				Racine-Samson, L; Rockey, DC; Bissell, DM			The role of alpha 1 beta 1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; COLLAGEN MATRIX REORGANIZATION; SINUSOIDAL ENDOTHELIAL-CELLS; HUMAN SMOOTH-MUSCLE; RAT-LIVER; MURINE DEVELOPMENT; GENE-EXPRESSION; IN-VITRO; FIBROSIS; LIPOCYTES	An unresolved question in wound contraction concerns the identity of integrins mediating the attachment of tissue myofibroblasts to matrix in the injury site. Previous studies with cell lines have focussed on alpha 1 beta 1 and alpha 2 beta 1, the principal collagen-binding integrins, but have yielded conflicting data. We have examined this issue in wound healing in the liver, isolating the myofibroblast population (activated stellate cells) and quantitating expression of the alpha 1 and alpha 2 integrin subunits during the in vivo injury. Normal stellate cells displayed alpha 1 but no detectable alpha 2. During injury, alpha 1 expression was maintained; alpha 2 became detectable at the mRNA level but at all times was <8% of alpha 1 mRNA. Contraction of collagen lattices, studied with 24-h cultured cells and initiated by endothelin 1, was blocked 70% by anti-alpha 1 and 30% by anti-alpha 2 (both significant, p < 0.05). The inhibition by anti-alpha 2, which was unexpected, was attributable to culture-induced change in integrin expression; both the mRNA and protein for alpha 2 increased strikingly within 24 h of plating stellate cells on a collagen gel. We conclude that alpha 1 beta 1 is the sole integrin utilized by contracting myofibroblasts in vivo. Although alpha 2 beta 1 is capable of mediating contraction, its expression by myofibroblasts occurs largely, if not exclusively, in response to culture.	Univ Calif San Francisco, Dept Med, Gastrointestinal Unit, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Liver Ctr Lab, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Bissell, DM (corresponding author), Univ Calif San Francisco, Dept Med, Gastrointestinal Unit, Box 0538, San Francisco, CA 94110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031198, R37DK031198, P30DK026743, R01DK050574] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 31198, DK 50574, DK 26743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAKOKKO L, 1987, BIOCHEM J, V244, P75, DOI 10.1042/bj2440075; BALLARDINI G, 1988, VIRCHOWS ARCH B, V56, P45, DOI 10.1007/BF02890000; BELKIN VM, 1990, J CELL BIOL, V111, P2159, DOI 10.1083/jcb.111.5.2159; BIENKOWSKI RS, 1978, J BIOL CHEM, V253, P4356; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; Carloni V, 1996, GASTROENTEROLOGY, V110, P1127, DOI 10.1053/gast.1996.v110.pm8613002; CARVER W, 1995, J CELL PHYSIOL, V165, P425, DOI 10.1002/jcp.1041650224; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; COUVELARD A, 1993, AM J PATHOL, V143, P738; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P1233; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; HOUSSET C, 1993, P NATL ACAD SCI USA, V90, P9266, DOI 10.1073/pnas.90.20.9266; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; INGHAM KC, 1989, J BIOL CHEM, V264, P16977; IRLE C, 1980, J SUBMICR CYTOL PATH, V12, P209; IRVING MG, 1984, GASTROENTEROLOGY, V87, P1233; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; KAWADA N, 1992, BIOCHEM J, V285, P367, DOI 10.1042/bj2850367; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KOUNTOURAS J, 1984, BRIT J EXP PATHOL, V65, P305; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MENDRICK DL, 1995, LAB INVEST, V72, P367; MENDRICK DL, 1993, LAB INVEST, V69, P690; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; PINZANI M, 1992, J CLIN INVEST, V90, P642, DOI 10.1172/JCI115905; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; ROCKEY DC, 1992, J SUBMICR CYTOL PATH, V24, P193; ROCKEY DC, 1993, J CLIN INVEST, V92, P1795, DOI 10.1172/JCI116769; Rockey DC, 1996, HEPATOLOGY, V24, P233; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; Skalli O, 1988, MOL CELLULAR BIOL WO, P373; TSUKAMOTO H, 1990, SEMIN LIVER DIS, V10, P56, DOI 10.1055/s-2008-1040457; TURNER DC, 1989, J NEUROSCI, V9, P3287; VOLPES R, 1993, AM J PATHOL, V142, P1483; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wu JE, 1996, DEV DYNAM, V206, P169, DOI 10.1002/(SICI)1097-0177(199606)206:2<169::AID-AJA6>3.0.CO;2-G; WU JE, 1994, DEV DYNAM, V199, P292, DOI 10.1002/aja.1001990405; ZHANG JX, 1994, AM J PHYSIOL, V266, pG624, DOI 10.1152/ajpgi.1994.266.4.G624; ZUTTER MM, 1990, AM J PATHOL, V137, P113	44	141	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30911	30917		10.1074/jbc.272.49.30911	http://dx.doi.org/10.1074/jbc.272.49.30911			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388237	hybrid			2022-12-25	WOS:000071640800050
J	Sagawa, K; Kimura, T; Swieter, M; Siraganian, RP				Sagawa, K; Kimura, T; Swieter, M; Siraganian, RP			The protein-tyrosine phosphatase SHP-2 associates with tyrosine-phosphorylated adhesion molecule PECAM-1 (CD31)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; GROWTH-FACTOR RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; FC-GAMMA-RIIB; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; SH2 DOMAINS; MONOCLONAL-ANTIBODIES; MAST-CELL; IN-VIVO	Aggregation of many cell-surface receptors results in tyrosine phosphorylation of numerous proteins. We previously observed the tyrosine phosphorylation of the platelet/endothelial cell adhesion molecule, PECAM-1 (CD31), after Fc epsilon RI stimulation in rat basophilic leukemia RBL-2H3 cells. Here we found that PECAM-1 was also transiently tyrosine-phosphoryated after adherence of these cells to fibronectin, Similarly aggregation of the T cell receptor on Jurkat cells also induced this tyrosine phosphorylation, The protein-tyrosine phosphatase SHP-2 is a widely expressed cytosolic enzyme with two Src homology 2 (SH2) domains. SHP-2, but not the related protein-tyrosine phosphatase SHP-1, associated with PECAM-1. This association of the two proteins correlated with the extent of the tyrosine phosphorylation of PECAM-1. A fusion protein containing the two SH2 domains of SHP-2 precipitated PECAM-1 from cell lysates and also directly bound to phosphorylated PECAM-1, In immune precipitate phosphatase assays, there was tyrosine dephosphorylation of PECAM-1, Therefore, integrin and immune receptor activation results in tyrosine phosphorylation of PECAM-1 and the binding of the protein-tyrosine phosphatase SHP-2, which could regulate receptor-mediated signaling in cells.	NIDR, Receptors & Signal Transduct Sect, OIIB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Siraganian, RP (corresponding author), NIDR, Receptors & Signal Transduct Sect, OIIB, NIH, Bldg 10,Rm 1N106, Bethesda, MD 20892 USA.	rs53x@nih.gov						Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERMAN ME, 1995, J IMMUNOL, V154, P299; Berman ME, 1996, J IMMUNOL, V156, P1515; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DEFRANCO AL, 1995, SCIENCE, V268, P263, DOI 10.1126/science.7716518; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HUYER G, 1995, BIOCHEMISTRY-US, V34, P1040, DOI 10.1021/bi00003a039; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kimura T, 1996, J BIOL CHEM, V271, P27962, DOI 10.1074/jbc.271.44.27962; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; KIMURA T, 1997, IN PRESS J IMMUNOL, V159; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; Lu TT, 1996, P NATL ACAD SCI USA, V93, P11808, DOI 10.1073/pnas.93.21.11808; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MULLER WA, 1995, J LEUKOCYTE BIOL, V57, P523, DOI 10.1002/jlb.57.4.523; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Murohara T, 1996, J IMMUNOL, V156, P3550; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; SKUBITZ KM, 1994, J IMMUNOL, V152, P5902; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SWIETER M, 1995, J IMMUNOL, V155, P5330; TAN XH, 1993, J BIOL CHEM, V268, P6835; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251	66	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31086	31091		10.1074/jbc.272.49.31086	http://dx.doi.org/10.1074/jbc.272.49.31086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388260	hybrid			2022-12-25	WOS:000071640800073
J	Bi, S; Gavrilova, O; Gong, DW; Mason, MM; Reitman, M				Bi, S; Gavrilova, O; Gong, DW; Mason, MM; Reitman, M			Identification of a placental enhancer for the human leptin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE OBESE GENE; BINDING PROTEIN-ALPHA; OB GENE; TRANSCRIPTION FACTOR; PROMOTER ACTIVITY; HUMAN CHORIOCARCINOMA; ADIPOSE-CELLS; GROWTH-FACTOR; SUBUNIT GENE; FOOD-INTAKE	Leptin is a hormone that regulates metabolic efficiency, energy expenditure, and food intake. Leptin is produced chiefly in adipose cells, but in humans, mRNA encoding leptin is also present in the placenta. Here we elucidate the basis for placental leptin production. The same promoter is used for adipose and placental transcription. An upstream enhancer functions in the JEG-3 and JAR choriocarcinoma cell lines but not in adipocytes or HeLa cells. The minimal positive acting region is 60 base pairs in length. This region is within a MER11 repetitive element, suggesting that human placental expression of leptin is the result of insertion of this element. Binding analyses demonstrated three protein binding sites, designated placental leptin enhancer elements (PLE)1, PLE2, and PLE3. PLE2 binds Sp1. Enhancer activity was reduced by mutation of the PLE1 or PLE3 sites but was unaffected by alteration of PLE2. Proteins binding to PLE3 were present in JEG-3 and human placental nuclear extracts but not in extracts from non-placental sources. Upon triplication, the PLE3 element was a strong enhancer in choriocarcinoma cells but not in HeLa cells. The protein binding to the PLE3 motif appears to be a novel, placenta-specific transcription factor.	NIDDK,DIABET BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Reitman, Marc/B-4448-2013; Gong, Dawei/AAB-4283-2020	Reitman, Marc/0000-0002-0426-9475; bi, sheng/0000-0002-2441-0528				Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAMBERGER AM, 1995, J CLIN ENDOCR METAB, V80, P2021, DOI 10.1210/jc.80.7.2021; Butte NF, 1997, J CLIN ENDOCR METAB, V82, P585, DOI 10.1210/jc.82.2.585; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; CHEN HW, 1995, DNA CELL BIOL, V14, P681, DOI 10.1089/dna.1995.14.681; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; delaBrousse FC, 1996, P NATL ACAD SCI USA, V93, P4096, DOI 10.1073/pnas.93.9.4096; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; Gong DW, 1996, J BIOL CHEM, V271, P3971; GREEN ED, 1995, GENOME RES, V5, P5, DOI 10.1101/gr.5.1.5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; Heckert LL, 1996, J BIOL CHEM, V271, P31650, DOI 10.1074/jbc.271.49.31650; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAPLAN DJ, 1991, NUCLEIC ACIDS RES, V19, P4731, DOI 10.1093/nar/19.17.4731; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; Lee BJ, 1996, MOL CELL ENDOCRINOL, V118, P9, DOI 10.1016/0303-7207(95)03758-6; Leroy P, 1996, J BIOL CHEM, V271, P2365, DOI 10.1074/jbc.271.5.2365; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Mounzih K, 1997, ENDOCRINOLOGY, V138, P1190, DOI 10.1210/en.138.3.1190; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V214, P1260, DOI 10.1006/bbrc.1995.2422; NG YK, 1994, DEVELOPMENT, V120, P3257; PATTILLO RA, 1971, IN VITRO CELL DEV B, V6, P398; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; PICADOLEONARD J, 1987, DNA-J MOLEC CELL BIO, V6, P439, DOI 10.1089/dna.1987.6.439; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Scatena CD, 1996, ENDOCRINOLOGY, V137, P3000, DOI 10.1210/en.137.7.3000; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; SMITHBERG M., 1957, JOUR HEREDITY, V48, P97; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; Stephanou A, 1996, J MOL ENDOCRINOL, V16, P221, DOI 10.1677/jme.0.0160221; TODA K, 1995, J STEROID BIOCHEM, V53, P181, DOI 10.1016/0960-0760(95)00032-U; Trayhurn P, 1996, BIOCHEM BIOPH RES CO, V228, P605, DOI 10.1006/bbrc.1996.1704; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P1145, DOI 10.1210/jcem-63-5-1145; WADA N, 1993, J BIOL CHEM, V268, P14003; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	54	151	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30583	30588		10.1074/jbc.272.48.30583	http://dx.doi.org/10.1074/jbc.272.48.30583			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374555	hybrid			2022-12-25	WOS:A1997YH61300087
J	Yanai, K; Saito, T; Hirota, K; Kobayashi, H; Murakami, K; Fukamizu, A				Yanai, K; Saito, T; Hirota, K; Kobayashi, H; Murakami, K; Fukamizu, A			Molecular variation of the human angiotensinogen core promoter element located between the TATA box and transcription initiation site affects its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; BLOOD-PRESSURE REGULATION; FACTOR USF; HUMAN HYPERTENSION; MULTIPLE FORMS; GENE; IDENTIFICATION; REGION; RENIN; EXPRESSION	Recent genetic studies indicate that several molecular variants discovered in angiotensinogen (AG), the precursor of vasoactive octapeptide angiotensin II, could potentially be responsible for inherited predisposition to human blood pressure variation, We have previously shown that a ubiquitously expressed nuclear factor, AGCF1, bound to AGCE1 (AG core promoter element 1 including the core nucleotides, CTCGTG, CTC-type) located between the TATA box and transcription initiation site (positions -25 to -1) is an authentic regulator of human AG transcription, In the present study, we showed that AGCF1 has biologically and immunologically similar properties to those of a helix-loop-helix nuclear factor USF1 and examined the effects of two other naturally occurring molecular variants (ATCGTG, ATC-type and ATTGTG, ATT-type) found in the AGCE1 position on the human AG transcriptional activity, Competitive gel-shift and transfection experiments demonstrated that the transcriptional activity for the CTC- and ATC-type promoters was 2.5 times higher than that for the ATT-type through the alteration of AGCF1-binding affinity, These results suggest the possible involvement of USF1 as a component in AGCF1 formation and the potential importance of AGCE1 variation in blood pressure regulation through human AG expression.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,TSUKUBA ADV RES ALLIANCE,MOL FUNCT LAB,TSUKUBA,IBARAKI 305,JAPAN; NATL FOOD RES INST,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan			fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				ARGRIMSSON R, 1993, NAT GENET, V4, P114; CARTHEW RW, 1987, GENE DEV, V1, P978; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doria A, 1996, HYPERTENSION, V27, P1134, DOI 10.1161/01.HYP.27.5.1134; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FASOLA AF, 1968, J APPL PHYSIOL, V25, P410, DOI 10.1152/jappl.1968.25.4.410; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; FUKAMIZU A, 1995, TRENDS ENDOCRIN MET, V6, P279, DOI 10.1016/1043-2760(95)00156-5; GOULD AB, 1971, CARDIOVASC RES, V5, P86, DOI 10.1093/cvr/5.1.86; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HYDER SM, 1992, J BIOL CHEM, V267, P18047; ISHIGAMI T, 1995, CIRCULATION, V91, P951, DOI 10.1161/01.CIR.91.4.951; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KAMITANI A, 1995, HYPERTENSION, V25, P950, DOI 10.1161/01.HYP.25.5.950; KATSUYA T, 1995, LANCET, V345, P1600, DOI 10.1016/S0140-6736(95)90115-9; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4458; LIFTON RP, 1995, P NATL ACAD SCI USA, V92, P8545, DOI 10.1073/pnas.92.19.8545; LYNCH KR, 1991, HYPERTENSION, V17, P263, DOI 10.1161/01.HYP.17.3.263; Morishita R, 1996, HYPERTENSION, V27, P502, DOI 10.1161/01.HYP.27.3.502; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NIBU Y, 1994, J BIOL CHEM, V269, P28598; NIBU Y, 1994, BIOCHEM BIOPH RES CO, V205, P1102, DOI 10.1006/bbrc.1994.2779; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; PHILLIPS MI, 1993, REGUL PEPTIDES, V43, P1; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; Sato N, 1997, HYPERTENSION, V30, P321, DOI 10.1161/01.HYP.30.3.321; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIMADA S, 1995, ENDOCRINE, V3, P543, DOI 10.1007/BF02738831; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; TAMURA K, 1992, JPN HEART J, V33, P113; WALKER WG, 1979, HYPERTENSION, V1, P473; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; Yanai K, 1996, J BIOL CHEM, V271, P15981, DOI 10.1074/jbc.271.27.15981	44	49	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30558	30562		10.1074/jbc.272.48.30558	http://dx.doi.org/10.1074/jbc.272.48.30558			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374551	hybrid			2022-12-25	WOS:A1997YH61300083
J	HernandezAlcoceba, R; Saniger, L; Campos, J; Nunez, MC; Khaless, F; Gallo, MA; Espinosa, A; Lacal, JC				HernandezAlcoceba, R; Saniger, L; Campos, J; Nunez, MC; Khaless, F; Gallo, MA; Espinosa, A; Lacal, JC			Choline kinase inhibitors as a novel approach for antiproliferative drug design	ONCOGENE			English	Article						oncogenes; choline kinase; antiproliferative drugs; growth factors; phosphorylcholine; ras; src; fos; hemicholinium-3	XENOPUS-LAEVIS OOCYTES; ETHANOLAMINE UPTAKE; LIPID-METABOLISM; GROWTH-FACTORS; RAS PROTEINS; IN-VITRO; ACTIVATION; CELLS; HEMICHOLINIUM-3; RAF-1	Recent progress in deciphering the molecular basis of carcinogenesis is of utmost importance to the development of new anticancer strategies, To this end, it is essential to understand the regulation of both normal cell proliferation and its alterations in cancer cells, We have previously demonstrated that in ras-transformed cells there is an increased level of phosphorylcholine (PCho) resulting from a constitutive activation on choiline kinase (ChoK), The importance of ChoK for the regulation of cell proliferation has also been proposed since an inhibitior for this enzyme, hemicholinium-3 (HC-3), drastically reduces entry into S phase after stimulation with growth factors, Here we report synthesis of several new compounds which are highly specific inhibitors for ChoK, with up to 1000-fold or 600-fold increased inhibitory activity, compared to HC-3 under ex vivo or in vitro conditions respectively, These novel compounds also drastically reduce entry into the S phase after stimulation with specific growth factors, A more profound inhibition of cell proliferation was observed in ras-, src- and mos-transformed cells in the presence of ChoK inhibitors, compared to their parental, untransformed NIH3T3 cells, By contrast, this effect was not observed in fos-transformed cells, While ras, src and mos transformation is associated with elevated levels of ChoK activity, fos-induced transformation does not affect ChoK activity, The inhibitory effect on proliferation of the new compounds correlates with their ability to inhibit the production of phosphorylcholine in whole cells, a proposed novel second messenger for cell proliferation. These results strongly support a critical role of choline kinase in the regulation of cell growth and makes this enzyme a novel target for the design of new antiproliferative and anticancer drugs.	CSIC,INST INVEST BIOMED,MADRID,SPAIN; UNIV GRANADA,DEPT QUIM ORGAN,FAC FARM,GRANADA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Granada			Rosa, Joaquín/L-8436-2014; Lacal, Juan Carlos/AAL-2235-2020; del Carmen Nuñez-Carretero, M/L-7150-2014; Ubeda, Antonio Espinosa/L-8504-2014; Lacal, Juan Carlos/N-9064-2015	Rosa, Joaquín/0000-0002-9035-8123; Ubeda, Antonio Espinosa/0000-0001-9542-564X; Lacal, Juan Carlos/0000-0002-1908-2777				BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bhakoo KK, 1996, CANCER RES, V56, P4630; CANNON JG, 1990, J MED CHEM, V33, P577, DOI 10.1021/jm00164a017; CANNON JG, 1994, MED RES REV, V14, P505, DOI 10.1002/med.2610140503; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CUADRADO A, 1993, ONCOGENE, V8, P2959; delPeso L, 1997, BIOCHEM J, V322, P519; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DEVITA VT, 1993, CANCER PRINCIPLES PR; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GUYENET P, 1973, MOL PHARMACOL, V9, P630; HAMZA M, 1983, BIOCHEM PHARMACOL, V32, P1893, DOI 10.1016/0006-2952(83)90055-2; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Kerr DJ, 1994, NEW MOL TARGETS CANC; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; MACARA I, 1989, MOL CELL BIOL, V10, P325; MACDONALD JS, 1995, MANUAL ONCOLOGIC THE; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; POLAK RL, 1977, J NEUROCHEM, V29, P477, DOI 10.1111/j.1471-4159.1977.tb10696.x; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; RONEN SM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P203, DOI 10.1016/0925-4439(92)90039-P; RONEN SM, 1991, BIOCHIM BIOPHYS ACTA, V1095, P5, DOI 10.1016/0167-4889(91)90038-Y; Rosa JC, 1996, J MED CHEM, V39, P4247, DOI 10.1021/jm950884a; TEEGARDEN D, 1990, J BIOL CHEM, V265, P16638; TUCEK S, 1985, J NEUROCHEM, V4, P12; VICIANA PR, 1994, NATURE, V370, P527; VOJTEK AB, 1993, CELL, V74, P204; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZLATKINE P, 1993, BIOCHIM BIOPHYS ACTA, V1153, P237, DOI 10.1016/0005-2736(93)90410-2	35	141	147	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2289	2301		10.1038/sj.onc.1201414	http://dx.doi.org/10.1038/sj.onc.1201414			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393874				2022-12-25	WOS:A1997YE15700004
J	Amariglio, F; Tchang, F; Prioleau, MN; Soussi, T; Cibert, C; Mechali, M				Amariglio, F; Tchang, F; Prioleau, MN; Soussi, T; Cibert, C; Mechali, M			A functional analysis of p53 during early development of Xenopus laevis	ONCOGENE			English	Article						replication; transcription; egg; oocyte	WILD-TYPE P53; TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION DOMAIN; DNA-REPLICATION INVITRO; T-ANTIGEN; GENE AMPLIFICATION; NUCLEAR EXCLUSION; TUMOR-ANTIGEN; EGG EXTRACTS; HOST PROTEIN	p53 is a nuclear protein that acts like a tumor suppressor and is involved in regulation of cellular growth, In Xenopus, the p53 protein is highly expressed during oogenesis and is strictly cytoplasmic in the oocyte, We have analysed its participation in DNA replication and transcription during early development, using the egg and oocyte as model-systems. The injection of sperm nuclei into Xenopus eggs is followed by DNA replication and mitotic events, We show that the endogenous p53 enters the nuclei and moves through a series of discrete subnuclear loci whose distribution is S-phase specific, A specific peripheral nuclear localization of p53 is observed before entry into S-phase, followed by an internal localization which is strictly dependent on ongoing DNA synthesis, At no stage in the cell cycle, however, did we observe any co-localization with RPA or PCNA, which were used as initiation or elongation markers for DNA replication, We also show that injection into the nucleus of the oocyte of small amounts of either Xenopus or human p53 - less than 10% of the cytoplasmic storage - is sufficient to block RNA polymerase II-dependent transcription from a coinjected TATA-box-containing reporter plasmid. Transcription is rescued by microinjection of the TATA-box binding protein (TBP), suggesting that nuclear exclusion of p53 during oogenesis may be necessary for transcription of maternal genes, These characteristics are discussed in relation to the regulation of nuclear activities during early embryogenesis.	CNRS, INST JACQUES MONOD, F-7251 PARID 05, FRANCE; INST CURIE, UMR 218, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)			Prioleau, Marie-Noelle/G-9824-2014; , prioleau/S-6007-2019	, prioleau/0000-0003-2585-4005; soussi, thierry/0000-0001-8184-3293				ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BRAIN R, 1994, ONCOGENE, V9, P1775; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GURDON JB, 1986, J CELL SCI, P287; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; JACKSON P, 1993, ONCOGENE, V8, P589; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIENZLE H, 1989, EUR J BIOCHEM, V184, P181, DOI 10.1111/j.1432-1033.1989.tb15005.x; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAY E, 1991, ONCOGENE, V6, P1363; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; MIYAMOTO N, 1990, BIOCHEM BIOPH RES CO, V168, P604, DOI 10.1016/0006-291X(90)92363-5; MODAK SP, 1993, ONCOGENE, V8, P645; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; PRIOLEAU MN, 1995, EMBO J, V14, P5073, DOI 10.1002/j.1460-2075.1995.tb00189.x; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	67	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2191	2199		10.1038/sj.onc.1201395	http://dx.doi.org/10.1038/sj.onc.1201395			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393977				2022-12-25	WOS:A1997YD01900007
J	Ermekova, KS; Zambrano, N; Linn, H; Minopoli, G; Gertler, F; Russo, T; Sudol, M				Ermekova, KS; Zambrano, N; Linn, H; Minopoli, G; Gertler, F; Russo, T; Sudol, M			The WW domain of neural protein FE65 interacts with proline-rich motifs in Mena, the mammalian homolog of Drosophila enabled	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ABL TYROSINE KINASE; PHOSPHOTYROSINE-BINDING DOMAIN; ALZHEIMERS-DISEASE; BETA-PROTEIN; SH3 DOMAIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; ENDOCYTIC PATHWAY; MOLECULAR-CLONING	The neural protein FE65 contains two types of protein-protein interaction modules: one WW binding domain and two phosphotyrosine binding domains. The carboxyl-terminal phosphotyrosine binding domain of FE65 interacts in vivo with the beta-amyloid precursor protein, which is implicated in Alzheimer disease. To understand the function of this adapter protein, we identified binding partners for the FE65 WW domain. Proline-rich sequences sharing a proline-proline-leucine-proline core motif were recovered by screening expression libraries for ligands of the FE65 WW domain. Five proteins of molecular masses 60, 75, 80, 140, and 200 kDa could be purified from mouse brain lysates by affinity to the FE65 WW domain. We identified two of these five proteins as the 80- and 180-kDa isoforms encoded by Mena, the mammalian homolog of the Drosophila Enabled gene. Using the SPOTs technique of peptide synthesis, we identified the sequences in Mena that interact with the FE65 WW domain and found that they contain the signature proline-proline-leucine-proline motif. Finally, we demonstrated that Mena binds to FE65 in vivo by coimmunoprecipitation assay from COS cell extracts. The specificity of the Mena-FE65 WW domain association was confirmed by competition assays. Further characterization of the FE65-Mena complex may identify a physiological role for these proteins in beta-amyloid precursor protein biogenesis and may help in understanding the mechanism of molecular changes that underlie Alzheimer disease.	CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; MIT, Dept Biol, Cambridge, MA 02138 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Naples Federico II; Massachusetts Institute of Technology (MIT)	Sudol, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem, Box 1020,1 Gustave Levy Pl, New York, NY 10029 USA.		Russo, Tommaso/K-1331-2016; Zambrano, Nicola/B-9352-2014	Russo, Tommaso/0000-0003-4426-0106; Zambrano, Nicola/0000-0001-9395-3481	NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER; NCI NIH HHS [CA01605, CA45757] Funding Source: Medline; Telethon [E.0522] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Telethon(Fondazione Telethon)		BEARER EL, 1991, J CELL BIOL, V115, P1629, DOI 10.1083/jcb.115.6.1629; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BLANKEMEYERMENGE B, 1990, TETRAHEDRON LETT, V31, P1701, DOI 10.1016/S0040-4039(00)88858-9; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHEN HI, 1996, TECH PROTEIN CHEM, V7, P3; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; ERMEKOVA KS, 1997, IN PRESS ADV EXP MED; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; JOHNSTON PA, 1990, J BIOL CHEM, V265, P17946; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; MACHESKY L, 1997, CURR BIOL, V7, P161; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; McLoughlin DM, 1996, FEBS LETT, V397, P197; NIEBUHR K, 1997, IN PRESS EMBO J; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; ONODA K, 1993, CELL MOTIL CYTOSKEL, V26, P227, DOI 10.1002/cm.970260306; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; STAUB O, 1996, EMBO J, V15, P1045; SUDOL M, 1994, ONCOGENE, V9, P2145; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; SUDOL M, 1993, NEUROCHEM INT, V22, P369, DOI 10.1016/0197-0186(93)90019-2; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399	57	205	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32869	32877		10.1074/jbc.272.52.32869	http://dx.doi.org/10.1074/jbc.272.52.32869			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407065	hybrid			2022-12-25	WOS:000071182900026
J	Lo, HW; Ali-Osman, F				Lo, HW; Ali-Osman, F			Genomic cloning of hGSTP1*C, an allelic human Pi class glutathione S-transferase gene variant and functional characterization of its retinoic acid response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYLATING AGENT RESISTANCE; DRUG-RESISTANCE; CELL-LINES; BREAST-CANCER; LUNG-TUMOR; EXPRESSION; PROMOTER; IDENTIFICATION; TRANSCRIPTION; SEQUENCES	The complete hGSTP1*C, consisting of 7 exons and 6 introns contained in 3116 base pairs, was isolated from a cosmid genomic library of a glioblastoma multiforme cell line. Although the promoter of hGSTP1*C was identical to that of the previously reported GST-Pi gene, several of its structural features had not been previously described. These include several nucleotide transitions and transversions. Transitions of A --> G at +1404 and C --> T at +2294 in exons 5 and 6, respectively, changed codons Ile(104) to Val(104) and Ala(113) to Val(113). The gene also contained a guanine insertion at +51 in the insulin response element in intron 1 and six tandem repeats and one palindromic retinoic acid response element (RARE) consensus half-sites, A(G)GG(T)TC(G)A in intron 5. Retinoic acid (RA) treatment increased GST-Pi gene expression significantly in MGR3 cells. GST-Pi gene constructs with and without RARE deletion were used to show the RARE requirement for GST-PI gene induction by Rk The isolation of the hGSTP1*C gene and the evidence that it contains functional RAREs should contribute to a better understanding of the molecular regulation of the GST-Pi gene in human cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Expt Pediat, Sect Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ali-Osman, F (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Expt Pediat, Sect Mol Therapeut, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Lo, Hui-Wen/0000-0002-0681-7914	NATIONAL CANCER INSTITUTE [R01CA055835] Funding Source: NIH RePORTER; NCI NIH HHS [CA55835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali-Osman Francis, 1996, P63; ALIOSMAN F, 1990, CANCER RES, V50, P6976; AliOsman F, 1997, J BIOL CHEM, V272, P10004; ALIOSMAN F, 1997, IN PRESS J CLIN CANC; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; CHAMBON P, 1991, RETINOIDS 10 YEARS, P38; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRYSOGELOS SA, 1993, NUCLEIC ACIDS RES, V21, P5736, DOI 10.1093/nar/21.24.5736; COMMANDEUR JNM, 1995, PHARMACOL REV, V47, P271; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIILIO C, 1988, CARCINOGENESIS, V9, P335; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GILBERT L, 1993, J CLIN ONCOL, V11, P49, DOI 10.1200/JCO.1993.11.1.49; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARA A, 1990, CANCER, V66, P2563, DOI 10.1002/1097-0142(19901215)66:12<2563::AID-CNCR2820661219>3.0.CO;2-A; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HOFFMANN B, 1990, J MOL ENDOCRINOL, V4, P1734; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUNG M, 1993, BIOCHEM BIOPH RES CO, V190, P462, DOI 10.1006/bbrc.1993.1070; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEWIS AD, 1988, CARCINOGENESIS, V9, P1283, DOI 10.1093/carcin/9.7.1283; LI Y, 1992, J BIOL CHEM, V267, P15097; LIPKIN SM, 1992, P NATL ACAD SCI USA, V89, P1209, DOI 10.1073/pnas.89.4.1209; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Moffat GJ, 1996, J BIOL CHEM, V271, P20740, DOI 10.1074/jbc.271.34.20740; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; MORROW CS, 1990, CANCER CELL-MON REV, V2, P15; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NIITSU Y, 1989, CANCER-AM CANCER SOC, V63, P317, DOI 10.1002/1097-0142(19890115)63:2<317::AID-CNCR2820630219>3.0.CO;2-P; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHEA TC, 1988, CANCER RES, V48, P527; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STRANGE RC, 1992, BIOCHIM BIOPHYS ACTA, V1139, P222, DOI 10.1016/0925-4439(92)90138-D; TAKIMOTO Y, 1993, JPN J CANCER RES, V84, P1268, DOI 10.1111/j.1349-7006.1993.tb02833.x; TEW KD, 1994, CANCER RES, V54, P4313; TIDEFELT U, 1992, CANCER RES, V52, P3281; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9091; VASIOS GW, 1991, EMBO J, V10, P1141; WANG YY, 1989, CANCER RES, V49, P6185; WAXMAN DJ, 1990, CANCER RES, V50, P6449; Xia CL, 1996, BIOCHEM J, V313, P155, DOI 10.1042/bj3130155; XIA CL, 1993, BIOCHEM J, V292, P845, DOI 10.1042/bj2920845; YANGYEN HF, 1991, NEW BIOL, V3, P1206	60	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32743	32749		10.1074/jbc.272.52.32743	http://dx.doi.org/10.1074/jbc.272.52.32743			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407047	hybrid			2022-12-25	WOS:000071182900008
J	Vries, RGJ; Flynn, A; Patel, JC; Wang, XM; Denton, RM; Proud, CG				Vries, RGJ; Flynn, A; Patel, JC; Wang, XM; Denton, RM; Proud, CG			Heat shock increases the association of binding protein-1 with initiation factor 4E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-DEPENDENT TRANSLATION; EPIDIDYMAL FAT-CELLS; MESSENGER-RNA CAP; HELA-CELLS; PHAS-I; FACTOR EIF-4E; 3T3-L1 ADIPOCYTES; ALPHA-SUBUNIT; PHOSPHORYLATION; INSULIN	The effects of heat shock on the regulation of the cap-binding initiation factor 4E (eIF4E) and its inhibitory binding protein, 4E-BP1, have been examined in Chinese hamster ovary cells and in cardiac myocytes. Heat shock increased the association between eIF4E and 4E-EP1, and this was associated with a dephosphorylation of 4E-BP1. These effects did not appear to be due wholly to decreased activity of the p70 S6 kinase pathway, which is implicated in the control of 4E-BP1, and they were not mediated by the stress-activated p38 microtubule-associated protein kinase pathway. Increased binding of 4E-BP1 to eIF4E correlated with a decrease in the amount of eIF4G which co-purified with the latter, This could account for the previously observed impairment of eIF4F function during heat shock, and, since heat shock protein mRNAs are believed to be relatively cap-independent, could provide a mechanism for the selective up-regulation of the synthesis of heat shock proteins and other stress proteins during heat shock.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Kent; University of Bristol	Proud, CG (corresponding author), Univ Dundee, Dept Anat & Physiol, Dundee DD1 4HN, Scotland.	CGPROUD@bad.dundee.ac.uk	Denton, Richard/ABC-9914-2020	Proud, Christopher/0000-0003-0704-6442				Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BELSHAM G J, 1980, Biochemical Society Transactions, V8, P382; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; DIGGLE TA, 1995, BIOCHEM J, V306, P135, DOI 10.1042/bj3060135; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; DIGGLE TA, 1992, BIOCHEM J, V282, P729, DOI 10.1042/bj2820729; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1995, BIOCHEMISTRY-US, V34, P2985, DOI 10.1021/bi00009a030; DUNCAN RF, 1996, TRANSLATIONAL CONTRO, P271; Fadden P, 1997, J BIOL CHEM, V272, P10240; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Fleurent M, 1997, J BIOL CHEM, V272, P4006, DOI 10.1074/jbc.272.7.4006; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Flynn A, 1996, CANCER SURV, V27, P293; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MACEJAK DG, 1990, ENZYME, V44, P310, DOI 10.1159/000468767; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; MUNOZ A, 1984, VIROLOGY, V137, P150, DOI 10.1016/0042-6822(84)90018-7; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; RAMAIAH KVA, 1994, MOL CELL BIOL, V14, P4546, DOI 10.1128/MCB.14.7.4546; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; RHOADS RE, 1994, BIOCHIMIE, V76, P831, DOI 10.1016/0300-9084(94)90184-8; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SHANTZ LM, 1994, CANCER RES, V54, P2313; SIERRA JM, 1994, MOL BIOL REP, V19, P211, DOI 10.1007/BF00986963; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WANG XM, 1994, AM J PHYSIOL-HEART C, V36, pH1759; WELSH GI, 1993, FEBS LETT, V316, P241, DOI 10.1016/0014-5793(93)81300-O; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007	63	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32779	32784		10.1074/jbc.272.52.32779	http://dx.doi.org/10.1074/jbc.272.52.32779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407052	hybrid			2022-12-25	WOS:000071182900013
J	Sakurai, H; Fukasawa, T				Sakurai, H; Fukasawa, T			Yeast Gal11 and transcription factor IIE function through a common pathway in transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; BASAL TRANSCRIPTION; PROMOTER ELEMENTS; GENE ACTIVATION; IN-VIVO; HOLOENZYME; INITIATION; PROTEIN; DNA	The global transcription regulator Gal11, a component of RNA polymerase II holoenzyme, is required for full expression of many genes in yeast. We previously reported that Gal11 binds the small (Tfa2) and large (Tfa1) subunits of the general transcription factor (TF) TIE through Gal11 functional domains A and B, respectively. Here we demonstrate that the C-terminal basic region in Tfa2 is responsible for binding to domain A, whereas both the N-terminal hydrophobic and internal glutamic acid-rich regions in Tfa1 are responsible for binding to domain B. Yeast cells bearing a C-terminal deletion encompassing the Gal11-interacting region in each of the two TFIIE subunits, being viable, exhibited no obvious phenotype. In contrast, combination of the two deletions (TFIIE-Delta C) showed phenotypes similar to those of gal11 null mutations. The levels of mRNA from TATA-containing genes, but not from TATA-less genes, decreased in TFIIE-Delta C to an extent comparable to that in the gal11 null mutant. Combination of TFIIE-Delta C with a gal11 null mutation did not result in an enhanced effect, suggesting that both TFIIE and Gal11 act in a common regulatory pathway, In a reconstituted cell-free system, Gal11 protein stimulated basal transcription in the presence of wild-type TFIIE. Such a stimulation was not seen in the presence of TFIIE-Delta C.	Kanazawa Univ, Fac Med, Sch Hlth Sci, Kanazawa, Ishikawa 920, Japan; Kazusa DNA Res Inst, Kisarazu, Chiba 292, Japan	Kanazawa University; Kazusa DNA Research Institute	Sakurai, H (corresponding author), Kanazawa Univ, Fac Med, Sch Hlth Sci, 5-11-80 Kodatsuno, Kanazawa, Ishikawa 920, Japan.							BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BJORKLUND S, 1996, TRENDS BIOCHEM SCI, V21, P327; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FASSLER JS, 1989, MOL CELL BIOL, V9, P5602, DOI 10.1128/MCB.9.12.5602; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; GRIGGS DW, 1993, MOL CELL BIOL, V13, P4999, DOI 10.1128/MCB.13.8.4999; Gustafsson CM, 1997, J BIOL CHEM, V272, P48; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; INOKUCHI K, 1987, MOL CELL BIOL, V7, P3185, DOI 10.1128/MCB.7.9.3185; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KIPLING D, 1991, NUCLEIC ACIDS RES, V19, P1385, DOI 10.1093/nar/19.7.1385; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LONG RM, 1991, MOL CELL BIOL, V11, P2311, DOI 10.1128/MCB.11.4.2311; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MUNHOLLAND JM, 1990, NUCLEIC ACIDS RES, V18, P6061, DOI 10.1093/nar/18.20.6061; NOGI Y, 1980, CURR GENET, V2, P115, DOI 10.1007/BF00420623; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PELLMAN D, 1990, NATURE, V348, P82, DOI 10.1038/348082a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; SAKURAI H, 1994, MOL CELL BIOL, V14, P6819, DOI 10.1128/MCB.14.10.6819; Sakurai H, 1997, J BIOL CHEM, V272, P15936, DOI 10.1074/jbc.272.25.15936; Sakurai H, 1996, P NATL ACAD SCI USA, V93, P9488, DOI 10.1073/pnas.93.18.9488; SAKURAI H, 1994, FEBS LETT, V351, P176, DOI 10.1016/0014-5793(94)80098-7; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; Sakurai H, 1996, FEBS LETT, V398, P113, DOI 10.1016/S0014-5793(96)01219-7; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; Shi XM, 1997, MOL CELL BIOL, V17, P1160, DOI 10.1128/MCB.17.3.1160; SIKORSKI RS, 1989, GENETICS, V122, P19; SUSSEL L, 1995, GENETICS, V141, P873; SUZUKI Y, 1988, MOL CELL BIOL, V12, P4806; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P25044; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VALLIER LG, 1991, GENETICS, V129, P675; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	52	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32663	32669		10.1074/jbc.272.51.32663	http://dx.doi.org/10.1074/jbc.272.51.32663			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405484	hybrid			2022-12-25	WOS:000071108000103
J	Chamberlain, LH; Burgoyne, RD				Chamberlain, LH; Burgoyne, RD			The molecular chaperone function of the secretory vesicle cysteine string proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; ATPASE ACTIVITY; J-DOMAIN; SUBSTRATE-BINDING; ENDOPLASMIC-RETICULUM; SYNAPTIC VESICLES; NMR STRUCTURE; REPLICATION; DROSOPHILA	The ''J'' domains of eukaryotic DnaJ-like proteins specify interaction with various Hsp70s. The conserved tripeptide, HPD, present in all J domains has been shown to be important for the interaction between yeast and bacterial DnaJ/Hsp70 protein pairs. We have characterized mutations in the HPD motif of the synaptic vesicle protein cysteine-string protein (Csp). Mutation of the histidine (H43Q) or aspartic acid (D45A) residues of this motif reduced the ability of Csp to stimulate the ATPase activity of mammalian Hsc70, The H43Q and D45A mutant proteins were not able to stimulate the ATPase activity of Hsc70 to any significant extent. The mutant proteins were characterized by competition assays, tryptic digestion analysis, and direct binding analysis from which it was seen that these proteins were defective in binding to Hsc70. Thus, the HPD motif of Csp is required for binding to Hsc70. We also analyzed the interaction between Csp and a model substrate protein, denatured firefly luciferase. Both Csp1 and the C-terminally truncated isoform Csp2 were able to prevent aggregation of heat-denatured luciferase, and they also cooperated with Hsc70 to prevent aggregation. In addition, complexes of Csp1 or Csp2 with Hsc70 and luciferase were isolated, confirming that these proteins interact and that Csps can bind directly to denatured proteins. Csp1 and Csp2 isoforms must differ in some aspect other than interaction with Hsc70 and substrate protein. These results show that both Csp1 and Csp2 can bind a partially unfolded protein and act as chaperones, This suggests that Csps may have a general chaperone function in regulated exocytosis.	UNIV LIVERPOOL,PHYSIOL LAB,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALFANO C, 1989, J BIOL CHEM, V264, P10709; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1362; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 1996, J BIOL CHEM, V271, P19514, DOI 10.1074/jbc.271.32.19514; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; Coppola T, 1996, FEBS LETT, V391, P269, DOI 10.1016/0014-5793(96)00750-8; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Kwon OJ, 1996, MOL BIOL CELL, V7, P2599; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MASTROGIACOMO A, 1995, MOL BRAIN RES, V28, P12, DOI 10.1016/0169-328X(94)00172-B; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Pupier S, 1997, J NEUROSCI, V17, P2722; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	42	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31420	31426		10.1074/jbc.272.50.31420	http://dx.doi.org/10.1074/jbc.272.50.31420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395474	hybrid			2022-12-25	WOS:A1997YL41900033
J	Friedman, JE; Sun, Y; Ishizuka, T; Farrell, CJ; McCormack, SE; Herron, LM; Hakimi, P; Lechner, P; Yun, JS				Friedman, JE; Sun, Y; Ishizuka, T; Farrell, CJ; McCormack, SE; Herron, LM; Hakimi, P; Lechner, P; Yun, JS			Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; INSULIN-RECEPTOR SUBSTRATE-1; TISSUE-SPECIFIC EXPRESSION; GROWTH-HORMONE GENE; DIETARY-REGULATION; RESPONSE UNIT; PEPCK GENE; RESISTANCE; PROMOTER; MUSCLE	The molecular mechanisms underlying increased hepatic phosphoenolpyruvate carboxykinase (PEPCK) gene transcription and gluconeogenesis in type II diabetes are largely unknown, To examine the involvement of glucocorticoids and the cis-acting insulin response sequence (IRS, -416/-407) in the genetically obese db/db mouse model, we generated crosses between C57BL/KsJ-db/+ mice and transgenic mice that express -460 or -2000 base pairs of the rat PEPCK gene promoter containing an intact or mutated IRS, linked to a reporter gene. Transgenic mice expressing the intact PEPCK(460)-CRP (C-reactive protein) transgene bred to near homozygosity at the db locus were obese, hyperinsulinemic, and developed fasting hyperglycemia (389 +/- 26 mg/100 ml) between 4 and 10 weeks of age, Levels of CRP reporter gene expression were increased 2-fold despite severe hyperinsulinemia compared with non-diabetic non-obese transgenic mice, Reporter gene expression was also increased 2-fold in transgenic obese diabetic db/db mice bearing a mutation in the IRS, -2000(IRS)-hGx, compared with non-obese non-diabetic transgenic 2000(IRS)-hGx mice. Treatment of obese diabetic db/db transgenic mice with the glucocorticoid receptor blocker RU 486 decreased plasma glucose by 50% and reduced PEPCK, GLUT2, glucose-6-phosphatase, tyrosine aminotransferase, CRP, and hGx reporter gene expression to levels similar to those of non-obese normoglycemic transgenic mice, Taken together, these results establish that -460 bp of 5'-flanking sequence is sufficient to mediate the induction of PEPCK gene transcription in genetically obese db/db mice during the development of hyperglycemia, The results further demonstrate that the mechanism underlying increased expression of gluconeogenic enzymes in the db/db mouse requires the action of glucocorticoids and occurs independently of factors acting through the PEPCK IRS (-416/-407) promoter binding site.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; OHIO UNIV,EDISON ANIM BIOTECHNOL CTR,ATHENS,OH 45107	Case Western Reserve University; University System of Ohio; Ohio University	Friedman, JE (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.		Hakimi, Parvin/AAB-1643-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050272] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50272] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOGARDUS C, 1993, DIABETES CARE, V16, P228, DOI 10.2337/diacare.16.1.228; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN DL, 1982, DIABETES, V31, P1; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; CONSOLI A, 1990, J CLIN INVEST, V86, P2038, DOI 10.1172/JCI114940; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; HANSON RW, 1972, AM J CLIN NUTR, V25, P1010; HOFMANN CA, 1992, ENDOCRINOLOGY, V130, P735, DOI 10.1210/en.130.2.735; IDZERDA RL, 1989, MOL CELL BIOL, V9, P5154, DOI 10.1128/MCB.9.11.5154; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KUSUNOKI M, 1995, DIABETES, V44, P718, DOI 10.2337/diabetes.44.6.718; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANGLEY SC, 1990, AM J PHYSIOL, V259, pR539, DOI 10.1152/ajpregu.1990.259.3.R539; LEITER EH, 1987, J IMMUNOL, V10, P3224; Lin CS, 1995, IMMUNOL CELL BIOL, V73, P521, DOI 10.1038/icb.1995.82; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; Ludwig DS, 1996, J CLIN ENDOCR METAB, V81, P503, DOI 10.1210/jc.81.2.503; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; NOGUCHI T, 1993, FEBS LETT, V328, P145, DOI 10.1016/0014-5793(93)80982-Z; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OKADA S, 1992, AM J PHYSIOL, V262, pR1106, DOI 10.1152/ajpregu.1992.262.6.R1106; OLEFSKY JM, 1981, DIABETES, V30, P148, DOI 10.2337/diab.30.2.148; PATEL YM, 1994, J BIOL CHEM, V269, P5619; RESHEF L, 1960, METABOLISM, V9, P551; ROESLER WJ, 1985, MOL CELL BIOCHEM, V92, P99; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; SHAFRIR E, 1988, FRONTIERS DIABETES R, P304; SHIMOMURA Y, 1987, HORM METAB RES, V19, P295, DOI 10.1055/s-2007-1011804; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; WILLIAMSSON JR, 1966, P NATL ACAD SCI USA, V6, P247; YANG SH, 1995, BIOCHEM J, V310, P375, DOI 10.1042/bj3100375	41	92	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31475	31481		10.1074/jbc.272.50.31475	http://dx.doi.org/10.1074/jbc.272.50.31475			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395482	hybrid			2022-12-25	WOS:A1997YL41900041
J	Higashida, H; Yokoyama, S; Hashii, M; Taketo, M; Higashida, M; Takayasu, T; Ohshima, T; Takasawa, S; Okamoto, H; Noda, M				Higashida, H; Yokoyama, S; Hashii, M; Taketo, M; Higashida, M; Takayasu, T; Ohshima, T; Takasawa, S; Okamoto, H; Noda, M			Muscarinic receptor-mediated dual regulation of ADP-ribosyl cyclase in NG108-15 neuronal cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; RYANODINE RECEPTOR; CA2+ RELEASE; SIGNAL TRANSDUCTION; INSULIN-SECRETION; CD38; CALCIUM; ACETYLCHOLINE; ACTIVATION; HYDROLYSIS	Cyclic ADP-ribose (cADP-ribose) is an endogenous modulator of ryanodine-sensitive Ca2+ release channels. An unsolved question is whether or not cADP-ribose mediates intracellular signals from hormone or neurotransmitter receptors. The first step in this study was to develop a TLC method to measure ADP-ribosyl cyclase, by which conversion of [H-3]NAD(+) to [H-3]cADP-ribose was confirmed in COS-7 cells overexpressing human CD38. A membrane fraction of NG108-15 neuroblastoma x glioma hybrid cells possessed ADP-ribosyl cyclase activity measured by TLC. Carbamylcholine increased this activity by 2.6-fold in NG108-15 cells overexpressing mi or m3 muscarinic acetylcholine receptors (mAChRs), but inhibited it by 30-52% in cells expressing m2 and/or m4 mAChRs. Both of these effects were mimicked by GTP, Pretreatment of cells with cholera toxin blocked the activation, whereas pertussis toxin blocked the inhibition. Application of carbamylcholine caused significant decreases in NAD(+) concentrations in untreated m1-transformed NG108-15 cells, but an increase in cholera toxin-treated cells. These results suggest that mAChRs couple to ADP-ribosyl cyclase within cell membranes via trimeric G proteins and can thereby control cellular function by regulating cADP-ribose formation.	KANAZAWA UNIV,SCH MED,DEPT LEGAL MED,KANAZAWA,ISHIKAWA 920,JAPAN; TOHOKU UNIV,SCH MED,DEPT BIOCHEM,SENDAI,MIYAGI 98077,JAPAN; KYUSHU UNIV,SCH MED,DEPT PHYSIOL,FUKUOKA 812,JAPAN	Kanazawa University; Tohoku University; Kyushu University	Higashida, H (corresponding author), KANAZAWA UNIV,SCH MED,NEUROINFORMAT RES INST,DEPT BIOPHYS,13-1 TAKARA MACHI,KANAZAWA,ISHIKAWA 920,JAPAN.		higashida, haruhiro/L-3773-2015	higashida, haruhiro/0000-0002-1779-0606				BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; DeFlora A, 1997, J BIOL CHEM, V272, P12945, DOI 10.1074/jbc.272.20.12945; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; Genazzani AA, 1997, J BIOL CHEM, V272, P7669, DOI 10.1074/jbc.272.12.7669; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; Higashida H, 1996, FEBS LETT, V379, P236, DOI 10.1016/0014-5793(95)01516-7; HIGASHIDA H, 1995, J PHYSIOL-LONDON, V482, P317, DOI 10.1113/jphysiol.1995.sp020520; HIGASHIDA H, 1982, J CELL PHYSIOL, V110, P107, DOI 10.1002/jcp.1041100202; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; INAGEDA K, 1995, J BIOCHEM-TOKYO, V117, P125, DOI 10.1093/oxfordjournals.jbchem.a124698; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; Mathes C, 1996, J NEUROSCI, V16, P1702; MATSUZAWA H, 1975, P NATL ACAD SCI USA, V72, P3472, DOI 10.1073/pnas.72.9.3472; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MESZAROS V, 1995, BIOCHEM BIOPH RES CO, V210, P452, DOI 10.1006/bbrc.1995.1681; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; Noda M, 1996, J LIPID MEDIAT CELL, V14, P175, DOI 10.1016/0929-7855(96)00523-8; Okamoto H, 1997, METHOD ENZYMOL, V280, P306; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOHGO A, 1994, J BIOL CHEM, V269, P28555; Tohgo A, 1997, J BIOL CHEM, V272, P3879, DOI 10.1074/jbc.272.7.3879; Vu CQ, 1996, J BIOL CHEM, V271, P4747; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; Willmott N, 1996, J BIOL CHEM, V271, P3699; YOKOYAMA S, 1994, BIOCHEM BIOPH RES CO, V200, P634, DOI 10.1006/bbrc.1994.1495; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	46	82	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31272	31277		10.1074/jbc.272.50.31272	http://dx.doi.org/10.1074/jbc.272.50.31272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395453	hybrid			2022-12-25	WOS:A1997YL41900012
J	Mann, CJ; Troussard, AA; Yen, FT; Hannouche, N; Najib, J; Fruchart, JC; Lotteau, V; Andre, P; Bihain, BE				Mann, CJ; Troussard, AA; Yen, FT; Hannouche, N; Najib, J; Fruchart, JC; Lotteau, V; Andre, P; Bihain, BE			Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRANSGENIC MICE; LDL-RECEPTOR; APO-CIII; HIGH-AFFINITY; LIPASE; HYPERTRIGLYCERIDEMIA; METABOLISM; GENE; PROTEIN	ApoC-III overexpression in mice results in severe hypertriglyceridemia due primarily to a delay in the clearance of triglyceride-rich lipoproteins. We have, in primary cultures of rat hepatocytes, characterized a lipolysis-stimulated receptor (LSR), The apparent number of LSR that are available on rat liver plasma membranes is negatively correlated with plasma triglyceride concentrations measured in the fed state, We therefore proposed that the primary physiological role of the LSR is to contribute to the cellular uptake of triglyceride-rich lipoproteins. We have now tested the effect of apoC-III on the binding of triglyceride rich lipoproteins to LSR, Supplementation of I-125-very low density lipoprotein (VLDL) with apoC-III inhibited the LSR-mediated binding, internalization, and degradation of I-125-VLDL in primary cultures of rat hepatocytes. Studies using isolated rat liver plasma membranes showed that enrichment of human VLDL and chylomicrons with synthetic or purified human apoC-III decreased their binding to the LSR by about 40%, Supplementation of triglyceride-rich lipoproteins under the same conditions with human apoC-II had no such inhibitory effect, despite the fact that this apoprotein bound as efficiently as apoC-III to these particles. Preincubation of LDL with apoC-III did not modify its binding to LSR, Partitioning studies using I-125-apoC-III showed that this lack of effect was due to apoC-III's inability to efficiently associate with LDL. Purified human apoC-III1 was as efficient as the synthetic nonsialylated form of apoC-III in inhibiting binding of VLDL to LSR, However, despite a 2-fold greater binding of apoC-III2 to VLDL, this isoform was a less efficient inhibitor of the binding of VLDL to LSR than apoC-III1 or nonsialylated apoC-III, Desialylation of apoC-III2 by treatment with neuraminidase increased the inhibition of VLDL binding to LSR to a level similar to that observed with apoC-III1 and nonsialylated apoC-III. We propose that apoC-III regulates in part the rate of removal of triglyceride-rich particles by inhibiting their binding to the ESR, and that the level of inhibition is determined by the degree of apoC-III sialylation.	INSERM,U391,F-35043 RENNES,FRANCE; INST PASTEUR,SERLIA,F-59019 LILLE,FRANCE; INSERM,U325,F-59019 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)			Yen, Frances T/G-9175-2014; André, Patrice/M-8139-2014; lotteau, vincent/M-8143-2014	Yen, Frances T/0000-0001-8740-4304; André, Patrice/0000-0002-5834-7395; Lotteau, Vincent/0000-0003-0997-3282				AaltoSetala K, 1996, J LIPID RES, V37, P1802; AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BARTLES JR, 1990, METHOD ENZYMOL, V191, P825; BIHAIN BE, 1992, BIOCHEMISTRY-US, V31, P4628, DOI 10.1021/bi00134a013; BIHAIN BE, 1989, J BIOL CHEM, V264, P17316; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRADLEY WA, 1984, J BIOL CHEM, V259, P4728; BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; CAMPS L, 1991, J LIPID RES, V32, P1877; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P1881, DOI 10.1021/bi00406a013; CLAVEY V, 1995, ARTERIOSCL THROM VAS, V15, P963, DOI 10.1161/01.ATV.15.7.963; DallingaThie GM, 1996, J LIPID RES, V37, P136; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; Ebara T, 1997, J CLIN INVEST, V99, P2672, DOI 10.1172/JCI119456; FORTE TM, 1984, J CLIN INVEST, V74, P1601, DOI 10.1172/JCI111576; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1977, INT CELL BIOL 1976 1, P639; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAVEL RJ, 1995, METABOLIC MOL BASES, P1841; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JACKSON RL, 1986, METHOD ENZYMOL, V128, P288; JACKSON RL, 1986, BIOCHIM BIOPHYS ACTA, V875, P211, DOI 10.1016/0005-2760(86)90170-0; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRAUSS RM, 1973, CIRC RES, V33, P403, DOI 10.1161/01.RES.33.4.403; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MANN CJ, 1995, BIOCHEMISTRY-US, V35, P10421; Markwell M A, 1981, Methods Enzymol, V72, P296; MasucciMagoulas L, 1997, SCIENCE, V275, P391, DOI 10.1126/science.275.5298.391; MCCONATHY WJ, 1992, J LIPID RES, V33, P995; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORELL AG, 1966, J BIOL CHEM, V241, P3745; QUARFORDT SH, 1982, J BIOL CHEM, V257, P4642; Sanan DA, 1997, J LIPID RES, V38, P1002; SCHACHTER NS, 1996, J CLIN INVEST, V98, P846; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; WALLINDER L, 1979, BIOCHIM BIOPHYS ACTA, V575, P166, DOI 10.1016/0005-2760(79)90142-5; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WICK U, 1995, CLIN GENET, V47, P184; WINDLER E, 1985, J LIPID RES, V26, P556; YANG CY, 1993, J LIPID RES, V34, P1311; YEN FT, 1994, BIOCHEMISTRY-US, V33, P1172, DOI 10.1021/bi00171a017	48	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31348	31354		10.1074/jbc.272.50.31348	http://dx.doi.org/10.1074/jbc.272.50.31348			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395464	hybrid			2022-12-25	WOS:A1997YL41900023
J	Alonso, MA; Fan, L; Alarcon, B				Alonso, MA; Fan, L; Alarcon, B			Multiple sorting signals determine apical localization of a nonglycosylated integral membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; ANCHORED PROTEINS; RECEPTOR COMPLEX; ANTIGEN RECEPTOR; MDCK CELLS; N-GLYCANS; TRANSPORT; SUBUNITS; SURFACE; CHAIN	In polarized cells, newly synthesized proteins are sorted in the trans-Golgi network and from there delivered to either the apical or basolateral membranes, Madin-Darby canine kidney (MDCK) cells have been widely used as a model system 60 study sorting determinants to the apical and basolateral surfaces, Whereas sorting signals for basolateral transmembrane proteins seem to reside in their cytoplasmic domains, apical determinants appear to reside in the N-glycans of secretory proteins or in the glycolipid tails of glycosylphosphatidylinositol-linked proteins, We show in this study that a surface-expressed form of CD3-epsilon, a nonglycosylated type I membrane protein, is exclusively targeted to the apical membrane in MDCK cells by a glycolipid-independent transport pathway, Deletion of the cytoplasmic tail does not affect its distribution, whereas deletion of the transmembrane domain results in secretion from both surfaces although still predominantly through the apical membrane, The transmembrane domain of CD3-epsilon appended to rat growth hormone, a secretory protein that lacks apical and basolateral determinants, promotes basolateral localization of the chimeric protein, However, a growth hormone chimera containing both the transmembrane and cytoplasmic domains of CD3-epsilon resulted in localization to the apical and basolateral membranes, These results suggest there are multiple determinants in CD3-epsilon that affect its distribution in polarized MDCK cells, Whereas the transmembrane domain contains a basolateral determinant, the ectodomain and the cytoplasmic domain contain apical determinants.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Alarcon, B (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain.		Alarcon, Balbino/N-9648-2016; Alonso, Miguel A/J-3945-2016	Alarcon, Balbino/0000-0001-7820-1070; Alonso, Miguel A/0000-0002-7001-8826				ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; BORST J, 1983, EUR J IMMUNOL, V13, P576, DOI 10.1002/eji.1830130712; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; Graichen R, 1996, J BIOL CHEM, V271, P15854, DOI 10.1074/jbc.271.27.15854; Harlow E., 1988, ANTIBODIES LAB MANUA; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; PESSANO S, 1985, EMBO J, V4, P337, DOI 10.1002/j.1460-2075.1985.tb03634.x; PETTEY CL, 1987, J BIOL CHEM, V262, P4854; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	30	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30748	30752		10.1074/jbc.272.49.30748	http://dx.doi.org/10.1074/jbc.272.49.30748			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388213	hybrid			2022-12-25	WOS:000071640800026
J	Ottilie, S; Diaz, JL; Horne, W; Chang, J; Wang, Y; Wilson, G; Chang, S; Weeks, S; Fritz, LC; Oltersdorf, T				Ottilie, S; Diaz, JL; Horne, W; Chang, J; Wang, Y; Wilson, G; Chang, S; Weeks, S; Fritz, LC; Oltersdorf, T			Dimerization properties of human BAD - Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-X-L proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HOMOLOG BAK; APOPTOSIS; INHIBITION; BCL-X(L); GENE; DISTINCT; BH1	Bad, an inducer of programmed cell death, was recently isolated from a mouse cDNA library by its ability to bind to the anti-apoptotic protein BCL-2. Sequence analysis suggested that Bad was a member of the BCL-2 gene family that encodes both inducers and inhibitors of programmed cell death. To further analyze the role of BAD in the network of homo- and heterodimers formed by the BCL-2 family, we have cloned the human homologue of BAD and assessed its biological activity and its interactions with wild type and mutant BCL-2 family proteins. Our results indicate that the human BAD protein, like its mouse homologue, is able to induce apoptosis when transfected into mammalian cells. Furthermore, in yeast two-hybrid assays as well as quantitative in vitro interaction assays, human Bad interacted with BCL-2 and BCL-X-L. Sequence alignments of human BAD revealed the presence of a BH-3 homology domain as seen in other BCL-2 family proteins, Peptides derived from this domain were able to completely inhibit the dimerization of BAD with BCL-X-L. Thus, as previously shown for BAX, BAK, BCL-2, and BCL-X-L, the BH3 domain of BAD is required for its dimerization with other BCL-2 family proteins. BAD was further analyzed for its ability to bind to various mutants of BCL-2 and BCL-X-L that have lost the ability to bind BAX and BAK, some of which retain biological activity and some of which do not. Surprisingly, all of the mutated BCL-2 and BCL-X-L proteins analyzed strongly interacted with human BAD. Our data thus indicate that mutations in BCL-2 and BCL-X-L can differentially affect the heterodimeric binding of different death-promoting proteins and have implications concerning the relationship between heterodimerization and biological activity.	IDUN Pharmaceut Inc, La Jolla, CA 92037 USA		Oltersdorf, T (corresponding author), IDUN Pharmaceut Inc, 11085 N Torrey Pines Rd, La Jolla, CA 92037 USA.							BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Diaz JL, 1997, J BIOL CHEM, V272, P11350; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; JACOBSON MD, 1994, CURR BIOL, V4, P3337; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; Maniatis T., 1982, MOL CLONING LAB MANU; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ottilie S, 1997, J BIOL CHEM, V272, P16955, DOI 10.1074/jbc.272.27.16955; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; ZHANG HC, 1995, BIOCHEM BIOPH RES CO, V208, P950, DOI 10.1006/bbrc.1995.1426	31	127	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30866	30872		10.1074/jbc.272.49.30866	http://dx.doi.org/10.1074/jbc.272.49.30866			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388232	hybrid			2022-12-25	WOS:000071640800045
J	Feldman, BJ; Reid, TR; Cleary, ML				Feldman, BJ; Reid, TR; Cleary, ML			Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice	ONCOGENE			English	Article						E2a-Pbx1; Pim1; lymphomagenesis; retroviral mutagenesis; progression	E-MU-MYC; PRE-B; DNA-BINDING; BONE-MARROW; C-MYC; LEUKEMIA; E2A; FUSION; PROTEINS; PBX1	Mice transgenic for the leukemia oncogene E2A-PBX1 invariably develop lethal, high-grade T-cell lymphomas by 5 months of age. In this study, retroviral insertional mutagenesis was employed to identify oncogenes that cooperate with the E2A-PBX1 transgene in lymphomagenesis. Neonatal retroviral infection substantially reduced length of survival due to accelerated development of lymphomas (81 versus 130 days). The Pim1 gene was targeted by retroviral insertions in 48% of accelerated lymphomas whereas less than 5% contained activated c-Myc and none contained activated Pim2. However, Pim1 DNA rearrangements were frequently sub-stoichiometric and not present at all sites of involvement in an otherwise monoclonal lymphoma indicating that Pim1 activation occurred late in the course of lymphomagenesis. Tumor subpopulations containing activated Pim1 alleles displayed a substantial growth advantage over Pim1 negative cells following serial transfer to secondary, syngeneic recipients. Cooperative interactions were observed in intercrossed Pim1 and E2A-PBX1 transgenic mice in which all double transgenic progeny developed lethal, diffuse T lineage lymphomas by 3 months of age, whereas only 13% of E2A-PBX1 and none of Pim1 single transgenic intercross progeny developed lymphomas by 1 year, Tumors from double transgenic mice were monoclonal providing evidence that additional genetic events were required for transformation, Therefore, Pim1 and E2a-Pbx1 cooperate in T lineage lymphomagenesis but they are not sufficient and the role of Pim1 is more likely to be associated with tumor progression.	STANFORD UNIV,MED CTR,DEPT PATHOL,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER; NCI NIH HHS [CA42971] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; ADAMS JM, 1992, CANCER SURV, V15, P119; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BREUER M, 1991, CANCER RES, V51, P958; Buckley AR, 1996, CELL GROWTH DIFFER, V7, P1713; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CUYPERS HT, 1984, CELL, V37, P141; CUYPERS HTM, 1986, J VIROL, V60, P230, DOI 10.1128/JVI.60.1.230-241.1986; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DOMEN J, 1993, LEUKEMIA, V7, pS108; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Giordano V, 1997, J IMMUNOL, V158, P4097; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HOOVER D, 1991, J BIOL CHEM, V266, P14018; HUNGER SP, 1991, BLOOD, V77, P687; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1994, ONCOGENE, V9, P3159; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Liang H, 1996, ARCH BIOCHEM BIOPHYS, V330, P259, DOI 10.1006/abbi.1996.0251; LILLY M, 1992, ONCOGENE, V7, P727; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MULI AL, 1996, EMBO J, V15, P2425; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; SORENSEN IK, 1966, CARCINOGENESIS, V17, P2221; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1981, CELL, V24, P729, DOI 10.1016/0092-8674(81)90099-4; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	45	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2735	2742		10.1038/sj.onc.1201670	http://dx.doi.org/10.1038/sj.onc.1201670			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9401000				2022-12-25	WOS:A1997YH46800011
J	Shridhar, V; Sun, QC; Miller, OJ; Kalemkerian, GP; Petros, J; Smith, DI				Shridhar, V; Sun, QC; Miller, OJ; Kalemkerian, GP; Petros, J; Smith, DI			Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas	ONCOGENE			English	Article						7q31.2 loss; renal cell carcinoma; fragile sites	TUMOR-SUPPRESSOR GENE; PRIMARY BREAST-CANCER; SQUAMOUS-CELL; FREQUENT LOSS; FRAGILE SITE; HOMOZYGOUS DELETION; ALLELIC LOSSES; LUNG-CANCER; 7Q31.1; LOCUS	Cytogenetic and molecular analysis of DNA sequences with highly polymorphic microsatellite markers have implicated allele loss in several chromosomal regions including 3p, 6p, 6q, 8p, 9p, 9q, 11p and 14q in the pathogenesis of sporadic renal cell carcinomas (RCCs), Deletions involving the long arm of chromosome 7 have not been described in RCCs although they have been seen in several other tumor types, However, there have been no detailed analysis of loss of heterozygosity (LOH) of 7q sequences in sporadic RCCs, We therefore studied LOH for DNA sequences on 7q with 10 highly polymorphic markers in 92 matched normal/tumor samples representing sporadic RCCs including papillary, nonpapillary, and oncocytomas in order to determine whether allelic loss could be detected in a tumor type with no visible 7q rearrangements at the cytogenetic level, We found chromosome 7q allele loss in 59 of 92 cases (64%) involving one, two, or more microsatellite markers, The most common allele loss included loci D7S522 (24%) and D7S649 (30%) at 7q31.1-31.2, a region that contains one of the common fragile sites, FRA7G. By comparative multiplex PCR analysis, we detected a homozygous deletion of one marker in the 7q 31.1-31.2 region in one tumor, RC21. These results support the idea that a tumor suppressor gene in 7q31 is involved in the pathogenesis of sporadic renal cell carcinomas.	MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,DIV EXPT PATHOL,ROCHESTER,MN 55905; WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,KARMANOS CANC INST,DETROIT,MI 48201; EMORY UNIV,SCH MED,DEPT UROL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,WINSHIP CANC CTR,ATLANTA,GA 30322; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48201	Mayo Clinic; Barbara Ann Karmanos Cancer Institute; Wayne State University; Emory University; Emory University; Wayne State University					NCI NIH HHS [CA48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achille A, 1996, CANCER RES, V56, P3808; ANGLARD P, 1994, CANCER RES, V51, P1073; BARBI G, 1984, HUM GENET, V68, P290, DOI 10.1007/BF00292586; BERGER R, 1985, CYTOGENET CELL GENET, V40, P490, DOI 10.1159/000132181; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COLLARD JG, 1987, CANCER RES, V47, P6666; COQUELLE A, 1997, CELL, V89, P219; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; MILES J, 1988, CANCER GENET CYTOGEN, V34, P135, DOI 10.1016/0165-4608(88)90180-X; MORITA R, 1991, CANCER RES, V51, P820; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OGAWA O, 1991, CANCER RES, V51, P949; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PRESTI JC, 1993, CANCER RES, V53, P5780; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; TAKAHASHI S, 1995, CANCER RES, V55, P4114; THONES W, 1986, PATHOL RES PRACT, V181, P125; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; TSAI YC, 1990, CANCER RES, V50, P44; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	45	69	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2727	2733		10.1038/sj.onc.1201448	http://dx.doi.org/10.1038/sj.onc.1201448			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400999				2022-12-25	WOS:A1997YH46800010
J	Ahmed, MM; Sells, SF; Venkatasubbarao, K; Fruitwala, SM; Muthukkumar, S; Harp, C; Mohiuddin, M; Rangnekar, VM				Ahmed, MM; Sells, SF; Venkatasubbarao, K; Fruitwala, SM; Muthukkumar, S; Harp, C; Mohiuddin, M; Rangnekar, VM			Ionizing radiation-inducible apoptosis in the absence of p53 linked to transcription factor EGR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; WILD-TYPE P53; GENE-PRODUCT; GROWTH; PROTEIN; BINDING; CARCINOMA; ICE; IRRADIATION; EXPRESSION	The tumor suppressor protein p53 is a pivotal regulator of apoptosis, and prostate cancer cells that lack p53 protein are moderately resistant to apoptotic death by ionizing radiation. Genes encoding the transcription factor early growth response-1 (EGR-1) and cytokine tumor necrosis factor-alpha (TNF-alpha) were induced upon irradiation of prostate cancer cells, and inhibition of EGR-1 function resulted in abrogation of both TNF-alpha induction and apoptosis. Induction of the TNF-alpha gene by ionizing radiation and EGR-1 was mediated via a GC-rich EGR-1-binding moth in the TNF-alpha promoter. Because TNF-alpha induces apoptosis in prostate cancer cells, these findings suggest that, in the absence of p53, ionizing radiation-inducible apoptosis is mediated by EGR-1 via TNF-alpha transactivation.	Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Lucille P Markey Canc Ctr, Combs Res Bldg,Rm 303,800 Rose St, Lexington, KY 40536 USA.		Ahmed, Mansoor/AAK-5988-2020		NCI NIH HHS [CA60872, CA52837] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060872, R29CA052837] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DAY ML, 1993, CANCER RES, V53, P5597; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; EWING CM, 1995, CANCER RES, V55, P4813; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1995, CANCER RES, V55, P5054; HUANG RP, 1995, ONCOGENE, V55, P5054; ISAACS WB, 1991, CANCER RES, V51, P4716; KAIGHN ME, 1979, INVEST UROL, V17, P16; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIESLING VJ, 1980, J UROLOGY, V124, P851, DOI 10.1016/S0022-5347(17)55697-9; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KURTH KH, 1977, J UROLOGY, V117, P615, DOI 10.1016/S0022-5347(17)58555-9; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEA DE, 1962, ACTIONS RAD LIVING C, P74; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE WR, 1995, CANCER, V75, P1909, DOI 10.1002/1097-0142(19950401)75:7+<1909::AID-CNCR2820751625>3.0.CO;2-F; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLLENKAMP JS, 1975, J UROLOGY, V113, P374, DOI 10.1016/S0022-5347(17)59485-9; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reid S, 1996, J IMMUNOL METHODS, V192, P43, DOI 10.1016/0022-1759(96)00004-X; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TAKASHIBA S, 1993, GENE, V131, P307, DOI 10.1016/0378-1119(93)90314-S; VANVELDHUIZEN PJ, 1993, PROSTATE, V22, P23, DOI 10.1002/pros.2990220104; WEICHSELBAUM RR, 1992, SEMIN ONCOL, V19, P14; WHEELER JA, 1993, CANCER, V71, P3783, DOI 10.1002/1097-0142(19930601)71:11<3783::AID-CNCR2820711149>3.0.CO;2-X; WHITE RWD, 1993, J UROL 2, V149, pA376; WITTE L, 1989, CANCER RES, V49, P5066; WOOD DP, 1994, CANCER, V74, P2533, DOI 10.1002/1097-0142(19941101)74:9<2533::AID-CNCR2820740922>3.0.CO;2-D	50	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33056	33061		10.1074/jbc.272.52.33056	http://dx.doi.org/10.1074/jbc.272.52.33056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407088	hybrid			2022-12-25	WOS:000071182900049
J	Jing, SQ; Yu, YB; Fang, M; Hu, Z; Holst, PL; Boone, T; Delaney, J; Schultz, H; Zhou, RP; Fox, GM				Jing, SQ; Yu, YB; Fang, M; Hu, Z; Holst, PL; Boone, T; Delaney, J; Schultz, H; Zhou, RP; Fox, GM			GFR alpha-2 and GFR alpha-3 are two new receptors for ligands of the GDNF family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING GDNF; MIDBRAIN DOPAMINERGIC-NEURONS; INDUCED CELL-DEATH; NEUROTROPHIC FACTOR; RET PROTOONCOGENE; IN-VIVO; TYROSINE KINASE; TRANSFORMING GENE; SIGNAL SEQUENCE; SURVIVAL FACTOR	The receptor for glial cell line-derived neurotrophic factor (GDNF) consists of GFR alpha-1 and Ret. Neurturin is a GDNF-related neurotrophin whose receptor is presently unknown. Here we report that neurturin can bind to either GFR alpha-1 or GFR alpha-2, a novel receptor related to GFR alpha-1. Both GFR alpha-1 and GFR alpha-2 mediate neurturin-induced Ret phosphorylation. GDNF can also bind to either GFR alpha-1 or GFR alpha-2, and activate Ret in the presence of either binding receptor. Although both ligands interact with both receptors, cells expressing GFR alpha-1 bind GDNF more efficiently than neurturin, while cells expressing GFR alpha-2 bind neurturin preferentially. Crosslinking and Ret activation data also suggest that while there is cross-talk, GFR alpha-1 is the primary receptor for GDNF and GFR alpha-2 exhibits a preference for neurturin. We have also cloned a cDNA that apparently codes for a third member of the GFR alpha receptor family. This putative receptor, designated GFR alpha-3, is closely related in amino acid sequence and is nearly identical in the spacing of its cysteine residues to both GFR alpha-1 and GFR alpha-2. Analysis of the tissue distribution of GFR alpha-1, GFR alpha-2, GFR alpha-3, and Ret by Northern blot reveals overlapping but distinct patterns of expression. Consistent with a role in GDNF function, the GFR alpha s and Ret are expressed in many of the same tissues, suggesting that GFR alpha s mediate the action of GDNF family ligands in vivo.	Amgen Inc, Dept Mol Genome, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Proc Dev, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Computat Biol, Thousand Oaks, CA 91320 USA; Rutgers State Univ, Coll Pharm, Canc Res Lab, Piscataway, NJ 08855 USA	Amgen; Amgen; Amgen; Rutgers State University New Brunswick	Jing, SQ (corresponding author), Amgen Inc, Dept Mol Genome, Thousand Oaks, CA 91320 USA.							Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Borrello MG, 1995, ONCOGENE, V11, P2419; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EBENDAL T, 1995, J NEUROSCI RES, V40, P276, DOI 10.1002/jnr.490400217; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IKEDA I, 1990, ONCOGENE, V5, P1291; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MOUNT HTJ, 1995, P NATL ACAD SCI USA, V92, P9092, DOI 10.1073/pnas.92.20.9092; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SAUER H, 1995, P NATL ACAD SCI USA, V92, P8935, DOI 10.1073/pnas.92.19.8935; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SPRINGER JE, 1994, EXP NEUROL, V127, P167, DOI 10.1006/exnr.1994.1091; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1997, J NEUROSCI, V17, P3554; TSUZUKI T, 1995, ONCOGENE, V10, P191; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; ZURN AD, 1994, NEUROREPORT, V6, P113, DOI 10.1097/00001756-199412300-00030	44	190	216	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33111	33117		10.1074/jbc.272.52.33111	http://dx.doi.org/10.1074/jbc.272.52.33111			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407096	hybrid			2022-12-25	WOS:000071182900057
J	Puig, A; Primm, TP; Surendran, R; Lee, JC; Ballard, KD; Orkiszewski, RS; Makarov, V; Gilbert, HF				Puig, A; Primm, TP; Surendran, R; Lee, JC; Ballard, KD; Orkiszewski, RS; Makarov, V; Gilbert, HF			A 21-kDa C-terminal fragment of protein disulfide isomerase has isomerase, chaperone, and anti-chaperone activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ENDOPLASMIC-RETICULUM; ACTIVE-SITE; ESCHERICHIA-COLI; PEPTIDE BINDING; RIBONUCLEASE-A; THIOREDOXIN; CATALYSIS; DOMAINS; BONDS	A catalyst of disulfide formation and isomerization during protein folding protein-disulfide isomerase (PDI) has two catalytic sites housed in two domains homologous to thioredoxin, one near the N terminus and the other near the C terminus. The thioredoxin domains, by themselves, can catalyze disulfide formation, but they are unable to catalyze disulfide isomerizations (Darby, N. J. and Creighton, T. E. (1995) Biochemistry 34, 11725-11735), A 21-kDa, C-terminal fragment of PDI (amino acids 308-491), termed weePDI, comprises the C-terminal third of the molecule. The k(cat) for ribonuclease oxidative folding by weePDI is 0.26 +/- 0.02 min(-1), 3-fold lower than the wild-type enzyme but indistinguishable from the activity of a full-length mutant of PDI in which both active site cysteines of the N-terminal thioredoxin domain have been mutated to serine, Eliminating the ability of weePDI to escape easily from covalent complexes with substrate by mutating the active site cysteine nearer the C terminus to serine has a large effect on the isomerase activity of weePDI compared with its effect on the full-length enzyme, weePDI also displays chaperone and anti-chaperone activity characteristic of the full-length molecule, As isolated, weePDI is a disulfide-linked dimer in which the single cysteine (Cys-326) outside active site cross-links two weePDI monomers. The presence of the intermolecular disulfide decreases the activity by more than 2-fold. The results imply that the functions of the core thioredoxin domains of PDI and other members of the thioredoxin superfamily might be modified quite easily by the addition of relatively small accessory domains.	Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston	Gilbert, HF (corresponding author), Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA.				NIGMS NIH HHS [GM-45579, GM40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379, R01GM045579] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bevington PR, 1969, DATA REDUCTION ERROR; CAI H, 1994, J BIOL CHEM, V269, P24550; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; DESUTTER K, 1994, GENE, V141, P163, DOI 10.1016/0378-1119(94)90566-5; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; HAUGEJORDEN SM, 1992, DNA CELL BIOL, V5, P405; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDSTROMLJUNG J, 1995, J BIOL CHEM, V270, P7822, DOI 10.1074/jbc.270.14.7822; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; URADE R, 1992, J BIOL CHEM, V267, P15152; VUORI K, 1992, J BIOL CHEM, V267, P7211; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; Walker KW, 1997, J BIOL CHEM, V272, P8845; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	38	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32988	32994		10.1074/jbc.272.52.32988	http://dx.doi.org/10.1074/jbc.272.52.32988			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407079	hybrid			2022-12-25	WOS:000071182900040
J	Ryden, M; Ibanez, CF				Ryden, M; Ibanez, CF			A second determinant of binding to the p75 neurotrophin receptor revealed by alanine-scanning mutagenesis of a conserved loop in nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK RECEPTORS; NGF; ACTIVATION; P75(LNGFR); INDUCTION; RESIDUES; ALLOWS; BDNF; SITE	In the neurotrophin family, variable regions contain solvent-accessible residues important for receptor binding specificity, whereas many of the conserved residues are buried in hydrophobic cores or in the dimer interface, A stretch of six amino acids (from Asp-72 to Asn-77) in nerve growth factor (NGF) represents an exception to this general rule, These residues are highly conserved and yet form an exposed hydrophilic loop region away from other known determinants of receptor binding, We have investigated the functional importance of this region in NGF using alanine-scanning mutagenesis. Individual mutation of Asp-72, Lys-74, or His-75 to alanine (mutants D72A, K74A, and H75A, respectively) reduced the binding affinity for the p75 neurotrophin receptor by 4-10-fold, Only the D72A mutant showed an additional impairment in binding to the TrkA receptor, which was accompanied by reduced biological activity in PC12 cells, indicating a structural and/or conformational effect of this mutation, Replacement of Ser-73 or Asn-77 with alanine (mutants S78A and N77A, respectively) had no measurable effects on receptor binding, The triple mutant K74A/H75A/N77A exhibited properties that were consistent with the combined effects of the individual mutations, namely impaired binding to p75 without deficits in its interaction with TrkA, In contrast, in the triple mutant D72A/S73A/K74A, the simultaneous replacement of Asp-72 and Lys-74 with alanine had a compensatory effect such that binding to both p75 and TrkA was comparable to that of wild-type NGF, despite the deficits seen in the individual replacements, This molecule, however, was produced at low levels, and its biological activity in sympathetic ganglion explants was reduced, which, together with results from TrkA phosphorylation assays, indicated a reduced stability during prolonged culture conditions, Taken together, these data reveal a second region of interaction with the p75 receptor in NGF with the positively charged residues Lys-74 and His-75 as candidate points of contact, In addition, Asp-72 appears to be a structurally important side chain for stabilizing the conformation of the loop through interactions with neighboring residues.	Karolinska Inst, Dept Neurosci, Mol Neurobiol Lab, S-17177 Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Mol Neurobiol Lab, S-17177 Stockholm, Sweden.							Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Ebendal T, 1989, NERVE GROWTH FACTORS, V12, P81; Frade JM, 1996, NATURE, V383, P166; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; IBANEZ CF, 1995, LIFE DEATH NERVOUS S, V67; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; Ryden M, 1996, J BIOL CHEM, V271, P5623, DOI 10.1074/jbc.271.10.5623; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278	25	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33085	33091		10.1074/jbc.272.52.33085	http://dx.doi.org/10.1074/jbc.272.52.33085			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407092	hybrid			2022-12-25	WOS:000071182900053
J	Ferguson, AT; Vertino, PM; Spitzner, JR; Baylin, SB; Muller, MT; Davidson, NE				Ferguson, AT; Vertino, PM; Spitzner, JR; Baylin, SB; Muller, MT; Davidson, NE			Role of estrogen receptor gene demethylation and DNA methyltransferase DNA adduct formation in 5-aza-2 '-deoxycytidine-induced cytotoxicity in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID LEUKEMIAS; CPG ISLAND; EPITHELIAL-CELLS; SUPPRESSOR GENE; COLON-CANCER; METHYLATION; EXPRESSION; HYPOMETHYLATION; INHIBITION; MECHANISM	The cytosine analog 5-aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase, Its cytotoxicity has been attributed to several possible mechanisms including reexpression of growth suppressor genes and formation of covalent adducts between DNA methyltransferase and 5-aza-2'-deoxycytidine-substituted DNA which may lead to steric inhibition of DNA function, In this study, we use a panel of human breast cancer cell lines as a model system to examine the relative contribution of two mechanisms, gene reactivation and adduct formation. Estrogen receptor-negative cells, which have a hypermethylated estrogen receptor gene promoter, are more sensitive than estrogen receptor-positive cells and underwent apoptosis in response to 5-aza-2-deoxycytidine. For the first time, we show that reactivation of a gene silenced by methylation, estrogen receptor, plays a major role in this toxicity in one estrogen receptor-negative cell line as treatment of the cells with anti-estrogen-blocked cell death, However, drug sensitivity of other tumor cell lines correlated best with increased levels of DNA methyltransferase activity and formation DNA DNA methyltransferase adducts as analyzed in situ. Therefore, both reexpression of genes like estrogen receptor and formation of covalent enzyme DNA adducts can play a role in 5-aza-2'-deoxycytidine toxicity in cancer cells.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Emory Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, Atlanta, GA 30335 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Johns Hopkins University; Johns Hopkins Medicine; Emory University; University System of Ohio; Ohio State University	Davidson, NE (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 422 N Bond St, Baltimore, MD 21231 USA.				NATIONAL CANCER INSTITUTE [P30CA016058, U01CA063185, R01CA043318] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63185, CA 43318, CA 16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1988, CANCER RES, V40, P277; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; CHABOT GG, 1983, BIOCHEM PHARMACOL, V32, P1327, DOI 10.1016/0006-2952(83)90293-9; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; CHRISTMAN JK, 1985, J BIOL CHEM, V260, P4059; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FERGUSON AT, 1995, CANCER RES, V55, P2279; FERGUSON AT, 1994, J VIROL, V68, P4274, DOI 10.1128/JVI.68.7.4274-4286.1994; GABBARA S, 1995, BIOCHEM J, V307, P87, DOI 10.1042/bj3070087; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; Graham JD, 1995, J BIOL CHEM, V270, P30693, DOI 10.1074/jbc.270.51.30693; HERMAN JG, 1995, CANCER RES, V55, P4525; Howell A, 1996, BRIT J CANCER, V74, P300, DOI 10.1038/bjc.1996.357; HUANG Y, 1991, J BIOL CHEM, V266, P17424; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Issa JPJ, 1996, CANCER RES, V56, P973; JABLONKA E, 1985, CHROMOSOMA, V93, P152, DOI 10.1007/BF00293162; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; MCCLOSKEY DE, 1995, CANCER RES, V55, P3233; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; MOMPARLER RL, 1985, PHARMACOL THERAPEUT, V30, P287, DOI 10.1016/0163-7258(85)90053-1; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; PINTO A, 1984, BLOOD, V64, P922; PINTO A, 1993, LEUKEMIA, V7, P51; SANTI D, 1984, P NATL ACAD SCI USA, V81, P6996; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZAJCHOWSKI DA, 1993, CANCER RES, V53, P5004	43	136	140	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32260	32266		10.1074/jbc.272.51.32260	http://dx.doi.org/10.1074/jbc.272.51.32260			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405430	hybrid			2022-12-25	WOS:000071108000049
J	So, T; Ito, H; Koga, T; Watanabe, S; Ueda, T; Imoto, T				So, T; Ito, H; Koga, T; Watanabe, S; Ueda, T; Imoto, T			Depression of T-cell epitope generation by stabilizing hen lysozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGEN-PRESENTING CELLS; DISULFIDE BONDS; THERMAL INACTIVATION; QUATERNARY STRUCTURE; TOLERANCE INDUCTION; TRANSITION-STATE; GROWTH-FACTOR; CROSS-LINKS; PROTEINS	Conformational stability of proteins is an important factor that determines their resistance/susceptibility to proteolytic digestion. Intracellular proteolysis is the key step in antigen presentation events for protein antigens; hence, it is likely that increasing protein stability reduces the antigenicity of proteins, We prepared three hen egg white lysozyme derivatives possessing different stabilities by chemical modification to clarify the relationship between conformational stability and the antigenicity of the protein, One of the derivatives was conformationally unstabilized by removing one intramolecular disulfide bond, whereas the two others were stabilized by the addition of an intramolecular crosslink. The antigenicity of these derivatives was evaluated using hen egg white lysozyme-specific T-cell hybridoma cells and a B-lymphoma cell line, A20, as antigen-presenting cells. With an increase in conformational stability, the T-cell response decreased. However, the reduction was not derived from the inefficiency of internalization to A20 cells nor the alteration of antigenicity by chemical modifications. Moreover, from analyses of their susceptibility to proteolysis and the kinetics of presentation of the T-cell epitope, it was confirmed that increasing protein stability led to the depression of T-cell epitope generation by increasing resistance to proteolysis. These results have an important implication in devising a new strategy for manipulating T-cell response by the stability of protein antigen.	Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 81282, Japan; Kyushu Univ, Sch Dent, Dept Biochem, Fukuoka 81282, Japan	Kyushu University; Kyushu University	Imoto, T (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 81282, Japan.		So, Takanori/R-6175-2019	So, Takanori/0000-0003-3004-8526				ADORINI L, 1988, P NATL ACAD SCI USA, V85, P5181, DOI 10.1073/pnas.85.14.5181; AHERN TJ, 1985, SCIENCE, V228, P1280, DOI 10.1126/science.4001942; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; BEDDELL CR, 1975, J MOL BIOL, V97, P643, DOI 10.1016/S0022-2836(75)80064-7; Beernink PT, 1996, P NATL ACAD SCI USA, V93, P5374, DOI 10.1073/pnas.93.11.5374; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CHILLER JM, 1971, SCIENCE, V171, P813, DOI 10.1126/science.171.3973.813; COLLINS DS, 1991, J IMMUNOL, V147, P4054; COOPER A, 1992, J MOL BIOL, V225, P939, DOI 10.1016/0022-2836(92)90094-Z; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DIMENT S, 1988, J BIOL CHEM, V263, P6901; GAMMON G, 1991, J EXP MED, V173, P609, DOI 10.1084/jem.173.3.609; GILLIS S, 1978, J IMMUNOL, V120, P2027; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; Imoto T, 1997, CELL MOL LIFE SCI, V53, P215, DOI 10.1007/PL00000593; IMOTO T, 1974, BIOCHIM BIOPHYS ACTA, V336, P264, DOI 10.1016/0005-2795(74)90403-6; IMOTO T, 1973, J MOL BIOL, V80, P637, DOI 10.1016/0022-2836(73)90201-5; IMOTO T, 1986, J MOL BIOL, V190, P647, DOI 10.1016/0022-2836(86)90250-0; Janssen R, 1996, INT IMMUNOL, V8, P829, DOI 10.1093/intimm/8.6.829; JENSEN PE, 1993, J IMMUNOL, V150, P3347; JOHNSON RE, 1978, BIOCHEMISTRY-US, V17, P1479, DOI 10.1021/bi00601a019; JOHNSON RE, 1990, PROTEIN ENG, V3, P325; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KIM KJ, 1979, J IMMUNOL, V122, P549; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; LEVICH JD, 1987, J IMMUNOL, V138, P3675; LEVICH JD, 1985, J IMMUNOL, V135, P873; LEVINE TP, 1992, P NATL ACAD SCI USA, V89, P8342, DOI 10.1073/pnas.89.17.8342; LIN SH, 1984, BIOCHEMISTRY-US, V23, P5504, DOI 10.1021/bi00318a019; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MATTHYSSENS GE, 1972, EUR J BIOCHEM, V26, P449, DOI 10.1111/j.1432-1033.1972.tb01786.x; MCCOY KL, 1993, J IMMUNOL, V151, P6757; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PACE CN, 1984, BIOCHEM J, V219, P411, DOI 10.1042/bj2190411; PACE CN, 1988, J BIOL CHEM, V263, P11820; PARKS DE, 1980, J IMMUNOL, V124, P1230; POLAND DC, 1965, BIOPOLYMERS, V3, P373; RADFORD SE, 1991, BIOCHEM J, V273, P211, DOI 10.1042/bj2730211; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; ROUAS N, 1993, J IMMUNOL, V150, P782; RUVINOV SB, 1994, J BIOL CHEM, V269, P11703; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2489; So T, 1996, IMMUNOL LETT, V49, P91, DOI 10.1016/0165-2478(95)02488-3; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; STREICHER HZ, 1984, P NATL ACAD SCI-BIOL, V81, P6831, DOI 10.1073/pnas.81.21.6831; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3086; UEDA T, 1985, BIOCHEMISTRY-US, V24, P6316, DOI 10.1021/bi00343a042; YAMADA H, 1993, J BIOCHEM-TOKYO, V114, P398, DOI 10.1093/oxfordjournals.jbchem.a124188; YAMADA H, 1994, J BIOCHEM-TOKYO, V116, P852, DOI 10.1093/oxfordjournals.jbchem.a124606	55	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32136	32140		10.1074/jbc.272.51.32136	http://dx.doi.org/10.1074/jbc.272.51.32136			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405412	hybrid			2022-12-25	WOS:000071108000031
J	Breault, DT; Lichtler, AC; Rowe, DW				Breault, DT; Lichtler, AC; Rowe, DW			COL1A1 transgene expression in stably transfected osteoblastic cells - Relative contributions of first intron, 3'-flanking sequences, and sequences derived from the body of the human COL1A1 minigene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(I) COLLAGEN GENE; PUTATIVE REGULATORY SEQUENCES; 3' UNTRANSLATED REGION; I PROCOLLAGEN COL1A1; 1ST INTRON; MESSENGER-RNA; DIFFERENTIAL UTILIZATION; 3'-UNTRANSLATED REGION; CHROMATIN STRUCTURE; CULTURED-CELLS	Collagen reporter gene constructs have be used to identify cell-specific sequences needed for transcriptional activation, The elements required for endogenous levels of COL1A1 expression, however, have not been elucidated, The human COL1A1 minigene is expressed at high levels and likely harbors sequence elements required for endogenous levels of activity, Using stably transfected osteoblastic Pyla cells, me studied a series of constructs (pOBColCAT) designed to characterize further the elements required for high level of expression. pOBColCAT, which contains the COL1A1 first intron, was expressed at 50-100-fold higher levels than ColCAT 3.6, which lacks the first intron. This difference is best explained by improved mRNA processing rather than a transcriptional effect, Furthermore, variation in activity observed with the intron deletion constructs is best explained by altered mRNA splicing, Two major regions of the human COL1A1 minigene, the 3'-flanking sequences and the minigene body, were introduced into pOBColCAT to assess both transcriptional enhancing activity and the effect on mRNA stability, Analysis of the minigene body, which includes the first five exons and introns fused with the terminal six introns and exons, revealed an orientation-independent 5-fold increase in CAT activity, In contrast the 3'-flanking sequences gave rise to a modest 61% increase in CAT activity, Neither region increased the mRNA half-life of the parent construct, suggesting that CAT-specific mRNA instability elements may serve as dominant negative regulators of stability. This study suggests that other sites within the body of the COL1A1 minigene are important for high expression, e.g. during periods of rapid extracellular matrix production.	UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,L5090,FARMINGTON,CT 06030	University of Connecticut			Breault, David/HDN-6048-2022					Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAKER CC, 1990, RECOMBINANT SYSTEMS IN PROTEIN EXPRESSION, P75; BARKSDALE SK, 1995, MOL CELL BIOL, V15, P2962; BARSH GS, 1984, J BIOL CHEM, V259, P4906; BEDALOV A, 1995, J BONE MINER RES, V10, P1443; BEDALOV A, 1994, J BIOL CHEM, V269, P4903; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; Breault D, 1996, MATRIX BIOL, V15, P62, DOI 10.1016/S0945-053X(96)90141-9; BREINDL M, 1984, CELL, V38, P9, DOI 10.1016/0092-8674(84)90521-X; DIEGELMANN RF, 1972, DEV BIOL, V28, P443, DOI 10.1016/0012-1606(72)90028-0; FALL PM, 1994, J BONE MINER RES, V9, P1935; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HERGET T, 1989, MOL CELL BIOL, V9, P2828, DOI 10.1128/MCB.9.7.2828; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; KREBSBACH PH, 1993, MOL CELL BIOL, V13, P5168, DOI 10.1128/MCB.13.9.5168; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; Liska Deann J., 1992, Gene Expression, V2, P379; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; LISKA DJ, 1990, CELL REGUL, V1, P487, DOI 10.1091/mbc.1.6.487; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; MAATTA A, 1995, BBA-GENE STRUCT EXPR, V1260, P294, DOI 10.1016/0167-4781(94)00207-J; MAATTA A, 1993, BIOCHEM J, V295, P691; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; MOEN RC, 1979, J BIOL CHEM, V254, P3526; NEEL H, 1993, GENE DEV, V7, P2194, DOI 10.1101/gad.7.11.2194; NESIC D, 1994, GENE DEV, V8, P363, DOI 10.1101/gad.8.3.363; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RAISZ LG, 1993, MOL ENDOCRINOL, V7, P17, DOI 10.1210/me.7.1.17; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SALVATORI R, 1992, BIOTECHNIQUES, V13, P510; SEGEL IH, 1976, BIOCH CALCULATIONS, P297; SOKOLOV BP, 1995, J BIOL CHEM, V270, P9622, DOI 10.1074/jbc.270.16.9622; SOKOLOV BP, 1993, BIOCHEMISTRY-US, V32, P9242, DOI 10.1021/bi00086a033	38	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31241	31250		10.1074/jbc.272.50.31241	http://dx.doi.org/10.1074/jbc.272.50.31241			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395449	hybrid			2022-12-25	WOS:A1997YL41900008
J	Roychowdhury, S; Rasenick, MM				Roychowdhury, S; Rasenick, MM			G protein beta 1 gamma 2 subunits promote microtubule assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SIGNAL-TRANSDUCTION; CYTOPLASMIC MICROTUBULES; REGULATORY PROTEIN; GTP-BINDING; TUBULIN; RECEPTORS; DOMAINS; CELLS; ASSOCIATION	alpha and beta gamma subunits of G proteins are thought to transduce signals from cell surface receptors to intracellular effector molecules. G(alpha) and G(beta gamma) have also been implicated in cell growth and differentiation, perhaps due to their association with cytoskeletal components. In this report G(beta gamma) is shown to modulate the cytoskeleton by regulation of microtubule assembly, Specificity among beta gamma species exists, as beta 1 gamma 2 stimulates microtubule assembly, and beta 1 gamma 1 is without any effect. Furthermore, a mutant beta 1 gamma 2, beta 1 gamma 2(C68S), which does not undergo prenylation and subsequent carboxyl-terminal processing on the gamma subunit, does not stimulate the formation of microtubules. beta immunoreactivity was detected exclusively in the microtubule fraction after assembly in the presence of beta 1 gamma 2, suggesting a preferential association with microtubules rather than soluble tubulin. Crude microtubule fractions from ovine brain contain G(beta gamma), and electron tron microscopy reveals a specific association with microtubules. The decoration of microtubules by G(beta gamma) appears to be strikingly similar to the periodic pattern observed for microtubule-associated proteins, suggesting a similar site of activation of microtubule assembly by both agents. It is suggested that reformation of the cytoskeleton represents an additional cellular process mediated by G(beta gamma).	UNIV ILLINOIS,DEPT PSYCHIAT,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roychowdhury, S (corresponding author), UNIV ILLINOIS,COLL MED,DEPT PHYSIOL & BIOPHYS,M-C 901,835 S WOLCOTT AVE,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 39595, MH 00669] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Avila J, 1990, MICROTUBULE PROTEINS, V1st; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burns RG, 1996, TRENDS CELL BIOL, V6, P297, DOI 10.1016/0962-8924(96)10024-6; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; Dustin P., 1984, MICROTUBULES; FUKUDA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658A0; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOSAWA T, 1995, J BIOL CHEM, V270, P1734; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LEE JC, 1975, BIOCHEMISTRY-US, V14, P5183, DOI 10.1021/bi00694a025; LEIBER D, 1993, J BIOL CHEM, V268, P3833; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LI QW, 1994, J BIOL CHEM, V269, P31777; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LIN CT, 1992, LAB INVEST, V67, P770; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; NEER EJ, 1994, PROTEIN SCI, V3, P3; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; PURICH DL, 1984, ADV PROTEIN CHEM, V36, P133, DOI 10.1016/S0065-3233(08)60297-1; RASENICK MM, 1981, NATURE, V294, P560, DOI 10.1038/294560a0; Ravindra R, 1996, J CELL BIOCHEM, V61, P392, DOI 10.1002/(SICI)1097-4644(19960601)61:3<392::AID-JCB6>3.3.CO;2-M; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; SAGA CR, 1995, BIOCHEMISTRY-US, V34, P7409; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SIMON M, 1991, SCIENCE, V252, P8002; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WANG N, 1991, BIOCHEMISTRY-US, V30, P10957, DOI 10.1021/bi00109a021; WANG N, 1990, J BIOL CHEM, V265, P1239; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; Yan K, 1996, J NEUROCHEM, V66, P1489; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	46	72	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31576	31581		10.1074/jbc.272.50.31576	http://dx.doi.org/10.1074/jbc.272.50.31576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395495	hybrid			2022-12-25	WOS:A1997YL41900054
J	Zheng, GX; Blumenthal, KM; Ji, YG; Shardy, DL; Cohen, SB; Stavnezer, E				Zheng, GX; Blumenthal, KM; Ji, YG; Shardy, DL; Cohen, SB; Stavnezer, E			High affinity dimerization by ski involves parallel pairing of a novel bipartite alpha-helical domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COIL LEUCINE-ZIPPER; ELECTROSTATIC REPULSIONS; SECONDARY STRUCTURE; ONCOGENE; PROTEINS; GCN4; ACTIVATION; STABILITY; ACCURACY; FAMILY	c-Ski protein possesses a C-terminal dimerization domain that was deleted during the generation of v-ski, and has been implicated in the increased potency of c-ski in cellular transformation compared with the viral gene. The domain is predicted to consist of an extended alpha-helical segment made up of two motifs: a tandem repeat (TR) consisting of five imperfect repeats of 25 residues each and a leucine zipper (LZ) consisting of six heptad repeats. We have examined the structure and dimerization of TR or LZ individually or the entire TR-LZ domain. Using a quenched chemical cross-linking method, we show that the TR dimerizes with moderate efficiency (K-d = 4 x 10(-6) M), whereas LZ dimerizes poorly (K-d > 2 x 10(-5) M). However, the entire TR-LZ domain dimerizes efficiently (K-d = 2 x 10(-8) M), showing a cooperative effect of the two motifs, CD analyses indicate that all three proteins contain predominantly helices. Limited proteolysis of the TR-LZ dimer indicates that the two helical motifs are linked by a small loop. Interchain disulfide bond formation indicates that both the LZ and TR helices are oriented in parallel. We propose a model for the dimer interface in the TR region consisting of discontinuous clusters of hydrophobic residues forming ''leucine buttons.''	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; UNIV CINCINNATI, COLL MED, DEPT MOL GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	Case Western Reserve University; University of Cincinnati					NCI NIH HHS [CA43600] Funding Source: Medline; NHLBI NIH HHS [HL51555] Funding Source: Medline; NIGMS NIH HHS [GM48676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P552; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; Hurme R, 1996, J BIOL CHEM, V271, P12626, DOI 10.1074/jbc.271.21.12626; Institutionen B Universitet Uppsala S, 1963, PURE APPL CHEM, V233; KENAR KT, 1995, PROTEIN SCI, V4, P1934, DOI 10.1002/pro.5560040929; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; KOHN WD, 1995, PROTEIN SCI, V4, P237; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NAGASE T, 1993, J BIOL CHEM, V268, P13710; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SLEEMAN JP, 1993, ONCOGENE, V8, P67; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; STURAVE P, 1989, MOL CELL BIOL, V9, P1989; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1991, ONCOGENE, V6, P353; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	34	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31855	31864		10.1074/jbc.272.50.31855	http://dx.doi.org/10.1074/jbc.272.50.31855			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395532	hybrid			2022-12-25	WOS:A1997YL41900091
J	Dustin, ML; Golan, DE; Zhu, DM; Miller, JM; Meier, W; Davies, EA; van der Merwe, PA				Dustin, ML; Golan, DE; Zhu, DM; Miller, JM; Meier, W; Davies, EA; van der Merwe, PA			Low affinity interaction of human or rat T cell adhesion molecule CD2 with its ligand aligns adhering membranes to achieve high physiological affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-3; MHC CLASS-II; CYTOPLASMIC DOMAIN; RECEPTOR; BINDING; LFA-3; CD48; ACTIVATION; MOBILITY; PROTEIN	The mechanism by which low affinity adhesion molecules function to produce stable cell-cell adhesion is unknown. In solution, the interaction of human CD2 with its ligand CD58 is of low affinity (500 mM(-1)) and the interaction of rat CD2 with its ligand CD48 is of still lower affinity (40 mM(-1)). At the molecular level, however, the two systems are likely to be topologically identical. Fluorescently labeled glycosylphosphatidylinositol-anchored CD48 and CD58 were prepared and incorporated into supported phospholipid bilayers, in which the ligands were capable of free lateral diffusion, Quantitative fluorescence imaging was used to study the binding of cell surface human and rat CD2 molecules to the fluorescent ligands in contact areas between Jurkat cells and the bilayers. These studies provide two major conclusions. First, CD2/ligand interactions cooperate to align membranes with nanometer precision leading to a physiologically effective two-dimensional affinity. This process does not require the intact cytoplasmic tail of CD2. Second, the degree of membrane alignment that can be achieved by topologically similar receptors deteriorates with decreasing affinity. This suggests an affinity limit for the ability of this mode of cooperativity to achieve stable cell-cell adhesion at approximately 10 mM(-1).	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Biogen Inc, Cambridge, MA 02142 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Biol Chem & Mol Pharmacol,Hematol Oncol Div, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Hematol Oncol Div, Boston, MA 02115 USA; Univ Oxford, Sir William Dunn Sch Pathol, MRC, Cellular Immunol Unit, Oxford OX1 3RE, England	Washington University (WUSTL); Washington University (WUSTL); Biogen; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Oxford	Dustin, ML (corresponding author), Washington Univ, Sch Med, Ctr Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.		van der Merwe, P. Anton/F-8539-2011; Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BELL GI, 1984, BIOPHYS J, V45, P1051, DOI 10.1016/S0006-3495(84)84252-6; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASASNOVA SJM, 1997, NATURE, V387, P312; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Dustin ML, 1997, J BIOL CHEM, V272, P15782, DOI 10.1074/jbc.272.25.15782; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; IZZARD CS, 1976, J CELL SCI, V21, P129; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KAGEYAMA S, 1995, J IMMUNOL, V154, P567; Knorr R, 1997, J EXP MED, V186, P719, DOI 10.1084/jem.186.5.719; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; KUO SC, 1993, BIOPHYS J, V65, P2191, DOI 10.1016/S0006-3495(93)81277-3; LIU SJ, 1995, BIOPHYS J, V68, P459, DOI 10.1016/S0006-3495(95)80207-9; MEGE JL, 1986, J THEOR BIOL, V119, P147, DOI 10.1016/S0022-5193(86)80070-4; Melton E, 1996, EUR J IMMUNOL, V26, P2952, DOI 10.1002/eji.1830261222; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; SAKIHAMA T, 1995, IMMUNOL TODAY, V16, P581, DOI 10.1016/0167-5699(95)80081-6; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANDRIN MS, 1993, J IMMUNOL, V151, P4606; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAVERNOR AS, 1994, EUR J BIOCHEM, V219, P969, DOI 10.1111/j.1432-1033.1994.tb18579.x; Trinkaus J. P., 1984, CELLS ORGANS FORCES; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1993, EUR J IMMUNOL, V23, P1373, DOI 10.1002/eji.1830230628; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; VARHAGEN AM, 1996, EUR J IMMUNOL, V26, P2841; WARD MD, 1994, BIOPHYS J, V67, P2522, DOI 10.1016/S0006-3495(94)80742-8; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368	51	161	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30889	30898		10.1074/jbc.272.49.30889	http://dx.doi.org/10.1074/jbc.272.49.30889			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388235	hybrid			2022-12-25	WOS:000071640800048
J	Ramirez, MT; Zhao, XL; Schulman, H; Brown, JH				Ramirez, MT; Zhao, XL; Schulman, H; Brown, JH			The nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN-2; ALPHA-ADRENERGIC STIMULATION; CALCIUM INFLUX; CELLS; PHOSPHORYLATION; IDENTIFICATION; VOLTAGE; PATHWAY; OVEREXPRESSION; ACTIVATION	Cultured neonatal ventricular myocytes display features of myocardial hypertrophy including increased cell size, myofilament organization, and reexpression of the embryonic gene for atrial natriuretic factor (ANF). KN-93, an inhibitor of multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase II), blocked the induction of these responses by the alpha(1)-adrenergic receptor agonist phenylephrine, whereas its inactive analog KN-92 did not, To directly determine whether CaM kinase II could regulate ANF gene expression, we transiently expressed each of three isoforms of CaM kinase II ((alpha, delta(B), and delta(C)) along with an ANF promoter/luciferase reporter gene. The delta(B) isoform markedly increased luciferase gene expression, whereas comparable levels of the delta(C) and alpha isoforms were ineffective, Expression of delta(B)-CaM kinase II also potentiated phenylephrine-mediated ANF gene expression, and this effect was blocked by KN-93 but not by KN-92, The ability of delta(B)-CaM kinase II to transactivate a truncated ANF promoter, containing a serum response element (SRE) required for phenylephrine inducible gene expression, was lost when this SRE was mutated. The delta(B) isoform of CaM kinase II has been shown to exhibit nuclear localization, Coexpression of the non-nuclear delta(C) or alpha isoforms, which can form multimers with the delta(B) isoform, prevented the nuclear localization of delta(B)-CaM kinase II and also blocked its effects on ANF reporter gene and protein expression, In addition, a chimeric alpha-CaM kinase II which contains the nuclear localization signal of the delta(B) isoform was able to induce ANF reporter gene expression, albeit to a lesser extent than delta(B)-CaM kinase II, These data are the first to assign a function to the delta(B) isoform of CaM kinase II and to link its nuclear localization to subsequent activation of cardiac gene expression.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Stanford University	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NHLBI NIH HHS [HL28143, HL46345] Funding Source: Medline; NIGMS NIH HHS [GM40600] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, R37HL028143, P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; EDMAN CF, 1994, BBA-MOL CELL RES, V1221, P89, DOI 10.1016/0167-4889(94)90221-6; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LAPOINTE MC, 1990, HYPERTENSION, V15, P20, DOI 10.1161/01.HYP.15.1.20; Li L, 1997, J PHYSIOL-LONDON, V501, P17, DOI 10.1111/j.1469-7793.1997.017bo.x; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MISRA RP, 1994, J BIOL CHEM, V269, P25483; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; SAMAREL AM, 1992, AM J PHYSIOL, V263, pC642, DOI 10.1152/ajpcell.1992.263.3.C642; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; Wang Y, 1996, MOL CELL BIOL, V16, P5915; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659	34	168	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31203	31208		10.1074/jbc.272.49.31203	http://dx.doi.org/10.1074/jbc.272.49.31203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388275	hybrid			2022-12-25	WOS:000071640800088
J	Ozers, MS; Hill, JJ; Ervin, K; Wood, JR; Nardulli, AM; Royer, CA; Gorski, J				Ozers, MS; Hill, JJ; Ervin, K; Wood, JR; Nardulli, AM; Royer, CA; Gorski, J			Equilibrium binding of estrogen receptor with DNA using fluorescence anisotropy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTORS; CONFORMATIONAL CHANGE; NUMERICAL-ANALYSIS; STEROID-HORMONES; AMINO-ACIDS; DOMAIN; LIGAND	Interaction of estrogen receptor (ER) with DNA sequences known as estrogen response elements (ERE) is required for estrogen regulation of the expression of target genes, To characterize the affinity and specificity of ER interaction with ERE sequences in vitro under equilibrium conditions, fluorescence anisotropy assays were performed using recombinant, purified ER and a fluorescein-labeled 35 base pair oligonucleotide bearing an idealized palindromic ERE, In buffer containing 100 mM KCl, the baculovirus-expressed, purified human EW bound with similar affinity to the consensus ERE and a mutant ERE with a single base pair change per half site. Above 225 mM KCl, ER exhibited discrimination between the consensus and mutated ERE targets, Between 225 and 275 mM KCl, binding to the consensus ERE was independent of salt concentration and occurred with an equilibrium dissociation constant (Rd) Of 1.8 +/- 0.6 nM, whereas binding to the mutant ERE was not detected at ER concentrations below 100 nn under the same conditions. At 300 mM KCl, the K-d for the consensus ERE increased approximately 25-fold, suggesting complex salt concentration dependence, Both estrogen-occupied and unoccupied ER bound to the consensus ERE sequence with similar affinity, indicating that estrogen affects ER activity at a step other than DNA binding, Unlike the full-length ER, the recombinant DNA binding domain of ER did not discriminate between the consensus and mutated ERE sequences even at buffer salt concentrations greater than 200 mM NaCl, suggesting that ER sequences outside the DNA binding domain may be important in promoting specific binding.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53706; PANVERA CORP,MADISON,WI 53711; UNIV ILLINOIS,DEPT MOL & INTEGRAT PHYSIOL,URBANA,IL 61801	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Urbana-Champaign			Royer, Catherine A/E-5266-2016; Wood, Jennifer R/S-3213-2019	Royer, Catherine A/0000-0002-2670-3391; Wood, Jennifer R/0000-0001-9337-5837	NICHD NIH HHS [HD08192, HD07259, HD31299] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD008192, R29HD031299, T32HD007259, R37HD008192] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FERNANDO T, 1992, BIOCHEMISTRY-US, V31, P3429, DOI 10.1021/bi00128a018; FRITSCH M, 1992, BIOCHEMISTRY-US, V31, P5303, DOI 10.1021/bi00138a009; FRITSCH M, 1993, BIOCHEMISTRY-US, V32, P14000, DOI 10.1021/bi00213a033; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; FURLOW JD, 1993, J BIOL CHEM, V268, P12519; HANSEN JC, 1986, J BIOL CHEM, V261, P13990; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; Hill JJ, 1997, METHOD ENZYMOL, V278, P390; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P13717, DOI 10.1021/bi00042a001; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; LUNDEEN S, 1996, HDB ENDOCRINOLOGY, P121; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MURDOCH FE, 1991, BIOCHEMISTRY-US, V30, P10838, DOI 10.1021/bi00109a005; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; NARDULLI AM, 1991, J BIOL CHEM, V266, P24070; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; ROYER CA, 1993, ANAL BIOCHEM, V210, P91, DOI 10.1006/abio.1993.1155; ROYER CA, 1992, METHOD ENZYMOL, V210, P481; ROYER CA, 1990, ANAL BIOCHEM, V191, P287, DOI 10.1016/0003-2697(90)90221-T; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1	46	75	79	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30405	30411		10.1074/jbc.272.48.30405	http://dx.doi.org/10.1074/jbc.272.48.30405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374531	hybrid			2022-12-25	WOS:A1997YH61300063
J	Waltz, SE; McDowell, SA; Muraoka, RS; Air, EL; Flick, LM; Chen, YQ; Wang, MH; Degen, SJF				Waltz, SE; McDowell, SA; Muraoka, RS; Air, EL; Flick, LM; Chen, YQ; Wang, MH; Degen, SJF			Functional characterization of domains contained in hepatocyte growth factor-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-STIMULATING PROTEIN; RECEPTOR TYROSINE KINASE; SCATTER FACTOR; KRINGLE DOMAINS; MESSENGER-RNA; MET RECEPTOR; HUMAN-SERUM; GENE; EXPRESSION; RON	To delineate the functional protein domains necessary for the biological activity of hepatocyte growth factor-like protein (HGFL), we created various site-directed and deletion mutated cDNAs coding for this protein, Wild-type and mutated versions of HGFL were produced after transfection of the corresponding cDNAs into tissue culture cells, The biological importance of the domains within HGFL was then examined by addition of recombinant wild-type or mutant forms of HGFL to assays aimed at elucidating regions involved in the stimulation of DNA synthesis, the induction of shape changes in macrophages, and the ability to stimulate cell scattering, Mutant proteins lacking the serine protease-like domain (light chain) were not biologically active in any of the assays tested and could not compete with wild-type HGFL in cell scattering experiments. These data, in addition to direct enzyme-linked immunosorbent assay analyses, suggest that the light chain may play an important role in the interaction of HGFL with its receptor, Ron, Elimination of the proposed protease cleavage site between the heavy and light chains (by mutation of Arg-483 to Glu) produced a protein with activity comparable to wild-type HGFL, Further studies with this mutated protein uncovered an additional proteolytic cleavage site that produces biologically active protein. Deletion of the various kringle domains or the amino-terminal hairpin loop had various effects in the multiple assays, These data suggest that the heavy chain may play a pivotal role ill determining the functional aspects of HGFL.	CHILDRENS HOSP RES FDN,DIV DEV BIOL,CINCINNATI,OH 45229; UNIV CINCINNATI,GRAD PROGRAM DEV BIOL,CINCINNATI,OH 45229; WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV PULM MED,DETROIT,MI 48201	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Wayne State University				Waltz, Susan/0000-0003-3572-4642	NHLBI NIH HHS [HL07527] Funding Source: Medline; NIDDK NIH HHS [DK09466, DK47003] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009466] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZERRA JA, 1994, BIOCHEM BIOPH RES CO, V203, P666, DOI 10.1006/bbrc.1994.2234; BEZERRA JA, 1993, PROTEIN SCI, V2, P666; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HAN S, 1993, HEPATOCYTE GROWTH FA, P61; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LEE HS, 1995, BIOCHEM BIOPH RES CO, V210, P1017, DOI 10.1006/bbrc.1995.1758; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; QUANTIN B, 1995, DEV DYNAM, V204, P383, DOI 10.1002/aja.1002040405; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; STOKER M, 1987, NATURE, V327, P230; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; WALTZ SE, IN PRESS ONCOGENE; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1994, J BIOL CHEM, V269, P3436; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	44	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30526	30537		10.1074/jbc.272.48.30526	http://dx.doi.org/10.1074/jbc.272.48.30526			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374547	hybrid			2022-12-25	WOS:A1997YH61300079
J	Hu, MCT; Qiu, WR; Wang, YP				Hu, MCT; Qiu, WR; Wang, YP			JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases	ONCOGENE			English	Article						p53; c-Jun kinase; phosphorylation; tumor suppressor protein	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; JUN ACTIVATION DOMAIN; MAP KINASE; IN-VIVO; PHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; INDUCED APOPTOSIS; CELLS	The function of the tumor suppressor protein p53 is modulated by post-translational events, primarily by phosphorylation. p53 is phosphorylated at multiple sites by a variety of protein kinases depending on the cellular environment. It has been suggested that serine 34 of mouse p53 is specifically phosphorylated by a stress-activated protein kinase in response to ultraviolet radiation. Since serine 34 is a major site of phosphorylation of mouse p53 in vivo and its specific protein kinase is still not definitively identified yet, we have examined the c-Jun N-terminal kinase 1 (JNK1) activity on p53 by expressing JNK1 in 293T cells. We show here that activated JNK1 phosphorylates mouse p53 specifically at serine 34 in vitro, while a dominanant-negative JNK1 mutant does not phosphorylate p53. More importantly, JNK1 associates with p53 in vivo, with or without activation, confirming that JNK1 is indeed a p53 kinase. Interestingly, activated JNK2 and JNK3 also phosphorylate serine 34 of mouse p53. Furthermore, JNK2 and JNK3 also associate with p53 in vivo, indicating that not only JNK1, but also JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Phosphorylation of p53 by JNKs may play an important role in nuclear signal transduction in response to environmental stress or tumorigenic agents.			Hu, MCT (corresponding author), AMGEN INC, DEPT CELL BIOL, THOUSAND OAKS, CA 91320 USA.							ALESSI DR, 1993, ONCOGENE, V8, P2015; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hecker D, 1996, ONCOGENE, V12, P953; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JAMAL S, 1995, ONCOGENE, V10, P2095; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YANG CL, 1995, CANCER RES, V55, P4210	55	107	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2277	2287		10.1038/sj.onc.1201401	http://dx.doi.org/10.1038/sj.onc.1201401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393873				2022-12-25	WOS:A1997YE15700003
J	Clark, J; Lu, YJ; Sidhar, SK; Parker, C; Gill, S; Smedley, D; Hamoudi, R; Linehan, WM; Shipley, J; Cooper, CS				Clark, J; Lu, YJ; Sidhar, SK; Parker, C; Gill, S; Smedley, D; Hamoudi, R; Linehan, WM; Shipley, J; Cooper, CS			Fusion of splicing factor genes PSF and NonO (p54(nrb)) to the TFE3 gene in papillary renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; PSF splicing factor; NonO (p54(nrb)) splicing factor; chromosome translocations; TFE3 transcription factor	TUMOR-SUPPRESSOR GENE; ALVEOLAR RHABDOMYOSARCOMA; TRANSLOCATION X-1; BINDING PROTEIN; TRANSCRIPTION; CYTOGENETICS; RNA; BREAKPOINT; SARCOMA; ADENOCARCINOMA	We demonstrate that the cytogenetically defined translocation t(X;1)(p11.2;p34) observed in papillary renal cell carcinomas results in the fusion of the splicing factor gene PSF located at 1p34 to the TFE3 helix-loop-helix transcription factor gene at Xp11.2. In addition we define an X chromosome inversion inv(X)(p11.2;q12) that results in the fusion of the NonO (p54(nrb)) gene to TFE3. NonO (p54(nrb)), the human homologue of the Drosophila gene NonA(diss) which controls the male courtship song, is closely related to PSF and also believed to be involved in RNA splicing. In each case the rearrangement results in the fusion of almost the entire splicing factor protein to the TFE3 DIVA-binding domain. These observations suggest the possibility of intriguing links between the processes of RNA splicing, DNA transcription and oncogenesis.	INST CANC RES, HADDOW LABS, SECT CELL BIOL & EXPT PATHOL, SUTTON SM2 5NG, SURREY, ENGLAND; INST CANC RES, HADDOW LABS, CANC GENE CLONING LAB, SUTTON SM2 5NG, SURREY, ENGLAND; NCI, UROL ONCOL SECT, BETHESDA, MD 20892 USA	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Clark, J (corresponding author), INST CANC RES, HADDOW LABS, SECT MOL CARCINOGENESIS, SUTTON SM2 5NG, SURREY, ENGLAND.			Lu, Yong-Jie/0000-0001-6174-6621; Hamoudi, Rifat/0000-0002-1402-0868; Shipley, Janet/0000-0001-6748-8678				ANGLARD P, 1992, CANCER RES, V52, P348; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; DAVIS RJ, 1994, CANCER RES, V54, P2869; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; DIJKHUIZEN T, 1995, GENE CHROMOSOME CANC, V14, P43, DOI 10.1002/gcc.2870140108; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; ELFVING P, 1995, CYTOGENET CELL GENET, V69, P90, DOI 10.1159/000133945; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; JEON IS, 1995, ONCOGENE, V10, P1229; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; Mitelman F., 1994, CATALOG CHROMOSOME A; Murphy W, 1994, ATLAS TUMOUR PATHOLO; OHJIMI Y, 1993, CANCER GENET CYTOGEN, V70, P77, DOI 10.1016/0165-4608(93)90136-A; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Savage Paul D., 1994, Current Opinion in Oncology, V6, P301, DOI 10.1097/00001622-199405000-00013; SHIPLEY JM, 1995, CYTOGENET CELL GENET, V71, P280, DOI 10.1159/000134127; SHIPLEY JM, 1993, CYTOGENET CELL GENET, V64, P233, DOI 10.1159/000133585; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; TOMLINSON GE, 1991, CANCER GENET CYTOGEN, V57, P11, DOI 10.1016/0165-4608(91)90184-V; TONK V, 1995, CANCER GENET CYTOGEN, V81, P72, DOI 10.1016/S0165-4608(94)00195-2; VANDENBERG E, 1993, INT J CANCER, V55, P223, DOI 10.1002/ijc.2910550210; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 1996, CYTOGENET CELL GENET, V75, P2, DOI 10.1159/000134444; YANG YS, 1993, MOL CELL BIOL, V13, P5593, DOI 10.1128/MCB.13.9.5593; YOSHIDA AA, 1995, P ANN ASS CANC RES, V26, P31; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	37	242	259	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2233	2239		10.1038/sj.onc.1201394	http://dx.doi.org/10.1038/sj.onc.1201394			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393982	Green Published			2022-12-25	WOS:A1997YD01900012
J	Shiohara, M; Gombart, AF; Berman, JD; Koike, K; Komiyama, A; Koeffler, HP				Shiohara, M; Gombart, AF; Berman, JD; Koike, K; Komiyama, A; Koeffler, HP			Cytostatic effect of TNF alpha on cancer cells is independent of p21(WAF1)	ONCOGENE			English	Article						ME180; p21(WAF1); TNF alpha; antisense	TUMOR-NECROSIS-FACTOR; CYCLIN-DEPENDENT KINASES; NF-KAPPA-B; MANGANOUS SUPEROXIDE-DISMUTASE; HUMAN LEUKEMIC-CELLS; POSTTRANSCRIPTIONAL STABILIZATION; P53-INDEPENDENT INDUCTION; TERMINAL DIFFERENTIATION; INHIBITOR P21; G(1) ARREST	Tumor necrosis factor alpha (TNF alpha) is a cytotoxic/cgtostatic compound for a variety of human cancer cells. The p21(WAF1) protein is a cyclin-dependent kinase inhibitor (CDKI) that binds to cyclin/cyclin-dependent kinase (CDK) complexes and inhibits their kinase activities, thereby leading to cell cycle arrest. We found that the cytostatic effect of TNF alpha on the cervical cancer cell line, ME180, was concomitant with an arrest of these cells in the G0/G1 phase of the cell-cycle. This corresponded with an increase in both p21(WAF1) mRNA and protein levels which likely occurred via a p53-independent pathway since ME180 is infected with the human papilloma virus. To elucidate the role of p21(WAF1) in the TNF alpha-mediated growth and cell cycle arrest, we stably transformed ME180 cells with an antisense p21(WAF1)- expression vector. Two clones with reduced levels of p21(WAF1) both in their basal state as well as after their exposure to TNF alpha were selected. The growth of these cells was still inhibited by TNF alpha and they arrested in G0/G1 similar to wildtype or empty vector transfected cells. These results indicate that although p21(WAF1) expression increases dramatically with TNF alpha treatment, it may not play a critical role in the cytostatic effect of TNF alpha on ME180 cervical cancer cells.	SHINSHU UNIV, SCH MED, DEPT PEDIAT, MATSUMOTO, NAGANO 390, JAPAN	Shinshu University	Shiohara, M (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI RES INST, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90048 USA.				NCI NIH HHS [CA26038, CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710, R01CA026038, P30CA042710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elstner E, 1997, J CLIN INVEST, V99, P349, DOI 10.1172/JCI119164; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Gorospe M, 1996, CANCER RES, V56, P475; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUO K, 1995, MOL CELL BIOL, V15, P3823; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HERZOG TJ, 1992, CYTOKINE, V4, P214, DOI 10.1016/1043-4666(92)90058-Y; HIRAMA T, 1995, BLOOD, V86, P841; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LI Y, 1994, ONCOGENE, V9, P2261; MANCHESTER KM, 1993, BIOCHEM J, V290, P185, DOI 10.1042/bj2900185; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; ROSENBLUM MG, 1989, CRIT REV IMMUNOL, V9, P21; Sambrook J, 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang QM, 1996, CANCER RES, V56, P264; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668	50	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1605	1609		10.1038/sj.onc.1201315	http://dx.doi.org/10.1038/sj.onc.1201315			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380413				2022-12-25	WOS:A1997XX36900012
J	Baldin, V; Cans, C; Knibiehler, M; Ducommun, B				Baldin, V; Cans, C; Knibiehler, M; Ducommun, B			Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its proteasome-dependent degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; KINASE INHIBITOR; PROTEIN; ACTIVATION; HOMOLOG; MITOSIS; PATHWAY	In eukaryotes the activity of CDK1 (CDC2), a cyclin-dependent kinase that initiates the structural changes that culminate in the segregation of chromosomes at mitosis, is regulated by the synergistic and opposing activities of a cascade of kinases and phosphatases. Dephosphorylation of threonine 14 and tyrosine 15 of CDK1 by the CDC25 phosphatases is a key step in the activation of the CDK1-cyclin B protein kinase. Little is currently known about the role and the regulation of CDC25B. Here we report in vitro and in vivo data that indicate that CDC25B is degraded by the proteasome. This degradation is dependent upon phosphorylation by the CDK1-cyclin A complex but not by CDK1-cyclin B. These results indicate that CDK1-cyclin A phosphorylation targets CDC25B for degradation and that this might be an important component of cell cycle regulation at the G(2)/M transition.	Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.		BALDIN, Véronique/Y-8397-2019; DUCOMMUN, Bernard/B-3208-2008; Holt, Janet E/B-2415-2013	BALDIN, Véronique/0000-0001-8523-0494; DUCOMMUN, Bernard/0000-0002-7126-8368				Adams J, 1996, ANNU REP MED CHEM, V31, P279, DOI 10.1016/S0065-7743(08)60467-4; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GOUBIN F, 1995, ONCOGENE, V10, P2281; HARPER JW, 1993, CELL, V75, P805; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGATA A, 1991, NEW BIOL, V3, P959; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	23	87	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32731	32734		10.1074/jbc.272.52.32731	http://dx.doi.org/10.1074/jbc.272.52.32731			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407044	hybrid			2022-12-25	WOS:000071182900005
J	Llorca, O; Perez-Perez, J; Carrascosa, JL; Galan, A; Muga, A; Valpuesta, JM				Llorca, O; Perez-Perez, J; Carrascosa, JL; Galan, A; Muga, A; Valpuesta, JM			Effects of the inter-ring communication in GroEL structural and functional asymmetry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHAPERONIN GROEL; CRYSTAL-STRUCTURE; CENTRAL CAVITY; PROTEIN; RELEASE; POLYPEPTIDE; RESOLUTION; COMPLEXES; BINDING; MECHANISM	The chaperonin GroEL consists of a double-ring structure that assists protein folding in the presence of GroES and ATP, Recent studies suggest that the 7-mer ring is the functional unit where protein folding takes place, Nevertheless, both GroEL rings are required to complete the reaction cycle through signals transmitted between the two rings, Electron microscopy, image processing, and biochemical analysis of GroEL, a single-ring mutant (SR1) and a inter-ring communication affected mutant (A126V), in the presence of ATP and adenylyl imidodiphosphate, have allowed the identification of a conformational change in the apical domains that is strictly dependent on the communication be tween the two GroEL rings, It is deduced from these results that the binding of nucleotide to both GroEL rings generates, as a consequence of the inter-ring communication, a functionally and structurally asymmetric particle. This asymmetric particle has a ring with a small conformational change in its apical domains and high affinity toward unfolded substrate and GroES, and the other ring has a larger conformational change in its apical domains and lower affinity toward substrate and GroES.	CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Inst Nacl Invest Agr, Madrid 28040, Spain; Univ Basque Country, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA); University of Basque Country	Valpuesta, JM (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus Univ Autonoma Madrid, E-28049 Madrid, Spain.	jmv@cnb.uam.es	Valpuesta, Jose M/AAA-6002-2019; Muga, Arturo/N-1174-2014; Llorca, Oscar/P-2784-2019; Llorca, Oscar/K-1144-2014; Valpuesta, José M/T-1977-2017	Muga, Arturo/0000-0003-0345-6882; Llorca, Oscar/0000-0001-5705-0699; Llorca, Oscar/0000-0001-5705-0699; Valpuesta, José M/0000-0001-7468-8053; Perez-Perez, Julian/0000-0001-6091-0012				Aharoni A, 1996, J MOL BIOL, V258, P732, DOI 10.1006/jmbi.1996.0282; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Corrales FJ, 1996, FOLD DES, V1, P265, DOI 10.1016/S1359-0278(96)00040-5; DELAFRAGA LG, 1995, ULTRAMICROSCOPY, V60, P385, DOI 10.1016/0304-3991(95)00080-1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; GUPTA RS, 1995, MOL MICROBIOL, V15, P1, DOI 10.1111/j.1365-2958.1995.tb02216.x; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; HUNTER WM, 1978, HDB EXPT IMMUNOLOGY, P608; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; Lin ZL, 1996, P NATL ACAD SCI USA, V93, P1977, DOI 10.1073/pnas.93.5.1977; Llorca O, 1997, FEBS LETT, V405, P195, DOI 10.1016/S0014-5793(97)00186-5; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Llorca O, 1996, J BIOL CHEM, V271, P68, DOI 10.1074/jbc.271.1.68; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; MARTIN A, 1995, NUCLEIC ACIDS RES, V23, P1642, DOI 10.1093/nar/23.9.1642; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PEREZPEREZ J, 1995, GENE, V158, P141, DOI 10.1016/0378-1119(95)00127-R; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; Sparrer H, 1997, P NATL ACAD SCI USA, V94, P1096, DOI 10.1073/pnas.94.4.1096; Torok Z, 1996, J BIOL CHEM, V271, P16180, DOI 10.1074/jbc.271.27.16180; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001	43	18	18	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32925	32932		10.1074/jbc.272.52.32925	http://dx.doi.org/10.1074/jbc.272.52.32925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407071	hybrid			2022-12-25	WOS:000071182900032
J	Spiro, C; McMurray, CT				Spiro, C; McMurray, CT			Switching of DNA secondary structure in proenkephalin transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENKEPHALIN ENHANCER; CAMP-RESPONSE-ELEMENT; RAT PRODYNORPHIN GENE; HAIRPIN FORMATION; MOLECULAR MECHANISMS; BINDING PROTEIN; MESSENGER-RNA; CYCLIC-AMP; EXPRESSION; REGION	Proper transcriptional regulation of the proenkephalin gene requires a switch between distinct factor binding sites that cannot exist at the same time. Each of the sites is formed from a nearly palindromic region that contains two functionally defined cAMP response elements. The region can switch between cruciform and linear duplex. Formation of the cruciform creates an alternative binding site for mediators of second messenger-directed transcription and abolishes the site present in the native duplex form. Use of the cruciform site has been shown to correlate with activated transcription. Analysis of DNA structure, protein binding, and gene expression from plasmids with mutant enhancers shows, however, that both sites are required for regulation of transcription. The two distinct structures form within the same enhancer. Shifting the balance between the two alters transcriptional response.	Mayo Clin & Mayo Fdn, Dept Pharmacol, Rochester, MN 55905 USA	Mayo Clinic	McMurray, CT (corresponding author), Mayo Clin & Mayo Fdn, Dept Pharmacol, 200 1st St Sw, Rochester, MN 55905 USA.				NIDDK NIH HHS [DK 43694-01A2] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORSOOK D, 1994, MOL ENDOCRINOL, V8, P240, DOI 10.1210/me.8.2.240; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COMB M, 1983, DNA-J MOLEC CELL BIO, V2, P213, DOI 10.1089/dna.1983.2.213; DOUGLASS J, 1991, MOL BRAIN RES, V9, P79, DOI 10.1016/0169-328X(91)90132-H; DOUGLASS J, 1994, MOL ENDOCRINOL, V8, P333, DOI 10.1210/me.8.3.333; GACY AM, 1994, BIOCHEMISTRY-US, V33, P11951, DOI 10.1021/bi00205a034; GACY AM, 1996, ROLE DNA HAIRPIN STR; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KONRADI C, 1994, J NEUROSCI, V14, P5623; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAFORGE KS, 1995, MOL CELL BIOL, V15, P2080; MCMURRAY CT, 1991, P NATL ACAD SCI USA, V88, P666, DOI 10.1073/pnas.88.2.666; MCMURRAY CT, 1994, BIOCHEMISTRY-US, V33, P11960, DOI 10.1021/bi00205a035; ROSEN H, 1984, J BIOL CHEM, V259, P4309; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; WILLIAMS JS, 1993, DNA CELL BIOL, V12, P183, DOI 10.1089/dna.1993.12.183; ZHU YS, 1994, DNA CELL BIOL, V13, P25, DOI 10.1089/dna.1994.13.25	23	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33145	33152		10.1074/jbc.272.52.33145	http://dx.doi.org/10.1074/jbc.272.52.33145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407101	hybrid			2022-12-25	WOS:000071182900062
J	Vassilatis, DK; Arena, JP; Plasterk, RHA; Wilkinson, HA; Schaeffer, JM; Cully, DF; van der Ploeg, LHT				Vassilatis, DK; Arena, JP; Plasterk, RHA; Wilkinson, HA; Schaeffer, JM; Cully, DF; van der Ploeg, LHT			Genetic and biochemical evidence for a novel avermectin-sensitive chloride channel in Caenorhabditis elegans - Isolation and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; BINDING-SITE; INSECT MUSCLE; MESSENGER-RNA; ASCARIS-SUUM; EXPRESSION; GLYCOPROTEIN; RECEPTORS; MECHANISM; EXCISION	Avermectins are a class of macrocyclic lactones that is widely used in crop protection and to treat helminth infections in man and animals. Two complementary DNAs (GluCl alpha and GluCl beta) encoding chloride channels that are gated by avermectin and glutamate, respectively, were isolated from Caenorhabditis elegans. To study the role of these subunits in conferring avermectin sensitivity we isolated a mutant C. elegans strain with a Tc1 transposable element insertion that functionally inactivated the GluCl alpha gene (GluCl alpha::Tc1). GluCl alpha::Tc1 animals exhibit a normal phenotype including typical avermectin sensitivity, Xenopus oocytes expressing GluCl alpha::Tc1 strain mRNA elicited reduced amplitude avermectin and glutamate-dependent chloride currents. Avermectin binding assays in GluCl alpha::Tc1 strain membranes showed the presence of high affinity binding sites, with a reduced B-max. These experiments suggest that GluCl alpha is a target for avermectin and that additional glutamate-gated and avermectin-sensitive chloride channel subunits exist in C. elegans. We isolated a cDNA (GluCl alpha 2) encoding a chloride channel that shares 75% amino acid identity with GluCl alpha. This subunit forms homomeric channels that are gated irreversibly by avermectin and reversibly by glutamate, GluCl alpha 2 coassembles with GluCl beta to form heteromeric channels that are gated by both ligands. The presence of subunits related to GluCl alpha may explain the low level and rarity of target site involvement in resistance to the avermectin class of compounds.	Merck Res Labs, Dept Genet & Mol Biol, Rahway, NJ 07065 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Merck Res Labs, Dept Cellular Biochem & Physiol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Parasite Biochem & Cell Biol, Rahway, NJ 07065 USA	Merck & Company; Columbia University; Netherlands Cancer Institute; Merck & Company; Merck & Company	Vassilatis, DK (corresponding author), Merck Res Labs, Dept Cell Biol & Physiol, RY80Y-300,POB 2000, Rahway, NJ 07065 USA.	demetrios_vassilatis@merck.com						ARENA JP, 1995, J PARASITOL, V81, P286, DOI 10.2307/3283936; ARENA JP, 1992, MOL BRAIN RES, V15, P339, DOI 10.1016/0169-328X(92)90127-W; ARENA JP, 1994, PARASITOL TODAY, V10, P35, DOI 10.1016/0169-4758(94)90357-3; ARENA JP, 1991, MOL PHARMACOL, V40, P368; AVERY L, 1993, J EXP BIOL, V175, P283; BOEDTKER H, 1971, BIOCHIM BIOPHYS ACTA, V240, P448, DOI 10.1016/0005-2787(71)90539-9; BROEKS A, 1995, EMBO J, V14, P1858, DOI 10.1002/j.1460-2075.1995.tb07178.x; Campbell WW, 1989, IVERMECTIN ABAMECTIN; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CULLCANDY SG, 1976, J PHYSIOL-LONDON, V255, P449, DOI 10.1113/jphysiol.1976.sp011289; CULLY DF, 1991, MOL PHARMACOL, V40, P326; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Cully DF, 1996, J BIOL CHEM, V271, P20187, DOI 10.1074/jbc.271.33.20187; Cully DF, 1996, PARASITOLOGY, V113, pS191, DOI 10.1017/S0031182000077970; DUCE IR, 1985, BRIT J PHARMACOL, V85, P395, DOI 10.1111/j.1476-5381.1985.tb08874.x; DUCE IR, 1985, BRIT J PHARMACOL, V86, P431; EMMONS SW, 1984, CELL, V36, P599, DOI 10.1016/0092-8674(84)90339-8; Etter A, 1996, J BIOL CHEM, V271, P16035, DOI 10.1074/jbc.271.27.16035; Fleming JT, 1997, J NEUROSCI, V17, P5843; FRASER SP, 1990, MOL BRAIN RES, V8, P331, DOI 10.1016/0169-328X(90)90047-H; KASS IS, 1982, EXP PARASITOL, V54, P166, DOI 10.1016/0014-4894(82)90123-0; LEA T J, 1973, Comparative and General Pharmacology, V4, P333, DOI 10.1016/0010-4035(73)90045-1; LINGLE C, 1981, BRAIN RES, V212, P481, DOI 10.1016/0006-8993(81)90482-0; Martin RJ, 1996, PARASITOLOGY, V112, P247, DOI 10.1017/S0031182000084833; PLASTERK RHA, 1992, EMBO J, V11, P287, DOI 10.1002/j.1460-2075.1992.tb05051.x; PONG SS, 1980, NEUROPHARMACOLOGY, V19, P311, DOI 10.1016/0028-3908(80)90155-0; ROHERER SP, 1992, P NATL ACAD SCI USA, V89, P4168, DOI 10.1073/pnas.89.9.4168; ROHRER SP, 1994, J PARASITOL, V80, P493, DOI 10.2307/3283426; Sangster N, 1996, PARASITOLOGY, V113, pS201, DOI 10.1017/S0031182000077982; SCHAEFFER JM, 1989, BIOCHEM PHARMACOL, V38, P2329, DOI 10.1016/0006-2952(89)90473-5; SCOTT RH, 1985, PESTIC SCI, V16, P599, DOI 10.1002/ps.2780160605; SHOOP WL, 1993, PARASITOL TODAY, V9, P154, DOI 10.1016/0169-4758(93)90136-4; SULSTON J, 1988, METHODS BULK GROWTH, P602; Thompson DP, 1996, PARASITOLOGY, V113, pS217, DOI 10.1017/S0031182000077994; VANDENBERG RJ, 1993, MOL PHARMACOL, V44, P198; Vassilatis DK, 1997, J MOL EVOL, V44, P501, DOI 10.1007/PL00006174; VASSILATIS DK, 1992, J BIOL CHEM, V267, P18459; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7432	38	97	102	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33167	33174		10.1074/jbc.272.52.33167	http://dx.doi.org/10.1074/jbc.272.52.33167			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407104	hybrid			2022-12-25	WOS:000071182900065
J	Zhao, J; Cannon, B; Nedergaard, J				Zhao, J; Cannon, B; Nedergaard, J			alpha(1)-adrenergic stimulation potentiates the thermogenic action of beta(3)-adrenoreceptor-generated cAMP in brown fat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; ADIPOCYTE RESPIRATION; ADRENERGIC-RECEPTORS; UNCOUPLING PROTEIN; BETA-ADRENOCEPTOR; ALPHA-1-ADRENERGIC STIMULATION; BINDING-SITES; CULTURE; NOREPINEPHRINE; EXPRESSION	The relationship between cAMP levels and thermogenesis was investigated in brown fat cells from Syrian hamsters, Irrespective of whether the selective beta(3)-, beta(2)-, and beta(1)-agonists BRL 37344, salbutamol, and dobutamine or the physiological agonist norepinephrine was used to stimulate the cells, increases in cAMP levels were mediated via the beta(3)-receptor, as were the thermogenic effects, However, the relationship "thermogenesis per cAMP" was much lower for agents other than norepinephrine, Similarly, forskolin, although more potent than norepinephrine in elevating cAMP, was less potent in inducing thermogenesis, The selective alpha(1)-agonist cirazoline was in itself without effect on cAMP levels or thermogenesis, but when added to forskolin-stimulated cells, potentiated thermogenesis, up to the norepineph rine level, without affecting cAMP. This potentiation could not be inhibited by chelerythrine, but could be mimicked by Ca2+ ionophores, It was apparently not mediated via calmodulin-dependent protein kinase and was not an effect on mitochondrial respiratory control, The ability of all cAMP-elevating agents to induce thermogenesis in brown fat cells has earlier been interpreted to mean that it is only through the beta-receptors and the resulting increase in cAMP levels that thermogenesis is induced, However, it is here concluded that the thermogenic response to norepinephrine involves two interacting parts, one mediated via beta-receptors and cAMP and the other via alpha(1)-receptors and increases in cytosolic Ca2+ levels.	Univ Stockholm, Arrhenius Lab F3, Wenner Gren Inst, S-10691 Stockholm, Sweden	Stockholm University	Nedergaard, J (corresponding author), Univ Stockholm, Arrhenius Lab F3, Wenner Gren Inst, S-10691 Stockholm, Sweden.		Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Cannon, Barbara/B-3089-2016	Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587				ARCH JRS, 1989, P NUTR SOC, V48, P215, DOI 10.1079/PNS19890032; ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; BARGE RM, 1988, AM J PHYSIOL, V254, pE323, DOI 10.1152/ajpendo.1988.254.3.E323; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; BUKOWIECKI L, 1980, AM J PHYSIOL, V238, pE552, DOI 10.1152/ajpendo.1980.238.6.E552; BUKOWIECKI LJ, 1986, BROWN ADIPOSE TISSUE, P105; CANNON B, 1985, ESSAYS BIOCHEM, V20, P110; CONNOLLY E, 1984, EUR J BIOCHEM, V141, P187, DOI 10.1111/j.1432-1033.1984.tb08173.x; Costain WJ, 1996, CAN J PHYSIOL PHARM, V74, P234, DOI 10.1139/cjpp-74-3-234; DASSO L, 1990, FEBS LETT, V262, P25, DOI 10.1016/0014-5793(90)80144-8; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Granneman JG, 1997, MOL PHARMACOL, V51, P644, DOI 10.1124/mol.51.4.644; HERRON D, 1989, AM J PHYSIOL, V257, pC920, DOI 10.1152/ajpcell.1989.257.5.C920; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HOLLENGA C, 1991, BRIT J PHARMACOL, V102, P577, DOI 10.1111/j.1476-5381.1991.tb12215.x; HORWITZ BA, 1969, P NATL ACAD SCI USA, V64, P113, DOI 10.1073/pnas.64.1.113; KikuchiUtsumi K, 1997, BIOCHEM J, V322, P417, DOI 10.1042/bj3220417; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; Kuusela P, 1997, BIOCHEM J, V321, P759, DOI 10.1042/bj3210759; LAFONTAN M, 1994, CELL SIGNAL, V6, P363, DOI 10.1016/0898-6568(94)90085-X; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LEE SC, 1993, AM J PHYSIOL, V264, pC217, DOI 10.1152/ajpcell.1993.264.1.C217; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCMAHON KK, 1982, LIFE SCI, V30, P1185, DOI 10.1016/0024-3205(82)90661-0; MOHELL N, 1987, AM J PHYSIOL, V253, pC301, DOI 10.1152/ajpcell.1987.253.2.C301; MOHELL N, 1984, MOL PHARMACOL, V25, P64; MOHELL N, 1983, EUR J PHARMACOL, V93, P183, DOI 10.1016/0014-2999(83)90136-X; MOHELL N, 1983, EUR J PHARMACOL, V92, P15, DOI 10.1016/0014-2999(83)90103-6; NANBERG E, 1984, BIOCHIM BIOPHYS ACTA, V804, P291, DOI 10.1016/0167-4889(84)90132-0; NANBERG E, 1986, FEBS LETT, V195, P319, DOI 10.1016/0014-5793(86)80185-5; NANBERG E, 1987, BIOCHIM BIOPHYS ACTA, V930, P438, DOI 10.1016/0167-4889(87)90017-6; NECHAD M, 1987, AM J PHYSIOL, V253, pC889, DOI 10.1152/ajpcell.1987.253.6.C889; Nedergaard J, 1995, INT J DEV BIOL, V39, P827; NEDERGAARD J, 1979, EUR J BIOCHEM, V95, P139, DOI 10.1111/j.1432-1033.1979.tb12948.x; NEDERGAARD J, 1982, INT REV CYTOL, V74, P187, DOI 10.1016/S0074-7696(08)61173-0; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 1972, EUR J BIOCHEM, V31, P526, DOI 10.1111/j.1432-1033.1972.tb02561.x; Nisoli E, 1996, MOL PHARMACOL, V49, P7; NISOLI E, 1995, ARCH INT PHARMACOD T, V329, P436; NORONHA M, 1991, METABOLISM, V40, P1327, DOI 10.1016/0026-0495(91)90038-X; PAPPONE PA, 1995, J GEN PHYSIOL, V106, P231, DOI 10.1085/jgp.106.2.231; PETTERSSON B, 1976, EUR J BIOCHEM, V62, P383, DOI 10.1111/j.1432-1033.1976.tb10170.x; PETTERSSON B, 1977, EUR J BIOCHEM, V72, P235, DOI 10.1111/j.1432-1033.1977.tb11244.x; RAASMAJA A, 1989, ENDOCRINOLOGY, V125, P2502, DOI 10.1210/endo-125-5-2502; RAASMAJA A, 1984, BIOSCIENCE REP, V4, P851, DOI 10.1007/BF01138167; RAASMAJA A, 1985, EUR J PHARMACOL, V106, P489; RAASMAJA A, 1986, BIOCHEM J, V249, P831; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; SCHIMMEL RJ, 1983, AM J PHYSIOL, V244, pC362, DOI 10.1152/ajpcell.1983.244.5.C362; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; SMITH RE, 1969, PHYSIOL REV, V49, P330, DOI 10.1152/physrev.1969.49.2.330; SVOBODA P, 1979, EUR J BIOCHEM, V102, P203, DOI 10.1111/j.1432-1033.1979.tb06281.x; THONBERG H, 1994, J BIOL CHEM, V269, P33179; UENLIUS L, 1993, AM J PHYSIOL, V265, pC1340; WILCKE M, 1989, BIOCHEM BIOPH RES CO, V163, P292, DOI 10.1016/0006-291X(89)92134-7; ZHAO J, 1994, AM J PHYSIOL-CELL PH, V267, pC969, DOI 10.1152/ajpcell.1994.267.4.C969	58	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32847	32856		10.1074/jbc.272.52.32847	http://dx.doi.org/10.1074/jbc.272.52.32847			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407062	hybrid			2022-12-25	WOS:000071182900023
J	Hazan, RB; Kang, L; Roe, S; Borgen, PI; Rimm, DL				Hazan, RB; Kang, L; Roe, S; Borgen, PI; Rimm, DL			Vinculin is associated with the E-cadherin adhesion complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; ALPHA-CATENIN EXPRESSION; ACTIN-BINDING; BETA-CATENIN; F-ACTIN; INTRAMOLECULAR ASSOCIATION; FUNCTIONAL DOMAINS; EPITHELIAL-CELLS; TAIL DOMAINS; PROTEIN	Cadherins mediate calcium-dependent cell-cell adhesion, and this activity is regulated by cytoplasmic interactions between cadherins, catenins, and the actin-based cytoskeleton, alpha-Catenin plays a critical role in the transmembrane anchorage of cadherins, and deletion of alpha-catenin has been shown to inactivate cadherin-mediated adhesion, resulting in a nonadhesive phenotype, Here we show that serum starvation increases E-cadherin expression and induces E-cadherin-dependent adhesion in the MDA-MB-468 breast cancer cell line. This adhesion occurred despite a lack of alpha-catenin expression, which was caused by mutations in the alpha-catenin gene. Coprecipitation analysis suggests that this adhesion may be mediated by cytoplasmic connections from cadherins to the cytoskeleton involving vinculin. A high level of vinculin associated with E-cadherin immunoprecipitates was observed in MDA-MB-468 cells. In contrast, vinculin was not detected in E-cadherin complexes in the A431 and MCF-7 epithelial carcinoma cell lines, which express alpha-catenin. However, in reciprocal immunoprecipitations using anti-vinculin antibodies, E-cadherin associated strongly with vinculin in MDA-MB-468 cells and, to a lesser extent, in A431 and MCF-7 cells. These results suggest that both alpha-catenin and vinculin may be present in the adhesion complex, To test the hypothesis that vinculin associates with E-cadherin complexes via beta-catenin, excess recombinant beta-catenin or alpha-catenin fusion protein was added to MDA-MB-468 cell lysates, Both specifically inhibited the coprecipitation of E-cadherin with vinculin, suggesting competition for the same binding site. These results suggest that vinculin plays a role in the establishment or regulation of the cadherin-based cell adhesion complex by direct interaction with beta-catenin.	Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Memorial Sloan Kettering Cancer Center; Yale University	Hazan, RB (corresponding author), Mt Sinai Med Ctr, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.			Rimm, David/0000-0001-5820-4397				ABERLE H, 1994, J CELL SCI, V107, P3655; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; Haftek M, 1996, J INVEST DERMATOL, V106, P498, DOI 10.1111/1523-1747.ep12343791; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; KAM Z, 1995, J CELL SCI, V108, P1051; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kemler R, 1992, Semin Cell Biol, V3, P149; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Koslov ER, 1997, J BIOL CHEM, V272, P27301, DOI 10.1074/jbc.272.43.27301; MCGREGOR A, 1994, BIOCHEM J, V301, P225, DOI 10.1042/bj3010225; MCNEILL H, 1993, J CELL BIOL, V120, P1217, DOI 10.1083/jcb.120.5.1217; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MILAM LM, 1985, J MOL BIOL, V184, P543, DOI 10.1016/0022-2836(85)90301-8; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; Nagafuchi A, 1993, Semin Cell Biol, V4, P175, DOI 10.1006/scel.1993.1021; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nieset JE, 1997, J CELL SCI, V110, P1013; Obama H, 1997, J BIOL CHEM, V272, P11017; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; OTTO JJ, 1990, CELL MOTIL CYTOSKEL, V16, P1, DOI 10.1002/cm.970160102; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Roe S, 1996, MOL BIOL CELL, V7, P1658; ROE S, 1997, IN PRESS CELL ADHESI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SOMMERS CL, 1994, CANCER RES, V54, P3544; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WILKINS JA, 1982, CELL, V28, P83, DOI 10.1016/0092-8674(82)90377-4; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085; YAP AS, 1995, CELL MOTIL CYTOSKEL, V32, P318, DOI 10.1002/cm.970320408	53	127	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32448	32453		10.1074/jbc.272.51.32448	http://dx.doi.org/10.1074/jbc.272.51.32448			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405455	hybrid			2022-12-25	WOS:000071108000074
J	Hitomi, K; Kim, ST; Iwai, S; Harima, N; Otoshi, E; Ikenaga, M; Todo, T				Hitomi, K; Kim, ST; Iwai, S; Harima, N; Otoshi, E; Ikenaga, M; Todo, T			Binding and catalytic properties of Xenopus (6-4) photolyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ACTION MECHANISM; DAMAGED DNA; PHOTOPRODUCTS; PURIFICATION; SUBSTRATE; MAMMALS; ENZYME	Xenopus (6-4) photolyase binds with high affinity to DNA bearing a (6-4) photoproduct and repairs it in a light-dependent reaction, To clarify its repair mechanism of (6-4) photolyase, we determined its binding and catalytic properties using synthetic DNA substrate which carries a photoproduct at a single location. The (6-4) photolyase binds to T[6-4]T in double-stranded DNA with high affinity (K-D = 10(-9)) and to T[6-4]T in single-stranded DNA and T[Dewar]T in double-and single-stranded DNA although with slightly lower affinity (K-D = similar to 2 x 10(-8)). Majority of the T[6-4]T-(6-4) photolyase complex dissociates very slowly (k(off) = 2.9 x 10(-5) s(-1)). Its absolute action spectrum without a second chromophore in the 850-600 nm region closely matches the absorption spectrum of the enzyme. The quantum yield (phi) of repair is approximately 0.11. The fully reduced form (E-FADH(-)) of (6-4) photolyase is catalytically active. Direct analysis of the photoreactivated product showed that (6-4) photolyase restores the original pyrimidines. These findings demonstrate that cis,syn-cyclobutane pyrimidine dimer photolyase and (6-4) photolyase are quite similar, but they are different with regard to the binding properties.	Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 60601, Japan; Biomol Engn Res Inst, Suita, Osaka 565, Japan; Kyoto Univ, Fac Med, Dept Dermatol, Sakyo Ku, Kyoto 60601, Japan	Kyoto University; Kyoto University	Todo, T (corresponding author), Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 60601, Japan.							CHEN JJ, 1994, PLANT CELL, V6, P1311, DOI 10.1105/tpc.6.9.1311; FOWLER KW, 1982, J AM CHEM SOC, V104, P1050, DOI 10.1021/ja00368a023; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; Heelis PF, 1997, J AM CHEM SOC, V119, P2936, DOI 10.1021/ja9639877; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATO T, 1994, NUCLEIC ACIDS RES, V22, P4119, DOI 10.1093/nar/22.20.4119; KIM ST, 1994, J BIOL CHEM, V269, P8535; Kim ST, 1996, PHOTOCHEM PHOTOBIOL, V63, P292, DOI 10.1111/j.1751-1097.1996.tb03028.x; Kung HC, 1997, J BIOL CHEM, V272, P9227; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; RAHN RO, 1969, PHOTOCHEM PHOTOBIOL, V10, P131, DOI 10.1111/j.1751-1097.1969.tb07230.x; REARDON JT, 1993, J BIOL CHEM, V268, P21301; RUPERT CS, 1962, J GEN PHYSIOL, V45, P725, DOI 10.1085/jgp.45.4.725; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SANCAR GB, 1987, J BIOL CHEM, V262, P478; SEGEL IH, 1975, ENZYME KINETICS, P109; Todo T, 1997, NUCLEIC ACIDS RES, V25, P764, DOI 10.1093/nar/25.4.764; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; TODO T, 1992, MUTAT RES, V273, P85, DOI 10.1016/0921-8777(92)90052-5; Wang S.Y., 1976, PHOTOCHEM PHOTOBIOL, P295; WANG SY, 1969, BIOCHEM BIOPH RES CO, V29, P545; WOLFENDEN R, 1987, ENZYME MECHANISMS, P97; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580	32	99	100	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32591	32598		10.1074/jbc.272.51.32591	http://dx.doi.org/10.1074/jbc.272.51.32591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405474	hybrid			2022-12-25	WOS:000071108000093
J	Kroll, J; Waltenberger, J				Kroll, J; Waltenberger, J			The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; PERMEABILITY FACTOR; PHOSPHOTYROSINE PHOSPHATASE; UP-REGULATION; SH3 DOMAINS; C-KIT; KINASE; MITOGEN; PHOSPHORYLATION; ANGIOGENESIS	Vascular endothelial growth factor A (here referred to as VEGF) is an endothelium-specific growth factor that binds to two distinct receptor tyrosine kinases, designated Flt-1 and KDR/Flk-1. VEGF stimulates autophosphorylation of both receptors, but little is known about their signal transduction properties. In this study, we used porcine aortic endothelial (PAE) cells overexpressing KDR (PAE/KDR) to evaluate the interaction of KDR with intracellular proteins and compared them with Flt-1-expressing PAE cells (PAE/Flt-1). VEGF-induced stimulation of KDR results in the association and phosphorylation of the 46, 52-, and 66-kDa isoforms of Shc and the induction of Shc-Grb2 complex formation. In a similar fashion, KDR associates with Grb2 and Nck in a ligand-dependent fashion, suggesting Shc, Grb2, and Nck as potential candidates involved in the regulation of endothelial function. Another strong candidate is mitogen-activated protein (MAP) kinase, which is strongly activated in response to VEGF stimulation as demonstrated by phosphorylation of the specific substrate myelin basic protein. Inhibition of MAP kinase activation by PD98059, a specific MAP kinase kinase inhibitor, results in inhibition of VEGF-induced proliferation of PAE/KDR cells. In contrast, VEGF-induced stimulation of Flt-1 does not activate MAP kinase in PAE/Flt-1 cells, In this study we provide the first two examples of molecules potentially capable of functionally counteracting the endothelial response to VEGF, namely SHP-1 and SHP-2. These two SH2 protein-tyrosine phosphatases physically associate with KDR secondary to VEGF stimulation, raising the interesting possibility that both molecules participate in the generation and/or modulation of VEGF-induced signals. Taken together, our results substantially broaden the spectrum of HDR-associating molecules, indicating that endothelial function and angiogenesis are regulated by a diverse network of signal transduction cascades.	Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany	Ulm University	Waltenberger, J (corresponding author), Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, Robert Koch Str 8, D-89081 Ulm, Germany.		Waltenberger, Johannes/I-1813-2013	Waltenberger, Johannes/0000-0002-2417-9880				Adachi M, 1996, CELL, V85, P15; APRELIKOVA O, 1992, CANCER RES, V52, P746; BANAI S, 1994, CARDIOVASC RES, V28, P1176, DOI 10.1093/cvr/28.8.1176; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; FOURNIER E, 1995, ONCOGENE, V11, P921; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hunter T, 1996, BIOCHEM SOC T, V24, P307, DOI 10.1042/bst0240307; Joukov V, 1996, EMBO J, V15, P290; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Strawn LM, 1996, CANCER RES, V56, P3540; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; YAMANE A, 1994, ONCOGENE, V9, P2683; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	58	377	390	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32521	32527		10.1074/jbc.272.51.32521	http://dx.doi.org/10.1074/jbc.272.51.32521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405464	hybrid			2022-12-25	WOS:000071108000083
J	Mori, K; Tobimatsu, T; Hara, T; Toraya, T				Mori, K; Tobimatsu, T; Hara, T; Toraya, T			Characterization, sequencing, and expression of the genes encoding a reactivating factor for glycerol-inactivated adenosylcobalamin-dependent diol dehydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; CITROBACTER-FREUNDII; ESCHERICHIA-COLI; COENZYME; CLONING; ENTEROBACTERIACEAE; 1,2-PROPANEDIOL; FERMENTATION	Diol dehydratase undergoes suicide inactivation by glycerol during catalysis involving irreversible cleavage of the Go-G bond of adenosylcobalamin. In permeabilized Klebsiella oxytoca and Klebsiella pneumoniae cells, the glycerol-inactivated holoenzyme or the enzyme-cyanocobalamin complex is rapidly activated by the exchange of the inactivated coenzyme or cyanocobalamin for free adenosylcobalamin in the presence of ATP and Mg2+ (Honda, S., Toraya, T., and Fukui, S. (1980) J. Bacteriol. 143, 1458-1465; Ushio, K., Honda, S., Toraya, T., and Fukui, S. (1982) J. Nutr. Sci. Vitaminol. 28, 225-236). Permeabilized Escherichia coli cells co-expressing the diol dehydratase genes with two open reading frames in the 3'-flanking region were capable; of reactivating glycerol-inactivated diol dehydratase as well as activating the enzyme-cyanocobalamin complex in situ in the presence of free adenosylcobalamin, ATP, and Mg2+. These open reading frames, designated as ddrA and ddrB genes, were identified as the genes of a putative reactivating factor for inactivated diol dehydratase. The genes encoded polypeptides consisting of 610 and 125 amino acid residues with predicted molecular weights of 64,266 and 13,620, respectively. Go-expression of the open reading frame in the 5'-flanking region was stimulatory but not obligatory for conferring the reactivating activity upon E. coli. Thus, the product of this gene was considered not an essential component of the reactivating factor.	Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 700, Japan	Okayama University	Toraya, T (corresponding author), Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 700, Japan.		Mori, Koichi/ABC-7268-2021; MORI, Koichi/B-2567-2011; TOBIMATSU, Takamasa/B-2646-2011	Mori, Koichi/0000-0001-8865-2107; 				BACHOVCHIN WW, 1977, BIOCHEMISTRY-US, V16, P1082, DOI 10.1021/bi00625a009; BACHOVCHIN WW, 1977, BIOCHEMISTRY-US, V17, P2218; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FORAGE RG, 1982, J BACTERIOL, V151, P591, DOI 10.1128/JB.151.2.591-599.1982; FORAGE RG, 1982, J BACTERIOL, V149, P413, DOI 10.1128/JB.149.2.413-419.1982; FORAGE RG, 1979, BIOCHIM BIOPHYS ACTA, V569, P249, DOI 10.1016/0005-2744(79)90060-3; HONDA S, 1980, J BACTERIOL, V143, P1458, DOI 10.1128/JB.143.3.1458-1465.1980; HOSOI N, 1978, J FERMENT TECHNOL, V56, P566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HA, 1963, J BIOL CHEM, V238, P2367; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POZNANSKAYA AA, 1977, BIOCHIM BIOPHYS ACTA, V484, P236, DOI 10.1016/0005-2744(77)90128-0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER Z, 1966, ACTA BIOCHIM POL, V13, P311; Seyfried M, 1996, J BACTERIOL, V178, P5793, DOI 10.1128/jb.178.19.5793-5796.1996; SHIBUI T, 1988, AGR BIOL CHEM TOKYO, V52, P983; Tobimatsu T, 1996, J BIOL CHEM, V271, P22352, DOI 10.1074/jbc.271.37.22352; TOBIMATSU T, 1995, J BIOL CHEM, V270, P7142, DOI 10.1074/jbc.270.13.7142; TORAYA T, 1994, MET IONS BIOL SYST, V30, P217; TORAYA T, 1977, J BIOL CHEM, V252, P963; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; TORAYA T, 1977, EUR J BIOCHEM, V76, P285, DOI 10.1111/j.1432-1033.1977.tb11594.x; TORAYA T, 1980, J BACTERIOL, V141, P1439, DOI 10.1128/JB.141.3.1439-1442.1980; TORAYA T, 1978, J BACTERIOL, V135, P726, DOI 10.1128/JB.135.2.726-729.1978; TORAYA T, 1979, J BACTERIOL, V139, P39, DOI 10.1128/JB.139.1.39-47.1979; Toraya T., 1982, B12, P233; USHIO K, 1982, J NUTR SCI VITAMINOL, V28, P225; Walter D, 1997, J BACTERIOL, V179, P1013, DOI 10.1128/jb.179.4.1013-1022.1997	30	57	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32034	32041		10.1074/jbc.272.51.32034	http://dx.doi.org/10.1074/jbc.272.51.32034			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405397	hybrid			2022-12-25	WOS:000071108000016
J	Tasheva, ES; Corpuz, LM; Funderburgh, JL; Conrad, GW				Tasheva, ES; Corpuz, LM; Funderburgh, JL; Conrad, GW			Differential splicing and alternative polyadenylation generate multiple mimecan mRNA transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN CORE PROTEIN; HUMAN DECORIN GENE; PRE-MESSENGER-RNA; MOLECULAR-CLONING; OSTEOINDUCTIVE FACTOR; TRANSLATIONAL CONTROL; SECONDARY STRUCTURE; CDNA; SEQUENCE; HOMOLOGY	We previously showed the 25-kDa corneal keratan sulfate proteoglycan to be a translation product of the gene producing osteoglycin and proposed the name mimecan for this gene and its product, We also demonstrated three mimecan RNA transcripts using Northern blot analysis, In this report, we investigate the mechanisms accounting for these transcripts, Ribonuclease protection analysis and reverse transcription-polymerase chain reaction of bovine corneal mRNA detected a mimecan transcript that lacked 278 base pairs of the 5'-untranslated region between residues 62 and 340. This splice variant represents the predominant form of mimecan mRNA in bovine cornea and sclera, It was also detectable in other bovine tissues as a minor transcript. Two additional cDNA clones that were isolated contained 398 bases of nucleotide sequence at the 3'-end of mimecan cDNA, not present in the published sequence. Ribonuclease protection analyses with the 3'-probe, which included the new sequence, allow detection of three RNA transcripts while 5'-probes recognized only two, These results indicate that the three canonical polyadenylation sites in the 3'-untranslated region of mimican mRNA are alternatively selected. Possible roles for this previously undetected degree of diversity of mimecan RNA isoforms transcribed in the same tissue are discussed.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University	Tasheva, ES (corresponding author), Kansas State Univ, Div Biol, Ackert Hall, Manhattan, KS 66506 USA.				NEI NIH HHS [EY00952, EY09368] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000952, R01EY009368] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BALVAY L, 1993, BIOESSAYS, V15, P165, DOI 10.1002/bies.950150304; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; POLEEV A, 1995, EUR J BIOCHEM, V228, P899, DOI 10.1111/j.1432-1033.1995.tb20338.x; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SANTRA M, 1994, J BIOL CHEM, V269, P579; SCHULZ VP, 1990, J MOL BIOL, V211, P427, DOI 10.1016/0022-2836(90)90363-Q; Seydoux G, 1996, CURR OPIN GENET DEV, V6, P555, DOI 10.1016/S0959-437X(96)80083-9; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; TACKE R, 1991, GENE DEV, V5, P1416, DOI 10.1101/gad.5.8.1416; TASHEVA ES, 1993, LEUKEMIA, V7, P318; TSEN GS, 1995, J BIOL CHEM, V270, P15934, DOI 10.1074/jbc.270.27.15934; UJITA M, 1995, GENE, V158, P237, DOI 10.1016/0378-1119(95)00070-M; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	30	32	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32551	32556		10.1074/jbc.272.51.32551	http://dx.doi.org/10.1074/jbc.272.51.32551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405469	hybrid			2022-12-25	WOS:000071108000088
J	Wawersik, M; Paladini, RD; Noensie, E; Coulombe, PA				Wawersik, M; Paladini, RD; Noensie, E; Coulombe, PA			A proline residue in the alpha-helical rod domain of type I keratin 16 destabilizes keratin heterotetramers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; SITE-SPECIFIC MUTAGENESIS; INTERMEDIATE FILAMENTS; COILED-COIL; EPIDERMAL KERATINS; EXPRESSION; DIFFERENTIATION; PHOSPHORYLATION; SEQUENCE; INVITRO	The type I keratins 14 (K14) and 16 (K16) are distinct in their assembly properties and their expression pattern despite a high degree of sequence identity, Understanding K16 function and regulation is of interest, given its strong induction in keratinocytes located at the wound edge after injury to stratified epithelia, We reported previously that, compared with K14, K16 forms unstable heterotetramers with either K5 or K6 as the type II keratin pairing partner (Paladini, R. D., Takahashi, K., Brave, N. S., and Coulombe, P. A. (1996) J. Cell Biol. 132, 381-397), We show here that yet another related type I keratin, K17, forms stable heterotetramers with a variety of type II keratins, further accentuating the unique nature of K16, Analysis of chimeric K14-K16 proteins in a heterotetramer formation assay indicated that the instability determinant resides in a 220-amino acid segment within the alpha-helical rod domain of K16. Site-directed mutagenesis revealed that Pro(188), an amino acid residue located in subdomain 1B of the rod, accounts quantitatively for the instability of K16-containing heterotetramers under denaturing conditions, In vitro polymerization studies suggest that the presence of pro(188) correlates with a reduction in assembly efficiency, In addition to their implications for the stable conformation of the keratin heterotetramers, these findings suggest that the tetramer-forming properties of K16 may influence its partitioning between the soluble and polymer pools, and hence contribute to its regulation in epithelial cells under resting and wound repair conditions.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Coulombe, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044232] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44232] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; AEBI U, 1988, PROTOPLASMA, V145, P73, DOI 10.1007/BF01349341; Bachant JB, 1996, J CELL BIOL, V132, P153, DOI 10.1083/jcb.132.1.153; BADER BL, 1990, DIFFERENTIATION, V45, P109, DOI 10.1111/j.1432-0436.1990.tb00464.x; CHOU CF, 1993, J CELL SCI, V105, P433; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; ECKERT RL, 1988, P NATL ACAD SCI USA, V85, P1114, DOI 10.1073/pnas.85.4.1114; ENGEL A, 1985, J ULTRA MOL STRUCT R, V90, P323, DOI 10.1016/S0022-5320(85)80010-1; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1994, J INVEST DERMATOL, V103, pS25, DOI 10.1111/1523-1747.ep12398924; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GILMARTIN ME, 1980, J INVEST DERMATOL, V75, P211, DOI 10.1111/1523-1747.ep12522887; HATZFELD M, 1994, J CELL SCI, V107, P1959; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KNAPP AC, 1986, J CELL BIOL, V103, P657, DOI 10.1083/jcb.103.2.657; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Ku NO, 1997, J CLIN INVEST, V99, P19, DOI 10.1172/JCI119127; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; LOWTHERT LA, 1995, BIOCHEM BIOPH RES CO, V206, P370, DOI 10.1006/bbrc.1995.1051; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; MENG JJ, 1994, J BIOL CHEM, V269, P18679; Moir RD, 1993, CURR OPIN CELL BIOL, V5, P408, DOI 10.1016/0955-0674(93)90004-A; MOLL R, 1983, DIFFERENTIATION, V23, P256; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; OGUIN WM, 1990, CELLULAR MOL BIOL IN, P301; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; PALADINI RD, 1995, BIOCHEM BIOPH RES CO, V215, P517, DOI 10.1006/bbrc.1995.2495; PARRY DAD, 1990, CELLULAR MOL BIOL IN, P175; QUINLAN R, 1994, PROTEIN PROFILE, V1, P779; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1993, BIOCHEMISTRY-US, V32, P10046, DOI 10.1021/bi00089a021; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1993, J BIOL CHEM, V268, P24916; Stewart M, 1993, CURR OPIN CELL BIOL, V5, P3, DOI 10.1016/S0955-0674(05)80002-X; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; TROYANOVSKY SM, 1992, EUR J CELL BIOL, V59, P127; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; YOSHIKAWA K, 1995, J INVEST DERMATOL, V104, P396, DOI 10.1111/1523-1747.ep12665888	55	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32557	32565		10.1074/jbc.272.51.32557	http://dx.doi.org/10.1074/jbc.272.51.32557			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405470	hybrid			2022-12-25	WOS:000071108000089
J	Angermayr, M; Bandlow, W				Angermayr, M; Bandlow, W			The type of basal promoter determines the regulated or constitutive mode of transcription in the common control region of the yeast gene pair GCY1/RIO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; SITE-SPECIFIC MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; PHENOTYPIC SELECTION; ACTIVATION; ELEMENT; DNA; SEQUENCES; COMPLEX	The yeast genes, GCY1 and RIO1, are transcribed divergently from the 869-base pair intergenic region, GCY1 is inducible by galactose about 25-fold due to Gal4p-binding to a single UAS(GAL), whereas RIO1 is constitutively expressed, GCY1 has a TATA box obeying the consensus TATAAA, whereas the RIO1 5'-upstream region lacks such a motif. In vitro mutagenesis of the TATA motif of GCY1, on the one hand, and introduction of a TATA-element into the promoter of RIO1, on the other hand, as well as inversion of the intergenic region have revealed that transcription of GCY1 and RIO1 is only regulated by Gal4p when a consensus TATA motif is included in their core promoters but not in its absence, The data imply that only transcription complexes that assemble at a consensus TATA box are compatible with specific transactivators, such as Gal4p. As a result, the adjacent gene is subject to regulated expression. By contrast, if a consensus TATA sequence is absent, the initiation complex does not respond to regulatory transcription factors, and consequently, the respective gene is constitutively transcribed. On the other hand, we show that two blocks of homo-oligomeric (dA.dT) sequences do not function as boundary sequences that might confine regulatory action of Gal4p to GCY1.	UNIV MUNICH,INST GENET & MIKROBIOL,D-80638 MUNICH,GERMANY	University of Munich								AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUARENTE L, 1988, CELL, V52, P303, DOI 10.1016/S0092-8674(88)80020-5; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERMANN H, 1992, GENE, V119, P137, DOI 10.1016/0378-1119(92)90079-5; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KESZENMANPEREYRA D, 1988, CURR GENET, V13, P21, DOI 10.1007/BF00365751; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MAGDOLEN V, 1990, GENE, V90, P105, DOI 10.1016/0378-1119(90)90445-W; Maniatis T., 1982, MOL CLONING; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; POON D, 1994, J BIOL CHEM, V269, P23135; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROTENBERG MO, 1986, MOL CELL BIOL, V6, P674, DOI 10.1128/MCB.6.2.674; SAKURAI H, 1994, MOL CELL BIOL, V14, P6819, DOI 10.1128/MCB.14.10.6819; SAKURAI H, 1996, FEBS LETT, V39, P113; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; YOCUM RR, 1984, MOL CELL BIOL, V4, P1984	41	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31630	31635		10.1074/jbc.272.50.31630	http://dx.doi.org/10.1074/jbc.272.50.31630			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395503	hybrid			2022-12-25	WOS:A1997YL41900062
J	Chan, VC; Ramshaw, JAM; Kirkpatrick, A; Beck, K; Brodsky, B				Chan, VC; Ramshaw, JAM; Kirkpatrick, A; Beck, K; Brodsky, B			Positional preferences of ionizable residues in Gly-X-Y triplets of the collagen triple-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSTATIC INTERACTIONS; CHAIN CONFORMATION; MOLECULAR PACKING; MODEL PEPTIDES; COILED COILS; STABILIZATION; ENERGETICS; PROTEINS; ORIGINS; DESIGN	Collagens contain a high amount of charged residues involved in triple-helix stability, fibril formation, and ligand binding. The contribution of charged residues to stability was analyzed utilizing a host-guest peptide system with a single Gly-X-Y triplet embedded within Ac(Gly-Pro-Hyp)(3)-Gly-X-Y-(Gly-Pro-Hyp)(4)-Gly-Gly-NH2. The ionizable residues Arg, Lys, Glu, and Asp were incorporated into the X position of Gly-X-Hyp; in the Y position of Gly-Pro-Y; or as pairs of oppositely charged residues occupying X and Y positions, The Gly-X-Hyp peptides had similar thermal stabilities, only marginally less stable than Gly-Pro-Hyp, whereas Gly-Pro-Y peptides showed a wide thermal stability range (T-m = 30-45 degrees C). The stability of peptides with oppositely charged residues in the X and Y positions appears to reflect simple additivity of the individual residues, except when X is occupied by a basic residue and Y = Asp, The side chains of Glu, Lys, and Arg have the potential to form hydrogen bonds with available peptide backbone carbonyl groups within the triple-helix, whereas the shorter Asp side chain does not, This may relate to the unique involvement of Asp residues in energetically favorable ion pair formation. These studies clarify the dependence of triple-helix stability on the identity, position, and ionization state of charged residues.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; CSIRO,DEPT MOL SCI,PARKVILLE,VIC 3052,AUSTRALIA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Beck, Konrad/AAX-1351-2020; Ramshaw, John AM/A-9411-2011	Beck, Konrad/0000-0001-5098-9484; Ramshaw, John A.M./0000-0002-2131-3685	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019626] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 19626] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BANSAL M, 1978, INT J PEPT PROT RES, V11, P73; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Brodsky B, 1995, FASEB J, V9, P1537, DOI 10.1096/fasebj.9.15.8529832; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; BRODSKY B, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P55; BROWN EM, 1993, J AM LEATHER CHEM AS, V88, P2; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; DOYLE BB, 1974, BIOCHEM BIOPH RES CO, V60, P858, DOI 10.1016/0006-291X(74)90320-9; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; HOFMANN H, 1980, J MOL BIOL, V141, P293, DOI 10.1016/0022-2836(80)90182-5; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HULMES DJS, 1973, J MOL BIOL, V79, P137, DOI 10.1016/0022-2836(73)90275-1; JONES EY, 1991, J MOL BIOL, V218, P209, DOI 10.1016/0022-2836(91)90885-A; KADLER K, 1995, PROTEIN PROFILE, V2, P491; KATZ EP, 1992, J MOL BIOL, V228, P963, DOI 10.1016/0022-2836(92)90878-N; KATZ EP, 1990, BIOPOLYMERS, V29, P791, DOI 10.1002/bip.360290413; LI ST, 1975, J MOL BIOL, V98, P835, DOI 10.1016/S0022-2836(75)80015-5; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SALEM G, 1975, FEBS LETT, V51, P94, DOI 10.1016/0014-5793(75)80861-1; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; TRAUB W, 1976, FEBS LETT, V68, P245, DOI 10.1016/0014-5793(76)80446-2; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; VITAGLIANO L, 1993, BIOCHEMISTRY-US, V32, P7354, DOI 10.1021/bi00080a004; Wada A, 1976, Adv Biophys, P1; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; WALLACE DG, 1990, BIOPOLYMERS, V29, P1015, DOI 10.1002/bip.360290613; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	40	80	82	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31441	31446		10.1074/jbc.272.50.31441	http://dx.doi.org/10.1074/jbc.272.50.31441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395477	hybrid, Green Accepted			2022-12-25	WOS:A1997YL41900036
J	Cheng, YS; Champliaud, MF; Burgeson, RE; Marinkovich, MP; Yurchenco, PD				Cheng, YS; Champliaud, MF; Burgeson, RE; Marinkovich, MP; Yurchenco, PD			Self-assembly of laminin isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; MUSCULAR-DYSTROPHY; HEPARIN-BINDING; SHORT ARM; CHAIN; EXPRESSION; ADHESION; NETWORK; GENE; KERATINOCYTES	The alpha, beta, and gamma subunits of basement membrane laminins can combine into different heterotrimeric molecules with either three full short arms (e.g. laminins-1-4), or molecules containing one (laminins-6-9) or more (laminin-5) short arm truncations. Laminin-1 (alpha 1 beta 1 gamma 1), self-assembles through a calcium-dependent thermal gelation requiring binding interactions between N-terminal short arm domains, forming a meshwork polymer thought to contribute to basement membrane architecture (Yurchenco, P. D., and Cheng, Y. S. (1993) J. Biol. Chem. 268, 17286-17299). However, it has been unclear whether other isoforms share this property, and if so, which ones. To begin to address this, we evaluated laminin-2 (alpha 2 beta 1 gamma 1), laminin-4 (alpha 2 beta 2 gamma 1), laminin-5 (alpha 3A beta 3 gamma 2), and laminin-6 (alpha 3A beta 1 gamma 1). The first two isoforms were found to self-aggregate in a concentration- and temperature-dependent manner and a close self-assembly relationship among laminins-1, -2, and -4 were demonstrated by: (a) polymerization of all three proteins was inhibited by EDTA and laminin-1 short arm fragments, (b) polymerization of laminin-1 was inhibited by fragments of laminins-2 and -4, (c) laminin-2 and, to a lesser degree, laminin-4, even well below their own critical concentration, co-aggregated with laminin-1, evidence for co-polymerization. Laminin-5, on the other hand, neither polymerized nor co-polymerized with laminin-1. Laminin-6 failed to co-aggregate with laminin-l at all concentrations evaluated, evidence for a lack of a related self-assembly activity. The data support the hypothesis that all three short arms are required for self-assembly and suggest that the short arm domain structure of laminin isoforms affect their architecture-forming properties in basement membranes.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL & LAB MED,PISCATAWAY,NJ 08854; PALO ALTO VET AFFAIRS HLTH CARE SYST,DIV DERMATOL,PALO ALTO,CA 94061; STANFORD UNIV,SCH MED,DEPT DERMATOL,STANFORD,CA 94305; HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,CUTANEOUS BIOL RES CTR,CHARLESTOWN,MA 02129	Rutgers State University New Brunswick; Rutgers State University Medical Center; Stanford University; Harvard University				Yurchenco, Peter/0000-0003-0387-2317	NIAMS NIH HHS [P01-AR-44012, R01-AR 35689] Funding Source: Medline; NIDDK NIH HHS [R01-DK36425] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035689, P01AR044012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN JC, 1994, J CELL SCI, V107, P329; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; Engvall E, 1996, J CELL BIOCHEM, V61, P493; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; Mayer U., 1994, EXTRACELLULAR MATRIX, P389, DOI [10.1016/B978-0-12-775170-2.50017-2, DOI 10.1016/B978-0-12-775170-2.50017-2]; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miquel C, 1996, EXP CELL RES, V224, P279, DOI 10.1006/excr.1996.0138; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1994, METHOD ENZYMOL, V245, P489; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; Yurchenco PD., 1994, EXTRACELLULAR MATRIX, P351	30	198	202	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31525	31532		10.1074/jbc.272.50.31525	http://dx.doi.org/10.1074/jbc.272.50.31525			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395489	hybrid			2022-12-25	WOS:A1997YL41900048
J	Crosbie, RH; Heighway, J; Venzke, DP; Lee, JC; Campbell, KP				Crosbie, RH; Heighway, J; Venzke, DP; Lee, JC; Campbell, KP			Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; EXTRACELLULAR-MATRIX; CONGENITAL FIBROSIS; EXTRAOCULAR-MUSCLES; GENE; CHROMOSOME-12; SARCOLEMMA; LINKAGE	The dystrophin-glycoprotein complex is a multisubunit protein complex that spans the sarcolemma and forms a link between the subsarcolemmal cytoskeleton and the extracellular matrix. Primary mutations in the genes encoding the proteins of this complex are associated with several forms of muscular dystrophy. Here we report the cloning and characterization of sarcospan, a unique 25-kDa member of this complex. Topology algorithms predict that sarcospan contains four transmembrane spanning helices with both N- and C-terminal domains located intracellularly. Phylogenetic analysis reveals that sarcospan's arrangement in the membrane as well as its primary sequence are similar to that of the tetraspan superfamily of proteins. Sarcospan co-localizes and co-purifies with the dystrophin-glycoprotein complex, demonstrating that it is an integral component of the complex. We also show that sarcospan expression is dramatically reduced in muscle from patients with Duchenne muscular dystrophy. This suggests that localization of sarcospan to the membrane is dependent on proper dystrophin expression. The gene encoding sarcospan maps to human chromosome 12p11.2, which falls within the genetic locus for congenital fibrosis of the extraocular muscle, an autosomal dominant muscular dystrophy.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT NEUROL,IOWA CITY,IA 52242; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research				Venzke, David/0000-0001-8180-9562; Campbell, Kevin/0000-0003-2066-5889				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; ENGLE EC, 1994, NAT GENET, V7, P69, DOI 10.1038/ng0594-69; ENGLE EC, 1995, AM J HUM GENET, V57, P1086; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Heighway J, 1996, GENOMICS, V35, P207, DOI 10.1006/geno.1996.0340; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Jung D, 1996, J BIOL CHEM, V271, P32321, DOI 10.1074/jbc.271.50.32321; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; SCOTT AF, 1994, GENOMICS, V20, P227, DOI 10.1006/geno.1994.1157; Stone K. L., 1993, PRACTICAL GUIDE PROT, P43; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; WILLIAMS KR, 1997, IN PRESS TECHNIQUES, V6; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; [No title captured]	21	160	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31221	31224		10.1074/jbc.272.50.31221	http://dx.doi.org/10.1074/jbc.272.50.31221			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395445	hybrid, Green Published			2022-12-25	WOS:A1997YL41900004
J	Vivaudou, M; Chan, KW; Sui, JL; Jan, LY; Reuveny, E; Logothetis, DE				Vivaudou, M; Chan, KW; Sui, JL; Jan, LY; Reuveny, E; Logothetis, DE			Probing the G-protein regulation of GIRK1 and GIRK4, the two subunits of the K-ACh channel, using functional homomeric mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MUSCARINIC POTASSIUM CHANNEL; GTP-BINDING PROTEINS; INWARD-RECTIFIER; I-KACH; XENOPUS OOCYTES; RECTIFICATION; EXPRESSION; CLONING; RESIDUE	In heart, G-protein-activated channels are complexes of two homologous proteins, GIRK1 and GIRK4. Expression of either protein alone results in barely active or non-active channels, making it difficult to assess the individual contribution of each subunit to the channel complex. The residue Phe(137), located within the H5 region of GIRK1, is critical to the synergy between GIRK1 and GIRK4 (Chan, K. W., Sui, J. L., Vivaudou, M., and Logothetis, D. E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14193-14198). By modifying this residue or the matching residue of GIRK4, Ser(143), we have been able to generate mutant proteins that produced large inwardly rectifying, G-protein-modulated currents when expressed alone in Xenopus oocytes. The enhanced activity of the heterologous expression of each of two active mutants, GIRK1(F137S) and GIRK4(S143T), was not caused by association with an endogenous oocyte channel subunit, and these mutants did not display apparent differences in the ability to localize to the cell surface compared with their wild-type counterparts. when these functional mutant channels were compared individually with wild-type heteromeric channels, they responded with only small differences to a number of maneuvers involving coexpression with muscarinic receptors, G-protein beta gamma subunits, wild-type or mutated G-protein alpha subunits, and active protomers of pertussis toxin. These experiments, which confirmed the crucial, though not exclusive, role of G beta gamma in regulating channel activity, demonstrated that GIRK1(F137S) and GIRK4(S143T), and by extrapolation their wild-type counterparts, interact in a qualitatively similar way with G-protein subunits. These findings suggest that functionally important sites of interaction with G-proteins are likely to be located within the homologous regions of GIRK1 and GIRK4 rather than within the divergent terminal regions. They also raise the question of the functional advantage of a heteromeric over homomeric design for G-protein-gated channels.	CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Weizmann Institute of Science			Vivaudou, Michel/C-5338-2008	Vivaudou, Michel/0000-0002-9777-3127; Jan, Lily/0000-0003-3938-8498	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054185] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; Kofuji P, 1996, J PHYSIOL-LONDON, V490, P633, DOI 10.1113/jphysiol.1996.sp021173; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; SUI JL, 1988, IN PRESS ADV 2 MESSP; VIVAUDOU M, 1997, BIOPHYS J, V72, P11; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7	35	127	130	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31553	31560		10.1074/jbc.272.50.31553	http://dx.doi.org/10.1074/jbc.272.50.31553			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395492	hybrid			2022-12-25	WOS:A1997YL41900051
J	Zeng, YC; Bannon, G; Thomas, VH; Rice, K; Drake, R; Elbein, A				Zeng, YC; Bannon, G; Thomas, VH; Rice, K; Drake, R; Elbein, A			Purification and specificity of beta 1,2-xylosyltransferase, an enzyme that contributes to the allergenicity of some plant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; ATOPIC-DERMATITIS; GLYCANS; IGE; ANTIBODIES; CHALLENGES; POLLEN; VENOM; WHEAT	The enzyme that transfers D-xylose from UDP-xylose to the beta-linked mannose of plant N-linked oligosaccharides was purified about 51,000-fold to apparent homogeneity from soybean microsomes. On SDS gels, two proteins of 56 and 59 kDa were detected and both were labeled to the same extent by the photoaffinity label, 5-N-3-UDP-[P-32]xylose. Labeling of both proteins was inhibited by cold UDP-xylose, but not by UDP-glucose. The amount of 5-N-3-UDP-[P-32]xylose that bound to the two protein bands was greatly increased in the presence of oligosaccharide accepters. The best acceptor for xylose transfer and for stimulation of UDP-xylose binding was GlcNAc(2)Man(3)GlcNAc(2)-T, but GlcNAc(1)Man(3)GlcNAc(2), with the GlcNAc on the 3-branch, was also a good acceptor and a good stimulator. A number of other N-linked oligosaccharides were poor accepters, especially those with galactose units at the nonreducing termini, Many of the properties of this enzyme have been described, and the product of the reaction of UDP-xylose and GlcNAc(2)Man(3)(GlcNAc)(2) was characterized as GlcNAc beta 1, 2Man alpha 1,6(GlcNAc beta 1,2Man alpha 1,3) (Xyl beta 1,2)Man beta 1,4GlcNA c(2)-T by chemical and NMR methods.	UNIV ARKANSAS MED SCI,DEPT BIOCHEM & MOL BIOL,LITTLE ROCK,AR 72205; UNIV MICHIGAN,COLL PHARM,DEPT MED CHEM,ANN ARBOR,MI 48109	University of Arkansas System; University of Arkansas Medical Sciences; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ARMENTIA A, 1993, CLIN EXP ALLERGY, V23, P410, DOI 10.1111/j.1365-2222.1993.tb00347.x; BERZOKSKY JA, 1985, SCIENCE, V219, P932; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P172; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; DIXON RA, 1985, PLANT CELL CULTURE; DRAKE RR, 1989, J BIOL CHEM, V264, P11928; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; GARCIACASADO G, 1995, FEBS LETT, V364, P36, DOI 10.1016/0014-5793(95)00355-D; HANSEN MY, 1994, ALLERGY, V49, P235, DOI 10.1111/j.1398-9995.1994.tb02655.x; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; KYOSSEV ZN, 1995, EUR J BIOCHEM, V228, P109, DOI 10.1111/j.1432-1033.1995.0109o.x; MULDER H, 1995, EUR J BIOCHEM, V232, P272, DOI 10.1111/j.1432-1033.1995.tb20809.x; RODGERS MW, 1992, BIOCHEM J, V288, P817, DOI 10.1042/bj2880817; SILVA M, 1994, ARCH BIOCHEM BIOPHYS, V312, P151; TAMURA T, 1994, ANAL BIOCHEM, V216, P335, DOI 10.1006/abio.1994.1050; TEZUKA K, 1992, EUR J BIOCHEM, V203, P401, DOI 10.1111/j.1432-1033.1992.tb16564.x; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; Vieths S., 1994, Food and Agricultural Immunology, V6, P453, DOI 10.1080/09540109409354857	23	43	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31340	31347		10.1074/jbc.272.50.31340	http://dx.doi.org/10.1074/jbc.272.50.31340			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395463	hybrid			2022-12-25	WOS:A1997YL41900022
J	Zha, HB; Reed, JC				Zha, HB; Reed, JC			Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY; BCL-X(L); HOMODIMERIZATION; CHEMOTHERAPY; INHIBITION; EXPRESSION; APOPTOSIS; DISTINCT; SURVIVAL; DOMAINS	The pro-apoptotic protein Bax can homodimerize with itself and heterodimerize with the anti-apoptotic protein Bcl-2, but the significance of these protein-protein interactions remains unclear. Alanine substitution mutations were created in a well conserved IGDE motif found within the BH3 domain of Bax (residues 66-69) and the resulting mutant Bax proteins were tested for ability to homodimerize with themselves and to heterodimerize with Bcl-2, Correlations were made with cell death induction by these mutants of Bax both in mammalian cells where Bax may function through several mechanisms, and in yeast where Bax may exert its lethal actions through a more limited repertoire of mechanisms perhaps related to its ability to form ion channels in intracellular membranes, Two of the mutants, Bax(D68A) and Bax(E69A), retained the ability to homodimerize but failed to interact with Bcl-2 as determined by yeast two-hybrid assays and co-immunoprecipitation analysis using transfected mammalian cells, The Bax(E69A) protein exhibited a lethal phenotype in yeast, which could be specifically suppressed by co-expression of Bcl-2, despite its failure to dimerize with Bcl-2, Both the Bax(D68A) and Bax(E69A) proteins induced apoptosis when overexpressed in human 293 cells, despite an inability to bind to Bcl-2, Moreover, co-expression of Bcl-2 with Bax(D68A) and Bax(E69A) rescued mammalian cells from apoptosis, In contrast, a mutant of Bax lacking the IGDE motif, Bax(Delta IGDE), was incapable of either homodimerizing with itself or heterodimerizing with Bcl-2 and was inactive at promoting cell death in either yeast or mammalian cells, Although failing to interact with Bcl-2, the Bax(D68A) and Bax(E69A) mutants retained the ability to bind to Bid, a putative Bax-activating member of the Bcl-2 family, and collaborated with Bid in inducing apoptosis, When taken together with previous observations, these findings indicate that (i) Bax can induce apoptosis in mammalian cells irrespective of heterodimerization with Bcl-2 and (ii) Bcl-2 can rescue both mammalian cells and yeast from the lethal effects of Bax without heterodimerizing with it, However, these results do not exclude the possibility that BH3-dependent homodimerization of Bax or interactions with Bax activators such as Bid may either assist or be required for the cell death-inducing mechanism of this protein.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Diaz JL, 1997, J BIOL CHEM, V272, P11350; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OBLATTMONTAL M, 1993, J BIOL CHEM, V268, P14601; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1996, J BIOL CHEM, V271, P32073, DOI 10.1074/jbc.271.50.32073; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494	31	145	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31482	31488		10.1074/jbc.272.50.31482	http://dx.doi.org/10.1074/jbc.272.50.31482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395483	hybrid, Green Published			2022-12-25	WOS:A1997YL41900042
J	Fritz, G; Kaina, B				Fritz, G; Kaina, B			rhoB encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGING TREATMENTS; EPIDERMAL GROWTH-FACTOR; ACTIN STRESS FIBERS; C-JUN; SIGNALING PATHWAY; MAMMALIAN-CELLS; CDC42 GTPASES; ACTIVATION; INDUCTION; INHIBITOR	The small GTPase RhoB is immediate-early inducible by DNA damaging treatments and thus part of the early response of eukaryotic cells to genotoxic stress. To investigate the regulation of this cellular response, we isolated the gene for rhoB from a mouse genomic Library, Sequence analysis of the rhoB gene showed that its coding region does not contain introns, The promoter region of rhoB harbors regulatory elements such as TATA, CAAT, and Sp1 boxes but not consensus sequences for AP-1, Elk-1, or c-Jun/ATF-2. The rhoB promoter was activated by UV irradiation, but not by 12-O-tetradecanoylphorbol-13-acetate treatment. rhoB promoter deletion constructs revealed a fragment of 0.17 kilobases in size which was sufficient in eliciting the UV response. This minimal promoter fragment contains TATA and CAAT boxes but no other known regulatory elements, Neither MEK inhibitor PD98059 nor p38 kinase inhibitor SB203580 blocked stimulation of rhoB by UVC (UV Light, 254 nm) which indicates that ERK or p38 mitogen-activated protein (MAP) kinase are not involved in the UV induction of rhoB, Also, phosphatidylinositol 3-kinase inhibitor wortmannin, which blocks UV stimulation of both JNK and p38 MAP kinase, did not inhibit rhoB activation. Furthermore, activation of JNK by interleukin-1 beta did not affect rhoB expression. These data indicate that JNK is not involved in the regulation of rhoB, Overexpression of wild-type Rac as well as the Rho guanine-dissociation inhibitor caused activation of rhoB, Wild-type RhoB inhibited both basal and UV stimulated rhoB promoter activity, indicating a negative regulatory feedback by RhoB itself, The data provide evidence both for a signal transduction pathway independent of JNK, ERK, and p38 MAP kinase to be involved in the induction of rhoB by genotype stress, and furthermore, indicate autoregulation of rhoB.			Fritz, G (corresponding author), Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.							ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRITSCHE M, 1993, ONCOGENE, V8, P307; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P201; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KAINA B, 1990, DNA REPAIR MECHANISM, P149; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MILLER CC, 1994, J BIOL CHEM, V269, P3529; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WIEGERS W, 1991, EUR J CELL BIOL, V54, P237; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	63	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30637	30644		10.1074/jbc.272.49.30637	http://dx.doi.org/10.1074/jbc.272.49.30637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388198	hybrid			2022-12-25	WOS:000071640800011
J	Karow, JK; Chakraverty, RK; Hickson, ID				Karow, JK; Chakraverty, RK; Hickson, ID			The Bloom's syndrome gene product is a 3 '-5 ' DNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECQ; GENOME STABILITY; WERNER SYNDROME; HOMOLOG; CLONING; SGS1; EXPRESSION; INTERACTS; DISEASE; PROTEIN	Bloom's syndrome (BS) is an autosomal recessive condition characterized by short stature, immunodeficiency, and a greatly elevated frequency of many types of cancer. The gene mutated in BS, BLM, encodes a protein containing seven "signature" motifs conserved in a wide range of DNA and RNA helicases, BLM is most closely related to the subfamily of DEXH box-containing DNA helicases of which the prototypical member is Escherichia coli RecQ, To analyze its biochemical properties, me have overexpressed an oligohistidine-tagged version of the BLM gene product in Saccharomyces cerevisiae and purified the protein to apparent homogeneity using nickel chelate affinity chromatography. The recombinant BLM protein possesses an ATPase activity that is strongly stimulated by either single or double-stranded DNA. Moreover, BLM exhibits ATP-and Mg2+-dependent DNA helicase activity that displays 3'-5' directionality. Because many of the mutations in BS individuals are predicted to truncate the BLM protein and thus eliminate the "helicase" motifs or map to conserved positions within these motifs, our data strongly suggest that these mutations will disable the 3'-5' helicase function of the BLM protein.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Hickson, ID (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England.		Hickson, Ian/AAJ-7548-2020	Chakraverty, Ronjon/0000-0003-2301-2664; Hickson, Ian/0000-0002-0583-566X				AUSTIN CA, 1995, J BIOL CHEM, V270, P15739, DOI 10.1074/jbc.270.26.15739; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Duguet M, 1997, J CELL SCI, V110, P1345; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; Ellis NA, 1996, NATURE, V381, P110, DOI 10.1038/381110a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Lombard DB, 1996, TRENDS GENET, V12, P283, DOI 10.1016/0168-9525(96)30065-6; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; PURANAM LL, 1994, J BIOL CHEM, V269, P29838; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; THWEATT R, 1993, BIOESSAYS, V15, P421, DOI 10.1002/bies.950150609; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WASSERMAN RA, 1993, CANCER RES, V53, P3591; Watt PM, 1996, CURR BIOL, V6, P265, DOI 10.1016/S0960-9822(02)00474-8; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	22	318	324	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30611	30614		10.1074/jbc.272.49.30611	http://dx.doi.org/10.1074/jbc.272.49.30611			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388193	hybrid			2022-12-25	WOS:000071640800006
J	Lin, RZ; Hu, ZW; Chin, JH; Hoffman, BB				Lin, RZ; Hu, ZW; Chin, JH; Hoffman, BB			Heat shock activates c-Src tyrosine kinases and phosphatidylinositol 3-kinase in NIH3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; GROWTH-FACTOR; MAPKAP KINASE-2; S6 KINASE; FACTOR-I; PHOSPHORYLATION; CELLS; RECEPTORS; STRESS; CASCADE	There is increasing evidence that cellular responses to stress are in part regulated by protein kinases, although specific mechanisms are not well defined, The purpose of these experiments was to investigate potential upstream signaling events activated during heat shock in NIH3T3 fibroblasts. Experiments were designed to ask whether heat shock activates p60 c-Src tyrosine kinase or phosphatidylinositol 3-kinase (PI 3-kinase). Using in vitro protein kinase activity assays, it was demonstrated that heat shock stimulates c-Src and PI 3-kinase activity in a time-dependent manner, Also, there was increased PI 3-kinase activity in anti-phosphotyrosine and anti-c-Src immunoprecipitated immunocomplexes from heated cells, Heat shock activated mitogen-activated protein kinase (MAPK) and p70 S6 kinase (S6K) in these cells, The role of PI 3-kinase in regulating heat shock activation of MAPK and p70 S6K was investigated using wortmannin, a specific pharmacological inhibitor of PI 3-kinase. The results demonstrated that wortmannin inhibited heat shock activation of p70 S6K but only partially inhibited heat activation of MAPK, A dominant negative Raf mutant inhibited activation of MAPK by heat shock but did not inhibit heat shock stimulation of p70 S6K. Genistein, a tyrosine kinase inhibitor, and suramin, a growth factor receptor inhibitor, both inhibited heat shock stimulation of MAPK activity and tyrosine phosphorylation of MAPK. Furthermore, a selective epidermal growth factor receptor (EGFR) inhibitor, tryphostin AG1478, and a dominant negative EGFR mutant also inhibited heat shock activation of MAPK. Heat shock induced EGFR phosphorylation. These results suggest that early up stream signaling events in response to heat stress may involve activation of PI 3-kinase and tyrosine kinases, such as c-Src, and a growth factor receptor, such as EGFR; activation of important downstream pathways, such as MAPK and p70 S6K, occur by divergent signaling mechanisms similar to growth factor stimulation.	Stanford Univ, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care System, Palo Alto, CA 94394 USA; Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94394 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Geriatric Research Education & Clinical Center	Hoffman, BB (corresponding author), Vet Affairs Med Ctr, 3801 Miranda Ave,GRECC 182B, Palo Alto, CA 94304 USA.		Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41315] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; COFFER PJ, 1995, ONCOGENE, V11, P561; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; ENGEL K, 1995, J CELL BIOCHEM, V57, P321, DOI 10.1002/jcb.240570216; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Huot J, 1996, CANCER RES, V56, P273; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MAHER PA, 1989, J CELL BIOL, V108, P2029, DOI 10.1083/jcb.108.6.2029; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; Rao GN, 1996, ONCOGENE, V13, P713; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; YANO H, 1993, J BIOL CHEM, V268, P25846	31	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31196	31202		10.1074/jbc.272.49.31196	http://dx.doi.org/10.1074/jbc.272.49.31196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388274	hybrid			2022-12-25	WOS:000071640800087
J	Lu, M; Farrell, PJ; Johnson, R; Iatrou, K				Lu, M; Farrell, PJ; Johnson, R; Iatrou, K			A baculovirus (Bombyx mori nuclear polyhedrosis virus) repeat element functions as a powerful constitutive enhancer in transfected insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC ACTIN GENE; DNA-REPLICATION; HOMOLOGOUS DNA; EARLY PROMOTER; SV40 ENHANCER; RECOMBINANT BACULOVIRUSES; ORGYIA-PSEUDOTSUGATA; PUTATIVE ORIGINS; BINDING-PROTEIN; EXPRESSION	It has been previously reported that baculovirus homologous regions, the regions of baculovirus genomes that contain the origins of DNA replication, can augment the expression of a small number of baculovirus genes in vitro, We are now reporting that a region of the genome of Bombyx mori nuclear polyhedrosis virus (BmNPV) containing the homologous region 3 (HR3) acts as an enhancer for the promoter of a nonviral gene, the cytoplasmic actin gene of the silkmoth B. mori. Incorporation of the HR3 sequences of BmNPV into an actin promoter based expression cassette results in an augmentation of transgene expression in transfected cells by two orders of magnitude relative to the control re combinant expression cassette, This increase is due to a corresponding increase in the rate of transcription from the actin promoter and not to replication of the expression cassette and occurs only when the HR3 element is linked to the expression cassette in cis, A comparable degree of enhancement in the activity of the silkworm actin promoter occurs also in heterologous lepidopteran cells, Concomitant supplementation of transfected cells with the BmIE1 trans-activator, which was previously shown to be capable of functioning in vitro as a transcriptional co-activator of the cytoplasmic actin gene promoter, results in more than a 1,000-fold increase in the level of expression of recombinant proteins placed under the control of the actin gene promoter, These findings provide the foundation for the development of a nonlytic insect cell expression system for continuous high-level expression of recombinant proteins. Such a system should provide levels of expression of recombinant proteins comparable to those obtained from baculovirus expression systems and should also have the additional advantage of continuous production in a cellular environment that, in contrast to that generated by a baculovirus infection, supports continuously proper posttranslational modifications of recombinant proteins and the capability of expression of proteins from genomic as well as cDNA sequences.	Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada	University of Calgary	Iatrou, K (corresponding author), Univ Calgary, Dept Med Biochem, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Johnson, Russell/0000-0002-5850-9059				AHRENS CH, 1995, VIROLOGY, V207, P572, DOI 10.1006/viro.1995.1119; ARIF BM, 1984, EMBO J, V3, P525, DOI 10.1002/j.1460-2075.1984.tb01841.x; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BLISSARD GW, 1990, ANNU REV ENTOMOL, V35, P127, DOI 10.1146/annurev.en.35.010190.001015; Bonning BC, 1996, ANNU REV ENTOMOL, V41, P191, DOI 10.1146/annurev.en.41.010196.001203; CARSON DD, 1991, J VIROL, V65, P945, DOI 10.1128/JVI.65.2.945-951.1991; COCHRAN MA, 1983, J VIROL, V45, P961, DOI 10.1128/JVI.45.3.961-970.1983; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DICKSON JA, 1991, J VIROL, V65, P4006, DOI 10.1128/JVI.65.8.4006-4016.1991; GRUSS P, 1981, P NATL ACAD SCI-BIOL, V78, P943, DOI 10.1073/pnas.78.2.943; GUARINO LA, 1986, J VIROL, V60, P224, DOI 10.1128/JVI.60.1.224-229.1986; GUARINO LA, 1991, J VIROL, V65, P3676, DOI 10.1128/JVI.65.7.3676-3680.1991; GUARINO LA, 1987, J VIROL, V61, P2091, DOI 10.1128/JVI.61.7.2091-2099.1987; GUARINO LA, 1986, J VIROL, V60, P215, DOI 10.1128/JVI.60.1.215-223.1986; HAMMOCK BD, 1977, ANAL BIOCHEM, V82, P573, DOI 10.1016/0003-2697(77)90196-8; HOOPES RR, 1991, P NATL ACAD SCI USA, V88, P4513, DOI 10.1073/pnas.88.10.4513; IATROU K, 1985, J VIROL, V54, P436, DOI 10.1128/JVI.54.2.436-445.1985; JOHNSON R, 1992, VIROLOGY, V190, P815, DOI 10.1016/0042-6822(92)90919-G; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; KOGAN PH, 1994, J VIROL, V68, P813, DOI 10.1128/JVI.68.2.813-822.1994; KOOL M, 1993, J GEN VIROL, V74, P2661, DOI 10.1099/0022-1317-74-12-2661; KOOL M, 1993, VIROLOGY, V192, P94, DOI 10.1006/viro.1993.1011; KUZIO J, 1984, VIROLOGY, V139, P185, DOI 10.1016/0042-6822(84)90339-8; LEISY DJ, 1993, VIROLOGY, V196, P722, DOI 10.1006/viro.1993.1529; Lu ML, 1997, GENE, V185, P69, DOI 10.1016/S0378-1119(96)00632-4; Lu ML, 1996, J GEN VIROL, V77, P3135, DOI 10.1099/0022-1317-77-12-3135; Lu ML, 1996, VIROLOGY, V218, P103, DOI 10.1006/viro.1996.0170; MAEDA S, 1990, J GEN VIROL, V71, P1851, DOI 10.1099/0022-1317-71-8-1851; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MOUNIER N, 1986, BIOCHIMIE, V68, P1053, DOI 10.1016/S0300-9084(86)80179-1; MOUNIER N, 1991, INSECT BIOCHEM, V21, P293, DOI 10.1016/0020-1790(91)90019-B; NISSEN MS, 1989, J VIROL, V63, P493, DOI 10.1128/JVI.63.2.493-503.1989; PEARSON M, 1992, SCIENCE, V257, P1382, DOI 10.1126/science.1529337; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SHERIDAN PL, 1995, J BIOL CHEM, V270, P4575, DOI 10.1074/jbc.270.9.4575; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; THEILMANN DA, 1992, VIROLOGY, V187, P97, DOI 10.1016/0042-6822(92)90298-4	37	88	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30724	30728		10.1074/jbc.272.49.30724	http://dx.doi.org/10.1074/jbc.272.49.30724			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388209	hybrid			2022-12-25	WOS:000071640800022
J	Rohr, O; Aunis, D; Schaeffer, E				Rohr, O; Aunis, D; Schaeffer, E			COUP-TF and Sp1 interact and cooperate in the transcriptional activation of the human immunodeficiency virus type 1 long terminal repeat in human microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; HUMAN BRAIN-CELLS; HIV-1 INFECTION; GENE-EXPRESSION; IN-VITRO; RECEPTOR SUPERFAMILY; POSITIVE REGULATION; TRANSGENIC MICE; NEURONAL CELLS	We have recently reported that chicken ovalbumin upstream promoter transcription factor (COUP-TF) activates human immunodeficiency virus type 1 (HIV-1) gene transcription in glial and neuronal cells. Here, we have examined the role of COUP-TF in microglial cells, the major target cells for HIV-1 infection in brain. We show that COUP-TF activates gene expression from both the lymphotropic LAI and the macrophage-tropic JR-FL HIV-1 strains, Although COUP-TF binds to the -352/-320 nuclear receptor responsive element of the long terminal repeat, it functions as a transcriptional activator by acting on the -68/+29 minimal promoter. This region is a direct target of transcription factors Sp1 and Sp3. We report the discovery and features of a physical and functional interplay between COUP-TF and Sp1. Our cotransfection experiments provide evidence for a functional synergism between Sp1 and COUP-TF leading to enhanced transcriptional activity of the HIV-1 long terminal repeat through the Sp1 element, In contrast, Sp3 functions as a repressor of Sp1- or COUP-TF-induced activation. We further demonstrate that COUP-TF and Sp1 are capable of physically interacting, via the DNA-binding domain of COUP-TF, in vitro and in the cell, These findings reveal how the novel interplay of Sp1 and COUP-TF families of transcription factors regulate HIV-1 gene expression.	INSERM, Unite 338, F-67084 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Schaeffer, E (corresponding author), INSERM, Unite 338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.		Dominique, Aunis/W-1419-2019	ROHR, Olivier/0000-0001-8992-2025				Albright AV, 1996, VIROLOGY, V217, P211, DOI 10.1006/viro.1996.0108; BUSY JM, 1995, VIROLOGY, V210, P361; CANONNEHERGAUX F, 1995, J VIROL, V69, P6634, DOI 10.1128/JVI.69.11.6634-6642.1995; CORBOY JR, 1992, SCIENCE, V258, P1804, DOI 10.1126/science.1465618; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HATCH WC, 1994, AIDS RES HUM RETROV, V10, P1597, DOI 10.1089/aid.1994.10.1597; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; ING NH, 1992, J BIOL CHEM, V267, P17617; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADOWAKI Y, 1995, P NATL ACAD SCI USA, V92, P4432, DOI 10.1073/pnas.92.10.4432; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KAMINE J, 1992, J VIROL, V66, P3932, DOI 10.1128/JVI.66.6.3932-3936.1992; KIMURA A, 1993, J BIOL CHEM, V268, P11125; Kingsman SM, 1996, EUR J BIOCHEM, V240, P491, DOI 10.1111/j.1432-1033.1996.0491h.x; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Kurth J, 1996, J VIROL, V70, P7686, DOI 10.1128/JVI.70.11.7686-7694.1996; Leng X, 1996, MOL CELL BIOL, V16, P2332; LI YC, 1994, J BIOL CHEM, V269, P30616; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MOSES AV, 1994, J VIROL, V68, P298, DOI 10.1128/JVI.68.1.298-307.1994; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PERRY VH, 1994, J LEUKOCYTE BIOL, V56, P399, DOI 10.1002/jlb.56.3.399; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; Portegies P, 1991, AIDS, V5 Suppl 2, pS211, DOI 10.1097/00002030-199101001-00029; Power SC, 1996, MOL CELL BIOL, V16, P778; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Rahman A, 1995, J BIOL CHEM, V270, P31059, DOI 10.1074/jbc.270.52.31059; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; Sawaya BE, 1996, J BIOL CHEM, V271, P22895, DOI 10.1074/jbc.271.37.22895; Sawaya BE, 1996, J BIOL CHEM, V271, P23572, DOI 10.1074/jbc.271.38.23572; SAWAYA BE, 1995, NUCLEIC ACIDS RES, V23, P2206, DOI 10.1093/nar/23.12.2206; SCHAEFFER E, 1993, J BIOL CHEM, V268, P23399; Strizki JM, 1996, J VIROL, V70, P7654, DOI 10.1128/JVI.70.11.7654-7662.1996; SUNE C, 1995, J VIROL, V69, P6572; TAYLOR JP, 1994, ADV NEUROIMMUNOL, V4, P291, DOI 10.1016/S0960-5428(06)80270-6; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	50	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31149	31155		10.1074/jbc.272.49.31149	http://dx.doi.org/10.1074/jbc.272.49.31149			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388268	Green Published, hybrid			2022-12-25	WOS:000071640800081
J	Verdone, L; Cesari, F; Denis, CL; Di Mauro, E; Caserta, R				Verdone, L; Cesari, F; Denis, CL; Di Mauro, E; Caserta, R			Factors affecting Saccharomyces cerevisiae ADH2 chromatin remodeling and transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL DEHYDROGENASE-II; IN-VIVO; REGULATED TRANSCRIPTION; ACTIVATE TRANSCRIPTION; PHO5 PROMOTER; RNA-SYNTHESIS; DNA-SEQUENCE; N-TERMINI; YEAST; NUCLEOSOME	The chromatin structure of the Saccharomyces cerevisiae ADH2 gene is modified during the switch from repressing (high glucose) to derepressing (low glucose) conditions of growth. Loss of protection toward micrococcal nuclease cleavage for the nucleosomes covering the TATA box and the RNA initiation sites (-1 and +1, respectively) is the major modification taking place and is strictly dependent on the presence of the transcriptional activator ADR1. To identify separate functions involved in the transition from a repressed to a transcribing promoter, we have analyzed the ADH2 chromatin organization in various genetic backgrounds. Deletion of the CCR4 gene coding for a general transcription factor impaired ADH2 expression without affecting chromatin remodeling, Growing yeast at 37 degrees C also resulted in chromatin remodeling at the ADH2 locus even under glucose repressing conditions. However, although this temperature-induced remodeling was dependent on the ADR1 protein, no ADH2 mRNA was observed. In addition, inactivating RNA polymerase II (and therefore, elongation) was found to have no effect on the ability to reconfigure nucleosomes. Taken together, these data indicate that chromatin remodeling by itself is insufficient to induce transcription at the ADH2 promoter.	Univ Rome La Sapienza, Dipartimento Genet & Biol Mol, CNR, Ctr Studio Acidi Nucl, I-00185 Rome, Italy; Univ Rome La Sapienza, Dipartimento Genet & Biol Mol, Fdn Inst Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome; University System Of New Hampshire; University of New Hampshire	Caserta, R (corresponding author), Univ Rome La Sapienza, Dipartimento Genet & Biol Mol, CNR, Ctr Studio Acidi Nucl, I-00185 Rome, Italy.		Verdone, Loredana/AGG-5450-2022	Caserta, Micaela/0000-0003-1647-5118; Verdone, Loredana/0000-0002-8854-1068	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041215] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Burns LG, 1997, BBA-GENE STRUCT EXPR, V1350, P159; BUTTINELLI M, 1995, P NATL ACAD SCI USA, V92, P10747, DOI 10.1073/pnas.92.23.10747; BUTTINELLI M, 1995, METH MOL G, V6, P168; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CASERTA M, 1996, BIOESSAYS, V18, P947; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; CIRIACY M, 1979, MOL GEN GENET, V176, P427, DOI 10.1007/BF00333107; DENIS CL, 1983, MOL CELL BIOL, V3, P360, DOI 10.1128/MCB.3.3.360; DENIS CL, 1986, MOL CELL BIOL, V6, P4026, DOI 10.1128/MCB.6.11.4026; DENIS CL, 1992, MOL CELL BIOL, V12, P1507, DOI 10.1128/MCB.12.4.1507; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; DONOVIEL MS, 1995, MOL CELL BIOL, V15, P3442; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; FASHER KD, 1993, J MOL BIOL, V231, P658; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GANDREAU L, 1997, CELL, V89, P55; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Lenfant F, 1996, EMBO J, V15, P3974, DOI 10.1002/j.1460-2075.1996.tb00771.x; LINXWEILER W, 1985, CELL, V42, P281; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pereira GG, 1996, EUR J BIOCHEM, V238, P181, DOI 10.1111/j.1432-1033.1996.0181q.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; RUSSELL DW, 1983, J BIOL CHEM, V258, P2674; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SELLECK SB, 1988, P NATL ACAD SCI USA, V85, P5399, DOI 10.1073/pnas.85.15.5399; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SHUSTER J, 1986, MOL CELL BIOL, V6, P1894, DOI 10.1128/MCB.6.6.1894; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Surridge C, 1996, NATURE, V380, P287, DOI 10.1038/380287a0; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Tanaka S, 1996, J MOL BIOL, V257, P919, DOI 10.1006/jmbi.1996.0212; Travers AA, 1996, J MOL BIOL, V257, P486, DOI 10.1006/jmbi.1996.0178; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VALLARI RC, 1992, MOL CELL BIOL, V12, P1663, DOI 10.1128/MCB.12.4.1663; vanHolde K, 1996, BIOESSAYS, V18, P697, DOI 10.1002/bies.950180903; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VENDITTI S, 1988, BIOCHIM BIOPHYS ACTA, V951, P139, DOI 10.1016/0167-4781(88)90034-6; VENDITTI S, 1994, MOL GEN GENET, V242, P100, DOI 10.1007/BF00277353; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; Verdone L, 1996, MOL CELL BIOL, V16, P1978; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Wolffe AP, 1996, CURR BIOL, V6, P234, DOI 10.1016/S0960-9822(02)00465-7; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	60	32	33	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30828	30834		10.1074/jbc.272.49.30828	http://dx.doi.org/10.1074/jbc.272.49.30828			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388226	hybrid			2022-12-25	WOS:000071640800039
J	deBoer, CJ; Vaandrager, JW; vanKrieken, JHJM; Holmes, Z; Kluin, PM; Schuuring, E				deBoer, CJ; Vaandrager, JW; vanKrieken, JHJM; Holmes, Z; Kluin, PM; Schuuring, E			Visualization of mono-allelic chromosomal aberrations 3' and 5' of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization	ONCOGENE			English	Article						11q13; t(11;14); NHL; translocation	MESSENGER-RNA DEGRADATION; HUMAN BREAST-CANCER; UNTRANSLATED REGION; SQUAMOUS-CELL; BCL-1 GENE; OVEREXPRESSION; TRANSLOCATION; AMPLIFICATION; EXPRESSION; PRAD1	In mantle cell lymphoma (MCL), in addition to the characteristic t(11;14)(q13;q32), rearrangements on the 3' side of the cyclin D1 gene have been described. In a series of 32 MCL we found three cases with 3'-rearrangements by Southern blot analysis with a probe representing the 3' untranslated region of the cyclin D1 gene. All three were characterized by the absence of the 4.5 kb transcript, and instead, two cases showed overexpression of the 1.7 kb and a third case (MCLp14) an aberrant 2.5 kb transcript. At the genomic level, fine mapping experiments showed in the 3' untranslated region a 2 kb deletion in MCLp14 and a breakpoint in the other two cases. Fiber FISH analysis showed that in all three cases the 3' aberration co-exists with a regular t(11;14) breakpoint 5' of cyclin D1 on a single allele. Fiber FISH analysis of 16 additional MCL revealed two other such cases with breakpoints 5' and 3' of cyclin D1. These mono-allelic aberrations affecting the cyclin D1 gene suggest that the t(11;14) as a first step switches on transcription, and then sequences in the untranslated region of cyclin D1 are affected to stabilize the message.	LEIDEN UNIV, MED CTR, DEPT PATHOL, NL-2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV, MED CTR, DEPT HEMATOL, NL-2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC			van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040				AKIYAMA N, 1994, CANCER RES, V54, P377; Bigoni R, 1996, ONCOGENE, V13, P797; BOSCH F, 1995, BRIT J HAEMATOL, V91, P1025, DOI 10.1111/j.1365-2141.1995.tb05429.x; BOSCH F, 1994, BLOOD, V84, P2726; BROOKES S, 1992, GENE CHROMOSOME CANC, V4, P290, DOI 10.1002/gcc.2870040404; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Courjal F, 1996, INT J CANCER, V69, P247; DEBOER CJ, 1995, BLOOD, V86, P2715, DOI 10.1182/blood.V86.7.2715.bloodjournal8672715; DEBOER CJ, 1995, ONCOGENE, V10, P1833; deBoer CJ, 1997, ANN ONCOL, V8, P109, DOI 10.1023/A:1008207005567; DEBOER CJ, 1993, CANCER RES, V53, P4148; deBoer CJ, 1996, ANN ONCOL, V7, P251; FLORIJN RJ, 1995, HUM MOL GENET, V4, P831, DOI 10.1093/hmg/4.5.831; GILLETT C, 1994, CANCER RES, V54, P1812; HAYASHI T, 1994, INT J HEMATOL, V59, P281; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KLUIN PM, 1996, CURR DIAGN PATHOL, V3, P187; KOMATSU H, 1994, BLOOD, V84, P1226; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1994, BLOOD, V83, P3689; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Vaandrager JW, 1997, BLOOD, V89, P349, DOI 10.1182/blood.V89.1.349.349_349_349; WILLIAMS ME, 1994, ANN ONCOL, V5, pS71, DOI 10.1093/annonc/5.suppl_1.S71; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	34	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1599	1603		10.1038/sj.onc.1201320	http://dx.doi.org/10.1038/sj.onc.1201320			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380412				2022-12-25	WOS:A1997XX36900011
J	Rossi, FM; Margulis, M; Tang, CM; Kao, JPY				Rossi, FM; Margulis, M; Tang, CM; Kao, JPY			N-Nmoc-L-glutamate, a new caged glutamate with high chemical stability and low pre-photolysis activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID NEUROTRANSMITTERS; ORTHO-NITROBENZYL ESTERS; RECEPTOR DESENSITIZATION; PHOTOLABILE PRECURSORS; TIME REGION; PHOTOCHEMISTRY; RELEASE; ACTIVATION; CHANNEL; PHOTOREARRANGEMENT	We report the synthesis, the physicochemical characterization, and biological evaluation of a new caged glutamate, N-(o-nitromandelyl)oxycarbonyl-L-glutamic acid (Nmoc-Glu), that liberates free glutamate on photolysis. The low affinity of certain glutamate receptors and their rapid entry into desensitization have effectively prevented the creation of an ideal caged glutamate, In the absence of an ideal compound, Nmoc-Glu was designed to resist spontaneous hydrolysis while maintaining reasonable photorelease yield and kinetics, Chemical and physiological analyses reveal that Nmoc-Glu, indeed, has exceptionally low residual activity and high chemical stability, The quantum yield of Nmoc-Glu is 0.11, Photolytic uncaging and release of free glutamate occur in two steps, consisting of an initial light-induced cleavage that proceeds on the sub-millisecond time scale, and a subsequent light-independent, pH-dependent decarboxylation step that proceeds on the millisecond time scale, The low residual activity and high chemical stability of Nmoc-Glu are important advantages in applications where pre-photolysis Glu receptor activation and desensitization must be minimized.	Univ Maryland, Sch Med, Ctr Med Biotechnol, Inst Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Kao, JPY (corresponding author), Univ Maryland, Sch Med, Ctr Med Biotechnol, Inst Biotechnol, Rm S219,725 W Lombard St, Baltimore, MD 21201 USA.			Rossi, Francis/0000-0002-8997-720X; Kao, Joseph/0000-0002-8875-2180	NIGMS NIH HHS [GM-46956] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046956] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1993, ANNU REV PHYSIOL, V55, P755, DOI 10.1146/annurev.ph.55.030193.003543; ADAMS SR, 1988, J AM CHEM SOC, V110, P3212, DOI 10.1021/ja00218a034; AMMALA C, 1991, BIOCHIM BIOPHYS ACTA, V1092, P347; BILLINGTON AP, 1992, BIOCHEMISTRY-US, V31, P5500, DOI 10.1021/bi00139a011; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; CAPLOW M, 1968, J AM CHEM SOC, V90, P6795, DOI 10.1021/ja01026a041; CORRIE JET, 1993, J PHYSIOL-LONDON, V465, P1; GEE KR, 1994, J AM CHEM SOC, V116, P8366, DOI 10.1021/ja00097a054; GEE KR, 1995, J ORG CHEM, V60, P4260, DOI 10.1021/jo00118a050; Gee KR, 1996, J ORG CHEM, V61, P1228, DOI 10.1021/jo951635x; Green T.W., 1991, PROTECTIVE GROUPS OR, P309; IIJIMA T, 1986, P NATL ACAD SCI USA, V83, P654, DOI 10.1073/pnas.83.3.654; Kao J. P. Y., 1993, OPTICAL MICROSCOPY E, P27; KATZ LC, 1994, J NEUROSCI METH, V54, P205, DOI 10.1016/0165-0270(94)90194-5; LIVINGSTON R, 1971, TECHNIQUES CHEM, V3, P13; MAYER ML, 1984, J PHYSIOL-LONDON, V354, P29, DOI 10.1113/jphysiol.1984.sp015360; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; MILBURN T, 1989, BIOCHEMISTRY-US, V28, P49, DOI 10.1021/bi00427a008; MOORE WJ, 1972, PHYSICAL CHEM, P345; NICHOLS CG, 1990, PFLUG ARCH EUR J PHY, V415, P510, DOI 10.1007/BF00373635; RABEK JF, 1982, EXPT METHODS PHOTOCH, P902; RITCHIE CD, 1975, PHYSICAL ORGANIC CHE, P80; Rossi FM, 1997, J BIOL CHEM, V272, P3266, DOI 10.1074/jbc.272.6.3266; SCHUPP H, 1987, J PHOTOCHEM, V36, P85, DOI 10.1016/0047-2670(87)87064-8; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TANG CM, 1994, NEURON, V13, P1385, DOI 10.1016/0896-6273(94)90423-5; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; WANG SSH, 1995, NEURON, V15, P755, DOI 10.1016/0896-6273(95)90167-1; WIEBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752, DOI 10.1073/pnas.91.19.8752; WIEBOLDT R, 1994, BIOCHEMISTRY-US, V33, P1526, DOI 10.1021/bi00172a032; WILCOX M, 1990, J ORG CHEM, V55, P1585, DOI 10.1021/jo00292a038; YAMADA KA, 1993, J NEUROSCI, V13, P3904; YIP RW, 1991, J PHYS CHEM-US, V95, P6078, DOI 10.1021/j100169a009; YIP RW, 1985, J PHYS CHEM-US, V89, P5328, DOI 10.1021/j100271a002; ZHU QQ, 1987, J PHOTOCHEM, V39, P317, DOI 10.1016/0047-2670(87)80041-2	37	50	53	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					32933	32939		10.1074/jbc.272.52.32933	http://dx.doi.org/10.1074/jbc.272.52.32933			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407072	hybrid			2022-12-25	WOS:000071182900033
J	Hemken, PM; Bellin, RM; Sernett, SW; Becker, B; Huiatt, TW; Robson, RM				Hemken, PM; Bellin, RM; Sernett, SW; Becker, B; Huiatt, TW; Robson, RM			Molecular characteristics of the novel intermediate filament protein paranemin - Sequence reveals EAP-300 and IFAP-400 are highly homologous to paranemin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROPHORETIC TRANSFER; NEUROFILAMENT PROTEIN; POLYACRYLAMIDE GELS; SECONDARY-STRUCTURE; SKELETAL-MUSCLE; CHICKEN GIZZARD; NERVOUS-SYSTEM; SMOOTH-MUSCLE; MESSENGER-RNA; AMINO-ACIDS	Paranemin was initially found to copurify with the intermediate filament (IF) proteins vimentin and desmin from embryonic chick skeletal muscle and was described as an IF-associated protein (IFAP). We have purified paranemin from embryonic chick skeletal muscle, prepared antibodies, and demonstrated that they label at the Z-lines of both adult avian and porcine cardiac and skeletal muscle myofibrils. We determined the cDNA sequence of paranemin by immunoscreening a lambda gt22A cDNA library from embryonic chick skeletal muscle. Northern blot analysis revealed a single transcript of 5.3 kilobases, which is much smaller than predicted from the size of paranemin (280 kDa) by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The derived amino acid sequence of paranemin (1,606 residues; 178,161 kDa) contains the conserved IF rod domain (308 amino acids), which has highest homology to the rod domains of nestin and tanabin. Thus, paranemin is an IF protein rather than an IFAP. Sequence analysis also revealed that the partial cDNA sequences of two proteins, namely EAP-300 and IFAPa-400, are almost identical to regions of the cDNA sequence of paranemin. The complete paranemin cDNA was expressed in a cell line (SW13) with, and without, detectable cytoplasmic IFs. Antibody labeling of these cells suggests that paranemin does not form IFs by itself, but rather is incorporated into heteropolymeric IFs with vimentin.	Iowa State Univ, Muscle Biol Grp, Dept Biochem & Biophys, Ames, IA 50011 USA; Iowa State Univ, Muscle Biol Grp, Dept Anim Sci, Ames, IA 50011 USA	Iowa State University; Iowa State University	Robson, RM (corresponding author), Iowa State Univ, Muscle Biol Grp, Dept Biochem & Biophys, 3110 Mol Biol Bldg, Ames, IA 50011 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BECKER B, 1995, BIOCHEM BIOPH RES CO, V213, P796, DOI 10.1006/bbrc.1995.2200; BELLIN RM, 1998, GUIDEBOOK CYTOSKELET; BRECKLER J, 1982, J CELL BIOL, V92, P795, DOI 10.1083/jcb.92.3.795; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1989, J MUSCLE RES CELL M, V10, P95, DOI 10.1007/BF01739964; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Carpenter DA, 1996, J CELL SCI, V109, P2493; CHABOT P, 1990, DEV BRAIN RES, V54, P195, DOI 10.1016/0165-3806(90)90142-L; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Chou YH, 1997, CURR OPIN CELL BIOL, V9, P49, DOI 10.1016/S0955-0674(97)80151-2; COSSETTE LJ, 1991, J CELL SCI, V98, P251; CUI CQ, 1995, J CELL SCI, V108, P3279; DAVIS LG, 1986, METHOD MOL BIOL, P143; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Duval M, 1995, BIOCHEM CELL BIOL, V73, P651, DOI 10.1139/o95-072; Foisner R, 1997, BIOESSAYS, V19, P297, DOI 10.1002/bies.950190407; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUJII T, 1987, J BIOL CHEM, V262, P2757; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; Goll D.E., 1977, P15; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HEDBERG KK, 1986, EXP CELL RES, V163, P509, DOI 10.1016/0014-4827(86)90081-9; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; Hemken Philip M., 1996, Molecular Biology of the Cell, V7, p557A; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HUIATT TW, 1980, J BIOL CHEM, V255, P6981; HUYNH TV, 1985, JDNA CLONING PRACTIC, P76; KELLY MM, 1995, DEV BRAIN RES, V85, P31, DOI 10.1016/0165-3806(94)00185-3; KLYMKOWSKY MW, 1995, CURR OPIN CELL BIOL, V7, P46, DOI 10.1016/0955-0674(95)80044-1; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; MAIZEL JV, 1981, P NATL ACAD SCI-BIOL, V78, P7665, DOI 10.1073/pnas.78.12.7665; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCABE CF, 1992, DEV BRAIN RES, V70, P9, DOI 10.1016/0165-3806(92)90099-I; MCCABE CF, 1992, DEV BRAIN RES, V66, P11, DOI 10.1016/0165-3806(92)90135-J; MCCABE CF, 1995, DEV DYNAM, V203, P51, DOI 10.1002/aja.1002030106; MCKEARN TJ, 1979, IMMUNOL REV, V47, P91, DOI 10.1111/j.1600-065X.1979.tb00290.x; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; OSHEA JM, 1981, BIOCHEM J, V195, P345, DOI 10.1042/bj1950345; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETER M, 1989, J MOL BIOL, V208, P393, DOI 10.1016/0022-2836(89)90504-4; PRICE MG, 1983, J CELL BIOL, V97, P1860, DOI 10.1083/jcb.97.6.1860; PRICE MG, 1991, ADV STRUCTURAL BIOL, V1, P175; RAATS JMH, 1990, J CELL BIOL, V111, P1971, DOI 10.1083/jcb.111.5.1971; RICHARDSON FL, 1981, EUR J CELL BIOL, V26, P91; Robson RM, 1989, CURR OPIN CELL BIOL, V1, P36, DOI 10.1016/S0955-0674(89)80034-1; SAMBROOK J, 1969, MOL CLONING LAB MANU; SARRIA AJ, 1994, J CELL SCI, V107, P1593; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SIMARD JL, 1992, DEV BRAIN RES, V70, P173, DOI 10.1016/0165-3806(92)90195-3; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Sun DM, 1997, J NEUROCHEM, V68, P917; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TOKUYASU KT, 1985, ANN NY ACAD SCI, V455, P200, DOI 10.1111/j.1749-6632.1985.tb50413.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINCENT M, 1988, BIOCHEM CELL BIOL, V66, P184, DOI 10.1139/o88-025; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; WICHE G, 1991, J CELL BIOL, V114, P83, DOI 10.1083/jcb.114.1.83; YAGYU M, 1990, P 12 INT C EL MICR, V3, P454; ZEHNER ZE, 1987, J BIOL CHEM, V262, P8112	76	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32489	32499		10.1074/jbc.272.51.32489	http://dx.doi.org/10.1074/jbc.272.51.32489			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405460	hybrid			2022-12-25	WOS:000071108000079
J	Iwata, T; Minucci, S; McGowan, M; Carper, D				Iwata, T; Minucci, S; McGowan, M; Carper, D			Identification of a novel cis-element required for the constitutive activity and osmotic response of the rat aldose reductase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; TRANSCRIPTION; INVIVO; CELLS; EXPRESSION; PROTEIN; STRESS	A new and essential cis-element AEE (aldose reductase enhancer element), necessary for the constitutive activity and the osmotic stress response of rat aldose reductase transcription in a rat liver cell line, has been identified. In transient transfection assays, an increase in promoter activity, up to 3.8-fold, was observed with osmotic stress (600 mosm/kg H2O) using a luciferase reporter gene construct containing aldose reductase promoter sequence from -1,094 base pair (bp) to +23 bp. A deletion between -1,071 and -895 bp reduced the constitutive activity and abolished the osmotic response of the promoter. Exonuclease III mediated in vivo DNA footprinting and dimethyl sulfate in vivo footprinting revealed DNA protection of a 32-bp region and two guanosines (G) within this region protected from methylation, respectively. Electrophoretic gel mobility shift assays using whole liver cell extracts showed protein binding, under both normal and stressed conditions. Deletion of the sequence between the two guanosines protected by in vivo dimethyl sulfate DNA footprinting (GAAGAGTG) in a luciferase construct (-1,094 bp to +23 bp) abolished the constitutive promoter activity. One copy of AEE fused to the thymidine kinase promoter gave a maximum constitutive activity of 7.7-fold and a maximum osmotic response activity of 6.7-fold.	NEI, Lab Mechanisms Ocular Dis, NIH, Bethesda, MD 20892 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Carper, D (corresponding author), NEI, Lab Mechanisms Ocular Dis, NIH, 9000 Rockville Pike,Bldg 6,Rm 232, Bethesda, MD 20892 USA.		Minucci, Saverio/J-9669-2012					ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BARTELS D, 1991, EMBO J, V10, P1037, DOI 10.1002/j.1460-2075.1991.tb08042.x; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Daoudal S, 1997, J BIOL CHEM, V272, P2615, DOI 10.1074/jbc.272.5.2615; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; FERRARIS JD, 1994, P NATL ACAD SCI USA, V91, P10742, DOI 10.1073/pnas.91.22.10742; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GRAHAM C, 1991, GENE, V107, P259, DOI 10.1016/0378-1119(91)90326-7; KANEKO M, 1990, EXP CELL RES, V188, P135, DOI 10.1016/0014-4827(90)90288-L; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; NISHIMURA C, 1988, BIOCHEM BIOPH RES CO, V153, P1051, DOI 10.1016/S0006-291X(88)81335-4; ROBISON WG, 1983, SCIENCE, V221, P1170; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; VANHEYNINGEN R, 1959, NATURE, V184, P194, DOI 10.1038/184194b0; WANG K, 1993, J BIOL CHEM, V268, P16052	23	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32500	32506		10.1074/jbc.272.51.32500	http://dx.doi.org/10.1074/jbc.272.51.32500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405461	hybrid			2022-12-25	WOS:000071108000080
J	Kuras, R; de Vitry, C; Choquet, Y; Girard-Bascou, J; Culler, D; Buschlen, S; Merchant, S; Wollman, FA				Kuras, R; de Vitry, C; Choquet, Y; Girard-Bascou, J; Culler, D; Buschlen, S; Merchant, S; Wollman, FA			Molecular genetic identification of a pathway for heme binding to cytochrome b(6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE POLYPEPTIDES; SITE-DIRECTED MUTAGENESIS; IRON-SULFUR PROTEIN; C-TYPE CYTOCHROMES; CHLAMYDOMONAS-REINHARDTII; CHLOROPLAST TRANSFORMATION; AXIAL LIGANDS; BC1 COMPLEX; PURIFICATION; BIOSYNTHESIS	Heme binding to cytochrome b(6) is resistant, in part, to denaturing conditions that typically destroy the noncovalent interactions between the b hemes and their apoproteins, suggesting that one of two b hemes of holocytochrome b(6) is tightly bound to the polypeptide, We exploited this property to define a pathway for the conversion of apo- to holocytochrome b(6), and to identify mutants that are blocked at one step of this pathway, Chlamydomonas reinhardtii strains carrying substitutions in either one of the four histidines that coordinate the b(h) or b(1) hemes to the apoprotein were created, These mutations resulted in the appearance of distinct immunoreactive species of cytochrome b(6), which allowed us to specifically identify cytochrome b(6) with altered b(h) or b(1) ligation, In gabaculine-treated (i.e. heme-depleted) wild type and site-directed mutant strains, we established that (i) the single immunoreactive band, observed in strains carrying the b(1) site-directed mutations, corresponds to apocytochrome b(6) and (ii) the additional band present in strains carrying b(h) site-directed mutations corresponds to a b(1)-heme-dependent intermediate in the formation of holocytochrome b(6). Five nuclear mutants (ccb strains) that are defective in holocytochrome b(6) formation display a phenotype that is indistinguishable from that of strains carrying site-directed b(h) ligand mutants, The defect is specific for cytochrome b(6) assembly, because the ccb strains can synthesize other b cytochromes and all c-type cytochromes. The ccb strains, which define four nuclear loci (CCB1, CCB2, CCB3, and CCB4), provide the first evidence that a b-type cytochrome requires trans-acting factors for its heme association.	CNRS, Inst Biol Physicochim, UPR 9072, F-75005 Paris, France; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Centre National de la Recherche Scientifique (CNRS); University of California System; University of California Los Angeles	Wollman, FA (corresponding author), CNRS, Inst Biol Physicochim, UPR 9072, 13 Rue Pierre & Marie Curie, F-75005 Paris, France.		Choquet, Yves/ABE-3084-2020; Choquet, Yves/M-5533-2019	Choquet, Yves/0000-0003-4760-3397	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048350, K04GM000594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM00594, GM 48350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ascoli F, 1981, Methods Enzymol, V76, P72; Bald D., 1992, RES PHOTOSYNTHESIS, VI, P629; Bennoun P, 1982, METHODS CHLOROPLAST, P25; BERRY EA, 1991, J BIOL CHEM, V266, P9064; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; CRAMER WA, 1994, J BIOENERG BIOMEMBR, V26, P31, DOI 10.1007/BF00763218; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRIVELLONE MD, 1994, J BIOL CHEM, V269, P21284; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DELEPELAIRE P, 1983, PHOTOBIOCH PHOTOBIOP, V6, P279; deVitry C, 1996, J BIOL CHEM, V271, P10667, DOI 10.1074/jbc.271.18.10667; DEVITRY C, 1994, J BIOL CHEM, V269, P7603; Finazzi G, 1997, BIOCHEMISTRY-US, V36, P2867, DOI 10.1021/bi962717y; GIRARDBASCOU J, 1995, PHOTOSYNTHESIS LIGHT, V3, P683; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; Gumpel NJ, 1995, PLANT MOL BIOL, V29, P921, DOI 10.1007/BF00014966; HARRIS EH, 1989, CHLAMYDOMANAS SOURCE; HOWE G, 1994, J BIOL CHEM, V269, P5824; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1994, PHOTOSYNTH RES, V40, P147, DOI 10.1007/BF00019332; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, EUR J BIOCHEM, V117, P591; HURT EC, 1984, FEBS LETT, V168, P149, DOI 10.1016/0014-5793(84)80225-2; HURT EC, 1983, FEBS LETT, V153, P413, DOI 10.1016/0014-5793(83)80655-3; Ketchner SL, 1996, BBA-BIOENERGETICS, V1273, P195, DOI 10.1016/0005-2728(95)00157-3; KINDLE KL, 1991, P NATL ACAD SCI USA, V88, P1721, DOI 10.1073/pnas.88.5.1721; KRANZ RG, 1995, ANOXYGENIC PHOTOSYNT, P709; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; PALMER G, 1994, BIOCHEMISTRY-US, V33, P176, DOI 10.1021/bi00167a023; PHILLIPS AL, 1983, EUR J BIOCHEM, V137, P553, DOI 10.1111/j.1432-1033.1983.tb07861.x; Pierre Y, 1997, J BIOL CHEM, V272, P21901, DOI 10.1074/jbc.272.35.21901; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; SIMPKIN D, 1989, BIOCHEMISTRY-US, V33, P176; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WU M, 1989, J BIOL CHEM, V264, P11122; WYNN RM, 1988, BIOCHIM BIOPHYS ACTA, V935, P115, DOI 10.1016/0005-2728(88)90208-3; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017; Zito F, 1997, PLANT MOL BIOL, V33, P79, DOI 10.1023/A:1005734809834	57	87	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32427	32435		10.1074/jbc.272.51.32427	http://dx.doi.org/10.1074/jbc.272.51.32427			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405452	hybrid			2022-12-25	WOS:000071108000071
J	Winter, H; Hofmann, I; Langbein, L; Rogers, MA; Schweizer, J				Winter, H; Hofmann, I; Langbein, L; Rogers, MA; Schweizer, J			A splice site mutation in the gene of the human type I hair keratin hHa1 results in the expression of a tailless keratin isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT ASSEMBLY INVITRO; INTERMEDIATE FILAMENTS; MESSENGER-RNA; DONOR SITE; SEQUENCE; PROTEINS; CYTOKERATINS; ORGANIZATION; FOLLICLE; VIMENTIN	In this study, we have elucidated the molecular mechanisms underlying the expression of an acidic 41-kDa protein inherited as an autosomal dominant trait of the hair keratin pattern of about 5% of the human population. We show that this protein is a size variant of the large type I hair cortex keratin hHa1 due to a genetic polymorphism in the hHa1 gene. We detected a G-A substitution in the 5' splice site of intron 6 of the hHa1 gene, which segregates with the 41-kDa protein phenotype in two pedigrees and is responsible for the formation of an abnormally spliced hHa1 mRNA species. The use of an alternative 5' splice site leads to the retention of 41 nucleotides of the initial intron 6 sequences in the mature transcript. The open reading frame of the aberrant mRNA creates a premature stop codon immediately downstream of the mutation site. The resulting hHa1 protein variant, hHa1-t, is about 6-kDa smaller than the 47-kDa hHa1 hair keratin and lacks the complete nonhelical tail domain. We show that the tailless hHa1-t is functional, since both recombinant hHa1 and hHa1-t form identical keratin intermediate filaments when assembled in vitro with a type II hair keratin partner. This finding confirms the view of a noninvolvement of the keratin tail domain in filament assembly and explains the lack of a pathological hair phenotype in hHa1-t positive individuals.	German Canc Res Ctr, Res Program 2, D-69120 Heidelberg, Germany; German Canc Res Ctr, Res Program 1, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Winter, H (corresponding author), German Canc Res Ctr, Res Program 2, 5th Floor,Room 522,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; BADEN HP, 1977, AM J HUM GENET, V27, P472; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; BERTOLINO AP, 1988, J INVEST DERMATOL, V91, P541, DOI 10.1111/1523-1747.ep12476901; BERTOLINO AP, 1990, J INVEST DERMATOL, V94, P293; Bowden P E, 1994, J Dermatol Sci, V7 Suppl, pS152, DOI 10.1016/0923-1811(94)90046-9; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P1125; COOPER DN, 1993, HUMAN GENE MUTATIONS; Costa EJ, 1996, BRAZ J MED BIOL RES, V29, P1427; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; FINK P, 1995, BBA-GENE STRUCT EXPR, V1264, P12, DOI 10.1016/0167-4781(95)00122-W; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; HATZFELD M, 1990, J CELL SCI, V97, P317; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HEID HW, 1986, DIFFERENTIATION, V37, P215; HOFMANN I, 1991, EUR J CELL BIOL, V56, P328; Hofmann I, 1997, EUR J CELL BIOL, V72, P122; HRDY DB, 1977, AM J HUM GENET, V29, P98; Hunter TC, 1996, SOMAT CELL MOLEC GEN, V22, P145, DOI 10.1007/BF02369904; KRAWCZAK M, 1992, HUM GENET, V90, P41; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGBEIN L, 1993, DIFFERENTIATION, V55, P57, DOI 10.1111/j.1432-0436.1993.tb00033.x; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; MARSHALL RC, 1980, J INVEST DERMATOL, V75, P264, DOI 10.1111/1523-1747.ep12523296; MARUYAMA T, 1995, EUR J BIOCHEM, V232, P700, DOI 10.1111/j.1432-1033.1995.700zz.x; OHNO K, 1988, J BIOL CHEM, V263, P18563; POWELL B, 1992, DEVELOPMENT, V114, P417; Powell B C, 1997, EXS, V78, P59; Powell B.C., 1990, CELLULAR MOL BIOL IN, P267; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; RENNER W, 1981, J MOL BIOL, V149, P285, DOI 10.1016/0022-2836(81)90303-X; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROGERS MA, 1995, EXP CELL RES, V220, P357, DOI 10.1006/excr.1995.1326; Rogers MA, 1997, DIFFERENTIATION, V61, P187, DOI 10.1046/j.1432-0436.1997.6130187.x; Rogers MA, 1996, J INVEST DERMATOL, V107, P633, DOI 10.1111/1523-1747.ep12584243; SCHIMKAT M, 1990, HUM GENET, V85, P311; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1993, BIOCHEM BIOPH RES CO, V197, P840, DOI 10.1006/bbrc.1993.2555; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P3692, DOI 10.1073/pnas.78.6.3692; STEINERT PM, 1995, INTERMEDIATE FILAMEN, P145; STEINERT PM, 1995, INTERMEDIATE FILAMEN, P123; Westgate GE, 1996, INT CONGR SER, V1111, P167; WILSON AK, 1992, J CELL BIOL, V119, P401, DOI 10.1083/jcb.119.2.401; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; WINTER H, 1994, EXP CELL RES, V212, P190, DOI 10.1006/excr.1994.1134; WINTER H, 1997, IN PRESS HUM GENET; YU JL, 1993, J INVEST DERMATOL, V101, pS56, DOI 10.1111/1523-1747.ep12362635	49	25	25	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32345	32352		10.1074/jbc.272.51.32345	http://dx.doi.org/10.1074/jbc.272.51.32345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405442	hybrid			2022-12-25	WOS:000071108000061
J	Finkenzeller, D; Kromer, B; Thompson, J; Zimmermann, W				Finkenzeller, D; Kromer, B; Thompson, J; Zimmermann, W			cea5, a structurally divergent member of the murine carcinoembryonic antigen gene family, is exclusively expressed during early placental development in trophoblast giant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANCY-SPECIFIC GLYCOPROTEIN; MOLECULE C-CAM; MOUSE HEPATITIS-VIRUS; ADHESION MOLECULE; BILIARY GLYCOPROTEIN; COLORECTAL CARCINOMAS; ECTO-ATPASE; RAT-LIVER; RECEPTOR; IDENTIFICATION	The carcinoembryonic antigen (CEA) gene family encodes a large family of glycoproteins. Some are probably involved in the homeostasis/development of epithelial cells and granulocyte activation, while others e.g. the pregnancy-specific glycoproteins, are expressed in the placenta and are essential for a positive outcome of pregnancy, In this paper, we have characterized cea5, a member of the murine CEA gene family, RNase protection and in situ hybridization analyses revealed that Cea5 mRNA is exclusively synthesized in primary and secondary trophoblast giant cells of the placenta only during early stages of development, Bull-length Cea5 cDNA was obtained by a reverse transcription-polymerase chain reaction using day 10.5 post-coitum placental RNA, The 1.6-kilobase pair (kb) Cea5 mRNA encodes a secreted glycoprotein with a predicted size of 30 kDa, It is composed of a leader peptide (L), one immunoglobulin (Ig) variable or N, and one Ig constant-like or A domain, This domain organization is unique within the human and murine CEA families, Two overlapping cosmid clones covering 54 kb of the cea5 gene locus were mapped, cea5 consists of three exons (L, N, A/3'-untranslated region exon) located within a 4-kb region, rnCGM2, the rat cea5 counterpart, exhibits the same restricted expression pattern, This together with their exceptional conservation within the rat and murine CEA families and their absence from the human CEA family suggests that cea5 and rnCGM2 are of functional importance for rodent placental development.	UNIV FREIBURG,INST IMMUNOBIOL,D-79104 FREIBURG,GERMANY	University of Freiburg			Zimmermann, Wolfgang/L-9277-2013					ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BRANDRIFF BF, 1992, GENOMICS, V12, P773, DOI 10.1016/0888-7543(92)90308-F; CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; Chen DS, 1995, P NATL ACAD SCI USA, V92, P12095, DOI 10.1073/pnas.92.26.12095; CHEN HW, 1994, BIOCHEMISTRY-US, V33, P9615, DOI 10.1021/bi00198a030; CHEN HW, 1992, DNA CELL BIOL, V11, P139, DOI 10.1089/dna.1992.11.139; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; Earley K, 1996, BIOCHEM J, V315, P799, DOI 10.1042/bj3150799; EDLUND M, 1993, EUR J BIOCHEM, V213, P1109, DOI 10.1111/j.1432-1033.1993.tb17860.x; HAUCK W, 1995, J BIOL CHEM, V270, P3602, DOI 10.1074/jbc.270.8.3602; HAUCK W, 1994, EUR J BIOCHEM, V223, P529, DOI 10.1111/j.1432-1033.1994.tb19022.x; HSIEH JT, 1995, CANCER RES, V55, P190; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P469; KECK U, 1995, EUR J BIOCHEM, V229, P455, DOI 10.1111/j.1432-1033.1995.0455k.x; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; KODELJA V, 1989, J BIOL CHEM, V264, P6906; Kromer B, 1996, EUR J BIOCHEM, V242, P280, DOI 10.1111/j.1432-1033.1996.0280r.x; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; KUIJPERS TW, 1993, J IMMUNOL, V151, P4934; KUROKI M, 1991, BIOCHEM BIOPH RES CO, V176, P578, DOI 10.1016/S0006-291X(05)80223-2; LI WH, 1985, MOL BIOL EVOL, V2, P150; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEDELLEC P, 1994, J VIROL, V68, P4525; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; OLSEN A, 1994, GENOMICS, V23, P659, DOI 10.1006/geno.1994.1555; REBSTOCK S, 1993, DEV DYNAM, V198, P171, DOI 10.1002/aja.1001980303; REBSTOCK S, 1990, J BIOL CHEM, V265, P7872; ROSENBERG M, 1993, CANCER RES, V53, P4938; RUDERT F, 1992, MAMM GENOME, V3, P262, DOI 10.1007/BF00292154; RUTHERFURD KJ, 1995, MOL ENDOCRINOL, V9, P1297, DOI 10.1210/me.9.10.1297; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1; STOCKS SC, 1992, BIOCHEM J, V288, P23, DOI 10.1042/bj2880023; Stubbs L, 1996, GENOMICS, V35, P499, DOI 10.1006/geno.1996.0390; TEGLUND S, 1994, GENOMICS, V23, P669, DOI 10.1006/geno.1994.1556; Thompson J, 1997, CANCER RES, V57, P1776; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; THOMPSON JA, 1995, TUMOR BIOL, V16, P10, DOI 10.1159/000217923; Turbide C, 1997, CANCER RES, V57, P2781; TURBIDE C, 1991, J BIOL CHEM, V266, P309; ZIMMERMANN W, 1997, IN PRESS CELL ADHESI	54	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31369	31376		10.1074/jbc.272.50.31369	http://dx.doi.org/10.1074/jbc.272.50.31369			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395467	hybrid			2022-12-25	WOS:A1997YL41900026
J	Fraizer, GC; Shimamura, R; Zhang, XH; Saunders, GF				Fraizer, GC; Shimamura, R; Zhang, XH; Saunders, GF			PAX 8 regulates human WT1 transcription through a novel DNA binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR GENE; PAIRED BOX GENE; SUPPRESSOR GENE; KIDNEY DEVELOPMENT; PROMOTER ACTIVITY; MESSENGER-RNA; EXPRESSION; SEQUENCE; GROWTH; REPRESSION	The Wilms' tumor gene (WT1) is an essential gene for kidney and gonadal development, although how WT1 expression is induced in these tissues is not known, One kidney transcription factor likely to play a role in this regulation is PAX 8, The co-expression of WT1 and PAX 8 during kidney development and in Wilms' tumors with an epithelium predominant histology suggested a possible interaction, and indeed, we identified potential core PAX-binding sites in the WT1 promoter, Endogenous PAX 8 plays an important role in the activation of the WT1 promoter, since promoter activity is much stronger in cells with PAX 8 than without, Using binding assays, we searched for evidence of PAX 8-DNA interactions throughout the 652-base pair human WT1 promoter and found only one functional PAX 8 site with DNA binding activity, located 250 base pairs 5' of the minimal promoter, The responsiveness of the PAX 8 site was con firmed by assessing its ability to function as an enhancer significantly activating the minimal promoter in a position-and orientation-independent manner. Using transfection assays, we demonstrated that either endogenous or exogenously added PAX 8 activated the WT1 promoter and that this promoter up-regulation depended upon the presence of an intact PAX 8-binding site, In contrast, the previously reported core PAX 8-binding sites identified by computer analysis of the WT1 promoter failed to specifically bind in vitro translated PAX 8 protein or activate the minimal promoter, Thus, we identified a novel functional binding site for the transcription factor PAX 8, suggesting that part of its role in kidney development may be as a modulator of WT1 expression in the kidney.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Saunders, GF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, P01CA034936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 34936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 1996, ONCOGENE, V13, P2197; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dehbi M, 1996, ONCOGENE, V13, P447; Dehbi M, 1996, EMBO J, V15, P4297, DOI 10.1002/j.1460-2075.1996.tb00804.x; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; HEWITT SM, 1995, CANCER RES, V55, P5386; HEWITT SM, 1997, IN PRESS ANTICANCER; HOFMANN W, 1993, ONCOGENE, V8, P3123; HSU SY, 1995, MOL ENDOCRINOL, V9, P1356, DOI 10.1210/me.9.10.1356; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; Jun S, 1996, DEVELOPMENT, V122, P2639; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; Patmasiriwat P, 1996, LEUKEMIA, V10, P1127; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POLEEV A, 1992, DEVELOPMENT, V116, P611; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SEKIYA M, 1994, BLOOD, V83, P1876; SHIMAMURA R, 1997, IN PRESS CLIN CANC R; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Song DL, 1996, DEVELOPMENT, V122, P627; Stuart ET, 1996, CELL GROWTH DIFFER, V7, P405; TAGGE EP, 1994, J PEDIATR SURG, V29, P134, DOI 10.1016/0022-3468(94)90308-5; Tang HK, 1997, HUM MOL GENET, V6, P381, DOI 10.1093/hmg/6.3.381; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	56	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30678	30687		10.1074/jbc.272.49.30678	http://dx.doi.org/10.1074/jbc.272.49.30678			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388203	hybrid			2022-12-25	WOS:000071640800016
J	Leveillard, T; Wasylyk, B				Leveillard, T; Wasylyk, B			The MDM2 C-terminal region binds to TAF(II)250 and is required for MDM2 regulation of the cyclin A promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RING FINGER DOMAIN; TATA-BOX-BINDING; WILD-TYPE P53; TUMOR-SUPPRESSOR P53; SOFT-TISSUE SARCOMAS; A GENE-TRANSCRIPTION; CELL-CYCLE; S-PHASE; P53-ASSOCIATED PROTEIN; TRANSACTIVATION DOMAIN	MDM2 proto-oncogene expression is aberrant in many human tumors. Its normal role is to modulate the functions of p53. The N terminus of MDM2 interacts with p53, whereas the properties of the rest of the molecule are poorly understood. We show that MDM2 binds to the general transcription factor TFIID in vivo. The C-terminal Ring finger interacts with TAF(II)250/CCG1, and the central acidic domain interacts with TBP. Expression of MDM2 activates the cyclin A gene promoter but not c-fos, showing that the effects of MDM2 are specific. Deletion of the C-terminal region of MDM2 abolishes activation, showing that the C-terminal domain of MDM2 is functionally important. We found that increasing MDM2 expression to higher levels inhibits the cyclin A promoter. Inhibition appears to result from titration of general transcription factors because MDM2 overexpression inhibits c-fos as well as other promoters in vivo and basal transcription in vitro. The mechanisms of repression of the cyclin A and fos promoters appear to be different. Cyclin A repression is lost by deleting the C terminus, whereas that of c-fos is lost by removal of the acidic domain, These results reinforce the conclusion that the C terminus of MDM2 mediates effects on the cyclin A promoter, MDM2 transformed cells contain elevated levels of cyclin A mRNA, showing that activation occurs under physiological conditions. There is a positive correlation between MDM2 binding to TAF(II)250 and MDM2 activation of the cyclin A promoter. The C-terminal region of MDM2, which contains the Ring finger, interacts with TAF(II)250 and is required for regulation of the cyclin A promoter by MDM2. Our results link the activity of MDM2, a transforming protein implicated in many human tumors, with cyclin A, a regulator of the cell cycle.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Wasylyk, Bohdan/ABG-6778-2020; Léveillard, Thierry/AAR-1804-2020	Wasylyk, Bohdan/0000-0002-1718-1237; Léveillard, Thierry/0000-0001-5692-8770				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CORDONCARDO C, 1994, CANCER RES, V54, P794; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; Fisher RP, 1997, CURR OPIN GENET DEV, V7, P32, DOI 10.1016/S0959-437X(97)80106-2; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GERARD M, 1991, J BIOL CHEM, V266, P20940; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GIROD SC, 1995, ANTICANCER RES, V15, P1453; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Gorgoulis VG, 1996, J PATHOL, V180, P129; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAYASHIDA T, 1994, GENE, V141, P267; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Huet X, 1996, MOL CELL BIOL, V16, P3789; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JUVEN T, 1993, ONCOGENE, V8, P3411; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; Keleti J, 1996, AM J PATHOL, V149, P143; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1995, ONCOGENE, V10, P2001; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEACH FS, 1993, CANCER RES, V53, P2231; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Leveillard Thierry, 1993, Gene Expression, V3, P135; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumura T, 1996, ONCOLOGY, V53, P308; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MIYASHITA T, 1995, CELL, V80, P293; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PRICE BD, 1994, CANCER RES, V54, P896; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Roeder RG, 1996, METHOD ENZYMOL, V273, P165; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHELDON M, 1995, CURR BIOL, V5, P43, DOI 10.1016/S0960-9822(95)00014-5; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; THOME KZ, 1996, ONCOGENE, V13, P2323; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WALDMAN T, 1995, CANCER RES, V55, P5187; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	113	67	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30651	30661		10.1074/jbc.272.49.30651	http://dx.doi.org/10.1074/jbc.272.49.30651			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388200	hybrid			2022-12-25	WOS:000071640800013
J	Lin, FT; Krueger, KM; Kendall, HE; Daaka, Y; Fredericks, ZL; Pitcher, JA; Lefkowitz, RJ				Lin, FT; Krueger, KM; Kendall, HE; Daaka, Y; Fredericks, ZL; Pitcher, JA; Lefkowitz, RJ			Clathrin-mediated endocytosis of the beta-adrenergic receptor is regulated by phosphorylation/dephosphorylation of beta-arrestin1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PLASMA-MEMBRANE; COATED VESICLES; BETA(2)-ADRENERGIC RECEPTOR; ARRESTIN; BINDING; INTERNALIZATION; SPECIFICITY; ADAPTERS; DESENSITIZATION	beta-Arrestins serve a dual regulatory role in the life cycle of G protein-coupled receptors such as the ,beta(2)-adrenergic receptor, First, they mediate rapid desensitization by binding to G protein-coupled receptor kinase-phosphorylated receptors, Second, they target the receptors for internalization into endosomal vesicles, wherein receptor dephosphorylation and resensitization occur, Here we report that phosphorylation of a carboxyl terminal serine (Ser-412) in beta-arrestin1 regulates its endocytotic but not its desensitization function, Cytoplasmic beta-arrestin1 is constitutively phosphorylated and is recruited to the plasma membrane by agonist stimulation of the receptors. At the plasma membrane, beta-arrestin1 is rapidly dephosphorylated, a process that is required for its clathrin binding and receptor endocytosis but not for its receptor binding and desensitization. Once internalized, beta-arrestin1 is re-phosphorylated., Thus, as with the classical endocytic adaptor protein complex AP2, beta-arrestin1 functions as a clathrin adaptor in receptor endocytosis which is regulated by dephosphorylation at the plasma membrane.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BENETT N, 1988, BIOCHEMISTRY-US, V27, P1710; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; GRAHAM JM, 1992, CELL BIOL LUBFAX; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HEUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; JONES DH, 1992, BIOTECHNIQUES, V12, P575; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEFTON BM, 1991, METHOD ENZYMOL, V291, P245; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; YU SS, 1993, J BIOL CHEM, V268, P337; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	43	200	209	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31051	31057		10.1074/jbc.272.49.31051	http://dx.doi.org/10.1074/jbc.272.49.31051			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388255	hybrid			2022-12-25	WOS:000071640800068
J	Raman, N; Black, PN; DiRusso, CC				Raman, N; Black, PN; DiRusso, CC			Characterization of the fatty acid-responsive transcription factor FadR - Biochemical and genetic analyses of the native conformation and functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT NEGATIVE MUTATIONS; ESCHERICHIA-COLI; ACYL-COENZYME; DNA-BINDING; REPRESSOR; PROTEIN; EXPRESSION; REGULATOR; RECOGNITION; METABOLISM	In Escherichia coli, fatty acid synthesis and degradation are coordinately controlled at the level of transcription by FadR. FadR represses transcription of at least eight genes required for fatty acid transport and beta-oxidation and activates transcription of at least two genes required for unsaturated fatty acid biosynthesis and the gene encoding the transcriptional regulator of the ace-BAK operon encoding the glyoxylate shunt enzymes, IclR, FadR dependent DNA binding and transcriptional activation is prevented by long chain fatty acyl-CoA. In the present work, we provide physical and genetic evidence that FadR exists as a homodimer in solution and in vivo. Native polyacrylamide gel electrophoresis and glycerol gradient ultracentrifugation of the purified protein show that native FadR was a homodimer in solution with an apparent molecular mass of 53.5 and 57.8 kDa, respectively, Dominant negative mutations in fadR were generated by random and site-directed mutagenesis, Each mutation mapped to the amino terminus of the protein (residues 1-66) and resulted in a decrease in DNA binding in vitro. In an effort to separate domains of FadR required for DNA binding, dimerization, and ligand binding, chimeric protein fusions between the DNA binding domain of LexA and different regions of FadR were constructed. One fusion, LexA1-87-FadR102-239, was able to repress the LexA reporter sulA-lacZ, and beta-galactosidase activities were derepressed by fatty acids, suggesting that the fusion protein had determinants both for dimerization and ligand binding, These studies support the conclusion that native FadR exists as a stable homo-dimer in solution and that determinants for DNA binding and acyl-CoA binding are found within the amino terminus and carboxyl terminus, respectively.	Albany Med Coll, Dept Biochem & Mol Biol, Albany, NY 12208 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	Albany Medical College; University of Tennessee System; University of Tennessee Health Science Center	DiRusso, CC (corresponding author), Albany Med Coll, Dept Biochem & Mol Biol, A-10,47 New Scotland Ave, Albany, NY 12208 USA.	concetta_dirusso@ccgateway.amc.edu		Black, Paul/0000-0002-6272-6881				BADE H, 1984, J IMMUNOL METHODS, V72, P421, DOI 10.1016/0022-1759(84)90010-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSTOS SA, 1993, P NATL ACAD SCI USA, V90, P5638, DOI 10.1073/pnas.90.12.5638; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1993, MOL MICROBIOL, V7, P311, DOI 10.1111/j.1365-2958.1993.tb01122.x; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DiRusso CC, 1996, GWUMC DEPT, P15; Farewell A, 1996, J BACTERIOL, V178, P6443, DOI 10.1128/jb.178.22.6443-6450.1996; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; Gui LZ, 1996, J BACTERIOL, V178, P4704, DOI 10.1128/jb.178.15.4704-4709.1996; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; ISACKSON PJ, 1985, P NATL ACAD SCI USA, V82, P6226, DOI 10.1073/pnas.82.18.6226; JO YL, 1986, J BIOL CHEM, V261, P15253; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LIN LL, 1988, J BACTERIOL, V170, P2163, DOI 10.1128/jb.170.5.2163-2173.1988; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Miller J.H., 1972, EXPT MOL GENETICS; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; Scopes RK., 1987, PROTEIN PURIFICATION, V2nd ed; SHAMAH SM, 1995, METHOD ENZYMOL, V254, P567; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIDA KI, 1993, J MOL BIOL, V231, P167, DOI 10.1006/jmbi.1993.1270	36	50	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30645	30650		10.1074/jbc.272.49.30645	http://dx.doi.org/10.1074/jbc.272.49.30645			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388199	hybrid			2022-12-25	WOS:000071640800012
J	Sacerdoti-Sierra, N; Jaffe, CL				Sacerdoti-Sierra, N; Jaffe, CL			Release of ecto-protein kinases by the protozoan parasite Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; SURFACE; CELL; GROWTH; INHIBITION; TARGET	Leishmania major promastigotes have externally oriented ecto-protein kinases (PK) that are capable of phosphorylating both endogenous membrane substrates and foreign proteins. Live parasites phosphorylate protamine sulfate, casein, and phosvitin but not bovine serum albumin. Addition of exogenous PK substrates, such as phosvitin or casein, induced the shedding of ecto-PK that are capable of phosphorylating protamine sulfate. No phosphorylation of protamine sulfate was seen when cell-free supernatants from promastigotes incubated with either buffer alone or bovine serum albumin were used. A second enzyme, a constitutively released PR that phosphorylates casein or phosvitin and not protamine sulfate or mixed histones, was identified and characterized. This PK is inhibited by 5 mu M staurosporine, 50 mu g/ml heparin, and 75 mu M CKI-7, concentrations typical of the IC50 found for other eukaryotic casein kinases (CK). The constitutively shed ecto PK specifically phosphorylated a peptide substrate for CK1 but not for CK2, suggesting that this shed PK is similar to CK1.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Parasitol, Kuvin Ctr Study Infect & Trop Dis, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Jaffe, CL (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Parasitol, Kuvin Ctr Study Infect & Trop Dis, POB 12272, IL-91120 Jerusalem, Israel.	cjaffe@cc.huji.ac.il	Jaffe, Charles/AAU-8686-2020	Jaffe, Charles/0000-0002-2042-9993				ASSEFA D, 1995, BBA-MOL BASIS DIS, V1270, P157, DOI 10.1016/0925-4439(94)00080-A; Becker S, 1997, PARASITOL RES, V83, P273, DOI 10.1007/s004360050246; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CORBIN JD, 1983, METHOD ENZYMOL, V99, P317; DEY CS, 1988, BIOCHEM INT, V17, P367; EKDAHL KN, 1995, J IMMUNOL, V154, P6502; FORSBERG PO, 1990, J BIOL CHEM, V265, P2941; FRIEDBERG I, 1995, J BIOL CHEM, V270, P20560, DOI 10.1074/jbc.270.35.20560; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HARTMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1136, P189, DOI 10.1016/0167-4889(92)90256-B; Hermoso T., 1996, Molecular and immune mechanisms in the pathogenesis of cutaneous leishmaniasis., P71; HERMOSO T, 1991, EMBO J, V10, P4061, DOI 10.1002/j.1460-2075.1991.tb04982.x; HOGAN MV, 1995, J NEUROCHEM, V65, P2022; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JACKSON PR, 1985, SCIENCE, V227, P435, DOI 10.1126/science.2578226; Jaffe C. L., 1984, Genes and antigens of parasites. A laboratory manual. Proceedings of a course held 14 November-17 December 1983, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil., P47; KUBLER D, 1983, P NATL ACAD SCI-BIOL, V80, P4021, DOI 10.1073/pnas.80.13.4021; KUBLER D, 1989, J BIOL CHEM, V264, P14549; KUBLER D, 1982, EUR J CELL BIOL, V26, P306; LESTER DS, 1990, BIOCHIM BIOPHYS ACTA, V1052, P293, DOI 10.1016/0167-4889(90)90224-2; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; MUKHOPADHYAY NK, 1989, BIOCHEM J, V264, P519; PAAS Y, 1995, ARCH BIOCHEM BIOPHYS, V316, P780, DOI 10.1006/abbi.1995.1104; PETERS W, 1987, LEISHMANIASIS BIOL M, V1, P941; SimanTov MM, 1996, MOL BIOCHEM PARASIT, V77, P201, DOI 10.1016/0166-6851(96)02601-1; SKUBITZ KM, 1991, J IMMUNOL, V147, P638; VILGRAIN I, 1991, MOL ENDOCRINOL, V5, P1003, DOI 10.1210/mend-5-7-1003; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313	30	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30760	30765		10.1074/jbc.272.49.30760	http://dx.doi.org/10.1074/jbc.272.49.30760			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388215	hybrid			2022-12-25	WOS:000071640800028
J	Seidel, G; Adermann, K; Schindler, T; Ejchart, A; Jaenicke, R; Forssmann, WG; Rosch, P				Seidel, G; Adermann, K; Schindler, T; Ejchart, A; Jaenicke, R; Forssmann, WG; Rosch, P			Solution structure of porcine delta sleep-inducing peptide immunoreactive peptide a homolog of the shortsighted gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; HELICAL COILED-COILS; GCN4 LEUCINE-ZIPPER; STRUCTURE PREDICTION; ELECTROSTATIC INTERACTIONS; CRYSTAL-STRUCTURE; MODEL PROTEIN; CHAIN-LENGTH; STABILITY; DOMAIN	The 77-residue delta sleep inducing peptide immunoreactive peptide (DIP) is a close homolog of the Drosophila melanogaster shortsighted gene product. Porcine DIP (pDIP) and a peptide containing a leucine zipper-related partial sequence of pDIP, pDIP(9-46), was synthesized and studied by circular dichroism and nuclear magnetic resonance spectroscopy in combination with molecular dynamics calculations. Ultracentrifugation, size exclusion chromatography, and model calculations indicated that pDIP forms a dimer. This was confirmed by the observation of concentration-dependent thermal folding-unfolding transitions. From CD spectroscopy and thermal folding-unfolding transitions of pDIP(9-46), it was concluded that the dimerization of pDIP is a result of interaction between helical structures localized in the leucine zipper motif. The three-dimensional structure of the protein was determined with a modified simulated annealing protocol using experimental data derived from nuclear magnetic resonance spectra and a modeling approach based on an established strategy for coiled coil structures. The left handed super helical structure of the leucine zipper type sequence resulting from the modeling approach is in agreement with known leucine zipper structures. In addition to the hydrophobic interactions between the amino acids at the heptade positions a and d, the structure of pDTP is stabilized by the formation of interhelical i to i' + 5 salt bridges. This result was confirmed by the pH dependence of the thermal-folding transitions. In addition to the amphipatic helix of the leucine zipper, a second helix is formed in the NH2-terminal part of pDIP. This helix exhibits more 3(10)-helix character and is less stable than the leucine zipper helix. For the COOH-terminal region of pDIP no elements of regular secondary structure were observed.	Univ Bayreuth, Lehrstuhl Biopolymere, D-95447 Bayreuth, Germany; Niedersachs Inst Peptid Forsch GmbH, D-30625 Hannover, Germany; Univ Bayreuth, Lehrstuhl Biochem, D-95447 Bayreuth, Germany; Univ Regensburg, Inst Biophys & Phys Biochem, D-93053 Regensburg, Germany	University of Bayreuth; University of Bayreuth; University of Regensburg	Rosch, P (corresponding author), Univ Bayreuth, Lehrstuhl Biopolymere, Univ Str 30, D-95447 Bayreuth, Germany.		Rösch, Paul/I-5445-2014	Rösch, Paul/0000-0003-3330-2446				Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BRUNGER A, 1993, XPLOR VERSION 3 1; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DEFRANCESCO R, 1991, BIOCHEMISTRY-US, V30, P143, DOI 10.1021/bi00215a021; DELANO WL, 1994, PROTEINS, V20, P105, DOI 10.1002/prot.340200202; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; FAIRMAN R, 1995, PROTEIN SCI, V4, P1457, DOI 10.1002/pro.5560040803; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HODGES R S, 1988, Peptide Research, V1, P19; HU JC, 1992, NUCLEIC ACIDS MOL BI, V6, P82; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jardetzky O., 1981, NMR MOL BIOL; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; KOHN WD, 1995, PROTEIN SCI, V4, P237; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MEHTA PK, 1995, PROTEIN SCI, V4, P2517, DOI 10.1002/pro.5560041208; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MONNIER M, 1977, EXPERIENTIA, V33, P548, DOI 10.1007/BF01922266; MUHLEGOLL C, 1995, BIOCHEMISTRY-US, V34, P13554, DOI 10.1021/bi00041a035; NAUTIYAL S, 1995, BIOCHEMISTRY-US, V34, P11645, DOI 10.1021/bi00037a001; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; PRICE NC, 1995, MOL BIOL BIOTECHNOLO; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SAUDEK V, 1990, PROTEIN ENG, V4, P3, DOI 10.1093/protein/4.1.3; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; SILLARD R, 1993, EUR J BIOCHEM, V216, P429, DOI 10.1111/j.1432-1033.1993.tb18160.x; STONE D, 1975, PROTEINS CONTRACTILE, P125; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Vogel P, 1996, BBA-GENE STRUCT EXPR, V1309, P200, DOI 10.1016/S0167-4781(96)00177-7; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; YU H, 1996, J MOL BIOL, V255, P367; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365; ZHU BY, 1993, PROTEIN SCI, V2, P383	70	11	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30918	30927		10.1074/jbc.272.49.30918	http://dx.doi.org/10.1074/jbc.272.49.30918			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388238	hybrid, Green Submitted			2022-12-25	WOS:000071640800051
J	Yan, ZF; Chen, MX; Perucho, M; Friedman, E				Yan, ZF; Chen, MX; Perucho, M; Friedman, E			Oncogenic Ki-ras but not oncogenic Ha-ras blocks integrin beta 1-chain maturation in colon epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; KERATINOCYTE TERMINAL DIFFERENTIATION; ASN-LINKED OLIGOSACCHARIDES; CARCINOMA-CELLS; ADHESION RECEPTORS; COLORECTAL-CANCER; PLASMA-MEMBRANE; APICAL POLARITY; BLADDER-CANCER; ALPHA-SUBUNITS	Human colorectal tumors commonly contain mutations in Ki-ras but rarely, if ever, in Ha-ras. The selectivity for Ki-ras mutations in this tumor was explored using the HD6-4 colon epithelial cell line which contains no ras mutations, after adhesion to an extracellular matrix, HD6-4 cells polarize into columnar goblet cells with distinct apical and basal regions. Stable HD6-4 transfectants were made with mini-gene constructs of the oncogenic cellular Ki-ras4B(G12V) gene, the oncogenic Ha-ras(G12V) gene, or mini-gene constructs of wild-type Ki-ras4B as a control, Ki-ras mutations, but not Ha-ras mutations, disrupted colon epithelial cell apicobasal polarity and adhesion to collagen I and laminin. Three Ha-ras transfectants and three Ki-ras transfectants exhibited Ras proteins expressing the Val-12 mutation by Western blotting with pan-ras(G12V) antibody. Only wild-type Ki-ras transfectant cells and oncogenic Ha-ras transfectant cells synthesized the mature, fully glycosylated forms of beta 1 integrin. Instead of the mature integrin beta 1-chain, a faster migrating beta 1-chain intermediate was detected on the cell surface and in the cytoplasm of the oncogenic Ki-ras transfectants. Expression of the oncogenic Ki-ras gene caused the altered beta 1 integrin maturation because phosphorothiolated antisense oligonucleotides to Ki-ras reduced expression of both the mutant Hi-Ras protein and the aberrant integrin beta 1-chain and increased expression of the mature integrin beta 1-chain. Altered glycosylation generated the new beta 1-integrin form since integrin core beta 1-chain proteins of the same molecular weight were yielded in Ki-ras, Ha-ras, and control transfectants after removal of sugar residues with endoglycosidase F or following tunicamycin treatment to inhibit glycosylation. The selective effect of oncogenic Ki-ras on beta 1 integrin glycosylation was not due to selective activation of mitogen activated protein kinases because both mutated Ki- and Ha-ras genes activated this pathway and increased cell proliferation. Since blocking the glycosylation of integrin beta 1-chain inhibited the adherence, polarization, and subsequent differentiation of colon epithelial cells, the selective effects of the oncogenic cellular Ki-ras gene on integrin beta 1-chain glycosylation may account, at least in part, for the selection of Ki-ras mutations in human colon tumors.	SUNY Hlth Sci Ctr, Dept Pathol, Syracuse, NY 13210 USA; Burnham Inst, La Jolla, CA 92037 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Sanford Burnham Prebys Medical Discovery Institute	Friedman, E (corresponding author), SUNY Hlth Sci Ctr, Dept Pathol, 2305 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.			Perucho, Manuel/0000-0002-2169-2662	NATIONAL CANCER INSTITUTE [R01CA045783, R01CA067405] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA45783, R01 CA67405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; AUGENLICHT LH, 1987, CANCER RES, V47, P3763; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURCHILL SA, 1994, BRIT J UROL, V73, P516, DOI 10.1111/j.1464-410X.1994.tb07636.x; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CELANO P, 1993, CELL GROWTH DIFFER, V4, P341; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EASTON EW, 1991, J BIOL CHEM, V266, P21674; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA S, 1995, CANCER LETT, V91, P145, DOI 10.1016/0304-3835(95)03735-F; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HEINO J, 1989, J BIOL CHEM, V264, P380; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HUANG F, 1994, ONCOGENE, V9, P3701; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAHN S, 1987, ANTICANCER RES, V7, P639; KOIVISTO L, 1994, BIOCHEM J, V300, P771, DOI 10.1042/bj3000771; KORETZ K, 1991, AM J PATHOL, V138, P741; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENTER M, 1994, J BIOL CHEM, V269, P12263; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MIYOSHI E, 1995, J BIOL CHEM, V270, P28311; OJAKIAN GK, 1994, J CELL SCI, V107, P561; PIGATELLI M, 1990, BRIT J CANCER, V61, P636; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; SHIBATA D, 1993, J NATL CANCER I, V85, P1058, DOI 10.1093/jnci/85.13.1058; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUCHY B, 1992, INT J CANCER, V52, P30, DOI 10.1002/ijc.2910520107; WANG AZ, 1990, J CELL SCI, V95, P153; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YAN ZF, 1992, ONCOGENE, V7, P801; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	49	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30928	30936		10.1074/jbc.272.49.30928	http://dx.doi.org/10.1074/jbc.272.49.30928			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388239	hybrid			2022-12-25	WOS:000071640800052
J	Iravani, M; Dhat, R; Price, CM				Iravani, M; Dhat, R; Price, CM			Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15(INK4B)) in childhood acute lymphoblastic leukemia	ONCOGENE			English	Article						MTS1; p16(INK4A); MTS2; p15(INK4B); methylation; childhood leukemia	DEPENDENT KINASE INHIBITORS; CELL-CYCLE ARREST; DNA METHYLATION; HUMAN CANCERS; TGF-BETA; P16; INACTIVATION; HYPERMETHYLATION; EXPRESSION; FREQUENCY	The multi tumor suppressor genes MTS1 (CDKN2 p16(INK4A)) and MTS2 (CDKN1, p15(INK4B)) located at 9p21-22 are inactivated in some human cancers via several mechanisms including deletion and hypermethylation, We have investigated the deletion and methylation status of MTS1 and MTS2 in childhood acute lymphoblastic leukemia (ALL) of both T-cell (17 cases) and B-cell phenotypes (29 cases), and p16(INK4A) and p15(INK4B) mRNA expression in 36 of these cases, Biallelic or monoallelic loss of both MTS1 and MTS2 was observed in 12 cases of B-ALL and nine cases of T-ALL. Two cases of T-ALL showed deletion of MTS1 but not MTS2 The 5' CpG region of MTS2 was hypermethylated in 12 cases of precursor B-ALL and eight cases of T-ALL but no hypermethylation was found in the 5' CPG region of MTS1, All cases with homozygous deletion of MTS1 or MTS2 had no or low levels of mRNA expression and similar low levels of expression were found in cases in which MTS2 was present but fully methylated, Thus hypermethylation of MTS2, in contrast to MTS1, is frequent in childhood ALL, Furthermore our data show that although inactivation of MTS1 by deletion is common, inactivation of MTS2 by a combination of deletion and hypermethylation is more frequent in both B-ALL (20/29, 69%) and T-ALL (17/17, 100%), This suggests that both MTS1 and MTS2 are important targets of the 9p21-22 deletion.	INST CANC RES,CHESTER BEATTY LABS,LEUKAEMIA RES FUND CTR,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costello JF, 1996, CANCER RES, V56, P2405; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; GREGER V, 1994, HUM GENET, V94, P491; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAIDAR MA, 1995, BLOOD, V86, P311, DOI 10.1182/blood.V86.1.311.bloodjournal861311; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAMA T, 1995, BLOOD, V86, P841; Jamal R, 1996, LEUKEMIA, V10, P629; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LI Y, 1994, CANCER RES, V54, P6078; Lo KW, 1996, CANCER RES, V56, P2721; MARCO JAG, 1996, BLOOD, V88, P1568; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nagatake M, 1996, CANCER RES, V56, P1886; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; PRICE CM, 1992, BLOOD, V80, P1033; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; Reed AL, 1996, CANCER RES, V56, P3630; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sambrook J., 2002, MOL CLONING LAB MANU; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; ZULUETA MG, 1995, CANCER RES, V55, P4531	39	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2609	2614		10.1038/sj.onc.1201428	http://dx.doi.org/10.1038/sj.onc.1201428			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399648				2022-12-25	WOS:A1997YG73200010
J	Hamdane, M; DavidCordonnier, MH; DHalluin, JC				Hamdane, M; DavidCordonnier, MH; DHalluin, JC			Activation of p65 NF-kappa B protein by p210(BCR-ABL) in myeloid cell line (p210(BCR-ABL) activates p65 NF-kappa B)	ONCOGENE			English	Article						p210(BCR-ABL); tyrosine kinase; signal transduction; NF-kappa B activity; p65 NF-kappa B (RelA); myeloid cells	CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; TYROSINE KINASE-ACTIVITY; CHRONIC MYELOCYTIC-LEUKEMIA; C-ABL; TRANSCRIPTIONAL ACTIVATION; PHILADELPHIA-CHROMOSOME; V-ABL; ANTISENSE INHIBITION; IMMUNOGLOBULIN GENES	The chimeric tyrosine kinase p210(BCR-ABL) is involved in the pathogenesis of chronic myelogenous leukemia. It transforms immature hematopoietic cells in vitro and abrogates IL-3-dependent growth. The mechanisms by which p210(BCR-ABL) mediates its oncogenicity are not well elucidated. Identifying transcription factors targeted by the chimeric protein may help to clarify these mechanisms. We have analysed the effect of p210(BCR-ABL) expression on NF-kappa B activity in DA1 cells (an IL-3-dependent murine myeloid progenitor cell line). A specific stimulation of NF-kappa B activity by kinase-active wild-type p210(BCR-ABL) has been evidenced by transcriptional activation assays. Electrophoretic mobility supershift assays revealed the presence of p65 protein (RelA) DNA binding activity in p210(BCR-ABL) transformed DA1 cells but not in parental DA1 cells. Activation of RelA in transformed DA1 cells may occur by protein stabilization. Experiments using oligonucleotides antisense to RelA showed that p210(BCR-ABL) transfected cells failed to survive after IL-3 removal. Moreover, inhibition of cellular growth was shown following treatment of p210(BCR-ABL) transformed DA1 cells by p65 antisense oligonucleotides. This study suggests that p65 NF-kappa B may be an effector for p210(BCR-ABL) and probably contributes to its induced transformation process.	INSERM U124,INST RECH CANC LILLE,F-59045 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			DAVID-CORDONNIER, Marie-Helene/P-9909-2019; David-Cordonnier, Marie-Helene/M-3725-2018	DAVID-CORDONNIER, Marie-Helene/0000-0001-9831-5577; David-Cordonnier, Marie-Helene/0000-0001-9831-5577; Hamdane, Malika/0000-0001-7971-8696				AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; CARLESSO N, 1994, ONCOGENE, V9, P149; COOK WD, 1982, P NATL ACAD SCI USA, V72, P2917; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IHLE JN, 1985, CONTEMP TOP MOLEC IM, V10, P93; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KERR LD, 1994, BIOESSAYS, V16, P453, DOI 10.1002/bies.950160702; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LI WJ, 1988, ONCOGENE, V2, P559; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MANDANAS RA, 1993, BLOOD, V82, P1838; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NARAYANAN R, 1992, ONCOGENE, V7, P553; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1992, ONCOGENE, V7, P2095; Neumann M, 1996, ANTICANCER RES, V16, P1075; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PEREZ JR, 1994, MOL CELL BIOL, V14, P5326, DOI 10.1128/MCB.14.8.5326; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1996, ONCOGENE, V12, P839; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHMITZ ML, 1995, IMMUNOBIOLOGY, V193, P116, DOI 10.1016/S0171-2985(11)80534-6; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Shuai K, 1996, ONCOGENE, V13, P247; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SOKOLOSKI JA, 1993, BLOOD, V82, P625; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107	75	66	69	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2267	2275		10.1038/sj.onc.1201411	http://dx.doi.org/10.1038/sj.onc.1201411			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393872				2022-12-25	WOS:A1997YE15700002
J	Mishra, L; Tully, RE; Monga, SPS; Yu, P; Cai, T; Makalowski, W; Mezey, E; Pavan, WJ; Mishra, B				Mishra, L; Tully, RE; Monga, SPS; Yu, P; Cai, T; Makalowski, W; Mezey, E; Pavan, WJ; Mishra, B			Praja1, a novel gene encoding a RING-H2 motif in mouse development	ONCOGENE			English	Article						Praja1 gene; PRAJA1 protein; RING-H2 domain; molecular cloning; liver development; chromosome localization; explant cultures	ZINC-FINGER; PROTEIN; DOMAIN; FAMILY; GRANIN	As part of a cloning strategy to identify genes involved in early mouse liver development we have isolated Praja1, a gene with similar sequences to the Drosophila melanogaster gene goliath (gl) which is involved in the fate of mesodermal cells ultimately forming gut musculatures, fat body, and the heart, Praja1 is a 2.1 kb gene encoding a putative 396 amino acid ORF and includes a COOH-terminal RING-H2 domain, Using the Jackson Laboratory BSS panel, we have localized Praja1 on chromosome X at 36 cM, which may be a candidate gene for mouse sla (sex linked sideroblastic anemia), near the X inactivation center gene, Xist, Northern blot analysis demonstrated three transcripts (3.1, 2.6 and 2.1 kb) in mRNA from adult mouse tissues brain, liver, and kidney as well as in mRNA from developing mouse embryos (days 7, 11, 15 and 17 post coitus, p.c.). In vitro transcription/translation yielded a product with an M-r of 59 kD, Immunohistochemical staining of in vitro liver explant cultures using a heterologous antibody against praja1 demonstrated cytoplasmic staining of cuboidal cells that have hepatocyte morphology and organization, The presence of the RING-H2 domain, a proline-rich region at the COOH-end, and regions rich in acidic amino acids, leads to the hypothesis that the Praja1 product is possibly involved in mediating protein-protein interactions, possibly as part of a protein sorting or transport pathway, This is strengthened by the similarity of Praja1 to rat Neurodap1, whose product has been shown to localize to the endoplasmic reticulum and golgi in brain.	NATL HUMAN GENOME RES INST, LAB GENET DIS RES, CLIN GENE THERAPY BRANCH, NIH, BETHESDA, MD USA; NATL CTR BIOTECHNOL INFORMAT, NIH, BETHESDA, MD USA; JOHNS HOPKINS SCH MED, BALTIMORE, MD USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; Johns Hopkins University; Johns Hopkins Medicine	Mishra, L (corresponding author), VET ADM MED CTR, LAB DEV MOL BIOL, WASHINGTON, DC 20422 USA.		Makalowski, Wojciech/I-2843-2016; Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691; Pavan, William/0000-0001-8281-5120; Mishra, Lopa/0000-0002-6850-0808; Cai, Tao/0000-0002-2877-8637; Makalowski, Wojciech/0000-0003-2303-9541; Monga, Satdarshan/0000-0002-8437-3378				BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BOUCHARD ML, 1993, GENE, V125, P205, DOI 10.1016/0378-1119(93)90330-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FALCONER DS, 1962, GENET RES, V3, P248, DOI 10.1017/S0016672300035035; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Herman GE, 1996, MAMM GENOME, V6, pS317; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Konat Gregory W., 1994, P37; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN NM, 1975, MED BIOL, V53, P427; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAYAMA M, 1995, J NEUROSCI, V15, P5238; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHEVACH E, 1991, CURRENT PROTOCOLS IM; Silhavy T.J., 1984, EXPT GENE FUSIONS	23	40	41	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2361	2368		10.1038/sj.onc.1201405	http://dx.doi.org/10.1038/sj.onc.1201405			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393880				2022-12-25	WOS:A1997YE15700010
J	Pelicano, L; Li, FS; Schindler, C; ChelbiAlix, MK				Pelicano, L; Li, FS; Schindler, C; ChelbiAlix, MK			Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action	ONCOGENE			English	Article						interferon; retinoic acid; STAT; IRF-1; signalisation pathways	2'5' OLIGOADENYLATE SYNTHETASE; PML GROWTH-SUPPRESSOR; CONSTITUTIVE EXPRESSION; GENE-EXPRESSION; IFN-ALPHA; TRANSCRIPTIONAL ACTIVATOR; PROMYELOCYTIC LEUKEMIA; VIRUS-INFECTION; CELL-LINES; INDUCTION	Retinoic acid (RA) and interferons (IFNs) are negative regulators of cell proliferation, In vitro and in vivo, their combination leads to a more potent growth inhibition, However, the molecular mechanisms by which RA and IFNs potentiate each other are not fully understood. As some IFN-induced gene products regulate cell growth and/or antiviral activity, we analysed the effects of RA on their expressions. RA increases the level of 2'5'oligoadenylate synthetase, p68 kinase, the promyelocytic leukemia protein (PML) and Sp100 in both HL-60 and WISH cells. Moreover, RA and IFN act cooperatively to increase the expression of these proteins, RA also inhibits vesicular stomatitis virus replication and induces a higher antiviral state and growth inhibition when combined with IFN. RA stimulates the IFN regulatory factor 1 (IRF-1) gene expression directly through the GAS motif and causes the induction and secretion of IFN alpha. Additional mechanisms could he involved as RA increases the level of signal transducing activators of transcription (STAT) proteins, and enhances the IFN-induced STAT activation, suggesting that cooperative effects by RA and IFN are mediated through multiple pathways.	HOP ST LOUIS,CNRS,UPR 9051,F-75010 PARIS,FRANCE; COLUMBIA UNIV COLL PHYS & SURG,DIV MOL MED,NEW YORK,NY 10032	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Columbia University								Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOURGEADE MF, 1984, CANCER RES, V44, P5355; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHELBIALIX MK, 1986, BIOCHEM BIOPH RES CO, V141, P1042, DOI 10.1016/S0006-291X(86)80149-8; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHELBIALIX MK, 1994, J CELL PHYSIOL, V158, P47, DOI 10.1002/jcp.1041580107; CHELBIALIX MK, 1996, TUMOR BIOL REGULATIO, P17; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FERBUS D, 1985, MOL CELL BIOCHEM, V67, P125, DOI 10.1007/BF02370171; FREY JR, 1991, CANCER LETT, V57, P223, DOI 10.1016/0304-3835(91)90161-A; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; JUSTESEN J, 1980, NUCLEIC ACIDS RES, V8, P3073, DOI 10.1093/nar/8.14.3073; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LANCILLOTTI F, 1995, CANCER RES, V55, P3158; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Mangelsdorf David J., 1994, P319; Matikainen S, 1996, BLOOD, V88, P114; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROMEO G, 1989, TRENDS GENET, V5, P19, DOI 10.1016/0168-9525(89)90007-3; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1995, RECEPTOR, V5, P81; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Stadler M, 1995, ONCOGENE, V11, P2565; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9	50	89	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2349	2359		10.1038/sj.onc.1201410	http://dx.doi.org/10.1038/sj.onc.1201410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393879				2022-12-25	WOS:A1997YE15700009
